Famotidine	0 10 B-Chemical
-	10 1 O
associated	11 10 O
delirium	22 8 B-Disease
.	30 1 O

A	32 1 O
series	34 6 O
of	41 2 O
six	44 3 O
cases	48 5 O
.	53 1 O

Famotidine	55 10 B-Chemical
is	66 2 O
a	69 1 O
histamine	71 9 O
H2	81 2 O
-	83 1 O
receptor	84 8 O
antagonist	93 10 O
used	104 4 O
in	109 2 O
inpatient	112 9 O
settings	122 8 O
for	131 3 O
prevention	135 10 O
of	146 2 O
stress	149 6 O
ulcers	156 6 B-Disease
and	163 3 O
is	167 2 O
showing	170 7 O
increasing	178 10 O
popularity	189 10 O
because	200 7 O
of	208 2 O
its	211 3 O
low	215 3 O
cost	219 4 O
.	223 1 O

Although	225 8 O
all	234 3 O
of	238 2 O
the	241 3 O
currently	245 9 O
available	255 9 O
H2	265 2 O
-	267 1 O
receptor	268 8 O
antagonists	277 11 O
have	289 4 O
shown	294 5 O
the	300 3 O
propensity	304 10 O
to	315 2 O
cause	318 5 O
delirium	324 8 B-Disease
,	332 1 O
only	334 4 O
two	339 3 O
previously	343 10 O
reported	354 8 O
cases	363 5 O
have	369 4 O
been	374 4 O
associated	379 10 O
with	390 4 O
famotidine	395 10 B-Chemical
.	405 1 O

The	407 3 O
authors	411 7 O
report	419 6 O
on	426 2 O
six	429 3 O
cases	433 5 O
of	439 2 O
famotidine	442 10 B-Chemical
-	452 1 O
associated	453 10 O
delirium	464 8 B-Disease
in	473 2 O
hospitalized	476 12 O
patients	489 8 O
who	498 3 O
cleared	502 7 O
completely	510 10 O
upon	521 4 O
removal	526 7 O
of	534 2 O
famotidine	537 10 B-Chemical
.	547 1 O

The	549 3 O
pharmacokinetics	553 16 O
of	570 2 O
famotidine	573 10 B-Chemical
are	584 3 O
reviewed	588 8 O
,	596 1 O
with	598 4 O
no	603 2 O
change	606 6 O
in	613 2 O
its	616 3 O
metabolism	620 10 O
in	631 2 O
the	634 3 O
elderly	638 7 O
population	646 10 O
seen	657 4 O
.	661 1 O

The	663 3 O
implications	667 12 O
of	680 2 O
using	683 5 O
famotidine	689 10 B-Chemical
in	700 2 O
elderly	703 7 O
persons	711 7 O
are	719 3 O
discussed	723 9 O
.	732 1 O

Indomethacin	0 12 B-Chemical
induced	13 7 O
hypotension	21 11 B-Disease
in	33 2 O
sodium	36 6 B-Chemical
and	43 3 O
volume	47 6 O
depleted	54 8 O
rats	63 4 O
.	67 1 O

After	69 5 O
a	75 1 O
single	77 6 O
oral	84 4 O
dose	89 4 O
of	94 2 O
4	97 1 O
mg	99 2 O
/	101 1 O
kg	102 2 O
indomethacin	105 12 B-Chemical
(	118 1 O
IDM	119 3 B-Chemical
)	122 1 O
to	124 2 O
sodium	127 6 B-Chemical
and	134 3 O
volume	138 6 O
depleted	145 8 O
rats	154 4 O
plasma	159 6 O
renin	166 5 O
activity	172 8 O
(	181 1 O
PRA	182 3 O
)	185 1 O
and	187 3 O
systolic	191 8 O
blood	200 5 O
pressure	206 8 O
fell	215 4 O
significantly	220 13 O
within	234 6 O
four	241 4 O
hours	246 5 O
.	251 1 O

In	253 2 O
sodium	256 6 B-Chemical
repleted	263 8 O
animals	272 7 O
indomethacin	280 12 B-Chemical
did	293 3 O
not	297 3 O
change	301 6 O
systolic	308 8 O
blood	317 5 O
pressure	323 8 O
(	332 1 O
BP	333 2 O
)	335 1 O
although	337 8 O
plasma	346 6 O
renin	353 5 O
activity	359 8 O
was	368 3 O
decreased	372 9 O
.	381 1 O

Thus	383 4 O
,	387 1 O
indomethacin	389 12 B-Chemical
by	402 2 O
inhibition	405 10 O
of	416 2 O
prostaglandin	419 13 B-Chemical
synthesis	433 9 O
may	443 3 O
diminish	447 8 O
the	456 3 O
blood	460 5 O
pressure	466 8 O
maintaining	475 11 O
effect	487 6 O
of	494 2 O
the	497 3 O
stimulated	501 10 O
renin	512 5 O
-	517 1 O
angiotensin	518 11 B-Chemical
system	530 6 O
in	537 2 O
sodium	540 6 B-Chemical
and	547 3 O
volume	551 6 O
depletion	558 9 O
.	567 1 O

Late	0 4 O
-	4 1 O
onset	5 5 O
scleroderma	11 11 B-Disease
renal	23 5 I-Disease
crisis	29 6 I-Disease
induced	36 7 O
by	44 2 O
tacrolimus	47 10 B-Chemical
and	58 3 O
prednisolone	62 12 B-Chemical
:	74 1 O
a	76 1 O
case	78 4 O
report	83 6 O
.	89 1 O

Scleroderma	91 11 B-Disease
renal	103 5 I-Disease
crisis	109 6 I-Disease
(	116 1 O
SRC	117 3 B-Disease
)	120 1 O
is	122 2 O
a	125 1 O
rare	127 4 O
complication	132 12 O
of	145 2 O
systemic	148 8 B-Disease
sclerosis	157 9 I-Disease
(	167 1 O
SSc	168 3 B-Disease
)	171 1 O
but	173 3 O
can	177 3 O
be	181 2 O
severe	184 6 O
enough	191 6 O
to	198 2 O
require	201 7 O
temporary	209 9 O
or	219 2 O
permanent	222 9 O
renal	232 5 O
replacement	238 11 O
therapy	250 7 O
.	257 1 O

Moderate	259 8 O
to	268 2 O
high	271 4 O
dose	276 4 O
corticosteroid	281 14 B-Chemical
use	296 3 O
is	300 2 O
recognized	303 10 O
as	314 2 O
a	317 1 O
major	319 5 O
risk	325 4 O
factor	330 6 O
for	337 3 O
SRC	341 3 B-Disease
.	344 1 O

Furthermore	346 11 O
,	357 1 O
there	359 5 O
have	365 4 O
been	370 4 O
reports	375 7 O
of	383 2 O
thrombotic	386 10 B-Disease
microangiopathy	397 15 I-Disease
precipitated	413 12 O
by	426 2 O
cyclosporine	429 12 B-Chemical
in	442 2 O
patients	445 8 O
with	454 4 O
SSc	459 3 B-Disease
.	462 1 O

In	464 2 O
this	467 4 O
article	472 7 O
,	479 1 O
we	481 2 O
report	484 6 O
a	491 1 O
patient	493 7 O
with	501 4 O
SRC	506 3 B-Disease
induced	510 7 O
by	518 2 O
tacrolimus	521 10 B-Chemical
and	532 3 O
corticosteroids	536 15 B-Chemical
.	551 1 O

The	553 3 O
aim	557 3 O
of	561 2 O
this	564 4 O
work	569 4 O
is	574 2 O
to	577 2 O
call	580 4 O
attention	585 9 O
to	595 2 O
the	598 3 O
risk	602 4 O
of	607 2 O
tacrolimus	610 10 B-Chemical
use	621 3 O
in	625 2 O
patients	628 8 O
with	637 4 O
SSc	642 3 B-Disease
.	645 1 O

The	0 3 O
risk	4 4 O
and	9 3 O
associated	13 10 O
factors	24 7 O
of	32 2 O
methamphetamine	35 15 B-Chemical
psychosis	51 9 B-Disease
in	61 2 O
methamphetamine	64 15 B-Chemical
-	79 1 O
dependent	80 9 O
patients	90 8 O
in	99 2 O
Malaysia	102 8 O
.	110 1 O

OBJECTIVE	112 9 O
:	121 1 O
The	123 3 O
objective	127 9 O
of	137 2 O
this	140 4 O
study	145 5 O
was	151 3 O
to	155 2 O
determine	158 9 O
the	168 3 O
risk	172 4 O
of	177 2 O
lifetime	180 8 O
and	189 3 O
current	193 7 O
methamphetamine	201 15 B-Chemical
-	216 1 O
induced	217 7 O
psychosis	225 9 B-Disease
in	235 2 O
patients	238 8 O
with	247 4 O
methamphetamine	252 15 B-Chemical
dependence	268 10 O
.	278 1 O

The	280 3 O
association	284 11 O
between	296 7 O
psychiatric	304 11 O
co	316 2 O
-	318 1 O
morbidity	319 9 O
and	329 3 O
methamphetamine	333 15 B-Chemical
-	348 1 O
induced	349 7 O
psychosis	357 9 B-Disease
was	367 3 O
also	371 4 O
studied	376 7 O
.	383 1 O

METHODS	385 7 O
:	392 1 O
This	394 4 O
was	399 3 O
a	403 1 O
cross	405 5 O
-	410 1 O
sectional	411 9 O
study	421 5 O
conducted	427 9 O
concurrently	437 12 O
at	450 2 O
a	453 1 O
teaching	455 8 O
hospital	464 8 O
and	473 3 O
a	477 1 O
drug	479 4 O
rehabilitation	484 14 O
center	499 6 O
in	506 2 O
Malaysia	509 8 O
.	517 1 O

Patients	519 8 O
with	528 4 O
the	533 3 O
diagnosis	537 9 O
of	547 2 O
methamphetamine	550 15 B-Chemical
based	566 5 O
on	572 2 O
DSM	575 3 O
-	578 1 O
IV	579 2 O
were	582 4 O
interviewed	587 11 O
using	599 5 O
the	605 3 O
Mini	609 4 O
International	614 13 O
Neuropsychiatric	628 16 O
Interview	645 9 O
(	655 1 O
M	656 1 O
.	657 1 O
I	658 1 O
.	659 1 O
N	660 1 O
.	661 1 O
I	662 1 O
.	663 1 O
)	664 1 O
for	666 3 O
methamphetamine	670 15 B-Chemical
-	685 1 O
induced	686 7 O
psychosis	694 9 B-Disease
and	704 3 O
other	708 5 O
Axis	714 4 O
I	719 1 O
psychiatric	721 11 B-Disease
disorders	733 9 I-Disease
.	742 1 O

The	744 3 O
information	748 11 O
on	760 2 O
sociodemographic	763 16 O
background	780 10 O
and	791 3 O
drug	795 4 O
use	800 3 O
history	804 7 O
was	812 3 O
obtained	816 8 O
from	825 4 O
interview	830 9 O
or	840 2 O
medical	843 7 O
records	851 7 O
.	858 1 O

RESULTS	860 7 O
:	867 1 O
Of	869 2 O
292	872 3 O
subjects	876 8 O
,	884 1 O
47	886 2 O
.	888 1 O
9	889 1 O
%	890 1 O
of	892 2 O
the	895 3 O
subjects	899 8 O
had	908 3 O
a	912 1 O
past	914 4 O
history	919 7 O
of	927 2 O
psychotic	930 9 B-Disease
symptoms	940 8 I-Disease
and	949 3 O
13	953 2 O
.	955 1 O
0	956 1 O
%	957 1 O
of	959 2 O
the	962 3 O
patients	966 8 O
were	975 4 O
having	980 6 O
current	987 7 O
psychotic	995 9 B-Disease
symptoms	1005 8 I-Disease
.	1013 1 O

Co	1015 2 O
-	1017 1 O
morbid	1018 6 O
major	1025 5 O
depressive	1031 10 B-Disease
disorder	1042 8 I-Disease
(	1051 1 O
OR	1052 2 O
=	1054 1 O
7	1055 1 O
.	1056 1 O
18	1057 2 O
,	1059 1 O
95	1061 2 O
CI	1064 2 O
=	1066 1 O
2	1067 1 O
.	1068 1 O
612	1069 3 O
-	1072 1 O
19	1073 2 O
.	1075 1 O
708	1076 3 O
)	1079 1 O
,	1080 1 O
bipolar	1082 7 B-Disease
disorder	1090 8 I-Disease
(	1099 1 O
OR	1100 2 O
=	1102 1 O
13	1103 2 O
.	1105 1 O
807	1106 3 O
,	1109 1 O
95	1111 2 O
CI	1114 2 O
=	1116 1 O
5	1117 1 O
.	1118 1 O
194	1119 3 O
-	1122 1 O
36	1123 2 O
.	1125 1 O
706	1126 3 O
)	1129 1 O
,	1130 1 O
antisocial	1132 10 B-Disease
personality	1143 11 I-Disease
disorder	1155 8 I-Disease
(	1164 1 O
OR	1165 2 O
=	1167 1 O
12	1168 2 O
.	1170 1 O
619	1171 3 O
,	1174 1 O
95	1176 2 O
CI	1179 2 O
=	1181 1 O
6	1182 1 O
.	1183 1 O
702	1184 3 O
-	1187 1 O
23	1188 2 O
.	1190 1 O
759	1191 3 O
)	1194 1 O
and	1196 3 O
heavy	1200 5 O
methamphetamine	1206 15 B-Chemical
uses	1222 4 O
were	1227 4 O
significantly	1232 13 O
associated	1246 10 O
with	1257 4 O
lifetime	1262 8 O
methamphetamine	1271 15 B-Chemical
-	1286 1 O
induced	1287 7 O
psychosis	1295 9 B-Disease
after	1305 5 O
adjusted	1311 8 O
for	1320 3 O
other	1324 5 O
factors	1330 7 O
.	1337 1 O

Major	1339 5 B-Disease
depressive	1345 10 I-Disease
disorder	1356 8 I-Disease
(	1365 1 O
OR	1366 2 O
=	1368 1 O
2	1369 1 O
.	1370 1 O
870	1371 3 O
,	1374 1 O
CI	1376 2 O
=	1378 1 O
1	1379 1 O
.	1380 1 O
154	1381 3 O
-	1384 1 O
7	1385 1 O
.	1386 1 O
142	1387 3 O
)	1390 1 O
and	1392 3 O
antisocial	1396 10 B-Disease
personality	1407 11 I-Disease
disorder	1419 8 I-Disease
(	1428 1 O
OR	1429 2 O
=	1431 1 O
3	1432 1 O
.	1433 1 O
299	1434 3 O
,	1437 1 O
95	1439 2 O
CI	1442 2 O
=	1444 1 O
1	1445 1 O
.	1446 1 O
375	1447 3 O
-	1450 1 O
7	1451 1 O
.	1452 1 O
914	1453 3 O
)	1456 1 O
were	1458 4 O
the	1463 3 O
only	1467 4 O
factors	1472 7 O
associated	1480 10 O
with	1491 4 O
current	1496 7 O
psychosis	1504 9 B-Disease
.	1513 1 O

CONCLUSION	1515 10 O
:	1525 1 O
There	1527 5 O
was	1533 3 O
a	1537 1 O
high	1539 4 O
risk	1544 4 O
of	1549 2 O
psychosis	1552 9 B-Disease
in	1562 2 O
patients	1565 8 O
with	1574 4 O
methamphetamine	1579 15 B-Chemical
dependence	1595 10 O
.	1605 1 O

It	1607 2 O
was	1610 3 O
associated	1614 10 O
with	1625 4 O
co	1630 2 O
-	1632 1 O
morbid	1633 6 O
affective	1640 9 B-Disease
disorder	1650 8 I-Disease
,	1658 1 O
antisocial	1660 10 B-Disease
personality	1671 11 I-Disease
,	1682 1 O
and	1684 3 O
heavy	1688 5 O
methamphetamine	1694 15 B-Chemical
use	1710 3 O
.	1713 1 O

It	1715 2 O
is	1718 2 O
recommended	1721 11 O
that	1733 4 O
all	1738 3 O
cases	1742 5 O
of	1748 2 O
methamphetamine	1751 15 B-Chemical
dependence	1767 10 O
should	1778 6 O
be	1785 2 O
screened	1788 8 O
for	1797 3 O
psychotic	1801 9 B-Disease
symptoms	1811 8 I-Disease
.	1819 1 O

Cerebellar	0 10 O
sensory	11 7 O
processing	19 10 O
alterations	30 11 O
impact	42 6 O
motor	49 5 O
cortical	55 8 O
plasticity	64 10 O
in	75 2 O
Parkinson	78 9 B-Disease
'	87 1 I-Disease
s	88 1 I-Disease
disease	90 7 I-Disease
:	97 1 O
clues	99 5 O
from	105 4 O
dyskinetic	110 10 B-Disease
patients	121 8 O
.	129 1 O

The	131 3 O
plasticity	135 10 O
of	146 2 O
primary	149 7 O
motor	157 5 O
cortex	163 6 O
(	170 1 O
M1	171 2 O
)	173 1 O
in	175 2 O
patients	178 8 O
with	187 4 O
Parkinson	192 9 B-Disease
'	201 1 I-Disease
s	202 1 I-Disease
disease	204 7 I-Disease
(	212 1 O
PD	213 2 B-Disease
)	215 1 O
and	217 3 O
levodopa	221 8 B-Chemical
-	229 1 O
induced	230 7 O
dyskinesias	238 11 B-Disease
(	250 1 O
LIDs	251 4 B-Disease
)	255 1 O
is	257 2 O
severely	260 8 O
impaired	269 8 O
.	277 1 O

We	279 2 O
recently	282 8 O
reported	291 8 O
in	300 2 O
young	303 5 O
healthy	309 7 O
subjects	317 8 O
that	326 4 O
inhibitory	331 10 O
cerebellar	342 10 O
stimulation	353 11 O
enhanced	365 8 O
the	374 3 O
sensorimotor	378 12 O
plasticity	391 10 O
of	402 2 O
M1	405 2 O
that	408 4 O
was	413 3 O
induced	417 7 O
by	425 2 O
paired	428 6 O
associative	435 11 O
stimulation	447 11 O
(	459 1 O
PAS	460 3 O
)	463 1 O
.	464 1 O

This	466 4 O
study	471 5 O
demonstrates	477 12 O
that	490 4 O
the	495 3 O
deficient	499 9 O
sensorimotor	509 12 O
M1	522 2 O
plasticity	525 10 O
in	536 2 O
16	539 2 O
patients	542 8 O
with	551 4 O
LIDs	556 4 B-Disease
could	561 5 O
be	567 2 O
reinstated	570 10 O
by	581 2 O
a	584 1 O
single	586 6 O
session	593 7 O
of	601 2 O
real	604 4 O
inhibitory	609 10 O
cerebellar	620 10 O
stimulation	631 11 O
but	643 3 O
not	647 3 O
sham	651 4 O
stimulation	656 11 O
.	667 1 O

This	669 4 O
was	674 3 O
evident	678 7 O
only	686 4 O
when	691 4 O
a	696 1 O
sensory	698 7 O
component	706 9 O
was	716 3 O
involved	720 8 O
in	729 2 O
the	732 3 O
induction	736 9 O
of	746 2 O
plasticity	749 10 O
,	759 1 O
indicating	761 10 O
that	772 4 O
cerebellar	777 10 O
sensory	788 7 O
processing	796 10 O
function	807 8 O
is	816 2 O
involved	819 8 O
in	828 2 O
the	831 3 O
resurgence	835 10 O
of	846 2 O
M1	849 2 O
plasticity	852 10 O
.	862 1 O

The	864 3 O
benefit	868 7 O
of	876 2 O
inhibitory	879 10 O
cerebellar	890 10 O
stimulation	901 11 O
on	913 2 O
LIDs	916 4 B-Disease
is	921 2 O
known	924 5 O
.	929 1 O

To	931 2 O
explore	934 7 O
whether	942 7 O
this	950 4 O
benefit	955 7 O
is	963 2 O
linked	966 6 O
to	973 2 O
the	976 3 O
restoration	980 11 O
of	992 2 O
sensorimotor	995 12 O
plasticity	1008 10 O
of	1019 2 O
M1	1022 2 O
,	1024 1 O
we	1026 2 O
conducted	1029 9 O
an	1039 2 O
additional	1042 10 O
study	1053 5 O
looking	1059 7 O
at	1067 2 O
changes	1070 7 O
in	1078 2 O
LIDs	1081 4 B-Disease
and	1086 3 O
PAS	1090 3 O
-	1093 1 O
induced	1094 7 O
plasticity	1102 10 O
after	1113 5 O
10	1119 2 O
sessions	1122 8 O
of	1131 2 O
either	1134 6 O
bilateral	1141 9 O
,	1150 1 O
real	1152 4 O
inhibitory	1157 10 O
cerebellar	1168 10 O
stimulation	1179 11 O
or	1191 2 O
sham	1194 4 O
stimulation	1199 11 O
.	1210 1 O

Only	1212 4 O
real	1217 4 O
and	1222 3 O
not	1226 3 O
sham	1230 4 O
stimulation	1235 11 O
had	1247 3 O
an	1251 2 O
antidyskinetic	1254 14 O
effect	1269 6 O
and	1276 3 O
it	1280 2 O
was	1283 3 O
paralleled	1287 10 O
by	1298 2 O
a	1301 1 O
resurgence	1303 10 O
in	1314 2 O
the	1317 3 O
sensorimotor	1321 12 O
plasticity	1334 10 O
of	1345 2 O
M1	1348 2 O
.	1350 1 O

These	1352 5 O
results	1358 7 O
suggest	1366 7 O
that	1374 4 O
alterations	1379 11 O
in	1391 2 O
cerebellar	1394 10 O
sensory	1405 7 O
processing	1413 10 O
function	1424 8 O
,	1432 1 O
occurring	1434 9 O
secondary	1444 9 O
to	1454 2 O
abnormal	1457 8 O
basal	1466 5 O
ganglia	1472 7 O
signals	1480 7 O
reaching	1488 8 O
it	1497 2 O
,	1499 1 O
may	1501 3 O
be	1505 2 O
an	1508 2 O
important	1511 9 O
element	1521 7 O
contributing	1529 12 O
to	1542 2 O
the	1545 3 O
maladaptive	1549 11 O
sensorimotor	1561 12 O
plasticity	1574 10 O
of	1585 2 O
M1	1588 2 O
and	1591 3 O
the	1595 3 O
emergence	1599 9 O
of	1609 2 O
abnormal	1612 8 B-Disease
involuntary	1621 11 I-Disease
movements	1633 9 I-Disease
.	1642 1 O

The	0 3 O
function	4 8 O
of	13 2 O
P2X3	16 4 O
receptor	21 8 O
and	30 3 O
NK1	34 3 O
receptor	38 8 O
antagonists	47 11 O
on	59 2 O
cyclophosphamide	62 16 B-Chemical
-	78 1 O
induced	79 7 O
cystitis	87 8 B-Disease
in	96 2 O
rats	99 4 O
.	103 1 O

PURPOSE	105 7 O
:	112 1 O
The	114 3 O
purpose	118 7 O
of	126 2 O
the	129 3 O
study	133 5 O
is	139 2 O
to	142 2 O
explore	145 7 O
the	153 3 O
function	157 8 O
of	166 2 O
P2X3	169 4 O
and	174 3 O
NK1	178 3 O
receptors	182 9 O
antagonists	192 11 O
on	204 2 O
cyclophosphamide	207 16 B-Chemical
(	224 1 O
CYP	225 3 B-Chemical
)	228 1 O
-	229 1 O
induced	230 7 O
cystitis	238 8 B-Disease
in	247 2 O
rats	250 4 O
.	254 1 O

METHODS	256 7 O
:	263 1 O
Sixty	265 5 O
female	271 6 O
Sprague	278 7 O
-	285 1 O
Dawley	286 6 O
(	293 1 O
SD	294 2 O
)	296 1 O
rats	298 4 O
were	303 4 O
randomly	308 8 O
divided	317 7 O
into	325 4 O
three	330 5 O
groups	336 6 O
.	342 1 O

The	344 3 O
rats	348 4 O
in	353 2 O
the	356 3 O
control	360 7 O
group	368 5 O
were	374 4 O
intraperitoneally	379 17 O
(	397 1 O
i	398 1 O
.	399 1 O
p	400 1 O
.	401 1 O
)	402 1 O
injected	404 8 O
with	413 4 O
0	418 1 O
.	419 1 O
9	420 1 O
%	421 1 O
saline	423 6 O
(	430 1 O
4	431 1 O
ml	433 2 O
/	435 1 O
kg	436 2 O
)	438 1 O
;	439 1 O
the	441 3 O
rats	445 4 O
in	450 2 O
the	453 3 O
model	457 5 O
group	463 5 O
were	469 4 O
i	474 1 O
.	475 1 O
p	476 1 O
.	477 1 O
injected	479 8 O
with	488 4 O
CYP	493 3 B-Chemical
(	497 1 O
150	498 3 O
mg	502 2 O
/	504 1 O
kg	505 2 O
)	507 1 O
;	508 1 O
and	510 3 O
the	514 3 O
rats	518 4 O
in	523 2 O
the	526 3 O
intervention	530 12 O
group	543 5 O
were	549 4 O
i	554 1 O
.	555 1 O
p	556 1 O
.	557 1 O
injected	559 8 O
with	568 4 O
CYP	573 3 B-Chemical
with	577 4 O
subsequently	582 12 O
perfusion	595 9 O
of	605 2 O
bladder	608 7 O
with	616 4 O
P2X3	621 4 O
and	626 3 O
NK1	630 3 O
receptors	634 9 O
'	643 1 O
antagonists	645 11 O
,	656 1 O
Suramin	658 7 B-Chemical
and	666 3 O
GR	670 2 B-Chemical
82334	673 5 I-Chemical
.	678 1 O

Spontaneous	680 11 O
pain	692 4 B-Disease
behaviors	697 9 O
following	707 9 O
the	717 3 O
administration	721 14 O
of	736 2 O
CYP	739 3 B-Chemical
were	743 4 O
observed	748 8 O
.	756 1 O

Urodynamic	758 10 O
parameters	769 10 O
,	779 1 O
bladder	781 7 O
pressure	789 8 O
-	797 1 O
volume	798 6 O
curve	805 5 O
,	810 1 O
maximum	812 7 O
voiding	820 7 O
pressure	828 8 O
(	837 1 O
MVP	838 3 O
)	841 1 O
,	842 1 O
and	844 3 O
maximum	848 7 O
cystometric	856 11 O
capacity	868 8 O
(	877 1 O
MCC	878 3 O
)	881 1 O
,	882 1 O
were	884 4 O
recorded	889 8 O
.	897 1 O

Pathological	899 12 O
changes	912 7 O
in	920 2 O
bladder	923 7 O
tissue	931 6 O
were	938 4 O
observed	943 8 O
.	951 1 O

Immunofluorescence	953 18 O
was	972 3 O
used	976 4 O
to	981 2 O
detect	984 6 O
the	991 3 O
expression	995 10 O
of	1006 2 O
P2X3	1009 4 O
and	1014 3 O
NK1	1018 3 O
receptors	1022 9 O
in	1032 2 O
bladder	1035 7 O
.	1042 1 O

RESULTS	1044 7 O
:	1051 1 O
Cyclophosphamide	1053 16 B-Chemical
treatment	1070 9 O
increased	1080 9 O
the	1090 3 O
spontaneous	1094 11 O
pain	1106 4 B-Disease
behaviors	1111 9 O
scores	1121 6 O
.	1127 1 O

The	1129 3 O
incidence	1133 9 O
of	1143 2 O
bladder	1146 7 O
instability	1154 11 O
during	1166 6 O
urine	1173 5 O
storage	1179 7 O
period	1187 6 O
of	1194 2 O
model	1197 5 O
group	1203 5 O
was	1209 3 O
significantly	1213 13 O
higher	1227 6 O
than	1234 4 O
intervention	1239 12 O
group	1252 5 O
(	1258 1 O
X	1259 1 O
(	1260 1 O
2	1261 1 O
)	1262 1 O
=	1264 1 O
7	1266 1 O
.	1267 1 O
619	1268 3 O
,	1271 1 O
P	1273 1 O
=	1275 1 O
0	1277 1 O
.	1278 1 O
007	1279 3 O
)	1282 1 O
and	1284 3 O
control	1288 7 O
group	1296 5 O
(	1302 1 O
X	1303 1 O
(	1304 1 O
2	1305 1 O
)	1306 1 O
=	1308 1 O
13	1310 2 O
.	1312 1 O
755	1313 3 O
,	1316 1 O
P	1318 1 O
=	1320 1 O
0	1322 1 O
.	1323 1 O
000	1324 3 O
)	1327 1 O
.	1328 1 O

MCC	1330 3 O
in	1334 2 O
the	1337 3 O
model	1341 5 O
group	1347 5 O
was	1353 3 O
lower	1357 5 O
than	1363 4 O
the	1368 3 O
control	1372 7 O
and	1380 3 O
intervention	1384 12 O
groups	1397 6 O
(	1404 1 O
P	1405 1 O
<	1407 1 O
0	1409 1 O
.	1410 1 O
01	1411 2 O
)	1413 1 O
.	1414 1 O

Histological	1416 12 O
changes	1429 7 O
evident	1437 7 O
in	1445 2 O
model	1448 5 O
and	1454 3 O
intervention	1458 12 O
groups	1471 6 O
rats	1478 4 O
'	1482 1 O
bladder	1484 7 O
included	1492 8 O
edema	1501 5 B-Disease
,	1506 1 O
vasodilation	1508 12 O
,	1520 1 O
and	1522 3 O
infiltration	1526 12 O
of	1539 2 O
inflammatory	1542 12 O
cells	1555 5 O
.	1560 1 O

In	1562 2 O
model	1565 5 O
group	1571 5 O
,	1576 1 O
the	1578 3 O
expression	1582 10 O
of	1593 2 O
P2X3	1596 4 O
receptor	1601 8 O
increased	1610 9 O
in	1620 2 O
urothelium	1623 10 O
and	1634 3 O
suburothelium	1638 13 O
,	1651 1 O
and	1653 3 O
NK1	1657 3 O
receptor	1661 8 O
increased	1670 9 O
in	1680 2 O
suburothelium	1683 13 O
,	1696 1 O
while	1698 5 O
the	1704 3 O
expression	1708 10 O
of	1719 2 O
them	1722 4 O
in	1727 2 O
intervention	1730 12 O
group	1743 5 O
was	1749 3 O
lower	1753 5 O
.	1758 1 O

CONCLUSIONS	1760 11 O
:	1771 1 O
In	1773 2 O
CYP	1776 3 B-Chemical
-	1779 1 O
induced	1780 7 O
cystitis	1788 8 B-Disease
,	1796 1 O
the	1798 3 O
expression	1802 10 O
of	1813 2 O
P2X3	1816 4 O
and	1821 3 O
NK1	1825 3 O
receptors	1829 9 O
increased	1839 9 O
in	1849 2 O
urothelium	1852 10 O
and	1863 3 O
/	1866 1 O
or	1867 2 O
suburothelium	1870 13 O
.	1883 1 O

Perfusion	1885 9 O
of	1895 2 O
bladder	1898 7 O
with	1906 4 O
P2X3	1911 4 O
and	1916 3 O
NK1	1920 3 O
receptors	1924 9 O
antagonists	1934 11 O
ameliorated	1946 11 O
the	1958 3 O
bladder	1962 7 O
function	1970 8 O
.	1978 1 O

Acute	0 5 O
hepatitis	6 9 B-Disease
associated	16 10 O
with	27 4 O
clopidogrel	32 11 B-Chemical
:	43 1 O
a	45 1 O
case	47 4 O
report	52 6 O
and	59 3 O
review	63 6 O
of	70 2 O
the	73 3 O
literature	77 10 O
.	87 1 O

Drug	89 4 O
-	93 1 O
induced	94 7 O
hepatotoxicity	102 14 B-Disease
is	117 2 O
a	120 1 O
common	122 6 O
cause	129 5 O
of	135 2 O
acute	138 5 O
hepatitis	144 9 B-Disease
,	153 1 O
and	155 3 O
the	159 3 O
recognition	163 11 O
of	175 2 O
the	178 3 O
responsible	182 11 O
drug	194 4 O
may	199 3 O
be	203 2 O
difficult	206 9 O
.	215 1 O

We	217 2 O
describe	220 8 O
a	229 1 O
case	231 4 O
of	236 2 O
clopidogrel	239 11 B-Chemical
-	250 1 O
related	251 7 O
acute	259 5 O
hepatitis	265 9 B-Disease
.	274 1 O

The	276 3 O
diagnosis	280 9 O
is	290 2 O
strongly	293 8 O
suggested	302 9 O
by	312 2 O
an	315 2 O
accurate	318 8 O
medical	327 7 O
history	335 7 O
and	343 3 O
liver	347 5 O
biopsy	353 6 O
.	359 1 O

Reports	361 7 O
about	369 5 O
cases	375 5 O
of	381 2 O
hepatotoxicity	384 14 B-Disease
due	399 3 O
to	403 2 O
clopidogrel	406 11 B-Chemical
are	418 3 O
increasing	422 10 O
in	433 2 O
the	436 3 O
last	440 4 O
few	445 3 O
years	449 5 O
,	454 1 O
after	456 5 O
the	462 3 O
increased	466 9 O
use	476 3 O
of	480 2 O
this	483 4 O
drug	488 4 O
.	492 1 O

In	494 2 O
conclusion	497 10 O
,	507 1 O
we	509 2 O
believe	512 7 O
that	520 4 O
physicians	525 10 O
should	536 6 O
carefully	543 9 O
consider	553 8 O
the	562 3 O
risk	566 4 O
of	571 2 O
drug	574 4 O
-	578 1 O
induced	579 7 O
hepatic	587 7 B-Disease
injury	595 6 I-Disease
when	602 4 O
clopidogrel	607 11 B-Chemical
is	619 2 O
prescribed	622 10 O
.	632 1 O

Bortezomib	0 10 B-Chemical
and	11 3 O
dexamethasone	15 13 B-Chemical
as	29 2 O
salvage	32 7 O
therapy	40 7 O
in	48 2 O
patients	51 8 O
with	60 4 O
relapsed	65 8 O
/	73 1 O
refractory	74 10 O
multiple	85 8 B-Disease
myeloma	94 7 I-Disease
:	101 1 O
analysis	103 8 O
of	112 2 O
long	115 4 O
-	119 1 O
term	120 4 O
clinical	125 8 O
outcomes	134 8 O
.	142 1 O

Bortezomib	144 10 B-Chemical
(	155 1 O
bort	156 4 B-Chemical
)	160 1 O
-	161 1 O
dexamethasone	162 13 B-Chemical
(	176 1 O
dex	177 3 B-Chemical
)	180 1 O
is	182 2 O
an	185 2 O
effective	188 9 O
therapy	198 7 O
for	206 3 O
relapsed	210 8 O
/	218 1 O
refractory	219 10 O
(	230 1 O
R	231 1 O
/	232 1 O
R	233 1 O
)	234 1 O
multiple	236 8 B-Disease
myeloma	245 7 I-Disease
(	253 1 O
MM	254 2 B-Disease
)	256 1 O
.	257 1 O

This	259 4 O
retrospective	264 13 O
study	278 5 O
investigated	284 12 O
the	297 3 O
combination	301 11 O
of	313 2 O
bort	316 4 B-Chemical
(	321 1 O
1	322 1 O
.	323 1 O
3	324 1 O
mg	326 2 O
/	328 1 O
m	329 1 O
(	330 1 O
2	331 1 O
)	332 1 O
on	334 2 O
days	337 4 O
1	342 1 O
,	343 1 O
4	345 1 O
,	346 1 O
8	348 1 O
,	349 1 O
and	351 3 O
11	355 2 O
every	358 5 O
3	364 1 O
weeks	366 5 O
)	371 1 O
and	373 3 O
dex	377 3 B-Chemical
(	381 1 O
20	382 2 O
mg	385 2 O
on	388 2 O
the	391 3 O
day	395 3 O
of	399 2 O
and	402 3 O
the	406 3 O
day	410 3 O
after	414 5 O
bort	420 4 B-Chemical
)	424 1 O
as	426 2 O
salvage	429 7 O
treatment	437 9 O
in	447 2 O
85	450 2 O
patients	453 8 O
with	462 4 O
R	467 1 O
/	468 1 O
R	469 1 O
MM	471 2 B-Disease
after	474 5 O
prior	480 5 O
autologous	486 10 O
stem	497 4 O
cell	502 4 O
transplantation	507 15 O
or	523 2 O
conventional	526 12 O
chemotherapy	539 12 O
.	551 1 O

The	553 3 O
median	557 6 O
number	564 6 O
of	571 2 O
prior	574 5 O
lines	580 5 O
of	586 2 O
therapy	589 7 O
was	597 3 O
2	601 1 O
.	602 1 O

Eighty	604 6 O
-	610 1 O
seven	611 5 O
percent	617 7 O
of	625 2 O
the	628 3 O
patients	632 8 O
had	641 3 O
received	645 8 O
immunomodulatory	654 16 O
drugs	671 5 O
included	677 8 O
in	686 2 O
some	689 4 O
line	694 4 O
of	699 2 O
therapy	702 7 O
before	710 6 O
bort	717 4 B-Chemical
-	721 1 O
dex	722 3 B-Chemical
.	725 1 O

The	727 3 O
median	731 6 O
number	738 6 O
of	745 2 O
bort	748 4 B-Chemical
-	752 1 O
dex	753 3 B-Chemical
cycles	757 6 O
was	764 3 O
6	768 1 O
,	769 1 O
up	771 2 O
to	774 2 O
a	777 1 O
maximum	779 7 O
of	787 2 O
12	790 2 O
cycles	793 6 O
.	799 1 O

On	801 2 O
an	804 2 O
intention	807 9 O
-	816 1 O
to	817 2 O
-	819 1 O
treat	820 5 O
basis	826 5 O
,	831 1 O
55	833 2 O
%	836 1 O
of	838 2 O
the	841 3 O
patients	845 8 O
achieved	854 8 O
at	863 2 O
least	866 5 O
partial	872 7 O
response	880 8 O
,	888 1 O
including	890 9 O
19	900 2 O
%	903 1 O
CR	905 2 O
and	908 3 O
35	912 2 O
%	915 1 O
achieved	917 8 O
at	926 2 O
least	929 5 O
very	935 4 O
good	940 4 O
partial	945 7 O
response	953 8 O
.	961 1 O

Median	963 6 O
durations	970 9 O
of	980 2 O
response	983 8 O
,	991 1 O
time	993 4 O
to	998 2 O
next	1001 4 O
therapy	1006 7 O
and	1014 3 O
treatment	1018 9 O
-	1027 1 O
free	1028 4 O
interval	1033 8 O
were	1042 4 O
8	1047 1 O
,	1048 1 O
11	1050 2 O
.	1052 1 O
2	1053 1 O
,	1054 1 O
and	1056 3 O
5	1060 1 O
.	1061 1 O
1	1062 1 O
months	1064 6 O
,	1070 1 O
respectively	1072 12 O
.	1084 1 O

The	1086 3 O
most	1090 4 O
relevant	1095 8 O
adverse	1104 7 O
event	1112 5 O
was	1118 3 O
peripheral	1122 10 B-Disease
neuropathy	1133 10 I-Disease
,	1143 1 O
which	1145 5 O
occurred	1151 8 O
in	1160 2 O
78	1163 2 O
%	1166 1 O
of	1168 2 O
the	1171 3 O
patients	1175 8 O
(	1184 1 O
grade	1185 5 O
II	1191 2 O
,	1193 1 O
38	1195 2 O
%	1198 1 O
;	1199 1 O
grade	1201 5 O
III	1207 3 O
,	1210 1 O
21	1212 2 O
%	1215 1 O
)	1216 1 O
and	1218 3 O
led	1222 3 O
to	1226 2 O
treatment	1229 9 O
discontinuation	1239 15 O
in	1255 2 O
6	1258 1 O
%	1260 1 O
.	1261 1 O

With	1263 4 O
a	1268 1 O
median	1270 6 O
follow	1277 6 O
up	1284 2 O
of	1287 2 O
22	1290 2 O
months	1293 6 O
,	1299 1 O
median	1301 6 O
time	1308 4 O
to	1313 2 O
progression	1316 11 O
,	1327 1 O
progression	1329 11 O
-	1340 1 O
free	1341 4 O
survival	1346 8 O
(	1355 1 O
PFS	1356 3 O
)	1359 1 O
and	1361 3 O
overall	1365 7 O
survival	1373 8 O
(	1382 1 O
OS	1383 2 O
)	1385 1 O
were	1387 4 O
8	1392 1 O
.	1393 1 O
9	1394 1 O
,	1395 1 O
8	1397 1 O
.	1398 1 O
7	1399 1 O
,	1400 1 O
and	1402 3 O
22	1406 2 O
months	1409 6 O
,	1415 1 O
respectively	1417 12 O
.	1429 1 O

Prolonged	1431 9 O
PFS	1441 3 O
and	1445 3 O
OS	1449 2 O
were	1452 4 O
observed	1457 8 O
in	1466 2 O
patients	1469 8 O
achieving	1478 9 O
CR	1488 2 O
and	1491 3 O
receiving	1495 9 O
bort	1505 4 B-Chemical
-	1509 1 O
dex	1510 3 B-Chemical
a	1514 1 O
single	1516 6 O
line	1523 4 O
of	1528 2 O
prior	1531 5 O
therapy	1537 7 O
.	1544 1 O

Bort	1546 4 B-Chemical
-	1550 1 O
dex	1551 3 B-Chemical
was	1555 3 O
an	1559 2 O
effective	1562 9 O
salvage	1572 7 O
treatment	1580 9 O
for	1590 3 O
MM	1594 2 B-Disease
patients	1597 8 O
,	1605 1 O
particularly	1607 12 O
for	1620 3 O
those	1624 5 O
in	1630 2 O
first	1633 5 O
relapse	1639 7 O
.	1646 1 O

Pubertal	0 8 O
exposure	9 8 O
to	18 2 O
Bisphenol	21 9 B-Chemical
A	31 1 I-Chemical
increases	33 9 O
anxiety	43 7 B-Disease
-	50 1 O
like	51 4 O
behavior	56 8 O
and	65 3 O
decreases	69 9 O
acetylcholinesterase	79 20 O
activity	100 8 O
of	109 2 O
hippocampus	112 11 O
in	124 2 O
adult	127 5 O
male	133 4 O
mice	138 4 O
.	142 1 O

The	144 3 O
negative	148 8 O
effects	157 7 O
of	165 2 O
Bisphenol	168 9 B-Chemical
A	178 1 I-Chemical
(	180 1 O
BPA	181 3 B-Chemical
)	184 1 O
on	186 2 O
neurodevelopment	189 16 O
and	206 3 O
behaviors	210 9 O
have	220 4 O
been	225 4 O
well	230 4 O
established	235 11 O
.	246 1 O

Acetylcholinesterase	248 20 O
(	269 1 O
AChE	270 4 O
)	274 1 O
is	276 2 O
a	279 1 O
regulatory	281 10 O
enzyme	292 6 O
which	299 5 O
is	305 2 O
involved	308 8 O
in	317 2 O
anxiety	320 7 B-Disease
-	327 1 O
like	328 4 O
behavior	333 8 O
.	341 1 O

This	343 4 O
study	348 5 O
investigated	354 12 O
behavioral	367 10 O
phenotypes	378 10 O
and	389 3 O
AChE	393 4 O
activity	398 8 O
in	407 2 O
male	410 4 O
mice	415 4 O
following	420 9 O
BPA	430 3 B-Chemical
exposure	434 8 O
during	443 6 O
puberty	450 7 O
.	457 1 O

On	459 2 O
postnatal	462 9 O
day	472 3 O
(	476 1 O
PND	477 3 O
)	480 1 O
35	482 2 O
,	484 1 O
male	486 4 O
mice	491 4 O
were	496 4 O
exposed	501 7 O
to	509 2 O
50mg	512 4 O
BPA	517 3 B-Chemical
/	520 1 O
kg	521 2 O
diet	524 4 O
per	529 3 O
day	533 3 O
for	537 3 O
a	541 1 O
period	543 6 O
of	550 2 O
35	553 2 O
days	556 4 O
.	560 1 O

On	562 2 O
PND71	565 5 O
,	570 1 O
a	572 1 O
behavioral	574 10 O
assay	585 5 O
was	591 3 O
performed	595 9 O
using	605 5 O
the	611 3 O
elevated	615 8 O
plus	624 4 O
maze	629 4 O
(	634 1 O
EPM	635 3 O
)	638 1 O
and	640 3 O
the	644 3 O
light	648 5 O
/	653 1 O
dark	654 4 O
test	659 4 O
.	663 1 O

In	665 2 O
addition	668 8 O
,	676 1 O
AChE	678 4 O
activity	683 8 O
was	692 3 O
measured	696 8 O
in	705 2 O
the	708 3 O
prefrontal	712 10 O
cortex	723 6 O
,	729 1 O
hypothalamus	731 12 O
,	743 1 O
cerebellum	745 10 O
and	756 3 O
hippocampus	760 11 O
.	771 1 O

Results	773 7 O
from	781 4 O
our	786 3 O
behavioral	790 10 O
phenotyping	801 11 O
indicated	813 9 O
that	823 4 O
anxiety	828 7 B-Disease
-	835 1 O
like	836 4 O
behavior	841 8 O
was	850 3 O
increased	854 9 O
in	864 2 O
mice	867 4 O
exposed	872 7 O
to	880 2 O
BPA	883 3 B-Chemical
.	886 1 O

AChE	888 4 O
activity	893 8 O
was	902 3 O
significantly	906 13 O
decreased	920 9 O
in	930 2 O
the	933 3 O
hippocampus	937 11 O
of	949 2 O
mice	952 4 O
with	957 4 O
BPA	962 3 B-Chemical
compared	966 8 O
to	975 2 O
control	978 7 O
mice	986 4 O
,	990 1 O
whereas	992 7 O
no	1000 2 O
difference	1003 10 O
was	1014 3 O
found	1018 5 O
in	1024 2 O
the	1027 3 O
prefrontal	1031 10 O
cortex	1042 6 O
,	1048 1 O
hypothalamus	1050 12 O
and	1063 3 O
cerebellum	1067 10 O
.	1077 1 O

Our	1079 3 O
findings	1083 8 O
showed	1092 6 O
that	1099 4 O
pubertal	1104 8 O
BPA	1113 3 B-Chemical
exposure	1117 8 O
increased	1126 9 O
anxiety	1136 7 B-Disease
-	1143 1 O
like	1144 4 O
behavior	1149 8 O
,	1157 1 O
which	1159 5 O
may	1165 3 O
be	1169 2 O
associated	1172 10 O
with	1183 4 O
decreased	1188 9 O
AChE	1198 4 O
activity	1203 8 O
of	1212 2 O
the	1215 3 O
hippocampus	1219 11 O
in	1231 2 O
adult	1234 5 O
male	1240 4 O
mice	1245 4 O
.	1249 1 O

Further	1251 7 O
studies	1259 7 O
are	1267 3 O
necessary	1271 9 O
to	1281 2 O
investigate	1284 11 O
the	1296 3 O
cholinergic	1300 11 O
signaling	1312 9 O
of	1322 2 O
the	1325 3 O
hippocampus	1329 11 O
in	1341 2 O
PBE	1344 3 O
induced	1348 7 O
anxiety	1356 7 B-Disease
-	1363 1 O
like	1364 4 O
behaviors	1369 9 O
.	1378 1 O

Biochemical	0 11 O
effects	12 7 O
of	20 2 O
Solidago	23 8 O
virgaurea	32 9 O
extract	42 7 O
on	50 2 O
experimental	53 12 O
cardiotoxicity	66 14 B-Disease
.	80 1 O

Cardiovascular	82 14 B-Disease
diseases	97 8 I-Disease
(	106 1 O
CVDs	107 4 B-Disease
)	111 1 O
are	113 3 O
the	117 3 O
major	121 5 O
health	127 6 O
problem	134 7 O
of	142 2 O
advanced	145 8 O
as	154 2 O
well	157 4 O
as	162 2 O
developing	165 10 O
countries	176 9 O
of	186 2 O
the	189 3 O
world	193 5 O
.	198 1 O

The	200 3 O
aim	204 3 O
of	208 2 O
the	211 3 O
present	215 7 O
study	223 5 O
was	229 3 O
to	233 2 O
investigate	236 11 O
the	248 3 O
protective	252 10 O
effect	263 6 O
of	270 2 O
the	273 3 O
Solidago	277 8 O
virgaurea	286 9 O
extract	296 7 O
on	304 2 O
isoproterenol	307 13 B-Chemical
-	320 1 O
induced	321 7 O
cardiotoxicity	329 14 B-Disease
in	344 2 O
rats	347 4 O
.	351 1 O

The	353 3 O
subcutaneous	357 12 O
injection	370 9 O
of	380 2 O
isoproterenol	383 13 B-Chemical
(	397 1 O
30	398 2 O
mg	401 2 O
/	403 1 O
kg	404 2 O
)	406 1 O
into	408 4 O
rats	413 4 O
twice	418 5 O
at	424 2 O
an	427 2 O
interval	430 8 O
of	439 2 O
24	442 2 O
h	445 1 O
,	446 1 O
for	448 3 O
two	452 3 O
consecutive	456 11 O
days	468 4 O
,	472 1 O
led	474 3 O
to	478 2 O
a	481 1 O
significant	483 11 O
increase	495 8 O
in	504 2 O
serum	507 5 O
lactate	513 7 B-Chemical
dehydrogenase	521 13 O
,	534 1 O
creatine	536 8 B-Chemical
phosphokinase	545 13 O
,	558 1 O
alanine	560 7 B-Chemical
transaminase	568 12 O
,	580 1 O
aspartate	582 9 B-Chemical
transaminase	592 12 O
,	604 1 O
and	606 3 O
angiotensin	610 11 B-Chemical
-	621 1 O
converting	622 10 O
enzyme	633 6 O
activities	640 10 O
,	650 1 O
total	652 5 O
cholesterol	658 11 B-Chemical
,	669 1 O
triglycerides	671 13 B-Chemical
,	684 1 O
free	686 4 O
serum	691 5 O
fatty	697 5 B-Chemical
acid	703 4 I-Chemical
,	707 1 O
cardiac	709 7 O
tissue	717 6 O
malondialdehyde	724 15 B-Chemical
(	740 1 O
MDA	741 3 B-Chemical
)	744 1 O
,	745 1 O
and	747 3 O
nitric	751 6 B-Chemical
oxide	758 5 I-Chemical
levels	764 6 O
and	771 3 O
a	775 1 O
significant	777 11 O
decrease	789 8 O
in	798 2 O
levels	801 6 O
of	808 2 O
glutathione	811 11 B-Chemical
and	823 3 O
superoxide	827 10 B-Chemical
dismutase	838 9 O
in	848 2 O
cardiac	851 7 O
tissue	859 6 O
as	866 2 O
compared	869 8 O
to	878 2 O
the	881 3 O
normal	885 6 O
control	892 7 O
group	900 5 O
(	906 1 O
P	907 1 O
<	909 1 O
0	911 1 O
.	912 1 O
05	913 2 O
)	915 1 O
.	916 1 O

Pretreatment	918 12 O
with	931 4 O
S	936 1 O
.	937 1 O
virgaurea	939 9 O
extract	949 7 O
for	957 3 O
5	961 1 O
weeks	963 5 O
at	969 2 O
a	972 1 O
dose	974 4 O
of	979 2 O
250	982 3 O
mg	986 2 O
/	988 1 O
kg	989 2 O
followed	992 8 O
by	1001 2 O
isoproterenol	1004 13 B-Chemical
injection	1018 9 O
significantly	1028 13 O
prevented	1042 9 O
the	1052 3 O
observed	1056 8 O
alterations	1065 11 O
.	1076 1 O

Captopril	1078 9 B-Chemical
(	1088 1 O
50	1089 2 O
mg	1092 2 O
/	1094 1 O
kg	1095 2 O
/	1097 1 O
day	1098 3 O
,	1101 1 O
given	1103 5 O
orally	1109 6 O
)	1115 1 O
,	1116 1 O
an	1118 2 O
inhibitor	1121 9 O
of	1131 2 O
angiotensin	1134 11 B-Chemical
-	1145 1 O
converting	1146 10 O
enzyme	1157 6 O
used	1164 4 O
as	1169 2 O
a	1172 1 O
standard	1174 8 O
cardioprotective	1183 16 O
drug	1200 4 O
,	1204 1 O
was	1206 3 O
used	1210 4 O
as	1215 2 O
a	1218 1 O
positive	1220 8 O
control	1229 7 O
in	1237 2 O
this	1240 4 O
study	1245 5 O
.	1250 1 O

The	1252 3 O
data	1256 4 O
of	1261 2 O
the	1264 3 O
present	1268 7 O
study	1276 5 O
suggest	1282 7 O
that	1290 4 O
S	1295 1 O
.	1296 1 O
virgaurea	1298 9 O
extract	1308 7 O
exerts	1316 6 O
its	1323 3 O
protective	1327 10 O
effect	1338 6 O
by	1345 2 O
decreasing	1348 10 O
MDA	1359 3 B-Chemical
level	1363 5 O
and	1369 3 O
increasing	1373 10 O
the	1384 3 O
antioxidant	1388 11 O
status	1400 6 O
in	1407 2 O
isoproterenol	1410 13 B-Chemical
-	1423 1 O
treated	1424 7 O
rats	1432 4 O
.	1436 1 O

The	1438 3 O
study	1442 5 O
emphasizes	1448 10 O
the	1459 3 O
beneficial	1463 10 O
action	1474 6 O
of	1481 2 O
S	1484 1 O
.	1485 1 O
virgaurea	1487 9 O
extract	1497 7 O
as	1505 2 O
a	1508 1 O
cardioprotective	1510 16 O
agent	1527 5 O
.	1532 1 O

"	0 1 O
Real	1 4 O
-	5 1 O
world	6 5 O
"	11 1 O
data	13 4 O
on	18 2 O
the	21 3 O
efficacy	25 8 O
and	34 3 O
safety	38 6 O
of	45 2 O
lenalidomide	48 12 B-Chemical
and	61 3 O
dexamethasone	65 13 B-Chemical
in	79 2 O
patients	82 8 O
with	91 4 O
relapsed	96 8 O
/	104 1 O
refractory	105 10 O
multiple	116 8 B-Disease
myeloma	125 7 I-Disease
who	133 3 O
were	137 4 O
treated	142 7 O
according	150 9 O
to	160 2 O
the	163 3 O
standard	167 8 O
clinical	176 8 O
practice	185 8 O
:	193 1 O
a	195 1 O
study	197 5 O
of	203 2 O
the	206 3 O
Greek	210 5 O
Myeloma	216 7 B-Disease
Study	224 5 O
Group	230 5 O
.	235 1 O

Lenalidomide	237 12 B-Chemical
and	250 3 O
dexamethasone	254 13 B-Chemical
(	268 1 O
RD	269 2 B-Chemical
)	271 1 O
is	273 2 O
a	276 1 O
standard	278 8 O
of	287 2 O
care	290 4 O
for	295 3 O
relapsed	299 8 O
/	307 1 O
refractory	308 10 O
multiple	319 8 B-Disease
myeloma	328 7 I-Disease
(	336 1 O
RRMM	337 4 B-Disease
)	341 1 O
,	342 1 O
but	344 3 O
there	348 5 O
is	354 2 O
limited	357 7 O
published	365 9 O
data	375 4 O
on	380 2 O
its	383 3 O
efficacy	387 8 O
and	396 3 O
safety	400 6 O
in	407 2 O
the	410 3 O
"	414 1 O
real	415 4 O
world	420 5 O
"	425 1 O
(	427 1 O
RW	428 2 O
)	430 1 O
,	431 1 O
according	433 9 O
to	443 2 O
the	446 3 O
International	450 13 O
Society	464 7 O
of	472 2 O
Pharmacoeconomics	475 17 O
and	493 3 O
Outcomes	497 8 O
Research	506 8 O
definition	515 10 O
.	525 1 O

We	527 2 O
studied	530 7 O
212	538 3 O
RRMM	542 4 B-Disease
patients	547 8 O
who	556 3 O
received	560 8 O
RD	569 2 B-Chemical
in	572 2 O
RW	575 2 O
.	577 1 O

Objective	579 9 O
response	589 8 O
(	598 1 O
>	599 1 O
PR	600 2 O
(	603 1 O
partial	604 7 O
response	612 8 O
)	620 1 O
)	621 1 O
rate	623 4 O
was	628 3 O
77	632 2 O
.	634 1 O
4	635 1 O
%	637 1 O
(	639 1 O
complete	640 8 O
response	649 8 O
(	658 1 O
CR	659 2 O
)	661 1 O
,	662 1 O
20	664 2 O
.	666 1 O
2	667 1 O
%	669 1 O
)	670 1 O
.	671 1 O

Median	673 6 O
time	680 4 O
to	685 2 O
first	688 5 O
and	694 3 O
best	698 4 O
response	703 8 O
was	712 3 O
2	716 1 O
and	718 3 O
5	722 1 O
months	724 6 O
,	730 1 O
respectively	732 12 O
.	744 1 O

Median	746 6 O
time	753 4 O
to	758 2 O
CR	761 2 O
when	764 4 O
RD	769 2 B-Chemical
was	772 3 O
given	776 5 O
as	782 2 O
2nd	785 3 O
or	789 2 O
>	792 1 O
2	793 1 O
(	794 1 O
nd	795 2 O
)	797 1 O
-	798 1 O
line	799 4 O
treatment	804 9 O
at	814 2 O
4	817 1 O
and	819 3 O
11	823 2 O
months	826 6 O
,	832 1 O
respectively	834 12 O
.	846 1 O

Quality	848 7 O
of	856 2 O
response	859 8 O
was	868 3 O
independent	872 11 O
of	884 2 O
previous	887 8 O
lines	896 5 O
of	902 2 O
therapies	905 9 O
or	915 2 O
previous	918 8 O
exposure	927 8 O
to	936 2 O
thalidomide	939 11 B-Chemical
or	951 2 O
bortezomib	954 10 B-Chemical
.	964 1 O

Median	966 6 O
duration	973 8 O
of	982 2 O
response	985 8 O
was	994 3 O
34	998 2 O
.	1000 1 O
4	1001 1 O
months	1003 6 O
,	1009 1 O
and	1011 3 O
it	1015 2 O
was	1018 3 O
higher	1022 6 O
in	1029 2 O
patients	1032 8 O
who	1041 3 O
received	1045 8 O
RD	1054 2 B-Chemical
until	1057 5 O
progression	1063 11 O
(	1075 1 O
not	1076 3 O
reached	1080 7 O
versus	1088 6 O
19	1095 2 O
months	1098 6 O
,	1104 1 O
p	1106 1 O
<	1108 1 O
0	1110 1 O
.	1111 1 O
001	1112 3 O
)	1115 1 O
.	1116 1 O

Improvement	1118 11 O
of	1130 2 O
humoral	1133 7 O
immunity	1141 8 O
occurred	1150 8 O
in	1159 2 O
60	1162 2 O
%	1165 1 O
of	1167 2 O
responders	1170 10 O
(	1181 1 O
p	1182 1 O
<	1184 1 O
0	1186 1 O
.	1187 1 O
001	1188 3 O
)	1191 1 O
and	1193 3 O
in	1197 2 O
the	1200 3 O
majority	1204 8 O
of	1213 2 O
patients	1216 8 O
who	1225 3 O
achieved	1229 8 O
stable	1238 6 O
disease	1245 7 O
.	1252 1 O

Adverse	1254 7 O
events	1262 6 O
were	1269 4 O
reported	1274 8 O
in	1283 2 O
68	1286 2 O
.	1288 1 O
9	1289 1 O
%	1291 1 O
of	1293 2 O
patients	1296 8 O
(	1305 1 O
myelosuppression	1306 16 B-Disease
in	1323 2 O
49	1326 2 O
.	1328 1 O
4	1329 1 O
%	1331 1 O
)	1332 1 O
and	1334 3 O
12	1338 2 O
.	1340 1 O
7	1341 1 O
%	1343 1 O
of	1345 2 O
patients	1348 8 O
needed	1357 6 O
hospitalization	1364 15 O
.	1379 1 O

Peripheral	1381 10 B-Disease
neuropathy	1392 10 I-Disease
was	1403 3 O
observed	1407 8 O
only	1416 4 O
in	1421 2 O
2	1424 1 O
.	1425 1 O
5	1426 1 O
%	1428 1 O
of	1430 2 O
patients	1433 8 O
and	1442 3 O
deep	1446 4 B-Disease
vein	1451 4 I-Disease
thrombosis	1456 10 I-Disease
in	1467 2 O
5	1470 1 O
.	1471 1 O
7	1472 1 O
%	1474 1 O
.	1475 1 O

Dose	1477 4 O
reductions	1482 10 O
were	1493 4 O
needed	1498 6 O
in	1505 2 O
31	1508 2 O
%	1511 1 O
of	1513 2 O
patients	1516 8 O
and	1525 3 O
permanent	1529 9 O
discontinuation	1539 15 O
in	1555 2 O
38	1558 2 O
.	1560 1 O
9	1561 1 O
%	1563 1 O
.	1564 1 O

Median	1566 6 O
time	1573 4 O
to	1578 2 O
treatment	1581 9 O
discontinuation	1591 15 O
was	1607 3 O
16	1611 2 O
.	1613 1 O
8	1614 1 O
months	1616 6 O
.	1622 1 O

Performance	1624 11 O
status	1636 6 O
(	1643 1 O
PS	1644 2 O
)	1646 1 O
and	1648 3 O
initial	1652 7 O
lenalidomide	1660 12 B-Chemical
dose	1673 4 O
predicted	1678 9 O
for	1688 3 O
treatment	1692 9 O
discontinuation	1702 15 O
.	1717 1 O

Extra	1719 5 O
-	1724 1 O
medullary	1725 9 O
relapses	1735 8 O
occurred	1744 8 O
in	1753 2 O
3	1756 1 O
.	1757 1 O
8	1758 1 O
%	1760 1 O
of	1762 2 O
patients	1765 8 O
.	1773 1 O

Our	1775 3 O
study	1779 5 O
confirms	1785 8 O
that	1794 4 O
RD	1799 2 B-Chemical
is	1802 2 O
effective	1805 9 O
and	1815 3 O
safe	1819 4 O
in	1824 2 O
RRMM	1827 4 B-Disease
in	1832 2 O
the	1835 3 O
RW	1839 2 O
;	1841 1 O
it	1843 2 O
produces	1846 8 O
durable	1855 7 O
responses	1863 9 O
especially	1873 10 O
in	1884 2 O
patients	1887 8 O
who	1896 3 O
continue	1900 8 O
on	1909 2 O
treatment	1912 9 O
till	1922 4 O
progression	1927 11 O
and	1939 3 O
improves	1943 8 O
humoral	1952 7 O
immunity	1960 8 O
even	1969 4 O
in	1974 2 O
patients	1977 8 O
with	1986 4 O
stable	1991 6 O
disease	1998 7 O
.	2005 1 O

The	0 3 O
cytogenetic	4 11 O
action	16 6 O
of	23 2 O
ifosfamide	26 10 B-Chemical
,	36 1 O
mesna	38 5 B-Chemical
,	43 1 O
and	45 3 O
their	49 5 O
combination	55 11 O
on	67 2 O
peripheral	70 10 O
rabbit	81 6 O
lymphocytes	88 11 O
:	99 1 O
an	101 2 O
in	104 2 O
vivo	107 4 O
/	111 1 O
in	112 2 O
vitro	115 5 O
cytogenetic	121 11 O
study	133 5 O
.	138 1 O

Ifosfamide	140 10 B-Chemical
(	151 1 O
IFO	152 3 B-Chemical
)	155 1 O
is	157 2 O
an	160 2 O
alkylating	163 10 O
nitrogen	174 8 B-Chemical
mustard	183 7 O
,	190 1 O
administrated	192 13 O
as	206 2 O
an	209 2 O
antineoplasmic	212 14 O
agent	227 5 O
.	232 1 O

It	234 2 O
is	237 2 O
characterized	240 13 O
by	254 2 O
its	257 3 O
intense	261 7 O
urotoxic	269 8 O
action	278 6 O
,	284 1 O
leading	286 7 O
to	294 2 O
hemorrhagic	297 11 B-Disease
cystitis	309 8 I-Disease
.	317 1 O

This	319 4 O
side	324 4 O
effect	329 6 O
of	336 2 O
IFO	339 3 B-Chemical
raises	343 6 O
the	350 3 O
requirement	354 11 O
for	366 3 O
the	370 3 O
co	374 2 O
-	376 1 O
administration	377 14 O
with	392 4 O
sodium	397 6 B-Chemical
2	404 1 I-Chemical
-	405 1 I-Chemical
sulfanylethanesulfonate	406 23 I-Chemical
(	430 1 O
Mesna	431 5 B-Chemical
)	436 1 O
aiming	438 6 O
to	445 2 O
avoid	448 5 O
or	454 2 O
minimize	457 8 O
this	466 4 O
effect	471 6 O
.	477 1 O

IFO	479 3 B-Chemical
and	483 3 O
Mesna	487 5 B-Chemical
were	493 4 O
administrated	498 13 O
separately	512 10 O
on	523 2 O
rabbit	526 6 O
'	532 1 O
s	533 1 O
lymphocytes	535 11 O
in	547 2 O
vivo	550 4 O
,	554 1 O
which	556 5 O
were	562 4 O
later	567 5 O
developed	573 9 O
in	583 2 O
vitro	586 5 O
.	591 1 O

Cytogenetic	593 11 O
markers	605 7 O
for	613 3 O
sister	617 6 O
chromatid	624 9 O
exchanges	634 9 O
(	644 1 O
SCEs	645 4 O
)	649 1 O
,	650 1 O
proliferation	652 13 O
rate	666 4 O
index	671 5 O
(	677 1 O
PRI	678 3 O
)	681 1 O
and	683 3 O
Mitotic	687 7 O
Index	695 5 O
were	701 4 O
recorded	706 8 O
.	714 1 O

Mesna	716 5 B-Chemical
'	721 1 O
s	722 1 O
action	724 6 O
,	730 1 O
in	732 2 O
conjunction	735 11 O
with	747 4 O
IFO	752 3 B-Chemical
reduces	756 7 O
the	764 3 O
frequency	768 9 O
of	778 2 O
SCEs	781 4 O
,	785 1 O
in	787 2 O
comparison	790 10 O
with	801 4 O
the	806 3 O
SCEs	810 4 O
recordings	815 10 O
obtained	826 8 O
when	835 4 O
IFO	840 3 B-Chemical
is	844 2 O
administered	847 12 O
alone	860 5 O
.	865 1 O

In	867 2 O
addition	870 8 O
to	879 2 O
this	882 4 O
,	886 1 O
when	888 4 O
high	893 4 O
concentrations	898 14 O
of	913 2 O
Mesna	916 5 B-Chemical
were	922 4 O
administered	927 12 O
alone	940 5 O
significant	946 11 O
reductions	958 10 O
of	969 2 O
the	972 3 O
PRI	976 3 O
were	980 4 O
noted	985 5 O
,	990 1 O
than	992 4 O
with	997 4 O
IFO	1002 3 B-Chemical
acting	1006 6 O
at	1013 2 O
the	1016 3 O
same	1020 4 O
concentration	1025 13 O
on	1039 2 O
the	1042 3 O
lymphocytes	1046 11 O
.	1057 1 O

Mesna	1059 5 B-Chemical
significantly	1065 13 O
reduces	1079 7 O
IFO	1087 3 B-Chemical
'	1090 1 O
s	1091 1 O
genotoxicity	1093 12 B-Disease
,	1105 1 O
while	1107 5 O
when	1113 4 O
administered	1118 12 O
in	1131 2 O
high	1134 4 O
concentrations	1139 14 O
it	1154 2 O
acts	1157 4 O
in	1162 2 O
an	1165 2 O
inhibitory	1168 10 O
fashion	1179 7 O
on	1187 2 O
the	1190 3 O
cytostatic	1194 10 O
action	1205 6 O
of	1212 2 O
the	1215 3 O
drug	1219 4 O
.	1223 1 O

Risk	0 4 O
factors	5 7 O
and	13 3 O
predictors	17 10 O
of	28 2 O
levodopa	31 8 B-Chemical
-	39 1 O
induced	40 7 O
dyskinesia	48 10 B-Disease
among	59 5 O
multiethnic	65 11 O
Malaysians	77 10 O
with	88 4 O
Parkinson	93 9 B-Disease
'	102 1 I-Disease
s	103 1 I-Disease
disease	105 7 I-Disease
.	112 1 O

Chronic	114 7 O
pulsatile	122 9 O
levodopa	132 8 B-Chemical
therapy	141 7 O
for	149 3 O
Parkinson	153 9 B-Disease
'	162 1 I-Disease
s	163 1 I-Disease
disease	165 7 I-Disease
(	173 1 O
PD	174 2 B-Disease
)	176 1 O
leads	178 5 O
to	184 2 O
the	187 3 O
development	191 11 O
of	203 2 O
motor	206 5 O
fluctuations	212 12 O
and	225 3 O
dyskinesia	229 10 B-Disease
.	239 1 O

We	241 2 O
studied	244 7 O
the	252 3 O
prevalence	256 10 O
and	267 3 O
predictors	271 10 O
of	282 2 O
levodopa	285 8 B-Chemical
-	293 1 O
induced	294 7 O
dyskinesia	302 10 B-Disease
among	313 5 O
multiethnic	319 11 O
Malaysian	331 9 O
patients	341 8 O
with	350 4 O
PD	355 2 B-Disease
.	357 1 O

METHODS	359 7 O
:	366 1 O
This	368 4 O
is	373 2 O
a	376 1 O
cross	378 5 O
-	383 1 O
sectional	384 9 O
study	394 5 O
involving	400 9 O
95	410 2 O
patients	413 8 O
with	422 4 O
PD	427 2 B-Disease
on	430 2 O
uninterrupted	433 13 O
levodopa	447 8 B-Chemical
therapy	456 7 O
for	464 3 O
at	468 2 O
least	471 5 O
6	477 1 O
months	479 6 O
.	485 1 O

The	487 3 O
instrument	491 10 O
used	502 4 O
was	507 3 O
the	511 3 O
UPDRS	515 5 O
questionnaires	521 14 O
.	535 1 O

The	537 3 O
predictors	541 10 O
of	552 2 O
dyskinesia	555 10 B-Disease
were	566 4 O
determined	571 10 O
using	582 5 O
multivariate	588 12 O
logistic	601 8 O
regression	610 10 O
analysis	621 8 O
.	629 1 O

RESULTS	631 7 O
:	638 1 O
The	640 3 O
mean	644 4 O
age	649 3 O
was	653 3 O
65	657 2 O
.	659 1 O
6	660 1 O
+	662 1 O
8	664 1 O
.	665 1 O
5	666 1 O
years	668 5 O
.	673 1 O

The	675 3 O
mean	679 4 O
onset	684 5 O
age	690 3 O
was	694 3 O
58	698 2 O
.	700 1 O
5	701 1 O
+	703 1 O
9	705 1 O
.	706 1 O
8	707 1 O
years	709 5 O
.	714 1 O

The	716 3 O
median	720 6 O
disease	727 7 O
duration	735 8 O
was	744 3 O
6	748 1 O
(	750 1 O
7	751 1 O
)	752 1 O
years	754 5 O
.	759 1 O

Dyskinesia	761 10 B-Disease
was	772 3 O
present	776 7 O
in	784 2 O
44	787 2 O
%	789 1 O
(	791 1 O
n	792 1 O
=	794 1 O
42	796 2 O
)	798 1 O
with	800 4 O
median	805 6 O
levodopa	812 8 B-Chemical
therapy	821 7 O
of	829 2 O
3	832 1 O
years	834 5 O
.	839 1 O

There	841 5 O
were	847 4 O
64	852 2 O
.	854 1 O
3	855 1 O
%	856 1 O
Chinese	858 7 O
,	865 1 O
31	867 2 O
%	869 1 O
Malays	871 6 O
,	877 1 O
and	879 3 O
3	883 1 O
.	884 1 O
7	885 1 O
%	886 1 O
Indians	888 7 O
and	896 3 O
other	900 5 O
ethnic	906 6 O
groups	913 6 O
.	919 1 O

Eighty	921 6 O
-	927 1 O
one	928 3 O
percent	932 7 O
of	940 2 O
patients	943 8 O
with	952 4 O
dyskinesia	957 10 B-Disease
had	968 3 O
clinical	972 8 O
fluctuations	981 12 O
.	993 1 O

Patients	995 8 O
with	1004 4 O
dyskinesia	1009 10 B-Disease
had	1020 3 O
lower	1024 5 O
onset	1030 5 O
age	1036 3 O
(	1040 1 O
p	1042 1 O
<	1044 1 O
0	1046 1 O
.	1047 1 O
001	1048 3 O
)	1051 1 O
,	1052 1 O
longer	1054 6 O
duration	1061 8 O
of	1070 2 O
levodopa	1073 8 B-Chemical
therapy	1082 7 O
(	1090 1 O
p	1092 1 O
<	1094 1 O
0	1096 1 O
.	1097 1 O
001	1098 3 O
)	1101 1 O
,	1102 1 O
longer	1104 6 O
disease	1111 7 O
duration	1119 8 O
(	1128 1 O
p	1130 1 O
<	1132 1 O
0	1134 1 O
.	1135 1 O
001	1136 3 O
)	1139 1 O
,	1140 1 O
higher	1142 6 O
total	1149 5 O
daily	1155 5 O
levodopa	1161 8 B-Chemical
dose	1170 4 O
(	1175 1 O
p	1177 1 O
<	1179 1 O
0	1181 1 O
.	1182 1 O
001	1183 3 O
)	1186 1 O
,	1187 1 O
and	1189 3 O
higher	1193 6 O
total	1200 5 O
UPDRS	1206 5 O
scores	1212 6 O
(	1219 1 O
p	1221 1 O
=	1223 1 O
0	1225 1 O
.	1226 1 O
005	1227 3 O
)	1230 1 O
than	1232 4 O
patients	1237 8 O
without	1246 7 O
dyskinesia	1254 10 B-Disease
.	1264 1 O

The	1266 3 O
three	1270 5 O
significant	1276 11 O
predictors	1288 10 O
of	1299 2 O
dyskinesia	1302 10 B-Disease
were	1313 4 O
duration	1318 8 O
of	1327 2 O
levodopa	1330 8 B-Chemical
therapy	1339 7 O
,	1346 1 O
onset	1348 5 O
age	1354 3 O
,	1357 1 O
and	1359 3 O
total	1363 5 O
daily	1369 5 O
levodopa	1375 8 B-Chemical
dose	1384 4 O
.	1388 1 O

CONCLUSIONS	1390 11 O
:	1401 1 O
The	1403 3 O
prevalence	1407 10 O
of	1418 2 O
levodopa	1421 8 B-Chemical
-	1429 1 O
induced	1430 7 O
dyskinesia	1438 10 B-Disease
in	1449 2 O
our	1452 3 O
patients	1456 8 O
was	1465 3 O
44	1469 2 O
%	1471 1 O
.	1472 1 O

The	1474 3 O
most	1478 4 O
significant	1483 11 O
predictors	1495 10 O
were	1506 4 O
duration	1511 8 O
of	1520 2 O
levodopa	1523 8 B-Chemical
therapy	1532 7 O
,	1539 1 O
total	1541 5 O
daily	1547 5 O
levodopa	1553 8 B-Chemical
dose	1562 4 O
,	1566 1 O
and	1568 3 O
onset	1572 5 O
age	1578 3 O
.	1581 1 O

An	0 2 O
unexpected	3 10 O
diagnosis	14 9 O
in	24 2 O
a	27 1 O
renal	29 5 O
-	34 1 O
transplant	35 10 O
patient	46 7 O
with	54 4 O
proteinuria	59 11 B-Disease
treated	71 7 O
with	79 4 O
everolimus	84 10 B-Chemical
:	94 1 O
AL	96 2 B-Disease
amyloidosis	99 11 B-Disease
.	110 1 O

Proteinuria	112 11 B-Disease
is	124 2 O
an	127 2 O
expected	130 8 O
complication	139 12 O
in	152 2 O
transplant	155 10 O
patients	166 8 O
treated	175 7 O
with	183 4 O
mammalian	188 9 O
target	198 6 O
of	205 2 O
rapamycin	208 9 B-Chemical
inhibitors	218 10 O
(	229 1 O
mTOR	230 4 O
-	234 1 O
i	235 1 O
)	236 1 O
.	237 1 O

However	239 7 O
,	246 1 O
clinical	248 8 O
suspicion	257 9 O
should	267 6 O
always	274 6 O
be	281 2 O
supported	284 9 O
by	294 2 O
histological	297 12 O
evidence	310 8 O
in	319 2 O
order	322 5 O
to	328 2 O
investigate	331 11 O
potential	343 9 O
alternate	353 9 O
diagnoses	363 9 O
such	373 4 O
as	378 2 O
acute	381 5 O
or	387 2 O
chronic	390 7 O
rejection	398 9 O
,	407 1 O
interstitial	409 12 O
fibrosis	422 8 B-Disease
and	431 3 O
tubular	435 7 O
atrophy	443 7 B-Disease
,	450 1 O
or	452 2 O
recurrent	455 9 O
or	465 2 O
de	468 2 O
novo	471 4 O
glomerulopathy	476 14 B-Disease
.	490 1 O

In	492 2 O
this	495 4 O
case	500 4 O
we	505 2 O
report	508 6 O
the	515 3 O
unexpected	519 10 O
diagnosis	530 9 O
of	540 2 O
amyloidosis	543 11 B-Disease
in	555 2 O
a	558 1 O
renal	560 5 O
-	565 1 O
transplant	566 10 O
patient	577 7 O
with	585 4 O
pre	590 3 O
-	593 1 O
transplant	594 10 O
monoclonal	605 10 O
gammapathy	616 10 O
of	627 2 O
undetermined	630 12 O
significance	643 12 O
who	656 3 O
developed	660 9 O
proteinuria	670 11 B-Disease
after	682 5 O
conversion	688 10 O
from	699 4 O
tacrolimus	704 10 B-Chemical
to	715 2 O
everolimus	718 10 B-Chemical
.	728 1 O

An	0 2 O
investigation	3 13 O
of	17 2 O
the	20 3 O
pattern	24 7 O
of	32 2 O
kidney	35 6 B-Disease
injury	42 6 I-Disease
in	49 2 O
HIV	52 3 O
-	55 1 O
positive	56 8 O
persons	65 7 O
exposed	73 7 O
to	81 2 O
tenofovir	84 9 B-Chemical
disoproxil	94 10 I-Chemical
fumarate	105 8 I-Chemical
:	113 1 O
an	115 2 O
examination	118 11 O
of	130 2 O
a	133 1 O
large	135 5 O
population	141 10 O
database	152 8 O
(	161 1 O
MHRA	162 4 O
database	167 8 O
)	175 1 O
.	176 1 O

The	178 3 O
potential	182 9 O
for	192 3 O
tenofovir	196 9 B-Chemical
to	206 2 O
cause	209 5 O
a	215 1 O
range	217 5 O
of	223 2 O
kidney	226 6 O
syndromes	233 9 O
has	243 3 O
been	247 4 O
established	252 11 O
from	264 4 O
mechanistic	269 11 O
and	281 3 O
randomised	285 10 O
clinical	296 8 O
trials	305 6 O
.	311 1 O

However	313 7 O
,	320 1 O
the	322 3 O
exact	326 5 O
pattern	332 7 O
of	340 2 O
kidney	343 6 O
involvement	350 11 O
is	362 2 O
still	365 5 O
uncertain	371 9 O
.	380 1 O

We	382 2 O
undertook	385 9 O
a	395 1 O
descriptive	397 11 O
analysis	409 8 O
of	418 2 O
Yellow	421 6 O
Card	428 4 O
records	433 7 O
of	441 2 O
407	444 3 O
HIV	448 3 O
-	451 1 O
positive	452 8 O
persons	461 7 O
taking	469 6 O
tenofovir	476 9 B-Chemical
disoproxil	486 10 I-Chemical
fumarate	497 8 I-Chemical
(	506 1 O
TDF	507 3 B-Chemical
)	510 1 O
as	512 2 O
part	515 4 O
of	520 2 O
their	523 5 O
antiretroviral	529 14 O
therapy	544 7 O
regimen	552 7 O
and	560 3 O
submitted	564 9 O
to	574 2 O
the	577 3 O
Medicines	581 9 O
and	591 3 O
Healthcare	595 10 O
Products	606 8 O
Regulatory	615 10 O
Agency	626 6 O
(	633 1 O
MHRA	634 4 O
)	638 1 O
with	640 4 O
suspected	645 9 O
kidney	655 6 O
adverse	662 7 O
effects	670 7 O
.	677 1 O

Reports	679 7 O
that	687 4 O
satisfy	692 7 O
defined	700 7 O
criteria	708 8 O
were	717 4 O
classified	722 10 O
as	733 2 O
acute	736 5 B-Disease
kidney	742 6 I-Disease
injury	749 6 I-Disease
,	755 1 O
kidney	757 6 B-Disease
tubular	764 7 I-Disease
dysfunction	772 11 I-Disease
and	784 3 O
Fanconi	788 7 B-Disease
syndrome	796 8 I-Disease
.	804 1 O

Of	806 2 O
the	809 3 O
407	813 3 O
Yellow	817 6 O
Card	824 4 O
records	829 7 O
analysed	837 8 O
,	845 1 O
106	847 3 O
satisfied	851 9 O
criteria	861 8 O
for	870 3 O
TDF	874 3 B-Chemical
-	877 1 O
related	878 7 O
kidney	886 6 B-Disease
disease	893 7 I-Disease
,	900 1 O
of	902 2 O
which	905 5 O
53	911 2 O
(	914 1 O
50	915 2 O
%	917 1 O
)	918 1 O
had	920 3 O
features	924 8 O
of	933 2 O
kidney	936 6 B-Disease
tubular	943 7 I-Disease
dysfunction	951 11 I-Disease
,	962 1 O
35	964 2 O
(	967 1 O
33	968 2 O
%	970 1 O
)	971 1 O
were	973 4 O
found	978 5 O
to	984 2 O
have	987 4 O
features	992 8 O
of	1001 2 O
glomerular	1004 10 B-Disease
dysfunction	1015 11 I-Disease
and	1027 3 O
18	1031 2 O
(	1034 1 O
17	1035 2 O
%	1037 1 O
)	1038 1 O
had	1040 3 O
Fanconi	1044 7 B-Disease
syndrome	1052 8 I-Disease
.	1060 1 O

The	1062 3 O
median	1066 6 O
TDF	1073 3 B-Chemical
exposure	1077 8 O
was	1086 3 O
316	1090 3 O
days	1094 4 O
(	1099 1 O
interquartile	1100 13 O
range	1114 5 O
120	1120 3 O
-	1123 1 O
740	1124 3 O
)	1127 1 O
.	1128 1 O

The	1130 3 O
incidence	1134 9 O
of	1144 2 O
hospitalisation	1147 15 O
for	1163 3 O
TDF	1167 3 B-Chemical
kidney	1171 6 O
adverse	1178 7 O
effects	1186 7 O
was	1194 3 O
high	1198 4 O
,	1202 1 O
particularly	1204 12 O
amongst	1217 7 O
patients	1225 8 O
with	1234 4 O
features	1239 8 O
of	1248 2 O
Fanconi	1251 7 B-Disease
syndrome	1259 8 I-Disease
.	1267 1 O

The	1269 3 O
pattern	1273 7 O
of	1281 2 O
kidney	1284 6 O
syndromes	1291 9 O
in	1301 2 O
this	1304 4 O
population	1309 10 O
series	1320 6 O
mirrors	1327 7 O
that	1335 4 O
reported	1340 8 O
in	1349 2 O
randomised	1352 10 O
clinical	1363 8 O
trials	1372 6 O
.	1378 1 O

Cessation	1380 9 O
of	1390 2 O
TDF	1393 3 B-Chemical
was	1397 3 O
associated	1401 10 O
with	1412 4 O
complete	1417 8 O
restoration	1426 11 O
of	1438 2 O
kidney	1441 6 O
function	1448 8 O
in	1457 2 O
up	1460 2 O
half	1463 4 O
of	1468 2 O
the	1471 3 O
patients	1475 8 O
in	1484 2 O
this	1487 4 O
report	1492 6 O
.	1498 1 O

Incidence	0 9 O
of	10 2 O
postoperative	13 13 B-Disease
delirium	27 8 I-Disease
is	36 2 O
high	39 4 O
even	44 4 O
in	49 2 O
a	52 1 O
population	54 10 O
without	65 7 O
known	73 5 O
risk	79 4 O
factors	84 7 O
.	91 1 O

PURPOSE	93 7 O
:	100 1 O
Postoperative	102 13 B-Disease
delirium	116 8 I-Disease
is	125 2 O
a	128 1 O
recognized	130 10 O
complication	141 12 O
in	154 2 O
populations	157 11 O
at	169 2 O
risk	172 4 O
.	176 1 O

The	178 3 O
aim	182 3 O
of	186 2 O
this	189 4 O
study	194 5 O
is	200 2 O
to	203 2 O
assess	206 6 O
the	213 3 O
prevalence	217 10 O
of	228 2 O
early	231 5 O
postoperative	237 13 B-Disease
delirium	251 8 I-Disease
in	260 2 O
a	263 1 O
population	265 10 O
without	276 7 O
known	284 5 O
risk	290 4 O
factors	295 7 O
admitted	303 8 O
to	312 2 O
the	315 3 O
ICU	319 3 O
for	323 3 O
postoperative	327 13 O
monitoring	341 10 O
after	352 5 O
elective	358 8 O
major	367 5 O
surgery	373 7 O
.	380 1 O

The	382 3 O
secondary	386 9 O
outcome	396 7 O
investigated	404 12 O
is	417 2 O
to	420 2 O
identify	423 8 O
eventual	432 8 O
independent	441 11 O
risk	453 4 O
factors	458 7 O
among	466 5 O
demographic	472 11 O
data	484 4 O
and	489 3 O
anesthetic	493 10 O
drugs	504 5 O
used	510 4 O
.	514 1 O

METHODS	516 7 O
:	523 1 O
An	525 2 O
observational	528 13 O
,	541 1 O
prospective	543 11 O
study	555 5 O
was	561 3 O
conducted	565 9 O
on	575 2 O
a	578 1 O
consecutive	580 11 O
cohort	592 6 O
of	599 2 O
patients	602 8 O
admitted	611 8 O
to	620 2 O
our	623 3 O
ICU	627 3 O
within	631 6 O
and	638 3 O
for	642 3 O
at	646 2 O
least	649 5 O
24	655 2 O
h	658 1 O
after	660 5 O
major	666 5 O
surgical	672 8 O
procedures	681 10 O
.	691 1 O

Exclusion	693 9 O
criteria	703 8 O
were	712 4 O
any	717 3 O
preexisting	721 11 O
predisposing	733 12 O
factor	746 6 O
for	753 3 O
delirium	757 8 B-Disease
or	766 2 O
other	769 5 O
potentially	775 11 O
confounding	787 11 O
neurological	799 12 B-Disease
dysfunctions	812 12 I-Disease
.	824 1 O

Patients	826 8 O
were	835 4 O
assessed	840 8 O
daily	849 5 O
using	855 5 O
the	861 3 O
confusion	865 9 B-Disease
assessment	875 10 O
method	886 6 O
for	893 3 O
the	897 3 O
ICU	901 3 O
scale	905 5 O
for	911 3 O
3	915 1 O
days	917 4 O
after	922 5 O
the	928 3 O
surgical	932 8 O
procedure	941 9 O
.	950 1 O

Early	952 5 O
postoperative	958 13 B-Disease
delirium	972 8 I-Disease
incidence	981 9 O
risk	991 4 O
factors	996 7 O
were	1004 4 O
then	1009 4 O
assessed	1014 8 O
through	1023 7 O
three	1031 5 O
different	1037 9 O
multiple	1047 8 O
regression	1056 10 O
models	1067 6 O
.	1073 1 O

RESULTS	1075 7 O
:	1082 1 O
According	1084 9 O
to	1094 2 O
the	1097 3 O
confusion	1101 9 O
assessment	1111 10 O
method	1122 6 O
for	1129 3 O
the	1133 3 O
ICU	1137 3 O
scale	1141 5 O
,	1146 1 O
28	1148 2 O
%	1151 1 O
of	1153 2 O
patients	1156 8 O
were	1165 4 O
diagnosed	1170 9 O
with	1180 4 O
early	1185 5 O
postoperative	1191 13 B-Disease
delirium	1205 8 I-Disease
.	1213 1 O

The	1215 3 O
use	1219 3 O
of	1223 2 O
thiopentone	1226 11 B-Chemical
was	1238 3 O
significantly	1242 13 O
associated	1256 10 O
with	1267 4 O
an	1272 2 O
eight	1275 5 O
-	1280 1 O
fold	1281 4 O
-	1285 1 O
higher	1286 6 O
risk	1293 4 O
for	1298 3 O
delirium	1302 8 B-Disease
compared	1311 8 O
to	1320 2 O
propofol	1323 8 B-Chemical
(	1332 1 O
57	1333 2 O
.	1335 1 O
1	1336 1 O
%	1337 1 O
vs	1339 2 O
.	1341 1 O
7	1343 1 O
.	1344 1 O
1	1345 1 O
%	1346 1 O
,	1347 1 O
RR	1349 2 O
=	1352 1 O
8	1354 1 O
.	1355 1 O
0	1356 1 O
,	1357 1 O
X2	1359 2 O
=	1362 1 O
4	1364 1 O
.	1365 1 O
256	1366 3 O
;	1369 1 O
df	1371 2 O
=	1374 1 O
1	1376 1 O
;	1377 1 O
0	1379 1 O
.	1380 1 O
05	1381 2 O
<	1384 1 O
p	1386 1 O
<	1388 1 O
0	1390 1 O
.	1391 1 O
02	1392 2 O
)	1394 1 O
.	1395 1 O

CONCLUSION	1397 10 O
:	1407 1 O
In	1409 2 O
this	1412 4 O
study	1417 5 O
early	1423 5 O
postoperative	1429 13 B-Disease
delirium	1443 8 I-Disease
was	1452 3 O
found	1456 5 O
to	1462 2 O
be	1465 2 O
a	1468 1 O
very	1470 4 O
common	1475 6 O
complication	1482 12 O
after	1495 5 O
major	1501 5 O
surgery	1507 7 O
,	1514 1 O
even	1516 4 O
in	1521 2 O
a	1524 1 O
population	1526 10 O
without	1537 7 O
known	1545 5 O
risk	1551 4 O
factors	1556 7 O
.	1563 1 O

Thiopentone	1565 11 B-Chemical
was	1577 3 O
independently	1581 13 O
associated	1595 10 O
with	1606 4 O
an	1611 2 O
increase	1614 8 O
in	1623 2 O
its	1626 3 O
relative	1630 8 O
risk	1639 4 O
.	1643 1 O

A	0 1 O
single	2 6 O
neurotoxic	9 10 B-Disease
dose	20 4 O
of	25 2 O
methamphetamine	28 15 B-Chemical
induces	44 7 O
a	52 1 O
long	54 4 O
-	58 1 O
lasting	59 7 O
depressive	67 10 B-Disease
-	77 1 O
like	78 4 O
behaviour	83 9 O
in	93 2 O
mice	96 4 O
.	100 1 O

Methamphetamine	102 15 B-Chemical
(	118 1 O
METH	119 4 B-Chemical
)	123 1 O
triggers	125 8 O
a	134 1 O
disruption	136 10 O
of	147 2 O
the	150 3 O
monoaminergic	154 13 O
system	168 6 O
and	175 3 O
METH	179 4 B-Chemical
abuse	184 5 O
leads	190 5 O
to	196 2 O
negative	199 8 O
emotional	208 9 O
states	218 6 O
including	225 9 O
depressive	235 10 B-Disease
symptoms	246 8 I-Disease
during	255 6 O
drug	262 4 O
withdrawal	267 10 O
.	277 1 O

However	279 7 O
,	286 1 O
it	288 2 O
is	291 2 O
currently	294 9 O
unknown	304 7 O
if	312 2 O
the	315 3 O
acute	319 5 O
toxic	325 5 O
dosage	331 6 O
of	338 2 O
METH	341 4 B-Chemical
also	346 4 O
causes	351 6 O
a	358 1 O
long	360 4 O
-	364 1 O
lasting	365 7 O
depressive	373 10 B-Disease
phenotype	384 9 O
and	394 3 O
persistent	398 10 O
monoaminergic	409 13 O
deficits	423 8 O
.	431 1 O

Thus	433 4 O
,	437 1 O
we	439 2 O
now	442 3 O
assessed	446 8 O
the	455 3 O
depressive	459 10 B-Disease
-	469 1 O
like	470 4 O
behaviour	475 9 O
in	485 2 O
mice	488 4 O
at	493 2 O
early	496 5 O
and	502 3 O
long	506 4 O
-	510 1 O
term	511 4 O
periods	516 7 O
following	524 9 O
a	534 1 O
single	536 6 O
high	543 4 O
METH	548 4 B-Chemical
dose	553 4 O
(	558 1 O
30	559 2 O
mg	562 2 O
/	564 1 O
kg	565 2 O
,	567 1 O
i	569 1 O
.	570 1 O
p	571 1 O
.	572 1 O
)	573 1 O
.	574 1 O

METH	576 4 B-Chemical
did	581 3 O
not	585 3 O
alter	589 5 O
the	595 3 O
motor	599 5 O
function	605 8 O
and	614 3 O
procedural	618 10 O
memory	629 6 O
of	636 2 O
mice	639 4 O
as	644 2 O
assessed	647 8 O
by	656 2 O
swimming	659 8 O
speed	668 5 O
and	674 3 O
escape	678 6 O
latency	685 7 O
to	693 2 O
find	696 4 O
the	701 3 O
platform	705 8 O
in	714 2 O
a	717 1 O
cued	719 4 O
version	724 7 O
of	732 2 O
the	735 3 O
water	739 5 O
maze	745 4 O
task	750 4 O
.	754 1 O

However	756 7 O
,	763 1 O
METH	765 4 B-Chemical
significantly	770 13 O
increased	784 9 O
the	794 3 O
immobility	798 10 O
time	809 4 O
in	814 2 O
the	817 3 O
tail	821 4 O
suspension	826 10 O
test	837 4 O
at	842 2 O
3	845 1 O
and	847 3 O
49	851 2 O
days	854 4 O
post	859 4 O
-	863 1 O
administration	864 14 O
.	878 1 O

This	880 4 O
depressive	885 10 B-Disease
-	895 1 O
like	896 4 O
profile	901 7 O
induced	909 7 O
by	917 2 O
METH	920 4 B-Chemical
was	925 3 O
accompanied	929 11 O
by	941 2 O
a	944 1 O
marked	946 6 O
depletion	953 9 O
of	963 2 O
frontostriatal	966 14 O
dopaminergic	981 12 O
and	994 3 O
serotonergic	998 12 O
neurotransmission	1011 17 O
,	1028 1 O
indicated	1030 9 O
by	1040 2 O
a	1043 1 O
reduction	1045 9 O
in	1055 2 O
the	1058 3 O
levels	1062 6 O
of	1069 2 O
dopamine	1072 8 B-Chemical
,	1080 1 O
DOPAC	1082 5 B-Chemical
and	1088 3 O
HVA	1092 3 B-Chemical
,	1095 1 O
tyrosine	1097 8 B-Chemical
hydroxylase	1106 11 O
and	1118 3 O
serotonin	1122 9 B-Chemical
,	1131 1 O
observed	1133 8 O
at	1142 2 O
both	1145 4 O
3	1150 1 O
and	1152 3 O
49	1156 2 O
days	1159 4 O
post	1164 4 O
-	1168 1 O
administration	1169 14 O
.	1183 1 O

In	1185 2 O
parallel	1188 8 O
,	1196 1 O
another	1198 7 O
neurochemical	1206 13 O
feature	1220 7 O
of	1228 2 O
depression	1231 10 B-Disease
-	1241 1 O
-	1242 1 O
astroglial	1243 10 O
dysfunction	1254 11 O
-	1265 1 O
-	1266 1 O
was	1267 3 O
unaffected	1271 10 O
in	1282 2 O
the	1285 3 O
cortex	1289 6 O
and	1296 3 O
the	1300 3 O
striatal	1304 8 O
levels	1313 6 O
of	1320 2 O
the	1323 3 O
astrocytic	1327 10 O
protein	1338 7 O
marker	1346 6 O
,	1352 1 O
glial	1354 5 O
fibrillary	1360 10 O
acidic	1371 6 O
protein	1378 7 O
,	1385 1 O
were	1387 4 O
only	1392 4 O
transiently	1397 11 O
increased	1409 9 O
at	1419 2 O
3	1422 1 O
days	1424 4 O
.	1428 1 O

These	1430 5 O
findings	1436 8 O
demonstrate	1445 11 O
for	1457 3 O
the	1461 3 O
first	1465 5 O
time	1471 4 O
that	1476 4 O
a	1481 1 O
single	1483 6 O
high	1490 4 O
dose	1495 4 O
of	1500 2 O
METH	1503 4 B-Chemical
induces	1508 7 O
long	1516 4 O
-	1520 1 O
lasting	1521 7 O
depressive	1529 10 B-Disease
-	1539 1 O
like	1540 4 O
behaviour	1545 9 O
in	1555 2 O
mice	1558 4 O
associated	1563 10 O
with	1574 4 O
a	1579 1 O
persistent	1581 10 O
disruption	1592 10 O
of	1603 2 O
frontostriatal	1606 14 O
dopaminergic	1621 12 O
and	1634 3 O
serotonergic	1638 12 O
homoeostasis	1651 12 O
.	1663 1 O

Linezolid	0 9 B-Chemical
-	9 1 O
induced	10 7 O
optic	18 5 B-Disease
neuropathy	24 10 I-Disease
.	34 1 O

Many	36 4 O
systemic	41 8 O
antimicrobials	50 14 O
have	65 4 O
been	70 4 O
implicated	75 10 O
to	86 2 O
cause	89 5 O
ocular	95 6 O
adverse	102 7 O
effects	110 7 O
.	117 1 O

This	119 4 O
is	124 2 O
especially	127 10 O
relevant	138 8 O
in	147 2 O
multidrug	150 9 O
therapy	160 7 O
where	168 5 O
more	174 4 O
than	179 4 O
one	184 3 O
drug	188 4 O
can	193 3 O
cause	197 5 O
a	203 1 O
similar	205 7 O
ocular	213 6 O
adverse	220 7 O
effect	228 6 O
.	234 1 O

We	236 2 O
describe	239 8 O
a	248 1 O
case	250 4 O
of	255 2 O
progressive	258 11 O
loss	270 4 B-Disease
of	275 2 I-Disease
vision	278 6 I-Disease
associated	285 10 O
with	296 4 O
linezolid	301 9 B-Chemical
therapy	311 7 O
.	318 1 O

A	320 1 O
45	322 2 O
-	324 1 O
year	325 4 O
-	329 1 O
old	330 3 O
male	334 4 O
patient	339 7 O
who	347 3 O
was	351 3 O
on	355 2 O
treatment	358 9 O
with	368 4 O
multiple	373 8 O
second	382 6 O
-	388 1 O
line	389 4 O
anti	394 4 O
-	398 1 O
tuberculous	399 11 O
drugs	411 5 O
including	417 9 O
linezolid	427 9 B-Chemical
and	437 3 O
ethambutol	441 10 B-Chemical
for	452 3 O
extensively	456 11 B-Disease
drug	468 4 I-Disease
-	472 1 I-Disease
resistant	473 9 I-Disease
tuberculosis	483 12 I-Disease
(	496 1 O
XDR	497 3 B-Disease
-	500 1 I-Disease
TB	501 2 I-Disease
)	503 1 O
presented	505 9 O
to	515 2 O
us	518 2 O
with	521 4 O
painless	526 8 O
progressive	535 11 O
loss	547 4 B-Disease
of	552 2 I-Disease
vision	555 6 I-Disease
in	562 2 O
both	565 4 O
eyes	570 4 O
.	574 1 O

Color	576 5 O
vision	582 6 O
was	589 3 O
defective	593 9 O
and	603 3 O
fundus	607 6 O
examination	614 11 O
revealed	626 8 O
optic	635 5 B-Disease
disc	641 4 I-Disease
edema	646 5 I-Disease
in	652 2 O
both	655 4 O
eyes	660 4 O
.	664 1 O

Ethambutol	666 10 B-Chemical
-	676 1 O
induced	677 7 O
toxic	685 5 B-Disease
optic	691 5 I-Disease
neuropathy	697 10 I-Disease
was	708 3 O
suspected	712 9 O
and	722 3 O
tablet	726 6 O
ethambutol	733 10 B-Chemical
was	744 3 O
withdrawn	748 9 O
.	757 1 O

Deterioration	759 13 B-Disease
of	773 2 I-Disease
vision	776 6 I-Disease
occurred	783 8 O
despite	792 7 O
withdrawal	800 10 O
of	811 2 O
ethambutol	814 10 B-Chemical
.	824 1 O

Discontinuation	826 15 O
of	842 2 O
linezolid	845 9 B-Chemical
resulted	855 8 O
in	864 2 O
marked	867 6 O
improvement	874 11 O
of	886 2 O
vision	889 6 O
.	895 1 O

Our	897 3 O
report	901 6 O
emphasizes	908 10 O
the	919 3 O
need	923 4 O
for	928 3 O
monitoring	932 10 O
of	943 2 O
visual	946 6 O
function	953 8 O
in	962 2 O
patients	965 8 O
on	974 2 O
long	977 4 O
-	981 1 O
term	982 4 O
linezolid	987 9 B-Chemical
treatment	997 9 O
.	1006 1 O

Resuscitation	0 13 O
with	14 4 O
lipid	19 5 O
,	24 1 O
epinephrine	26 11 B-Chemical
,	37 1 O
or	39 2 O
both	42 4 O
in	47 2 O
levobupivacaine	50 15 B-Chemical
-	65 1 O
induced	66 7 O
cardiac	74 7 B-Disease
toxicity	82 8 I-Disease
in	91 2 O
newborn	94 7 O
piglets	102 7 O
.	109 1 O

BACKGROUND	111 10 O
:	121 1 O
The	123 3 O
optimal	127 7 O
dosing	135 6 O
regimens	142 8 O
of	151 2 O
lipid	154 5 O
emulsion	160 8 O
,	168 1 O
epinephrine	170 11 B-Chemical
,	181 1 O
or	183 2 O
both	186 4 O
are	191 3 O
not	195 3 O
yet	199 3 O
determined	203 10 O
in	214 2 O
neonates	217 8 O
in	226 2 O
cases	229 5 O
of	235 2 O
local	238 5 O
anaesthetic	244 11 O
systemic	256 8 O
toxicity	265 8 B-Disease
(	274 1 O
LAST	275 4 O
)	279 1 O
.	280 1 O

METHODS	282 7 O
:	289 1 O
Newborn	291 7 O
piglets	299 7 O
received	307 8 O
levobupivacaine	316 15 B-Chemical
until	332 5 O
cardiovascular	338 14 B-Disease
collapse	353 8 I-Disease
occurred	362 8 O
.	370 1 O

Standard	372 8 O
cardiopulmonary	381 15 O
resuscitation	397 13 O
was	411 3 O
started	415 7 O
and	423 3 O
electrocardiogram	427 17 O
(	445 1 O
ECG	446 3 O
)	449 1 O
was	451 3 O
monitored	455 9 O
for	465 3 O
ventricular	469 11 B-Disease
tachycardia	481 11 I-Disease
,	492 1 O
fibrillation	494 12 B-Disease
,	506 1 O
or	508 2 O
QRS	511 3 O
prolongation	515 12 O
.	527 1 O

Piglets	529 7 O
were	537 4 O
then	542 4 O
randomly	547 8 O
allocated	556 9 O
to	566 2 O
four	569 4 O
groups	574 6 O
:	580 1 O
control	582 7 O
(	590 1 O
saline	591 6 O
)	597 1 O
,	598 1 O
Intralipid	600 10 O
(	610 1 O
)	612 1 O
alone	614 5 O
,	619 1 O
epinephrine	621 11 B-Chemical
alone	633 5 O
,	638 1 O
or	640 2 O
a	643 1 O
combination	645 11 O
of	657 2 O
Intralipd	660 9 O
plus	670 4 O
epinephrine	675 11 B-Chemical
.	686 1 O

Resuscitation	688 13 O
continued	702 9 O
for	712 3 O
30	716 2 O
min	719 3 O
or	723 2 O
until	726 5 O
there	732 5 O
was	738 3 O
a	742 1 O
return	744 6 O
of	751 2 O
spontaneous	754 11 O
circulation	766 11 O
(	778 1 O
ROSC	779 4 O
)	783 1 O
accompanied	785 11 O
by	797 2 O
a	800 1 O
mean	802 4 O
arterial	807 8 O
pressure	816 8 O
at	825 2 O
or	828 2 O
superior	831 8 O
to	840 2 O
the	843 3 O
baseline	847 8 O
pressure	856 8 O
and	865 3 O
normal	869 6 O
sinus	876 5 O
rhythm	882 6 O
for	889 3 O
a	893 1 O
period	895 6 O
of	902 2 O
30	905 2 O
min	908 3 O
.	911 1 O

RESULTS	913 7 O
:	920 1 O
ROSC	922 4 O
was	927 3 O
achieved	931 8 O
in	940 2 O
only	943 4 O
one	948 3 O
of	952 2 O
the	955 3 O
control	959 7 O
piglets	967 7 O
compared	975 8 O
with	984 4 O
most	989 4 O
of	994 2 O
the	997 3 O
treated	1001 7 O
piglets	1009 7 O
.	1016 1 O

Mortality	1018 9 O
was	1028 3 O
not	1032 3 O
significantly	1036 13 O
different	1050 9 O
between	1060 7 O
the	1068 3 O
three	1072 5 O
treatment	1078 9 O
groups	1088 6 O
,	1094 1 O
but	1096 3 O
was	1100 3 O
significantly	1104 13 O
lower	1118 5 O
in	1124 2 O
all	1127 3 O
the	1131 3 O
treatment	1135 9 O
groups	1145 6 O
compared	1152 8 O
with	1161 4 O
control	1166 7 O
.	1173 1 O

The	1175 3 O
number	1179 6 O
of	1186 2 O
ECG	1189 3 O
abnormalities	1193 13 O
was	1207 3 O
zero	1211 4 O
in	1216 2 O
the	1219 3 O
Intralipid	1223 10 O
only	1234 4 O
group	1239 5 O
,	1244 1 O
but	1246 3 O
14	1250 2 O
and	1253 3 O
17	1257 2 O
,	1259 1 O
respectively	1261 12 O
,	1273 1 O
in	1275 2 O
the	1278 3 O
epinephrine	1282 11 B-Chemical
and	1294 3 O
epinephrine	1298 11 B-Chemical
plus	1310 4 O
lipid	1315 5 O
groups	1321 6 O
(	1328 1 O
P	1329 1 O
<	1330 1 O
0	1331 1 O
.	1332 1 O
05	1333 2 O
)	1335 1 O
.	1336 1 O

CONCLUSIONS	1338 11 O
:	1349 1 O
Lipid	1351 5 O
emulsion	1357 8 O
with	1366 4 O
or	1371 2 O
without	1374 7 O
epinephrine	1382 11 B-Chemical
,	1393 1 O
or	1395 2 O
epinephrine	1398 11 B-Chemical
alone	1410 5 O
were	1416 4 O
equally	1421 7 O
effective	1429 9 O
in	1439 2 O
achieving	1442 9 O
a	1452 1 O
return	1454 6 O
to	1461 2 O
spontaneous	1464 11 O
circulation	1476 11 O
in	1488 2 O
this	1491 4 O
model	1496 5 O
of	1502 2 O
LAST	1505 4 O
.	1509 1 O

Epinephrine	1511 11 B-Chemical
alone	1523 5 O
or	1529 2 O
in	1532 2 O
combination	1535 11 O
with	1547 4 O
lipid	1552 5 O
was	1558 3 O
associated	1562 10 O
with	1573 4 O
an	1578 2 O
increased	1581 9 O
number	1591 6 O
of	1598 2 O
ECG	1601 3 O
abnormalities	1605 13 O
compared	1619 8 O
with	1628 4 O
lipid	1633 5 O
emulsion	1639 8 O
alone	1648 5 O
.	1653 1 O

Incidence	0 9 O
of	10 2 O
heparin	13 7 B-Chemical
-	20 1 O
induced	21 7 O
thrombocytopenia	29 16 B-Disease
type	46 4 I-Disease
II	51 2 I-Disease
and	54 3 O
postoperative	58 13 O
recovery	72 8 O
of	81 2 O
platelet	84 8 O
count	93 5 O
in	99 2 O
liver	102 5 O
graft	108 5 O
recipients	114 10 O
:	124 1 O
a	126 1 O
retrospective	128 13 O
cohort	142 6 O
analysis	149 8 O
.	157 1 O

BACKGROUND	159 10 O
:	169 1 O
Thrombocytopenia	171 16 B-Disease
in	188 2 O
patients	191 8 O
with	200 4 O
end	205 3 B-Disease
-	208 1 I-Disease
stage	209 5 I-Disease
liver	215 5 I-Disease
disease	221 7 I-Disease
is	229 2 O
a	232 1 O
common	234 6 O
disorder	241 8 O
caused	250 6 O
mainly	257 6 O
by	264 2 O
portal	267 6 B-Disease
hypertension	274 12 I-Disease
,	286 1 O
low	288 3 O
levels	292 6 O
of	299 2 O
thrombopoetin	302 13 O
,	315 1 O
and	317 3 O
endotoxemia	321 11 B-Disease
.	332 1 O

The	334 3 O
impact	338 6 O
of	345 2 O
immune	348 6 O
-	354 1 O
mediated	355 8 O
heparin	364 7 B-Chemical
-	371 1 O
induced	372 7 O
thrombocytopenia	380 16 B-Disease
type	397 4 I-Disease
II	402 2 I-Disease
(	405 1 O
HIT	406 3 B-Disease
type	410 4 I-Disease
II	415 2 I-Disease
)	417 1 O
as	419 2 O
a	422 1 O
cause	424 5 O
of	430 2 O
thrombocytopenia	433 16 B-Disease
after	450 5 O
liver	456 5 O
transplantation	462 15 O
is	478 2 O
not	481 3 O
yet	485 3 O
understood	489 10 O
,	499 1 O
with	501 4 O
few	506 3 O
literature	510 10 O
citations	521 9 O
reporting	531 9 O
contradictory	541 13 O
results	555 7 O
.	562 1 O

The	564 3 O
aim	568 3 O
of	572 2 O
our	575 3 O
study	579 5 O
was	585 3 O
to	589 2 O
demonstrate	592 11 O
the	604 3 O
perioperative	608 13 O
course	622 6 O
of	629 2 O
thrombocytopenia	632 16 B-Disease
after	649 5 O
liver	655 5 O
transplantation	661 15 O
and	677 3 O
determine	681 9 O
the	691 3 O
occurrence	695 10 O
of	706 2 O
clinical	709 8 O
HIT	718 3 B-Disease
type	722 4 I-Disease
II	727 2 I-Disease
.	729 1 O

METHOD	731 6 O
:	737 1 O
We	739 2 O
retrospectively	742 15 O
evaluated	758 9 O
the	768 3 O
medical	772 7 O
records	780 7 O
of	788 2 O
205	791 3 O
consecutive	795 11 O
adult	807 5 O
patients	813 8 O
who	822 3 O
underwent	826 9 O
full	836 4 O
-	840 1 O
size	841 4 O
liver	846 5 O
transplantation	852 15 O
between	868 7 O
January	876 7 O
2006	884 4 O
and	889 3 O
December	893 8 O
2010	902 4 O
due	907 3 O
to	911 2 O
end	914 3 B-Disease
-	917 1 I-Disease
stage	918 5 I-Disease
or	924 2 I-Disease
malignant	927 9 I-Disease
liver	937 5 I-Disease
disease	943 7 I-Disease
.	950 1 O

Preoperative	952 12 O
platelet	965 8 O
count	974 5 O
,	979 1 O
postoperative	981 13 O
course	995 6 O
of	1002 2 O
platelets	1005 9 O
,	1014 1 O
and	1016 3 O
clinical	1020 8 O
signs	1029 5 O
of	1035 2 O
HIT	1038 3 B-Disease
type	1042 4 I-Disease
II	1047 2 I-Disease
were	1050 4 O
analyzed	1055 8 O
.	1063 1 O

RESULTS	1065 7 O
:	1072 1 O
A	1074 1 O
total	1076 5 O
of	1082 2 O
155	1085 3 O
(	1089 1 O
75	1090 2 O
.	1092 1 O
6	1093 1 O
%	1094 1 O
)	1095 1 O
of	1097 2 O
205	1100 3 O
patients	1104 8 O
had	1113 3 O
thrombocytopenia	1117 16 B-Disease
before	1134 6 O
transplantation	1141 15 O
,	1156 1 O
significantly	1158 13 O
influenced	1172 10 O
by	1183 2 O
Model	1186 5 O
of	1192 2 O
End	1195 3 B-Disease
-	1198 1 I-Disease
Stage	1199 5 I-Disease
Liver	1205 5 I-Disease
Disease	1211 7 I-Disease
score	1219 5 O
and	1225 3 O
liver	1229 5 B-Disease
cirrhosis	1235 9 I-Disease
.	1244 1 O

The	1246 3 O
platelet	1250 8 O
count	1259 5 O
exceeded	1265 8 O
100	1274 3 O
,	1277 1 O
000	1278 3 O
/	1281 1 O
uL	1282 2 O
in	1285 2 O
most	1288 4 O
of	1293 2 O
the	1296 3 O
patients	1300 8 O
(	1309 1 O
n	1310 1 O
=	1312 1 O
193	1314 3 O
)	1317 1 O
at	1319 2 O
a	1322 1 O
medium	1324 6 O
of	1331 2 O
7	1334 1 O
d	1336 1 O
.	1337 1 O

Regarding	1339 9 O
HIT	1349 3 B-Disease
II	1353 2 I-Disease
,	1355 1 O
there	1357 5 O
were	1363 4 O
four	1368 4 O
(	1373 1 O
1	1374 1 O
.	1375 1 O
95	1376 2 O
%	1378 1 O
)	1379 1 O
patients	1381 8 O
with	1390 4 O
a	1395 1 O
background	1397 10 O
of	1408 2 O
HIT	1411 3 B-Disease
type	1415 4 I-Disease
II	1420 2 I-Disease
.	1422 1 O

CONCLUSIONS	1424 11 O
:	1435 1 O
The	1437 3 O
incidence	1441 9 O
of	1451 2 O
HIT	1454 3 B-Disease
in	1458 2 O
patients	1461 8 O
with	1470 4 O
end	1475 3 B-Disease
-	1478 1 I-Disease
stage	1479 5 I-Disease
hepatic	1485 7 I-Disease
failure	1493 7 I-Disease
is	1501 2 O
,	1503 1 O
with	1505 4 O
about	1510 5 O
1	1516 1 O
.	1517 1 O
95	1518 2 O
%	1520 1 O
,	1521 1 O
rare	1523 4 O
.	1527 1 O

For	1529 3 O
further	1533 7 O
reduction	1541 9 O
of	1551 2 O
HIT	1554 3 B-Disease
type	1558 4 I-Disease
II	1563 2 I-Disease
,	1565 1 O
the	1567 3 O
use	1571 3 O
of	1575 2 O
intravenous	1578 11 O
heparin	1590 7 B-Chemical
should	1598 6 O
be	1605 2 O
avoided	1608 7 O
and	1616 3 O
the	1620 3 O
prophylactic	1624 12 O
anticoagulation	1637 15 O
should	1653 6 O
be	1660 2 O
performed	1663 9 O
with	1673 4 O
low	1678 3 O
-	1681 1 O
molecular	1682 9 O
-	1691 1 O
weight	1692 6 O
heparin	1699 7 B-Chemical
after	1707 5 O
normalization	1713 13 O
of	1727 2 O
platelet	1730 8 O
count	1739 5 O
.	1744 1 O

Takotsubo	0 9 B-Disease
syndrome	10 8 I-Disease
(	19 1 O
or	20 2 O
apical	23 6 B-Disease
ballooning	30 10 I-Disease
syndrome	41 8 I-Disease
)	49 1 O
secondary	51 9 O
to	61 2 O
Zolmitriptan	64 12 B-Chemical
.	76 1 O

Takotsubo	78 9 B-Disease
syndrome	88 8 I-Disease
(	97 1 O
TS	98 2 B-Disease
)	100 1 O
,	101 1 O
also	103 4 O
known	108 5 O
as	114 2 O
broken	117 6 B-Disease
heart	124 5 I-Disease
syndrome	130 8 I-Disease
,	138 1 O
is	140 2 O
characterized	143 13 O
by	157 2 O
left	160 4 O
ventricle	165 9 O
apical	175 6 O
ballooning	182 10 O
with	193 4 O
elevated	198 8 O
cardiac	207 7 O
biomarkers	215 10 O
and	226 3 O
electrocardiographic	230 20 O
changes	251 7 O
suggestive	259 10 O
of	270 2 O
an	273 2 O
acute	276 5 B-Disease
coronary	282 8 I-Disease
syndrome	291 8 I-Disease
(	300 1 O
ie	301 2 O
,	303 1 O
ST	305 2 O
-	307 1 O
segment	308 7 O
elevation	316 9 O
,	325 1 O
T	327 1 O
wave	329 4 O
inversions	334 10 O
,	344 1 O
and	346 3 O
pathologic	350 10 O
Q	361 1 O
waves	363 5 O
)	368 1 O
.	369 1 O

We	371 2 O
report	374 6 O
a	381 1 O
case	383 4 O
of	388 2 O
54	391 2 O
-	393 1 O
year	394 4 O
-	398 1 O
old	399 3 O
woman	403 5 O
with	409 4 O
medical	414 7 O
history	422 7 O
of	430 2 O
mitral	433 6 B-Disease
valve	440 5 I-Disease
prolapse	446 8 I-Disease
and	455 3 O
migraines	459 9 B-Disease
,	468 1 O
who	470 3 O
was	474 3 O
admitted	478 8 O
to	487 2 O
the	490 3 O
hospital	494 8 O
for	503 3 O
substernal	507 10 O
chest	518 5 B-Disease
pain	524 4 I-Disease
and	529 3 O
electrocardiogram	533 17 O
demonstrated	551 12 O
1	564 1 O
/	565 1 O
2	566 1 O
mm	568 2 O
ST	571 2 O
-	573 1 O
segment	574 7 O
elevation	582 9 O
in	592 2 O
leads	595 5 O
II	601 2 O
,	603 1 O
III	605 3 O
,	608 1 O
aVF	610 3 O
,	613 1 O
V5	615 2 O
,	617 1 O
and	619 3 O
V6	623 2 O
and	626 3 O
positive	630 8 O
troponin	639 8 O
I	648 1 O
.	649 1 O

Emergent	651 8 O
coronary	660 8 O
angiogram	669 9 O
revealed	679 8 O
normal	688 6 O
coronary	695 8 O
arteries	704 8 O
with	713 4 O
moderately	718 10 O
reduced	729 7 O
left	737 4 O
ventricular	742 11 O
ejection	754 8 O
fraction	763 8 O
with	772 4 O
wall	777 4 O
motion	782 6 O
abnormalities	789 13 O
consistent	803 10 O
with	814 4 O
TS	819 2 B-Disease
.	821 1 O

Detailed	823 8 O
history	832 7 O
obtained	840 8 O
retrospectively	849 15 O
revealed	865 8 O
that	874 4 O
the	879 3 O
patient	883 7 O
took	891 4 O
zolmitriptan	896 12 B-Chemical
sparingly	909 9 O
only	919 4 O
when	924 4 O
she	929 3 O
had	933 3 O
migraines	937 9 B-Disease
.	946 1 O

But	948 3 O
before	952 6 O
this	959 4 O
event	964 5 O
,	969 1 O
she	971 3 O
was	975 3 O
taking	979 6 O
zolmitriptan	986 12 B-Chemical
2	999 1 O
-	1000 1 O
3	1001 1 O
times	1003 5 O
daily	1009 5 O
for	1015 3 O
several	1019 7 O
days	1027 4 O
because	1032 7 O
of	1040 2 O
a	1043 1 O
persistent	1045 10 O
migraine	1056 8 B-Disease
headache	1065 8 I-Disease
.	1073 1 O

She	1075 3 O
otherwise	1079 9 O
reported	1089 8 O
that	1098 4 O
she	1103 3 O
is	1107 2 O
quite	1110 5 O
active	1116 6 O
,	1122 1 O
rides	1124 5 O
horses	1130 6 O
,	1136 1 O
and	1138 3 O
does	1142 4 O
show	1147 4 O
jumping	1152 7 O
without	1160 7 O
any	1168 3 O
limitations	1172 11 O
in	1184 2 O
her	1187 3 O
physical	1191 8 O
activity	1200 8 O
.	1208 1 O

There	1210 5 O
was	1216 3 O
no	1220 2 O
evidence	1223 8 O
of	1232 2 O
any	1235 3 O
recent	1239 6 O
stress	1246 6 O
or	1253 2 O
status	1256 6 B-Disease
migrainosus	1263 11 I-Disease
.	1274 1 O

Extensive	1276 9 O
literature	1286 10 O
search	1297 6 O
revealed	1304 8 O
multiple	1313 8 O
cases	1322 5 O
of	1328 2 O
coronary	1331 8 B-Disease
artery	1340 6 I-Disease
vasospasm	1347 9 I-Disease
secondary	1357 9 O
to	1367 2 O
zolmitriptan	1370 12 B-Chemical
,	1382 1 O
but	1384 3 O
none	1388 4 O
of	1393 2 O
the	1396 3 O
cases	1400 5 O
were	1406 4 O
associated	1411 10 O
with	1422 4 O
TS	1427 2 B-Disease
.	1429 1 O

Depression	0 10 B-Disease
,	10 1 O
impulsiveness	12 13 B-Disease
,	25 1 O
sleep	27 5 O
,	32 1 O
and	34 3 O
memory	38 6 O
in	45 2 O
past	48 4 O
and	53 3 O
present	57 7 O
polydrug	65 8 O
users	74 5 O
of	80 2 O
3	83 1 B-Chemical
,	84 1 I-Chemical
4	85 1 I-Chemical
-	86 1 I-Chemical
methylenedioxymethamphetamine	87 29 I-Chemical
(	117 1 O
MDMA	118 4 B-Chemical
,	122 1 O
ecstasy	124 7 B-Chemical
)	131 1 O
.	132 1 O

RATIONALE	134 9 O
:	143 1 O
Ecstasy	145 7 B-Chemical
(	153 1 O
3	154 1 B-Chemical
,	155 1 I-Chemical
4	156 1 I-Chemical
-	157 1 I-Chemical
methylenedioxymethamphetamine	158 29 I-Chemical
,	187 1 O
MDMA	189 4 B-Chemical
)	193 1 O
is	195 2 O
a	198 1 O
worldwide	200 9 O
recreational	210 12 O
drug	223 4 O
of	228 2 O
abuse	231 5 O
.	236 1 O

Unfortunately	238 13 O
,	251 1 O
the	253 3 O
results	257 7 O
from	265 4 O
human	270 5 O
research	276 8 O
investigating	285 13 O
its	299 3 O
psychological	303 13 O
effects	317 7 O
have	325 4 O
been	330 4 O
inconsistent	335 12 O
.	347 1 O

OBJECTIVES	349 10 O
:	359 1 O
The	361 3 O
present	365 7 O
study	373 5 O
aimed	379 5 O
to	385 2 O
be	388 2 O
the	391 3 O
largest	395 7 O
to	403 2 O
date	406 4 O
in	411 2 O
sample	414 6 O
size	421 4 O
and	426 3 O
5HT	430 3 O
-	433 1 O
related	434 7 O
behaviors	442 9 O
;	451 1 O
the	453 3 O
first	457 5 O
to	463 2 O
compare	466 7 O
present	474 7 O
ecstasy	482 7 B-Chemical
users	490 5 O
with	496 4 O
past	501 4 O
users	506 5 O
after	512 5 O
an	518 2 O
abstinence	521 10 O
of	532 2 O
4	535 1 O
or	537 2 O
more	540 4 O
years	545 5 O
,	550 1 O
and	552 3 O
the	556 3 O
first	560 5 O
to	566 2 O
include	569 7 O
robust	577 6 O
controls	584 8 O
for	593 3 O
other	597 5 O
recreational	603 12 O
substances	616 10 O
.	626 1 O

METHODS	628 7 O
:	635 1 O
A	637 1 O
sample	639 6 O
of	646 2 O
997	649 3 O
participants	653 12 O
(	666 1 O
52	667 2 O
%	670 1 O
male	672 4 O
)	676 1 O
was	678 3 O
recruited	682 9 O
to	692 2 O
four	695 4 O
control	700 7 O
groups	708 6 O
(	715 1 O
non	716 3 O
-	719 1 O
drug	720 4 O
(	725 1 O
ND	726 2 O
)	728 1 O
,	729 1 O
alcohol	731 7 B-Chemical
/	738 1 O
nicotine	739 8 B-Chemical
(	748 1 O
AN	749 2 B-Chemical
)	751 1 O
,	752 1 O
cannabis	754 8 B-Chemical
/	762 1 O
alcohol	763 7 B-Chemical
/	770 1 O
nicotine	771 8 B-Chemical
(	780 1 O
CAN	781 3 B-Chemical
)	784 1 O
,	785 1 O
non	787 3 O
-	790 1 O
ecstasy	791 7 B-Chemical
polydrug	799 8 O
(	808 1 O
PD	809 2 O
)	811 1 O
)	812 1 O
,	813 1 O
and	815 3 O
two	819 3 O
ecstasy	823 7 B-Chemical
polydrug	831 8 O
groups	840 6 O
(	847 1 O
present	848 7 O
(	856 1 O
MDMA	857 4 B-Chemical
)	861 1 O
and	863 3 O
past	867 4 O
users	872 5 O
(	878 1 O
EX	879 2 O
-	881 1 O
MDMA	882 4 B-Chemical
)	886 1 O
.	887 1 O

Participants	889 12 O
completed	902 9 O
a	912 1 O
drug	914 4 O
history	919 7 O
questionnaire	927 13 O
,	940 1 O
Beck	942 4 O
Depression	947 10 B-Disease
Inventory	958 9 O
,	967 1 O
Barratt	969 7 O
Impulsiveness	977 13 B-Disease
Scale	991 5 O
,	996 1 O
Pittsburgh	998 10 O
Sleep	1009 5 O
Quality	1015 7 O
Index	1023 5 O
,	1028 1 O
and	1030 3 O
Wechsler	1034 8 O
Memory	1043 6 O
Scale	1050 5 O
-	1055 1 O
Revised	1056 7 O
which	1064 5 O
,	1069 1 O
in	1071 2 O
total	1074 5 O
,	1079 1 O
provided	1081 8 O
13	1090 2 O
psychometric	1093 12 O
measures	1106 8 O
.	1114 1 O

RESULTS	1116 7 O
:	1123 1 O
While	1125 5 O
the	1131 3 O
CAN	1135 3 B-Chemical
and	1139 3 O
PD	1143 2 O
groups	1146 6 O
tended	1153 6 O
to	1160 2 O
record	1163 6 O
greater	1170 7 O
deficits	1178 8 O
than	1187 4 O
the	1192 3 O
non	1196 3 O
-	1199 1 O
drug	1200 4 O
controls	1205 8 O
,	1213 1 O
the	1215 3 O
MDMA	1219 4 B-Chemical
and	1224 3 O
EX	1228 2 O
-	1230 1 O
MDMA	1231 4 B-Chemical
groups	1236 6 O
recorded	1243 8 O
greater	1252 7 O
deficits	1260 8 O
than	1269 4 O
all	1274 3 O
the	1278 3 O
control	1282 7 O
groups	1290 6 O
on	1297 2 O
ten	1300 3 O
of	1304 2 O
the	1307 3 O
13	1311 2 O
psychometric	1314 12 O
measures	1327 8 O
.	1335 1 O

Strikingly	1337 10 O
,	1347 1 O
despite	1349 7 O
prolonged	1357 9 O
abstinence	1367 10 O
(	1378 1 O
mean	1379 4 O
,	1383 1 O
4	1385 1 O
.	1386 1 O
98	1387 2 O
;	1389 1 O
range	1391 5 O
,	1396 1 O
4	1398 1 O
-	1399 1 O
9	1400 1 O
years	1402 5 O
)	1407 1 O
,	1408 1 O
past	1410 4 O
ecstasy	1415 7 B-Chemical
users	1423 5 O
showed	1429 6 O
few	1436 3 O
signs	1440 5 O
of	1446 2 O
recovery	1449 8 O
.	1457 1 O

Compared	1459 8 O
with	1468 4 O
present	1473 7 O
ecstasy	1481 7 B-Chemical
users	1489 5 O
,	1494 1 O
the	1496 3 O
past	1500 4 O
users	1505 5 O
showed	1511 6 O
no	1518 2 O
change	1521 6 O
for	1528 3 O
ten	1532 3 O
measures	1536 8 O
,	1544 1 O
increased	1546 9 O
impairment	1556 10 O
for	1567 3 O
two	1571 3 O
measures	1575 8 O
,	1583 1 O
and	1585 3 O
improvement	1589 11 O
on	1601 2 O
just	1604 4 O
one	1609 3 O
measure	1613 7 O
.	1620 1 O

CONCLUSIONS	1622 11 O
:	1633 1 O
Given	1635 5 O
this	1641 4 O
record	1646 6 O
of	1653 2 O
impaired	1656 8 B-Disease
memory	1665 6 I-Disease
and	1672 3 O
clinically	1676 10 O
significant	1687 11 O
levels	1699 6 O
of	1706 2 O
depression	1709 10 B-Disease
,	1719 1 O
impulsiveness	1721 13 B-Disease
,	1734 1 O
and	1736 3 O
sleep	1740 5 B-Disease
disturbance	1746 11 I-Disease
,	1757 1 O
the	1759 3 O
prognosis	1763 9 O
for	1773 3 O
the	1777 3 O
current	1781 7 O
generation	1789 10 O
of	1800 2 O
ecstasy	1803 7 B-Chemical
users	1811 5 O
is	1817 2 O
a	1820 1 O
major	1822 5 O
cause	1828 5 O
for	1834 3 O
concern	1838 7 O
.	1845 1 O

Association	0 11 O
of	12 2 O
common	15 6 O
genetic	22 7 O
variants	30 8 O
of	39 2 O
HOMER1	42 6 O
gene	49 4 O
with	54 4 O
levodopa	59 8 B-Chemical
adverse	68 7 O
effects	76 7 O
in	84 2 O
Parkinson	87 9 B-Disease
'	96 1 I-Disease
s	97 1 I-Disease
disease	99 7 I-Disease
patients	107 8 O
.	115 1 O

Levodopa	117 8 B-Chemical
is	126 2 O
the	129 3 O
most	133 4 O
effective	138 9 O
symptomatic	148 11 O
therapy	160 7 O
for	168 3 O
Parkinson	172 9 B-Disease
'	181 1 I-Disease
s	182 1 I-Disease
disease	184 7 I-Disease
,	191 1 O
but	193 3 O
its	197 3 O
chronic	201 7 O
use	209 3 O
could	213 5 O
lead	219 4 O
to	224 2 O
chronic	227 7 O
adverse	235 7 O
outcomes	243 8 O
,	251 1 O
such	253 4 O
as	258 2 O
motor	261 5 O
fluctuations	267 12 O
,	279 1 O
dyskinesia	281 10 B-Disease
and	292 3 O
visual	296 6 B-Disease
hallucinations	303 14 I-Disease
.	317 1 O

HOMER1	319 6 O
is	326 2 O
a	329 1 O
protein	331 7 O
with	339 4 O
pivotal	344 7 O
function	352 8 O
in	361 2 O
glutamate	364 9 B-Chemical
transmission	374 12 O
,	386 1 O
which	388 5 O
has	394 3 O
been	398 4 O
related	403 7 O
to	411 2 O
the	414 3 O
pathogenesis	418 12 O
of	431 2 O
these	434 5 O
complications	440 13 O
.	453 1 O

This	455 4 O
study	460 5 O
investigates	466 12 O
whether	479 7 O
polymorphisms	487 13 O
in	501 2 O
the	504 3 O
HOMER1	508 6 O
gene	515 4 O
promoter	520 8 O
region	529 6 O
are	536 3 O
associated	540 10 O
with	551 4 O
the	556 3 O
occurrence	560 10 O
of	571 2 O
the	574 3 O
chronic	578 7 O
complications	586 13 O
of	600 2 O
levodopa	603 8 B-Chemical
therapy	612 7 O
.	619 1 O

A	621 1 O
total	623 5 O
of	629 2 O
205	632 3 O
patients	636 8 O
with	645 4 O
idiopathic	650 10 B-Disease
Parkinson	661 9 I-Disease
'	670 1 I-Disease
s	671 1 I-Disease
disease	673 7 I-Disease
were	681 4 O
investigated	686 12 O
.	698 1 O

Patients	700 8 O
were	709 4 O
genotyped	714 9 O
for	724 3 O
rs4704559	728 9 O
,	737 1 O
rs10942891	739 10 O
and	750 3 O
rs4704560	754 9 O
by	764 2 O
allelic	767 7 O
discrimination	775 14 O
with	790 4 O
Taqman	795 6 O
assays	802 6 O
.	808 1 O

The	810 3 O
rs4704559	814 9 O
G	824 1 O
allele	826 6 O
was	833 3 O
associated	837 10 O
with	848 4 O
a	853 1 O
lower	855 5 O
prevalence	861 10 O
of	872 2 O
dyskinesia	875 10 B-Disease
(	886 1 O
prevalence	887 10 O
ratio	898 5 O
(	904 1 O
PR	905 2 O
)	907 1 O
=	908 1 O
0	909 1 O
.	910 1 O
615	911 3 O
,	914 1 O
95	916 2 O
%	918 1 O
confidence	920 10 O
interval	931 8 O
(	940 1 O
CI	941 2 O
)	943 1 O
0	945 1 O
.	946 1 O
426	947 3 O
-	950 1 O
0	951 1 O
.	952 1 O
887	953 3 O
,	956 1 O
P	958 1 O
=	959 1 O
0	960 1 O
.	961 1 O
009	962 3 O
)	965 1 O
and	967 3 O
visual	971 6 B-Disease
hallucinations	978 14 I-Disease
(	993 1 O
PR	994 2 O
=	996 1 O
0	997 1 O
.	998 1 O
515	999 3 O
,	1002 1 O
95	1004 2 O
%	1006 1 O
CI	1008 2 O
0	1011 1 O
.	1012 1 O
295	1013 3 O
-	1016 1 O
0	1017 1 O
.	1018 1 O
899	1019 3 O
,	1022 1 O
P	1024 1 O
=	1025 1 O
0	1026 1 O
.	1027 1 O
020	1028 3 O
)	1031 1 O
.	1032 1 O

Our	1034 3 O
data	1038 4 O
suggest	1043 7 O
that	1051 4 O
HOMER1	1056 6 O
rs4704559	1063 9 O
G	1073 1 O
allele	1075 6 O
has	1082 3 O
a	1086 1 O
protective	1088 10 O
role	1099 4 O
for	1104 3 O
the	1108 3 O
development	1112 11 O
of	1124 2 O
levodopa	1127 8 B-Chemical
adverse	1136 7 O
effects	1144 7 O
.	1151 1 O

Crocin	0 6 B-Chemical
improves	7 8 O
lipid	16 5 O
dysregulation	22 13 O
in	36 2 O
subacute	39 8 O
diazinon	48 8 B-Chemical
exposure	57 8 O
through	66 7 O
ERK1	74 4 O
/	78 1 O
2	79 1 O
pathway	81 7 O
in	89 2 O
rat	92 3 O
liver	96 5 O
.	101 1 O

INTRODUCTION	103 12 O
:	115 1 O
Diazinon	117 8 B-Chemical
Yis	126 3 O
one	130 3 O
of	134 2 O
the	137 3 O
most	141 4 O
broadly	146 7 O
used	154 4 O
organophosphorus	159 16 B-Chemical
insecticides	176 12 O
in	189 2 O
agriculture	192 11 O
.	203 1 O

It	205 2 O
has	208 3 O
been	212 4 O
shown	217 5 O
that	223 4 O
exposure	228 8 O
to	237 2 O
diazinon	240 8 B-Chemical
may	249 3 O
interfere	253 9 O
with	263 4 O
lipid	268 5 O
metabolism	274 10 O
.	284 1 O

Moreover	286 8 O
,	294 1 O
the	296 3 O
hypolipidemic	300 13 O
effect	314 6 O
of	321 2 O
crocin	324 6 B-Chemical
has	331 3 O
been	335 4 O
established	340 11 O
.	351 1 O

Earlier	353 7 O
studies	361 7 O
revealed	369 8 O
the	378 3 O
major	382 5 O
role	388 4 O
of	393 2 O
Extracellular	396 13 O
signal	410 6 O
-	416 1 O
regulated	417 9 O
kinase	427 6 O
(	434 1 O
ERK	435 3 O
)	438 1 O
pathways	440 8 O
in	449 2 O
low	452 3 O
-	455 1 O
density	456 7 O
lipoprotein	464 11 O
receptor	476 8 O
(	485 1 O
LDLr	486 4 O
)	490 1 O
expression	492 10 O
.	502 1 O

The	504 3 O
aim	508 3 O
of	512 2 O
this	515 4 O
study	520 5 O
was	526 3 O
to	530 2 O
evaluate	533 8 O
changes	542 7 O
in	550 2 O
the	553 3 O
regulation	557 10 O
of	568 2 O
lipid	571 5 O
metabolism	577 10 O
,	587 1 O
ERK	589 3 O
and	593 3 O
LDLr	597 4 O
expression	602 10 O
in	613 2 O
the	616 3 O
liver	620 5 O
of	626 2 O
rats	629 4 O
exposed	634 7 O
to	642 2 O
subacute	645 8 O
diazinon	654 8 B-Chemical
.	662 1 O

Furthermore	664 11 O
ameliorating	676 12 O
effect	689 6 O
of	696 2 O
crocin	699 6 B-Chemical
on	706 2 O
diazinon	709 8 B-Chemical
induced	718 7 O
disturbed	726 9 O
cholesterol	736 11 B-Chemical
homeostasis	748 11 O
was	760 3 O
studied	764 7 O
.	771 1 O

METHODS	773 7 O
:	780 1 O
24	782 2 O
Rats	785 4 O
were	790 4 O
divided	795 7 O
into	803 4 O
4	808 1 O
groups	810 6 O
and	817 3 O
received	821 8 O
following	830 9 O
treatments	840 10 O
for	851 3 O
4	855 1 O
weeks	857 5 O
;	862 1 O
Corn	864 4 O
oil	869 3 O
(	873 1 O
control	874 7 O
)	881 1 O
,	882 1 O
diazinon	884 8 B-Chemical
(	893 1 O
15mg	894 4 O
/	898 1 O
kg	899 2 O
per	902 3 O
day	906 3 O
,	909 1 O
orally	911 6 O
)	917 1 O
and	919 3 O
crocin	923 6 B-Chemical
(	930 1 O
12	931 2 O
.	933 1 O
5	934 1 O
and	936 3 O
25mg	940 4 O
/	944 1 O
kg	945 2 O
per	948 3 O
day	952 3 O
,	955 1 O
intraperitoneally	957 17 O
)	974 1 O
in	976 2 O
combination	979 11 O
with	991 4 O
diazinon	996 8 B-Chemical
(	1005 1 O
15	1006 2 O
mg	1009 2 O
/	1011 1 O
kg	1012 2 O
)	1014 1 O
.	1015 1 O

The	1017 3 O
levels	1021 6 O
of	1028 2 O
cholesterol	1031 11 B-Chemical
,	1042 1 O
triglyceride	1044 12 B-Chemical
and	1057 3 O
LDL	1061 3 O
in	1065 2 O
blood	1068 5 O
of	1074 2 O
rats	1077 4 O
were	1082 4 O
analyzed	1087 8 O
.	1095 1 O

Moreover	1097 8 O
mRNA	1106 4 O
levels	1111 6 O
of	1118 2 O
LDLr	1121 4 O
and	1126 3 O
ERK1	1130 4 O
/	1134 1 O
2	1135 1 O
as	1137 2 O
well	1140 4 O
as	1145 2 O
protein	1148 7 O
levels	1156 6 O
of	1163 2 O
total	1166 5 O
and	1172 3 O
activated	1176 9 O
forms	1186 5 O
of	1192 2 O
ERK1	1195 4 O
/	1199 1 O
2	1200 1 O
in	1202 2 O
rat	1205 3 O
liver	1209 5 O
were	1215 4 O
evaluated	1220 9 O
by	1230 2 O
Western	1233 7 O
blotting	1241 8 O
and	1250 3 O
quantitative	1254 12 O
real	1267 4 O
time	1272 4 O
polymerase	1277 10 O
chain	1288 5 O
reaction	1294 8 O
analysis	1303 8 O
.	1311 1 O

RESULTS	1313 7 O
:	1320 1 O
Our	1322 3 O
data	1326 4 O
showed	1331 6 O
that	1338 4 O
subacute	1343 8 O
exposure	1352 8 O
to	1361 2 O
diazinon	1364 8 B-Chemical
significantly	1373 13 O
increased	1387 9 O
concentrations	1397 14 O
of	1412 2 O
cholesterol	1415 11 B-Chemical
,	1426 1 O
triglyceride	1428 12 B-Chemical
and	1441 3 O
LDL	1445 3 O
.	1448 1 O

Moreover	1450 8 O
diazinon	1459 8 B-Chemical
decreased	1468 9 O
ERK1	1478 4 O
/	1482 1 O
2	1483 1 O
protein	1485 7 O
phosphorylation	1493 15 O
and	1509 3 O
LDLr	1513 4 O
transcript	1518 10 O
.	1528 1 O

Crocin	1530 6 B-Chemical
reduced	1537 7 O
inhibition	1545 10 O
of	1556 2 O
ERK	1559 3 O
activation	1563 10 O
and	1574 3 O
diazinon	1578 8 B-Chemical
-	1586 1 O
induced	1587 7 O
hyperlipemia	1595 12 B-Disease
and	1608 3 O
increased	1612 9 O
levels	1622 6 O
of	1629 2 O
LDLr	1632 4 O
transcript	1637 10 O
.	1647 1 O

CONCLUSIONS	1649 11 O
:	1660 1 O
Crocin	1662 6 B-Chemical
may	1669 3 O
be	1673 2 O
considered	1676 10 O
as	1687 2 O
a	1690 1 O
novel	1692 5 O
protective	1698 10 O
agent	1709 5 O
in	1715 2 O
diazinon	1718 8 B-Chemical
-	1726 1 O
induced	1727 7 O
hyperlipemia	1735 12 B-Disease
through	1748 7 O
modulating	1756 10 O
of	1767 2 O
ERK	1770 3 O
pathway	1774 7 O
and	1782 3 O
increase	1786 8 O
of	1795 2 O
LDLr	1798 4 O
expression	1803 10 O
.	1813 1 O

GEM	0 3 B-Chemical
-	3 1 O
P	4 1 O
chemotherapy	6 12 O
is	19 2 O
active	22 6 O
in	29 2 O
the	32 3 O
treatment	36 9 O
of	46 2 O
relapsed	49 8 O
Hodgkin	58 7 B-Disease
lymphoma	66 8 I-Disease
.	74 1 O

Hodgkin	76 7 B-Disease
lymphoma	84 8 I-Disease
(	93 1 O
HL	94 2 B-Disease
)	96 1 O
is	98 2 O
a	101 1 O
relatively	103 10 O
chemosensitive	114 14 O
malignancy	129 10 B-Disease
.	139 1 O

However	141 7 O
,	148 1 O
for	150 3 O
those	154 5 O
who	160 3 O
relapse	164 7 O
,	171 1 O
high	173 4 O
-	177 1 O
dose	178 4 O
chemotherapy	183 12 O
with	196 4 O
autologous	201 10 O
stem	212 4 O
cell	217 4 O
transplant	222 10 O
is	233 2 O
the	236 3 O
treatment	240 9 O
of	250 2 O
choice	253 6 O
which	260 5 O
relies	266 6 O
on	273 2 O
adequate	276 8 O
disease	285 7 O
control	293 7 O
with	301 4 O
salvage	306 7 O
chemotherapy	314 12 O
.	326 1 O

Regimens	328 8 O
commonly	337 8 O
used	346 4 O
often	351 5 O
require	357 7 O
inpatient	365 9 O
administration	375 14 O
and	390 3 O
can	394 3 O
be	398 2 O
difficult	401 9 O
to	411 2 O
deliver	414 7 O
due	422 3 O
to	426 2 O
toxicity	429 8 B-Disease
.	437 1 O

Gemcitabine	439 11 B-Chemical
and	451 3 O
cisplatin	455 9 B-Chemical
have	465 4 O
activity	470 8 O
in	479 2 O
HL	482 2 B-Disease
,	484 1 O
non	486 3 O
-	489 1 O
overlapping	490 11 O
toxicity	502 8 B-Disease
with	511 4 O
first	516 5 O
-	521 1 O
line	522 4 O
chemotherapeutics	527 17 O
,	544 1 O
and	546 3 O
may	550 3 O
be	554 2 O
delivered	557 9 O
in	567 2 O
an	570 2 O
outpatient	573 10 O
setting	584 7 O
.	591 1 O

In	593 2 O
this	596 4 O
retrospective	601 13 O
single	615 6 O
-	621 1 O
centre	622 6 O
analysis	629 8 O
,	637 1 O
patients	639 8 O
with	648 4 O
relapsed	653 8 O
or	662 2 O
refractory	665 10 O
HL	676 2 B-Disease
treated	679 7 O
with	687 4 O
gemcitabine	692 11 B-Chemical
1	704 1 O
,	705 1 O
000	706 3 O
mg	710 2 O
/	712 1 O
m	713 1 O
(	714 1 O
2	715 1 O
)	716 1 O
day	718 3 O
(	722 1 O
D	723 1 O
)	724 1 O
1	725 1 O
,	726 1 O
D8	728 2 O
and	731 3 O
D15	735 3 O
;	738 1 O
methylprednisolone	740 18 B-Chemical
1	759 1 O
,	760 1 O
000	761 3 O
mg	765 2 O
D1	768 2 O
-	770 1 O
5	771 1 O
;	772 1 O
and	774 3 O
cisplatin	778 9 B-Chemical
100	788 3 O
mg	792 2 O
/	794 1 O
m	795 1 O
(	796 1 O
2	797 1 O
)	798 1 O
D15	800 3 O
,	803 1 O
every	805 5 O
28	811 2 O
days	814 4 O
(	819 1 O
GEM	820 3 B-Chemical
-	823 1 O
P	824 1 O
)	825 1 O
were	827 4 O
included	832 8 O
.	840 1 O

Demographic	842 11 O
,	853 1 O
survival	855 8 O
,	863 1 O
response	865 8 O
and	874 3 O
toxicity	878 8 B-Disease
data	887 4 O
were	892 4 O
recorded	897 8 O
.	905 1 O

Forty	907 5 O
-	912 1 O
one	913 3 O
eligible	917 8 O
patients	926 8 O
were	935 4 O
identified	940 10 O
:	950 1 O
median	952 6 O
age	959 3 O
27	963 2 O
.	965 1 O

One	967 3 O
hundred	971 7 O
and	979 3 O
twenty	983 6 O
-	989 1 O
two	990 3 O
cycles	994 6 O
of	1001 2 O
GEM	1004 3 B-Chemical
-	1007 1 O
P	1008 1 O
were	1010 4 O
administered	1015 12 O
in	1028 2 O
total	1031 5 O
(	1037 1 O
median	1038 6 O
3	1045 1 O
cycles	1047 6 O
;	1053 1 O
range	1055 5 O
1	1061 1 O
-	1062 1 O
6	1063 1 O
)	1064 1 O
.	1065 1 O

Twenty	1067 6 O
of	1074 2 O
41	1077 2 O
(	1080 1 O
48	1081 2 O
%	1084 1 O
)	1085 1 O
patients	1087 8 O
received	1096 8 O
GEM	1105 3 B-Chemical
-	1108 1 O
P	1109 1 O
as	1111 2 O
second	1114 6 O
-	1120 1 O
line	1121 4 O
treatment	1126 9 O
and	1136 3 O
11	1140 2 O
/	1142 1 O
41	1143 2 O
(	1146 1 O
27	1147 2 O
%	1150 1 O
)	1151 1 O
as	1153 2 O
third	1156 5 O
-	1161 1 O
line	1162 4 O
therapy	1167 7 O
.	1174 1 O

Overall	1176 7 O
response	1184 8 O
rate	1193 4 O
(	1198 1 O
ORR	1199 3 O
)	1202 1 O
to	1204 2 O
GEM	1207 3 B-Chemical
-	1210 1 O
P	1211 1 O
in	1213 2 O
the	1216 3 O
entire	1220 6 O
cohort	1227 6 O
was	1234 3 O
80	1238 2 O
%	1241 1 O
(	1243 1 O
complete	1244 8 O
response	1253 8 O
(	1262 1 O
CR	1263 2 O
)	1265 1 O
37	1267 2 O
%	1270 1 O
,	1271 1 O
partial	1273 7 O
response	1281 8 O
44	1290 2 O
%	1293 1 O
)	1294 1 O
with	1296 4 O
14	1301 2 O
/	1303 1 O
15	1304 2 O
CR	1307 2 O
confirmed	1310 9 O
as	1320 2 O
a	1323 1 O
metabolic	1325 9 O
CR	1335 2 O
on	1338 2 O
PET	1341 3 O
and	1345 3 O
ORR	1349 3 O
of	1353 2 O
85	1356 2 O
%	1359 1 O
in	1361 2 O
the	1364 3 O
20	1368 2 O
second	1371 6 O
-	1377 1 O
line	1378 4 O
patients	1383 8 O
.	1391 1 O

The	1393 3 O
most	1397 4 O
common	1402 6 O
grade	1409 5 O
3	1415 1 O
/	1416 1 O
4	1417 1 O
toxicities	1419 10 B-Disease
were	1430 4 O
haematological	1435 14 O
:	1449 1 O
neutropenia	1451 11 B-Disease
54	1463 2 O
%	1466 1 O
and	1468 3 O
thrombocytopenia	1472 16 B-Disease
51	1489 2 O
%	1492 1 O
.	1493 1 O

Median	1495 6 O
follow	1502 6 O
-	1508 1 O
up	1509 2 O
from	1512 4 O
the	1517 3 O
start	1521 5 O
of	1527 2 O
GEM	1530 3 B-Chemical
-	1533 1 O
P	1534 1 O
was	1536 3 O
4	1540 1 O
.	1541 1 O
5	1542 1 O
years	1544 5 O
.	1549 1 O

Following	1551 9 O
GEM	1561 3 B-Chemical
-	1564 1 O
P	1565 1 O
,	1566 1 O
5	1568 1 O
-	1569 1 O
year	1570 4 O
progression	1575 11 O
-	1586 1 O
free	1587 4 O
survival	1592 8 O
was	1601 3 O
46	1605 2 O
%	1608 1 O
(	1610 1 O
95	1611 2 O
%	1614 1 O
confidence	1616 10 O
interval	1627 8 O
(	1636 1 O
CI	1637 2 O
)	1639 1 O
,	1640 1 O
30	1642 2 O
-	1644 1 O
62	1645 2 O
%	1648 1 O
)	1649 1 O
and	1651 3 O
5	1655 1 O
-	1656 1 O
year	1657 4 O
overall	1662 7 O
survival	1670 8 O
was	1679 3 O
59	1683 2 O
%	1686 1 O
(	1688 1 O
95	1689 2 O
%	1692 1 O
CI	1694 2 O
,	1696 1 O
43	1698 2 O
-	1700 1 O
74	1701 2 O
%	1704 1 O
)	1705 1 O
.	1706 1 O

Fourteen	1708 8 O
of	1717 2 O
41	1720 2 O
patients	1723 8 O
proceeded	1732 9 O
directly	1742 8 O
to	1751 2 O
autologous	1754 10 O
transplant	1765 10 O
.	1775 1 O

GEM	1777 3 B-Chemical
-	1780 1 O
P	1781 1 O
is	1783 2 O
a	1786 1 O
salvage	1788 7 O
chemotherapy	1796 12 O
with	1809 4 O
relatively	1814 10 O
high	1825 4 O
response	1830 8 O
rates	1839 5 O
,	1844 1 O
leading	1846 7 O
to	1854 2 O
successful	1857 10 O
transplantation	1868 15 O
in	1884 2 O
appropriate	1887 11 O
patients	1899 8 O
,	1907 1 O
in	1909 2 O
the	1912 3 O
treatment	1916 9 O
of	1926 2 O
relapsed	1929 8 O
or	1938 2 O
refractory	1941 10 O
HL	1952 2 B-Disease
.	1954 1 O

Basal	0 5 O
functioning	6 11 O
of	18 2 O
the	21 3 O
hypothalamic	25 12 O
-	37 1 O
pituitary	38 9 O
-	47 1 O
adrenal	48 7 O
(	56 1 O
HPA	57 3 O
)	60 1 O
axis	62 4 O
and	67 3 O
psychological	71 13 O
distress	85 8 O
in	94 2 O
recreational	97 12 O
ecstasy	110 7 B-Chemical
polydrug	118 8 O
users	127 5 O
.	132 1 O

RATIONALE	134 9 O
:	143 1 O
Ecstasy	145 7 B-Chemical
(	153 1 O
MDMA	154 4 B-Chemical
)	158 1 O
is	160 2 O
a	163 1 O
psychostimulant	165 15 O
drug	181 4 O
which	186 5 O
is	192 2 O
increasingly	195 12 O
associated	208 10 O
with	219 4 O
psychobiological	224 16 B-Disease
dysfunction	241 11 I-Disease
.	252 1 O

While	254 5 O
some	260 4 O
recent	265 6 O
studies	272 7 O
suggest	280 7 O
acute	288 5 O
changes	294 7 O
in	302 2 O
neuroendocrine	305 14 O
function	320 8 O
,	328 1 O
less	330 4 O
is	335 2 O
known	338 5 O
about	344 5 O
long	350 4 O
-	354 1 O
term	355 4 O
changes	360 7 O
in	368 2 O
HPA	371 3 O
functionality	375 13 O
in	389 2 O
recreational	392 12 O
users	405 5 O
.	410 1 O

OBJECTIVES	412 10 O
:	422 1 O
The	424 3 O
current	428 7 O
study	436 5 O
is	442 2 O
the	445 3 O
first	449 5 O
to	455 2 O
explore	458 7 O
the	466 3 O
effects	470 7 O
of	478 2 O
ecstasy	481 7 B-Chemical
-	488 1 O
polydrug	489 8 O
use	498 3 O
on	502 2 O
psychological	505 13 O
distress	519 8 O
and	528 3 O
basal	532 5 O
functioning	538 11 O
of	550 2 O
the	553 3 O
HPA	557 3 O
axis	561 4 O
through	566 7 O
assessing	574 9 O
the	584 3 O
secretion	588 9 O
of	598 2 O
cortisol	601 8 B-Chemical
across	610 6 O
the	617 3 O
diurnal	621 7 O
period	629 6 O
.	635 1 O

METHOD	637 6 O
:	643 1 O
Seventy	645 7 O
-	652 1 O
six	653 3 O
participants	657 12 O
(	670 1 O
21	671 2 O
nonusers	674 8 O
,	682 1 O
29	684 2 O
light	687 5 O
ecstasy	693 7 B-Chemical
-	700 1 O
polydrug	701 8 O
users	710 5 O
,	715 1 O
26	717 2 O
heavy	720 5 O
ecstasy	726 7 B-Chemical
-	733 1 O
polydrug	734 8 O
users	743 5 O
)	748 1 O
completed	750 9 O
a	760 1 O
substance	762 9 O
use	772 3 O
inventory	776 9 O
and	786 3 O
measures	790 8 O
of	799 2 O
psychological	802 13 O
distress	816 8 O
at	825 2 O
baseline	828 8 O
,	836 1 O
then	838 4 O
two	843 3 O
consecutive	847 11 O
days	859 4 O
of	864 2 O
cortisol	867 8 B-Chemical
sampling	876 8 O
(	885 1 O
on	886 2 O
awakening	889 9 O
,	898 1 O
30	900 2 O
min	903 3 O
post	907 4 O
awakening	912 9 O
,	921 1 O
between	923 7 O
1400	931 4 O
and	936 3 O
1600	940 4 O
hours	945 5 O
and	951 3 O
pre	955 3 O
bedtime	959 7 O
)	966 1 O
.	967 1 O

On	969 2 O
day	972 3 O
2	976 1 O
,	977 1 O
participants	979 12 O
also	992 4 O
attended	997 8 O
the	1006 3 O
laboratory	1010 10 O
to	1021 2 O
complete	1024 8 O
a	1033 1 O
20	1035 2 O
-	1037 1 O
min	1038 3 O
multitasking	1042 12 O
stressor	1055 8 O
.	1063 1 O

RESULTS	1065 7 O
:	1072 1 O
Both	1074 4 O
user	1079 4 O
groups	1084 6 O
exhibited	1091 9 O
significantly	1101 13 O
greater	1115 7 O
levels	1123 6 O
of	1130 2 O
anxiety	1133 7 B-Disease
and	1141 3 O
depression	1145 10 B-Disease
than	1156 4 O
nonusers	1161 8 O
.	1169 1 O

On	1171 2 O
day	1174 3 O
1	1178 1 O
,	1179 1 O
all	1181 3 O
participants	1185 12 O
exhibited	1198 9 O
a	1208 1 O
typical	1210 7 O
cortisol	1218 8 B-Chemical
profile	1227 7 O
,	1234 1 O
though	1236 6 O
light	1243 5 O
users	1249 5 O
had	1255 3 O
significantly	1259 13 O
elevated	1273 8 O
levels	1282 6 O
pre	1289 3 O
-	1292 1 O
bed	1293 3 O
.	1296 1 O

On	1298 2 O
day	1301 3 O
2	1305 1 O
,	1306 1 O
heavy	1308 5 O
users	1314 5 O
demonstrated	1320 12 O
elevated	1333 8 O
levels	1342 6 O
upon	1349 4 O
awakening	1354 9 O
and	1364 3 O
all	1368 3 O
ecstasy	1372 7 B-Chemical
-	1379 1 O
polydrug	1380 8 O
users	1389 5 O
demonstrated	1395 12 O
elevated	1408 8 O
pre	1417 3 O
-	1420 1 O
bed	1421 3 O
levels	1425 6 O
compared	1432 8 O
to	1441 2 O
non	1444 3 O
-	1447 1 O
users	1448 5 O
.	1453 1 O

Significant	1455 11 O
between	1467 7 O
group	1475 5 O
differences	1481 11 O
were	1493 4 O
also	1498 4 O
observed	1503 8 O
in	1512 2 O
afternoon	1515 9 O
cortisol	1525 8 B-Chemical
levels	1534 6 O
and	1541 3 O
in	1545 2 O
overall	1548 7 O
cortisol	1556 8 B-Chemical
secretion	1565 9 O
across	1575 6 O
the	1582 3 O
day	1586 3 O
.	1589 1 O

CONCLUSIONS	1591 11 O
:	1602 1 O
The	1604 3 O
increases	1608 9 O
in	1618 2 O
anxiety	1621 7 B-Disease
and	1629 3 O
depression	1633 10 B-Disease
are	1644 3 O
in	1648 2 O
line	1651 4 O
with	1656 4 O
previous	1661 8 O
observations	1670 12 O
in	1683 2 O
recreational	1686 12 O
ecstasy	1699 7 B-Chemical
-	1706 1 O
polydrug	1707 8 O
users	1716 5 O
.	1721 1 O

Dysregulated	1723 12 O
diurnal	1736 7 O
cortisol	1744 8 B-Chemical
may	1753 3 O
be	1757 2 O
indicative	1760 10 O
of	1771 2 O
inappropriate	1774 13 O
anticipation	1788 12 O
of	1801 2 O
forthcoming	1804 11 O
demands	1816 7 O
and	1824 3 O
hypersecretion	1828 14 O
may	1843 3 O
lead	1847 4 O
to	1852 2 O
the	1855 3 O
increased	1859 9 O
psychological	1869 13 O
and	1883 3 O
physical	1887 8 O
morbidity	1896 9 O
associated	1906 10 O
with	1917 4 O
heavy	1922 5 O
recreational	1928 12 O
use	1941 3 O
of	1945 2 O
ecstasy	1948 7 B-Chemical
.	1955 1 O

Ifosfamide	0 10 B-Chemical
related	11 7 O
encephalopathy	19 14 B-Disease
:	33 1 O
the	35 3 O
need	39 4 O
for	44 3 O
a	48 1 O
timely	50 6 O
EEG	57 3 O
evaluation	61 10 O
.	71 1 O

BACKGROUND	73 10 O
:	83 1 O
Ifosfamide	85 10 B-Chemical
is	96 2 O
an	99 2 O
alkylating	102 10 O
agent	113 5 O
useful	119 6 O
in	126 2 O
the	129 3 O
treatment	133 9 O
of	143 2 O
a	146 1 O
wide	148 4 O
range	153 5 O
of	159 2 O
cancers	162 7 B-Disease
including	170 9 O
sarcomas	180 8 B-Disease
,	188 1 O
lymphoma	190 8 B-Disease
,	198 1 O
gynecologic	200 11 B-Disease
and	212 3 I-Disease
testicular	216 10 I-Disease
cancers	227 7 I-Disease
.	234 1 O

Encephalopathy	236 14 B-Disease
has	251 3 O
been	255 4 O
reported	260 8 O
in	269 2 O
10	272 2 O
-	274 1 O
40	275 2 O
%	277 1 O
of	279 2 O
patients	282 8 O
receiving	291 9 O
high	301 4 O
-	305 1 O
dose	306 4 O
IV	311 2 O
ifosfamide	314 10 B-Chemical
.	324 1 O

OBJECTIVE	326 9 O
:	335 1 O
To	337 2 O
highlight	340 9 O
the	350 3 O
role	354 4 O
of	359 2 O
electroencephalogram	362 20 O
(	383 1 O
EEG	384 3 O
)	387 1 O
in	389 2 O
the	392 3 O
early	396 5 O
detection	402 9 O
and	412 3 O
management	416 10 O
of	427 2 O
ifosfamide	430 10 B-Chemical
related	441 7 O
encephalopathy	449 14 B-Disease
.	463 1 O

METHODS	465 7 O
:	472 1 O
Retrospective	474 13 O
chart	488 5 O
review	494 6 O
including	501 9 O
clinical	511 8 O
data	520 4 O
and	525 3 O
EEG	529 3 O
recordings	533 10 O
was	544 3 O
done	548 4 O
on	553 2 O
five	556 4 O
patients	561 8 O
,	569 1 O
admitted	571 8 O
to	580 2 O
MD	583 2 O
Anderson	586 8 O
Cancer	595 6 B-Disease
Center	602 6 O
between	609 7 O
years	617 5 O
2009	623 4 O
and	628 3 O
2012	632 4 O
,	636 1 O
who	638 3 O
developed	642 9 O
ifosfamide	652 10 B-Chemical
related	663 7 O
acute	671 5 O
encephalopathy	677 14 B-Disease
.	691 1 O

RESULTS	693 7 O
:	700 1 O
All	702 3 O
five	706 4 O
patients	711 8 O
experienced	720 11 O
symptoms	732 8 O
of	741 2 O
encephalopathy	744 14 B-Disease
soon	759 4 O
after	764 5 O
(	770 1 O
within	771 6 O
12	778 2 O
h	781 1 O
-	782 1 O
2	783 1 O
days	785 4 O
)	789 1 O
receiving	791 9 O
ifosfamide	801 10 B-Chemical
.	811 1 O

Two	813 3 O
patients	817 8 O
developed	826 9 O
generalized	836 11 O
convulsions	848 11 B-Disease
while	860 5 O
one	866 3 O
patient	870 7 O
developed	878 9 O
continuous	888 10 O
non	899 3 B-Disease
-	902 1 I-Disease
convulsive	903 10 I-Disease
status	914 6 I-Disease
epilepticus	921 11 I-Disease
(	933 1 O
NCSE	934 4 B-Disease
)	938 1 O
that	940 4 O
required	945 8 O
ICU	954 3 O
admission	958 9 O
and	968 3 O
intubation	972 10 O
.	982 1 O

Initial	984 7 O
EEG	992 3 O
showed	996 6 O
epileptiform	1003 12 O
discharges	1016 10 O
in	1027 2 O
three	1030 5 O
patients	1036 8 O
;	1044 1 O
run	1046 3 O
of	1050 2 O
triphasic	1053 9 O
waves	1063 5 O
in	1069 2 O
one	1072 3 O
patient	1076 7 O
and	1084 3 O
moderate	1088 8 O
degree	1097 6 O
diffuse	1104 7 O
generalized	1112 11 O
slowing	1124 7 O
.	1131 1 O

Mixed	1133 5 O
pattern	1139 7 O
with	1147 4 O
the	1152 3 O
presence	1156 8 O
of	1165 2 O
both	1168 4 O
sharps	1173 6 O
and	1180 3 O
triphasic	1184 9 O
waves	1194 5 O
were	1200 4 O
also	1205 4 O
noted	1210 5 O
.	1215 1 O

Repeat	1217 6 O
EEGs	1224 4 O
within	1229 6 O
24	1236 2 O
_	1238 1 O
h	1239 1 O
of	1241 2 O
symptom	1244 7 O
onset	1252 5 O
showed	1258 6 O
marked	1265 6 O
improvement	1272 11 O
that	1284 4 O
was	1289 3 O
correlated	1293 10 O
with	1304 4 O
clinical	1309 8 O
improvement	1318 11 O
.	1329 1 O

CONCLUSIONS	1331 11 O
:	1342 1 O
Severity	1344 8 O
of	1353 2 O
ifosfamide	1356 10 B-Chemical
related	1367 7 O
encephalopathy	1375 14 B-Disease
correlates	1390 10 O
with	1401 4 O
EEG	1406 3 O
changes	1410 7 O
.	1417 1 O

We	1419 2 O
suggest	1422 7 O
a	1430 1 O
timely	1432 6 O
EEG	1439 3 O
evaluation	1443 10 O
for	1454 3 O
patients	1458 8 O
receiving	1467 9 O
ifosfamide	1477 10 B-Chemical
who	1488 3 O
develop	1492 7 O
features	1500 8 O
of	1509 2 O
encephalopathy	1512 14 B-Disease
.	1526 1 O

Incidence	0 9 O
of	10 2 O
contrast	13 8 B-Chemical
-	21 1 O
induced	22 7 O
nephropathy	30 11 B-Disease
in	42 2 O
hospitalised	45 12 O
patients	58 8 O
with	67 4 O
cancer	72 6 B-Disease
.	78 1 O

OBJECTIVES	80 10 O
:	90 1 O
To	92 2 O
determine	95 9 O
the	105 3 O
frequency	109 9 O
of	119 2 O
and	122 3 O
possible	126 8 O
factors	135 7 O
related	143 7 O
to	151 2 O
contrast	154 8 B-Chemical
-	162 1 O
induced	163 7 O
nephropathy	171 11 B-Disease
(	183 1 O
CIN	184 3 O
)	187 1 O
in	189 2 O
hospitalised	192 12 O
patients	205 8 O
with	214 4 O
cancer	219 6 B-Disease
.	225 1 O

METHODS	227 7 O
:	234 1 O
Ninety	236 6 O
adult	243 5 O
patients	249 8 O
were	258 4 O
enrolled	263 8 O
.	271 1 O

Patients	273 8 O
with	282 4 O
risk	287 4 O
factors	292 7 O
for	300 3 O
acute	304 5 B-Disease
renal	310 5 I-Disease
failure	316 7 I-Disease
were	324 4 O
excluded	329 8 O
.	337 1 O

Blood	339 5 O
samples	345 7 O
were	353 4 O
examined	358 8 O
the	367 3 O
day	371 3 O
before	375 6 O
contrast	382 8 B-Chemical
-	390 1 O
enhanced	391 8 O
computed	400 8 O
tomography	409 10 O
(	420 1 O
CT	421 2 O
)	423 1 O
and	425 3 O
serially	429 8 O
for	438 3 O
3	442 1 O
days	444 4 O
thereafter	449 10 O
.	459 1 O

CIN	461 3 O
was	465 3 O
defined	469 7 O
as	477 2 O
an	480 2 O
increase	483 8 O
in	492 2 O
serum	495 5 O
creatinine	501 10 B-Chemical
(	512 1 O
Cr	513 2 B-Chemical
)	515 1 O
of	517 2 O
0	520 1 O
.	521 1 O
5	522 1 O
mg	524 2 O
/	526 1 O
dl	527 2 O
or	530 2 O
more	533 4 O
,	537 1 O
or	539 2 O
elevation	542 9 O
of	552 2 O
Cr	555 2 B-Chemical
to	558 2 O
25	561 2 O
%	564 1 O
over	566 4 O
baseline	571 8 O
.	579 1 O

Relationships	581 13 O
between	595 7 O
CIN	603 3 O
and	607 3 O
possible	611 8 O
risk	620 4 O
factors	625 7 O
were	633 4 O
investigated	638 12 O
.	650 1 O

RESULTS	652 7 O
:	659 1 O
CIN	661 3 O
was	665 3 O
detected	669 8 O
in	678 2 O
18	681 2 O
/	683 1 O
90	684 2 O
(	687 1 O
20	688 2 O
%	691 1 O
)	692 1 O
patients	694 8 O
.	702 1 O

CIN	704 3 O
developed	708 9 O
in	718 2 O
25	721 2 O
.	723 1 O
5	724 1 O
%	726 1 O
patients	728 8 O
who	737 3 O
underwent	741 9 O
chemotherapy	751 12 O
and	764 3 O
in	768 2 O
11	771 2 O
%	774 1 O
patients	776 8 O
who	785 3 O
did	789 3 O
not	793 3 O
(	797 1 O
P	798 1 O
=	800 1 O
0	802 1 O
.	803 1 O
1	804 1 O
)	805 1 O
.	806 1 O

CIN	808 3 O
more	812 4 O
frequently	817 10 O
developed	828 9 O
in	838 2 O
patients	841 8 O
who	850 3 O
had	854 3 O
undergone	858 9 O
CT	868 2 O
within	871 6 O
45	878 2 O
days	881 4 O
after	886 5 O
the	892 3 O
last	896 4 O
chemotherapy	901 12 O
(	914 1 O
P	915 1 O
=	917 1 O
0	919 1 O
.	920 1 O
005	921 3 O
)	924 1 O
;	925 1 O
it	927 2 O
was	930 3 O
also	934 4 O
an	939 2 O
independent	942 11 O
risk	954 4 O
factor	959 6 O
(	966 1 O
P	967 1 O
=	969 1 O
0	971 1 O
.	972 1 O
017	973 3 O
)	976 1 O
.	977 1 O

CIN	979 3 O
was	983 3 O
significantly	987 13 O
more	1001 4 O
after	1006 5 O
treatment	1012 9 O
with	1022 4 O
bevacizumab	1027 11 B-Chemical
/	1038 1 O
irinotecan	1039 10 B-Chemical
(	1050 1 O
P	1051 1 O
=	1053 1 O
0	1055 1 O
.	1056 1 O
021	1057 3 O
)	1060 1 O
and	1062 3 O
in	1066 2 O
patients	1069 8 O
with	1078 4 O
hypertension	1083 12 B-Disease
(	1096 1 O
P	1097 1 O
=	1099 1 O
0	1101 1 O
.	1102 1 O
044	1103 3 O
)	1106 1 O
.	1107 1 O

CONCLUSIONS	1109 11 O
:	1120 1 O
The	1122 3 O
incidence	1126 9 O
of	1136 2 O
CIN	1139 3 O
after	1143 5 O
CT	1149 2 O
in	1152 2 O
hospitalised	1155 12 O
oncological	1168 11 O
patients	1180 8 O
was	1189 3 O
20	1193 2 O
%	1196 1 O
.	1197 1 O

CIN	1199 3 O
developed	1203 9 O
4	1213 1 O
.	1214 1 O
5	1215 1 O
-	1216 1 O
times	1217 5 O
more	1223 4 O
frequently	1228 10 O
in	1239 2 O
patients	1242 8 O
with	1251 4 O
cancer	1256 6 B-Disease
who	1263 3 O
had	1267 3 O
undergone	1271 9 O
recent	1281 6 O
chemotherapy	1288 12 O
.	1300 1 O

Hypertension	1302 12 B-Disease
and	1315 3 O
the	1319 3 O
combination	1323 11 O
of	1335 2 O
bevacizumab	1338 11 B-Chemical
/	1349 1 O
irinotecan	1350 10 B-Chemical
may	1361 3 O
be	1365 2 O
additional	1368 10 O
risk	1379 4 O
factors	1384 7 O
for	1392 3 O
CIN	1396 3 O
development	1400 11 O
.	1411 1 O

KEY	1413 3 O
POINTS	1417 6 O
:	1423 1 O
.	1425 1 O

Contrast	1427 8 B-Chemical
-	1435 1 O
induced	1436 7 O
nephropathy	1444 11 B-Disease
(	1456 1 O
CIN	1457 3 O
)	1460 1 O
is	1462 2 O
a	1465 1 O
concern	1467 7 O
for	1475 3 O
oncological	1479 11 O
patients	1491 8 O
undergoing	1500 10 O
CT	1511 2 O
.	1513 1 O

.	1515 1 O
CIN	1517 3 O
occurs	1521 6 O
more	1528 4 O
often	1533 5 O
when	1539 4 O
CT	1544 2 O
is	1547 2 O
performed	1550 9 O
<	1560 1 O
45	1561 2 O
days	1564 4 O
after	1569 5 O
chemotherapy	1575 12 O
.	1587 1 O

.	1589 1 O
Hypertension	1591 12 B-Disease
and	1604 3 O
treatment	1608 9 O
with	1618 4 O
bevacizumab	1623 11 B-Chemical
appear	1635 6 O
to	1642 2 O
be	1645 2 O
additional	1648 10 O
risk	1659 4 O
factors	1664 7 O
.	1671 1 O

Syndrome	0 8 B-Disease
of	9 2 I-Disease
inappropriate	12 13 I-Disease
antidiuretic	26 12 I-Disease
hormone	39 7 I-Disease
secretion	47 9 O
associated	57 10 O
with	68 4 O
desvenlafaxine	73 14 B-Chemical
.	87 1 O

OBJECTIVE	89 9 O
:	98 1 O
To	100 2 O
report	103 6 O
a	110 1 O
case	112 4 O
of	117 2 O
syndrome	120 8 B-Disease
of	129 2 I-Disease
inappropriate	132 13 I-Disease
anti	146 4 I-Disease
-	150 1 I-Disease
diuretic	151 8 I-Disease
hormone	160 7 I-Disease
(	168 1 O
SIADH	169 5 B-Disease
)	174 1 O
secretion	176 9 O
associated	186 10 O
with	197 4 O
desvenlafaxine	202 14 B-Chemical
.	216 1 O

CASE	218 4 O
SUMMARY	223 7 O
:	230 1 O
A	232 1 O
57	234 2 O
-	236 1 O
year	237 4 O
old	242 3 O
female	246 6 O
with	253 4 O
hyponatraemia	258 13 B-Disease
.	271 1 O

Her	273 3 O
medications	277 11 O
included	289 8 O
desvenlafaxine	298 14 B-Chemical
,	312 1 O
and	314 3 O
symptoms	318 8 O
included	327 8 O
nausea	336 6 B-Disease
,	342 1 O
anxiety	344 7 B-Disease
and	352 3 O
confusion	356 9 B-Disease
.	365 1 O

The	367 3 O
serum	371 5 O
sodium	377 6 B-Chemical
at	384 2 O
this	387 4 O
time	392 4 O
was	397 3 O
120	401 3 O
mmol	405 4 O
/	409 1 O
L	410 1 O
,	411 1 O
serum	413 5 O
osmolality	419 10 O
was	430 3 O
263	434 3 O
mosmol	438 6 O
/	444 1 O
kg	445 2 O
,	447 1 O
urine	449 5 O
osmolality	455 10 O
410	466 3 O
mosmol	470 6 O
/	476 1 O
kg	477 2 O
and	480 3 O
urine	484 5 O
sodium	490 6 B-Chemical
63	497 2 O
mmol	500 4 O
/	504 1 O
L	505 1 O
,	506 1 O
consistent	508 10 O
with	519 4 O
a	524 1 O
diagnosis	526 9 O
of	536 2 O
SIADH	539 5 B-Disease
.	544 1 O

Desvenlafaxine	546 14 B-Chemical
was	561 3 O
ceased	565 6 O
and	572 3 O
fluid	576 5 O
restriction	582 11 O
implemented	594 11 O
.	605 1 O

After	607 5 O
4	613 1 O
days	615 4 O
the	620 3 O
sodium	624 6 B-Chemical
increased	631 9 O
to	641 2 O
128	644 3 O
mmol	648 4 O
/	652 1 O
L	653 1 O
and	655 3 O
fluid	659 5 O
restriction	665 11 O
was	677 3 O
relaxed	681 7 O
.	688 1 O

During	690 6 O
her	697 3 O
further	701 7 O
3	709 1 O
weeks	711 5 O
inpatient	717 9 O
admission	727 9 O
the	737 3 O
serum	741 5 O
sodium	747 6 B-Chemical
ranged	754 6 O
from	761 4 O
134	766 3 O
to	770 2 O
137	773 3 O
mmol	777 4 O
/	781 1 O
L	782 1 O
during	784 6 O
treatment	791 9 O
with	801 4 O
mirtazapine	806 11 B-Chemical
.	817 1 O

DISCUSSION	819 10 O
:	829 1 O
SIADH	831 5 B-Disease
has	837 3 O
been	841 4 O
widely	846 6 O
reported	853 8 O
with	862 4 O
a	867 1 O
range	869 5 O
of	875 2 O
antidepressants	878 15 O
.	893 1 O

This	895 4 O
case	900 4 O
report	905 6 O
suggests	912 8 O
that	921 4 O
desvenlafaxine	926 14 B-Chemical
might	941 5 O
cause	947 5 O
clinically	953 10 O
significant	964 11 O
hyponatremia	976 12 B-Disease
.	988 1 O

CONCLUSIONS	990 11 O
:	1001 1 O
Clinicians	1003 10 O
should	1014 6 O
be	1021 2 O
aware	1024 5 O
of	1030 2 O
the	1033 3 O
potential	1037 9 O
for	1047 3 O
antidepressants	1051 15 O
to	1067 2 O
cause	1070 5 O
hyponatremia	1076 12 B-Disease
,	1088 1 O
and	1089 3 O
take	1093 4 O
appropriate	1098 11 O
corrective	1110 10 O
action	1121 6 O
where	1128 5 O
necessary	1134 9 O
.	1143 1 O

Oxidative	0 9 O
stress	10 6 O
on	17 2 O
cardiotoxicity	20 14 B-Disease
after	35 5 O
treatment	41 9 O
with	51 4 O
single	56 6 O
and	63 3 O
multiple	67 8 O
doses	76 5 O
of	82 2 O
doxorubicin	85 11 B-Chemical
.	96 1 O

The	98 3 O
mechanism	102 9 O
of	112 2 O
doxorubicin	115 11 B-Chemical
(	127 1 O
DOX	128 3 B-Chemical
)	131 1 O
-	132 1 O
induced	133 7 O
cardiotoxicity	141 14 B-Disease
remains	156 7 O
controversial	164 13 O
.	177 1 O

Wistar	179 6 O
rats	186 4 O
(	191 1 O
n	192 1 O
=	194 1 O
66	196 2 O
)	198 1 O
received	200 8 O
DOX	209 3 B-Chemical
injections	213 10 O
intraperitoneally	224 17 O
and	242 3 O
were	246 4 O
randomly	251 8 O
assigned	260 8 O
to	269 2 O
2	272 1 O
experimental	274 12 O
protocols	287 9 O
:	296 1 O
(	298 1 O
1	299 1 O
)	300 1 O
rats	302 4 O
were	307 4 O
killed	312 6 O
before	319 6 O
(	326 1 O
-	327 1 O
24	328 2 O
h	331 1 O
,	332 1 O
n	334 1 O
=	336 1 O
8	338 1 O
)	339 1 O
and	341 3 O
24	345 2 O
h	348 1 O
after	350 5 O
(	356 1 O
+	357 1 O
24	358 2 O
h	361 1 O
,	362 1 O
n	364 1 O
=	366 1 O
8	368 1 O
)	369 1 O
a	371 1 O
single	373 6 O
dose	380 4 O
of	385 2 O
DOX	388 3 B-Chemical
(	392 1 O
4	393 1 O
mg	395 2 O
/	397 1 O
kg	398 2 O
body	401 4 O
weight	406 6 O
)	412 1 O
to	414 2 O
determine	417 9 O
the	427 3 O
DOX	431 3 B-Chemical
acute	435 5 O
effect	441 6 O
and	448 3 O
(	452 1 O
2	453 1 O
)	454 1 O
rats	456 4 O
(	461 1 O
n	462 1 O
=	464 1 O
58	466 2 O
)	468 1 O
received	470 8 O
4	479 1 O
injections	481 10 O
of	492 2 O
DOX	495 3 B-Chemical
(	499 1 O
4	500 1 O
mg	502 2 O
/	504 1 O
kg	505 2 O
body	508 4 O
weight	513 6 O
/	519 1 O
week	520 4 O
)	524 1 O
and	526 3 O
were	530 4 O
killed	535 6 O
before	542 6 O
the	549 3 O
first	553 5 O
injection	559 9 O
(	569 1 O
M0	570 2 O
)	572 1 O
and	574 3 O
1	578 1 O
week	580 4 O
after	585 5 O
each	591 4 O
injection	596 9 O
(	606 1 O
M1	607 2 O
,	609 1 O
M2	611 2 O
,	613 1 O
M3	615 2 O
,	617 1 O
and	619 3 O
M4	623 2 O
)	625 1 O
to	627 2 O
determine	630 9 O
the	640 3 O
chronological	644 13 O
effects	658 7 O
.	665 1 O

Animals	667 7 O
used	675 4 O
at	680 2 O
M0	683 2 O
(	686 1 O
n	687 1 O
=	689 1 O
8	691 1 O
)	692 1 O
were	694 4 O
also	699 4 O
used	704 4 O
at	709 2 O
moment	712 6 O
-	719 1 O
24	720 2 O
h	723 1 O
of	725 2 O
acute	728 5 O
study	734 5 O
.	739 1 O

Cardiac	741 7 O
total	749 5 O
antioxidant	755 11 O
performance	767 11 O
(	779 1 O
TAP	780 3 O
)	783 1 O
,	784 1 O
DNA	786 3 O
damage	790 6 O
,	796 1 O
and	798 3 O
morphology	802 10 O
analyses	813 8 O
were	822 4 O
carried	827 7 O
out	835 3 O
at	839 2 O
each	842 4 O
time	847 4 O
point	852 5 O
.	857 1 O

Single	859 6 O
dose	866 4 O
of	871 2 O
DOX	874 3 B-Chemical
was	878 3 O
associated	882 10 O
with	893 4 O
increased	898 9 O
cardiac	908 7 B-Disease
disarrangement	916 14 I-Disease
,	930 1 O
necrosis	932 8 B-Disease
,	940 1 O
and	942 3 O
DNA	946 3 O
damage	950 6 O
(	957 1 O
strand	958 6 O
breaks	965 6 O
(	972 1 O
SBs	973 3 O
)	976 1 O
and	978 3 O
oxidized	982 8 O
pyrimidines	991 11 O
)	1002 1 O
and	1004 3 O
decreased	1008 9 O
TAP	1018 3 O
.	1021 1 O

The	1023 3 O
chronological	1027 13 O
study	1041 5 O
showed	1047 6 O
an	1054 2 O
effect	1057 6 O
of	1064 2 O
a	1067 1 O
cumulative	1069 10 O
dose	1080 4 O
on	1085 2 O
body	1088 4 O
weight	1093 6 O
(	1100 1 O
R	1101 1 O
=	1103 1 O
-	1105 1 O
0	1106 1 O
.	1107 1 O
99	1108 2 O
,	1110 1 O
p	1112 1 O
=	1114 1 O
0	1116 1 O
.	1117 1 O
011	1118 3 O
)	1121 1 O
,	1122 1 O
necrosis	1124 8 B-Disease
(	1133 1 O
R	1134 1 O
=	1136 1 O
1	1138 1 O
.	1139 1 O
00	1140 2 O
,	1142 1 O
p	1144 1 O
=	1146 1 O
0	1148 1 O
.	1149 1 O
004	1150 3 O
)	1153 1 O
,	1154 1 O
TAP	1156 3 O
(	1160 1 O
R	1161 1 O
=	1163 1 O
0	1165 1 O
.	1166 1 O
95	1167 2 O
,	1169 1 O
p	1171 1 O
=	1173 1 O
0	1175 1 O
.	1176 1 O
049	1177 3 O
)	1180 1 O
,	1181 1 O
and	1183 3 O
DNA	1187 3 O
SBs	1191 3 O
(	1195 1 O
R	1196 1 O
=	1198 1 O
-	1200 1 O
0	1201 1 O
.	1202 1 O
95	1203 2 O
,	1205 1 O
p	1207 1 O
=	1209 1 O
0	1211 1 O
.	1212 1 O
049	1213 3 O
)	1216 1 O
.	1217 1 O

DNA	1219 3 O
SBs	1223 3 O
damage	1227 6 O
was	1234 3 O
negatively	1238 10 O
associated	1249 10 O
with	1260 4 O
TAP	1265 3 O
(	1269 1 O
R	1270 1 O
=	1272 1 O
-	1274 1 O
0	1275 1 O
.	1276 1 O
98	1277 2 O
,	1279 1 O
p	1281 1 O
=	1283 1 O
0	1285 1 O
.	1286 1 O
018	1287 3 O
)	1290 1 O
,	1291 1 O
and	1293 3 O
necrosis	1297 8 B-Disease
(	1306 1 O
R	1307 1 O
=	1309 1 O
-	1311 1 O
0	1312 1 O
.	1313 1 O
97	1314 2 O
,	1316 1 O
p	1318 1 O
=	1320 1 O
0	1322 1 O
.	1323 1 O
027	1324 3 O
)	1327 1 O
.	1328 1 O

Our	1330 3 O
results	1334 7 O
suggest	1342 7 O
that	1350 4 O
oxidative	1355 9 O
damage	1365 6 O
is	1372 2 O
associated	1375 10 O
with	1386 4 O
acute	1391 5 O
cardiotoxicity	1397 14 B-Disease
induced	1412 7 O
by	1420 2 O
a	1423 1 O
single	1425 6 O
dose	1432 4 O
of	1437 2 O
DOX	1440 3 B-Chemical
only	1444 4 O
.	1448 1 O

Increased	1450 9 O
resistance	1460 10 O
to	1471 2 O
the	1474 3 O
oxidative	1478 9 O
stress	1488 6 O
is	1495 2 O
plausible	1498 9 O
for	1508 3 O
the	1512 3 O
multiple	1516 8 O
dose	1525 4 O
of	1530 2 O
DOX	1533 3 B-Chemical
.	1536 1 O

Thus	1538 4 O
,	1542 1 O
different	1544 9 O
mechanisms	1554 10 O
may	1565 3 O
be	1569 2 O
involved	1572 8 O
in	1581 2 O
acute	1584 5 O
toxicity	1590 8 B-Disease
versus	1599 6 O
chronic	1606 7 O
toxicity	1614 8 B-Disease
.	1622 1 O

Tacrolimus	0 10 B-Chemical
-	10 1 O
related	11 7 O
seizure	19 7 B-Disease
after	27 5 O
pediatric	33 9 O
liver	43 5 O
transplantation	49 15 O
-	64 1 O
-	65 1 O
a	66 1 O
single	68 6 O
-	74 1 O
center	75 6 O
experience	82 10 O
.	92 1 O

To	94 2 O
identify	97 8 O
the	106 3 O
risk	110 4 O
factors	115 7 O
for	123 3 O
new	127 3 O
-	130 1 O
onset	131 5 O
seizures	137 8 B-Disease
after	146 5 O
pediatric	152 9 O
LT	162 2 O
and	165 3 O
to	169 2 O
assess	172 6 O
their	179 5 O
clinical	185 8 O
implications	194 12 O
and	207 3 O
long	211 4 O
-	215 1 O
term	216 4 O
prognosis	221 9 O
.	230 1 O

The	232 3 O
clinical	236 8 O
and	245 3 O
laboratory	249 10 O
data	260 4 O
of	265 2 O
27	268 2 O
consecutive	271 11 O
children	283 8 O
who	292 3 O
underwent	296 9 O
LT	306 2 O
from	309 4 O
January	314 7 O
2007	322 4 O
to	327 2 O
December	330 8 O
2010	339 4 O
in	344 2 O
our	347 3 O
center	351 6 O
were	358 4 O
analyzed	363 8 O
retrospectively	372 15 O
.	387 1 O

Patients	389 8 O
were	398 4 O
divided	403 7 O
into	411 4 O
seizures	416 8 B-Disease
group	425 5 O
and	431 3 O
a	435 1 O
non	437 3 O
-	440 1 O
seizures	441 8 B-Disease
group	450 5 O
.	455 1 O

Pre	457 3 O
-	460 1 O
operative	461 9 O
,	470 1 O
intra	472 5 O
-	477 1 O
operative	478 9 O
,	487 1 O
and	489 3 O
post	493 4 O
-	497 1 O
operative	498 9 O
data	508 4 O
were	513 4 O
collected	518 9 O
.	527 1 O

Seizures	529 8 B-Disease
occurred	538 8 O
in	547 2 O
four	550 4 O
children	555 8 O
,	563 1 O
an	565 2 O
incidence	568 9 O
of	578 2 O
14	581 2 O
.	583 1 O
8	584 1 O
%	585 1 O
.	586 1 O

All	588 3 O
exhibited	592 9 O
generalized	602 11 O
tonic	614 5 B-Disease
-	619 1 I-Disease
clonic	620 6 I-Disease
seizures	627 8 I-Disease
within	636 6 O
the	643 3 O
first	647 5 O
two	653 3 O
wk	657 2 O
after	660 5 O
LT	666 2 O
.	668 1 O

Univariate	670 10 O
analysis	681 8 O
showed	690 6 O
that	697 4 O
the	702 3 O
risk	706 4 O
factors	711 7 O
associated	719 10 O
with	730 4 O
seizures	735 8 B-Disease
after	744 5 O
pediatric	750 9 O
LT	760 2 O
included	763 8 O
gender	772 6 O
,	778 1 O
pediatric	780 9 O
end	790 3 B-Disease
-	793 1 I-Disease
stage	794 5 I-Disease
liver	800 5 I-Disease
disease	806 7 I-Disease
score	814 5 O
before	820 6 O
surgery	827 7 O
,	834 1 O
Child	836 5 O
-	841 1 O
Pugh	842 4 O
score	847 5 O
before	853 6 O
surgery	860 7 O
,	867 1 O
serum	869 5 O
total	875 5 O
bilirubin	881 9 B-Chemical
after	891 5 O
surgery	897 7 O
,	904 1 O
and	906 3 O
trough	910 6 O
TAC	917 3 B-Chemical
level	921 5 O
.	926 1 O

Multivariate	928 12 O
analysis	941 8 O
showed	950 6 O
that	957 4 O
trough	962 6 O
TAC	969 3 B-Chemical
level	973 5 O
was	979 3 O
the	983 3 O
only	987 4 O
independent	992 11 O
risk	1004 4 O
factor	1009 6 O
associated	1016 10 O
with	1027 4 O
the	1032 3 O
seizures	1036 8 B-Disease
.	1044 1 O

All	1046 3 O
children	1050 8 O
who	1059 3 O
experienced	1063 11 O
seizures	1075 8 B-Disease
survived	1084 8 O
with	1093 4 O
good	1098 4 O
graft	1103 5 O
function	1109 8 O
and	1118 3 O
remained	1122 8 O
seizure	1131 7 B-Disease
-	1138 1 O
free	1139 4 O
without	1144 7 O
anti	1152 4 O
-	1156 1 O
epileptic	1157 9 B-Disease
drugs	1167 5 O
over	1173 4 O
a	1178 1 O
mean	1180 4 O
follow	1185 6 O
-	1191 1 O
up	1192 2 O
period	1195 6 O
of	1202 2 O
33	1205 2 O
.	1207 1 O
7	1208 1 O
+	1210 1 O
14	1212 2 O
.	1214 1 O
6	1215 1 O
months	1217 6 O
.	1223 1 O

High	1225 4 O
trough	1230 6 O
TAC	1237 3 B-Chemical
level	1241 5 O
was	1247 3 O
the	1251 3 O
predominant	1255 11 O
factor	1267 6 O
that	1274 4 O
contributed	1279 11 O
to	1291 2 O
seizures	1294 8 B-Disease
in	1303 2 O
the	1306 3 O
early	1310 5 O
post	1316 4 O
-	1320 1 O
operative	1321 9 O
period	1331 6 O
after	1338 5 O
pediatric	1344 9 O
LT	1354 2 O
.	1356 1 O

High	1358 4 O
PELD	1363 4 O
and	1368 3 O
Child	1372 5 O
-	1377 1 O
Pugh	1378 4 O
scores	1383 6 O
before	1390 6 O
LT	1397 2 O
and	1400 3 O
high	1404 4 O
post	1409 4 O
-	1413 1 O
operative	1414 9 O
serum	1424 5 O
Tbil	1430 4 O
may	1435 3 O
be	1439 2 O
contributory	1442 12 O
risk	1455 4 O
factors	1460 7 O
for	1468 3 O
TAC	1472 3 B-Chemical
-	1475 1 O
related	1476 7 O
seizures	1484 8 B-Disease
.	1492 1 O

The	0 3 O
flavonoid	4 9 B-Chemical
apigenin	14 8 B-Chemical
delays	23 6 O
forgetting	30 10 O
of	41 2 O
passive	44 7 O
avoidance	52 9 O
conditioning	62 12 O
in	75 2 O
rats	78 4 O
.	82 1 O

The	84 3 O
present	88 7 O
experiments	96 11 O
were	108 4 O
performed	113 9 O
to	123 2 O
study	126 5 O
the	132 3 O
effect	136 6 O
of	143 2 O
the	146 3 O
flavonoid	150 9 B-Chemical
apigenin	160 8 B-Chemical
(	169 1 O
20	170 2 O
mg	173 2 O
/	175 1 O
kg	176 2 O
intraperitoneally	179 17 O
(	197 1 O
i	198 1 O
.	199 1 O
p	200 1 O
.	201 1 O
)	202 1 O
,	203 1 O
1	205 1 O
h	207 1 O
before	209 6 O
acquisition	216 11 O
)	227 1 O
,	228 1 O
on	230 2 O
24	233 2 O
h	236 1 O
retention	238 9 O
performance	248 11 O
and	260 3 O
forgetting	264 10 O
of	275 2 O
a	278 1 O
step	280 4 O
-	284 1 O
through	285 7 O
passive	293 7 O
avoidance	301 9 O
task	311 4 O
,	315 1 O
in	317 2 O
young	320 5 O
male	326 4 O
Wistar	331 6 O
rats	338 4 O
.	342 1 O

There	344 5 O
were	350 4 O
no	355 2 O
differences	358 11 O
between	370 7 O
saline	378 6 O
-	384 1 O
and	386 3 O
apigenin	390 8 B-Chemical
-	398 1 O
treated	399 7 O
groups	407 6 O
in	414 2 O
the	417 3 O
24	421 2 O
h	424 1 O
retention	426 9 O
trial	436 5 O
.	441 1 O

Furthermore	443 11 O
,	454 1 O
apigenin	456 8 B-Chemical
did	465 3 O
not	469 3 O
prevent	473 7 O
the	481 3 O
amnesia	485 7 B-Disease
induced	493 7 O
by	501 2 O
scopolamine	504 11 B-Chemical
(	516 1 O
1mg	517 3 O
/	520 1 O
kg	521 2 O
,	523 1 O
i	525 1 O
.	526 1 O
p	527 1 O
.	528 1 O
,	529 1 O
30	531 2 O
min	534 3 O
before	538 6 O
the	545 3 O
acquisition	549 11 O
)	560 1 O
.	561 1 O

The	563 3 O
saline	567 6 O
-	573 1 O
and	575 3 O
apigenin	579 8 B-Chemical
-	587 1 O
treated	588 7 O
rats	596 4 O
that	601 4 O
did	606 3 O
not	610 3 O
step	614 4 O
through	619 7 O
into	627 4 O
the	632 3 O
dark	636 4 O
compartment	641 11 O
during	653 6 O
the	660 3 O
cut	664 3 O
-	667 1 O
off	668 3 O
time	672 4 O
(	677 1 O
540	678 3 O
s	682 1 O
)	683 1 O
were	685 4 O
retested	690 8 O
weekly	699 6 O
for	706 3 O
up	710 2 O
to	713 2 O
eight	716 5 O
weeks	722 5 O
.	727 1 O

In	729 2 O
the	732 3 O
saline	736 6 O
treated	743 7 O
group	751 5 O
,	756 1 O
the	758 3 O
first	762 5 O
significant	768 11 O
decline	780 7 O
in	788 2 O
passive	791 7 O
avoidance	799 9 O
response	809 8 O
was	818 3 O
observed	822 8 O
at	831 2 O
four	834 4 O
weeks	839 5 O
,	844 1 O
and	846 3 O
complete	850 8 O
memory	859 6 B-Disease
loss	866 4 I-Disease
was	871 3 O
found	875 5 O
five	881 4 O
weeks	886 5 O
after	892 5 O
the	898 3 O
acquisition	902 11 O
of	914 2 O
the	917 3 O
passive	921 7 O
avoidance	929 9 O
task	939 4 O
.	943 1 O

At	945 2 O
the	948 3 O
end	952 3 O
of	956 2 O
the	959 3 O
experimental	963 12 O
period	976 6 O
,	982 1 O
60	984 2 O
%	986 1 O
of	988 2 O
the	991 3 O
animals	995 7 O
treated	1003 7 O
with	1011 4 O
apigenin	1016 8 B-Chemical
still	1025 5 O
did	1031 3 O
not	1035 3 O
step	1039 4 O
through	1044 7 O
.	1051 1 O

These	1053 5 O
data	1059 4 O
suggest	1064 7 O
that	1072 4 O
1	1077 1 O
)	1078 1 O
apigenin	1080 8 B-Chemical
delays	1089 6 O
the	1096 3 O
long	1100 4 O
-	1104 1 O
term	1105 4 O
forgetting	1110 10 O
but	1121 3 O
did	1125 3 O
not	1129 3 O
modulate	1133 8 O
the	1142 3 O
24	1146 2 O
h	1149 1 O
retention	1151 9 O
of	1161 2 O
fear	1164 4 O
memory	1169 6 O
and	1176 3 O
2	1180 1 O
)	1181 1 O
the	1183 3 O
obtained	1187 8 O
beneficial	1196 10 O
effect	1207 6 O
of	1214 2 O
apigenin	1217 8 B-Chemical
on	1226 2 O
the	1229 3 O
passive	1233 7 O
avoidance	1241 9 O
conditioning	1251 12 O
is	1264 2 O
mediated	1267 8 O
by	1276 2 O
mechanisms	1279 10 O
that	1290 4 O
do	1295 2 O
not	1298 3 O
implicate	1302 9 O
its	1312 3 O
action	1316 6 O
on	1323 2 O
the	1326 3 O
muscarinic	1330 10 O
cholinergic	1341 11 O
system	1353 6 O
.	1359 1 O

Cholecystokinin	0 15 B-Chemical
-	15 1 I-Chemical
octapeptide	16 11 I-Chemical
restored	28 8 O
morphine	37 8 B-Chemical
-	45 1 O
induced	46 7 O
hippocampal	54 11 O
long	66 4 O
-	70 1 O
term	71 4 O
potentiation	76 12 O
impairment	89 10 O
in	100 2 O
rats	103 4 O
.	107 1 O

Cholecystokinin	109 15 B-Chemical
-	124 1 I-Chemical
octapeptide	125 11 I-Chemical
(	137 1 O
CCK	138 3 B-Chemical
-	141 1 I-Chemical
8	142 1 I-Chemical
)	143 1 O
,	144 1 O
which	146 5 O
is	152 2 O
a	155 1 O
typical	157 7 O
brain	165 5 O
-	170 1 O
gut	171 3 O
peptide	175 7 O
,	182 1 O
exerts	184 6 O
a	191 1 O
wide	193 4 O
range	198 5 O
of	204 2 O
biological	207 10 O
activities	218 10 O
on	229 2 O
the	232 3 O
central	236 7 O
nervous	244 7 O
system	252 6 O
.	258 1 O

We	260 2 O
have	263 4 O
previously	268 10 O
reported	279 8 O
that	288 4 O
CCK	293 3 B-Chemical
-	296 1 I-Chemical
8	297 1 I-Chemical
significantly	299 13 O
alleviated	313 10 O
morphine	324 8 B-Chemical
-	332 1 O
induced	333 7 O
amnesia	341 7 B-Disease
and	349 3 O
reversed	353 8 O
spine	362 5 O
density	368 7 O
decreases	376 9 O
in	386 2 O
the	389 3 O
CA1	393 3 O
region	397 6 O
of	404 2 O
the	407 3 O
hippocampus	411 11 O
in	423 2 O
morphine	426 8 B-Chemical
-	434 1 O
treated	435 7 O
animals	443 7 O
.	450 1 O

Here	452 4 O
,	456 1 O
we	458 2 O
investigated	461 12 O
the	474 3 O
effects	478 7 O
of	486 2 O
CCK	489 3 B-Chemical
-	492 1 I-Chemical
8	493 1 I-Chemical
on	495 2 O
long	498 4 O
-	502 1 O
term	503 4 O
potentiation	508 12 O
(	521 1 O
LTP	522 3 O
)	525 1 O
in	527 2 O
the	530 3 O
lateral	534 7 O
perforant	542 9 O
path	552 4 O
(	557 1 O
LPP	558 3 O
)	561 1 O
-	562 1 O
granule	563 7 O
cell	571 4 O
synapse	576 7 O
of	584 2 O
rat	587 3 O
dentate	591 7 O
gyrus	599 5 O
(	605 1 O
DG	606 2 O
)	608 1 O
in	610 2 O
acute	613 5 O
saline	619 6 O
or	626 2 O
morphine	629 8 B-Chemical
-	637 1 O
treated	638 7 O
rats	646 4 O
.	650 1 O

Population	652 10 O
spikes	663 6 O
(	670 1 O
PS	671 2 O
)	673 1 O
,	674 1 O
which	676 5 O
were	682 4 O
evoked	687 6 O
by	694 2 O
stimulation	697 11 O
of	709 2 O
the	712 3 O
LPP	716 3 O
,	719 1 O
were	721 4 O
recorded	726 8 O
in	735 2 O
the	738 3 O
DG	742 2 O
region	745 6 O
.	751 1 O

Acute	753 5 O
morphine	759 8 B-Chemical
(	768 1 O
30mg	769 4 O
/	773 1 O
kg	774 2 O
,	776 1 O
s	778 1 O
.	779 1 O
c	780 1 O
.	781 1 O
)	782 1 O
treatment	784 9 O
significantly	794 13 O
attenuated	808 10 O
hippocampal	819 11 O
LTP	831 3 O
and	835 3 O
CCK	839 3 B-Chemical
-	842 1 I-Chemical
8	843 1 I-Chemical
(	845 1 O
1ug	846 3 O
,	849 1 O
i	851 1 O
.	852 1 O
c	853 1 O
.	854 1 O
v	855 1 O
.	856 1 O
)	857 1 O
restored	859 8 O
the	868 3 O
amplitude	872 9 O
of	882 2 O
PS	885 2 O
that	888 4 O
was	893 3 O
attenuated	897 10 O
by	908 2 O
morphine	911 8 B-Chemical
injection	920 9 O
.	929 1 O

Furthermore	931 11 O
,	942 1 O
microinjection	944 14 O
of	959 2 O
CCK	962 3 B-Chemical
-	965 1 I-Chemical
8	966 1 I-Chemical
(	968 1 O
0	969 1 O
.	970 1 O
1	971 1 O
and	973 3 O
1ug	977 3 O
,	980 1 O
i	982 1 O
.	983 1 O
c	984 1 O
.	985 1 O
v	986 1 O
.	987 1 O
)	988 1 O
also	990 4 O
significantly	995 13 O
augmented	1009 9 O
hippocampal	1019 11 O
LTP	1031 3 O
in	1035 2 O
saline	1038 6 O
-	1044 1 O
treated	1045 7 O
(	1053 1 O
1ml	1054 3 O
/	1057 1 O
kg	1058 2 O
,	1060 1 O
s	1062 1 O
.	1063 1 O
c	1064 1 O
.	1065 1 O
)	1066 1 O
rats	1068 4 O
.	1072 1 O

Pre	1074 3 O
-	1077 1 O
treatment	1078 9 O
of	1088 2 O
the	1091 3 O
CCK2	1095 4 O
receptor	1100 8 O
antagonist	1109 10 O
L	1120 1 O
-	1121 1 O
365	1122 3 O
,	1125 1 O
260	1126 3 O
(	1130 1 O
10ug	1131 4 O
,	1135 1 O
i	1137 1 O
.	1138 1 O
c	1139 1 O
.	1140 1 O
v	1141 1 O
)	1142 1 O
reversed	1144 8 O
the	1153 3 O
effects	1157 7 O
of	1165 2 O
CCK	1168 3 B-Chemical
-	1171 1 I-Chemical
8	1172 1 I-Chemical
,	1173 1 O
but	1175 3 O
the	1179 3 O
CCK1	1183 4 O
receptor	1188 8 O
antagonist	1197 10 O
L	1208 1 O
-	1209 1 O
364	1210 3 O
,	1213 1 O
718	1214 3 O
(	1218 1 O
10ug	1219 4 O
,	1223 1 O
i	1225 1 O
.	1226 1 O
c	1227 1 O
.	1228 1 O
v	1229 1 O
)	1230 1 O
did	1232 3 O
not	1236 3 O
.	1239 1 O

The	1241 3 O
present	1245 7 O
results	1253 7 O
demonstrate	1261 11 O
that	1273 4 O
CCK	1278 3 B-Chemical
-	1281 1 I-Chemical
8	1282 1 I-Chemical
attenuates	1284 10 O
the	1295 3 O
effect	1299 6 O
of	1306 2 O
morphine	1309 8 B-Chemical
on	1318 2 O
hippocampal	1321 11 O
LTP	1333 3 O
through	1337 7 O
CCK2	1345 4 O
receptors	1350 9 O
and	1360 3 O
suggest	1364 7 O
an	1372 2 O
ameliorative	1375 12 O
function	1388 8 O
of	1397 2 O
CCK	1400 3 B-Chemical
-	1403 1 I-Chemical
8	1404 1 I-Chemical
on	1406 2 O
morphine	1409 8 B-Chemical
-	1417 1 O
induced	1418 7 O
memory	1426 6 B-Disease
impairment	1433 10 I-Disease
.	1443 1 O

Glial	0 5 O
activation	6 10 O
and	17 3 O
post	21 4 O
-	25 1 O
synaptic	26 8 O
neurotoxicity	35 13 B-Disease
:	48 1 O
the	50 3 O
key	54 3 O
events	58 6 O
in	65 2 O
Streptozotocin	68 14 B-Chemical
(	83 1 O
ICV	84 3 O
)	87 1 O
induced	89 7 O
memory	97 6 B-Disease
impairment	104 10 I-Disease
in	115 2 O
rats	118 4 O
.	122 1 O

In	124 2 O
the	127 3 O
present	131 7 O
study	139 5 O
the	145 3 O
role	149 4 O
of	154 2 O
glial	157 5 O
activation	163 10 O
and	174 3 O
post	178 4 O
synaptic	183 8 O
toxicity	192 8 B-Disease
in	201 2 O
ICV	204 3 O
Streptozotocin	208 14 B-Chemical
(	223 1 O
STZ	224 3 B-Chemical
)	227 1 O
induced	229 7 O
memory	237 6 B-Disease
impaired	244 8 I-Disease
rats	253 4 O
was	258 3 O
explored	262 8 O
.	270 1 O

In	272 2 O
experiment	275 10 O
set	286 3 O
up	290 2 O
1	293 1 O
:	294 1 O
Memory	296 6 B-Disease
deficit	303 7 I-Disease
was	311 3 O
found	315 5 O
in	321 2 O
Morris	324 6 O
water	331 5 O
maze	337 4 O
test	342 4 O
on	347 2 O
14	350 2 O
-	352 1 O
16	353 2 O
days	356 4 O
after	361 5 O
STZ	367 3 B-Chemical
(	371 1 O
ICV	372 3 O
;	375 1 O
3mg	377 3 O
/	380 1 O
Kg	381 2 O
)	383 1 O
administration	385 14 O
.	399 1 O

STZ	401 3 B-Chemical
causes	405 6 O
increased	412 9 O
expression	422 10 O
of	433 2 O
GFAP	436 4 O
,	440 1 O
CD11b	442 5 O
and	448 3 O
TNF	452 3 O
-	455 1 O
a	456 1 O
indicating	458 10 O
glial	469 5 O
activation	475 10 O
and	486 3 O
neuroinflammation	490 17 B-Disease
.	507 1 O

STZ	509 3 B-Chemical
also	513 4 O
significantly	518 13 O
increased	532 9 O
the	542 3 O
level	546 5 O
of	552 2 O
ROS	555 3 O
,	558 1 O
nitrite	560 7 B-Chemical
,	567 1 O
Ca	569 2 B-Chemical
(	571 1 O
2	572 1 O
+	573 1 O
)	574 1 O
and	576 3 O
reduced	580 7 O
the	588 3 O
mitochondrial	592 13 O
activity	606 8 O
in	615 2 O
synaptosomal	618 12 O
preparation	631 11 O
illustrating	643 12 O
free	656 4 O
radical	661 7 O
generation	669 10 O
and	680 3 O
excitotoxicity	684 14 B-Disease
.	698 1 O

Increased	700 9 O
expression	710 10 O
and	721 3 O
activity	725 8 O
of	734 2 O
Caspase	737 7 O
-	744 1 O
3	745 1 O
was	747 3 O
also	751 4 O
observed	756 8 O
in	765 2 O
STZ	768 3 B-Chemical
treated	772 7 O
rat	780 3 O
which	784 5 O
specify	790 7 O
apoptotic	798 9 O
cell	808 4 O
death	813 5 O
in	819 2 O
hippocampus	822 11 O
and	834 3 O
cortex	838 6 O
.	844 1 O

STZ	846 3 B-Chemical
treatment	850 9 O
showed	860 6 O
decrease	867 8 O
expression	876 10 O
of	887 2 O
post	890 4 O
synaptic	895 8 O
markers	904 7 O
CaMKIIa	912 7 O
and	920 3 O
PSD	924 3 O
-	927 1 O
95	928 2 O
,	930 1 O
while	932 5 O
,	937 1 O
expression	939 10 O
of	950 2 O
pre	953 3 O
synaptic	957 8 O
markers	966 7 O
(	974 1 O
synaptophysin	975 13 O
and	989 3 O
SNAP	993 4 O
-	997 1 O
25	998 2 O
)	1000 1 O
remains	1002 7 O
unaltered	1010 9 O
indicating	1020 10 O
selective	1031 9 O
post	1041 4 O
synaptic	1046 8 O
neurotoxicity	1055 13 B-Disease
.	1068 1 O

Oral	1070 4 O
treatment	1075 9 O
with	1085 4 O
Memantine	1090 9 B-Chemical
(	1100 1 O
10mg	1101 4 O
/	1105 1 O
kg	1106 2 O
)	1108 1 O
and	1110 3 O
Ibuprofen	1114 9 B-Chemical
(	1124 1 O
50	1125 2 O
mg	1128 2 O
/	1130 1 O
kg	1131 2 O
)	1133 1 O
daily	1135 5 O
for	1141 3 O
13	1145 2 O
days	1148 4 O
attenuated	1153 10 O
STZ	1164 3 B-Chemical
induced	1168 7 O
glial	1176 5 O
activation	1182 10 O
,	1192 1 O
apoptotic	1194 9 O
cell	1204 4 O
death	1209 5 O
and	1215 3 O
post	1219 4 O
synaptic	1224 8 O
neurotoxicity	1233 13 B-Disease
in	1247 2 O
rat	1250 3 O
brain	1254 5 O
.	1259 1 O

Further	1261 7 O
,	1268 1 O
in	1270 2 O
experiment	1273 10 O
set	1284 3 O
up	1288 2 O
2	1291 1 O
:	1292 1 O
where	1294 5 O
memory	1300 6 O
function	1307 8 O
was	1316 3 O
not	1320 3 O
affected	1324 8 O
i	1333 1 O
.	1334 1 O
e	1335 1 O
.	1336 1 O
7	1338 1 O
-	1339 1 O
9	1340 1 O
days	1342 4 O
after	1347 5 O
STZ	1353 3 B-Chemical
treatment	1357 9 O
.	1366 1 O

The	1368 3 O
level	1372 5 O
of	1378 2 O
GFAP	1381 4 O
,	1385 1 O
CD11b	1387 5 O
,	1392 1 O
TNF	1394 3 O
-	1397 1 O
a	1398 1 O
,	1399 1 O
ROS	1401 3 O
and	1405 3 O
nitrite	1409 7 B-Chemical
levels	1417 6 O
were	1424 4 O
increased	1429 9 O
.	1438 1 O

On	1440 2 O
the	1443 3 O
other	1447 5 O
hand	1453 4 O
,	1457 1 O
apoptotic	1459 9 O
marker	1469 6 O
,	1475 1 O
synaptic	1477 8 O
markers	1486 7 O
,	1493 1 O
mitochondrial	1495 13 O
activity	1509 8 O
and	1518 3 O
Ca	1522 2 B-Chemical
(	1524 1 O
2	1525 1 O
+	1526 1 O
)	1527 1 O
levels	1529 6 O
remained	1536 8 O
unaffected	1545 10 O
.	1555 1 O

Collective	1557 10 O
data	1568 4 O
indicates	1573 9 O
that	1583 4 O
neuroinflammatory	1588 17 B-Disease
process	1606 7 O
and	1614 3 O
oxidative	1618 9 O
stress	1628 6 O
occurs	1635 6 O
earlier	1642 7 O
to	1650 2 O
apoptosis	1653 9 O
and	1663 3 O
does	1667 4 O
not	1672 3 O
affect	1676 6 O
memory	1683 6 O
function	1690 8 O
.	1698 1 O

Present	1700 7 O
study	1708 5 O
clearly	1714 7 O
suggests	1722 8 O
that	1731 4 O
glial	1736 5 O
activation	1742 10 O
and	1753 3 O
post	1757 4 O
synaptic	1762 8 O
neurotoxicity	1771 13 B-Disease
are	1785 3 O
the	1789 3 O
key	1793 3 O
factors	1797 7 O
in	1805 2 O
STZ	1808 3 B-Chemical
induced	1812 7 O
memory	1820 6 B-Disease
impairment	1827 10 I-Disease
and	1838 3 O
neuronal	1842 8 O
cell	1851 4 O
death	1856 5 O
.	1861 1 O

Comparison	0 10 O
of	11 2 O
effects	14 7 O
of	22 2 O
isotonic	25 8 O
sodium	34 6 B-Chemical
chloride	41 8 I-Chemical
with	50 4 O
diltiazem	55 9 B-Chemical
in	65 2 O
prevention	68 10 O
of	79 2 O
contrast	82 8 B-Chemical
-	90 1 O
induced	91 7 O
nephropathy	99 11 B-Disease
.	110 1 O

INTRODUCTION	112 12 O
AND	125 3 O
OBJECTIVE	129 9 O
:	138 1 O
Contrast	140 8 B-Chemical
-	148 1 O
induced	149 7 O
nephropathy	157 11 B-Disease
(	169 1 O
CIN	170 3 O
)	173 1 O
significantly	175 13 O
increases	189 9 O
the	199 3 O
morbidity	203 9 O
and	213 3 O
mortality	217 9 O
of	227 2 O
patients	230 8 O
.	238 1 O

The	240 3 O
aim	244 3 O
of	248 2 O
this	251 4 O
study	256 5 O
is	262 2 O
to	265 2 O
investigate	268 11 O
and	280 3 O
compare	284 7 O
the	292 3 O
protective	296 10 O
effects	307 7 O
of	315 2 O
isotonic	318 8 O
sodium	327 6 B-Chemical
chloride	334 8 I-Chemical
with	343 4 O
sodium	348 6 B-Chemical
bicarbonate	355 11 I-Chemical
infusion	367 8 O
and	376 3 O
isotonic	380 8 O
sodium	389 6 B-Chemical
chloride	396 8 I-Chemical
infusion	405 8 O
with	414 4 O
diltiazem	419 9 B-Chemical
,	428 1 O
a	430 1 O
calcium	432 7 B-Chemical
channel	440 7 O
blocker	448 7 O
,	455 1 O
in	457 2 O
preventing	460 10 O
CIN	471 3 O
.	474 1 O

MATERIALS	476 9 O
AND	486 3 O
METHODS	490 7 O
:	497 1 O
Our	499 3 O
study	503 5 O
included	509 8 O
patients	518 8 O
who	527 3 O
were	531 4 O
administered	536 12 O
30	549 2 O
-	551 1 O
60	552 2 O
mL	555 2 O
of	558 2 O
iodinated	561 9 O
contrast	571 8 B-Chemical
agent	580 5 O
for	586 3 O
percutaneous	590 12 O
coronary	603 8 O
angiography	612 11 O
(	624 1 O
PCAG	625 4 O
)	629 1 O
,	630 1 O
all	632 3 O
with	636 4 O
creatinine	641 10 B-Chemical
values	652 6 O
between	659 7 O
1	667 1 O
.	668 1 O
1	669 1 O
and	671 3 O
3	675 1 O
.	676 1 O
1	677 1 O
mg	679 2 O
/	681 1 O
dL	682 2 O
.	684 1 O

Patients	686 8 O
were	695 4 O
divided	700 7 O
into	708 4 O
three	713 5 O
groups	719 6 O
and	726 3 O
each	730 4 O
group	735 5 O
had	741 3 O
20	745 2 O
patients	748 8 O
.	756 1 O

The	758 3 O
first	762 5 O
group	768 5 O
of	774 2 O
patients	777 8 O
was	786 3 O
administered	790 12 O
isotonic	803 8 O
sodium	812 6 B-Chemical
chloride	819 8 I-Chemical
;	827 1 O
the	829 3 O
second	833 6 O
group	840 5 O
was	846 3 O
administered	850 12 O
a	863 1 O
solution	865 8 O
that	874 4 O
of	879 2 O
5	882 1 O
%	883 1 O
dextrose	885 8 B-Chemical
and	894 3 O
sodium	898 6 B-Chemical
bicarbonate	905 11 I-Chemical
,	916 1 O
while	918 5 O
the	924 3 O
third	928 5 O
group	934 5 O
was	940 3 O
administered	944 12 O
isotonic	957 8 O
sodium	966 6 B-Chemical
chloride	973 8 I-Chemical
before	982 6 O
and	989 3 O
after	993 5 O
the	999 3 O
contrast	1003 8 B-Chemical
injection	1012 9 O
.	1021 1 O

The	1023 3 O
third	1027 5 O
group	1033 5 O
received	1039 8 O
an	1048 2 O
additional	1051 10 O
injection	1062 9 O
of	1072 2 O
diltiazem	1075 9 B-Chemical
the	1085 3 O
day	1089 3 O
before	1093 6 O
and	1100 3 O
first	1104 5 O
2	1110 1 O
days	1112 4 O
after	1117 5 O
the	1123 3 O
contrast	1127 8 B-Chemical
injection	1136 9 O
.	1145 1 O

All	1147 3 O
of	1151 2 O
the	1154 3 O
patients	1158 8 O
'	1166 1 O
plasma	1168 6 O
blood	1175 5 B-Chemical
urea	1181 4 I-Chemical
nitrogen	1186 8 I-Chemical
(	1195 1 O
BUN	1196 3 B-Chemical
)	1199 1 O
and	1201 3 O
creatinine	1205 10 B-Chemical
levels	1216 6 O
were	1223 4 O
measured	1228 8 O
on	1237 2 O
the	1240 3 O
second	1244 6 O
and	1251 3 O
seventh	1255 7 O
day	1263 3 O
after	1267 5 O
the	1273 3 O
administration	1277 14 O
of	1292 2 O
intravenous	1295 11 O
contrast	1307 8 B-Chemical
material	1316 8 O
.	1324 1 O

RESULTS	1326 7 O
:	1333 1 O
The	1335 3 O
basal	1339 5 O
creatinine	1345 10 B-Chemical
levels	1356 6 O
were	1363 4 O
similar	1368 7 O
for	1376 3 O
all	1380 3 O
three	1384 5 O
groups	1390 6 O
(	1397 1 O
p	1398 1 O
>	1400 1 O
0	1402 1 O
.	1403 1 O
05	1404 2 O
)	1406 1 O
.	1407 1 O

Among	1409 5 O
a	1415 1 O
total	1417 5 O
of	1423 2 O
60	1426 2 O
patients	1429 8 O
included	1438 8 O
in	1447 2 O
the	1450 3 O
study	1454 5 O
,	1459 1 O
16	1461 2 O
patients	1464 8 O
developed	1473 9 O
acute	1483 5 B-Disease
renal	1489 5 I-Disease
failure	1495 7 I-Disease
(	1503 1 O
ARF	1504 3 B-Disease
)	1507 1 O
on	1509 2 O
the	1512 3 O
second	1516 6 O
day	1523 3 O
after	1527 5 O
contrast	1533 8 B-Chemical
material	1542 8 O
was	1551 3 O
injected	1555 8 O
(	1564 1 O
26	1565 2 O
.	1567 1 O
6	1568 1 O
%	1569 1 O
)	1570 1 O
.	1571 1 O

The	1573 3 O
number	1577 6 O
of	1584 2 O
patients	1587 8 O
who	1596 3 O
developed	1600 9 O
ARF	1610 3 B-Disease
on	1614 2 O
the	1617 3 O
second	1621 6 O
day	1628 3 O
after	1632 5 O
the	1638 3 O
injection	1642 9 O
in	1652 2 O
the	1655 3 O
first	1659 5 O
group	1665 5 O
was	1671 3 O
five	1675 4 O
(	1680 1 O
25	1681 2 O
%	1683 1 O
)	1684 1 O
,	1685 1 O
in	1687 2 O
the	1690 3 O
second	1694 6 O
group	1701 5 O
was	1707 3 O
six	1711 3 O
(	1715 1 O
30	1716 2 O
%	1718 1 O
)	1719 1 O
and	1721 3 O
the	1725 3 O
third	1729 5 O
group	1735 5 O
was	1741 3 O
five	1745 4 O
(	1750 1 O
25	1751 2 O
%	1753 1 O
)	1754 1 O
(	1756 1 O
p	1757 1 O
>	1759 1 O
0	1761 1 O
.	1762 1 O
05	1763 2 O
)	1765 1 O
.	1766 1 O

CONCLUSION	1768 10 O
:	1778 1 O
There	1780 5 O
was	1786 3 O
no	1790 2 O
significant	1793 11 O
difference	1805 10 O
between	1816 7 O
isotonic	1824 8 O
sodium	1833 6 B-Chemical
chloride	1840 8 I-Chemical
,	1848 1 O
sodium	1850 6 B-Chemical
bicarbonate	1857 11 I-Chemical
and	1869 3 O
isotonic	1873 8 O
sodium	1882 6 B-Chemical
chloride	1889 8 I-Chemical
with	1898 4 O
diltiazem	1903 9 B-Chemical
application	1913 11 O
in	1925 2 O
prevention	1928 10 O
of	1939 2 O
CIN	1942 3 O
.	1945 1 O

Neurocognitive	0 14 O
and	15 3 O
neuroradiologic	19 15 O
central	35 7 O
nervous	43 7 O
system	51 6 O
late	58 4 O
effects	63 7 O
in	71 2 O
children	74 8 O
treated	83 7 O
on	91 2 O
Pediatric	94 9 O
Oncology	104 8 O
Group	113 5 O
(	119 1 O
POG	120 3 O
)	123 1 O
P9605	125 5 O
(	131 1 O
standard	132 8 O
risk	141 4 O
)	145 1 O
and	147 3 O
P9201	151 5 O
(	157 1 O
lesser	158 6 O
risk	165 4 O
)	169 1 O
acute	171 5 B-Disease
lymphoblastic	177 13 I-Disease
leukemia	191 8 I-Disease
protocols	200 9 O
(	210 1 O
ACCL0131	211 8 O
)	219 1 O
:	220 1 O
a	222 1 O
methotrexate	224 12 B-Chemical
consequence	237 11 O
?	248 1 O

A	250 1 O
report	252 6 O
from	259 4 O
the	264 3 O
Children	268 8 O
'	276 1 O
s	277 1 O
Oncology	279 8 O
Group	288 5 O
.	293 1 O

Concerns	295 8 O
about	304 5 O
long	310 4 O
-	314 1 O
term	315 4 O
methotrexate	320 12 B-Chemical
(	333 1 O
MTX	334 3 B-Chemical
)	337 1 O
neurotoxicity	339 13 B-Disease
in	353 2 O
the	356 3 O
1990s	360 5 O
led	366 3 O
to	370 2 O
modifications	373 13 O
in	387 2 O
intrathecal	390 11 O
(	402 1 O
IT	403 2 O
)	405 1 O
therapy	407 7 O
,	414 1 O
leucovorin	416 10 O
rescue	427 6 O
,	433 1 O
and	435 3 O
frequency	439 9 O
of	449 2 O
systemic	452 8 O
MTX	461 3 B-Chemical
administration	465 14 O
in	480 2 O
children	483 8 O
with	492 4 O
acute	497 5 B-Disease
lymphoblastic	503 13 I-Disease
leukemia	517 8 I-Disease
.	525 1 O

In	527 2 O
this	530 4 O
study	535 5 O
,	540 1 O
neurocognitive	542 14 O
outcomes	557 8 O
and	566 3 O
neuroradiologic	570 15 O
evidence	586 8 O
of	595 2 O
leukoencephalopathy	598 19 B-Disease
were	618 4 O
compared	623 8 O
in	632 2 O
children	635 8 O
treated	644 7 O
with	652 4 O
intense	657 7 O
central	665 7 O
nervous	673 7 O
system	681 6 O
(	688 1 O
CNS	689 3 O
)	692 1 O
-	693 1 O
directed	694 8 O
therapy	703 7 O
(	711 1 O
P9605	712 5 O
)	717 1 O
versus	719 6 O
those	726 5 O
receiving	732 9 O
fewer	742 5 O
CNS	748 3 O
-	751 1 O
directed	752 8 O
treatment	761 9 O
days	771 4 O
during	776 6 O
intensive	783 9 O
consolidation	793 13 O
(	807 1 O
P9201	808 5 O
)	813 1 O
.	814 1 O

A	816 1 O
total	818 5 O
of	824 2 O
66	827 2 O
children	830 8 O
from	839 4 O
16	844 2 O
Pediatric	847 9 O
Oncology	857 8 O
Group	866 5 O
institutions	872 12 O
with	885 4 O
"	890 1 O
standard	891 8 O
-	899 1 O
risk	900 4 O
"	904 1 O
acute	906 5 B-Disease
lymphoblastic	912 13 I-Disease
leukemia	926 8 I-Disease
,	934 1 O
1	936 1 O
.	937 1 O
00	938 2 O
to	941 2 O
9	944 1 O
.	945 1 O
99	946 2 O
years	949 5 O
at	955 2 O
diagnosis	958 9 O
,	967 1 O
without	969 7 O
evidence	977 8 O
of	986 2 O
CNS	989 3 O
leukemia	993 8 B-Disease
at	1002 2 O
diagnosis	1005 9 O
were	1015 4 O
enrolled	1020 8 O
on	1029 2 O
ACCL0131	1032 8 O
:	1040 1 O
28	1042 2 O
from	1045 4 O
P9201	1050 5 O
and	1056 3 O
38	1060 2 O
from	1063 4 O
P9605	1068 5 O
.	1073 1 O

Magnetic	1075 8 O
resonance	1084 9 O
imaging	1094 7 O
scans	1102 5 O
and	1108 3 O
standard	1112 8 O
neuropsychological	1121 18 O
tests	1140 5 O
were	1146 4 O
performed	1151 9 O
>	1161 1 O
2	1162 1 O
.	1163 1 O
6	1164 1 O
years	1166 5 O
after	1172 5 O
the	1178 3 O
end	1182 3 O
of	1186 2 O
treatment	1189 9 O
.	1198 1 O

Significantly	1200 13 O
more	1214 4 O
P9605	1219 5 O
patients	1225 8 O
developed	1234 9 O
leukoencephalopathy	1244 19 B-Disease
compared	1264 8 O
with	1273 4 O
P9201	1278 5 O
patients	1284 8 O
(	1293 1 O
68	1294 2 O
%	1296 1 O
,	1297 1 O
95	1299 2 O
%	1301 1 O
confidence	1303 10 O
interval	1314 8 O
49	1323 2 O
%	1325 1 O
-	1326 1 O
83	1327 2 O
%	1329 1 O
vs	1331 2 O
.	1333 1 O
22	1335 2 O
%	1337 1 O
,	1338 1 O
95	1340 2 O
%	1342 1 O
confidence	1344 10 O
interval	1355 8 O
5	1364 1 O
%	1365 1 O
-	1366 1 O
44	1367 2 O
%	1369 1 O
;	1370 1 O
P	1372 1 O
=	1373 1 O
0	1374 1 O
.	1375 1 O
001	1376 3 O
)	1379 1 O
identified	1381 10 O
as	1392 2 O
late	1395 4 O
as	1400 2 O
7	1403 1 O
.	1404 1 O
7	1405 1 O
years	1407 5 O
after	1413 5 O
the	1419 3 O
end	1423 3 O
of	1427 2 O
treatment	1430 9 O
.	1439 1 O

Overall	1441 7 O
,	1448 1 O
40	1450 2 O
%	1452 1 O
of	1454 2 O
patients	1457 8 O
scored	1466 6 O
<	1473 1 O
85	1474 2 O
on	1477 2 O
either	1480 6 O
Verbal	1487 6 O
or	1494 2 O
Performance	1497 11 O
IQ	1509 2 O
.	1511 1 O

Children	1513 8 O
on	1522 2 O
both	1525 4 O
studies	1530 7 O
had	1538 3 O
significant	1542 11 O
attention	1554 9 B-Disease
problems	1564 8 I-Disease
,	1572 1 O
but	1574 3 O
P9605	1578 5 O
children	1584 8 O
scored	1593 6 O
below	1600 5 O
average	1606 7 O
on	1614 2 O
more	1617 4 O
neurocognitive	1622 14 O
measures	1637 8 O
than	1646 4 O
those	1651 5 O
treated	1657 7 O
on	1665 2 O
P9201	1668 5 O
(	1674 1 O
82	1675 2 O
%	1677 1 O
,	1678 1 O
14	1680 2 O
/	1682 1 O
17	1683 2 O
measures	1686 8 O
vs	1695 2 O
.	1697 1 O
24	1699 2 O
%	1701 1 O
,	1702 1 O
4	1704 1 O
/	1705 1 O
17	1706 2 O
measures	1709 8 O
)	1717 1 O
.	1718 1 O

This	1720 4 O
supports	1725 8 O
ongoing	1734 7 O
concerns	1742 8 O
about	1751 5 O
intensive	1757 9 O
MTX	1767 3 B-Chemical
exposure	1771 8 O
as	1780 2 O
a	1783 1 O
major	1785 5 O
contributor	1791 11 O
to	1803 2 O
CNS	1806 3 O
late	1810 4 O
effects	1815 7 O
.	1822 1 O

Tranexamic	0 10 B-Chemical
acid	11 4 I-Chemical
overdosage	16 10 O
-	26 1 O
induced	27 7 O
generalized	35 11 O
seizure	47 7 B-Disease
in	55 2 O
renal	58 5 B-Disease
failure	64 7 I-Disease
.	71 1 O

We	73 2 O
report	76 6 O
a	83 1 O
45	85 2 O
-	87 1 O
year	88 4 O
-	92 1 O
old	93 3 O
lady	97 4 O
with	102 4 O
chronic	107 7 B-Disease
kidney	115 6 I-Disease
disease	122 7 I-Disease
stage	130 5 O
4	136 1 O
due	138 3 O
to	142 2 O
chronic	145 7 O
tubulointerstial	153 16 B-Disease
disease	170 7 I-Disease
.	177 1 O

She	179 3 O
was	183 3 O
admitted	187 8 O
to	196 2 O
our	199 3 O
center	203 6 O
for	210 3 O
severe	214 6 O
anemia	221 6 B-Disease
due	228 3 O
to	232 2 O
menorrhagia	235 11 B-Disease
and	247 3 O
deterioration	251 13 B-Disease
of	265 2 I-Disease
renal	268 5 I-Disease
function	274 8 I-Disease
.	282 1 O

She	284 3 O
was	288 3 O
infused	292 7 O
three	300 5 O
units	306 5 O
of	312 2 O
packed	315 6 O
cells	322 5 O
during	328 6 O
a	335 1 O
session	337 7 O
of	345 2 O
hemodialysis	348 12 O
.	360 1 O

Tranexamic	362 10 B-Chemical
acid	373 4 I-Chemical
(	378 1 O
TNA	379 3 B-Chemical
)	382 1 O
1	384 1 O
g	386 1 O
8	388 1 O
-	389 1 O
hourly	390 6 O
was	397 3 O
administered	401 12 O
to	414 2 O
her	417 3 O
to	421 2 O
control	424 7 O
bleeding	432 8 B-Disease
per	441 3 O
vaginum	445 7 O
.	452 1 O

Two	454 3 O
hours	458 5 O
after	464 5 O
the	470 3 O
sixth	474 5 O
dose	480 4 O
of	485 2 O
TNA	488 3 B-Chemical
,	491 1 O
she	493 3 O
had	497 3 O
an	501 2 O
episode	504 7 O
of	512 2 O
generalized	515 11 O
tonic	527 5 B-Disease
clonic	533 6 I-Disease
convulsions	540 11 I-Disease
.	551 1 O

TNA	553 3 B-Chemical
was	557 3 O
discontinued	561 12 O
.	573 1 O

Investigations	575 14 O
of	590 2 O
the	593 3 O
patient	597 7 O
revealed	605 8 O
no	614 2 O
biochemical	617 11 O
or	629 2 O
structural	632 10 O
central	643 7 O
nervous	651 7 B-Disease
system	659 6 I-Disease
abnormalities	666 13 I-Disease
that	680 4 O
could	685 5 O
have	691 4 O
provoked	696 8 O
the	705 3 O
convulsions	709 11 B-Disease
.	720 1 O

She	722 3 O
did	726 3 O
not	730 3 O
require	734 7 O
any	742 3 O
further	746 7 O
dialytic	754 8 O
support	763 7 O
.	770 1 O

She	772 3 O
had	776 3 O
no	780 2 O
further	783 7 O
episodes	791 8 O
of	800 2 O
convulsion	803 10 B-Disease
till	814 4 O
dis	819 3 O
-	822 1 O
charge	823 6 O
and	830 3 O
during	834 6 O
the	841 3 O
two	845 3 O
months	849 6 O
of	856 2 O
follow	859 6 O
-	865 1 O
up	866 2 O
.	868 1 O

Thus	870 4 O
,	874 1 O
the	876 3 O
precipitating	880 13 O
cause	894 5 O
of	900 2 O
convulsions	903 11 B-Disease
was	915 3 O
believed	919 8 O
to	928 2 O
be	931 2 O
an	934 2 O
overdose	937 8 B-Disease
of	946 2 O
TNA	949 3 B-Chemical
.	952 1 O

Pre	0 3 O
-	3 1 O
treatment	4 9 O
of	14 2 O
bupivacaine	17 11 B-Chemical
-	28 1 O
induced	29 7 O
cardiovascular	37 14 B-Disease
depression	52 10 I-Disease
using	63 5 O
different	69 9 O
lipid	79 5 O
formulations	85 12 O
of	98 2 O
propofol	101 8 B-Chemical
.	109 1 O

BACKGROUND	111 10 O
:	121 1 O
Pre	123 3 O
-	126 1 O
treatment	127 9 O
with	137 4 O
lipid	142 5 O
emulsions	148 9 O
has	158 3 O
been	162 4 O
shown	167 5 O
to	173 2 O
increase	176 8 O
lethal	185 6 O
doses	192 5 O
of	198 2 O
bupivacaine	201 11 B-Chemical
,	212 1 O
and	214 3 O
the	218 3 O
lipid	222 5 O
content	228 7 O
of	236 2 O
propofol	239 8 B-Chemical
may	248 3 O
alleviate	252 9 O
bupivacaine	262 11 B-Chemical
-	273 1 O
induced	274 7 O
cardiotoxicity	282 14 B-Disease
.	296 1 O

The	298 3 O
aim	302 3 O
of	306 2 O
this	309 4 O
study	314 5 O
is	320 2 O
to	323 2 O
investigate	326 11 O
the	338 3 O
effects	342 7 O
of	350 2 O
propofol	353 8 B-Chemical
in	362 2 O
intralipid	365 10 O
or	376 2 O
medialipid	379 10 O
emulsions	390 9 O
on	400 2 O
bupivacaine	403 11 B-Chemical
-	414 1 O
induced	415 7 O
cardiotoxicity	423 14 B-Disease
.	437 1 O

METHODS	439 7 O
:	446 1 O
Rats	448 4 O
were	453 4 O
anaesthetised	458 13 O
with	472 4 O
ketamine	477 8 B-Chemical
and	486 3 O
were	490 4 O
given	495 5 O
0	501 1 O
.	502 1 O
5	503 1 O
mg	505 2 O
/	507 1 O
kg	508 2 O
/	510 1 O
min	511 3 O
propofol	515 8 B-Chemical
in	524 2 O
intralipid	527 10 O
(	538 1 O
Group	539 5 O
P	545 1 O
)	546 1 O
,	547 1 O
propofol	549 8 B-Chemical
in	558 2 O
medialipid	561 10 O
(	572 1 O
Group	573 5 O
L	579 1 O
)	580 1 O
,	581 1 O
or	583 2 O
saline	586 6 O
(	593 1 O
Group	594 5 O
C	600 1 O
)	601 1 O
over	603 4 O
20	608 2 O
min	611 3 O
.	614 1 O

Thereafter	616 10 O
,	626 1 O
2	628 1 O
mg	630 2 O
/	632 1 O
kg	633 2 O
/	635 1 O
min	636 3 O
bupivacaine	640 11 B-Chemical
0	652 1 O
.	653 1 O
5	654 1 O
%	655 1 O
was	657 3 O
infused	661 7 O
.	668 1 O

We	670 2 O
recorded	673 8 O
time	682 4 O
to	687 2 O
first	690 5 O
dysrhythmia	696 11 B-Disease
occurrence	708 10 O
,	718 1 O
respective	720 10 O
times	731 5 O
to	737 2 O
25	740 2 O
%	742 1 O
and	744 3 O
50	748 2 O
%	750 1 O
reduction	752 9 O
of	762 2 O
the	765 3 O
heart	769 5 O
rate	775 4 O
(	780 1 O
HR	781 2 O
)	783 1 O
and	785 3 O
mean	789 4 O
arterial	794 8 O
pressure	803 8 O
,	811 1 O
and	813 3 O
time	817 4 O
to	822 2 O
asystole	825 8 B-Disease
and	834 3 O
total	838 5 O
amount	844 6 O
of	851 2 O
bupivacaine	854 11 B-Chemical
consumption	866 11 O
.	877 1 O

Blood	879 5 O
and	885 3 O
tissue	889 6 O
samples	896 7 O
were	904 4 O
collected	909 9 O
following	919 9 O
asystole	929 8 B-Disease
.	937 1 O

RESULTS	939 7 O
:	946 1 O
The	948 3 O
time	952 4 O
to	957 2 O
first	960 5 O
dysrhythmia	966 11 B-Disease
occurrence	978 10 O
,	988 1 O
time	990 4 O
to	995 2 O
25	998 2 O
%	1000 1 O
and	1002 3 O
50	1006 2 O
%	1008 1 O
reductions	1010 10 O
in	1021 2 O
HR	1024 2 O
,	1026 1 O
and	1028 3 O
time	1032 4 O
to	1037 2 O
asystole	1040 8 B-Disease
were	1049 4 O
longer	1054 6 O
in	1061 2 O
Group	1064 5 O
P	1070 1 O
than	1072 4 O
the	1077 3 O
other	1081 5 O
groups	1087 6 O
.	1093 1 O

The	1095 3 O
cumulative	1099 10 O
bupivacaine	1110 11 B-Chemical
dose	1122 4 O
given	1127 5 O
at	1133 2 O
those	1136 5 O
time	1142 4 O
points	1147 6 O
was	1154 3 O
higher	1158 6 O
in	1165 2 O
Group	1168 5 O
P	1174 1 O
.	1175 1 O
Plasma	1177 6 O
bupivacaine	1184 11 B-Chemical
levels	1196 6 O
were	1203 4 O
significantly	1208 13 O
lower	1222 5 O
in	1228 2 O
Group	1231 5 O
P	1237 1 O
than	1239 4 O
in	1244 2 O
Group	1247 5 O
C	1253 1 O
.	1254 1 O
Bupivacaine	1256 11 B-Chemical
levels	1268 6 O
in	1275 2 O
the	1278 3 O
brain	1282 5 O
and	1288 3 O
heart	1292 5 O
were	1298 4 O
significantly	1303 13 O
lower	1317 5 O
in	1323 2 O
Group	1326 5 O
P	1332 1 O
and	1334 3 O
Group	1338 5 O
L	1344 1 O
than	1346 4 O
in	1351 2 O
Group	1354 5 O
C	1360 1 O
.	1361 1 O

CONCLUSION	1363 10 O
:	1373 1 O
We	1375 2 O
conclude	1378 8 O
that	1387 4 O
pre	1392 3 O
-	1395 1 O
treatment	1396 9 O
with	1406 4 O
propofol	1411 8 B-Chemical
in	1420 2 O
intralipid	1423 10 O
,	1433 1 O
compared	1435 8 O
with	1444 4 O
propofol	1449 8 B-Chemical
in	1458 2 O
medialipid	1461 10 O
or	1472 2 O
saline	1475 6 O
,	1481 1 O
delayed	1483 7 O
the	1491 3 O
onset	1495 5 O
of	1501 2 O
bupivacaine	1504 11 B-Chemical
-	1515 1 O
induced	1516 7 O
cardiotoxic	1524 11 B-Disease
effects	1536 7 O
as	1544 2 O
well	1547 4 O
as	1552 2 O
reduced	1555 7 O
plasma	1563 6 O
bupivacaine	1570 11 B-Chemical
levels	1582 6 O
.	1588 1 O

Further	1590 7 O
studies	1598 7 O
are	1606 3 O
needed	1610 6 O
to	1617 2 O
explore	1620 7 O
tissue	1628 6 O
bupivacaine	1635 11 B-Chemical
levels	1647 6 O
of	1654 2 O
propofol	1657 8 B-Chemical
in	1666 2 O
medialipid	1669 10 O
and	1680 3 O
adapt	1684 5 O
these	1690 5 O
results	1696 7 O
to	1704 2 O
clinical	1707 8 O
practice	1716 8 O
.	1724 1 O

Drug	0 4 B-Disease
-	4 1 I-Disease
Induced	5 7 I-Disease
Acute	13 5 I-Disease
Liver	19 5 I-Disease
Injury	25 6 I-Disease
Within	32 6 O
12	39 2 O
Hours	42 5 O
After	48 5 O
Fluvastatin	54 11 B-Chemical
Therapy	66 7 O
.	73 1 O

Although	75 8 O
statins	84 7 B-Chemical
are	92 3 O
generally	96 9 O
well	106 4 O
-	110 1 O
tolerated	111 9 O
drugs	121 5 O
,	126 1 O
recent	128 6 O
cases	135 5 O
of	141 2 O
drug	144 4 B-Disease
-	148 1 I-Disease
induced	149 7 I-Disease
liver	157 5 I-Disease
injury	163 6 I-Disease
associated	170 10 O
with	181 4 O
their	186 5 O
use	192 3 O
have	196 4 O
been	201 4 O
reported	206 8 O
.	214 1 O

A	216 1 O
52	218 2 O
-	220 1 O
year	221 4 O
-	225 1 O
old	226 3 O
Chinese	230 7 O
man	238 3 O
reported	242 8 O
with	251 4 O
liver	256 5 B-Disease
damage	262 6 I-Disease
,	268 1 O
which	270 5 O
appeared	276 8 O
12	285 2 O
hours	288 5 O
after	294 5 O
beginning	300 9 O
treatment	310 9 O
with	320 4 O
fluvastatin	325 11 B-Chemical
.	336 1 O

Patient	338 7 O
presented	346 9 O
with	356 4 O
complaints	361 10 O
of	372 2 O
increasing	375 10 O
nausea	386 6 B-Disease
,	392 1 O
anorexia	394 8 B-Disease
,	402 1 O
and	404 3 O
upper	408 5 O
abdominal	414 9 B-Disease
pain	424 4 I-Disease
.	428 1 O

His	430 3 O
laboratory	434 10 O
values	445 6 O
showed	452 6 O
elevated	459 8 O
creatine	468 8 B-Chemical
kinase	477 6 O
and	484 3 O
transaminases	488 13 O
.	501 1 O

Testing	503 7 O
for	511 3 O
autoantibodies	515 14 O
was	530 3 O
also	534 4 O
negative	539 8 O
.	547 1 O

The	549 3 O
liver	553 5 O
biochemistries	559 14 O
eventually	574 10 O
normalized	585 10 O
within	596 6 O
3	603 1 O
weeks	605 5 O
of	611 2 O
stopping	614 8 O
the	623 3 O
fluvastatin	627 11 B-Chemical
.	638 1 O

Therefore	640 9 O
,	649 1 O
when	651 4 O
prescribing	656 11 O
statins	668 7 O
,	675 1 O
the	677 3 O
possibility	681 11 O
of	693 2 O
hepatic	696 7 B-Disease
damage	704 6 I-Disease
should	711 6 O
be	718 2 O
taken	721 5 O
into	727 4 O
account	732 7 O
.	739 1 O

Fluconazole	0 11 B-Chemical
associated	12 10 O
agranulocytosis	23 15 B-Disease
and	39 3 O
thrombocytopenia	43 16 B-Disease
.	59 1 O

CASE	61 4 O
:	65 1 O
We	67 2 O
describe	70 8 O
a	79 1 O
second	81 6 O
case	88 4 O
of	93 2 O
fluconazole	96 11 B-Chemical
associated	108 10 O
agranulocytosis	119 15 B-Disease
with	135 4 O
thrombocytopenia	140 16 B-Disease
and	157 3 O
recovery	161 8 O
upon	170 4 O
discontinuation	175 15 O
of	191 2 O
therapy	194 7 O
.	201 1 O

The	203 3 O
patient	207 7 O
began	215 5 O
to	221 2 O
have	224 4 O
changes	229 7 O
in	237 2 O
white	240 5 O
blood	246 5 O
cells	252 5 O
and	258 3 O
platelets	262 9 O
within	272 6 O
48	279 2 O
h	282 1 O
of	284 2 O
administration	287 14 O
of	302 2 O
fluconazole	305 11 B-Chemical
and	317 3 O
began	321 5 O
to	327 2 O
recover	330 7 O
with	338 4 O
48	343 2 O
h	346 1 O
of	348 2 O
discontinuation	351 15 O
.	366 1 O

This	368 4 O
case	373 4 O
highlights	378 10 O
that	389 4 O
drug	394 4 O
-	398 1 O
induced	399 7 O
blood	407 5 B-Disease
dyscrasias	413 10 I-Disease
can	424 3 O
occur	428 5 O
unexpectedly	434 12 O
as	447 2 O
a	450 1 O
result	452 6 O
of	459 2 O
treatment	462 9 O
with	472 4 O
a	477 1 O
commonly	479 8 O
used	488 4 O
drug	493 4 O
thought	498 7 O
to	506 2 O
be	509 2 O
"	512 1 O
safe	513 4 O
"	517 1 O
.	518 1 O

CONCLUSION	520 10 O
:	530 1 O
According	532 9 O
to	542 2 O
Naranjo	545 7 O
'	552 1 O
s	553 1 O
algorithm	555 9 O
the	565 3 O
likelihood	569 10 O
that	580 4 O
our	585 3 O
patient	589 7 O
'	596 1 O
s	597 1 O
agranulocytosis	599 15 B-Disease
and	615 3 O
thrombocytopenia	619 16 B-Disease
occurred	636 8 O
as	645 2 O
a	648 1 O
result	650 6 O
of	657 2 O
therapy	660 7 O
with	668 4 O
fluconazole	673 11 B-Chemical
is	685 2 O
probable	688 8 O
,	696 1 O
with	698 4 O
a	703 1 O
total	705 5 O
of	711 2 O
six	714 3 O
points	718 6 O
.	724 1 O

We	726 2 O
feel	729 4 O
that	734 4 O
the	739 3 O
weight	743 6 O
of	750 2 O
the	753 3 O
overall	757 7 O
evidence	765 8 O
of	774 2 O
this	777 4 O
evidence	782 8 O
is	791 2 O
strong	794 6 O
.	800 1 O

In	802 2 O
particular	805 10 O
the	816 3 O
temporal	820 8 O
relationship	829 12 O
of	842 2 O
bone	845 4 B-Disease
marrow	850 6 I-Disease
suppression	857 11 I-Disease
to	869 2 O
the	872 3 O
initiation	876 10 O
of	887 2 O
fluconazole	890 11 B-Chemical
and	902 3 O
the	906 3 O
abatement	910 9 O
of	920 2 O
symptoms	923 8 O
that	932 4 O
rapidly	937 7 O
reversed	945 8 O
immediately	954 11 O
following	966 9 O
discontinuation	976 15 O
.	991 1 O

Two	0 3 O
-	3 1 O
dimensional	4 11 O
speckle	16 7 O
tracking	24 8 O
echocardiography	33 16 O
combined	50 8 O
with	59 4 O
high	64 4 O
-	68 1 O
sensitive	69 9 O
cardiac	79 7 O
troponin	87 8 O
T	96 1 O
in	98 2 O
early	101 5 O
detection	107 9 O
and	117 3 O
prediction	121 10 O
of	132 2 O
cardiotoxicity	135 14 B-Disease
during	150 6 O
epirubicine	157 11 B-Chemical
-	168 1 O
based	169 5 O
chemotherapy	175 12 O
.	187 1 O

AIMS	189 4 O
:	193 1 O
To	195 2 O
investigate	198 11 O
whether	210 7 O
alterations	218 11 O
of	230 2 O
myocardial	233 10 B-Disease
strain	244 6 I-Disease
and	251 3 O
high	255 4 O
-	259 1 O
sensitive	260 9 O
cardiac	270 7 O
troponin	278 8 O
T	287 1 O
(	289 1 O
cTnT	290 4 O
)	294 1 O
could	296 5 O
predict	302 7 O
future	310 6 O
cardiac	317 7 B-Disease
dysfunction	325 11 I-Disease
in	337 2 O
patients	340 8 O
after	349 5 O
epirubicin	355 10 B-Chemical
exposure	366 8 O
.	374 1 O

METHODS	376 7 O
:	383 1 O
Seventy	385 7 O
-	392 1 O
five	393 4 O
patients	398 8 O
with	407 4 O
non	412 3 B-Disease
-	415 1 I-Disease
Hodgkin	416 7 I-Disease
lymphoma	424 8 I-Disease
treated	433 7 O
with	441 4 O
epirubicin	446 10 B-Chemical
were	457 4 O
studied	462 7 O
.	469 1 O

Blood	471 5 O
collection	477 10 O
and	488 3 O
echocardiography	492 16 O
were	509 4 O
performed	514 9 O
at	524 2 O
baseline	527 8 O
,	535 1 O
1	537 1 O
day	539 3 O
after	543 5 O
the	549 3 O
third	553 5 O
cycle	559 5 O
,	564 1 O
and	566 3 O
1	570 1 O
day	572 3 O
after	576 5 O
completion	582 10 O
of	593 2 O
chemotherapy	596 12 O
.	608 1 O

Patients	610 8 O
were	619 4 O
studied	624 7 O
using	632 5 O
echocardiography	638 16 O
during	655 6 O
follow	662 6 O
-	668 1 O
up	669 2 O
.	671 1 O

Global	673 6 O
longitudinal	680 12 O
(	693 1 O
GLS	694 3 O
)	697 1 O
,	698 1 O
circumferential	700 15 O
(	716 1 O
GCS	717 3 O
)	720 1 O
,	721 1 O
and	723 3 O
radial	727 6 O
strain	734 6 O
(	741 1 O
GRS	742 3 O
)	745 1 O
were	747 4 O
calculated	752 10 O
using	763 5 O
speckle	769 7 O
tracking	777 8 O
echocardiography	786 16 O
.	802 1 O

Left	804 4 O
ventricular	809 11 O
ejection	821 8 O
fraction	830 8 O
was	839 3 O
analysed	843 8 O
by	852 2 O
real	855 4 O
-	859 1 O
time	860 4 O
3D	865 2 O
echocardiography	868 16 O
.	884 1 O

Cardiotoxicity	886 14 B-Disease
was	901 3 O
defined	905 7 O
as	913 2 O
a	916 1 O
reduction	918 9 O
of	928 2 O
the	931 3 O
LVEF	935 4 O
of	940 2 O
>	943 1 O
5	944 1 O
%	945 1 O
to	947 2 O
<	950 1 O
55	951 2 O
%	953 1 O
with	955 4 O
symptoms	960 8 O
of	969 2 O
heart	972 5 B-Disease
failure	978 7 I-Disease
or	986 2 O
an	989 2 O
asymptomatic	992 12 O
reduction	1005 9 O
of	1015 2 O
the	1018 3 O
LVEF	1022 4 O
of	1027 2 O
>	1030 1 O
10	1031 2 O
%	1033 1 O
to	1035 2 O
<	1038 1 O
55	1039 2 O
%	1041 1 O
.	1042 1 O

RESULTS	1044 7 O
:	1051 1 O
Fourteen	1053 8 O
patients	1062 8 O
(	1071 1 O
18	1072 2 O
.	1074 1 O
67	1075 2 O
%	1077 1 O
)	1078 1 O
developed	1080 9 O
cardiotoxicity	1090 14 B-Disease
after	1105 5 O
treatment	1111 9 O
.	1120 1 O

GLS	1122 3 O
(	1126 1 O
-	1127 1 O
18	1128 2 O
.	1130 1 O
48	1131 2 O
+	1134 1 O
1	1136 1 O
.	1137 1 O
72	1138 2 O
%	1140 1 O
vs	1142 2 O
.	1144 1 O
-	1146 1 O
15	1147 2 O
.	1149 1 O
96	1150 2 O
+	1153 1 O
1	1155 1 O
.	1156 1 O
6	1157 1 O
%	1158 1 O
)	1159 1 O
,	1160 1 O
GCS	1162 3 O
(	1166 1 O
-	1167 1 O
20	1168 2 O
.	1170 1 O
93	1171 2 O
+	1174 1 O
2	1176 1 O
.	1177 1 O
86	1178 2 O
%	1180 1 O
vs	1182 2 O
.	1184 1 O
-	1186 1 O
19	1187 2 O
.	1189 1 O
20	1190 2 O
+	1193 1 O
3	1195 1 O
.	1196 1 O
21	1197 2 O
%	1199 1 O
)	1200 1 O
,	1201 1 O
and	1203 3 O
GRS	1207 3 O
(	1211 1 O
39	1212 2 O
.	1214 1 O
23	1215 2 O
+	1218 1 O
6	1220 1 O
.	1221 1 O
44	1222 2 O
%	1224 1 O
vs	1226 2 O
.	1228 1 O
34	1230 2 O
.	1232 1 O
98	1233 2 O
+	1236 1 O
6	1238 1 O
.	1239 1 O
2	1240 1 O
%	1241 1 O
)	1242 1 O
were	1244 4 O
markedly	1249 8 O
reduced	1258 7 O
and	1266 3 O
cTnT	1270 4 O
was	1275 3 O
elevated	1279 8 O
from	1288 4 O
0	1293 1 O
.	1294 1 O
0010	1295 4 O
+	1300 1 O
0	1302 1 O
.	1303 1 O
0020	1304 4 O
to	1309 2 O
0	1312 1 O
.	1313 1 O
0073	1314 4 O
+	1319 1 O
0	1321 1 O
.	1322 1 O
0038	1323 4 O
ng	1328 2 O
/	1330 1 O
mL	1331 2 O
(	1334 1 O
P	1335 1 O
all	1337 3 O
<	1341 1 O
0	1343 1 O
.	1344 1 O
01	1345 2 O
)	1347 1 O
at	1349 2 O
the	1352 3 O
completion	1356 10 O
of	1367 2 O
chemotherapy	1370 12 O
compared	1383 8 O
with	1392 4 O
baseline	1397 8 O
values	1406 6 O
.	1412 1 O

A	1414 1 O
>	1416 1 O
15	1417 2 O
.	1419 1 O
9	1420 1 O
%	1421 1 O
decrease	1423 8 O
in	1432 2 O
GLS	1435 3 O
[	1439 1 O
sensitivity	1440 11 O
,	1451 1 O
86	1453 2 O
%	1455 1 O
;	1456 1 O
specificity	1458 11 O
,	1469 1 O
75	1471 2 O
%	1473 1 O
;	1474 1 O
area	1476 4 O
under	1481 5 O
the	1487 3 O
curve	1491 5 O
(	1497 1 O
AUC	1498 3 O
)	1501 1 O
=	1503 1 O
0	1505 1 O
.	1506 1 O
815	1507 3 O
;	1510 1 O
P	1512 1 O
=	1514 1 O
0	1516 1 O
.	1517 1 O
001	1518 3 O
]	1521 1 O
and	1523 3 O
a	1527 1 O
>	1529 1 O
0	1530 1 O
.	1531 1 O
004	1532 3 O
ng	1536 2 O
/	1538 1 O
mL	1539 2 O
elevation	1542 9 O
in	1552 2 O
cTnT	1555 4 O
(	1560 1 O
sensitivity	1561 11 O
,	1572 1 O
79	1574 2 O
%	1576 1 O
;	1577 1 O
specificity	1579 11 O
,	1590 1 O
64	1592 2 O
%	1594 1 O
;	1595 1 O
AUC	1597 3 O
=	1601 1 O
0	1603 1 O
.	1604 1 O
757	1605 3 O
;	1608 1 O
P	1610 1 O
=	1612 1 O
0	1614 1 O
.	1615 1 O
005	1616 3 O
)	1619 1 O
from	1621 4 O
baseline	1626 8 O
to	1635 2 O
the	1638 3 O
third	1642 5 O
cycle	1648 5 O
of	1654 2 O
chemotherapy	1657 12 O
predicted	1670 9 O
later	1680 5 O
cardiotoxicity	1686 14 B-Disease
.	1700 1 O

The	1702 3 O
decrease	1706 8 O
in	1715 2 O
GLS	1718 3 O
remained	1722 8 O
the	1731 3 O
only	1735 4 O
independent	1740 11 O
predictor	1752 9 O
of	1762 2 O
cardiotoxicity	1765 14 B-Disease
(	1780 1 O
P	1781 1 O
=	1783 1 O
0	1785 1 O
.	1786 1 O
000	1787 3 O
)	1790 1 O
.	1791 1 O

CONCLUSIONS	1793 11 O
:	1804 1 O
GLS	1806 3 O
combined	1810 8 O
with	1819 4 O
cTnT	1824 4 O
may	1829 3 O
provide	1833 7 O
a	1841 1 O
reliable	1843 8 O
and	1852 3 O
non	1856 3 O
-	1859 1 O
invasive	1860 8 O
method	1869 6 O
to	1876 2 O
predict	1879 7 O
cardiac	1887 7 B-Disease
dysfunction	1895 11 I-Disease
in	1907 2 O
patients	1910 8 O
receiving	1919 9 O
anthracycline	1929 13 B-Chemical
-	1942 1 O
based	1943 5 O
chemotherapy	1949 12 O
.	1961 1 O

Prevention	0 10 O
of	11 2 O
etomidate	14 9 B-Chemical
-	23 1 O
induced	24 7 O
myoclonus	32 9 B-Disease
:	41 1 O
which	43 5 O
is	49 2 O
superior	52 8 O
:	60 1 O
Fentanyl	62 8 B-Chemical
,	70 1 O
midazolam	72 9 B-Chemical
,	81 1 O
or	83 2 O
a	86 1 O
combination	88 11 O
?	99 1 O

A	101 1 O
Retrospective	103 13 O
comparative	117 11 O
study	129 5 O
.	134 1 O

BACKGROUND	136 10 O
:	146 1 O
In	148 2 O
this	151 4 O
retrospective	156 13 O
comparative	170 11 O
study	182 5 O
,	187 1 O
we	189 2 O
aimed	192 5 O
to	198 2 O
compare	201 7 O
the	209 3 O
effectiveness	213 13 O
of	227 2 O
fentanyl	230 8 B-Chemical
,	238 1 O
midazolam	240 9 B-Chemical
,	249 1 O
and	251 3 O
a	255 1 O
combination	257 11 O
of	269 2 O
fentanyl	272 8 B-Chemical
and	281 3 O
midazolam	285 9 B-Chemical
to	295 2 O
prevent	298 7 O
etomidate	306 9 B-Chemical
-	315 1 O
induced	316 7 O
myoclonus	324 9 B-Disease
.	333 1 O

MATERIAL	335 8 O
AND	344 3 O
METHODS	348 7 O
:	355 1 O
This	357 4 O
study	362 5 O
was	368 3 O
performed	372 9 O
based	382 5 O
on	388 2 O
anesthesia	391 10 O
records	402 7 O
.	409 1 O

Depending	411 9 O
on	421 2 O
the	424 3 O
drugs	428 5 O
that	434 4 O
would	439 5 O
be	445 2 O
given	448 5 O
before	454 6 O
the	461 3 O
induction	465 9 O
of	475 2 O
anesthesia	478 10 O
with	489 4 O
etomidate	494 9 B-Chemical
,	503 1 O
the	505 3 O
patients	509 8 O
were	518 4 O
separated	523 9 O
into	533 4 O
4	538 1 O
groups	540 6 O
:	546 1 O
no	548 2 O
pretreatment	551 12 O
(	564 1 O
Group	565 5 O
NP	571 2 O
)	573 1 O
,	574 1 O
fentanyl	576 8 B-Chemical
1	585 1 O
ug	587 2 O
.	589 1 O
kg	590 2 O
-	592 1 O
1	593 1 O
(	595 1 O
Group	596 5 O
F	602 1 O
)	603 1 O
,	604 1 O
midazolam	606 9 B-Chemical
0	616 1 O
.	617 1 O
03	618 2 O
mg	621 2 O
.	623 1 O
kg	624 2 O
-	626 1 O
1	627 1 O
(	629 1 O
Group	630 5 O
M	636 1 O
)	637 1 O
,	638 1 O
and	640 3 O
midazolam	644 9 B-Chemical
0	654 1 O
.	655 1 O
015	656 3 O
mg	660 2 O
.	662 1 O
kg	663 2 O
-	665 1 O
1	666 1 O
+	668 1 O
fentanyl	670 8 B-Chemical
0	679 1 O
.	680 1 O
5	681 1 O
ug	683 2 O
.	685 1 O
kg	686 2 O
-	688 1 O
1	689 1 O
(	691 1 O
Group	692 5 O
FM	698 2 O
)	700 1 O
.	701 1 O

Patients	703 8 O
who	712 3 O
received	716 8 O
the	725 3 O
same	729 4 O
anesthetic	734 10 O
procedure	745 9 O
were	755 4 O
selected	760 8 O
:	768 1 O
2	770 1 O
minutes	772 7 O
after	780 5 O
intravenous	786 11 O
injections	798 10 O
of	809 2 O
the	812 3 O
pretreatment	816 12 O
drugs	829 5 O
,	834 1 O
anesthesia	836 10 O
is	847 2 O
induced	850 7 O
with	858 4 O
0	863 1 O
.	864 1 O
3	865 1 O
mg	867 2 O
.	869 1 O
kg	870 2 O
-	872 1 O
1	873 1 O
etomidate	875 9 B-Chemical
injected	885 8 O
intravenously	894 13 O
over	908 4 O
a	913 1 O
period	915 6 O
of	922 2 O
20	925 2 O
-	927 1 O
30	928 2 O
seconds	931 7 O
.	938 1 O

Myoclonic	940 9 B-Disease
movements	950 9 I-Disease
are	960 3 O
evaluated	964 9 O
,	973 1 O
which	975 5 O
were	981 4 O
observed	986 8 O
and	995 3 O
graded	999 6 O
according	1006 9 O
to	1016 2 O
clinical	1019 8 O
severity	1028 8 O
during	1037 6 O
the	1044 3 O
2	1048 1 O
minutes	1050 7 O
after	1058 5 O
etomidate	1064 9 B-Chemical
injection	1074 9 O
.	1083 1 O

The	1085 3 O
severity	1089 8 O
of	1098 2 O
pain	1101 4 B-Disease
due	1106 3 O
to	1110 2 O
etomidate	1113 9 B-Chemical
injection	1123 9 O
,	1132 1 O
mean	1134 4 O
arterial	1139 8 O
pressure	1148 8 O
,	1156 1 O
heart	1158 5 O
rate	1164 4 O
,	1168 1 O
and	1170 3 O
adverse	1174 7 O
effects	1182 7 O
were	1190 4 O
also	1195 4 O
evaluated	1200 9 O
.	1209 1 O

RESULTS	1211 7 O
:	1218 1 O
Study	1220 5 O
results	1226 7 O
showed	1234 6 O
that	1241 4 O
myoclonus	1246 9 B-Disease
incidence	1256 9 O
was	1266 3 O
85	1270 2 O
%	1272 1 O
,	1273 1 O
40	1275 2 O
%	1277 1 O
,	1278 1 O
70	1280 2 O
%	1282 1 O
,	1283 1 O
and	1285 3 O
25	1289 2 O
%	1291 1 O
in	1293 2 O
Group	1296 5 O
NP	1302 2 O
,	1304 1 O
Group	1306 5 O
F	1312 1 O
,	1313 1 O
Group	1315 5 O
M	1321 1 O
,	1322 1 O
and	1324 3 O
Group	1328 5 O
FM	1334 2 O
,	1336 1 O
respectively	1338 12 O
,	1350 1 O
and	1352 3 O
were	1356 4 O
significantly	1361 13 O
lower	1375 5 O
in	1381 2 O
Group	1384 5 O
F	1390 1 O
and	1392 3 O
Group	1396 5 O
FM	1402 2 O
.	1404 1 O

CONCLUSIONS	1406 11 O
:	1417 1 O
We	1419 2 O
conclude	1422 8 O
that	1431 4 O
pretreatment	1436 12 O
with	1449 4 O
fentanyl	1454 8 B-Chemical
or	1463 2 O
combination	1466 11 O
of	1478 2 O
fentanyl	1481 8 B-Chemical
and	1490 3 O
midazolam	1494 9 B-Chemical
was	1504 3 O
effective	1508 9 O
in	1518 2 O
preventing	1521 10 O
etomidate	1532 9 B-Chemical
-	1541 1 O
induced	1542 7 O
myoclonus	1550 9 B-Disease
.	1559 1 O

Cholestatic	0 11 B-Disease
presentation	12 12 O
of	25 2 O
yellow	28 6 O
phosphorus	35 10 B-Chemical
poisoning	46 9 B-Disease
.	55 1 O

Yellow	57 6 O
phosphorus	64 10 B-Chemical
,	74 1 O
a	76 1 O
component	78 9 O
of	88 2 O
certain	91 7 O
pesticide	99 9 O
pastes	109 6 O
and	116 3 O
fireworks	120 9 O
,	129 1 O
is	131 2 O
well	134 4 O
known	139 5 O
to	145 2 O
cause	148 5 O
hepatotoxicity	154 14 B-Disease
.	168 1 O

Poisoning	170 9 B-Disease
with	180 4 O
yellow	185 6 O
phosphorus	192 10 B-Chemical
classically	203 11 O
manifests	215 9 O
with	225 4 O
acute	230 5 B-Disease
hepatitis	236 9 I-Disease
leading	246 7 O
to	254 2 O
acute	257 5 B-Disease
liver	263 5 I-Disease
failure	269 7 I-Disease
which	277 5 O
may	283 3 O
need	287 4 O
liver	292 5 O
transplantation	298 15 O
.	313 1 O

We	315 2 O
present	318 7 O
a	326 1 O
case	328 4 O
of	333 2 O
yellow	336 6 O
phosphorus	343 10 B-Chemical
poisoning	354 9 B-Disease
in	364 2 O
which	367 5 O
a	373 1 O
patient	375 7 O
presented	383 9 O
with	393 4 O
florid	398 6 O
clinical	405 8 O
features	414 8 O
of	423 2 O
cholestasis	426 11 B-Disease
highlighting	438 12 O
the	451 3 O
fact	455 4 O
that	460 4 O
cholestasis	465 11 B-Disease
can	477 3 O
rarely	481 6 O
be	488 2 O
a	491 1 O
presenting	493 10 O
feature	504 7 O
of	512 2 O
yellow	515 6 O
phosphorus	522 10 B-Chemical
hepatotoxicity	533 14 B-Disease
.	547 1 O

Vasovagal	0 9 B-Disease
syncope	10 7 I-Disease
and	18 3 O
severe	22 6 O
bradycardia	29 11 B-Disease
following	41 9 O
intranasal	51 10 O
dexmedetomidine	62 15 B-Chemical
for	78 3 O
pediatric	82 9 O
procedural	92 10 O
sedation	103 8 O
.	111 1 O

We	113 2 O
report	116 6 O
syncope	123 7 B-Disease
and	131 3 O
bradycardia	135 11 B-Disease
in	147 2 O
an	150 2 O
11	153 2 O
-	155 1 O
year	156 4 O
-	160 1 O
old	161 3 O
girl	165 4 O
following	170 9 O
administration	180 14 O
of	195 2 O
intranasal	198 10 O
dexmedetomidine	209 15 B-Chemical
for	225 3 O
sedation	229 8 O
for	238 3 O
a	242 1 O
voiding	244 7 O
cystourethrogram	252 16 O
.	268 1 O

Following	270 9 O
successful	280 10 O
completion	291 10 O
of	302 2 O
VCUG	305 4 O
and	310 3 O
a	314 1 O
60	316 2 O
-	318 1 O
min	319 3 O
recovery	323 8 O
period	332 6 O
,	338 1 O
the	340 3 O
patient	344 7 O
'	351 1 O
s	352 1 O
level	354 5 O
of	360 2 O
consciousness	363 13 O
and	377 3 O
vital	381 5 O
signs	387 5 O
returned	393 8 O
to	402 2 O
presedation	405 11 O
levels	417 6 O
.	423 1 O

Upon	425 4 O
leaving	430 7 O
the	438 3 O
sedation	442 8 O
area	451 4 O
,	455 1 O
the	457 3 O
patient	461 7 O
collapsed	469 9 O
,	478 1 O
with	480 4 O
no	485 2 O
apparent	488 8 O
inciting	497 8 O
event	506 5 O
.	511 1 O

The	513 3 O
patient	517 7 O
quickly	525 7 O
regained	533 8 O
consciousness	542 13 O
and	556 3 O
no	560 2 O
injury	563 6 O
occurred	570 8 O
.	578 1 O

The	580 3 O
primary	584 7 O
abnormality	592 11 O
found	604 5 O
was	610 3 O
persistent	614 10 O
bradycardia	625 11 B-Disease
,	636 1 O
and	638 3 O
she	642 3 O
was	646 3 O
admitted	650 8 O
to	659 2 O
the	662 3 O
hospital	666 8 O
for	675 3 O
telemetric	679 10 O
observation	690 11 O
.	701 1 O

The	703 3 O
bradycardia	707 11 B-Disease
lasted	719 6 O
~	726 1 O
2	727 1 O
h	729 1 O
,	730 1 O
and	732 3 O
further	736 7 O
cardiac	744 7 O
workup	752 6 O
revealed	759 8 O
no	768 2 O
underlying	771 10 O
abnormality	782 11 O
.	793 1 O

Unanticipated	795 13 O
and	809 3 O
previously	813 10 O
unreported	824 10 O
outcomes	835 8 O
may	844 3 O
be	848 2 O
witnessed	851 9 O
as	861 2 O
we	864 2 O
expand	867 6 O
the	874 3 O
use	878 3 O
of	882 2 O
certain	885 7 O
sedatives	893 9 O
to	903 2 O
alternative	906 11 O
routes	918 6 O
of	925 2 O
administration	928 14 O
.	942 1 O

Paradoxical	0 11 O
severe	12 6 O
agitation	19 9 B-Disease
induced	29 7 O
by	37 2 O
add	40 3 O
-	43 1 O
on	44 2 O
high	47 4 O
-	51 1 O
doses	52 5 O
quetiapine	58 10 B-Chemical
in	69 2 O
schizo	72 6 B-Disease
-	78 1 I-Disease
affective	79 9 I-Disease
disorder	89 8 I-Disease
.	97 1 O

We	99 2 O
report	102 6 O
the	109 3 O
case	113 4 O
of	118 2 O
a	121 1 O
35	123 2 O
-	125 1 O
year	126 4 O
-	130 1 O
old	131 3 O
patient	135 7 O
suffering	143 9 O
from	153 4 O
schizo	158 6 B-Disease
-	164 1 I-Disease
affective	165 9 I-Disease
disorder	175 8 I-Disease
since	184 5 O
the	190 3 O
age	194 3 O
of	198 2 O
19	201 2 O
years	204 5 O
,	209 1 O
treated	211 7 O
by	219 2 O
a	222 1 O
combination	224 11 O
of	236 2 O
first	239 5 O
-	244 1 O
generation	245 10 O
antipsychotics	256 14 O
,	270 1 O
zuclopenthixol	272 14 B-Chemical
(	287 1 O
100	288 3 O
mg	292 2 O
/	294 1 O
day	295 3 O
)	298 1 O
and	300 3 O
lithium	304 7 B-Chemical
(	312 1 O
1200	313 4 O
mg	318 2 O
/	320 1 O
day	321 3 O
)	324 1 O
(	326 1 O
serum	327 5 O
lithium	333 7 B-Chemical
=	340 1 O
0	341 1 O
.	342 1 O
85	343 2 O
mEq	346 3 O
/	349 1 O
l	350 1 O
)	351 1 O
.	352 1 O

This	354 4 O
patient	359 7 O
had	367 3 O
no	371 2 O
associated	374 10 O
personality	385 11 B-Disease
disorder	397 8 I-Disease
(	406 1 O
particularly	407 12 O
no	420 2 O
antisocial	423 10 B-Disease
disorder	434 8 I-Disease
)	442 1 O
and	444 3 O
no	448 2 O
substance	451 9 B-Disease
abuse	461 5 I-Disease
disorder	467 8 I-Disease
.	475 1 O

Within	477 6 O
the	484 3 O
48	488 2 O
h	491 1 O
following	493 9 O
the	503 3 O
gradual	507 7 O
introduction	515 12 O
of	528 2 O
quetiapine	531 10 B-Chemical
(	542 1 O
up	543 2 O
to	546 2 O
600	549 3 O
mg	553 2 O
/	555 1 O
day	556 3 O
)	559 1 O
,	560 1 O
the	562 3 O
patient	566 7 O
presented	574 9 O
severe	584 6 O
agitation	591 9 B-Disease
without	601 7 O
an	609 2 O
environmental	612 13 O
explanation	626 11 O
,	637 1 O
contrasting	639 11 O
with	651 4 O
the	656 3 O
absence	660 7 O
of	668 2 O
a	671 1 O
history	673 7 O
of	681 2 O
aggressiveness	684 14 B-Disease
or	699 2 O
personality	702 11 B-Disease
disorder	714 8 I-Disease
.	722 1 O

The	724 3 O
diagnoses	728 9 O
of	738 2 O
manic	741 5 B-Disease
shift	747 5 O
and	753 3 O
akathisia	757 9 B-Disease
were	767 4 O
dismissed	772 9 O
.	781 1 O

The	783 3 O
withdrawal	787 10 O
and	798 3 O
the	802 3 O
gradual	806 7 O
reintroduction	814 14 O
of	829 2 O
quetiapine	832 10 B-Chemical
2	843 1 O
weeks	845 5 O
later	851 5 O
,	856 1 O
which	858 5 O
led	864 3 O
to	868 2 O
another	871 7 O
severe	879 6 O
agitation	886 9 B-Disease
,	895 1 O
enabled	897 7 O
us	905 2 O
to	908 2 O
attribute	911 9 O
the	921 3 O
agitation	925 9 B-Disease
specifically	935 12 O
to	948 2 O
quetiapine	951 10 B-Chemical
.	961 1 O

Antioxidant	0 11 O
effects	12 7 O
of	20 2 O
bovine	23 6 O
lactoferrin	30 11 O
on	42 2 O
dexamethasone	45 13 B-Chemical
-	58 1 O
induced	59 7 O
hypertension	67 12 B-Disease
in	80 2 O
rat	83 3 O
.	86 1 O

Dexamethasone	88 13 B-Chemical
-	101 1 O
(	103 1 O
Dex	104 3 B-Chemical
-	107 1 O
)	108 1 O
induced	110 7 O
hypertension	118 12 B-Disease
is	131 2 O
associated	134 10 O
with	145 4 O
enhanced	150 8 O
oxidative	159 9 O
stress	169 6 O
.	175 1 O

Lactoferrin	177 11 O
(	189 1 O
LF	190 2 O
)	192 1 O
is	194 2 O
an	197 2 O
iron	200 4 B-Chemical
-	204 1 O
binding	205 7 O
glycoprotein	213 12 O
with	226 4 O
antihypertensive	231 16 O
properties	248 10 O
.	258 1 O

In	260 2 O
this	263 4 O
study	268 5 O
,	273 1 O
we	275 2 O
investigated	278 12 O
the	291 3 O
effect	295 6 O
of	302 2 O
chronic	305 7 O
administration	313 14 O
of	328 2 O
LF	331 2 O
on	334 2 O
oxidative	337 9 O
stress	347 6 O
and	354 3 O
hypertension	358 12 B-Disease
upon	371 4 O
Dex	376 3 B-Chemical
administration	380 14 O
.	394 1 O

Male	396 4 O
Wistar	401 6 O
rats	408 4 O
were	413 4 O
treated	418 7 O
by	426 2 O
Dex	429 3 B-Chemical
(	433 1 O
30	434 2 O
u	438 1 O
g	440 1 O
/	441 1 O
kg	442 2 O
/	444 1 O
day	445 3 O
subcutaneously	449 14 O
)	463 1 O
or	465 2 O
saline	468 6 O
for	475 3 O
14	479 2 O
days	482 4 O
.	486 1 O

Oral	488 4 O
bovine	493 6 O
LF	500 2 O
(	503 1 O
30	504 2 O
,	506 1 O
100	508 3 O
,	511 1 O
300	513 3 O
mg	517 2 O
/	519 1 O
kg	520 2 O
)	522 1 O
was	524 3 O
given	528 5 O
from	534 4 O
day	539 3 O
8	543 1 O
to	545 2 O
14	548 2 O
in	551 2 O
a	554 1 O
reversal	556 8 O
study	565 5 O
.	570 1 O

In	572 2 O
a	575 1 O
prevention	577 10 O
study	588 5 O
,	593 1 O
rats	595 4 O
received	600 8 O
4	609 1 O
days	611 4 O
of	616 2 O
LF	619 2 O
treatment	622 9 O
followed	632 8 O
by	641 2 O
Dex	644 3 B-Chemical
and	648 3 O
continued	652 9 O
during	662 6 O
the	669 3 O
test	673 4 O
period	678 6 O
.	684 1 O

Systolic	686 8 O
blood	695 5 O
pressure	701 8 O
(	710 1 O
SBP	711 3 O
)	714 1 O
was	716 3 O
measured	720 8 O
using	729 5 O
tail	735 4 O
-	739 1 O
cuff	740 4 O
method	745 6 O
.	751 1 O

Thymus	753 6 O
weight	760 6 O
was	767 3 O
used	771 4 O
as	776 2 O
a	779 1 O
marker	781 6 O
of	788 2 O
glucocorticoid	791 14 O
activity	806 8 O
.	814 1 O

Plasma	816 6 O
hydrogen	823 8 B-Chemical
peroxide	832 8 I-Chemical
(	841 1 O
H2O2	842 4 B-Chemical
)	846 1 O
concentration	848 13 O
and	862 3 O
ferric	866 6 O
reducing	873 8 O
antioxidant	882 11 O
power	894 5 O
(	900 1 O
FRAP	901 4 O
)	905 1 O
value	907 5 O
were	913 4 O
determined	918 10 O
.	928 1 O

Dexamethasone	930 13 B-Chemical
significantly	944 13 O
increased	958 9 O
SBP	968 3 O
and	972 3 O
plasma	976 6 O
H2O2	983 4 B-Chemical
level	988 5 O
and	994 3 O
decreased	998 9 O
thymus	1008 6 O
and	1015 3 O
body	1019 4 O
weights	1024 7 O
.	1031 1 O

LF	1033 2 O
lowered	1036 7 O
(	1044 1 O
P	1045 1 O
<	1047 1 O
0	1049 1 O
.	1050 1 O
01	1051 2 O
)	1053 1 O
and	1055 3 O
dose	1059 4 O
dependently	1064 11 O
prevented	1076 9 O
(	1086 1 O
P	1087 1 O
<	1089 1 O
0	1091 1 O
.	1092 1 O
001	1093 3 O
)	1096 1 O
Dex	1098 3 B-Chemical
-	1101 1 O
induced	1102 7 O
hypertension	1110 12 B-Disease
.	1122 1 O

LF	1124 2 O
prevented	1127 9 O
body	1137 4 O
weight	1142 6 B-Disease
loss	1149 4 I-Disease
and	1154 3 O
significantly	1158 13 O
reduced	1172 7 O
the	1180 3 O
elevated	1184 8 O
plasma	1193 6 O
H2O2	1200 4 B-Chemical
and	1205 3 O
increased	1209 9 O
FRAP	1219 4 O
values	1224 6 O
.	1230 1 O

Chronic	1232 7 O
administration	1240 14 O
of	1255 2 O
LF	1258 2 O
strongly	1261 8 O
reduced	1270 7 O
the	1278 3 O
blood	1282 5 O
pressure	1288 8 O
and	1297 3 O
production	1301 10 O
of	1312 2 O
ROS	1315 3 O
and	1319 3 O
improved	1323 8 O
antioxidant	1332 11 O
capacity	1344 8 O
in	1353 2 O
Dex	1356 3 B-Chemical
-	1359 1 O
induced	1360 7 O
hypertension	1368 12 B-Disease
,	1380 1 O
suggesting	1382 10 O
the	1393 3 O
role	1397 4 O
of	1402 2 O
inhibition	1405 10 O
of	1416 2 O
oxidative	1419 9 O
stress	1429 6 O
as	1436 2 O
another	1439 7 O
mechanism	1447 9 O
of	1457 2 O
antihypertensive	1460 16 O
action	1477 6 O
of	1484 2 O
LF	1487 2 O
.	1489 1 O

The	0 3 O
association	4 11 O
between	16 7 O
tranexamic	24 10 B-Chemical
acid	35 4 I-Chemical
and	40 3 O
convulsive	44 10 B-Disease
seizures	55 8 B-Disease
after	64 5 O
cardiac	70 7 O
surgery	78 7 O
:	85 1 O
a	87 1 O
multivariate	89 12 O
analysis	102 8 O
in	111 2 O
11	114 2 O
529	117 3 O
patients	121 8 O
.	129 1 O

Because	131 7 O
of	139 2 O
a	142 1 O
lack	144 4 O
of	149 2 O
contemporary	152 12 O
data	165 4 O
regarding	170 9 O
seizures	180 8 B-Disease
after	189 5 O
cardiac	195 7 O
surgery	203 7 O
,	210 1 O
we	212 2 O
undertook	215 9 O
a	225 1 O
retrospective	227 13 O
analysis	241 8 O
of	250 2 O
prospectively	253 13 O
collected	267 9 O
data	277 4 O
from	282 4 O
11	287 2 O
529	290 3 O
patients	294 8 O
in	303 2 O
whom	306 4 O
cardiopulmonary	311 15 O
bypass	327 6 O
was	334 3 O
used	338 4 O
from	343 4 O
January	348 7 O
2004	356 4 O
to	361 2 O
December	364 8 O
2010	373 4 O
.	377 1 O

A	379 1 O
convulsive	381 10 B-Disease
seizure	392 7 B-Disease
was	400 3 O
defined	404 7 O
as	412 2 O
a	415 1 O
transient	417 9 O
episode	427 7 O
of	435 2 O
disturbed	438 9 O
brain	448 5 O
function	454 8 O
characterised	463 13 O
by	477 2 O
abnormal	480 8 B-Disease
involuntary	489 11 I-Disease
motor	501 5 I-Disease
movements	507 9 I-Disease
.	516 1 O

Multivariate	518 12 O
regression	531 10 O
analysis	542 8 O
was	551 3 O
performed	555 9 O
to	565 2 O
identify	568 8 O
independent	577 11 O
predictors	589 10 O
of	600 2 O
postoperative	603 13 O
seizures	617 8 B-Disease
.	625 1 O

A	627 1 O
total	629 5 O
of	635 2 O
100	638 3 O
(	642 1 O
0	643 1 O
.	644 1 O
9	645 1 O
%	646 1 O
)	647 1 O
patients	649 8 O
developed	658 9 O
postoperative	668 13 O
convulsive	682 10 B-Disease
seizures	693 8 B-Disease
.	701 1 O

Generalised	703 11 B-Disease
and	715 3 I-Disease
focal	719 5 I-Disease
seizures	725 8 I-Disease
were	734 4 O
identified	739 10 O
in	750 2 O
68	753 2 O
and	756 3 O
32	760 2 O
patients	763 8 O
,	771 1 O
respectively	773 12 O
.	785 1 O

The	787 3 O
median	791 6 O
(	798 1 O
IQR	799 3 O
[	803 1 O
range	804 5 O
]	809 1 O
)	810 1 O
time	812 4 O
after	817 5 O
surgery	823 7 O
when	831 4 O
the	836 3 O
seizure	840 7 B-Disease
occurred	848 8 O
was	857 3 O
7	861 1 O
(	863 1 O
6	864 1 O
-	865 1 O
12	866 2 O
[	869 1 O
1	870 1 O
-	871 1 O
216	872 3 O
]	875 1 O
)	876 1 O
h	878 1 O
and	880 3 O
8	884 1 O
(	886 1 O
6	887 1 O
-	888 1 O
11	889 2 O
[	892 1 O
4	893 1 O
-	894 1 O
18	895 2 O
]	897 1 O
)	898 1 O
h	900 1 O
,	901 1 O
respectively	903 12 O
.	915 1 O

Epileptiform	917 12 O
findings	930 8 O
on	939 2 O
electroencephalography	942 22 O
were	965 4 O
seen	970 4 O
in	975 2 O
19	978 2 O
patients	981 8 O
.	989 1 O

Independent	991 11 O
predictors	1003 10 O
of	1014 2 O
postoperative	1017 13 O
seizures	1031 8 B-Disease
included	1040 8 O
age	1049 3 O
,	1052 1 O
female	1054 6 O
sex	1061 3 O
,	1064 1 O
redo	1066 4 O
cardiac	1071 7 O
surgery	1079 7 O
,	1086 1 O
calcification	1088 13 O
of	1102 2 O
ascending	1105 9 O
aorta	1115 5 O
,	1120 1 O
congestive	1122 10 B-Disease
heart	1133 5 I-Disease
failure	1139 7 I-Disease
,	1146 1 O
deep	1148 4 O
hypothermic	1153 11 B-Disease
circulatory	1165 11 O
arrest	1177 6 O
,	1183 1 O
duration	1185 8 O
of	1194 2 O
aortic	1197 6 O
cross	1204 5 O
-	1209 1 O
clamp	1210 5 O
and	1216 3 O
tranexamic	1220 10 B-Chemical
acid	1231 4 I-Chemical
.	1235 1 O

When	1237 4 O
tested	1242 6 O
in	1249 2 O
a	1252 1 O
multivariate	1254 12 O
regression	1267 10 O
analysis	1278 8 O
,	1286 1 O
tranexamic	1288 10 B-Chemical
acid	1299 4 I-Chemical
was	1304 3 O
a	1308 1 O
strong	1310 6 O
independent	1317 11 O
predictor	1329 9 O
of	1339 2 O
seizures	1342 8 B-Disease
(	1351 1 O
OR	1352 2 O
14	1355 2 O
.	1357 1 O
3	1358 1 O
,	1359 1 O
95	1361 2 O
%	1363 1 O
CI	1365 2 O
5	1368 1 O
.	1369 1 O
5	1370 1 O
-	1371 1 O
36	1372 2 O
.	1374 1 O
7	1375 1 O
;	1376 1 O
p	1378 1 O
<	1380 1 O
0	1382 1 O
.	1383 1 O
001	1384 3 O
)	1387 1 O
.	1388 1 O

Patients	1390 8 O
with	1399 4 O
convulsive	1404 10 B-Disease
seizures	1415 8 B-Disease
had	1424 3 O
2	1428 1 O
.	1429 1 O
5	1430 1 O
times	1432 5 O
higher	1438 6 O
in	1445 2 O
-	1447 1 O
hospital	1448 8 O
mortality	1457 9 O
rates	1467 5 O
and	1473 3 O
twice	1477 5 O
the	1483 3 O
length	1487 6 O
of	1494 2 O
hospital	1497 8 O
stay	1506 4 O
compared	1511 8 O
with	1520 4 O
patients	1525 8 O
without	1534 7 O
convulsive	1542 10 B-Disease
seizures	1553 8 B-Disease
.	1561 1 O

Mean	1563 4 O
(	1568 1 O
IQR	1569 3 O
[	1573 1 O
range	1574 5 O
]	1579 1 O
)	1580 1 O
length	1582 6 O
of	1589 2 O
stay	1592 4 O
in	1597 2 O
the	1600 3 O
intensive	1604 9 O
care	1614 4 O
unit	1619 4 O
was	1624 3 O
115	1628 3 O
(	1632 1 O
49	1633 2 O
-	1635 1 O
228	1636 3 O
[	1640 1 O
32	1641 2 O
-	1643 1 O
481	1644 3 O
]	1647 1 O
)	1648 1 O
h	1650 1 O
in	1652 2 O
patients	1655 8 O
with	1664 4 O
convulsive	1669 10 B-Disease
seizures	1680 8 B-Disease
compared	1689 8 O
with	1698 4 O
26	1703 2 O
(	1706 1 O
22	1707 2 O
-	1709 1 O
69	1710 2 O
[	1713 1 O
14	1714 2 O
-	1716 1 O
1080	1717 4 O
]	1721 1 O
)	1722 1 O
h	1724 1 O
in	1726 2 O
patients	1729 8 O
without	1738 7 O
seizures	1746 8 B-Disease
(	1755 1 O
p	1756 1 O
<	1758 1 O
0	1760 1 O
.	1761 1 O
001	1762 3 O
)	1765 1 O
.	1766 1 O

Convulsive	1768 10 B-Disease
seizures	1779 8 B-Disease
are	1788 3 O
a	1792 1 O
serious	1794 7 O
postoperative	1802 13 B-Disease
complication	1816 12 I-Disease
after	1829 5 O
cardiac	1835 7 O
surgery	1843 7 O
.	1850 1 O

As	1852 2 O
tranexamic	1855 10 B-Chemical
acid	1866 4 I-Chemical
is	1871 2 O
the	1874 3 O
only	1878 4 O
modifiable	1883 10 O
factor	1894 6 O
,	1900 1 O
its	1902 3 O
administration	1906 14 O
,	1920 1 O
particularly	1922 12 O
in	1935 2 O
doses	1938 5 O
exceeding	1944 9 O
80	1954 2 O
mg	1957 2 O
.	1959 1 O
kg	1960 2 O
(	1962 1 O
-	1963 1 O
1	1964 1 O
)	1965 1 O
,	1966 1 O
should	1968 6 O
be	1975 2 O
weighed	1978 7 O
against	1986 7 O
the	1994 3 O
risk	1998 4 O
of	2003 2 O
postoperative	2006 13 O
seizures	2020 8 B-Disease
.	2028 1 O

Dysfunctional	0 13 B-Disease
overnight	14 9 I-Disease
memory	24 6 I-Disease
consolidation	31 13 O
in	45 2 O
ecstasy	48 7 B-Chemical
users	56 5 O
.	61 1 O

Sleep	63 5 O
plays	69 5 O
an	75 2 O
important	78 9 O
role	88 4 O
in	93 2 O
the	96 3 O
consolidation	100 13 O
and	114 3 O
integration	118 11 O
of	130 2 O
memory	133 6 O
in	140 2 O
a	143 1 O
process	145 7 O
called	153 6 O
overnight	160 9 O
memory	170 6 O
consolidation	177 13 O
.	190 1 O

Previous	192 8 O
studies	201 7 O
indicate	209 8 O
that	218 4 O
ecstasy	223 7 B-Chemical
users	231 5 O
have	237 4 O
marked	242 6 O
and	249 3 O
persistent	253 10 O
neurocognitive	264 14 O
and	279 3 O
sleep	283 5 B-Disease
-	288 1 I-Disease
related	289 7 I-Disease
impairments	297 11 I-Disease
.	308 1 O

We	310 2 O
extend	313 6 O
past	320 4 O
research	325 8 O
by	334 2 O
examining	337 9 O
overnight	347 9 O
memory	357 6 O
consolidation	364 13 O
among	378 5 O
regular	384 7 O
ecstasy	392 7 B-Chemical
users	400 5 O
(	406 1 O
n	407 1 O
=	408 1 O
12	409 2 O
)	411 1 O
and	413 3 O
drug	417 4 O
naive	422 5 O
healthy	428 7 O
controls	436 8 O
(	445 1 O
n	446 1 O
=	447 1 O
26	448 2 O
)	450 1 O
.	451 1 O

Memory	453 6 O
recall	460 6 O
of	467 2 O
word	470 4 O
pairs	475 5 O
was	481 3 O
evaluated	485 9 O
before	495 6 O
and	502 3 O
after	506 5 O
a	512 1 O
period	514 6 O
of	521 2 O
sleep	524 5 O
,	529 1 O
with	531 4 O
and	536 3 O
without	540 7 O
interference	548 12 O
prior	561 5 O
to	567 2 O
testing	570 7 O
.	577 1 O

In	579 2 O
addition	582 8 O
,	590 1 O
we	592 2 O
assessed	595 8 O
neurocognitive	604 14 O
performances	619 12 O
across	632 6 O
tasks	639 5 O
of	645 2 O
learning	648 8 O
,	656 1 O
memory	658 6 O
and	665 3 O
executive	669 9 O
functioning	679 11 O
.	690 1 O

Ecstasy	692 7 B-Chemical
users	700 5 O
demonstrated	706 12 O
impaired	719 8 B-Disease
overnight	728 9 I-Disease
memory	738 6 I-Disease
consolidation	745 13 O
,	758 1 O
a	760 1 O
finding	762 7 O
that	770 4 O
was	775 3 O
more	779 4 O
pronounced	784 10 O
following	795 9 O
associative	805 11 O
interference	817 12 O
.	829 1 O

Additionally	831 12 O
,	843 1 O
ecstasy	845 7 B-Chemical
users	853 5 O
demonstrated	859 12 O
impairments	872 11 O
on	884 2 O
tasks	887 5 O
recruiting	893 10 O
frontostriatal	904 14 O
and	919 3 O
hippocampal	923 11 O
neural	935 6 O
circuitry	942 9 O
,	951 1 O
in	953 2 O
the	956 3 O
domains	960 7 O
of	968 2 O
proactive	971 9 O
interference	981 12 O
memory	994 6 O
,	1000 1 O
long	1002 4 O
-	1006 1 O
term	1007 4 O
memory	1012 6 O
,	1018 1 O
encoding	1020 8 O
,	1028 1 O
working	1030 7 O
memory	1038 6 O
and	1045 3 O
complex	1049 7 O
planning	1057 8 O
.	1065 1 O

We	1067 2 O
suggest	1070 7 O
that	1078 4 O
ecstasy	1083 7 B-Chemical
-	1090 1 O
associated	1091 10 O
dysfunction	1102 11 O
in	1114 2 O
fronto	1117 6 O
-	1123 1 O
temporal	1124 8 O
circuitry	1133 9 O
may	1143 3 O
underlie	1147 8 O
overnight	1156 9 O
consolidation	1166 13 O
memory	1180 6 B-Disease
impairments	1187 11 I-Disease
in	1199 2 O
regular	1202 7 O
ecstasy	1210 7 B-Chemical
users	1218 5 O
.	1223 1 O

Normoammonemic	0 14 O
encephalopathy	15 14 B-Disease
:	29 1 O
solely	31 6 O
valproate	38 9 B-Chemical
induced	48 7 O
or	56 2 O
multiple	59 8 O
mechanisms	68 10 O
?	78 1 O

A	80 1 O
77	82 2 O
-	84 1 O
year	85 4 O
-	89 1 O
old	90 3 O
woman	94 5 O
presented	100 9 O
with	110 4 O
subacute	115 8 O
onset	124 5 O
progressive	130 11 O
confusion	142 9 B-Disease
,	151 1 O
aggression	153 10 B-Disease
,	163 1 O
auditory	165 8 B-Disease
hallucinations	174 14 I-Disease
and	189 3 O
delusions	193 9 B-Disease
.	202 1 O

In	204 2 O
the	207 3 O
preceding	211 9 O
months	221 6 O
,	227 1 O
the	229 3 O
patient	233 7 O
had	241 3 O
a	245 1 O
number	247 6 O
of	254 2 O
admissions	257 10 O
with	268 4 O
transient	273 9 O
unilateral	283 10 O
hemiparesis	294 11 B-Disease
with	306 4 O
facial	311 6 O
droop	318 5 O
,	323 1 O
and	325 3 O
had	329 3 O
been	333 4 O
started	338 7 O
on	346 2 O
valproate	349 9 B-Chemical
for	359 3 O
presumed	363 8 O
hemiplegic	372 10 B-Disease
migraine	383 8 I-Disease
.	391 1 O

Valproate	393 9 B-Chemical
was	403 3 O
withdrawn	407 9 O
soon	417 4 O
after	422 5 O
admission	428 9 O
and	438 3 O
her	442 3 O
cognitive	446 9 O
abilities	456 9 O
have	466 4 O
gradually	471 9 O
improved	481 8 O
over	490 4 O
3	495 1 O
months	497 6 O
of	504 2 O
follow	507 6 O
-	513 1 O
up	514 2 O
.	516 1 O

Valproate	518 9 B-Chemical
levels	528 6 O
taken	535 5 O
prior	541 5 O
to	547 2 O
withdrawal	550 10 O
were	561 4 O
subtherapeutic	566 14 O
and	581 3 O
the	585 3 O
patient	589 7 O
was	597 3 O
normoammonaemic	601 15 O
.	616 1 O

EEG	618 3 O
undertaken	622 10 O
during	633 6 O
inpatient	640 9 O
stay	650 4 O
showed	655 6 O
changes	662 7 O
consistent	670 10 O
with	681 4 O
encephalopathy	686 14 B-Disease
,	700 1 O
and	702 3 O
low	706 3 O
titre	710 5 O
N	716 1 B-Chemical
-	717 1 I-Chemical
methyl	718 6 I-Chemical
-	724 1 I-Chemical
D	725 1 I-Chemical
-	726 1 I-Chemical
aspartate	727 9 I-Chemical
(	737 1 O
NMDA	738 4 B-Chemical
)	742 1 O
receptor	744 8 O
antibodies	753 10 O
were	764 4 O
present	769 7 O
in	777 2 O
this	780 4 O
patient	785 7 O
.	792 1 O

The	794 3 O
possible	798 8 O
aetiologies	807 11 O
of	819 2 O
valproate	822 9 B-Chemical
-	831 1 O
induced	832 7 O
encephalopathy	840 14 B-Disease
and	855 3 O
NMDA	859 4 B-Chemical
receptor	864 8 O
-	872 1 O
associated	873 10 O
encephalitis	884 12 B-Disease
present	897 7 O
a	905 1 O
diagnostic	907 10 O
dilemma	918 7 O
.	925 1 O

We	927 2 O
present	930 7 O
a	938 1 O
putative	940 8 O
combinatorial	949 13 O
hypothesis	963 10 O
to	974 2 O
explain	977 7 O
this	985 4 O
patient	990 7 O
'	997 1 O
s	998 1 O
symptoms	1000 8 O
.	1008 1 O

Cerebellar	0 10 B-Disease
and	11 3 I-Disease
oculomotor	15 10 I-Disease
dysfunction	26 11 I-Disease
induced	38 7 O
by	46 2 O
rapid	49 5 O
infusion	55 8 O
of	64 2 O
pethidine	67 9 B-Chemical
.	76 1 O

Pethidine	78 9 B-Chemical
is	88 2 O
an	91 2 O
opioid	94 6 O
that	101 4 O
gains	106 5 O
its	112 3 O
popularity	116 10 O
for	127 3 O
the	131 3 O
effective	135 9 O
pain	145 4 B-Disease
control	150 7 O
through	158 7 O
acting	166 6 O
on	173 2 O
the	176 3 O
opioid	180 6 O
-	186 1 O
receptors	187 9 O
.	196 1 O

However	198 7 O
,	205 1 O
rapid	207 5 O
pain	213 4 B-Disease
relief	218 6 O
sometimes	225 9 O
brings	235 6 O
about	242 5 O
unfavourable	248 12 O
side	261 4 O
effects	266 7 O
that	274 4 O
largely	279 7 O
limit	287 5 O
its	293 3 O
clinical	297 8 O
utility	306 7 O
.	313 1 O

Common	315 6 O
side	322 4 O
effects	327 7 O
include	335 7 O
nausea	343 6 B-Disease
,	349 1 O
vomiting	351 8 B-Disease
and	360 3 O
hypotension	364 11 B-Disease
.	375 1 O

In	377 2 O
patients	380 8 O
with	389 4 O
impaired	394 8 B-Disease
renal	403 5 I-Disease
and	409 3 I-Disease
liver	413 5 I-Disease
function	419 8 I-Disease
,	427 1 O
and	429 3 O
those	433 5 O
who	439 3 O
need	443 4 O
long	448 4 O
-	452 1 O
term	453 4 O
pain	458 4 B-Disease
control	463 7 O
,	470 1 O
pethidine	472 9 B-Chemical
may	482 3 O
cause	486 5 O
excitatory	492 10 O
central	503 7 O
nervous	511 7 O
system	519 6 O
(	526 1 O
CNS	527 3 O
)	530 1 O
effects	532 7 O
through	540 7 O
its	548 3 O
neurotoxic	552 10 B-Disease
metabolite	563 10 O
,	573 1 O
norpethidine	575 12 B-Chemical
,	587 1 O
resulting	589 9 O
in	599 2 O
irritability	602 12 B-Disease
and	615 3 O
seizure	619 7 B-Disease
attack	627 6 O
.	633 1 O

On	635 2 O
the	638 3 O
contrary	642 8 O
,	650 1 O
though	652 6 O
not	659 3 O
clinically	663 10 O
apparent	674 8 O
,	682 1 O
pethidine	684 9 B-Chemical
potentially	694 11 O
causes	706 6 O
inhibitory	713 10 O
impacts	724 7 O
on	732 2 O
the	735 3 O
CNS	739 3 O
and	743 3 O
impairs	747 7 O
normal	755 6 O
cerebellar	762 10 O
and	773 3 O
oculomotor	777 10 O
function	788 8 O
in	797 2 O
the	800 3 O
short	804 5 O
term	810 4 O
.	814 1 O

In	816 2 O
this	819 4 O
case	824 4 O
report	829 6 O
,	835 1 O
we	837 2 O
highlight	840 9 O
opioid	850 6 O
'	856 1 O
s	857 1 O
inhibitory	859 10 O
side	870 4 O
effects	875 7 O
on	883 2 O
the	886 3 O
cerebellar	890 10 O
structure	901 9 O
that	911 4 O
causes	916 6 O
dysmetria	923 9 B-Disease
,	932 1 O
dysarthria	934 10 B-Disease
,	944 1 O
reduced	946 7 O
smooth	954 6 O
pursuit	961 7 O
gain	969 4 O
and	974 3 O
decreased	978 9 O
saccadic	988 8 O
velocity	997 8 O
.	1005 1 O

Baboon	0 6 B-Disease
syndrome	7 8 I-Disease
induced	16 7 O
by	24 2 O
ketoconazole	27 12 B-Chemical
.	39 1 O

A	41 1 O
27	43 2 O
-	45 1 O
year	46 4 O
-	50 1 O
old	51 3 O
male	55 4 O
patient	60 7 O
presented	68 9 O
with	78 4 O
a	83 1 O
maculopapular	85 13 B-Disease
eruption	99 8 I-Disease
on	108 2 O
the	111 3 O
flexural	115 8 O
areas	124 5 O
and	130 3 O
buttocks	134 8 O
after	143 5 O
using	149 5 O
oral	155 4 O
ketoconazole	160 12 B-Chemical
.	172 1 O

The	174 3 O
patient	178 7 O
was	186 3 O
diagnosed	190 9 O
with	200 4 O
drug	205 4 O
-	209 1 O
induced	210 7 O
baboon	218 6 B-Disease
syndrome	225 8 I-Disease
based	234 5 O
on	240 2 O
his	243 3 O
history	247 7 O
,	254 1 O
which	256 5 O
included	262 8 O
prior	271 5 O
sensitivity	277 11 O
to	289 2 O
topical	292 7 O
ketoconazole	300 12 B-Chemical
,	312 1 O
a	314 1 O
physical	316 8 O
examination	325 11 O
,	336 1 O
and	338 3 O
histopathological	342 17 O
findings	360 8 O
.	368 1 O

Baboon	370 6 B-Disease
syndrome	377 8 I-Disease
is	386 2 O
a	389 1 O
drug	391 4 O
-	395 1 O
or	397 2 O
contact	400 7 O
allergen	408 8 O
-	416 1 O
related	417 7 O
maculopapular	425 13 B-Disease
eruption	439 8 I-Disease
that	448 4 O
typically	453 9 O
involves	463 8 O
the	472 3 O
flexural	476 8 O
and	485 3 O
gluteal	489 7 O
areas	497 5 O
.	502 1 O

To	504 2 O
the	507 3 O
best	511 4 O
of	516 2 O
our	519 3 O
knowledge	523 9 O
,	532 1 O
this	534 4 O
is	539 2 O
the	542 3 O
first	546 5 O
reported	552 8 O
case	561 4 O
of	566 2 O
ketoconazole	569 12 B-Chemical
-	581 1 O
induced	582 7 O
baboon	590 6 B-Disease
syndrome	597 8 I-Disease
in	606 2 O
the	609 3 O
English	613 7 O
literature	621 10 O
.	631 1 O

A	0 1 O
Case	2 4 O
of	7 2 O
Sudden	10 6 B-Disease
Cardiac	17 7 I-Disease
Death	25 5 I-Disease
due	31 3 O
to	35 2 O
Pilsicainide	38 12 B-Chemical
-	50 1 O
Induced	51 7 O
Torsades	59 8 B-Disease
de	68 2 I-Disease
Pointes	71 7 I-Disease
.	78 1 O

An	80 2 O
84	83 2 O
-	85 1 O
year	86 4 O
-	90 1 O
old	91 3 O
male	95 4 O
received	100 8 O
oral	109 4 O
pilsicainide	114 12 B-Chemical
,	126 1 O
a	128 1 O
pure	130 4 O
sodium	135 6 B-Chemical
channel	142 7 O
blocker	150 7 O
with	158 4 O
slow	163 4 O
recovery	168 8 O
kinetics	177 8 O
,	185 1 O
to	187 2 O
convert	190 7 O
his	198 3 O
paroxysmal	202 10 O
atrial	213 6 B-Disease
fibrillation	220 12 I-Disease
to	233 2 O
a	236 1 O
sinus	238 5 O
rhythm	244 6 O
;	250 1 O
the	252 3 O
patient	256 7 O
developed	264 9 O
sudden	274 6 B-Disease
cardiac	281 7 I-Disease
death	289 5 I-Disease
two	295 3 O
days	299 4 O
later	304 5 O
.	309 1 O

The	311 3 O
Holter	315 6 O
electrocardiogram	322 17 O
,	339 1 O
which	341 5 O
was	347 3 O
worn	351 4 O
by	356 2 O
chance	359 6 O
,	365 1 O
revealed	367 8 O
torsade	376 7 B-Disease
de	384 2 I-Disease
pointes	387 7 I-Disease
with	395 4 O
gradually	400 9 O
prolonged	410 9 O
QT	420 2 O
intervals	423 9 O
.	432 1 O

This	434 4 O
drug	439 4 O
is	444 2 O
rapidly	447 7 O
absorbed	455 8 O
from	464 4 O
the	469 3 O
gastrointestinal	473 16 O
tract	490 5 O
,	495 1 O
and	497 3 O
most	501 4 O
of	506 2 O
it	509 2 O
is	512 2 O
excreted	515 8 O
from	524 4 O
the	529 3 O
kidney	533 6 O
.	539 1 O

Although	541 8 O
the	550 3 O
patient	554 7 O
'	561 1 O
s	562 1 O
renal	564 5 O
function	570 8 O
was	579 3 O
not	583 3 O
highly	587 6 O
impaired	594 8 O
and	603 3 O
the	607 3 O
dose	611 4 O
of	616 2 O
pilsicainide	619 12 B-Chemical
was	632 3 O
low	636 3 O
,	639 1 O
the	641 3 O
plasma	645 6 O
concentration	652 13 O
of	666 2 O
pilsicainide	669 12 B-Chemical
may	682 3 O
have	686 4 O
been	691 4 O
high	696 4 O
,	700 1 O
which	702 5 O
can	708 3 O
produce	712 7 O
torsades	720 8 B-Disease
de	729 2 I-Disease
pointes	732 7 I-Disease
in	740 2 O
the	743 3 O
octogenarian	747 12 O
.	759 1 O

Although	761 8 O
the	770 3 O
oral	774 4 O
administration	779 14 O
of	794 2 O
class	797 5 O
IC	803 2 O
drugs	806 5 O
,	811 1 O
including	813 9 O
pilsicainide	823 12 B-Chemical
,	835 1 O
is	837 2 O
effective	840 9 O
to	850 2 O
terminate	853 9 O
atrial	863 6 B-Disease
fibrillation	870 12 I-Disease
,	882 1 O
careful	884 7 O
consideration	892 13 O
must	906 4 O
be	911 2 O
taken	914 5 O
before	920 6 O
giving	927 6 O
these	934 5 O
drugs	940 5 O
to	946 2 O
octogenarians	949 13 O
.	962 1 O

All	0 3 B-Chemical
-	3 1 I-Chemical
trans	4 5 I-Chemical
retinoic	10 8 I-Chemical
acid	19 4 I-Chemical
-	23 1 O
induced	24 7 O
inflammatory	32 12 O
myositis	45 8 B-Disease
in	54 2 O
a	57 1 O
patient	59 7 O
with	67 4 O
acute	72 5 B-Disease
promyelocytic	78 13 I-Disease
leukemia	92 8 I-Disease
.	100 1 O

All	102 3 B-Chemical
-	105 1 I-Chemical
trans	106 5 I-Chemical
retinoic	112 8 I-Chemical
acid	121 4 I-Chemical
(	126 1 O
ATRA	127 4 B-Chemical
)	131 1 O
,	132 1 O
a	134 1 O
component	136 9 O
of	146 2 O
standard	149 8 O
therapy	158 7 O
for	166 3 O
acute	170 5 B-Disease
promyelocytic	176 13 I-Disease
leukemia	190 8 I-Disease
(	199 1 O
APL	200 3 B-Disease
)	203 1 O
,	204 1 O
is	206 2 O
associated	209 10 O
with	220 4 O
potentially	225 11 O
serious	237 7 O
but	245 3 O
treatable	249 9 O
adverse	259 7 O
effects	267 7 O
involving	275 9 O
numerous	285 8 O
organ	294 5 O
systems	300 7 O
,	307 1 O
including	309 9 O
rare	319 4 O
skeletal	324 8 O
muscle	333 6 O
involvement	340 11 O
.	351 1 O

Only	353 4 O
a	358 1 O
handful	360 7 O
of	368 2 O
cases	371 5 O
of	377 2 O
ATRA	380 4 B-Chemical
-	384 1 O
induced	385 7 O
myositis	393 8 B-Disease
in	402 2 O
children	405 8 O
have	414 4 O
been	419 4 O
reported	424 8 O
,	432 1 O
and	434 3 O
none	438 4 O
in	443 2 O
the	446 3 O
radiology	450 9 O
literature	460 10 O
.	470 1 O

We	472 2 O
present	475 7 O
such	483 4 O
a	488 1 O
case	490 4 O
in	495 2 O
a	498 1 O
15	500 2 O
-	502 1 O
year	503 4 O
-	507 1 O
old	508 3 O
boy	512 3 O
with	516 4 O
APL	521 3 B-Disease
,	524 1 O
where	526 5 O
recognition	532 11 O
of	544 2 O
imaging	547 7 O
findings	555 8 O
played	564 6 O
a	571 1 O
crucial	573 7 O
role	581 4 O
in	586 2 O
making	589 6 O
the	596 3 O
diagnosis	600 9 O
and	610 3 O
facilitated	614 11 O
prompt	626 6 O
,	632 1 O
effective	634 9 O
treatment	644 9 O
.	653 1 O

Tolerability	0 12 O
of	13 2 O
lomustine	16 9 B-Chemical
in	26 2 O
combination	29 11 O
with	41 4 O
cyclophosphamide	46 16 B-Chemical
in	63 2 O
dogs	66 4 O
with	71 4 O
lymphoma	76 8 B-Disease
.	84 1 O

This	86 4 O
retrospective	91 13 O
study	105 5 O
describes	111 9 O
toxicity	121 8 B-Disease
associated	130 10 O
with	141 4 O
a	146 1 O
protocol	148 8 O
of	157 2 O
lomustine	160 9 B-Chemical
(	170 1 O
CCNU	171 4 B-Chemical
)	175 1 O
and	177 3 O
cyclophosphamide	181 16 B-Chemical
(	198 1 O
CTX	199 3 B-Chemical
)	202 1 O
in	204 2 O
dogs	207 4 O
with	212 4 O
lymphoma	217 8 B-Disease
.	225 1 O

CCNU	227 4 B-Chemical
was	232 3 O
administered	236 12 O
per	249 3 O
os	253 2 O
(	256 1 O
PO	257 2 O
)	259 1 O
at	261 2 O
a	264 1 O
targeted	266 8 O
dosage	275 6 O
of	282 2 O
60	285 2 O
mg	288 2 O
/	290 1 O
m	291 1 O
(	292 1 O
2	293 1 O
)	294 1 O
body	296 4 O
surface	301 7 O
area	309 4 O
on	314 2 O
day	317 3 O
0	321 1 O
,	322 1 O
CTX	324 3 B-Chemical
was	328 3 O
administered	332 12 O
PO	345 2 O
at	348 2 O
a	351 1 O
targeted	353 8 O
dosage	362 6 O
of	369 2 O
250	372 3 O
mg	376 2 O
/	378 1 O
m	379 1 O
(	380 1 O
2	381 1 O
)	382 1 O
divided	384 7 O
over	392 4 O
days	397 4 O
0	402 1 O
through	404 7 O
4	412 1 O
,	413 1 O
and	415 3 O
all	419 3 O
dogs	423 4 O
received	428 8 O
prophylactic	437 12 O
antibiotics	450 11 O
.	461 1 O

Ninety	463 6 O
treatments	470 10 O
were	481 4 O
given	486 5 O
to	492 2 O
the	495 3 O
57	499 2 O
dogs	502 4 O
included	507 8 O
in	516 2 O
the	519 3 O
study	523 5 O
.	528 1 O

Neutropenia	530 11 B-Disease
was	542 3 O
the	546 3 O
principal	550 9 O
toxic	560 5 O
effect	566 6 O
,	572 1 O
and	574 3 O
the	578 3 O
overall	582 7 O
frequency	590 9 O
of	600 2 O
grade	603 5 O
4	609 1 O
neutropenia	611 11 B-Disease
after	623 5 O
the	629 3 O
first	633 5 O
treatment	639 9 O
of	649 2 O
CCNU	652 4 B-Chemical
/	656 1 O
CTX	657 3 B-Chemical
was	661 3 O
30	665 2 O
%	667 1 O
(	669 1 O
95	670 2 O
%	672 1 O
confidence	674 10 O
interval	685 8 O
,	693 1 O
19	695 2 O
-	697 1 O
43	698 2 O
%	700 1 O
)	701 1 O
.	702 1 O

The	704 3 O
mean	708 4 O
body	713 4 O
weight	718 6 O
of	725 2 O
dogs	728 4 O
with	733 4 O
grade	738 5 O
4	744 1 O
neutropenia	746 11 B-Disease
(	758 1 O
19	759 2 O
.	761 1 O
7	762 1 O
kg	764 2 O
+	767 1 O
13	769 2 O
.	771 1 O
4	772 1 O
kg	774 2 O
)	776 1 O
was	778 3 O
significantly	782 13 O
less	796 4 O
than	801 4 O
the	806 3 O
mean	810 4 O
body	815 4 O
weight	820 6 O
of	827 2 O
dogs	830 4 O
that	835 4 O
did	840 3 O
not	844 3 O
develop	848 7 O
grade	856 5 O
4	862 1 O
neutropenia	864 11 B-Disease
(	876 1 O
31	877 2 O
.	879 1 O
7	880 1 O
kg	882 2 O
+	885 1 O
12	887 2 O
.	889 1 O
4	890 1 O
kg	892 2 O
;	894 1 O
P	896 1 O
=	898 1 O
.	900 1 O
005	901 3 O
)	904 1 O
.	905 1 O

One	907 3 O
dog	911 3 O
(	915 1 O
3	916 1 O
%	917 1 O
)	918 1 O
developed	920 9 O
hematologic	930 11 O
changes	942 7 O
suggestive	950 10 O
of	961 2 O
hepatotoxicity	964 14 B-Disease
.	978 1 O

No	980 2 O
dogs	983 4 O
had	988 3 O
evidence	992 8 O
of	1001 2 O
either	1004 6 O
renal	1011 5 B-Disease
toxicity	1017 8 I-Disease
or	1026 2 O
hemorrhagic	1029 11 B-Disease
cystitis	1041 8 I-Disease
.	1049 1 O

Adverse	1051 7 O
gastrointestinal	1059 16 O
effects	1076 7 O
were	1084 4 O
uncommon	1089 8 O
.	1097 1 O

On	1099 2 O
the	1102 3 O
basis	1106 5 O
of	1112 2 O
the	1115 3 O
findings	1119 8 O
reported	1128 8 O
herein	1137 6 O
,	1143 1 O
a	1145 1 O
dose	1147 4 O
of	1152 2 O
60	1155 2 O
mg	1158 2 O
/	1160 1 O
m	1161 1 O
(	1162 1 O
2	1163 1 O
)	1164 1 O
of	1166 2 O
CCNU	1169 4 B-Chemical
combined	1174 8 O
with	1183 4 O
250	1188 3 O
mg	1192 2 O
/	1194 1 O
m	1195 1 O
(	1196 1 O
2	1197 1 O
)	1198 1 O
of	1200 2 O
CTX	1203 3 B-Chemical
(	1207 1 O
divided	1208 7 O
over	1216 4 O
5	1221 1 O
days	1223 4 O
)	1227 1 O
q	1229 1 O
4	1231 1 O
wk	1233 2 O
is	1236 2 O
tolerable	1239 9 O
in	1249 2 O
tumor	1252 5 B-Disease
-	1257 1 O
bearing	1258 7 O
dogs	1266 4 O
.	1270 1 O

Nelarabine	0 10 B-Chemical
neurotoxicity	11 13 B-Disease
with	25 4 O
concurrent	30 10 O
intrathecal	41 11 O
chemotherapy	53 12 O
:	65 1 O
Case	67 4 O
report	72 6 O
and	79 3 O
review	83 6 O
of	90 2 O
literature	93 10 O
.	103 1 O

Severe	105 6 O
nelarabine	112 10 B-Chemical
neurotoxicity	123 13 B-Disease
in	137 2 O
a	140 1 O
patient	142 7 O
who	150 3 O
received	154 8 O
concurrent	163 10 O
intrathecal	174 11 O
(	186 1 O
IT	187 2 O
)	189 1 O
chemotherapy	191 12 O
is	204 2 O
reported	207 8 O
.	215 1 O

A	217 1 O
37	219 2 O
-	221 1 O
year	222 4 O
-	226 1 O
old	227 3 O
Caucasian	231 9 O
woman	241 5 O
with	247 4 O
a	252 1 O
history	254 7 O
of	262 2 O
T	265 1 B-Disease
-	266 1 I-Disease
cell	267 4 I-Disease
lymphoblastic	272 13 I-Disease
lymphoma	286 8 I-Disease
was	295 3 O
admitted	299 8 O
for	308 3 O
relapsed	312 8 O
disease	321 7 O
.	328 1 O

She	330 3 O
was	334 3 O
originally	338 10 O
treated	349 7 O
with	357 4 O
induction	362 9 O
chemotherapy	372 12 O
followed	385 8 O
by	394 2 O
an	397 2 O
autologous	400 10 O
transplant	411 10 O
.	421 1 O

She	423 3 O
developed	427 9 O
relapsed	437 8 O
disease	446 7 O
10	454 2 O
months	457 6 O
later	464 5 O
with	470 4 O
leukemic	475 8 B-Disease
involvement	484 11 O
.	495 1 O

She	497 3 O
was	501 3 O
re	505 2 O
-	507 1 O
induced	508 7 O
with	516 4 O
nelarabine	521 10 B-Chemical
1500	532 4 O
mg	537 2 O
/	539 1 O
m	540 1 O
(	541 1 O
2	542 1 O
)	543 1 O
on	545 2 O
days	548 4 O
1	553 1 O
,	554 1 O
3	556 1 O
,	557 1 O
and	559 3 O
5	563 1 O
with	565 4 O
1	570 1 O
dose	572 4 O
of	577 2 O
IT	580 2 O
cytarabine	583 10 B-Chemical
100	594 3 O
mg	598 2 O
on	601 2 O
day	604 3 O
2	608 1 O
as	610 2 O
central	613 7 O
nervous	621 7 O
system	629 6 O
(	636 1 O
CNS	637 3 O
)	640 1 O
prophylaxis	642 11 O
.	653 1 O

At	655 2 O
the	658 3 O
time	662 4 O
of	667 2 O
treatment	670 9 O
,	679 1 O
she	681 3 O
was	685 3 O
on	689 2 O
continuous	692 10 O
renal	703 5 O
replacement	709 11 O
therapy	721 7 O
due	729 3 O
to	733 2 O
sequelae	736 8 O
of	745 2 O
tumor	748 5 B-Disease
lysis	754 5 I-Disease
syndrome	760 8 I-Disease
(	769 1 O
TLS	770 3 B-Disease
)	773 1 O
.	774 1 O

She	776 3 O
tolerated	780 9 O
therapy	790 7 O
well	798 4 O
,	802 1 O
entered	804 7 O
a	812 1 O
complete	814 8 O
remission	823 9 O
,	832 1 O
and	834 3 O
recovered	838 9 O
her	848 3 O
renal	852 5 O
function	858 8 O
.	866 1 O

She	868 3 O
received	872 8 O
a	881 1 O
second	883 6 O
cycle	890 5 O
of	896 2 O
nelarabine	899 10 B-Chemical
without	910 7 O
additional	918 10 O
IT	929 2 O
prophylaxis	932 11 O
one	944 3 O
month	948 5 O
later	954 5 O
.	959 1 O

A	961 1 O
week	963 4 O
after	968 5 O
this	974 4 O
second	979 6 O
cycle	986 5 O
,	991 1 O
she	993 3 O
noted	997 5 O
numbness	1003 8 O
in	1012 2 O
her	1015 3 O
lower	1019 5 O
extremities	1025 11 O
.	1036 1 O

Predominantly	1038 13 O
sensory	1052 7 O
,	1059 1 O
though	1061 6 O
also	1068 4 O
motor	1073 5 O
and	1079 3 O
autonomic	1083 9 O
,	1092 1 O
peripheral	1094 10 B-Disease
neuropathy	1105 10 I-Disease
started	1116 7 O
in	1124 2 O
her	1127 3 O
feet	1131 4 O
,	1135 1 O
ascended	1137 8 O
proximally	1146 10 O
to	1157 2 O
the	1160 3 O
mid	1164 3 O
-	1167 1 O
thoracic	1168 8 O
region	1177 6 O
,	1183 1 O
and	1185 3 O
eventually	1189 10 O
included	1200 8 O
her	1209 3 O
distal	1213 6 O
upper	1220 5 O
extremities	1226 11 O
.	1237 1 O

A	1239 1 O
magnetic	1241 8 O
resonance	1250 9 O
imaging	1260 7 O
(	1268 1 O
MRI	1269 3 O
)	1272 1 O
of	1274 2 O
her	1277 3 O
spine	1281 5 O
demonstrated	1287 12 O
changes	1300 7 O
from	1308 4 O
C2	1313 2 O
to	1316 2 O
C6	1319 2 O
consistent	1322 10 O
with	1333 4 O
subacute	1338 8 O
combined	1347 8 O
degeneration	1356 12 O
.	1368 1 O

Nelarabine	1370 10 B-Chemical
was	1381 3 O
felt	1385 4 O
to	1390 2 O
be	1393 2 O
the	1396 3 O
cause	1400 5 O
of	1406 2 O
her	1409 3 O
symptoms	1413 8 O
.	1421 1 O

Her	1423 3 O
neuropathy	1427 10 B-Disease
stabilized	1438 10 O
and	1449 3 O
showed	1453 6 O
slight	1460 6 O
improvement	1467 11 O
and	1479 3 O
ultimately	1483 10 O
received	1494 8 O
an	1503 2 O
unrelated	1506 9 O
,	1515 1 O
reduced	1517 7 O
-	1524 1 O
intensity	1525 9 O
allogeneic	1535 10 O
transplant	1546 10 O
while	1557 5 O
in	1563 2 O
complete	1566 8 O
remission	1575 9 O
,	1584 1 O
but	1586 3 O
relapsed	1590 8 O
disease	1599 7 O
10	1607 2 O
weeks	1610 5 O
later	1616 5 O
.	1621 1 O

She	1623 3 O
is	1627 2 O
currently	1630 9 O
being	1640 5 O
treated	1646 7 O
with	1654 4 O
best	1659 4 O
supportive	1664 10 O
care	1675 4 O
.	1679 1 O

To	1681 2 O
our	1684 3 O
knowledge	1688 9 O
,	1697 1 O
this	1699 4 O
is	1704 2 O
the	1707 3 O
first	1711 5 O
published	1717 9 O
case	1727 4 O
report	1732 6 O
of	1739 2 O
severe	1742 6 O
neurotoxicity	1749 13 B-Disease
caused	1763 6 O
by	1770 2 O
nelarabine	1773 10 B-Chemical
in	1784 2 O
a	1787 1 O
patient	1789 7 O
who	1797 3 O
received	1801 8 O
concurrent	1810 10 O
IT	1821 2 O
chemotherapy	1824 12 O
.	1836 1 O

Valproate	0 9 B-Chemical
-	9 1 O
induced	10 7 O
hyperammonemic	18 14 B-Disease
encephalopathy	33 14 B-Disease
in	48 2 O
a	51 1 O
renal	53 5 O
transplanted	59 12 O
patient	72 7 O
.	79 1 O

Neurological	81 12 B-Disease
complications	94 13 I-Disease
after	108 5 O
renal	114 5 O
transplantation	120 15 O
constitute	136 10 O
an	147 2 O
important	150 9 O
cause	160 5 O
of	166 2 O
morbidity	169 9 O
and	179 3 O
mortality	183 9 O
.	192 1 O

Their	194 5 O
differential	200 12 O
diagnosis	213 9 O
is	223 2 O
difficult	226 9 O
and	236 3 O
essential	240 9 O
for	250 3 O
subsequent	254 10 O
patient	265 7 O
'	272 1 O
s	273 1 O
management	275 10 O
.	285 1 O

Valproate	287 9 B-Chemical
-	296 1 O
induced	297 7 O
hyperammonemic	305 14 B-Disease
encephalopathy	320 14 B-Disease
is	335 2 O
an	338 2 O
uncommon	341 8 O
but	350 3 O
serious	354 7 O
effect	362 6 O
of	369 2 O
valproate	372 9 B-Chemical
treatment	382 9 O
.	391 1 O

Here	393 4 O
,	397 1 O
we	399 2 O
describe	402 8 O
the	411 3 O
case	415 4 O
of	420 2 O
a	423 1 O
15	425 2 O
-	427 1 O
year	428 4 O
-	432 1 O
old	433 3 O
girl	437 4 O
who	442 3 O
was	446 3 O
on	450 2 O
a	453 1 O
long	455 4 O
-	459 1 O
term	460 4 O
therapy	465 7 O
with	473 4 O
valproate	478 9 B-Chemical
due	488 3 O
to	492 2 O
epilepsy	495 8 B-Disease
and	504 3 O
revealed	508 8 O
impaired	517 8 B-Disease
consciousness	526 13 I-Disease
with	540 4 O
hyperammonemia	545 14 B-Disease
12	560 2 O
days	563 4 O
after	568 5 O
renal	574 5 O
transplantation	580 15 O
.	595 1 O

After	597 5 O
withdraw	603 8 O
of	612 2 O
valproate	615 9 B-Chemical
,	624 1 O
patients	626 8 O
'	634 1 O
symptoms	636 8 O
resolved	645 8 O
within	654 6 O
24	661 2 O
h	664 1 O
.	665 1 O

Clinicians	667 10 O
should	678 6 O
increase	685 8 O
their	694 5 O
awareness	700 9 O
for	710 3 O
potential	714 9 O
complication	724 12 O
of	737 2 O
valproate	740 9 B-Chemical
,	749 1 O
especially	751 10 O
in	762 2 O
transplanted	765 12 O
patients	778 8 O
.	786 1 O

Necrotising	0 11 B-Disease
fasciitis	12 9 I-Disease
after	22 5 O
bortezomib	28 10 B-Chemical
and	39 3 O
dexamethasone	43 13 B-Chemical
-	56 1 O
containing	57 10 O
regimen	68 7 O
in	76 2 O
an	79 2 O
elderly	82 7 O
patient	90 7 O
of	98 2 O
Waldenstrom	101 11 B-Disease
macroglobulinaemia	113 18 I-Disease
.	131 1 O

Bortezomib	133 10 B-Chemical
and	144 3 O
high	148 4 O
-	152 1 O
dose	153 4 O
dexamethasone	158 13 B-Chemical
-	171 1 O
containing	172 10 O
regimens	183 8 O
are	192 3 O
considered	196 10 O
to	207 2 O
be	210 2 O
generally	213 9 O
tolerable	223 9 O
with	233 4 O
few	238 3 O
severe	242 6 O
bacterial	249 9 B-Disease
infections	259 10 I-Disease
in	270 2 O
patients	273 8 O
with	282 4 O
B	287 1 O
-	288 1 O
cell	289 4 O
malignancies	294 12 B-Disease
.	306 1 O

However	308 7 O
,	315 1 O
information	317 11 O
is	329 2 O
limited	332 7 O
concerning	340 10 O
the	351 3 O
safety	355 6 O
of	362 2 O
the	365 3 O
regimen	369 7 O
in	377 2 O
elderly	380 7 O
patients	388 8 O
.	396 1 O

We	398 2 O
report	401 6 O
a	408 1 O
case	410 4 O
of	415 2 O
a	418 1 O
76	420 2 O
-	422 1 O
year	423 4 O
-	427 1 O
old	428 3 O
man	432 3 O
with	436 4 O
Waldenstrom	441 11 B-Disease
macroglobulinaemia	453 18 I-Disease
who	472 3 O
suffered	476 8 O
necrotising	485 11 B-Disease
fasciitis	497 9 I-Disease
without	507 7 O
neutropenia	515 11 B-Disease
after	527 5 O
the	533 3 O
combination	537 11 O
treatment	549 9 O
with	559 4 O
bortezomib	564 10 B-Chemical
,	574 1 O
high	576 4 O
-	580 1 O
dose	581 4 O
dexamethasone	586 13 B-Chemical
and	600 3 O
rituximab	604 9 O
.	613 1 O

Despite	615 7 O
immediate	623 9 O
intravenous	633 11 O
antimicrobial	645 13 O
therapy	659 7 O
,	666 1 O
he	668 2 O
succumbed	671 9 O
23	681 2 O
h	684 1 O
after	686 5 O
the	692 3 O
onset	696 5 O
.	701 1 O

Physicians	703 10 O
should	714 6 O
recognise	721 9 O
the	731 3 O
possibility	735 11 O
of	747 2 O
fatal	750 5 O
bacterial	756 9 B-Disease
infections	766 10 I-Disease
related	777 7 O
to	785 2 O
bortezomib	788 10 B-Chemical
plus	799 4 O
high	804 4 O
-	808 1 O
dose	809 4 O
dexamethasone	814 13 B-Chemical
in	828 2 O
elderly	831 7 O
patients	839 8 O
,	847 1 O
and	849 3 O
we	853 2 O
believe	856 7 O
this	864 4 O
case	869 4 O
warrants	874 8 O
further	883 7 O
investigation	891 13 O
.	904 1 O

An	0 2 O
integrated	3 10 O
characterization	14 16 O
of	31 2 O
serological	34 11 O
,	45 1 O
pathological	47 12 O
,	59 1 O
and	61 3 O
functional	65 10 O
events	76 6 O
in	83 2 O
doxorubicin	86 11 B-Chemical
-	97 1 O
induced	98 7 O
cardiotoxicity	106 14 B-Disease
.	120 1 O

Many	122 4 O
efficacious	127 11 O
cancer	139 6 B-Disease
treatments	146 10 O
cause	157 5 O
significant	163 11 O
cardiac	175 7 O
morbidity	183 9 O
,	192 1 O
yet	194 3 O
biomarkers	198 10 O
or	209 2 O
functional	212 10 O
indices	223 7 O
of	231 2 O
early	234 5 O
damage	240 6 O
,	246 1 O
which	248 5 O
would	254 5 O
allow	260 5 O
monitoring	266 10 O
and	277 3 O
intervention	281 12 O
,	293 1 O
are	295 3 O
lacking	299 7 O
.	306 1 O

In	308 2 O
this	311 4 O
study	316 5 O
,	321 1 O
we	323 2 O
have	326 4 O
utilized	331 8 O
a	340 1 O
rat	342 3 O
model	346 5 O
of	352 2 O
progressive	355 11 O
doxorubicin	367 11 B-Chemical
(	379 1 O
DOX	380 3 B-Chemical
)	383 1 O
-	384 1 O
induced	385 7 O
cardiomyopathy	393 14 B-Disease
,	407 1 O
applying	409 8 O
multiple	418 8 O
approaches	427 10 O
,	437 1 O
including	439 9 O
cardiac	449 7 O
magnetic	457 8 O
resonance	466 9 O
imaging	476 7 O
(	484 1 O
MRI	485 3 O
)	488 1 O
,	489 1 O
to	491 2 O
provide	494 7 O
the	502 3 O
most	506 4 O
comprehensive	511 13 O
characterization	525 16 O
to	542 2 O
date	545 4 O
of	550 2 O
the	553 3 O
timecourse	557 10 O
of	568 2 O
serological	571 11 O
,	582 1 O
pathological	584 12 O
,	596 1 O
and	598 3 O
functional	602 10 O
events	613 6 O
underlying	620 10 O
this	631 4 O
toxicity	636 8 B-Disease
.	644 1 O

Hannover	646 8 O
Wistar	655 6 O
rats	662 4 O
were	667 4 O
dosed	672 5 O
with	678 4 O
1	683 1 O
.	684 1 O
25	685 2 O
mg	688 2 O
/	690 1 O
kg	691 2 O
DOX	694 3 B-Chemical
weekly	698 6 O
for	705 3 O
8	709 1 O
weeks	711 5 O
followed	717 8 O
by	726 2 O
a	729 1 O
4	731 1 O
week	733 4 O
off	738 3 O
-	741 1 O
dosing	742 6 O
"	749 1 O
recovery	750 8 O
"	758 1 O
period	760 6 O
.	766 1 O

Electron	768 8 O
microscopy	777 10 O
of	788 2 O
the	791 3 O
myocardium	795 10 O
revealed	806 8 O
subcellular	815 11 B-Disease
degeneration	827 12 I-Disease
and	840 3 O
marked	844 6 O
mitochondrial	851 13 O
changes	865 7 O
after	873 5 O
a	879 1 O
single	881 6 O
dose	888 4 O
.	892 1 O

Histopathological	894 17 O
analysis	912 8 O
revealed	921 8 O
progressive	930 11 O
cardiomyocyte	942 13 B-Disease
degeneration	956 12 I-Disease
,	968 1 O
hypertrophy	970 11 B-Disease
/	981 1 O
cytomegaly	982 10 O
,	992 1 O
and	994 3 O
extensive	998 9 O
vacuolation	1008 11 O
after	1020 5 O
two	1026 3 O
doses	1030 5 O
.	1035 1 O

Extensive	1037 9 O
replacement	1047 11 O
fibrosis	1059 8 B-Disease
(	1068 1 O
quantified	1069 10 O
by	1080 2 O
Sirius	1083 6 O
red	1090 3 O
staining	1094 8 O
)	1102 1 O
developed	1104 9 O
during	1114 6 O
the	1121 3 O
off	1125 3 O
-	1128 1 O
dosing	1129 6 O
period	1136 6 O
.	1142 1 O

Functional	1144 10 O
indices	1155 7 O
assessed	1163 8 O
by	1172 2 O
cardiac	1175 7 O
MRI	1183 3 O
(	1187 1 O
including	1188 9 O
left	1198 4 O
ventricular	1203 11 O
ejection	1215 8 O
fraction	1224 8 O
(	1233 1 O
LVEF	1234 4 O
)	1238 1 O
,	1239 1 O
cardiac	1241 7 O
output	1249 6 O
,	1255 1 O
and	1257 3 O
E	1261 1 O
/	1262 1 O
A	1263 1 O
ratio	1265 5 O
)	1270 1 O
declined	1272 8 O
progressively	1281 13 O
,	1294 1 O
reaching	1296 8 O
statistical	1305 11 O
significance	1317 12 O
after	1330 5 O
two	1336 3 O
doses	1340 5 O
and	1346 3 O
culminating	1350 11 O
in	1362 2 O
"	1365 1 O
clinical	1366 8 O
"	1374 1 O
LV	1376 2 B-Disease
dysfunction	1379 11 I-Disease
by	1391 2 O
12	1394 2 O
weeks	1397 5 O
.	1402 1 O

Significant	1404 11 O
increases	1416 9 O
in	1426 2 O
peak	1429 4 O
myocardial	1434 10 O
contrast	1445 8 O
enhancement	1454 11 O
and	1466 3 O
serological	1470 11 O
cardiac	1482 7 O
troponin	1490 8 O
I	1499 1 O
(	1501 1 O
cTnI	1502 4 O
)	1506 1 O
emerged	1508 7 O
after	1516 5 O
eight	1522 5 O
doses	1528 5 O
,	1533 1 O
importantly	1535 11 O
preceding	1547 9 O
the	1557 3 O
LVEF	1561 4 O
decline	1566 7 O
to	1574 2 O
<	1577 1 O
50	1578 2 O
%	1580 1 O
.	1581 1 O

Troponin	1583 8 O
I	1592 1 O
levels	1594 6 O
positively	1601 10 O
correlated	1612 10 O
with	1623 4 O
delayed	1628 7 O
and	1636 3 O
peak	1640 4 O
gadolinium	1645 10 B-Chemical
contrast	1656 8 O
enhancement	1665 11 O
,	1676 1 O
histopathological	1678 17 O
grading	1696 7 O
,	1703 1 O
and	1705 3 O
diastolic	1709 9 B-Disease
dysfunction	1719 11 I-Disease
.	1730 1 O

In	1732 2 O
summary	1735 7 O
,	1742 1 O
subcellular	1744 11 O
cardiomyocyte	1756 13 B-Disease
degeneration	1770 12 I-Disease
was	1783 3 O
the	1787 3 O
earliest	1791 8 O
marker	1800 6 O
,	1806 1 O
followed	1808 8 O
by	1817 2 O
progressive	1820 11 O
functional	1832 10 O
decline	1843 7 O
and	1851 3 O
histopathological	1855 17 O
manifestations	1873 14 O
.	1887 1 O

Myocardial	1889 10 O
contrast	1900 8 O
enhancement	1909 11 O
and	1921 3 O
elevations	1925 10 O
in	1936 2 O
cTnI	1939 4 O
occurred	1944 8 O
later	1953 5 O
.	1958 1 O

However	1960 7 O
,	1967 1 O
all	1969 3 O
indices	1973 7 O
predated	1981 8 O
"	1990 1 O
clinical	1991 8 O
"	1999 1 O
LV	2001 2 B-Disease
dysfunction	2004 11 I-Disease
and	2016 3 O
thus	2020 4 O
warrant	2025 7 O
further	2033 7 O
evaluation	2041 10 O
as	2052 2 O
predictive	2055 10 O
biomarkers	2066 10 O
.	2076 1 O

Intradermal	0 11 O
glutamate	12 9 B-Chemical
and	22 3 O
capsaicin	26 9 B-Chemical
injections	36 10 O
:	46 1 O
intra	48 5 O
-	53 1 O
and	55 3 O
interindividual	59 15 O
variability	75 11 O
of	87 2 O
provoked	90 8 O
hyperalgesia	99 12 B-Disease
and	112 3 O
allodynia	116 9 B-Disease
.	125 1 O

Intradermal	127 11 O
injections	139 10 O
of	150 2 O
glutamate	153 9 B-Chemical
and	163 3 O
capsaicin	167 9 B-Chemical
are	177 3 O
attractive	181 10 O
to	192 2 O
use	195 3 O
in	199 2 O
human	202 5 O
experimental	208 12 O
pain	221 4 B-Disease
models	226 6 O
because	233 7 O
hyperalgesia	241 12 B-Disease
and	254 3 O
allodynia	258 9 B-Disease
mimic	268 5 O
isolated	274 8 O
aspects	283 7 O
of	291 2 O
clinical	294 8 O
pain	303 4 B-Disease
disorders	308 9 I-Disease
.	317 1 O

The	319 3 O
aim	323 3 O
of	327 2 O
the	330 3 O
present	334 7 O
study	342 5 O
was	348 3 O
to	352 2 O
investigate	355 11 O
the	367 3 O
reproducibility	371 15 O
of	387 2 O
these	390 5 O
models	396 6 O
.	402 1 O

Twenty	404 6 O
healthy	411 7 O
male	419 4 O
volunteers	424 10 O
(	435 1 O
mean	436 4 O
age	441 3 O
24	445 2 O
years	448 5 O
;	453 1 O
range	455 5 O
18	461 2 O
-	463 1 O
38	464 2 O
years	467 5 O
)	472 1 O
received	474 8 O
intradermal	483 11 O
injections	495 10 O
of	506 2 O
glutamate	509 9 B-Chemical
and	519 3 O
capsaicin	523 9 B-Chemical
in	533 2 O
the	536 3 O
volar	540 5 O
forearm	546 7 O
.	553 1 O

Magnitudes	555 10 O
of	566 2 O
secondary	569 9 O
pinprick	579 8 O
hyperalgesia	588 12 B-Disease
and	601 3 O
brush	605 5 O
-	610 1 O
evoked	611 6 O
allodynia	618 9 B-Disease
were	628 4 O
investigated	633 12 O
using	646 5 O
von	652 3 O
Frey	656 4 O
filaments	661 9 O
(	671 1 O
gauges	672 6 O
10	679 2 O
,	681 1 O
15	683 2 O
,	685 1 O
60	687 2 O
and	690 3 O
100	694 3 O
g	698 1 O
)	699 1 O
and	701 3 O
brush	705 5 O
strokes	711 7 O
.	718 1 O

Areas	720 5 O
of	726 2 O
secondary	729 9 B-Disease
hyperalgesia	739 12 I-Disease
and	752 3 O
allodynia	756 9 B-Disease
were	766 4 O
quantified	771 10 O
immediately	782 11 O
after	794 5 O
injection	800 9 O
and	810 3 O
after	814 5 O
15	820 2 O
,	822 1 O
30	824 2 O
and	827 3 O
60	831 2 O
min	834 3 O
.	837 1 O

Two	839 3 O
identical	843 9 O
experiments	853 11 O
separated	865 9 O
by	875 2 O
at	878 2 O
least	881 5 O
7	887 1 O
days	889 4 O
were	894 4 O
performed	899 9 O
.	908 1 O

Reproducibility	910 15 O
across	926 6 O
and	933 3 O
within	937 6 O
volunteers	944 10 O
(	955 1 O
inter	956 5 O
-	961 1 O
and	963 3 O
intra	967 5 O
-	972 1 O
individual	973 10 O
variation	984 9 O
,	993 1 O
respectively	995 12 O
)	1007 1 O
was	1009 3 O
assessed	1013 8 O
using	1022 5 O
intraclass	1028 10 O
correlation	1039 11 O
coefficient	1051 11 O
(	1063 1 O
ICC	1064 3 O
)	1067 1 O
and	1069 3 O
coefficient	1073 11 O
of	1085 2 O
variation	1088 9 O
(	1098 1 O
CV	1099 2 O
)	1101 1 O
.	1102 1 O

Secondary	1104 9 O
pinprick	1114 8 O
hyperalgesia	1123 12 B-Disease
was	1136 3 O
observed	1140 8 O
as	1149 2 O
a	1152 1 O
marked	1154 6 O
increase	1161 8 O
in	1170 2 O
the	1173 3 O
visual	1177 6 O
analogue	1184 8 O
scale	1193 5 O
(	1199 1 O
VAS	1200 3 O
)	1203 1 O
response	1205 8 O
to	1214 2 O
von	1217 3 O
Frey	1221 4 O
gauges	1226 6 O
60	1233 2 O
and	1236 3 O
100	1240 3 O
g	1244 1 O
(	1246 1 O
P	1247 1 O
<	1249 1 O
0	1251 1 O
.	1252 1 O
001	1253 3 O
)	1256 1 O
after	1258 5 O
glutamate	1264 9 B-Chemical
injection	1274 9 O
.	1283 1 O

For	1285 3 O
capsaicin	1289 9 B-Chemical
,	1298 1 O
secondary	1300 9 O
pinprick	1310 8 O
hyperalgesia	1319 12 B-Disease
was	1332 3 O
detected	1336 8 O
with	1345 4 O
all	1350 3 O
von	1354 3 O
Frey	1358 4 O
gauges	1363 6 O
(	1370 1 O
P	1371 1 O
<	1373 1 O
0	1375 1 O
.	1376 1 O
001	1377 3 O
)	1380 1 O
.	1381 1 O

Glutamate	1383 9 B-Chemical
evoked	1393 6 O
reproducible	1400 12 O
VAS	1413 3 O
response	1417 8 O
to	1426 2 O
all	1429 3 O
von	1433 3 O
Frey	1437 4 O
gauges	1442 6 O
(	1449 1 O
ICC	1450 3 O
>	1454 1 O
0	1456 1 O
.	1457 1 O
60	1458 2 O
)	1460 1 O
and	1462 3 O
brush	1466 5 O
strokes	1472 7 O
(	1480 1 O
ICC	1481 3 O
>	1485 1 O
0	1487 1 O
.	1488 1 O
83	1489 2 O
)	1491 1 O
.	1492 1 O

Capsaicin	1494 9 B-Chemical
injection	1504 9 O
was	1514 3 O
reproducible	1518 12 O
for	1531 3 O
secondary	1535 9 B-Disease
hyperalgesia	1545 12 I-Disease
(	1558 1 O
ICC	1559 3 O
>	1563 1 O
0	1565 1 O
.	1566 1 O
70	1567 2 O
)	1569 1 O
and	1571 3 O
allodynia	1575 9 B-Disease
(	1585 1 O
ICC	1586 3 O
>	1590 1 O
0	1592 1 O
.	1593 1 O
71	1594 2 O
)	1596 1 O
.	1597 1 O

Intra	1599 5 O
-	1604 1 O
individual	1605 10 O
variability	1616 11 O
was	1628 3 O
generally	1632 9 O
lower	1642 5 O
for	1648 3 O
the	1652 3 O
VAS	1656 3 O
response	1660 8 O
to	1669 2 O
von	1672 3 O
Frey	1676 4 O
and	1681 3 O
brush	1685 5 O
compared	1691 8 O
with	1700 4 O
areas	1705 5 O
of	1711 2 O
secondary	1714 9 B-Disease
hyperalgesia	1724 12 I-Disease
and	1737 3 O
allodynia	1741 9 B-Disease
.	1750 1 O

In	1752 2 O
conclusion	1755 10 O
,	1765 1 O
glutamate	1767 9 B-Chemical
and	1777 3 O
capsaicin	1781 9 B-Chemical
yield	1791 5 O
reproducible	1797 12 O
hyperalgesic	1810 12 B-Disease
and	1823 3 O
allodynic	1827 9 B-Disease
responses	1837 9 O
,	1846 1 O
and	1848 3 O
the	1852 3 O
present	1856 7 O
model	1864 5 O
is	1870 2 O
well	1873 4 O
suited	1878 6 O
for	1885 3 O
basic	1889 5 O
research	1895 8 O
,	1903 1 O
as	1905 2 O
well	1908 4 O
as	1913 2 O
for	1916 3 O
assessing	1920 9 O
the	1930 3 O
modulation	1934 10 O
of	1945 2 O
central	1948 7 O
phenomena	1956 9 O
.	1965 1 O

Ocular	0 6 O
-	6 1 O
specific	7 8 O
ER	16 2 O
stress	19 6 O
reduction	26 9 O
rescues	36 7 O
glaucoma	44 8 B-Disease
in	53 2 O
murine	56 6 O
glucocorticoid	63 14 O
-	77 1 O
induced	78 7 O
glaucoma	86 8 B-Disease
.	94 1 O

Administration	96 14 O
of	111 2 O
glucocorticoids	114 15 O
induces	130 7 O
ocular	138 6 B-Disease
hypertension	145 12 I-Disease
in	158 2 O
some	161 4 O
patients	166 8 O
.	174 1 O

If	176 2 O
untreated	179 9 O
,	188 1 O
these	190 5 O
patients	196 8 O
can	205 3 O
develop	209 7 O
a	217 1 O
secondary	219 9 O
glaucoma	229 8 B-Disease
that	238 4 O
resembles	243 9 O
primary	253 7 B-Disease
open	261 4 I-Disease
-	265 1 I-Disease
angle	266 5 I-Disease
glaucoma	272 8 I-Disease
(	281 1 O
POAG	282 4 B-Disease
)	286 1 O
.	287 1 O

The	289 3 O
underlying	293 10 O
pathology	304 9 O
of	314 2 O
glucocorticoid	317 14 O
-	331 1 O
induced	332 7 O
glaucoma	340 8 B-Disease
is	349 2 O
not	352 3 O
fully	356 5 O
understood	362 10 O
,	372 1 O
due	374 3 O
in	378 2 O
part	381 4 O
to	386 2 O
lack	389 4 O
of	394 2 O
an	397 2 O
appropriate	400 11 O
animal	412 6 O
model	419 5 O
.	424 1 O

Here	426 4 O
,	430 1 O
we	432 2 O
developed	435 9 O
a	445 1 O
murine	447 6 O
model	454 5 O
of	460 2 O
glucocorticoid	463 14 O
-	477 1 O
induced	478 7 O
glaucoma	486 8 B-Disease
that	495 4 O
exhibits	500 8 O
glaucoma	509 8 B-Disease
features	518 8 O
that	527 4 O
are	532 3 O
observed	536 8 O
in	545 2 O
patients	548 8 O
.	556 1 O

Treatment	558 9 O
of	568 2 O
WT	571 2 O
mice	574 4 O
with	579 4 O
topical	584 7 O
ocular	592 6 O
0	599 1 O
.	600 1 O
1	601 1 O
%	602 1 O
dexamethasone	604 13 B-Chemical
led	618 3 O
to	622 2 O
elevation	625 9 O
of	635 2 O
intraocular	638 11 O
pressure	650 8 O
(	659 1 O
IOP	660 3 O
)	663 1 O
,	664 1 O
functional	666 10 O
and	677 3 O
structural	681 10 O
loss	692 4 O
of	697 2 O
retinal	700 7 B-Disease
ganglion	708 8 I-Disease
cells	717 5 O
,	722 1 O
and	724 3 O
axonal	728 6 B-Disease
degeneration	735 12 I-Disease
,	747 1 O
resembling	749 10 O
glucocorticoid	760 14 O
-	774 1 O
induced	775 7 O
glaucoma	783 8 B-Disease
in	792 2 O
human	795 5 O
patients	801 8 O
.	809 1 O

Furthermore	811 11 O
,	822 1 O
dexamethasone	824 13 B-Chemical
-	837 1 O
induced	838 7 O
ocular	846 6 B-Disease
hypertension	853 12 I-Disease
was	866 3 O
associated	870 10 O
with	881 4 O
chronic	886 7 O
ER	894 2 O
stress	897 6 O
of	904 2 O
the	907 3 O
trabecular	911 10 O
meshwork	922 8 O
(	931 1 O
TM	932 2 O
)	934 1 O
.	935 1 O

Similar	937 7 O
to	945 2 O
patients	948 8 O
,	956 1 O
withdrawal	958 10 O
of	969 2 O
dexamethasone	972 13 B-Chemical
treatment	986 9 O
reduced	996 7 O
elevated	1004 8 O
IOP	1013 3 O
and	1017 3 O
ER	1021 2 O
stress	1024 6 O
in	1031 2 O
this	1034 4 O
animal	1039 6 O
model	1046 5 O
.	1051 1 O

Dexamethasone	1053 13 B-Chemical
induced	1067 7 O
the	1075 3 O
transcriptional	1079 15 O
factor	1095 6 O
CHOP	1102 4 O
,	1106 1 O
a	1108 1 O
marker	1110 6 O
for	1117 3 O
chronic	1121 7 O
ER	1129 2 O
stress	1132 6 O
,	1138 1 O
in	1140 2 O
the	1143 3 O
anterior	1147 8 O
segment	1156 7 O
tissues	1164 7 O
,	1171 1 O
and	1173 3 O
Chop	1177 4 O
deletion	1182 8 O
reduced	1191 7 O
ER	1199 2 O
stress	1202 6 O
in	1209 2 O
these	1212 5 O
tissues	1218 7 O
and	1226 3 O
prevented	1230 9 O
dexamethasone	1240 13 B-Chemical
-	1253 1 O
induced	1254 7 O
ocular	1262 6 B-Disease
hypertension	1269 12 I-Disease
.	1281 1 O

Furthermore	1283 11 O
,	1294 1 O
reduction	1296 9 O
of	1306 2 O
ER	1309 2 O
stress	1312 6 O
in	1319 2 O
the	1322 3 O
TM	1326 2 O
with	1329 4 O
sodium	1334 6 B-Chemical
4	1341 1 I-Chemical
-	1342 1 I-Chemical
phenylbutyrate	1343 14 I-Chemical
prevented	1358 9 O
dexamethasone	1368 13 B-Chemical
-	1381 1 O
induced	1382 7 O
ocular	1390 6 B-Disease
hypertension	1397 12 I-Disease
in	1410 2 O
WT	1413 2 O
mice	1416 4 O
.	1420 1 O

Our	1422 3 O
data	1426 4 O
indicate	1431 8 O
that	1440 4 O
ER	1445 2 O
stress	1448 6 O
contributes	1455 11 O
to	1467 2 O
glucocorticoid	1470 14 O
-	1484 1 O
induced	1485 7 O
ocular	1493 6 B-Disease
hypertension	1500 12 I-Disease
and	1513 3 O
suggest	1517 7 O
that	1525 4 O
reducing	1530 8 O
ER	1539 2 O
stress	1542 6 O
has	1549 3 O
potential	1553 9 O
as	1563 2 O
a	1566 1 O
therapeutic	1568 11 O
strategy	1580 8 O
for	1589 3 O
treating	1593 8 O
glucocorticoid	1602 14 O
-	1616 1 O
induced	1617 7 O
glaucoma	1625 8 B-Disease
.	1633 1 O

Effects	0 7 O
of	8 2 O
ginsenosides	11 12 B-Chemical
on	24 2 O
opioid	27 6 O
-	33 1 O
induced	34 7 O
hyperalgesia	42 12 B-Disease
in	55 2 O
mice	58 4 O
.	62 1 O

Opioid	64 6 O
-	70 1 O
induced	71 7 O
hyperalgesia	79 12 B-Disease
(	92 1 O
OIH	93 3 B-Disease
)	96 1 O
is	98 2 O
characterized	101 13 O
by	115 2 O
nociceptive	118 11 O
sensitization	130 13 O
caused	144 6 O
by	151 2 O
the	154 3 O
cessation	158 9 O
of	168 2 O
chronic	171 7 O
opioid	179 6 O
use	186 3 O
.	189 1 O

OIH	191 3 B-Disease
can	195 3 O
limit	199 5 O
the	205 3 O
clinical	209 8 O
use	218 3 O
of	222 2 O
opioid	225 6 O
analgesics	232 10 O
and	243 3 O
complicate	247 10 O
withdrawal	258 10 O
from	269 4 O
opioid	274 6 B-Disease
addiction	281 9 I-Disease
.	290 1 O

In	292 2 O
this	295 4 O
study	300 5 O
,	305 1 O
we	307 2 O
investigated	310 12 O
the	323 3 O
effects	327 7 O
of	335 2 O
Re	338 2 B-Chemical
,	340 1 I-Chemical
Rg1	342 3 I-Chemical
,	345 1 I-Chemical
and	347 3 I-Chemical
Rb1	351 3 I-Chemical
ginsenosides	355 12 I-Chemical
,	367 1 O
the	369 3 O
bioactive	373 9 O
components	383 10 O
of	394 2 O
ginseng	397 7 O
,	404 1 O
on	406 2 O
OIH	409 3 B-Disease
.	412 1 O

OIH	414 3 B-Disease
was	418 3 O
achieved	422 8 O
in	431 2 O
mice	434 4 O
after	439 5 O
subcutaneous	445 12 O
administration	458 14 O
of	473 2 O
morphine	476 8 B-Chemical
for	485 3 O
7	489 1 O
consecutive	491 11 O
days	503 4 O
three	508 5 O
times	514 5 O
per	520 3 O
day	524 3 O
.	527 1 O

During	529 6 O
withdrawal	536 10 O
(	547 1 O
days	548 4 O
8	553 1 O
and	555 3 O
9	559 1 O
)	560 1 O
,	561 1 O
these	563 5 O
mice	569 4 O
were	574 4 O
administered	579 12 O
Re	592 2 B-Chemical
,	594 1 O
Rg1	596 3 B-Chemical
,	599 1 O
or	601 2 O
Rb1	604 3 B-Chemical
intragastrically	608 16 O
two	625 3 O
times	629 5 O
per	635 3 O
day	639 3 O
.	642 1 O

On	644 2 O
the	647 3 O
test	651 4 O
day	656 3 O
(	660 1 O
day	661 3 O
10	665 2 O
)	667 1 O
,	668 1 O
mice	670 4 O
were	675 4 O
subjected	680 9 O
to	690 2 O
the	693 3 O
thermal	697 7 O
sensitivity	705 11 O
test	717 4 O
and	722 3 O
the	726 3 O
acetic	730 6 B-Chemical
acid	737 4 I-Chemical
-	741 1 O
induced	742 7 O
writhing	750 8 O
test	759 4 O
.	763 1 O

Re	765 2 B-Chemical
(	768 1 O
300	769 3 O
mg	773 2 O
/	775 1 O
kg	776 2 O
)	778 1 O
inhibited	780 9 O
OIH	790 3 B-Disease
in	794 2 O
both	797 4 O
the	802 3 O
thermal	806 7 O
sensitivity	814 11 O
test	826 4 O
and	831 3 O
the	835 3 O
acetic	839 6 B-Chemical
acid	846 4 I-Chemical
-	850 1 O
induced	851 7 O
writhing	859 8 O
test	868 4 O
.	872 1 O

However	874 7 O
,	881 1 O
the	883 3 O
Rg1	887 3 B-Chemical
and	891 3 I-Chemical
Rb1	895 3 I-Chemical
ginsenosides	899 12 I-Chemical
failed	912 6 O
to	919 2 O
prevent	922 7 O
OIH	930 3 B-Disease
in	934 2 O
either	937 6 O
test	944 4 O
.	948 1 O

Furthermore	950 11 O
,	961 1 O
Rg1	963 3 B-Chemical
showed	967 6 O
a	974 1 O
tendency	976 8 O
to	985 2 O
aggravate	988 9 O
OIH	998 3 B-Disease
in	1002 2 O
the	1005 3 O
acetic	1009 6 B-Chemical
acid	1016 4 I-Chemical
-	1020 1 O
induced	1021 7 O
writhing	1029 8 O
test	1038 4 O
.	1042 1 O

Our	1044 3 O
data	1048 4 O
suggested	1053 9 O
that	1063 4 O
the	1068 3 O
ginsenoside	1072 11 B-Chemical
Re	1084 2 I-Chemical
,	1086 1 O
but	1088 3 O
not	1092 3 O
Rg1	1096 3 B-Chemical
or	1100 2 O
Rb1	1103 3 B-Chemical
,	1106 1 O
may	1108 3 O
contribute	1112 10 O
toward	1123 6 O
reversal	1130 8 O
of	1139 2 O
OIH	1142 3 B-Disease
.	1145 1 O

A	0 1 O
comparison	2 10 O
of	13 2 O
severe	16 6 O
hemodynamic	23 11 O
disturbances	35 12 O
between	48 7 O
dexmedetomidine	56 15 B-Chemical
and	72 3 O
propofol	76 8 B-Chemical
for	85 3 O
sedation	89 8 O
in	98 2 O
neurocritical	101 13 O
care	115 4 O
patients	120 8 O
.	128 1 O

OBJECTIVE	130 9 O
:	139 1 O
Dexmedetomidine	141 15 B-Chemical
and	157 3 O
propofol	161 8 B-Chemical
are	170 3 O
commonly	174 8 O
used	183 4 O
sedatives	188 9 O
in	198 2 O
neurocritical	201 13 O
care	215 4 O
as	220 2 O
they	223 4 O
allow	228 5 O
for	234 3 O
frequent	238 8 O
neurologic	247 10 O
examinations	258 12 O
.	270 1 O

However	272 7 O
,	279 1 O
both	281 4 O
agents	286 6 O
are	293 3 O
associated	297 10 O
with	308 4 O
significant	313 11 O
hemodynamic	325 11 O
side	337 4 O
effects	342 7 O
.	349 1 O

The	351 3 O
primary	355 7 O
objective	363 9 O
of	373 2 O
this	376 4 O
study	381 5 O
is	387 2 O
to	390 2 O
compare	393 7 O
the	401 3 O
prevalence	405 10 O
of	416 2 O
severe	419 6 O
hemodynamic	426 11 O
effects	438 7 O
in	446 2 O
neurocritical	449 13 O
care	463 4 O
patients	468 8 O
receiving	477 9 O
dexmedetomidine	487 15 B-Chemical
and	503 3 O
propofol	507 8 B-Chemical
.	515 1 O

DESIGN	517 6 O
:	523 1 O
Multicenter	525 11 O
,	536 1 O
retrospective	538 13 O
,	551 1 O
propensity	553 10 O
-	563 1 O
matched	564 7 O
cohort	572 6 O
study	579 5 O
.	584 1 O

SETTING	586 7 O
:	593 1 O
Neurocritical	595 13 O
care	609 4 O
units	614 5 O
at	620 2 O
two	623 3 O
academic	627 8 O
medical	636 7 O
centers	644 7 O
with	652 4 O
dedicated	657 9 O
neurocritical	667 13 O
care	681 4 O
teams	686 5 O
and	692 3 O
board	696 5 O
-	701 1 O
certified	702 9 O
neurointensivists	712 17 O
.	729 1 O

PATIENTS	731 8 O
:	739 1 O
Neurocritical	741 13 O
care	755 4 O
patients	760 8 O
admitted	769 8 O
between	778 7 O
July	786 4 O
2009	791 4 O
and	796 3 O
September	800 9 O
2012	810 4 O
were	815 4 O
evaluated	820 9 O
and	830 3 O
then	834 4 O
matched	839 7 O
1	847 1 O
:	848 1 O
1	849 1 O
based	851 5 O
on	857 2 O
propensity	860 10 O
scoring	871 7 O
of	879 2 O
baseline	882 8 O
characteristics	891 15 O
.	906 1 O

INTERVENTIONS	908 13 O
:	921 1 O
Continuous	923 10 O
sedation	934 8 O
with	943 4 O
dexmedetomidine	948 15 B-Chemical
or	964 2 O
propofol	967 8 B-Chemical
.	975 1 O

MEASUREMENTS	977 12 O
AND	990 3 O
MAIN	994 4 O
RESULTS	999 7 O
:	1006 1 O
A	1008 1 O
total	1010 5 O
of	1016 2 O
342	1019 3 O
patients	1023 8 O
(	1032 1 O
105	1033 3 O
dexmedetomidine	1037 15 B-Chemical
and	1053 3 O
237	1057 3 O
propofol	1061 8 B-Chemical
)	1069 1 O
were	1071 4 O
included	1076 8 O
in	1085 2 O
the	1088 3 O
analysis	1092 8 O
,	1100 1 O
with	1102 4 O
190	1107 3 O
matched	1111 7 O
(	1119 1 O
95	1120 2 O
in	1123 2 O
each	1126 4 O
group	1131 5 O
)	1136 1 O
by	1138 2 O
propensity	1141 10 O
score	1152 5 O
.	1157 1 O

The	1159 3 O
primary	1163 7 O
outcome	1171 7 O
of	1179 2 O
this	1182 4 O
study	1187 5 O
was	1193 3 O
a	1197 1 O
composite	1199 9 O
of	1209 2 O
severe	1212 6 O
hypotension	1219 11 B-Disease
(	1231 1 O
mean	1232 4 O
arterial	1237 8 O
pressure	1246 8 O
<	1255 1 O
60	1257 2 O
mm	1260 2 O
Hg	1263 2 O
)	1265 1 O
and	1267 3 O
bradycardia	1271 11 B-Disease
(	1283 1 O
heart	1284 5 O
rate	1290 4 O
<	1295 1 O
50	1297 2 O
beats	1300 5 O
/	1305 1 O
min	1306 3 O
)	1309 1 O
during	1311 6 O
sedative	1318 8 O
infusion	1327 8 O
.	1335 1 O

No	1337 2 O
difference	1340 10 O
in	1351 2 O
the	1354 3 O
primary	1358 7 O
composite	1366 9 O
outcome	1376 7 O
in	1384 2 O
both	1387 4 O
the	1392 3 O
unmatched	1396 9 O
(	1406 1 O
30	1407 2 O
%	1409 1 O
vs	1411 2 O
30	1414 2 O
%	1416 1 O
,	1417 1 O
p	1419 1 O
=	1421 1 O
0	1423 1 O
.	1424 1 O
94	1425 2 O
)	1427 1 O
or	1429 2 O
matched	1432 7 O
cohorts	1440 7 O
(	1448 1 O
28	1449 2 O
%	1451 1 O
vs	1453 2 O
34	1456 2 O
%	1458 1 O
,	1459 1 O
p	1461 1 O
=	1463 1 O
0	1465 1 O
.	1466 1 O
35	1467 2 O
)	1469 1 O
could	1471 5 O
be	1477 2 O
found	1480 5 O
.	1485 1 O

When	1487 4 O
analyzed	1492 8 O
separately	1501 10 O
,	1511 1 O
no	1513 2 O
differences	1516 11 O
could	1528 5 O
be	1534 2 O
found	1537 5 O
in	1543 2 O
the	1546 3 O
prevalence	1550 10 O
of	1561 2 O
severe	1564 6 O
hypotension	1571 11 B-Disease
or	1583 2 O
bradycardia	1586 11 B-Disease
in	1598 2 O
either	1601 6 O
the	1608 3 O
unmatched	1612 9 O
or	1622 2 O
matched	1625 7 O
cohorts	1633 7 O
.	1640 1 O

CONCLUSIONS	1642 11 O
:	1653 1 O
Severe	1655 6 O
hypotension	1662 11 B-Disease
and	1674 3 O
bradycardia	1678 11 B-Disease
occur	1690 5 O
at	1696 2 O
similar	1699 7 O
prevalence	1707 10 O
in	1718 2 O
neurocritical	1721 13 O
care	1735 4 O
patients	1740 8 O
who	1749 3 O
receive	1753 7 O
dexmedetomidine	1761 15 B-Chemical
or	1777 2 O
propofol	1780 8 B-Chemical
.	1788 1 O

Providers	1790 9 O
should	1800 6 O
similarly	1807 9 O
consider	1817 8 O
the	1826 3 O
likelihood	1830 10 O
of	1841 2 O
hypotension	1844 11 B-Disease
or	1856 2 O
bradycardia	1859 11 B-Disease
before	1871 6 O
starting	1878 8 O
either	1887 6 O
sedative	1894 8 O
.	1902 1 O

Hydroxytyrosol	0 14 B-Chemical
ameliorates	15 11 O
oxidative	27 9 O
stress	37 6 O
and	44 3 O
mitochondrial	48 13 B-Disease
dysfunction	62 11 I-Disease
in	74 2 O
doxorubicin	77 11 B-Chemical
-	88 1 O
induced	89 7 O
cardiotoxicity	97 14 B-Disease
in	112 2 O
rats	115 4 O
with	120 4 O
breast	125 6 B-Disease
cancer	132 6 I-Disease
.	138 1 O

Oxidative	140 9 O
stress	150 6 O
is	157 2 O
involved	160 8 O
in	169 2 O
several	172 7 O
processes	180 9 O
including	190 9 O
cancer	200 6 B-Disease
,	206 1 O
aging	208 5 O
and	214 3 O
cardiovascular	218 14 B-Disease
disease	233 7 I-Disease
,	240 1 O
and	242 3 O
has	246 3 O
been	250 4 O
shown	255 5 O
to	261 2 O
potentiate	264 10 O
the	275 3 O
therapeutic	279 11 O
effect	291 6 O
of	298 2 O
drugs	301 5 O
such	307 4 O
as	312 2 O
doxorubicin	315 11 B-Chemical
.	326 1 O

Doxorubicin	328 11 B-Chemical
causes	340 6 O
significant	347 11 O
cardiotoxicity	359 14 B-Disease
characterized	374 13 O
by	388 2 O
marked	391 6 O
increases	398 9 O
in	408 2 O
oxidative	411 9 O
stress	421 6 O
and	428 3 O
mitochondrial	432 13 B-Disease
dysfunction	446 11 I-Disease
.	457 1 O

Herein	459 6 O
,	465 1 O
we	467 2 O
investigate	470 11 O
whether	482 7 O
doxorubicin	490 11 B-Chemical
-	501 1 O
associated	502 10 O
chronic	513 7 O
cardiac	521 7 B-Disease
toxicity	529 8 I-Disease
can	538 3 O
be	542 2 O
ameliorated	545 11 O
with	557 4 O
the	562 3 O
antioxidant	566 11 O
hydroxytyrosol	578 14 B-Chemical
in	593 2 O
rats	596 4 O
with	601 4 O
breast	606 6 B-Disease
cancer	613 6 I-Disease
.	619 1 O

Thirty	621 6 O
-	627 1 O
six	628 3 O
rats	632 4 O
bearing	637 7 O
breast	645 6 B-Disease
tumors	652 6 I-Disease
induced	659 7 O
chemically	667 10 O
were	678 4 O
divided	683 7 O
into	691 4 O
4	696 1 O
groups	698 6 O
:	704 1 O
control	706 7 O
,	713 1 O
hydroxytyrosol	715 14 B-Chemical
(	730 1 O
0	731 1 O
.	732 1 O
5mg	733 3 O
/	736 1 O
kg	737 2 O
,	739 1 O
5days	741 5 O
/	746 1 O
week	747 4 O
)	751 1 O
,	752 1 O
doxorubicin	754 11 B-Chemical
(	766 1 O
1mg	767 3 O
/	770 1 O
kg	771 2 O
/	773 1 O
week	774 4 O
)	778 1 O
,	779 1 O
and	781 3 O
doxorubicin	785 11 B-Chemical
plus	797 4 O
hydroxytyrosol	802 14 B-Chemical
.	816 1 O

Cardiac	818 7 B-Disease
disturbances	826 12 I-Disease
at	839 2 O
the	842 3 O
cellular	846 8 O
and	855 3 O
mitochondrial	859 13 O
level	873 5 O
,	878 1 O
mitochondrial	880 13 O
electron	894 8 O
transport	903 9 O
chain	913 5 O
complexes	919 9 O
I	929 1 O
-	930 1 O
IV	931 2 O
and	934 3 O
apoptosis	938 9 O
-	947 1 O
inducing	948 8 O
factor	957 6 O
,	963 1 O
and	965 3 O
oxidative	969 9 O
stress	979 6 O
markers	986 7 O
have	994 4 O
been	999 4 O
analyzed	1004 8 O
.	1012 1 O

Hydroxytyrosol	1014 14 B-Chemical
improved	1029 8 O
the	1038 3 O
cardiac	1042 7 B-Disease
disturbances	1050 12 I-Disease
enhanced	1063 8 O
by	1072 2 O
doxorubicin	1075 11 B-Chemical
by	1087 2 O
significantly	1090 13 O
reducing	1104 8 O
the	1113 3 O
percentage	1117 10 O
of	1128 2 O
altered	1131 7 O
mitochondria	1139 12 O
and	1152 3 O
oxidative	1156 9 O
damage	1166 6 O
.	1172 1 O

These	1174 5 O
results	1180 7 O
suggest	1188 7 O
that	1196 4 O
hydroxytyrosol	1201 14 B-Chemical
improve	1216 7 O
the	1224 3 O
mitochondrial	1228 13 O
electron	1242 8 O
transport	1251 9 O
chain	1261 5 O
.	1266 1 O

This	1268 4 O
study	1273 5 O
demonstrates	1279 12 O
that	1292 4 O
hydroxytyrosol	1297 14 B-Chemical
protect	1312 7 O
rat	1320 3 O
heart	1324 5 B-Disease
damage	1330 6 I-Disease
provoked	1337 8 O
by	1346 2 O
doxorubicin	1349 11 B-Chemical
decreasing	1361 10 O
oxidative	1372 9 O
damage	1382 6 O
and	1389 3 O
mitochondrial	1393 13 O
alterations	1407 11 O
.	1418 1 O

Amiodarone	0 10 B-Chemical
-	10 1 O
induced	11 7 O
myxoedema	19 9 B-Disease
coma	29 4 I-Disease
.	33 1 O

A	35 1 O
62	37 2 O
-	39 1 O
year	40 4 O
-	44 1 O
old	45 3 O
man	49 3 O
was	53 3 O
found	57 5 O
to	63 2 O
have	66 4 O
bradycardia	71 11 B-Disease
,	82 1 O
hypothermia	84 11 B-Disease
and	96 3 O
respiratory	100 11 B-Disease
failure	112 7 I-Disease
3	120 1 O
weeks	122 5 O
after	128 5 O
initiation	134 10 O
of	145 2 O
amiodarone	148 10 B-Chemical
therapy	159 7 O
for	167 3 O
atrial	171 6 B-Disease
fibrillation	178 12 I-Disease
.	190 1 O

Thyroid	192 7 O
-	199 1 O
stimulating	200 11 O
hormone	212 7 O
was	220 3 O
found	224 5 O
to	230 2 O
be	233 2 O
168	236 3 O
uIU	240 3 O
/	243 1 O
mL	244 2 O
(	247 1 O
nl	248 2 O
.	250 1 O
0	252 1 O
.	253 1 O
3	254 1 O
-	255 1 O
5	256 1 O
uIU	258 3 O
/	261 1 O
mL	262 2 O
)	264 1 O
and	266 3 O
free	270 4 O
thyroxine	275 9 B-Chemical
(	285 1 O
FT4	286 3 O
)	289 1 O
was	291 3 O
<	295 1 O
0	296 1 O
.	297 1 O
2	298 1 O
ng	300 2 O
/	302 1 O
dL	303 2 O
(	306 1 O
nl	307 2 O
.	309 1 O
0	311 1 O
.	312 1 O
8	313 1 O
-	314 1 O
1	315 1 O
.	316 1 O
8	317 1 O
ng	319 2 O
/	321 1 O
dL	322 2 O
)	324 1 O
.	325 1 O

He	327 2 O
received	330 8 O
intravenous	339 11 O
fluids	351 6 O
,	357 1 O
vasopressor	359 11 O
therapy	371 7 O
and	379 3 O
stress	383 6 O
dose	390 4 O
steroids	395 8 B-Chemical
;	403 1 O
he	405 2 O
was	408 3 O
intubated	412 9 O
and	422 3 O
admitted	426 8 O
to	435 2 O
the	438 3 O
intensive	442 9 O
care	452 4 O
unit	457 4 O
.	461 1 O

He	463 2 O
received	466 8 O
500	475 3 O
ug	479 2 O
of	482 2 O
intravenous	485 11 O
levothyroxine	497 13 B-Chemical
in	511 2 O
the	514 3 O
first	518 5 O
18	524 2 O
h	527 1 O
of	529 2 O
therapy	532 7 O
,	539 1 O
and	541 3 O
150	545 3 O
ug	549 2 O
intravenous	552 11 O
daily	564 5 O
thereafter	570 10 O
.	580 1 O

Haemodynamic	582 12 O
improvement	595 11 O
,	606 1 O
along	608 5 O
with	614 4 O
complete	619 8 O
recovery	628 8 O
of	637 2 O
mental	640 6 O
status	647 6 O
,	653 1 O
occurred	655 8 O
after	664 5 O
48	670 2 O
h	673 1 O
.	674 1 O

Twelve	676 6 O
hours	683 5 O
after	689 5 O
the	695 3 O
initiation	699 10 O
of	710 2 O
therapy	713 7 O
,	720 1 O
FT4	722 3 O
was	726 3 O
0	730 1 O
.	731 1 O
96	732 2 O
ng	735 2 O
/	737 1 O
dL	738 2 O
.	740 1 O

The	742 3 O
patient	746 7 O
was	754 3 O
maintained	758 10 O
on	769 2 O
levothyroxine	772 13 B-Chemical
175	786 3 O
(	790 1 O
g	791 1 O
POorally	793 8 O
daily	802 5 O
.	807 1 O

A	809 1 O
thyroid	811 7 O
ultrasound	819 10 O
showed	830 6 O
diffuse	837 7 O
heterogeneity	845 13 O
.	858 1 O

The	860 3 O
24	864 2 O
hour	867 4 O
excretion	872 9 O
of	882 2 O
iodine	885 6 B-Chemical
was	892 3 O
3657	896 4 O
(	901 1 O
mcg	902 3 O
(	906 1 O
25	907 2 O
-	909 1 O
756	910 3 O
(	914 1 O
mcg	916 3 O
)	919 1 O
.	920 1 O

The	922 3 O
only	926 4 O
two	931 3 O
cases	935 5 O
of	941 2 O
amiodarone	944 10 B-Chemical
-	954 1 O
induced	955 7 O
myxoedema	963 9 B-Disease
coma	973 4 I-Disease
in	978 2 O
the	981 3 O
literature	985 10 O
report	996 6 O
patient	1003 7 O
death	1011 5 O
despite	1017 7 O
supportive	1025 10 O
therapy	1036 7 O
and	1044 3 O
thyroid	1048 7 O
hormone	1056 7 O
replacement	1064 11 O
.	1075 1 O

This	1077 4 O
case	1082 4 O
represents	1087 10 O
the	1098 3 O
most	1102 4 O
thoroughly	1107 10 O
investigated	1118 12 O
case	1131 4 O
of	1136 2 O
amiodarone	1139 10 B-Chemical
-	1149 1 O
induced	1150 7 O
myxoedema	1158 9 B-Disease
coma	1168 4 I-Disease
with	1173 4 O
a	1178 1 O
history	1180 7 O
significant	1188 11 O
for	1200 3 O
subclinical	1204 11 O
thyroid	1216 7 B-Disease
disease	1224 7 I-Disease
.	1231 1 O

Use	0 3 O
of	4 2 O
argatroban	7 10 B-Chemical
and	18 3 O
catheter	22 8 O
-	30 1 O
directed	31 8 O
thrombolysis	40 12 B-Disease
with	53 4 O
alteplase	58 9 O
in	68 2 O
an	71 2 O
oncology	74 8 O
patient	83 7 O
with	91 4 O
heparin	96 7 B-Chemical
-	103 1 O
induced	104 7 O
thrombocytopenia	112 16 B-Disease
with	129 4 O
thrombosis	134 10 B-Disease
.	144 1 O

PURPOSE	146 7 O
:	153 1 O
The	155 3 O
case	159 4 O
of	164 2 O
an	167 2 O
oncology	170 8 O
patient	179 7 O
who	187 3 O
developed	191 9 O
heparin	201 7 B-Chemical
-	208 1 O
induced	209 7 O
thrombocytopenia	217 16 B-Disease
with	234 4 O
thrombosis	239 10 B-Disease
(	250 1 O
HITT	251 4 B-Disease
)	255 1 O
and	257 3 O
was	261 3 O
treated	265 7 O
with	273 4 O
argatroban	278 10 B-Chemical
plus	289 4 O
catheter	294 8 O
-	302 1 O
directed	303 8 O
thrombolysis	312 12 B-Disease
(	325 1 O
CDT	326 3 O
)	329 1 O
with	331 4 O
alteplase	336 9 O
is	346 2 O
presented	349 9 O
.	358 1 O

SUMMARY	360 7 O
:	367 1 O
A	369 1 O
63	371 2 O
-	373 1 O
year	374 4 O
-	378 1 O
old	379 3 O
Caucasian	383 9 O
man	393 3 O
with	397 4 O
renal	402 5 O
amyloidosis	408 11 B-Disease
undergoing	420 10 O
peripheral	431 10 O
blood	442 5 O
stem	448 4 O
cell	453 4 O
collection	458 10 O
for	469 3 O
an	473 2 O
autologous	476 10 O
stem	487 4 O
cell	492 4 O
transplant	497 10 O
developed	508 9 O
extensive	518 9 O
bilateral	528 9 O
upper	538 5 B-Disease
-	543 1 I-Disease
extremity	544 9 I-Disease
deep	554 4 I-Disease
venous	559 6 I-Disease
thrombosis	566 10 I-Disease
(	577 1 O
DVT	578 3 B-Disease
)	581 1 O
and	583 3 O
pulmonary	587 9 B-Disease
embolism	597 8 I-Disease
secondary	606 9 O
to	616 2 O
heparin	619 7 B-Chemical
-	626 1 O
induced	627 7 O
thrombocytopenia	635 16 B-Disease
.	651 1 O

A	653 1 O
continuous	655 10 O
i	666 1 O
.	667 1 O
v	668 1 O
.	669 1 O
infusion	671 8 O
of	680 2 O
argatroban	683 10 B-Chemical
was	694 3 O
initiated	698 9 O
,	707 1 O
and	709 3 O
the	713 3 O
patient	717 7 O
was	725 3 O
managed	729 7 O
on	737 2 O
the	740 3 O
general	744 7 O
medical	752 7 O
floor	760 5 O
.	765 1 O

After	767 5 O
one	773 3 O
week	777 4 O
of	782 2 O
therapy	785 7 O
,	792 1 O
he	794 2 O
was	797 3 O
transferred	801 11 O
to	813 2 O
the	816 3 O
intensive	820 9 O
care	830 4 O
unit	835 4 O
with	840 4 O
cardiopulmonary	845 15 O
compromise	861 10 O
related	872 7 O
to	880 2 O
superior	883 8 B-Disease
vena	892 4 I-Disease
cava	897 4 I-Disease
(	902 1 I-Disease
SVC	903 3 I-Disease
)	906 1 I-Disease
syndrome	908 8 I-Disease
.	916 1 O

A	918 1 O
percutaneous	920 12 O
mechanical	933 10 O
thrombectomy	944 12 O
and	957 3 O
CDT	961 3 O
with	965 4 O
alteplase	970 9 O
were	980 4 O
attempted	985 9 O
,	994 1 O
but	996 3 O
the	1000 3 O
procedure	1004 9 O
was	1014 3 O
aborted	1018 7 O
due	1026 3 O
to	1030 2 O
epistaxis	1033 9 B-Disease
.	1042 1 O

The	1044 3 O
epistaxis	1048 9 B-Disease
resolved	1058 8 O
the	1067 3 O
next	1071 4 O
day	1076 3 O
,	1079 1 O
and	1081 3 O
the	1085 3 O
patient	1089 7 O
was	1097 3 O
restarted	1101 9 O
on	1111 2 O
argatroban	1114 10 B-Chemical
.	1124 1 O

A	1126 1 O
second	1128 6 O
percutaneous	1135 12 O
mechanical	1148 10 O
thrombectomy	1159 12 O
was	1172 3 O
performed	1176 9 O
six	1186 3 O
days	1190 4 O
later	1195 5 O
and	1201 3 O
resulted	1205 8 O
in	1214 2 O
partial	1217 7 O
revascularization	1225 17 O
of	1243 2 O
the	1246 3 O
SVC	1250 3 O
and	1254 3 O
central	1258 7 O
veins	1266 5 O
.	1271 1 O

Postthrombectomy	1273 16 O
continuous	1290 10 O
CDT	1301 3 O
with	1305 4 O
alteplase	1310 9 O
was	1320 3 O
commenced	1324 9 O
while	1334 5 O
argatroban	1340 10 B-Chemical
was	1351 3 O
withheld	1355 8 O
,	1363 1 O
and	1365 3 O
complete	1369 8 O
patency	1378 7 O
of	1386 2 O
the	1389 3 O
SVC	1393 3 O
and	1397 3 O
central	1401 7 O
veins	1409 5 O
was	1415 3 O
achieved	1419 8 O
after	1428 5 O
three	1434 5 O
days	1440 4 O
of	1445 2 O
therapy	1448 7 O
.	1455 1 O

Alteplase	1457 9 O
was	1467 3 O
discontinued	1471 12 O
,	1483 1 O
and	1485 3 O
the	1489 3 O
patient	1493 7 O
was	1501 3 O
reinitiated	1505 11 O
on	1517 2 O
argatroban	1520 10 B-Chemical
;	1530 1 O
ultimately	1532 10 O
,	1542 1 O
he	1544 2 O
was	1547 3 O
transitioned	1551 12 O
to	1564 2 O
warfarin	1567 8 B-Chemical
for	1576 3 O
long	1580 4 O
-	1584 1 O
term	1585 4 O
anticoagulation	1590 15 O
.	1605 1 O

Although	1607 8 O
the	1616 3 O
patient	1620 7 O
recovered	1628 9 O
,	1637 1 O
he	1639 2 O
experienced	1642 11 O
permanent	1654 9 O
vision	1664 6 B-Disease
and	1671 3 I-Disease
hearing	1675 7 I-Disease
loss	1683 4 I-Disease
,	1687 1 O
as	1689 2 O
well	1692 4 O
as	1697 2 O
end	1700 3 B-Disease
-	1703 1 I-Disease
stage	1704 5 I-Disease
renal	1710 5 I-Disease
disease	1716 7 I-Disease
.	1723 1 O

CONCLUSION	1725 10 O
:	1735 1 O
A	1737 1 O
63	1739 2 O
-	1741 1 O
year	1742 4 O
-	1746 1 O
old	1747 3 O
man	1751 3 O
with	1755 4 O
renal	1760 5 O
amyloidosis	1766 11 B-Disease
and	1778 3 O
SVC	1782 3 B-Disease
syndrome	1786 8 I-Disease
secondary	1795 9 O
to	1805 2 O
HITT	1808 4 B-Disease
was	1813 3 O
successfully	1817 12 O
treated	1830 7 O
with	1838 4 O
argatroban	1843 10 B-Chemical
and	1854 3 O
CDT	1858 3 O
with	1862 4 O
alteplase	1867 9 O
.	1876 1 O

Effects	0 7 O
of	8 2 O
dehydroepiandrosterone	11 22 B-Chemical
in	34 2 O
amphetamine	37 11 B-Chemical
-	48 1 O
induced	49 7 O
schizophrenia	57 13 B-Disease
models	71 6 O
in	78 2 O
mice	81 4 O
.	85 1 O

OBJECTIVE	87 9 O
:	96 1 O
To	98 2 O
examine	101 7 O
the	109 3 O
effects	113 7 O
of	121 2 O
dehydroepiandrosterone	124 22 B-Chemical
(	147 1 O
DHEA	148 4 B-Chemical
)	152 1 O
on	154 2 O
animal	157 6 O
models	164 6 O
of	171 2 O
schizophrenia	174 13 B-Disease
.	187 1 O

METHODS	189 7 O
:	196 1 O
Seventy	198 7 O
Swiss	206 5 O
albino	212 6 O
female	219 6 O
mice	226 4 O
(	231 1 O
25	232 2 O
-	234 1 O
35	235 2 O
g	238 1 O
)	239 1 O
were	241 4 O
divided	246 7 O
into	254 4 O
4	259 1 O
groups	261 6 O
:	267 1 O
amphetamine	269 11 B-Chemical
-	280 1 O
free	281 4 O
(	286 1 O
control	287 7 O
)	294 1 O
,	295 1 O
amphetamine	297 11 B-Chemical
,	308 1 O
50	310 2 O
,	312 1 O
and	314 3 O
100	318 3 O
mg	322 2 O
/	324 1 O
kg	325 2 O
DHEA	328 4 B-Chemical
.	332 1 O

The	334 3 O
DHEA	338 4 B-Chemical
was	343 3 O
administered	347 12 O
intraperitoneally	360 17 O
(	378 1 O
ip	379 2 O
)	381 1 O
for	383 3 O
5	387 1 O
days	389 4 O
.	393 1 O

Amphetamine	395 11 B-Chemical
(	407 1 O
3	408 1 O
mg	410 2 O
/	412 1 O
kg	413 2 O
ip	416 2 O
)	418 1 O
induced	420 7 O
hyper	428 5 B-Disease
locomotion	434 10 O
,	444 1 O
apomorphine	446 11 B-Chemical
(	458 1 O
1	459 1 O
.	460 1 O
5	461 1 O
mg	463 2 O
/	465 1 O
kg	466 2 O
subcutaneously	469 14 O
[	484 1 O
sc	485 2 O
]	487 1 O
)	488 1 O
induced	490 7 O
climbing	498 8 O
,	506 1 O
and	508 3 O
haloperidol	512 11 B-Chemical
(	524 1 O
1	525 1 O
.	526 1 O
5	527 1 O
mg	529 2 O
/	531 1 O
kg	532 2 O
sc	535 2 O
)	537 1 O
induced	539 7 O
catalepsy	547 9 B-Disease
tests	557 5 O
were	563 4 O
used	568 4 O
as	573 2 O
animal	576 6 O
models	583 6 O
of	590 2 O
schizophrenia	593 13 B-Disease
.	606 1 O

The	608 3 O
study	612 5 O
was	618 3 O
conducted	622 9 O
at	632 2 O
the	635 3 O
Animal	639 6 O
Experiment	646 10 O
Laboratories	657 12 O
,	669 1 O
Department	671 10 O
of	682 2 O
Pharmacology	685 12 O
,	697 1 O
Medical	699 7 O
School	707 6 O
,	713 1 O
Eskisehir	715 9 O
Osmangazi	725 9 O
University	735 10 O
,	745 1 O
Eskisehir	747 9 O
,	756 1 O
Turkey	758 6 O
between	765 7 O
March	773 5 O
and	779 3 O
May	783 3 O
2012	787 4 O
.	791 1 O

Statistical	793 11 O
analysis	805 8 O
was	814 3 O
carried	818 7 O
out	826 3 O
using	830 5 O
Kruskal	836 7 O
-	843 1 O
Wallis	844 6 O
test	851 4 O
for	856 3 O
hyper	860 5 B-Disease
locomotion	866 10 O
,	876 1 O
and	878 3 O
one	882 3 O
-	885 1 O
way	886 3 O
ANOVA	890 5 O
for	896 3 O
climbing	900 8 O
and	909 3 O
catalepsy	913 9 B-Disease
tests	923 5 O
.	928 1 O

RESULTS	930 7 O
:	937 1 O
In	939 2 O
the	942 3 O
amphetamine	946 11 B-Chemical
-	957 1 O
induced	958 7 O
locomotion	966 10 O
test	977 4 O
,	981 1 O
there	983 5 O
were	989 4 O
significant	994 11 O
increases	1006 9 O
in	1016 2 O
all	1019 3 O
movements	1023 9 O
compared	1033 8 O
with	1042 4 O
the	1047 3 O
amphetamine	1051 11 B-Chemical
-	1062 1 O
free	1063 4 O
group	1068 5 O
.	1073 1 O

Both	1075 4 O
DHEA	1080 4 B-Chemical
50	1085 2 O
mg	1088 2 O
/	1090 1 O
kg	1091 2 O
(	1094 1 O
p	1095 1 O
<	1096 1 O
0	1097 1 O
.	1098 1 O
05	1099 2 O
)	1101 1 O
,	1102 1 O
and	1104 3 O
100	1108 3 O
mg	1112 2 O
/	1114 1 O
kg	1115 2 O
(	1118 1 O
p	1119 1 O
<	1120 1 O
0	1121 1 O
.	1122 1 O
01	1123 2 O
)	1125 1 O
significantly	1127 13 O
decreased	1141 9 O
all	1151 3 O
movements	1155 9 O
compared	1165 8 O
with	1174 4 O
the	1179 3 O
amphetamine	1183 11 B-Chemical
-	1194 1 O
induced	1195 7 O
locomotion	1203 10 O
group	1214 5 O
.	1219 1 O

There	1221 5 O
was	1227 3 O
a	1231 1 O
significant	1233 11 O
difference	1245 10 O
between	1256 7 O
groups	1264 6 O
in	1271 2 O
the	1274 3 O
haloperidol	1278 11 B-Chemical
-	1289 1 O
induced	1290 7 O
catalepsy	1298 9 B-Disease
test	1308 4 O
(	1313 1 O
p	1314 1 O
<	1315 1 O
0	1316 1 O
.	1317 1 O
05	1318 2 O
)	1320 1 O
.	1321 1 O

There	1323 5 O
was	1329 3 O
no	1333 2 O
significant	1336 11 O
difference	1348 10 O
between	1359 7 O
groups	1367 6 O
in	1374 2 O
terms	1377 5 O
of	1383 2 O
total	1386 5 O
climbing	1392 8 O
time	1401 4 O
in	1406 2 O
the	1409 3 O
apomorphine	1413 11 B-Chemical
-	1424 1 O
induced	1425 7 O
climbing	1433 8 O
test	1442 4 O
(	1447 1 O
p	1448 1 O
>	1449 1 O
0	1450 1 O
.	1451 1 O
05	1452 2 O
)	1454 1 O
.	1455 1 O

CONCLUSION	1457 10 O
:	1467 1 O
We	1469 2 O
observed	1472 8 O
that	1481 4 O
DHEA	1486 4 B-Chemical
reduced	1491 7 O
locomotor	1499 9 O
activity	1509 8 O
and	1518 3 O
increased	1522 9 O
catalepsy	1532 9 B-Disease
at	1542 2 O
both	1545 4 O
doses	1550 5 O
,	1555 1 O
while	1557 5 O
it	1563 2 O
had	1566 3 O
no	1570 2 O
effect	1573 6 O
on	1580 2 O
climbing	1583 8 O
behavior	1592 8 O
.	1600 1 O

We	1602 2 O
suggest	1605 7 O
that	1613 4 O
DHEA	1618 4 B-Chemical
displays	1623 8 O
typical	1632 7 O
neuroleptic	1640 11 O
-	1651 1 O
like	1652 4 O
effects	1657 7 O
,	1664 1 O
and	1666 3 O
may	1670 3 O
be	1674 2 O
used	1677 4 O
in	1682 2 O
the	1685 3 O
treatment	1689 9 O
of	1699 2 O
schizophrenia	1702 13 B-Disease
.	1715 1 O

Availability	0 12 O
of	13 2 O
human	16 5 O
induced	22 7 O
pluripotent	30 11 O
stem	42 4 O
cell	47 4 O
-	51 1 O
derived	52 7 O
cardiomyocytes	60 14 O
in	75 2 O
assessment	78 10 O
of	89 2 O
drug	92 4 O
potential	97 9 O
for	107 3 O
QT	111 2 B-Disease
prolongation	114 12 I-Disease
.	126 1 O

Field	128 5 O
potential	134 9 O
duration	144 8 O
(	153 1 O
FPD	154 3 O
)	157 1 O
in	159 2 O
human	162 5 O
-	167 1 O
induced	168 7 O
pluripotent	176 11 O
stem	188 4 O
cell	193 4 O
-	197 1 O
derived	198 7 O
cardiomyocytes	206 14 O
(	221 1 O
hiPS	222 4 O
-	226 1 O
CMs	227 3 O
)	230 1 O
,	231 1 O
which	233 5 O
can	239 3 O
express	243 7 O
QT	251 2 O
interval	254 8 O
in	263 2 O
an	266 2 O
electrocardiogram	269 17 O
,	286 1 O
is	288 2 O
reported	291 8 O
to	300 2 O
be	303 2 O
a	306 1 O
useful	308 6 O
tool	315 4 O
to	320 2 O
predict	323 7 O
K	331 1 B-Chemical
(	332 1 O
+	333 1 O
)	334 1 O
channel	336 7 O
and	344 3 O
Ca	348 2 B-Chemical
(	350 1 O
2	351 1 O
+	352 1 O
)	353 1 O
channel	355 7 O
blocker	363 7 O
effects	371 7 O
on	379 2 O
QT	382 2 O
interval	385 8 O
.	393 1 O

However	395 7 O
,	402 1 O
there	404 5 O
is	410 2 O
no	413 2 O
report	416 6 O
showing	423 7 O
that	431 4 O
this	436 4 O
technique	441 9 O
can	451 3 O
be	455 2 O
used	458 4 O
to	463 2 O
predict	466 7 O
multichannel	474 12 O
blocker	487 7 O
potential	495 9 O
for	505 3 O
QT	509 2 B-Disease
prolongation	512 12 I-Disease
.	524 1 O

The	526 3 O
aim	530 3 O
of	534 2 O
this	537 4 O
study	542 5 O
is	548 2 O
to	551 2 O
show	554 4 O
that	559 4 O
FPD	564 3 O
from	568 4 O
MEA	573 3 O
(	577 1 O
Multielectrode	578 14 O
array	593 5 O
)	598 1 O
of	600 2 O
hiPS	603 4 O
-	607 1 O
CMs	608 3 O
can	612 3 O
detect	616 6 O
QT	623 2 B-Disease
prolongation	626 12 I-Disease
induced	639 7 O
by	647 2 O
multichannel	650 12 O
blockers	663 8 O
.	671 1 O

hiPS	673 4 O
-	677 1 O
CMs	678 3 O
were	682 4 O
seeded	687 6 O
onto	694 4 O
MEA	699 3 O
and	703 3 O
FPD	707 3 O
was	711 3 O
measured	715 8 O
for	724 3 O
2min	728 4 O
every	733 5 O
10min	739 5 O
for	745 3 O
30min	749 5 O
after	755 5 O
drug	761 4 O
exposure	766 8 O
for	775 3 O
the	779 3 O
vehicle	783 7 O
and	791 3 O
each	795 4 O
drug	800 4 O
concentration	805 13 O
.	818 1 O

IKr	820 3 O
and	824 3 O
IKs	828 3 O
blockers	832 8 O
concentration	841 13 O
-	854 1 O
dependently	855 11 O
prolonged	867 9 O
corrected	877 9 O
FPD	887 3 O
(	891 1 O
FPDc	892 4 O
)	896 1 O
,	897 1 O
whereas	899 7 O
Ca	907 2 B-Chemical
(	909 1 O
2	910 1 O
+	911 1 O
)	912 1 O
channel	914 7 O
blockers	922 8 O
concentration	931 13 O
-	944 1 O
dependently	945 11 O
shortened	957 9 O
FPDc	967 4 O
.	971 1 O

Also	973 4 O
,	977 1 O
the	979 3 O
multichannel	983 12 O
blockers	996 8 O
Amiodarone	1005 10 B-Chemical
,	1015 1 O
Paroxetine	1017 10 B-Chemical
,	1027 1 O
Terfenadine	1029 11 B-Chemical
and	1041 3 O
Citalopram	1045 10 B-Chemical
prolonged	1056 9 O
FPDc	1066 4 O
in	1071 2 O
a	1074 1 O
concentration	1076 13 O
dependent	1090 9 O
manner	1100 6 O
.	1106 1 O

Finally	1108 7 O
,	1115 1 O
the	1117 3 O
IKr	1121 3 O
blockers	1125 8 O
,	1133 1 O
Terfenadine	1135 11 B-Chemical
and	1147 3 O
Citalopram	1151 10 B-Chemical
,	1161 1 O
which	1163 5 O
are	1169 3 O
reported	1173 8 O
to	1182 2 O
cause	1185 5 O
Torsade	1191 7 B-Disease
de	1199 2 I-Disease
Pointes	1202 7 I-Disease
(	1210 1 O
TdP	1211 3 B-Disease
)	1214 1 O
in	1216 2 O
clinical	1219 8 O
practice	1228 8 O
,	1236 1 O
produced	1238 8 O
early	1247 5 O
afterdepolarization	1253 19 O
(	1273 1 O
EAD	1274 3 O
)	1277 1 O
.	1278 1 O

hiPS	1280 4 O
-	1284 1 O
CMs	1285 3 O
using	1289 5 O
MEA	1295 3 O
system	1299 6 O
and	1306 3 O
FPDc	1310 4 O
can	1315 3 O
predict	1319 7 O
the	1327 3 O
effects	1331 7 O
of	1339 2 O
drug	1342 4 O
candidates	1347 10 O
on	1358 2 O
QT	1361 2 O
interval	1364 8 O
.	1372 1 O

This	1374 4 O
study	1379 5 O
also	1385 4 O
shows	1390 5 O
that	1396 4 O
this	1401 4 O
assay	1406 5 O
can	1412 3 O
help	1416 4 O
detect	1421 6 O
EAD	1428 3 O
for	1432 3 O
drugs	1436 5 O
with	1442 4 O
TdP	1447 3 B-Disease
potential	1451 9 O
.	1460 1 O

Dermal	0 6 O
developmental	7 13 O
toxicity	21 8 B-Disease
of	30 2 O
N	33 1 O
-	34 1 O
phenylimide	35 11 O
herbicides	47 10 O
in	58 2 O
rats	61 4 O
.	65 1 O

BACKGROUND	67 10 O
:	77 1 O
S	79 1 B-Chemical
-	80 1 I-Chemical
53482	81 5 I-Chemical
and	87 3 O
S	91 1 B-Chemical
-	92 1 I-Chemical
23121	93 5 I-Chemical
are	99 3 O
N	103 1 O
-	104 1 O
phenylimide	105 11 O
herbicides	117 10 O
and	128 3 O
produced	132 8 O
embryolethality	141 15 B-Disease
,	156 1 O
teratogenicity	158 14 B-Disease
(	173 1 O
mainly	174 6 O
ventricular	181 11 B-Disease
septal	193 6 I-Disease
defects	200 7 I-Disease
and	208 3 O
wavy	212 4 O
ribs	217 4 O
)	221 1 O
,	222 1 O
and	224 3 O
growth	228 6 B-Disease
retardation	235 11 I-Disease
in	247 2 O
rats	250 4 O
in	255 2 O
conventional	258 12 O
oral	271 4 O
developmental	276 13 O
toxicity	290 8 B-Disease
studies	299 7 O
.	306 1 O

Our	308 3 O
objective	312 9 O
in	322 2 O
this	325 4 O
study	330 5 O
was	336 3 O
to	340 2 O
investigate	343 11 O
whether	355 7 O
the	363 3 O
compounds	367 9 O
induce	377 6 O
developmental	384 13 O
toxicity	398 8 B-Disease
via	407 3 O
the	411 3 O
dermal	415 6 O
route	422 5 O
,	427 1 O
which	429 5 O
is	435 2 O
more	438 4 O
relevant	443 8 O
to	452 2 O
occupational	455 12 O
exposure	468 8 O
,	476 1 O
hence	478 5 O
better	484 6 O
addressing	491 10 O
human	502 5 O
health	508 6 O
risks	515 5 O
.	520 1 O

METHODS	522 7 O
:	529 1 O
S	531 1 B-Chemical
-	532 1 I-Chemical
53482	533 5 I-Chemical
was	539 3 O
administered	543 12 O
dermally	556 8 O
to	565 2 O
rats	568 4 O
at	573 2 O
30	576 2 O
,	578 1 O
100	580 3 O
,	583 1 O
and	585 3 O
300	589 3 O
mg	593 2 O
/	595 1 O
kg	596 2 O
during	599 6 O
organogenesis	606 13 O
,	619 1 O
and	621 3 O
S	625 1 B-Chemical
-	626 1 I-Chemical
23121	627 5 I-Chemical
was	633 3 O
administered	637 12 O
at	650 2 O
200	653 3 O
,	656 1 O
400	658 3 O
,	661 1 O
and	663 3 O
800	667 3 O
mg	671 2 O
/	673 1 O
kg	674 2 O
(	677 1 O
the	678 3 O
maximum	682 7 O
applicable	690 10 O
dose	701 4 O
level	706 5 O
)	711 1 O
.	712 1 O

Fetuses	714 7 O
were	722 4 O
obtained	727 8 O
by	736 2 O
a	739 1 O
Cesarean	741 8 O
section	750 7 O
and	758 3 O
examined	762 8 O
for	771 3 O
external	775 8 O
,	783 1 O
visceral	785 8 O
,	793 1 O
and	795 3 O
skeletal	799 8 O
alterations	808 11 O
.	819 1 O

RESULTS	821 7 O
:	828 1 O
Dermal	830 6 O
exposure	837 8 O
of	846 2 O
rats	849 4 O
to	854 2 O
S	857 1 B-Chemical
-	858 1 I-Chemical
53482	859 5 I-Chemical
at	865 2 O
300	868 3 O
mg	872 2 O
/	874 1 O
kg	875 2 O
produced	878 8 O
patterns	887 8 O
of	896 2 O
developmental	899 13 O
toxicity	913 8 B-Disease
similar	922 7 O
to	930 2 O
those	933 5 O
resulting	939 9 O
from	949 4 O
oral	954 4 O
exposure	959 8 O
.	967 1 O

Toxicity	969 8 B-Disease
included	978 8 O
embryolethality	987 15 B-Disease
,	1002 1 O
teratogenicity	1004 14 B-Disease
,	1018 1 O
and	1020 3 O
growth	1024 6 B-Disease
retardation	1031 11 I-Disease
.	1042 1 O

Dermal	1044 6 O
administration	1051 14 O
of	1066 2 O
S	1069 1 B-Chemical
-	1070 1 I-Chemical
23121	1071 5 I-Chemical
at	1077 2 O
800	1080 3 O
mg	1084 2 O
/	1086 1 O
kg	1087 2 O
resulted	1090 8 O
in	1099 2 O
an	1102 2 O
increased	1105 9 O
incidence	1115 9 O
of	1125 2 O
embryonic	1128 9 B-Disease
death	1138 5 I-Disease
and	1144 3 O
ventricular	1148 11 B-Disease
septal	1160 6 I-Disease
defect	1167 6 I-Disease
,	1173 1 O
but	1175 3 O
retarded	1179 8 O
fetal	1188 5 O
growth	1194 6 O
was	1201 3 O
not	1205 3 O
observed	1209 8 O
as	1218 2 O
it	1221 2 O
was	1224 3 O
following	1228 9 O
oral	1238 4 O
exposure	1243 8 O
to	1252 2 O
S	1255 1 B-Chemical
-	1256 1 I-Chemical
23121	1257 5 I-Chemical
.	1262 1 O

CONCLUSIONS	1264 11 O
:	1275 1 O
Based	1277 5 O
on	1283 2 O
the	1286 3 O
results	1290 7 O
,	1297 1 O
S	1299 1 B-Chemical
-	1300 1 I-Chemical
53482	1301 5 I-Chemical
and	1307 3 O
S	1311 1 B-Chemical
-	1312 1 I-Chemical
23121	1313 5 I-Chemical
were	1319 4 O
teratogenic	1324 11 B-Disease
when	1336 4 O
administered	1341 12 O
dermally	1354 8 O
to	1363 2 O
pregnant	1366 8 O
rats	1375 4 O
as	1380 2 O
were	1383 4 O
the	1388 3 O
compounds	1392 9 O
administered	1402 12 O
orally	1415 6 O
.	1421 1 O

Thus	1423 4 O
,	1427 1 O
investigation	1429 13 O
of	1443 2 O
the	1446 3 O
mechanism	1450 9 O
and	1460 3 O
its	1464 3 O
human	1468 5 O
relevancy	1474 9 O
become	1484 6 O
more	1491 4 O
important	1496 9 O
.	1505 1 O

Rates	0 5 O
of	6 2 O
Renal	9 5 B-Disease
Toxicity	15 8 I-Disease
in	24 2 O
Cancer	27 6 B-Disease
Patients	34 8 O
Receiving	43 9 O
Cisplatin	53 9 B-Chemical
With	63 4 O
and	68 3 O
Without	72 7 O
Mannitol	80 8 B-Chemical
.	88 1 O

BACKGROUND	90 10 O
:	100 1 O
Cisplatin	102 9 B-Chemical
is	112 2 O
a	115 1 O
widely	117 6 O
used	124 4 O
antineoplastic	129 14 O
.	143 1 O

One	145 3 O
of	149 2 O
the	152 3 O
major	156 5 O
complications	162 13 O
of	176 2 O
cisplatin	179 9 B-Chemical
use	189 3 O
is	193 2 O
dose	196 4 O
-	200 1 O
limiting	201 8 O
nephrotoxicity	210 14 B-Disease
.	224 1 O

There	226 5 O
are	232 3 O
many	236 4 O
strategies	241 10 O
to	252 2 O
prevent	255 7 O
this	263 4 O
toxicity	268 8 B-Disease
,	276 1 O
including	278 9 O
the	288 3 O
use	292 3 O
of	296 2 O
mannitol	299 8 B-Chemical
as	308 2 O
a	311 1 O
nephroprotectant	313 16 O
in	330 2 O
combination	333 11 O
with	345 4 O
hydration	350 9 O
.	359 1 O

OBJECTIVE	361 9 O
:	370 1 O
We	372 2 O
aimed	375 5 O
to	381 2 O
evaluate	384 8 O
the	393 3 O
rates	397 5 O
of	403 2 O
cisplatin	406 9 B-Chemical
-	415 1 O
induced	416 7 O
nephrotoxicity	424 14 B-Disease
in	439 2 O
cancer	442 6 B-Disease
patients	449 8 O
receiving	458 9 O
single	468 6 O
-	474 1 O
agent	475 5 O
cisplatin	481 9 B-Chemical
with	491 4 O
and	496 3 O
without	500 7 O
mannitol	508 8 B-Chemical
.	516 1 O

METHODS	518 7 O
:	525 1 O
This	527 4 O
single	532 6 O
-	538 1 O
center	539 6 O
retrospective	546 13 O
analysis	560 8 O
was	569 3 O
a	573 1 O
quasi	575 5 O
experiment	581 10 O
created	592 7 O
by	600 2 O
the	603 3 O
national	607 8 O
mannitol	616 8 B-Chemical
shortage	625 8 O
.	633 1 O

Data	635 4 O
were	640 4 O
collected	645 9 O
on	655 2 O
adult	658 5 O
cancer	664 6 B-Disease
patients	671 8 O
receiving	680 9 O
single	690 6 O
-	696 1 O
agent	697 5 O
cisplatin	703 9 B-Chemical
as	713 2 O
an	716 2 O
outpatient	719 10 O
from	730 4 O
January	735 7 O
2011	743 4 O
to	748 2 O
September	751 9 O
2012	761 4 O
.	765 1 O

The	767 3 O
primary	771 7 O
outcome	779 7 O
was	787 3 O
acute	791 5 B-Disease
kidney	797 6 I-Disease
injury	804 6 I-Disease
(	811 1 O
AKI	812 3 B-Disease
)	815 1 O
.	816 1 O

RESULTS	818 7 O
:	825 1 O
We	827 2 O
evaluated	830 9 O
143	840 3 O
patients	844 8 O
who	853 3 O
received	857 8 O
single	866 6 O
-	872 1 O
agent	873 5 O
cisplatin	879 9 B-Chemical
;	888 1 O
97	890 2 O
.	892 1 O
2	893 1 O
%	894 1 O
of	896 2 O
patients	899 8 O
had	908 3 O
head	912 4 B-Disease
and	917 3 I-Disease
neck	921 4 I-Disease
cancer	926 6 I-Disease
as	933 2 O
their	936 5 O
primary	942 7 O
malignancy	950 10 B-Disease
.	960 1 O

Patients	962 8 O
who	971 3 O
did	975 3 O
not	979 3 O
receive	983 7 O
mannitol	991 8 B-Chemical
were	1000 4 O
more	1005 4 O
likely	1010 6 O
to	1017 2 O
develop	1020 7 O
nephrotoxicity	1028 14 B-Disease
:	1042 1 O
odds	1044 4 O
ratio	1049 5 O
[	1055 1 O
OR	1056 2 O
]	1058 1 O
=	1060 1 O
2	1062 1 O
.	1063 1 O
646	1064 3 O
(	1068 1 O
95	1069 2 O
%	1071 1 O
CI	1073 2 O
=	1076 1 O
1	1078 1 O
.	1079 1 O
008	1080 3 O
,	1083 1 O
6	1085 1 O
.	1086 1 O
944	1087 3 O
;	1090 1 O
P	1092 1 O
=	1094 1 O
0	1096 1 O
.	1097 1 O
048	1098 3 O
)	1101 1 O
.	1102 1 O

Patients	1104 8 O
who	1113 3 O
received	1117 8 O
the	1126 3 O
100	1130 3 O
mg	1134 2 O
/	1136 1 O
m	1137 1 O
(	1138 1 O
2	1139 1 O
)	1140 1 O
dosing	1142 6 O
and	1149 3 O
patients	1153 8 O
who	1162 3 O
had	1166 3 O
a	1170 1 O
history	1172 7 O
of	1180 2 O
hypertension	1183 12 B-Disease
also	1196 4 O
had	1201 3 O
a	1205 1 O
higher	1207 6 O
likelihood	1214 10 O
of	1225 2 O
developing	1228 10 O
nephrotoxicity	1239 14 B-Disease
:	1253 1 O
OR	1255 2 O
=	1258 1 O
11	1260 2 O
.	1262 1 O
494	1263 3 O
(	1267 1 O
95	1268 2 O
%	1270 1 O
CI	1272 2 O
=	1275 1 O
4	1277 1 O
.	1278 1 O
149	1279 3 O
,	1282 1 O
32	1284 2 O
.	1286 1 O
258	1287 3 O
;	1290 1 O
P	1292 1 O
<	1294 1 O
0	1296 1 O
.	1297 1 O
0001	1298 4 O
)	1302 1 O
and	1304 3 O
OR	1308 2 O
=	1311 1 O
3	1313 1 O
.	1314 1 O
219	1315 3 O
(	1319 1 O
95	1320 2 O
%	1322 1 O
CI	1324 2 O
=	1327 1 O
1	1329 1 O
.	1330 1 O
228	1331 3 O
,	1334 1 O
8	1336 1 O
.	1337 1 O
439	1338 3 O
;	1341 1 O
P	1343 1 O
=	1345 1 O
0	1347 1 O
.	1348 1 O
017	1349 3 O
)	1352 1 O
,	1353 1 O
respectively	1355 12 O
.	1367 1 O

CONCLUSIONS	1369 11 O
:	1380 1 O
When	1382 4 O
limited	1387 7 O
quantities	1395 10 O
of	1406 2 O
mannitol	1409 8 B-Chemical
are	1418 3 O
available	1422 9 O
,	1431 1 O
it	1433 2 O
should	1436 6 O
preferentially	1443 14 O
be	1458 2 O
given	1461 5 O
to	1467 2 O
patients	1470 8 O
at	1479 2 O
particularly	1482 12 O
high	1495 4 O
risk	1500 4 O
of	1505 2 O
nephrotoxicity	1508 14 B-Disease
.	1522 1 O

Our	1524 3 O
analysis	1528 8 O
suggests	1537 8 O
that	1546 4 O
those	1551 5 O
patients	1557 8 O
receiving	1566 9 O
the	1576 3 O
dosing	1580 6 O
schedule	1587 8 O
of	1596 2 O
100	1599 3 O
mg	1603 2 O
/	1605 1 O
m	1606 1 O
(	1607 1 O
2	1608 1 O
)	1609 1 O
cisplatin	1611 9 B-Chemical
every	1621 5 O
3	1627 1 O
weeks	1629 5 O
and	1635 3 O
those	1639 5 O
with	1645 4 O
hypertension	1650 12 B-Disease
are	1663 3 O
at	1667 2 O
the	1670 3 O
greatest	1674 8 O
risk	1683 4 O
of	1688 2 O
nephrotoxicity	1691 14 B-Disease
and	1706 3 O
would	1710 5 O
benefit	1716 7 O
from	1724 4 O
the	1729 3 O
addition	1733 8 O
of	1742 2 O
mannitol	1745 8 B-Chemical
.	1753 1 O

Metformin	0 9 B-Chemical
protects	10 8 O
against	19 7 O
seizures	27 8 B-Disease
,	35 1 O
learning	37 8 B-Disease
and	46 3 I-Disease
memory	50 6 I-Disease
impairments	57 11 I-Disease
and	69 3 O
oxidative	73 9 O
damage	83 6 O
induced	90 7 O
by	98 2 O
pentylenetetrazole	101 18 B-Chemical
-	119 1 O
induced	120 7 O
kindling	128 8 O
in	137 2 O
mice	140 4 O
.	144 1 O

Cognitive	146 9 B-Disease
impairment	156 10 I-Disease
,	166 1 O
the	168 3 O
most	172 4 O
common	177 6 O
and	184 3 O
severe	188 6 O
comorbidity	195 11 O
of	207 2 O
epilepsy	210 8 B-Disease
,	218 1 O
greatly	220 7 O
diminishes	228 10 O
the	239 3 O
quality	243 7 O
of	251 2 O
life	254 4 O
.	258 1 O

However	260 7 O
,	267 1 O
current	269 7 O
therapeutic	277 11 O
interventions	289 13 O
for	303 3 O
epilepsy	307 8 B-Disease
can	316 3 O
also	320 4 O
cause	325 5 O
untoward	331 8 O
cognitive	340 9 O
effects	350 7 O
.	357 1 O

Thus	359 4 O
,	363 1 O
there	365 5 O
is	371 2 O
an	374 2 O
urgent	377 6 O
need	384 4 O
for	389 3 O
new	393 3 O
kinds	397 5 O
of	403 2 O
agents	406 6 O
targeting	413 9 O
both	423 4 O
seizures	428 8 B-Disease
and	437 3 O
cognition	441 9 B-Disease
deficits	451 8 I-Disease
.	459 1 O

Oxidative	461 9 O
stress	471 6 O
is	478 2 O
considered	481 10 O
to	492 2 O
play	495 4 O
an	500 2 O
important	503 9 O
role	513 4 O
in	518 2 O
epileptogenesis	521 15 O
and	537 3 O
cognitive	541 9 B-Disease
deficits	551 8 I-Disease
,	559 1 O
and	561 3 O
antioxidants	565 12 O
have	578 4 O
a	583 1 O
putative	585 8 O
antiepileptic	594 13 O
potential	608 9 O
.	617 1 O

Metformin	619 9 B-Chemical
,	628 1 O
the	630 3 O
most	634 4 O
commonly	639 8 O
prescribed	648 10 O
antidiabetic	659 12 O
oral	672 4 O
drug	677 4 O
,	681 1 O
has	683 3 O
antioxidant	687 11 O
properties	699 10 O
.	709 1 O

This	711 4 O
study	716 5 O
was	722 3 O
designed	726 8 O
to	735 2 O
evaluate	738 8 O
the	747 3 O
ameliorative	751 12 O
effects	764 7 O
of	772 2 O
metformin	775 9 B-Chemical
on	785 2 O
seizures	788 8 B-Disease
,	796 1 O
cognitive	798 9 B-Disease
impairment	808 10 I-Disease
and	819 3 O
brain	823 5 O
oxidative	829 9 O
stress	839 6 O
markers	846 7 O
observed	854 8 O
in	863 2 O
pentylenetetrazole	866 18 B-Chemical
-	884 1 O
induced	885 7 O
kindling	893 8 O
animals	902 7 O
.	909 1 O

Male	911 4 O
C57BL	916 5 O
/	921 1 O
6	922 1 O
mice	924 4 O
were	929 4 O
administered	934 12 O
with	947 4 O
subconvulsive	952 13 O
dose	966 4 O
of	971 2 O
pentylenetetrazole	974 18 B-Chemical
(	993 1 O
37	994 2 O
mg	997 2 O
/	999 1 O
kg	1000 2 O
,	1002 1 O
i	1004 1 O
.	1005 1 O
p	1006 1 O
.	1007 1 O
)	1008 1 O
every	1010 5 O
other	1016 5 O
day	1022 3 O
for	1026 3 O
14	1030 2 O
injections	1033 10 O
.	1043 1 O

Metformin	1045 9 B-Chemical
was	1055 3 O
injected	1059 8 O
intraperitoneally	1068 17 O
in	1086 2 O
dose	1089 4 O
of	1094 2 O
200mg	1097 5 O
/	1102 1 O
kg	1103 2 O
along	1106 5 O
with	1112 4 O
alternate	1117 9 O
-	1126 1 O
day	1127 3 O
PTZ	1131 3 B-Chemical
.	1134 1 O

We	1136 2 O
found	1139 5 O
that	1145 4 O
metformin	1150 9 B-Chemical
suppressed	1160 10 O
the	1171 3 O
progression	1175 11 O
of	1187 2 O
kindling	1190 8 O
,	1198 1 O
ameliorated	1200 11 O
the	1212 3 O
cognitive	1216 9 B-Disease
impairment	1226 10 I-Disease
and	1237 3 O
decreased	1241 9 O
brain	1251 5 O
oxidative	1257 9 O
stress	1267 6 O
.	1273 1 O

Thus	1275 4 O
the	1280 3 O
present	1284 7 O
study	1292 5 O
concluded	1298 9 O
that	1308 4 O
metformin	1313 9 B-Chemical
may	1323 3 O
be	1327 2 O
a	1330 1 O
potential	1332 9 O
agent	1342 5 O
for	1348 3 O
the	1352 3 O
treatment	1356 9 O
of	1366 2 O
epilepsy	1369 8 B-Disease
as	1378 2 O
well	1381 4 O
as	1386 2 O
a	1389 1 O
protective	1391 10 O
medicine	1402 8 O
against	1411 7 O
cognitive	1419 9 B-Disease
impairment	1429 10 I-Disease
induced	1440 7 O
by	1448 2 O
seizures	1451 8 B-Disease
.	1459 1 O

P53	0 3 O
inhibition	4 10 O
exacerbates	15 11 O
late	27 4 O
-	31 1 O
stage	32 5 O
anthracycline	38 13 B-Chemical
cardiotoxicity	52 14 B-Disease
.	66 1 O

AIMS	68 4 O
:	72 1 O
Doxorubicin	74 11 B-Chemical
(	86 1 O
DOX	87 3 B-Chemical
)	90 1 O
is	92 2 O
an	95 2 O
effective	98 9 O
anti	108 4 O
-	112 1 O
cancer	113 6 B-Disease
therapeutic	120 11 O
,	131 1 O
but	133 3 O
is	137 2 O
associated	140 10 O
with	151 4 O
both	156 4 O
acute	161 5 O
and	167 3 O
late	171 4 O
-	175 1 O
stage	176 5 O
cardiotoxicity	182 14 B-Disease
.	196 1 O

Children	198 8 O
are	207 3 O
particularly	211 12 O
sensitive	224 9 O
to	234 2 O
DOX	237 3 B-Chemical
-	240 1 O
induced	241 7 O
heart	249 5 B-Disease
failure	255 7 I-Disease
.	262 1 O

Here	264 4 O
,	268 1 O
the	270 3 O
impact	274 6 O
of	281 2 O
p53	284 3 O
inhibition	288 10 O
on	299 2 O
acute	302 5 O
vs	308 2 O
.	310 1 O
late	312 4 O
-	316 1 O
stage	317 5 O
DOX	323 3 B-Chemical
cardiotoxicity	327 14 B-Disease
was	342 3 O
examined	346 8 O
in	355 2 O
a	358 1 O
juvenile	360 8 O
model	369 5 O
.	374 1 O

METHODS	376 7 O
AND	384 3 O
RESULTS	388 7 O
:	395 1 O
Two	397 3 O
-	400 1 O
week	401 4 O
-	405 1 O
old	406 3 O
MHC	410 3 O
-	413 1 O
CB7	414 3 O
mice	418 4 O
(	423 1 O
which	424 5 O
express	430 7 O
dominant	438 8 O
-	446 1 O
interfering	447 11 O
p53	459 3 O
in	463 2 O
cardiomyocytes	466 14 O
)	480 1 O
and	482 3 O
their	486 5 O
non	492 3 O
-	495 1 O
transgenic	496 10 O
(	507 1 O
NON	508 3 O
-	511 1 O
TXG	512 3 O
)	515 1 O
littermates	517 11 O
received	529 8 O
weekly	538 6 O
DOX	545 3 B-Chemical
injections	549 10 O
for	560 3 O
5	564 1 O
weeks	566 5 O
(	572 1 O
25	573 2 O
mg	576 2 O
/	578 1 O
kg	579 2 O
cumulative	582 10 O
dose	593 4 O
)	597 1 O
.	598 1 O

One	600 3 O
week	604 4 O
after	609 5 O
the	615 3 O
last	619 4 O
DOX	624 3 B-Chemical
treatment	628 9 O
(	638 1 O
acute	639 5 O
stage	645 5 O
)	650 1 O
,	651 1 O
MHC	653 3 O
-	656 1 O
CB7	657 3 O
mice	661 4 O
exhibited	666 9 O
improved	676 8 O
cardiac	685 7 O
function	693 8 O
and	702 3 O
lower	706 5 O
levels	712 6 O
of	719 2 O
cardiomyocyte	722 13 O
apoptosis	736 9 O
when	746 4 O
compared	751 8 O
with	760 4 O
the	765 3 O
NON	769 3 O
-	772 1 O
TXG	773 3 O
mice	777 4 O
.	781 1 O

Surprisingly	783 12 O
,	795 1 O
by	797 2 O
13	800 2 O
weeks	803 5 O
following	809 9 O
the	819 3 O
last	823 4 O
DOX	828 3 B-Chemical
treatment	832 9 O
(	842 1 O
late	843 4 O
stage	848 5 O
)	853 1 O
,	854 1 O
MHC	856 3 O
-	859 1 O
CB7	860 3 O
exhibited	864 9 O
a	874 1 O
progressive	876 11 O
decrease	888 8 O
in	897 2 O
cardiac	900 7 O
function	908 8 O
and	917 3 O
higher	921 6 O
rates	928 5 O
of	934 2 O
cardiomyocyte	937 13 O
apoptosis	951 9 O
when	961 4 O
compared	966 8 O
with	975 4 O
NON	980 3 O
-	983 1 O
TXG	984 3 O
mice	988 4 O
.	992 1 O

p53	994 3 O
inhibition	998 10 O
blocked	1009 7 O
transient	1017 9 O
DOX	1027 3 B-Chemical
-	1030 1 O
induced	1031 7 O
STAT3	1039 5 O
activation	1045 10 O
in	1056 2 O
MHC	1059 3 O
-	1062 1 O
CB7	1063 3 O
mice	1067 4 O
,	1071 1 O
which	1073 5 O
was	1079 3 O
associated	1083 10 O
with	1094 4 O
enhanced	1099 8 O
induction	1108 9 O
of	1118 2 O
the	1121 3 O
DNA	1125 3 O
repair	1129 6 O
proteins	1136 8 O
Ku70	1145 4 O
and	1150 3 O
Ku80	1154 4 O
.	1158 1 O

Mice	1160 4 O
with	1165 4 O
cardiomyocyte	1170 13 O
-	1183 1 O
restricted	1184 10 O
deletion	1195 8 O
of	1204 2 O
STAT3	1207 5 O
exhibited	1213 9 O
worse	1223 5 O
cardiac	1229 7 O
function	1237 8 O
,	1245 1 O
higher	1247 6 O
levels	1254 6 O
of	1261 2 O
cardiomyocyte	1264 13 O
apoptosis	1278 9 O
,	1287 1 O
and	1289 3 O
a	1293 1 O
greater	1295 7 O
induction	1303 9 O
of	1313 2 O
Ku70	1316 4 O
and	1321 3 O
Ku80	1325 4 O
in	1330 2 O
response	1333 8 O
to	1342 2 O
DOX	1345 3 B-Chemical
treatment	1349 9 O
during	1359 6 O
the	1366 3 O
acute	1370 5 O
stage	1376 5 O
when	1382 4 O
compared	1387 8 O
with	1396 4 O
control	1401 7 O
animals	1409 7 O
.	1416 1 O

CONCLUSION	1418 10 O
:	1428 1 O
These	1430 5 O
data	1436 4 O
support	1441 7 O
a	1449 1 O
model	1451 5 O
wherein	1457 7 O
a	1465 1 O
p53	1467 3 O
-	1470 1 O
dependent	1471 9 O
cardioprotective	1481 16 O
pathway	1498 7 O
,	1505 1 O
mediated	1507 8 O
via	1516 3 O
STAT3	1520 5 O
activation	1526 10 O
,	1536 1 O
mitigates	1538 9 O
DOX	1548 3 B-Chemical
-	1551 1 O
induced	1552 7 O
myocardial	1560 10 O
stress	1571 6 O
during	1578 6 O
drug	1585 4 O
delivery	1590 8 O
.	1598 1 O

Furthermore	1600 11 O
,	1611 1 O
these	1613 5 O
data	1619 4 O
suggest	1624 7 O
an	1632 2 O
explanation	1635 11 O
as	1647 2 O
to	1650 2 O
how	1653 3 O
p53	1657 3 O
inhibition	1661 10 O
can	1672 3 O
result	1676 6 O
in	1683 2 O
cardioprotection	1686 16 O
during	1703 6 O
drug	1710 4 O
treatment	1715 9 O
and	1725 3 O
,	1728 1 O
paradoxically	1730 13 O
,	1743 1 O
enhanced	1745 8 O
cardiotoxicity	1754 14 B-Disease
long	1769 4 O
after	1774 5 O
the	1780 3 O
cessation	1784 9 O
of	1794 2 O
drug	1797 4 O
treatment	1802 9 O
.	1811 1 O

Metronidazole	0 13 B-Chemical
-	13 1 O
induced	14 7 O
encephalopathy	22 14 B-Disease
:	36 1 O
an	38 2 O
uncommon	41 8 O
scenario	50 8 O
.	58 1 O

Metronidazole	60 13 B-Chemical
can	74 3 O
produce	78 7 O
neurological	86 12 O
complications	99 13 O
although	113 8 O
it	122 2 O
is	125 2 O
not	128 3 O
a	132 1 O
common	134 6 O
scenario	141 8 O
.	149 1 O

We	151 2 O
present	154 7 O
a	162 1 O
case	164 4 O
where	169 5 O
a	175 1 O
patient	177 7 O
developed	185 9 O
features	195 8 O
of	204 2 O
encephalopathy	207 14 B-Disease
following	222 9 O
prolonged	232 9 O
metronidazole	242 13 B-Chemical
intake	256 6 O
.	262 1 O

Magnetic	264 8 O
resonance	273 9 O
imaging	283 7 O
(	291 1 O
MRI	292 3 O
)	295 1 O
brain	297 5 O
showed	303 6 O
abnormal	310 8 O
signal	319 6 O
intensity	326 9 O
involving	336 9 O
both	346 4 O
dentate	351 7 O
nuclei	359 6 O
of	366 2 O
cerebellum	369 10 O
and	380 3 O
splenium	384 8 O
of	393 2 O
corpus	396 6 O
callosum	403 8 O
.	411 1 O

The	413 3 O
diagnosis	417 9 O
of	427 2 O
metronidazole	430 13 B-Chemical
toxicity	444 8 B-Disease
was	453 3 O
made	457 4 O
by	462 2 O
the	465 3 O
MRI	469 3 O
findings	473 8 O
and	482 3 O
supported	486 9 O
clinically	496 10 O
.	506 1 O

Aconitine	0 9 B-Chemical
-	9 1 O
induced	10 7 O
Ca2	18 3 B-Chemical
+	21 1 O
overload	23 8 O
causes	32 6 O
arrhythmia	39 10 B-Disease
and	50 3 O
triggers	54 8 O
apoptosis	63 9 O
through	73 7 O
p38	81 3 O
MAPK	85 4 O
signaling	90 9 O
pathway	100 7 O
in	108 2 O
rats	111 4 O
.	115 1 O

Aconitine	117 9 B-Chemical
is	127 2 O
a	130 1 O
major	132 5 O
bioactive	138 9 O
diterpenoid	148 11 O
alkaloid	160 8 O
with	169 4 O
high	174 4 O
content	179 7 O
derived	187 7 O
from	195 4 O
herbal	200 6 O
aconitum	207 8 O
plants	216 6 O
.	222 1 O

Emerging	224 8 O
evidence	233 8 O
indicates	242 9 O
that	252 4 O
voltage	257 7 O
-	264 1 O
dependent	265 9 O
Na	275 2 B-Chemical
(	277 1 O
+	278 1 O
)	279 1 O
channels	281 8 O
have	290 4 O
pivotal	295 7 O
roles	303 5 O
in	309 2 O
the	312 3 O
cardiotoxicity	316 14 B-Disease
of	331 2 O
aconitine	334 9 B-Chemical
.	343 1 O

However	345 7 O
,	352 1 O
no	354 2 O
reports	357 7 O
are	365 3 O
available	369 9 O
on	379 2 O
the	382 3 O
role	386 4 O
of	391 2 O
Ca	394 2 B-Chemical
(	396 1 O
2	397 1 O
+	398 1 O
)	399 1 O
in	401 2 O
aconitine	404 9 B-Chemical
poisoning	414 9 B-Disease
.	423 1 O

In	425 2 O
this	428 4 O
study	433 5 O
,	438 1 O
we	440 2 O
explored	443 8 O
the	452 3 O
importance	456 10 O
of	467 2 O
pathological	470 12 O
Ca	483 2 B-Chemical
(	485 1 O
2	486 1 O
+	487 1 O
)	488 1 O
signaling	490 9 O
in	500 2 O
aconitine	503 9 B-Chemical
poisoning	513 9 B-Disease
in	523 2 O
vitro	526 5 O
and	532 3 O
in	536 2 O
vivo	539 4 O
.	543 1 O

We	545 2 O
found	548 5 O
that	554 4 O
Ca	559 2 B-Chemical
(	561 1 O
2	562 1 O
+	563 1 O
)	564 1 O
overload	566 8 O
lead	575 4 O
to	580 2 O
accelerated	583 11 O
beating	595 7 O
rhythm	603 6 O
in	610 2 O
adult	613 5 O
rat	619 3 O
ventricular	623 11 O
myocytes	635 8 O
and	644 3 O
caused	648 6 O
arrhythmia	655 10 B-Disease
in	666 2 O
conscious	669 9 O
freely	679 6 O
moving	686 6 O
rats	693 4 O
.	697 1 O

To	699 2 O
investigate	702 11 O
effects	714 7 O
of	722 2 O
aconitine	725 9 B-Chemical
on	735 2 O
myocardial	738 10 B-Disease
injury	749 6 I-Disease
,	755 1 O
we	757 2 O
performed	760 9 O
cytotoxicity	770 12 B-Disease
assay	783 5 O
in	789 2 O
neonatal	792 8 O
rat	801 3 O
ventricular	805 11 O
myocytes	817 8 O
(	826 1 O
NRVMs	827 5 O
)	832 1 O
,	833 1 O
as	835 2 O
well	838 4 O
as	843 2 O
measured	846 8 O
lactate	855 7 B-Chemical
dehydrogenase	863 13 O
level	877 5 O
in	883 2 O
the	886 3 O
culture	890 7 O
medium	898 6 O
of	905 2 O
NRVMs	908 5 O
and	914 3 O
activities	918 10 O
of	929 2 O
serum	932 5 O
cardiac	938 7 O
enzymes	946 7 O
in	954 2 O
rats	957 4 O
.	961 1 O

The	963 3 O
results	967 7 O
showed	975 6 O
that	982 4 O
aconitine	987 9 B-Chemical
resulted	997 8 O
in	1006 2 O
myocardial	1009 10 B-Disease
injury	1020 6 I-Disease
and	1027 3 O
reduced	1031 7 O
NRVMs	1039 5 O
viability	1045 9 O
dose	1055 4 O
-	1059 1 O
dependently	1060 11 O
.	1071 1 O

To	1073 2 O
confirm	1076 7 O
the	1084 3 O
pro	1088 3 O
-	1091 1 O
apoptotic	1092 9 O
effects	1102 7 O
,	1109 1 O
we	1111 2 O
performed	1114 9 O
flow	1124 4 O
cytometric	1129 10 O
detection	1140 9 O
,	1149 1 O
cardiac	1151 7 O
histology	1159 9 O
,	1168 1 O
transmission	1170 12 O
electron	1183 8 O
microscopy	1192 10 O
and	1203 3 O
terminal	1207 8 O
deoxynucleotidyl	1216 16 O
transferase	1233 11 O
-	1244 1 O
mediated	1245 8 O
dUTP	1254 4 B-Chemical
-	1258 1 O
biotin	1259 6 B-Chemical
nick	1266 4 O
end	1271 3 O
labeling	1275 8 O
assay	1284 5 O
.	1289 1 O

The	1291 3 O
results	1295 7 O
showed	1303 6 O
that	1310 4 O
aconitine	1315 9 B-Chemical
stimulated	1325 10 O
apoptosis	1336 9 O
time	1346 4 O
-	1350 1 O
dependently	1351 11 O
.	1362 1 O

The	1364 3 O
expression	1368 10 O
analysis	1379 8 O
of	1388 2 O
Ca	1391 2 B-Chemical
(	1393 1 O
2	1394 1 O
+	1395 1 O
)	1396 1 O
handling	1398 8 O
proteins	1407 8 O
demonstrated	1416 12 O
that	1429 4 O
aconitine	1434 9 B-Chemical
promoted	1444 8 O
Ca	1453 2 B-Chemical
(	1455 1 O
2	1456 1 O
+	1457 1 O
)	1458 1 O
overload	1460 8 O
through	1469 7 O
the	1477 3 O
expression	1481 10 O
regulation	1492 10 O
of	1503 2 O
Ca	1506 2 B-Chemical
(	1508 1 O
2	1509 1 O
+	1510 1 O
)	1511 1 O
handling	1513 8 O
proteins	1522 8 O
.	1530 1 O

The	1532 3 O
expression	1536 10 O
analysis	1547 8 O
of	1556 2 O
apoptosis	1559 9 O
-	1568 1 O
related	1569 7 O
proteins	1577 8 O
revealed	1586 8 O
that	1595 4 O
pro	1600 3 O
-	1603 1 O
apoptotic	1604 9 O
protein	1614 7 O
expression	1622 10 O
was	1633 3 O
upregulated	1637 11 O
,	1648 1 O
and	1650 3 O
anti	1654 4 O
-	1658 1 O
apoptotic	1659 9 O
protein	1669 7 O
BCL	1677 3 O
-	1680 1 O
2	1681 1 O
expression	1683 10 O
was	1694 3 O
downregulated	1698 13 O
.	1711 1 O

Furthermore	1713 11 O
,	1724 1 O
increased	1726 9 O
phosphorylation	1736 15 O
of	1752 2 O
MAPK	1755 4 O
family	1760 6 O
members	1767 7 O
,	1774 1 O
especially	1776 10 O
the	1787 3 O
P	1791 1 O
-	1792 1 O
P38	1793 3 O
/	1796 1 O
P38	1797 3 O
ratio	1801 5 O
was	1807 3 O
found	1811 5 O
in	1817 2 O
cardiac	1820 7 O
tissues	1828 7 O
.	1835 1 O

Hence	1837 5 O
,	1842 1 O
our	1844 3 O
results	1848 7 O
suggest	1856 7 O
that	1864 4 O
aconitine	1869 9 B-Chemical
significantly	1879 13 O
aggravates	1893 10 O
Ca	1904 2 B-Chemical
(	1906 1 O
2	1907 1 O
+	1908 1 O
)	1909 1 O
overload	1911 8 O
and	1920 3 O
causes	1924 6 O
arrhythmia	1931 10 B-Disease
and	1942 3 O
finally	1946 7 O
promotes	1954 8 O
apoptotic	1963 9 O
development	1973 11 O
via	1985 3 O
phosphorylation	1989 15 O
of	2005 2 O
P38	2008 3 O
mitogen	2012 7 O
-	2019 1 O
activated	2020 9 O
protein	2030 7 O
kinase	2038 6 O
.	2044 1 O

Chronic	0 7 O
treatment	8 9 O
with	18 4 O
metformin	23 9 B-Chemical
suppresses	33 10 O
toll	44 4 O
-	48 1 O
like	49 4 O
receptor	54 8 O
4	63 1 O
signaling	65 9 O
and	75 3 O
attenuates	79 10 O
left	90 4 B-Disease
ventricular	95 11 I-Disease
dysfunction	107 11 I-Disease
following	119 9 O
myocardial	129 10 B-Disease
infarction	140 10 I-Disease
.	150 1 O

Acute	152 5 O
treatment	158 9 O
with	168 4 O
metformin	173 9 B-Chemical
has	183 3 O
a	187 1 O
protective	189 10 O
effect	200 6 O
in	207 2 O
myocardial	210 10 B-Disease
infarction	221 10 I-Disease
by	232 2 O
suppression	235 11 O
of	247 2 O
inflammatory	250 12 O
responses	263 9 O
due	273 3 O
to	277 2 O
activation	280 10 O
of	291 2 O
AMP	294 3 B-Chemical
-	297 1 O
activated	298 9 O
protein	308 7 O
kinase	316 6 O
(	323 1 O
AMPK	324 4 O
)	328 1 O
.	329 1 O

In	331 2 O
the	334 3 O
present	338 7 O
study	346 5 O
,	351 1 O
the	353 3 O
effect	357 6 O
of	364 2 O
chronic	367 7 O
pre	375 3 O
-	378 1 O
treatment	379 9 O
with	389 4 O
metformin	394 9 B-Chemical
on	404 2 O
cardiac	407 7 B-Disease
dysfunction	415 11 I-Disease
and	427 3 O
toll	431 4 O
-	435 1 O
like	436 4 O
receptor	441 8 O
4	450 1 O
(	452 1 O
TLR4	453 4 O
)	457 1 O
activities	459 10 O
following	470 9 O
myocardial	480 10 B-Disease
infarction	491 10 I-Disease
and	502 3 O
their	506 5 O
relation	512 8 O
with	521 4 O
AMPK	526 4 O
were	531 4 O
assessed	536 8 O
.	544 1 O

Male	546 4 O
Wistar	551 6 O
rats	558 4 O
were	563 4 O
randomly	568 8 O
assigned	577 8 O
to	586 2 O
one	589 3 O
of	593 2 O
5	596 1 O
groups	598 6 O
(	605 1 O
n	606 1 O
=	607 1 O
6	608 1 O
)	609 1 O
:	610 1 O
normal	612 6 O
control	619 7 O
and	627 3 O
groups	631 6 O
were	638 4 O
injected	643 8 O
isoproterenol	652 13 B-Chemical
after	666 5 O
chronic	672 7 O
pre	680 3 O
-	683 1 O
treatment	684 9 O
with	694 4 O
0	699 1 O
,	700 1 O
25	702 2 O
,	704 1 O
50	706 2 O
,	708 1 O
or	710 2 O
100mg	713 5 O
/	718 1 O
kg	719 2 O
of	722 2 O
metformin	725 9 B-Chemical
twice	735 5 O
daily	741 5 O
for	747 3 O
14	751 2 O
days	754 4 O
.	758 1 O

Isoproterenol	760 13 B-Chemical
(	774 1 O
100mg	775 5 O
/	780 1 O
kg	781 2 O
)	783 1 O
was	785 3 O
injected	789 8 O
subcutaneously	798 14 O
on	813 2 O
the	816 3 O
13th	820 4 O
and	825 3 O
14th	829 4 O
days	834 4 O
to	839 2 O
induce	842 6 O
acute	849 5 B-Disease
myocardial	855 10 I-Disease
infarction	866 10 I-Disease
.	876 1 O

Isoproterenol	878 13 B-Chemical
alone	892 5 O
decreased	898 9 O
left	908 4 O
ventricular	913 11 O
systolic	925 8 O
pressure	934 8 O
and	943 3 O
myocardial	947 10 O
contractility	958 13 O
indexed	972 7 O
as	980 2 O
LVdp	983 4 O
/	987 1 O
dtmax	988 5 O
and	994 3 O
LVdp	998 4 O
/	1002 1 O
dtmin	1003 5 O
.	1008 1 O

The	1010 3 O
left	1014 4 B-Disease
ventricular	1019 11 I-Disease
dysfunction	1031 11 I-Disease
was	1043 3 O
significantly	1047 13 O
lower	1061 5 O
in	1067 2 O
the	1070 3 O
groups	1074 6 O
treated	1081 7 O
with	1089 4 O
25	1094 2 O
and	1097 3 O
50mg	1101 4 O
/	1105 1 O
kg	1106 2 O
of	1109 2 O
metformin	1112 9 B-Chemical
.	1121 1 O

Metfromin	1123 9 O
markedly	1133 8 O
lowered	1142 7 O
isoproterenol	1150 13 B-Chemical
-	1163 1 O
induced	1164 7 O
elevation	1172 9 O
in	1182 2 O
the	1185 3 O
levels	1189 6 O
of	1196 2 O
TLR4	1199 4 O
mRNA	1204 4 O
,	1208 1 O
myeloid	1210 7 O
differentiation	1218 15 O
protein	1234 7 O
88	1242 2 O
(	1245 1 O
MyD88	1246 5 O
)	1251 1 O
,	1252 1 O
tumor	1254 5 B-Disease
necrosis	1260 8 B-Disease
factor	1269 6 O
-	1275 1 O
alpha	1276 5 O
(	1282 1 O
TNF	1283 3 O
-	1286 1 O
a	1287 1 O
)	1288 1 O
,	1289 1 O
and	1291 3 O
interleukin	1295 11 O
6	1307 1 O
(	1309 1 O
IL	1310 2 O
-	1312 1 O
6	1313 1 O
)	1314 1 O
in	1316 2 O
the	1319 3 O
heart	1323 5 O
tissues	1329 7 O
.	1336 1 O

Similar	1338 7 O
changes	1346 7 O
were	1354 4 O
also	1359 4 O
seen	1364 4 O
in	1369 2 O
the	1372 3 O
serum	1376 5 O
levels	1382 6 O
of	1389 2 O
TNF	1392 3 O
-	1395 1 O
a	1396 1 O
and	1398 3 O
IL	1402 2 O
-	1404 1 O
6	1405 1 O
.	1406 1 O

However	1408 7 O
,	1415 1 O
the	1417 3 O
lower	1421 5 O
doses	1427 5 O
of	1433 2 O
25	1436 2 O
and	1439 3 O
50mg	1443 4 O
/	1447 1 O
kg	1448 2 O
were	1451 4 O
more	1456 4 O
effective	1461 9 O
than	1471 4 O
100mg	1476 5 O
/	1481 1 O
kg	1482 2 O
.	1484 1 O

Phosphorylated	1486 14 O
AMPKa	1501 5 O
(	1507 1 O
p	1508 1 O
-	1509 1 O
AMPK	1510 4 O
)	1514 1 O
in	1516 2 O
the	1519 3 O
myocardium	1523 10 O
was	1534 3 O
significantly	1538 13 O
elevated	1552 8 O
by	1561 2 O
25mg	1564 4 O
/	1568 1 O
kg	1569 2 O
of	1572 2 O
metformin	1575 9 B-Chemical
,	1584 1 O
slightly	1586 8 O
by	1595 2 O
50mg	1598 4 O
/	1602 1 O
kg	1603 2 O
,	1605 1 O
but	1607 3 O
not	1611 3 O
by	1615 2 O
100mg	1618 5 O
/	1623 1 O
kg	1624 2 O
.	1626 1 O

Chronic	1628 7 O
pre	1636 3 O
-	1639 1 O
treatment	1640 9 O
with	1650 4 O
metformin	1655 9 B-Chemical
reduces	1665 7 O
post	1673 4 O
-	1677 1 O
myocardial	1678 10 B-Disease
infarction	1689 10 I-Disease
cardiac	1700 7 O
dysfunction	1708 11 O
and	1720 3 O
suppresses	1724 10 O
inflammatory	1735 12 O
responses	1748 9 O
,	1757 1 O
possibly	1759 8 O
through	1768 7 O
inhibition	1776 10 O
of	1787 2 O
TLR4	1790 4 O
activities	1795 10 O
.	1805 1 O

This	1807 4 O
mechanism	1812 9 O
can	1822 3 O
be	1826 2 O
considered	1829 10 O
as	1840 2 O
a	1843 1 O
target	1845 6 O
to	1852 2 O
protect	1855 7 O
infarcted	1863 9 O
myocardium	1873 10 O
.	1883 1 O

Neuroleptic	0 11 B-Disease
malignant	12 9 I-Disease
syndrome	22 8 I-Disease
induced	31 7 O
by	39 2 O
combination	42 11 O
therapy	54 7 O
with	62 4 O
tetrabenazine	67 13 B-Chemical
and	81 3 O
tiapride	85 8 B-Chemical
in	94 2 O
a	97 1 O
Japanese	99 8 O
patient	108 7 O
with	116 4 O
Huntington	121 10 B-Disease
'	131 1 I-Disease
s	132 1 I-Disease
disease	134 7 I-Disease
at	142 2 O
the	145 3 O
terminal	149 8 O
stage	158 5 O
of	164 2 O
recurrent	167 9 O
breast	177 6 B-Disease
cancer	184 6 I-Disease
.	190 1 O

We	192 2 O
herein	195 6 O
describe	202 8 O
the	211 3 O
case	215 4 O
of	220 2 O
an	223 2 O
81	226 2 O
-	228 1 O
year	229 4 O
-	233 1 O
old	234 3 O
Japanese	238 8 O
woman	247 5 O
with	253 4 O
neuroleptic	258 11 B-Disease
malignant	270 9 I-Disease
syndrome	280 8 I-Disease
that	289 4 O
occurred	294 8 O
36	303 2 O
days	306 4 O
after	311 5 O
the	317 3 O
initiation	321 10 O
of	332 2 O
combination	335 11 O
therapy	347 7 O
with	355 4 O
tiapride	360 8 B-Chemical
(	369 1 O
75	370 2 O
mg	373 2 O
/	375 1 O
day	376 3 O
)	379 1 O
and	381 3 O
tetrabenazine	385 13 B-Chemical
(	399 1 O
12	400 2 O
.	402 1 O
5	403 1 O
mg	405 2 O
/	407 1 O
day	408 3 O
)	411 1 O
for	413 3 O
Huntington	417 10 B-Disease
'	427 1 I-Disease
s	428 1 I-Disease
disease	430 7 I-Disease
.	437 1 O

The	439 3 O
patient	443 7 O
had	451 3 O
been	455 4 O
treated	460 7 O
with	468 4 O
tiapride	473 8 B-Chemical
or	482 2 O
tetrabenazine	485 13 B-Chemical
alone	499 5 O
without	505 7 O
any	513 3 O
adverse	517 7 O
effects	525 7 O
before	533 6 O
the	540 3 O
administration	544 14 O
of	559 2 O
the	562 3 O
combination	566 11 O
therapy	578 7 O
.	585 1 O

She	587 3 O
also	591 4 O
had	596 3 O
advanced	600 8 O
breast	609 6 B-Disease
cancer	616 6 I-Disease
when	623 4 O
the	628 3 O
combination	632 11 O
therapy	644 7 O
was	652 3 O
initiated	656 9 O
.	665 1 O

To	667 2 O
the	670 3 O
best	674 4 O
of	679 2 O
our	682 3 O
knowledge	686 9 O
,	695 1 O
the	697 3 O
occurrence	701 10 O
of	712 2 O
neuroleptic	715 11 B-Disease
malignant	727 9 I-Disease
syndrome	737 8 I-Disease
due	746 3 O
to	750 2 O
combination	753 11 O
therapy	765 7 O
with	773 4 O
tetrabenazine	778 13 B-Chemical
and	792 3 O
tiapride	796 8 B-Chemical
has	805 3 O
not	809 3 O
been	813 4 O
previously	818 10 O
reported	829 8 O
.	837 1 O

Tetrabenazine	839 13 B-Chemical
should	853 6 O
be	860 2 O
administered	863 12 O
very	876 4 O
carefully	881 9 O
in	891 2 O
combination	894 11 O
with	906 4 O
other	911 5 O
neuroleptic	917 11 B-Chemical
drugs	929 5 I-Chemical
,	934 1 O
particularly	936 12 O
in	949 2 O
patients	952 8 O
with	961 4 O
a	966 1 O
worsening	968 9 O
general	978 7 O
condition	986 9 O
.	995 1 O

A	0 1 O
metoprolol	2 10 B-Chemical
-	12 1 O
terbinafine	13 11 B-Chemical
combination	25 11 O
induced	37 7 O
bradycardia	45 11 B-Disease
.	56 1 O

To	58 2 O
report	61 6 O
a	68 1 O
sinus	70 5 B-Disease
bradycardia	76 11 I-Disease
induced	88 7 O
by	96 2 O
metoprolol	99 10 B-Chemical
and	110 3 O
terbinafine	114 11 B-Chemical
drug	126 4 O
-	130 1 O
drug	131 4 O
interaction	136 11 O
and	148 3 O
its	152 3 O
management	156 10 O
.	166 1 O

A	168 1 O
63	170 2 O
year	173 4 O
-	177 1 O
old	178 3 O
Caucasian	182 9 O
man	192 3 O
on	196 2 O
metoprolol	199 10 B-Chemical
200	210 3 O
mg	214 2 O
/	216 1 O
day	217 3 O
for	221 3 O
stable	225 6 O
coronary	232 8 B-Disease
artery	241 6 I-Disease
disease	248 7 I-Disease
was	256 3 O
prescribed	260 10 O
a	271 1 O
90	273 2 O
-	275 1 O
day	276 3 O
course	280 6 O
of	287 2 O
oral	290 4 O
terbinafine	295 11 B-Chemical
250	307 3 O
mg	311 2 O
/	313 1 O
day	314 3 O
for	318 3 O
onychomycosis	322 13 B-Disease
.	335 1 O

On	337 2 O
the	340 3 O
49th	344 4 O
day	349 3 O
of	353 2 O
terbinafine	356 11 B-Chemical
therapy	368 7 O
,	375 1 O
he	377 2 O
was	380 3 O
brought	384 7 O
to	392 2 O
the	395 3 O
emergency	399 9 O
room	409 4 O
for	414 3 O
a	418 1 O
decrease	420 8 O
of	429 2 O
his	432 3 O
global	436 6 O
health	443 6 O
status	450 6 O
,	456 1 O
confusion	458 9 B-Disease
and	468 3 O
falls	472 5 O
.	477 1 O

The	479 3 O
electrocardiogram	483 17 O
revealed	501 8 O
a	510 1 O
37	512 2 O
beats	515 5 O
/	520 1 O
min	521 3 O
sinus	525 5 B-Disease
bradycardia	531 11 I-Disease
.	542 1 O

A	544 1 O
score	546 5 O
of	552 2 O
7	555 1 O
on	557 2 O
the	560 3 O
Naranjo	564 7 O
adverse	572 7 B-Disease
drug	580 4 I-Disease
reaction	585 8 I-Disease
probability	594 11 O
scale	606 5 O
indicates	612 9 O
a	622 1 O
probable	624 8 O
relationship	633 12 O
between	646 7 O
the	654 3 O
patient	658 7 O
'	665 1 O
s	666 1 O
sinus	668 5 B-Disease
bradycardia	674 11 I-Disease
and	686 3 O
the	690 3 O
drug	694 4 O
interaction	699 11 O
between	711 7 O
metoprolol	719 10 B-Chemical
and	730 3 O
terbinafine	734 11 B-Chemical
.	745 1 O

The	747 3 O
heart	751 5 O
rate	757 4 O
ameliorated	762 11 O
first	774 5 O
with	780 4 O
a	785 1 O
decrease	787 8 O
in	796 2 O
the	799 3 O
dose	803 4 O
of	808 2 O
metoprolol	811 10 B-Chemical
.	821 1 O

It	823 2 O
was	826 3 O
subsequently	830 12 O
changed	843 7 O
to	851 2 O
bisoprolol	854 10 B-Chemical
and	865 3 O
the	869 3 O
heart	873 5 O
rate	879 4 O
remained	884 8 O
normal	893 6 O
.	899 1 O

By	901 2 O
inhibiting	904 10 O
the	915 3 O
cytochrome	919 10 O
P450	930 4 O
2D6	935 3 O
,	938 1 O
terbinafine	940 11 B-Chemical
had	952 3 O
decreased	956 9 O
metoprolol	966 10 B-Chemical
'	976 1 O
s	977 1 O
clearance	979 9 O
,	988 1 O
leading	990 7 O
in	998 2 O
metoprolol	1001 10 B-Chemical
accumulation	1012 12 O
which	1025 5 O
has	1031 3 O
resulted	1035 8 O
in	1044 2 O
clinically	1047 10 O
significant	1058 11 O
sinus	1070 5 B-Disease
bradycardia	1076 11 I-Disease
.	1087 1 O

Optochiasmatic	0 14 O
and	15 3 O
peripheral	19 10 B-Disease
neuropathy	30 10 I-Disease
due	41 3 O
to	45 2 O
ethambutol	48 10 B-Chemical
overtreatment	59 13 O
.	72 1 O

Ethambutol	74 10 B-Chemical
is	85 2 O
known	88 5 O
to	94 2 O
cause	97 5 O
optic	103 5 B-Disease
neuropathy	109 10 I-Disease
and	120 3 O
,	123 1 O
more	125 4 O
rarely	130 6 O
,	136 1 O
axonal	138 6 O
polyneuropathy	145 14 B-Disease
.	159 1 O

We	161 2 O
characterize	164 12 O
the	177 3 O
clinical	181 8 O
,	189 1 O
neurophysiological	191 18 O
,	209 1 O
and	211 3 O
neuroimaging	215 12 O
findings	228 8 O
in	237 2 O
a	240 1 O
72	242 2 O
-	244 1 O
year	245 4 O
-	249 1 O
old	250 3 O
man	254 3 O
who	258 3 O
developed	262 9 O
visual	272 6 B-Disease
loss	279 4 I-Disease
and	284 3 O
paresthesias	288 12 B-Disease
after	301 5 O
11	307 2 O
weeks	310 5 O
of	316 2 O
exposure	319 8 O
to	328 2 O
a	331 1 O
supratherapeutic	333 16 O
dose	350 4 O
of	355 2 O
ethambutol	358 10 B-Chemical
.	368 1 O

This	370 4 O
case	375 4 O
demonstrates	380 12 O
the	393 3 O
selective	397 9 O
vulnerability	407 13 O
of	421 2 O
the	424 3 O
anterior	428 8 O
visual	437 6 O
pathways	444 8 O
and	453 3 O
peripheral	457 10 O
nerves	468 6 O
to	475 2 O
ethambutol	478 10 B-Chemical
toxicity	489 8 B-Disease
.	497 1 O

Testosterone	0 12 B-Chemical
ameliorates	13 11 O
streptozotocin	25 14 B-Chemical
-	39 1 O
induced	40 7 O
memory	48 6 B-Disease
impairment	55 10 I-Disease
in	66 2 O
male	69 4 O
rats	74 4 O
.	78 1 O

AIM	80 3 O
:	83 1 O
To	85 2 O
study	88 5 O
the	94 3 O
effects	98 7 O
of	106 2 O
testosterone	109 12 B-Chemical
on	122 2 O
streptozotocin	125 14 B-Chemical
(	140 1 O
STZ	141 3 B-Chemical
)	144 1 O
-	145 1 O
induced	146 7 O
memory	154 6 B-Disease
impairment	161 10 I-Disease
in	172 2 O
male	175 4 O
rats	180 4 O
.	184 1 O

METHODS	186 7 O
:	193 1 O
Adult	195 5 O
male	201 4 O
Wistar	206 6 O
rats	213 4 O
were	218 4 O
intracerebroventricularly	223 25 O
(	249 1 O
icv	250 3 O
)	253 1 O
infused	255 7 O
with	263 4 O
STZ	268 3 B-Chemical
(	272 1 O
750	273 3 O
ug	277 2 O
)	279 1 O
on	281 2 O
d	284 1 O
1	286 1 O
and	288 3 O
d	292 1 O
3	294 1 O
,	295 1 O
and	297 3 O
a	301 1 O
passive	303 7 O
avoidance	311 9 O
task	321 4 O
was	326 3 O
assessed	330 8 O
2	339 1 O
weeks	341 5 O
after	347 5 O
the	353 3 O
first	357 5 O
injection	363 9 O
of	373 2 O
STZ	376 3 B-Chemical
.	379 1 O

Castration	381 10 O
surgery	392 7 O
was	400 3 O
performed	404 9 O
in	414 2 O
another	417 7 O
group	425 5 O
of	431 2 O
rats	434 4 O
,	438 1 O
and	440 3 O
the	444 3 O
passive	448 7 O
avoidance	456 9 O
task	466 4 O
was	471 3 O
assessed	475 8 O
4	484 1 O
weeks	486 5 O
after	492 5 O
the	498 3 O
operation	502 9 O
.	511 1 O

Testosterone	513 12 B-Chemical
(	526 1 O
1	527 1 O
mg	529 2 O
.	531 1 O
kg	532 2 O
(	534 1 O
-	535 1 O
1	536 1 O
)	537 1 O
.	538 1 O
d	539 1 O
(	540 1 O
-	541 1 O
1	542 1 O
)	543 1 O
,	544 1 O
sc	546 2 O
)	548 1 O
,	549 1 O
the	551 3 O
androgen	555 8 B-Chemical
receptor	564 8 O
antagonist	573 10 O
flutamide	584 9 B-Chemical
(	594 1 O
10	595 2 O
mg	598 2 O
.	600 1 O
kg	601 2 O
(	603 1 O
-	604 1 O
1	605 1 O
)	606 1 O
.	607 1 O
d	608 1 O
(	609 1 O
-	610 1 O
1	611 1 O
)	612 1 O
,	613 1 O
ip	615 2 O
)	617 1 O
,	618 1 O
the	620 3 O
estrogen	624 8 B-Chemical
receptor	633 8 O
antagonist	642 10 O
tamoxifen	653 9 B-Chemical
(	663 1 O
1	664 1 O
mg	666 2 O
.	668 1 O
kg	669 2 O
(	671 1 O
-	672 1 O
1	673 1 O
)	674 1 O
.	675 1 O
d	676 1 O
(	677 1 O
-	678 1 O
1	679 1 O
)	680 1 O
,	681 1 O
ip	683 2 O
)	685 1 O
or	687 2 O
the	690 3 O
aromatase	694 9 O
inhibitor	704 9 O
letrozole	714 9 B-Chemical
(	724 1 O
4	725 1 O
mg	727 2 O
.	729 1 O
kg	730 2 O
(	732 1 O
-	733 1 O
1	734 1 O
)	735 1 O
.	736 1 O
d	737 1 O
(	738 1 O
-	739 1 O
1	740 1 O
)	741 1 O
,	742 1 O
ip	744 2 O
)	746 1 O
were	748 4 O
administered	753 12 O
for	766 3 O
6	770 1 O
d	772 1 O
after	774 5 O
the	780 3 O
first	784 5 O
injection	790 9 O
of	800 2 O
STZ	803 3 B-Chemical
.	806 1 O

RESULTS	808 7 O
:	815 1 O
STZ	817 3 B-Chemical
administration	821 14 O
and	836 3 O
castration	840 10 O
markedly	851 8 O
decreased	860 9 O
both	870 4 O
STL1	875 4 O
(	880 1 O
the	881 3 O
short	885 5 O
memory	891 6 O
)	897 1 O
and	899 3 O
STL2	903 4 O
(	908 1 O
the	909 3 O
long	913 4 O
memory	918 6 O
)	924 1 O
in	926 2 O
passive	929 7 O
avoidance	937 9 O
tests	947 5 O
.	952 1 O

Testosterone	954 12 B-Chemical
replacement	967 11 O
almost	979 6 O
restored	986 8 O
the	995 3 O
STL1	999 4 O
and	1004 3 O
STL2	1008 4 O
in	1013 2 O
castrated	1016 9 O
rats	1026 4 O
,	1030 1 O
and	1032 3 O
significantly	1036 13 O
prolonged	1050 9 O
the	1060 3 O
STL1	1064 4 O
and	1069 3 O
STL2	1073 4 O
in	1078 2 O
STZ	1081 3 B-Chemical
-	1084 1 O
treated	1085 7 O
rats	1093 4 O
.	1097 1 O

Administration	1099 14 O
of	1114 2 O
flutamide	1117 9 B-Chemical
,	1126 1 O
letrozole	1128 9 B-Chemical
or	1138 2 O
tamoxifen	1141 9 B-Chemical
significantly	1151 13 O
impaired	1165 8 B-Disease
the	1174 3 I-Disease
memory	1178 6 I-Disease
in	1185 2 O
intact	1188 6 O
rats	1195 4 O
,	1199 1 O
and	1201 3 O
significantly	1205 13 O
attenuated	1219 10 O
the	1230 3 O
testosterone	1234 12 B-Chemical
replacement	1247 11 O
in	1259 2 O
improving	1262 9 O
STZ	1272 3 B-Chemical
-	1275 1 O
and	1277 3 O
castration	1281 10 O
-	1291 1 O
induced	1292 7 O
memory	1300 6 B-Disease
impairment	1307 10 I-Disease
.	1317 1 O

CONCLUSION	1319 10 O
:	1329 1 O
Testosterone	1331 12 B-Chemical
administration	1344 14 O
ameliorates	1359 11 O
STZ	1371 3 B-Chemical
-	1374 1 O
and	1376 3 O
castration	1380 10 O
-	1390 1 O
induced	1391 7 O
memory	1399 6 B-Disease
impairment	1406 10 I-Disease
in	1417 2 O
male	1420 4 O
Wistar	1425 6 O
rats	1432 4 O
.	1436 1 O

Behavioral	0 10 O
and	11 3 O
neurochemical	15 13 O
studies	29 7 O
in	37 2 O
mice	40 4 O
pretreated	45 10 O
with	56 4 O
garcinielliptone	61 16 B-Chemical
FC	78 2 I-Chemical
in	81 2 O
pilocarpine	84 11 B-Chemical
-	95 1 O
induced	96 7 O
seizures	104 8 B-Disease
.	112 1 O

Garcinielliptone	114 16 B-Chemical
FC	131 2 I-Chemical
(	134 1 O
GFC	135 3 B-Chemical
)	138 1 O
isolated	140 8 O
from	149 4 O
hexanic	154 7 O
fraction	162 8 O
seed	171 4 O
extract	176 7 O
of	184 2 O
species	187 7 O
Platonia	195 8 O
insignis	204 8 O
Mart	213 4 O
.	217 1 O

It	219 2 O
is	222 2 O
widely	225 6 O
used	232 4 O
in	237 2 O
folk	240 4 O
medicine	245 8 O
to	254 2 O
treat	257 5 O
skin	263 4 B-Disease
diseases	268 8 I-Disease
in	277 2 O
both	280 4 O
humans	285 6 O
and	292 3 O
animals	296 7 O
as	304 2 O
well	307 4 O
as	312 2 O
the	315 3 O
seed	319 4 O
decoction	324 9 O
has	334 3 O
been	338 4 O
used	343 4 O
to	348 2 O
treat	351 5 O
diarrheas	357 9 B-Disease
and	367 3 O
inflammatory	371 12 B-Disease
diseases	384 8 I-Disease
.	392 1 O

However	394 7 O
,	401 1 O
there	403 5 O
is	409 2 O
no	412 2 O
research	415 8 O
on	424 2 O
GFC	427 3 B-Chemical
effects	431 7 O
in	439 2 O
the	442 3 O
central	446 7 O
nervous	454 7 O
system	462 6 O
of	469 2 O
rodents	472 7 O
.	479 1 O

The	481 3 O
present	485 7 O
study	493 5 O
aimed	499 5 O
to	505 2 O
evaluate	508 8 O
the	517 3 O
GFC	521 3 B-Chemical
effects	525 7 O
at	533 2 O
doses	536 5 O
of	542 2 O
25	545 2 O
,	547 1 O
50	549 2 O
or	552 2 O
75	555 2 O
mg	558 2 O
/	560 1 O
kg	561 2 O
on	564 2 O
seizure	567 7 B-Disease
parameters	575 10 O
to	586 2 O
determine	589 9 O
their	599 5 O
anticonvulsant	605 14 O
activity	620 8 O
and	629 3 O
its	633 3 O
effects	637 7 O
on	645 2 O
amino	648 5 B-Chemical
acid	654 4 I-Chemical
(	659 1 O
r	660 1 B-Chemical
-	661 1 I-Chemical
aminobutyric	662 12 I-Chemical
acid	675 4 I-Chemical
(	680 1 O
GABA	681 4 B-Chemical
)	685 1 O
,	686 1 O
glutamine	688 9 B-Chemical
,	697 1 O
aspartate	699 9 B-Chemical
and	709 3 O
glutathione	713 11 B-Chemical
)	724 1 O
levels	726 6 O
as	733 2 O
well	736 4 O
as	741 2 O
on	744 2 O
acetylcholinesterase	747 20 O
(	768 1 O
AChE	769 4 O
)	773 1 O
activity	775 8 O
in	784 2 O
mice	787 4 O
hippocampus	792 11 O
after	804 5 O
seizures	810 8 B-Disease
.	818 1 O

GFC	820 3 B-Chemical
produced	824 8 O
an	833 2 O
increased	836 9 O
latency	846 7 O
to	854 2 O
first	857 5 O
seizure	863 7 B-Disease
,	870 1 O
at	872 2 O
doses	875 5 O
25mg	881 4 O
/	885 1 O
kg	886 2 O
(	889 1 O
20	890 2 O
.	892 1 O
12	893 2 O
+	896 1 O
2	898 1 O
.	899 1 O
20	900 2 O
min	903 3 O
)	906 1 O
,	907 1 O
50mg	909 4 O
/	913 1 O
kg	914 2 O
(	917 1 O
20	918 2 O
.	920 1 O
95	921 2 O
+	924 1 O
2	926 1 O
.	927 1 O
21	928 2 O
min	931 3 O
)	934 1 O
or	936 2 O
75	939 2 O
mg	942 2 O
/	944 1 O
kg	945 2 O
(	948 1 O
23	949 2 O
.	951 1 O
43	952 2 O
+	955 1 O
1	957 1 O
.	958 1 O
99	959 2 O
min	962 3 O
)	965 1 O
when	967 4 O
compared	972 8 O
with	981 4 O
seized	986 6 O
mice	993 4 O
.	997 1 O

In	999 2 O
addition	1002 8 O
,	1010 1 O
GABA	1012 4 B-Chemical
content	1017 7 O
of	1025 2 O
mice	1028 4 O
hippocampus	1033 11 O
treated	1045 7 O
with	1053 4 O
GFC75	1058 5 O
plus	1064 4 O
P400	1069 4 O
showed	1074 6 O
an	1081 2 O
increase	1084 8 O
of	1093 2 O
46	1096 2 O
.	1098 1 O
90	1099 2 O
%	1101 1 O
when	1103 4 O
compared	1108 8 O
with	1117 4 O
seized	1122 6 O
mice	1129 4 O
.	1133 1 O

In	1135 2 O
aspartate	1138 9 B-Chemical
,	1147 1 O
glutamine	1149 9 B-Chemical
and	1159 3 O
glutamate	1163 9 B-Chemical
levels	1173 6 O
detected	1180 8 O
a	1189 1 O
decrease	1191 8 O
of	1200 2 O
5	1203 1 O
.	1204 1 O
21	1205 2 O
%	1207 1 O
,	1208 1 O
13	1210 2 O
.	1212 1 O
55	1213 2 O
%	1215 1 O
and	1217 3 O
21	1221 2 O
.	1223 1 O
80	1224 2 O
%	1226 1 O
,	1227 1 O
respectively	1229 12 O
in	1242 2 O
mice	1245 4 O
hippocampus	1250 11 O
treated	1262 7 O
with	1270 4 O
GFC75	1275 5 O
plus	1281 4 O
P400	1286 4 O
when	1291 4 O
compared	1296 8 O
with	1305 4 O
seized	1310 6 O
mice	1317 4 O
.	1321 1 O

Hippocampus	1323 11 O
mice	1335 4 O
treated	1340 7 O
with	1348 4 O
GFC75	1353 5 O
plus	1359 4 O
P400	1364 4 O
showed	1369 6 O
an	1376 2 O
increase	1379 8 O
in	1388 2 O
AChE	1391 4 O
activity	1396 8 O
(	1405 1 O
63	1406 2 O
.	1408 1 O
30	1409 2 O
%	1411 1 O
)	1412 1 O
when	1414 4 O
compared	1419 8 O
with	1428 4 O
seized	1433 6 O
mice	1440 4 O
.	1444 1 O

The	1446 3 O
results	1450 7 O
indicate	1458 8 O
that	1467 4 O
GFC	1472 3 B-Chemical
can	1476 3 O
exert	1480 5 O
anticonvulsant	1486 14 O
activity	1501 8 O
and	1510 3 O
reduce	1514 6 O
the	1521 3 O
frequency	1525 9 O
of	1535 2 O
installation	1538 12 O
of	1551 2 O
pilocarpine	1554 11 B-Chemical
-	1565 1 O
induced	1566 7 O
status	1574 6 B-Disease
epilepticus	1581 11 I-Disease
,	1592 1 O
as	1594 2 O
demonstrated	1597 12 O
by	1610 2 O
increase	1613 8 O
in	1622 2 O
latency	1625 7 O
to	1633 2 O
first	1636 5 O
seizure	1642 7 B-Disease
and	1650 3 O
decrease	1654 8 O
in	1663 2 O
mortality	1666 9 O
rate	1676 4 O
of	1681 2 O
animals	1684 7 O
.	1691 1 O

In	1693 2 O
conclusion	1696 10 O
,	1706 1 O
our	1708 3 O
data	1712 4 O
suggest	1717 7 O
that	1725 4 O
GFC	1730 3 B-Chemical
may	1734 3 O
influence	1738 9 O
in	1748 2 O
epileptogenesis	1751 15 O
and	1767 3 O
promote	1771 7 O
anticonvulsant	1779 14 O
actions	1794 7 O
in	1802 2 O
pilocarpine	1805 11 B-Chemical
model	1817 5 O
by	1823 2 O
modulating	1826 10 O
the	1837 3 O
GABA	1841 4 B-Chemical
and	1846 3 O
glutamate	1850 9 B-Chemical
contents	1860 8 O
and	1869 3 O
of	1873 2 O
AChE	1876 4 O
activity	1881 8 O
in	1890 2 O
seized	1893 6 O
mice	1900 4 O
hippocampus	1905 11 O
.	1916 1 O

This	1918 4 O
compound	1923 8 O
may	1932 3 O
be	1936 2 O
useful	1939 6 O
to	1946 2 O
produce	1949 7 O
neuronal	1957 8 O
protection	1966 10 O
and	1977 3 O
it	1981 2 O
can	1984 3 O
be	1988 2 O
considered	1991 10 O
as	2002 2 O
an	2005 2 O
anticonvulsant	2008 14 O
agent	2023 5 O
.	2028 1 O

Standard	0 8 O
operating	9 9 O
procedures	19 10 O
for	30 3 O
antibiotic	34 10 O
therapy	45 7 O
and	53 3 O
the	57 3 O
occurrence	61 10 O
of	72 2 O
acute	75 5 B-Disease
kidney	81 6 I-Disease
injury	88 6 I-Disease
:	94 1 O
a	96 1 O
prospective	98 11 O
,	109 1 O
clinical	111 8 O
,	119 1 O
non	121 3 O
-	124 1 O
interventional	125 14 O
,	139 1 O
observational	141 13 O
study	155 5 O
.	160 1 O

INTRODUCTION	162 12 O
:	174 1 O
Acute	176 5 B-Disease
kidney	182 6 I-Disease
injury	189 6 I-Disease
(	196 1 O
AKI	197 3 B-Disease
)	200 1 O
occurs	202 6 O
in	209 2 O
7	212 1 O
%	213 1 O
of	215 2 O
hospitalized	218 12 O
and	231 3 O
66	235 2 O
%	237 1 O
of	239 2 O
Intensive	242 9 O
Care	252 4 O
Unit	257 4 O
(	262 1 O
ICU	263 3 O
)	266 1 O
patients	268 8 O
.	276 1 O

It	278 2 O
increases	281 9 O
mortality	291 9 O
,	300 1 O
hospital	302 8 O
length	311 6 O
of	318 2 O
stay	321 4 O
,	325 1 O
and	327 3 O
costs	331 5 O
.	336 1 O

The	338 3 O
aim	342 3 O
of	346 2 O
this	349 4 O
study	354 5 O
was	360 3 O
to	364 2 O
investigate	367 11 O
,	378 1 O
whether	380 7 O
there	388 5 O
is	394 2 O
an	397 2 O
association	400 11 O
between	412 7 O
adherence	420 9 O
to	430 2 O
guidelines	433 10 O
(	444 1 O
standard	445 8 O
operating	454 9 O
procedures	464 10 O
(	475 1 O
SOP	476 3 O
)	479 1 O
)	480 1 O
for	482 3 O
potentially	486 11 O
nephrotoxic	498 11 B-Disease
antibiotics	510 11 O
and	522 3 O
the	526 3 O
occurrence	530 10 O
of	541 2 O
AKI	544 3 B-Disease
.	547 1 O

METHODS	549 7 O
:	556 1 O
This	558 4 O
study	563 5 O
was	569 3 O
carried	573 7 O
out	581 3 O
as	585 2 O
a	588 1 O
prospective	590 11 O
,	601 1 O
clinical	603 8 O
,	611 1 O
non	613 3 O
-	616 1 O
interventional	617 14 O
,	631 1 O
observational	633 13 O
study	647 5 O
.	652 1 O

Data	654 4 O
collection	659 10 O
was	670 3 O
performed	674 9 O
over	684 4 O
a	689 1 O
total	691 5 O
of	697 2 O
170	700 3 O
days	704 4 O
in	709 2 O
three	712 5 O
ICUs	718 4 O
at	723 2 O
Charite	726 7 O
-	734 1 O
Universitaetsmedizin	736 20 O
Berlin	757 6 O
.	763 1 O

A	765 1 O
total	767 5 O
of	773 2 O
675	776 3 O
patients	780 8 O
were	789 4 O
included	794 8 O
;	802 1 O
163	804 3 O
of	808 2 O
these	811 5 O
had	817 3 O
therapy	821 7 O
with	829 4 O
vancomycin	834 10 B-Chemical
,	844 1 O
gentamicin	846 10 B-Chemical
,	856 1 O
or	858 2 O
tobramycin	861 10 B-Chemical
;	871 1 O
were	873 4 O
>	878 1 O
18	879 2 O
years	882 5 O
;	887 1 O
and	889 3 O
treated	893 7 O
in	901 2 O
the	904 3 O
ICU	908 3 O
for	912 3 O
>	916 1 O
24	917 2 O
hours	920 5 O
.	925 1 O

Patients	927 8 O
with	936 4 O
an	941 2 O
adherence	944 9 O
to	954 2 O
SOP	957 3 O
>	961 1 O
70	962 2 O
%	964 1 O
were	966 4 O
classified	971 10 O
into	982 4 O
the	987 3 O
high	991 4 O
adherence	996 9 O
group	1006 5 O
(	1012 1 O
HAG	1013 3 O
)	1016 1 O
and	1018 3 O
patients	1022 8 O
with	1031 4 O
an	1036 2 O
adherence	1039 9 O
of	1049 2 O
<	1052 1 O
70	1053 2 O
%	1055 1 O
into	1057 4 O
the	1062 3 O
low	1066 3 O
adherence	1070 9 O
group	1080 5 O
(	1086 1 O
LAG	1087 3 O
)	1090 1 O
.	1091 1 O

AKI	1093 3 B-Disease
was	1097 3 O
defined	1101 7 O
according	1109 9 O
to	1119 2 O
RIFLE	1122 5 O
criteria	1128 8 O
.	1136 1 O

Adherence	1138 9 O
to	1148 2 O
SOPs	1151 4 O
was	1156 3 O
evaluated	1160 9 O
by	1170 2 O
retrospective	1173 13 O
expert	1187 6 O
audit	1194 5 O
.	1199 1 O

Development	1201 11 O
of	1213 2 O
AKI	1216 3 B-Disease
was	1220 3 O
compared	1224 8 O
between	1233 7 O
groups	1241 6 O
with	1248 4 O
exact	1253 5 O
Chi2	1259 4 O
-	1263 1 O
test	1264 4 O
and	1269 3 O
multivariate	1273 12 O
logistic	1286 8 O
regression	1295 10 O
analysis	1306 8 O
(	1315 1 O
two	1316 3 O
-	1319 1 O
sided	1320 5 O
P	1326 1 O
<	1328 1 O
0	1329 1 O
.	1330 1 O
05	1331 2 O
)	1333 1 O
.	1334 1 O

RESULTS	1336 7 O
:	1343 1 O
LAG	1345 3 O
consisted	1349 9 O
of	1359 2 O
75	1362 2 O
patients	1365 8 O
(	1374 1 O
46	1375 2 O
%	1377 1 O
)	1378 1 O
versus	1380 6 O
88	1387 2 O
HAG	1390 3 O
patients	1394 8 O
(	1403 1 O
54	1404 2 O
%	1406 1 O
)	1407 1 O
.	1408 1 O

AKI	1410 3 B-Disease
occurred	1414 8 O
significantly	1423 13 O
more	1437 4 O
often	1442 5 O
in	1448 2 O
LAG	1451 3 O
with	1455 4 O
36	1460 2 O
%	1462 1 O
versus	1464 6 O
21	1471 2 O
%	1473 1 O
in	1475 2 O
HAG	1478 3 O
(	1482 1 O
P	1483 1 O
=	1485 1 O
0	1487 1 O
.	1488 1 O
035	1489 3 O
)	1492 1 O
.	1493 1 O

Basic	1495 5 O
characteristics	1501 15 O
were	1517 4 O
comparable	1522 10 O
,	1532 1 O
except	1534 6 O
an	1541 2 O
increased	1544 9 O
rate	1554 4 O
of	1559 2 O
soft	1562 4 O
tissue	1567 6 O
infections	1574 10 B-Disease
in	1585 2 O
LAG	1588 3 O
.	1591 1 O

Multivariate	1593 12 O
analysis	1606 8 O
revealed	1615 8 O
an	1624 2 O
odds	1627 4 O
ratio	1632 5 O
of	1638 2 O
2	1641 1 O
.	1642 1 O
5	1643 1 O
-	1644 1 O
fold	1645 4 O
for	1650 3 O
LAG	1654 3 O
to	1658 2 O
develop	1661 7 O
AKI	1669 3 B-Disease
compared	1673 8 O
with	1682 4 O
HAG	1687 3 O
(	1691 1 O
95	1692 2 O
%	1694 1 O
confidence	1696 10 O
interval	1707 8 O
1	1716 1 O
.	1717 1 O
195	1718 3 O
to	1722 2 O
5	1725 1 O
.	1726 1 O
124	1727 3 O
,	1730 1 O
P	1732 1 O
=	1734 1 O
0	1736 1 O
.	1737 1 O
039	1738 3 O
)	1741 1 O
.	1742 1 O

CONCLUSION	1744 10 O
:	1754 1 O
Low	1756 3 O
adherence	1760 9 O
to	1770 2 O
SOPs	1773 4 O
for	1778 3 O
potentially	1782 11 O
nephrotoxic	1794 11 B-Disease
antibiotics	1806 11 O
was	1818 3 O
associated	1822 10 O
with	1833 4 O
a	1838 1 O
higher	1840 6 O
occurrence	1847 10 O
of	1858 2 O
AKI	1861 3 B-Disease
.	1864 1 O

TRIAL	1866 5 O
REGISTRATION	1872 12 O
:	1884 1 O
Current	1886 7 O
Controlled	1894 10 O
Trials	1905 6 O
ISRCTN54598675	1912 14 O
.	1926 1 O

Registered	1928 10 O
17	1939 2 O
August	1942 6 O
2007	1949 4 O
.	1953 1 O

Rhabdomyolysis	0 14 B-Disease
in	15 2 O
a	18 1 O
hepatitis	20 9 B-Disease
C	30 1 I-Disease
virus	32 5 I-Disease
infected	38 8 I-Disease
patient	47 7 O
treated	55 7 O
with	63 4 O
telaprevir	68 10 B-Chemical
and	79 3 O
simvastatin	83 11 B-Chemical
.	94 1 O

A	96 1 O
46	98 2 O
-	100 1 O
year	101 4 O
old	106 3 O
man	110 3 O
with	114 4 O
a	119 1 O
chronic	121 7 O
hepatitis	129 9 B-Disease
C	139 1 I-Disease
virus	141 5 I-Disease
infection	147 9 I-Disease
received	157 8 O
triple	166 6 O
therapy	173 7 O
with	181 4 O
ribavirin	186 9 B-Chemical
,	195 1 O
pegylated	197 9 B-Chemical
interferon	207 10 I-Chemical
and	218 3 O
telaprevir	222 10 B-Chemical
.	232 1 O

The	234 3 O
patient	238 7 O
also	246 4 O
received	251 8 O
simvastatin	260 11 B-Chemical
.	271 1 O

One	273 3 O
month	277 5 O
after	283 5 O
starting	289 8 O
the	298 3 O
antiviral	302 9 O
therapy	312 7 O
,	319 1 O
the	321 3 O
patient	325 7 O
was	333 3 O
admitted	337 8 O
to	346 2 O
the	349 3 O
hospital	353 8 O
because	362 7 O
he	370 2 O
developed	373 9 O
rhabdomyolysis	383 14 B-Disease
.	397 1 O

At	399 2 O
admission	402 9 O
simvastatin	412 11 B-Chemical
and	424 3 O
all	428 3 O
antiviral	432 9 O
drugs	442 5 O
were	448 4 O
discontinued	453 12 O
because	466 7 O
toxicity	474 8 B-Disease
due	483 3 O
to	487 2 O
a	490 1 O
drug	492 4 O
-	496 1 O
drug	497 4 O
interaction	502 11 O
was	514 3 O
suspected	518 9 O
.	527 1 O

The	529 3 O
creatine	533 8 B-Chemical
kinase	542 6 O
peaked	549 6 O
at	556 2 O
62	559 2 O
,	561 1 O
246	562 3 O
IU	566 2 O
/	568 1 O
L	569 1 O
and	571 3 O
the	575 3 O
patient	579 7 O
was	587 3 O
treated	591 7 O
with	599 4 O
intravenous	604 11 O
normal	616 6 O
saline	623 6 O
.	629 1 O

The	631 3 O
patient	635 7 O
'	642 1 O
s	643 1 O
renal	645 5 O
function	651 8 O
remained	660 8 O
unaffected	669 10 O
.	679 1 O

Fourteen	681 8 O
days	690 4 O
after	695 5 O
hospitalization	701 15 O
,	716 1 O
creatine	718 8 B-Chemical
kinase	727 6 O
level	734 5 O
had	740 3 O
returned	744 8 O
to	753 2 O
230	756 3 O
IU	760 2 O
/	762 1 O
L	763 1 O
and	765 3 O
the	769 3 O
patient	773 7 O
was	781 3 O
discharged	785 10 O
.	795 1 O

Telaprevir	797 10 B-Chemical
was	808 3 O
considered	812 10 O
the	823 3 O
probable	827 8 O
causative	836 9 O
agent	846 5 O
of	852 2 O
an	855 2 O
interaction	858 11 O
with	870 4 O
simvastatin	875 11 B-Chemical
according	887 9 O
to	897 2 O
the	900 3 O
Drug	904 4 O
Interaction	909 11 O
Probability	921 11 O
Scale	933 5 O
.	938 1 O

The	940 3 O
interaction	944 11 O
is	956 2 O
due	959 3 O
to	963 2 O
inhibition	966 10 O
of	977 2 O
CYP3A4	980 6 O
-	986 1 O
mediated	987 8 O
simvastatin	996 11 B-Chemical
clearance	1008 9 O
.	1017 1 O

Simvastatin	1019 11 B-Chemical
plasma	1031 6 O
concentration	1038 13 O
increased	1052 9 O
30	1062 2 O
times	1065 5 O
in	1071 2 O
this	1074 4 O
patient	1079 7 O
and	1087 3 O
statin	1091 6 B-Chemical
induced	1098 7 O
muscle	1106 6 B-Disease
toxicity	1113 8 I-Disease
is	1122 2 O
related	1125 7 O
to	1133 2 O
the	1136 3 O
concentration	1140 13 O
of	1154 2 O
the	1157 3 O
statin	1161 6 B-Chemical
in	1168 2 O
blood	1171 5 O
.	1176 1 O

In	1178 2 O
conclusion	1181 10 O
,	1191 1 O
with	1193 4 O
this	1198 4 O
case	1203 4 O
we	1208 2 O
illustrate	1211 10 O
that	1222 4 O
telaprevir	1227 10 B-Chemical
as	1238 2 O
well	1241 4 O
as	1246 2 O
statins	1249 7 B-Chemical
are	1257 3 O
susceptible	1261 11 O
to	1273 2 O
clinical	1276 8 O
relevant	1285 8 O
drug	1294 4 O
-	1298 1 O
drug	1299 4 O
interactions	1304 12 O
.	1316 1 O

Combination	0 11 O
of	12 2 O
bortezomib	15 10 B-Chemical
,	25 1 O
thalidomide	27 11 B-Chemical
,	38 1 O
and	40 3 O
dexamethasone	44 13 B-Chemical
(	58 1 O
VTD	59 3 O
)	62 1 O
as	64 2 O
a	67 1 O
consolidation	69 13 O
therapy	83 7 O
after	91 5 O
autologous	97 10 O
stem	108 4 O
cell	113 4 O
transplantation	118 15 O
for	134 3 O
symptomatic	138 11 O
multiple	150 8 B-Disease
myeloma	159 7 I-Disease
in	167 2 O
Japanese	170 8 O
patients	179 8 O
.	187 1 O

Consolidation	189 13 O
therapy	203 7 O
for	211 3 O
patients	215 8 O
with	224 4 O
multiple	229 8 B-Disease
myeloma	238 7 I-Disease
(	246 1 O
MM	247 2 B-Disease
)	249 1 O
has	251 3 O
been	255 4 O
widely	260 6 O
adopted	267 7 O
to	275 2 O
improve	278 7 O
treatment	286 9 O
response	296 8 O
following	305 9 O
autologous	315 10 O
stem	326 4 O
cell	331 4 O
transplantation	336 15 O
.	351 1 O

In	353 2 O
this	356 4 O
study	361 5 O
,	366 1 O
we	368 2 O
retrospectively	371 15 O
analyzed	387 8 O
the	396 3 O
safety	400 6 O
and	407 3 O
efficacy	411 8 O
of	420 2 O
combination	423 11 O
regimen	435 7 O
of	443 2 O
bortezomib	446 10 B-Chemical
,	456 1 O
thalidomide	458 11 B-Chemical
,	469 1 O
and	471 3 O
dexamethasone	475 13 B-Chemical
(	489 1 O
VTD	490 3 O
)	493 1 O
as	495 2 O
consolidation	498 13 O
therapy	512 7 O
in	520 2 O
24	523 2 O
Japanese	526 8 O
patients	535 8 O
with	544 4 O
newly	549 5 O
diagnosed	555 9 O
MM	565 2 B-Disease
.	567 1 O

VTD	569 3 O
consisted	573 9 O
of	583 2 O
bortezomib	586 10 B-Chemical
at	597 2 O
a	600 1 O
dose	602 4 O
of	607 2 O
1	610 1 O
.	611 1 O
3	612 1 O
mg	614 2 O
/	616 1 O
m	617 1 O
(	618 1 O
2	619 1 O
)	620 1 O
and	622 3 O
dexamethasone	626 13 B-Chemical
at	640 2 O
a	643 1 O
dose	645 4 O
of	650 2 O
40	653 2 O
mg	656 2 O
/	658 1 O
day	659 3 O
on	663 2 O
days	666 4 O
1	671 1 O
,	672 1 O
8	674 1 O
,	675 1 O
15	677 2 O
,	679 1 O
and	681 3 O
22	685 2 O
of	688 2 O
a	691 1 O
35	693 2 O
-	695 1 O
day	696 3 O
cycle	700 5 O
,	705 1 O
with	707 4 O
daily	712 5 O
oral	718 4 O
thalidomide	723 11 B-Chemical
at	735 2 O
a	738 1 O
dose	740 4 O
of	745 2 O
100	748 3 O
mg	752 2 O
/	754 1 O
day	755 3 O
.	758 1 O

Grade	760 5 O
3	766 1 O
-	767 1 O
4	768 1 O
neutropenia	770 11 B-Disease
and	782 3 O
thrombocytopenia	786 16 B-Disease
were	803 4 O
documented	808 10 O
in	819 2 O
four	822 4 O
and	827 3 O
three	831 5 O
patients	837 8 O
(	846 1 O
17	847 2 O
and	850 3 O
13	854 2 O
%	857 1 O
)	858 1 O
,	859 1 O
respectively	861 12 O
,	873 1 O
but	875 3 O
drug	879 4 O
dose	884 4 O
reduction	889 9 O
due	899 3 O
to	903 2 O
cytopenia	906 9 B-Disease
was	916 3 O
not	920 3 O
required	924 8 O
in	933 2 O
any	936 3 O
case	940 4 O
.	944 1 O

Peripheral	946 10 B-Disease
neuropathy	957 10 I-Disease
was	968 3 O
common	972 6 O
(	979 1 O
63	980 2 O
%	983 1 O
)	984 1 O
,	985 1 O
but	987 3 O
severe	991 6 O
grade	998 5 O
3	1004 1 O
-	1005 1 O
4	1006 1 O
peripheral	1008 10 B-Disease
neuropathy	1019 10 I-Disease
was	1030 3 O
not	1034 3 O
observed	1038 8 O
.	1046 1 O

Very	1048 4 O
good	1053 4 O
partial	1058 7 O
response	1066 8 O
or	1075 2 O
better	1078 6 O
response	1085 8 O
(	1094 1 O
>	1095 1 O
VGPR	1096 4 O
)	1100 1 O
rates	1102 5 O
before	1108 6 O
and	1115 3 O
after	1119 5 O
consolidation	1125 13 O
therapy	1139 7 O
were	1147 4 O
54	1152 2 O
and	1155 3 O
79	1159 2 O
%	1162 1 O
,	1163 1 O
respectively	1165 12 O
.	1177 1 O

Patients	1179 8 O
had	1188 3 O
a	1192 1 O
significant	1194 11 O
probability	1206 11 O
of	1218 2 O
improving	1221 9 O
from	1231 4 O
<	1236 1 O
VGPR	1237 4 O
before	1242 6 O
consolidation	1249 13 O
therapy	1263 7 O
to	1271 2 O
>	1274 1 O
VGPR	1275 4 O
after	1280 5 O
consolidation	1286 13 O
therapy	1300 7 O
(	1308 1 O
p	1309 1 O
=	1311 1 O
0	1313 1 O
.	1314 1 O
041	1315 3 O
)	1318 1 O
.	1319 1 O

The	1321 3 O
VTD	1325 3 O
regimen	1329 7 O
may	1337 3 O
be	1341 2 O
safe	1344 4 O
and	1349 3 O
effective	1353 9 O
as	1363 2 O
a	1366 1 O
consolidation	1368 13 O
therapy	1382 7 O
in	1390 2 O
the	1393 3 O
treatment	1397 9 O
of	1407 2 O
MM	1410 2 O
in	1413 2 O
Japanese	1416 8 O
population	1425 10 O
.	1435 1 O

Conversion	0 10 O
to	11 2 O
sirolimus	14 9 B-Chemical
ameliorates	24 11 O
cyclosporine	36 12 B-Chemical
-	48 1 O
induced	49 7 O
nephropathy	57 11 B-Disease
in	69 2 O
the	72 3 O
rat	76 3 O
:	79 1 O
focus	81 5 O
on	87 2 O
serum	90 5 O
,	95 1 O
urine	97 5 O
,	102 1 O
gene	104 4 O
,	108 1 O
and	110 3 O
protein	114 7 O
renal	122 5 O
expression	128 10 O
biomarkers	139 10 O
.	149 1 O

Protocols	151 9 O
of	161 2 O
conversion	164 10 O
from	175 4 O
cyclosporin	180 11 B-Chemical
A	192 1 I-Chemical
(	194 1 O
CsA	195 3 B-Chemical
)	198 1 O
to	200 2 O
sirolimus	203 9 B-Chemical
(	213 1 O
SRL	214 3 B-Chemical
)	217 1 O
have	219 4 O
been	224 4 O
widely	229 6 O
used	236 4 O
in	241 2 O
immunotherapy	244 13 O
after	258 5 O
transplantation	264 15 O
to	280 2 O
prevent	283 7 O
CsA	291 3 B-Chemical
-	294 1 O
induced	295 7 O
nephropathy	303 11 B-Disease
,	314 1 O
but	316 3 O
the	320 3 O
molecular	324 9 O
mechanisms	334 10 O
underlying	345 10 O
these	356 5 O
protocols	362 9 O
remain	372 6 O
nuclear	379 7 O
.	386 1 O

This	388 4 O
study	393 5 O
aimed	399 5 O
to	405 2 O
identify	408 8 O
the	417 3 O
molecular	421 9 O
pathways	431 8 O
and	440 3 O
putative	444 8 O
biomarkers	453 10 O
of	464 2 O
CsA	467 3 B-Chemical
-	470 1 O
to	471 2 O
-	473 1 O
SRL	474 3 B-Chemical
conversion	478 10 O
in	489 2 O
a	492 1 O
rat	494 3 O
model	498 5 O
.	503 1 O

Four	505 4 O
animal	510 6 O
groups	517 6 O
(	524 1 O
n	525 1 O
=	527 1 O
6	529 1 O
)	530 1 O
were	532 4 O
tested	537 6 O
during	544 6 O
9	551 1 O
weeks	553 5 O
:	558 1 O
control	560 7 O
,	567 1 O
CsA	569 3 B-Chemical
,	572 1 O
SRL	574 3 B-Chemical
,	577 1 O
and	579 3 O
conversion	583 10 O
(	594 1 O
CsA	595 3 B-Chemical
for	599 3 O
3	603 1 O
weeks	605 5 O
followed	611 8 O
by	620 2 O
SRL	623 3 B-Chemical
for	627 3 O
6	631 1 O
weeks	633 5 O
)	638 1 O
.	639 1 O

Classical	641 9 O
and	651 3 O
emergent	655 8 O
serum	664 5 O
,	669 1 O
urinary	671 7 O
,	678 1 O
and	680 3 O
kidney	684 6 O
tissue	691 6 O
(	698 1 O
gene	699 4 O
and	704 3 O
protein	708 7 O
expression	716 10 O
)	726 1 O
markers	728 7 O
were	736 4 O
assessed	741 8 O
.	749 1 O

Renal	751 5 B-Disease
lesions	757 7 I-Disease
were	765 4 O
analyzed	770 8 O
in	779 2 O
hematoxylin	782 11 B-Chemical
and	794 3 O
eosin	798 5 B-Chemical
,	803 1 O
periodic	805 8 O
acid	814 4 O
-	818 1 O
Schiff	819 6 O
,	825 1 O
and	827 3 O
Masson	831 6 O
'	837 1 O
s	838 1 O
trichrome	840 9 O
stains	850 6 O
.	856 1 O

SRL	858 3 B-Chemical
-	861 1 O
treated	862 7 O
rats	870 4 O
presented	875 9 O
proteinuria	885 11 B-Disease
and	897 3 O
NGAL	901 4 O
(	906 1 O
serum	907 5 O
and	913 3 O
urinary	917 7 O
)	924 1 O
as	926 2 O
the	929 3 O
best	933 4 O
markers	938 7 O
of	946 2 O
renal	949 5 B-Disease
impairment	955 10 I-Disease
.	965 1 O

Short	967 5 O
CsA	973 3 B-Chemical
treatment	977 9 O
presented	987 9 O
slight	997 6 O
or	1004 2 O
even	1007 4 O
absent	1012 6 O
kidney	1019 6 B-Disease
lesions	1026 7 I-Disease
and	1034 3 O
TGF	1038 3 O
-	1041 1 O
b	1042 1 O
,	1043 1 O
NF	1045 2 O
-	1047 1 O
kb	1049 2 O
,	1051 1 O
mTOR	1053 4 O
,	1057 1 O
PCNA	1059 4 O
,	1063 1 O
TP53	1065 4 O
,	1069 1 O
KIM	1071 3 O
-	1074 1 O
1	1075 1 O
,	1076 1 O
and	1078 3 O
CTGF	1082 4 O
as	1087 2 O
relevant	1090 8 O
gene	1099 4 O
and	1104 3 O
protein	1108 7 O
changes	1116 7 O
.	1123 1 O

Prolonged	1125 9 O
CsA	1135 3 B-Chemical
exposure	1139 8 O
aggravated	1148 10 O
renal	1159 5 B-Disease
damage	1165 6 I-Disease
,	1171 1 O
without	1173 7 O
clear	1181 5 O
changes	1187 7 O
on	1195 2 O
the	1198 3 O
traditional	1202 11 O
markers	1214 7 O
,	1221 1 O
but	1223 3 O
with	1227 4 O
changes	1232 7 O
in	1240 2 O
serums	1243 6 O
TGF	1250 3 O
-	1253 1 O
b	1255 1 O
and	1257 3 O
IL	1261 2 O
-	1263 1 O
7	1264 1 O
,	1265 1 O
TBARs	1267 5 O
clearance	1273 9 O
,	1282 1 O
and	1284 3 O
kidney	1288 6 O
TGF	1295 3 O
-	1298 1 O
b	1299 1 O
and	1301 3 O
mTOR	1305 4 O
.	1309 1 O

Conversion	1311 10 O
to	1322 2 O
SRL	1325 3 B-Chemical
prevented	1329 9 O
CsA	1339 3 B-Chemical
-	1342 1 O
induced	1343 7 O
renal	1351 5 B-Disease
damage	1357 6 I-Disease
evolution	1364 9 O
(	1374 1 O
absent	1375 6 O
/	1381 1 O
mild	1382 4 O
grade	1387 5 O
lesions	1393 7 O
)	1400 1 O
,	1401 1 O
while	1403 5 O
NGAL	1409 4 O
(	1414 1 O
serum	1415 5 O
versus	1421 6 O
urine	1428 5 O
)	1433 1 O
seems	1435 5 O
to	1441 2 O
be	1444 2 O
a	1447 1 O
feasible	1449 8 O
biomarker	1458 9 O
of	1468 2 O
CsA	1471 3 B-Chemical
replacement	1475 11 O
to	1487 2 O
SRL	1490 3 B-Chemical
.	1493 1 O

Kinin	0 5 O
B2	6 2 O
receptor	9 8 O
deletion	18 8 O
and	27 3 O
blockage	31 8 O
ameliorates	40 11 O
cisplatin	52 9 B-Chemical
-	61 1 O
induced	62 7 O
acute	70 5 B-Disease
renal	76 5 I-Disease
injury	82 6 I-Disease
.	88 1 O

Cisplatin	90 9 B-Chemical
treatment	100 9 O
has	110 3 O
been	114 4 O
adopted	119 7 O
in	127 2 O
some	130 4 O
chemotherapies	135 14 O
;	149 1 O
however	151 7 O
,	158 1 O
this	160 4 O
drug	165 4 O
can	170 3 O
induce	174 6 O
acute	181 5 B-Disease
kidney	187 6 I-Disease
injury	194 6 I-Disease
due	201 3 O
its	205 3 O
ability	209 7 O
to	217 2 O
negatively	220 10 O
affect	231 6 O
renal	238 5 O
function	244 8 O
,	252 1 O
augment	254 7 O
serum	262 5 O
levels	268 6 O
of	275 2 O
creatinine	278 10 B-Chemical
and	289 3 O
urea	293 4 B-Chemical
,	297 1 O
increase	299 8 O
the	308 3 O
acute	312 5 B-Disease
tubular	318 7 I-Disease
necrosis	326 8 I-Disease
score	335 5 O
and	341 3 O
up	345 2 O
-	347 1 O
regulate	348 8 O
cytokines	357 9 O
(	367 1 O
e	368 1 O
.	369 1 O
g	370 1 O
.	371 1 O
,	372 1 O
IL	374 2 O
-	376 1 O
1b	377 2 O
and	380 3 O
TNF	384 3 O
-	387 1 O
a	388 1 O
)	389 1 O
.	390 1 O

The	392 3 O
kinin	396 5 O
B2	402 2 O
receptor	405 8 O
has	414 3 O
been	418 4 O
associated	423 10 O
with	434 4 O
the	439 3 O
inflammation	443 12 B-Disease
process	456 7 O
,	463 1 O
as	465 2 O
well	468 4 O
as	473 2 O
the	476 3 O
regulation	480 10 O
of	491 2 O
cytokine	494 8 O
expression	503 10 O
,	513 1 O
and	515 3 O
its	519 3 O
deletion	523 8 O
resulted	532 8 O
in	541 2 O
an	544 2 O
improvement	547 11 O
in	559 2 O
the	562 3 O
diabetic	566 8 B-Disease
nephropathy	575 11 I-Disease
status	587 6 O
.	593 1 O

To	595 2 O
examine	598 7 O
the	606 3 O
role	610 4 O
of	615 2 O
the	618 3 O
kinin	622 5 O
B2	628 2 O
receptor	631 8 O
in	640 2 O
cisplatin	643 9 B-Chemical
-	652 1 O
induced	653 7 O
acute	661 5 B-Disease
kidney	667 6 I-Disease
injury	674 6 I-Disease
,	680 1 O
kinin	682 5 O
B2	688 2 O
receptor	691 8 O
knockout	700 8 O
mice	709 4 O
were	714 4 O
challenged	719 10 O
with	730 4 O
cisplatin	735 9 B-Chemical
.	744 1 O

Additionally	746 12 O
,	758 1 O
WT	760 2 O
mice	763 4 O
were	768 4 O
treated	773 7 O
with	781 4 O
a	786 1 O
B2	788 2 O
receptor	791 8 O
antagonist	800 10 O
after	811 5 O
cisplatin	817 9 B-Chemical
administration	827 14 O
.	841 1 O

B2	843 2 O
receptor	846 8 O
-	854 1 O
deficient	855 9 O
mice	865 4 O
were	870 4 O
less	875 4 O
sensitive	880 9 O
to	890 2 O
this	893 4 O
drug	898 4 O
than	903 4 O
the	908 3 O
WT	912 2 O
mice	915 4 O
,	919 1 O
as	921 2 O
shown	924 5 O
by	930 2 O
reduced	933 7 O
weight	941 6 B-Disease
loss	948 4 I-Disease
,	952 1 O
better	954 6 O
preservation	961 12 O
of	974 2 O
kidney	977 6 O
function	984 8 O
,	992 1 O
down	994 4 O
regulation	999 10 O
of	1010 2 O
inflammatory	1013 12 O
cytokines	1026 9 O
and	1036 3 O
less	1040 4 O
acute	1045 5 B-Disease
tubular	1051 7 I-Disease
necrosis	1059 8 I-Disease
.	1067 1 O

Moreover	1069 8 O
,	1077 1 O
treatment	1079 9 O
with	1089 4 O
the	1094 3 O
kinin	1098 5 O
B2	1104 2 O
receptor	1107 8 O
antagonist	1116 10 O
effectively	1127 11 O
reduced	1139 7 O
the	1147 3 O
levels	1151 6 O
of	1158 2 O
serum	1161 5 O
creatinine	1167 10 B-Chemical
and	1178 3 O
blood	1182 5 O
urea	1188 4 B-Chemical
after	1193 5 O
cisplatin	1199 9 B-Chemical
administration	1209 14 O
.	1223 1 O

Thus	1225 4 O
,	1229 1 O
our	1231 3 O
data	1235 4 O
suggest	1240 7 O
that	1248 4 O
the	1253 3 O
kinin	1257 5 O
B2	1263 2 O
receptor	1266 8 O
is	1275 2 O
involved	1278 8 O
in	1287 2 O
cisplatin	1290 9 B-Chemical
-	1299 1 O
induced	1300 7 O
acute	1308 5 B-Disease
kidney	1314 6 I-Disease
injury	1321 6 I-Disease
by	1328 2 O
mediating	1331 9 O
the	1341 3 O
necrotic	1345 8 B-Disease
process	1354 7 O
and	1362 3 O
the	1366 3 O
expression	1370 10 O
of	1381 2 O
inflammatory	1384 12 O
cytokines	1397 9 O
,	1406 1 O
thus	1408 4 O
resulting	1413 9 O
in	1423 2 O
declined	1426 8 O
renal	1435 5 O
function	1441 8 O
.	1449 1 O

These	1451 5 O
results	1457 7 O
highlight	1465 9 O
the	1475 3 O
kinin	1479 5 O
B2	1485 2 O
receptor	1488 8 O
antagonist	1497 10 O
treatment	1508 9 O
in	1518 2 O
amelioration	1521 12 O
of	1534 2 O
nephrotoxicity	1537 14 B-Disease
induced	1552 7 O
by	1560 2 O
cisplatin	1563 9 B-Chemical
therapy	1573 7 O
.	1580 1 O

Safety	0 6 O
and	7 3 O
efficacy	11 8 O
of	20 2 O
fluocinolone	23 12 B-Chemical
acetonide	36 9 I-Chemical
intravitreal	46 12 O
implant	59 7 O
(	67 1 O
0	68 1 O
.	69 1 O
59	70 2 O
mg	73 2 O
)	75 1 O
in	77 2 O
birdshot	80 8 B-Disease
retinochoroidopathy	89 19 I-Disease
.	108 1 O

PURPOSE	110 7 O
:	117 1 O
To	119 2 O
report	122 6 O
the	129 3 O
treatment	133 9 O
outcomes	143 8 O
of	152 2 O
the	155 3 O
fluocinolone	159 12 B-Chemical
acetonide	172 9 I-Chemical
intravitreal	182 12 O
implant	195 7 O
(	203 1 O
0	204 1 O
.	205 1 O
59	206 2 O
mg	209 2 O
)	211 1 O
in	213 2 O
patients	216 8 O
with	225 4 O
birdshot	230 8 B-Disease
retinochoroidopathy	239 19 I-Disease
whose	259 5 O
disease	265 7 O
is	273 2 O
refractory	276 10 O
or	287 2 O
intolerant	290 10 O
to	301 2 O
conventional	304 12 O
immunomodulatory	317 16 O
therapy	334 7 O
.	341 1 O

METHODS	343 7 O
:	350 1 O
A	352 1 O
retrospective	354 13 O
case	368 4 O
series	373 6 O
involving	380 9 O
11	390 2 O
birdshot	393 8 B-Disease
retinochoroidopathy	402 19 I-Disease
patients	422 8 O
(	431 1 O
11	432 2 O
eyes	435 4 O
)	439 1 O
.	440 1 O

Eleven	442 6 O
patients	449 8 O
(	458 1 O
11	459 2 O
eyes	462 4 O
)	466 1 O
underwent	468 9 O
surgery	478 7 O
for	486 3 O
fluocinolone	490 12 B-Chemical
acetonide	503 9 I-Chemical
implant	513 7 O
(	521 1 O
0	522 1 O
.	523 1 O
59	524 2 O
mg	527 2 O
)	529 1 O
.	530 1 O

Treatment	532 9 O
outcomes	542 8 O
of	551 2 O
interest	554 8 O
were	563 4 O
noted	568 5 O
at	574 2 O
baseline	577 8 O
,	585 1 O
before	587 6 O
fluocinolone	594 12 B-Chemical
acetonide	607 9 I-Chemical
implant	617 7 O
,	624 1 O
and	626 3 O
then	630 4 O
at	635 2 O
6	638 1 O
months	640 6 O
,	646 1 O
1	648 1 O
year	650 4 O
,	654 1 O
2	656 1 O
years	658 5 O
,	663 1 O
3	665 1 O
years	667 5 O
,	672 1 O
and	674 3 O
beyond	678 6 O
3	685 1 O
years	687 5 O
.	692 1 O

Disease	694 7 O
activity	702 8 O
markers	711 7 O
,	718 1 O
including	720 9 O
signs	730 5 O
of	736 2 O
ocular	739 6 O
inflammation	746 12 B-Disease
,	758 1 O
evidence	760 8 O
of	769 2 O
retinal	772 7 B-Disease
vasculitis	780 10 I-Disease
,	790 1 O
Swedish	792 7 O
interactive	800 11 O
threshold	812 9 O
algorithm	822 9 O
-	831 1 O
short	832 5 O
wavelength	838 10 O
automated	849 9 O
perimetry	859 9 O
Humphrey	869 8 O
visual	878 6 O
field	885 5 O
analysis	891 8 O
,	899 1 O
electroretinographic	901 20 O
parameters	922 10 O
,	932 1 O
and	934 3 O
optical	938 7 O
coherence	946 9 O
tomography	956 10 O
were	967 4 O
recorded	972 8 O
.	980 1 O

Data	982 4 O
on	987 2 O
occurrence	990 10 O
of	1001 2 O
cataract	1004 8 B-Disease
and	1013 3 O
raised	1017 6 B-Disease
intraocular	1024 11 I-Disease
pressure	1036 8 I-Disease
were	1045 4 O
collected	1050 9 O
in	1060 2 O
all	1063 3 O
eyes	1067 4 O
.	1071 1 O

RESULTS	1073 7 O
:	1080 1 O
Intraocular	1082 11 O
inflammation	1094 12 B-Disease
was	1107 3 O
present	1111 7 O
in	1119 2 O
54	1122 2 O
.	1124 1 O
5	1125 1 O
,	1126 1 O
9	1128 1 O
.	1129 1 O
9	1130 1 O
,	1131 1 O
11	1133 2 O
.	1135 1 O
1	1136 1 O
,	1137 1 O
and	1139 3 O
0	1143 1 O
%	1144 1 O
of	1146 2 O
patients	1149 8 O
at	1158 2 O
baseline	1161 8 O
,	1169 1 O
6	1171 1 O
months	1173 6 O
,	1179 1 O
1	1181 1 O
year	1183 4 O
,	1187 1 O
2	1189 1 O
years	1191 5 O
,	1196 1 O
3	1198 1 O
years	1200 5 O
,	1205 1 O
and	1207 3 O
beyond	1211 6 O
3	1218 1 O
years	1220 5 O
after	1226 5 O
receiving	1232 9 O
the	1242 3 O
implant	1246 7 O
,	1253 1 O
respectively	1255 12 O
.	1267 1 O

Active	1269 6 O
vasculitis	1276 10 B-Disease
was	1287 3 O
noted	1291 5 O
in	1297 2 O
36	1300 2 O
.	1302 1 O
3	1303 1 O
%	1304 1 O
patients	1306 8 O
at	1315 2 O
baseline	1318 8 O
and	1327 3 O
0	1331 1 O
%	1332 1 O
at	1334 2 O
3	1337 1 O
years	1339 5 O
of	1345 2 O
follow	1348 6 O
-	1354 1 O
up	1355 2 O
.	1357 1 O

More	1359 4 O
than	1364 4 O
20	1369 2 O
%	1371 1 O
(	1373 1 O
47	1374 2 O
.	1376 1 O
61	1377 2 O
-	1379 1 O
67	1380 2 O
.	1382 1 O
2	1383 1 O
%	1384 1 O
)	1385 1 O
reduction	1387 9 O
in	1397 2 O
central	1400 7 O
retinal	1408 7 O
thickness	1416 9 O
was	1426 3 O
noted	1430 5 O
in	1436 2 O
all	1439 3 O
patients	1443 8 O
with	1452 4 O
cystoid	1457 7 B-Disease
macular	1465 7 I-Disease
edema	1473 5 I-Disease
at	1479 2 O
6	1482 1 O
months	1484 6 O
,	1490 1 O
1	1492 1 O
year	1494 4 O
,	1498 1 O
2	1500 1 O
years	1502 5 O
,	1507 1 O
and	1509 3 O
3	1513 1 O
years	1515 5 O
postimplant	1521 11 O
.	1532 1 O

At	1534 2 O
baseline	1537 8 O
,	1545 1 O
54	1547 2 O
.	1549 1 O
5	1550 1 O
%	1551 1 O
patients	1553 8 O
were	1562 4 O
on	1567 2 O
immunomodulatory	1570 16 O
agents	1587 6 O
.	1593 1 O

This	1595 4 O
percentage	1600 10 O
decreased	1611 9 O
to	1621 2 O
45	1624 2 O
.	1626 1 O
45	1627 2 O
,	1629 1 O
44	1631 2 O
.	1633 1 O
4	1634 1 O
,	1635 1 O
and	1637 3 O
14	1641 2 O
.	1643 1 O
28	1644 2 O
%	1646 1 O
at	1648 2 O
1	1651 1 O
year	1653 4 O
,	1657 1 O
2	1659 1 O
years	1661 5 O
,	1666 1 O
and	1668 3 O
3	1672 1 O
years	1674 5 O
postimplant	1680 11 O
,	1691 1 O
respectively	1693 12 O
.	1705 1 O

Adverse	1707 7 O
events	1715 6 O
included	1722 8 O
increased	1731 9 B-Disease
intraocular	1741 11 I-Disease
pressure	1753 8 I-Disease
(	1762 1 O
54	1763 2 O
.	1765 1 O
5	1766 1 O
%	1767 1 O
)	1768 1 O
and	1770 3 O
cataract	1774 8 B-Disease
formation	1783 9 O
(	1793 1 O
100	1794 3 O
%	1797 1 O
)	1798 1 O
.	1799 1 O

CONCLUSION	1801 10 O
:	1811 1 O
The	1813 3 O
data	1817 4 O
suggest	1822 7 O
that	1830 4 O
fluocinolone	1835 12 B-Chemical
acetonide	1848 9 I-Chemical
implant	1858 7 O
(	1866 1 O
0	1867 1 O
.	1868 1 O
59	1869 2 O
mg	1872 2 O
)	1874 1 O
helps	1876 5 O
to	1882 2 O
control	1885 7 O
inflammation	1893 12 B-Disease
in	1906 2 O
otherwise	1909 9 O
treatment	1919 9 O
-	1928 1 O
refractory	1929 10 O
cases	1940 5 O
of	1946 2 O
birdshot	1949 8 B-Disease
retinochoroidopathy	1958 19 I-Disease
.	1977 1 O

It	1979 2 O
is	1982 2 O
associated	1985 10 O
with	1996 4 O
significant	2001 11 O
side	2013 4 O
effects	2018 7 O
of	2026 2 O
cataract	2029 8 B-Disease
and	2038 3 O
ocular	2042 6 B-Disease
hypertension	2049 12 I-Disease
requiring	2062 9 O
treatment	2072 9 O
.	2081 1 O

Optimal	0 7 O
precurarizing	8 13 O
dose	22 4 O
of	27 2 O
rocuronium	30 10 B-Chemical
to	41 2 O
decrease	44 8 O
fasciculation	53 13 B-Disease
and	67 3 O
myalgia	71 7 B-Disease
following	79 9 O
succinylcholine	89 15 B-Chemical
administration	105 14 O
.	119 1 O

BACKGROUND	121 10 O
:	131 1 O
Succinylcholine	133 15 B-Chemical
commonly	149 8 O
produces	158 8 O
frequent	167 8 O
adverse	176 7 O
effects	184 7 O
,	191 1 O
including	193 9 O
muscle	203 6 B-Disease
fasciculation	210 13 I-Disease
and	224 3 O
myalgia	228 7 B-Disease
.	235 1 O

The	237 3 O
current	241 7 O
study	249 5 O
identified	255 10 O
the	266 3 O
optimal	270 7 O
dose	278 4 O
of	283 2 O
rocuronium	286 10 B-Chemical
to	297 2 O
prevent	300 7 O
succinylcholine	308 15 B-Chemical
-	323 1 O
induced	324 7 O
fasciculation	332 13 B-Disease
and	346 3 O
myalgia	350 7 B-Disease
and	358 3 O
evaluated	362 9 O
the	372 3 O
influence	376 9 O
of	386 2 O
rocuronium	389 10 B-Chemical
on	400 2 O
the	403 3 O
speed	407 5 O
of	413 2 O
onset	416 5 O
produced	422 8 O
by	431 2 O
succinylcholine	434 15 B-Chemical
.	449 1 O

METHODS	451 7 O
:	458 1 O
This	460 4 O
randomized	465 10 O
,	475 1 O
double	477 6 O
-	483 1 O
blinded	484 7 O
study	492 5 O
was	498 3 O
conducted	502 9 O
in	512 2 O
100	515 3 O
patients	519 8 O
randomly	528 8 O
allocated	537 9 O
into	547 4 O
five	552 4 O
groups	557 6 O
of	564 2 O
20	567 2 O
patients	570 8 O
each	579 4 O
.	583 1 O

Patients	585 8 O
were	594 4 O
randomized	599 10 O
to	610 2 O
receive	613 7 O
0	621 1 O
.	622 1 O
02	623 2 O
,	625 1 O
0	627 1 O
.	628 1 O
03	629 2 O
,	631 1 O
0	633 1 O
.	634 1 O
04	635 2 O
,	637 1 O
0	639 1 O
.	640 1 O
05	641 2 O
and	644 3 O
0	648 1 O
.	649 1 O
06	650 2 O
mg	653 2 O
/	655 1 O
kg	656 2 O
rocuronium	659 10 B-Chemical
as	670 2 O
a	673 1 O
precurarizing	675 13 O
dose	689 4 O
.	693 1 O

Neuromuscular	695 13 O
monitoring	709 10 O
after	720 5 O
each	726 4 O
precurarizing	731 13 O
dose	745 4 O
was	750 3 O
recorded	754 8 O
from	763 4 O
the	768 3 O
adductor	772 8 O
pollicis	781 8 O
muscle	790 6 O
using	797 5 O
acceleromyography	803 17 O
with	821 4 O
train	826 5 O
-	831 1 O
of	832 2 O
-	834 1 O
four	835 4 O
stimulation	840 11 O
of	852 2 O
the	855 3 O
ulnar	859 5 O
nerve	865 5 O
.	870 1 O

All	872 3 O
patients	876 8 O
received	885 8 O
succinylcholine	894 15 B-Chemical
1	910 1 O
.	911 1 O
5	912 1 O
mg	914 2 O
/	916 1 O
kg	917 2 O
at	920 2 O
2	923 1 O
minutes	925 7 O
after	933 5 O
the	939 3 O
precurarization	943 15 O
,	958 1 O
and	960 3 O
were	964 4 O
assessed	969 8 O
the	978 3 O
incidence	982 9 O
and	992 3 O
severity	996 8 O
of	1005 2 O
fasciculations	1008 14 B-Disease
,	1022 1 O
while	1024 5 O
myalgia	1030 7 B-Disease
was	1038 3 O
assessed	1042 8 O
at	1051 2 O
24	1054 2 O
hours	1057 5 O
after	1063 5 O
surgery	1069 7 O
.	1076 1 O

RESULTS	1078 7 O
:	1085 1 O
The	1087 3 O
incidence	1091 9 O
and	1101 3 O
severity	1105 8 O
of	1114 2 O
visible	1117 7 O
muscle	1125 6 B-Disease
fasciculation	1132 13 I-Disease
was	1146 3 O
significantly	1150 13 O
less	1164 4 O
with	1169 4 O
increasing	1174 10 O
the	1185 3 O
amount	1189 6 O
of	1196 2 O
precurarizing	1199 13 O
dose	1213 4 O
of	1218 2 O
rocuronium	1221 10 B-Chemical
(	1232 1 O
P	1233 1 O
<	1235 1 O
0	1237 1 O
.	1238 1 O
001	1239 3 O
)	1242 1 O
.	1243 1 O

Those	1245 5 O
of	1251 2 O
myalgia	1254 7 B-Disease
tend	1262 4 O
to	1267 2 O
decrease	1270 8 O
according	1279 9 O
to	1289 2 O
increasing	1292 10 O
the	1303 3 O
amount	1307 6 O
of	1314 2 O
precurarizing	1317 13 O
dose	1331 4 O
of	1336 2 O
rocuronium	1339 10 B-Chemical
,	1349 1 O
but	1351 3 O
there	1355 5 O
was	1361 3 O
no	1365 2 O
significance	1368 12 O
(	1381 1 O
P	1382 1 O
=	1384 1 O
0	1386 1 O
.	1387 1 O
072	1388 3 O
)	1391 1 O
.	1392 1 O

The	1394 3 O
onset	1398 5 O
time	1404 4 O
of	1409 2 O
succinylcholine	1412 15 B-Chemical
was	1428 3 O
significantly	1432 13 O
longer	1446 6 O
with	1453 4 O
increasing	1458 10 O
the	1469 3 O
amount	1473 6 O
of	1480 2 O
precurarizing	1483 13 O
dose	1497 4 O
of	1502 2 O
rocuronium	1505 10 B-Chemical
(	1516 1 O
P	1517 1 O
<	1519 1 O
0	1521 1 O
.	1522 1 O
001	1523 3 O
)	1526 1 O
.	1527 1 O

CONCLUSIONS	1529 11 O
:	1540 1 O
Precurarization	1542 15 O
with	1558 4 O
0	1563 1 O
.	1564 1 O
04	1565 2 O
mg	1568 2 O
/	1570 1 O
kg	1571 2 O
rocuronium	1574 10 B-Chemical
was	1585 3 O
the	1589 3 O
optimal	1593 7 O
dose	1601 4 O
considering	1606 11 O
the	1618 3 O
reduction	1622 9 O
in	1632 2 O
the	1635 3 O
incidence	1639 9 O
and	1649 3 O
severity	1653 8 O
of	1662 2 O
fasciculation	1665 13 B-Disease
and	1679 3 O
myalgia	1683 7 B-Disease
with	1691 4 O
acceptable	1696 10 O
onset	1707 5 O
time	1713 4 O
,	1717 1 O
and	1719 3 O
the	1723 3 O
safe	1727 4 O
and	1732 3 O
effective	1736 9 O
precurarization	1746 15 O
.	1761 1 O

Absence	0 7 O
of	8 2 O
PKC	11 3 O
-	14 1 O
alpha	15 5 O
attenuates	21 10 O
lithium	32 7 B-Chemical
-	39 1 O
induced	40 7 O
nephrogenic	48 11 B-Disease
diabetes	60 8 I-Disease
insipidus	69 9 I-Disease
.	78 1 O

Lithium	80 7 B-Chemical
,	87 1 O
an	89 2 O
effective	92 9 O
antipsychotic	102 13 O
,	115 1 O
induces	117 7 O
nephrogenic	125 11 B-Disease
diabetes	137 8 I-Disease
insipidus	146 9 I-Disease
(	156 1 O
NDI	157 3 B-Disease
)	160 1 O
in	162 2 O
40	166 2 O
%	168 1 O
of	170 2 O
patients	173 8 O
.	181 1 O

The	183 3 O
decreased	187 9 O
capacity	197 8 O
to	206 2 O
concentrate	209 11 O
urine	221 5 O
is	227 2 O
likely	230 6 O
due	237 3 O
to	241 2 O
lithium	244 7 B-Chemical
acutely	252 7 O
disrupting	260 10 O
the	271 3 O
cAMP	275 4 B-Chemical
pathway	280 7 O
and	288 3 O
chronically	292 11 O
reducing	304 8 O
urea	313 4 B-Chemical
transporter	318 11 O
(	330 1 O
UT	331 2 O
-	333 1 O
A1	334 2 O
)	336 1 O
and	338 3 O
water	342 5 O
channel	348 7 O
(	356 1 O
AQP2	357 4 O
)	361 1 O
expression	363 10 O
in	374 2 O
the	377 3 O
inner	381 5 O
medulla	387 7 O
.	394 1 O

Targeting	396 9 O
an	406 2 O
alternative	409 11 O
signaling	421 9 O
pathway	431 7 O
,	438 1 O
such	440 4 O
as	445 2 O
PKC	448 3 O
-	451 1 O
mediated	452 8 O
signaling	461 9 O
,	470 1 O
may	472 3 O
be	476 2 O
an	479 2 O
effective	482 9 O
method	492 6 O
of	499 2 O
treating	502 8 O
lithium	511 7 B-Chemical
-	518 1 O
induced	519 7 O
polyuria	527 8 B-Disease
.	535 1 O

PKC	537 3 O
-	540 1 O
alpha	541 5 O
null	547 4 O
mice	552 4 O
(	557 1 O
PKCa	558 4 O
KO	563 2 O
)	565 1 O
and	567 3 O
strain	571 6 O
-	577 1 O
matched	578 7 O
wild	586 4 O
type	591 4 O
(	596 1 O
WT	597 2 O
)	599 1 O
controls	601 8 O
were	610 4 O
treated	615 7 O
with	623 4 O
lithium	628 7 B-Chemical
for	636 3 O
0	640 1 O
,	641 1 O
3	643 1 O
or	645 2 O
5	648 1 O
days	650 4 O
.	654 1 O

WT	656 2 O
mice	659 4 O
had	664 3 O
increased	668 9 O
urine	678 5 O
output	684 6 O
and	691 3 O
lowered	695 7 O
urine	703 5 O
osmolality	709 10 O
after	720 5 O
3	726 1 O
and	728 3 O
5	732 1 O
days	734 4 O
of	739 2 O
treatment	742 9 O
whereas	752 7 O
PKCa	760 4 O
KO	765 2 O
mice	768 4 O
had	773 3 O
no	777 2 O
change	780 6 O
in	787 2 O
urine	790 5 O
output	796 6 O
or	803 2 O
concentration	806 13 O
.	819 1 O

Western	821 7 O
blot	829 4 O
analysis	834 8 O
revealed	843 8 O
that	852 4 O
AQP2	857 4 O
expression	862 10 O
in	873 2 O
medullary	876 9 O
tissues	886 7 O
was	894 3 O
lowered	898 7 O
after	906 5 O
3	912 1 O
and	914 3 O
5	918 1 O
days	920 4 O
in	925 2 O
WT	928 2 O
mice	931 4 O
;	935 1 O
however	937 7 O
,	944 1 O
AQP2	946 4 O
was	951 3 O
unchanged	955 9 O
in	965 2 O
PKCa	968 4 O
KO	973 2 O
.	975 1 O

Similar	977 7 O
results	985 7 O
were	993 4 O
observed	998 8 O
with	1007 4 O
UT	1012 2 O
-	1014 1 O
A1	1015 2 O
expression	1018 10 O
.	1028 1 O

Animals	1030 7 O
were	1038 4 O
also	1043 4 O
treated	1048 7 O
with	1056 4 O
lithium	1061 7 B-Chemical
for	1069 3 O
6	1073 1 O
weeks	1075 5 O
.	1080 1 O

Lithium	1082 7 B-Chemical
-	1089 1 O
treated	1090 7 O
WT	1098 2 O
mice	1101 4 O
had	1106 3 O
19	1110 2 O
-	1112 1 O
fold	1113 4 O
increased	1118 9 O
urine	1128 5 O
output	1134 6 O
whereas	1141 7 O
treated	1149 7 O
PKCa	1157 4 O
KO	1162 2 O
animals	1165 7 O
had	1173 3 O
a	1177 1 O
4	1179 1 O
-	1180 1 O
fold	1181 4 O
increase	1186 8 O
in	1195 2 O
output	1198 6 O
.	1204 1 O

AQP2	1206 4 O
and	1211 3 O
UT	1215 2 O
-	1217 1 O
A1	1218 2 O
expression	1221 10 O
was	1232 3 O
lowered	1236 7 O
in	1244 2 O
6	1247 1 O
week	1249 4 O
lithium	1254 7 B-Chemical
-	1261 1 O
treated	1262 7 O
WT	1270 2 O
animals	1273 7 O
whereas	1281 7 O
in	1289 2 O
treated	1292 7 O
PKCa	1300 4 O
KO	1305 2 O
mice	1308 4 O
,	1312 1 O
AQP2	1314 4 O
was	1319 3 O
only	1323 4 O
reduced	1328 7 O
by	1336 2 O
2	1339 1 O
-	1340 1 O
fold	1341 4 O
and	1346 3 O
UT	1350 2 O
-	1352 1 O
A1	1353 2 O
expression	1356 10 O
was	1367 3 O
unaffected	1371 10 O
.	1381 1 O

Urinary	1383 7 O
sodium	1391 6 B-Chemical
,	1397 1 O
potassium	1399 9 B-Chemical
and	1409 3 O
calcium	1413 7 B-Chemical
were	1421 4 O
elevated	1426 8 O
in	1435 2 O
lithium	1438 7 B-Chemical
-	1445 1 O
fed	1446 3 O
WT	1450 2 O
but	1453 3 O
not	1457 3 O
in	1461 2 O
lithium	1464 7 B-Chemical
-	1471 1 O
fed	1472 3 O
PKCa	1476 4 O
KO	1481 2 O
mice	1484 4 O
.	1488 1 O

Our	1490 3 O
data	1494 4 O
show	1499 4 O
that	1504 4 O
ablation	1509 8 O
of	1518 2 O
PKCa	1521 4 O
preserves	1526 9 O
AQP2	1536 4 O
and	1541 3 O
UT	1545 2 O
-	1547 1 O
A1	1548 2 O
protein	1551 7 O
expression	1559 10 O
and	1570 3 O
localization	1574 12 O
in	1587 2 O
lithium	1590 7 B-Chemical
-	1597 1 O
induced	1598 7 O
NDI	1606 3 B-Disease
,	1609 1 O
and	1611 3 O
prevents	1615 8 O
the	1624 3 O
development	1628 11 O
of	1640 2 O
the	1643 3 O
severe	1647 6 O
polyuria	1654 8 B-Disease
associated	1663 10 O
with	1674 4 O
lithium	1679 7 B-Chemical
therapy	1687 7 O
.	1694 1 O

Is	0 2 O
Dysguesia	3 9 B-Disease
Going	13 5 O
to	19 2 O
be	22 2 O
a	25 1 O
Rare	27 4 O
or	32 2 O
a	35 1 O
Common	37 6 O
Side	44 4 O
-	48 1 O
effect	49 6 O
of	56 2 O
Amlodipine	59 10 B-Chemical
?	69 1 O

A	71 1 O
very	73 4 O
rare	78 4 O
side	83 4 O
-	87 1 O
effect	88 6 O
of	95 2 O
amlodipine	98 10 B-Chemical
is	109 2 O
dysguesia	112 9 B-Disease
.	121 1 O

A	123 1 O
review	125 6 O
of	132 2 O
the	135 3 O
literature	139 10 O
produced	150 8 O
only	159 4 O
one	164 3 O
case	168 4 O
.	172 1 O

We	174 2 O
report	177 6 O
a	184 1 O
case	186 4 O
about	191 5 O
a	197 1 O
female	199 6 O
with	206 4 O
essential	211 9 O
hypertension	221 12 B-Disease
on	234 2 O
drug	237 4 O
treatment	242 9 O
with	252 4 O
amlodipine	257 10 B-Chemical
developed	268 9 O
loss	278 4 B-Disease
of	283 2 I-Disease
taste	286 5 I-Disease
sensation	292 9 I-Disease
.	301 1 O

Condition	303 9 O
moderately	313 10 O
improved	324 8 O
on	333 2 O
stoppage	336 8 O
of	345 2 O
the	348 3 O
drug	352 4 O
for	357 3 O
25	361 2 O
days	364 4 O
.	368 1 O

We	370 2 O
conclude	373 8 O
that	382 4 O
amlodipine	387 10 B-Chemical
can	398 3 O
cause	402 5 O
dysguesia	408 9 B-Disease
.	417 1 O

Here	419 4 O
,	423 1 O
we	425 2 O
describe	428 8 O
the	437 3 O
clinical	441 8 O
presentation	450 12 O
and	463 3 O
review	467 6 O
the	474 3 O
relevant	478 8 O
literature	487 10 O
on	498 2 O
amlodipine	501 10 B-Chemical
and	512 3 O
dysguesia	516 9 B-Disease
.	525 1 O

Rhabdomyolysis	0 14 B-Disease
in	15 2 O
association	18 11 O
with	30 4 O
simvastatin	35 11 B-Chemical
and	47 3 O
dosage	51 6 O
increment	58 9 O
in	68 2 O
clarithromycin	71 14 B-Chemical
.	85 1 O

Clarithromycin	87 14 B-Chemical
is	102 2 O
the	105 3 O
most	109 4 O
documented	114 10 O
cytochrome	125 10 O
P450	136 4 O
3A4	141 3 O
(	145 1 O
CYP3A4	146 6 O
)	152 1 O
inhibitor	154 9 O
to	164 2 O
cause	167 5 O
an	173 2 O
adverse	176 7 O
interaction	184 11 O
with	196 4 O
simvastatin	201 11 B-Chemical
.	212 1 O

This	214 4 O
particular	219 10 O
case	230 4 O
is	235 2 O
of	238 2 O
interest	241 8 O
as	250 2 O
rhabdomyolysis	253 14 B-Disease
only	268 4 O
occurred	273 8 O
after	282 5 O
an	288 2 O
increase	291 8 O
in	300 2 O
the	303 3 O
dose	307 4 O
of	312 2 O
clarithromycin	315 14 B-Chemical
.	329 1 O

The	331 3 O
patient	335 7 O
developed	343 9 O
raised	353 6 O
cardiac	360 7 O
biomarkers	368 10 O
without	379 7 O
any	387 3 O
obvious	391 7 O
cardiac	399 7 O
issues	407 6 O
,	413 1 O
a	415 1 O
phenomenon	417 10 O
that	428 4 O
has	433 3 O
been	437 4 O
linked	442 6 O
to	449 2 O
rhabdomyolysis	452 14 B-Disease
previously	467 10 O
.	477 1 O

To	479 2 O
date	482 4 O
,	486 1 O
there	488 5 O
has	494 3 O
been	498 4 O
no	503 2 O
reported	506 8 O
effect	515 6 O
of	522 2 O
rhabdomyolysis	525 14 B-Disease
on	540 2 O
the	543 3 O
structure	547 9 O
and	557 3 O
function	561 8 O
of	570 2 O
cardiac	573 7 O
muscle	581 6 O
.	587 1 O

Clinicians	589 10 O
need	600 4 O
to	605 2 O
be	608 2 O
aware	611 5 O
of	617 2 O
prescribing	620 11 O
concomitant	632 11 O
medications	644 11 O
that	656 4 O
increase	661 8 O
the	670 3 O
risk	674 4 O
of	679 2 O
myopathy	682 8 B-Disease
or	691 2 O
inhibit	694 7 O
the	702 3 O
CYP3A4	706 6 O
enzyme	713 6 O
.	719 1 O

Our	721 3 O
case	725 4 O
suggests	730 8 O
that	739 4 O
troponin	744 8 O
elevation	753 9 O
could	763 5 O
be	769 2 O
associated	772 10 O
with	783 4 O
statin	788 6 B-Chemical
induced	795 7 O
rhabdomyolysis	803 14 B-Disease
,	817 1 O
which	819 5 O
may	825 3 O
warrant	829 7 O
further	837 7 O
studies	845 7 O
.	852 1 O

Characterization	0 16 O
of	17 2 O
a	20 1 O
novel	22 5 O
BCHE	28 4 O
"	33 1 O
silent	34 6 O
"	40 1 O
allele	42 6 O
:	48 1 O
point	50 5 O
mutation	56 8 O
(	65 1 O
p	66 1 O
.	67 1 O
Val204Asp	68 9 O
)	77 1 O
causes	79 6 O
loss	86 4 O
of	91 2 O
activity	94 8 O
and	103 3 O
prolonged	107 9 O
apnea	117 5 B-Disease
with	123 4 O
suxamethonium	128 13 B-Chemical
.	141 1 O

Butyrylcholinesterase	143 21 B-Disease
deficiency	165 10 I-Disease
is	176 2 O
characterized	179 13 O
by	193 2 O
prolonged	196 9 O
apnea	206 5 B-Disease
after	212 5 O
the	218 3 O
use	222 3 O
of	226 2 O
muscle	229 6 O
relaxants	236 9 O
(	246 1 O
suxamethonium	247 13 B-Chemical
or	261 2 O
mivacurium	264 10 B-Chemical
)	274 1 O
in	276 2 O
patients	279 8 O
who	288 3 O
have	292 4 O
mutations	297 9 O
in	307 2 O
the	310 3 O
BCHE	314 4 O
gene	319 4 O
.	323 1 O

Here	325 4 O
,	329 1 O
we	331 2 O
report	334 6 O
a	341 1 O
case	343 4 O
of	348 2 O
prolonged	351 9 O
neuromuscular	361 13 O
block	375 5 O
after	381 5 O
administration	387 14 O
of	402 2 O
suxamethonium	405 13 B-Chemical
leading	419 7 O
to	427 2 O
the	430 3 O
discovery	434 9 O
of	444 2 O
a	447 1 O
novel	449 5 O
BCHE	455 4 O
variant	460 7 O
(	468 1 O
c	469 1 O
.	470 1 O
695T	471 4 O
>	475 1 O
A	476 1 O
,	477 1 O
p	479 1 O
.	480 1 O
Val204Asp	481 9 O
)	490 1 O
.	491 1 O

Inhibition	493 10 O
studies	504 7 O
,	511 1 O
kinetic	513 7 O
analysis	521 8 O
and	530 3 O
molecular	534 9 O
dynamics	544 8 O
were	553 4 O
undertaken	558 10 O
to	569 2 O
understand	572 10 O
how	583 3 O
this	587 4 O
mutation	592 8 O
disrupts	601 8 O
the	610 3 O
catalytic	614 9 O
triad	624 5 O
and	630 3 O
determines	634 10 O
a	645 1 O
"	647 1 O
silent	648 6 O
"	654 1 O
phenotype	656 9 O
.	665 1 O

Low	667 3 O
activity	671 8 O
of	680 2 O
patient	683 7 O
plasma	691 6 O
butyrylcholinesterase	698 21 O
with	720 4 O
butyrylthiocholine	725 18 B-Chemical
(	744 1 O
BTC	745 3 B-Chemical
)	748 1 O
and	750 3 O
benzoylcholine	754 14 B-Chemical
,	768 1 O
and	770 3 O
values	774 6 O
of	781 2 O
dibucaine	784 9 B-Chemical
and	794 3 O
fluoride	798 8 B-Chemical
numbers	807 7 O
fit	815 3 O
with	819 4 O
heterozygous	824 12 O
atypical	837 8 O
silent	846 6 O
genotype	853 8 O
.	861 1 O

Electrophoretic	863 15 O
analysis	879 8 O
of	888 2 O
plasma	891 6 O
BChE	898 4 O
of	903 2 O
the	906 3 O
proband	910 7 O
and	918 3 O
his	922 3 O
mother	926 6 O
showed	933 6 O
that	940 4 O
patient	945 7 O
has	953 3 O
a	957 1 O
reduced	959 7 O
amount	967 6 O
of	974 2 O
tetrameric	977 10 O
enzyme	988 6 O
in	995 2 O
plasma	998 6 O
and	1005 3 O
that	1009 4 O
minor	1014 5 O
fast	1020 4 O
-	1024 1 O
moving	1025 6 O
BChE	1032 4 O
components	1037 10 O
:	1047 1 O
monomer	1049 7 O
,	1056 1 O
dimer	1058 5 O
,	1063 1 O
and	1065 3 O
monomer	1069 7 O
-	1076 1 O
albumin	1077 7 O
conjugate	1085 9 O
are	1095 3 O
missing	1099 7 O
.	1106 1 O

Kinetic	1108 7 O
analysis	1116 8 O
showed	1125 6 O
that	1132 4 O
the	1137 3 O
p	1141 1 O
.	1142 1 O
Val204Asp	1143 9 O
/	1152 1 O
p	1153 1 O
.	1154 1 O
Asp70Gly	1155 8 O
-	1163 1 O
p	1164 1 O
.	1165 1 O
Ala539Thr	1166 9 O
BChE	1176 4 O
displays	1181 8 O
a	1190 1 O
pure	1192 4 O
Michaelian	1197 10 O
behavior	1208 8 O
with	1217 4 O
BTC	1222 3 B-Chemical
as	1226 2 O
the	1229 3 O
substrate	1233 9 O
.	1242 1 O

Both	1244 4 O
catalytic	1249 9 O
parameters	1259 10 O
Km	1270 2 O
=	1273 1 O
265	1275 3 O
uM	1279 2 O
for	1282 3 O
BTC	1286 3 B-Chemical
,	1289 1 O
two	1291 3 O
times	1295 5 O
higher	1301 6 O
than	1308 4 O
that	1313 4 O
of	1318 2 O
the	1321 3 O
atypical	1325 8 O
enzyme	1334 6 O
,	1340 1 O
and	1342 3 O
a	1346 1 O
low	1348 3 O
Vmax	1352 4 O
are	1357 3 O
consistent	1361 10 O
with	1372 4 O
the	1377 3 O
absence	1381 7 O
of	1389 2 O
activity	1392 8 O
against	1401 7 O
suxamethonium	1409 13 B-Chemical
.	1422 1 O

Molecular	1424 9 O
dynamic	1434 7 O
(	1442 1 O
MD	1443 2 O
)	1445 1 O
simulations	1447 11 O
showed	1459 6 O
that	1466 4 O
the	1471 3 O
overall	1475 7 O
effect	1483 6 O
of	1490 2 O
the	1493 3 O
mutation	1497 8 O
p	1506 1 O
.	1507 1 O
Val204Asp	1508 9 O
is	1518 2 O
disruption	1521 10 O
of	1532 2 O
hydrogen	1535 8 B-Chemical
bonding	1544 7 O
between	1552 7 O
Gln223	1560 6 O
and	1567 3 O
Glu441	1571 6 O
,	1577 1 O
leading	1579 7 O
Ser198	1587 6 O
and	1594 3 O
His438	1598 6 O
to	1605 2 O
move	1608 4 O
away	1613 4 O
from	1618 4 O
each	1623 4 O
other	1628 5 O
with	1634 4 O
subsequent	1639 10 O
disruption	1650 10 O
of	1661 2 O
the	1664 3 O
catalytic	1668 9 O
triad	1678 5 O
functionality	1684 13 O
regardless	1698 10 O
of	1709 2 O
the	1712 3 O
type	1716 4 O
of	1721 2 O
substrate	1724 9 O
.	1733 1 O

MD	1735 2 O
also	1738 4 O
showed	1743 6 O
that	1750 4 O
the	1755 3 O
enzyme	1759 6 O
volume	1766 6 O
is	1773 2 O
increased	1776 9 O
,	1785 1 O
suggesting	1787 10 O
a	1798 1 O
pre	1800 3 O
-	1803 1 O
denaturation	1804 12 O
state	1817 5 O
.	1822 1 O

This	1824 4 O
fits	1829 4 O
with	1834 4 O
the	1839 3 O
reduced	1843 7 O
concentration	1851 13 O
of	1865 2 O
p	1868 1 O
.	1869 1 O
Ala204Asp	1870 9 O
/	1879 1 O
p	1880 1 O
.	1881 1 O
Asp70Gly	1882 8 O
-	1890 1 O
p	1891 1 O
.	1892 1 O
Ala539Thr	1893 9 O
tetrameric	1903 10 O
enzyme	1914 6 O
in	1921 2 O
the	1924 3 O
plasma	1928 6 O
and	1935 3 O
non	1939 3 O
-	1942 1 O
detectable	1943 10 O
fast	1954 4 O
moving	1959 6 O
-	1965 1 O
bands	1966 5 O
on	1972 2 O
electrophoresis	1975 15 O
gels	1991 4 O
.	1995 1 O

Delayed	0 7 O
anemia	8 6 B-Disease
after	15 5 O
treatment	21 9 O
with	31 4 O
injectable	36 10 O
artesunate	47 10 B-Chemical
in	58 2 O
the	61 3 O
Democratic	65 10 O
Republic	76 8 O
of	85 2 O
the	88 3 O
Congo	92 5 O
:	97 1 O
a	99 1 O
manageable	101 10 O
issue	112 5 O
.	117 1 O

Cases	119 5 O
of	125 2 O
delayed	128 7 O
hemolytic	136 9 B-Disease
anemia	146 6 I-Disease
have	153 4 O
been	158 4 O
described	163 9 O
after	173 5 O
treatment	179 9 O
with	189 4 O
injectable	194 10 O
artesunate	205 10 B-Chemical
,	215 1 O
the	217 3 O
current	221 7 O
World	229 5 O
Health	235 6 O
Organization	242 12 O
(	255 1 O
WHO	256 3 O
)	259 1 O
-	260 1 O
recommended	261 11 O
first	273 5 O
-	278 1 O
line	279 4 O
drug	284 4 O
for	289 3 O
the	293 3 O
treatment	297 9 O
of	307 2 O
severe	310 6 O
malaria	317 7 B-Disease
.	324 1 O

A	326 1 O
total	328 5 O
of	334 2 O
350	337 3 O
patients	341 8 O
(	350 1 O
215	351 3 O
[	355 1 O
61	356 2 O
.	358 1 O
4	359 1 O
%	360 1 O
]	361 1 O
<	363 1 O
5	365 1 O
years	367 5 O
of	373 2 O
age	376 3 O
and	380 3 O
135	384 3 O
[	388 1 O
38	389 2 O
.	391 1 O
6	392 1 O
%	393 1 O
]	394 1 O
>	396 1 O
5	398 1 O
years	400 5 O
of	406 2 O
age	409 3 O
)	412 1 O
were	414 4 O
followed	419 8 O
-	427 1 O
up	428 2 O
after	431 5 O
treatment	437 9 O
with	447 4 O
injectable	452 10 O
artesunate	463 10 B-Chemical
for	474 3 O
severe	478 6 O
malaria	485 7 B-Disease
in	493 2 O
hospitals	496 9 O
and	506 3 O
health	510 6 O
centers	517 7 O
of	525 2 O
the	528 3 O
Democratic	532 10 O
Republic	543 8 O
of	552 2 O
the	555 3 O
Congo	559 5 O
.	564 1 O

Complete	566 8 O
series	575 6 O
of	582 2 O
hemoglobin	585 10 O
(	596 1 O
Hb	597 2 O
)	599 1 O
measurements	601 12 O
were	614 4 O
available	619 9 O
for	629 3 O
201	633 3 O
patients	637 8 O
.	645 1 O

A	647 1 O
decrease	649 8 O
in	658 2 O
Hb	661 2 O
levels	664 6 O
between	671 7 O
2	679 1 O
and	681 3 O
5	685 1 O
g	687 1 O
/	688 1 O
dL	689 2 O
was	692 3 O
detected	696 8 O
in	705 2 O
23	708 2 O
(	711 1 O
11	712 2 O
.	714 1 O
4	715 1 O
%	716 1 O
)	717 1 O
patients	719 8 O
during	728 6 O
the	735 3 O
follow	739 6 O
-	745 1 O
up	746 2 O
period	749 6 O
.	755 1 O

For	757 3 O
five	761 4 O
patients	766 8 O
,	774 1 O
Hb	776 2 O
levels	779 6 O
decreased	786 9 O
below	796 5 O
5	802 1 O
g	804 1 O
/	805 1 O
dL	806 2 O
during	809 6 O
at	816 2 O
least	819 5 O
one	825 3 O
follow	829 6 O
-	835 1 O
up	836 2 O
visit	839 5 O
.	844 1 O

All	846 3 O
cases	850 5 O
of	856 2 O
delayed	859 7 O
anemia	867 6 B-Disease
were	874 4 O
clinically	879 10 O
manageable	890 10 O
and	901 3 O
resolved	905 8 O
within	914 6 O
one	921 3 O
month	925 5 O
.	930 1 O

Regulation	0 10 O
of	11 2 O
signal	14 6 O
transducer	21 10 O
and	32 3 O
activator	36 9 O
of	46 2 O
transcription	49 13 O
3	63 1 O
and	65 3 O
apoptotic	69 9 O
pathways	79 8 O
by	88 2 O
betaine	91 7 B-Chemical
attenuates	99 10 O
isoproterenol	110 13 B-Chemical
-	123 1 O
induced	124 7 O
acute	132 5 O
myocardial	138 10 B-Disease
injury	149 6 I-Disease
in	156 2 O
rats	159 4 O
.	163 1 O

The	165 3 O
present	169 7 O
study	177 5 O
was	183 3 O
designed	187 8 O
to	196 2 O
investigate	199 11 O
the	211 3 O
cardioprotective	215 16 O
effects	232 7 O
of	240 2 O
betaine	243 7 B-Chemical
on	251 2 O
acute	254 5 O
myocardial	260 10 B-Disease
ischemia	271 8 I-Disease
induced	280 7 O
experimentally	288 14 O
in	303 2 O
rats	306 4 O
focusing	311 8 O
on	320 2 O
regulation	323 10 O
of	334 2 O
signal	337 6 O
transducer	344 10 O
and	355 3 O
activator	359 9 O
of	369 2 O
transcription	372 13 O
3	386 1 O
(	388 1 O
STAT3	389 5 O
)	394 1 O
and	396 3 O
apoptotic	400 9 O
pathways	410 8 O
as	419 2 O
the	422 3 O
potential	426 9 O
mechanism	436 9 O
underlying	446 10 O
the	457 3 O
drug	461 4 O
effect	466 6 O
.	472 1 O

Male	474 4 O
Sprague	479 7 O
Dawley	487 6 O
rats	494 4 O
were	499 4 O
treated	504 7 O
with	512 4 O
betaine	517 7 B-Chemical
(	525 1 O
100	526 3 O
,	529 1 O
200	531 3 O
,	534 1 O
and	536 3 O
400	540 3 O
mg	544 2 O
/	546 1 O
kg	547 2 O
)	549 1 O
orally	551 6 O
for	558 3 O
40	562 2 O
days	565 4 O
.	569 1 O

Acute	571 5 O
myocardial	577 10 B-Disease
ischemic	588 8 I-Disease
injury	597 6 I-Disease
was	604 3 O
induced	608 7 O
in	616 2 O
rats	619 4 O
by	624 2 O
subcutaneous	627 12 O
injection	640 9 O
of	650 2 O
isoproterenol	653 13 B-Chemical
(	667 1 O
85	668 2 O
mg	671 2 O
/	673 1 O
kg	674 2 O
)	676 1 O
,	677 1 O
for	679 3 O
two	683 3 O
consecutive	687 11 O
days	699 4 O
.	703 1 O

Serum	705 5 O
cardiac	711 7 O
marker	719 6 O
enzyme	726 6 O
,	732 1 O
histopathological	734 17 O
variables	752 9 O
and	762 3 O
expression	766 10 O
of	777 2 O
protein	780 7 O
levels	788 6 O
were	795 4 O
analyzed	800 8 O
.	808 1 O

Oral	810 4 O
administration	815 14 O
of	830 2 O
betaine	833 7 B-Chemical
(	841 1 O
200	842 3 O
and	846 3 O
400	850 3 O
mg	854 2 O
/	856 1 O
kg	857 2 O
)	859 1 O
significantly	861 13 O
reduced	875 7 O
the	883 3 O
level	887 5 O
of	893 2 O
cardiac	896 7 O
marker	904 6 O
enzyme	911 6 O
in	918 2 O
the	921 3 O
serum	925 5 O
and	931 3 O
prevented	935 9 O
left	945 4 O
ventricular	950 11 B-Disease
remodeling	962 10 I-Disease
.	972 1 O

Western	974 7 O
blot	982 4 O
analysis	987 8 O
showed	996 6 O
that	1003 4 O
isoproterenol	1008 13 B-Chemical
-	1021 1 O
induced	1022 7 O
phosphorylation	1030 15 O
of	1046 2 O
STAT3	1049 5 O
was	1055 3 O
maintained	1059 10 O
or	1070 2 O
further	1073 7 O
enhanced	1081 8 O
by	1090 2 O
betaine	1093 7 B-Chemical
treatment	1101 9 O
in	1111 2 O
myocardium	1114 10 O
.	1124 1 O

Furthermore	1126 11 O
,	1137 1 O
betaine	1139 7 B-Chemical
(	1147 1 O
200	1148 3 O
and	1152 3 O
400	1156 3 O
mg	1160 2 O
/	1162 1 O
kg	1163 2 O
)	1165 1 O
treatment	1167 9 O
increased	1177 9 O
the	1187 3 O
ventricular	1191 11 O
expression	1203 10 O
of	1214 2 O
Bcl	1217 3 O
-	1220 1 O
2	1221 1 O
and	1223 3 O
reduced	1227 7 O
the	1235 3 O
level	1239 5 O
of	1245 2 O
Bax	1248 3 O
,	1251 1 O
therefore	1253 9 O
causing	1263 7 O
a	1271 1 O
significant	1273 11 O
increase	1285 8 O
in	1294 2 O
the	1297 3 O
ratio	1301 5 O
of	1307 2 O
Bcl	1310 3 O
-	1313 1 O
2	1314 1 O
/	1315 1 O
Bax	1316 3 O
.	1319 1 O

The	1321 3 O
protective	1325 10 O
role	1336 4 O
of	1341 2 O
betaine	1344 7 B-Chemical
on	1352 2 O
myocardial	1355 10 B-Disease
damage	1366 6 I-Disease
was	1373 3 O
further	1377 7 O
confirmed	1385 9 O
by	1395 2 O
histopathological	1398 17 O
examination	1416 11 O
.	1427 1 O

In	1429 2 O
summary	1432 7 O
,	1439 1 O
our	1441 3 O
results	1445 7 O
showed	1453 6 O
that	1460 4 O
betaine	1465 7 B-Chemical
pretreatment	1473 12 O
attenuated	1486 10 O
isoproterenol	1497 13 B-Chemical
-	1510 1 O
induced	1511 7 O
acute	1519 5 O
myocardial	1525 10 B-Disease
ischemia	1536 8 I-Disease
via	1545 3 O
the	1549 3 O
regulation	1553 10 O
of	1564 2 O
STAT3	1567 5 O
and	1573 3 O
apoptotic	1577 9 O
pathways	1587 8 O
.	1595 1 O

Quetiapine	0 10 B-Chemical
-	10 1 O
induced	11 7 O
neutropenia	19 11 B-Disease
in	31 2 O
a	34 1 O
bipolar	36 7 B-Disease
patient	44 7 O
with	52 4 O
hepatocellular	57 14 B-Disease
carcinoma	72 9 I-Disease
.	81 1 O

OBJECTIVE	83 9 O
:	92 1 O
Quetiapine	94 10 B-Chemical
is	105 2 O
a	108 1 O
dibenzothiazepine	110 17 O
derivative	128 10 O
,	138 1 O
similar	140 7 O
to	148 2 O
clozapine	151 9 B-Chemical
,	160 1 O
which	162 5 O
has	168 3 O
the	172 3 O
highest	176 7 O
risk	184 4 O
of	189 2 O
causing	192 7 O
blood	200 5 B-Disease
dyscrasias	206 10 I-Disease
,	216 1 O
especially	218 10 O
neutropenia	229 11 B-Disease
.	240 1 O

There	242 5 O
are	248 3 O
some	252 4 O
case	257 4 O
reports	262 7 O
about	270 5 O
this	276 4 O
side	281 4 O
effect	286 6 O
of	293 2 O
quetiapine	296 10 B-Chemical
,	306 1 O
but	308 3 O
possible	312 8 O
risk	321 4 O
factors	326 7 O
are	334 3 O
seldom	338 6 O
discussed	345 9 O
and	355 3 O
identified	359 10 O
.	369 1 O

A	371 1 O
case	373 4 O
of	378 2 O
a	381 1 O
patient	383 7 O
with	391 4 O
hepatocellular	396 14 B-Disease
carcinoma	411 9 I-Disease
that	421 4 O
developed	426 9 O
neutropenia	436 11 B-Disease
after	448 5 O
treatment	454 9 O
with	464 4 O
quetiapine	469 10 B-Chemical
is	480 2 O
described	483 9 O
here	493 4 O
.	497 1 O

CASE	499 4 O
REPORT	504 6 O
:	510 1 O
A	512 1 O
62	514 2 O
-	516 1 O
year	517 4 O
-	521 1 O
old	522 3 O
Taiwanese	526 9 O
widow	536 5 O
with	542 4 O
bipolar	547 7 B-Disease
disorder	555 8 I-Disease
was	564 3 O
diagnosed	568 9 O
with	578 4 O
hepatocellular	583 14 B-Disease
carcinoma	598 9 I-Disease
at	608 2 O
age	611 3 O
60	615 2 O
.	617 1 O

She	619 3 O
developed	623 9 O
leucopenia	633 10 B-Disease
after	644 5 O
being	650 5 O
treated	656 7 O
with	664 4 O
quetiapine	669 10 B-Chemical
.	679 1 O

After	681 5 O
quetiapine	687 10 B-Chemical
was	698 3 O
discontinued	702 12 O
,	714 1 O
her	716 3 O
white	720 5 O
blood	726 5 O
cell	732 4 O
count	737 5 O
returned	743 8 O
to	752 2 O
normal	755 6 O
.	761 1 O

CONCLUSIONS	763 11 O
:	774 1 O
Although	776 8 O
neutropenia	785 11 B-Disease
is	797 2 O
not	800 3 O
a	804 1 O
common	806 6 O
side	813 4 O
effect	818 6 O
of	825 2 O
quetiapine	828 10 B-Chemical
,	838 1 O
physicians	840 10 O
should	851 6 O
be	858 2 O
cautious	861 8 O
about	870 5 O
its	876 3 O
presentation	880 12 O
and	893 3 O
associated	897 10 O
risk	908 4 O
factors	913 7 O
.	920 1 O

Hepatic	922 7 B-Disease
dysfunction	930 11 I-Disease
may	942 3 O
be	946 2 O
one	949 3 O
of	953 2 O
the	956 3 O
possible	960 8 O
risk	969 4 O
factors	974 7 O
,	981 1 O
and	983 3 O
concomitant	987 11 O
fever	999 5 B-Disease
may	1005 3 O
be	1009 2 O
a	1012 1 O
diagnostic	1014 10 O
marker	1025 6 O
for	1032 3 O
adverse	1036 7 O
reaction	1044 8 O
to	1053 2 O
quetiapine	1056 10 B-Chemical
.	1066 1 O

Lateral	0 7 O
antebrachial	8 12 O
cutaneous	21 9 O
neuropathy	31 10 B-Disease
after	42 5 O
steroid	48 7 B-Chemical
injection	56 9 O
at	66 2 O
lateral	69 7 O
epicondyle	77 10 O
.	87 1 O

BACKGROUND	89 10 O
AND	100 3 O
OBJECTIVES	104 10 O
:	114 1 O
This	116 4 O
report	121 6 O
aimed	128 5 O
to	134 2 O
present	137 7 O
a	145 1 O
case	147 4 O
of	152 2 O
lateral	155 7 O
antebrachial	163 12 O
cutaneous	176 9 O
neuropathy	186 10 B-Disease
(	197 1 O
LACNP	198 5 O
)	203 1 O
that	205 4 O
occurred	210 8 O
after	219 5 O
a	225 1 O
steroid	227 7 B-Chemical
injection	235 9 O
in	245 2 O
the	248 3 O
lateral	252 7 O
epicondyle	260 10 O
to	271 2 O
treat	274 5 O
lateral	280 7 B-Disease
epicondylitis	288 13 I-Disease
in	302 2 O
a	305 1 O
40	307 2 O
-	309 1 O
year	310 4 O
-	314 1 O
old	315 3 O
woman	319 5 O
.	324 1 O

MATERIAL	326 8 O
AND	335 3 O
METHOD	339 6 O
:	345 1 O
A	347 1 O
40	349 2 O
-	351 1 O
year	352 4 O
-	356 1 O
old	357 3 O
woman	361 5 O
presented	367 9 O
with	377 4 O
decreased	382 9 O
sensation	392 9 O
and	402 3 O
paresthesia	406 11 B-Disease
over	418 4 O
her	423 3 O
right	427 5 O
lateral	433 7 O
forearm	441 7 O
;	448 1 O
the	450 3 O
paresthesia	454 11 B-Disease
had	466 3 O
occurred	470 8 O
after	479 5 O
a	485 1 O
steroid	487 7 B-Chemical
injection	495 9 O
in	505 2 O
the	508 3 O
right	512 5 O
lateral	518 7 O
epicondyle	526 10 O
3	537 1 O
months	539 6 O
before	546 6 O
.	552 1 O

Her	554 3 O
sensation	558 9 O
of	568 2 O
light	571 5 O
touch	577 5 O
and	583 3 O
pain	587 4 B-Disease
was	592 3 O
diminished	596 10 O
over	607 4 O
the	612 3 O
lateral	616 7 O
side	624 4 O
of	629 2 O
the	632 3 O
right	636 5 O
forearm	642 7 O
and	650 3 O
wrist	654 5 O
area	660 4 O
.	664 1 O

RESULTS	666 7 O
:	673 1 O
The	675 3 O
sensory	679 7 O
action	687 6 O
potential	694 9 O
amplitude	704 9 O
of	714 2 O
the	717 3 O
right	721 5 O
lateral	727 7 O
antebrachial	735 12 O
cutaneous	748 9 O
nerve	758 5 O
(	764 1 O
LACN	765 4 O
)	769 1 O
(	771 1 O
6	772 1 O
.	773 1 O
2	774 1 O
uV	776 2 O
)	778 1 O
was	780 3 O
lower	784 5 O
than	790 4 O
that	795 4 O
of	800 2 O
the	803 3 O
left	807 4 O
(	812 1 O
13	813 2 O
.	815 1 O
1	816 1 O
uV	818 2 O
)	820 1 O
.	821 1 O

The	823 3 O
difference	827 10 O
of	838 2 O
amplitude	841 9 O
between	851 7 O
both	859 4 O
sides	864 5 O
was	870 3 O
significant	874 11 O
because	886 7 O
there	894 5 O
was	900 3 O
more	904 4 O
than	909 4 O
a	914 1 O
50	916 2 O
%	918 1 O
reduction	920 9 O
.	929 1 O

She	931 3 O
was	935 3 O
diagnosed	939 9 O
with	949 4 O
right	954 5 O
LACNP	960 5 O
(	966 1 O
mainly	967 6 O
axonal	974 6 O
involvement	981 11 O
)	992 1 O
on	994 2 O
the	997 3 O
basis	1001 5 O
of	1007 2 O
the	1010 3 O
clinical	1014 8 O
manifestation	1023 13 O
and	1037 3 O
the	1041 3 O
electrodiagnostic	1045 17 O
findings	1063 8 O
.	1071 1 O

Her	1073 3 O
symptoms	1077 8 O
improved	1086 8 O
through	1095 7 O
physical	1103 8 O
therapy	1112 7 O
but	1120 3 O
persisted	1124 9 O
to	1134 2 O
some	1137 4 O
degree	1142 6 O
.	1148 1 O

CONCLUSION	1150 10 O
:	1160 1 O
This	1162 4 O
report	1167 6 O
describes	1174 9 O
the	1184 3 O
case	1188 4 O
of	1193 2 O
a	1196 1 O
woman	1198 5 O
with	1204 4 O
LACNP	1209 5 O
that	1215 4 O
developed	1220 9 O
after	1230 5 O
a	1236 1 O
steroid	1238 7 B-Chemical
injection	1246 9 O
for	1256 3 O
the	1260 3 O
treatment	1264 9 O
of	1274 2 O
lateral	1277 7 B-Disease
epicondylitis	1285 13 I-Disease
.	1298 1 O

An	1300 2 O
electrodiagnostic	1303 17 O
study	1321 5 O
,	1326 1 O
including	1328 9 O
a	1338 1 O
nerve	1340 5 O
conduction	1346 10 O
study	1357 5 O
of	1363 2 O
the	1366 3 O
LACN	1370 4 O
,	1374 1 O
was	1376 3 O
helpful	1380 7 O
to	1388 2 O
diagnose	1391 8 O
right	1400 5 O
LACNP	1406 5 O
and	1412 3 O
to	1416 2 O
find	1419 4 O
the	1424 3 O
passage	1428 7 O
of	1436 2 O
the	1439 3 O
LACN	1443 4 O
on	1448 2 O
the	1451 3 O
lateral	1455 7 O
epicondyle	1463 10 O
.	1473 1 O

Curcumin	0 8 B-Chemical
prevents	9 8 O
maleate	18 7 B-Chemical
-	25 1 O
induced	26 7 O
nephrotoxicity	34 14 B-Disease
:	48 1 O
relation	50 8 O
to	59 2 O
hemodynamic	62 11 O
alterations	74 11 O
,	85 1 O
oxidative	87 9 O
stress	97 6 O
,	103 1 O
mitochondrial	105 13 O
oxygen	119 6 B-Chemical
consumption	126 11 O
and	138 3 O
activity	142 8 O
of	151 2 O
respiratory	154 11 O
complex	166 7 O
I	174 1 O
.	175 1 O

The	177 3 O
potential	181 9 O
protective	191 10 O
effect	202 6 O
of	209 2 O
the	212 3 O
dietary	216 7 O
antioxidant	224 11 O
curcumin	236 8 B-Chemical
(	245 1 O
120	246 3 O
mg	250 2 O
/	252 1 O
Kg	253 2 O
/	255 1 O
day	256 3 O
for	260 3 O
6	264 1 O
days	266 4 O
)	270 1 O
against	272 7 O
the	280 3 O
renal	284 5 B-Disease
injury	290 6 I-Disease
induced	297 7 O
by	305 2 O
maleate	308 7 B-Chemical
was	316 3 O
evaluated	320 9 O
.	329 1 O

Tubular	331 7 O
proteinuria	339 11 B-Disease
and	351 3 O
oxidative	355 9 O
stress	365 6 O
were	372 4 O
induced	377 7 O
by	385 2 O
a	388 1 O
single	390 6 O
injection	397 9 O
of	407 2 O
maleate	410 7 B-Chemical
(	418 1 O
400	419 3 O
mg	423 2 O
/	425 1 O
kg	426 2 O
)	428 1 O
in	430 2 O
rats	433 4 O
.	437 1 O

Maleate	439 7 B-Chemical
-	446 1 O
induced	447 7 O
renal	455 5 B-Disease
injury	461 6 I-Disease
included	468 8 O
increase	477 8 O
in	486 2 O
renal	489 5 O
vascular	495 8 O
resistance	504 10 O
and	515 3 O
in	519 2 O
the	522 3 O
urinary	526 7 O
excretion	534 9 O
of	544 2 O
total	547 5 O
protein	553 7 O
,	560 1 O
glucose	562 7 B-Chemical
,	569 1 O
sodium	571 6 B-Chemical
,	577 1 O
neutrophil	579 10 O
gelatinase	590 10 O
-	600 1 O
associated	601 10 O
lipocalin	612 9 O
(	622 1 O
NGAL	623 4 O
)	627 1 O
and	629 3 O
N	633 1 O
-	634 1 O
acetyl	635 6 O
b	642 1 O
-	643 1 O
D	644 1 O
-	645 1 O
glucosaminidase	646 15 O
(	662 1 O
NAG	663 3 O
)	666 1 O
,	667 1 O
upregulation	669 12 O
of	682 2 O
kidney	685 6 B-Disease
injury	692 6 I-Disease
molecule	699 8 O
(	708 1 O
KIM	709 3 O
)	712 1 O
-	713 1 O
1	714 1 O
,	715 1 O
decrease	717 8 O
in	726 2 O
renal	729 5 O
blood	735 5 O
flow	741 4 O
and	746 3 O
claudin	750 7 O
-	757 1 O
2	758 1 O
expression	760 10 O
besides	771 7 O
of	779 2 O
necrosis	782 8 B-Disease
and	791 3 O
apoptosis	795 9 O
of	805 2 O
tubular	808 7 O
cells	816 5 O
on	822 2 O
24	825 2 O
h	828 1 O
.	829 1 O

Oxidative	831 9 O
stress	841 6 O
was	848 3 O
determined	852 10 O
by	863 2 O
measuring	866 9 O
the	876 3 O
oxidation	880 9 O
of	890 2 O
lipids	893 6 O
and	900 3 O
proteins	904 8 O
and	913 3 O
diminution	917 10 O
in	928 2 O
renal	931 5 O
Nrf2	937 4 O
levels	942 6 O
.	948 1 O

Studies	950 7 O
were	958 4 O
also	963 4 O
conducted	968 9 O
in	978 2 O
renal	981 5 O
epithelial	987 10 O
LLC	998 3 O
-	1001 1 O
PK1	1002 3 O
cells	1006 5 O
and	1012 3 O
in	1016 2 O
mitochondria	1019 12 O
isolated	1032 8 O
from	1041 4 O
kidneys	1046 7 O
of	1054 2 O
all	1057 3 O
the	1061 3 O
experimental	1065 12 O
groups	1078 6 O
.	1084 1 O

Maleate	1086 7 B-Chemical
induced	1094 7 O
cell	1102 4 O
damage	1107 6 O
and	1114 3 O
reactive	1118 8 O
oxygen	1127 6 B-Chemical
species	1134 7 O
(	1142 1 O
ROS	1143 3 O
)	1146 1 O
production	1148 10 O
in	1159 2 O
LLC	1162 3 O
-	1165 1 O
PK1	1166 3 O
cells	1170 5 O
in	1176 2 O
culture	1179 7 O
.	1186 1 O

In	1188 2 O
addition	1191 8 O
,	1199 1 O
maleate	1201 7 B-Chemical
treatment	1209 9 O
reduced	1219 7 O
oxygen	1227 6 B-Chemical
consumption	1234 11 O
in	1246 2 O
ADP	1249 3 B-Chemical
-	1252 1 O
stimulated	1253 10 O
mitochondria	1264 12 O
and	1277 3 O
diminished	1281 10 O
respiratory	1292 11 O
control	1304 7 O
index	1312 5 O
when	1318 4 O
using	1323 5 O
malate	1329 6 B-Chemical
/	1335 1 O
glutamate	1336 9 B-Chemical
as	1346 2 O
substrate	1349 9 O
.	1358 1 O

The	1360 3 O
activities	1364 10 O
of	1375 2 O
both	1378 4 O
complex	1383 7 O
I	1391 1 O
and	1393 3 O
aconitase	1397 9 O
were	1407 4 O
also	1412 4 O
diminished	1417 10 O
.	1427 1 O

All	1429 3 O
the	1433 3 O
above	1437 5 O
-	1442 1 O
described	1443 9 O
alterations	1453 11 O
were	1465 4 O
prevented	1470 9 O
by	1480 2 O
curcumin	1483 8 B-Chemical
.	1491 1 O

It	1493 2 O
is	1496 2 O
concluded	1499 9 O
that	1509 4 O
curcumin	1514 8 B-Chemical
is	1523 2 O
able	1526 4 O
to	1531 2 O
attenuate	1534 9 O
in	1544 2 O
vivo	1547 4 O
maleate	1552 7 B-Chemical
-	1559 1 O
induced	1560 7 O
nephropathy	1568 11 B-Disease
and	1580 3 O
in	1584 2 O
vitro	1587 5 O
cell	1593 4 O
damage	1598 6 O
.	1604 1 O

The	1606 3 O
in	1610 2 O
vivo	1613 4 O
protection	1618 10 O
was	1629 3 O
associated	1633 10 O
to	1644 2 O
the	1647 3 O
prevention	1651 10 O
of	1662 2 O
oxidative	1665 9 O
stress	1675 6 O
and	1682 3 O
preservation	1686 12 O
of	1699 2 O
mitochondrial	1702 13 O
oxygen	1716 6 B-Chemical
consumption	1723 11 O
and	1735 3 O
activity	1739 8 O
of	1748 2 O
respiratory	1751 11 O
complex	1763 7 O
I	1771 1 O
,	1772 1 O
and	1774 3 O
the	1778 3 O
in	1782 2 O
vitro	1785 5 O
protection	1791 10 O
was	1802 3 O
associated	1806 10 O
to	1817 2 O
the	1820 3 O
prevention	1824 10 O
of	1835 2 O
ROS	1838 3 O
production	1842 10 O
.	1852 1 O

Incidence	0 9 O
of	10 2 O
solid	13 5 O
tumours	19 7 B-Disease
among	27 5 O
pesticide	33 9 O
applicators	43 11 O
exposed	55 7 O
to	63 2 O
the	66 3 O
organophosphate	70 15 B-Chemical
insecticide	86 11 O
diazinon	98 8 B-Chemical
in	107 2 O
the	110 3 O
Agricultural	114 12 O
Health	127 6 O
Study	134 5 O
:	139 1 O
an	141 2 O
updated	144 7 O
analysis	152 8 O
.	160 1 O

OBJECTIVE	162 9 O
:	171 1 O
Diazinon	173 8 B-Chemical
,	181 1 O
a	183 1 O
common	185 6 O
organophosphate	192 15 B-Chemical
insecticide	208 11 O
with	220 4 O
genotoxic	225 9 O
properties	235 10 O
,	245 1 O
was	247 3 O
previously	251 10 O
associated	262 10 O
with	273 4 O
lung	278 4 B-Disease
cancer	283 6 I-Disease
in	290 2 O
the	293 3 O
Agricultural	297 12 O
Health	310 6 O
Study	317 5 O
(	323 1 O
AHS	324 3 O
)	327 1 O
cohort	329 6 O
,	335 1 O
but	337 3 O
few	341 3 O
other	345 5 O
epidemiological	351 15 O
studies	367 7 O
have	375 4 O
examined	380 8 O
diazinon	389 8 B-Chemical
-	397 1 O
associated	398 10 O
cancer	409 6 B-Disease
risk	416 4 O
.	420 1 O

We	422 2 O
used	425 4 O
updated	430 7 O
diazinon	438 8 B-Chemical
exposure	447 8 O
and	456 3 O
cancer	460 6 B-Disease
incidence	467 9 O
information	477 11 O
to	489 2 O
evaluate	492 8 O
solid	501 5 O
tumour	507 6 B-Disease
risk	514 4 O
in	519 2 O
the	522 3 O
AHS	526 3 O
.	529 1 O

METHODS	531 7 O
:	538 1 O
Male	540 4 O
pesticide	545 9 O
applicators	555 11 O
in	567 2 O
Iowa	570 4 O
and	575 3 O
North	579 5 O
Carolina	585 8 O
reported	594 8 O
lifetime	603 8 O
diazinon	612 8 B-Chemical
use	621 3 O
at	625 2 O
enrolment	628 9 O
(	638 1 O
1993	639 4 O
-	643 1 O
1997	644 4 O
)	648 1 O
and	650 3 O
follow	654 6 O
-	660 1 O
up	661 2 O
(	664 1 O
1998	665 4 O
-	669 1 O
2005	670 4 O
)	674 1 O
;	675 1 O
cancer	677 6 B-Disease
incidence	684 9 O
was	694 3 O
assessed	698 8 O
through	707 7 O
2010	715 4 O
(	719 1 O
North	720 5 O
Carolina	726 8 O
)	734 1 O
/	735 1 O
2011	736 4 O
(	740 1 O
Iowa	741 4 O
)	745 1 O
.	746 1 O

Among	748 5 O
applicators	754 11 O
with	766 4 O
usage	771 5 O
information	777 11 O
sufficient	789 10 O
to	800 2 O
evaluate	803 8 O
exposure	812 8 O
-	820 1 O
response	821 8 O
patterns	830 8 O
,	838 1 O
we	840 2 O
used	843 4 O
Poisson	848 7 O
regression	856 10 O
to	867 2 O
estimate	870 8 O
adjusted	879 8 O
rate	888 4 O
ratios	893 6 O
(	900 1 O
RRs	901 3 O
)	904 1 O
and	906 3 O
95	910 2 O
%	912 1 O
CI	914 2 O
for	917 3 O
cancer	921 6 B-Disease
sites	928 5 O
with	934 4 O
>	939 1 O
10	940 2 O
exposed	943 7 O
cases	951 5 O
for	957 3 O
both	961 4 O
lifetime	966 8 O
(	975 1 O
LT	976 2 O
)	978 1 O
exposure	980 8 O
days	989 4 O
and	994 3 O
intensity	998 9 O
-	1007 1 O
weighted	1008 8 O
(	1017 1 O
IW	1018 2 O
)	1020 1 O
lifetime	1022 8 O
exposure	1031 8 O
days	1040 4 O
(	1045 1 O
accounting	1046 10 O
for	1057 3 O
factors	1061 7 O
impacting	1069 9 O
exposure	1079 8 O
)	1087 1 O
.	1088 1 O

RESULTS	1090 7 O
:	1097 1 O
We	1099 2 O
observed	1102 8 O
elevated	1111 8 O
lung	1120 4 B-Disease
cancer	1125 6 I-Disease
risks	1132 5 O
(	1138 1 O
N	1139 1 O
=	1140 1 O
283	1141 3 O
)	1144 1 O
among	1146 5 O
applicators	1152 11 O
with	1164 4 O
the	1169 3 O
greatest	1173 8 O
number	1182 6 O
of	1189 2 O
LT	1192 2 O
(	1195 1 O
RR	1196 2 O
=	1198 1 O
1	1199 1 O
.	1200 1 O
60	1201 2 O
;	1203 1 O
95	1205 2 O
%	1207 1 O
CI	1209 2 O
1	1212 1 O
.	1213 1 O
11	1214 2 O
to	1217 2 O
2	1220 1 O
.	1221 1 O
31	1222 2 O
;	1224 1 O
Ptrend	1226 6 O
=	1232 1 O
0	1233 1 O
.	1234 1 O
02	1235 2 O
)	1237 1 O
and	1239 3 O
IW	1243 2 O
days	1246 4 O
of	1251 2 O
diazinon	1254 8 B-Chemical
use	1263 3 O
(	1267 1 O
RR	1268 2 O
=	1270 1 O
1	1271 1 O
.	1272 1 O
41	1273 2 O
;	1275 1 O
95	1277 2 O
%	1279 1 O
CI	1281 2 O
0	1284 1 O
.	1285 1 O
98	1286 2 O
to	1289 2 O
2	1292 1 O
.	1293 1 O
04	1294 2 O
;	1296 1 O
Ptrend	1298 6 O
=	1304 1 O
0	1305 1 O
.	1306 1 O
08	1307 2 O
)	1309 1 O
.	1310 1 O

Kidney	1312 6 B-Disease
cancer	1319 6 I-Disease
(	1326 1 O
N	1327 1 O
=	1328 1 O
94	1329 2 O
)	1331 1 O
risks	1333 5 O
were	1339 4 O
non	1344 3 O
-	1347 1 O
significantly	1348 13 O
elevated	1362 8 O
(	1371 1 O
RRLT	1372 4 O
days	1377 4 O
=	1381 1 O
1	1382 1 O
.	1383 1 O
77	1384 2 O
;	1386 1 O
95	1388 2 O
%	1390 1 O
CI	1392 2 O
0	1395 1 O
.	1396 1 O
90	1397 2 O
to	1400 2 O
3	1403 1 O
.	1404 1 O
51	1405 2 O
;	1407 1 O
Ptrend	1409 6 O
=	1415 1 O
0	1416 1 O
.	1417 1 O
09	1418 2 O
;	1420 1 O
RRIW	1422 4 O
days	1427 4 O
1	1432 1 O
.	1433 1 O
37	1434 2 O
;	1436 1 O
95	1438 2 O
%	1440 1 O
CI	1442 2 O
0	1445 1 O
.	1446 1 O
64	1447 2 O
to	1450 2 O
2	1453 1 O
.	1454 1 O
92	1455 2 O
;	1457 1 O
Ptrend	1459 6 O
=	1465 1 O
0	1466 1 O
.	1467 1 O
50	1468 2 O
)	1470 1 O
,	1471 1 O
as	1473 2 O
were	1476 4 O
risks	1481 5 O
for	1487 3 O
aggressive	1491 10 O
prostate	1502 8 B-Disease
cancer	1511 6 I-Disease
(	1518 1 O
N	1519 1 O
=	1520 1 O
656	1521 3 O
)	1524 1 O
.	1525 1 O

CONCLUSIONS	1527 11 O
:	1538 1 O
Our	1540 3 O
updated	1544 7 O
evaluation	1552 10 O
of	1563 2 O
diazinon	1566 8 B-Chemical
provides	1575 8 O
additional	1584 10 O
evidence	1595 8 O
of	1604 2 O
an	1607 2 O
association	1610 11 O
with	1622 4 O
lung	1627 4 B-Disease
cancer	1632 6 I-Disease
risk	1639 4 O
.	1643 1 O

Newly	1645 5 O
identified	1651 10 O
links	1662 5 O
to	1668 2 O
kidney	1671 6 B-Disease
cancer	1678 6 I-Disease
and	1685 3 O
associations	1689 12 O
with	1702 4 O
aggressive	1707 10 O
prostate	1718 8 B-Disease
cancer	1727 6 I-Disease
require	1734 7 O
further	1742 7 O
evaluation	1750 10 O
.	1760 1 O

Associations	0 12 O
of	13 2 O
Ozone	16 5 B-Chemical
and	22 3 O
PM2	26 3 O
.	29 1 O
5	30 1 O
Concentrations	32 14 O
With	47 4 O
Parkinson	52 9 B-Disease
'	61 1 I-Disease
s	62 1 I-Disease
Disease	64 7 I-Disease
Among	72 5 O
Participants	78 12 O
in	91 2 O
the	94 3 O
Agricultural	98 12 O
Health	111 6 O
Study	118 5 O
.	123 1 O

OBJECTIVE	125 9 O
:	134 1 O
This	136 4 O
study	141 5 O
describes	147 9 O
associations	157 12 O
of	170 2 O
ozone	173 5 B-Chemical
and	179 3 O
fine	183 4 O
particulate	188 11 B-Chemical
matter	200 6 I-Chemical
with	207 4 O
Parkinson	212 9 B-Disease
'	221 1 I-Disease
s	222 1 I-Disease
disease	224 7 I-Disease
observed	232 8 O
among	241 5 O
farmers	247 7 O
in	255 2 O
North	258 5 O
Carolina	264 8 O
and	273 3 O
Iowa	277 4 O
.	281 1 O

METHODS	283 7 O
:	290 1 O
We	292 2 O
used	295 4 O
logistic	300 8 O
regression	309 10 O
to	320 2 O
determine	323 9 O
the	333 3 O
associations	337 12 O
of	350 2 O
these	353 5 O
pollutants	359 10 O
with	370 4 O
self	375 4 O
-	379 1 O
reported	380 8 O
,	388 1 O
doctor	390 6 O
-	396 1 O
diagnosed	397 9 O
Parkinson	407 9 B-Disease
'	416 1 I-Disease
s	417 1 I-Disease
disease	419 7 I-Disease
.	426 1 O

Daily	428 5 O
predicted	434 9 O
pollutant	444 9 O
concentrations	454 14 O
were	469 4 O
used	474 4 O
to	479 2 O
derive	482 6 O
surrogates	489 10 O
of	500 2 O
long	503 4 O
-	507 1 O
term	508 4 O
exposure	513 8 O
and	522 3 O
link	526 4 O
them	531 4 O
to	536 2 O
study	539 5 O
participants	545 12 O
'	557 1 O
geocoded	559 8 O
addresses	568 9 O
.	577 1 O

RESULTS	579 7 O
:	586 1 O
We	588 2 O
observed	591 8 O
positive	600 8 O
associations	609 12 O
of	622 2 O
Parkinson	625 9 B-Disease
'	634 1 I-Disease
s	635 1 I-Disease
disease	637 7 I-Disease
with	645 4 O
ozone	650 5 B-Chemical
(	656 1 O
odds	657 4 O
ratio	662 5 O
=	668 1 O
1	670 1 O
.	671 1 O
39	672 2 O
;	674 1 O
95	676 2 O
%	678 1 O
CI	680 2 O
:	682 1 O
0	684 1 O
.	685 1 O
98	686 2 O
to	689 2 O
1	692 1 O
.	693 1 O
98	694 2 O
)	696 1 O
and	698 3 O
fine	702 4 O
particulate	707 11 B-Chemical
matter	719 6 I-Chemical
(	726 1 O
odds	727 4 O
ratio	732 5 O
=	738 1 O
1	740 1 O
.	741 1 O
34	742 2 O
;	744 1 O
95	746 2 O
%	748 1 O
CI	750 2 O
:	752 1 O
0	754 1 O
.	755 1 O
93	756 2 O
to	759 2 O
1	762 1 O
.	763 1 O
93	764 2 O
)	766 1 O
in	768 2 O
North	771 5 O
Carolina	777 8 O
but	786 3 O
not	790 3 O
in	794 2 O
Iowa	797 4 O
.	801 1 O

CONCLUSIONS	803 11 O
:	814 1 O
The	816 3 O
plausibility	820 12 O
of	833 2 O
an	836 2 O
effect	839 6 O
of	846 2 O
ambient	849 7 O
concentrations	857 14 O
of	872 2 O
these	875 5 O
pollutants	881 10 O
on	892 2 O
Parkinson	895 9 B-Disease
'	904 1 I-Disease
s	905 1 I-Disease
disease	907 7 I-Disease
risk	915 4 O
is	920 2 O
supported	923 9 O
by	933 2 O
experimental	936 12 O
data	949 4 O
demonstrating	954 13 O
damage	968 6 O
to	975 2 O
dopaminergic	978 12 O
neurons	991 7 O
at	999 2 O
relevant	1002 8 O
concentrations	1011 14 O
.	1025 1 O

Additional	1027 10 O
studies	1038 7 O
are	1046 3 O
needed	1050 6 O
to	1057 2 O
address	1060 7 O
uncertainties	1068 13 O
related	1082 7 O
to	1090 2 O
confounding	1093 11 O
and	1105 3 O
to	1109 2 O
examine	1112 7 O
temporal	1120 8 O
aspects	1129 7 O
of	1137 2 O
the	1140 3 O
associations	1144 12 O
we	1157 2 O
observed	1160 8 O
.	1168 1 O

Low	0 3 O
functional	4 10 O
programming	15 11 O
of	27 2 O
renal	30 5 O
AT2R	36 4 O
mediates	41 8 O
the	50 3 O
developmental	54 13 O
origin	68 6 O
of	75 2 O
glomerulosclerosis	78 18 B-Disease
in	97 2 O
adult	100 5 O
offspring	106 9 O
induced	116 7 O
by	124 2 O
prenatal	127 8 O
caffeine	136 8 B-Chemical
exposure	145 8 O
.	153 1 O

UNASSIGNED	155 10 O
:	165 1 O
Our	167 3 O
previous	171 8 O
study	180 5 O
has	186 3 O
indicated	190 9 O
that	200 4 O
prenatal	205 8 O
caffeine	214 8 B-Chemical
exposure	223 8 O
(	232 1 O
PCE	233 3 O
)	236 1 O
could	238 5 O
induce	244 6 O
intrauterine	251 12 B-Disease
growth	264 6 I-Disease
retardation	271 11 I-Disease
(	283 1 O
IUGR	284 4 B-Disease
)	288 1 O
of	290 2 O
offspring	293 9 O
.	302 1 O

Recent	304 6 O
research	311 8 O
suggested	320 9 O
that	330 4 O
IUGR	335 4 B-Disease
is	340 2 O
a	343 1 O
risk	345 4 O
factor	350 6 O
for	357 3 O
glomerulosclerosis	361 18 B-Disease
.	379 1 O

However	381 7 O
,	388 1 O
whether	390 7 O
PCE	398 3 O
could	402 5 O
induce	408 6 O
glomerulosclerosis	415 18 B-Disease
and	434 3 O
its	438 3 O
underlying	442 10 O
mechanisms	453 10 O
remain	464 6 O
unknown	471 7 O
.	478 1 O

This	480 4 O
study	485 5 O
aimed	491 5 O
to	497 2 O
demonstrate	500 11 O
the	512 3 O
induction	516 9 O
to	526 2 O
glomerulosclerosis	529 18 B-Disease
in	548 2 O
adult	551 5 O
offspring	557 9 O
by	567 2 O
PCE	570 3 O
and	574 3 O
its	578 3 O
intrauterine	582 12 O
programming	595 11 O
mechanisms	607 10 O
.	617 1 O

A	619 1 O
rat	621 3 O
model	625 5 O
of	631 2 O
IUGR	634 4 B-Disease
was	639 3 O
established	643 11 O
by	655 2 O
PCE	658 3 O
,	661 1 O
male	663 4 O
fetuses	668 7 O
and	676 3 O
adult	680 5 O
offspring	686 9 O
at	696 2 O
the	699 3 O
age	703 3 O
of	707 2 O
postnatal	710 9 O
week	720 4 O
24	725 2 O
were	728 4 O
euthanized	733 10 O
.	743 1 O

The	745 3 O
results	749 7 O
revealed	757 8 O
that	766 4 O
the	771 3 O
adult	775 5 O
offspring	781 9 O
kidneys	791 7 O
in	799 2 O
the	802 3 O
PCE	806 3 O
group	810 5 O
exhibited	816 9 O
glomerulosclerosis	826 18 B-Disease
as	845 2 O
well	848 4 O
as	853 2 O
interstitial	856 12 B-Disease
fibrosis	869 8 I-Disease
,	877 1 O
accompanied	879 11 O
by	891 2 O
elevated	894 8 O
levels	903 6 O
of	910 2 O
serum	913 5 O
creatinine	919 10 B-Chemical
and	930 3 O
urine	934 5 O
protein	940 7 O
.	947 1 O

Renal	949 5 O
angiotensin	955 11 B-Chemical
II	967 2 I-Chemical
receptor	970 8 O
type	979 4 O
2	984 1 O
(	986 1 O
AT2R	987 4 O
)	991 1 O
gene	993 4 O
expression	998 10 O
in	1009 2 O
adult	1012 5 O
offspring	1018 9 O
was	1028 3 O
reduced	1032 7 O
by	1040 2 O
PCE	1043 3 O
,	1046 1 O
whereas	1048 7 O
the	1056 3 O
renal	1060 5 O
angiotensin	1066 11 B-Chemical
II	1078 2 I-Chemical
receptor	1081 8 O
type	1090 4 O
1a	1095 2 O
(	1098 1 O
AT1aR	1099 5 O
)	1104 1 O
/	1105 1 O
AT2R	1106 4 O
expression	1111 10 O
ratio	1122 5 O
was	1128 3 O
increased	1132 9 O
.	1141 1 O

The	1143 3 O
fetal	1147 5 O
kidneys	1153 7 O
in	1161 2 O
the	1164 3 O
PCE	1168 3 O
group	1172 5 O
displayed	1178 9 O
an	1188 2 O
enlarged	1191 8 O
Bowman	1200 6 O
'	1206 1 O
s	1207 1 O
space	1209 5 O
and	1215 3 O
a	1219 1 O
shrunken	1221 8 O
glomerular	1230 10 O
tuft	1241 4 O
,	1245 1 O
accompanied	1247 11 O
by	1259 2 O
a	1262 1 O
reduced	1264 7 O
cortex	1272 6 O
width	1279 5 O
and	1285 3 O
an	1289 2 O
increase	1292 8 O
in	1301 2 O
the	1304 3 O
nephrogenic	1308 11 O
zone	1320 4 O
/	1324 1 O
cortical	1325 8 O
zone	1334 4 O
ratio	1339 5 O
.	1344 1 O

Observation	1346 11 O
by	1358 2 O
electronic	1361 10 O
microscope	1372 10 O
revealed	1383 8 O
structural	1392 10 O
damage	1403 6 O
of	1410 2 O
podocytes	1413 9 O
;	1422 1 O
the	1424 3 O
reduced	1428 7 O
expression	1436 10 O
level	1447 5 O
of	1453 2 O
podocyte	1456 8 O
marker	1465 6 O
genes	1472 5 O
,	1477 1 O
nephrin	1479 7 O
and	1487 3 O
podocin	1491 7 O
,	1498 1 O
was	1500 3 O
also	1504 4 O
detected	1509 8 O
by	1518 2 O
q	1521 1 O
-	1522 1 O
PCR	1523 3 O
.	1526 1 O

Moreover	1528 8 O
,	1536 1 O
AT2R	1538 4 O
gene	1543 4 O
and	1548 3 O
protein	1552 7 O
expressions	1560 11 O
in	1572 2 O
fetal	1575 5 O
kidneys	1581 7 O
were	1589 4 O
inhibited	1594 9 O
by	1604 2 O
PCE	1607 3 O
,	1610 1 O
associated	1612 10 O
with	1623 4 O
the	1628 3 O
repression	1632 10 O
of	1643 2 O
the	1646 3 O
gene	1650 4 O
expression	1655 10 O
of	1666 2 O
glial	1669 5 O
-	1674 1 O
cell	1675 4 O
-	1679 1 O
line	1680 4 O
-	1684 1 O
derived	1685 7 O
neurotrophic	1693 12 O
factor	1706 6 O
(	1713 1 O
GDNF	1714 4 O
)	1718 1 O
/	1719 1 O
tyrosine	1720 8 B-Chemical
kinase	1729 6 O
receptor	1736 8 O
(	1745 1 O
c	1746 1 O
-	1747 1 O
Ret	1748 3 O
)	1751 1 O
signaling	1753 9 O
pathway	1763 7 O
.	1770 1 O

These	1772 5 O
results	1778 7 O
demonstrated	1786 12 O
that	1799 4 O
PCE	1804 3 O
could	1808 5 O
induce	1814 6 O
dysplasia	1821 9 B-Disease
of	1831 2 I-Disease
fetal	1834 5 I-Disease
kidneys	1840 7 I-Disease
as	1848 2 O
well	1851 4 O
as	1856 2 O
glomerulosclerosis	1859 18 B-Disease
of	1878 2 O
adult	1881 5 O
offspring	1887 9 O
,	1896 1 O
and	1898 3 O
the	1902 3 O
low	1906 3 O
functional	1910 10 O
programming	1921 11 O
of	1933 2 O
renal	1936 5 O
AT2R	1942 4 O
might	1947 5 O
mediate	1953 7 O
the	1961 3 O
developmental	1965 13 O
origin	1979 6 O
of	1986 2 O
adult	1989 5 O
glomerulosclerosis	1995 18 B-Disease
.	2013 1 O

1	0 1 B-Chemical
,	1 1 I-Chemical
3	2 1 I-Chemical
-	3 1 I-Chemical
Butadiene	4 9 I-Chemical
,	13 1 O
CML	15 3 B-Disease
and	19 3 O
the	23 3 O
t	27 1 O
(	28 1 O
9	29 1 O
:	30 1 O
22	31 2 O
)	33 1 O
translocation	35 13 O
:	48 1 O
A	50 1 O
reality	52 7 O
check	60 5 O
.	65 1 O

UNASSIGNED	67 10 O
:	77 1 O
Epidemiological	79 15 O
studies	95 7 O
of	103 2 O
1	106 1 B-Chemical
,	107 1 I-Chemical
3	108 1 I-Chemical
-	109 1 I-Chemical
butadiene	110 9 I-Chemical
have	120 4 O
suggest	125 7 O
that	133 4 O
exposures	138 9 O
to	148 2 O
humans	151 6 O
are	158 3 O
associated	162 10 O
with	173 4 O
chronic	178 7 B-Disease
myeloid	186 7 I-Disease
leukemia	194 8 I-Disease
(	203 1 O
CML	204 3 B-Disease
)	207 1 O
.	208 1 O

CML	210 3 B-Disease
has	214 3 O
a	218 1 O
well	220 4 O
-	224 1 O
documented	225 10 O
association	236 11 O
with	248 4 O
ionizing	253 8 O
radiation	262 9 O
,	271 1 O
but	273 3 O
reports	277 7 O
of	285 2 O
associations	288 12 O
with	301 4 O
chemical	306 8 O
exposures	315 9 O
have	325 4 O
been	330 4 O
questioned	335 10 O
.	345 1 O

Ionizing	347 8 O
radiation	356 9 O
is	366 2 O
capable	369 7 O
of	377 2 O
inducing	380 8 O
the	389 3 O
requisite	393 9 O
CML	403 3 B-Disease
-	406 1 O
associated	407 10 O
t	418 1 O
(	419 1 O
9	420 1 O
:	421 1 O
22	422 2 O
)	424 1 O
translocation	426 13 O
(	440 1 O
Philadelphia	441 12 B-Disease
chromosome	454 10 I-Disease
)	464 1 O
in	466 2 O
appropriate	469 11 O
cells	481 5 O
in	487 2 O
vitro	490 5 O
but	496 3 O
,	499 1 O
thus	501 4 O
far	506 3 O
,	509 1 O
chemicals	511 9 O
have	521 4 O
not	526 3 O
shown	530 5 O
this	536 4 O
capacity	541 8 O
.	549 1 O

We	551 2 O
have	554 4 O
proposed	559 8 O
that	568 4 O
1	573 1 B-Chemical
,	574 1 I-Chemical
3	575 1 I-Chemical
-	576 1 I-Chemical
butadiene	577 9 I-Chemical
metabolites	587 11 O
be	599 2 O
so	602 2 O
tested	605 6 O
as	612 2 O
a	615 1 O
reality	617 7 O
check	625 5 O
on	631 2 O
the	634 3 O
epidemiological	638 15 O
reports	654 7 O
.	661 1 O

In	663 2 O
order	666 5 O
to	672 2 O
conduct	675 7 O
reliable	683 8 O
testing	692 7 O
in	700 2 O
this	703 4 O
regard	708 6 O
,	714 1 O
it	716 2 O
is	719 2 O
essential	722 9 O
that	732 4 O
a	737 1 O
positive	739 8 O
control	748 7 O
for	756 3 O
induction	760 9 O
be	770 2 O
available	773 9 O
.	782 1 O

We	784 2 O
have	787 4 O
used	792 4 O
ionizing	797 8 O
radiation	806 9 O
to	816 2 O
develop	819 7 O
such	827 4 O
a	832 1 O
control	834 7 O
.	841 1 O

Results	843 7 O
described	851 9 O
here	861 4 O
demonstrate	866 11 O
that	878 4 O
this	883 4 O
agent	888 5 O
does	894 4 O
in	899 2 O
fact	902 4 O
induce	907 6 O
pathogenic	914 10 O
t	925 1 O
(	926 1 O
9	927 1 O
:	928 1 O
22	929 2 O
)	931 1 O
translocations	933 14 O
in	948 2 O
a	951 1 O
human	953 5 O
myeloid	959 7 O
cell	967 4 O
line	972 4 O
in	977 2 O
vitro	980 5 O
,	985 1 O
but	987 3 O
does	991 4 O
so	996 2 O
at	999 2 O
low	1002 3 O
frequencies	1006 11 O
.	1017 1 O

Conditions	1019 10 O
that	1030 4 O
will	1035 4 O
be	1040 2 O
required	1043 8 O
for	1052 3 O
studies	1056 7 O
of	1064 2 O
1	1067 1 B-Chemical
,	1068 1 I-Chemical
3	1069 1 I-Chemical
-	1070 1 I-Chemical
butadiene	1071 9 I-Chemical
are	1081 3 O
discussed	1085 9 O
.	1094 1 O

Cancer	0 6 B-Disease
incidence	7 9 O
and	17 3 O
metolachlor	21 11 B-Chemical
use	33 3 O
in	37 2 O
the	40 3 O
Agricultural	44 12 O
Health	57 6 O
Study	64 5 O
:	69 1 O
An	71 2 O
update	74 6 O
.	80 1 O

UNASSIGNED	82 10 O
:	92 1 O
Metolachlor	94 11 B-Chemical
,	105 1 O
a	107 1 O
widely	109 6 O
used	116 4 O
herbicide	121 9 O
,	130 1 O
is	132 2 O
classified	135 10 O
as	146 2 O
a	149 1 O
Group	151 5 O
C	157 1 O
carcinogen	159 10 O
by	170 2 O
the	173 3 O
U	177 1 O
.	178 1 O
S	179 1 O
.	180 1 O

Environmental	182 13 O
Protection	196 10 O
Agency	207 6 O
based	214 5 O
on	220 2 O
increased	223 9 O
liver	233 5 B-Disease
neoplasms	239 9 I-Disease
in	249 2 O
female	252 6 O
rats	259 4 O
.	263 1 O

Epidemiologic	265 13 O
studies	279 7 O
of	287 2 O
the	290 3 O
health	294 6 O
effects	301 7 O
of	309 2 O
metolachlor	312 11 B-Chemical
have	324 4 O
been	329 4 O
limited	334 7 O
.	341 1 O

The	343 3 O
Agricultural	347 12 O
Health	360 6 O
Study	367 5 O
(	373 1 O
AHS	374 3 O
)	377 1 O
is	379 2 O
a	382 1 O
prospective	384 11 O
cohort	396 6 O
study	403 5 O
including	409 9 O
licensed	419 8 O
private	428 7 O
and	436 3 O
commercial	440 10 O
pesticide	451 9 O
applicators	461 11 O
in	473 2 O
Iowa	476 4 O
and	481 3 O
North	485 5 O
Carolina	491 8 O
enrolled	500 8 O
1993	509 4 O
-	513 1 O
1997	514 4 O
.	518 1 O

We	520 2 O
evaluated	523 9 O
cancer	533 6 B-Disease
incidence	540 9 O
through	550 7 O
2010	558 4 O
/	562 1 O
2011	563 4 O
(	568 1 O
NC	569 2 O
/	571 1 O
IA	572 2 O
)	574 1 O
for	576 3 O
49	580 2 O
,	582 1 O
616	583 3 O
applicators	587 11 O
,	598 1 O
53	600 2 O
%	602 1 O
of	604 2 O
whom	607 4 O
reported	612 8 O
ever	621 4 O
using	626 5 O
metolachlor	632 11 B-Chemical
.	643 1 O

We	645 2 O
used	648 4 O
Poisson	653 7 O
regression	661 10 O
to	672 2 O
evaluate	675 8 O
relations	684 9 O
between	694 7 O
two	702 3 O
metrics	706 7 O
of	714 2 O
metolachlor	717 11 B-Chemical
use	729 3 O
(	733 1 O
lifetime	734 8 O
days	743 4 O
,	747 1 O
intensity	749 9 O
-	758 1 O
weighted	759 8 O
lifetime	768 8 O
days	777 4 O
)	781 1 O
and	783 3 O
cancer	787 6 B-Disease
incidence	794 9 O
.	803 1 O

We	805 2 O
saw	808 3 O
no	812 2 O
association	815 11 O
between	827 7 O
metolachlor	835 11 B-Chemical
use	847 3 O
and	851 3 O
incidence	855 9 O
of	865 2 O
all	868 3 O
cancers	872 7 B-Disease
combined	880 8 O
(	889 1 O
n	890 1 O
=	892 1 O
5	894 1 O
,	895 1 O
701	896 3 O
with	900 4 O
a	905 1 O
5	907 1 O
-	908 1 O
year	909 4 O
lag	914 3 O
)	917 1 O
or	919 2 O
most	922 4 O
site	927 4 O
-	931 1 O
specific	932 8 O
cancers	941 7 B-Disease
.	948 1 O

For	950 3 O
liver	954 5 B-Disease
cancer	960 6 I-Disease
,	966 1 O
in	968 2 O
analyses	971 8 O
restricted	980 10 O
to	991 2 O
exposed	994 7 O
workers	1002 7 O
,	1009 1 O
elevations	1011 10 O
observed	1022 8 O
at	1031 2 O
higher	1034 6 O
categories	1041 10 O
of	1052 2 O
use	1055 3 O
were	1059 4 O
not	1064 3 O
statistically	1068 13 O
significant	1082 11 O
.	1093 1 O

However	1095 7 O
,	1102 1 O
trends	1104 6 O
for	1111 3 O
both	1115 4 O
lifetime	1120 8 O
and	1129 3 O
intensity	1133 9 O
-	1142 1 O
weighted	1143 8 O
lifetime	1152 8 O
days	1161 4 O
of	1166 2 O
metolachor	1169 10 B-Chemical
use	1180 3 O
were	1184 4 O
positive	1189 8 O
and	1198 3 O
statistically	1202 13 O
significant	1216 11 O
with	1228 4 O
an	1233 2 O
unexposed	1236 9 O
reference	1246 9 O
group	1256 5 O
.	1261 1 O

A	1263 1 O
similar	1265 7 O
pattern	1273 7 O
was	1281 3 O
observed	1285 8 O
for	1294 3 O
follicular	1298 10 B-Disease
cell	1309 4 I-Disease
lymphoma	1314 8 I-Disease
,	1322 1 O
but	1324 3 O
no	1328 2 O
other	1331 5 O
lymphoma	1337 8 B-Disease
subtypes	1346 8 O
.	1354 1 O

An	1356 2 O
earlier	1359 7 O
suggestion	1367 10 O
of	1378 2 O
increased	1381 9 O
lung	1391 4 B-Disease
cancer	1396 6 I-Disease
risk	1403 4 O
at	1408 2 O
high	1411 4 O
levels	1416 6 O
of	1423 2 O
metolachlor	1426 11 B-Chemical
use	1438 3 O
in	1442 2 O
this	1445 4 O
cohort	1450 6 O
was	1457 3 O
not	1461 3 O
confirmed	1465 9 O
in	1475 2 O
this	1478 4 O
update	1483 6 O
.	1489 1 O

This	1491 4 O
suggestion	1496 10 O
of	1507 2 O
an	1510 2 O
association	1513 11 O
between	1525 7 O
metolachlor	1533 11 B-Chemical
and	1545 3 O
liver	1549 5 B-Disease
cancer	1555 6 I-Disease
among	1562 5 O
pesticide	1568 9 O
applicators	1578 11 O
is	1590 2 O
a	1593 1 O
novel	1595 5 O
finding	1601 7 O
and	1609 3 O
echoes	1613 6 O
observation	1620 11 O
of	1632 2 O
increased	1635 9 O
liver	1645 5 B-Disease
neoplasms	1651 9 I-Disease
in	1661 2 O
some	1664 4 O
animal	1669 6 O
studies	1676 7 O
.	1683 1 O

However	1685 7 O
,	1692 1 O
our	1694 3 O
findings	1698 8 O
for	1707 3 O
both	1711 4 O
liver	1716 5 B-Disease
cancer	1722 6 I-Disease
and	1729 3 O
follicular	1733 10 O
cell	1744 4 O
lymphoma	1749 8 B-Disease
warrant	1758 7 O
follow	1766 6 O
-	1772 1 O
up	1773 2 O
to	1776 2 O
better	1779 6 O
differentiate	1786 13 O
effects	1800 7 O
of	1808 2 O
metolachlor	1811 11 B-Chemical
use	1823 3 O
from	1827 4 O
other	1832 5 O
factors	1838 7 O
.	1845 1 O

Mechanisms	0 10 O
Underlying	11 10 O
Latent	22 6 O
Disease	29 7 O
Risk	37 4 O
Associated	42 10 O
with	53 4 O
Early	58 5 O
-	63 1 O
Life	64 4 O
Arsenic	69 7 B-Chemical
Exposure	77 8 O
:	85 1 O
Current	87 7 O
Research	95 8 O
Trends	104 6 O
and	111 3 O
Scientific	115 10 O
Gaps	126 4 O
.	130 1 O

BACKGROUND	132 10 O
:	142 1 O
Millions	144 8 O
of	153 2 O
individuals	156 11 O
worldwide	168 9 O
,	177 1 O
particularly	179 12 O
those	192 5 O
living	198 6 O
in	205 2 O
rural	208 5 O
and	214 3 O
developing	218 10 O
areas	229 5 O
,	234 1 O
are	236 3 O
exposed	240 7 O
to	248 2 O
harmful	251 7 O
levels	259 6 O
of	266 2 O
inorganic	269 9 B-Chemical
arsenic	279 7 I-Chemical
(	287 1 O
iAs	288 3 B-Chemical
)	291 1 O
in	293 2 O
their	296 5 O
drinking	302 8 O
water	311 5 O
.	316 1 O

Inorganic	318 9 B-Chemical
As	328 2 I-Chemical
exposure	331 8 O
during	340 6 O
key	347 3 O
developmental	351 13 O
periods	365 7 O
is	373 2 O
associated	376 10 O
with	387 4 O
a	392 1 O
variety	394 7 O
of	402 2 O
adverse	405 7 O
health	413 6 O
effects	420 7 O
including	428 9 O
those	438 5 O
that	444 4 O
are	449 3 O
evident	453 7 O
in	461 2 O
adulthood	464 9 O
.	473 1 O

There	475 5 O
is	481 2 O
considerable	484 12 O
interest	497 8 O
in	506 2 O
identifying	509 11 O
the	521 3 O
molecular	525 9 O
mechanisms	535 10 O
that	546 4 O
relate	551 6 O
early	558 5 O
-	563 1 O
life	564 4 O
iAs	569 3 B-Chemical
exposure	573 8 O
to	582 2 O
the	585 3 O
development	589 11 O
of	601 2 O
these	604 5 O
latent	610 6 O
diseases	617 8 O
,	625 1 O
particularly	627 12 O
in	640 2 O
relationship	643 12 O
to	656 2 O
cancer	659 6 B-Disease
.	665 1 O

OBJECTIVES	667 10 O
:	677 1 O
This	679 4 O
work	684 4 O
summarizes	689 10 O
research	700 8 O
on	709 2 O
the	712 3 O
molecular	716 9 O
mechanisms	726 10 O
that	737 4 O
underlie	742 8 O
the	751 3 O
increased	755 9 O
risk	765 4 O
of	770 2 O
cancer	773 6 B-Disease
development	780 11 O
in	792 2 O
adulthood	795 9 O
that	805 4 O
is	810 2 O
associated	813 10 O
with	824 4 O
early	829 5 O
-	834 1 O
life	835 4 O
iAs	840 3 B-Chemical
exposure	844 8 O
.	852 1 O

DISCUSSION	854 10 O
:	864 1 O
Epigenetic	866 10 O
reprogramming	877 13 O
that	891 4 O
imparts	896 7 O
functional	904 10 O
changes	915 7 O
in	923 2 O
gene	926 4 O
expression	931 10 O
,	941 1 O
the	943 3 O
development	947 11 O
of	959 2 O
cancer	962 6 B-Disease
stem	969 4 O
cells	974 5 O
,	979 1 O
and	981 3 O
immunomodulation	985 16 O
are	1002 3 O
plausible	1006 9 O
underlying	1016 10 O
mechanisms	1027 10 O
by	1038 2 O
which	1041 5 O
early	1047 5 O
-	1052 1 O
life	1053 4 O
iAs	1058 3 B-Chemical
exposure	1062 8 O
elicits	1071 7 O
latent	1079 6 O
carcinogenic	1086 12 O
effects	1099 7 O
.	1106 1 O

CONCLUSIONS	1108 11 O
:	1119 1 O
Evidence	1121 8 O
is	1130 2 O
mounting	1133 8 O
that	1142 4 O
relates	1147 7 O
early	1155 5 O
-	1160 1 O
life	1161 4 O
iAs	1166 3 B-Chemical
exposure	1170 8 O
and	1179 3 O
cancer	1183 6 B-Disease
development	1190 11 O
later	1202 5 O
in	1208 2 O
life	1211 4 O
.	1215 1 O

Future	1217 6 O
research	1224 8 O
should	1233 6 O
include	1240 7 O
animal	1248 6 O
studies	1255 7 O
that	1263 4 O
address	1268 7 O
mechanistic	1276 11 O
hypotheses	1288 10 O
and	1299 3 O
studies	1303 7 O
of	1311 2 O
human	1314 5 O
populations	1320 11 O
that	1332 4 O
integrate	1337 9 O
early	1347 5 O
-	1352 1 O
life	1353 4 O
exposure	1358 8 O
,	1366 1 O
molecular	1368 9 O
alterations	1378 11 O
,	1389 1 O
and	1391 3 O
latent	1395 6 O
disease	1402 7 O
outcomes	1410 8 O
.	1418 1 O

On	0 2 O
the	3 3 O
antiarrhythmic	7 14 O
activity	22 8 O
of	31 2 O
one	34 3 O
N	38 1 O
-	39 1 O
substituted	40 11 O
piperazine	52 10 B-Chemical
derivative	63 10 O
of	74 2 O
trans	77 5 B-Chemical
-	82 1 I-Chemical
2	83 1 I-Chemical
-	84 1 I-Chemical
amino	85 5 I-Chemical
-	90 1 I-Chemical
3	91 1 I-Chemical
-	92 1 I-Chemical
hydroxy	93 7 I-Chemical
-	100 1 I-Chemical
1	101 1 I-Chemical
,	102 1 I-Chemical
2	104 1 I-Chemical
,	105 1 I-Chemical
3	107 1 I-Chemical
,	108 1 I-Chemical
4	110 1 I-Chemical
-	111 1 I-Chemical
tetrahydroanaphthalene	112 22 I-Chemical
.	134 1 O

The	136 3 O
antiarrhythmic	140 14 O
activity	155 8 O
of	164 2 O
the	167 3 O
compound	171 8 O
N	180 1 B-Chemical
-	181 1 I-Chemical
(	182 1 I-Chemical
trans	183 5 I-Chemical
-	188 1 I-Chemical
3	189 1 I-Chemical
-	190 1 I-Chemical
hydroxy	191 7 I-Chemical
-	198 1 I-Chemical
1	199 1 I-Chemical
,	200 1 I-Chemical
2	201 1 I-Chemical
,	202 1 I-Chemical
3	203 1 I-Chemical
,	204 1 I-Chemical
4	205 1 I-Chemical
-	206 1 I-Chemical
tetrahydro	207 10 I-Chemical
-	217 1 I-Chemical
2	218 1 I-Chemical
-	219 1 I-Chemical
naphthyl	220 8 I-Chemical
)	228 1 I-Chemical
-	229 1 I-Chemical
N	230 1 I-Chemical
-	231 1 I-Chemical
(	232 1 I-Chemical
3	233 1 I-Chemical
-	234 1 I-Chemical
oxo	235 3 I-Chemical
-	238 1 I-Chemical
3	239 1 I-Chemical
-	240 1 I-Chemical
phenyl	241 6 I-Chemical
-	247 1 I-Chemical
2	248 1 I-Chemical
-	249 1 I-Chemical
methylpropyl	250 12 I-Chemical
)	262 1 I-Chemical
-	263 1 I-Chemical
piperazine	264 10 I-Chemical
hydrochloride	275 13 I-Chemical
,	288 1 O
referred	290 8 O
to	299 2 O
as	302 2 O
P11	305 3 B-Chemical
,	308 1 O
is	310 2 O
studied	313 7 O
on	321 2 O
anaesthesized	324 13 O
cats	338 4 O
and	343 3 O
Wistar	347 6 O
albino	354 6 O
rats	361 4 O
,	365 1 O
as	367 2 O
well	370 4 O
as	375 2 O
on	378 2 O
non	381 3 O
-	384 1 O
anaesthesized	385 13 O
rabbits	399 7 O
.	406 1 O

Four	408 4 O
types	413 5 O
of	419 2 O
experimental	422 12 O
arrhythmia	435 10 B-Disease
are	446 3 O
used	450 4 O
-	454 1 O
-	455 1 O
with	456 4 O
BaCl2	461 5 B-Chemical
,	466 1 O
with	468 4 O
chloroform	473 10 B-Chemical
-	483 1 O
adrenaline	484 10 B-Chemical
,	494 1 O
with	496 4 O
strophantine	501 12 B-Chemical
G	514 1 I-Chemical
and	516 3 O
with	520 4 O
aconitine	525 9 B-Chemical
.	534 1 O

The	536 3 O
compound	540 8 O
P11	549 3 B-Chemical
is	553 2 O
introduced	556 10 O
in	567 2 O
doses	570 5 O
of	576 2 O
0	579 1 O
.	580 1 O
25	581 2 O
and	584 3 O
0	588 1 O
.	589 1 O
50	590 2 O
mg	593 2 O
/	595 1 O
kg	596 2 O
intravenously	599 13 O
and	613 3 O
10	617 2 O
mg	620 2 O
/	622 1 O
kg	623 2 O
orally	626 6 O
.	632 1 O

The	634 3 O
compound	638 8 O
manifests	647 9 O
antiarrhythmic	657 14 O
activity	672 8 O
in	681 2 O
all	684 3 O
models	688 6 O
of	695 2 O
experimental	698 12 O
arrhythmia	711 10 B-Disease
used	722 4 O
,	726 1 O
causing	728 7 O
greatest	736 8 O
inhibition	745 10 O
on	756 2 O
the	759 3 O
arrhythmia	763 10 B-Disease
induced	774 7 O
by	782 2 O
chloroform	785 10 B-Chemical
-	795 1 O
adrenaline	796 10 B-Chemical
(	807 1 O
in	808 2 O
90	811 2 O
per	814 3 O
cent	818 4 O
)	822 1 O
and	824 3 O
with	828 4 O
BaCl2	833 5 B-Chemical
(	839 1 O
in	840 2 O
84	843 2 O
per	846 3 O
cent	850 4 O
)	854 1 O
.	855 1 O

The	857 3 O
results	861 7 O
obtained	869 8 O
are	878 3 O
associated	882 10 O
with	893 4 O
the	898 3 O
beta	902 4 O
-	906 1 O
adrenoblocking	907 14 O
and	922 3 O
with	926 4 O
the	931 3 O
membrane	935 8 O
-	943 1 O
stabilizing	944 11 O
action	956 6 O
of	963 2 O
the	966 3 O
compound	970 8 O
.	978 1 O

Experimental	0 12 O
progressive	13 11 O
muscular	25 8 B-Disease
dystrophy	34 9 I-Disease
and	44 3 O
its	48 3 O
treatment	52 9 O
with	62 4 O
high	67 4 O
doses	72 5 O
anabolizing	78 11 O
agents	90 6 O
.	96 1 O

We	98 2 O
are	101 3 O
still	105 5 O
a	111 1 O
long	113 4 O
way	118 3 O
from	122 4 O
discovering	127 11 O
an	139 2 O
unequivocal	142 11 O
pathogenetic	154 12 O
interpretation	167 14 O
of	182 2 O
progressive	185 11 O
muscular	197 8 B-Disease
dystrophy	206 9 I-Disease
in	216 2 O
man	219 3 O
.	222 1 O

Noteworthy	224 10 O
efforts	235 7 O
have	243 4 O
been	248 4 O
made	253 4 O
in	258 2 O
the	261 3 O
experimental	265 12 O
field	278 5 O
;	283 1 O
a	285 1 O
recessive	287 9 O
autosomic	297 9 O
form	307 4 O
found	312 5 O
in	318 2 O
the	321 3 O
mouse	325 5 O
seems	331 5 O
to	337 2 O
bear	340 4 O
the	345 3 O
closest	349 7 O
resemblance	357 11 O
to	369 2 O
the	372 3 O
human	376 5 O
form	382 4 O
from	387 4 O
the	392 3 O
genetic	396 7 O
point	404 5 O
of	410 2 O
view	413 4 O
.	417 1 O

Myopathy	419 8 B-Disease
due	428 3 O
to	432 2 O
lack	435 4 O
of	440 2 O
vitamin	443 7 B-Chemical
E	451 1 I-Chemical
and	453 3 O
myopathy	457 8 B-Disease
induced	466 7 O
by	474 2 O
certain	477 7 O
viruses	485 7 O
have	493 4 O
much	498 4 O
in	503 2 O
common	506 6 O
anatomically	513 12 O
and	526 3 O
pathologically	530 14 O
with	545 4 O
the	550 3 O
human	554 5 O
form	560 4 O
.	564 1 O

The	566 3 O
authors	570 7 O
induced	578 7 O
myodystrophy	586 12 B-Disease
in	599 2 O
the	602 3 O
rat	606 3 O
by	610 2 O
giving	613 6 O
it	620 2 O
a	623 1 O
diet	625 4 O
lacking	630 7 O
in	638 2 O
vitamin	641 7 B-Chemical
E	649 1 I-Chemical
.	650 1 O

The	652 3 O
pharmacological	656 15 O
characteristics	672 15 O
of	688 2 O
vitamin	691 7 B-Chemical
E	699 1 I-Chemical
and	701 3 O
the	705 3 O
degenerative	709 12 O
changes	722 7 O
brought	730 7 O
about	738 5 O
by	744 2 O
its	747 3 O
deficiency	751 10 O
,	761 1 O
especially	763 10 O
in	774 2 O
the	777 3 O
muscles	781 7 O
,	788 1 O
are	790 3 O
illustrated	794 11 O
.	805 1 O

It	807 2 O
is	810 2 O
thus	813 4 O
confirmed	818 9 O
that	828 4 O
the	833 3 O
histological	837 12 O
characteristics	850 15 O
of	866 2 O
myopathic	869 9 B-Disease
rat	879 3 O
muscle	883 6 O
induced	890 7 O
experimentally	898 14 O
are	913 3 O
extraordinarily	917 15 O
similar	933 7 O
to	941 2 O
those	944 5 O
of	950 2 O
human	953 5 O
myopathy	959 8 B-Disease
as	968 2 O
confirmed	971 9 O
during	981 6 O
biopsies	988 8 O
performed	997 9 O
at	1007 2 O
the	1010 3 O
Orthopaedic	1014 11 O
Traumatological	1026 15 O
Centre	1042 6 O
,	1048 1 O
Florence	1050 8 O
.	1058 1 O

The	1060 3 O
encouraging	1064 11 O
results	1076 7 O
obtained	1084 8 O
in	1093 2 O
various	1096 7 O
authoratative	1104 13 O
departments	1118 11 O
in	1130 2 O
myopathic	1133 9 B-Disease
patients	1143 8 O
by	1152 2 O
using	1155 5 O
anabolizing	1161 11 O
steroids	1173 8 B-Chemical
have	1182 4 O
encouraged	1187 10 O
the	1198 3 O
authors	1202 7 O
to	1210 2 O
investigate	1213 11 O
the	1225 3 O
beneficial	1229 10 O
effects	1240 7 O
of	1248 2 O
one	1251 3 O
anabolizing	1255 11 O
agent	1267 5 O
(	1273 1 O
Dianabol	1274 8 B-Chemical
,	1282 1 O
CIBA	1284 4 B-Chemical
)	1288 1 O
at	1290 2 O
high	1293 4 O
doses	1298 5 O
in	1304 2 O
rats	1307 4 O
rendered	1312 8 O
myopathic	1321 9 B-Disease
by	1331 2 O
a	1334 1 O
diet	1336 4 O
deficient	1341 9 O
in	1351 2 O
vitamin	1354 7 B-Chemical
E	1362 1 I-Chemical
.	1363 1 O

In	1365 2 O
this	1368 4 O
way	1373 3 O
they	1377 4 O
obtained	1382 8 O
appreciable	1391 11 O
changes	1403 7 O
in	1411 2 O
body	1414 4 O
weight	1419 6 O
(	1426 1 O
increased	1427 9 O
from	1437 4 O
50	1442 2 O
to	1445 2 O
70	1448 2 O
g	1451 1 O
after	1453 5 O
forty	1459 5 O
days	1465 4 O
at	1470 2 O
a	1473 1 O
dose	1475 4 O
of	1480 2 O
5	1483 1 O
mg	1485 2 O
per	1488 3 O
day	1492 3 O
of	1496 2 O
anabolizing	1499 11 O
agent	1511 5 O
)	1516 1 O
,	1517 1 O
but	1519 3 O
most	1523 4 O
of	1528 2 O
all	1531 3 O
they	1535 4 O
found	1540 5 O
histological	1546 12 O
changes	1559 7 O
due	1567 3 O
to	1571 2 O
"	1574 1 O
regenerative	1575 12 O
"	1587 1 O
changes	1589 7 O
in	1597 2 O
the	1600 3 O
muscle	1604 6 O
tissue	1611 6 O
,	1617 1 O
which	1619 5 O
however	1625 7 O
maintained	1633 10 O
its	1644 3 O
myopathic	1648 9 B-Disease
characteristics	1658 15 O
in	1674 2 O
the	1677 3 O
control	1681 7 O
animals	1689 7 O
that	1697 4 O
were	1702 4 O
not	1707 3 O
treated	1711 7 O
with	1719 4 O
the	1724 3 O
anabolizing	1728 11 O
agent	1740 5 O
.	1745 1 O

The	1747 3 O
authors	1751 7 O
conclude	1759 8 O
by	1768 2 O
affirming	1771 9 O
the	1781 3 O
undoubted	1785 9 O
efficacy	1795 8 O
of	1804 2 O
the	1807 3 O
anabolizing	1811 11 O
steroids	1823 8 B-Chemical
in	1832 2 O
experimental	1835 12 O
myopathic	1848 9 B-Disease
disease	1858 7 I-Disease
,	1865 1 O
but	1867 3 O
they	1871 4 O
have	1876 4 O
reservations	1881 12 O
as	1894 2 O
to	1897 2 O
the	1900 3 O
transfer	1904 8 O
of	1913 2 O
the	1916 3 O
results	1920 7 O
into	1928 4 O
the	1933 3 O
human	1937 5 O
field	1943 5 O
,	1948 1 O
where	1950 5 O
high	1956 4 O
dosage	1961 6 O
cannot	1968 6 O
be	1975 2 O
carried	1978 7 O
out	1986 3 O
continuously	1990 12 O
because	2003 7 O
of	2011 2 O
the	2014 3 O
effects	2018 7 O
of	2026 2 O
the	2029 3 O
drug	2033 4 O
on	2038 2 O
virility	2041 8 O
;	2049 1 O
because	2051 7 O
the	2059 3 O
tissue	2063 6 O
injury	2070 6 O
too	2077 3 O
often	2081 5 O
occurs	2087 6 O
at	2094 2 O
an	2097 2 O
irreversible	2100 12 O
stage	2113 5 O
vis	2119 3 O
-	2122 1 O
a	2123 1 O
-	2124 1 O
vis	2125 3 O
the	2129 3 O
"	2133 1 O
regeneration	2134 12 O
"	2146 1 O
of	2148 2 O
the	2151 3 O
muscle	2155 6 O
tissue	2162 6 O
;	2168 1 O
and	2170 3 O
finally	2174 7 O
because	2182 7 O
the	2190 3 O
dystrophic	2194 10 O
injurious	2205 9 O
agent	2215 5 O
is	2221 2 O
certainly	2224 9 O
not	2234 3 O
the	2238 3 O
lack	2242 4 O
of	2247 2 O
vitamin	2250 7 B-Chemical
E	2258 1 I-Chemical
but	2260 3 O
something	2264 9 O
as	2274 2 O
yet	2277 3 O
unknown	2281 7 O
.	2288 1 O

Fetal	0 5 O
risks	6 5 O
due	12 3 O
to	16 2 O
warfarin	19 8 B-Chemical
therapy	28 7 O
during	36 6 O
pregnancy	43 9 O
.	52 1 O

Two	54 3 O
mothers	58 7 O
with	66 4 O
heart	71 5 O
valve	77 5 O
prosthesis	83 10 O
were	94 4 O
treated	99 7 O
with	107 4 O
warfarin	112 8 B-Chemical
during	121 6 O
pregnancy	128 9 O
.	137 1 O

In	139 2 O
the	142 3 O
first	146 5 O
case	152 4 O
a	157 1 O
caesarean	159 9 O
section	169 7 O
was	177 3 O
done	181 4 O
one	186 3 O
week	190 4 O
after	195 5 O
replacement	201 11 O
of	213 2 O
warfarin	216 8 B-Chemical
with	225 4 O
heparin	230 7 B-Chemical
.	237 1 O

The	239 3 O
baby	243 4 O
died	248 4 O
of	253 2 O
cerebral	256 8 B-Disease
and	265 3 I-Disease
pulmonary	269 9 I-Disease
hemorrhage	279 10 I-Disease
.	289 1 O

The	291 3 O
second	295 6 O
mother	302 6 O
had	309 3 O
a	313 1 O
male	315 4 O
infant	320 6 O
by	327 2 O
caesarean	330 9 O
section	340 7 O
.	347 1 O

The	349 3 O
baby	353 4 O
showed	358 6 O
warfarin	365 8 B-Chemical
-	373 1 O
induced	374 7 O
embryopathy	382 11 B-Disease
with	394 4 O
nasal	399 5 B-Disease
hypoplasia	405 10 I-Disease
and	416 3 O
stippled	420 8 B-Disease
epiphyses	429 9 I-Disease
(	439 1 O
chondrodysplasia	440 16 B-Disease
punctata	457 8 I-Disease
)	465 1 O
.	466 1 O

Nasal	468 5 B-Disease
hypoplasia	474 10 I-Disease
with	485 4 O
or	490 2 O
without	493 7 O
stippled	501 8 B-Disease
epiphyses	510 9 I-Disease
has	520 3 O
now	524 3 O
been	528 4 O
reported	533 8 O
in	542 2 O
11	545 2 O
infants	548 7 O
born	556 4 O
to	561 2 O
mothers	564 7 O
treated	572 7 O
with	580 4 O
warfarin	585 8 B-Chemical
during	594 6 O
the	601 3 O
first	605 5 O
trimester	611 9 O
,	620 1 O
and	622 3 O
a	626 1 O
causal	628 6 O
association	635 11 O
is	647 2 O
probable	650 8 O
.	658 1 O

In	660 2 O
view	663 4 O
of	668 2 O
the	671 3 O
risks	675 5 O
to	681 2 O
both	684 4 O
mother	689 6 O
and	696 3 O
fetus	700 5 O
in	706 2 O
women	709 5 O
with	715 4 O
prosthetic	720 10 O
cardiac	731 7 O
valves	739 6 O
it	746 2 O
is	749 2 O
recommended	752 11 O
that	764 4 O
therapeutic	769 11 O
abortion	781 8 O
be	790 2 O
advised	793 7 O
as	801 2 O
the	804 3 O
first	808 5 O
alternative	814 11 O
.	825 1 O

Isradipine	0 10 B-Chemical
treatment	11 9 O
for	21 3 O
hypertension	25 12 B-Disease
in	38 2 O
general	41 7 O
practice	49 8 O
in	58 2 O
Hong	61 4 O
Kong	66 4 O
.	70 1 O

A	72 1 O
6	74 1 O
-	75 1 O
week	76 4 O
open	81 4 O
study	86 5 O
of	92 2 O
the	95 3 O
introduction	99 12 O
of	112 2 O
isradipine	115 10 B-Chemical
treatment	126 9 O
was	136 3 O
conducted	140 9 O
in	150 2 O
general	153 7 O
practice	161 8 O
in	170 2 O
Hong	173 4 O
Kong	178 4 O
.	182 1 O

303	184 3 O
Chinese	188 7 O
patients	196 8 O
with	205 4 O
mild	210 4 O
to	215 2 O
moderate	218 8 O
hypertension	227 12 B-Disease
entered	240 7 O
the	248 3 O
study	252 5 O
.	257 1 O

Side	259 4 O
effects	264 7 O
were	272 4 O
reported	277 8 O
in	286 2 O
21	289 2 O
%	291 1 O
of	293 2 O
patients	296 8 O
and	305 3 O
caused	309 6 O
withdrawal	316 10 O
from	327 4 O
the	332 3 O
study	336 5 O
in	342 2 O
3	345 1 O
patients	347 8 O
.	355 1 O

The	357 3 O
main	361 4 O
side	366 4 O
-	370 1 O
effects	371 7 O
were	379 4 O
headache	384 8 B-Disease
,	392 1 O
dizziness	394 9 B-Disease
,	403 1 O
palpitation	405 11 B-Disease
and	417 3 O
flushing	421 8 B-Disease
and	430 3 O
these	434 5 O
were	440 4 O
not	445 3 O
more	449 4 O
frequent	454 8 O
than	463 4 O
reported	468 8 O
in	477 2 O
other	480 5 O
studies	486 7 O
with	494 4 O
isradipine	499 10 B-Chemical
or	510 2 O
with	513 4 O
placebo	518 7 O
.	525 1 O

Supine	527 6 O
blood	534 5 O
pressure	540 8 O
was	549 3 O
reduced	553 7 O
(	561 1 O
P	562 1 O
less	564 4 O
than	569 4 O
0	574 1 O
.	575 1 O
01	576 2 O
)	578 1 O
from	580 4 O
170	585 3 O
+	589 1 O
/	590 1 O
-	591 1 O
20	593 2 O
/	595 1 O
102	596 3 O
+	600 1 O
/	601 1 O
-	602 1 O
6	604 1 O
mmHg	606 4 O
to	611 2 O
153	614 3 O
+	618 1 O
/	619 1 O
-	620 1 O
19	622 2 O
/	624 1 O
92	625 2 O
+	628 1 O
/	629 1 O
-	630 1 O
8	632 1 O
,	633 1 O
147	635 3 O
+	639 1 O
/	640 1 O
-	641 1 O
18	643 2 O
/	645 1 O
88	646 2 O
+	649 1 O
/	650 1 O
-	651 1 O
7	653 1 O
and	655 3 O
144	659 3 O
+	663 1 O
/	664 1 O
-	665 1 O
14	667 2 O
/	669 1 O
87	670 2 O
+	673 1 O
/	674 1 O
-	675 1 O
6	677 1 O
mmHg	679 4 O
at	684 2 O
2	687 1 O
,	688 1 O
4	690 1 O
and	692 3 O
6	696 1 O
weeks	698 5 O
respectively	704 12 O
in	717 2 O
evaluable	720 9 O
patients	730 8 O
.	738 1 O

Similar	740 7 O
reductions	748 10 O
occurred	759 8 O
in	768 2 O
standing	771 8 O
blood	780 5 O
pressure	786 8 O
and	795 3 O
there	799 5 O
was	805 3 O
no	809 2 O
evidence	812 8 O
of	821 2 O
postural	824 8 B-Disease
hypotension	833 11 I-Disease
.	844 1 O

Normalization	846 13 O
and	860 3 O
responder	864 9 O
rates	874 5 O
at	880 2 O
6	883 1 O
weeks	885 5 O
were	891 4 O
86	896 2 O
%	898 1 O
and	900 3 O
69	904 2 O
%	906 1 O
respectively	908 12 O
.	920 1 O

Dosage	922 6 O
was	929 3 O
increased	933 9 O
from	943 4 O
2	948 1 O
.	949 1 O
5	950 1 O
mg	952 2 O
b	955 1 O
.	956 1 O
d	957 1 O
.	958 1 O
to	960 2 O
5	963 1 O
mg	965 2 O
b	968 1 O
.	969 1 O
d	970 1 O
.	971 1 O
at	973 2 O
4	976 1 O
weeks	978 5 O
in	984 2 O
patients	987 8 O
with	996 4 O
diastolic	1001 9 O
blood	1011 5 O
pressure	1017 8 O
greater	1026 7 O
than	1034 4 O
90	1039 2 O
mmHg	1042 4 O
and	1047 3 O
their	1051 5 O
further	1057 7 O
response	1065 8 O
was	1074 3 O
greater	1078 7 O
than	1086 4 O
those	1091 5 O
remaining	1097 9 O
on	1107 2 O
2	1110 1 O
.	1111 1 O
5	1112 1 O
mg	1114 2 O
b	1117 1 O
.	1118 1 O
d	1119 1 O
.	1120 1 O

Tachyphylaxis	0 13 O
to	14 2 O
systemic	17 8 O
but	26 3 O
not	30 3 O
to	34 2 O
airway	37 6 O
responses	44 9 O
during	54 6 O
prolonged	61 9 O
therapy	71 7 O
with	79 4 O
high	84 4 O
dose	89 4 O
inhaled	94 7 O
salbutamol	102 10 B-Chemical
in	113 2 O
asthmatics	116 10 B-Disease
.	126 1 O

High	128 4 O
doses	133 5 O
of	139 2 O
inhaled	142 7 O
salbutamol	150 10 B-Chemical
produce	161 7 O
substantial	169 11 O
improvements	181 12 O
in	194 2 O
airway	197 6 O
response	204 8 O
in	213 2 O
patients	216 8 O
with	225 4 O
asthma	230 6 B-Disease
,	236 1 O
and	238 3 O
are	242 3 O
associated	246 10 O
with	257 4 O
dose	262 4 O
-	266 1 O
dependent	267 9 O
systemic	277 8 O
beta	286 4 O
-	290 1 O
adrenoceptor	291 12 O
responses	304 9 O
.	313 1 O

The	315 3 O
purpose	319 7 O
of	327 2 O
the	330 3 O
present	334 7 O
study	342 5 O
was	348 3 O
to	352 2 O
investigate	355 11 O
whether	367 7 O
tachyphylaxis	375 13 O
occurs	389 6 O
during	396 6 O
prolonged	403 9 O
treatment	413 9 O
with	423 4 O
high	428 4 O
dose	433 4 O
inhaled	438 7 O
salbutamol	446 10 B-Chemical
.	456 1 O

Twelve	458 6 O
asthmatic	465 9 B-Disease
patients	475 8 O
(	484 1 O
FEV1	485 4 O
,	489 1 O
81	491 2 O
+	494 1 O
/	495 1 O
-	496 1 O
4	498 1 O
%	499 1 O
predicted	501 9 O
)	510 1 O
,	511 1 O
requiring	513 9 O
only	523 4 O
occasional	528 10 O
inhaled	539 7 O
beta	547 4 O
-	551 1 O
agonists	552 8 O
as	561 2 O
their	564 5 O
sole	570 4 O
therapy	575 7 O
,	582 1 O
were	584 4 O
given	589 5 O
a	595 1 O
14	597 2 O
-	599 1 O
day	600 3 O
treatment	604 9 O
with	614 4 O
high	619 4 O
dose	624 4 O
inhaled	629 7 O
salbutamol	637 10 B-Chemical
(	648 1 O
HDS	649 3 O
)	652 1 O
,	653 1 O
4	655 1 O
,	656 1 O
000	657 3 O
micrograms	661 10 O
daily	672 5 O
,	677 1 O
low	679 3 O
dose	683 4 O
inhaled	688 7 O
salbutamol	696 10 B-Chemical
(	707 1 O
LDS	708 3 O
)	711 1 O
,	712 1 O
800	714 3 O
micrograms	718 10 O
daily	729 5 O
,	734 1 O
or	736 2 O
placebo	739 7 O
(	747 1 O
PI	748 2 O
)	750 1 O
by	752 2 O
metered	755 7 O
-	762 1 O
dose	763 4 O
inhaler	768 7 O
in	776 2 O
a	779 1 O
double	781 6 O
-	787 1 O
blind	788 5 O
,	793 1 O
randomized	795 10 O
crossover	806 9 O
design	816 6 O
.	822 1 O

During	824 6 O
the	831 3 O
14	835 2 O
-	837 1 O
day	838 3 O
run	842 3 O
-	845 1 O
in	846 2 O
and	849 3 O
during	853 6 O
washout	860 7 O
periods	868 7 O
,	875 1 O
inhaled	877 7 O
beta	885 4 O
-	889 1 O
agonists	890 8 O
were	899 4 O
withheld	904 8 O
and	913 3 O
ipratropium	917 11 B-Chemical
bromide	929 7 I-Chemical
was	937 3 O
substituted	941 11 O
for	953 3 O
rescue	957 6 O
purposes	964 8 O
.	972 1 O

At	974 2 O
the	977 3 O
end	981 3 O
of	985 2 O
each	988 4 O
14	993 2 O
-	995 1 O
day	996 3 O
treatment	1000 9 O
,	1009 1 O
a	1011 1 O
dose	1013 4 O
-	1017 1 O
response	1018 8 O
curve	1027 5 O
(	1033 1 O
DRC	1034 3 O
)	1037 1 O
was	1039 3 O
performed	1043 9 O
,	1052 1 O
and	1054 3 O
airway	1058 6 O
(	1065 1 O
FEV1	1066 4 O
,	1070 1 O
FEF25	1072 5 O
-	1077 1 O
75	1078 2 O
)	1080 1 O
chronotropic	1082 12 O
(	1095 1 O
HR	1096 2 O
)	1098 1 O
,	1099 1 O
tremor	1101 6 B-Disease
,	1107 1 O
and	1109 3 O
metabolic	1113 9 O
(	1123 1 O
K	1124 1 B-Chemical
,	1125 1 O
Glu	1127 3 B-Chemical
)	1130 1 O
responses	1132 9 O
were	1142 4 O
measured	1147 8 O
at	1156 2 O
each	1159 4 O
step	1164 4 O
(	1169 1 O
from	1170 4 O
100	1175 3 O
to	1179 2 O
4	1182 1 O
,	1183 1 O
000	1184 3 O
micrograms	1188 10 O
)	1198 1 O
.	1199 1 O

Treatment	1201 9 O
had	1211 3 O
no	1215 2 O
significant	1218 11 O
effect	1230 6 O
on	1237 2 O
baseline	1240 8 O
values	1249 6 O
.	1255 1 O

There	1257 5 O
were	1263 4 O
dose	1268 4 O
-	1272 1 O
dependent	1273 9 O
increases	1283 9 O
in	1293 2 O
FEV1	1296 4 O
and	1301 3 O
FEF25	1305 5 O
-	1310 1 O
75	1311 2 O
(	1314 1 O
p	1315 1 O
less	1317 4 O
than	1322 4 O
0	1327 1 O
.	1328 1 O
001	1329 3 O
)	1332 1 O
,	1333 1 O
and	1335 3 O
pretreatment	1339 12 O
with	1352 4 O
HDS	1357 3 O
did	1361 3 O
not	1365 3 O
displace	1369 8 O
the	1378 3 O
DRC	1382 3 O
to	1386 2 O
the	1389 3 O
right	1393 5 O
.	1398 1 O

DRC	1400 3 O
for	1404 3 O
HR	1408 2 O
(	1411 1 O
p	1412 1 O
less	1414 4 O
than	1419 4 O
0	1424 1 O
.	1425 1 O
001	1426 3 O
)	1429 1 O
,	1430 1 O
K	1432 1 B-Chemical
(	1434 1 O
p	1435 1 O
less	1437 4 O
than	1442 4 O
0	1447 1 O
.	1448 1 O
001	1449 3 O
)	1452 1 O
,	1453 1 O
and	1455 3 O
Glu	1459 3 B-Chemical
(	1463 1 O
p	1464 1 O
less	1466 4 O
than	1471 4 O
0	1476 1 O
.	1477 1 O
005	1478 3 O
)	1481 1 O
were	1483 4 O
attenuated	1488 10 O
after	1499 5 O
treatment	1505 9 O
with	1515 4 O
HDS	1520 3 O
compared	1524 8 O
with	1533 4 O
PI	1538 2 O
.	1540 1 O

There	1542 5 O
were	1548 4 O
also	1553 4 O
differences	1558 11 O
between	1570 7 O
HDS	1578 3 O
and	1582 3 O
LDS	1586 3 O
for	1590 3 O
HR	1594 2 O
(	1597 1 O
p	1598 1 O
less	1600 4 O
than	1605 4 O
0	1610 1 O
.	1611 1 O
001	1612 3 O
)	1615 1 O
and	1617 3 O
Glu	1621 3 B-Chemical
(	1625 1 O
p	1626 1 O
less	1628 4 O
than	1633 4 O
0	1638 1 O
.	1639 1 O
05	1640 2 O
)	1642 1 O
responses	1644 9 O
.	1653 1 O

Frequency	1655 9 O
and	1665 3 O
severity	1669 8 O
of	1678 2 O
subjective	1681 10 O
adverse	1692 7 O
effects	1700 7 O
were	1708 4 O
also	1713 4 O
reduced	1718 7 O
after	1726 5 O
HDS	1732 3 O
:	1735 1 O
tremor	1737 6 B-Disease
(	1744 1 O
p	1745 1 O
less	1747 4 O
than	1752 4 O
0	1757 1 O
.	1758 1 O
001	1759 3 O
)	1762 1 O
,	1763 1 O
palpitations	1765 12 B-Disease
(	1778 1 O
p	1779 1 O
less	1781 4 O
than	1786 4 O
0	1791 1 O
.	1792 1 O
001	1793 3 O
)	1796 1 O
.	1797 1 O
(	1798 1 O
ABSTRACT	1799 8 O
TRUNCATED	1808 9 O
AT	1818 2 O
250	1821 3 O
WORDS	1825 5 O
)	1830 1 O

Increased	0 9 O
anxiogenic	10 10 O
effects	21 7 O
of	29 2 O
caffeine	32 8 B-Chemical
in	41 2 O
panic	44 5 B-Disease
disorders	50 9 I-Disease
.	59 1 O

The	61 3 O
effects	65 7 O
of	73 2 O
oral	76 4 O
administration	81 14 O
of	96 2 O
caffeine	99 8 B-Chemical
(	108 1 O
10	109 2 O
mg	112 2 O
/	114 1 O
kg	115 2 O
)	117 1 O
on	119 2 O
behavioral	122 10 O
ratings	133 7 O
,	140 1 O
somatic	142 7 O
symptoms	150 8 O
,	158 1 O
blood	160 5 O
pressure	166 8 O
and	175 3 O
plasma	179 6 O
levels	186 6 O
of	193 2 O
3	196 1 B-Chemical
-	197 1 I-Chemical
methoxy	198 7 I-Chemical
-	205 1 I-Chemical
4	206 1 I-Chemical
-	207 1 I-Chemical
hydroxyphenethyleneglycol	208 25 I-Chemical
(	234 1 O
MHPG	235 4 B-Chemical
)	239 1 O
and	241 3 O
cortisol	245 8 B-Chemical
were	254 4 O
determined	259 10 O
in	270 2 O
17	273 2 O
healthy	276 7 O
subjects	284 8 O
and	293 3 O
21	297 2 O
patients	300 8 O
meeting	309 7 O
DSM	317 3 O
-	320 1 O
III	321 3 O
criteria	325 8 O
for	334 3 O
agoraphobia	338 11 B-Disease
with	350 4 O
panic	355 5 B-Disease
attacks	361 7 I-Disease
or	369 2 O
panic	372 5 B-Disease
disorder	378 8 I-Disease
.	386 1 O

Caffeine	388 8 B-Chemical
produced	397 8 O
significantly	406 13 O
greater	420 7 O
increases	428 9 O
in	438 2 O
subject	441 7 O
-	448 1 O
rated	449 5 O
anxiety	455 7 B-Disease
,	462 1 O
nervousness	464 11 O
,	475 1 O
fear	477 4 O
,	481 1 O
nausea	483 6 B-Disease
,	489 1 O
palpitations	491 12 B-Disease
,	503 1 O
restlessness	505 12 B-Disease
,	517 1 O
and	519 3 O
tremors	523 7 B-Disease
in	531 2 O
the	534 3 O
patients	538 8 O
compared	547 8 O
with	556 4 O
healthy	561 7 O
subjects	569 8 O
.	577 1 O

In	579 2 O
the	582 3 O
patients	586 8 O
,	594 1 O
but	596 3 O
not	600 3 O
the	604 3 O
healthy	608 7 O
subjects	616 8 O
,	624 1 O
these	626 5 O
symptoms	632 8 O
were	641 4 O
significantly	646 13 O
correlated	660 10 O
with	671 4 O
plasma	676 6 O
caffeine	683 8 B-Chemical
levels	692 6 O
.	698 1 O

Seventy	700 7 O
-	707 1 O
one	708 3 O
percent	712 7 O
of	720 2 O
the	723 3 O
patients	727 8 O
reported	736 8 O
that	745 4 O
the	750 3 O
behavioral	754 10 O
effects	765 7 O
of	773 2 O
caffeine	776 8 B-Chemical
were	785 4 O
similar	790 7 O
to	798 2 O
those	801 5 O
experienced	807 11 O
during	819 6 O
panic	826 5 B-Disease
attacks	832 7 I-Disease
.	839 1 O

Caffeine	841 8 B-Chemical
did	850 3 O
not	854 3 O
alter	858 5 O
plasma	864 6 O
MHPG	871 4 B-Chemical
levels	876 6 O
in	883 2 O
either	886 6 O
the	893 3 O
healthy	897 7 O
subjects	905 8 O
or	914 2 O
patients	917 8 O
.	925 1 O

Caffeine	927 8 B-Chemical
increased	936 9 O
plasma	946 6 O
cortisol	953 8 B-Chemical
levels	962 6 O
equally	969 7 O
in	977 2 O
the	980 3 O
patient	984 7 O
and	992 3 O
healthy	996 7 O
groups	1004 6 O
.	1010 1 O

Because	1012 7 O
caffeine	1020 8 B-Chemical
is	1029 2 O
an	1032 2 O
adenosine	1035 9 B-Chemical
receptor	1045 8 O
antagonist	1054 10 O
,	1064 1 O
these	1066 5 O
results	1072 7 O
suggest	1080 7 O
that	1088 4 O
some	1093 4 O
panic	1098 5 B-Disease
disorder	1104 8 I-Disease
patients	1113 8 O
may	1122 3 O
have	1126 4 O
abnormalities	1131 13 B-Disease
in	1145 2 I-Disease
neuronal	1148 8 I-Disease
systems	1157 7 I-Disease
involving	1165 9 O
adenosine	1175 9 B-Chemical
.	1184 1 O

Patients	1186 8 O
with	1195 4 O
anxiety	1200 7 B-Disease
disorders	1208 9 I-Disease
may	1218 3 O
benefit	1222 7 O
by	1230 2 O
avoiding	1233 8 O
caffeine	1242 8 B-Chemical
-	1250 1 O
containing	1251 10 O
foods	1262 5 O
and	1268 3 O
beverages	1272 9 O
.	1281 1 O

Human	0 5 O
and	6 3 O
canine	10 6 O
ventricular	17 11 O
vasoactive	29 10 O
intestinal	40 10 O
polypeptide	51 11 O
:	62 1 O
decrease	64 8 O
with	73 4 O
heart	78 5 B-Disease
failure	84 7 I-Disease
.	91 1 O

Vasoactive	93 10 O
intestinal	104 10 O
polypeptide	115 11 O
(	127 1 O
VIP	128 3 O
)	131 1 O
is	133 2 O
a	136 1 O
systemic	138 8 O
and	147 3 O
coronary	151 8 O
vasodilator	160 11 O
that	172 4 O
may	177 3 O
have	181 4 O
positive	186 8 O
inotropic	195 9 O
properties	205 10 O
.	215 1 O

Myocardial	217 10 O
levels	228 6 O
of	235 2 O
VIP	238 3 O
were	242 4 O
assayed	247 7 O
before	255 6 O
and	262 3 O
after	266 5 O
the	272 3 O
development	276 11 O
of	288 2 O
heart	291 5 B-Disease
failure	297 7 I-Disease
in	305 2 O
two	308 3 O
canine	312 6 O
models	319 6 O
.	325 1 O

In	327 2 O
the	330 3 O
first	334 5 O
,	339 1 O
cobalt	341 6 B-Chemical
cardiomyopathy	348 14 B-Disease
was	363 3 O
induced	367 7 O
in	375 2 O
eight	378 5 O
dogs	384 4 O
;	388 1 O
VIP	390 3 O
(	394 1 O
by	395 2 O
radioimmunoassay	398 16 O
)	414 1 O
decreased	416 9 O
from	426 4 O
35	431 2 O
+	434 1 O
/	435 1 O
-	436 1 O
11	438 2 O
pg	441 2 O
/	443 1 O
mg	444 2 O
protein	447 7 O
(	455 1 O
mean	456 4 O
+	461 1 O
/	462 1 O
-	463 1 O
SD	465 2 O
)	467 1 O
to	469 2 O
5	472 1 O
+	474 1 O
/	475 1 O
-	476 1 O
4	478 1 O
pg	480 2 O
/	482 1 O
mg	483 2 O
protein	486 7 O
(	494 1 O
P	495 1 O
less	497 4 O
than	502 4 O
0	507 1 O
.	508 1 O
05	509 2 O
)	511 1 O
.	512 1 O

In	514 2 O
six	517 3 O
dogs	521 4 O
with	526 4 O
doxorubicin	531 11 B-Chemical
-	542 1 O
induced	543 7 O
heart	551 5 B-Disease
failure	557 7 I-Disease
,	564 1 O
VIP	566 3 O
decreased	570 9 O
from	580 4 O
31	585 2 O
+	588 1 O
/	589 1 O
-	590 1 O
7	592 1 O
to	594 2 O
11	597 2 O
+	600 1 O
/	601 1 O
-	602 1 O
4	604 1 O
pg	606 2 O
/	608 1 O
mg	609 2 O
protein	612 7 O
(	620 1 O
P	621 1 O
less	623 4 O
than	628 4 O
0	633 1 O
.	634 1 O
05	635 2 O
)	637 1 O
.	638 1 O

In	640 2 O
addition	643 8 O
,	651 1 O
VIP	653 3 O
content	657 7 O
of	665 2 O
left	668 4 O
ventricular	673 11 O
muscle	685 6 O
of	692 2 O
resected	695 8 O
failing	704 7 O
hearts	712 6 O
in	719 2 O
10	722 2 O
patients	725 8 O
receiving	734 9 O
a	744 1 O
heart	746 5 O
transplant	752 10 O
was	763 3 O
compared	767 8 O
with	776 4 O
the	781 3 O
papillary	785 9 O
muscles	795 7 O
in	803 2 O
14	806 2 O
patients	809 8 O
(	818 1 O
five	819 4 O
with	824 4 O
rheumatic	829 9 B-Disease
disease	839 7 I-Disease
,	846 1 O
nine	848 4 O
with	853 4 O
myxomatous	858 10 B-Disease
degeneration	869 12 I-Disease
)	881 1 O
receiving	883 9 O
mitral	893 6 O
valve	900 5 O
prostheses	906 10 O
.	916 1 O

The	918 3 O
lowest	922 6 O
myocardial	929 10 O
VIP	940 3 O
concentration	944 13 O
was	958 3 O
found	962 5 O
in	968 2 O
the	971 3 O
hearts	975 6 O
of	982 2 O
patients	985 8 O
with	994 4 O
coronary	999 8 B-Disease
disease	1008 7 I-Disease
(	1016 1 O
one	1017 3 O
patient	1021 7 O
receiving	1029 9 O
a	1039 1 O
transplant	1041 10 O
and	1052 3 O
three	1056 5 O
receiving	1062 9 O
mitral	1072 6 O
prostheses	1079 10 O
)	1089 1 O
(	1091 1 O
6	1092 1 O
.	1093 1 O
3	1094 1 O
+	1096 1 O
/	1097 1 O
-	1098 1 O
1	1100 1 O
.	1101 1 O
9	1102 1 O
pg	1104 2 O
/	1106 1 O
mg	1107 2 O
protein	1110 7 O
)	1117 1 O
.	1118 1 O

The	1120 3 O
other	1124 5 O
patients	1130 8 O
undergoing	1139 10 O
transplantation	1150 15 O
had	1166 3 O
an	1170 2 O
average	1173 7 O
ejection	1181 8 O
fraction	1190 8 O
of	1199 2 O
17	1202 2 O
%	1204 1 O
+	1206 1 O
/	1207 1 O
-	1208 1 O
6	1210 1 O
%	1211 1 O
and	1213 3 O
a	1217 1 O
VIP	1219 3 O
level	1223 5 O
of	1229 2 O
8	1232 1 O
.	1233 1 O
8	1234 1 O
+	1236 1 O
/	1237 1 O
-	1238 1 O
3	1240 1 O
.	1241 1 O
9	1242 1 O
pg	1244 2 O
/	1246 1 O
mg	1247 2 O
protein	1250 7 O
.	1257 1 O

The	1259 3 O
hearts	1263 6 O
without	1270 7 O
coronary	1278 8 B-Disease
artery	1287 6 I-Disease
disease	1294 7 I-Disease
(	1302 1 O
average	1303 7 O
ejection	1311 8 O
fraction	1320 8 O
of	1329 2 O
this	1332 4 O
group	1337 5 O
62	1343 2 O
%	1345 1 O
+	1347 1 O
/	1348 1 O
-	1349 1 O
10	1351 2 O
%	1353 1 O
)	1354 1 O
had	1356 3 O
a	1360 1 O
VIP	1362 3 O
concentration	1366 13 O
of	1380 2 O
14	1383 2 O
.	1385 1 O
1	1386 1 O
+	1388 1 O
/	1389 1 O
-	1390 1 O
7	1392 1 O
.	1393 1 O
9	1394 1 O
pg	1396 2 O
/	1398 1 O
mg	1399 2 O
protein	1402 7 O
,	1409 1 O
and	1411 3 O
this	1415 4 O
was	1420 3 O
greater	1424 7 O
than	1432 4 O
in	1437 2 O
hearts	1440 6 O
of	1447 2 O
the	1450 3 O
patients	1454 8 O
with	1463 4 O
coronary	1468 8 B-Disease
disease	1477 7 I-Disease
and	1485 3 O
the	1489 3 O
hearts	1493 6 O
of	1500 2 O
patients	1503 8 O
receiving	1512 9 O
a	1522 1 O
transplant	1524 10 O
(	1535 1 O
P	1536 1 O
less	1538 4 O
than	1543 4 O
0	1548 1 O
.	1549 1 O
05	1550 2 O
)	1552 1 O
.	1553 1 O

Myocardial	1555 10 O
catecholamines	1566 14 B-Chemical
were	1581 4 O
also	1586 4 O
determined	1591 10 O
in	1602 2 O
14	1605 2 O
subjects	1608 8 O
;	1616 1 O
a	1618 1 O
weak	1620 4 O
correlation	1625 11 O
(	1637 1 O
r	1638 1 O
=	1640 1 O
0	1642 1 O
.	1643 1 O
57	1644 2 O
,	1646 1 O
P	1648 1 O
less	1650 4 O
than	1655 4 O
0	1660 1 O
.	1661 1 O
05	1662 2 O
)	1664 1 O
between	1666 7 O
the	1674 3 O
tissue	1678 6 O
concentrations	1685 14 O
of	1700 2 O
VIP	1703 3 O
and	1707 3 O
norepinephrine	1711 14 B-Chemical
was	1726 3 O
noted	1730 5 O
.	1735 1 O
(	1736 1 O
ABSTRACT	1737 8 O
TRUNCATED	1746 9 O
AT	1756 2 O
250	1759 3 O
WORDS	1763 5 O
)	1768 1 O

Interstrain	0 11 O
variation	12 9 O
in	22 2 O
acute	25 5 O
toxic	31 5 O
response	37 8 O
to	46 2 O
caffeine	49 8 B-Chemical
among	58 5 O
inbred	64 6 O
mice	71 4 O
.	75 1 O

Acute	77 5 O
toxic	83 5 O
dosage	89 6 O
-	95 1 O
dependent	96 9 O
behavioral	106 10 O
effects	117 7 O
of	125 2 O
caffeine	128 8 B-Chemical
were	137 4 O
compared	142 8 O
in	151 2 O
adult	154 5 O
males	160 5 O
from	166 4 O
seven	171 5 O
inbred	177 6 O
mouse	184 5 O
strains	190 7 O
(	198 1 O
A	199 1 O
/	200 1 O
J	201 1 O
,	202 1 O
BALB	204 4 O
/	208 1 O
cJ	209 2 O
,	211 1 O
CBA	213 3 O
/	216 1 O
J	217 1 O
,	218 1 O
C3H	220 3 O
/	223 1 O
HeJ	224 3 O
,	227 1 O
C57BL	229 5 O
/	234 1 O
6J	235 2 O
,	237 1 O
DBA	239 3 O
/	242 1 O
2J	243 2 O
,	245 1 O
SWR	247 3 O
/	250 1 O
J	251 1 O
)	252 1 O
.	253 1 O

C57BL	255 5 O
/	260 1 O
6J	261 2 O
,	263 1 O
chosen	265 6 O
as	272 2 O
a	275 1 O
"	277 1 O
prototypic	278 10 O
"	288 1 O
mouse	290 5 O
strain	296 6 O
,	302 1 O
was	304 3 O
used	308 4 O
to	313 2 O
determine	316 9 O
behavioral	326 10 O
responses	337 9 O
to	347 2 O
a	350 1 O
broad	352 5 O
range	358 5 O
(	364 1 O
5	365 1 O
-	366 1 O
500	367 3 O
mg	371 2 O
/	373 1 O
kg	374 2 O
)	376 1 O
of	378 2 O
caffeine	381 8 B-Chemical
doses	390 5 O
.	395 1 O

Five	397 4 O
phenotypic	402 10 O
characteristics	413 15 O
-	428 1 O
-	429 1 O
locomotor	430 9 O
activity	440 8 O
,	448 1 O
righting	450 8 O
ability	459 7 O
,	466 1 O
clonic	468 6 B-Disease
seizure	475 7 I-Disease
induction	483 9 O
,	492 1 O
stress	494 6 O
-	500 1 O
induced	501 7 O
lethality	509 9 O
,	518 1 O
death	520 5 O
without	526 7 O
external	534 8 O
stress	543 6 O
-	549 1 O
-	550 1 O
were	551 4 O
scored	556 6 O
at	563 2 O
various	566 7 O
caffeine	574 8 B-Chemical
doses	583 5 O
in	589 2 O
drug	592 4 O
-	596 1 O
naive	597 5 O
animals	603 7 O
under	611 5 O
empirically	617 11 O
optimized	629 9 O
,	638 1 O
rigidly	640 7 O
constant	648 8 O
experimental	657 12 O
conditions	670 10 O
.	680 1 O

Mice	682 4 O
(	687 1 O
n	688 1 O
=	690 1 O
12	692 2 O
for	695 3 O
each	699 4 O
point	704 5 O
)	709 1 O
received	711 8 O
single	720 6 O
IP	727 2 O
injections	730 10 O
of	741 2 O
a	744 1 O
fixed	746 5 O
volume	752 6 O
/	758 1 O
g	759 1 O
body	761 4 O
weight	766 6 O
of	773 2 O
physiological	776 13 O
saline	790 6 O
carrier	797 7 O
with	805 4 O
or	810 2 O
without	813 7 O
caffeine	821 8 B-Chemical
in	830 2 O
doses	833 5 O
ranging	839 7 O
from	847 4 O
125	852 3 O
-	855 1 O
500	856 3 O
mg	860 2 O
/	862 1 O
kg	863 2 O
.	865 1 O

Loss	867 4 O
of	872 2 O
righting	875 8 O
ability	884 7 O
was	892 3 O
scored	896 6 O
at	903 2 O
1	906 1 O
,	907 1 O
3	909 1 O
,	910 1 O
5	912 1 O
min	914 3 O
post	918 4 O
dosing	923 6 O
and	930 3 O
at	934 2 O
5	937 1 O
min	939 3 O
intervals	943 9 O
thereafter	953 10 O
for	964 3 O
20	968 2 O
min	971 3 O
.	974 1 O

In	976 2 O
the	979 3 O
same	983 4 O
animals	988 7 O
the	996 3 O
occurrence	1000 10 O
of	1011 2 O
clonic	1014 6 B-Disease
seizures	1021 8 I-Disease
was	1030 3 O
scored	1034 6 O
as	1041 2 O
to	1044 2 O
time	1047 4 O
of	1052 2 O
onset	1055 5 O
and	1061 3 O
severity	1065 8 O
for	1074 3 O
20	1078 2 O
min	1081 3 O
after	1085 5 O
drug	1091 4 O
administration	1096 14 O
.	1110 1 O

When	1112 4 O
these	1117 5 O
proceeded	1123 9 O
to	1133 2 O
tonic	1136 5 B-Disease
seizures	1142 8 I-Disease
,	1150 1 O
death	1152 5 O
occurred	1158 8 O
in	1167 2 O
less	1170 4 O
than	1175 4 O
20	1180 2 O
min	1183 3 O
.	1186 1 O

Animals	1188 7 O
surviving	1196 9 O
for	1206 3 O
20	1210 2 O
min	1213 3 O
were	1217 4 O
immediately	1222 11 O
stressed	1234 8 O
by	1243 2 O
a	1246 1 O
swim	1248 4 O
test	1253 4 O
in	1258 2 O
25	1261 2 O
degrees	1264 7 O
C	1272 1 O
water	1274 5 O
,	1279 1 O
and	1281 3 O
death	1285 5 O
-	1290 1 O
producing	1291 9 O
tonic	1301 5 B-Disease
seizures	1307 8 I-Disease
were	1316 4 O
scored	1321 6 O
for	1328 3 O
2	1332 1 O
min	1334 3 O
.	1337 1 O

In	1339 2 O
other	1342 5 O
animals	1348 7 O
locomotor	1356 9 O
activity	1366 8 O
was	1375 3 O
measured	1379 8 O
15	1388 2 O
or	1391 2 O
60	1394 2 O
min	1397 3 O
after	1401 5 O
caffeine	1407 8 B-Chemical
administration	1416 14 O
.	1430 1 O

By	1432 2 O
any	1435 3 O
single	1439 6 O
behavioral	1446 10 O
criterion	1457 9 O
or	1467 2 O
a	1470 1 O
combination	1472 11 O
of	1484 2 O
these	1487 5 O
criteria	1493 8 O
,	1501 1 O
marked	1503 6 O
differences	1510 11 O
in	1522 2 O
response	1525 8 O
to	1534 2 O
toxic	1537 5 O
caffeine	1543 8 B-Chemical
doses	1552 5 O
were	1558 4 O
observed	1563 8 O
between	1572 7 O
strains	1580 7 O
.	1587 1 O

These	1589 5 O
results	1595 7 O
indicate	1603 8 O
that	1612 4 O
behavioral	1617 10 O
toxicity	1628 8 B-Disease
testing	1637 7 O
of	1645 2 O
alkylxanthines	1648 14 B-Chemical
in	1663 2 O
a	1666 1 O
single	1668 6 O
mouse	1675 5 O
strain	1681 6 O
may	1688 3 O
be	1692 2 O
misleading	1695 10 O
and	1706 3 O
suggest	1710 7 O
that	1718 4 O
toxic	1723 5 O
responses	1729 9 O
of	1739 2 O
the	1742 3 O
central	1746 7 O
nervous	1754 7 O
system	1762 6 O
to	1769 2 O
this	1772 4 O
class	1777 5 O
of	1783 2 O
compounds	1786 9 O
are	1796 3 O
genetically	1800 11 O
influenced	1812 10 O
in	1823 2 O
mammals	1826 7 O
.	1833 1 O

Invasive	0 8 O
carcinoma	9 9 B-Disease
of	19 2 I-Disease
the	22 3 I-Disease
renal	26 5 I-Disease
pelvis	32 6 I-Disease
following	39 9 O
cyclophosphamide	49 16 B-Chemical
therapy	66 7 O
for	74 3 O
nonmalignant	78 12 O
disease	91 7 O
.	98 1 O

A	100 1 O
47	102 2 O
-	104 1 O
year	105 4 O
-	109 1 O
old	110 3 O
woman	114 5 O
with	120 4 O
right	125 5 O
hydroureteronephrosis	131 21 B-Disease
due	153 3 O
to	157 2 O
ureterovesical	160 14 O
junction	175 8 O
obstruction	184 11 O
had	196 3 O
gross	200 5 O
hematuria	206 9 B-Disease
after	216 5 O
being	222 5 O
treated	228 7 O
for	236 3 O
five	240 4 O
years	245 5 O
wtih	251 4 O
cyclophosphamide	256 16 B-Chemical
for	273 3 O
cerebral	277 8 B-Disease
vasculitis	286 10 I-Disease
.	296 1 O

A	298 1 O
right	300 5 O
nephroureterectomy	306 18 O
was	325 3 O
required	329 8 O
for	338 3 O
control	342 7 O
of	350 2 O
bleeding	353 8 B-Disease
.	361 1 O

The	363 3 O
pathology	367 9 O
specimen	377 8 O
contained	386 9 O
clinically	396 10 O
occult	407 6 O
invasive	414 8 O
carcinoma	423 9 B-Disease
of	433 2 I-Disease
the	436 3 I-Disease
renal	440 5 I-Disease
pelvis	446 6 I-Disease
.	452 1 O

Although	454 8 O
the	463 3 O
ability	467 7 O
of	475 2 O
cyclophosphamide	478 16 B-Chemical
to	495 2 O
cause	498 5 O
hemorrhagic	504 11 B-Disease
cystitis	516 8 I-Disease
and	525 3 O
urine	529 5 O
cytologic	535 9 O
abnormalities	545 13 O
indistinguishable	559 17 O
from	577 4 O
high	582 4 O
grade	587 5 O
carcinoma	593 9 B-Disease
is	603 2 O
well	606 4 O
known	611 5 O
,	616 1 O
it	618 2 O
is	621 2 O
less	624 4 O
widely	629 6 O
appreciated	636 11 O
that	648 4 O
it	653 2 O
is	656 2 O
also	659 4 O
associated	664 10 O
with	675 4 O
carcinoma	680 9 B-Disease
of	690 2 I-Disease
the	693 3 I-Disease
urinary	697 7 I-Disease
tract	705 5 I-Disease
.	710 1 O

Twenty	712 6 O
carcinomas	719 10 B-Disease
of	730 2 I-Disease
the	733 3 I-Disease
urinary	737 7 I-Disease
bladder	745 7 I-Disease
and	753 3 O
one	757 3 O
carcinoma	761 9 B-Disease
of	771 2 I-Disease
the	774 3 I-Disease
prostate	778 8 I-Disease
have	787 4 O
been	792 4 O
reported	797 8 O
in	806 2 O
association	809 11 O
with	821 4 O
its	826 3 O
use	830 3 O
.	833 1 O

The	835 3 O
present	839 7 O
case	847 4 O
is	852 2 O
the	855 3 O
first	859 5 O
carcinoma	865 9 B-Disease
of	875 2 I-Disease
the	878 3 I-Disease
renal	882 5 I-Disease
pelvis	888 6 I-Disease
reported	895 8 O
in	904 2 O
association	907 11 O
with	919 4 O
cyclophosphamide	924 16 B-Chemical
treatment	941 9 O
.	950 1 O

It	952 2 O
is	955 2 O
the	958 3 O
third	962 5 O
urinary	968 7 B-Disease
tract	976 5 I-Disease
cancer	982 6 I-Disease
reported	989 8 O
in	998 2 O
association	1001 11 O
with	1013 4 O
cyclophosphamide	1018 16 B-Chemical
treatment	1035 9 O
for	1045 3 O
nonmalignant	1049 12 O
disease	1062 7 O
.	1069 1 O

The	1071 3 O
association	1075 11 O
of	1087 2 O
the	1090 3 O
tumor	1094 5 B-Disease
with	1100 4 O
preexisting	1105 11 O
hydroureteronephrosis	1117 21 B-Disease
suggests	1139 8 O
that	1148 4 O
stasis	1153 6 O
prolonged	1160 9 O
and	1170 3 O
intensified	1174 11 O
exposure	1186 8 O
of	1195 2 O
upper	1198 5 O
urinary	1204 7 O
tract	1212 5 O
epithelium	1218 10 O
to	1229 2 O
cyclophosphamide	1232 16 B-Chemical
.	1248 1 O

Patients	1250 8 O
who	1259 3 O
are	1263 3 O
candidates	1267 10 O
for	1278 3 O
long	1282 4 O
-	1286 1 O
term	1287 4 O
cyclophosphamide	1292 16 B-Chemical
treatment	1309 9 O
should	1319 6 O
be	1326 2 O
routinely	1329 9 O
evaluated	1339 9 O
for	1349 3 O
obstructive	1353 11 B-Disease
uropathy	1365 8 I-Disease
.	1373 1 O

Ascending	0 9 O
dose	10 4 O
tolerance	15 9 O
study	25 5 O
of	31 2 O
intramuscular	34 13 O
carbetocin	48 10 B-Chemical
administered	59 12 O
after	72 5 O
normal	78 6 O
vaginal	85 7 O
birth	93 5 O
.	98 1 O

OBJECTIVE	100 9 O
:	109 1 O
To	111 2 O
determine	114 9 O
the	124 3 O
maximum	128 7 O
tolerated	136 9 O
dose	146 4 O
(	151 1 O
MTD	152 3 O
)	155 1 O
of	157 2 O
carbetocin	160 10 B-Chemical
(	171 1 O
a	172 1 O
long	174 4 O
-	178 1 O
acting	179 6 O
synthetic	186 9 O
analogue	196 8 O
of	205 2 O
oxytocin	208 8 B-Chemical
)	216 1 O
,	217 1 O
when	219 4 O
administered	224 12 O
immediately	237 11 O
after	249 5 O
vaginal	255 7 O
delivery	263 8 O
at	272 2 O
term	275 4 O
.	279 1 O

MATERIALS	281 9 O
AND	291 3 O
METHODS	295 7 O
:	302 1 O
Carbetocin	304 10 B-Chemical
was	315 3 O
given	319 5 O
as	325 2 O
an	328 2 O
intramuscular	331 13 O
injection	345 9 O
immediately	355 11 O
after	367 5 O
the	373 3 O
birth	377 5 O
of	383 2 O
the	386 3 O
infant	390 6 O
in	397 2 O
45	400 2 O
healthy	403 7 O
women	411 5 O
with	417 4 O
normal	422 6 O
singleton	429 9 O
pregnancies	439 11 O
who	451 3 O
delivered	455 9 O
vaginally	465 9 O
at	475 2 O
term	478 4 O
.	482 1 O

Dosage	484 6 O
groups	491 6 O
of	498 2 O
15	501 2 O
,	503 1 O
30	505 2 O
,	507 1 O
50	509 2 O
,	511 1 O
75	513 2 O
,	515 1 O
100	517 3 O
,	520 1 O
125	522 3 O
,	525 1 O
150	527 3 O
,	530 1 O
175	532 3 O
or	536 2 O
200	539 3 O
microg	543 6 O
carbetocin	550 10 B-Chemical
were	561 4 O
assigned	566 8 O
to	575 2 O
blocks	578 6 O
of	585 2 O
three	588 5 O
women	594 5 O
according	600 9 O
to	610 2 O
the	613 3 O
continual	617 9 O
reassessment	627 12 O
method	640 6 O
(	647 1 O
CRM	648 3 O
)	651 1 O
.	652 1 O

RESULTS	654 7 O
:	661 1 O
All	663 3 O
dosage	667 6 O
groups	674 6 O
consisted	681 9 O
of	691 2 O
three	694 5 O
women	700 5 O
,	705 1 O
except	707 6 O
those	714 5 O
with	720 4 O
100	725 3 O
microg	729 6 O
(	736 1 O
n	737 1 O
=	738 1 O
6	739 1 O
)	740 1 O
and	742 3 O
200	746 3 O
microg	750 6 O
(	757 1 O
n	758 1 O
=	759 1 O
18	760 2 O
)	762 1 O
.	763 1 O

Recorded	765 8 O
were	774 4 O
dose	779 4 O
-	783 1 O
limiting	784 8 O
adverse	793 7 O
events	801 6 O
:	807 1 O
hyper	809 5 B-Disease
-	814 1 I-Disease
or	816 2 I-Disease
hypotension	819 11 I-Disease
(	831 1 O
three	832 5 O
)	837 1 O
,	838 1 O
severe	840 6 O
abdominal	847 9 B-Disease
pain	857 4 I-Disease
(	862 1 O
0	863 1 O
)	864 1 O
,	865 1 O
vomiting	867 8 B-Disease
(	876 1 O
0	877 1 O
)	878 1 O
and	880 3 O
retained	884 8 B-Disease
placenta	893 8 I-Disease
(	902 1 O
four	903 4 O
)	907 1 O
.	908 1 O

Serious	910 7 O
adverse	918 7 O
events	926 6 O
occurred	933 8 O
in	942 2 O
seven	945 5 O
women	951 5 O
:	956 1 O
six	958 3 O
cases	962 5 O
with	968 4 O
blood	973 5 B-Disease
loss	979 4 I-Disease
>	984 1 O
or	986 2 O
=	989 1 O
1000	991 4 O
ml	996 2 O
,	998 1 O
four	1000 4 O
cases	1005 5 O
of	1011 2 O
manual	1014 6 O
placenta	1021 8 O
removal	1030 7 O
,	1037 1 O
five	1039 4 O
cases	1044 5 O
of	1050 2 O
additional	1053 10 O
oxytocics	1064 9 O
administration	1074 14 O
and	1089 3 O
five	1093 4 O
cases	1098 5 O
of	1104 2 O
blood	1107 5 O
transfusion	1113 11 O
.	1124 1 O

Maximum	1126 7 O
blood	1134 5 B-Disease
loss	1140 4 I-Disease
was	1145 3 O
greatest	1149 8 O
at	1158 2 O
the	1161 3 O
upper	1165 5 O
and	1171 3 O
lower	1175 5 O
dose	1181 4 O
levels	1186 6 O
,	1192 1 O
and	1194 3 O
lowest	1198 6 O
in	1205 2 O
the	1208 3 O
70	1212 2 O
-	1214 1 O
125	1215 3 O
microg	1219 6 O
dose	1226 4 O
range	1231 5 O
.	1236 1 O

Four	1238 4 O
out	1243 3 O
of	1247 2 O
six	1250 3 O
cases	1254 5 O
with	1260 4 O
blood	1265 5 B-Disease
loss	1271 4 I-Disease
>	1276 1 O
or	1278 2 O
=	1281 1 O
1000	1283 4 O
ml	1288 2 O
occurred	1291 8 O
in	1300 2 O
the	1303 3 O
200	1307 3 O
microg	1311 6 O
group	1318 5 O
.	1323 1 O

The	1325 3 O
majority	1329 8 O
of	1338 2 O
additional	1341 10 O
administration	1352 14 O
of	1367 2 O
oxytocics	1370 9 O
(	1380 1 O
4	1381 1 O
/	1382 1 O
5	1383 1 O
)	1384 1 O
and	1386 3 O
blood	1390 5 O
transfusion	1396 11 O
(	1408 1 O
3	1409 1 O
/	1410 1 O
5	1411 1 O
)	1412 1 O
occurred	1414 8 O
in	1423 2 O
the	1426 3 O
dose	1430 4 O
groups	1435 6 O
of	1442 2 O
200	1445 3 O
microg	1449 6 O
.	1455 1 O

All	1457 3 O
retained	1461 8 O
placentae	1470 9 O
were	1480 4 O
found	1485 5 O
in	1491 2 O
the	1494 3 O
group	1498 5 O
of	1504 2 O
200	1507 3 O
microg	1511 6 O
.	1517 1 O

CONCLUSION	1519 10 O
:	1529 1 O
The	1531 3 O
MTD	1535 3 O
was	1539 3 O
calculated	1543 10 O
to	1554 2 O
be	1557 2 O
at	1560 2 O
200	1563 3 O
microg	1567 6 O
carbetocin	1574 10 B-Chemical
.	1584 1 O

A	0 1 O
pilot	2 5 O
study	8 5 O
to	14 2 O
assess	17 6 O
the	24 3 O
safety	28 6 O
of	35 2 O
dobutamine	38 10 B-Chemical
stress	49 6 O
echocardiography	56 16 O
in	73 2 O
the	76 3 O
emergency	80 9 O
department	90 10 O
evaluation	101 10 O
of	112 2 O
cocaine	115 7 B-Chemical
-	122 1 O
associated	123 10 O
chest	134 5 B-Disease
pain	140 4 I-Disease
.	144 1 O

STUDY	146 5 O
OBJECTIVE	152 9 O
:	161 1 O
Chest	163 5 B-Disease
pain	169 4 I-Disease
in	174 2 O
the	177 3 O
setting	181 7 O
of	189 2 O
cocaine	192 7 B-Chemical
use	200 3 O
poses	204 5 O
a	210 1 O
diagnostic	212 10 O
dilemma	223 7 O
.	230 1 O

Dobutamine	232 10 B-Chemical
stress	243 6 O
echocardiography	250 16 O
(	267 1 O
DSE	268 3 O
)	271 1 O
is	273 2 O
a	276 1 O
widely	278 6 O
available	285 9 O
and	295 3 O
sensitive	299 9 O
test	309 4 O
for	314 3 O
evaluating	318 10 O
cardiac	329 7 O
ischemia	337 8 B-Disease
.	345 1 O

Because	347 7 O
of	355 2 O
the	358 3 O
theoretical	362 11 O
concern	374 7 O
regarding	382 9 O
administration	392 14 O
of	407 2 O
dobutamine	410 10 B-Chemical
in	421 2 O
the	424 3 O
setting	428 7 O
of	436 2 O
cocaine	439 7 B-Chemical
use	447 3 O
,	450 1 O
we	452 2 O
conducted	455 9 O
a	465 1 O
pilot	467 5 O
study	473 5 O
to	479 2 O
assess	482 6 O
the	489 3 O
safety	493 6 O
of	500 2 O
DSE	503 3 O
in	507 2 O
emergency	510 9 O
department	520 10 O
patients	531 8 O
with	540 4 O
cocaine	545 7 B-Chemical
-	552 1 O
associated	553 10 O
chest	564 5 B-Disease
pain	570 4 I-Disease
.	574 1 O

METHODS	576 7 O
:	583 1 O
A	585 1 O
prospective	587 11 O
case	599 4 O
series	604 6 O
was	611 3 O
conducted	615 9 O
in	625 2 O
the	628 3 O
intensive	632 9 O
diagnostic	642 10 O
and	653 3 O
treatment	657 9 O
unit	667 4 O
in	672 2 O
the	675 3 O
ED	679 2 O
of	682 2 O
an	685 2 O
urban	688 5 O
tertiary	694 8 O
-	702 1 O
care	703 4 O
teaching	708 8 O
hospital	717 8 O
.	725 1 O

Patients	727 8 O
were	736 4 O
eligible	741 8 O
for	750 3 O
DSE	754 3 O
if	758 2 O
they	761 4 O
had	766 3 O
used	770 4 O
cocaine	775 7 B-Chemical
within	783 6 O
24	790 2 O
hours	793 5 O
preceding	799 9 O
the	809 3 O
onset	813 5 O
of	819 2 O
chest	822 5 B-Disease
pain	828 4 I-Disease
and	833 3 O
had	837 3 O
a	841 1 O
normal	843 6 O
ECG	850 3 O
and	854 3 O
tropinin	858 8 O
I	867 1 O
level	869 5 O
.	874 1 O

Patients	876 8 O
exhibiting	885 10 O
signs	896 5 O
of	902 2 O
continuing	905 10 O
cocaine	916 7 B-Chemical
toxicity	924 8 B-Disease
were	933 4 O
excluded	938 8 O
from	947 4 O
the	952 3 O
study	956 5 O
.	961 1 O

All	963 3 O
patients	967 8 O
were	976 4 O
admitted	981 8 O
to	990 2 O
the	993 3 O
hospital	997 8 O
for	1006 3 O
serial	1010 6 O
testing	1017 7 O
after	1025 5 O
the	1031 3 O
DSE	1035 3 O
testing	1039 7 O
in	1047 2 O
the	1050 3 O
intensive	1054 9 O
diagnostic	1064 10 O
and	1075 3 O
treatment	1079 9 O
unit	1089 4 O
.	1093 1 O

RESULTS	1095 7 O
:	1102 1 O
Twenty	1104 6 O
-	1110 1 O
four	1111 4 O
patients	1116 8 O
were	1125 4 O
enrolled	1130 8 O
.	1138 1 O

Two	1140 3 O
patients	1144 8 O
had	1153 3 O
inadequate	1157 10 O
resting	1168 7 O
images	1176 6 O
,	1182 1 O
one	1184 3 O
DSE	1188 3 O
was	1192 3 O
terminated	1196 10 O
because	1207 7 O
of	1215 2 O
inferior	1218 8 O
hypokinesis	1227 11 B-Disease
,	1238 1 O
another	1240 7 O
DSE	1248 3 O
was	1252 3 O
terminated	1256 10 O
because	1267 7 O
of	1275 2 O
a	1278 1 O
rate	1280 4 O
-	1284 1 O
related	1285 7 O
atrial	1293 6 O
conduction	1300 10 O
deficit	1311 7 O
,	1318 1 O
and	1320 3 O
1	1324 1 O
patient	1326 7 O
did	1334 3 O
not	1338 3 O
reach	1342 5 O
the	1348 3 O
target	1352 6 O
heart	1359 5 O
rate	1365 4 O
.	1369 1 O

Thus	1371 4 O
,	1375 1 O
19	1377 2 O
patients	1380 8 O
completed	1389 9 O
a	1399 1 O
DSE	1401 3 O
and	1405 3 O
reached	1409 7 O
their	1417 5 O
target	1423 6 O
heart	1430 5 O
rates	1436 5 O
.	1441 1 O

None	1443 4 O
of	1448 2 O
the	1451 3 O
patients	1455 8 O
experienced	1464 11 O
signs	1476 5 O
of	1482 2 O
exaggerated	1485 11 O
adrenergic	1497 10 O
response	1508 8 O
,	1516 1 O
which	1518 5 O
was	1524 3 O
defined	1528 7 O
as	1536 2 O
a	1539 1 O
systolic	1541 8 O
blood	1550 5 O
pressure	1556 8 O
of	1565 2 O
greater	1568 7 O
than	1576 4 O
200	1581 3 O
mm	1585 2 O
Hg	1588 2 O
or	1591 2 O
the	1594 3 O
occurrence	1598 10 O
of	1609 2 O
tachydysrhythmias	1612 17 B-Disease
(	1630 1 O
excluding	1631 9 O
sinus	1641 5 B-Disease
tachycardia	1647 11 I-Disease
)	1658 1 O
.	1659 1 O

Further	1661 7 O
suggesting	1669 10 O
lack	1680 4 O
of	1685 2 O
exaggerated	1688 11 O
adrenergic	1700 10 O
response	1711 8 O
,	1719 1 O
13	1721 2 O
(	1724 1 O
65	1725 2 O
%	1727 1 O
)	1728 1 O
of	1730 2 O
20	1733 2 O
patients	1736 8 O
required	1745 8 O
supplemental	1754 12 O
atropine	1767 8 B-Chemical
to	1776 2 O
reach	1779 5 O
their	1785 5 O
target	1791 6 O
heart	1798 5 O
rates	1804 5 O
.	1809 1 O

CONCLUSION	1811 10 O
:	1821 1 O
No	1823 2 O
exaggerated	1826 11 O
adrenergic	1838 10 O
response	1849 8 O
was	1858 3 O
detected	1862 8 O
when	1871 4 O
dobutamine	1876 10 B-Chemical
was	1887 3 O
administered	1891 12 O
to	1904 2 O
patients	1907 8 O
with	1916 4 O
cocaine	1921 7 B-Chemical
-	1928 1 O
related	1929 7 O
chest	1937 5 B-Disease
pain	1943 4 I-Disease
.	1947 1 O

Amiodarone	0 10 B-Chemical
-	10 1 O
induced	11 7 O
torsade	19 7 B-Disease
de	27 2 I-Disease
pointes	30 7 I-Disease
during	38 6 O
bladder	45 7 O
irrigation	53 10 O
:	63 1 O
an	65 2 O
unusual	68 7 O
presentation	76 12 O
-	88 1 O
-	89 1 O
a	90 1 O
case	92 4 O
report	97 6 O
.	103 1 O

The	105 3 O
authors	109 7 O
present	117 7 O
a	125 1 O
case	127 4 O
of	132 2 O
early	135 5 O
(	141 1 O
within	142 6 O
4	149 1 O
days	151 4 O
)	155 1 O
development	157 11 O
of	169 2 O
torsade	172 7 B-Disease
de	180 2 I-Disease
pointes	183 7 I-Disease
(	191 1 O
TdP	192 3 B-Disease
)	195 1 O
associated	197 10 O
with	208 4 O
oral	213 4 O
amiodarone	218 10 B-Chemical
therapy	229 7 O
.	236 1 O

Consistent	238 10 O
with	249 4 O
other	254 5 O
reports	260 7 O
this	268 4 O
case	273 4 O
of	278 2 O
TdP	281 3 B-Disease
occurred	285 8 O
in	294 2 O
the	297 3 O
context	301 7 O
of	309 2 O
multiple	312 8 O
exacerbating	321 12 O
factors	334 7 O
including	342 9 O
hypokalemia	352 11 B-Disease
and	364 3 O
digoxin	368 7 B-Chemical
excess	376 6 O
.	382 1 O

Transient	384 9 O
prolongation	394 12 O
of	407 2 O
the	410 3 O
QT	414 2 O
during	417 6 O
bladder	424 7 O
irrigation	432 10 O
prompted	443 8 O
the	452 3 O
episode	456 7 O
of	464 2 O
TdP	467 3 B-Disease
.	470 1 O

It	472 2 O
is	475 2 O
well	478 4 O
known	483 5 O
that	489 4 O
bradycardia	494 11 B-Disease
exacerbates	506 11 O
acquired	518 8 O
TdP	527 3 B-Disease
.	530 1 O

The	532 3 O
authors	536 7 O
speculate	544 9 O
that	554 4 O
the	559 3 O
increased	563 9 O
vagal	573 5 O
tone	579 4 O
during	584 6 O
bladder	591 7 O
irrigation	599 10 O
,	609 1 O
a	611 1 O
vagal	613 5 O
maneuver	619 8 O
,	627 1 O
in	629 2 O
the	632 3 O
context	636 7 O
of	644 2 O
amiodarone	647 10 B-Chemical
therapy	658 7 O
resulted	666 8 O
in	675 2 O
amiodarone	678 10 B-Chemical
-	688 1 O
induced	689 7 O
proarrhythmia	697 13 B-Disease
.	710 1 O

In	712 2 O
the	715 3 O
absence	719 7 O
of	727 2 O
amiodarone	730 10 B-Chemical
therapy	741 7 O
,	748 1 O
a	750 1 O
second	752 6 O
bladder	759 7 O
irrigation	767 10 O
did	778 3 O
not	782 3 O
induce	786 6 O
TdP	793 3 B-Disease
despite	797 7 O
hypokalemia	805 11 B-Disease
and	817 3 O
hypomagnesemia	821 14 B-Disease
.	835 1 O

Acute	0 5 B-Disease
renal	6 5 I-Disease
insufficiency	12 13 I-Disease
after	26 5 O
high	32 4 O
-	36 1 O
dose	37 4 O
melphalan	42 9 B-Chemical
in	52 2 O
patients	55 8 O
with	64 4 O
primary	69 7 B-Disease
systemic	77 8 I-Disease
amyloidosis	86 11 I-Disease
during	98 6 O
stem	105 4 O
cell	110 4 O
transplantation	115 15 O
.	130 1 O

BACKGROUND	132 10 O
:	142 1 O
Patients	144 8 O
with	153 4 O
primary	158 7 B-Disease
systemic	166 8 I-Disease
amyloidosis	175 11 I-Disease
(	187 1 O
AL	188 2 B-Disease
)	190 1 O
have	192 4 O
a	197 1 O
poor	199 4 O
prognosis	204 9 O
.	213 1 O

Median	215 6 O
survival	222 8 O
time	231 4 O
from	236 4 O
standard	241 8 O
treatments	250 10 O
is	261 2 O
only	264 4 O
17	269 2 O
months	272 6 O
.	278 1 O

High	280 4 O
-	284 1 O
dose	285 4 O
intravenous	290 11 O
melphalan	302 9 B-Chemical
followed	312 8 O
by	321 2 O
peripheral	324 10 O
blood	335 5 O
stem	341 4 O
cell	346 4 O
transplant	351 10 O
(	362 1 O
PBSCT	363 5 O
)	368 1 O
appears	370 7 O
to	378 2 O
be	381 2 O
the	384 3 O
most	388 4 O
promising	393 9 O
therapy	403 7 O
,	410 1 O
but	412 3 O
treatment	416 9 O
mortality	426 9 O
can	436 3 O
be	440 2 O
high	443 4 O
.	447 1 O

The	449 3 O
authors	453 7 O
have	461 4 O
noted	466 5 O
the	472 3 O
development	476 11 O
of	488 2 O
acute	491 5 B-Disease
renal	497 5 I-Disease
insufficiency	503 13 I-Disease
immediately	517 11 O
after	529 5 O
melphalan	535 9 B-Chemical
conditioning	545 12 O
.	557 1 O

This	559 4 O
study	564 5 O
was	570 3 O
undertaken	574 10 O
to	585 2 O
further	588 7 O
examine	596 7 O
its	604 3 O
risk	608 4 O
factors	613 7 O
and	621 3 O
impact	625 6 O
on	632 2 O
posttransplant	635 14 O
mortality	650 9 O
.	659 1 O

METHODS	661 7 O
:	668 1 O
Consecutive	670 11 O
AL	682 2 B-Disease
patients	685 8 O
who	694 3 O
underwent	698 9 O
PBSCT	708 5 O
were	714 4 O
studied	719 7 O
retrospectively	727 15 O
.	742 1 O

Acute	744 5 B-Disease
renal	750 5 I-Disease
insufficiency	756 13 I-Disease
(	770 1 O
ARI	771 3 B-Disease
)	774 1 O
after	776 5 O
high	782 4 O
-	786 1 O
dose	787 4 O
melphalan	792 9 B-Chemical
was	802 3 O
defined	806 7 O
by	814 2 O
a	817 1 O
minimum	819 7 O
increase	827 8 O
of	836 2 O
0	839 1 O
.	840 1 O
5	841 1 O
mg	843 2 O
/	845 1 O
dL	846 2 O
(	849 1 O
44	850 2 O
micromol	853 8 O
/	861 1 O
L	862 1 O
)	863 1 O
in	865 2 O
the	868 3 O
serum	872 5 O
creatinine	878 10 B-Chemical
level	889 5 O
that	895 4 O
is	900 2 O
greater	903 7 O
than	911 4 O
50	916 2 O
%	918 1 O
of	920 2 O
baseline	923 8 O
immediately	932 11 O
after	944 5 O
conditioning	950 12 O
.	962 1 O

Urine	964 5 O
sediment	970 8 O
score	979 5 O
was	985 3 O
the	989 3 O
sum	993 3 O
of	997 2 O
the	1000 3 O
individual	1004 10 O
types	1015 5 O
of	1021 2 O
sediment	1024 8 O
identified	1033 10 O
on	1044 2 O
urine	1047 5 O
microscopy	1053 10 O
.	1063 1 O

RESULTS	1065 7 O
:	1072 1 O
Of	1074 2 O
the	1077 3 O
80	1081 2 O
patients	1084 8 O
studied	1093 7 O
,	1100 1 O
ARI	1102 3 B-Disease
developed	1106 9 O
in	1116 2 O
18	1119 2 O
.	1121 1 O
8	1122 1 O
%	1123 1 O
of	1125 2 O
the	1128 3 O
patients	1132 8 O
after	1141 5 O
high	1147 4 O
-	1151 1 O
dose	1152 4 O
melphalan	1157 9 B-Chemical
.	1166 1 O

Univariate	1168 10 O
analysis	1179 8 O
identified	1188 10 O
age	1199 3 O
,	1202 1 O
hypoalbuminemia	1204 15 B-Disease
,	1219 1 O
heavy	1221 5 O
proteinuria	1227 11 B-Disease
,	1238 1 O
diuretic	1240 8 O
use	1249 3 O
,	1252 1 O
and	1254 3 O
urine	1258 5 O
sediment	1264 8 O
score	1273 5 O
(	1279 1 O
>	1280 1 O
3	1281 1 O
)	1282 1 O
as	1284 2 O
risk	1287 4 O
factors	1292 7 O
.	1299 1 O

Age	1301 3 O
and	1305 3 O
urine	1309 5 O
sediment	1315 8 O
score	1324 5 O
remained	1330 8 O
independently	1339 13 O
significant	1353 11 O
risk	1365 4 O
factors	1370 7 O
in	1378 2 O
the	1381 3 O
multivariate	1385 12 O
analysis	1398 8 O
.	1406 1 O

Patients	1408 8 O
who	1417 3 O
had	1421 3 O
ARI	1425 3 B-Disease
after	1429 5 O
high	1435 4 O
-	1439 1 O
dose	1440 4 O
melphalan	1445 9 B-Chemical
underwent	1455 9 O
dialysis	1465 8 O
more	1474 4 O
often	1479 5 O
(	1485 1 O
P	1486 1 O
=	1488 1 O
0	1490 1 O
.	1491 1 O
007	1492 3 O
)	1495 1 O
,	1496 1 O
and	1498 3 O
had	1502 3 O
a	1506 1 O
worse	1508 5 O
1	1514 1 O
-	1515 1 O
year	1516 4 O
survival	1521 8 O
(	1530 1 O
P	1531 1 O
=	1533 1 O
0	1535 1 O
.	1536 1 O
03	1537 2 O
)	1539 1 O
.	1540 1 O

CONCLUSION	1542 10 O
:	1552 1 O
The	1554 3 O
timing	1558 6 O
of	1565 2 O
renal	1568 5 B-Disease
injury	1574 6 I-Disease
strongly	1581 8 O
suggests	1590 8 O
melphalan	1599 9 B-Chemical
as	1609 2 O
the	1612 3 O
causative	1616 9 O
agent	1626 5 O
.	1631 1 O

Ongoing	1633 7 O
tubular	1641 7 B-Disease
injury	1649 6 I-Disease
may	1656 3 O
be	1660 2 O
a	1663 1 O
prerequisite	1665 12 O
for	1678 3 O
renal	1682 5 B-Disease
injury	1688 6 I-Disease
by	1695 2 O
melphalan	1698 9 B-Chemical
as	1708 2 O
evidenced	1711 9 O
by	1721 2 O
the	1724 3 O
active	1728 6 O
urinary	1735 7 O
sediment	1743 8 O
.	1751 1 O

Development	1753 11 O
of	1765 2 O
ARI	1768 3 B-Disease
adversely	1772 9 O
affected	1782 8 O
the	1791 3 O
outcome	1795 7 O
after	1803 5 O
PBSCT	1809 5 O
.	1814 1 O

Effective	1816 9 O
preventive	1826 10 O
measures	1837 8 O
may	1846 3 O
help	1850 4 O
decrease	1855 8 O
the	1864 3 O
treatment	1868 9 O
mortality	1878 9 O
of	1888 2 O
PBSCT	1891 5 O
in	1897 2 O
AL	1900 2 B-Disease
patients	1903 8 O
.	1911 1 O

Impaired	0 8 B-Disease
fear	9 4 I-Disease
recognition	14 11 I-Disease
in	26 2 O
regular	29 7 O
recreational	37 12 O
cocaine	50 7 B-Chemical
users	58 5 O
.	63 1 O

INTRODUCTION	65 12 O
:	77 1 O
The	79 3 O
ability	83 7 O
to	91 2 O
read	94 4 O
facial	99 6 O
expressions	106 11 O
is	118 2 O
essential	121 9 O
for	131 3 O
normal	135 6 O
human	142 5 O
social	148 6 O
interaction	155 11 O
.	166 1 O

The	168 3 O
aim	172 3 O
of	176 2 O
the	179 3 O
present	183 7 O
study	191 5 O
was	197 3 O
to	201 2 O
conduct	204 7 O
the	212 3 O
first	216 5 O
investigation	222 13 O
of	236 2 O
facial	239 6 O
expression	246 10 O
recognition	257 11 O
performance	269 11 O
in	281 2 O
recreational	284 12 O
cocaine	297 7 B-Chemical
users	305 5 O
.	310 1 O

MATERIALS	312 9 O
AND	322 3 O
METHODS	326 7 O
:	333 1 O
Three	335 5 O
groups	341 6 O
,	347 1 O
comprised	349 9 O
of	359 2 O
21	362 2 O
cocaine	365 7 B-Chemical
naive	373 5 O
participants	379 12 O
(	392 1 O
CN	393 2 O
)	395 1 O
,	396 1 O
30	399 2 O
occasional	402 10 O
cocaine	413 7 B-Chemical
(	421 1 O
OC	422 2 O
)	424 1 O
,	425 1 O
and	427 3 O
48	431 2 O
regular	434 7 O
recreational	442 12 O
cocaine	455 7 B-Chemical
(	463 1 O
RC	464 2 O
)	466 1 O
users	468 5 O
,	473 1 O
were	475 4 O
compared	480 8 O
.	488 1 O

An	490 2 O
emotional	493 9 O
facial	503 6 O
expression	510 10 O
(	521 1 O
EFE	522 3 O
)	525 1 O
task	527 4 O
consisting	532 10 O
of	543 2 O
a	546 1 O
male	548 4 O
and	553 3 O
female	557 6 O
face	564 4 O
expressing	569 10 O
six	580 3 O
basic	584 5 O
emotions	590 8 O
(	599 1 O
happiness	600 9 O
,	609 1 O
surprise	611 8 O
,	619 1 O
sadness	621 7 O
,	628 1 O
anger	630 5 O
,	635 1 O
fear	637 4 O
,	641 1 O
and	643 3 O
disgust	647 7 O
)	654 1 O
was	656 3 O
administered	660 12 O
.	672 1 O

Mean	674 4 O
percent	679 7 O
accuracy	687 8 O
and	696 3 O
latencies	700 9 O
for	710 3 O
correct	714 7 O
responses	722 9 O
across	732 6 O
eight	739 5 O
presentations	745 13 O
of	759 2 O
each	762 4 O
basic	767 5 O
emotion	773 7 O
were	781 4 O
derived	786 7 O
.	793 1 O

Participants	795 12 O
were	808 4 O
also	813 4 O
assessed	818 8 O
with	827 4 O
the	832 3 O
"	836 1 O
Eyes	837 4 O
task	842 4 O
"	846 1 O
to	848 2 O
investigate	851 11 O
their	863 5 O
ability	869 7 O
to	877 2 O
recognize	880 9 O
more	890 4 O
complex	895 7 O
emotional	903 9 O
states	913 6 O
and	920 3 O
the	924 3 O
Symptom	928 7 O
CheckList	936 9 O
-	945 1 O
90	946 2 O
-	948 1 O
Revised	949 7 O
to	957 2 O
measure	960 7 O
psychopathology	968 15 O
.	983 1 O

RESULTS	985 7 O
:	992 1 O
There	994 5 O
were	1000 4 O
no	1005 2 O
group	1008 5 O
differences	1014 11 O
in	1026 2 O
psychopathology	1029 15 O
or	1045 2 O
"	1048 1 O
eyes	1049 4 O
task	1054 4 O
"	1058 1 O
performance	1060 11 O
,	1071 1 O
but	1073 3 O
the	1077 3 O
RC	1081 2 O
group	1084 5 O
,	1089 1 O
who	1091 3 O
otherwise	1095 9 O
had	1105 3 O
similar	1109 7 O
illicit	1117 7 O
substance	1125 9 O
use	1135 3 O
histories	1139 9 O
to	1149 2 O
the	1152 3 O
OC	1156 2 O
group	1159 5 O
,	1164 1 O
exhibited	1166 9 O
impaired	1176 8 B-Disease
fear	1185 4 I-Disease
recognition	1190 11 I-Disease
accuracy	1202 8 O
compared	1211 8 O
to	1220 2 O
the	1223 3 O
OC	1227 2 O
and	1230 3 O
CN	1234 2 O
groups	1237 6 O
.	1243 1 O

The	1245 3 O
RC	1249 2 O
group	1252 5 O
also	1258 4 O
correctly	1263 9 O
identified	1273 10 O
anger	1284 5 O
,	1289 1 O
fear	1291 4 O
,	1295 1 O
happiness	1297 9 O
,	1306 1 O
and	1308 3 O
surprise	1312 8 O
,	1320 1 O
more	1322 4 O
slowly	1327 6 O
than	1334 4 O
CN	1339 2 O
,	1341 1 O
but	1343 3 O
not	1347 3 O
OC	1351 2 O
participants	1354 12 O
.	1366 1 O

The	1368 3 O
OC	1372 2 O
group	1375 5 O
was	1381 3 O
slower	1385 6 O
than	1392 4 O
CN	1397 2 O
when	1400 4 O
correctly	1405 9 O
identifying	1415 11 O
disgust	1427 7 O
.	1434 1 O

The	1436 3 O
selective	1440 9 O
deficit	1450 7 B-Disease
in	1458 2 I-Disease
fear	1461 4 I-Disease
recognition	1466 11 I-Disease
accuracy	1478 8 O
manifested	1487 10 O
by	1498 2 O
the	1501 3 O
RC	1505 2 O
group	1508 5 O
cannot	1514 6 O
be	1521 2 O
explained	1524 9 O
by	1534 2 O
the	1537 3 O
subacute	1541 8 O
effects	1550 7 O
of	1558 2 O
cocaine	1561 7 B-Chemical
,	1568 1 O
or	1570 2 O
ecstasy	1573 7 B-Chemical
,	1580 1 O
because	1582 7 O
recent	1590 6 O
and	1597 3 O
less	1601 4 O
recent	1606 6 O
users	1613 5 O
of	1619 2 O
these	1622 5 O
drugs	1628 5 O
within	1634 6 O
this	1641 4 O
group	1646 5 O
were	1652 4 O
similarly	1657 9 O
impaired	1667 8 O
.	1675 1 O

Possible	1677 8 O
parallels	1686 9 O
between	1696 7 O
RC	1704 2 O
users	1707 5 O
and	1713 3 O
psychopaths	1717 11 B-Disease
with	1729 4 O
respect	1734 7 O
to	1742 2 O
impaired	1745 8 B-Disease
fear	1754 4 I-Disease
recognition	1759 11 I-Disease
,	1770 1 O
amygdala	1772 8 B-Disease
dysfunction	1781 11 I-Disease
,	1792 1 O
and	1794 3 O
etiology	1798 8 O
are	1807 3 O
discussed	1811 9 O
.	1820 1 O

Corneal	0 7 B-Disease
ulcers	8 6 I-Disease
associated	15 10 O
with	26 4 O
aerosolized	31 11 O
crack	43 5 B-Chemical
cocaine	49 7 I-Chemical
use	57 3 O
.	60 1 O

PURPOSE	62 7 O
:	69 1 O
We	71 2 O
report	74 6 O
4	81 1 O
cases	83 5 O
of	89 2 O
corneal	92 7 B-Disease
ulcers	100 6 I-Disease
associated	107 10 O
with	118 4 O
drug	123 4 B-Disease
abuse	128 5 I-Disease
.	133 1 O

The	135 3 O
pathogenesis	139 12 O
of	152 2 O
these	155 5 O
ulcers	161 6 B-Disease
and	168 3 O
management	172 10 O
of	183 2 O
these	186 5 O
patients	192 8 O
are	201 3 O
also	205 4 O
reviewed	210 8 O
.	218 1 O

METHODS	220 7 O
:	227 1 O
Review	229 6 O
of	236 2 O
all	239 3 O
cases	243 5 O
of	249 2 O
corneal	252 7 B-Disease
ulcers	260 6 I-Disease
associated	267 10 O
with	278 4 O
drug	283 4 B-Disease
abuse	288 5 I-Disease
seen	294 4 O
at	299 2 O
our	302 3 O
institution	306 11 O
from	318 4 O
July	323 4 O
2006	328 4 O
to	333 2 O
December	336 8 O
2006	345 4 O
.	349 1 O

RESULTS	351 7 O
:	358 1 O
Four	360 4 O
patients	365 8 O
with	374 4 O
corneal	379 7 B-Disease
ulcers	387 6 I-Disease
associated	394 10 O
with	405 4 O
crack	410 5 B-Chemical
cocaine	416 7 I-Chemical
use	424 3 O
were	428 4 O
reviewed	433 8 O
.	441 1 O

All	443 3 O
corneal	447 7 B-Disease
ulcers	455 6 I-Disease
were	462 4 O
cultured	467 8 O
,	475 1 O
and	477 3 O
the	481 3 O
patients	485 8 O
were	494 4 O
admitted	499 8 O
to	508 2 O
the	511 3 O
hospital	515 8 O
for	524 3 O
intensive	528 9 O
topical	538 7 O
antibiotic	546 10 O
treatment	557 9 O
.	566 1 O

Each	568 4 O
patient	573 7 O
received	581 8 O
comprehensive	590 13 O
health	604 6 O
care	611 4 O
,	615 1 O
including	617 9 O
medical	627 7 O
and	635 3 O
substance	639 9 B-Disease
abuse	649 5 I-Disease
consultations	655 13 O
.	668 1 O

Streptococcal	670 13 O
organisms	684 9 O
were	694 4 O
found	699 5 O
in	705 2 O
3	708 1 O
cases	710 5 O
and	716 3 O
Capnocytophaga	720 14 O
and	735 3 O
Brevibacterium	739 14 O
casei	754 5 O
in	760 2 O
1	763 1 O
patient	765 7 O
.	772 1 O

The	774 3 O
infections	778 10 B-Disease
responded	789 9 O
to	799 2 O
antibiotic	802 10 O
treatment	813 9 O
.	822 1 O

Two	824 3 O
patients	828 8 O
needed	837 6 O
a	844 1 O
lateral	846 7 O
tarsorrhaphy	854 12 O
for	867 3 O
persistent	871 10 O
epithelial	882 10 B-Disease
defects	893 7 I-Disease
.	900 1 O

CONCLUSIONS	902 11 O
:	913 1 O
Aerosolized	915 11 O
crack	927 5 B-Chemical
cocaine	933 7 I-Chemical
use	941 3 O
can	945 3 O
be	949 2 O
associated	952 10 O
with	963 4 O
the	968 3 O
development	972 11 O
of	984 2 O
corneal	987 7 B-Disease
ulcers	995 6 I-Disease
.	1001 1 O

Drug	1003 4 B-Disease
abuse	1008 5 I-Disease
provides	1014 8 O
additional	1023 10 O
challenges	1034 10 O
for	1045 3 O
management	1049 10 O
.	1059 1 O

Not	1061 3 O
only	1065 4 O
treatment	1070 9 O
of	1080 2 O
their	1083 5 O
infections	1089 10 B-Disease
but	1100 3 O
also	1104 4 O
the	1109 3 O
overall	1113 7 O
poor	1121 4 O
health	1126 6 O
of	1133 2 O
the	1136 3 O
patients	1140 8 O
and	1149 3 O
increased	1153 9 O
risk	1163 4 O
of	1168 2 O
noncompliance	1171 13 O
need	1185 4 O
to	1190 2 O
be	1193 2 O
addressed	1196 9 O
.	1205 1 O

Comprehensive	1207 13 O
care	1221 4 O
may	1226 3 O
provide	1230 7 O
the	1238 3 O
patient	1242 7 O
the	1250 3 O
opportunity	1254 11 O
to	1266 2 O
discontinue	1269 11 O
their	1281 5 O
substance	1287 9 B-Disease
abuse	1297 5 I-Disease
,	1302 1 O
improve	1304 7 O
their	1312 5 O
overall	1318 7 O
health	1326 6 O
,	1332 1 O
and	1334 3 O
prevent	1338 7 O
future	1346 6 O
corneal	1353 7 O
complications	1361 13 O
.	1374 1 O

Levetiracetam	0 13 B-Chemical
as	14 2 O
an	17 2 O
adjunct	20 7 O
to	28 2 O
phenobarbital	31 13 B-Chemical
treatment	45 9 O
in	55 2 O
cats	58 4 O
with	63 4 O
suspected	68 9 O
idiopathic	78 10 B-Disease
epilepsy	89 8 I-Disease
.	97 1 O

OBJECTIVE	99 9 O
:	108 1 O
To	110 2 O
assess	113 6 O
pharmacokinetics	120 16 O
,	136 1 O
efficacy	138 8 O
,	146 1 O
and	148 3 O
tolerability	152 12 O
of	165 2 O
oral	168 4 O
levetiracetam	173 13 B-Chemical
administered	187 12 O
as	200 2 O
an	203 2 O
adjunct	206 7 O
to	214 2 O
phenobarbital	217 13 B-Chemical
treatment	231 9 O
in	241 2 O
cats	244 4 O
with	249 4 O
poorly	254 6 O
controlled	261 10 O
suspected	272 9 O
idiopathic	282 10 B-Disease
epilepsy	293 8 I-Disease
.	301 1 O

DESIGN	303 6 O
-	309 1 O
Open	310 4 O
-	314 1 O
label	315 5 O
,	320 1 O
noncomparative	322 14 O
clinical	337 8 O
trial	346 5 O
.	351 1 O

ANIMALS	353 7 O
:	360 1 O
12	362 2 O
cats	365 4 O
suspected	370 9 O
to	380 2 O
have	383 4 O
idiopathic	388 10 B-Disease
epilepsy	399 8 I-Disease
that	408 4 O
was	413 3 O
poorly	417 6 O
controlled	424 10 O
with	435 4 O
phenobarbital	440 13 B-Chemical
or	454 2 O
that	457 4 O
had	462 3 O
unacceptable	466 12 O
adverse	479 7 O
effects	487 7 O
when	495 4 O
treated	500 7 O
with	508 4 O
phenobarbital	513 13 B-Chemical
.	526 1 O

PROCEDURES	528 10 O
:	538 1 O
Cats	540 4 O
were	545 4 O
treated	550 7 O
with	558 4 O
levetiracetam	563 13 B-Chemical
(	577 1 O
20	578 2 O
mg	581 2 O
/	583 1 O
kg	584 2 O
[	587 1 O
9	588 1 O
.	589 1 O
1	590 1 O
mg	592 2 O
/	594 1 O
lb	595 2 O
]	597 1 O
,	598 1 O
PO	600 2 O
,	602 1 O
q	604 1 O
8	606 1 O
h	608 1 O
)	609 1 O
.	610 1 O

After	612 5 O
a	618 1 O
minimum	620 7 O
of	628 2 O
1	631 1 O
week	633 4 O
of	638 2 O
treatment	641 9 O
,	650 1 O
serum	652 5 O
levetiracetam	658 13 B-Chemical
concentrations	672 14 O
were	687 4 O
measured	692 8 O
before	701 6 O
and	708 3 O
2	712 1 O
,	713 1 O
4	715 1 O
,	716 1 O
and	718 3 O
6	722 1 O
hours	724 5 O
after	730 5 O
drug	736 4 O
administration	741 14 O
,	755 1 O
and	757 3 O
maximum	761 7 O
and	769 3 O
minimum	773 7 O
serum	781 5 O
concentrations	787 14 O
and	802 3 O
elimination	806 11 O
half	818 4 O
-	822 1 O
life	823 4 O
were	828 4 O
calculated	833 10 O
.	843 1 O

Seizure	845 7 B-Disease
frequencies	853 11 O
before	865 6 O
and	872 3 O
after	876 5 O
initiation	882 10 O
of	893 2 O
levetiracetam	896 13 B-Chemical
treatment	910 9 O
were	920 4 O
compared	925 8 O
,	933 1 O
and	935 3 O
adverse	939 7 O
effects	947 7 O
were	955 4 O
recorded	960 8 O
.	968 1 O

RESULTS	970 7 O
:	977 1 O
Median	979 6 O
maximum	986 7 O
serum	994 5 O
levetiracetam	1000 13 B-Chemical
concentration	1014 13 O
was	1028 3 O
25	1032 2 O
.	1034 1 O
5	1035 1 O
microg	1037 6 O
/	1043 1 O
mL	1044 2 O
,	1046 1 O
median	1048 6 O
minimum	1055 7 O
serum	1063 5 O
levetiracetam	1069 13 B-Chemical
concentration	1083 13 O
was	1097 3 O
8	1101 1 O
.	1102 1 O
3	1103 1 O
microg	1105 6 O
/	1111 1 O
mL	1112 2 O
,	1114 1 O
and	1116 3 O
median	1120 6 O
elimination	1127 11 O
half	1139 4 O
-	1143 1 O
life	1144 4 O
was	1149 3 O
2	1153 1 O
.	1154 1 O
9	1155 1 O
hours	1157 5 O
.	1162 1 O

Median	1164 6 O
seizure	1171 7 B-Disease
frequency	1179 9 O
prior	1189 5 O
to	1195 2 O
treatment	1198 9 O
with	1208 4 O
levetiracetam	1213 13 B-Chemical
(	1227 1 O
2	1228 1 O
.	1229 1 O
1	1230 1 O
seizures	1232 8 B-Disease
/	1240 1 O
mo	1241 2 O
)	1243 1 O
was	1245 3 O
significantly	1249 13 O
higher	1263 6 O
than	1270 4 O
median	1275 6 O
seizure	1282 7 B-Disease
frequency	1290 9 O
after	1300 5 O
initiation	1306 10 O
of	1317 2 O
levetiracetam	1320 13 B-Chemical
treatment	1334 9 O
(	1344 1 O
0	1345 1 O
.	1346 1 O
42	1347 2 O
seizures	1350 8 B-Disease
/	1358 1 O
mo	1359 2 O
)	1361 1 O
,	1362 1 O
and	1364 3 O
7	1368 1 O
of	1370 2 O
10	1373 2 O
cats	1376 4 O
were	1381 4 O
classified	1386 10 O
as	1397 2 O
having	1400 6 O
responded	1407 9 O
to	1417 2 O
levetiracetam	1420 13 B-Chemical
treatment	1434 9 O
(	1444 1 O
ie	1445 2 O
,	1447 1 O
reduction	1449 9 O
in	1459 2 O
seizure	1462 7 B-Disease
frequency	1470 9 O
of	1480 2 O
>	1483 1 O
or	1484 2 O
=	1486 1 O
50	1487 2 O
%	1489 1 O
)	1490 1 O
.	1491 1 O

Two	1493 3 O
cats	1497 4 O
had	1502 3 O
transient	1506 9 O
lethargy	1516 8 B-Disease
and	1525 3 O
inappetence	1529 11 B-Disease
.	1540 1 O

CONCLUSIONS	1542 11 O
AND	1554 3 O
CLINICAL	1558 8 O
RELEVANCE	1567 9 O
:	1576 1 O
Results	1578 7 O
suggested	1586 9 O
that	1596 4 O
levetiracetam	1601 13 B-Chemical
is	1615 2 O
well	1618 4 O
tolerated	1623 9 O
in	1633 2 O
cats	1636 4 O
and	1641 3 O
may	1645 3 O
be	1649 2 O
useful	1652 6 O
as	1659 2 O
an	1662 2 O
adjunct	1665 7 O
to	1673 2 O
phenobarbital	1676 13 B-Chemical
treatment	1690 9 O
in	1700 2 O
cats	1703 4 O
with	1708 4 O
idiopathic	1713 10 B-Disease
epilepsy	1724 8 I-Disease
.	1732 1 O

Bilateral	0 9 O
haemorrhagic	10 12 B-Disease
infarction	23 10 I-Disease
of	34 2 I-Disease
the	37 3 I-Disease
globus	41 6 I-Disease
pallidus	48 8 I-Disease
after	57 5 O
cocaine	63 7 B-Chemical
and	71 3 O
alcohol	75 7 B-Chemical
intoxication	83 12 O
.	95 1 O

Cocaine	97 7 B-Chemical
is	105 2 O
a	108 1 O
risk	110 4 O
factor	115 6 O
for	122 3 O
both	126 4 O
ischemic	131 8 B-Disease
and	140 3 I-Disease
haemorrhagic	144 12 I-Disease
stroke	157 6 I-Disease
.	163 1 O

We	165 2 O
present	168 7 O
the	176 3 O
case	180 4 O
of	185 2 O
a	188 1 O
31	190 2 O
-	192 1 O
year	193 4 O
-	197 1 O
old	198 3 O
man	202 3 O
with	206 4 O
bilateral	211 9 O
ischemia	221 8 B-Disease
of	230 2 I-Disease
the	233 3 I-Disease
globus	237 6 I-Disease
pallidus	244 8 I-Disease
after	253 5 O
excessive	259 9 O
alcohol	269 7 B-Chemical
and	277 3 O
intranasal	281 10 O
cocaine	292 7 B-Chemical
use	300 3 O
.	303 1 O

Drug	305 4 O
-	309 1 O
related	310 7 O
globus	318 6 B-Disease
pallidus	325 8 I-Disease
infarctions	334 11 I-Disease
are	346 3 O
most	350 4 O
often	355 5 O
associated	361 10 O
with	372 4 O
heroin	377 6 B-Chemical
.	383 1 O

Bilateral	385 9 O
basal	395 5 B-Disease
ganglia	401 7 I-Disease
infarcts	409 8 I-Disease
after	418 5 O
the	424 3 O
use	428 3 O
of	432 2 O
cocaine	435 7 B-Chemical
,	442 1 O
without	444 7 O
concurrent	452 10 O
heroin	463 6 B-Chemical
use	470 3 O
,	473 1 O
have	475 4 O
never	480 5 O
been	486 4 O
reported	491 8 O
.	499 1 O

In	501 2 O
our	504 3 O
patient	508 7 O
,	515 1 O
transient	517 9 O
cardiac	527 7 B-Disease
arrhythmia	535 10 I-Disease
or	546 2 O
respiratory	549 11 B-Disease
dysfunction	561 11 I-Disease
related	573 7 O
to	581 2 O
cocaine	584 7 B-Chemical
and	592 3 O
/	595 1 O
or	596 2 O
ethanol	599 7 B-Chemical
use	607 3 O
were	611 4 O
the	616 3 O
most	620 4 O
likely	625 6 O
causes	632 6 O
of	639 2 O
cerebral	642 8 B-Disease
hypoperfusion	651 13 I-Disease
.	664 1 O

Acute	0 5 B-Disease
renal	6 5 I-Disease
failure	12 7 I-Disease
after	20 5 O
high	26 4 O
-	30 1 O
dose	31 4 O
methotrexate	36 12 B-Chemical
therapy	49 7 O
in	57 2 O
a	60 1 O
patient	62 7 O
with	70 4 O
ileostomy	75 9 O
.	84 1 O

High	86 4 O
-	90 1 O
dose	91 4 O
methotrexate	96 12 B-Chemical
(	109 1 O
HD	110 2 O
-	112 1 O
MTX	113 3 B-Chemical
)	116 1 O
is	118 2 O
an	121 2 O
important	124 9 O
treatment	134 9 O
for	144 3 O
Burkitt	148 7 B-Disease
lymphoma	156 8 I-Disease
,	164 1 O
but	166 3 O
can	170 3 O
cause	174 5 O
hepatic	180 7 B-Disease
and	188 3 I-Disease
renal	192 5 I-Disease
toxicity	198 8 I-Disease
when	207 4 O
its	212 3 O
clearance	216 9 O
is	226 2 O
delayed	229 7 O
.	236 1 O

We	238 2 O
report	241 6 O
a	248 1 O
case	250 4 O
of	255 2 O
acute	258 5 B-Disease
renal	264 5 I-Disease
failure	270 7 I-Disease
after	278 5 O
HD	284 2 O
-	286 1 O
MTX	287 3 B-Chemical
therapy	291 7 O
in	299 2 O
a	302 1 O
patient	304 7 O
with	312 4 O
ileostomy	317 9 O
,	326 1 O
The	328 3 O
patient	332 7 O
was	340 3 O
a	344 1 O
3	346 1 O
-	347 1 O
year	348 4 O
-	352 1 O
old	353 3 O
boy	357 3 O
who	361 3 O
had	365 3 O
received	369 8 O
a	378 1 O
living	380 6 O
-	386 1 O
related	387 7 O
liver	395 5 O
transplantation	401 15 O
for	417 3 O
congenital	421 10 O
biliary	432 7 B-Disease
atresia	440 7 I-Disease
.	447 1 O

At	449 2 O
day	452 3 O
833	456 3 O
after	460 5 O
the	466 3 O
transplantation	470 15 O
,	485 1 O
he	487 2 O
was	490 3 O
diagnosed	494 9 O
with	504 4 O
PTLD	509 4 B-Disease
(	514 1 O
post	515 4 B-Disease
-	519 1 I-Disease
transplantation	520 15 I-Disease
lymphoproliferative	536 19 I-Disease
disorder	556 8 I-Disease
,	564 1 O
Burkitt	566 7 B-Disease
-	573 1 I-Disease
type	574 4 I-Disease
malignant	579 9 I-Disease
lymphoma	589 8 I-Disease
)	597 1 O
.	598 1 O

During	600 6 O
induction	607 9 O
therapy	617 7 O
,	624 1 O
he	626 2 O
suffered	629 8 O
ileal	638 5 O
perforation	644 11 O
and	656 3 O
ileostomy	660 9 O
was	670 3 O
performed	674 9 O
.	683 1 O

Subsequent	685 10 O
HD	696 2 O
-	698 1 O
MTX	699 3 B-Chemical
therapy	703 7 O
caused	711 6 O
acute	718 5 B-Disease
renal	724 5 I-Disease
failure	730 7 I-Disease
that	738 4 O
required	743 8 O
continuous	752 10 O
hemodialysis	763 12 O
.	775 1 O

We	777 2 O
supposed	780 8 O
that	789 4 O
intravascular	794 13 O
hypovolemia	808 11 B-Disease
due	820 3 O
to	824 2 O
substantial	827 11 O
drainage	839 8 O
from	848 4 O
the	853 3 O
ileostoma	857 9 O
caused	867 6 O
acute	874 5 B-Disease
prerenal	880 8 I-Disease
failure	889 7 I-Disease
.	896 1 O

After	898 5 O
recovery	904 8 O
of	913 2 O
his	916 3 O
renal	920 5 O
function	926 8 O
,	934 1 O
we	936 2 O
could	939 5 O
safely	945 6 O
treat	952 5 O
the	958 3 O
patient	962 7 O
with	970 4 O
HD	975 2 O
-	977 1 O
MTX	978 3 B-Chemical
therapy	982 7 O
by	990 2 O
controlling	993 11 O
drainage	1005 8 O
from	1014 4 O
ileostoma	1019 9 O
with	1029 4 O
total	1034 5 O
parenteral	1040 10 O
nutrition	1051 9 O
.	1060 1 O

Antithrombotic	0 14 O
drug	15 4 O
use	20 3 O
,	23 1 O
cerebral	25 8 B-Disease
microbleeds	34 11 I-Disease
,	45 1 O
and	47 3 O
intracerebral	51 13 B-Disease
hemorrhage	65 10 I-Disease
:	75 1 O
a	77 1 O
systematic	79 10 O
review	90 6 O
of	97 2 O
published	100 9 O
and	110 3 O
unpublished	114 11 O
studies	126 7 O
.	133 1 O

BACKGROUND	135 10 O
AND	146 3 O
PURPOSE	150 7 O
:	157 1 O
Cerebral	159 8 B-Disease
microbleeds	168 11 I-Disease
(	180 1 O
MB	181 2 B-Disease
)	183 1 O
are	185 3 O
potential	189 9 O
risk	199 4 O
factors	204 7 O
for	212 3 O
intracerebral	216 13 B-Disease
hemorrhage	230 10 I-Disease
(	241 1 O
ICH	242 3 B-Disease
)	245 1 O
,	246 1 O
but	248 3 O
it	252 2 O
is	255 2 O
unclear	258 7 O
if	266 2 O
they	269 4 O
are	274 3 O
a	278 1 O
contraindication	280 16 O
to	297 2 O
using	300 5 O
antithrombotic	306 14 O
drugs	321 5 O
.	326 1 O

Insights	328 8 O
could	337 5 O
be	343 2 O
gained	346 6 O
by	353 2 O
pooling	356 7 O
data	364 4 O
on	369 2 O
MB	372 2 B-Disease
frequency	375 9 O
stratified	385 10 O
by	396 2 O
antithrombotic	399 14 O
use	414 3 O
in	418 2 O
cohorts	421 7 O
with	429 4 O
ICH	434 3 B-Disease
and	438 3 O
ischemic	442 8 B-Disease
stroke	451 6 I-Disease
(	458 1 O
IS	459 2 B-Disease
)	461 1 O
/	462 1 O
transient	463 9 B-Disease
ischemic	473 8 I-Disease
attack	482 6 I-Disease
(	489 1 O
TIA	490 3 B-Disease
)	493 1 O
.	494 1 O

METHODS	496 7 O
:	503 1 O
We	505 2 O
performed	508 9 O
a	518 1 O
systematic	520 10 O
review	531 6 O
of	538 2 O
published	541 9 O
and	551 3 O
unpublished	555 11 O
data	567 4 O
from	572 4 O
cohorts	577 7 O
with	585 4 O
stroke	590 6 B-Disease
or	597 2 O
TIA	600 3 B-Disease
to	604 2 O
compare	607 7 O
the	615 3 O
presence	619 8 O
of	628 2 O
MB	631 2 B-Disease
in	634 2 O
:	636 1 O
(	638 1 O
1	639 1 O
)	640 1 O
antithrombotic	642 14 O
users	657 5 O
vs	663 2 O
nonantithrombotic	666 17 O
users	684 5 O
with	690 4 O
ICH	695 3 B-Disease
;	698 1 O
(	700 1 O
2	701 1 O
)	702 1 O
antithrombotic	704 14 O
users	719 5 O
vs	725 2 O
nonusers	728 8 O
with	737 4 O
IS	742 2 B-Disease
/	744 1 O
TIA	745 3 B-Disease
;	748 1 O
and	750 3 O
(	754 1 O
3	755 1 O
)	756 1 O
ICH	758 3 B-Disease
vs	762 2 O
ischemic	765 8 B-Disease
events	774 6 O
stratified	781 10 O
by	792 2 O
antithrombotic	795 14 O
use	810 3 O
.	813 1 O

We	815 2 O
also	818 4 O
analyzed	823 8 O
published	832 9 O
and	842 3 O
unpublished	846 11 O
follow	858 6 O
-	864 1 O
up	865 2 O
data	868 4 O
to	873 2 O
determine	876 9 O
the	886 3 O
risk	890 4 O
of	895 2 O
ICH	898 3 B-Disease
in	902 2 O
antithrombotic	905 14 O
users	920 5 O
with	926 4 O
MB	931 2 B-Disease
.	933 1 O

RESULTS	935 7 O
:	942 1 O
In	944 2 O
a	947 1 O
pooled	949 6 O
analysis	956 8 O
of	965 2 O
1460	968 4 O
ICH	973 3 B-Disease
and	977 3 O
3817	981 4 O
IS	986 2 B-Disease
/	988 1 O
TIA	989 3 B-Disease
,	992 1 O
MB	994 2 B-Disease
were	997 4 O
more	1002 4 O
frequent	1007 8 O
in	1016 2 O
ICH	1019 3 B-Disease
vs	1023 2 O
IS	1026 2 B-Disease
/	1028 1 O
TIA	1029 3 B-Disease
in	1033 2 O
all	1036 3 O
treatment	1040 9 O
groups	1050 6 O
,	1056 1 O
but	1058 3 O
the	1062 3 O
excess	1066 6 O
increased	1073 9 O
from	1083 4 O
2	1088 1 O
.	1089 1 O
8	1090 1 O
(	1092 1 O
odds	1093 4 O
ratio	1098 5 O
;	1103 1 O
range	1105 5 O
,	1110 1 O
2	1112 1 O
.	1113 1 O
3	1114 1 O
-	1115 1 O
3	1116 1 O
.	1117 1 O
5	1118 1 O
)	1119 1 O
in	1121 2 O
nonantithrombotic	1124 17 O
users	1142 5 O
to	1148 2 O
5	1151 1 O
.	1152 1 O
7	1153 1 O
(	1155 1 O
range	1156 5 O
,	1161 1 O
3	1163 1 O
.	1164 1 O
4	1165 1 O
-	1166 1 O
9	1167 1 O
.	1168 1 O
7	1169 1 O
)	1170 1 O
in	1172 2 O
antiplatelet	1175 12 O
users	1188 5 O
and	1194 3 O
8	1198 1 O
.	1199 1 O
0	1200 1 O
(	1202 1 O
range	1203 5 O
,	1208 1 O
3	1210 1 O
.	1211 1 O
5	1212 1 O
-	1213 1 O
17	1214 2 O
.	1216 1 O
8	1217 1 O
)	1218 1 O
in	1220 2 O
warfarin	1223 8 B-Chemical
users	1232 5 O
(	1238 1 O
P	1239 1 O
difference	1241 10 O
=	1251 1 O
0	1252 1 O
.	1253 1 O
01	1254 2 O
)	1256 1 O
.	1257 1 O

There	1259 5 O
was	1265 3 O
also	1269 4 O
an	1274 2 O
excess	1277 6 O
of	1284 2 O
MB	1287 2 B-Disease
in	1290 2 O
warfarin	1293 8 B-Chemical
users	1302 5 O
vs	1308 2 O
nonusers	1311 8 O
with	1320 4 O
ICH	1325 3 B-Disease
(	1329 1 O
OR	1330 2 O
,	1332 1 O
2	1334 1 O
.	1335 1 O
7	1336 1 O
;	1337 1 O
95	1339 2 O
%	1341 1 O
CI	1343 2 O
,	1345 1 O
1	1347 1 O
.	1348 1 O
6	1349 1 O
-	1350 1 O
4	1351 1 O
.	1352 1 O
4	1353 1 O
;	1354 1 O
P	1356 1 O
<	1357 1 O
0	1358 1 O
.	1359 1 O
001	1360 3 O
)	1363 1 O
but	1365 3 O
none	1369 4 O
in	1374 2 O
warfarin	1377 8 B-Chemical
users	1386 5 O
with	1392 4 O
IS	1397 2 B-Disease
/	1399 1 O
TIA	1400 3 B-Disease
(	1404 1 O
OR	1405 2 O
,	1407 1 O
1	1409 1 O
.	1410 1 O
3	1411 1 O
;	1412 1 O
95	1414 2 O
%	1416 1 O
CI	1418 2 O
,	1420 1 O
0	1422 1 O
.	1423 1 O
9	1424 1 O
-	1425 1 O
1	1426 1 O
.	1427 1 O
7	1428 1 O
;	1429 1 O
P	1431 1 O
=	1432 1 O
0	1433 1 O
.	1434 1 O
33	1435 2 O
;	1437 1 O
P	1439 1 O
difference	1441 10 O
=	1451 1 O
0	1452 1 O
.	1453 1 O
01	1454 2 O
)	1456 1 O
.	1457 1 O

There	1459 5 O
was	1465 3 O
a	1469 1 O
smaller	1471 7 O
excess	1479 6 O
of	1486 2 O
MB	1489 2 B-Disease
in	1492 2 O
antiplatelet	1495 12 O
users	1508 5 O
vs	1514 2 O
nonusers	1517 8 O
with	1526 4 O
ICH	1531 3 B-Disease
(	1535 1 O
OR	1536 2 O
,	1538 1 O
1	1540 1 O
.	1541 1 O
7	1542 1 O
;	1543 1 O
95	1545 2 O
%	1547 1 O
CI	1549 2 O
,	1551 1 O
1	1553 1 O
.	1554 1 O
3	1555 1 O
-	1556 1 O
2	1557 1 O
.	1558 1 O
3	1559 1 O
;	1560 1 O
P	1562 1 O
<	1563 1 O
0	1564 1 O
.	1565 1 O
001	1566 3 O
)	1569 1 O
,	1570 1 O
but	1572 3 O
findings	1576 8 O
were	1585 4 O
similar	1590 7 O
for	1598 3 O
antiplatelet	1602 12 O
users	1615 5 O
with	1621 4 O
IS	1626 2 B-Disease
/	1628 1 O
TIA	1629 3 B-Disease
(	1633 1 O
OR	1634 2 O
,	1636 1 O
1	1638 1 O
.	1639 1 O
4	1640 1 O
;	1641 1 O
95	1643 2 O
%	1645 1 O
CI	1647 2 O
,	1649 1 O
1	1651 1 O
.	1652 1 O
2	1653 1 O
-	1654 1 O
1	1655 1 O
.	1656 1 O
7	1657 1 O
;	1658 1 O
P	1660 1 O
<	1661 1 O
0	1662 1 O
.	1663 1 O
001	1664 3 O
;	1667 1 O
P	1669 1 O
difference	1671 10 O
=	1681 1 O
0	1682 1 O
.	1683 1 O
25	1684 2 O
)	1686 1 O
.	1687 1 O

In	1689 2 O
pooled	1692 6 O
follow	1699 6 O
-	1705 1 O
up	1706 2 O
data	1709 4 O
for	1714 3 O
768	1718 3 O
antithrombotic	1722 14 O
users	1737 5 O
,	1742 1 O
presence	1744 8 O
of	1753 2 O
MB	1756 2 B-Disease
at	1759 2 O
baseline	1762 8 O
was	1771 3 O
associated	1775 10 O
with	1786 4 O
a	1791 1 O
substantially	1793 13 O
increased	1807 9 O
risk	1817 4 O
of	1822 2 O
subsequent	1825 10 O
ICH	1836 3 B-Disease
(	1840 1 O
OR	1841 2 O
,	1843 1 O
12	1845 2 O
.	1847 1 O
1	1848 1 O
;	1849 1 O
95	1851 2 O
%	1853 1 O
CI	1855 2 O
,	1857 1 O
3	1859 1 O
.	1860 1 O
4	1861 1 O
-	1862 1 O
42	1863 2 O
.	1865 1 O
5	1866 1 O
;	1867 1 O
P	1869 1 O
<	1870 1 O
0	1871 1 O
.	1872 1 O
001	1873 3 O
)	1876 1 O
.	1877 1 O

CONCLUSIONS	1879 11 O
:	1890 1 O
The	1892 3 O
excess	1896 6 O
of	1903 2 O
MB	1906 2 B-Disease
in	1909 2 O
warfarin	1912 8 B-Chemical
users	1921 5 O
with	1927 4 O
ICH	1932 3 B-Disease
compared	1936 8 O
to	1945 2 O
other	1948 5 O
groups	1954 6 O
suggests	1961 8 O
that	1970 4 O
MB	1975 2 B-Disease
increase	1978 8 O
the	1987 3 O
risk	1991 4 O
of	1996 2 O
warfarin	1999 8 B-Chemical
-	2007 1 O
associated	2008 10 O
ICH	2019 3 B-Disease
.	2022 1 O

Limited	2024 7 O
prospective	2032 11 O
data	2044 4 O
corroborate	2049 11 O
these	2061 5 O
findings	2067 8 O
,	2075 1 O
but	2077 3 O
larger	2081 6 O
prospective	2088 11 O
studies	2100 7 O
are	2108 3 O
urgently	2112 8 O
required	2121 8 O
.	2129 1 O

Verapamil	0 9 B-Chemical
stimulation	10 11 O
test	22 4 O
in	27 2 O
hyperprolactinemia	30 18 B-Disease
:	48 1 O
loss	50 4 O
of	55 2 O
prolactin	58 9 O
response	68 8 O
in	77 2 O
anatomic	80 8 O
or	89 2 O
functional	92 10 O
stalk	103 5 O
effect	109 6 O
.	115 1 O

AIM	117 3 O
:	120 1 O
Verapamil	122 9 B-Chemical
stimulation	132 11 O
test	144 4 O
was	149 3 O
previously	153 10 O
investigated	164 12 O
as	177 2 O
a	180 1 O
tool	182 4 O
for	187 3 O
differential	191 12 O
diagnosis	204 9 O
of	214 2 O
hyperprolactinemia	217 18 B-Disease
,	235 1 O
but	237 3 O
with	241 4 O
conflicting	246 11 O
results	258 7 O
.	265 1 O

Macroprolactinemia	267 18 B-Disease
was	286 3 O
never	290 5 O
considered	296 10 O
in	307 2 O
those	310 5 O
previous	316 8 O
studies	325 7 O
.	332 1 O

Here	334 4 O
,	338 1 O
we	340 2 O
aimed	343 5 O
to	349 2 O
re	352 2 O
-	354 1 O
investigate	355 11 O
the	367 3 O
diagnostic	371 10 O
value	382 5 O
of	388 2 O
verapamil	391 9 B-Chemical
in	401 2 O
a	404 1 O
population	406 10 O
who	417 3 O
were	421 4 O
all	426 3 O
screened	430 8 O
for	439 3 O
macroprolactinemia	443 18 B-Disease
.	461 1 O

Prolactin	463 9 O
responses	473 9 O
to	483 2 O
verapamil	486 9 B-Chemical
in	496 2 O
65	499 2 O
female	502 6 O
patients	509 8 O
(	518 1 O
age	519 3 O
:	522 1 O
29	524 2 O
.	526 1 O
9	527 1 O
+	529 1 O
/	530 1 O
-	531 1 O
8	533 1 O
.	534 1 O
1	535 1 O
years	537 5 O
)	542 1 O
with	544 4 O
hyperprolactinemia	549 18 B-Disease
were	568 4 O
tested	573 6 O
in	580 2 O
a	583 1 O
descriptive	585 11 O
,	596 1 O
matched	598 7 O
case	606 4 O
-	610 1 O
control	611 7 O
study	619 5 O
.	624 1 O

METHODS	626 7 O
:	633 1 O
Verapamil	635 9 B-Chemical
80	645 2 O
mg	648 2 O
,	650 1 O
p	652 1 O
.	653 1 O
o	654 1 O
.	655 1 O
was	657 3 O
administered	661 12 O
,	673 1 O
and	675 3 O
then	679 4 O
PRL	684 3 O
levels	688 6 O
were	695 4 O
measured	700 8 O
at	709 2 O
8th	712 3 O
and	716 3 O
16th	720 4 O
hours	725 5 O
,	730 1 O
by	732 2 O
immunometric	735 12 O
chemiluminescence	748 17 O
.	765 1 O

Verapamil	767 9 B-Chemical
responsiveness	777 14 O
was	792 3 O
determined	796 10 O
by	807 2 O
peak	810 4 O
percent	815 7 O
change	823 6 O
in	830 2 O
basal	833 5 O
prolactin	839 9 O
levels	849 6 O
(	856 1 O
PRL	857 3 O
)	860 1 O
.	861 1 O

RESULTS	863 7 O
:	870 1 O
Verapamil	872 9 B-Chemical
significantly	882 13 O
increased	896 9 O
PRL	906 3 O
levels	910 6 O
in	917 2 O
healthy	920 7 O
controls	928 8 O
(	937 1 O
N	938 1 O
.	939 1 O
8	941 1 O
,	942 1 O
PRL	944 3 O
:	947 1 O
183	949 3 O
%	952 1 O
)	953 1 O
,	954 1 O
macroprolactinoma	956 17 B-Disease
(	974 1 O
N	975 1 O
.	976 1 O
8	978 1 O
,	979 1 O
PRL	981 3 O
:	984 1 O
7	986 1 O
%	987 1 O
)	988 1 O
,	989 1 O
microprolactinoma	991 17 B-Disease
(	1009 1 O
N	1010 1 O
.	1011 1 O
19	1013 2 O
,	1015 1 O
PRL	1017 3 O
:	1020 1 O
21	1022 2 O
%	1024 1 O
)	1025 1 O
,	1026 1 O
macroprolactinemia	1028 18 B-Disease
(	1047 1 O
N	1048 1 O
.	1049 1 O
23	1051 2 O
,	1053 1 O
PRL	1055 3 O
:	1058 1 O
126	1060 3 O
%	1063 1 O
)	1064 1 O
,	1065 1 O
but	1067 3 O
not	1071 3 O
in	1075 2 O
pseudoprolactinoma	1078 18 B-Disease
(	1097 1 O
N	1098 1 O
.	1099 1 O
8	1101 1 O
,	1102 1 O
PRL	1104 3 O
:	1107 1 O
0	1109 1 O
.	1110 1 O
8	1111 1 O
%	1112 1 O
)	1113 1 O
,	1114 1 O
and	1116 3 O
risperidone	1120 11 B-Chemical
-	1131 1 O
induced	1132 7 O
hyperprolactinemia	1140 18 B-Disease
(	1159 1 O
N	1160 1 O
.	1161 1 O
7	1163 1 O
,	1164 1 O
PRL	1166 3 O
:	1169 1 O
3	1171 1 O
%	1172 1 O
)	1173 1 O
.	1174 1 O

ROC	1176 3 O
curve	1180 5 O
analysis	1186 8 O
revealed	1195 8 O
that	1204 4 O
unresponsiveness	1209 16 O
to	1226 2 O
verapamil	1229 9 B-Chemical
defined	1239 7 O
as	1247 2 O
PRL	1250 3 O
<	1254 1 O
7	1255 1 O
%	1256 1 O
,	1257 1 O
discriminated	1259 13 O
anatomical	1273 10 O
or	1284 2 O
functional	1287 10 O
stalk	1298 5 O
effect	1304 6 O
(	1311 1 O
sensitivity	1312 11 O
:	1323 1 O
74	1325 2 O
%	1327 1 O
,	1328 1 O
specificity	1330 11 O
:	1341 1 O
73	1343 2 O
%	1345 1 O
,	1346 1 O
AUC	1348 3 O
:	1351 1 O
0	1353 1 O
.	1354 1 O
855	1355 3 O
+	1358 1 O
/	1359 1 O
-	1360 1 O
0	1361 1 O
.	1362 1 O
04	1363 2 O
,	1365 1 O
P	1367 1 O
<	1369 1 O
0	1370 1 O
.	1371 1 O
001	1372 3 O
,	1375 1 O
CI	1377 2 O
:	1379 1 O
0	1381 1 O
.	1382 1 O
768	1383 3 O
-	1386 1 O
0	1387 1 O
.	1388 1 O
942	1389 3 O
)	1392 1 O
associated	1394 10 O
with	1405 4 O
pseudoprolactinoma	1410 18 B-Disease
or	1429 2 O
risperidone	1432 11 B-Chemical
-	1443 1 O
induced	1444 7 O
hyperprolactinemia	1452 18 B-Disease
,	1470 1 O
respectively	1472 12 O
.	1484 1 O

CONCLUSION	1486 10 O
:	1496 1 O
Verapamil	1498 9 B-Chemical
responsiveness	1508 14 O
is	1523 2 O
not	1526 3 O
a	1530 1 O
reliable	1532 8 O
finding	1541 7 O
for	1549 3 O
the	1553 3 O
differential	1557 12 O
diagnosis	1570 9 O
of	1580 2 O
hyperprolactinemia	1583 18 B-Disease
.	1601 1 O

However	1603 7 O
,	1610 1 O
verapamil	1612 9 B-Chemical
unresponsiveness	1622 16 O
discriminates	1639 13 O
stalk	1653 5 O
effect	1659 6 O
(	1666 1 O
i	1667 1 O
.	1668 1 O
e	1669 1 O
.	1670 1 O
,	1671 1 O
anatomically	1673 12 O
or	1686 2 O
functionally	1689 12 O
inhibited	1702 9 O
dopaminergic	1712 12 O
tonus	1725 5 O
)	1730 1 O
from	1732 4 O
other	1737 5 O
causes	1743 6 O
of	1750 2 O
hyperprolactinemia	1753 18 B-Disease
with	1772 4 O
varying	1777 7 O
degrees	1785 7 O
of	1793 2 O
responsiveness	1796 14 O
.	1810 1 O

Central	0 7 O
action	8 6 O
of	15 2 O
narcotic	18 8 O
analgesics	27 10 O
.	37 1 O

Part	39 4 O
IV	44 2 O
.	46 1 O

Noradrenergic	48 13 O
influences	62 10 O
on	73 2 O
the	76 3 O
activity	80 8 O
of	89 2 O
analgesics	92 10 O
in	103 2 O
rats	106 4 O
.	110 1 O

The	112 3 O
effect	116 6 O
of	123 2 O
clonidine	126 9 B-Chemical
,	135 1 O
naphazoline	137 11 B-Chemical
and	149 3 O
xylometazoline	153 14 B-Chemical
on	168 2 O
analgesia	171 9 O
induced	181 7 O
by	189 2 O
morphine	192 8 B-Chemical
,	200 1 O
codeine	202 7 B-Chemical
,	209 1 O
fentanyl	211 8 B-Chemical
and	220 3 O
pentazocine	224 11 B-Chemical
,	235 1 O
and	237 3 O
on	241 2 O
cataleptic	244 10 B-Disease
effect	255 6 O
of	262 2 O
morphine	265 8 B-Chemical
,	273 1 O
codine	275 6 B-Chemical
and	282 3 O
fentanyl	286 8 B-Chemical
was	295 3 O
studied	299 7 O
in	307 2 O
rats	310 4 O
.	314 1 O

The	316 3 O
biochemical	320 11 O
assays	332 6 O
on	339 2 O
the	342 3 O
influence	346 9 O
of	356 2 O
four	359 4 O
analgesics	364 10 O
on	375 2 O
the	378 3 O
brain	382 5 O
concentration	388 13 O
and	402 3 O
turnover	406 8 O
of	415 2 O
noradrenaline	418 13 B-Chemical
(	432 1 O
NA	433 2 B-Chemical
)	435 1 O
were	437 4 O
also	442 4 O
performed	447 9 O
.	456 1 O

It	458 2 O
was	461 3 O
found	465 5 O
that	471 4 O
three	476 5 O
drugs	482 5 O
stimulating	488 11 O
central	500 7 O
NA	508 2 B-Chemical
receptors	511 9 O
failed	521 6 O
to	528 2 O
affect	531 6 O
the	538 3 O
analgesic	542 9 O
ED50	552 4 O
of	557 2 O
all	560 3 O
antinociceptive	564 15 O
agents	580 6 O
and	587 3 O
they	591 4 O
enhanced	596 8 O
catalepsy	605 9 B-Disease
induced	615 7 O
by	623 2 O
morphine	626 8 B-Chemical
and	635 3 O
fentanyl	639 8 B-Chemical
.	647 1 O

Codeine	649 7 B-Chemical
catalepsy	657 9 B-Disease
was	667 3 O
increased	671 9 O
by	681 2 O
clonidine	684 9 B-Chemical
and	694 3 O
decreased	698 9 O
by	708 2 O
naphazoline	711 11 B-Chemical
and	723 3 O
xylometazoline	727 14 B-Chemical
.	741 1 O

The	743 3 O
brain	747 5 O
concentration	753 13 O
of	767 2 O
NA	770 2 B-Chemical
was	773 3 O
not	777 3 O
changed	781 7 O
by	789 2 O
morphine	792 8 B-Chemical
and	801 3 O
fentanyl	805 8 B-Chemical
,	813 1 O
but	815 3 O
one	819 3 O
of	823 2 O
the	826 3 O
doses	830 5 O
of	836 2 O
codeine	839 7 B-Chemical
(	847 1 O
45	848 2 O
mg	851 2 O
/	853 1 O
kg	854 2 O
)	856 1 O
slightly	858 8 O
enhanced	867 8 O
it	876 2 O
.	878 1 O

Pentazocine	880 11 B-Chemical
dose	892 4 O
-	896 1 O
dependently	897 11 O
decreased	909 9 O
the	919 3 O
brain	923 5 O
level	929 5 O
of	935 2 O
NA	938 2 B-Chemical
.	940 1 O

The	942 3 O
rate	946 4 O
of	951 2 O
NA	954 2 B-Chemical
turnover	957 8 O
was	966 3 O
not	970 3 O
altered	974 7 O
by	982 2 O
analgesics	985 10 O
except	996 6 O
for	1003 3 O
the	1007 3 O
higher	1011 6 O
dose	1018 4 O
of	1023 2 O
fentanyl	1026 8 B-Chemical
(	1035 1 O
0	1036 1 O
.	1037 1 O
2	1038 1 O
mg	1040 2 O
/	1042 1 O
kg	1043 2 O
)	1045 1 O
following	1047 9 O
which	1057 5 O
the	1063 3 O
disappearance	1067 13 O
of	1081 2 O
NA	1084 2 B-Chemical
from	1087 4 O
the	1092 3 O
brain	1096 5 O
was	1102 3 O
diminished	1106 10 O
.	1116 1 O

The	1118 3 O
results	1122 7 O
are	1130 3 O
discussed	1134 9 O
in	1144 2 O
the	1147 3 O
light	1151 5 O
of	1157 2 O
various	1160 7 O
and	1168 3 O
non	1172 3 O
-	1175 1 O
uniform	1176 7 O
data	1184 4 O
from	1189 4 O
the	1194 3 O
literature	1198 10 O
.	1208 1 O

It	1210 2 O
is	1213 2 O
suggested	1216 9 O
that	1226 4 O
in	1231 2 O
rats	1234 4 O
the	1239 3 O
brain	1243 5 O
NA	1249 2 B-Chemical
plays	1252 5 O
a	1258 1 O
less	1260 4 O
important	1265 9 O
function	1275 8 O
than	1284 4 O
the	1289 3 O
other	1293 5 O
monoamines	1299 10 B-Chemical
in	1310 2 O
the	1313 3 O
behavioural	1317 11 O
activity	1329 8 O
of	1338 2 O
potent	1341 6 O
analgesics	1348 10 O
.	1358 1 O

Modification	0 12 O
by	13 2 O
propranolol	16 11 B-Chemical
of	28 2 O
cardiovascular	31 14 O
effects	46 7 O
of	54 2 O
induced	57 7 O
hypoglycaemia	65 13 B-Disease
.	78 1 O

The	80 3 O
cardiovascular	84 14 O
effects	99 7 O
of	107 2 O
hypoglycaemia	110 13 B-Disease
,	123 1 O
with	125 4 O
and	130 3 O
without	134 7 O
beta	142 4 O
-	146 1 O
blockade	147 8 O
,	155 1 O
were	157 4 O
compared	162 8 O
in	171 2 O
fourteen	174 8 O
healthy	183 7 O
men	191 3 O
.	194 1 O

Eight	196 5 O
received	202 8 O
insulin	211 7 O
alone	219 5 O
,	224 1 O
and	226 3 O
eight	230 5 O
,	235 1 O
including	237 9 O
two	247 3 O
of	251 2 O
the	254 3 O
original	258 8 O
insulin	267 7 O
-	274 1 O
only	275 4 O
group	280 5 O
,	285 1 O
were	287 4 O
given	292 5 O
propranolol	298 11 B-Chemical
and	310 3 O
insulin	314 7 O
.	321 1 O

In	323 2 O
the	326 3 O
insulin	330 7 O
-	337 1 O
group	338 5 O
the	344 3 O
period	348 6 O
of	355 2 O
hypoglycaemia	358 13 B-Disease
was	372 3 O
associated	376 10 O
with	387 4 O
an	392 2 O
increase	395 8 O
in	404 2 O
heart	407 5 O
-	412 1 O
rate	413 4 O
and	418 3 O
a	422 1 O
fall	424 4 O
in	429 2 O
diastolic	432 9 O
blood	442 5 O
-	447 1 O
pressure	448 8 O
.	456 1 O

In	458 2 O
the	461 3 O
propranolol	465 11 B-Chemical
-	476 1 O
insulin	477 7 O
group	485 5 O
there	491 5 O
was	497 3 O
a	501 1 O
significant	503 11 O
fall	515 4 O
in	520 2 O
heart	523 5 O
-	528 1 O
rate	529 4 O
in	534 2 O
most	537 4 O
subjects	542 8 O
and	551 3 O
an	555 2 O
increase	558 8 O
in	567 2 O
diastolic	570 9 O
pressure	580 8 O
.	588 1 O

Typical	590 7 O
S	598 1 O
-	599 1 O
T	600 1 O
/	601 1 O
T	602 1 O
changes	604 7 O
occurred	612 8 O
in	621 2 O
the	624 3 O
insulin	628 7 O
-	635 1 O
group	636 5 O
but	642 3 O
in	646 2 O
none	649 4 O
of	654 2 O
the	657 3 O
propranolol	661 11 B-Chemical
-	672 1 O
insulin	673 7 O
group	681 5 O
.	686 1 O

Hypertension	688 12 B-Disease
in	701 2 O
diabetics	704 9 B-Disease
prone	714 5 O
to	720 2 O
hypoglycaemia	723 13 B-Disease
attacks	737 7 O
should	745 6 O
not	752 3 O
be	756 2 O
treated	759 7 O
with	767 4 O
beta	772 4 O
-	776 1 O
blockers	777 8 O
because	786 7 O
these	794 5 O
drugs	800 5 O
may	806 3 O
cause	810 5 O
a	816 1 O
sharp	818 5 O
rise	824 4 O
in	829 2 O
blood	832 5 O
-	837 1 O
pressure	838 8 O
in	847 2 O
such	850 4 O
patients	855 8 O
.	863 1 O

Prevention	0 10 O
and	11 3 O
treatment	15 9 O
of	25 2 O
endometrial	28 11 B-Disease
disease	40 7 I-Disease
in	48 2 O
climacteric	51 11 O
women	63 5 O
receiving	69 9 O
oestrogen	79 9 B-Chemical
therapy	89 7 O
.	96 1 O

The	98 3 O
treatment	102 9 O
regimens	112 8 O
are	121 3 O
described	125 9 O
in	135 2 O
74	138 2 O
patients	141 8 O
with	150 4 O
endometrial	155 11 B-Disease
disease	167 7 I-Disease
among	175 5 O
850	181 3 O
climacteric	185 11 O
women	197 5 O
receiving	203 9 O
oestrogen	213 9 B-Chemical
therapy	223 7 O
.	230 1 O

Cystic	232 6 O
hyperplasia	239 11 B-Disease
was	251 3 O
associated	255 10 O
with	266 4 O
unopposed	271 9 O
oestrogen	281 9 B-Chemical
therapy	291 7 O
without	299 7 O
progestagen	307 11 B-Chemical
.	318 1 O

Two	320 3 O
courses	324 7 O
of	332 2 O
21	335 2 O
days	338 4 O
of	343 2 O
5	346 1 O
mg	348 2 O
norethisterone	351 14 B-Chemical
daily	366 5 O
caused	372 6 O
reversion	379 9 O
to	389 2 O
normal	392 6 O
in	399 2 O
all	402 3 O
57	406 2 O
cases	409 5 O
of	415 2 O
cystic	418 6 O
hyperplasia	425 11 B-Disease
and	437 3 O
6	441 1 O
of	443 2 O
the	446 3 O
8	450 1 O
cases	452 5 O
of	458 2 O
atypical	461 8 O
hyperplasia	470 11 B-Disease
.	481 1 O

4	483 1 O
cases	485 5 O
of	491 2 O
endometrial	494 11 B-Disease
carcinoma	506 9 I-Disease
referred	516 8 O
from	525 4 O
elsewhere	530 9 O
demonstrated	540 12 O
the	553 3 O
problems	557 8 O
of	566 2 O
inappropriate	569 13 O
and	583 3 O
unsupervised	587 12 O
unopposed	600 9 O
oestrogen	610 9 B-Chemical
therapy	620 7 O
and	628 3 O
the	632 3 O
difficulty	636 10 O
in	647 2 O
distinguishing	650 14 O
severe	665 6 O
hyperplasia	672 11 B-Disease
from	684 4 O
malignancy	689 10 B-Disease
.	699 1 O

Cyclical	701 8 O
low	710 3 O
-	713 1 O
dose	714 4 O
oestrogen	719 9 B-Chemical
therapy	729 7 O
with	737 4 O
7	742 1 O
-	743 1 O
-	744 1 O
13	745 2 O
days	748 4 O
of	753 2 O
progestagen	756 11 B-Chemical
does	768 4 O
not	773 3 O
seem	777 4 O
to	782 2 O
increase	785 8 O
the	794 3 O
risk	798 4 O
of	803 2 O
endometrial	806 11 B-Disease
hyperplasia	818 11 I-Disease
or	830 2 O
carcinoma	833 9 B-Disease
.	842 1 O

Pure	0 4 B-Disease
red	5 3 I-Disease
cell	9 4 I-Disease
aplasia	14 7 I-Disease
,	21 1 O
toxic	23 5 B-Disease
dermatitis	29 10 I-Disease
and	40 3 O
lymphadenopathy	44 15 B-Disease
in	60 2 O
a	63 1 O
patient	65 7 O
taking	73 6 O
diphenylhydantoin	80 17 B-Chemical
.	97 1 O

A	99 1 O
patient	101 7 O
taking	109 6 O
diphenylhydantoin	116 17 B-Chemical
for	134 3 O
3	138 1 O
weeks	140 5 O
developed	146 9 O
a	156 1 O
generalized	158 11 O
skin	170 4 B-Disease
rash	175 4 I-Disease
,	179 1 O
lymphadenopathy	181 15 B-Disease
and	197 3 O
pure	201 4 B-Disease
red	206 3 I-Disease
cell	210 4 I-Disease
aplasia	215 7 I-Disease
.	222 1 O

After	224 5 O
withdrawal	230 10 O
of	241 2 O
the	244 3 O
pharmacon	248 9 O
all	258 3 O
symptoms	262 8 O
disappeared	271 11 O
spontaneously	283 13 O
.	296 1 O

Skin	298 4 B-Disease
rash	303 4 I-Disease
is	308 2 O
a	311 1 O
well	313 4 O
-	317 1 O
known	318 5 O
complication	324 12 O
of	337 2 O
diphenylhydantoin	340 17 B-Chemical
treatment	358 9 O
as	368 2 O
is	371 2 O
benign	374 6 O
and	381 3 O
malignant	385 9 O
lymphadenopathy	395 15 B-Disease
.	410 1 O

Pure	412 4 B-Disease
red	417 3 I-Disease
cell	421 4 I-Disease
aplasia	426 7 I-Disease
associated	434 10 O
with	445 4 O
diphenylhydantoin	450 17 B-Chemical
medication	468 10 O
has	479 3 O
been	483 4 O
reported	488 8 O
in	497 2 O
3	500 1 O
patients	502 8 O
.	510 1 O

The	512 3 O
exact	516 5 O
mechanism	522 9 O
by	532 2 O
which	535 5 O
diphenylhydantoin	541 17 B-Chemical
exerts	559 6 O
its	566 3 O
toxic	570 5 O
effects	576 7 O
is	584 2 O
not	587 3 O
known	591 5 O
.	596 1 O

In	598 2 O
this	601 4 O
patient	606 7 O
the	614 3 O
time	618 4 O
relation	623 8 O
between	632 7 O
the	640 3 O
ingestion	644 9 O
of	654 2 O
diphenylhydantoin	657 17 B-Chemical
and	675 3 O
the	679 3 O
occurrence	683 10 O
of	694 2 O
the	697 3 O
skin	701 4 B-Disease
rash	706 4 I-Disease
,	710 1 O
lymphadenopathy	712 15 B-Disease
and	728 3 O
pure	732 4 B-Disease
red	737 3 I-Disease
cell	741 4 I-Disease
aplasia	746 7 I-Disease
is	754 2 O
very	757 4 O
suggestive	762 10 O
of	773 2 O
a	776 1 O
direct	778 6 O
connection	785 10 O
.	795 1 O

Continuous	0 10 O
infusion	11 8 O
tobramycin	20 10 B-Chemical
combined	31 8 O
with	40 4 O
carbenicillin	45 13 B-Chemical
for	59 3 O
infections	63 10 B-Disease
in	74 2 O
cancer	77 6 B-Disease
patients	84 8 O
.	92 1 O

The	94 3 O
cure	98 4 O
rate	103 4 O
of	108 2 O
infections	111 10 B-Disease
in	122 2 O
cancer	125 6 B-Disease
patients	132 8 O
is	141 2 O
adversely	144 9 O
affected	154 8 O
by	163 2 O
neutropenia	166 11 B-Disease
(	178 1 O
less	179 4 O
than	184 4 O
1	189 1 O
,	190 1 O
000	191 3 O
/	194 1 O
mm3	195 3 O
)	198 1 O
.	199 1 O

In	201 2 O
particular	204 10 O
,	214 1 O
patients	216 8 O
with	225 4 O
severe	230 6 O
neutropenia	237 11 B-Disease
(	249 1 O
less	250 4 O
than	255 4 O
100	260 3 O
/	263 1 O
mm3	264 3 O
)	267 1 O
have	269 4 O
shown	274 5 O
a	280 1 O
poor	282 4 O
response	287 8 O
to	296 2 O
antibiotics	299 11 O
.	310 1 O

To	312 2 O
overcome	315 8 O
the	324 3 O
adverse	328 7 O
effects	336 7 O
of	344 2 O
neutropenia	347 11 B-Disease
,	358 1 O
tobramycin	360 10 B-Chemical
was	371 3 O
given	375 5 O
by	381 2 O
continuous	384 10 O
infusion	395 8 O
and	404 3 O
combined	408 8 O
with	417 4 O
intermittent	422 12 O
carbenicillin	435 13 B-Chemical
.	448 1 O

Tobramycin	450 10 B-Chemical
was	461 3 O
given	465 5 O
to	471 2 O
a	474 1 O
total	476 5 O
daily	482 5 O
dose	488 4 O
of	493 2 O
300	496 3 O
mg	500 2 O
/	502 1 O
m2	503 2 O
and	506 3 O
carbenicillin	510 13 B-Chemical
was	524 3 O
given	528 5 O
at	534 2 O
a	537 1 O
dose	539 4 O
of	544 2 O
5	547 1 O
gm	549 2 O
every	552 5 O
four	558 4 O
hours	563 5 O
.	568 1 O

There	570 5 O
were	576 4 O
125	581 3 O
infectious	585 10 O
episodes	596 8 O
in	605 2 O
116	608 3 O
cancer	612 6 B-Disease
patients	619 8 O
receiving	628 9 O
myelosuppressive	638 16 O
chemotherapy	655 12 O
.	667 1 O

The	669 3 O
overall	673 7 O
cure	681 4 O
rate	686 4 O
was	691 3 O
70	695 2 O
%	697 1 O
.	698 1 O

Pneumonia	700 9 B-Disease
was	710 3 O
the	714 3 O
most	718 4 O
common	723 6 O
infection	730 9 B-Disease
and	740 3 O
61	744 2 O
%	746 1 O
of	748 2 O
59	751 2 O
episodes	754 8 O
were	763 4 O
cured	768 5 O
.	773 1 O

Gram	775 4 O
-	779 1 O
negative	780 8 O
bacilli	789 7 O
were	797 4 O
the	802 3 O
most	806 4 O
common	811 6 O
causative	818 9 O
organisms	828 9 O
and	838 3 O
69	842 2 O
%	844 1 O
of	846 2 O
these	849 5 O
infections	855 10 B-Disease
were	866 4 O
cured	871 5 O
.	876 1 O

The	878 3 O
most	882 4 O
common	887 6 O
pathogen	894 8 O
was	903 3 O
Klebsiella	907 10 O
pneumoniae	918 10 B-Disease
and	929 3 O
this	933 4 O
,	937 1 O
together	939 8 O
with	948 4 O
Escherichia	953 11 O
coli	965 4 O
and	970 3 O
Pseudomonas	974 11 O
aeruginosa	986 10 O
,	996 1 O
accounted	998 9 O
for	1008 3 O
74	1012 2 O
%	1014 1 O
of	1016 2 O
all	1019 3 O
gram	1023 4 B-Disease
-	1027 1 I-Disease
negative	1028 8 I-Disease
bacillary	1037 9 I-Disease
infections	1047 10 I-Disease
.	1057 1 O

Response	1059 8 O
was	1068 3 O
not	1072 3 O
influenced	1076 10 O
by	1087 2 O
the	1090 3 O
initial	1094 7 O
neutrophil	1102 10 O
count	1113 5 O
,	1118 1 O
with	1120 4 O
a	1125 1 O
62	1127 2 O
%	1129 1 O
cure	1131 4 O
rate	1136 4 O
for	1141 3 O
39	1145 2 O
episodes	1148 8 O
associated	1157 10 O
with	1168 4 O
severe	1173 6 O
neutropenia	1180 11 B-Disease
.	1191 1 O

However	1193 7 O
,	1200 1 O
failure	1202 7 O
of	1210 2 O
the	1213 3 O
neutrophil	1217 10 O
count	1228 5 O
to	1234 2 O
increase	1237 8 O
during	1246 6 O
therapy	1253 7 O
adversely	1261 9 O
affected	1271 8 O
response	1280 8 O
.	1288 1 O

Azotemia	1290 8 B-Disease
was	1299 3 O
the	1303 3 O
major	1307 5 O
side	1313 4 O
effect	1318 6 O
recognized	1325 10 O
,	1335 1 O
and	1337 3 O
it	1341 2 O
occurred	1344 8 O
in	1353 2 O
11	1356 2 O
%	1358 1 O
of	1360 2 O
episodes	1363 8 O
.	1371 1 O

Major	1373 5 O
azotemia	1379 8 B-Disease
(	1388 1 O
serum	1389 5 O
creatinine	1395 10 B-Chemical
greater	1406 7 O
than	1414 4 O
2	1419 1 O
.	1420 1 O
5	1421 1 O
mg	1423 2 O
/	1425 1 O
dl	1426 2 O
or	1429 2 O
BUN	1432 3 O
greater	1436 7 O
than	1444 4 O
50	1449 2 O
mg	1452 2 O
/	1454 1 O
dl	1455 2 O
)	1457 1 O
occurred	1459 8 O
in	1468 2 O
only	1471 4 O
2	1476 1 O
%	1477 1 O
.	1478 1 O

Azotemia	1480 8 B-Disease
was	1489 3 O
not	1493 3 O
related	1497 7 O
to	1505 2 O
duration	1508 8 O
of	1517 2 O
therapy	1520 7 O
or	1528 2 O
serum	1531 5 O
tobramycin	1537 10 B-Chemical
concentration	1548 13 O
.	1561 1 O

This	1563 4 O
antibiotic	1568 10 O
regimen	1579 7 O
showed	1587 6 O
both	1594 4 O
therapeutic	1599 11 O
efficacy	1611 8 O
and	1620 3 O
acceptable	1624 10 O
renal	1635 5 B-Disease
toxicity	1641 8 I-Disease
for	1650 3 O
these	1654 5 O
patients	1660 8 O
.	1668 1 O

Recurrent	0 9 O
subarachnoid	10 12 B-Disease
hemorrhage	23 10 I-Disease
associated	34 10 O
with	45 4 O
aminocaproic	50 12 B-Chemical
acid	63 4 I-Chemical
therapy	68 7 O
and	76 3 O
acute	80 5 B-Disease
renal	86 5 I-Disease
artery	92 6 I-Disease
thrombosis	99 10 I-Disease
.	109 1 O

Case	111 4 O
report	116 6 O
.	122 1 O

Epsilon	124 7 B-Chemical
aminocaproic	132 12 I-Chemical
acid	145 4 I-Chemical
(	150 1 O
EACA	151 4 B-Chemical
)	155 1 O
has	157 3 O
been	161 4 O
used	166 4 O
to	171 2 O
prevent	174 7 O
rebleeding	182 10 O
in	193 2 O
patients	196 8 O
with	205 4 O
subarachnoid	210 12 B-Disease
hemorrhage	223 10 I-Disease
(	234 1 O
SAH	235 3 B-Disease
)	238 1 O
.	239 1 O

Although	241 8 O
this	250 4 O
agent	255 5 O
does	261 4 O
decrease	266 8 O
the	275 3 O
frequency	279 9 O
of	289 2 O
rebleeding	292 10 O
,	302 1 O
several	304 7 O
reports	312 7 O
have	320 4 O
described	325 9 O
thrombotic	335 10 B-Disease
complications	346 13 O
of	360 2 O
EACA	363 4 B-Chemical
therapy	368 7 O
.	375 1 O

These	377 5 O
complications	383 13 O
have	397 4 O
included	402 8 O
clinical	411 8 O
deterioration	420 13 O
and	434 3 O
intracranial	438 12 B-Disease
vascular	451 8 I-Disease
thrombosis	460 10 I-Disease
in	471 2 O
patients	474 8 O
with	483 4 O
SAH	488 3 B-Disease
,	491 1 O
arteriolar	493 10 O
and	504 3 O
capillary	508 9 O
fibrin	518 6 O
thrombi	525 7 B-Disease
in	533 2 O
patients	536 8 O
with	545 4 O
fibrinolytic	550 12 O
syndromes	563 9 O
treated	573 7 O
with	581 4 O
EACA	586 4 B-Chemical
,	590 1 O
or	592 2 O
other	595 5 O
thromboembolic	601 14 B-Disease
phenomena	616 9 I-Disease
.	625 1 O

Since	627 5 O
intravascular	633 13 O
fibrin	647 6 O
thrombi	654 7 B-Disease
are	662 3 O
often	666 5 O
observed	672 8 O
in	681 2 O
patients	684 8 O
with	693 4 O
fibrinolytic	698 12 O
disorders	711 9 O
,	720 1 O
EACA	722 4 B-Chemical
should	727 6 O
not	734 3 O
be	738 2 O
implicated	741 10 O
in	752 2 O
the	755 3 O
pathogenesis	759 12 O
of	772 2 O
fibrin	775 6 O
thrombi	782 7 B-Disease
in	790 2 O
patients	793 8 O
with	802 4 O
disseminated	807 12 B-Disease
intravascular	820 13 I-Disease
coagulation	834 11 I-Disease
or	846 2 O
other	849 5 O
"	855 1 O
consumption	856 11 B-Disease
coagulopathies	868 14 I-Disease
.	882 1 O
"	883 1 O
This	885 4 O
report	890 6 O
describes	897 9 O
subtotal	907 8 O
infarction	916 10 B-Disease
of	927 2 O
the	930 3 O
kidney	934 6 O
due	941 3 O
to	945 2 O
thrombosis	948 10 B-Disease
of	959 2 I-Disease
a	962 1 I-Disease
normal	964 6 I-Disease
renal	971 5 I-Disease
artery	977 6 I-Disease
.	983 1 O

This	985 4 O
occlusion	990 9 O
occurred	1000 8 O
after	1009 5 O
EACA	1015 4 B-Chemical
therapy	1020 7 O
in	1028 2 O
a	1031 1 O
patient	1033 7 O
with	1041 4 O
SAH	1046 3 B-Disease
and	1050 3 O
histopathological	1054 17 O
documentation	1072 13 O
of	1086 2 O
recurrent	1089 9 O
SAH	1099 3 B-Disease
.	1102 1 O

The	1104 3 O
corresponding	1108 13 O
clinical	1122 8 O
event	1131 5 O
was	1137 3 O
characterized	1141 13 O
by	1155 2 O
marked	1158 6 O
hypertension	1165 12 B-Disease
and	1178 3 O
abrupt	1182 6 O
neurological	1189 12 O
deterioration	1202 13 O
.	1215 1 O

Long	0 4 O
-	4 1 O
term	5 4 O
propranolol	10 11 B-Chemical
therapy	22 7 O
in	30 2 O
pregnancy	33 9 O
:	42 1 O
maternal	44 8 O
and	53 3 O
fetal	57 5 O
outcome	63 7 O
.	70 1 O

Propranolol	72 11 B-Chemical
,	83 1 O
a	85 1 O
beta	87 4 O
-	91 1 O
adrenergic	92 10 O
blocking	103 8 O
agent	112 5 O
,	117 1 O
has	119 3 O
found	123 5 O
an	129 2 O
important	132 9 O
position	142 8 O
in	151 2 O
the	154 3 O
practice	158 8 O
of	167 2 O
medicine	170 8 O
.	178 1 O

Its	180 3 O
use	184 3 O
in	188 2 O
pregnancy	191 9 O
,	200 1 O
however	202 7 O
,	209 1 O
is	211 2 O
an	214 2 O
open	217 4 O
question	222 8 O
as	231 2 O
a	234 1 O
number	236 6 O
of	243 2 O
detrimental	246 11 O
side	258 4 O
effects	263 7 O
have	271 4 O
been	276 4 O
reported	281 8 O
in	290 2 O
the	293 3 O
fetus	297 5 O
and	303 3 O
neonate	307 7 O
.	314 1 O

Ten	316 3 O
patients	320 8 O
and	329 3 O
12	333 2 O
pregnancies	336 11 O
are	348 3 O
reported	352 8 O
where	361 5 O
chronic	367 7 O
propranolol	375 11 B-Chemical
has	387 3 O
been	391 4 O
administered	396 12 O
.	408 1 O

Five	410 4 O
patients	415 8 O
with	424 4 O
serial	429 6 O
pregnancies	436 11 O
with	448 4 O
and	453 3 O
without	457 7 O
propranolol	465 11 B-Chemical
therapy	477 7 O
are	485 3 O
also	489 4 O
examined	494 8 O
.	502 1 O

Maternal	504 8 O
,	512 1 O
fetal	514 5 O
,	519 1 O
and	521 3 O
neonatal	525 8 O
complications	534 13 O
are	548 3 O
examined	552 8 O
.	560 1 O

An	562 2 O
attempt	565 7 O
is	573 2 O
made	576 4 O
to	581 2 O
differentiate	584 13 O
drug	598 4 O
-	602 1 O
related	603 7 O
complications	611 13 O
from	625 4 O
maternal	630 8 O
disease	639 7 O
-	646 1 O
-	647 1 O
related	648 7 O
complications	656 13 O
.	669 1 O

We	671 2 O
conclude	674 8 O
that	683 4 O
previously	688 10 O
reported	699 8 O
hypoglycemia	708 12 B-Disease
,	720 1 O
hyperbilirubinemia	722 18 B-Disease
,	740 1 O
polycythemia	742 12 B-Disease
,	754 1 O
neonatal	756 8 B-Disease
apnea	765 5 I-Disease
,	770 1 O
and	772 3 O
bradycardia	776 11 B-Disease
are	788 3 O
not	792 3 O
invariable	796 10 O
and	807 3 O
cannot	811 6 O
be	818 2 O
statistically	821 13 O
correlated	835 10 O
with	846 4 O
chronic	851 7 O
propranolol	859 11 B-Chemical
therapy	871 7 O
.	878 1 O

Growth	880 6 B-Disease
retardation	887 11 I-Disease
,	898 1 O
however	900 7 O
,	907 1 O
appears	909 7 O
to	917 2 O
be	920 2 O
significant	923 11 O
in	935 2 O
both	938 4 O
of	943 2 O
our	946 3 O
series	950 6 O
.	956 1 O

Use	0 3 O
of	4 2 O
propranolol	7 11 B-Chemical
in	19 2 O
the	22 3 O
treatment	26 9 O
of	36 2 O
idiopathic	39 10 B-Disease
orthostatic	50 11 I-Disease
hypotension	62 11 I-Disease
.	73 1 O

Five	75 4 O
patients	80 8 O
with	89 4 O
idiopathic	94 10 B-Disease
orthostatic	105 11 I-Disease
hypotension	117 11 I-Disease
who	129 3 O
had	133 3 O
physiologic	137 11 O
and	149 3 O
biochemical	153 11 O
evidence	165 8 O
of	174 2 O
severe	177 6 O
autonomic	184 9 O
dysfunction	194 11 O
were	206 4 O
included	211 8 O
in	220 2 O
the	223 3 O
study	227 5 O
.	232 1 O

They	234 4 O
all	239 3 O
exhibited	243 9 O
markedly	253 8 O
reduced	262 7 O
plasma	270 6 O
catecholamines	277 14 B-Chemical
and	292 3 O
plasma	296 6 O
renin	303 5 O
activity	309 8 O
in	318 2 O
both	321 4 O
recumbent	326 9 O
and	336 3 O
upright	340 7 O
positions	348 9 O
and	358 3 O
had	362 3 O
marked	366 6 O
hypersensitivity	373 16 B-Disease
to	390 2 O
the	393 3 O
pressor	397 7 O
effects	405 7 O
of	413 2 O
infused	416 7 O
norepinephrine	424 14 B-Chemical
.	438 1 O

Treatment	440 9 O
with	450 4 O
propanolol	455 10 B-Chemical
administered	466 12 O
intravenously	479 13 O
(	493 1 O
1	494 1 O
-	495 1 O
5	496 1 O
mg	498 2 O
)	500 1 O
produced	502 8 O
increases	511 9 O
in	521 2 O
supine	524 6 O
and	531 3 O
upright	535 7 O
blood	543 5 O
pressure	549 8 O
in	558 2 O
4	561 1 O
of	563 2 O
the	566 3 O
5	570 1 O
individuals	572 11 O
with	584 4 O
rises	589 5 O
ranging	595 7 O
from	603 4 O
11	608 2 O
/	610 1 O
6	611 1 O
to	613 2 O
22	616 2 O
/	618 1 O
11	619 2 O
mmHg	622 4 O
.	626 1 O

Chronic	628 7 O
oral	636 4 O
administration	641 14 O
of	656 2 O
propranolol	659 11 B-Chemical
(	671 1 O
40	672 2 O
-	674 1 O
160	675 3 O
mg	679 2 O
/	681 1 O
day	682 3 O
)	685 1 O
also	687 4 O
elevated	692 8 O
the	701 3 O
blood	705 5 O
pressures	711 9 O
of	721 2 O
these	724 5 O
individuals	730 11 O
with	742 4 O
increases	747 9 O
in	757 2 O
the	760 3 O
order	764 5 O
of	770 2 O
20	773 2 O
-	775 1 O
35	776 2 O
/	778 1 O
15	779 2 O
-	781 1 O
25	782 2 O
mmg	785 3 O
being	789 5 O
observed	795 8 O
.	803 1 O

In	805 2 O
1	808 1 O
patient	810 7 O
,	817 1 O
marked	819 6 O
hypertension	826 12 B-Disease
was	839 3 O
induced	843 7 O
by	851 2 O
propranolol	854 11 B-Chemical
and	866 3 O
the	870 3 O
drug	874 4 O
had	879 3 O
to	883 2 O
be	886 2 O
withdrawn	889 9 O
.	898 1 O

It	900 2 O
otherwise	903 9 O
was	913 3 O
well	917 4 O
tolerated	922 9 O
and	932 3 O
no	936 2 O
important	939 9 O
side	949 4 O
effects	954 7 O
were	962 4 O
observed	967 8 O
.	975 1 O

Treatment	977 9 O
has	987 3 O
been	991 4 O
continued	996 9 O
in	1006 2 O
3	1009 1 O
individuals	1011 11 O
for	1023 3 O
6	1027 1 O
-	1028 1 O
13	1029 2 O
months	1032 6 O
with	1039 4 O
persistence	1044 11 O
of	1056 2 O
the	1059 3 O
pressor	1063 7 O
effect	1071 6 O
,	1077 1 O
although	1079 8 O
there	1088 5 O
appears	1094 7 O
to	1102 2 O
have	1105 4 O
been	1110 4 O
some	1115 4 O
decrease	1120 8 O
in	1129 2 O
the	1132 3 O
degree	1136 6 O
of	1143 2 O
response	1146 8 O
with	1155 4 O
time	1160 4 O
.	1164 1 O

Hemodynamic	1166 11 O
measurements	1178 12 O
in	1191 2 O
1	1194 1 O
of	1196 2 O
the	1199 3 O
patients	1203 8 O
demonstrated	1212 12 O
an	1225 2 O
increase	1228 8 O
in	1237 2 O
total	1240 5 O
peripheral	1246 10 O
resistance	1257 10 O
and	1268 3 O
essentially	1272 11 O
no	1284 2 O
change	1287 6 O
in	1294 2 O
cardiac	1297 7 O
output	1305 6 O
following	1312 9 O
propranolol	1322 11 B-Chemical
therapy	1334 7 O
.	1341 1 O

The	1343 3 O
studies	1347 7 O
suggest	1355 7 O
that	1363 4 O
propranolol	1368 11 B-Chemical
is	1380 2 O
a	1383 1 O
useful	1385 6 O
drug	1392 4 O
in	1397 2 O
selected	1400 8 O
patients	1409 8 O
with	1418 4 O
severe	1423 6 O
idiopathic	1430 10 B-Disease
orthostatic	1441 11 I-Disease
hypotension	1453 11 I-Disease
.	1464 1 O

Total	0 5 O
intravenous	6 11 O
anesthesia	18 10 O
with	29 4 O
etomidate	34 9 B-Chemical
.	43 1 O

III	45 3 O
.	48 1 O

Some	50 4 O
observations	55 12 O
in	68 2 O
adults	71 6 O
.	77 1 O

An	79 2 O
investigation	82 13 O
was	96 3 O
undertaken	100 10 O
to	111 2 O
determine	114 9 O
the	124 3 O
dosage	128 6 O
of	135 2 O
etomidate	138 9 B-Chemical
required	148 8 O
to	157 2 O
maintain	160 8 O
sleep	169 5 O
in	175 2 O
adults	178 6 O
undergoing	185 10 O
surgery	196 7 O
under	204 5 O
regional	210 8 O
local	219 5 O
anesthesia	225 10 O
.	235 1 O

Premedication	237 13 O
of	251 2 O
diazepam	254 8 B-Chemical
10	263 2 O
mg	266 2 O
and	269 3 O
atropine	273 8 B-Chemical
0	282 1 O
.	283 1 O
5	284 1 O
mg	286 2 O
was	289 3 O
given	293 5 O
,	298 1 O
and	300 3 O
sleep	304 5 O
was	310 3 O
induced	314 7 O
and	322 3 O
maintained	326 10 O
by	337 2 O
intermittent	340 12 O
intravenous	353 11 O
injections	365 10 O
of	376 2 O
etomidate	379 9 B-Chemical
0	389 1 O
.	390 1 O
1	391 1 O
/	392 1 O
mg	393 2 O
/	395 1 O
kg	396 2 O
,	398 1 O
given	400 5 O
whenever	406 8 O
the	415 3 O
patient	419 7 O
would	427 5 O
open	433 4 O
his	438 3 O
eyes	442 4 O
on	447 2 O
request	450 7 O
.	457 1 O

A	459 1 O
mean	461 4 O
overall	466 7 O
dose	474 4 O
of	479 2 O
etomidate	482 9 B-Chemical
17	492 2 O
.	494 1 O
4	495 1 O
microgram	497 9 O
/	506 1 O
kg	507 2 O
/	509 1 O
min	510 3 O
.	513 1 O
was	515 3 O
required	519 8 O
to	528 2 O
maintain	531 8 O
sleep	540 5 O
,	545 1 O
but	547 3 O
great	551 5 O
individual	557 10 O
variation	568 9 O
occurred	578 8 O
,	586 1 O
with	588 4 O
older	593 5 O
patients	599 8 O
requiring	608 9 O
less	618 4 O
drug	623 4 O
.	627 1 O

The	629 3 O
investigation	633 13 O
was	647 3 O
discontinued	651 12 O
after	664 5 O
18	670 2 O
patients	673 8 O
because	682 7 O
of	690 2 O
the	693 3 O
frequency	697 9 O
and	707 3 O
intensity	711 9 O
of	721 2 O
side	724 4 O
-	728 1 O
effects	729 7 O
,	736 1 O
particularly	738 12 O
pain	751 4 B-Disease
and	756 3 O
myoclonia	760 9 B-Disease
,	769 1 O
which	771 5 O
caused	777 6 O
the	784 3 O
technique	788 9 O
to	798 2 O
be	801 2 O
abandoned	804 9 O
in	814 2 O
two	817 3 O
cases	821 5 O
.	826 1 O

It	828 2 O
is	831 2 O
considered	834 10 O
unlikely	845 8 O
that	854 4 O
etomidate	859 9 B-Chemical
will	869 4 O
prove	874 5 O
to	880 2 O
be	883 2 O
the	886 3 O
hypnotic	890 8 O
of	899 2 O
choice	902 6 O
for	909 3 O
a	913 1 O
totally	915 7 O
intravenous	923 11 O
anesthetic	935 10 O
technique	946 9 O
in	956 2 O
adults	959 6 O
because	966 7 O
of	974 2 O
the	977 3 O
high	981 4 O
incidence	986 9 O
of	996 2 O
myoclonia	999 9 B-Disease
after	1009 5 O
prolonged	1015 9 O
administration	1025 14 O
.	1039 1 O

In	1041 2 O
several	1044 7 O
patients	1052 8 O
uncontrollable	1061 14 O
muscle	1076 6 O
movements	1083 9 O
persisted	1093 9 O
for	1103 3 O
many	1107 4 O
minutes	1112 7 O
after	1120 5 O
complete	1126 8 O
recovery	1135 8 O
of	1144 2 O
consciousness	1147 13 O
.	1160 1 O

A	0 1 O
method	2 6 O
for	9 3 O
the	13 3 O
measurement	17 11 O
of	29 2 O
tremor	32 6 B-Disease
,	38 1 O
and	40 3 O
a	44 1 O
comparison	46 10 O
of	57 2 O
the	60 3 O
effects	64 7 O
of	72 2 O
tocolytic	75 9 O
beta	85 4 O
-	89 1 O
mimetics	90 8 O
.	98 1 O

A	100 1 O
method	102 6 O
permitting	109 10 O
measurement	120 11 O
of	132 2 O
finger	135 6 O
tremor	142 6 B-Disease
as	149 2 O
a	152 1 O
displacement	154 12 O
-	166 1 O
time	167 4 O
curve	172 5 O
is	178 2 O
described	181 9 O
,	190 1 O
using	192 5 O
a	198 1 O
test	200 4 O
system	205 6 O
with	212 4 O
simple	217 6 O
amplitude	224 9 O
calibration	234 11 O
.	245 1 O

The	247 3 O
coordinates	251 11 O
of	263 2 O
the	266 3 O
inversion	270 9 O
points	280 6 O
of	287 2 O
the	290 3 O
displacement	294 12 O
-	306 1 O
time	307 4 O
curves	312 6 O
were	319 4 O
transferred	324 11 O
through	336 7 O
graphical	344 9 O
input	354 5 O
equipment	360 9 O
to	370 2 O
punched	373 7 O
tape	381 4 O
.	385 1 O

By	387 2 O
means	390 5 O
of	396 2 O
a	399 1 O
computer	401 8 O
program	410 7 O
,	417 1 O
periods	419 7 O
and	427 3 O
amplitudes	431 10 O
of	442 2 O
tremor	445 6 B-Disease
oscillations	452 12 O
were	465 4 O
calculated	470 10 O
and	481 3 O
classified	485 10 O
.	495 1 O

The	497 3 O
event	501 5 O
frequency	507 9 O
for	517 3 O
each	521 4 O
class	526 5 O
of	532 2 O
periods	535 7 O
and	543 3 O
amplitudes	547 10 O
was	558 3 O
determined	562 10 O
.	572 1 O

The	574 3 O
actions	578 7 O
of	586 2 O
fenoterol	589 9 B-Chemical
-	598 1 I-Chemical
hydrobromide	599 12 I-Chemical
,	611 1 O
ritodrin	613 8 B-Chemical
-	621 1 I-Chemical
HCl	622 3 I-Chemical
and	626 3 O
placebo	630 7 O
given	638 5 O
to	644 2 O
10	647 2 O
healthy	650 7 O
subjects	658 8 O
by	667 2 O
intravenous	670 11 O
infusion	682 8 O
in	691 2 O
a	694 1 O
double	696 6 O
-	702 1 O
blind	703 5 O
crossover	709 9 O
study	719 5 O
were	725 4 O
tested	730 6 O
by	737 2 O
this	740 4 O
method	745 6 O
.	751 1 O

At	753 2 O
therapeutic	756 11 O
doses	768 5 O
both	774 4 O
substances	779 10 O
raised	790 6 O
the	797 3 O
mean	801 4 O
tremor	806 6 B-Disease
amplitude	813 9 O
to	823 2 O
about	826 5 O
three	832 5 O
times	838 5 O
the	844 3 O
control	848 7 O
level	856 5 O
.	861 1 O

At	863 2 O
the	866 3 O
same	870 4 O
time	875 4 O
,	879 1 O
the	881 3 O
mean	885 4 O
period	890 6 O
within	897 6 O
each	904 4 O
class	909 5 O
of	915 2 O
amplitudes	918 10 O
shortened	929 9 O
by	939 2 O
10	942 2 O
-	944 1 O
-	945 1 O
20	946 2 O
ms	949 2 O
,	951 1 O
whereas	953 7 O
the	961 3 O
mean	965 4 O
periods	970 7 O
calculated	978 10 O
from	989 4 O
all	994 3 O
oscillations	998 12 O
together	1011 8 O
did	1020 3 O
not	1024 3 O
change	1028 6 O
significantly	1035 13 O
.	1048 1 O

After	1050 5 O
the	1056 3 O
end	1060 3 O
of	1064 2 O
fenoterol	1067 9 B-Chemical
-	1076 1 I-Chemical
hydrobromide	1077 12 I-Chemical
infusion	1090 8 O
,	1098 1 O
tremor	1100 6 B-Disease
amplitudes	1107 10 O
decreased	1118 9 O
significantly	1128 13 O
faster	1142 6 O
than	1149 4 O
those	1154 5 O
following	1160 9 O
ritodrin	1170 8 B-Chemical
-	1178 1 I-Chemical
HCl	1179 3 I-Chemical
infusion	1183 8 O
.	1191 1 O

Bilateral	0 9 O
retinal	10 7 B-Disease
artery	18 6 I-Disease
and	25 3 I-Disease
choriocapillaris	29 16 I-Disease
occlusion	46 9 I-Disease
following	56 9 O
the	66 3 O
injection	70 9 O
of	80 2 O
long	83 4 O
-	87 1 O
acting	88 6 O
corticosteroid	95 14 B-Chemical
suspensions	110 11 O
in	122 2 O
combination	125 11 O
with	137 4 O
other	142 5 O
drugs	148 5 O
:	153 1 O
I	155 1 O
.	156 1 O

Clinical	158 8 O
studies	167 7 O
.	174 1 O

Two	176 3 O
well	180 4 O
-	184 1 O
documented	185 10 O
cases	196 5 O
of	202 2 O
bilateral	205 9 O
retinal	215 7 B-Disease
artery	223 6 I-Disease
and	230 3 I-Disease
choriocapillaris	234 16 I-Disease
occlusions	251 10 I-Disease
with	262 4 O
blindness	267 9 B-Disease
following	277 9 O
head	287 4 O
and	292 3 O
neck	296 4 O
soft	301 4 O
-	305 1 O
tissue	306 6 O
injection	313 9 O
with	323 4 O
methylprednisolone	328 18 B-Chemical
acetate	347 7 I-Chemical
in	355 2 O
combination	358 11 O
with	370 4 O
lidocaine	375 9 B-Chemical
,	384 1 O
epinephrine	386 11 B-Chemical
,	397 1 O
or	399 2 O
penicillin	402 10 B-Chemical
are	413 3 O
reported	417 8 O
.	425 1 O

One	427 3 O
case	431 4 O
had	436 3 O
only	440 4 O
a	445 1 O
unilateral	447 10 O
injection	458 9 O
.	467 1 O

The	469 3 O
acute	473 5 O
observations	479 12 O
included	492 8 O
hazy	501 4 O
sensorium	506 9 O
,	515 1 O
superior	517 8 O
gaze	526 4 O
palsy	531 5 B-Disease
,	536 1 O
pupillary	538 9 B-Disease
abnormalities	548 13 I-Disease
,	561 1 O
and	563 3 O
conjunctival	567 12 O
hemorrhages	580 11 B-Disease
with	592 4 O
edema	597 5 B-Disease
.	602 1 O

Follow	604 6 O
-	610 1 O
up	611 2 O
changes	614 7 O
showed	622 6 O
marked	629 6 O
visual	636 6 B-Disease
loss	643 4 I-Disease
,	647 1 O
constricted	649 11 O
visual	661 6 O
fields	668 6 O
,	674 1 O
optic	676 5 O
nerve	682 5 O
pallor	688 6 O
,	694 1 O
vascular	696 8 O
attenuation	705 11 O
,	716 1 O
and	718 3 O
chorioretinal	722 13 B-Disease
atrophy	736 7 I-Disease
.	743 1 O

The	745 3 O
literature	749 10 O
is	760 2 O
reviewed	763 8 O
,	771 1 O
and	773 3 O
possible	777 8 O
causes	786 6 O
are	793 3 O
discussed	797 9 O
.	806 1 O

Cephalothin	0 11 B-Chemical
-	11 1 O
induced	12 7 O
immune	20 6 O
hemolytic	27 9 B-Disease
anemia	37 6 I-Disease
.	43 1 O

A	45 1 O
patient	47 7 O
with	55 4 O
renal	60 5 B-Disease
disease	66 7 I-Disease
developed	74 9 O
Coombs	84 6 O
-	90 1 O
positive	91 8 O
hemolytic	100 9 B-Disease
anemia	110 6 I-Disease
while	117 5 O
receiving	123 9 O
cephalothin	133 11 B-Chemical
therapy	145 7 O
.	152 1 O

An	154 2 O
anti	157 4 O
-	161 1 O
cephalothin	162 11 B-Chemical
IgG	174 3 O
antibody	178 8 O
was	187 3 O
detected	191 8 O
in	200 2 O
the	203 3 O
patient	207 7 O
'	214 1 O
s	215 1 O
serum	217 5 O
and	223 3 O
in	227 2 O
the	230 3 O
eluates	234 7 O
from	242 4 O
her	247 3 O
erythrocytes	251 12 O
.	263 1 O

In	265 2 O
addition	268 8 O
,	276 1 O
nonimmunologic	278 14 O
binding	293 7 O
of	301 2 O
normal	304 6 O
and	311 3 O
patient	315 7 O
'	322 1 O
s	323 1 O
serum	325 5 O
proteins	331 8 O
to	340 2 O
her	343 3 O
own	347 3 O
and	351 3 O
cephalothin	355 11 B-Chemical
-	366 1 O
coated	367 6 O
normal	374 6 O
red	381 3 O
cells	385 5 O
was	391 3 O
demonstrated	395 12 O
.	407 1 O

Skin	409 4 O
tests	414 5 O
and	420 3 O
in	424 2 O
vitro	427 5 O
lymphocyte	433 10 O
stimulation	444 11 O
revealed	456 8 O
that	465 4 O
the	470 3 O
patient	474 7 O
was	482 3 O
sensitized	486 10 O
to	497 2 O
cephalothin	500 11 B-Chemical
and	512 3 O
also	516 4 O
to	521 2 O
ampicillin	524 10 B-Chemical
.	534 1 O

Careful	536 7 O
investigation	544 13 O
of	558 2 O
drug	561 4 O
-	565 1 O
induced	566 7 O
hemolytic	574 9 B-Disease
anemias	584 7 I-Disease
reveals	592 7 O
the	600 3 O
complexity	604 10 O
of	615 2 O
the	618 3 O
immune	622 6 O
mechanisms	629 10 O
involved	640 8 O
.	648 1 O

Kaliuretic	0 10 O
effect	11 6 O
of	18 2 O
L	21 1 B-Chemical
-	22 1 I-Chemical
dopa	23 4 I-Chemical
treatment	28 9 O
in	38 2 O
parkinsonian	41 12 B-Disease
patients	54 8 O
.	62 1 O

Hypokalemia	64 11 B-Disease
,	75 1 O
sometimes	77 9 O
severe	87 6 O
,	93 1 O
was	95 3 O
observed	99 8 O
in	108 2 O
some	111 4 O
L	116 1 B-Chemical
-	117 1 I-Chemical
dopa	118 4 I-Chemical
-	122 1 O
treated	123 7 O
parkinsonian	131 12 B-Disease
patients	144 8 O
.	152 1 O

The	154 3 O
influence	158 9 O
of	168 2 O
L	171 1 B-Chemical
-	172 1 I-Chemical
dopa	173 4 I-Chemical
on	178 2 O
the	181 3 O
renal	185 5 O
excretion	191 9 O
of	201 2 O
potassium	204 9 B-Chemical
was	214 3 O
studied	218 7 O
in	226 2 O
3	229 1 O
patients	231 8 O
with	240 4 O
hypokalemia	245 11 B-Disease
and	257 3 O
in	261 2 O
5	264 1 O
normokalemic	266 12 O
patients	279 8 O
by	288 2 O
determination	291 13 O
of	305 2 O
renal	308 5 O
plasma	314 6 O
flow	321 4 O
,	325 1 O
glomerular	327 10 O
filtration	338 10 O
rate	349 4 O
,	353 1 O
plasma	355 6 O
concentration	362 13 O
of	376 2 O
potassium	379 9 B-Chemical
and	389 3 O
sodium	393 6 B-Chemical
as	400 2 O
well	403 4 O
as	408 2 O
urinary	411 7 O
excretion	419 9 O
of	429 2 O
potassium	432 9 B-Chemical
,	441 1 O
sodium	443 6 B-Chemical
and	450 3 O
aldosterone	454 11 B-Chemical
.	465 1 O

L	467 1 B-Chemical
-	468 1 I-Chemical
Dopa	469 4 I-Chemical
intake	474 6 O
was	481 3 O
found	485 5 O
to	491 2 O
cause	494 5 O
an	500 2 O
increased	503 9 O
excretion	513 9 O
of	523 2 O
potassium	526 9 B-Chemical
,	535 1 O
and	537 3 O
sometimes	541 9 O
also	551 4 O
of	556 2 O
sodium	559 6 B-Chemical
,	565 1 O
in	567 2 O
the	570 3 O
hypokalemic	574 11 O
but	586 3 O
not	590 3 O
in	594 2 O
the	597 3 O
normokalemic	601 12 O
patients	614 8 O
.	622 1 O

This	624 4 O
effect	629 6 O
on	636 2 O
the	639 3 O
renal	643 5 O
function	649 8 O
could	658 5 O
be	664 2 O
prohibited	667 10 O
by	678 2 O
the	681 3 O
administration	685 14 O
of	700 2 O
a	703 1 O
peripheral	705 10 O
dopa	716 4 O
decarbodylase	721 13 O
inhibitor	735 9 O
.	744 1 O

It	746 2 O
is	749 2 O
not	752 3 O
known	756 5 O
why	762 3 O
this	766 4 O
effect	771 6 O
occurred	778 8 O
in	787 2 O
some	790 4 O
individuals	795 11 O
but	807 3 O
not	811 3 O
in	815 2 O
others	818 6 O
,	824 1 O
but	826 3 O
our	830 3 O
results	834 7 O
indicate	842 8 O
a	851 1 O
correlation	853 11 O
between	865 7 O
aldosterone	873 11 B-Chemical
production	885 10 O
and	896 3 O
this	900 4 O
renal	905 5 O
effect	911 6 O
of	918 2 O
L	921 1 B-Chemical
-	922 1 I-Chemical
dopa	923 4 I-Chemical
.	927 1 O

Phenytoin	0 9 B-Chemical
encephalopathy	10 14 B-Disease
as	25 2 O
probable	28 8 O
idiosyncratic	37 13 O
reaction	51 8 O
:	59 1 O
case	61 4 O
report	66 6 O
.	72 1 O

A	74 1 O
case	76 4 O
of	81 2 O
phenytoin	84 9 B-Chemical
(	94 1 O
DPH	95 3 B-Chemical
)	98 1 O
encephalopathy	100 14 B-Disease
with	115 4 O
increasing	120 10 O
seizures	131 8 B-Disease
and	140 3 O
EEG	144 3 O
and	148 3 O
mental	152 6 O
changes	159 7 O
is	167 2 O
described	170 9 O
.	179 1 O

Despite	181 7 O
adequate	189 8 O
oral	198 4 O
dosage	203 6 O
of	210 2 O
DPH	213 3 B-Chemical
(	217 1 O
5	218 1 O
mg	220 2 O
/	222 1 O
kg	223 2 O
/	225 1 O
daily	226 5 O
)	231 1 O
the	233 3 O
plasma	237 6 O
level	244 5 O
was	250 3 O
very	254 4 O
low	259 3 O
(	263 1 O
2	264 1 O
.	265 1 O
8	266 1 O
microgramg	268 10 O
/	278 1 O
ml	279 2 O
)	281 1 O
.	282 1 O

The	284 3 O
encephalopathy	288 14 B-Disease
was	303 3 O
probably	307 8 O
an	316 2 O
idiosyncratic	319 13 O
and	333 3 O
not	337 3 O
toxic	341 5 O
or	347 2 O
allergic	350 8 O
reaction	359 8 O
.	367 1 O

In	369 2 O
fact	372 4 O
the	377 3 O
concentration	381 13 O
of	395 2 O
free	398 4 O
DPH	403 3 B-Chemical
was	407 3 O
normal	411 6 O
,	417 1 O
the	419 3 O
patient	423 7 O
presented	431 9 O
a	441 1 O
retarded	443 8 O
morbilliform	452 12 O
rash	465 4 B-Disease
during	470 6 O
DPH	477 3 B-Chemical
treatment	481 9 O
,	490 1 O
the	492 3 O
protidogram	496 11 O
was	508 3 O
normal	512 6 O
,	518 1 O
and	520 3 O
an	524 2 O
intradermic	527 11 O
DPH	539 3 B-Chemical
injection	543 9 O
had	553 3 O
no	557 2 O
local	560 5 O
effect	566 6 O
.	572 1 O

The	574 3 O
authors	578 7 O
conclude	586 8 O
that	595 4 O
in	600 2 O
a	603 1 O
patient	605 7 O
starting	613 8 O
DPH	622 3 B-Chemical
treatment	626 9 O
an	636 2 O
unexpected	639 10 O
increase	650 8 O
in	659 2 O
seizures	662 8 B-Disease
,	670 1 O
with	672 4 O
EEG	677 3 O
and	681 3 O
mental	685 6 O
changes	692 7 O
occurring	700 9 O
simultaneously	710 14 O
,	724 1 O
should	726 6 O
alert	733 5 O
the	739 3 O
physician	743 9 O
to	753 2 O
the	756 3 O
possible	760 8 O
need	769 4 O
for	774 3 O
eliminating	778 11 O
DPH	790 3 B-Chemical
from	794 4 O
the	799 3 O
therapeutic	803 11 O
regimen	815 7 O
,	822 1 O
even	824 4 O
if	829 2 O
plasma	832 6 O
concentrations	839 14 O
are	854 3 O
low	858 3 O
.	861 1 O

Effects	0 7 O
of	8 2 O
exercise	11 8 O
on	20 2 O
the	23 3 O
severity	27 8 O
of	36 2 O
isoproterenol	39 13 B-Chemical
-	52 1 O
induced	53 7 O
myocardial	61 10 B-Disease
infarction	72 10 I-Disease
.	82 1 O

The	84 3 O
effect	88 6 O
of	95 2 O
exercise	98 8 O
on	107 2 O
the	110 3 O
severity	114 8 O
of	123 2 O
isoproterenol	126 13 B-Chemical
-	139 1 O
induced	140 7 O
myocardial	148 10 B-Disease
infarction	159 10 I-Disease
was	170 3 O
studied	174 7 O
in	182 2 O
male	185 4 O
rats	190 4 O
.	194 1 O

Ninety	196 6 O
-	202 1 O
three	203 5 O
rats	209 4 O
were	214 4 O
randomly	219 8 O
divided	228 7 O
into	236 4 O
three	241 5 O
groups	247 6 O
.	253 1 O

The	255 3 O
exercise	259 8 O
-	267 1 O
isoproterenol	268 13 B-Chemical
(	282 1 O
E	283 1 O
-	284 1 O
1	285 1 O
)	286 1 O
and	288 3 O
exercise	292 8 O
control	301 7 O
(	309 1 O
EC	310 2 O
)	312 1 O
groups	314 6 O
exercised	321 9 O
daily	331 5 O
for	337 3 O
thirty	341 6 O
days	348 4 O
on	353 2 O
a	356 1 O
treadmill	358 9 O
at	368 2 O
1	371 1 O
mph	373 3 O
,	376 1 O
2	378 1 O
%	379 1 O
grade	381 5 O
while	387 5 O
animals	393 7 O
of	401 2 O
the	404 3 O
sedentary	408 9 O
-	417 1 O
isoproterenol	418 13 B-Chemical
(	432 1 O
S	433 1 O
-	434 1 O
I	435 1 O
)	436 1 O
group	438 5 O
remained	444 8 O
sedentary	453 9 O
.	462 1 O

Eight	464 5 O
animals	470 7 O
were	478 4 O
assigned	483 8 O
to	492 2 O
the	495 3 O
sedentary	499 9 O
control	509 7 O
(	517 1 O
SC	518 2 O
)	520 1 O
group	522 5 O
which	528 5 O
remained	534 8 O
sedentary	543 9 O
throughout	553 10 O
the	564 3 O
experimental	568 12 O
period	581 6 O
.	587 1 O

Forty	589 5 O
-	594 1 O
eight	595 5 O
hours	601 5 O
after	607 5 O
the	613 3 O
final	617 5 O
exercise	623 8 O
period	632 6 O
,	638 1 O
S	640 1 O
-	641 1 O
I	642 1 O
and	644 3 O
E	648 1 O
-	649 1 O
I	650 1 O
animals	652 7 O
received	660 8 O
a	669 1 O
single	671 6 O
subcutaneous	678 12 O
injection	691 9 O
of	701 2 O
isoproterenol	704 13 B-Chemical
(	718 1 O
250	719 3 O
mg	723 2 O
/	725 1 O
kg	726 2 O
body	729 4 O
weight	734 6 O
)	740 1 O
.	741 1 O

Animals	743 7 O
of	751 2 O
the	754 3 O
S	758 1 O
-	759 1 O
I	760 1 O
group	762 5 O
exhibited	768 9 O
significantly	778 13 O
(	792 1 O
Pp	793 2 O
less	796 4 O
than	801 4 O
0	806 1 O
.	807 1 O
05	808 2 O
)	810 1 O
greater	812 7 O
mortality	820 9 O
from	830 4 O
the	835 3 O
effects	839 7 O
of	847 2 O
isoproterenol	850 13 B-Chemical
than	864 4 O
animals	869 7 O
of	877 2 O
the	880 3 O
E	884 1 O
-	885 1 O
I	886 1 O
group	888 5 O
.	893 1 O

Serum	895 5 O
CPK	901 3 O
activity	905 8 O
for	914 3 O
E	918 1 O
-	919 1 O
I	920 1 O
animals	922 7 O
was	930 3 O
significantly	934 13 O
(	948 1 O
p	949 1 O
less	951 4 O
than	956 4 O
0	961 1 O
.	962 1 O
05	963 2 O
)	965 1 O
greater	967 7 O
than	975 4 O
for	980 3 O
animals	984 7 O
in	992 2 O
the	995 3 O
S	999 1 O
-	1000 1 O
I	1001 1 O
and	1003 3 O
EC	1007 2 O
groups	1010 6 O
twenty	1017 6 O
hours	1024 5 O
following	1030 9 O
isoproterenol	1040 13 B-Chemical
injection	1054 9 O
.	1063 1 O

No	1065 2 O
statistically	1068 13 O
significant	1082 11 O
differences	1094 11 O
were	1106 4 O
observed	1111 8 O
between	1120 7 O
the	1128 3 O
two	1132 3 O
isoproterenol	1136 13 B-Chemical
treated	1150 7 O
groups	1158 6 O
for	1165 3 O
severity	1169 8 O
of	1178 2 O
the	1181 3 O
induced	1185 7 O
lesions	1193 7 O
,	1200 1 O
changes	1202 7 O
in	1210 2 O
heart	1213 5 O
weight	1219 6 O
,	1225 1 O
or	1227 2 O
heart	1230 5 O
weight	1236 6 O
to	1243 2 O
body	1246 4 O
weight	1251 6 O
ratios	1258 6 O
.	1264 1 O

The	1266 3 O
results	1270 7 O
indicated	1278 9 O
that	1288 4 O
exercise	1293 8 O
reduced	1302 7 O
the	1310 3 O
mortality	1314 9 O
associated	1324 10 O
with	1335 4 O
the	1340 3 O
effects	1344 7 O
of	1352 2 O
large	1355 5 O
dosages	1361 7 O
of	1369 2 O
isoproterenol	1372 13 B-Chemical
but	1386 3 O
had	1390 3 O
little	1394 6 O
on	1401 2 O
the	1404 3 O
severity	1408 8 O
of	1417 2 O
the	1420 3 O
infarction	1424 10 B-Disease
.	1434 1 O

Effect	0 6 O
of	7 2 O
D	10 1 B-Chemical
-	11 1 I-Chemical
Glucarates	12 10 I-Chemical
on	23 2 O
basic	26 5 O
antibiotic	32 10 O
-	42 1 O
induced	43 7 O
renal	51 5 B-Disease
damage	57 6 I-Disease
in	64 2 O
rats	67 4 O
.	71 1 O

Dehydrated	73 10 B-Disease
rats	84 4 O
regularly	89 9 O
develop	99 7 O
acute	107 5 B-Disease
renal	113 5 I-Disease
failure	119 7 I-Disease
following	127 9 O
single	137 6 O
injection	144 9 O
of	154 2 O
aminoglycoside	157 14 B-Chemical
antibiotics	172 11 O
combined	184 8 O
with	193 4 O
dextran	198 7 O
or	206 2 O
of	209 2 O
antibiotics	212 11 O
only	224 4 O
.	228 1 O

Oral	230 4 O
administration	235 14 O
of	250 2 O
2	253 1 B-Chemical
,	254 1 I-Chemical
5	255 1 I-Chemical
-	256 1 I-Chemical
di	257 2 I-Chemical
-	259 1 I-Chemical
O	260 1 I-Chemical
-	261 1 I-Chemical
acetyl	262 6 I-Chemical
-	268 1 I-Chemical
D	269 1 I-Chemical
-	270 1 I-Chemical
glucaro	271 7 I-Chemical
-	278 1 I-Chemical
1	279 1 I-Chemical
,	280 1 I-Chemical
4	281 1 I-Chemical
-	282 1 I-Chemical
6	283 1 I-Chemical
,	284 1 I-Chemical
3	285 1 I-Chemical
-	286 1 I-Chemical
dilactone	287 9 I-Chemical
protected	297 9 O
rats	307 4 O
against	312 7 O
renal	320 5 B-Disease
failure	326 7 I-Disease
induced	334 7 O
by	342 2 O
kanamycin	345 9 B-Chemical
-	354 1 O
dextran	355 7 O
.	362 1 O

The	364 3 O
protective	368 10 O
effect	379 6 O
was	386 3 O
prevalent	390 9 O
among	400 5 O
D	406 1 B-Chemical
-	407 1 I-Chemical
glucarates	408 10 I-Chemical
,	418 1 O
and	420 3 O
also	424 4 O
to	429 2 O
other	432 5 O
saccharic	438 9 B-Chemical
acid	448 4 I-Chemical
,	452 1 O
hexauronic	454 10 B-Chemical
acids	465 5 I-Chemical
and	471 3 O
hexaaldonic	475 11 B-Chemical
acids	487 5 I-Chemical
,	492 1 O
although	494 8 O
to	503 2 O
a	506 1 O
lesser	508 6 O
degree	515 6 O
,	521 1 O
but	523 3 O
not	527 3 O
to	531 2 O
a	534 1 O
hexaaldose	536 10 O
,	546 1 O
sugar	548 5 B-Chemical
alcohols	554 8 I-Chemical
,	562 1 O
substances	564 10 O
inthe	575 5 O
TCA	581 3 B-Chemical
cycle	585 5 O
and	591 3 O
other	595 5 O
acidic	601 6 O
compounds	608 9 O
.	617 1 O

D	619 1 B-Chemical
-	620 1 I-Chemical
Glucarates	621 10 I-Chemical
were	632 4 O
effective	637 9 O
against	647 7 O
renal	655 5 B-Disease
damage	661 6 I-Disease
induced	668 7 O
by	676 2 O
peptide	679 7 O
antibiotics	687 11 O
as	699 2 O
well	702 4 O
as	707 2 O
various	710 7 O
aminoglycoside	718 14 B-Chemical
antibitocis	733 11 O
.	744 1 O

Dose	746 4 O
-	750 1 O
responses	751 9 O
were	761 4 O
observed	766 8 O
in	775 2 O
the	778 3 O
protective	782 10 O
effect	793 6 O
of	800 2 O
D	803 1 B-Chemical
-	804 1 I-Chemical
Glucarates	805 10 I-Chemical
.	815 1 O

With	817 4 O
a	822 1 O
D	824 1 B-Chemical
-	825 1 I-Chemical
glucarate	826 9 I-Chemical
of	836 2 O
a	839 1 O
fixed	841 5 O
size	847 4 O
of	852 2 O
dose	855 4 O
,	859 1 O
approximately	861 13 O
the	875 3 O
same	879 4 O
degree	884 6 O
of	891 2 O
protection	894 10 O
was	905 3 O
obtained	909 8 O
against	918 7 O
renal	926 5 B-Disease
damages	932 7 I-Disease
induced	940 7 O
by	948 2 O
different	951 9 O
basic	961 5 O
antibiotics	967 11 O
despite	979 7 O
large	987 5 O
disparities	993 11 O
in	1005 2 O
administration	1008 14 O
doses	1023 5 O
of	1029 2 O
different	1032 9 O
antibiotics	1042 11 O
.	1053 1 O

D	1055 1 B-Chemical
-	1056 1 I-Chemical
Glucarates	1057 10 I-Chemical
had	1068 3 O
the	1072 3 O
ability	1076 7 O
to	1084 2 O
prevent	1087 7 O
renal	1095 5 B-Disease
damage	1101 6 I-Disease
but	1108 3 O
not	1112 3 O
to	1116 2 O
cure	1119 4 O
it	1124 2 O
.	1126 1 O

Rats	1128 4 O
excreted	1133 8 O
acidic	1142 6 O
urine	1149 5 O
when	1155 4 O
they	1160 4 O
were	1165 4 O
spared	1170 6 O
from	1177 4 O
renal	1182 5 B-Disease
lesions	1188 7 I-Disease
by	1196 2 O
monosaccharides	1199 15 B-Chemical
.	1214 1 O

The	1216 3 O
reduction	1220 9 O
effect	1230 6 O
of	1237 2 O
D	1240 1 B-Chemical
-	1241 1 I-Chemical
glucarates	1242 10 I-Chemical
against	1253 7 O
nephrotoxicity	1261 14 B-Disease
of	1276 2 O
basic	1279 5 O
antibiotics	1285 11 O
was	1297 3 O
discussed	1301 9 O
.	1310 1 O

Paraplegia	0 10 B-Disease
following	11 9 O
intrathecal	21 11 O
methotrexate	33 12 B-Chemical
:	45 1 O
report	47 6 O
of	54 2 O
a	57 1 O
case	59 4 O
and	64 3 O
review	68 6 O
of	75 2 O
the	78 3 O
literature	82 10 O
.	92 1 O

A	94 1 O
patient	96 7 O
who	104 3 O
developed	108 9 O
paraplegia	118 10 B-Disease
following	129 9 O
the	139 3 O
intrathecal	143 11 O
instillation	155 12 O
of	168 2 O
methotrexate	171 12 B-Chemical
is	184 2 O
discribed	187 9 O
.	196 1 O

The	198 3 O
ten	202 3 O
previously	206 10 O
reported	217 8 O
cases	226 5 O
of	232 2 O
this	235 4 O
unusual	240 7 O
complication	248 12 O
are	261 3 O
reviewed	265 8 O
.	273 1 O

The	275 3 O
following	279 9 O
factors	289 7 O
appear	297 6 O
to	304 2 O
predispose	307 10 O
to	318 2 O
the	321 3 O
development	325 11 O
of	337 2 O
this	340 4 O
complication	345 12 O
:	357 1 O
abnormal	359 8 O
cerebrospinal	368 13 O
dynamics	382 8 O
related	391 7 O
to	399 2 O
the	402 3 O
presence	406 8 O
of	415 2 O
central	418 7 B-Disease
nervous	426 7 I-Disease
system	434 6 I-Disease
leukemia	441 8 I-Disease
,	449 1 O
and	451 3 O
epidural	455 8 O
cerebrospinal	464 13 O
leakage	478 7 O
;	485 1 O
elevated	487 8 O
cerebrospinal	496 13 O
fluid	510 5 O
methothexate	516 12 B-Chemical
concentration	529 13 O
related	543 7 O
to	551 2 O
abnormal	554 8 O
cerebrospinal	563 13 O
fluid	577 5 O
dynamics	583 8 O
and	592 3 O
to	596 2 O
inappropriately	599 15 O
high	615 4 O
methotrexate	620 12 B-Chemical
doses	633 5 O
based	639 5 O
on	645 2 O
body	648 4 O
surface	653 7 O
area	661 4 O
calculations	666 12 O
in	679 2 O
older	682 5 O
children	688 8 O
and	697 3 O
adults	701 6 O
;	707 1 O
the	709 3 O
presence	713 8 O
of	722 2 O
neurotoxic	725 10 B-Disease
preservatives	736 13 O
in	750 2 O
commercially	753 12 O
available	766 9 O
methotrexate	776 12 B-Chemical
preparations	789 12 O
and	802 3 O
diluents	806 8 O
;	814 1 O
and	816 3 O
the	820 3 O
use	824 3 O
of	828 2 O
methotrexate	831 12 B-Chemical
diluents	844 8 O
of	853 2 O
unphysiologic	856 13 O
pH	870 2 O
,	872 1 O
ionic	874 5 O
content	880 7 O
and	888 3 O
osmolarity	892 10 O
.	902 1 O

The	904 3 O
role	908 4 O
of	913 2 O
methotrexate	916 12 B-Chemical
contaminants	929 12 O
,	941 1 O
local	943 5 O
folate	949 6 B-Disease
deficiency	956 10 I-Disease
,	966 1 O
and	968 3 O
cranial	972 7 O
irradiation	980 11 O
in	992 2 O
the	995 3 O
pathogenesis	999 12 O
of	1012 2 O
intrathecal	1015 11 O
methotrexate	1027 12 B-Chemical
toxicity	1040 8 B-Disease
is	1049 2 O
unclear	1052 7 O
.	1059 1 O

The	1061 3 O
incidence	1065 9 O
of	1075 2 O
neurotoxicity	1078 13 B-Disease
may	1092 3 O
be	1096 2 O
reduced	1099 7 O
by	1107 2 O
employing	1110 9 O
lower	1120 5 O
doses	1126 5 O
of	1132 2 O
methotrexate	1135 12 B-Chemical
in	1148 2 O
the	1151 3 O
presence	1155 8 O
of	1164 2 O
central	1167 7 B-Disease
nervous	1175 7 I-Disease
system	1183 6 I-Disease
leukemia	1190 8 I-Disease
,	1198 1 O
in	1200 2 O
older	1203 5 O
children	1209 8 O
and	1218 3 O
adults	1222 6 O
,	1228 1 O
and	1230 3 O
in	1234 2 O
the	1237 3 O
presence	1241 8 O
of	1250 2 O
epidural	1253 8 O
leakage	1262 7 O
.	1269 1 O

Only	1271 4 O
preservative	1276 12 O
-	1288 1 O
free	1289 4 O
methotrexate	1294 12 B-Chemical
in	1307 2 O
Elliott	1310 7 O
'	1317 1 O
s	1318 1 O
B	1320 1 O
Solution	1322 8 O
at	1331 2 O
a	1334 1 O
concentration	1336 13 O
of	1350 2 O
not	1353 3 O
more	1357 4 O
than	1362 4 O
1	1367 1 O
mg	1369 2 O
/	1371 1 O
ml	1372 2 O
should	1375 6 O
be	1382 2 O
used	1385 4 O
for	1390 3 O
intrathecal	1394 11 O
administration	1406 14 O
.	1420 1 O

Periodic	1422 8 O
monitoring	1431 10 O
of	1442 2 O
cerebruspinal	1445 13 O
fluid	1459 5 O
methotrexate	1465 12 B-Chemical
levels	1478 6 O
may	1485 3 O
be	1489 2 O
predictive	1492 10 O
of	1503 2 O
the	1506 3 O
development	1510 11 O
of	1522 2 O
serious	1525 7 O
neurotoxicity	1533 13 B-Disease
.	1546 1 O

Centrally	0 9 O
mediated	10 8 O
cardiovascular	19 14 O
effects	34 7 O
of	42 2 O
intracisternal	45 14 O
application	60 11 O
of	72 2 O
carbachol	75 9 B-Chemical
in	85 2 O
anesthetized	88 12 O
rats	101 4 O
.	105 1 O

The	107 3 O
pressor	111 7 O
response	119 8 O
to	128 2 O
the	131 3 O
intracisternal	135 14 O
(	150 1 O
i	151 1 O
.	152 1 O
c	153 1 O
.	154 1 O
)	155 1 O
injection	157 9 O
of	167 2 O
carbachol	170 9 B-Chemical
(	180 1 O
1	181 1 O
mug	183 3 O
)	186 1 O
in	188 2 O
anesthetized	191 12 O
rats	204 4 O
was	209 3 O
analyzed	213 8 O
.	221 1 O

This	223 4 O
response	228 8 O
was	237 3 O
significantly	241 13 O
reduced	255 7 O
by	263 2 O
the	266 3 O
intravenous	270 11 O
(	282 1 O
i	283 1 O
.	284 1 O
v	285 1 O
.	286 1 O
)	287 1 O
injection	289 9 O
of	299 2 O
guanethidine	302 12 B-Chemical
(	315 1 O
5	316 1 O
mg	318 2 O
)	320 1 O
,	321 1 O
hexamethonium	323 13 B-Chemical
(	337 1 O
10	338 2 O
mg	341 2 O
)	343 1 O
or	345 2 O
phentolamine	348 12 B-Chemical
(	361 1 O
5	362 1 O
mg	364 2 O
)	366 1 O
,	367 1 O
and	369 3 O
conversely	373 10 O
,	383 1 O
potentiated	385 11 O
by	397 2 O
i	400 1 O
.	401 1 O
v	402 1 O
.	403 1 O
desmethylimipramine	405 19 B-Chemical
(	425 1 O
0	426 1 O
.	427 1 O
3	428 1 O
mg	430 2 O
)	432 1 O
,	433 1 O
while	435 5 O
propranolol	441 11 B-Chemical
(	453 1 O
0	454 1 O
.	455 1 O
5	456 1 O
mg	458 2 O
)	460 1 O
i	462 1 O
.	463 1 O
v	464 1 O
.	465 1 O
selectively	467 11 O
inhibited	479 9 O
the	489 3 O
enlargement	493 11 B-Disease
of	505 2 I-Disease
pulse	508 5 I-Disease
pressure	514 8 I-Disease
and	523 3 O
the	527 3 O
tachycardia	531 11 B-Disease
following	543 9 O
i	553 1 O
.	554 1 O
c	555 1 O
.	556 1 O
carbachol	558 9 B-Chemical
(	568 1 O
1	569 1 O
mug	571 3 O
)	574 1 O
.	575 1 O

On	577 2 O
the	580 3 O
other	584 5 O
hand	590 4 O
,	594 1 O
the	596 3 O
pressor	600 7 O
response	608 8 O
to	617 2 O
i	620 1 O
.	621 1 O
c	622 1 O
.	623 1 O
carbachol	625 9 B-Chemical
(	635 1 O
1	636 1 O
mug	638 3 O
)	641 1 O
was	643 3 O
almost	647 6 O
completely	654 10 O
blocked	665 7 O
by	673 2 O
i	676 1 O
.	677 1 O
c	678 1 O
.	679 1 O
atropine	681 8 B-Chemical
(	690 1 O
3	691 1 O
mug	693 3 O
)	696 1 O
or	698 2 O
hexamethonium	701 13 B-Chemical
(	715 1 O
500	716 3 O
mug	720 3 O
)	723 1 O
,	724 1 O
and	726 3 O
significantly	730 13 O
reduced	744 7 O
by	752 2 O
i	755 1 O
.	756 1 O
c	757 1 O
.	758 1 O
chlorpromazine	760 14 B-Chemical
(	775 1 O
50	776 2 O
mug	779 3 O
)	782 1 O
but	784 3 O
significantly	788 13 O
potentiated	802 11 O
by	814 2 O
i	817 1 O
.	818 1 O
c	819 1 O
.	820 1 O
desmethylimipramine	822 19 B-Chemical
(	842 1 O
30	843 2 O
mug	846 3 O
)	849 1 O
.	850 1 O

The	852 3 O
pressor	856 7 O
response	864 8 O
to	873 2 O
i	876 1 O
.	877 1 O
c	878 1 O
.	879 1 O
carbachol	881 9 B-Chemical
(	891 1 O
1	892 1 O
mug	894 3 O
)	897 1 O
remained	899 8 O
unchanged	908 9 O
after	918 5 O
sectioning	924 10 O
of	935 2 O
the	938 3 O
bilateral	942 9 O
cervical	952 8 O
vagal	961 5 O
nerves	967 6 O
but	974 3 O
disappeared	978 11 O
after	990 5 O
sectioning	996 10 O
of	1007 2 O
the	1010 3 O
spinal	1014 6 O
cord	1021 4 O
(	1026 1 O
C7	1027 2 O
-	1029 1 O
C8	1030 2 O
)	1032 1 O
.	1033 1 O

From	1035 4 O
the	1040 3 O
above	1044 5 O
result	1050 6 O
it	1057 2 O
is	1060 2 O
suggested	1063 9 O
that	1073 4 O
the	1078 3 O
pressor	1082 7 O
response	1090 8 O
to	1099 2 O
i	1102 1 O
.	1103 1 O
c	1104 1 O
.	1105 1 O
carbachol	1107 9 B-Chemical
ortral	1117 6 O
and	1124 3 O
peripheral	1128 10 O
adrenergic	1139 10 O
mechanisms	1150 10 O
,	1160 1 O
and	1162 3 O
that	1166 4 O
the	1171 3 O
sympathetic	1175 11 O
trunk	1187 5 O
is	1193 2 O
the	1196 3 O
main	1200 4 O
pathway	1205 7 O
.	1212 1 O

Hyperglycemic	0 13 B-Disease
effect	14 6 O
of	21 2 O
amino	24 5 B-Chemical
compounds	30 9 O
structurally	40 12 O
related	53 7 O
to	61 2 O
caproate	64 8 B-Chemical
in	73 2 O
rats	76 4 O
.	80 1 O

The	82 3 O
chronic	86 7 O
feeding	94 7 O
of	102 2 O
small	105 5 O
amounts	111 7 O
(	119 1 O
0	120 1 O
.	121 1 O
3	122 1 O
-	123 1 O
3	124 1 O
%	125 1 O
of	127 2 O
diet	130 4 O
weight	135 6 O
)	141 1 O
of	143 2 O
certain	146 7 O
amino	154 5 B-Chemical
derivatives	160 11 O
of	172 2 O
caproate	175 8 B-Chemical
resulted	184 8 O
in	193 2 O
hyperglycemia	196 13 B-Disease
,	209 1 O
an	211 2 O
elevated	214 8 O
glucose	223 7 B-Chemical
tolerance	231 9 O
curve	241 5 O
and	247 3 O
,	250 1 O
occasionally	252 12 O
,	264 1 O
glucosuria	266 10 B-Disease
.	276 1 O

Effective	278 9 O
compounds	288 9 O
included	298 8 O
norleucine	307 10 B-Chemical
,	317 1 O
norvaline	319 9 B-Chemical
,	328 1 O
glutamate	330 9 B-Chemical
,	339 1 O
epsilon	341 7 B-Chemical
-	348 1 I-Chemical
aminocaproate	349 13 I-Chemical
,	362 1 O
methionine	364 10 B-Chemical
,	374 1 O
and	376 3 O
leucine	380 7 B-Chemical
.	387 1 O

Fatty	0 5 B-Disease
liver	6 5 I-Disease
induced	12 7 O
by	20 2 O
tetracycline	23 12 B-Chemical
in	36 2 O
the	39 3 O
rat	43 3 O
.	46 1 O

Dose	48 4 O
-	52 1 O
response	53 8 O
relationships	62 13 O
and	76 3 O
effect	80 6 O
of	87 2 O
sex	90 3 O
.	93 1 O

Dose	95 4 O
-	99 1 O
response	100 8 O
relationships	109 13 O
,	122 1 O
biochemical	124 11 O
mechanisms	136 10 O
,	146 1 O
and	148 3 O
sex	152 3 O
differences	156 11 O
in	168 2 O
the	171 3 O
experimental	175 12 O
fatty	188 5 B-Disease
liver	194 5 I-Disease
induced	200 7 O
by	208 2 O
tetracycline	211 12 B-Chemical
were	224 4 O
studied	229 7 O
in	237 2 O
the	240 3 O
intact	244 6 O
rat	251 3 O
and	255 3 O
with	259 4 O
the	264 3 O
isolated	268 8 O
perfused	277 8 O
rat	286 3 O
liver	290 5 O
in	296 2 O
vitro	299 5 O
.	304 1 O

In	306 2 O
the	309 3 O
intact	313 6 O
male	320 4 O
and	325 3 O
female	329 6 O
rat	336 3 O
,	339 1 O
no	341 2 O
direct	344 6 O
relationship	351 12 O
was	364 3 O
observed	368 8 O
between	377 7 O
dose	385 4 O
of	390 2 O
tetracycline	393 12 B-Chemical
and	406 3 O
hepatic	410 7 O
accumulation	418 12 O
of	431 2 O
triglyceride	434 12 B-Chemical
.	446 1 O

With	448 4 O
provision	453 9 O
of	463 2 O
adequate	466 8 O
oleic	475 5 B-Chemical
acid	481 4 I-Chemical
as	486 2 O
a	489 1 O
substrate	491 9 O
for	501 3 O
the	505 3 O
isolated	509 8 O
perfused	518 8 O
liver	527 5 O
,	532 1 O
a	534 1 O
direct	536 6 O
relationship	543 12 O
was	556 3 O
observed	560 8 O
between	569 7 O
dose	577 4 O
of	582 2 O
tetracycline	585 12 B-Chemical
and	598 3 O
both	602 4 O
accumulation	607 12 O
of	620 2 O
triglyceride	623 12 B-Chemical
in	636 2 O
the	639 3 O
liver	643 5 O
and	649 3 O
depression	653 10 B-Disease
of	664 2 O
output	667 6 O
of	674 2 O
triglyceride	677 12 B-Chemical
by	690 2 O
livers	693 6 O
from	700 4 O
male	705 4 O
and	710 3 O
female	714 6 O
rats	721 4 O
.	725 1 O

Marked	727 6 O
differences	734 11 O
were	746 4 O
observed	751 8 O
between	760 7 O
female	768 6 O
and	775 3 O
male	779 4 O
rats	784 4 O
with	789 4 O
regard	794 6 O
to	801 2 O
base	804 4 O
line	809 4 O
(	814 1 O
control	815 7 O
)	822 1 O
hepatic	824 7 O
concentration	832 13 O
of	846 2 O
triglyceride	849 12 B-Chemical
and	862 3 O
output	866 6 O
of	873 2 O
triglyceride	876 12 B-Chemical
.	888 1 O

Accumulation	890 12 O
of	903 2 O
hepatic	906 7 O
triglyceride	914 12 B-Chemical
,	926 1 O
as	928 2 O
a	931 1 O
per	933 3 O
cent	937 4 O
of	942 2 O
control	945 7 O
values	953 6 O
,	959 1 O
in	961 2 O
response	964 8 O
to	973 2 O
graded	976 6 O
doses	983 5 O
of	989 2 O
tetracycline	992 12 B-Chemical
,	1004 1 O
did	1006 3 O
not	1010 3 O
differ	1014 6 O
significantly	1021 13 O
between	1035 7 O
male	1043 4 O
,	1047 1 O
female	1049 6 O
and	1056 3 O
pregnant	1060 8 O
rat	1069 3 O
livers	1073 6 O
.	1079 1 O

However	1081 7 O
,	1088 1 O
livers	1090 6 O
from	1097 4 O
female	1102 6 O
,	1108 1 O
and	1110 3 O
especially	1114 10 O
pregnant	1125 8 O
female	1134 6 O
rats	1141 4 O
,	1145 1 O
were	1147 4 O
strikingly	1152 10 O
resistant	1163 9 O
to	1173 2 O
the	1176 3 O
effects	1180 7 O
of	1188 2 O
tetracycline	1191 12 B-Chemical
on	1204 2 O
depression	1207 10 B-Disease
of	1218 2 O
output	1221 6 O
of	1228 2 O
triglyceride	1231 12 B-Chemical
under	1244 5 O
these	1250 5 O
experimental	1256 12 O
conditions	1269 10 O
.	1279 1 O

These	1281 5 O
differences	1287 11 O
between	1299 7 O
the	1307 3 O
sexes	1311 5 O
could	1317 5 O
not	1323 3 O
be	1327 2 O
related	1330 7 O
to	1338 2 O
altered	1341 7 O
disposition	1349 11 O
of	1361 2 O
tetracycline	1364 12 B-Chemical
or	1377 2 O
altered	1380 7 O
uptake	1388 6 O
of	1395 2 O
oleic	1398 5 B-Chemical
acid	1404 4 I-Chemical
.	1408 1 O

Depressed	1410 9 O
hepatic	1420 7 O
secretion	1428 9 O
of	1438 2 O
triglyceride	1441 12 B-Chemical
accounted	1454 9 O
only	1464 4 O
for	1469 3 O
30	1473 2 O
to	1476 2 O
50	1479 2 O
%	1481 1 O
of	1483 2 O
accumulated	1486 11 O
hepatic	1498 7 O
triglyceride	1506 12 B-Chemical
,	1518 1 O
indicating	1520 10 O
that	1531 4 O
additional	1536 10 O
mechanisms	1547 10 O
must	1558 4 O
be	1563 2 O
involved	1566 8 O
in	1575 2 O
the	1578 3 O
production	1582 10 O
of	1593 2 O
the	1596 3 O
triglyceride	1600 12 B-Chemical
-	1612 1 O
rich	1613 4 O
fatty	1618 5 B-Disease
liver	1624 5 I-Disease
in	1630 2 O
response	1633 8 O
to	1642 2 O
tetracycline	1645 12 B-Chemical
.	1657 1 O

Fatal	0 5 O
myeloencephalopathy	6 19 B-Disease
due	26 3 O
to	30 2 O
intrathecal	33 11 O
vincristine	45 11 B-Chemical
administration	57 14 O
.	71 1 O

Vincristine	73 11 B-Chemical
was	85 3 O
accidentally	89 12 O
given	102 5 O
intrathecally	108 13 O
to	122 2 O
a	125 1 O
child	127 5 O
with	133 4 O
leukaemia	138 9 B-Disease
,	147 1 O
producing	149 9 O
sensory	159 7 B-Disease
and	167 3 I-Disease
motor	171 5 I-Disease
dysfunction	177 11 I-Disease
followed	189 8 O
by	198 2 O
encephalopathy	201 14 B-Disease
and	216 3 O
death	220 5 O
.	225 1 O

Separate	227 8 O
times	236 5 O
for	242 3 O
administering	246 13 O
vincristine	260 11 B-Chemical
and	272 3 O
intrathecal	276 11 O
therapy	288 7 O
is	296 2 O
recommended	299 11 O
.	310 1 O

Progesterone	0 12 B-Chemical
potentiation	13 12 O
of	26 2 O
bupivacaine	29 11 B-Chemical
arrhythmogenicity	41 17 O
in	59 2 O
pentobarbital	62 13 B-Chemical
-	75 1 O
anesthetized	76 12 O
rats	89 4 O
and	94 3 O
beating	98 7 O
rat	106 3 O
heart	110 5 O
cell	116 4 O
cultures	121 8 O
.	129 1 O

The	131 3 O
effects	135 7 O
of	143 2 O
progesterone	146 12 B-Chemical
treatment	159 9 O
on	169 2 O
bupivacaine	172 11 B-Chemical
arrhythmogenicity	184 17 O
in	202 2 O
beating	205 7 O
rat	213 3 O
heart	217 5 O
myocyte	223 7 O
cultures	231 8 O
and	240 3 O
on	244 2 O
anesthetized	247 12 O
rats	260 4 O
were	265 4 O
determined	270 10 O
.	280 1 O

After	282 5 O
determining	288 11 O
the	300 3 O
bupivacaine	304 11 B-Chemical
AD50	316 4 O
(	321 1 O
the	322 3 O
concentration	326 13 O
of	340 2 O
bupivacaine	343 11 B-Chemical
that	355 4 O
caused	360 6 O
50	367 2 O
%	369 1 O
of	371 2 O
all	374 3 O
beating	378 7 O
rat	386 3 O
heart	390 5 O
myocyte	396 7 O
cultures	404 8 O
to	413 2 O
become	416 6 O
arrhythmic	423 10 B-Disease
)	433 1 O
,	434 1 O
we	436 2 O
determined	439 10 O
the	450 3 O
effect	454 6 O
of	461 2 O
1	464 1 O
-	465 1 O
hour	466 4 O
progesterone	471 12 B-Chemical
HCl	484 3 B-Chemical
exposure	488 8 O
on	497 2 O
myocyte	500 7 O
contractile	508 11 O
rhythm	520 6 O
.	526 1 O

Each	528 4 O
concentration	533 13 O
of	547 2 O
progesterone	550 12 B-Chemical
(	563 1 O
6	564 1 O
.	565 1 O
25	566 2 O
,	568 1 O
12	570 2 O
.	572 1 O
5	573 1 O
,	574 1 O
25	576 2 O
,	578 1 O
and	580 3 O
50	584 2 O
micrograms	587 10 O
/	597 1 O
ml	598 2 O
)	600 1 O
caused	602 6 O
a	609 1 O
significant	611 11 O
and	623 3 O
concentration	627 13 O
-	640 1 O
dependent	641 9 O
reduction	651 9 O
in	661 2 O
the	664 3 O
AD50	668 4 O
for	673 3 O
bupivacaine	677 11 B-Chemical
.	688 1 O

Estradiol	690 9 B-Chemical
treatment	700 9 O
also	710 4 O
increased	715 9 O
the	725 3 O
arrhythmogenicity	729 17 O
of	747 2 O
bupivacaine	750 11 B-Chemical
in	762 2 O
myocyte	765 7 O
cultures	773 8 O
,	781 1 O
but	783 3 O
was	787 3 O
only	791 4 O
one	796 3 O
fourth	800 6 O
as	807 2 O
potent	810 6 O
as	817 2 O
progesterone	820 12 B-Chemical
.	832 1 O

Neither	834 7 O
progesterone	842 12 B-Chemical
nor	855 3 O
estradiol	859 9 B-Chemical
effects	869 7 O
on	877 2 O
bupivacaine	880 11 B-Chemical
arrhythmogenicity	892 17 O
were	910 4 O
potentiated	915 11 O
by	927 2 O
epinephrine	930 11 B-Chemical
.	941 1 O

Chronic	943 7 O
progesterone	951 12 B-Chemical
pretreatment	964 12 O
(	977 1 O
5	978 1 O
mg	980 2 O
/	982 1 O
kg	983 2 O
/	985 1 O
day	986 3 O
for	990 3 O
21	994 2 O
days	997 4 O
)	1001 1 O
caused	1003 6 O
a	1010 1 O
significant	1012 11 O
increase	1024 8 O
in	1033 2 O
bupivacaine	1036 11 B-Chemical
arrhythmogenicity	1048 17 O
in	1066 2 O
intact	1069 6 O
pentobarbital	1076 13 B-Chemical
-	1089 1 O
anesthetized	1090 12 O
rats	1103 4 O
.	1107 1 O

There	1109 5 O
was	1115 3 O
a	1119 1 O
significant	1121 11 O
decrease	1133 8 O
in	1142 2 O
the	1145 3 O
time	1149 4 O
to	1154 2 O
onset	1157 5 O
of	1163 2 O
arrhythmia	1166 10 B-Disease
as	1177 2 O
compared	1180 8 O
with	1189 4 O
control	1194 7 O
nonprogesterone	1202 15 O
-	1217 1 O
treated	1218 7 O
rats	1226 4 O
(	1231 1 O
6	1232 1 O
.	1233 1 O
2	1234 1 O
+	1236 1 O
/	1237 1 O
-	1238 1 O
1	1240 1 O
.	1241 1 O
3	1242 1 O
vs	1244 2 O
.	1246 1 O
30	1248 2 O
.	1250 1 O
8	1251 1 O
+	1253 1 O
/	1254 1 O
-	1255 1 O
2	1257 1 O
.	1258 1 O
5	1259 1 O
min	1261 3 O
,	1264 1 O
mean	1266 4 O
+	1271 1 O
/	1272 1 O
-	1273 1 O
SE	1275 2 O
)	1277 1 O
.	1278 1 O

The	1280 3 O
results	1284 7 O
of	1292 2 O
this	1295 4 O
study	1300 5 O
indicate	1306 8 O
that	1315 4 O
progesterone	1320 12 B-Chemical
can	1333 3 O
potentiate	1337 10 O
bupivacaine	1348 11 B-Chemical
arrhythmogenicity	1360 17 O
both	1378 4 O
in	1383 2 O
vivo	1386 4 O
and	1391 3 O
in	1395 2 O
vitro	1398 5 O
.	1403 1 O

Potentiation	1405 12 O
of	1418 2 O
bupivacaine	1421 11 B-Chemical
arrhythmia	1433 10 B-Disease
in	1444 2 O
myocyte	1447 7 O
cultures	1455 8 O
suggests	1464 8 O
that	1473 4 O
this	1478 4 O
effect	1483 6 O
is	1490 2 O
at	1493 2 O
least	1496 5 O
partly	1502 6 O
mediated	1509 8 O
at	1518 2 O
the	1521 3 O
myocyte	1525 7 O
level	1533 5 O
.	1538 1 O

Acute	0 5 B-Disease
renal	6 5 I-Disease
failure	12 7 I-Disease
occurring	20 9 O
during	30 6 O
intravenous	37 11 O
desferrioxamine	49 15 B-Chemical
therapy	65 7 O
:	72 1 O
recovery	74 8 O
after	83 5 O
haemodialysis	89 13 O
.	102 1 O

A	104 1 O
patient	106 7 O
with	114 4 O
transfusion	119 11 O
-	130 1 O
dependent	131 9 O
thalassemia	141 11 B-Disease
was	153 3 O
undergoing	157 10 O
home	168 4 O
intravenous	173 11 O
desferrioxamine	185 15 B-Chemical
(	201 1 O
DFX	202 3 B-Chemical
)	205 1 O
treatment	207 9 O
by	217 2 O
means	220 5 O
of	226 2 O
a	229 1 O
totally	231 7 O
implanted	239 9 O
system	249 6 O
because	256 7 O
of	264 2 O
his	267 3 O
poor	271 4 O
compliance	276 10 O
with	287 4 O
the	292 3 O
nightly	296 7 O
subcutaneous	304 12 O
therapy	317 7 O
.	324 1 O

Due	326 3 O
to	330 2 O
an	333 2 O
accidental	336 10 O
malfunctioning	347 14 O
of	362 2 O
the	365 3 O
infusion	369 8 O
pump	378 4 O
,	382 1 O
the	384 3 O
patient	388 7 O
was	396 3 O
inadvertently	400 13 O
administered	414 12 O
a	427 1 O
toxic	429 5 O
dosage	435 6 O
of	442 2 O
the	445 3 O
drug	449 4 O
which	454 5 O
caused	460 6 O
renal	467 5 B-Disease
insufficiency	473 13 I-Disease
.	486 1 O

Given	488 5 O
the	494 3 O
progressive	498 11 O
deterioration	510 13 O
of	524 2 O
the	527 3 O
symptoms	531 8 O
and	540 3 O
of	544 2 O
the	547 3 O
laboratory	551 10 O
values	562 6 O
,	568 1 O
despite	570 7 O
adequate	578 8 O
medical	587 7 O
treatment	595 9 O
,	604 1 O
a	606 1 O
decision	608 8 O
was	617 3 O
made	621 4 O
to	626 2 O
introduce	629 9 O
haemodialytical	639 15 O
therapy	655 7 O
in	663 2 O
order	666 5 O
to	672 2 O
remove	675 6 O
the	682 3 O
drug	686 4 O
and	691 3 O
therapy	695 7 O
reduce	703 6 O
the	710 3 O
nephrotoxicity	714 14 B-Disease
.	728 1 O

From	730 4 O
the	735 3 O
results	739 7 O
obtained	747 8 O
,	755 1 O
haemodialysis	757 13 O
can	771 3 O
therefore	775 9 O
be	785 2 O
suggested	788 9 O
as	798 2 O
a	801 1 O
useful	803 6 O
therapy	810 7 O
in	818 2 O
rare	821 4 O
cases	826 5 O
of	832 2 O
progressive	835 11 O
acute	847 5 B-Disease
renal	853 5 I-Disease
failure	859 7 I-Disease
caused	867 6 O
by	874 2 O
desferrioxamine	877 15 B-Chemical
.	892 1 O

Neuroleptic	0 11 B-Chemical
-	11 1 O
associated	12 10 O
hyperprolactinemia	23 18 B-Disease
.	41 1 O

Can	43 3 O
it	47 2 O
be	50 2 O
treated	53 7 O
with	61 4 O
bromocriptine	66 13 B-Chemical
?	79 1 O

Six	81 3 O
stable	85 6 O
psychiatric	92 11 O
outpatients	104 11 O
with	116 4 O
hyperprolactinemia	121 18 B-Disease
and	140 3 O
amenorrhea	144 10 B-Disease
/	154 1 O
oligomenorrhea	155 14 B-Disease
associated	170 10 O
with	181 4 O
their	186 5 O
neuroleptic	192 11 B-Chemical
medications	204 11 I-Chemical
were	216 4 O
treated	221 7 O
with	229 4 O
bromocriptine	234 13 B-Chemical
.	247 1 O

Daily	249 5 O
dosages	255 7 O
of	263 2 O
5	266 1 O
-	267 1 O
10	268 2 O
mg	271 2 O
corrected	274 9 O
the	284 3 O
hyperprolactinemia	288 18 B-Disease
and	307 3 O
restored	311 8 O
menstruation	320 12 O
in	333 2 O
four	336 4 O
of	341 2 O
the	344 3 O
six	348 3 O
patients	352 8 O
.	360 1 O

One	362 3 O
woman	366 5 O
,	371 1 O
however	373 7 O
,	380 1 O
developed	382 9 O
worsened	392 8 O
psychiatric	401 11 B-Disease
symptoms	413 8 I-Disease
while	422 5 O
taking	428 6 O
bromocriptine	435 13 B-Chemical
,	448 1 O
and	450 3 O
it	454 2 O
was	457 3 O
discontinued	461 12 O
.	473 1 O

Thus	475 4 O
,	479 1 O
three	481 5 O
of	487 2 O
six	490 3 O
patients	494 8 O
had	503 3 O
their	507 5 O
menstrual	513 9 O
irregularity	523 12 O
successfully	536 12 O
corrected	549 9 O
with	559 4 O
bromocriptine	564 13 B-Chemical
.	577 1 O

This	579 4 O
suggests	584 8 O
that	593 4 O
bromocriptine	598 13 B-Chemical
should	612 6 O
be	619 2 O
further	622 7 O
evaluated	630 9 O
as	640 2 O
potential	643 9 O
therapy	653 7 O
for	661 3 O
neuroleptic	665 11 B-Chemical
-	676 1 O
associated	677 10 O
hyperprolactinemia	688 18 B-Disease
and	707 3 O
amenorrhea	711 10 B-Disease
/	721 1 O
galactorrhea	722 12 B-Disease
.	734 1 O

Ethacrynic	0 10 B-Chemical
acid	11 4 I-Chemical
-	15 1 O
induced	16 7 O
convulsions	24 11 B-Disease
and	36 3 O
brain	40 5 O
neurotransmitters	46 17 O
in	64 2 O
mice	67 4 O
.	71 1 O

Intracerebroventricular	73 23 O
injection	97 9 O
of	107 2 O
ethacrynic	110 10 B-Chemical
acid	121 4 I-Chemical
(	126 1 O
50	127 2 O
%	129 1 O
convulsive	131 10 B-Disease
dose	142 4 O
;	146 1 O
50	148 2 O
micrograms	151 10 O
/	161 1 O
mouse	162 5 O
)	167 1 O
accelerated	169 11 O
the	181 3 O
synthesis	185 9 O
/	194 1 O
turnover	195 8 O
of	204 2 O
5	207 1 B-Chemical
-	208 1 I-Chemical
hydroxytryptamine	209 17 I-Chemical
(	227 1 O
5	228 1 B-Chemical
-	229 1 I-Chemical
HT	230 2 I-Chemical
)	232 1 O
but	234 3 O
suppressed	238 10 O
the	249 3 O
synthesis	253 9 O
of	263 2 O
gamma	266 5 B-Chemical
-	271 1 I-Chemical
aminobutyric	272 12 I-Chemical
acid	285 4 I-Chemical
and	290 3 O
acetylcholine	294 13 B-Chemical
in	308 2 O
mouse	311 5 O
brain	317 5 O
.	322 1 O

These	324 5 O
effects	330 7 O
were	338 4 O
completely	343 10 O
antagonized	354 11 O
by	366 2 O
pretreatment	369 12 O
with	382 4 O
a	387 1 O
glutamate	389 9 B-Chemical
/	398 1 O
N	399 1 B-Chemical
-	400 1 I-Chemical
methyl	401 6 I-Chemical
-	407 1 I-Chemical
D	408 1 I-Chemical
-	409 1 I-Chemical
aspartate	410 9 I-Chemical
antagonist	420 10 O
,	430 1 O
aminophosphonovaleric	432 21 B-Chemical
acid	454 4 I-Chemical
.	458 1 O

In	460 2 O
ethacrynic	463 10 B-Chemical
acid	474 4 I-Chemical
-	478 1 O
induced	479 7 O
convulsions	487 11 B-Disease
,	498 1 O
these	500 5 O
neurotransmitter	506 16 O
systems	523 7 O
may	531 3 O
be	535 2 O
differentially	538 14 O
modulated	553 9 O
,	562 1 O
probably	564 8 O
through	573 7 O
activation	581 10 O
of	592 2 O
glutaminergic	595 13 O
neurons	609 7 O
in	617 2 O
the	620 3 O
brain	624 5 O
.	629 1 O

Pharmacology	0 12 O
of	13 2 O
gamma	16 5 B-Chemical
-	21 1 I-Chemical
aminobutyric	22 12 I-Chemical
acidA	35 5 O
receptor	41 8 O
complex	50 7 O
after	58 5 O
the	64 3 O
in	68 2 O
vivo	71 4 O
administration	76 14 O
of	91 2 O
the	94 3 O
anxioselective	98 14 O
and	113 3 O
anticonvulsant	117 14 O
beta	132 4 B-Chemical
-	136 1 I-Chemical
carboline	137 9 I-Chemical
derivative	147 10 O
abecarnil	158 9 B-Chemical
.	167 1 O

In	169 2 O
rodents	172 7 O
,	179 1 O
the	181 3 O
effect	185 6 O
of	192 2 O
the	195 3 O
beta	199 4 B-Chemical
-	203 1 I-Chemical
carboline	204 9 I-Chemical
derivative	214 10 O
isopropyl	225 9 B-Chemical
-	234 1 I-Chemical
6	235 1 I-Chemical
-	236 1 I-Chemical
benzyloxy	238 9 I-Chemical
-	247 1 I-Chemical
4	248 1 I-Chemical
-	249 1 I-Chemical
methoxymethyl	250 13 I-Chemical
-	263 1 I-Chemical
beta	264 4 I-Chemical
-	268 1 I-Chemical
carboline	269 9 I-Chemical
-	278 1 I-Chemical
3	279 1 I-Chemical
-	280 1 I-Chemical
carboxylate	281 11 I-Chemical
(	293 1 O
abecarrnil	294 10 B-Chemical
)	304 1 O
,	305 1 O
a	307 1 O
new	309 3 O
ligand	313 6 O
for	320 3 O
benzodiazepine	324 14 B-Chemical
receptors	339 9 O
possessing	349 10 O
anxiolytic	360 10 O
and	371 3 O
anticonvulsant	375 14 O
properties	390 10 O
,	400 1 O
was	402 3 O
evaluated	406 9 O
on	416 2 O
the	419 3 O
function	423 8 O
of	432 2 O
central	435 7 O
gamma	443 5 B-Chemical
-	448 1 I-Chemical
aminobutyric	449 12 I-Chemical
acid	462 4 I-Chemical
(	467 1 O
GABA	468 4 B-Chemical
)	472 1 O
A	473 1 O
receptor	475 8 O
complex	484 7 O
,	491 1 O
both	493 4 O
in	498 2 O
vitro	501 5 O
and	507 3 O
in	511 2 O
vivo	514 4 O
.	518 1 O

Added	520 5 O
in	526 2 O
vitro	529 5 O
to	535 2 O
rat	538 3 O
cortical	542 8 O
membrane	551 8 O
preparation	560 11 O
,	571 1 O
abecarnil	573 9 B-Chemical
increased	583 9 O
[	593 1 O
3H	594 2 O
]	596 1 O
GABA	597 4 B-Chemical
binding	602 7 O
,	609 1 O
enhanced	611 8 O
muscimol	620 8 B-Chemical
-	628 1 O
stimulated	629 10 O
36Cl	640 4 O
-	644 1 O
uptake	646 6 O
and	653 3 O
reduced	657 7 O
the	665 3 O
binding	669 7 O
of	677 2 O
t	680 1 B-Chemical
-	681 1 I-Chemical
[	682 1 I-Chemical
35S	683 3 I-Chemical
]	686 1 I-Chemical
butylbicyclophosphorothionate	687 29 I-Chemical
(	717 1 O
[	718 1 B-Chemical
35S	719 3 I-Chemical
]	722 1 I-Chemical
TBPS	723 4 I-Chemical
)	727 1 O
.	728 1 O

These	730 5 O
effects	736 7 O
were	744 4 O
similar	749 7 O
to	757 2 O
those	760 5 O
induced	766 7 O
by	774 2 O
diazepam	777 8 B-Chemical
,	785 1 O
whereas	787 7 O
the	795 3 O
partial	799 7 O
agonist	807 7 O
Ro	815 2 B-Chemical
16	818 2 I-Chemical
-	820 1 I-Chemical
6028	821 4 I-Chemical
(	826 1 O
tert	827 4 B-Chemical
-	831 1 I-Chemical
butyl	832 5 I-Chemical
-	837 1 I-Chemical
(	838 1 I-Chemical
S	839 1 I-Chemical
)	840 1 I-Chemical
-	841 1 I-Chemical
8	842 1 I-Chemical
-	843 1 I-Chemical
bromo	844 5 I-Chemical
-	849 1 I-Chemical
11	850 2 I-Chemical
,	852 1 I-Chemical
12	853 2 I-Chemical
,	855 1 I-Chemical
13	856 2 I-Chemical
,	858 1 I-Chemical
13a	859 3 I-Chemical
-	862 1 I-Chemical
tetrahydro	863 10 I-Chemical
-	873 1 I-Chemical
9	874 1 I-Chemical
-	875 1 I-Chemical
oxo	876 3 I-Chemical
-	879 1 I-Chemical
9H	880 2 I-Chemical
-	882 1 I-Chemical
imidazo	884 7 I-Chemical
[	891 1 I-Chemical
1	892 1 I-Chemical
,	893 1 I-Chemical
5	894 1 I-Chemical
-	895 1 I-Chemical
a	896 1 I-Chemical
]	897 1 I-Chemical
-	898 1 I-Chemical
pyrrolo	899 7 I-Chemical
-	906 1 I-Chemical
[	907 1 I-Chemical
2	908 1 I-Chemical
,	909 1 I-Chemical
1	910 1 I-Chemical
-	911 1 I-Chemical
c	912 1 I-Chemical
]	913 1 I-Chemical
[	914 1 I-Chemical
1	915 1 I-Chemical
,	916 1 I-Chemical
4	917 1 I-Chemical
]	918 1 I-Chemical
benzodiazepine	919 14 I-Chemical
-	933 1 I-Chemical
1	934 1 I-Chemical
-	935 1 I-Chemical
carboxylate	936 11 I-Chemical
)	947 1 O
showed	949 6 O
very	956 4 O
weak	961 4 O
efficacy	966 8 O
in	975 2 O
these	978 5 O
biochemical	984 11 O
tests	996 5 O
.	1001 1 O

After	1003 5 O
i	1009 1 O
.	1010 1 O
p	1011 1 O
.	1012 1 O
injection	1014 9 O
to	1024 2 O
rats	1027 4 O
,	1031 1 O
abecarnil	1033 9 B-Chemical
and	1043 3 O
diazepam	1047 8 B-Chemical
decreased	1056 9 O
in	1066 2 O
a	1069 1 O
time	1071 4 O
-	1075 1 O
dependent	1076 9 O
and	1086 3 O
dose	1090 4 O
-	1094 1 O
related	1095 7 O
(	1103 1 O
0	1104 1 O
.	1105 1 O
25	1106 2 O
-	1108 1 O
20	1109 2 O
mg	1112 2 O
/	1114 1 O
kg	1115 2 O
i	1118 1 O
.	1119 1 O
p	1120 1 O
.	1121 1 O
)	1122 1 O
manner	1124 6 O
[	1131 1 B-Chemical
35S	1132 3 I-Chemical
]	1135 1 I-Chemical
TBPS	1136 4 I-Chemical
binding	1141 7 O
measured	1149 8 O
ex	1158 2 O
vivo	1161 4 O
in	1166 2 O
the	1169 3 O
cerebral	1173 8 O
cortex	1182 6 O
.	1188 1 O

Moreover	1190 8 O
,	1198 1 O
both	1200 4 O
drugs	1205 5 O
at	1211 2 O
the	1214 3 O
dose	1218 4 O
of	1223 2 O
0	1226 1 O
.	1227 1 O
5	1228 1 O
mg	1230 2 O
/	1232 1 O
kg	1233 2 O
antagonized	1236 11 O
completely	1248 10 O
the	1259 3 O
convulsant	1263 10 O
activity	1274 8 O
and	1283 3 O
the	1287 3 O
increase	1291 8 O
of	1300 2 O
[	1303 1 B-Chemical
35S	1304 3 I-Chemical
]	1307 1 I-Chemical
TBPS	1308 4 I-Chemical
binding	1313 7 O
induced	1321 7 O
by	1329 2 O
isoniazide	1332 10 B-Chemical
(	1343 1 O
350	1344 3 O
mg	1348 2 O
/	1350 1 O
kg	1351 2 O
s	1354 1 O
.	1355 1 O
c	1356 1 O
.	1357 1 O
)	1358 1 O
as	1360 2 O
well	1363 4 O
as	1368 2 O
the	1371 3 O
increase	1375 8 O
of	1384 2 O
[	1387 1 B-Chemical
35S	1388 3 I-Chemical
]	1391 1 I-Chemical
TBPS	1392 4 I-Chemical
binding	1397 7 O
induced	1405 7 O
by	1413 2 O
foot	1416 4 O
-	1420 1 O
shock	1421 5 O
stress	1427 6 O
.	1433 1 O

To	1435 2 O
better	1438 6 O
correlate	1445 9 O
the	1455 3 O
biochemical	1459 11 O
and	1471 3 O
the	1475 3 O
pharmacological	1479 15 O
effects	1495 7 O
,	1502 1 O
we	1504 2 O
studied	1507 7 O
the	1515 3 O
action	1519 6 O
of	1526 2 O
abecarnil	1529 9 B-Chemical
on	1539 2 O
[	1542 1 B-Chemical
35S	1543 3 I-Chemical
]	1546 1 I-Chemical
TBPS	1547 4 I-Chemical
binding	1552 7 O
,	1559 1 O
exploratory	1561 11 O
motility	1573 8 O
and	1582 3 O
on	1586 2 O
isoniazid	1589 9 B-Chemical
-	1598 1 O
induced	1599 7 O
biochemical	1607 11 O
and	1619 3 O
pharmacological	1623 15 O
effects	1639 7 O
in	1647 2 O
mice	1650 4 O
.	1654 1 O

In	1656 2 O
these	1659 5 O
animals	1665 7 O
,	1672 1 O
abecarnil	1674 9 B-Chemical
produced	1684 8 O
a	1693 1 O
paralleled	1695 10 O
dose	1706 4 O
-	1710 1 O
dependent	1711 9 O
(	1721 1 O
0	1722 1 O
.	1723 1 O
05	1724 2 O
-	1726 1 O
1	1727 1 O
mg	1729 2 O
/	1731 1 O
kg	1732 2 O
i	1735 1 O
.	1736 1 O
p	1737 1 O
.	1738 1 O
)	1739 1 O
reduction	1741 9 O
of	1751 2 O
both	1754 4 O
motor	1759 5 O
behavior	1765 8 O
and	1774 3 O
cortical	1778 8 O
[	1787 1 O
35S	1788 3 O
]	1791 1 O
TBPS	1792 4 O
binding	1797 7 O
.	1804 1 O

Moreover	1806 8 O
,	1814 1 O
0	1816 1 O
.	1817 1 O
05	1818 2 O
mg	1821 2 O
/	1823 1 O
kg	1824 2 O
of	1827 2 O
this	1830 4 O
beta	1835 4 B-Chemical
-	1839 1 I-Chemical
carboline	1840 9 I-Chemical
reduced	1850 7 O
markedly	1858 8 O
the	1867 3 O
increase	1871 8 O
of	1880 2 O
[	1883 1 B-Chemical
35S	1884 3 I-Chemical
]	1887 1 I-Chemical
TBPS	1888 4 I-Chemical
binding	1893 7 O
and	1901 3 O
the	1905 3 O
convulsions	1909 11 B-Disease
induced	1921 7 O
by	1929 2 O
isoniazid	1932 9 B-Chemical
(	1942 1 O
200	1943 3 O
mg	1947 2 O
/	1949 1 O
kg	1950 2 O
s	1953 1 O
.	1954 1 O
c	1955 1 O
.	1956 1 O
)	1957 1 O
.	1958 1 O
(	1959 1 O
ABSTRACT	1960 8 O
TRUNCATED	1969 9 O
AT	1979 2 O
250	1982 3 O
WORDS	1986 5 O
)	1991 1 O

Recurrent	0 9 O
myocardial	10 10 B-Disease
infarction	21 10 I-Disease
in	32 2 O
a	35 1 O
postpartum	37 10 O
patient	48 7 O
receiving	56 9 O
bromocriptine	66 13 B-Chemical
.	79 1 O

Myocardial	81 10 B-Disease
infarction	92 10 I-Disease
in	103 2 O
puerperium	106 10 O
is	117 2 O
infrequently	120 12 O
reported	133 8 O
.	141 1 O

Spasm	143 5 B-Disease
,	148 1 O
coronary	150 8 O
dissection	159 10 O
,	169 1 O
or	171 2 O
atheromatous	174 12 O
etiology	187 8 O
has	196 3 O
been	200 4 O
described	205 9 O
.	214 1 O

Bromocriptine	216 13 B-Chemical
has	230 3 O
been	234 4 O
implicated	239 10 O
in	250 2 O
several	253 7 O
previous	261 8 O
case	270 4 O
reports	275 7 O
of	283 2 O
myocardial	286 10 B-Disease
infarction	297 10 I-Disease
in	308 2 O
the	311 3 O
puerperium	315 10 O
.	325 1 O

Our	327 3 O
case	331 4 O
(	336 1 O
including	337 9 O
an	347 2 O
inadvertent	350 11 O
rechallenge	362 11 O
)	373 1 O
suggests	375 8 O
such	384 4 O
a	389 1 O
relationship	391 12 O
.	403 1 O

Although	405 8 O
generally	414 9 O
regarded	424 8 O
as	433 2 O
"	436 1 O
safe	437 4 O
,	441 1 O
"	442 1 O
possible	444 8 O
serious	453 7 O
cardiac	461 7 O
effects	469 7 O
of	477 2 O
bromocriptine	480 13 B-Chemical
should	494 6 O
be	501 2 O
acknowledged	504 12 O
.	516 1 O

Asterixis	0 9 B-Disease
induced	10 7 O
by	18 2 O
carbamazepine	21 13 B-Chemical
therapy	35 7 O
.	42 1 O

There	44 5 O
are	50 3 O
very	54 4 O
few	59 3 O
reports	63 7 O
about	71 5 O
asterixis	77 9 B-Disease
as	87 2 O
a	90 1 O
side	92 4 O
effect	97 6 O
of	104 2 O
treatment	107 9 O
with	117 4 O
psychopharmacologic	122 19 O
agents	142 6 O
.	148 1 O

In	150 2 O
this	153 4 O
report	158 6 O
we	165 2 O
present	168 7 O
four	176 4 O
patients	181 8 O
treated	190 7 O
with	198 4 O
a	203 1 O
combination	205 11 O
of	217 2 O
different	220 9 O
psychotropic	230 12 O
drugs	243 5 O
,	248 1 O
in	250 2 O
whom	253 4 O
asterixis	258 9 B-Disease
was	268 3 O
triggered	272 9 O
either	282 6 O
by	289 2 O
adding	292 6 O
carbamazepine	299 13 B-Chemical
(	313 1 O
CBZ	314 3 B-Chemical
)	317 1 O
to	319 2 O
a	322 1 O
treatment	324 9 O
regimen	334 7 O
,	341 1 O
or	343 2 O
by	346 2 O
increasing	349 10 O
its	360 3 O
dosage	364 6 O
.	370 1 O

Neither	372 7 O
dosage	380 6 O
nor	387 3 O
serum	391 5 O
levels	397 6 O
of	404 2 O
CBZ	407 3 B-Chemical
were	411 4 O
in	416 2 O
a	419 1 O
higher	421 6 O
range	428 5 O
.	433 1 O

We	435 2 O
consider	438 8 O
asterixis	447 9 B-Disease
to	457 2 O
be	460 2 O
an	463 2 O
easily	466 6 O
overlooked	473 10 O
sign	484 4 O
of	489 2 O
neurotoxicity	492 13 B-Disease
,	505 1 O
which	507 5 O
may	513 3 O
occur	517 5 O
even	523 4 O
at	528 2 O
low	531 3 O
or	535 2 O
moderate	538 8 O
dosage	547 6 O
levels	554 6 O
,	560 1 O
if	562 2 O
certain	565 7 O
drugs	573 5 O
as	579 2 O
lithium	582 7 B-Chemical
or	590 2 O
clozapine	593 9 B-Chemical
are	603 3 O
used	607 4 O
in	612 2 O
combination	615 11 O
with	627 4 O
CBZ	632 3 B-Chemical
.	635 1 O

Pharmacodynamics	0 16 O
of	17 2 O
the	20 3 O
hypotensive	24 11 B-Disease
effect	36 6 O
of	43 2 O
levodopa	46 8 B-Chemical
in	55 2 O
parkinsonian	58 12 B-Disease
patients	71 8 O
.	79 1 O

Blood	81 5 O
pressure	87 8 O
effects	96 7 O
of	104 2 O
i	107 1 O
.	108 1 O
v	109 1 O
.	110 1 O
levodopa	112 8 B-Chemical
were	121 4 O
examined	126 8 O
in	135 2 O
parkinsonian	138 12 B-Disease
patients	151 8 O
with	160 4 O
stable	165 6 O
and	172 3 O
fluctuating	176 11 O
responses	188 9 O
to	198 2 O
levodopa	201 8 B-Chemical
.	209 1 O

The	211 3 O
magnitude	215 9 O
of	225 2 O
the	228 3 O
hypotensive	232 11 B-Disease
effect	244 6 O
of	251 2 O
levodopa	254 8 B-Chemical
was	263 3 O
concentration	267 13 O
dependent	281 9 O
and	291 3 O
was	295 3 O
fit	299 3 O
to	303 2 O
an	306 2 O
Emax	309 4 O
model	314 5 O
in	320 2 O
fluctuating	323 11 O
responders	335 10 O
.	345 1 O

Stable	347 6 O
responders	354 10 O
demonstrated	365 12 O
a	378 1 O
small	380 5 O
hypotensive	386 11 B-Disease
response	398 8 O
.	406 1 O

Baseline	408 8 O
blood	417 5 O
pressures	423 9 O
were	433 4 O
higher	438 6 O
in	445 2 O
fluctuating	448 11 O
patients	460 8 O
;	468 1 O
a	470 1 O
higher	472 6 O
baseline	479 8 O
blood	488 5 O
pressure	494 8 O
correlated	503 10 O
with	514 4 O
greater	519 7 O
hypotensive	527 11 B-Disease
effects	539 7 O
.	546 1 O

Antiparkinsonian	548 16 O
effects	565 7 O
of	573 2 O
levodopa	576 8 B-Chemical
temporally	585 10 O
correlated	596 10 O
with	607 4 O
blood	612 5 O
pressure	618 8 O
changes	627 7 O
.	634 1 O

Phenylalanine	636 13 B-Chemical
,	649 1 O
a	651 1 O
large	653 5 O
neutral	659 7 O
amino	667 5 B-Chemical
acid	673 4 I-Chemical
(	678 1 O
LNAA	679 4 O
)	683 1 O
competing	685 9 O
with	695 4 O
levodopa	700 8 B-Chemical
for	709 3 O
transport	713 9 O
across	723 6 O
the	730 3 O
blood	734 5 O
-	739 1 O
brain	740 5 O
barrier	746 7 O
,	753 1 O
reduced	755 7 O
the	763 3 O
hypotensive	767 11 B-Disease
and	779 3 O
antiparkinsonian	783 16 O
effects	800 7 O
of	808 2 O
levodopa	811 8 B-Chemical
.	819 1 O

We	821 2 O
conclude	824 8 O
that	833 4 O
levodopa	838 8 B-Chemical
has	847 3 O
a	851 1 O
central	853 7 O
hypotensive	861 11 B-Disease
action	873 6 O
that	880 4 O
parallels	885 9 O
the	895 3 O
motor	899 5 O
effects	905 7 O
in	913 2 O
fluctuating	916 11 O
patients	928 8 O
.	936 1 O

The	938 3 O
hypotensive	942 11 B-Disease
effect	954 6 O
appears	961 7 O
to	969 2 O
be	972 2 O
related	975 7 O
to	983 2 O
the	986 3 O
higher	990 6 O
baseline	997 8 O
blood	1006 5 O
pressure	1012 8 O
we	1021 2 O
observed	1024 8 O
in	1033 2 O
fluctuating	1036 11 O
patients	1048 8 O
relative	1057 8 O
to	1066 2 O
stable	1069 6 O
patients	1076 8 O
.	1084 1 O

Syndrome	0 8 B-Disease
of	9 2 I-Disease
inappropriate	12 13 I-Disease
secretion	26 9 I-Disease
of	36 2 I-Disease
antidiuretic	39 12 I-Disease
hormone	52 7 I-Disease
after	60 5 O
infusional	66 10 O
vincristine	77 11 B-Chemical
.	88 1 O

A	90 1 O
77	92 2 O
-	94 1 O
year	95 4 O
-	99 1 O
old	100 3 O
woman	104 5 O
with	110 4 O
refractory	115 10 O
multiple	126 8 B-Disease
myeloma	135 7 I-Disease
was	143 3 O
treated	147 7 O
with	155 4 O
a	160 1 O
4	162 1 O
-	163 1 O
day	164 3 O
continuous	168 10 O
intravenous	179 11 O
infusion	191 8 O
of	200 2 O
vincristine	203 11 B-Chemical
and	215 3 O
doxorubicin	219 11 B-Chemical
and	231 3 O
4	235 1 O
days	237 4 O
of	242 2 O
oral	245 4 O
dexamethasone	250 13 B-Chemical
.	263 1 O

Nine	265 4 O
days	270 4 O
after	275 5 O
her	281 3 O
second	285 6 O
cycle	292 5 O
she	298 3 O
presented	302 9 O
with	312 4 O
lethargy	317 8 B-Disease
and	326 3 O
weakness	330 8 B-Disease
associated	339 10 O
with	350 4 O
hyponatremia	355 12 B-Disease
.	367 1 O

Evaluation	369 10 O
revealed	380 8 O
the	389 3 O
syndrome	393 8 B-Disease
of	402 2 I-Disease
inappropriate	405 13 I-Disease
secretion	419 9 I-Disease
of	429 2 I-Disease
antidiuretic	432 12 I-Disease
hormone	445 7 I-Disease
,	452 1 O
which	454 5 O
was	460 3 O
attributed	464 10 O
to	475 2 O
the	478 3 O
vincristine	482 11 B-Chemical
infusion	494 8 O
.	502 1 O

After	504 5 O
normal	510 6 O
serum	517 5 O
sodium	523 6 B-Chemical
levels	530 6 O
returned	537 8 O
,	545 1 O
further	547 7 O
doxorubicin	555 11 B-Chemical
and	567 3 O
dexamethasone	571 13 B-Chemical
chemotherapy	585 12 O
without	598 7 O
vincristine	606 11 B-Chemical
did	618 3 O
not	622 3 O
produce	626 7 O
this	634 4 O
complication	639 12 O
.	651 1 O

Heart	0 5 B-Disease
failure	6 7 I-Disease
:	13 1 O
to	15 2 O
digitalise	18 10 O
or	29 2 O
not	32 3 O
?	35 1 O

The	37 3 O
view	41 4 O
against	46 7 O
.	53 1 O

Despite	55 7 O
extensive	63 9 O
clinical	73 8 O
experience	82 10 O
the	93 3 O
role	97 4 O
of	102 2 O
digoxin	105 7 B-Chemical
is	113 2 O
still	116 5 O
not	122 3 O
well	126 4 O
defined	131 7 O
.	138 1 O

In	140 2 O
patients	143 8 O
with	152 4 O
atrial	157 6 B-Disease
fibrillation	164 12 I-Disease
digoxin	177 7 B-Chemical
is	185 2 O
beneficial	188 10 O
for	199 3 O
ventricular	203 11 O
rate	215 4 O
control	220 7 O
.	227 1 O

For	229 3 O
patients	233 8 O
in	242 2 O
sinus	245 5 O
rhythm	251 6 O
and	258 3 O
heart	262 5 B-Disease
failure	268 7 I-Disease
the	276 3 O
situation	280 9 O
is	290 2 O
less	293 4 O
clear	298 5 O
.	303 1 O

Digoxin	305 7 B-Chemical
has	313 3 O
a	317 1 O
narrow	319 6 O
therapeutic	326 11 O
:	337 1 O
toxic	338 5 O
ratio	344 5 O
and	350 3 O
concentrations	354 14 O
are	369 3 O
affected	373 8 O
by	382 2 O
a	385 1 O
number	387 6 O
of	394 2 O
drugs	397 5 O
.	402 1 O

Also	404 4 O
,	408 1 O
digoxin	410 7 B-Chemical
has	418 3 O
undesirable	422 11 O
effects	434 7 O
such	442 4 O
as	447 2 O
increasing	450 10 O
peripheral	461 10 O
resistance	472 10 O
and	483 3 O
myocardial	487 10 O
demands	498 7 O
,	505 1 O
and	507 3 O
causing	511 7 O
arrhythmias	519 11 B-Disease
.	530 1 O

There	532 5 O
is	538 2 O
a	541 1 O
paucity	543 7 O
of	551 2 O
data	554 4 O
from	559 4 O
well	564 4 O
-	568 1 O
designed	569 8 O
trials	578 6 O
.	584 1 O

The	586 3 O
trials	590 6 O
that	597 4 O
are	602 3 O
available	606 9 O
are	616 3 O
generally	620 9 O
small	630 5 O
with	636 4 O
limitations	641 11 O
in	653 2 O
design	656 6 O
and	663 3 O
these	667 5 O
show	673 4 O
variation	678 9 O
in	688 2 O
patient	691 7 O
benefit	699 7 O
.	706 1 O

More	708 4 O
convincing	713 10 O
evidence	724 8 O
is	733 2 O
required	736 8 O
showing	745 7 O
that	753 4 O
digoxin	758 7 B-Chemical
improves	766 8 O
symptoms	775 8 O
or	784 2 O
exercise	787 8 O
capacity	796 8 O
.	804 1 O

Furthermore	806 11 O
,	817 1 O
no	819 2 O
trial	822 5 O
has	828 3 O
had	832 3 O
sufficient	836 10 O
power	847 5 O
to	853 2 O
evaluate	856 8 O
mortality	865 9 O
.	874 1 O

Pooled	876 6 O
analysis	883 8 O
of	892 2 O
the	895 3 O
effects	899 7 O
of	907 2 O
other	910 5 O
inotropic	916 9 O
drugs	926 5 O
shows	932 5 O
an	938 2 O
excess	941 6 O
mortality	948 9 O
and	958 3 O
there	962 5 O
is	968 2 O
a	971 1 O
possibility	973 11 O
that	985 4 O
digoxin	990 7 B-Chemical
may	998 3 O
increase	1002 8 O
mortality	1011 9 O
after	1021 5 O
myocardial	1027 10 B-Disease
infarction	1038 10 I-Disease
(	1049 1 O
MI	1050 2 B-Disease
)	1052 1 O
.	1053 1 O

Angiotensin	1055 11 B-Chemical
-	1066 1 O
converting	1067 10 O
enzyme	1078 6 O
(	1085 1 O
ACE	1086 3 O
)	1089 1 O
inhibitors	1091 10 O
should	1102 6 O
be	1109 2 O
used	1112 4 O
first	1117 5 O
as	1123 2 O
they	1126 4 O
are	1131 3 O
safer	1135 5 O
,	1140 1 O
do	1142 2 O
not	1145 3 O
require	1149 7 O
blood	1157 5 O
level	1163 5 O
monitoring	1169 10 O
,	1179 1 O
modify	1181 6 O
progression	1188 11 O
of	1200 2 O
disease	1203 7 O
,	1210 1 O
relieve	1212 7 O
symptoms	1220 8 O
,	1228 1 O
improve	1230 7 O
exercise	1238 8 O
tolerance	1247 9 O
and	1257 3 O
reduce	1261 6 O
mortality	1268 9 O
.	1277 1 O

Caution	1279 7 O
should	1287 6 O
be	1294 2 O
exercised	1297 9 O
in	1307 2 O
using	1310 5 O
digoxin	1316 7 B-Chemical
until	1324 5 O
large	1330 5 O
mortality	1336 9 O
trials	1346 6 O
are	1353 3 O
completed	1357 9 O
showing	1367 7 O
either	1375 6 O
benefit	1382 7 O
or	1390 2 O
harm	1393 4 O
.	1397 1 O

Until	1399 5 O
then	1405 4 O
digoxin	1410 7 B-Chemical
should	1418 6 O
be	1425 2 O
considered	1428 10 O
a	1439 1 O
third	1441 5 O
-	1446 1 O
line	1447 4 O
therapy	1452 7 O
.	1459 1 O

Intravascular	0 13 O
hemolysis	14 9 B-Disease
and	24 3 O
acute	28 5 B-Disease
renal	34 5 I-Disease
failure	40 7 I-Disease
following	48 9 O
intermittent	58 12 O
rifampin	71 8 B-Chemical
therapy	80 7 O
.	87 1 O

Renal	89 5 B-Disease
failure	95 7 I-Disease
is	103 2 O
a	106 1 O
rare	108 4 O
complication	113 12 O
associated	126 10 O
with	137 4 O
the	142 3 O
use	146 3 O
of	150 2 O
rifampin	153 8 B-Chemical
.	161 1 O

Intravascular	163 13 O
hemolysis	177 9 B-Disease
leading	187 7 O
to	195 2 O
acute	198 5 B-Disease
renal	204 5 I-Disease
failure	210 7 I-Disease
following	218 9 O
rifampin	228 8 B-Chemical
therapy	237 7 O
is	245 2 O
extremely	248 9 O
rare	258 4 O
.	262 1 O

Two	264 3 O
patients	268 8 O
with	277 4 O
leprosy	282 7 B-Disease
who	290 3 O
developed	294 9 O
hemolysis	304 9 B-Disease
and	314 3 O
acute	318 5 B-Disease
renal	324 5 I-Disease
failure	330 7 I-Disease
following	338 9 O
rifampin	348 8 B-Chemical
are	357 3 O
reported	361 8 O
.	369 1 O

Zidovudine	0 10 B-Chemical
-	10 1 O
induced	11 7 O
hepatitis	19 9 B-Disease
.	28 1 O

A	30 1 O
case	32 4 O
of	37 2 O
acute	40 5 O
hepatitis	46 9 B-Disease
induced	56 7 O
by	64 2 O
zidovudine	67 10 B-Chemical
in	78 2 O
a	81 1 O
38	83 2 O
-	85 1 O
year	86 4 O
-	90 1 O
old	91 3 O
patient	95 7 O
with	103 4 O
AIDS	108 4 B-Disease
is	113 2 O
presented	116 9 O
.	125 1 O

The	127 3 O
mechanism	131 9 O
whereby	141 7 O
the	149 3 O
hepatitis	153 9 B-Disease
was	163 3 O
induced	167 7 O
is	175 2 O
not	178 3 O
known	182 5 O
.	187 1 O

However	189 7 O
,	196 1 O
the	198 3 O
patient	202 7 O
tolerated	210 9 O
well	220 4 O
an	225 2 O
alternative	228 11 O
reverse	240 7 O
transcriptase	248 13 O
inhibitor	262 9 O
,	271 1 O
2	273 1 B-Chemical
'	274 1 I-Chemical
3	275 1 I-Chemical
'	276 1 I-Chemical
dideoxyinosine	278 14 I-Chemical
.	292 1 O

Physicians	294 10 O
caring	305 6 O
for	312 3 O
patients	316 8 O
with	325 4 O
AIDS	330 4 B-Disease
should	335 6 O
be	342 2 O
aware	345 5 O
of	351 2 O
this	354 4 O
hitherto	359 8 O
rarely	368 6 O
reported	375 8 O
complication	384 12 O
.	396 1 O

Thoracic	0 8 B-Disease
hematomyelia	9 12 I-Disease
secondary	22 9 O
to	32 2 O
coumadin	35 8 B-Chemical
anticoagulant	44 13 O
therapy	58 7 O
:	65 1 O
a	67 1 O
case	69 4 O
report	74 6 O
.	80 1 O

A	82 1 O
case	84 4 O
of	89 2 O
thoracic	92 8 B-Disease
hematomyelia	101 12 I-Disease
secondary	114 9 O
to	124 2 O
anticoagulant	127 13 O
therapy	141 7 O
is	149 2 O
presented	152 9 O
.	161 1 O

Clinical	163 8 O
features	172 8 O
,	180 1 O
similar	182 7 O
to	190 2 O
2	193 1 O
other	195 5 O
previously	201 10 O
reported	212 8 O
cases	221 5 O
,	226 1 O
are	228 3 O
discussed	232 9 O
.	241 1 O

A	243 1 O
high	245 4 O
index	250 5 O
of	256 2 O
suspicion	259 9 O
may	269 3 O
lead	273 4 O
to	278 2 O
a	281 1 O
quick	283 5 O
diagnostic	289 10 O
procedure	300 9 O
and	310 3 O
successful	314 10 O
decompressive	325 13 O
surgery	339 7 O
.	346 1 O

Mania	0 5 B-Disease
associated	6 10 O
with	17 4 O
fluoxetine	22 10 B-Chemical
treatment	33 9 O
in	43 2 O
adolescents	46 11 O
.	57 1 O

Fluoxetine	59 10 B-Chemical
,	69 1 O
a	71 1 O
selective	73 9 O
serotonin	83 9 B-Chemical
reuptake	93 8 O
inhibitor	102 9 O
,	111 1 O
is	113 2 O
gaining	116 7 O
increased	124 9 O
acceptance	134 10 O
in	145 2 O
the	148 3 O
treatment	152 9 O
of	162 2 O
adolescent	165 10 O
depression	176 10 B-Disease
.	186 1 O

Generally	188 9 O
safe	198 4 O
and	203 3 O
well	207 4 O
tolerated	212 9 O
by	222 2 O
adults	225 6 O
,	231 1 O
fluoxetine	233 10 B-Chemical
has	244 3 O
been	248 4 O
reported	253 8 O
to	262 2 O
induce	265 6 O
mania	272 5 B-Disease
.	277 1 O

The	279 3 O
cases	283 5 O
of	289 2 O
five	292 4 O
depressed	297 9 B-Disease
adolescents	307 11 O
,	318 1 O
14	320 2 O
-	322 1 O
16	323 2 O
years	326 5 O
of	332 2 O
age	335 3 O
,	338 1 O
who	340 3 O
developed	344 9 O
mania	354 5 B-Disease
during	360 6 O
pharmacotherapy	367 15 O
with	383 4 O
fluoxetine	388 10 B-Chemical
,	398 1 O
are	400 3 O
reported	404 8 O
here	413 4 O
.	417 1 O

Apparent	419 8 O
risk	428 4 O
factors	433 7 O
for	441 3 O
the	445 3 O
development	449 11 O
of	461 2 O
mania	464 5 B-Disease
or	470 2 O
hypomania	473 9 B-Disease
during	483 6 O
fluoxetine	490 10 B-Chemical
pharmacotherapy	501 15 O
in	517 2 O
this	520 4 O
population	525 10 O
were	536 4 O
the	541 3 O
combination	545 11 O
of	557 2 O
attention	560 9 B-Disease
-	569 1 I-Disease
deficit	570 7 I-Disease
hyperactivity	578 13 I-Disease
disorder	592 8 I-Disease
and	601 3 O
affective	605 9 O
instability	615 11 O
;	626 1 O
major	628 5 O
depression	634 10 B-Disease
with	645 4 O
psychotic	650 9 B-Disease
features	660 8 O
;	668 1 O
a	670 1 O
family	672 6 O
history	679 7 O
of	687 2 O
affective	690 9 B-Disease
disorder	700 8 I-Disease
,	708 1 O
especially	710 10 O
bipolar	721 7 B-Disease
disorder	729 8 I-Disease
;	737 1 O
and	739 3 O
a	743 1 O
diagnosis	745 9 O
of	755 2 O
bipolar	758 7 B-Disease
disorder	766 8 I-Disease
.	774 1 O

Further	776 7 O
study	784 5 O
is	790 2 O
needed	793 6 O
to	800 2 O
determine	803 9 O
the	813 3 O
optimal	817 7 O
dosage	825 6 O
and	832 3 O
to	836 2 O
identify	839 8 O
risk	848 4 O
factors	853 7 O
that	861 4 O
increase	866 8 O
individual	875 10 O
vulnerability	886 13 O
to	900 2 O
fluoxetine	903 10 B-Chemical
induced	914 7 O
mania	922 5 B-Disease
in	928 2 O
adolescents	931 11 O
.	942 1 O

Gemfibrozil	0 11 B-Chemical
-	11 1 O
lovastatin	12 10 B-Chemical
therapy	23 7 O
for	31 3 O
primary	35 7 O
hyperlipoproteinemias	43 21 B-Disease
.	64 1 O

The	66 3 O
specific	70 8 O
aim	79 3 O
of	83 2 O
this	86 4 O
retrospective	91 13 O
,	104 1 O
observational	106 13 O
study	120 5 O
was	126 3 O
to	130 2 O
assess	133 6 O
safety	140 6 O
and	147 3 O
efficacy	151 8 O
of	160 2 O
long	163 4 O
-	167 1 O
term	168 4 O
(	173 1 O
21	174 2 O
months	177 6 O
/	183 1 O
patient	184 7 O
)	191 1 O
,	192 1 O
open	194 4 O
-	198 1 O
label	199 5 O
,	204 1 O
gemfibrozil	206 11 B-Chemical
-	217 1 O
lovastatin	218 10 B-Chemical
treatment	229 9 O
in	239 2 O
80	242 2 O
patients	245 8 O
with	254 4 O
primary	259 7 O
mixed	267 5 O
hyperlipidemia	273 14 B-Disease
(	288 1 O
68	289 2 O
%	291 1 O
of	293 2 O
whom	296 4 O
had	301 3 O
atherosclerotic	305 15 B-Disease
vascular	321 8 I-Disease
disease	330 7 I-Disease
)	337 1 O
.	338 1 O

Because	340 7 O
ideal	348 5 O
lipid	354 5 O
targets	360 7 O
were	368 4 O
not	373 3 O
reached	377 7 O
(	385 1 O
low	386 3 O
-	389 1 O
density	390 7 O
lipoprotein	398 11 O
(	410 1 O
LDL	411 3 O
)	414 1 O
cholesterol	416 11 B-Chemical
less	428 4 O
than	433 4 O
130	438 3 O
mg	442 2 O
/	444 1 O
dl	445 2 O
,	447 1 O
high	449 4 O
-	453 1 O
density	454 7 O
lipoprotein	462 11 O
(	474 1 O
HDL	475 3 O
)	478 1 O
cholesterol	480 11 B-Chemical
greater	492 7 O
than	500 4 O
35	505 2 O
mg	508 2 O
/	510 1 O
dl	511 2 O
,	513 1 O
or	515 2 O
total	518 5 O
cholesterol	524 11 B-Chemical
/	535 1 O
HDL	536 3 O
cholesterol	540 11 B-Chemical
less	552 4 O
than	557 4 O
4	562 1 O
.	563 1 O
5	564 1 O
mg	566 2 O
/	568 1 O
dl	569 2 O
)	571 1 O
with	573 4 O
diet	578 4 O
plus	583 4 O
a	588 1 O
single	590 6 O
drug	597 4 O
,	601 1 O
gemfibrozil	603 11 B-Chemical
(	615 1 O
1	616 1 O
.	617 1 O
2	618 1 O
g	620 1 O
/	621 1 O
day	622 3 O
)	625 1 O
-	626 1 O
lovastatin	627 10 B-Chemical
(	638 1 O
primarily	639 9 O
20	649 2 O
or	652 2 O
40	655 2 O
mg	658 2 O
)	660 1 O
treatment	662 9 O
was	672 3 O
given	676 5 O
.	681 1 O

Follow	683 6 O
-	689 1 O
up	690 2 O
visits	693 6 O
were	700 4 O
scheduled	705 9 O
with	715 4 O
2	720 1 O
-	721 1 O
drug	722 4 O
therapy	727 7 O
every	735 5 O
6	741 1 O
to	743 2 O
8	746 1 O
weeks	748 5 O
,	753 1 O
an	755 2 O
average	758 7 O
of	766 2 O
10	769 2 O
.	771 1 O
3	772 1 O
visits	774 6 O
per	781 3 O
patient	785 7 O
,	792 1 O
with	794 4 O
741	799 3 O
batteries	803 9 O
of	813 2 O
6	816 1 O
liver	818 5 O
function	824 8 O
tests	833 5 O
and	839 3 O
714	843 3 O
creatine	847 8 B-Chemical
phosphokinase	856 13 O
levels	870 6 O
measured	877 8 O
.	885 1 O

Only	887 4 O
1	892 1 O
of	894 2 O
the	897 3 O
4	901 1 O
,	902 1 O
446	903 3 O
liver	907 5 O
function	913 8 O
tests	922 5 O
(	928 1 O
0	929 1 O
.	930 1 O
02	931 2 O
%	933 1 O
)	934 1 O
,	935 1 O
a	937 1 O
gamma	939 5 O
glutamyl	945 8 O
transferase	954 11 O
,	965 1 O
was	967 3 O
greater	971 7 O
than	979 4 O
or	984 2 O
equal	987 5 O
to	993 2 O
3	996 1 O
times	998 5 O
the	1004 3 O
upper	1008 5 O
normal	1014 6 O
limit	1021 5 O
.	1026 1 O

Of	1028 2 O
the	1031 3 O
714	1035 3 O
creatine	1039 8 B-Chemical
phosphokinase	1048 13 O
levels	1062 6 O
,	1068 1 O
9	1070 1 O
%	1071 1 O
were	1073 4 O
high	1078 4 O
;	1082 1 O
only	1084 4 O
1	1089 1 O
(	1091 1 O
0	1092 1 O
.	1093 1 O
1	1094 1 O
%	1095 1 O
)	1096 1 O
was	1098 3 O
greater	1102 7 O
than	1110 4 O
or	1115 2 O
equal	1118 5 O
to	1124 2 O
3	1127 1 O
times	1129 5 O
the	1135 3 O
upper	1139 5 O
normal	1145 6 O
limit	1152 5 O
.	1157 1 O

With	1159 4 O
2	1164 1 O
-	1165 1 O
drug	1166 4 O
therapy	1171 7 O
,	1178 1 O
mean	1180 4 O
total	1185 5 O
cholesterol	1191 11 B-Chemical
decreased	1203 9 O
22	1213 2 O
%	1215 1 O
from	1217 4 O
255	1222 3 O
to	1226 2 O
200	1229 3 O
mg	1233 2 O
/	1235 1 O
dl	1236 2 O
,	1238 1 O
triglyceride	1240 12 B-Chemical
levels	1253 6 O
decreased	1260 9 O
35	1270 2 O
%	1272 1 O
from	1274 4 O
236	1279 3 O
to	1283 2 O
154	1286 3 O
mg	1290 2 O
/	1292 1 O
dl	1293 2 O
,	1295 1 O
LDL	1297 3 O
cholesterol	1301 11 B-Chemical
decreased	1313 9 O
26	1323 2 O
%	1325 1 O
from	1327 4 O
176	1332 3 O
to	1336 2 O
131	1339 3 O
mg	1343 2 O
/	1345 1 O
dl	1346 2 O
,	1348 1 O
and	1350 3 O
the	1354 3 O
total	1358 5 O
cholesterol	1364 11 B-Chemical
/	1375 1 O
HDL	1376 3 O
cholesterol	1380 11 B-Chemical
ratio	1392 5 O
decreased	1398 9 O
24	1408 2 O
%	1410 1 O
from	1412 4 O
7	1417 1 O
.	1418 1 O
1	1419 1 O
to	1421 2 O
5	1424 1 O
.	1425 1 O
4	1426 1 O
,	1427 1 O
all	1429 3 O
p	1433 1 O
less	1435 4 O
than	1440 4 O
or	1445 2 O
equal	1448 5 O
to	1454 2 O
0	1457 1 O
.	1458 1 O
0001	1459 4 O
.	1463 1 O

Myositis	1465 8 B-Disease
,	1473 1 O
attributable	1475 12 O
to	1488 2 O
the	1491 3 O
drug	1495 4 O
combination	1500 11 O
and	1512 3 O
symptomatic	1516 11 O
enough	1528 6 O
to	1535 2 O
discontinue	1538 11 O
it	1550 2 O
,	1552 1 O
occurred	1554 8 O
in	1563 2 O
3	1566 1 O
%	1567 1 O
of	1569 2 O
patients	1572 8 O
,	1580 1 O
and	1582 3 O
in	1586 2 O
1	1589 1 O
%	1590 1 O
with	1592 4 O
concurrent	1597 10 O
high	1608 4 O
creatine	1613 8 B-Chemical
phosphokinase	1622 13 O
(	1636 1 O
769	1637 3 O
U	1641 1 O
/	1642 1 O
liter	1643 5 O
)	1648 1 O
;	1649 1 O
no	1651 2 O
patients	1654 8 O
had	1663 3 O
rhabdomyolysis	1667 14 B-Disease
or	1682 2 O
myoglobinuria	1685 13 B-Disease
.	1698 1 O
(	1699 1 O
ABSTRACT	1700 8 O
TRUNCATED	1709 9 O
AT	1719 2 O
250	1722 3 O
WORDS	1726 5 O
)	1731 1 O

Hepatocellular	0 14 B-Disease
carcinoma	15 9 I-Disease
in	25 2 O
Fanconi	28 7 B-Disease
'	35 1 I-Disease
s	36 1 I-Disease
anemia	38 6 I-Disease
treated	45 7 O
with	53 4 O
androgen	58 8 B-Chemical
and	67 3 O
corticosteroid	71 14 B-Chemical
.	85 1 O

The	87 3 O
case	91 4 O
of	96 2 O
an	99 2 O
11	102 2 O
-	104 1 O
year	105 4 O
-	109 1 O
old	110 3 O
boy	114 3 O
is	118 2 O
reported	121 8 O
who	130 3 O
was	134 3 O
known	138 5 O
to	144 2 O
have	147 4 O
Fanconi	152 7 B-Disease
'	159 1 I-Disease
s	160 1 I-Disease
anemia	162 6 I-Disease
for	169 3 O
3	173 1 O
years	175 5 O
and	181 3 O
was	185 3 O
treated	189 7 O
with	197 4 O
androgens	202 9 B-Chemical
,	211 1 O
corticosteroids	213 15 B-Chemical
and	229 3 O
transfusions	233 12 O
.	245 1 O

Two	247 3 O
weeks	251 5 O
before	257 6 O
his	264 3 O
death	268 5 O
he	274 2 O
was	277 3 O
readmitted	281 10 O
because	292 7 O
of	300 2 O
aplastic	303 8 O
crisis	312 6 O
with	319 4 O
septicemia	324 10 B-Disease
and	335 3 O
marked	339 6 O
abnormalities	346 13 O
in	360 2 O
liver	363 5 O
function	369 8 O
and	378 3 O
died	382 4 O
of	387 2 O
hemorrhagic	390 11 B-Disease
bronchopneumonia	402 16 I-Disease
.	418 1 O

At	420 2 O
autopsy	423 7 O
peliosis	431 8 B-Disease
and	440 3 O
multiple	444 8 O
hepatic	453 7 B-Disease
tumors	461 6 I-Disease
were	468 4 O
found	473 5 O
which	479 5 O
histologically	485 14 O
proved	500 6 O
to	507 2 O
be	510 2 O
well	513 4 O
-	517 1 O
differentiated	518 14 O
hepatocellular	533 14 B-Disease
carcinoma	548 9 I-Disease
.	557 1 O

This	559 4 O
case	564 4 O
contributes	569 11 O
to	581 2 O
the	584 3 O
previous	588 8 O
observations	597 12 O
that	610 4 O
non	615 3 O
-	618 1 O
metastasizing	619 13 O
hepatic	633 7 B-Disease
neoplasms	641 9 I-Disease
and	651 3 O
peliosis	655 8 B-Disease
can	664 3 O
develop	668 7 O
in	676 2 O
patients	679 8 O
with	688 4 O
androgen	693 8 B-Chemical
-	701 1 O
and	703 3 O
corticosteroid	707 14 B-Chemical
-	721 1 O
treated	722 7 O
Fanconi	730 7 B-Disease
'	737 1 I-Disease
s	738 1 I-Disease
anemia	740 6 I-Disease
.	746 1 O

Chronic	0 7 O
lesion	8 6 O
of	15 2 O
rostral	18 7 O
ventrolateral	26 13 O
medulla	40 7 O
in	48 2 O
spontaneously	51 13 O
hypertensive	65 12 B-Disease
rats	78 4 O
.	82 1 O

We	84 2 O
studied	87 7 O
the	95 3 O
effects	99 7 O
of	107 2 O
chronic	110 7 O
selective	118 9 O
neuronal	128 8 O
lesion	137 6 O
of	144 2 O
rostral	147 7 O
ventrolateral	155 13 O
medulla	169 7 O
on	177 2 O
mean	180 4 O
arterial	185 8 O
pressure	194 8 O
,	202 1 O
heart	204 5 O
rate	210 4 O
,	214 1 O
and	216 3 O
neurogenic	220 10 O
tone	231 4 O
in	236 2 O
conscious	239 9 O
,	248 1 O
unrestrained	250 12 O
spontaneously	263 13 O
hypertensive	277 12 B-Disease
rats	290 4 O
.	294 1 O

The	296 3 O
lesions	300 7 O
were	308 4 O
placed	313 6 O
via	320 3 O
bilateral	324 9 O
microinjections	334 15 O
of	350 2 O
30	353 2 O
nmol	356 4 O
/	360 1 O
200	361 3 O
nl	365 2 O
N	368 1 B-Chemical
-	369 1 I-Chemical
methyl	370 6 I-Chemical
-	376 1 I-Chemical
D	377 1 I-Chemical
-	378 1 I-Chemical
aspartic	379 8 I-Chemical
acid	388 4 I-Chemical
.	392 1 O

The	394 3 O
restimulation	398 13 O
of	412 2 O
this	415 4 O
area	420 4 O
with	425 4 O
N	430 1 B-Chemical
-	431 1 I-Chemical
methyl	432 6 I-Chemical
-	438 1 I-Chemical
D	439 1 I-Chemical
-	440 1 I-Chemical
aspartic	441 8 I-Chemical
acid	450 4 I-Chemical
15	455 2 O
days	458 4 O
postlesion	463 10 O
failed	474 6 O
to	481 2 O
produce	484 7 O
a	492 1 O
pressor	494 7 O
response	502 8 O
.	510 1 O

One	512 3 O
day	516 3 O
postlesion	520 10 O
,	530 1 O
the	532 3 O
resting	536 7 O
mean	544 4 O
arterial	549 8 O
pressure	558 8 O
was	567 3 O
significantly	571 13 O
decreased	585 9 O
in	595 2 O
lesioned	598 8 O
rats	607 4 O
when	612 4 O
compared	617 8 O
with	626 4 O
sham	631 4 O
rats	636 4 O
(	641 1 O
100	642 3 O
+	646 1 O
/	647 1 O
-	648 1 O
7	650 1 O
versus	652 6 O
173	659 3 O
+	663 1 O
/	664 1 O
-	665 1 O
4	667 1 O
mm	669 2 O
Hg	672 2 O
,	674 1 O
p	676 1 O
less	678 4 O
than	683 4 O
0	688 1 O
.	689 1 O
05	690 2 O
)	692 1 O
.	693 1 O

Fifteen	695 7 O
days	703 4 O
later	708 5 O
,	713 1 O
the	715 3 O
lesioned	719 8 O
group	728 5 O
still	734 5 O
showed	740 6 O
values	747 6 O
significantly	754 13 O
lower	768 5 O
than	774 4 O
the	779 3 O
sham	783 4 O
group	788 5 O
(	794 1 O
150	795 3 O
+	799 1 O
/	800 1 O
-	801 1 O
6	803 1 O
versus	805 6 O
167	812 3 O
+	816 1 O
/	817 1 O
-	818 1 O
5	820 1 O
mm	822 2 O
Hg	825 2 O
,	827 1 O
p	829 1 O
less	831 4 O
than	836 4 O
0	841 1 O
.	842 1 O
05	843 2 O
)	845 1 O
.	846 1 O

No	848 2 O
significant	851 11 O
heart	863 5 O
rate	869 4 O
differences	874 11 O
were	886 4 O
observed	891 8 O
between	900 7 O
the	908 3 O
sham	912 4 O
and	917 3 O
lesioned	921 8 O
groups	930 6 O
.	936 1 O

The	938 3 O
ganglionic	942 10 O
blocker	953 7 O
trimethaphan	961 12 B-Chemical
(	974 1 O
5	975 1 O
mg	977 2 O
/	979 1 O
kg	980 2 O
i	983 1 O
.	984 1 O
v	985 1 O
.	986 1 O
)	987 1 O
caused	989 6 O
similar	996 7 O
reductions	1004 10 O
in	1015 2 O
mean	1018 4 O
arterial	1023 8 O
pressure	1032 8 O
in	1041 2 O
both	1044 4 O
lesioned	1049 8 O
and	1058 3 O
sham	1062 4 O
groups	1067 6 O
.	1073 1 O

The	1075 3 O
trimethaphan	1079 12 B-Chemical
-	1091 1 O
induced	1092 7 O
hypotension	1100 11 B-Disease
was	1112 3 O
accompanied	1116 11 O
by	1128 2 O
a	1131 1 O
significant	1133 11 O
bradycardia	1145 11 B-Disease
in	1157 2 O
lesioned	1160 8 O
rats	1169 4 O
(	1174 1 O
-	1175 1 O
32	1176 2 O
+	1179 1 O
/	1180 1 O
-	1181 1 O
13	1183 2 O
beats	1186 5 O
per	1192 3 O
minute	1196 6 O
)	1202 1 O
but	1204 3 O
a	1208 1 O
tachycardia	1210 11 B-Disease
in	1222 2 O
sham	1225 4 O
rats	1230 4 O
(	1235 1 O
+	1236 1 O
33	1237 2 O
+	1240 1 O
/	1241 1 O
-	1242 1 O
12	1244 2 O
beats	1247 5 O
per	1253 3 O
minute	1257 6 O
)	1263 1 O
1	1265 1 O
day	1267 3 O
postlesion	1271 10 O
.	1281 1 O

Therefore	1283 9 O
,	1292 1 O
rostral	1294 7 O
ventrolateral	1302 13 O
medulla	1316 7 O
neurons	1324 7 O
appear	1332 6 O
to	1339 2 O
play	1342 4 O
a	1347 1 O
significant	1349 11 O
role	1361 4 O
in	1366 2 O
maintaining	1369 11 O
hypertension	1381 12 B-Disease
in	1394 2 O
conscious	1397 9 O
spontaneously	1407 13 O
hypertensive	1421 12 B-Disease
rats	1434 4 O
.	1438 1 O

Spinal	1440 6 O
or	1447 2 O
suprabulbar	1450 11 O
structures	1462 10 O
could	1473 5 O
be	1479 2 O
responsible	1482 11 O
for	1494 3 O
the	1498 3 O
gradual	1502 7 O
recovery	1510 8 O
of	1519 2 O
the	1522 3 O
hypertension	1526 12 B-Disease
in	1539 2 O
the	1542 3 O
lesioned	1546 8 O
rats	1555 4 O
.	1559 1 O

Damage	0 6 B-Disease
of	7 2 I-Disease
substantia	10 10 I-Disease
nigra	21 5 I-Disease
pars	27 4 I-Disease
reticulata	32 10 I-Disease
during	43 6 O
pilocarpine	50 11 B-Chemical
-	61 1 O
induced	62 7 O
status	70 6 B-Disease
epilepticus	77 11 I-Disease
in	89 2 O
the	92 3 O
rat	96 3 O
:	99 1 O
immunohistochemical	101 19 O
study	121 5 O
of	127 2 O
neurons	130 7 O
,	137 1 O
astrocytes	139 10 O
and	150 3 O
serum	154 5 O
-	159 1 O
protein	160 7 O
extravasation	168 13 O
.	181 1 O

The	183 3 O
substantia	187 10 O
nigra	198 5 O
has	204 3 O
a	208 1 O
gating	210 6 O
function	217 8 O
controlling	226 11 O
the	238 3 O
spread	242 6 O
of	249 2 O
epileptic	252 9 B-Disease
seizure	262 7 I-Disease
activity	270 8 O
.	278 1 O

Additionally	280 12 O
,	292 1 O
in	294 2 O
models	297 6 O
of	304 2 O
prolonged	307 9 B-Disease
status	317 6 I-Disease
epilepticus	324 11 I-Disease
the	336 3 O
pars	340 4 O
reticulata	345 10 O
of	356 2 O
substantia	359 10 O
nigra	370 5 O
(	376 1 O
SNR	377 3 O
)	380 1 O
suffers	382 7 O
from	390 4 O
a	395 1 O
massive	397 7 O
lesion	405 6 O
which	412 5 O
may	418 3 O
arise	422 5 O
from	428 4 O
a	433 1 O
massive	435 7 O
metabolic	443 9 B-Disease
derangement	453 11 I-Disease
and	465 3 O
hyperexcitation	469 15 O
developing	485 10 O
in	496 2 O
the	499 3 O
activated	503 9 O
SNR	513 3 O
.	516 1 O

In	518 2 O
this	521 4 O
study	526 5 O
,	531 1 O
status	533 6 B-Disease
epilepticus	540 11 I-Disease
was	552 3 O
induced	556 7 O
by	564 2 O
systemic	567 8 O
injection	576 9 O
of	586 2 O
pilocarpine	589 11 B-Chemical
in	601 2 O
rats	604 4 O
.	608 1 O

The	610 3 O
neuropathology	614 14 O
of	629 2 O
SNR	632 3 O
was	636 3 O
investigated	640 12 O
using	653 5 O
immunohistochemical	659 19 O
techniques	679 10 O
with	690 4 O
the	695 3 O
major	699 5 O
emphasis	705 8 O
on	714 2 O
the	717 3 O
time	721 4 O
-	725 1 O
course	726 6 O
of	733 2 O
changes	736 7 O
in	744 2 O
neurons	747 7 O
and	755 3 O
astrocytes	759 10 O
.	769 1 O

Animals	771 7 O
surviving	779 9 O
20	789 2 O
,	791 1 O
30	793 2 O
,	795 1 O
40	797 2 O
,	799 1 O
60	801 2 O
min	804 3 O
,	807 1 O
2	809 1 O
,	810 1 O
3	812 1 O
,	813 1 O
6	815 1 O
hours	817 5 O
,	822 1 O
1	824 1 O
,	825 1 O
2	827 1 O
,	828 1 O
and	830 3 O
3	834 1 O
days	836 4 O
after	841 5 O
induction	847 9 O
of	857 2 O
status	860 6 B-Disease
epilepticus	867 11 I-Disease
were	879 4 O
perfusion	884 9 O
-	893 1 O
fixed	894 5 O
,	899 1 O
and	901 3 O
brains	905 6 O
processed	912 9 O
for	922 3 O
immunohistochemical	926 19 O
staining	946 8 O
of	955 2 O
SNR	958 3 O
.	961 1 O

Nissl	963 5 O
-	968 1 O
staining	969 8 O
and	978 3 O
antibodies	982 10 O
against	993 7 O
the	1001 3 O
neuron	1005 6 O
-	1011 1 O
specific	1012 8 O
calcium	1021 7 B-Chemical
-	1028 1 O
binding	1029 7 O
protein	1037 7 O
,	1044 1 O
parvalbumin	1046 11 O
,	1057 1 O
served	1059 6 O
to	1066 2 O
detect	1069 6 O
neuronal	1076 8 B-Disease
damage	1085 6 I-Disease
in	1092 2 O
SNR	1095 3 O
.	1098 1 O

Antibodies	1100 10 O
against	1111 7 O
the	1119 3 O
astroglia	1123 9 O
-	1132 1 O
specific	1133 8 O
cytoskeletal	1142 12 O
protein	1155 7 O
,	1162 1 O
glial	1164 5 O
fibrillary	1170 10 O
acidic	1181 6 O
protein	1188 7 O
(	1196 1 O
GFAP	1197 4 O
)	1201 1 O
,	1202 1 O
and	1204 3 O
against	1208 7 O
the	1216 3 O
glial	1220 5 O
calcium	1226 7 B-Chemical
-	1233 1 O
binding	1234 7 O
protein	1242 7 O
,	1249 1 O
S	1251 1 O
-	1252 1 O
100	1253 3 O
protein	1257 7 O
,	1264 1 O
were	1266 4 O
used	1271 4 O
to	1276 2 O
assess	1279 6 O
the	1286 3 O
status	1290 6 O
of	1297 2 O
astrocytes	1300 10 O
.	1310 1 O

Immunohistochemical	1312 19 O
staining	1332 8 O
for	1341 3 O
serum	1345 5 O
-	1350 1 O
albumin	1351 7 O
and	1359 3 O
immunoglobulins	1363 15 O
in	1379 2 O
brain	1382 5 O
tissue	1388 6 O
was	1395 3 O
taken	1399 5 O
as	1405 2 O
indicator	1408 9 O
of	1418 2 O
blood	1421 5 O
-	1426 1 O
brain	1427 5 O
barrier	1433 7 O
disturbances	1441 12 O
and	1454 3 O
vasogenic	1458 9 B-Disease
edema	1468 5 I-Disease
formation	1474 9 O
.	1483 1 O

Immunohistochemical	1485 19 O
staining	1505 8 O
indicated	1514 9 O
loss	1524 4 O
of	1529 2 O
GFAP	1532 4 O
-	1536 1 O
staining	1537 8 O
already	1546 7 O
at	1554 2 O
30	1557 2 O
min	1560 3 O
after	1564 5 O
induction	1570 9 O
of	1580 2 O
seizures	1583 8 B-Disease
in	1592 2 O
an	1595 2 O
oval	1598 4 O
focus	1603 5 O
situated	1609 8 O
in	1618 2 O
the	1621 3 O
center	1625 6 O
of	1632 2 O
SNR	1635 3 O
while	1639 5 O
sparing	1645 7 O
medial	1653 6 O
and	1660 3 O
lateral	1664 7 O
aspects	1672 7 O
.	1679 1 O

At	1681 2 O
1	1684 1 O
h	1686 1 O
there	1688 5 O
was	1694 3 O
additional	1698 10 O
vacuolation	1709 11 O
in	1721 2 O
S	1724 1 O
-	1725 1 O
100	1726 3 O
protein	1730 7 O
staining	1738 8 O
.	1746 1 O

By	1748 2 O
2	1751 1 O
hours	1753 5 O
,	1758 1 O
parvalbumin	1760 11 O
-	1771 1 O
staining	1772 8 O
changed	1781 7 O
in	1789 2 O
the	1792 3 O
central	1796 7 O
SNR	1804 3 O
indicating	1808 10 O
neuronal	1819 8 B-Disease
damage	1828 6 I-Disease
,	1834 1 O
and	1836 3 O
Nissl	1840 5 O
-	1845 1 O
staining	1846 8 O
visualized	1855 10 O
some	1866 4 O
neuronal	1871 8 O
distortion	1880 10 O
.	1890 1 O

Staining	1892 8 O
for	1901 3 O
serum	1905 5 O
-	1910 1 O
proteins	1911 8 O
occurred	1920 8 O
in	1929 2 O
a	1932 1 O
patchy	1934 6 O
manner	1941 6 O
throughout	1948 10 O
the	1959 3 O
forebrain	1963 9 O
during	1973 6 O
the	1980 3 O
first	1984 5 O
hours	1990 5 O
.	1995 1 O

By	1997 2 O
6	2000 1 O
h	2002 1 O
,	2003 1 O
vasogenic	2005 9 B-Disease
edema	2015 5 I-Disease
covered	2021 7 O
the	2029 3 O
lesioned	2033 8 B-Disease
SNR	2042 3 I-Disease
.	2045 1 O

By	2047 2 O
24	2050 2 O
h	2053 1 O
,	2054 1 O
glial	2056 5 O
and	2062 3 O
neuronal	2066 8 O
markers	2075 7 O
indicated	2083 9 O
a	2093 1 O
massive	2095 7 O
lesion	2103 6 O
in	2110 2 O
the	2113 3 O
center	2117 6 O
of	2124 2 O
SNR	2127 3 O
.	2130 1 O

By	2132 2 O
48	2135 2 O
-	2137 1 O
72	2138 2 O
h	2141 1 O
,	2142 1 O
astrocytes	2144 10 O
surrounding	2155 11 O
the	2167 3 O
lesion	2171 6 O
increased	2178 9 O
in	2188 2 O
size	2191 4 O
,	2195 1 O
and	2197 3 O
polymorphic	2201 11 O
phagocytotic	2213 12 O
cells	2226 5 O
invaded	2232 7 O
the	2240 3 O
damaged	2244 7 O
area	2252 4 O
.	2256 1 O

In	2258 2 O
a	2261 1 O
further	2263 7 O
group	2271 5 O
of	2277 2 O
animals	2280 7 O
surviving	2288 9 O
1	2298 1 O
to	2300 2 O
5	2303 1 O
days	2305 4 O
,	2309 1 O
conventional	2311 12 O
paraffin	2324 8 O
-	2332 1 O
sections	2333 8 O
confirmed	2342 9 O
the	2352 3 O
neuronal	2356 8 O
and	2365 3 O
glial	2369 5 O
damage	2375 6 B-Disease
of	2382 2 I-Disease
SNR	2385 3 I-Disease
.	2388 1 O

Additional	2390 10 O
pathology	2401 9 O
of	2411 2 O
similar	2414 7 O
quality	2422 7 O
was	2430 3 O
found	2434 5 O
in	2440 2 O
the	2443 3 O
globus	2447 6 O
pallidus	2454 8 O
.	2462 1 O

Since	2464 5 O
astrocytes	2470 10 O
were	2481 4 O
always	2486 6 O
damaged	2493 7 O
in	2501 2 O
parallel	2504 8 O
with	2513 4 O
neurons	2518 7 O
in	2526 2 O
SNR	2529 3 O
it	2533 2 O
is	2536 2 O
proposed	2539 8 O
that	2548 4 O
the	2553 3 O
anatomical	2557 10 O
and	2568 3 O
functional	2572 10 O
interrelationship	2583 17 O
between	2601 7 O
neurons	2609 7 O
and	2617 3 O
astrocytes	2621 10 O
is	2632 2 O
particularly	2635 12 O
tight	2648 5 O
in	2654 2 O
SNR	2657 3 O
.	2660 1 O

Both	2662 4 O
cell	2667 4 O
elements	2672 8 O
may	2681 3 O
suffer	2685 6 O
in	2692 2 O
common	2695 6 O
from	2702 4 O
metabolic	2707 9 O
disturbance	2717 11 O
and	2729 3 O
neurotransmitter	2733 16 B-Disease
dysfunction	2750 11 I-Disease
as	2762 2 O
occur	2765 5 O
during	2771 6 O
massive	2778 7 O
status	2786 6 B-Disease
epilepticus	2793 11 I-Disease
.	2804 1 O

Reduced	0 7 O
cardiotoxicity	8 14 B-Disease
of	23 2 O
doxorubicin	26 11 B-Chemical
given	38 5 O
in	44 2 O
the	47 3 O
form	51 4 O
of	56 2 O
N	59 1 B-Chemical
-	60 1 I-Chemical
(	61 1 I-Chemical
2	62 1 I-Chemical
-	63 1 I-Chemical
hydroxypropyl	64 13 I-Chemical
)	77 1 I-Chemical
methacrylamide	78 14 I-Chemical
conjugates	93 10 O
:	103 1 O
and	105 3 O
experimental	109 12 O
study	122 5 O
in	128 2 O
the	131 3 O
rat	135 3 O
.	138 1 O

A	140 1 O
rat	142 3 O
model	146 5 O
was	152 3 O
used	156 4 O
to	161 2 O
evaluate	164 8 O
the	173 3 O
general	177 7 O
acute	185 5 O
toxicity	191 8 B-Disease
and	200 3 O
the	204 3 O
late	208 4 O
cardiotoxicity	213 14 B-Disease
of	228 2 O
4	231 1 O
mg	233 2 O
/	235 1 O
kg	236 2 O
doxorubicin	239 11 B-Chemical
(	251 1 O
DOX	252 3 B-Chemical
)	255 1 O
given	257 5 O
either	263 6 O
as	270 2 O
free	273 4 O
drug	278 4 O
or	283 2 O
in	286 2 O
the	289 3 O
form	293 4 O
of	298 2 O
three	301 5 O
N	307 1 B-Chemical
-	308 1 I-Chemical
(	309 1 I-Chemical
2	310 1 I-Chemical
-	311 1 I-Chemical
hydroxypropyl	312 13 I-Chemical
)	325 1 I-Chemical
methacrylamide	326 14 I-Chemical
(	341 1 O
HPMA	342 4 B-Chemical
)	346 1 O
copolymer	348 9 O
conjugates	358 10 O
.	368 1 O

In	370 2 O
these	373 5 O
HPMA	379 4 B-Chemical
copolymers	384 10 O
,	394 1 O
DOX	396 3 B-Chemical
was	400 3 O
covalently	404 10 O
bound	415 5 O
via	421 3 O
peptide	425 7 O
linkages	433 8 O
that	442 4 O
were	447 4 O
either	452 6 O
non	459 3 O
-	462 1 O
biodegradable	463 13 O
(	477 1 O
Gly	478 3 O
-	481 1 O
Gly	482 3 O
)	485 1 O
or	487 2 O
degradable	490 10 O
by	501 2 O
lysosomal	504 9 O
proteinases	514 11 O
(	526 1 O
Gly	527 3 B-Chemical
-	530 1 I-Chemical
Phe	531 3 I-Chemical
-	534 1 I-Chemical
Leu	535 3 I-Chemical
-	538 1 I-Chemical
Gly	539 3 I-Chemical
)	542 1 O
.	543 1 O

In	545 2 O
addition	548 8 O
,	556 1 O
one	558 3 O
biodegradable	562 13 O
conjugate	576 9 O
containing	586 10 O
galactosamine	597 13 B-Chemical
was	611 3 O
used	615 4 O
;	619 1 O
this	621 4 O
residue	626 7 O
was	634 3 O
targeted	638 8 O
to	647 2 O
the	650 3 O
liver	654 5 O
.	659 1 O

Over	661 4 O
the	666 3 O
first	670 5 O
3	676 1 O
weeks	678 5 O
after	684 5 O
the	690 3 O
i	694 1 O
.	695 1 O
v	696 1 O
.	697 1 O
administration	699 14 O
of	714 2 O
free	717 4 O
and	722 3 O
polymer	726 7 O
-	733 1 O
bound	734 5 O
DOX	740 3 B-Chemical
,	743 1 O
all	745 3 O
animals	749 7 O
showed	757 6 O
a	764 1 O
transient	766 9 O
reduction	776 9 O
in	786 2 O
body	789 4 O
weight	794 6 O
.	800 1 O

However	802 7 O
,	809 1 O
the	811 3 O
maximal	815 7 O
reduction	823 9 O
in	833 2 O
body	836 4 O
weight	841 6 O
seen	848 4 O
in	853 2 O
animals	856 7 O
that	864 4 O
received	869 8 O
polymer	878 7 O
-	885 1 O
bound	886 5 O
DOX	892 3 B-Chemical
(	896 1 O
4	897 1 O
mg	899 2 O
/	901 1 O
kg	902 2 O
)	904 1 O
was	906 3 O
significantly	910 13 O
lower	924 5 O
than	930 4 O
that	935 4 O
observed	940 8 O
in	949 2 O
those	952 5 O
that	958 4 O
received	963 8 O
free	972 4 O
DOX	977 3 B-Chemical
(	981 1 O
4	982 1 O
mg	984 2 O
/	986 1 O
kg	987 2 O
)	989 1 O
or	991 2 O
a	994 1 O
mixture	996 7 O
of	1004 2 O
the	1007 3 O
unmodified	1011 10 O
parent	1022 6 O
HPMA	1029 4 B-Chemical
copolymer	1034 9 O
and	1044 3 O
free	1048 4 O
DOX	1053 3 B-Chemical
(	1057 1 O
4	1058 1 O
mg	1060 2 O
/	1062 1 O
kg	1063 2 O
;	1065 1 O
P	1067 1 O
less	1069 4 O
than	1074 4 O
0	1079 1 O
.	1080 1 O
01	1081 2 O
)	1083 1 O
.	1084 1 O

Throughout	1086 10 O
the	1097 3 O
study	1101 5 O
(	1107 1 O
20	1108 2 O
weeks	1111 5 O
)	1116 1 O
,	1117 1 O
deaths	1119 6 O
related	1126 7 O
to	1134 2 O
cardiotoxicity	1137 14 B-Disease
were	1152 4 O
observed	1157 8 O
only	1166 4 O
in	1171 2 O
animals	1174 7 O
that	1182 4 O
received	1187 8 O
either	1196 6 O
free	1203 4 O
DOX	1208 3 B-Chemical
or	1212 2 O
the	1215 3 O
mixture	1219 7 O
of	1227 2 O
HPMA	1230 4 B-Chemical
copolymer	1235 9 O
and	1245 3 O
free	1249 4 O
DOX	1254 3 B-Chemical
;	1257 1 O
in	1259 2 O
these	1262 5 O
cases	1268 5 O
,	1273 1 O
histological	1275 12 O
investigations	1288 14 O
revealed	1303 8 O
marked	1312 6 O
changes	1319 7 O
in	1327 2 O
the	1330 3 O
heart	1334 5 O
that	1340 4 O
were	1345 4 O
consistent	1350 10 O
with	1361 4 O
DOX	1366 3 B-Chemical
-	1369 1 O
induced	1370 7 O
cardiotoxicity	1378 14 B-Disease
.	1392 1 O

Sequential	1394 10 O
measurements	1405 12 O
of	1418 2 O
cardiac	1421 7 O
output	1429 6 O
in	1436 2 O
surviving	1439 9 O
animals	1449 7 O
that	1457 4 O
received	1462 8 O
either	1471 6 O
free	1478 4 O
DOX	1483 3 B-Chemical
or	1487 2 O
the	1490 3 O
mixture	1494 7 O
of	1502 2 O
HPMA	1505 4 B-Chemical
copolymer	1510 9 O
and	1520 3 O
free	1524 4 O
DOX	1529 3 B-Chemical
showed	1533 6 O
a	1540 1 O
reduction	1542 9 O
of	1552 2 O
approximately	1555 13 O
30	1569 2 O
%	1571 1 O
in	1573 2 O
function	1576 8 O
beginning	1585 9 O
at	1595 2 O
the	1598 3 O
4th	1602 3 O
week	1606 4 O
after	1611 5 O
drug	1617 4 O
administration	1622 14 O
.	1636 1 O

The	1638 3 O
heart	1642 5 O
rate	1648 4 O
in	1653 2 O
these	1656 5 O
animals	1662 7 O
was	1670 3 O
approximately	1674 13 O
12	1688 2 O
%	1690 1 O
lower	1692 5 O
than	1698 4 O
that	1703 4 O
measured	1708 8 O
in	1717 2 O
age	1720 3 O
-	1723 1 O
matched	1724 7 O
control	1732 7 O
rats	1740 4 O
(	1745 1 O
P	1746 1 O
less	1748 4 O
than	1753 4 O
0	1758 1 O
.	1759 1 O
05	1760 2 O
)	1762 1 O
.	1763 1 O

Animals	1765 7 O
that	1773 4 O
were	1778 4 O
given	1783 5 O
the	1789 3 O
HPMA	1793 4 B-Chemical
copolymer	1798 9 O
conjugates	1808 10 O
containing	1819 10 O
DOX	1830 3 B-Chemical
exhibited	1834 9 O
no	1844 2 O
significant	1847 11 O
change	1859 6 O
in	1866 2 O
cardiac	1869 7 O
output	1877 6 O
throughout	1884 10 O
the	1895 3 O
study	1899 5 O
(	1905 1 O
P	1906 1 O
less	1908 4 O
than	1913 4 O
0	1918 1 O
.	1919 1 O
05	1920 2 O
)	1922 1 O
.	1923 1 O

In	1925 2 O
addition	1928 8 O
,	1936 1 O
no	1938 2 O
significant	1941 11 O
histological	1953 12 O
change	1966 6 O
was	1973 3 O
observed	1977 8 O
in	1986 2 O
the	1989 3 O
heart	1993 5 O
of	1999 2 O
animals	2002 7 O
that	2010 4 O
received	2015 8 O
DOX	2024 3 B-Chemical
in	2028 2 O
the	2031 3 O
form	2035 4 O
of	2040 2 O
HPMA	2043 4 B-Chemical
copolymer	2048 9 O
conjugates	2058 10 O
and	2069 3 O
were	2073 4 O
killed	2078 6 O
at	2085 2 O
the	2088 3 O
end	2092 3 O
of	2096 2 O
the	2099 3 O
study	2103 5 O
.	2108 1 O

However	2110 7 O
,	2117 1 O
these	2119 5 O
animals	2125 7 O
had	2133 3 O
shown	2137 5 O
a	2143 1 O
significant	2145 11 O
increase	2157 8 O
in	2166 2 O
heart	2169 5 O
rate	2175 4 O
beginning	2180 9 O
at	2190 2 O
8	2193 1 O
weeks	2195 5 O
after	2201 5 O
drug	2207 4 O
administration	2212 14 O
(	2227 1 O
P	2228 1 O
less	2230 4 O
than	2235 4 O
0	2240 1 O
.	2241 1 O
01	2242 2 O
)	2244 1 O
.	2245 1 O
(	2246 1 O
ABSTRACT	2247 8 O
TRUNCATED	2256 9 O
AT	2266 2 O
400	2269 3 O
WORDS	2273 5 O
)	2278 1 O

Topical	0 7 O
0	8 1 O
.	9 1 O
025	10 3 O
%	13 1 O
capsaicin	15 9 B-Chemical
in	25 2 O
chronic	28 7 O
post	36 4 B-Disease
-	40 1 I-Disease
herpetic	41 8 I-Disease
neuralgia	50 9 I-Disease
:	59 1 O
efficacy	61 8 O
,	69 1 O
predictors	71 10 O
of	82 2 O
response	85 8 O
and	94 3 O
long	98 4 O
-	102 1 O
term	103 4 O
course	108 6 O
.	114 1 O

In	116 2 O
order	119 5 O
to	125 2 O
evaluate	128 8 O
the	137 3 O
efficacy	141 8 O
,	149 1 O
time	151 4 O
-	155 1 O
course	156 6 O
of	163 2 O
action	166 6 O
and	173 3 O
predictors	177 10 O
of	188 2 O
response	191 8 O
to	200 2 O
topical	203 7 O
capsaicin	211 9 B-Chemical
,	220 1 O
39	222 2 O
patients	225 8 O
with	234 4 O
chronic	239 7 O
post	247 4 B-Disease
-	251 1 I-Disease
herpetic	252 8 I-Disease
neuralgia	261 9 I-Disease
(	271 1 O
PHN	272 3 B-Disease
)	275 1 O
,	276 1 O
median	278 6 O
duration	285 8 O
24	294 2 O
months	297 6 O
,	303 1 O
were	305 4 O
treated	310 7 O
with	318 4 O
0	323 1 O
.	324 1 O
025	325 3 O
%	328 1 O
capsaicin	330 9 B-Chemical
cream	340 5 O
for	346 3 O
8	350 1 O
weeks	352 5 O
.	357 1 O

During	359 6 O
therapy	366 7 O
the	374 3 O
patients	378 8 O
rated	387 5 O
their	393 5 O
pain	399 4 B-Disease
on	404 2 O
a	407 1 O
visual	409 6 O
analogue	416 8 O
scale	425 5 O
(	431 1 O
VAS	432 3 O
)	435 1 O
and	437 3 O
a	441 1 O
verbal	443 6 O
outcome	450 7 O
scale	458 5 O
.	463 1 O

A	465 1 O
follow	467 6 O
-	473 1 O
up	474 2 O
investigation	477 13 O
was	491 3 O
performed	495 9 O
10	505 2 O
-	507 1 O
12	508 2 O
months	511 6 O
after	518 5 O
study	524 5 O
onset	530 5 O
on	536 2 O
the	539 3 O
patients	543 8 O
who	552 3 O
had	556 3 O
improved	560 8 O
.	568 1 O

Nineteen	570 8 O
patients	579 8 O
(	588 1 O
48	589 2 O
.	591 1 O
7	592 1 O
%	593 1 O
)	594 1 O
substantially	596 13 O
improved	610 8 O
after	619 5 O
the	625 3 O
8	629 1 O
-	630 1 O
week	631 4 O
trial	636 5 O
;	641 1 O
5	643 1 O
(	645 1 O
12	646 2 O
.	648 1 O
8	649 1 O
%	650 1 O
)	651 1 O
discontinued	653 12 O
therapy	666 7 O
due	674 3 O
to	678 2 O
side	681 4 O
-	685 1 O
effects	686 7 O
such	694 4 O
as	699 2 O
intolerable	702 11 O
capsaicin	714 9 B-Chemical
-	723 1 O
induced	724 7 O
burning	732 7 O
sensations	740 10 O
(	751 1 O
4	752 1 O
)	753 1 O
or	755 2 O
mastitis	758 8 B-Disease
(	767 1 O
1	768 1 O
)	769 1 O
;	770 1 O
15	772 2 O
(	775 1 O
38	776 2 O
.	778 1 O
5	779 1 O
%	780 1 O
)	781 1 O
reported	783 8 O
no	792 2 O
benefit	795 7 O
.	802 1 O

The	804 3 O
decrease	808 8 O
in	817 2 O
VAS	820 3 O
ratings	824 7 O
was	832 3 O
significant	836 11 O
after	848 5 O
2	854 1 O
weeks	856 5 O
of	862 2 O
continuous	865 10 O
application	876 11 O
.	887 1 O

Of	889 2 O
the	892 3 O
responders	896 10 O
72	907 2 O
.	909 1 O
2	910 1 O
%	911 1 O
were	913 4 O
still	918 5 O
improved	924 8 O
at	933 2 O
the	936 3 O
follow	940 6 O
-	946 1 O
up	947 2 O
;	949 1 O
only	951 4 O
one	956 3 O
-	959 1 O
third	960 5 O
of	966 2 O
them	969 4 O
had	974 3 O
continued	978 9 O
application	988 11 O
irregularly	1000 11 O
.	1011 1 O

Treatment	1013 9 O
effect	1023 6 O
was	1030 3 O
not	1034 3 O
dependent	1038 9 O
on	1048 2 O
patient	1051 7 O
'	1058 1 O
s	1059 1 O
age	1061 3 O
,	1064 1 O
duration	1066 8 O
or	1075 2 O
localization	1078 12 O
of	1091 2 O
PHN	1094 3 B-Disease
(	1098 1 O
trigeminal	1099 10 O
involvement	1110 11 O
was	1122 3 O
excluded	1126 8 O
)	1134 1 O
,	1135 1 O
sensory	1137 7 B-Disease
disturbance	1145 11 I-Disease
or	1157 2 O
pain	1160 4 B-Disease
character	1165 9 O
.	1174 1 O

Treatment	1176 9 O
response	1186 8 O
was	1195 3 O
not	1199 3 O
correlated	1203 10 O
with	1214 4 O
the	1219 3 O
incidence	1223 9 O
,	1232 1 O
time	1234 4 O
-	1238 1 O
course	1239 6 O
or	1246 2 O
severity	1249 8 O
of	1258 2 O
capsaicin	1261 9 B-Chemical
-	1270 1 O
induced	1271 7 O
burning	1279 7 O
.	1286 1 O

If	1288 2 O
confirmed	1291 9 O
in	1301 2 O
controlled	1304 10 O
trials	1315 6 O
,	1321 1 O
the	1323 3 O
long	1327 4 O
-	1331 1 O
term	1332 4 O
results	1337 7 O
of	1345 2 O
this	1348 4 O
open	1353 4 O
,	1357 1 O
non	1359 3 O
-	1362 1 O
randomized	1363 10 O
study	1374 5 O
might	1380 5 O
indicate	1386 8 O
that	1395 4 O
the	1400 3 O
analgesic	1404 9 O
effect	1414 6 O
of	1421 2 O
capsaicin	1424 9 B-Chemical
in	1434 2 O
PHN	1437 3 B-Disease
is	1441 2 O
mediated	1444 8 O
by	1453 2 O
both	1456 4 O
interference	1461 12 O
with	1474 4 O
neuropeptide	1479 12 O
metabolism	1492 10 O
and	1503 3 O
morphological	1507 13 O
changes	1521 7 O
(	1529 1 O
perhaps	1530 7 O
degeneration	1538 12 O
)	1550 1 O
of	1552 2 O
nociceptive	1555 11 O
afferents	1567 9 O
.	1576 1 O

Serotonin	0 9 B-Chemical
reuptake	10 8 O
inhibitors	19 10 O
,	29 1 O
paranoia	31 8 B-Disease
,	39 1 O
and	41 3 O
the	45 3 O
ventral	49 7 O
basal	57 5 O
ganglia	63 7 O
.	70 1 O

Antidepressants	72 15 O
have	88 4 O
previously	93 10 O
been	104 4 O
associated	109 10 O
with	120 4 O
paranoid	125 8 B-Disease
reactions	134 9 O
in	144 2 O
psychiatric	147 11 O
patients	159 8 O
.	167 1 O

Five	169 4 O
cases	174 5 O
of	180 2 O
paranoid	183 8 B-Disease
exacerbation	192 12 O
with	205 4 O
the	210 3 O
serotonin	214 9 B-Chemical
reuptake	224 8 O
inhibitors	233 10 O
fluoxetine	244 10 B-Chemical
and	255 3 O
amitriptyline	259 13 B-Chemical
are	273 3 O
reported	277 8 O
here	286 4 O
.	290 1 O

Elements	292 8 O
common	301 6 O
to	308 2 O
these	311 5 O
cases	317 5 O
included	323 8 O
a	332 1 O
history	334 7 O
of	342 2 O
paranoid	345 8 B-Disease
symptomatology	354 14 O
and	369 3 O
the	373 3 O
concomitant	377 11 O
occurrence	389 10 O
of	400 2 O
depressive	403 10 B-Disease
and	414 3 I-Disease
psychotic	418 9 I-Disease
symptoms	428 8 I-Disease
.	436 1 O

Complicated	438 11 O
depressive	450 10 B-Disease
disorders	461 9 I-Disease
(	471 1 O
including	472 9 O
atypicality	482 11 O
of	494 2 O
course	497 6 O
and	504 3 O
symptomatology	508 14 O
,	522 1 O
chronicity	524 10 O
,	534 1 O
psychosis	536 9 B-Disease
,	545 1 O
bipolarity	547 10 O
,	557 1 O
and	559 3 O
secondary	563 9 O
onset	573 5 O
in	579 2 O
the	582 3 O
course	586 6 O
of	593 2 O
a	596 1 O
primary	598 7 O
psychosis	606 9 B-Disease
)	615 1 O
may	617 3 O
present	621 7 O
particular	629 10 O
vulnerability	640 13 O
to	654 2 O
paranoid	657 8 B-Disease
exacerbations	666 13 O
associated	680 10 O
with	691 4 O
serotonin	696 9 B-Chemical
reuptake	706 8 O
inhibitors	715 10 O
.	725 1 O

Although	727 8 O
the	736 3 O
pharmacology	740 12 O
and	753 3 O
neurobiology	757 12 O
of	770 2 O
paranoia	773 8 B-Disease
remain	782 6 O
cryptic	789 7 O
,	796 1 O
several	798 7 O
mechanisms	806 10 O
,	816 1 O
including	818 9 O
5HT3	828 4 O
receptor	833 8 O
-	841 1 O
mediated	842 8 O
dopamine	851 8 B-Chemical
release	860 7 O
,	867 1 O
beta	869 4 O
-	873 1 O
noradrenergic	874 13 O
receptor	888 8 O
downregulation	897 14 O
,	911 1 O
or	913 2 O
GABAB	916 5 O
receptor	922 8 O
upregulation	931 12 O
acting	944 6 O
in	951 2 O
the	954 3 O
vicinity	958 8 O
of	967 2 O
the	970 3 O
ventral	974 7 O
basal	982 5 O
ganglia	988 7 O
(	996 1 O
possibly	997 8 O
in	1006 2 O
lateral	1009 7 O
orbitofrontal	1017 13 O
or	1031 2 O
anterior	1034 8 O
cingulate	1043 9 O
circuits	1053 8 O
)	1061 1 O
,	1062 1 O
might	1064 5 O
apply	1070 5 O
to	1076 2 O
this	1079 4 O
phenomenon	1084 10 O
.	1094 1 O

These	1096 5 O
cases	1102 5 O
call	1108 4 O
attention	1113 9 O
to	1123 2 O
possible	1126 8 O
paranoid	1135 8 B-Disease
exacerbations	1144 13 O
with	1158 4 O
serotonin	1163 9 B-Chemical
reuptake	1173 8 O
blockers	1182 8 O
in	1191 2 O
select	1194 6 O
patients	1201 8 O
and	1210 3 O
raise	1214 5 O
neurobiological	1220 15 O
considerations	1236 14 O
regarding	1251 9 O
paranoia	1261 8 B-Disease
.	1269 1 O

Five	0 4 O
cases	5 5 O
of	11 2 O
encephalitis	14 12 B-Disease
during	27 6 O
treatment	34 9 O
of	44 2 O
loiasis	47 7 B-Disease
with	55 4 O
diethylcarbamazine	60 18 B-Chemical
.	78 1 O

Five	80 4 O
cases	85 5 O
of	91 2 O
encephalitis	94 12 B-Disease
following	107 9 O
treatment	117 9 O
with	127 4 O
diethylcarbamazine	132 18 B-Chemical
(	151 1 O
DEC	152 3 B-Chemical
)	155 1 O
were	157 4 O
observed	162 8 O
in	171 2 O
Congolese	174 9 O
patients	184 8 O
with	193 4 O
Loa	198 3 O
loa	202 3 O
filariasis	206 10 B-Disease
.	216 1 O

Two	218 3 O
cases	222 5 O
had	228 3 O
a	232 1 O
fatal	234 5 O
outcome	240 7 O
and	248 3 O
one	252 3 O
resulted	256 8 O
in	265 2 O
severe	268 6 O
sequelae	275 8 O
.	283 1 O

The	285 3 O
notable	289 7 O
fact	297 4 O
was	302 3 O
that	306 4 O
this	311 4 O
complication	316 12 O
occurred	329 8 O
in	338 2 O
three	341 5 O
patients	347 8 O
hospitalized	356 12 O
before	369 6 O
treatment	376 9 O
began	386 5 O
,	391 1 O
with	393 4 O
whom	398 4 O
particularly	403 12 O
strict	416 6 O
therapeutic	423 11 O
precautions	435 11 O
were	447 4 O
taken	452 5 O
,	457 1 O
i	459 1 O
.	460 1 O
e	461 1 O
.	462 1 O
,	463 1 O
initial	465 7 O
dose	473 4 O
less	478 4 O
than	483 4 O
10	488 2 O
mg	491 2 O
of	494 2 O
DEC	497 3 B-Chemical
,	500 1 O
very	502 4 O
gradual	507 7 O
dose	515 4 O
increases	520 9 O
,	529 1 O
and	531 3 O
associated	535 10 O
anti	546 4 O
-	550 1 O
allergic	551 8 O
treatment	560 9 O
.	569 1 O

This	571 4 O
type	576 4 O
of	581 2 O
drug	584 4 O
-	588 1 O
induced	589 7 O
complication	597 12 O
may	610 3 O
not	614 3 O
be	618 2 O
that	621 4 O
uncommon	626 8 O
in	635 2 O
highly	638 6 O
endemic	645 7 O
regions	653 7 O
.	660 1 O

It	662 2 O
occurs	665 6 O
primarily	672 9 O
,	681 1 O
but	683 3 O
not	687 3 O
exclusively	691 11 O
,	702 1 O
in	704 2 O
subjects	707 8 O
presenting	716 10 O
with	727 4 O
a	732 1 O
high	734 4 O
microfilarial	739 13 O
load	753 4 O
.	757 1 O

The	759 3 O
relationship	763 12 O
between	776 7 O
the	784 3 O
occurrence	788 10 O
of	799 2 O
encephalitis	802 12 B-Disease
and	815 3 O
the	819 3 O
decrease	823 8 O
in	832 2 O
microfilaremia	835 14 B-Disease
is	850 2 O
evident	853 7 O
.	860 1 O

The	862 3 O
pathophysiological	866 18 O
mechanisms	885 10 O
are	896 3 O
discussed	900 9 O
in	910 2 O
the	913 3 O
light	917 5 O
of	923 2 O
these	926 5 O
observations	932 12 O
and	945 3 O
the	949 3 O
few	953 3 O
other	957 5 O
comments	963 8 O
on	972 2 O
this	975 4 O
subject	980 7 O
published	988 9 O
in	998 2 O
the	1001 3 O
literature	1005 10 O
.	1015 1 O

Delirium	0 8 B-Disease
in	9 2 O
an	12 2 O
elderly	15 7 O
woman	23 5 O
possibly	29 8 O
associated	38 10 O
with	49 4 O
administration	54 14 O
of	69 2 O
misoprostol	72 11 B-Chemical
.	83 1 O

Misoprostol	85 11 B-Chemical
has	97 3 O
been	101 4 O
associated	106 10 O
with	117 4 O
adverse	122 7 O
reactions	130 9 O
,	139 1 O
including	141 9 O
gastrointestinal	151 16 O
symptoms	168 8 O
,	176 1 O
gynecologic	178 11 O
problems	190 8 O
,	198 1 O
and	200 3 O
headache	204 8 B-Disease
.	212 1 O

Changes	214 7 O
in	222 2 O
mental	225 6 O
status	232 6 O
,	238 1 O
however	240 7 O
,	247 1 O
have	249 4 O
not	254 3 O
been	258 4 O
reported	263 8 O
.	271 1 O

We	273 2 O
present	276 7 O
a	284 1 O
case	286 4 O
in	291 2 O
which	294 5 O
an	300 2 O
89	303 2 O
-	305 1 O
year	306 4 O
-	310 1 O
old	311 3 O
woman	315 5 O
in	321 2 O
a	324 1 O
long	326 4 O
-	330 1 O
term	331 4 O
care	336 4 O
facility	341 8 O
became	350 6 O
confused	357 8 O
after	366 5 O
the	372 3 O
initiation	376 10 O
of	387 2 O
misoprostol	390 11 B-Chemical
therapy	402 7 O
.	409 1 O

The	411 3 O
patient	415 7 O
'	422 1 O
s	423 1 O
change	425 6 O
in	432 2 O
mental	435 6 O
status	442 6 O
was	449 3 O
first	453 5 O
reported	459 8 O
nine	468 4 O
days	473 4 O
after	478 5 O
the	484 3 O
initiation	488 10 O
of	499 2 O
therapy	502 7 O
.	509 1 O

Her	511 3 O
delirium	515 8 B-Disease
significantly	524 13 O
improved	538 8 O
after	547 5 O
misoprostol	553 11 B-Chemical
was	565 3 O
discontinued	569 12 O
and	582 3 O
her	586 3 O
mental	590 6 O
status	597 6 O
returned	604 8 O
to	613 2 O
normal	616 6 O
within	623 6 O
a	630 1 O
week	632 4 O
.	636 1 O

Because	638 7 O
no	646 2 O
other	649 5 O
factors	655 7 O
related	663 7 O
to	671 2 O
this	674 4 O
patient	679 7 O
changed	687 7 O
significantly	695 13 O
,	708 1 O
the	710 3 O
delirium	714 8 B-Disease
experienced	723 11 O
by	735 2 O
this	738 4 O
patient	743 7 O
possibly	751 8 O
resulted	760 8 O
from	769 4 O
misoprostol	774 11 B-Chemical
therapy	786 7 O
.	793 1 O

Hepatocellular	0 14 O
oxidant	15 7 O
stress	23 6 O
following	30 9 O
intestinal	40 10 O
ischemia	51 8 B-Disease
-	59 1 O
reperfusion	60 11 B-Disease
injury	72 6 I-Disease
.	78 1 O

Reperfusion	80 11 O
of	92 2 O
ischemic	95 8 B-Disease
intestine	104 9 O
results	114 7 O
in	122 2 O
acute	125 5 O
liver	131 5 B-Disease
dysfunction	137 11 I-Disease
characterized	149 13 O
by	163 2 O
hepatocellular	166 14 O
enzyme	181 6 O
release	188 7 O
into	196 4 O
plasma	201 6 O
,	207 1 O
reduction	209 9 O
in	219 2 O
bile	222 4 O
flow	227 4 O
rate	232 4 O
,	236 1 O
and	238 3 O
neutrophil	242 10 O
sequestration	253 13 O
within	267 6 O
the	274 3 O
liver	278 5 O
.	283 1 O

The	285 3 O
pathophysiology	289 15 O
underlying	305 10 O
this	316 4 O
acute	321 5 O
hepatic	327 7 B-Disease
injury	335 6 I-Disease
is	342 2 O
unknown	345 7 O
.	352 1 O

This	354 4 O
study	359 5 O
was	365 3 O
undertaken	369 10 O
to	380 2 O
determine	383 9 O
whether	393 7 O
oxidants	401 8 O
are	410 3 O
associated	414 10 O
with	425 4 O
the	430 3 O
hepatic	434 7 B-Disease
injury	442 6 I-Disease
and	449 3 O
to	453 2 O
determine	456 9 O
the	466 3 O
relative	470 8 O
value	479 5 O
of	485 2 O
several	488 7 O
indirect	496 8 O
methods	505 7 O
of	513 2 O
assessing	516 9 O
oxidant	526 7 O
exposure	534 8 O
in	543 2 O
vivo	546 4 O
.	550 1 O

Rats	552 4 O
were	557 4 O
subjected	562 9 O
to	572 2 O
a	575 1 O
standardized	577 12 O
intestinal	590 10 O
ischemia	601 8 B-Disease
-	609 1 O
reperfusion	610 11 B-Disease
injury	622 6 I-Disease
.	628 1 O

Hepatic	630 7 O
tissue	638 6 O
was	645 3 O
assayed	649 7 O
for	657 3 O
lipid	661 5 O
peroxidation	667 12 O
products	680 8 O
and	689 3 O
oxidized	693 8 B-Chemical
and	702 3 I-Chemical
reduced	706 7 I-Chemical
glutathione	714 11 I-Chemical
.	725 1 O

There	727 5 O
was	733 3 O
no	737 2 O
change	740 6 O
in	747 2 O
hepatic	750 7 O
tissue	758 6 O
total	765 5 O
glutathione	771 11 B-Chemical
following	783 9 O
intestinal	793 10 O
ischemia	804 8 B-Disease
-	812 1 O
reperfusion	813 11 B-Disease
injury	825 6 I-Disease
.	831 1 O

Oxidized	833 8 B-Chemical
glutathione	842 11 I-Chemical
(	854 1 O
GSSG	855 4 B-Chemical
)	859 1 O
increased	861 9 O
significantly	871 13 O
following	885 9 O
30	895 2 O
and	898 3 O
60	902 2 O
min	905 3 O
of	909 2 O
reperfusion	912 11 O
.	923 1 O

There	925 5 O
was	931 3 O
no	935 2 O
increase	938 8 O
in	947 2 O
any	950 3 O
of	954 2 O
the	957 3 O
products	961 8 O
of	970 2 O
lipid	973 5 O
peroxidation	979 12 O
associated	992 10 O
with	1003 4 O
this	1008 4 O
injury	1013 6 O
.	1019 1 O

An	1021 2 O
increase	1024 8 O
in	1033 2 O
GSSG	1036 4 B-Chemical
within	1041 6 O
hepatic	1048 7 O
tissue	1056 6 O
during	1063 6 O
intestinal	1070 10 O
reperfusion	1081 11 O
suggests	1093 8 O
exposure	1102 8 O
of	1111 2 O
hepatocytes	1114 11 O
to	1126 2 O
an	1129 2 O
oxidant	1132 7 O
stress	1140 6 O
.	1146 1 O

The	1148 3 O
lack	1152 4 O
of	1157 2 O
a	1160 1 O
significant	1162 11 O
increase	1174 8 O
in	1183 2 O
products	1186 8 O
of	1195 2 O
lipid	1198 5 O
peroxidation	1204 12 O
suggests	1217 8 O
that	1226 4 O
the	1231 3 O
oxidant	1235 7 O
stress	1243 6 O
is	1250 2 O
of	1253 2 O
insufficient	1256 12 O
magnitude	1269 9 O
to	1279 2 O
result	1282 6 O
in	1289 2 O
irreversible	1292 12 O
injury	1305 6 O
to	1312 2 O
hepatocyte	1315 10 O
cell	1326 4 O
membranes	1331 9 O
.	1340 1 O

These	1342 5 O
data	1348 4 O
also	1353 4 O
suggest	1358 7 O
that	1366 4 O
the	1371 3 O
measurement	1375 11 O
of	1387 2 O
tissue	1390 6 O
GSSG	1397 4 B-Chemical
may	1402 3 O
be	1406 2 O
a	1409 1 O
more	1411 4 O
sensitive	1416 9 O
indicator	1426 9 O
of	1436 2 O
oxidant	1439 7 O
stress	1447 6 O
than	1454 4 O
measurement	1459 11 O
of	1471 2 O
products	1474 8 O
of	1483 2 O
lipid	1486 5 O
peroxidation	1492 12 O
.	1504 1 O

Diphenhydramine	0 15 B-Chemical
prevents	16 8 O
the	25 3 O
haemodynamic	29 12 O
changes	42 7 O
of	50 2 O
cimetidine	53 10 B-Chemical
in	64 2 O
ICU	67 3 O
patients	71 8 O
.	79 1 O

Cimetidine	81 10 B-Chemical
,	91 1 O
a	93 1 O
histamine	95 9 B-Chemical
2	105 1 O
(	107 1 O
H2	108 2 O
)	110 1 O
antagonist	112 10 O
,	122 1 O
produces	124 8 O
a	133 1 O
decrease	135 8 O
in	144 2 O
arterial	147 8 O
pressure	156 8 O
due	165 3 O
to	169 2 O
vasodilatation	172 14 O
,	186 1 O
especially	188 10 O
in	199 2 O
critically	202 10 O
ill	213 3 O
patients	217 8 O
.	225 1 O

This	227 4 O
may	232 3 O
be	236 2 O
because	239 7 O
cimetidine	247 10 B-Chemical
acts	258 4 O
as	263 2 O
a	266 1 O
histamine	268 9 B-Chemical
agonist	278 7 O
.	285 1 O

We	287 2 O
,	289 1 O
therefore	291 9 O
,	300 1 O
investigated	302 12 O
the	315 3 O
effects	319 7 O
of	327 2 O
the	330 3 O
histamine	334 9 B-Chemical
1	344 1 O
(	345 1 O
H1	346 2 O
)	348 1 O
receptor	350 8 O
antagonist	359 10 O
,	369 1 O
diphenhydramine	371 15 B-Chemical
,	386 1 O
on	388 2 O
the	391 3 O
haemodynamic	395 12 O
changes	408 7 O
observed	416 8 O
after	425 5 O
cimetidine	431 10 B-Chemical
in	442 2 O
ICU	445 3 O
patients	449 8 O
.	457 1 O

Each	459 4 O
patient	464 7 O
was	472 3 O
studied	476 7 O
on	484 2 O
two	487 3 O
separate	491 8 O
days	500 4 O
.	504 1 O

In	506 2 O
a	509 1 O
random	511 6 O
fashion	518 7 O
,	525 1 O
they	527 4 O
received	532 8 O
cimetidine	541 10 B-Chemical
200	552 3 O
mg	556 2 O
iv	559 2 O
on	562 2 O
one	565 3 O
day	569 3 O
,	572 1 O
and	574 3 O
on	578 2 O
the	581 3 O
other	585 5 O
,	590 1 O
a	592 1 O
pretreatment	594 12 O
of	607 2 O
diphenhydramine	610 15 B-Chemical
40	626 2 O
mg	629 2 O
iv	632 2 O
with	635 4 O
cimetidine	640 10 B-Chemical
200	651 3 O
mg	655 2 O
iv	658 2 O
.	660 1 O

In	662 2 O
the	665 3 O
non	669 3 O
-	672 1 O
pretreatment	673 12 O
group	686 5 O
,	691 1 O
mean	693 4 O
arterial	698 8 O
pressure	707 8 O
(	716 1 O
MAP	717 3 O
)	720 1 O
decreased	722 9 O
from	732 4 O
107	737 3 O
.	740 1 O
4	741 1 O
+	743 1 O
/	744 1 O
-	745 1 O
8	747 1 O
.	748 1 O
4	749 1 O
mmHg	751 4 O
to	756 2 O
86	759 2 O
.	761 1 O
7	762 1 O
+	764 1 O
/	765 1 O
-	766 1 O
11	768 2 O
.	770 1 O
4	771 1 O
mmHg	773 4 O
(	778 1 O
P	779 1 O
less	781 4 O
than	786 4 O
0	791 1 O
.	792 1 O
01	793 2 O
)	795 1 O
two	797 3 O
minutes	801 7 O
after	809 5 O
cimetidine	815 10 B-Chemical
.	825 1 O

Also	827 4 O
,	831 1 O
systemic	833 8 O
vascular	842 8 O
resistance	851 10 O
(	862 1 O
SVR	863 3 O
)	866 1 O
decreased	868 9 O
during	878 6 O
the	885 3 O
eight	889 5 O
-	894 1 O
minute	895 6 O
observation	902 11 O
period	914 6 O
(	921 1 O
P	922 1 O
less	924 4 O
than	929 4 O
0	934 1 O
.	935 1 O
01	936 2 O
)	938 1 O
.	939 1 O

In	941 2 O
contrast	944 8 O
,	952 1 O
in	954 2 O
the	957 3 O
pretreatment	961 12 O
group	974 5 O
,	979 1 O
little	981 6 O
haemodynamic	988 12 O
change	1001 6 O
was	1008 3 O
seen	1012 4 O
.	1016 1 O

We	1018 2 O
conclude	1021 8 O
that	1030 4 O
an	1035 2 O
H1	1038 2 O
antagonist	1041 10 O
may	1052 3 O
be	1056 2 O
useful	1059 6 O
in	1066 2 O
preventing	1069 10 O
hypotension	1080 11 B-Disease
caused	1092 6 O
by	1099 2 O
iv	1102 2 O
cimetidine	1105 10 B-Chemical
,	1115 1 O
since	1117 5 O
the	1123 3 O
vasodilating	1127 12 O
activity	1140 8 O
of	1149 2 O
cimetidine	1152 10 B-Chemical
is	1163 2 O
mediated	1166 8 O
,	1174 1 O
in	1176 2 O
part	1179 4 O
,	1183 1 O
through	1185 7 O
the	1193 3 O
H1	1197 2 O
receptor	1200 8 O
.	1208 1 O

Acute	0 5 B-Disease
renal	6 5 I-Disease
failure	12 7 I-Disease
due	20 3 O
to	24 2 O
rifampicin	27 10 B-Chemical
.	37 1 O

A	39 1 O
23	41 2 O
-	43 1 O
year	44 4 O
-	48 1 O
old	49 3 O
male	53 4 O
patient	58 7 O
with	66 4 O
bacteriologically	71 17 O
proven	89 6 O
pulmonary	96 9 B-Disease
tuberculosis	106 12 I-Disease
was	119 3 O
treated	123 7 O
with	131 4 O
the	136 3 O
various	140 7 O
regimens	148 8 O
of	157 2 O
antituberculosis	160 16 O
drugs	177 5 O
for	183 3 O
nearly	187 6 O
15	194 2 O
months	197 6 O
.	203 1 O

Rifampicin	205 10 B-Chemical
was	216 3 O
administered	220 12 O
thrice	233 6 O
as	240 2 O
one	243 3 O
of	247 2 O
the	250 3 O
3	254 1 O
-	255 1 O
4	256 1 O
drug	258 4 O
regimen	263 7 O
and	271 3 O
each	275 4 O
time	280 4 O
he	285 2 O
developed	288 9 O
untoward	298 8 O
side	307 4 O
effects	312 7 O
like	320 4 O
nausea	325 6 B-Disease
,	331 1 O
vomiting	333 8 B-Disease
and	342 3 O
fever	346 5 B-Disease
with	352 4 O
chills	357 6 O
and	364 3 O
rigors	368 6 O
.	374 1 O

The	376 3 O
last	380 4 O
such	385 4 O
episode	390 7 O
was	398 3 O
of	402 2 O
acute	405 5 O
renal	411 5 O
failure	417 7 O
at	425 2 O
which	428 5 O
stage	434 5 O
the	440 3 O
patient	444 7 O
was	452 3 O
seen	456 4 O
by	461 2 O
the	464 3 O
authors	468 7 O
of	476 2 O
this	479 4 O
report	484 6 O
.	490 1 O

The	492 3 O
patient	496 7 O
,	503 1 O
however	505 7 O
,	512 1 O
made	514 4 O
a	519 1 O
full	521 4 O
recovery	526 8 O
.	534 1 O

Severe	0 6 O
polyneuropathy	7 14 B-Disease
and	22 3 O
motor	26 5 O
loss	32 4 O
after	37 5 O
intrathecal	43 11 O
thiotepa	55 8 B-Chemical
combination	64 11 O
chemotherapy	76 12 O
:	88 1 O
description	90 11 O
of	102 2 O
two	105 3 O
cases	109 5 O
.	114 1 O

Two	116 3 O
cases	120 5 O
of	126 2 O
severe	129 6 O
delayed	136 7 O
neurologic	144 10 B-Disease
toxicity	155 8 I-Disease
related	164 7 O
to	172 2 O
the	175 3 O
administration	179 14 O
of	194 2 O
intrathecal	197 11 O
(	209 1 O
IT	210 2 O
)	212 1 O
combination	214 11 O
chemotherapy	226 12 O
including	239 9 O
thiotepa	249 8 B-Chemical
(	258 1 O
TSPA	259 4 B-Chemical
)	263 1 O
are	265 3 O
presented	269 9 O
.	278 1 O

Both	280 4 O
cases	285 5 O
developed	291 9 O
axonal	301 6 B-Disease
neuropathy	308 10 I-Disease
with	319 4 O
motor	324 5 O
predominance	330 12 O
in	343 2 O
the	346 3 O
lower	350 5 O
extremities	356 11 O
1	368 1 O
and	370 3 O
6	374 1 O
months	376 6 O
after	383 5 O
IT	389 2 O
chemotherapy	392 12 O
was	405 3 O
administered	409 12 O
.	421 1 O

Neurologic	423 10 B-Disease
toxicities	434 10 I-Disease
have	445 4 O
been	450 4 O
described	455 9 O
with	465 4 O
IT	470 2 O
-	472 1 O
methotrexate	473 12 B-Chemical
,	485 1 O
IT	487 2 O
-	489 1 O
cytosine	490 8 B-Chemical
arabinoside	499 11 I-Chemical
and	511 3 O
IT	515 2 O
-	517 1 O
TSPA	518 4 B-Chemical
.	522 1 O

To	524 2 O
our	527 3 O
knowledge	531 9 O
,	540 1 O
however	542 7 O
,	549 1 O
axonal	551 6 B-Disease
neuropathy	558 10 I-Disease
following	569 9 O
administration	579 14 O
of	594 2 O
these	597 5 O
three	603 5 O
agents	609 6 O
has	616 3 O
not	620 3 O
been	624 4 O
previously	629 10 O
described	640 9 O
.	649 1 O

In	651 2 O
spite	654 5 O
of	660 2 O
the	663 3 O
fact	667 4 O
that	672 4 O
TSPA	677 4 B-Chemical
is	682 2 O
a	685 1 O
useful	687 6 O
IT	694 2 O
agent	697 5 O
,	702 1 O
its	704 3 O
combination	708 11 O
with	720 4 O
MTX	725 3 B-Chemical
,	728 1 O
ara	730 3 B-Chemical
-	733 1 I-Chemical
C	734 1 I-Chemical
and	736 3 O
radiotherapy	740 12 O
could	753 5 O
cause	759 5 O
severe	765 6 O
neurotoxicity	772 13 B-Disease
.	785 1 O

This	787 4 O
unexpected	792 10 O
complication	803 12 O
indicates	816 9 O
the	826 3 O
need	830 4 O
for	835 3 O
further	839 7 O
toxicology	847 10 O
research	858 8 O
on	867 2 O
IT	870 2 O
-	872 1 O
TSPA	873 4 B-Chemical
.	877 1 O

Effects	0 7 O
of	8 2 O
cromakalim	11 10 B-Chemical
and	22 3 O
pinacidil	26 9 B-Chemical
on	36 2 O
large	39 5 O
epicardial	45 10 O
and	56 3 O
small	60 5 O
coronary	66 8 O
arteries	75 8 O
in	84 2 O
conscious	87 9 O
dogs	97 4 O
.	101 1 O

The	103 3 O
effects	107 7 O
of	115 2 O
i	118 1 O
.	119 1 O
v	120 1 O
.	121 1 O
bolus	123 5 O
administration	129 14 O
of	144 2 O
cromakalim	147 10 B-Chemical
(	158 1 O
1	159 1 O
-	160 1 O
10	161 2 O
micrograms	164 10 O
/	174 1 O
kg	175 2 O
)	177 1 O
and	179 3 O
pinacidil	183 9 B-Chemical
(	193 1 O
3	194 1 O
-	195 1 O
100	196 3 O
micrograms	200 10 O
/	210 1 O
kg	211 2 O
)	213 1 O
on	215 2 O
large	218 5 O
(	224 1 O
circumflex	225 10 O
artery	236 6 O
)	242 1 O
and	244 3 O
small	248 5 O
coronary	254 8 O
arteries	263 8 O
and	272 3 O
on	276 2 O
systemic	279 8 O
hemodynamics	288 12 O
were	301 4 O
investigated	306 12 O
in	319 2 O
chronically	322 11 O
instrumented	334 12 O
conscious	347 9 O
dogs	357 4 O
and	362 3 O
compared	366 8 O
to	375 2 O
those	378 5 O
of	384 2 O
nitroglycerin	387 13 B-Chemical
(	401 1 O
0	402 1 O
.	403 1 O
03	404 2 O
-	406 1 O
10	407 2 O
micrograms	410 10 O
/	420 1 O
kg	421 2 O
)	423 1 O
.	424 1 O

Nitroglycerin	426 13 B-Chemical
,	439 1 O
up	441 2 O
to	444 2 O
0	447 1 O
.	448 1 O
3	449 1 O
micrograms	451 10 O
/	461 1 O
kg	462 2 O
,	464 1 O
selectively	466 11 O
increased	478 9 O
circumflex	488 10 O
artery	499 6 O
diameter	506 8 O
(	515 1 O
CxAD	516 4 O
)	520 1 O
without	522 7 O
simultaneously	530 14 O
affecting	545 9 O
any	555 3 O
other	559 5 O
cardiac	565 7 O
or	573 2 O
systemic	576 8 O
hemodynamic	585 11 O
parameter	597 9 O
.	606 1 O

In	608 2 O
contrast	611 8 O
,	619 1 O
cromakalim	621 10 B-Chemical
and	632 3 O
pinacidil	636 9 B-Chemical
at	646 2 O
all	649 3 O
doses	653 5 O
and	659 3 O
nitroglycerin	663 13 B-Chemical
at	677 2 O
doses	680 5 O
higher	686 6 O
than	693 4 O
0	698 1 O
.	699 1 O
3	700 1 O
micrograms	702 10 O
/	712 1 O
kg	713 2 O
simultaneously	716 14 O
and	731 3 O
dose	735 4 O
-	739 1 O
dependently	740 11 O
increased	752 9 O
CxAD	762 4 O
,	766 1 O
coronary	768 8 O
blood	777 5 O
flow	783 4 O
and	788 3 O
heart	792 5 O
rate	798 4 O
and	803 3 O
decreased	807 9 O
coronary	817 8 O
vascular	826 8 O
resistance	835 10 O
and	846 3 O
aortic	850 6 O
pressure	857 8 O
.	865 1 O

Cromakalim	867 10 B-Chemical
was	878 3 O
approximately	882 13 O
8	896 1 O
-	897 1 O
to	899 2 O
9	902 1 O
.	903 1 O
5	904 1 O
-	905 1 O
fold	906 4 O
more	911 4 O
potent	916 6 O
than	923 4 O
pinacidil	928 9 B-Chemical
in	938 2 O
increasing	941 10 O
CxAD	952 4 O
.	956 1 O

Vasodilation	958 12 O
of	971 2 O
large	974 5 O
and	980 3 O
small	984 5 O
coronary	990 8 O
vessels	999 7 O
and	1007 3 O
hypotension	1011 11 B-Disease
induced	1023 7 O
by	1031 2 O
cromakalim	1034 10 B-Chemical
and	1045 3 O
pinacidil	1049 9 B-Chemical
were	1059 4 O
not	1064 3 O
affected	1068 8 O
by	1077 2 O
prior	1080 5 O
combined	1086 8 O
beta	1095 4 B-Chemical
adrenergic	1100 10 I-Chemical
and	1111 3 I-Chemical
muscarinic	1115 10 I-Chemical
receptors	1126 9 I-Chemical
blockade	1136 8 I-Chemical
but	1145 3 O
drug	1149 4 O
-	1153 1 O
induced	1154 7 O
tachycardia	1162 11 B-Disease
was	1174 3 O
abolished	1178 9 O
.	1187 1 O

When	1189 4 O
circumflex	1194 10 O
artery	1205 6 O
blood	1212 5 O
flow	1218 4 O
was	1223 3 O
maintained	1227 10 O
constant	1238 8 O
,	1246 1 O
the	1248 3 O
increases	1252 9 O
in	1262 2 O
CxAD	1265 4 O
induced	1270 7 O
by	1278 2 O
cromakalim	1281 10 B-Chemical
(	1292 1 O
10	1293 2 O
micrograms	1296 10 O
/	1306 1 O
kg	1307 2 O
)	1309 1 O
,	1310 1 O
pinacidil	1312 9 B-Chemical
(	1322 1 O
30	1323 2 O
micrograms	1326 10 O
/	1336 1 O
kg	1337 2 O
)	1339 1 O
and	1341 3 O
nitroglycerin	1345 13 B-Chemical
(	1359 1 O
10	1360 2 O
micrograms	1363 10 O
/	1373 1 O
kg	1374 2 O
)	1376 1 O
were	1378 4 O
reduced	1383 7 O
by	1391 2 O
68	1394 2 O
+	1397 1 O
/	1398 1 O
-	1399 1 O
7	1401 1 O
,	1402 1 O
54	1404 2 O
+	1407 1 O
/	1408 1 O
-	1409 1 O
9	1411 1 O
and	1413 3 O
1	1417 1 O
+	1419 1 O
/	1420 1 O
-	1421 1 O
1	1423 1 O
%	1424 1 O
,	1425 1 O
respectively	1427 12 O
.	1439 1 O

Thus	1441 4 O
,	1445 1 O
whereas	1447 7 O
nitroglycerin	1455 13 B-Chemical
preferentially	1469 14 O
and	1484 3 O
flow	1488 4 O
-	1492 1 O
independently	1493 13 O
dilates	1507 7 O
large	1515 5 O
coronary	1521 8 O
arteries	1530 8 O
,	1538 1 O
cromakalim	1540 10 B-Chemical
and	1551 3 O
pinacidil	1555 9 B-Chemical
dilate	1565 6 O
both	1572 4 O
large	1577 5 O
and	1583 3 O
small	1587 5 O
coronary	1593 8 O
arteries	1602 8 O
and	1611 3 O
this	1615 4 O
effect	1620 6 O
is	1627 2 O
not	1630 3 O
dependent	1634 9 O
upon	1644 4 O
the	1649 3 O
simultaneous	1653 12 O
beta	1666 4 O
adrenoceptors	1671 13 O
-	1684 1 O
mediated	1685 8 O
rise	1694 4 O
in	1699 2 O
myocardial	1702 10 O
metabolic	1713 9 O
demand	1723 6 O
.	1729 1 O

Finally	1731 7 O
,	1738 1 O
two	1740 3 O
mechanisms	1744 10 O
at	1755 2 O
least	1758 5 O
,	1763 1 O
direct	1765 6 O
vasodilation	1772 12 O
and	1785 3 O
flow	1789 4 O
dependency	1794 10 O
,	1804 1 O
are	1806 3 O
involved	1810 8 O
in	1819 2 O
the	1822 3 O
cromakalim	1826 10 B-Chemical
-	1836 1 O
and	1838 3 O
pinacidil	1842 9 B-Chemical
-	1851 1 O
induced	1852 7 O
increase	1860 8 O
in	1869 2 O
CxAD	1872 4 O
.	1876 1 O

Mefenamic	0 9 B-Chemical
acid	10 4 I-Chemical
-	14 1 O
induced	15 7 O
neutropenia	23 11 B-Disease
and	35 3 O
renal	39 5 B-Disease
failure	45 7 I-Disease
in	53 2 O
elderly	56 7 O
females	64 7 O
with	72 4 O
hypothyroidism	77 14 B-Disease
.	91 1 O

We	93 2 O
report	96 6 O
mefenamic	103 9 B-Chemical
acid	113 4 I-Chemical
-	117 1 O
induced	118 7 O
non	126 3 O
-	129 1 O
oliguric	130 8 O
renal	139 5 B-Disease
failure	145 7 I-Disease
and	153 3 O
severe	157 6 O
neutropenia	164 11 B-Disease
occurring	176 9 O
simultaneously	186 14 O
in	201 2 O
two	204 3 O
elderly	208 7 O
females	216 7 O
.	223 1 O

The	225 3 O
neutropenia	229 11 B-Disease
was	241 3 O
due	245 3 O
to	249 2 O
maturation	252 10 O
arrest	263 6 O
of	270 2 O
the	273 3 O
myeloid	277 7 O
series	285 6 O
in	292 2 O
one	295 3 O
patient	299 7 O
.	306 1 O

Both	308 4 O
patients	313 8 O
were	322 4 O
also	327 4 O
hypothyroid	332 11 B-Disease
,	343 1 O
but	345 3 O
it	349 2 O
is	352 2 O
not	355 3 O
clear	359 5 O
whether	365 7 O
this	373 4 O
was	378 3 O
a	382 1 O
predisposing	384 12 O
factor	397 6 O
to	404 2 O
the	407 3 O
development	411 11 O
of	423 2 O
these	426 5 O
adverse	432 7 O
reactions	440 9 O
.	449 1 O

However	451 7 O
,	458 1 O
it	460 2 O
would	463 5 O
seem	469 4 O
prudent	474 7 O
not	482 3 O
to	486 2 O
use	489 3 O
mefenamic	493 9 B-Chemical
acid	503 4 I-Chemical
in	508 2 O
hypothyroid	511 11 B-Disease
patients	523 8 O
until	532 5 O
the	538 3 O
hypothyroidism	542 14 B-Disease
has	557 3 O
been	561 4 O
corrected	566 9 O
.	575 1 O

Etiology	0 8 O
of	9 2 O
hypercalcemia	12 13 B-Disease
in	26 2 O
hemodialysis	29 12 O
patients	42 8 O
on	51 2 O
calcium	54 7 B-Chemical
carbonate	62 9 I-Chemical
therapy	72 7 O
.	79 1 O

Fourteen	81 8 O
of	90 2 O
39	93 2 O
dialysis	96 8 O
patients	105 8 O
(	114 1 O
36	115 2 O
%	117 1 O
)	118 1 O
became	120 6 O
hypercalcemic	127 13 B-Disease
after	141 5 O
switching	147 9 O
to	157 2 O
calcium	160 7 B-Chemical
carbonate	168 9 I-Chemical
as	178 2 O
their	181 5 O
principal	187 9 O
phosphate	197 9 B-Chemical
binder	207 6 O
.	213 1 O

In	215 2 O
order	218 5 O
to	224 2 O
identify	227 8 O
risk	236 4 O
factors	241 7 O
associated	249 10 O
with	260 4 O
the	265 3 O
development	269 11 O
of	281 2 O
hypercalcemia	284 13 B-Disease
,	297 1 O
indirect	299 8 O
parameters	308 10 O
of	319 2 O
intestinal	322 10 O
calcium	333 7 B-Chemical
reabsorption	341 12 O
and	354 3 O
bone	358 4 O
turnover	363 8 O
rate	372 4 O
in	377 2 O
these	380 5 O
14	386 2 O
patients	389 8 O
were	398 4 O
compared	403 8 O
with	412 4 O
results	417 7 O
in	425 2 O
14	428 2 O
eucalcemic	431 10 O
patients	442 8 O
matched	451 7 O
for	459 3 O
age	463 3 O
,	466 1 O
sex	468 3 O
,	471 1 O
length	473 6 O
of	480 2 O
time	483 4 O
on	488 2 O
dialysis	491 8 O
,	499 1 O
and	501 3 O
etiology	505 8 O
of	514 2 O
renal	517 5 B-Disease
disease	523 7 I-Disease
.	530 1 O

In	532 2 O
addition	535 8 O
to	544 2 O
experiencing	547 12 O
hypercalcemic	560 13 B-Disease
episodes	574 8 O
with	583 4 O
peak	588 4 O
calcium	593 7 B-Chemical
values	601 6 O
of	608 2 O
2	611 1 O
.	612 1 O
7	613 1 O
to	615 2 O
3	618 1 O
.	619 1 O
8	620 1 O
mmol	622 4 O
/	626 1 O
L	627 1 O
(	629 1 O
10	630 2 O
.	632 1 O
7	633 1 O
to	635 2 O
15	638 2 O
.	640 1 O
0	641 1 O
mg	643 2 O
/	645 1 O
dL	646 2 O
)	648 1 O
,	649 1 O
patients	651 8 O
in	660 2 O
the	663 3 O
hypercalcemic	667 13 B-Disease
group	681 5 O
exhibited	687 9 O
a	697 1 O
significant	699 11 O
increase	711 8 O
in	720 2 O
the	723 3 O
mean	727 4 O
calcium	732 7 B-Chemical
concentration	740 13 O
obtained	754 8 O
during	763 6 O
6	770 1 O
months	772 6 O
before	779 6 O
the	786 3 O
switch	790 6 O
,	796 1 O
compared	798 8 O
with	807 4 O
the	812 3 O
mean	816 4 O
value	821 5 O
obtained	827 8 O
during	836 6 O
the	843 3 O
7	847 1 O
months	849 6 O
of	856 2 O
observation	859 11 O
after	871 5 O
the	877 3 O
switch	881 6 O
(	888 1 O
2	889 1 O
.	890 1 O
4	891 1 O
+	893 1 O
/	894 1 O
-	895 1 O
0	897 1 O
.	898 1 O
03	899 2 O
to	902 2 O
2	905 1 O
.	906 1 O
5	907 1 O
+	909 1 O
/	910 1 O
-	911 1 O
0	913 1 O
.	914 1 O
03	915 2 O
mmol	918 4 O
/	922 1 O
L	923 1 O
[	925 1 O
9	926 1 O
.	927 1 O
7	928 1 O
+	930 1 O
/	931 1 O
-	932 1 O
0	934 1 O
.	935 1 O
2	936 1 O
to	938 2 O
10	941 2 O
.	943 1 O
2	944 1 O
+	946 1 O
/	947 1 O
-	948 1 O
0	950 1 O
.	951 1 O
1	952 1 O
mg	954 2 O
/	956 1 O
dL	957 2 O
]	959 1 O
,	960 1 O
P	962 1 O
=	964 1 O
0	966 1 O
.	967 1 O
006	968 3 O
)	971 1 O
.	972 1 O

In	974 2 O
contrast	977 8 O
,	985 1 O
eucalcemic	987 10 O
patients	998 8 O
exhibited	1007 9 O
no	1017 2 O
change	1020 6 O
in	1027 2 O
mean	1030 4 O
calcium	1035 7 B-Chemical
values	1043 6 O
over	1050 4 O
the	1055 3 O
same	1059 4 O
time	1064 4 O
period	1069 6 O
(	1076 1 O
2	1077 1 O
.	1078 1 O
3	1079 1 O
+	1081 1 O
/	1082 1 O
-	1083 1 O
0	1085 1 O
.	1086 1 O
05	1087 2 O
to	1090 2 O
2	1093 1 O
.	1094 1 O
3	1095 1 O
+	1097 1 O
/	1098 1 O
-	1099 1 O
0	1101 1 O
.	1102 1 O
05	1103 2 O
mmol	1106 4 O
/	1110 1 O
L	1111 1 O
[	1113 1 O
9	1114 1 O
.	1115 1 O
2	1116 1 O
+	1118 1 O
/	1119 1 O
-	1120 1 O
0	1122 1 O
.	1123 1 O
2	1124 1 O
to	1126 2 O
9	1129 1 O
.	1130 1 O
2	1131 1 O
+	1133 1 O
/	1134 1 O
-	1135 1 O
0	1137 1 O
.	1138 1 O
2	1139 1 O
mg	1141 2 O
/	1143 1 O
dL	1144 2 O
]	1146 1 O
)	1147 1 O
.	1148 1 O

CaCO3	1150 5 B-Chemical
dosage	1156 6 O
,	1162 1 O
calculated	1164 10 O
dietary	1175 7 O
calcium	1183 7 B-Chemical
intake	1191 6 O
,	1197 1 O
and	1199 3 O
circulating	1203 11 O
levels	1215 6 O
of	1222 2 O
vitamin	1225 7 B-Chemical
D	1233 1 I-Chemical
metabolites	1235 11 O
were	1247 4 O
similar	1252 7 O
in	1260 2 O
both	1263 4 O
groups	1268 6 O
.	1274 1 O

Physical	1276 8 O
activity	1285 8 O
index	1294 5 O
and	1300 3 O
predialysis	1304 11 O
serum	1316 5 O
bicarbonate	1322 11 B-Chemical
levels	1334 6 O
also	1341 4 O
were	1346 4 O
similar	1351 7 O
in	1359 2 O
both	1362 4 O
groups	1367 6 O
.	1373 1 O

However	1375 7 O
,	1382 1 O
there	1384 5 O
was	1390 3 O
a	1394 1 O
significant	1396 11 O
difference	1408 10 O
in	1419 2 O
parameters	1422 10 O
reflecting	1433 10 O
bone	1444 4 O
turnover	1449 8 O
rates	1458 5 O
between	1464 7 O
groups	1472 6 O
.	1478 1 O
(	1479 1 O
ABSTRACT	1480 8 O
TRUNCATED	1489 9 O
AT	1499 2 O
250	1502 3 O
WORDS	1506 5 O
)	1511 1 O

Methyldopa	0 10 B-Chemical
-	10 1 O
induced	11 7 O
hemolytic	19 9 B-Disease
anemia	29 6 I-Disease
in	36 2 O
a	39 1 O
15	41 2 O
year	44 4 O
old	49 3 O
presenting	53 10 O
as	64 2 O
near	67 4 O
-	71 1 O
syncope	72 7 B-Disease
.	79 1 O

Methyldopa	81 10 B-Chemical
is	92 2 O
an	95 2 O
antihypertensive	98 16 O
medication	115 10 O
which	126 5 O
is	132 2 O
available	135 9 O
generically	145 11 O
and	157 3 O
under	161 5 O
the	167 3 O
trade	171 5 O
name	177 4 O
Aldomet	182 7 B-Chemical
that	190 4 O
is	195 2 O
widely	198 6 O
prescribed	205 10 O
in	216 2 O
the	219 3 O
adult	223 5 O
population	229 10 O
and	240 3 O
infrequently	244 12 O
used	257 4 O
in	262 2 O
children	265 8 O
.	273 1 O

Methyldopa	275 10 B-Chemical
causes	286 6 O
an	293 2 O
autoimmune	296 10 B-Disease
hemolytic	307 9 I-Disease
anemia	317 6 I-Disease
in	324 2 O
a	327 1 O
small	329 5 O
percentage	335 10 O
of	346 2 O
patients	349 8 O
who	358 3 O
take	362 4 O
the	367 3 O
drug	371 4 O
.	375 1 O

We	377 2 O
report	380 6 O
a	387 1 O
case	389 4 O
of	394 2 O
methyldopa	397 10 B-Chemical
-	407 1 O
induced	408 7 O
hemolytic	416 9 B-Disease
anemia	426 6 I-Disease
in	433 2 O
a	436 1 O
15	438 2 O
-	440 1 O
year	441 4 O
-	445 1 O
old	446 3 O
boy	450 3 O
who	454 3 O
presented	458 9 O
to	468 2 O
the	471 3 O
emergency	475 9 B-Disease
department	485 10 I-Disease
with	496 4 O
near	501 4 O
-	505 1 O
syncope	506 7 B-Disease
.	513 1 O

The	515 3 O
boy	519 3 O
had	523 3 O
been	527 4 O
treated	532 7 O
with	540 4 O
intravenous	545 11 O
methyldopa	557 10 B-Chemical
during	568 6 O
a	575 1 O
trauma	577 6 B-Disease
admission	584 9 O
seven	594 5 O
weeks	600 5 O
prior	606 5 O
to	612 2 O
presentation	615 12 O
.	627 1 O

Evaluation	629 10 O
revealed	640 8 O
a	649 1 O
hemoglobin	651 10 O
of	662 2 O
three	665 5 O
grams	671 5 O
,	676 1 O
3	678 1 O
+	679 1 O
Coombs	681 6 O
'	687 1 O
test	689 4 O
with	694 4 O
polyspecific	699 12 O
anti	712 4 O
-	716 1 O
human	717 5 O
globulin	723 8 O
and	732 3 O
monospecific	736 12 O
IgG	749 3 O
reagents	753 8 O
,	761 1 O
and	763 3 O
a	767 1 O
warm	769 4 O
reacting	774 8 O
autoantibody	783 12 O
.	795 1 O

Transfusion	797 11 O
and	809 3 O
corticosteroid	813 14 B-Chemical
therapy	828 7 O
resulted	836 8 O
in	845 2 O
a	848 1 O
complete	850 8 O
recovery	859 8 O
of	868 2 O
the	871 3 O
patient	875 7 O
.	882 1 O

Emergency	884 9 O
physicians	894 10 O
treating	905 8 O
children	914 8 O
must	923 4 O
be	928 2 O
aware	931 5 O
of	937 2 O
this	940 4 O
syndrome	945 8 O
in	954 2 O
order	957 5 O
to	963 2 O
diagnose	966 8 O
and	975 3 O
treat	979 5 O
it	985 2 O
correctly	988 9 O
.	997 1 O

A	999 1 O
brief	1001 5 O
review	1007 6 O
of	1014 2 O
autoimmune	1017 10 O
and	1028 3 O
drug	1032 4 O
-	1036 1 O
induced	1037 7 O
hemolytic	1045 9 B-Disease
anemias	1055 7 I-Disease
is	1063 2 O
provided	1066 8 O
.	1074 1 O

The	0 3 O
long	4 4 O
-	8 1 O
term	9 4 O
safety	14 6 O
of	21 2 O
danazol	24 7 B-Chemical
in	32 2 O
women	35 5 O
with	41 4 O
hereditary	46 10 B-Disease
angioedema	57 10 I-Disease
.	67 1 O

Although	69 8 O
the	78 3 O
short	82 5 O
-	87 1 O
term	88 4 O
safety	93 6 O
(	100 1 O
less	101 4 O
than	106 4 O
or	111 2 O
equal	114 5 O
to	120 2 O
6	123 1 O
months	125 6 O
)	131 1 O
of	133 2 O
danazol	136 7 B-Chemical
has	144 3 O
been	148 4 O
established	153 11 O
in	165 2 O
a	168 1 O
variety	170 7 O
of	178 2 O
settings	181 8 O
,	189 1 O
no	191 2 O
information	194 11 O
exists	206 6 O
as	213 2 O
to	216 2 O
its	219 3 O
long	223 4 O
-	227 1 O
term	228 4 O
safety	233 6 O
.	239 1 O

We	241 2 O
therefore	244 9 O
investigated	254 12 O
the	267 3 O
long	271 4 O
-	275 1 O
term	276 4 O
safety	281 6 O
of	288 2 O
danazol	291 7 B-Chemical
by	299 2 O
performing	302 10 O
a	313 1 O
retrospective	315 13 O
chart	329 5 O
review	335 6 O
of	342 2 O
60	345 2 O
female	348 6 O
patients	355 8 O
with	364 4 O
hereditary	369 10 B-Disease
angioedema	380 10 I-Disease
treated	391 7 O
with	399 4 O
danazol	404 7 B-Chemical
for	412 3 O
a	416 1 O
continuous	418 10 O
period	429 6 O
of	436 2 O
6	439 1 O
months	441 6 O
or	448 2 O
longer	451 6 O
.	457 1 O

The	459 3 O
mean	463 4 O
age	468 3 O
of	472 2 O
the	475 3 O
patients	479 8 O
was	488 3 O
35	492 2 O
.	494 1 O
2	495 1 O
years	497 5 O
and	503 3 O
the	507 3 O
mean	511 4 O
duration	516 8 O
of	525 2 O
therapy	528 7 O
was	536 3 O
59	540 2 O
.	542 1 O
7	543 1 O
months	545 6 O
.	551 1 O

Virtually	553 9 O
all	563 3 O
patients	567 8 O
experienced	576 11 O
one	588 3 O
or	592 2 O
more	595 4 O
adverse	600 7 O
reactions	608 9 O
.	617 1 O

Menstrual	619 9 B-Disease
abnormalities	629 13 I-Disease
(	643 1 O
79	644 2 O
%	646 1 O
)	647 1 O
,	648 1 O
weight	650 6 B-Disease
gain	657 4 I-Disease
(	662 1 O
60	663 2 O
%	665 1 O
)	666 1 O
,	667 1 O
muscle	669 6 B-Disease
cramps	676 6 I-Disease
/	682 1 O
myalgias	683 8 B-Disease
(	692 1 O
40	693 2 O
%	695 1 O
)	696 1 O
,	697 1 O
and	699 3 O
transaminase	703 12 O
elevations	716 10 O
(	727 1 O
40	728 2 O
%	730 1 O
)	731 1 O
were	733 4 O
the	738 3 O
most	742 4 O
common	747 6 O
adverse	754 7 O
reactions	762 9 O
.	771 1 O

The	773 3 O
drug	777 4 O
was	782 3 O
discontinued	786 12 O
due	799 3 O
to	803 2 O
adverse	806 7 O
reactions	814 9 O
in	824 2 O
8	827 1 O
patients	829 8 O
.	837 1 O

No	839 2 O
patient	842 7 O
has	850 3 O
died	854 4 O
or	859 2 O
suffered	862 8 O
any	871 3 O
apparent	875 8 O
long	884 4 O
-	888 1 O
term	889 4 O
sequelae	894 8 O
that	903 4 O
were	908 4 O
directly	913 8 O
attributable	922 12 O
to	935 2 O
the	938 3 O
drug	942 4 O
.	946 1 O

We	948 2 O
conclude	951 8 O
that	960 4 O
,	964 1 O
despite	966 7 O
a	974 1 O
relatively	976 10 O
high	987 4 O
incidence	992 9 O
of	1002 2 O
adverse	1005 7 O
reactions	1013 9 O
,	1022 1 O
danazol	1024 7 B-Chemical
has	1032 3 O
proven	1036 6 O
to	1043 2 O
be	1046 2 O
remarkably	1049 10 O
safe	1060 4 O
over	1065 4 O
the	1070 3 O
long	1074 4 O
-	1078 1 O
term	1079 4 O
in	1084 2 O
this	1087 4 O
group	1092 5 O
of	1098 2 O
patients	1101 8 O
.	1109 1 O

Patient	0 7 O
tolerance	8 9 O
study	18 5 O
of	24 2 O
topical	27 7 O
chlorhexidine	35 13 B-Chemical
diphosphanilate	49 15 I-Chemical
:	64 1 O
a	66 1 O
new	68 3 O
topical	72 7 O
agent	80 5 O
for	86 3 O
burns	90 5 B-Disease
.	95 1 O

Effective	97 9 O
topical	107 7 O
antimicrobial	115 13 O
agents	129 6 O
decrease	136 8 O
infection	145 9 B-Disease
and	155 3 O
mortality	159 9 O
in	169 2 O
burn	172 4 B-Disease
patients	177 8 O
.	185 1 O

Chlorhexidine	187 13 B-Chemical
phosphanilate	201 13 I-Chemical
(	215 1 O
CHP	216 3 B-Chemical
)	219 1 O
,	220 1 O
a	222 1 O
new	224 3 O
broad	228 5 O
-	233 1 O
spectrum	234 8 O
antimicrobial	243 13 O
agent	257 5 O
,	262 1 O
has	264 3 O
been	268 4 O
evaluated	273 9 O
as	283 2 O
a	286 1 O
topical	288 7 O
burn	296 4 B-Disease
wound	301 5 O
dressing	307 8 O
in	316 2 O
cream	319 5 O
form	325 4 O
,	329 1 O
but	331 3 O
preliminary	335 11 O
clinical	347 8 O
trials	356 6 O
reported	363 8 O
that	372 4 O
it	377 2 O
was	380 3 O
painful	384 7 O
upon	392 4 O
application	397 11 O
.	408 1 O

This	410 4 O
study	415 5 O
compared	421 8 O
various	430 7 O
concentrations	438 14 O
of	453 2 O
CHP	456 3 B-Chemical
to	460 2 O
determine	463 9 O
if	473 2 O
a	476 1 O
tolerable	478 9 O
concentration	488 13 O
could	502 5 O
be	508 2 O
identified	511 10 O
with	522 4 O
retention	527 9 O
of	537 2 O
antimicrobial	540 13 O
efficacy	554 8 O
.	562 1 O

Twenty	564 6 O
-	570 1 O
nine	571 4 O
burn	576 4 B-Disease
patients	581 8 O
,	589 1 O
each	591 4 O
with	596 4 O
two	601 3 O
similar	605 7 O
burns	613 5 B-Disease
which	619 5 O
could	625 5 O
be	631 2 O
separately	634 10 O
treated	645 7 O
,	652 1 O
were	654 4 O
given	659 5 O
pairs	665 5 O
of	671 2 O
treatments	674 10 O
at	685 2 O
successive	688 10 O
12	699 2 O
-	701 1 O
h	702 1 O
intervals	704 9 O
over	714 4 O
a	719 1 O
3	721 1 O
-	722 1 O
day	723 3 O
period	727 6 O
.	733 1 O

One	735 3 O
burn	739 4 B-Disease
site	744 4 O
was	749 3 O
treated	753 7 O
with	761 4 O
each	766 4 O
of	771 2 O
four	774 4 O
different	779 9 O
CHP	789 3 B-Chemical
concentrations	793 14 O
,	807 1 O
from	809 4 O
0	814 1 O
.	815 1 O
25	816 2 O
per	819 3 O
cent	823 4 O
to	828 2 O
2	831 1 O
per	833 3 O
cent	837 4 O
,	841 1 O
their	843 5 O
vehicle	849 7 O
,	856 1 O
and	858 3 O
1	862 1 O
per	864 3 O
cent	868 4 O
silver	873 6 B-Chemical
sulphadiazine	880 13 I-Chemical
(	894 1 O
AgSD	895 4 B-Chemical
)	899 1 O
cream	901 5 O
,	906 1 O
an	908 2 O
antimicrobial	911 13 O
agent	925 5 O
frequently	931 10 O
used	942 4 O
for	947 3 O
topical	951 7 O
treatment	959 9 O
of	969 2 O
burn	972 4 B-Disease
wounds	977 6 O
.	983 1 O

The	985 3 O
other	989 5 O
site	995 4 O
was	1000 3 O
always	1004 6 O
treated	1011 7 O
with	1019 4 O
AgSD	1024 4 B-Chemical
cream	1029 5 O
.	1034 1 O

There	1036 5 O
was	1042 3 O
a	1046 1 O
direct	1048 6 O
relationship	1055 12 O
between	1068 7 O
CHP	1076 3 B-Chemical
concentration	1080 13 O
and	1094 3 O
patients	1098 8 O
'	1106 1 O
ratings	1108 7 O
of	1116 2 O
pain	1119 4 B-Disease
on	1124 2 O
an	1127 2 O
analogue	1130 8 O
scale	1139 5 O
.	1144 1 O

The	1146 3 O
0	1150 1 O
.	1151 1 O
25	1152 2 O
per	1155 3 O
cent	1159 4 O
CHP	1164 3 B-Chemical
cream	1168 5 O
was	1174 3 O
closest	1178 7 O
to	1186 2 O
AgSD	1189 4 B-Chemical
in	1194 2 O
pain	1197 4 B-Disease
tolerance	1202 9 O
;	1211 1 O
however	1213 7 O
,	1220 1 O
none	1222 4 O
of	1227 2 O
the	1230 3 O
treatments	1234 10 O
differed	1245 8 O
statistically	1254 13 O
from	1268 4 O
AgSD	1273 4 B-Chemical
or	1278 2 O
from	1281 4 O
each	1286 4 O
other	1291 5 O
.	1296 1 O

In	1298 2 O
addition	1301 8 O
,	1309 1 O
ease	1311 4 O
of	1316 2 O
application	1319 11 O
of	1331 2 O
CHP	1334 3 B-Chemical
creams	1338 6 O
was	1345 3 O
less	1349 4 O
satisfactory	1354 12 O
than	1367 4 O
that	1372 4 O
of	1377 2 O
AgSD	1380 4 B-Chemical
.	1384 1 O

It	1386 2 O
was	1389 3 O
concluded	1393 9 O
that	1403 4 O
formulations	1408 12 O
at	1421 2 O
or	1424 2 O
below	1427 5 O
0	1433 1 O
.	1434 1 O
5	1435 1 O
per	1437 3 O
cent	1441 4 O
CHP	1446 3 B-Chemical
may	1450 3 O
prove	1454 5 O
acceptable	1460 10 O
for	1471 3 O
wound	1475 5 O
care	1481 4 O
,	1485 1 O
but	1487 3 O
the	1491 3 O
vehicle	1495 7 O
system	1503 6 O
needs	1510 5 O
pharmaceutical	1516 14 O
improvement	1531 11 O
to	1543 2 O
render	1546 6 O
it	1553 2 O
more	1556 4 O
tolerable	1561 9 O
and	1571 3 O
easier	1575 6 O
to	1582 2 O
use	1585 3 O
.	1588 1 O

Dose	0 4 O
-	4 1 O
dependent	5 9 O
neurotoxicity	15 13 B-Disease
of	29 2 O
high	32 4 O
-	36 1 O
dose	37 4 O
busulfan	42 8 B-Chemical
in	51 2 O
children	54 8 O
:	62 1 O
a	64 1 O
clinical	66 8 O
and	75 3 O
pharmacological	79 15 O
study	95 5 O
.	100 1 O

Busulfan	102 8 B-Chemical
is	111 2 O
known	114 5 O
to	120 2 O
be	123 2 O
neurotoxic	126 10 B-Disease
in	137 2 O
animals	140 7 O
and	148 3 O
humans	152 6 O
,	158 1 O
but	160 3 O
its	164 3 O
acute	168 5 O
neurotoxicity	174 13 B-Disease
remains	188 7 O
poorly	196 6 O
characterized	203 13 O
in	217 2 O
children	220 8 O
.	228 1 O

We	230 2 O
report	233 6 O
here	240 4 O
a	245 1 O
retrospective	247 13 O
study	261 5 O
of	267 2 O
123	270 3 O
children	274 8 O
(	283 1 O
median	284 6 O
age	291 3 O
,	294 1 O
6	296 1 O
.	297 1 O
5	298 1 O
years	300 5 O
)	305 1 O
receiving	307 9 O
high	317 4 O
-	321 1 O
dose	322 4 O
busulfan	327 8 B-Chemical
in	336 2 O
combined	339 8 O
chemotherapy	348 12 O
before	361 6 O
bone	368 4 O
marrow	373 6 O
transplantation	380 15 O
for	396 3 O
malignant	400 9 O
solid	410 5 O
tumors	416 6 B-Disease
,	422 1 O
brain	424 5 B-Disease
tumors	430 6 I-Disease
excluded	437 8 O
.	445 1 O

Busulfan	447 8 B-Chemical
was	456 3 O
given	460 5 O
p	466 1 O
.	467 1 O
o	468 1 O
.	469 1 O
,	470 1 O
every	472 5 O
6	478 1 O
hours	480 5 O
for	486 3 O
16	490 2 O
doses	493 5 O
over	499 4 O
4	504 1 O
days	506 4 O
.	510 1 O

Two	512 3 O
total	516 5 O
doses	522 5 O
were	528 4 O
consecutively	533 13 O
used	547 4 O
:	551 1 O
16	553 2 O
mg	556 2 O
/	558 1 O
kg	559 2 O
,	561 1 O
then	563 4 O
600	568 3 O
mg	572 2 O
/	574 1 O
m2	575 2 O
.	577 1 O

The	579 3 O
dose	583 4 O
calculation	588 11 O
on	600 2 O
the	603 3 O
basis	607 5 O
of	613 2 O
body	616 4 O
surface	621 7 O
area	629 4 O
results	634 7 O
in	642 2 O
higher	645 6 O
doses	652 5 O
in	658 2 O
young	661 5 O
children	667 8 O
than	676 4 O
in	681 2 O
older	684 5 O
patients	690 8 O
(	699 1 O
16	700 2 O
to	703 2 O
28	706 2 O
mg	709 2 O
/	711 1 O
kg	712 2 O
)	714 1 O
.	715 1 O

Ninety	717 6 O
-	723 1 O
six	724 3 O
patients	728 8 O
were	737 4 O
not	742 3 O
given	746 5 O
anticonvulsive	752 14 O
prophylaxis	767 11 O
;	778 1 O
7	780 1 O
(	782 1 O
7	783 1 O
.	784 1 O
5	785 1 O
%	786 1 O
)	787 1 O
developed	789 9 O
seizures	799 8 B-Disease
during	808 6 O
the	815 3 O
4	819 1 O
days	821 4 O
of	826 2 O
the	829 3 O
busulfan	833 8 B-Chemical
course	842 6 O
or	849 2 O
within	852 6 O
24	859 2 O
h	862 1 O
after	864 5 O
the	870 3 O
last	874 4 O
dosing	879 6 O
.	885 1 O

When	887 4 O
the	892 3 O
total	896 5 O
busulfan	902 8 B-Chemical
dose	911 4 O
was	916 3 O
taken	920 5 O
into	926 4 O
account	931 7 O
,	938 1 O
there	940 5 O
was	946 3 O
a	950 1 O
significant	952 11 O
difference	964 10 O
in	975 2 O
terms	978 5 O
of	984 2 O
neurotoxicity	987 13 B-Disease
incidence	1001 9 O
among	1011 5 O
patients	1017 8 O
under	1026 5 O
16	1032 2 O
mg	1035 2 O
/	1037 1 O
kg	1038 2 O
(	1041 1 O
1	1042 1 O
of	1044 2 O
57	1047 2 O
,	1049 1 O
1	1051 1 O
.	1052 1 O
7	1053 1 O
%	1054 1 O
)	1055 1 O
and	1057 3 O
patients	1061 8 O
under	1070 5 O
600	1076 3 O
mg	1080 2 O
/	1082 1 O
m2	1083 2 O
(	1086 1 O
6	1087 1 O
of	1089 2 O
39	1092 2 O
,	1094 1 O
15	1096 2 O
.	1098 1 O
4	1099 1 O
%	1100 1 O
)	1101 1 O
(	1103 1 O
P	1104 1 O
less	1106 4 O
than	1111 4 O
0	1116 1 O
.	1117 1 O
02	1118 2 O
)	1120 1 O
.	1121 1 O

Twenty	1123 6 O
-	1129 1 O
seven	1130 5 O
patients	1136 8 O
were	1145 4 O
given	1150 5 O
a	1156 1 O
600	1158 3 O
-	1161 1 O
mg	1162 2 O
/	1164 1 O
m2	1165 2 O
busulfan	1168 8 B-Chemical
total	1177 5 O
dose	1183 4 O
with	1188 4 O
continuous	1193 10 O
i	1204 1 O
.	1205 1 O
v	1206 1 O
.	1207 1 O
infusion	1209 8 O
of	1218 2 O
clonazepam	1221 10 B-Chemical
;	1231 1 O
none	1233 4 O
had	1238 3 O
any	1242 3 O
neurological	1246 12 B-Disease
symptoms	1259 8 I-Disease
.	1267 1 O

Busulfan	1269 8 B-Chemical
levels	1278 6 O
were	1285 4 O
measured	1290 8 O
by	1299 2 O
a	1302 1 O
gas	1304 3 O
chromatographic	1308 15 O
-	1323 1 O
mass	1324 4 O
spectrometry	1329 12 O
assay	1342 5 O
in	1348 2 O
the	1351 3 O
plasma	1355 6 O
and	1362 3 O
cerebrospinal	1366 13 O
fluid	1380 5 O
of	1386 2 O
9	1389 1 O
children	1391 8 O
without	1400 7 O
central	1408 7 B-Disease
nervous	1416 7 I-Disease
system	1424 6 I-Disease
disease	1431 7 I-Disease
under	1439 5 O
600	1445 3 O
mg	1449 2 O
/	1451 1 O
m2	1452 2 O
busulfan	1455 8 B-Chemical
with	1464 4 O
clonazepam	1469 10 B-Chemical
:	1479 1 O
busulfan	1480 8 B-Chemical
cerebrospinal	1489 13 O
fluid	1503 5 O
:	1508 1 O
plasma	1509 6 O
ratio	1516 5 O
was	1522 3 O
1	1526 1 O
.	1527 1 O
39	1528 2 O
.	1530 1 O

This	1532 4 O
was	1537 3 O
significantly	1541 13 O
different	1555 9 O
(	1565 1 O
P	1566 1 O
less	1568 4 O
than	1573 4 O
0	1578 1 O
.	1579 1 O
02	1580 2 O
)	1582 1 O
from	1584 4 O
the	1589 3 O
cerebrospinal	1593 13 O
fluid	1607 5 O
:	1612 1 O
plasma	1613 6 O
ratio	1620 5 O
previously	1626 10 O
defined	1637 7 O
in	1645 2 O
children	1648 8 O
receiving	1657 9 O
a	1667 1 O
16	1669 2 O
-	1671 1 O
mg	1672 2 O
/	1674 1 O
kg	1675 2 O
total	1678 5 O
dose	1684 4 O
of	1689 2 O
busulfan	1692 8 B-Chemical
.	1700 1 O

This	1702 4 O
study	1707 5 O
shows	1713 5 O
that	1719 4 O
busulfan	1724 8 B-Chemical
neurotoxicity	1733 13 B-Disease
is	1747 2 O
dose	1750 4 O
-	1754 1 O
dependent	1755 9 O
in	1765 2 O
children	1768 8 O
and	1777 3 O
efficiently	1781 11 O
prevented	1793 9 O
by	1803 2 O
clonazepam	1806 10 B-Chemical
.	1816 1 O

A	1818 1 O
busulfan	1820 8 B-Chemical
dose	1829 4 O
calculated	1834 10 O
on	1845 2 O
the	1848 3 O
basis	1852 5 O
of	1858 2 O
body	1861 4 O
surface	1866 7 O
area	1874 4 O
,	1878 1 O
resulting	1880 9 O
in	1890 2 O
higher	1893 6 O
doses	1900 5 O
in	1906 2 O
young	1909 5 O
children	1915 8 O
,	1923 1 O
was	1925 3 O
followed	1929 8 O
by	1938 2 O
increased	1941 9 O
neurotoxicity	1951 13 B-Disease
,	1964 1 O
close	1966 5 O
to	1972 2 O
neurotoxicity	1975 13 B-Disease
incidence	1989 9 O
observed	1999 8 O
in	2008 2 O
adults	2011 6 O
.	2017 1 O

Since	2019 5 O
plasma	2025 6 O
pharmacokinetic	2032 15 O
studies	2048 7 O
showed	2056 6 O
a	2063 1 O
faster	2065 6 O
busulfan	2072 8 B-Chemical
clearance	2081 9 O
in	2091 2 O
children	2094 8 O
than	2103 4 O
in	2108 2 O
adults	2111 6 O
,	2117 1 O
this	2119 4 O
new	2124 3 O
dose	2128 4 O
may	2133 3 O
approximate	2137 11 O
more	2149 4 O
closely	2154 7 O
the	2162 3 O
adult	2166 5 O
systemic	2172 8 O
exposure	2181 8 O
obtained	2190 8 O
after	2199 5 O
the	2205 3 O
usual	2209 5 O
16	2215 2 O
-	2217 1 O
mg	2218 2 O
/	2220 1 O
kg	2221 2 O
total	2224 5 O
dose	2230 4 O
,	2234 1 O
with	2236 4 O
potential	2241 9 O
inferences	2251 10 O
in	2262 2 O
terms	2265 5 O
of	2271 2 O
anticancer	2274 10 O
or	2285 2 O
myeloablative	2288 13 O
effects	2302 7 O
.	2309 1 O

The	2311 3 O
busulfan	2315 8 B-Chemical
dose	2324 4 O
in	2329 2 O
children	2332 8 O
and	2341 3 O
infants	2345 7 O
undergoing	2353 10 O
bone	2364 4 O
marrow	2369 6 O
transplantation	2376 15 O
should	2392 6 O
be	2399 2 O
reconsidered	2402 12 O
on	2415 2 O
the	2418 3 O
basis	2422 5 O
of	2428 2 O
pharmacokinetic	2431 15 O
studies	2447 7 O
.	2454 1 O

Histamine	0 9 B-Chemical
antagonists	10 11 O
and	22 3 O
d	26 1 B-Chemical
-	27 1 I-Chemical
tubocurarine	28 12 I-Chemical
-	40 1 O
induced	41 7 O
hypotension	49 11 B-Disease
in	61 2 O
cardiac	64 7 O
surgical	72 8 O
patients	81 8 O
.	89 1 O

Hemodynamic	91 11 O
effects	103 7 O
and	111 3 O
histamine	115 9 B-Chemical
release	125 7 O
by	133 2 O
bolus	136 5 O
injection	142 9 O
of	152 2 O
0	155 1 O
.	156 1 O
35	157 2 O
mg	160 2 O
/	162 1 O
kg	163 2 O
of	166 2 O
d	169 1 B-Chemical
-	170 1 I-Chemical
tubocurarine	171 12 I-Chemical
were	184 4 O
studied	189 7 O
in	197 2 O
24	200 2 O
patients	203 8 O
.	211 1 O

H1	213 2 O
-	215 1 O
and	217 3 O
H2	221 2 O
-	223 1 O
histamine	224 9 B-Chemical
antagonists	234 11 O
or	246 2 O
placebo	249 7 O
were	257 4 O
given	262 5 O
before	268 6 O
dosing	275 6 O
with	282 4 O
d	287 1 B-Chemical
-	288 1 I-Chemical
tubocurarine	289 12 I-Chemical
in	302 2 O
a	305 1 O
randomized	307 10 O
double	318 6 O
-	324 1 O
blind	325 5 O
fashion	331 7 O
to	339 2 O
four	342 4 O
groups	347 6 O
:	353 1 O
group	355 5 O
1	361 1 O
-	362 1 O
-	363 1 O
placebo	364 7 O
;	371 1 O
group	373 5 O
2	379 1 O
-	380 1 O
-	381 1 O
cimetidine	382 10 B-Chemical
,	392 1 O
4	394 1 O
mg	396 2 O
/	398 1 O
kg	399 2 O
,	401 1 O
plus	403 4 O
placebo	408 7 O
;	415 1 O
group	417 5 O
3	423 1 O
-	424 1 O
-	425 1 O
chlorpheniramine	426 16 B-Chemical
,	442 1 O
0	444 1 O
.	445 1 O
1	446 1 O
mg	448 2 O
/	450 1 O
kg	451 2 O
,	453 1 O
plus	455 4 O
placebo	460 7 O
;	467 1 O
and	469 3 O
group	473 5 O
4	479 1 O
-	480 1 O
-	481 1 O
cimetidine	482 10 B-Chemical
plus	493 4 O
chlorpheniramine	498 16 B-Chemical
.	514 1 O

Histamine	516 9 B-Chemical
release	526 7 O
occurred	534 8 O
in	543 2 O
most	546 4 O
patients	551 8 O
,	559 1 O
the	561 3 O
highest	565 7 O
level	573 5 O
2	579 1 O
minutes	581 7 O
after	589 5 O
d	595 1 B-Chemical
-	596 1 I-Chemical
tubocurarine	597 12 I-Chemical
dosing	610 6 O
.	616 1 O

Group	618 5 O
1	624 1 O
had	626 3 O
a	630 1 O
moderate	632 8 O
negative	641 8 O
correlation	650 11 O
between	662 7 O
plasma	670 6 O
histamine	677 9 B-Chemical
change	687 6 O
and	694 3 O
systemic	698 8 O
vascular	707 8 O
resistance	716 10 O
(	727 1 O
r	728 1 O
=	730 1 O
0	732 1 O
.	733 1 O
58	734 2 O
;	736 1 O
P	738 1 O
less	740 4 O
than	745 4 O
0	750 1 O
.	751 1 O
05	752 2 O
)	754 1 O
not	756 3 O
present	760 7 O
in	768 2 O
group	771 5 O
4	777 1 O
.	778 1 O

Prior	780 5 O
dosing	786 6 O
with	793 4 O
antagonists	798 11 O
partially	810 9 O
prevented	820 9 O
the	830 3 O
fall	834 4 O
in	839 2 O
systemic	842 8 O
vascular	851 8 O
resistance	860 10 O
.	870 1 O

These	872 5 O
data	878 4 O
demonstrate	883 11 O
that	895 4 O
the	900 3 O
hemodynamic	904 11 O
changes	916 7 O
associated	924 10 O
with	935 4 O
d	940 1 B-Chemical
-	941 1 I-Chemical
tubocurarine	942 12 I-Chemical
dosing	955 6 O
are	962 3 O
only	966 4 O
partially	971 9 O
explained	981 9 O
by	991 2 O
histamine	994 9 B-Chemical
release	1004 7 O
.	1011 1 O

Thus	1013 4 O
prior	1018 5 O
dosing	1024 6 O
with	1031 4 O
H1	1036 2 O
-	1038 1 O
and	1040 3 O
H2	1044 2 O
-	1046 1 O
antagonists	1047 11 O
provides	1059 8 O
only	1068 4 O
partial	1073 7 O
protection	1081 10 O
.	1091 1 O

Convulsant	0 10 O
effect	11 6 O
of	18 2 O
lindane	21 7 B-Chemical
and	29 3 O
regional	33 8 O
brain	42 5 O
concentration	48 13 O
of	62 2 O
GABA	65 4 B-Chemical
and	70 3 O
dopamine	74 8 B-Chemical
.	82 1 O

Lindane	84 7 B-Chemical
(	92 1 O
gamma	93 5 B-Chemical
-	98 1 I-Chemical
hexachlorocyclohexane	99 21 I-Chemical
)	120 1 O
is	122 2 O
an	125 2 O
organochlorine	128 14 O
insecticide	143 11 O
with	155 4 O
known	160 5 O
neurotoxic	166 10 B-Disease
effects	177 7 O
.	184 1 O

Its	186 3 O
mechanism	190 9 O
of	200 2 O
action	203 6 O
is	210 2 O
not	213 3 O
well	217 4 O
understood	222 10 O
although	233 8 O
it	242 2 O
has	245 3 O
been	249 4 O
proposed	254 8 O
that	263 4 O
lindane	268 7 B-Chemical
acts	276 4 O
as	281 2 O
a	284 1 O
non	286 3 O
-	289 1 O
competitive	290 11 O
antagonist	302 10 O
at	313 2 O
the	316 3 O
gamma	320 5 B-Chemical
-	325 1 I-Chemical
aminobutyric	326 12 I-Chemical
acid	339 4 I-Chemical
(	344 1 O
GABA	345 4 B-Chemical
)	349 1 O
-	350 1 O
A	351 1 O
receptor	353 8 O
.	361 1 O

We	363 2 O
studied	366 7 O
the	374 3 O
effect	378 6 O
of	385 2 O
lindane	388 7 B-Chemical
(	396 1 O
150	397 3 O
mg	401 2 O
/	403 1 O
kg	404 2 O
)	406 1 O
on	408 2 O
the	411 3 O
GABAergic	415 9 O
and	425 3 O
dopaminergic	429 12 O
systems	442 7 O
by	450 2 O
measuring	453 9 O
the	463 3 O
concentration	467 13 O
of	481 2 O
GABA	484 4 B-Chemical
,	488 1 O
dopamine	490 8 B-Chemical
and	499 3 O
its	503 3 O
metabolites	507 11 O
in	519 2 O
7	522 1 O
brain	524 5 O
areas	530 5 O
at	536 2 O
the	539 3 O
onset	543 5 O
of	549 2 O
seizures	552 8 B-Disease
.	560 1 O

All	562 3 O
animals	566 7 O
suffered	574 8 O
tonic	583 5 O
convulsions	589 11 B-Disease
at	601 2 O
18	604 2 O
.	606 1 O
3	607 1 O
+	609 1 O
/	610 1 O
-	611 1 O
1	613 1 O
.	614 1 O
4	615 1 O
min	617 3 O
after	621 5 O
lindane	627 7 B-Chemical
administration	635 14 O
.	649 1 O

The	651 3 O
concentration	655 13 O
of	669 2 O
GABA	672 4 B-Chemical
was	677 3 O
only	681 4 O
slightly	686 8 O
but	695 3 O
significantly	699 13 O
decreased	713 9 O
in	723 2 O
the	726 3 O
colliculi	730 9 O
without	740 7 O
modifications	748 13 O
in	762 2 O
the	765 3 O
other	769 5 O
areas	775 5 O
.	780 1 O

The	782 3 O
concentration	786 13 O
of	800 2 O
dopamine	803 8 B-Chemical
was	812 3 O
increased	816 9 O
in	826 2 O
the	829 3 O
mesencephalon	833 13 O
and	847 3 O
that	851 4 O
of	856 2 O
its	859 3 O
metabolite	863 10 O
DOPAC	874 5 B-Chemical
was	880 3 O
also	884 4 O
increased	889 9 O
in	899 2 O
the	902 3 O
mesencephalon	906 13 O
and	920 3 O
the	924 3 O
striatum	928 8 O
.	936 1 O

Unusual	0 7 O
complications	8 13 O
of	22 2 O
antithyroid	25 11 O
drug	37 4 O
therapy	42 7 O
:	49 1 O
four	51 4 O
case	56 4 O
reports	61 7 O
and	69 3 O
review	73 6 O
of	80 2 O
literature	83 10 O
.	93 1 O

Two	95 3 O
cases	99 5 O
of	105 2 O
propylthiouracil	108 16 B-Chemical
-	124 1 O
associated	125 10 O
acute	136 5 O
hepatitis	142 9 B-Disease
,	151 1 O
one	153 3 O
case	157 4 O
of	162 2 O
fatal	165 5 O
methimazole	171 11 B-Chemical
-	182 1 O
associated	183 10 O
hepatocellular	194 14 B-Disease
necrosis	209 8 I-Disease
and	218 3 O
one	222 3 O
case	226 4 O
of	231 2 O
propylthiouracil	234 16 B-Chemical
-	250 1 O
associated	251 10 O
lupus	262 5 B-Disease
-	267 1 I-Disease
like	268 4 I-Disease
syndrome	273 8 I-Disease
are	282 3 O
described	286 9 O
.	295 1 O

The	297 3 O
literature	301 10 O
related	312 7 O
to	320 2 O
antithyroid	323 11 O
drug	335 4 O
side	340 4 O
effects	345 7 O
and	353 3 O
the	357 3 O
mechanisms	361 10 O
for	372 3 O
their	376 5 O
occurrence	382 10 O
are	393 3 O
reviewed	397 8 O
and	406 3 O
the	410 3 O
efficacy	414 8 O
and	423 3 O
complications	427 13 O
of	441 2 O
thyroidectomy	444 13 O
and	458 3 O
radioiodine	462 11 O
compared	474 8 O
to	483 2 O
those	486 5 O
of	492 2 O
antithyroid	495 11 O
drugs	507 5 O
.	512 1 O

It	514 2 O
is	517 2 O
concluded	520 9 O
that	530 4 O
in	535 2 O
most	538 4 O
circumstances	543 13 O
131I	557 4 O
is	562 2 O
the	565 3 O
therapy	569 7 O
of	577 2 O
choice	580 6 O
for	587 3 O
hyperthyroidism	591 15 B-Disease
.	606 1 O

Anticonvulsant	0 14 O
actions	15 7 O
of	23 2 O
MK	26 2 B-Chemical
-	28 1 I-Chemical
801	29 3 I-Chemical
on	33 2 O
the	36 3 O
lithium	40 7 B-Chemical
-	47 1 O
pilocarpine	48 11 B-Chemical
model	60 5 O
of	66 2 O
status	69 6 B-Disease
epilepticus	76 11 I-Disease
in	88 2 O
rats	91 4 O
.	95 1 O

MK	97 2 B-Chemical
-	99 1 I-Chemical
801	100 3 I-Chemical
,	103 1 O
a	105 1 O
noncompetitive	107 14 O
N	122 1 B-Chemical
-	123 1 I-Chemical
methyl	124 6 I-Chemical
-	130 1 I-Chemical
D	131 1 I-Chemical
-	132 1 I-Chemical
aspartate	133 9 I-Chemical
(	143 1 O
NMDA	144 4 B-Chemical
)	148 1 O
receptor	150 8 O
antagonist	159 10 O
,	169 1 O
was	171 3 O
tested	175 6 O
for	182 3 O
anticonvulsant	186 14 O
effects	201 7 O
in	209 2 O
rats	212 4 O
using	217 5 O
two	223 3 O
seizure	227 7 B-Disease
models	235 6 O
,	241 1 O
coadministration	243 16 O
of	260 2 O
lithium	263 7 B-Chemical
and	271 3 O
pilocarpine	275 11 B-Chemical
and	287 3 O
administration	291 14 O
of	306 2 O
a	309 1 O
high	311 4 O
dose	316 4 O
of	321 2 O
pilocarpine	324 11 B-Chemical
alone	336 5 O
.	341 1 O

Three	343 5 O
major	349 5 O
results	355 7 O
are	363 3 O
reported	367 8 O
.	375 1 O

First	377 5 O
,	382 1 O
pretreatment	384 12 O
with	397 4 O
MK	402 2 B-Chemical
-	404 1 I-Chemical
801	405 3 I-Chemical
produced	409 8 O
an	418 2 O
effective	421 9 O
and	431 3 O
dose	435 4 O
-	439 1 O
dependent	440 9 O
anticonvulsant	450 14 O
action	465 6 O
with	472 4 O
the	477 3 O
lithium	481 7 B-Chemical
-	488 1 O
pilocarpine	489 11 B-Chemical
model	501 5 O
but	507 3 O
not	511 3 O
with	515 4 O
rats	520 4 O
treated	525 7 O
with	533 4 O
pilocarpine	538 11 B-Chemical
alone	550 5 O
,	555 1 O
suggesting	557 10 O
that	568 4 O
different	573 9 O
biochemical	583 11 O
mechanisms	595 10 O
control	606 7 O
seizures	614 8 B-Disease
in	623 2 O
these	626 5 O
two	632 3 O
models	636 6 O
.	642 1 O

Second	644 6 O
,	650 1 O
the	652 3 O
anticonvulsant	656 14 O
effect	671 6 O
of	678 2 O
MK	681 2 B-Chemical
-	683 1 I-Chemical
801	684 3 I-Chemical
in	688 2 O
the	691 3 O
lithium	695 7 B-Chemical
-	702 1 O
pilocarpine	703 11 B-Chemical
model	715 5 O
only	721 4 O
occurred	726 8 O
after	735 5 O
initial	741 7 O
periods	749 7 O
of	757 2 O
seizure	760 7 B-Disease
activity	768 8 O
.	776 1 O

This	778 4 O
observation	783 11 O
is	795 2 O
suggested	798 9 O
to	808 2 O
be	811 2 O
an	814 2 O
in	817 2 O
vivo	820 4 O
demonstration	825 13 O
of	839 2 O
the	842 3 O
conclusion	846 10 O
derived	857 7 O
from	865 4 O
in	870 2 O
vitro	873 5 O
experiments	879 11 O
that	891 4 O
MK	896 2 B-Chemical
-	898 1 I-Chemical
801	899 3 I-Chemical
binding	903 7 O
requires	911 8 O
agonist	920 7 O
-	927 1 O
induced	928 7 O
opening	936 7 O
of	944 2 O
the	947 3 O
channel	951 7 O
sites	959 5 O
of	965 2 O
the	968 3 O
NMDA	972 4 B-Chemical
receptor	977 8 O
.	985 1 O

Third	987 5 O
,	992 1 O
although	994 8 O
it	1003 2 O
is	1006 2 O
relatively	1009 10 O
easy	1020 4 O
to	1025 2 O
block	1028 5 O
seizures	1034 8 B-Disease
induced	1043 7 O
by	1051 2 O
lithium	1054 7 B-Chemical
and	1062 3 O
pilocarpine	1066 11 B-Chemical
by	1078 2 O
administration	1081 14 O
of	1096 2 O
anticonvulsants	1099 15 O
prior	1115 5 O
to	1121 2 O
pilocarpine	1124 11 B-Chemical
,	1135 1 O
it	1137 2 O
is	1140 2 O
more	1143 4 O
difficult	1148 9 O
to	1158 2 O
terminate	1161 9 O
ongoing	1171 7 O
status	1179 6 B-Disease
epilepticus	1186 11 I-Disease
and	1198 3 O
block	1202 5 O
the	1208 3 O
lethality	1212 9 O
of	1222 2 O
the	1225 3 O
seizures	1229 8 B-Disease
.	1237 1 O

Administration	1239 14 O
of	1254 2 O
MK	1257 2 B-Chemical
-	1259 1 I-Chemical
801	1260 3 I-Chemical
30	1264 2 O
or	1267 2 O
60	1270 2 O
min	1273 3 O
after	1277 5 O
pilocarpine	1283 11 B-Chemical
,	1294 1 O
i	1296 1 O
.	1297 1 O
e	1298 1 O
.	1299 1 O
,	1300 1 O
during	1302 6 O
status	1309 6 B-Disease
epilepticus	1316 11 I-Disease
,	1327 1 O
gradually	1329 9 O
reduced	1339 7 O
electrical	1347 10 O
and	1358 3 O
behavioral	1362 10 O
seizure	1373 7 B-Disease
activity	1381 8 O
and	1390 3 O
greatly	1394 7 O
enhanced	1402 8 O
the	1411 3 O
survival	1415 8 O
rate	1424 4 O
.	1428 1 O

These	1430 5 O
results	1436 7 O
suggest	1444 7 O
that	1452 4 O
activation	1457 10 O
of	1468 2 O
NMDA	1471 4 B-Chemical
receptors	1476 9 O
plays	1486 5 O
an	1492 2 O
important	1495 9 O
role	1505 4 O
in	1510 2 O
status	1513 6 B-Disease
epilepticus	1520 11 I-Disease
and	1532 3 O
brain	1536 5 B-Disease
damage	1542 6 I-Disease
in	1549 2 O
the	1552 3 O
lithium	1556 7 B-Chemical
-	1563 1 O
pilocarpine	1564 11 B-Chemical
model	1576 5 O
.	1581 1 O

This	1583 4 O
was	1588 3 O
further	1592 7 O
supported	1600 9 O
by	1610 2 O
results	1613 7 O
showing	1621 7 O
that	1629 4 O
nonconvulsive	1634 13 O
doses	1648 5 O
of	1654 2 O
NMDA	1657 4 B-Chemical
and	1662 3 O
pilocarpine	1666 11 B-Chemical
were	1678 4 O
synergistic	1683 11 O
,	1694 1 O
resulting	1696 9 O
in	1706 2 O
status	1709 6 B-Disease
epilepticus	1716 11 I-Disease
and	1728 3 O
subsequent	1732 10 O
mortality	1743 9 O
.	1752 1 O

Nifedipine	0 10 B-Chemical
induced	11 7 O
bradycardia	19 11 B-Disease
in	31 2 O
a	34 1 O
patient	36 7 O
with	44 4 O
autonomic	49 9 B-Disease
neuropathy	59 10 I-Disease
.	69 1 O

An	71 2 O
80	74 2 O
year	77 4 O
old	82 3 O
diabetic	86 8 B-Disease
male	95 4 O
with	100 4 O
evidence	105 8 O
of	114 2 O
peripheral	117 10 B-Disease
and	128 3 I-Disease
autonomic	132 9 I-Disease
neuropathy	142 10 I-Disease
was	153 3 O
admitted	157 8 O
with	166 4 O
chest	171 5 B-Disease
pain	177 4 I-Disease
.	181 1 O

He	183 2 O
was	186 3 O
found	190 5 O
to	196 2 O
have	199 4 O
atrial	204 6 B-Disease
flutter	211 7 I-Disease
at	219 2 O
a	222 1 O
ventricular	224 11 O
rate	236 4 O
of	241 2 O
70	244 2 O
/	246 1 O
min	247 3 O
which	251 5 O
slowed	257 6 O
down	264 4 O
to	269 2 O
30	272 2 O
-	274 1 O
40	275 2 O
/	277 1 O
min	278 3 O
when	282 4 O
nifedipine	287 10 B-Chemical
(	298 1 O
60	299 2 O
mg	302 2 O
)	304 1 O
in	306 2 O
3	309 1 O
divided	311 7 O
doses	319 5 O
,	324 1 O
during	326 6 O
which	333 5 O
he	339 2 O
was	342 3 O
paced	346 5 O
at	352 2 O
a	355 1 O
rate	357 4 O
of	362 2 O
70	365 2 O
/	367 1 O
min	368 3 O
.	371 1 O

This	373 4 O
is	378 2 O
inconsistent	381 12 O
with	394 4 O
the	399 3 O
well	403 4 O
-	407 1 O
established	408 11 O
finding	420 7 O
that	428 4 O
nifedipine	433 10 B-Chemical
induces	444 7 O
tachycardia	452 11 B-Disease
in	464 2 O
normally	467 8 O
innervated	476 10 O
hearts	487 6 O
.	493 1 O

However	495 7 O
,	502 1 O
in	504 2 O
hearts	507 6 O
deprived	514 8 O
of	523 2 O
compensatory	526 12 O
sympathetic	539 11 O
drive	551 5 O
,	556 1 O
it	558 2 O
may	561 3 O
lead	565 4 O
to	570 2 O
bradycardia	573 11 B-Disease
.	584 1 O

The	0 3 O
effect	4 6 O
of	11 2 O
haloperidol	14 11 B-Chemical
in	26 2 O
cocaine	29 7 B-Chemical
and	37 3 O
amphetamine	41 11 B-Chemical
intoxication	53 12 O
.	65 1 O

The	67 3 O
effectiveness	71 13 O
of	85 2 O
haloperidol	88 11 B-Chemical
pretreatment	100 12 O
in	113 2 O
preventing	116 10 O
the	127 3 O
toxic	131 5 O
effects	137 7 O
of	145 2 O
high	148 4 O
doses	153 5 O
of	159 2 O
amphetamine	162 11 B-Chemical
and	174 3 O
cocaine	178 7 B-Chemical
was	186 3 O
studied	190 7 O
in	198 2 O
rats	201 4 O
.	205 1 O

In	207 2 O
this	210 4 O
model	215 5 O
,	220 1 O
toxic	222 5 O
effects	228 7 O
were	236 4 O
induced	241 7 O
by	249 2 O
intraperitoneal	252 15 O
(	268 1 O
i	269 1 O
.	270 1 O
p	271 1 O
.	272 1 O
)	273 1 O
injection	275 9 O
of	285 2 O
amphetamine	288 11 B-Chemical
75	300 2 O
mg	303 2 O
/	305 1 O
kg	306 2 O
(	309 1 O
100	310 3 O
%	313 1 O
death	315 5 O
rate	321 4 O
)	325 1 O
or	327 2 O
cocaine	330 7 B-Chemical
70	338 2 O
mg	341 2 O
/	343 1 O
kg	344 2 O
(	347 1 O
82	348 2 O
%	350 1 O
death	352 5 O
rate	358 4 O
)	362 1 O
.	363 1 O

Haloperidol	365 11 B-Chemical
failed	377 6 O
to	384 2 O
prevent	387 7 O
amphetamine	395 11 B-Chemical
-	406 1 O
induced	407 7 O
seizures	415 8 B-Disease
,	423 1 O
but	425 3 O
did	429 3 O
lower	433 5 O
the	439 3 O
mortality	443 9 O
rate	453 4 O
at	458 2 O
most	461 4 O
doses	466 5 O
tested	472 6 O
.	478 1 O

Haloperidol	480 11 B-Chemical
decreased	492 9 O
the	502 3 O
incidence	506 9 O
of	516 2 O
cocaine	519 7 B-Chemical
-	526 1 O
induced	527 7 O
seizures	535 8 B-Disease
at	544 2 O
the	547 3 O
two	551 3 O
highest	555 7 O
doses	563 5 O
,	568 1 O
but	570 3 O
the	574 3 O
lowering	578 8 O
of	587 2 O
the	590 3 O
mortality	594 9 O
rate	604 4 O
did	609 3 O
not	613 3 O
reach	617 5 O
statistical	623 11 O
significance	635 12 O
at	648 2 O
any	651 3 O
dose	655 4 O
.	659 1 O

These	661 5 O
data	667 4 O
suggest	672 7 O
a	680 1 O
protective	682 10 O
role	693 4 O
for	698 3 O
the	702 3 O
central	706 7 O
dopamine	714 8 B-Chemical
blocker	723 7 O
haloperidol	731 11 B-Chemical
against	743 7 O
death	751 5 O
from	757 4 O
high	762 4 O
-	766 1 O
dose	767 4 O
amphetamine	772 11 B-Chemical
exposure	784 8 O
without	793 7 O
reducing	801 8 O
the	810 3 O
incidence	814 9 O
of	824 2 O
seizures	827 8 B-Disease
.	835 1 O

In	837 2 O
contrast	840 8 O
,	848 1 O
haloperidol	850 11 B-Chemical
demonstrated	862 12 O
an	875 2 O
ability	878 7 O
to	886 2 O
reduce	889 6 O
cocaine	896 7 B-Chemical
-	903 1 O
induced	904 7 O
seizures	912 8 B-Disease
without	921 7 O
significantly	929 13 O
reducing	943 8 O
mortality	952 9 O
.	961 1 O

Autoradiographic	0 16 O
evidence	17 8 O
of	26 2 O
estrogen	29 8 B-Chemical
binding	38 7 O
sites	46 5 O
in	52 2 O
nuclei	55 6 O
of	62 2 O
diethylstilbesterol	65 19 B-Chemical
induced	85 7 O
hamster	93 7 O
renal	101 5 B-Disease
carcinomas	107 10 I-Disease
.	117 1 O

Estrogen	119 8 B-Chemical
binding	128 7 O
sites	136 5 O
were	142 4 O
demonstrated	147 12 O
by	160 2 O
autoradiography	163 15 O
in	179 2 O
one	182 3 O
transplantable	186 14 O
and	201 3 O
five	205 4 O
primary	210 7 O
diethylstilbesterol	218 19 B-Chemical
induced	238 7 O
renal	246 5 B-Disease
carcinomas	252 10 I-Disease
in	263 2 O
three	266 5 O
hamsters	272 8 O
.	280 1 O

Radiolabelling	282 14 O
,	296 1 O
following	298 9 O
the	308 3 O
in	312 2 O
vivo	315 4 O
injection	320 9 O
of	330 2 O
3H	333 2 O
-	335 1 O
17	336 2 O
beta	339 4 O
estradiol	344 9 B-Chemical
,	353 1 O
was	355 3 O
increased	359 9 O
only	369 4 O
over	374 4 O
the	379 3 O
nuclei	383 6 O
of	390 2 O
tumor	393 5 B-Disease
cells	399 5 O
;	404 1 O
stereologic	406 11 O
analysis	418 8 O
revealed	427 8 O
a	436 1 O
4	438 1 O
.	439 1 O
5	440 1 O
-	441 1 O
to	443 2 O
6	446 1 O
.	447 1 O
7	448 1 O
-	449 1 O
times	450 5 O
higher	456 6 O
concentration	463 13 O
of	477 2 O
reduced	480 7 O
silver	488 6 B-Chemical
grains	495 6 O
over	502 4 O
nuclei	507 6 O
than	514 4 O
cytoplasm	519 9 O
of	529 2 O
these	532 5 O
cells	538 5 O
.	543 1 O

Despite	545 7 O
rapid	553 5 O
tubular	559 7 O
excretion	567 9 O
of	577 2 O
estradiol	580 9 B-Chemical
which	590 5 O
peaked	596 6 O
in	603 2 O
less	606 4 O
than	611 4 O
1	616 1 O
h	618 1 O
,	619 1 O
the	621 3 O
normal	625 6 O
cells	632 5 O
did	638 3 O
not	642 3 O
appear	646 6 O
to	653 2 O
bind	656 4 O
the	661 3 O
ligand	665 6 O
.	671 1 O

This	673 4 O
is	678 2 O
the	681 3 O
first	685 5 O
published	691 9 O
report	701 6 O
documenting	708 11 O
the	720 3 O
preferential	724 12 O
in	737 2 O
vivo	740 4 O
binding	745 7 O
of	753 2 O
estrogen	756 8 B-Chemical
to	765 2 O
nuclei	768 6 O
of	775 2 O
cells	778 5 O
in	784 2 O
estrogen	787 8 B-Chemical
induced	796 7 O
hamster	804 7 O
renal	812 5 B-Disease
carcinomas	818 10 I-Disease
.	828 1 O

Bradycardia	0 11 B-Disease
due	12 3 O
to	16 2 O
biperiden	19 9 B-Chemical
.	28 1 O

In	30 2 O
a	33 1 O
38	35 2 O
-	37 1 O
year	38 4 O
-	42 1 O
old	43 3 O
male	47 4 O
patient	52 7 O
suffering	60 9 O
from	70 4 O
a	75 1 O
severe	77 6 O
postzosteric	84 12 B-Disease
trigeminal	97 10 B-Disease
neuralgia	108 9 I-Disease
,	117 1 O
intravenous	119 11 O
application	131 11 O
of	143 2 O
10	146 2 O
mg	149 2 O
biperiden	152 9 B-Chemical
lactate	162 7 I-Chemical
led	170 3 O
to	174 2 O
a	177 1 O
long	179 4 O
-	183 1 O
lasting	184 7 O
paradoxical	192 11 O
reaction	204 8 O
characterized	213 13 O
by	227 2 O
considerable	230 12 O
bradycardia	243 11 B-Disease
,	254 1 O
dysarthria	256 10 B-Disease
,	266 1 O
and	268 3 O
dysphagia	272 9 B-Disease
.	281 1 O

The	283 3 O
heart	287 5 O
rate	293 4 O
was	298 3 O
back	302 4 O
to	307 2 O
normal	310 6 O
within	317 6 O
12	324 2 O
hours	327 5 O
upon	333 4 O
administration	338 14 O
of	353 2 O
orciprenaline	356 13 B-Chemical
under	370 5 O
cardiac	376 7 O
monitoring	384 10 O
in	395 2 O
an	398 2 O
intensive	401 9 O
care	411 4 O
unit	416 4 O
.	420 1 O

Bradycardia	422 11 B-Disease
induced	434 7 O
by	442 2 O
biperiden	445 9 B-Chemical
is	455 2 O
attributed	458 10 O
to	469 2 O
the	472 3 O
speed	476 5 O
of	482 2 O
injection	485 9 O
and	495 3 O
to	499 2 O
a	502 1 O
dose	504 4 O
-	508 1 O
related	509 7 O
dual	517 4 O
effect	522 6 O
of	529 2 O
atropine	532 8 B-Chemical
-	540 1 O
like	541 4 O
drugs	546 5 O
on	552 2 O
muscarine	555 9 B-Chemical
receptors	565 9 O
.	574 1 O

Deliberate	0 10 O
hypotension	11 11 B-Disease
induced	23 7 O
by	31 2 O
labetalol	34 9 B-Chemical
with	44 4 O
halothane	49 9 B-Chemical
,	58 1 O
enflurane	60 9 B-Chemical
or	70 2 O
isoflurane	73 10 B-Chemical
for	84 3 O
middle	88 6 O
-	94 1 O
ear	95 3 O
surgery	99 7 O
.	106 1 O

The	108 3 O
feasibility	112 11 O
of	124 2 O
using	127 5 O
labetalol	133 9 B-Chemical
,	142 1 O
an	144 2 O
alpha	147 5 O
-	152 1 O
and	154 3 O
beta	158 4 O
-	162 1 O
adrenergic	163 10 O
blocking	174 8 O
agent	183 5 O
,	188 1 O
as	190 2 O
a	193 1 O
hypotensive	195 11 B-Disease
agent	207 5 O
in	213 2 O
combination	216 11 O
with	228 4 O
inhalation	233 10 O
anaesthetics	244 12 O
(	257 1 O
halothane	258 9 B-Chemical
,	267 1 O
enflurane	269 9 B-Chemical
or	279 2 O
isoflurane	282 10 B-Chemical
)	292 1 O
was	294 3 O
studied	298 7 O
in	306 2 O
23	309 2 O
adult	312 5 O
patients	318 8 O
undergoing	327 10 O
middle	338 6 O
-	344 1 O
ear	345 3 O
surgery	349 7 O
.	356 1 O

The	358 3 O
mean	362 4 O
arterial	367 8 O
pressure	376 8 O
was	385 3 O
decreased	389 9 O
from	399 4 O
86	404 2 O
+	407 1 O
/	408 1 O
-	409 1 O
5	411 1 O
(	413 1 O
s	414 1 O
.	415 1 O
e	416 1 O
.	417 1 O
mean	419 4 O
)	423 1 O
mmHg	425 4 O
to	430 2 O
52	433 2 O
+	436 1 O
/	437 1 O
-	438 1 O
1	440 1 O
mmHg	442 4 O
(	447 1 O
11	448 2 O
.	450 1 O
5	451 1 O
+	453 1 O
/	454 1 O
-	455 1 O
0	457 1 O
.	458 1 O
7	459 1 O
to	461 2 O
6	464 1 O
.	465 1 O
9	466 1 O
+	468 1 O
/	469 1 O
-	470 1 O
0	472 1 O
.	473 1 O
1	474 1 O
kPa	476 3 O
)	479 1 O
for	481 3 O
98	485 2 O
+	488 1 O
/	489 1 O
-	490 1 O
10	492 2 O
min	495 3 O
in	499 2 O
the	502 3 O
halothane	506 9 B-Chemical
(	516 1 O
H	517 1 B-Chemical
)	518 1 O
group	520 5 O
,	525 1 O
from	527 4 O
79	532 2 O
+	535 1 O
/	536 1 O
-	537 1 O
5	539 1 O
to	541 2 O
53	544 2 O
+	547 1 O
/	548 1 O
-	549 1 O
1	551 1 O
mmHg	553 4 O
(	558 1 O
10	559 2 O
.	561 1 O
5	562 1 O
+	564 1 O
/	565 1 O
-	566 1 O
0	568 1 O
.	569 1 O
7	570 1 O
to	572 2 O
7	575 1 O
.	576 1 O
1	577 1 O
+	579 1 O
/	580 1 O
-	581 1 O
0	583 1 O
.	584 1 O
1	585 1 O
kPa	587 3 O
)	590 1 O
for	592 3 O
129	596 3 O
+	600 1 O
/	601 1 O
-	602 1 O
11	604 2 O
min	607 3 O
in	611 2 O
the	614 3 O
enflurane	618 9 B-Chemical
(	628 1 O
E	629 1 B-Chemical
)	630 1 O
group	632 5 O
,	637 1 O
and	639 3 O
from	643 4 O
80	648 2 O
+	651 1 O
/	652 1 O
-	653 1 O
4	655 1 O
to	657 2 O
49	660 2 O
+	663 1 O
/	664 1 O
-	665 1 O
1	667 1 O
mmHg	669 4 O
(	674 1 O
10	675 2 O
.	677 1 O
7	678 1 O
+	680 1 O
/	681 1 O
-	682 1 O
0	684 1 O
.	685 1 O
5	686 1 O
to	688 2 O
6	691 1 O
.	692 1 O
5	693 1 O
+	695 1 O
/	696 1 O
-	697 1 O
0	699 1 O
.	700 1 O
1	701 1 O
kPa	703 3 O
)	706 1 O
for	708 3 O
135	712 3 O
+	716 1 O
/	717 1 O
-	718 1 O
15	720 2 O
min	723 3 O
in	727 2 O
the	730 3 O
isoflurane	734 10 B-Chemical
(	745 1 O
I	746 1 B-Chemical
)	747 1 O
group	749 5 O
.	754 1 O

The	756 3 O
mean	760 4 O
H	765 1 B-Chemical
concentration	767 13 O
during	781 6 O
hypotension	788 11 B-Disease
in	800 2 O
the	803 3 O
inspiratory	807 11 O
gas	819 3 O
was	823 3 O
0	827 1 O
.	828 1 O
7	829 1 O
+	831 1 O
/	832 1 O
-	833 1 O
0	835 1 O
.	836 1 O
1	837 1 O
vol	839 3 O
%	842 1 O
,	843 1 O
the	845 3 O
mean	849 4 O
E	854 1 B-Chemical
concentration	856 13 O
1	870 1 O
.	871 1 O
6	872 1 O
+	874 1 O
/	875 1 O
-	876 1 O
0	878 1 O
.	879 1 O
2	880 1 O
vol	882 3 O
%	885 1 O
,	886 1 O
and	888 3 O
the	892 3 O
mean	896 4 O
I	901 1 B-Chemical
concentration	903 13 O
1	917 1 O
.	918 1 O
0	919 1 O
+	921 1 O
/	922 1 O
-	923 1 O
0	925 1 O
.	926 1 O
1	927 1 O
vol	929 3 O
%	932 1 O
.	933 1 O

In	935 2 O
addition	938 8 O
,	946 1 O
the	948 3 O
patients	952 8 O
received	961 8 O
fentanyl	970 8 B-Chemical
and	979 3 O
d	983 1 B-Chemical
-	984 1 I-Chemical
tubocurarine	985 12 I-Chemical
.	997 1 O

The	999 3 O
initial	1003 7 O
dose	1011 4 O
of	1016 2 O
labetalol	1019 9 B-Chemical
for	1029 3 O
lowering	1033 8 O
blood	1042 5 O
pressure	1048 8 O
was	1057 3 O
similar	1061 7 O
,	1068 1 O
0	1070 1 O
.	1071 1 O
52	1072 2 O
-	1074 1 O
0	1075 1 O
.	1076 1 O
59	1077 2 O
mg	1080 2 O
/	1082 1 O
kg	1083 2 O
,	1085 1 O
in	1087 2 O
all	1090 3 O
the	1094 3 O
groups	1098 6 O
.	1104 1 O

During	1106 6 O
hypotension	1113 11 B-Disease
,	1124 1 O
the	1126 3 O
heart	1130 5 O
rate	1136 4 O
was	1141 3 O
stable	1145 6 O
without	1152 7 O
tachy	1160 5 B-Disease
-	1165 1 I-Disease
or	1167 2 I-Disease
bradycardia	1170 11 I-Disease
.	1181 1 O

The	1183 3 O
operating	1187 9 O
conditions	1197 10 O
regarding	1208 9 O
bleeding	1218 8 B-Disease
were	1227 4 O
estimated	1232 9 O
in	1242 2 O
a	1245 1 O
double	1247 6 O
-	1253 1 O
blind	1254 5 O
manner	1260 6 O
,	1266 1 O
and	1268 3 O
did	1272 3 O
not	1276 3 O
differ	1280 6 O
significantly	1287 13 O
between	1301 7 O
the	1309 3 O
groups	1313 6 O
.	1319 1 O

During	1321 6 O
hypotension	1328 11 B-Disease
,	1339 1 O
the	1341 3 O
serum	1345 5 O
creatinine	1351 10 B-Chemical
concentration	1362 13 O
rose	1376 4 O
significantly	1381 13 O
in	1395 2 O
all	1398 3 O
groups	1402 6 O
from	1409 4 O
the	1414 3 O
values	1418 6 O
before	1425 6 O
hypotension	1432 11 B-Disease
and	1444 3 O
returned	1448 8 O
postoperatively	1457 15 O
to	1473 2 O
the	1476 3 O
initial	1480 7 O
level	1488 5 O
in	1494 2 O
the	1497 3 O
other	1501 5 O
groups	1507 6 O
,	1513 1 O
except	1515 6 O
the	1522 3 O
isoflurane	1526 10 B-Chemical
group	1537 5 O
.	1542 1 O

After	1544 5 O
hypotension	1550 11 B-Disease
there	1562 5 O
was	1568 3 O
no	1572 2 O
rebound	1575 7 O
phenomenon	1583 10 O
in	1594 2 O
either	1597 6 O
blood	1604 5 O
pressure	1610 8 O
or	1619 2 O
heart	1622 5 O
rate	1628 4 O
.	1632 1 O

These	1634 5 O
results	1640 7 O
indicate	1648 8 O
that	1657 4 O
labetalol	1662 9 B-Chemical
induces	1672 7 O
easily	1680 6 O
adjustable	1687 10 O
hypotension	1698 11 B-Disease
without	1710 7 O
compensatory	1718 12 O
tachycardia	1731 11 B-Disease
and	1743 3 O
rebound	1747 7 O
hypertension	1755 12 B-Disease
.	1767 1 O

Convulsion	0 10 B-Disease
following	11 9 O
intravenous	21 11 O
fluorescein	33 11 B-Chemical
angiography	45 11 O
.	56 1 O

Tonic	58 5 B-Disease
-	63 1 I-Disease
clonic	64 6 I-Disease
seizures	71 8 I-Disease
followed	80 8 O
intravenous	89 11 O
fluorescein	101 11 B-Chemical
injection	113 9 O
for	123 3 O
fundus	127 6 O
angiography	134 11 O
in	146 2 O
a	149 1 O
47	151 2 O
-	153 1 O
year	154 4 O
-	158 1 O
old	159 3 O
male	163 4 O
.	167 1 O

Despite	169 7 O
precautions	177 11 O
this	189 4 O
adverse	194 7 O
reaction	202 8 O
recurred	211 8 O
on	220 2 O
re	223 2 O
-	225 1 O
exposure	226 8 O
to	235 2 O
intravenous	238 11 O
fluorescein	250 11 B-Chemical
.	261 1 O

Pharmacology	0 12 O
of	13 2 O
ACC	16 3 B-Chemical
-	19 1 I-Chemical
9653	20 4 I-Chemical
(	25 1 O
phenytoin	26 9 B-Chemical
prodrug	36 7 O
)	43 1 O
.	44 1 O

ACC	46 3 B-Chemical
-	49 1 I-Chemical
9653	50 4 I-Chemical
,	54 1 O
the	56 3 O
disodium	60 8 B-Chemical
phosphate	69 9 I-Chemical
ester	79 5 I-Chemical
of	85 2 O
3	88 1 B-Chemical
-	89 1 I-Chemical
hydroxymethyl	90 13 I-Chemical
-	103 1 I-Chemical
5	104 1 I-Chemical
,	105 1 I-Chemical
5	106 1 I-Chemical
-	107 1 I-Chemical
diphenylhydantoin	108 17 I-Chemical
,	125 1 O
is	127 2 O
a	130 1 O
prodrug	132 7 O
of	140 2 O
phenytoin	143 9 B-Chemical
with	153 4 O
advantageous	158 12 O
physicochemical	171 15 O
properties	187 10 O
.	197 1 O

ACC	199 3 B-Chemical
-	202 1 I-Chemical
9653	203 4 I-Chemical
is	208 2 O
rapidly	211 7 O
converted	219 9 O
enzymatically	229 13 O
to	243 2 O
phenytoin	246 9 B-Chemical
in	256 2 O
vivo	259 4 O
.	263 1 O

ACC	265 3 B-Chemical
-	268 1 I-Chemical
9653	269 4 I-Chemical
and	274 3 O
phenytoin	278 9 B-Chemical
sodium	288 6 I-Chemical
have	295 4 O
equivalent	300 10 O
anticonvulsant	311 14 O
activity	326 8 O
against	335 7 O
seizures	343 8 B-Disease
induced	352 7 O
by	360 2 O
maximal	363 7 O
electroshock	371 12 O
(	384 1 O
MES	385 3 O
)	388 1 O
in	390 2 O
mice	393 4 O
following	398 9 O
i	408 1 O
.	409 1 O
p	410 1 O
.	411 1 O
,	412 1 O
oral	414 4 O
,	418 1 O
or	420 2 O
i	423 1 O
.	424 1 O
v	425 1 O
.	426 1 O
administration	428 14 O
.	442 1 O

The	444 3 O
ED50	448 4 O
doses	453 5 O
were	459 4 O
16	464 2 O
mg	467 2 O
/	469 1 O
kg	470 2 O
for	473 3 O
i	477 1 O
.	478 1 O
v	479 1 O
.	480 1 O
ACC	482 3 B-Chemical
-	485 1 I-Chemical
9653	486 4 I-Chemical
and	491 3 O
8	495 1 O
mg	497 2 O
/	499 1 O
kg	500 2 O
for	503 3 O
i	507 1 O
.	508 1 O
v	509 1 O
.	510 1 O
phenytoin	512 9 B-Chemical
sodium	522 6 I-Chemical
.	528 1 O

ACC	530 3 B-Chemical
-	533 1 I-Chemical
9653	534 4 I-Chemical
and	539 3 O
phenytoin	543 9 B-Chemical
sodium	553 6 I-Chemical
have	560 4 O
similar	565 7 O
antiarrhythmic	573 14 O
activity	588 8 O
against	597 7 O
ouabain	605 7 B-Chemical
-	612 1 O
induced	613 7 O
ventricular	621 11 B-Disease
tachycardia	633 11 I-Disease
in	645 2 O
anesthetized	648 12 O
dogs	661 4 O
.	665 1 O

The	667 3 O
total	671 5 O
doses	677 5 O
of	683 2 O
ACC	686 3 B-Chemical
-	689 1 I-Chemical
9653	690 4 I-Chemical
or	695 2 O
phenytoin	698 9 B-Chemical
sodium	708 6 I-Chemical
necessary	715 9 O
to	725 2 O
convert	728 7 O
the	736 3 O
arrhythmia	740 10 B-Disease
to	751 2 O
a	754 1 O
normal	756 6 O
sinus	763 5 O
rhythm	769 6 O
were	776 4 O
24	781 2 O
+	784 1 O
/	785 1 O
-	786 1 O
6	788 1 O
and	790 3 O
14	794 2 O
+	797 1 O
/	798 1 O
-	799 1 O
3	801 1 O
mg	803 2 O
/	805 1 O
kg	806 2 O
,	808 1 O
respectively	810 12 O
.	822 1 O

Only	824 4 O
phenytoin	829 9 B-Chemical
sodium	839 6 I-Chemical
displayed	846 9 O
in	856 2 O
vitro	859 5 O
antiarrhythmic	865 14 O
activity	880 8 O
against	889 7 O
strophanthidin	897 14 B-Chemical
-	911 1 O
induced	912 7 O
arrhythmias	920 11 B-Disease
in	932 2 O
guinea	935 6 O
pig	942 3 O
right	946 5 O
atria	952 5 O
.	957 1 O

In	959 2 O
anesthetized	962 12 O
dogs	975 4 O
,	979 1 O
a	981 1 O
high	983 4 O
dose	988 4 O
of	993 2 O
ACC	996 3 B-Chemical
-	999 1 I-Chemical
9653	1000 4 I-Chemical
(	1005 1 O
31	1006 2 O
mg	1009 2 O
/	1011 1 O
kg	1012 2 O
)	1014 1 O
was	1016 3 O
infused	1020 7 O
over	1028 4 O
15	1033 2 O
,	1035 1 O
20	1037 2 O
,	1039 1 O
and	1041 3 O
30	1045 2 O
min	1048 3 O
and	1052 3 O
the	1056 3 O
responses	1060 9 O
were	1070 4 O
compared	1075 8 O
to	1084 2 O
an	1087 2 O
equimolar	1090 9 O
dose	1100 4 O
of	1105 2 O
phenytoin	1108 9 B-Chemical
sodium	1118 6 I-Chemical
(	1125 1 O
21	1126 2 O
mg	1129 2 O
/	1131 1 O
kg	1132 2 O
)	1134 1 O
.	1135 1 O

The	1137 3 O
ACC	1141 3 B-Chemical
-	1144 1 I-Chemical
9653	1145 4 I-Chemical
and	1150 3 O
phenytoin	1154 9 B-Chemical
sodium	1164 6 I-Chemical
treatments	1171 10 O
produced	1182 8 O
similar	1191 7 O
marked	1199 6 O
reductions	1206 10 O
in	1217 2 O
diastolic	1220 9 O
blood	1230 5 O
pressure	1236 8 O
and	1245 3 O
contractile	1249 11 O
force	1261 5 O
(	1267 1 O
LVdP	1268 4 O
/	1272 1 O
dt	1273 2 O
)	1275 1 O
.	1276 1 O

The	1278 3 O
maximum	1282 7 O
effects	1290 7 O
of	1298 2 O
each	1301 4 O
treatment	1306 9 O
occurred	1316 8 O
at	1325 2 O
the	1328 3 O
time	1332 4 O
of	1337 2 O
maximum	1340 7 O
phenytoin	1348 9 B-Chemical
sodium	1358 6 I-Chemical
levels	1365 6 O
.	1371 1 O

Acute	1373 5 O
toxicity	1379 8 B-Disease
studies	1388 7 O
of	1396 2 O
ACC	1399 3 B-Chemical
-	1402 1 I-Chemical
9653	1403 4 I-Chemical
and	1408 3 O
phenytoin	1412 9 B-Chemical
sodium	1422 6 I-Chemical
were	1429 4 O
carried	1434 7 O
out	1442 3 O
in	1446 2 O
mice	1449 4 O
,	1453 1 O
rats	1455 4 O
,	1459 1 O
rabbits	1461 7 O
,	1468 1 O
and	1470 3 O
dogs	1474 4 O
by	1479 2 O
i	1482 1 O
.	1483 1 O
v	1484 1 O
.	1485 1 O
,	1486 1 O
i	1488 1 O
.	1489 1 O
m	1490 1 O
.	1491 1 O
,	1492 1 O
and	1494 3 O
i	1498 1 O
.	1499 1 O
p	1500 1 O
.	1501 1 O
routes	1503 6 O
of	1510 2 O
administration	1513 14 O
.	1527 1 O

The	1529 3 O
systemic	1533 8 O
toxic	1542 5 O
signs	1548 5 O
of	1554 2 O
both	1557 4 O
agents	1562 6 O
were	1569 4 O
similar	1574 7 O
and	1582 3 O
occurred	1586 8 O
at	1595 2 O
approximately	1598 13 O
equivalent	1612 10 O
doses	1623 5 O
.	1628 1 O

Importantly	1630 11 O
,	1641 1 O
the	1643 3 O
local	1647 5 O
irritation	1653 10 O
of	1664 2 O
ACC	1667 3 B-Chemical
-	1670 1 I-Chemical
9653	1671 4 I-Chemical
was	1676 3 O
markedly	1680 8 O
less	1689 4 O
than	1694 4 O
phenytoin	1699 9 B-Chemical
sodium	1709 6 I-Chemical
following	1716 9 O
i	1726 1 O
.	1727 1 O
m	1728 1 O
.	1729 1 O
administration	1731 14 O
.	1745 1 O
(	1746 1 O
ABSTRACT	1747 8 O
TRUNCATED	1756 9 O
AT	1766 2 O
250	1769 3 O
WORDS	1773 5 O
)	1778 1 O

Phenytoin	0 9 B-Chemical
induced	10 7 O
fatal	18 5 O
hepatic	24 7 B-Disease
injury	32 6 I-Disease
.	38 1 O

A	40 1 O
61	42 2 O
year	45 4 O
old	50 3 O
female	54 6 O
developed	61 9 O
fatal	71 5 O
hepatic	77 7 B-Disease
failure	85 7 I-Disease
after	93 5 O
phenytoin	99 9 B-Chemical
administration	109 14 O
.	123 1 O

A	125 1 O
typical	127 7 O
multisystem	135 11 O
clinical	147 8 O
pattern	156 7 O
precedes	164 8 O
the	173 3 O
manifestations	177 14 O
of	192 2 O
hepatic	195 7 B-Disease
injury	203 6 I-Disease
.	209 1 O

The	211 3 O
hematologic	215 11 O
,	226 1 O
biochemical	228 11 O
and	240 3 O
pathologic	244 10 O
features	255 8 O
indicate	264 8 O
a	273 1 O
mixed	275 5 O
hepatocellular	281 14 B-Disease
damage	296 6 I-Disease
due	303 3 O
to	307 2 O
drug	310 4 B-Disease
hypersensitivity	315 16 I-Disease
.	331 1 O

In	333 2 O
a	336 1 O
patient	338 7 O
receiving	346 9 O
phenytoin	356 9 B-Chemical
who	366 3 O
presents	370 8 O
a	379 1 O
viral	381 5 O
-	386 1 O
like	387 4 O
illness	392 7 O
,	399 1 O
early	401 5 O
recognition	407 11 O
and	419 3 O
discontinuation	423 15 O
of	439 2 O
the	442 3 O
drug	446 4 O
are	451 3 O
mandatory	455 9 O
.	464 1 O

Treatment	0 9 O
of	10 2 O
lethal	13 6 O
pertussis	20 9 B-Chemical
vaccine	30 7 I-Chemical
reaction	38 8 O
with	47 4 O
histamine	52 9 B-Chemical
H1	62 2 O
antagonists	65 11 O
.	76 1 O

We	78 2 O
studied	81 7 O
mortality	89 9 O
after	99 5 O
pertussis	105 9 B-Disease
immunization	115 12 O
in	128 2 O
the	131 3 O
mouse	135 5 O
.	140 1 O

Without	142 7 O
treatment	150 9 O
,	159 1 O
73	161 2 O
of	164 2 O
92	167 2 O
animals	170 7 O
(	178 1 O
80	179 2 O
%	181 1 O
)	182 1 O
died	184 4 O
after	189 5 O
injection	195 9 O
of	205 2 O
bovine	208 6 O
serum	215 5 O
albumin	221 7 O
(	229 1 O
BSA	230 3 O
)	233 1 O
on	235 2 O
day	238 3 O
+	242 1 O
7	243 1 O
of	245 2 O
pertussis	248 9 B-Disease
immunization	258 12 O
.	270 1 O

After	272 5 O
pretreatment	278 12 O
with	291 4 O
3	296 1 O
mg	298 2 O
of	301 2 O
cyproheptadine	304 14 B-Chemical
,	318 1 O
2	320 1 O
mg	322 2 O
mianserin	325 9 B-Chemical
,	334 1 O
or	336 2 O
2	339 1 O
mg	341 2 O
chlorpheniramine	344 16 B-Chemical
,	360 1 O
only	362 4 O
5	367 1 O
of	369 2 O
105	372 3 O
animals	376 7 O
(	384 1 O
5	385 1 O
%	386 1 O
)	387 1 O
died	389 4 O
after	394 5 O
receiving	400 9 O
BSA	410 3 O
on	414 2 O
day	417 3 O
+	421 1 O
7	422 1 O
(	424 1 O
p	425 1 O
less	427 4 O
than	432 4 O
0	437 1 O
.	438 1 O
001	439 3 O
)	442 1 O
.	443 1 O

Blockade	445 8 O
of	454 2 O
histamine	457 9 B-Chemical
H1	467 2 O
receptors	470 9 O
may	480 3 O
reduce	484 6 O
mortality	491 9 O
in	501 2 O
pertussis	504 9 B-Disease
immunization	514 12 O
-	526 1 O
induced	527 7 O
encephalopathy	535 14 B-Disease
in	550 2 O
mice	553 4 O
.	557 1 O

Support	0 7 O
for	8 3 O
adrenaline	12 10 B-Chemical
-	22 1 O
hypertension	23 12 B-Disease
hypothesis	36 10 O
:	46 1 O
18	48 2 O
hour	51 4 O
pressor	56 7 O
effect	64 6 O
after	71 5 O
6	77 1 O
hours	79 5 O
adrenaline	85 10 B-Chemical
infusion	96 8 O
.	104 1 O

In	106 2 O
a	109 1 O
double	111 6 O
blind	118 5 O
,	123 1 O
crossover	125 9 O
study	135 5 O
6	141 1 O
h	143 1 O
infusions	145 9 O
of	155 2 O
adrenaline	158 10 B-Chemical
(	169 1 O
15	170 2 O
ng	173 2 O
/	175 1 O
kg	176 2 O
/	178 1 O
min	179 3 O
;	182 1 O
1	184 1 O
ng	186 2 O
=	189 1 O
5	191 1 O
.	192 1 O
458	193 3 O
pmol	197 4 O
)	201 1 O
,	202 1 O
noradrenaline	204 13 B-Chemical
(	218 1 O
30	219 2 O
ng	222 2 O
/	224 1 O
kg	225 2 O
/	227 1 O
min	228 3 O
;	231 1 O
1	233 1 O
ng	235 2 O
=	238 1 O
5	240 1 O
.	241 1 O
911	242 3 O
pmol	246 4 O
)	250 1 O
,	251 1 O
and	253 3 O
a	257 1 O
5	259 1 O
%	260 1 O
dextrose	262 8 B-Chemical
solution	271 8 O
(	280 1 O
5	281 1 O
.	282 1 O
4	283 1 O
ml	285 2 O
/	287 1 O
h	288 1 O
)	289 1 O
,	290 1 O
were	292 4 O
given	297 5 O
to	303 2 O
ten	306 3 O
healthy	310 7 O
volunteers	318 10 O
in	329 2 O
random	332 6 O
order	339 5 O
2	345 1 O
weeks	347 5 O
apart	353 5 O
.	358 1 O

By	360 2 O
means	363 5 O
of	369 2 O
intra	372 5 O
-	377 1 O
arterial	378 8 O
ambulatory	387 10 O
monitoring	398 10 O
the	409 3 O
haemodynamic	413 12 O
effects	426 7 O
were	434 4 O
followed	439 8 O
for	448 3 O
18	452 2 O
h	455 1 O
after	457 5 O
the	463 3 O
infusions	467 9 O
were	477 4 O
stopped	482 7 O
.	489 1 O

Adrenaline	491 10 B-Chemical
,	501 1 O
but	503 3 O
not	507 3 O
noradrenaline	511 13 B-Chemical
,	524 1 O
caused	526 6 O
a	533 1 O
delayed	535 7 O
and	543 3 O
protracted	547 10 O
pressor	558 7 O
effect	566 6 O
.	572 1 O

Over	574 4 O
the	579 3 O
total	583 5 O
postinfusion	589 12 O
period	602 6 O
systolic	609 8 O
and	618 3 O
diastolic	622 9 O
arterial	632 8 O
pressure	641 8 O
were	650 4 O
6	655 1 O
(	657 1 O
SEM	658 3 O
2	662 1 O
)	663 1 O
%	664 1 O
and	666 3 O
7	670 1 O
(	672 1 O
2	673 1 O
)	674 1 O
%	675 1 O
,	676 1 O
respectively	678 12 O
,	690 1 O
higher	692 6 O
than	699 4 O
after	704 5 O
dextrose	710 8 B-Chemical
infusion	719 8 O
(	728 1 O
ANOVA	729 5 O
,	734 1 O
p	736 1 O
less	738 4 O
than	743 4 O
0	748 1 O
.	749 1 O
001	750 3 O
)	753 1 O
.	754 1 O

Thus	756 4 O
,	760 1 O
"	762 1 O
stress	763 6 O
"	769 1 O
levels	771 6 O
of	778 2 O
adrenaline	781 10 B-Chemical
(	792 1 O
230	793 3 O
pg	797 2 O
/	799 1 O
ml	800 2 O
)	802 1 O
for	804 3 O
6	808 1 O
h	810 1 O
cause	812 5 O
a	818 1 O
delayed	820 7 O
and	828 3 O
protracted	832 10 O
pressor	843 7 O
effect	851 6 O
.	857 1 O

These	859 5 O
findings	865 8 O
are	874 3 O
strong	878 6 O
support	885 7 O
for	893 3 O
the	897 3 O
adrenaline	901 10 B-Chemical
-	911 1 O
hypertension	912 12 B-Disease
hypothesis	925 10 O
in	936 2 O
man	939 3 O
.	942 1 O

Effect	0 6 O
of	7 2 O
alkylxanthines	10 14 B-Chemical
on	25 2 O
gentamicin	28 10 B-Chemical
-	38 1 O
induced	39 7 O
acute	47 5 B-Disease
renal	53 5 I-Disease
failure	59 7 I-Disease
in	67 2 O
the	70 3 O
rat	74 3 O
.	77 1 O

Adenosine	79 9 B-Chemical
antagonists	89 11 O
have	101 4 O
been	106 4 O
previously	111 10 O
shown	122 5 O
to	128 2 O
be	131 2 O
of	134 2 O
benefit	137 7 O
in	145 2 O
some	148 4 O
ischaemic	153 9 B-Disease
and	163 3 O
nephrotoxic	167 11 B-Disease
models	179 6 O
of	186 2 O
acute	189 5 B-Disease
renal	195 5 I-Disease
failure	201 7 I-Disease
(	209 1 O
ARF	210 3 B-Disease
)	213 1 O
.	214 1 O

In	216 2 O
the	219 3 O
present	223 7 O
study	231 5 O
,	236 1 O
the	238 3 O
effects	242 7 O
of	250 2 O
three	253 5 O
alkylxanthines	259 14 B-Chemical
with	274 4 O
different	279 9 O
potencies	289 9 O
as	299 2 O
adenosine	302 9 B-Chemical
antagonists	312 11 O
8	324 1 B-Chemical
-	325 1 I-Chemical
phenyltheophylline	326 18 I-Chemical
,	344 1 O
theophylline	346 12 B-Chemical
and	359 3 O
enprofylline	363 12 B-Chemical
,	375 1 O
were	377 4 O
examined	382 8 O
in	391 2 O
rats	394 4 O
developing	399 10 O
acute	410 5 B-Disease
renal	416 5 I-Disease
failure	422 7 I-Disease
after	430 5 O
4	436 1 O
daily	438 5 O
injections	444 10 O
of	455 2 O
gentamicin	458 10 B-Chemical
(	469 1 O
200	470 3 O
mg	474 2 O
kg	477 2 O
-	479 1 O
1	480 1 O
)	481 1 O
.	482 1 O

Renal	484 5 O
function	490 8 O
was	499 3 O
assessed	503 8 O
by	512 2 O
biochemical	515 11 O
(	527 1 O
plasma	528 6 O
urea	535 4 B-Chemical
and	540 3 O
creatinine	544 10 B-Chemical
)	554 1 O
,	555 1 O
functional	557 10 O
(	568 1 O
urine	569 5 O
analysis	575 8 O
and	584 3 O
[	588 1 O
3H	589 2 O
]	591 1 O
inulin	592 6 O
and	599 3 O
[	603 1 O
14C	604 3 O
]	607 1 O
p	608 1 B-Chemical
-	609 1 I-Chemical
aminohippuric	610 13 I-Chemical
acid	624 4 I-Chemical
clearances	629 10 O
)	639 1 O
and	641 3 O
morphological	645 13 O
(	659 1 O
degree	660 6 O
of	667 2 O
necrosis	670 8 B-Disease
)	678 1 O
indices	680 7 O
.	687 1 O

The	689 3 O
various	693 7 O
drug	701 4 O
treatments	706 10 O
produced	717 8 O
improvements	726 12 O
in	739 2 O
some	742 4 O
,	746 1 O
but	748 3 O
not	752 3 O
all	756 3 O
,	759 1 O
measurements	761 12 O
of	774 2 O
renal	777 5 O
function	783 8 O
.	791 1 O

However	793 7 O
,	800 1 O
any	802 3 O
improvement	806 11 O
produced	818 8 O
by	827 2 O
drug	830 4 O
treatment	835 9 O
was	845 3 O
largely	849 7 O
a	857 1 O
result	859 6 O
of	866 2 O
a	869 1 O
beneficial	871 10 O
effect	882 6 O
exerted	889 7 O
by	897 2 O
its	900 3 O
vehicle	904 7 O
(	912 1 O
polyethylene	913 12 B-Chemical
glycol	926 6 I-Chemical
and	933 3 O
NaOH	937 4 B-Chemical
)	941 1 O
.	942 1 O

The	944 3 O
lack	948 4 O
of	953 2 O
any	956 3 O
consistent	960 10 O
protective	971 10 O
effect	982 6 O
noted	989 5 O
with	995 4 O
the	1000 3 O
alkylxanthines	1004 14 B-Chemical
tested	1019 6 O
in	1026 2 O
the	1029 3 O
present	1033 7 O
study	1041 5 O
indicates	1047 9 O
that	1057 4 O
adenosine	1062 9 B-Chemical
plays	1072 5 O
little	1078 6 O
,	1084 1 O
if	1086 2 O
any	1089 3 O
,	1092 1 O
pathophysiological	1094 18 O
role	1113 4 O
in	1118 2 O
gentamicin	1121 10 B-Chemical
-	1131 1 O
induced	1132 7 O
ARF	1140 3 B-Disease
.	1143 1 O

Adverse	0 7 O
ocular	8 6 O
reactions	15 9 O
possibly	25 8 O
associated	34 10 O
with	45 4 O
isotretinoin	50 12 B-Chemical
.	62 1 O

A	64 1 O
total	66 5 O
of	72 2 O
261	75 3 O
adverse	79 7 O
ocular	87 6 O
reactions	94 9 O
occurred	104 8 O
in	113 2 O
237	116 3 O
patients	120 8 O
who	129 3 O
received	133 8 O
isotretinoin	142 12 B-Chemical
,	154 1 O
a	156 1 O
commonly	158 8 O
used	167 4 O
drug	172 4 O
in	177 2 O
the	180 3 O
treatment	184 9 O
of	194 2 O
severe	197 6 O
cystic	204 6 O
acne	211 4 B-Disease
.	215 1 O

Blepharoconjunctivitis	217 22 B-Disease
,	239 1 O
subjective	241 10 O
complaints	252 10 O
of	263 2 O
dry	266 3 B-Disease
eyes	270 4 I-Disease
,	274 1 O
blurred	276 7 B-Disease
vision	284 6 I-Disease
,	290 1 O
contact	292 7 O
lens	300 4 O
intolerance	305 11 O
,	316 1 O
and	318 3 O
photodermatitis	322 15 B-Disease
are	338 3 O
reversible	342 10 O
side	353 4 O
effects	358 7 O
.	365 1 O

More	367 4 O
serious	372 7 O
ocular	380 6 O
adverse	387 7 O
reactions	395 9 O
include	405 7 O
papilledema	413 11 B-Disease
,	424 1 O
pseudotumor	426 11 B-Disease
cerebri	438 7 I-Disease
,	445 1 O
and	447 3 O
white	451 5 O
or	457 2 O
gray	460 4 O
subepithelial	465 13 O
corneal	479 7 B-Disease
opacities	487 9 I-Disease
;	496 1 O
all	498 3 O
of	502 2 O
these	505 5 O
are	511 3 O
reversible	515 10 O
if	526 2 O
the	529 3 O
drug	533 4 O
is	538 2 O
discontinued	541 12 O
.	553 1 O

Reported	555 8 O
cases	564 5 O
of	570 2 O
decreased	573 9 O
dark	583 4 O
adaptation	588 10 O
are	599 3 O
under	603 5 O
investigation	609 13 O
.	622 1 O

Isotretinoin	624 12 B-Chemical
is	637 2 O
contraindicated	640 15 O
in	656 2 O
pregnancy	659 9 O
because	669 7 O
of	677 2 O
the	680 3 O
many	684 4 O
reported	689 8 O
congenital	698 10 B-Disease
abnormalities	709 13 I-Disease
after	723 5 O
maternal	729 8 O
use	738 3 O
(	742 1 O
including	743 9 O
microphthalmos	753 14 B-Disease
,	767 1 O
orbital	769 7 O
hypertelorism	777 13 B-Disease
,	790 1 O
and	792 3 O
optic	796 5 B-Disease
nerve	802 5 I-Disease
hypoplasia	808 10 I-Disease
)	818 1 O
.	819 1 O

Procaterol	0 10 B-Chemical
and	11 3 O
terbutaline	15 11 B-Chemical
in	27 2 O
bronchial	30 9 B-Disease
asthma	40 6 I-Disease
.	46 1 O

A	48 1 O
double	50 6 O
-	56 1 O
blind	57 5 O
,	62 1 O
placebo	64 7 O
-	71 1 O
controlled	72 10 O
,	82 1 O
cross	84 5 O
-	89 1 O
over	90 4 O
study	95 5 O
.	100 1 O

Procaterol	102 10 B-Chemical
,	112 1 O
a	114 1 O
new	116 3 O
beta	120 4 O
-	124 1 O
2	125 1 O
adrenoceptor	127 12 O
stimulant	140 9 O
,	149 1 O
was	151 3 O
studied	155 7 O
in	163 2 O
a	166 1 O
double	168 6 O
-	174 1 O
blind	175 5 O
,	180 1 O
placebo	182 7 O
-	189 1 O
controlled	190 10 O
,	200 1 O
cross	202 5 O
-	207 1 O
over	208 4 O
trial	213 5 O
in	219 2 O
patients	222 8 O
with	231 4 O
bronchial	236 9 B-Disease
asthma	246 6 I-Disease
.	252 1 O

Oral	254 4 O
procaterol	259 10 B-Chemical
50	270 2 O
micrograms	273 10 O
b	284 1 O
.	285 1 O
d	286 1 O
.	287 1 O
,	288 1 O
procaterol	290 10 B-Chemical
100	301 3 O
micrograms	305 10 O
b	316 1 O
.	317 1 O
d	318 1 O
.	319 1 O
,	320 1 O
and	322 3 O
terbutaline	326 11 B-Chemical
5	338 1 O
mg	340 2 O
t	343 1 O
.	344 1 O
i	345 1 O
.	346 1 O
d	347 1 O
.	348 1 O
,	349 1 O
were	351 4 O
compared	356 8 O
when	365 4 O
given	370 5 O
randomly	376 8 O
in	385 2 O
1	388 1 O
-	389 1 O
week	390 4 O
treatment	395 9 O
periods	405 7 O
.	412 1 O

The	414 3 O
best	418 4 O
clinical	423 8 O
effect	432 6 O
was	439 3 O
found	443 5 O
with	449 4 O
terbutaline	454 11 B-Chemical
.	465 1 O

Both	467 4 O
anti	472 4 O
-	476 1 O
asthmatic	477 9 B-Disease
and	487 3 O
tremorgenic	491 11 B-Disease
effects	503 7 O
of	511 2 O
procaterol	514 10 B-Chemical
were	525 4 O
dose	530 4 O
-	534 1 O
related	535 7 O
.	542 1 O

Procaterol	544 10 B-Chemical
appeared	555 8 O
effective	564 9 O
in	574 2 O
the	577 3 O
doses	581 5 O
tested	587 6 O
,	593 1 O
and	595 3 O
a	599 1 O
twice	601 5 O
daily	607 5 O
regimen	613 7 O
would	621 5 O
appear	627 6 O
to	634 2 O
be	637 2 O
suitable	640 8 O
with	649 4 O
this	654 4 O
drug	659 4 O
.	663 1 O

Subacute	0 8 O
effects	9 7 O
of	17 2 O
propranolol	20 11 B-Chemical
and	32 3 O
B	36 1 O
24	38 2 O
/	40 1 O
76	41 2 O
on	44 2 O
isoproterenol	47 13 B-Chemical
-	60 1 O
induced	61 7 O
rat	69 3 O
heart	73 5 B-Disease
hypertrophy	79 11 I-Disease
in	91 2 O
correlation	94 11 O
with	106 4 O
blood	111 5 O
pressure	117 8 O
.	125 1 O

We	127 2 O
compared	130 8 O
the	139 3 O
potential	143 9 O
beta	153 4 O
-	157 1 O
receptor	158 8 O
blocker	167 7 O
,	174 1 O
B	176 1 O
24	178 2 O
/	180 1 O
76	181 2 O
i	184 1 O
.	185 1 O
e	186 1 O
.	187 1 O
1	189 1 O
-	190 1 O
(	191 1 O
2	192 1 O
,	193 1 O
4	194 1 O
-	195 1 O
dichlorophenoxy	196 15 O
)	211 1 O
-	212 1 O
3	213 1 O
[	214 1 O
2	215 1 O
-	216 1 O
3	217 1 O
,	218 1 O
4	219 1 O
-	220 1 O
dimethoxyphenyl	221 15 O
)	236 1 O
ethanolamino	237 12 O
]	249 1 O
-	250 1 O
prop	251 4 O
an	256 2 O
-	258 1 O
2	259 1 O
-	260 1 O
ol	261 2 O
,	263 1 O
which	265 5 O
is	271 2 O
characterized	274 13 O
by	288 2 O
beta	291 4 O
1	296 1 O
-	297 1 O
adrenoceptor	298 12 O
blocking	311 8 O
and	320 3 O
beta	324 4 O
2	329 1 O
-	330 1 O
adrenoceptor	331 12 O
stimulating	344 11 O
properties	356 10 O
with	367 4 O
propranolol	372 11 B-Chemical
.	383 1 O

The	385 3 O
studies	389 7 O
were	397 4 O
performed	402 9 O
using	412 5 O
an	418 2 O
experimental	421 12 O
model	434 5 O
of	440 2 O
isoproterenol	443 13 B-Chemical
-	456 1 O
induced	457 7 O
heart	465 5 B-Disease
hypertrophy	471 11 I-Disease
in	483 2 O
rats	486 4 O
.	490 1 O

A	492 1 O
correlation	494 11 O
of	506 2 O
the	509 3 O
blood	513 5 O
pressure	519 8 O
was	528 3 O
neither	532 7 O
found	540 5 O
in	546 2 O
the	549 3 O
development	553 11 O
nor	565 3 O
in	569 2 O
the	572 3 O
attempt	576 7 O
to	584 2 O
suppress	587 8 O
the	596 3 O
development	600 11 O
of	612 2 O
heart	615 5 B-Disease
hypertrophy	621 11 I-Disease
with	633 4 O
the	638 3 O
two	642 3 O
beta	646 4 O
-	650 1 O
receptor	651 8 O
blockers	660 8 O
.	668 1 O

Both	670 4 O
beta	675 4 O
-	679 1 O
blockers	680 8 O
influenced	689 10 O
the	700 3 O
development	704 11 O
of	716 2 O
hypertrophy	719 11 B-Disease
to	731 2 O
a	734 1 O
different	736 9 O
,	745 1 O
but	747 3 O
not	751 3 O
reproducible	755 12 O
extent	768 6 O
.	774 1 O

It	776 2 O
was	779 3 O
possible	783 8 O
to	792 2 O
suppress	795 8 O
the	804 3 O
increased	808 9 O
ornithine	818 9 B-Chemical
decarboxylase	828 13 O
activity	842 8 O
with	851 4 O
both	856 4 O
beta	861 4 O
-	865 1 O
blockers	866 8 O
in	875 2 O
hypertrophied	878 13 B-Disease
hearts	892 6 I-Disease
,	898 1 O
but	900 3 O
there	904 5 O
was	910 3 O
no	914 2 O
effect	917 6 O
on	924 2 O
the	927 3 O
heart	931 5 O
mass	937 4 O
.	941 1 O

Neither	943 7 O
propranolol	951 11 B-Chemical
nor	963 3 O
B	967 1 O
24	969 2 O
/	971 1 O
76	972 2 O
could	975 5 O
stop	981 4 O
the	986 3 O
changes	990 7 O
in	998 2 O
the	1001 3 O
characteristic	1005 14 O
myosin	1020 6 O
isoenzyme	1027 9 O
pattern	1037 7 O
of	1045 2 O
the	1048 3 O
hypertrophied	1052 13 B-Disease
rat	1066 3 O
heart	1070 5 O
.	1075 1 O

Thus	1077 4 O
,	1081 1 O
the	1083 3 O
investigations	1087 14 O
did	1102 3 O
not	1106 3 O
provide	1110 7 O
any	1118 3 O
evidence	1122 8 O
that	1131 4 O
the	1136 3 O
beta	1140 4 O
-	1144 1 O
receptor	1145 8 O
blockers	1154 8 O
propranolol	1163 11 B-Chemical
and	1175 3 O
B	1179 1 O
24	1181 2 O
/	1183 1 O
76	1184 2 O
have	1187 4 O
the	1192 3 O
potency	1196 7 O
to	1204 2 O
prevent	1207 7 O
isoproterenol	1215 13 B-Chemical
from	1229 4 O
producing	1234 9 O
heart	1244 5 B-Disease
hypertrophy	1250 11 I-Disease
.	1261 1 O

Comparison	0 10 O
of	11 2 O
the	14 3 O
effect	18 6 O
of	25 2 O
oxitropium	28 10 B-Chemical
bromide	39 7 I-Chemical
and	47 3 O
of	51 2 O
slow	54 4 O
-	58 1 O
release	59 7 O
theophylline	67 12 B-Chemical
on	80 2 O
nocturnal	83 9 O
asthma	93 6 B-Disease
.	99 1 O

The	101 3 O
effects	105 7 O
of	113 2 O
a	116 1 O
new	118 3 O
inhaled	122 7 O
antimuscarinic	130 14 O
drug	145 4 O
,	149 1 O
oxitropium	151 10 B-Chemical
bromide	162 7 I-Chemical
,	169 1 O
and	171 3 O
of	175 2 O
a	178 1 O
slow	180 4 O
-	184 1 O
release	185 7 O
theophylline	193 12 B-Chemical
preparation	206 11 O
upon	218 4 O
nocturnal	223 9 O
asthma	233 6 B-Disease
were	240 4 O
compared	245 8 O
in	254 2 O
a	257 1 O
placebo	259 7 O
-	266 1 O
controlled	267 10 O
double	278 6 O
-	284 1 O
blind	285 5 O
study	291 5 O
.	296 1 O

Two	298 3 O
samples	302 7 O
were	310 4 O
studied	315 7 O
:	322 1 O
12	324 2 O
patients	327 8 O
received	336 8 O
oxitropium	345 10 B-Chemical
at	356 2 O
600	359 3 O
micrograms	363 10 O
(	374 1 O
6	375 1 O
subjects	377 8 O
)	385 1 O
or	387 2 O
at	390 2 O
400	393 3 O
micrograms	397 10 O
t	408 1 O
.	409 1 O
i	410 1 O
.	411 1 O
d	412 1 O
.	413 1 O

(	415 1 O
6	416 1 O
subjects	418 8 O
)	426 1 O
whereas	428 7 O
11	436 2 O
received	439 8 O
theophylline	448 12 B-Chemical
at	461 2 O
300	464 3 O
mg	468 2 O
b	471 1 O
.	472 1 O
i	473 1 O
.	474 1 O
d	475 1 O
.	476 1 O

Morning	478 7 O
dipping	486 7 O
,	493 1 O
assessed	495 8 O
by	504 2 O
the	507 3 O
fall	511 4 O
in	516 2 O
peak	519 4 O
flow	524 4 O
overnight	529 9 O
,	538 1 O
was	540 3 O
significantly	544 13 O
reduced	558 7 O
in	566 2 O
the	569 3 O
periods	573 7 O
when	581 4 O
either	586 6 O
active	593 6 O
drug	600 4 O
was	605 3 O
taken	609 5 O
,	614 1 O
whereas	616 7 O
no	624 2 O
difference	627 10 O
was	638 3 O
noticed	642 7 O
during	650 6 O
the	657 3 O
placebo	661 7 O
administration	669 14 O
.	683 1 O

No	685 2 O
significant	688 11 O
difference	700 10 O
was	711 3 O
noticed	715 7 O
between	723 7 O
results	731 7 O
obtained	739 8 O
with	748 4 O
either	753 6 O
active	760 6 O
drug	767 4 O
,	771 1 O
as	773 2 O
well	776 4 O
as	781 2 O
with	784 4 O
either	789 6 O
dosage	796 6 O
of	803 2 O
oxitropium	806 10 B-Chemical
.	816 1 O

No	818 2 O
subject	821 7 O
reported	829 8 O
side	838 4 O
effects	843 7 O
of	851 2 O
oxitropium	854 10 B-Chemical
,	864 1 O
as	866 2 O
compared	869 8 O
to	878 2 O
three	881 5 O
subjects	887 8 O
reporting	896 9 O
nausea	906 6 B-Disease
,	912 1 O
vomiting	914 8 B-Disease
and	923 3 O
tremors	927 7 B-Disease
after	935 5 O
theophylline	941 12 B-Chemical
.	953 1 O

Oxitropium	955 10 B-Chemical
proves	966 6 O
to	973 2 O
be	976 2 O
a	979 1 O
valuable	981 8 O
alternative	990 11 O
to	1002 2 O
theophylline	1005 12 B-Chemical
in	1018 2 O
nocturnal	1021 9 O
asthma	1031 6 B-Disease
,	1037 1 O
since	1039 5 O
it	1045 2 O
is	1048 2 O
equally	1051 7 O
potent	1059 6 O
,	1065 1 O
safer	1067 5 O
and	1073 3 O
does	1077 4 O
not	1082 3 O
require	1086 7 O
the	1094 3 O
titration	1098 9 O
of	1108 2 O
dosage	1111 6 O
.	1117 1 O

Penicillin	0 10 B-Chemical
anaphylaxis	11 11 B-Disease
.	22 1 O

A	24 1 O
case	26 4 O
of	31 2 O
oral	34 4 O
penicillin	39 10 B-Chemical
anaphylaxis	50 11 B-Disease
is	62 2 O
described	65 9 O
,	74 1 O
and	76 3 O
the	80 3 O
terminology	84 11 O
,	95 1 O
occurrence	97 10 O
,	107 1 O
clinical	109 8 O
manifestations	118 14 O
,	132 1 O
pathogenesis	134 12 O
,	146 1 O
prevention	148 10 O
,	158 1 O
and	160 3 O
treatment	164 9 O
of	174 2 O
anaphylaxis	177 11 B-Disease
are	189 3 O
reviewed	193 8 O
.	201 1 O

Emergency	203 9 O
physicians	213 10 O
should	224 6 O
be	231 2 O
aware	234 5 O
of	240 2 O
oral	243 4 O
penicillin	248 10 B-Chemical
anaphylaxis	259 11 B-Disease
in	271 2 O
order	274 5 O
to	280 2 O
prevent	283 7 O
its	291 3 O
occurrence	295 10 O
by	306 2 O
prescribing	309 11 O
the	321 3 O
antibiotic	325 10 O
judiciously	336 11 O
and	348 3 O
knowledgeably	352 13 O
and	366 3 O
to	370 2 O
offer	373 5 O
optimal	379 7 O
medical	387 7 O
therapy	395 7 O
once	403 4 O
this	408 4 O
life	413 4 O
-	417 1 O
threatening	418 11 O
reaction	430 8 O
has	439 3 O
begun	443 5 O
.	448 1 O

Reversible	0 10 O
valproic	11 8 B-Chemical
acid	20 4 I-Chemical
-	24 1 O
induced	25 7 O
dementia	33 8 B-Disease
:	41 1 O
a	43 1 O
case	45 4 O
report	50 6 O
.	56 1 O

Reversible	58 10 O
valproic	69 8 B-Chemical
acid	78 4 I-Chemical
-	82 1 O
induced	83 7 O
dementia	91 8 B-Disease
was	100 3 O
documented	104 10 O
in	115 2 O
a	118 1 O
21	120 2 O
-	122 1 O
year	123 4 O
-	127 1 O
old	128 3 O
man	132 3 O
with	136 4 O
epilepsy	141 8 B-Disease
who	150 3 O
had	154 3 O
a	158 1 O
3	160 1 O
-	161 1 O
year	162 4 O
history	167 7 O
of	175 2 O
insidious	178 9 O
progressive	188 11 O
decline	200 7 O
in	208 2 O
global	211 6 O
cognitive	218 9 O
abilities	228 9 O
documented	238 10 O
by	249 2 O
serial	252 6 O
neuropsychological	259 18 O
studies	278 7 O
.	285 1 O

Repeat	287 6 O
neuropsychological	294 18 O
testing	313 7 O
7	321 1 O
weeks	323 5 O
after	329 5 O
discontinuation	335 15 O
of	351 2 O
the	354 3 O
drug	358 4 O
revealed	363 8 O
dramatic	372 8 O
improvement	381 11 O
in	393 2 O
IQ	396 2 O
,	398 1 O
memory	400 6 O
,	406 1 O
naming	408 6 O
,	414 1 O
and	416 3 O
other	420 5 O
tasks	426 5 O
commensurate	432 12 O
with	445 4 O
clinical	450 8 O
recovery	459 8 O
in	468 2 O
his	471 3 O
intellectual	475 12 O
capacity	488 8 O
.	496 1 O

Possible	498 8 O
pathophysiological	507 18 O
mechanisms	526 10 O
which	537 5 O
may	543 3 O
have	547 4 O
been	552 4 O
operative	557 9 O
in	567 2 O
this	570 4 O
case	575 4 O
include	580 7 O
:	587 1 O
a	589 1 O
direct	591 6 O
central	598 7 O
nervous	606 7 O
system	614 6 O
(	621 1 O
CNS	622 3 O
)	625 1 O
toxic	627 5 O
effect	633 6 O
of	640 2 O
valproic	643 8 B-Chemical
acid	652 4 I-Chemical
;	656 1 O
a	658 1 O
paradoxical	660 11 O
epileptogenic	672 13 O
effect	686 6 O
secondary	693 9 O
to	703 2 O
the	706 3 O
drug	710 4 O
;	714 1 O
and	716 3 O
an	720 2 O
indirect	723 8 O
CNS	732 3 O
toxic	736 5 O
effect	742 6 O
mediated	749 8 O
through	758 7 O
valproic	766 8 B-Chemical
acid	775 4 I-Chemical
-	779 1 O
induced	780 7 O
hyperammonemia	788 14 B-Disease
.	802 1 O

Reversal	0 8 O
of	9 2 O
scopolamine	12 11 B-Chemical
-	23 1 O
induced	24 7 O
amnesia	32 7 B-Disease
of	40 2 O
passive	43 7 O
avoidance	51 9 O
by	61 2 O
pre	64 3 O
-	67 1 O
and	69 3 O
post	73 4 O
-	77 1 O
training	78 8 O
naloxone	87 8 B-Chemical
.	95 1 O

In	97 2 O
a	100 1 O
series	102 6 O
of	109 2 O
five	112 4 O
experiments	117 11 O
,	128 1 O
the	130 3 O
modulating	134 10 O
role	145 4 O
of	150 2 O
naloxone	153 8 B-Chemical
on	162 2 O
a	165 1 O
scopolamine	167 11 B-Chemical
-	178 1 O
induced	179 7 O
retention	187 9 B-Disease
deficit	197 7 I-Disease
in	205 2 O
a	208 1 O
passive	210 7 O
avoidance	218 9 O
paradigm	228 8 O
was	237 3 O
investigated	241 12 O
in	254 2 O
mice	257 4 O
.	261 1 O

Scopolamine	263 11 B-Chemical
,	274 1 O
but	276 3 O
not	280 3 O
methyl	284 6 B-Chemical
scopolamine	291 11 I-Chemical
(	303 1 O
1	304 1 O
and	306 3 O
3	310 1 O
mg	312 2 O
/	314 1 O
kg	315 2 O
)	317 1 O
,	318 1 O
induced	320 7 O
an	328 2 O
amnesia	331 7 B-Disease
as	339 2 O
measured	342 8 O
by	351 2 O
latency	354 7 O
and	362 3 O
duration	366 8 O
parameters	375 10 O
.	385 1 O

Naloxone	387 8 B-Chemical
(	396 1 O
0	397 1 O
.	398 1 O
3	399 1 O
,	400 1 O
1	402 1 O
,	403 1 O
3	405 1 O
,	406 1 O
and	408 3 O
10	412 2 O
mg	415 2 O
/	417 1 O
kg	418 2 O
)	420 1 O
injected	422 8 O
prior	431 5 O
to	437 2 O
training	440 8 O
attenuated	449 10 O
the	460 3 O
retention	464 9 B-Disease
deficit	474 7 I-Disease
with	482 4 O
a	487 1 O
peak	489 4 O
of	494 2 O
activity	497 8 O
at	506 2 O
3	509 1 O
mg	511 2 O
/	513 1 O
kg	514 2 O
.	516 1 O

The	518 3 O
effect	522 6 O
of	529 2 O
naloxone	532 8 B-Chemical
could	541 5 O
be	547 2 O
antagonized	550 11 O
with	562 4 O
morphine	567 8 B-Chemical
(	576 1 O
1	577 1 O
,	578 1 O
3	580 1 O
,	581 1 O
and	583 3 O
10	587 2 O
mg	590 2 O
/	592 1 O
kg	593 2 O
)	595 1 O
,	596 1 O
demonstrating	598 13 O
the	612 3 O
opioid	616 6 O
specificity	623 11 O
of	635 2 O
the	638 3 O
naloxone	642 8 B-Chemical
effect	651 6 O
.	657 1 O

Post	659 4 O
-	663 1 O
training	664 8 O
administration	673 14 O
of	688 2 O
naloxone	691 8 B-Chemical
(	700 1 O
3	701 1 O
mg	703 2 O
/	705 1 O
kg	706 2 O
)	708 1 O
as	710 2 O
a	713 1 O
single	715 6 O
or	722 2 O
as	725 2 O
a	728 1 O
split	730 5 O
dose	736 4 O
also	741 4 O
attenuated	746 10 O
the	757 3 O
scopolamine	761 11 B-Chemical
-	772 1 O
induced	773 7 O
amnesia	781 7 B-Disease
.	788 1 O

Control	790 7 O
experiments	798 11 O
indicated	810 9 O
that	820 4 O
neither	825 7 O
an	833 2 O
increase	836 8 O
in	845 2 O
pain	848 4 B-Disease
sensitivity	853 11 O
(	865 1 O
pre	866 3 O
-	869 1 O
training	870 8 O
naloxone	879 8 B-Chemical
)	887 1 O
nor	889 3 O
an	893 2 O
induced	896 7 O
aversive	904 8 O
state	913 5 O
(	919 1 O
post	920 4 O
-	924 1 O
training	925 8 O
naloxone	934 8 B-Chemical
)	942 1 O
appear	944 6 O
to	951 2 O
be	954 2 O
responsible	957 11 O
for	969 3 O
the	973 3 O
influence	977 9 O
of	987 2 O
naloxone	990 8 B-Chemical
on	999 2 O
the	1002 3 O
scopolamine	1006 11 B-Chemical
-	1017 1 O
induced	1018 7 O
retention	1026 9 B-Disease
deficit	1036 7 I-Disease
.	1043 1 O

These	1045 5 O
results	1051 7 O
extend	1059 6 O
previous	1066 8 O
findings	1075 8 O
implicating	1084 11 O
a	1096 1 O
cholinergic	1098 11 O
-	1109 1 O
opioid	1110 6 O
interaction	1117 11 O
in	1129 2 O
memory	1132 6 O
processes	1139 9 O
.	1148 1 O

A	1150 1 O
possible	1152 8 O
mechanism	1161 9 O
for	1171 3 O
this	1175 4 O
interaction	1180 11 O
involving	1192 9 O
the	1202 3 O
septo	1206 5 O
-	1211 1 O
hippocampal	1212 11 O
cholinergic	1224 11 O
pathway	1236 7 O
is	1244 2 O
discussed	1247 9 O
.	1256 1 O

Electron	0 8 O
microscopic	9 11 O
investigations	21 14 O
of	36 2 O
the	39 3 O
cyclophosphamide	43 16 B-Chemical
-	59 1 O
induced	60 7 O
lesions	68 7 B-Disease
of	76 2 I-Disease
the	79 3 I-Disease
urinary	83 7 I-Disease
bladder	91 7 I-Disease
of	99 2 O
the	102 3 O
rat	106 3 O
and	110 3 O
their	114 5 O
prevention	120 10 O
by	131 2 O
mesna	134 5 B-Chemical
.	139 1 O

Fully	141 5 O
developed	147 9 O
cyclophosphamide	157 16 B-Chemical
-	173 1 O
induced	174 7 O
cystitis	182 8 B-Disease
is	191 2 O
characterized	194 13 O
by	208 2 O
nearly	211 6 O
complete	218 8 O
detachment	227 10 O
of	238 2 O
the	241 3 O
urothelium	245 10 O
,	255 1 O
severe	257 6 O
submucosal	264 10 O
edema	275 5 B-Disease
owing	281 5 O
to	287 2 O
damage	290 6 O
to	297 2 O
the	300 3 O
microvascular	304 13 O
bed	318 3 O
and	322 3 O
focal	326 5 O
muscle	332 6 O
necroses	339 8 B-Disease
.	347 1 O

The	349 3 O
initial	353 7 O
response	361 8 O
to	370 2 O
the	373 3 O
primary	377 7 O
attack	385 6 O
by	392 2 O
the	395 3 O
cyclophosphamide	399 16 B-Chemical
metabolites	416 11 O
seems	428 5 O
to	434 2 O
be	437 2 O
fragmentation	440 13 O
of	454 2 O
the	457 3 O
luminal	461 7 B-Chemical
membrane	469 8 O
.	477 1 O

This	479 4 O
damages	484 7 O
the	492 3 O
cellular	496 8 O
barrier	505 7 O
against	513 7 O
the	521 3 O
hypertonic	525 10 O
urine	536 5 O
.	541 1 O

Subsequent	543 10 O
breaks	554 6 O
in	561 2 O
the	564 3 O
lateral	568 7 O
cell	576 4 O
membranes	581 9 O
of	591 2 O
the	594 3 O
superficial	598 11 O
cells	610 5 O
and	616 3 O
in	620 2 O
all	623 3 O
the	627 3 O
plasma	631 6 O
membranes	638 9 O
of	648 2 O
the	651 3 O
intermediate	655 12 O
and	668 3 O
basal	672 5 O
cells	678 5 O
,	683 1 O
intercellular	685 13 O
and	699 3 O
intracellular	703 13 O
edema	717 5 B-Disease
and	723 3 O
disintegration	727 14 O
of	742 2 O
the	745 3 O
desmosomes	749 10 O
and	760 3 O
hemidesmosomes	764 14 O
lead	779 4 O
to	784 2 O
progressive	787 11 O
degeneration	799 12 O
and	812 3 O
detachment	816 10 O
of	827 2 O
the	830 3 O
epithelial	834 10 O
cells	845 5 O
with	851 4 O
exposure	856 8 O
and	865 3 O
splitting	869 9 O
of	879 2 O
the	882 3 O
basal	886 5 O
membrane	892 8 O
.	900 1 O

The	902 3 O
morphological	906 13 O
changes	920 7 O
of	928 2 O
the	931 3 O
endothelial	935 11 O
cells	947 5 O
,	952 1 O
which	954 5 O
become	960 6 O
more	967 4 O
pronounced	972 10 O
in	983 2 O
the	986 3 O
later	990 5 O
stages	996 6 O
of	1003 2 O
the	1006 3 O
experiment	1010 10 O
,	1020 1 O
the	1022 3 O
involvement	1026 11 O
of	1038 2 O
blood	1041 5 O
vessels	1047 7 O
regardless	1055 10 O
of	1066 2 O
their	1069 5 O
diameter	1075 8 O
and	1084 3 O
the	1088 3 O
location	1092 8 O
-	1100 1 O
dependent	1101 9 O
extent	1111 6 O
of	1118 2 O
the	1121 3 O
damage	1125 6 O
indicate	1132 8 O
a	1141 1 O
direct	1143 6 O
type	1150 4 O
of	1155 2 O
damage	1158 6 O
which	1165 5 O
is	1171 2 O
preceded	1174 8 O
by	1183 2 O
a	1186 1 O
mediator	1188 8 O
-	1196 1 O
induced	1197 7 O
increase	1205 8 O
in	1214 2 O
permeability	1217 12 O
,	1229 1 O
the	1231 3 O
morphological	1235 13 O
correlate	1249 9 O
of	1259 2 O
which	1262 5 O
is	1268 2 O
the	1271 3 O
formation	1275 9 O
of	1285 2 O
gaps	1288 4 O
in	1293 2 O
the	1296 3 O
interendothelial	1300 16 O
cell	1317 4 O
connections	1322 11 O
on	1334 2 O
the	1337 3 O
venules	1341 7 O
.	1348 1 O

These	1350 5 O
changes	1356 7 O
can	1364 3 O
be	1368 2 O
effectively	1371 11 O
prevented	1383 9 O
by	1393 2 O
mesna	1396 5 B-Chemical
.	1401 1 O

The	1403 3 O
only	1407 4 O
sign	1412 4 O
of	1417 2 O
a	1420 1 O
possible	1422 8 O
involvement	1431 11 O
is	1443 2 O
the	1446 3 O
increase	1450 8 O
in	1459 2 O
the	1462 3 O
number	1466 6 O
of	1473 2 O
specific	1476 8 O
granules	1485 8 O
with	1494 4 O
a	1499 1 O
presumed	1501 8 O
lysosomal	1510 9 O
function	1520 8 O
in	1529 2 O
the	1532 3 O
superficial	1536 11 O
cells	1548 5 O
.	1553 1 O

Increase	0 8 O
in	9 2 O
intragastric	12 12 O
pressure	25 8 O
during	34 6 O
suxamethonium	41 13 B-Chemical
-	54 1 O
induced	55 7 O
muscle	63 6 B-Disease
fasciculations	70 14 I-Disease
in	85 2 O
children	88 8 O
:	96 1 O
inhibition	98 10 O
by	109 2 O
alfentanil	112 10 B-Chemical
.	122 1 O

Changes	124 7 O
in	132 2 O
intragastric	135 12 O
pressure	148 8 O
after	157 5 O
the	163 3 O
administration	167 14 O
of	182 2 O
suxamethonium	185 13 B-Chemical
1	199 1 O
.	200 1 O
5	201 1 O
mg	203 2 O
kg	206 2 O
-	208 1 O
1	209 1 O
i	211 1 O
.	212 1 O
v	213 1 O
.	214 1 O
were	216 4 O
studied	221 7 O
in	229 2 O
32	232 2 O
children	235 8 O
(	244 1 O
mean	245 4 O
age	250 3 O
6	254 1 O
.	255 1 O
9	256 1 O
yr	258 2 O
)	260 1 O
pretreated	262 10 O
with	273 4 O
either	278 6 O
physiological	285 13 O
saline	299 6 O
or	306 2 O
alfentanil	309 10 B-Chemical
50	320 2 O
micrograms	323 10 O
kg	334 2 O
-	336 1 O
1	337 1 O
.	338 1 O

Anaesthesia	340 11 O
was	352 3 O
induced	356 7 O
with	364 4 O
thiopentone	369 11 B-Chemical
5	381 1 O
mg	383 2 O
kg	386 2 O
-	388 1 O
1	389 1 O
.	390 1 O

The	392 3 O
incidence	396 9 O
and	406 3 O
intensity	410 9 O
of	420 2 O
muscle	423 6 B-Disease
fasciculations	430 14 I-Disease
caused	445 6 O
by	452 2 O
suxamethonium	455 13 B-Chemical
were	469 4 O
significantly	474 13 O
greater	488 7 O
in	496 2 O
the	499 3 O
control	503 7 O
than	511 4 O
in	516 2 O
the	519 3 O
alfentanil	523 10 B-Chemical
group	534 5 O
.	539 1 O

The	541 3 O
intragastric	545 12 O
pressure	558 8 O
during	567 6 O
muscle	574 6 B-Disease
fasciculations	581 14 I-Disease
was	596 3 O
significantly	600 13 O
higher	614 6 O
in	621 2 O
the	624 3 O
control	628 7 O
group	636 5 O
(	642 1 O
16	643 2 O
+	646 1 O
/	647 1 O
-	648 1 O
0	650 1 O
.	651 1 O
7	652 1 O
(	654 1 O
SEM	655 3 O
)	658 1 O
cm	660 2 O
H2O	663 3 B-Chemical
)	666 1 O
than	668 4 O
in	673 2 O
the	676 3 O
alfentanil	680 10 B-Chemical
group	691 5 O
(	697 1 O
7	698 1 O
.	699 1 O
7	700 1 O
+	702 1 O
/	703 1 O
-	704 1 O
1	706 1 O
.	707 1 O
5	708 1 O
(	710 1 O
SEM	711 3 O
)	714 1 O
cm	716 2 O
H2O	719 3 B-Chemical
)	722 1 O
.	723 1 O

The	725 3 O
increase	729 8 O
in	738 2 O
intragastric	741 12 O
pressure	754 8 O
was	763 3 O
directly	767 8 O
related	776 7 O
to	784 2 O
the	787 3 O
intensity	791 9 O
of	801 2 O
muscle	804 6 B-Disease
fasciculations	811 14 I-Disease
(	826 1 O
regression	827 10 O
line	838 4 O
:	842 1 O
y	844 1 O
=	846 1 O
0	848 1 O
.	849 1 O
5	850 1 O
+	852 1 O
4	854 1 O
.	855 1 O
78x	856 3 O
with	860 4 O
r	865 1 O
of	867 2 O
0	870 1 O
.	871 1 O
78	872 2 O
)	874 1 O
.	875 1 O

It	877 2 O
is	880 2 O
concluded	883 9 O
that	893 4 O
intragastric	898 12 O
pressure	911 8 O
increases	920 9 O
significantly	930 13 O
during	944 6 O
muscle	951 6 B-Disease
fasciculations	958 14 I-Disease
caused	973 6 O
by	980 2 O
suxamethonium	983 13 B-Chemical
in	997 2 O
healthy	1000 7 O
children	1008 8 O
.	1016 1 O

Alfentanil	1018 10 B-Chemical
50	1029 2 O
micrograms	1032 10 O
kg	1043 2 O
-	1045 1 O
1	1046 1 O
effectively	1048 11 O
inhibits	1060 8 O
the	1069 3 O
incidence	1073 9 O
and	1083 3 O
intensity	1087 9 O
of	1097 2 O
suxamethonium	1100 13 B-Chemical
-	1113 1 O
induced	1114 7 O
muscle	1122 6 B-Disease
fasciculations	1129 14 I-Disease
;	1143 1 O
moreover	1145 8 O
,	1153 1 O
intragastric	1155 12 O
pressure	1168 8 O
remains	1177 7 O
at	1185 2 O
its	1188 3 O
control	1192 7 O
value	1200 5 O
.	1205 1 O

Acute	0 5 O
insulin	6 7 O
treatment	14 9 O
normalizes	24 10 O
the	35 3 O
resistance	39 10 O
to	50 2 O
the	53 3 O
cardiotoxic	57 11 B-Disease
effect	69 6 O
of	76 2 O
isoproterenol	79 13 B-Chemical
in	93 2 O
streptozotocin	96 14 B-Chemical
diabetic	111 8 B-Disease
rats	120 4 O
.	124 1 O

A	126 1 O
morphometric	128 12 O
study	141 5 O
of	147 2 O
isoproterenol	150 13 B-Chemical
induced	164 7 O
myocardial	172 10 O
fibrosis	183 8 B-Disease
.	191 1 O

The	193 3 O
acute	197 5 O
effect	203 6 O
of	210 2 O
insulin	213 7 O
treatment	221 9 O
on	231 2 O
the	234 3 O
earlier	238 7 O
reported	246 8 O
protective	255 10 O
effect	266 6 O
of	273 2 O
streptozotocin	276 14 B-Chemical
diabetes	291 8 B-Disease
against	300 7 O
the	308 3 O
cardiotoxic	312 11 B-Disease
effect	324 6 O
of	331 2 O
high	334 4 O
doses	339 5 O
of	345 2 O
isoproterenol	348 13 B-Chemical
(	362 1 O
ISO	363 3 B-Chemical
)	366 1 O
was	368 3 O
investigated	372 12 O
in	385 2 O
rats	388 4 O
.	392 1 O

Thirty	394 6 O
to	401 2 O
135	404 3 O
min	408 3 O
after	412 5 O
the	418 3 O
injection	422 9 O
of	432 2 O
crystalline	435 11 O
insulin	447 7 O
,	454 1 O
ISO	456 3 B-Chemical
was	460 3 O
given	464 5 O
subcutaneously	470 14 O
and	485 3 O
when	489 4 O
ISO	494 3 B-Chemical
induced	498 7 O
fibrosis	506 8 B-Disease
in	515 2 O
the	518 3 O
myocardium	522 10 O
was	533 3 O
morphometrically	537 16 O
analyzed	554 8 O
7	563 1 O
days	565 4 O
later	570 5 O
,	575 1 O
a	577 1 O
highly	579 6 O
significant	586 11 O
correlation	598 11 O
(	610 1 O
r	611 1 O
=	613 1 O
0	615 1 O
.	616 1 O
83	617 2 O
,	619 1 O
2	621 1 O
p	623 1 O
=	625 1 O
0	627 1 O
.	628 1 O
006	629 3 O
)	632 1 O
to	634 2 O
the	637 3 O
slope	641 5 O
of	647 2 O
the	650 3 O
fall	654 4 O
in	659 2 O
blood	662 5 O
glucose	668 7 B-Chemical
after	676 5 O
insulin	682 7 O
treatment	690 9 O
appeared	700 8 O
.	708 1 O

The	710 3 O
myocardial	714 10 O
content	725 7 O
of	733 2 O
catecholamines	736 14 B-Chemical
was	751 3 O
estimated	755 9 O
in	765 2 O
these	768 5 O
8	774 1 O
day	776 3 O
diabetic	780 8 B-Disease
rats	789 4 O
.	793 1 O

The	795 3 O
norepinephrine	799 14 B-Chemical
content	814 7 O
was	822 3 O
significantly	826 13 O
increased	840 9 O
while	850 5 O
epinephrine	856 11 B-Chemical
remained	868 8 O
unchanged	877 9 O
.	886 1 O

An	888 2 O
enhanced	891 8 O
sympathetic	900 11 O
nervous	912 7 O
system	920 6 O
activity	927 8 O
with	936 4 O
a	941 1 O
consequent	943 10 O
down	954 4 O
regulation	959 10 O
of	970 2 O
the	973 3 O
myocardial	977 10 O
beta	988 4 O
-	992 1 O
adrenergic	993 10 O
receptors	1004 9 O
could	1014 5 O
,	1019 1 O
therefore	1021 9 O
,	1030 1 O
explain	1032 7 O
this	1040 4 O
catecholamine	1045 13 B-Chemical
resistance	1059 10 O
.	1069 1 O

The	1071 3 O
rapid	1075 5 O
reversion	1081 9 O
after	1091 5 O
insulin	1097 7 O
treatment	1105 9 O
excludes	1115 8 O
the	1124 3 O
possibility	1128 11 O
that	1140 4 O
streptozotocin	1145 14 B-Chemical
in	1160 2 O
itself	1163 6 O
causes	1170 6 O
the	1177 3 O
ISO	1181 3 B-Chemical
resistance	1185 10 O
and	1196 3 O
points	1200 6 O
towards	1207 7 O
a	1215 1 O
direct	1217 6 O
insulin	1224 7 O
effect	1232 6 O
on	1239 2 O
myocardial	1242 10 O
catecholamine	1253 13 B-Chemical
sensitivity	1267 11 O
in	1279 2 O
diabetic	1282 8 B-Disease
rats	1291 4 O
.	1295 1 O

The	1297 3 O
phenomenon	1301 10 O
described	1312 9 O
might	1322 5 O
elucidate	1328 9 O
pathogenetic	1338 12 O
mechanisms	1351 10 O
behind	1362 6 O
toxic	1369 5 O
myocardial	1375 10 O
cell	1386 4 O
degeneration	1391 12 O
and	1404 3 O
may	1408 3 O
possibly	1412 8 O
have	1421 4 O
relevance	1426 9 O
for	1436 3 O
acute	1440 5 O
cardiovascular	1446 14 O
complications	1461 13 O
in	1475 2 O
diabetic	1478 8 B-Disease
patients	1487 8 O
.	1495 1 O

Differential	0 12 O
effects	13 7 O
of	21 2 O
non	24 3 O
-	27 1 O
steroidal	28 9 O
anti	38 4 O
-	42 1 O
inflammatory	43 12 O
drugs	56 5 O
on	62 2 O
seizures	65 8 B-Disease
produced	74 8 O
by	83 2 O
pilocarpine	86 11 B-Chemical
in	98 2 O
rats	101 4 O
.	105 1 O

The	107 3 O
muscarinic	111 10 O
cholinergic	122 11 O
agonist	134 7 O
pilocarpine	142 11 B-Chemical
induces	154 7 O
in	162 2 O
rats	165 4 O
seizures	170 8 B-Disease
and	179 3 O
status	183 6 B-Disease
epilepticus	190 11 I-Disease
followed	202 8 O
by	211 2 O
widespread	214 10 O
damage	225 6 O
to	232 2 O
the	235 3 O
forebrain	239 9 O
.	248 1 O

The	250 3 O
present	254 7 O
study	262 5 O
was	268 3 O
designed	272 8 O
to	281 2 O
investigate	284 11 O
the	296 3 O
effect	300 6 O
of	307 2 O
5	310 1 O
non	312 3 O
-	315 1 O
steroidal	316 9 O
anti	326 4 O
-	330 1 O
inflammatory	331 12 O
drugs	344 5 O
,	349 1 O
sodium	351 6 B-Chemical
salicylate	358 10 I-Chemical
,	368 1 O
phenylbutazone	370 14 B-Chemical
,	384 1 O
indomethacin	386 12 B-Chemical
,	398 1 O
ibuprofen	400 9 B-Chemical
and	410 3 O
mefenamic	414 9 B-Chemical
acid	424 4 I-Chemical
,	428 1 O
on	430 2 O
seizures	433 8 B-Disease
produced	442 8 O
by	451 2 O
pilocarpine	454 11 B-Chemical
.	465 1 O

Pretreatment	467 12 O
of	480 2 O
rats	483 4 O
with	488 4 O
sodium	493 6 B-Chemical
salicylate	500 10 I-Chemical
,	510 1 O
ED50	512 4 O
103	517 3 O
mg	521 2 O
/	523 1 O
kg	524 2 O
(	527 1 O
60	528 2 O
-	530 1 O
174	531 3 O
)	534 1 O
,	535 1 O
and	537 3 O
phenylbutazone	541 14 B-Chemical
,	555 1 O
59	557 2 O
mg	560 2 O
/	562 1 O
kg	563 2 O
(	566 1 O
50	567 2 O
-	569 1 O
70	570 2 O
)	572 1 O
converted	574 9 O
the	584 3 O
non	588 3 O
-	591 1 O
convulsant	592 10 O
dose	603 4 O
of	608 2 O
pilocarpine	611 11 B-Chemical
,	622 1 O
200	624 3 O
mg	628 2 O
/	630 1 O
kg	631 2 O
,	633 1 O
to	635 2 O
a	638 1 O
convulsant	640 10 O
one	651 3 O
.	654 1 O

Indomethacin	656 12 B-Chemical
,	668 1 O
1	670 1 O
-	671 1 O
10	672 2 O
mg	675 2 O
/	677 1 O
kg	678 2 O
,	680 1 O
and	682 3 O
ibuprofen	686 9 B-Chemical
,	695 1 O
10	697 2 O
-	699 1 O
100	700 3 O
mg	704 2 O
/	706 1 O
kg	707 2 O
,	709 1 O
failed	711 6 O
to	718 2 O
modulate	721 8 O
seizures	730 8 B-Disease
produced	739 8 O
by	748 2 O
pilocarpine	751 11 B-Chemical
.	762 1 O

Mefenamic	764 9 B-Chemical
acid	774 4 I-Chemical
,	778 1 O
26	780 2 O
(	783 1 O
22	784 2 O
-	786 1 O
30	787 2 O
)	789 1 O
mg	791 2 O
/	793 1 O
kg	794 2 O
,	796 1 O
prevented	798 9 O
seizures	808 8 B-Disease
and	817 3 O
protected	821 9 O
rats	831 4 O
from	836 4 O
seizure	841 7 B-Disease
-	848 1 O
related	849 7 O
brain	857 5 B-Disease
damage	863 6 I-Disease
induced	870 7 O
by	878 2 O
pilocarpine	881 11 B-Chemical
,	892 1 O
380	894 3 O
mg	898 2 O
/	900 1 O
kg	901 2 O
.	903 1 O

These	905 5 O
results	911 7 O
indicate	919 8 O
that	928 4 O
non	933 3 O
-	936 1 O
steroidal	937 9 O
anti	947 4 O
-	951 1 O
inflammatory	952 12 O
drugs	965 5 O
differentially	971 14 O
modulate	986 8 O
the	995 3 O
threshold	999 9 O
for	1009 3 O
pilocarpine	1013 11 B-Chemical
-	1024 1 O
induced	1025 7 O
seizures	1033 8 B-Disease
.	1041 1 O

Acute	0 5 B-Disease
neurologic	6 10 I-Disease
dysfunction	17 11 I-Disease
after	29 5 O
high	35 4 O
-	39 1 O
dose	40 4 O
etoposide	45 9 B-Chemical
therapy	55 7 O
for	63 3 O
malignant	67 9 B-Disease
glioma	77 6 I-Disease
.	83 1 O

Etoposide	85 9 B-Chemical
(	95 1 O
VP	96 2 B-Chemical
-	98 1 I-Chemical
16	99 2 I-Chemical
-	101 1 I-Chemical
213	102 3 I-Chemical
)	105 1 O
has	107 3 O
been	111 4 O
used	116 4 O
in	121 2 O
the	124 3 O
treatment	128 9 O
of	138 2 O
many	141 4 O
solid	146 5 O
tumors	152 6 B-Disease
and	159 3 O
hematologic	163 11 B-Disease
malignancies	175 12 I-Disease
.	187 1 O

When	189 4 O
used	194 4 O
in	199 2 O
high	202 4 O
doses	207 5 O
and	213 3 O
in	217 2 O
conjunction	220 11 O
with	232 4 O
autologous	237 10 O
bone	248 4 O
marrow	253 6 O
transplantation	260 15 O
,	275 1 O
this	277 4 O
agent	282 5 O
has	288 3 O
activity	292 8 O
against	301 7 O
several	309 7 O
treatment	317 9 O
-	326 1 O
resistant	327 9 O
cancers	337 7 B-Disease
including	345 9 O
malignant	355 9 B-Disease
glioma	365 6 I-Disease
.	371 1 O

In	373 2 O
six	376 3 O
of	380 2 O
eight	383 5 O
patients	389 8 O
(	398 1 O
75	399 2 O
%	401 1 O
)	402 1 O
who	404 3 O
we	408 2 O
treated	411 7 O
for	419 3 O
recurrent	423 9 O
or	433 2 O
resistant	436 9 O
glioma	446 6 B-Disease
,	452 1 O
sudden	454 6 O
severe	461 6 O
neurologic	468 10 B-Disease
deterioration	479 13 I-Disease
occurred	493 8 O
.	501 1 O

This	503 4 O
developed	508 9 O
a	518 1 O
median	520 6 O
of	527 2 O
9	530 1 O
days	532 4 O
after	537 5 O
initiation	543 10 O
of	554 2 O
high	557 4 O
-	561 1 O
dose	562 4 O
etoposide	567 9 B-Chemical
therapy	577 7 O
.	584 1 O

Significant	586 11 O
clinical	598 8 O
manifestations	607 14 O
have	622 4 O
included	627 8 O
confusion	636 9 B-Disease
,	645 1 O
papilledema	647 11 B-Disease
,	658 1 O
somnolence	660 10 B-Disease
,	670 1 O
exacerbation	672 12 O
of	685 2 O
motor	688 5 B-Disease
deficits	694 8 I-Disease
,	702 1 O
and	704 3 O
sharp	708 5 O
increase	714 8 O
in	723 2 O
seizure	726 7 B-Disease
activity	734 8 O
.	742 1 O

These	744 5 O
abnormalities	750 13 O
resolved	764 8 O
rapidly	773 7 O
after	781 5 O
initiation	787 10 O
of	798 2 O
high	801 4 O
-	805 1 O
dose	806 4 O
intravenous	811 11 O
dexamethasone	823 13 B-Chemical
therapy	837 7 O
.	844 1 O

In	846 2 O
all	849 3 O
patients	853 8 O
,	861 1 O
computerized	863 12 O
tomographic	876 11 O
(	888 1 O
CT	889 2 O
)	891 1 O
brain	893 5 O
scans	899 5 O
demonstrated	905 12 O
stability	918 9 O
in	928 2 O
tumor	931 5 B-Disease
size	937 4 O
and	942 3 O
peritumor	946 9 O
edema	956 5 B-Disease
when	962 4 O
compared	967 8 O
with	976 4 O
pretransplant	981 13 O
scans	995 5 O
.	1000 1 O

This	1002 4 O
complication	1007 12 O
appears	1020 7 O
to	1028 2 O
represent	1031 9 O
a	1041 1 O
significant	1043 11 O
new	1055 3 O
toxicity	1059 8 B-Disease
of	1068 2 O
high	1071 4 O
-	1075 1 O
dose	1076 4 O
etoposide	1081 9 B-Chemical
therapy	1091 7 O
for	1099 3 O
malignant	1103 9 B-Disease
glioma	1113 6 I-Disease
.	1119 1 O

Progressive	0 11 O
bile	12 4 B-Disease
duct	17 4 I-Disease
injury	22 6 I-Disease
after	29 5 O
thiabendazole	35 13 B-Chemical
administration	49 14 O
.	63 1 O

A	65 1 O
27	67 2 O
-	69 1 O
yr	70 2 O
-	72 1 O
old	73 3 O
man	77 3 O
developed	81 9 O
jaundice	91 8 B-Disease
2	100 1 O
wk	102 2 O
after	105 5 O
exposure	111 8 O
to	120 2 O
thiabendazole	123 13 B-Chemical
.	136 1 O

Cholestasis	138 11 B-Disease
persisted	150 9 O
for	160 3 O
3	164 1 O
yr	166 2 O
,	168 1 O
at	170 2 O
which	173 5 O
time	179 4 O
a	184 1 O
liver	186 5 O
transplant	192 10 O
was	203 3 O
performed	207 9 O
.	216 1 O

Two	218 3 O
liver	222 5 O
biopsy	228 6 O
specimens	235 9 O
and	245 3 O
the	249 3 O
hepatectomy	253 11 O
specimen	265 8 O
were	274 4 O
remarkable	279 10 O
for	290 3 O
almost	294 6 O
complete	301 8 O
disappearance	310 13 O
of	324 2 O
interlobular	327 12 O
bile	340 4 O
ducts	345 5 O
.	350 1 O

Prominent	352 9 O
fibrosis	362 8 B-Disease
and	371 3 O
hepatocellular	375 14 O
regeneration	390 12 O
were	403 4 O
also	408 4 O
present	413 7 O
;	420 1 O
however	422 7 O
,	429 1 O
the	431 3 O
lobular	435 7 O
architecture	443 12 O
was	456 3 O
preserved	460 9 O
.	469 1 O

This	471 4 O
case	476 4 O
represents	481 10 O
an	492 2 O
example	495 7 O
of	503 2 O
"	506 1 O
idiosyncratic	507 13 O
"	520 1 O
drug	522 4 B-Disease
-	526 1 I-Disease
induced	527 7 I-Disease
liver	535 5 I-Disease
damage	541 6 I-Disease
in	548 2 O
which	551 5 O
the	557 3 O
primary	561 7 O
target	569 6 O
of	576 2 O
injury	579 6 O
is	586 2 O
the	589 3 O
bile	593 4 O
duct	598 4 O
.	602 1 O

An	604 2 O
autoimmune	607 10 O
pathogenesis	618 12 O
of	631 2 O
the	634 3 O
bile	638 4 B-Disease
duct	643 4 I-Disease
destruction	648 11 I-Disease
is	660 2 O
suggested	663 9 O
.	672 1 O

Differential	0 12 O
effects	13 7 O
of	21 2 O
1	24 1 B-Chemical
,	25 1 I-Chemical
4	26 1 I-Chemical
-	27 1 I-Chemical
dihydropyridine	28 15 I-Chemical
calcium	44 7 B-Chemical
channel	52 7 I-Chemical
blockers	60 8 I-Chemical
:	68 1 O
therapeutic	70 11 O
implications	82 12 O
.	94 1 O

Increasing	96 10 O
recognition	107 11 O
of	119 2 O
the	122 3 O
importance	126 10 O
of	137 2 O
calcium	140 7 B-Chemical
in	148 2 O
the	151 3 O
pathogenesis	155 12 O
of	168 2 O
cardiovascular	171 14 B-Disease
disease	186 7 I-Disease
has	194 3 O
stimulated	198 10 O
research	209 8 O
into	218 4 O
the	223 3 O
use	227 3 O
of	231 2 O
calcium	234 7 B-Chemical
channel	242 7 I-Chemical
blocking	250 8 I-Chemical
agents	259 6 I-Chemical
for	266 3 O
treatment	270 9 O
of	280 2 O
a	283 1 O
variety	285 7 O
of	293 2 O
cardiovascular	296 14 B-Disease
diseases	311 8 I-Disease
.	319 1 O

The	321 3 O
favorable	325 9 O
efficacy	335 8 O
and	344 3 O
tolerability	348 12 O
profiles	361 8 O
of	370 2 O
these	373 5 O
agents	379 6 O
make	386 4 O
them	391 4 O
attractive	396 10 O
therapeutic	407 11 O
modalities	419 10 O
.	429 1 O

Clinical	431 8 O
applications	440 12 O
of	453 2 O
calcium	456 7 B-Chemical
channel	464 7 I-Chemical
blockers	472 8 I-Chemical
parallel	481 8 O
their	490 5 O
tissue	496 6 O
selectivity	503 11 O
.	514 1 O

In	516 2 O
contrast	519 8 O
to	528 2 O
verapamil	531 9 B-Chemical
and	541 3 O
diltiazem	545 9 B-Chemical
,	554 1 O
which	556 5 O
are	562 3 O
roughly	566 7 O
equipotent	574 10 O
in	585 2 O
their	588 5 O
actions	594 7 O
on	602 2 O
the	605 3 O
heart	609 5 O
and	615 3 O
vascular	619 8 O
smooth	628 6 O
muscle	635 6 O
,	641 1 O
the	643 3 O
dihydropyridine	647 15 B-Chemical
calcium	663 7 B-Chemical
channel	671 7 I-Chemical
blockers	679 8 I-Chemical
are	688 3 O
a	692 1 O
group	694 5 O
of	700 2 O
potent	703 6 O
peripheral	710 10 O
vasodilator	721 11 O
agents	733 6 O
that	740 4 O
exert	745 5 O
minimal	751 7 O
electrophysiologic	759 18 O
effects	778 7 O
on	786 2 O
cardiac	789 7 O
nodal	797 5 O
or	803 2 O
conduction	806 10 O
tissue	817 6 O
.	823 1 O

As	825 2 O
the	828 3 O
first	832 5 O
dihydropyridine	838 15 B-Chemical
available	854 9 O
for	864 3 O
use	868 3 O
in	872 2 O
the	875 3 O
United	879 6 O
States	886 6 O
,	892 1 O
nifedipine	894 10 B-Chemical
controls	905 8 O
angina	914 6 B-Disease
and	921 3 O
hypertension	925 12 B-Disease
with	938 4 O
minimal	943 7 O
depression	951 10 O
of	962 2 O
cardiac	965 7 O
function	973 8 O
.	981 1 O

Additional	983 10 O
members	994 7 O
of	1002 2 O
this	1005 4 O
group	1010 5 O
of	1016 2 O
calcium	1019 7 B-Chemical
channel	1027 7 I-Chemical
blockers	1035 8 I-Chemical
have	1044 4 O
been	1049 4 O
studied	1054 7 O
for	1062 3 O
a	1066 1 O
variety	1068 7 O
of	1076 2 O
indications	1079 11 O
for	1091 3 O
which	1095 5 O
they	1101 4 O
may	1106 3 O
offer	1110 5 O
advantages	1116 10 O
over	1127 4 O
current	1132 7 O
therapy	1140 7 O
.	1147 1 O

Once	1149 4 O
or	1154 2 O
twice	1157 5 O
daily	1163 5 O
dosage	1169 6 O
possible	1176 8 O
with	1185 4 O
nitrendipine	1190 12 B-Chemical
and	1203 3 O
nisoldipine	1207 11 B-Chemical
offers	1219 6 O
a	1226 1 O
convenient	1228 10 O
administration	1239 14 O
schedule	1254 8 O
,	1262 1 O
which	1264 5 O
encourages	1270 10 O
patient	1281 7 O
compliance	1289 10 O
in	1300 2 O
long	1303 4 O
-	1307 1 O
term	1308 4 O
therapy	1313 7 O
of	1321 2 O
hypertension	1324 12 B-Disease
.	1336 1 O

The	1338 3 O
coronary	1342 8 O
vasodilating	1351 12 O
properties	1364 10 O
of	1375 2 O
nisoldipine	1378 11 B-Chemical
have	1390 4 O
led	1395 3 O
to	1399 2 O
the	1402 3 O
investigation	1406 13 O
of	1420 2 O
this	1423 4 O
agent	1428 5 O
for	1434 3 O
use	1438 3 O
in	1442 2 O
angina	1445 6 B-Disease
.	1451 1 O

Selectivity	1453 11 O
for	1465 3 O
the	1469 3 O
cerebrovascular	1473 15 O
bed	1489 3 O
makes	1493 5 O
nimodipine	1499 10 B-Chemical
potentially	1510 11 O
useful	1522 6 O
in	1529 2 O
the	1532 3 O
treatment	1536 9 O
of	1546 2 O
subarachnoid	1549 12 B-Disease
hemorrhage	1562 10 I-Disease
,	1572 1 O
migraine	1574 8 B-Disease
headache	1583 8 I-Disease
,	1591 1 O
dementia	1593 8 B-Disease
,	1601 1 O
and	1603 3 O
stroke	1607 6 B-Disease
.	1613 1 O

In	1615 2 O
general	1618 7 O
,	1625 1 O
the	1627 3 O
dihydropyridine	1631 15 B-Chemical
calcium	1647 7 B-Chemical
channel	1655 7 I-Chemical
blockers	1663 8 I-Chemical
are	1672 3 O
usually	1676 7 O
well	1684 4 O
tolerated	1689 9 O
,	1698 1 O
with	1700 4 O
headache	1705 8 B-Disease
,	1713 1 O
facial	1715 6 O
flushing	1722 8 B-Disease
,	1730 1 O
palpitations	1732 12 B-Disease
,	1744 1 O
edema	1746 5 B-Disease
,	1751 1 O
nausea	1753 6 B-Disease
,	1759 1 O
anorexia	1761 8 B-Disease
,	1769 1 O
and	1771 3 O
dizziness	1775 9 B-Disease
being	1785 5 O
the	1791 3 O
more	1795 4 O
common	1800 6 O
adverse	1807 7 O
effects	1815 7 O
.	1822 1 O

The	0 3 O
enhancement	4 11 O
of	16 2 O
aminonucleoside	19 15 B-Chemical
nephrosis	35 9 B-Disease
by	45 2 O
the	48 3 O
co	52 2 O
-	54 1 O
administration	55 14 O
of	70 2 O
protamine	73 9 O
.	82 1 O

An	84 2 O
experimental	87 12 O
model	100 5 O
of	106 2 O
focal	109 5 B-Disease
segmental	115 9 I-Disease
glomerular	125 10 I-Disease
sclerosis	136 9 I-Disease
(	146 1 O
FSGS	147 4 B-Disease
)	151 1 O
was	153 3 O
developed	157 9 O
in	167 2 O
rats	170 4 O
by	175 2 O
the	178 3 O
combined	182 8 O
administration	191 14 O
of	206 2 O
puromycin	209 9 B-Chemical
-	218 1 I-Chemical
aminonucleoside	219 15 I-Chemical
(	235 1 O
AMNS	236 4 B-Chemical
)	240 1 O
and	242 3 O
protamine	246 9 B-Chemical
sulfate	256 7 I-Chemical
(	264 1 O
PS	265 2 B-Chemical
)	267 1 O
.	268 1 O

Male	270 4 O
Sprague	275 7 O
-	282 1 O
Dawley	283 6 O
rats	290 4 O
,	294 1 O
uninephrectomized	296 17 O
three	314 5 O
weeks	320 5 O
before	326 6 O
,	332 1 O
received	334 8 O
daily	343 5 O
injections	349 10 O
of	360 2 O
subcutaneous	363 12 O
AMNS	376 4 B-Chemical
(	381 1 O
1	382 1 O
mg	384 2 O
/	386 1 O
100	387 3 O
g	391 1 O
body	393 4 O
wt	398 2 O
)	400 1 O
and	402 3 O
intravenous	406 11 O
PS	418 2 B-Chemical
(	421 1 O
2	422 1 O
separated	424 9 O
doses	434 5 O
of	440 2 O
2	443 1 O
.	444 1 O
5	445 1 O
mg	447 2 O
/	449 1 O
100	450 3 O
g	454 1 O
body	456 4 O
wt	461 2 O
)	463 1 O
for	465 3 O
four	469 4 O
days	474 4 O
.	478 1 O

The	480 3 O
series	484 6 O
of	491 2 O
injections	494 10 O
were	505 4 O
repeated	510 8 O
another	519 7 O
three	527 5 O
times	533 5 O
at	539 2 O
10	542 2 O
day	545 3 O
intervals	549 9 O
.	558 1 O

The	560 3 O
animals	564 7 O
were	572 4 O
sacrificed	577 10 O
on	588 2 O
days	591 4 O
24	596 2 O
,	598 1 O
52	600 2 O
,	602 1 O
and	604 3 O
80	608 2 O
.	610 1 O

They	612 4 O
developed	617 9 O
nephrotic	627 9 B-Disease
syndrome	637 8 I-Disease
and	646 3 O
finally	650 7 O
renal	658 5 B-Disease
failure	664 7 I-Disease
.	671 1 O

The	673 3 O
time	677 4 O
-	681 1 O
course	682 6 O
curve	689 5 O
of	695 2 O
creatinine	698 10 B-Chemical
clearance	709 9 O
dropped	719 7 O
and	727 3 O
showed	731 6 O
significant	738 11 O
difference	750 10 O
(	761 1 O
P	762 1 O
less	764 4 O
than	769 4 O
0	774 1 O
.	775 1 O
01	776 2 O
)	778 1 O
from	780 4 O
that	785 4 O
of	790 2 O
each	793 4 O
control	798 7 O
group	806 5 O
,	811 1 O
such	813 4 O
as	818 2 O
,	820 1 O
AMNS	822 4 B-Chemical
alone	827 5 O
,	832 1 O
PS	834 2 B-Chemical
alone	837 5 O
or	843 2 O
saline	846 6 O
injected	853 8 O
.	861 1 O

Their	863 5 O
glomeruli	869 9 O
showed	879 6 O
changes	886 7 O
of	894 2 O
progressive	897 11 O
FSGS	909 4 B-Disease
.	913 1 O

The	915 3 O
ultrastructural	919 15 O
studies	935 7 O
in	943 2 O
the	946 3 O
initial	950 7 O
stage	958 5 O
revealed	964 8 O
significant	973 11 O
lack	985 4 O
of	990 2 O
particles	993 9 O
of	1003 2 O
perfused	1006 8 O
ruthenium	1015 9 B-Chemical
red	1025 3 O
on	1029 2 O
the	1032 3 O
lamina	1036 6 O
rara	1043 4 O
externa	1048 7 O
and	1056 3 O
marked	1060 6 O
changes	1067 7 O
in	1075 2 O
epithelial	1078 10 O
cell	1089 4 O
cytoplasm	1094 9 O
.	1103 1 O

Therefore	1105 9 O
,	1114 1 O
it	1116 2 O
is	1119 2 O
suggested	1122 9 O
that	1132 4 O
the	1137 3 O
administration	1141 14 O
of	1156 2 O
PS	1159 2 B-Chemical
enhances	1162 8 O
the	1171 3 O
toxicity	1175 8 B-Disease
of	1184 2 O
AMNS	1187 4 B-Chemical
on	1192 2 O
the	1195 3 O
glomerulus	1199 10 O
and	1210 3 O
readily	1214 7 O
produces	1222 8 O
progressive	1231 11 O
FSGS	1243 4 B-Disease
in	1248 2 O
rats	1251 4 O
resulting	1256 9 O
in	1266 2 O
the	1269 3 O
end	1273 3 B-Disease
-	1276 1 I-Disease
stage	1277 5 I-Disease
renal	1283 5 I-Disease
disease	1289 7 I-Disease
.	1296 1 O

Theophylline	0 12 B-Chemical
neurotoxicity	13 13 B-Disease
in	27 2 O
pregnant	30 8 O
rats	39 4 O
.	43 1 O

The	45 3 O
purpose	49 7 O
of	57 2 O
this	60 4 O
investigation	65 13 O
was	79 3 O
to	83 2 O
determine	86 9 O
whether	96 7 O
the	104 3 O
neurotoxicity	108 13 B-Disease
of	122 2 O
theophylline	125 12 B-Chemical
is	138 2 O
altered	141 7 O
in	149 2 O
advanced	152 8 O
pregnancy	161 9 O
.	170 1 O

Sprague	172 7 O
-	179 1 O
Dawley	180 6 O
rats	187 4 O
that	192 4 O
were	197 4 O
20	202 2 O
days	205 4 O
pregnant	210 8 O
and	219 3 O
nonpregnant	223 11 O
rats	235 4 O
of	240 2 O
the	243 3 O
same	247 4 O
age	252 3 O
and	256 3 O
strain	260 6 O
received	267 8 O
infusions	276 9 O
of	286 2 O
aminophylline	289 13 B-Chemical
until	303 5 O
onset	309 5 O
of	315 2 O
maximal	318 7 O
seizures	326 8 B-Disease
which	335 5 O
occurred	341 8 O
after	350 5 O
28	356 2 O
and	359 3 O
30	363 2 O
minutes	366 7 O
respectively	374 12 O
.	386 1 O

Theophylline	388 12 B-Chemical
concentrations	401 14 O
at	416 2 O
this	419 4 O
endpoint	424 8 O
in	433 2 O
serum	436 5 O
(	442 1 O
total	443 5 O
)	448 1 O
and	450 3 O
CSF	454 3 O
were	458 4 O
similar	463 7 O
but	471 3 O
serum	475 5 O
(	481 1 O
free	482 4 O
)	486 1 O
and	488 3 O
brain	492 5 O
concentrations	498 14 O
were	513 4 O
slightly	518 8 O
different	527 9 O
in	537 2 O
pregnant	540 8 O
rats	549 4 O
.	553 1 O

Theophylline	555 12 B-Chemical
serum	568 5 O
protein	574 7 O
binding	582 7 O
determined	590 10 O
by	601 2 O
equilibrium	604 11 O
dialysis	616 8 O
was	625 3 O
lower	629 5 O
in	635 2 O
pregnant	638 8 O
rats	647 4 O
.	651 1 O

Fetal	653 5 O
serum	659 5 O
concentrations	665 14 O
at	680 2 O
onset	683 5 O
of	689 2 O
seizures	692 8 B-Disease
in	701 2 O
the	704 3 O
mother	708 6 O
were	715 4 O
similar	720 7 O
to	728 2 O
maternal	731 8 O
brain	740 5 O
and	746 3 O
CSF	750 3 O
concentrations	754 14 O
and	769 3 O
correlated	773 10 O
significantly	784 13 O
with	798 4 O
the	803 3 O
former	807 6 O
.	813 1 O

It	815 2 O
is	818 2 O
concluded	821 9 O
that	831 4 O
advanced	836 8 O
pregnancy	845 9 O
has	855 3 O
a	859 1 O
negligible	861 10 O
effect	872 6 O
on	879 2 O
the	882 3 O
neurotoxic	886 10 B-Disease
response	897 8 O
to	906 2 O
theophylline	909 12 B-Chemical
in	922 2 O
rats	925 4 O
.	929 1 O

Hyperkalemia	0 12 B-Disease
induced	13 7 O
by	21 2 O
indomethacin	24 12 B-Chemical
and	37 3 O
naproxen	41 8 B-Chemical
and	50 3 O
reversed	54 8 O
by	63 2 O
fludrocortisone	66 15 B-Chemical
.	81 1 O

We	83 2 O
have	86 4 O
described	91 9 O
a	101 1 O
patient	103 7 O
with	111 4 O
severe	116 6 O
rheumatoid	123 10 B-Disease
arthritis	134 9 I-Disease
and	144 3 O
a	148 1 O
history	150 7 O
of	158 2 O
mefenamic	161 9 B-Chemical
acid	171 4 I-Chemical
nephropathy	176 11 B-Disease
in	188 2 O
whom	191 4 O
hyperkalemia	196 12 B-Disease
and	209 3 O
inappropriate	213 13 O
hypoaldosteronism	227 17 B-Disease
were	245 4 O
caused	250 6 O
by	257 2 O
both	260 4 O
indomethacin	265 12 B-Chemical
and	278 3 O
naproxen	282 8 B-Chemical
,	290 1 O
without	292 7 O
major	300 5 O
decline	306 7 O
in	314 2 O
renal	317 5 O
function	323 8 O
.	331 1 O

It	333 2 O
is	336 2 O
likely	339 6 O
that	346 4 O
preexisting	351 11 O
renal	363 5 B-Disease
disease	369 7 I-Disease
predisposed	377 11 O
this	389 4 O
patient	394 7 O
to	402 2 O
type	405 4 B-Disease
IV	410 2 I-Disease
renal	413 5 I-Disease
tubular	419 7 I-Disease
acidosis	427 8 I-Disease
with	436 4 O
prostaglandin	441 13 B-Chemical
synthetase	455 10 O
inhibitors	466 10 O
.	476 1 O

Because	478 7 O
he	486 2 O
was	489 3 O
unable	493 6 O
to	500 2 O
discontinue	503 11 O
nonsteroidal	515 12 O
anti	528 4 O
-	532 1 O
inflammatory	533 12 O
drug	546 4 O
therapy	551 7 O
,	558 1 O
fludrocortisone	560 15 B-Chemical
was	576 3 O
added	580 5 O
,	585 1 O
correcting	587 10 O
the	598 3 O
hyperkalemia	602 12 B-Disease
and	615 3 O
allowing	619 8 O
indomethacin	628 12 B-Chemical
therapy	641 7 O
to	649 2 O
be	652 2 O
continued	655 9 O
safely	665 6 O
.	671 1 O

Hypotension	0 11 B-Disease
as	12 2 O
a	15 1 O
manifestation	17 13 O
of	31 2 O
cardiotoxicity	34 14 B-Disease
in	49 2 O
three	52 5 O
patients	58 8 O
receiving	67 9 O
cisplatin	77 9 B-Chemical
and	87 3 O
5	91 1 B-Chemical
-	92 1 I-Chemical
fluorouracil	93 12 I-Chemical
.	105 1 O

Cardiac	107 7 O
symptoms	115 8 O
,	123 1 O
including	125 9 O
hypotension	135 11 B-Disease
,	146 1 O
developed	148 9 O
in	158 2 O
three	161 5 O
patients	167 8 O
with	176 4 O
advanced	181 8 O
colorectal	190 10 B-Disease
carcinoma	201 9 I-Disease
while	211 5 O
being	217 5 O
treated	223 7 O
with	231 4 O
cisplatin	236 9 B-Chemical
(	246 1 O
CDDP	247 4 B-Chemical
)	251 1 O
and	253 3 O
5	257 1 B-Chemical
-	258 1 I-Chemical
fluorouracil	259 12 I-Chemical
(	272 1 O
5	273 1 B-Chemical
-	274 1 I-Chemical
FU	275 2 I-Chemical
)	277 1 O
.	278 1 O

In	280 2 O
two	283 3 O
patients	287 8 O
,	295 1 O
hypotension	297 11 B-Disease
was	309 3 O
associated	313 10 O
with	324 4 O
severe	329 6 O
left	336 4 B-Disease
ventricular	341 11 I-Disease
dysfunction	353 11 I-Disease
.	364 1 O

All	366 3 O
three	370 5 O
patients	376 8 O
required	385 8 O
therapy	394 7 O
discontinuation	402 15 O
.	417 1 O

Cardiac	419 7 O
enzymes	427 7 O
remained	435 8 O
normal	444 6 O
despite	451 7 O
transient	459 9 O
electrocardiographic	469 20 O
(	490 1 O
EKG	491 3 O
)	494 1 O
changes	496 7 O
.	503 1 O

The	505 3 O
presentation	509 12 O
and	522 3 O
cardiac	526 7 O
evaluation	534 10 O
(	545 1 O
hemodynamic	546 11 O
,	557 1 O
echocardiographic	559 17 O
,	576 1 O
and	578 3 O
scintigraphic	582 13 O
)	595 1 O
of	597 2 O
these	600 5 O
patients	606 8 O
suggest	615 7 O
new	623 3 O
manifestations	627 14 O
of	642 2 O
5	645 1 B-Chemical
-	646 1 I-Chemical
FU	647 2 I-Chemical
cardiotoxicity	650 14 B-Disease
that	665 4 O
may	670 3 O
be	674 2 O
influenced	677 10 O
by	688 2 O
CDDP	691 4 B-Chemical
.	695 1 O

The	697 3 O
possible	701 8 O
pathophysiologic	710 16 O
mechanisms	727 10 O
are	738 3 O
discussed	742 9 O
.	751 1 O

Fatal	0 5 O
aplastic	6 8 B-Disease
anemia	15 6 I-Disease
in	22 2 O
a	25 1 O
patient	27 7 O
treated	35 7 O
with	43 4 O
carbamazepine	48 13 B-Chemical
.	61 1 O

A	63 1 O
case	65 4 O
of	70 2 O
fatal	73 5 O
aplastic	79 8 B-Disease
anemia	88 6 I-Disease
due	95 3 O
to	99 2 O
carbamazepine	102 13 B-Chemical
treatment	116 9 O
in	126 2 O
an	129 2 O
epileptic	132 9 B-Disease
woman	142 5 O
is	148 2 O
reported	151 8 O
.	159 1 O

Despite	161 7 O
concerns	169 8 O
of	178 2 O
fatal	181 5 O
bone	187 4 B-Disease
marrow	192 6 I-Disease
toxicity	199 8 I-Disease
due	208 3 O
to	212 2 O
carbamazepine	215 13 B-Chemical
,	228 1 O
this	230 4 O
is	235 2 O
only	238 4 O
the	243 3 O
fourth	247 6 O
documented	254 10 O
and	265 3 O
published	269 9 O
report	279 6 O
.	285 1 O

Carbamazepine	287 13 B-Chemical
is	301 2 O
a	304 1 O
safe	306 4 O
drug	311 4 O
,	315 1 O
but	317 3 O
physicians	321 10 O
and	332 3 O
patients	336 8 O
should	345 6 O
be	352 2 O
aware	355 5 O
of	361 2 O
the	364 3 O
exceedingly	368 11 O
rare	380 4 O
but	385 3 O
potentially	389 11 O
fatal	401 5 O
side	407 4 O
effects	412 7 O
,	419 1 O
better	421 6 O
prevented	428 9 O
by	438 2 O
clinical	441 8 O
than	450 4 O
by	455 2 O
laboratory	458 10 O
monitoring	469 10 O
.	479 1 O

Participation	0 13 O
of	14 2 O
a	17 1 O
bulbospinal	19 11 O
serotonergic	31 12 O
pathway	44 7 O
in	52 2 O
the	55 3 O
rat	59 3 O
brain	63 5 O
in	69 2 O
clonidine	72 9 B-Chemical
-	81 1 O
induced	82 7 O
hypotension	90 11 B-Disease
and	102 3 O
bradycardia	106 11 B-Disease
.	117 1 O

The	119 3 O
effects	123 7 O
of	131 2 O
microinjection	134 14 O
of	149 2 O
clonidine	152 9 B-Chemical
(	162 1 O
1	163 1 O
-	164 1 O
10	165 2 O
micrograms	168 10 O
in	179 2 O
1	182 1 O
microliter	184 10 O
)	194 1 O
into	196 4 O
a	201 1 O
region	203 6 O
adjacent	210 8 O
to	219 2 O
the	222 3 O
ventrolateral	226 13 O
surface	240 7 O
of	248 2 O
the	251 3 O
medulla	255 7 O
oblongata	263 9 O
on	273 2 O
cardiovascular	276 14 O
function	291 8 O
were	300 4 O
assessed	305 8 O
in	314 2 O
urethane	317 8 B-Chemical
-	325 1 O
anesthetized	326 12 O
rats	339 4 O
.	343 1 O

Intramedullary	345 14 O
administration	360 14 O
of	375 2 O
clonidine	378 9 B-Chemical
,	387 1 O
but	389 3 O
not	393 3 O
saline	397 6 O
vehicle	404 7 O
,	411 1 O
caused	413 6 O
a	420 1 O
dose	422 4 O
-	426 1 O
dependent	427 9 O
decrease	437 8 O
in	446 2 O
both	449 4 O
the	454 3 O
mean	458 4 O
arterial	463 8 O
pressure	472 8 O
and	481 3 O
the	485 3 O
heart	489 5 O
rate	495 4 O
.	499 1 O

The	501 3 O
clonidine	505 9 B-Chemical
-	514 1 O
induced	515 7 O
hypotension	523 11 B-Disease
was	535 3 O
antagonized	539 11 O
by	551 2 O
prior	554 5 O
spinal	560 6 O
transection	567 11 O
,	578 1 O
but	580 3 O
not	584 3 O
bilateral	588 9 O
vagotomy	598 8 O
.	606 1 O

On	608 2 O
the	611 3 O
other	615 5 O
hand	621 4 O
,	625 1 O
the	627 3 O
clonidine	631 9 B-Chemical
-	640 1 O
induced	641 7 O
bradycardia	649 11 B-Disease
was	661 3 O
antagonized	665 11 O
by	677 2 O
prior	680 5 O
bilateral	686 9 O
vagotomy	696 8 O
,	704 1 O
but	706 3 O
not	710 3 O
spinal	714 6 O
transection	721 11 O
.	732 1 O

Furthermore	734 11 O
,	745 1 O
selective	747 9 O
destruction	757 11 O
of	769 2 O
the	772 3 O
spinal	776 6 O
5	783 1 B-Chemical
-	784 1 I-Chemical
HT	785 2 I-Chemical
nerves	788 6 O
,	794 1 O
produced	796 8 O
by	805 2 O
bilateral	808 9 O
spinal	818 6 O
injection	825 9 O
of	835 2 O
5	838 1 B-Chemical
,	839 1 I-Chemical
7	840 1 I-Chemical
-	841 1 I-Chemical
dihydroxytryptamine	842 19 I-Chemical
,	861 1 O
reduced	863 7 O
the	871 3 O
magnitude	875 9 O
of	885 2 O
the	888 3 O
vasodepressor	892 13 O
or	906 2 O
the	909 3 O
bradycardiac	913 12 B-Disease
responses	926 9 O
to	936 2 O
clonidine	939 9 B-Chemical
microinjected	949 13 O
into	963 4 O
the	968 3 O
area	972 4 O
near	977 4 O
the	982 3 O
ventrolateral	986 13 O
surface	1000 7 O
of	1008 2 O
the	1011 3 O
medulla	1015 7 O
oblongata	1023 9 O
in	1033 2 O
rats	1036 4 O
.	1040 1 O

The	1042 3 O
data	1046 4 O
indicate	1051 8 O
that	1060 4 O
a	1065 1 O
bulbospinal	1067 11 O
serotonergic	1079 12 O
pathway	1092 7 O
is	1100 2 O
involved	1103 8 O
in	1112 2 O
development	1115 11 O
of	1127 2 O
clonidine	1130 9 B-Chemical
-	1139 1 O
induced	1140 7 O
hypotension	1148 11 B-Disease
and	1160 3 O
bradycardia	1164 11 B-Disease
.	1175 1 O

The	1177 3 O
induced	1181 7 O
hypotension	1189 11 B-Disease
is	1201 2 O
brought	1204 7 O
about	1212 5 O
by	1218 2 O
a	1221 1 O
decrease	1223 8 O
in	1232 2 O
sympathetic	1235 11 O
efferent	1247 8 O
activity	1256 8 O
,	1264 1 O
whereas	1266 7 O
the	1274 3 O
induced	1278 7 O
bradycardia	1286 11 B-Disease
was	1298 3 O
due	1302 3 O
to	1306 2 O
an	1309 2 O
increase	1312 8 O
in	1321 2 O
vagal	1324 5 O
efferent	1330 8 O
activity	1339 8 O
.	1347 1 O

Hypertension	0 12 B-Disease
in	13 2 O
neuroblastoma	16 13 B-Disease
induced	30 7 O
by	38 2 O
imipramine	41 10 B-Chemical
.	51 1 O

Hypertension	53 12 B-Disease
is	66 2 O
a	69 1 O
well	71 4 O
-	75 1 O
known	76 5 O
finding	82 7 O
in	90 2 O
some	93 4 O
patients	98 8 O
with	107 4 O
neuroblastoma	112 13 B-Disease
.	125 1 O

However	127 7 O
,	134 1 O
it	136 2 O
has	139 3 O
not	143 3 O
previously	147 10 O
been	158 4 O
described	163 9 O
in	173 2 O
association	176 11 O
with	188 4 O
the	193 3 O
use	197 3 O
of	201 2 O
Imipramine	204 10 B-Chemical
.	214 1 O

We	216 2 O
report	219 6 O
the	226 3 O
occurrence	230 10 O
of	241 2 O
severe	244 6 O
hypertension	251 12 B-Disease
(	264 1 O
blood	265 5 O
pressure	271 8 O
190	280 3 O
/	283 1 O
160	284 3 O
)	287 1 O
in	289 2 O
a	292 1 O
4	294 1 O
-	295 1 O
year	296 4 O
-	300 1 O
old	301 3 O
girl	305 4 O
with	310 4 O
neuroblastoma	315 13 B-Disease
who	329 3 O
was	333 3 O
given	337 5 O
Imipramine	343 10 B-Chemical
to	354 2 O
control	357 7 O
a	365 1 O
behavior	367 8 B-Disease
disorder	376 8 I-Disease
.	384 1 O

It	386 2 O
was	389 3 O
determined	393 10 O
later	404 5 O
that	410 4 O
this	415 4 O
patient	420 7 O
'	427 1 O
s	428 1 O
tumor	430 5 B-Disease
was	436 3 O
recurring	440 9 O
at	450 2 O
the	453 3 O
time	457 4 O
of	462 2 O
her	465 3 O
hypertensive	469 12 B-Disease
episode	482 7 O
.	489 1 O

Since	491 5 O
she	497 3 O
had	501 3 O
no	505 2 O
blood	508 5 O
pressure	514 8 O
elevation	523 9 O
at	533 2 O
initial	536 7 O
diagnosis	544 9 O
and	554 3 O
none	558 4 O
following	563 9 O
discontinuation	573 15 O
of	589 2 O
the	592 3 O
Imipramine	596 10 B-Chemical
(	607 1 O
when	608 4 O
she	613 3 O
was	617 3 O
in	621 2 O
florid	624 6 O
relapse	631 7 O
)	638 1 O
,	639 1 O
we	641 2 O
believe	644 7 O
that	652 4 O
this	657 4 O
drug	662 4 O
rather	667 6 O
than	674 4 O
her	679 3 O
underlying	683 10 O
disease	694 7 O
alone	702 5 O
caused	708 6 O
her	715 3 O
hypertension	719 12 B-Disease
.	731 1 O

The	733 3 O
mechanism	737 9 O
for	747 3 O
this	751 4 O
reaction	756 8 O
is	765 2 O
believed	768 8 O
to	777 2 O
be	780 2 O
increased	783 9 O
levels	793 6 O
of	800 2 O
vasoactive	803 10 O
catecholamines	814 14 B-Chemical
due	829 3 O
to	833 2 O
interference	836 12 O
of	849 2 O
their	852 5 O
physiologic	858 11 O
inactivation	870 12 O
by	883 2 O
Imipramine	886 10 B-Chemical
.	896 1 O

From	898 4 O
this	903 4 O
experience	908 10 O
,	918 1 O
we	920 2 O
urge	923 4 O
extreme	928 7 O
caution	936 7 O
in	944 2 O
the	947 3 O
use	951 3 O
of	955 2 O
tricyclic	958 9 O
antidepressants	968 15 O
in	984 2 O
children	987 8 O
with	996 4 O
active	1001 6 O
neuroblastoma	1008 13 B-Disease
.	1021 1 O

Rechallenge	0 11 O
of	12 2 O
patients	15 8 O
who	24 3 O
developed	28 9 O
oral	38 4 B-Disease
candidiasis	43 11 I-Disease
or	55 2 O
hoarseness	58 10 B-Disease
with	69 4 O
beclomethasone	74 14 B-Chemical
dipropionate	89 12 I-Chemical
.	101 1 O

Of	103 2 O
158	106 3 O
asthmatic	110 9 B-Disease
patients	120 8 O
who	129 3 O
were	133 4 O
placed	138 6 O
on	145 2 O
inhaled	148 7 O
beclomethasone	156 14 B-Chemical
,	170 1 O
15	172 2 O
(	175 1 O
9	176 1 O
.	177 1 O
5	178 1 O
%	179 1 O
)	180 1 O
developed	182 9 O
either	192 6 O
hoarseness	199 10 B-Disease
(	210 1 O
8	211 1 O
)	212 1 O
,	213 1 O
oral	215 4 O
thrush	220 6 B-Disease
(	227 1 O
6	228 1 O
)	229 1 O
,	230 1 O
or	232 2 O
both	235 4 O
(	240 1 O
1	241 1 O
)	242 1 O
.	243 1 O

When	245 4 O
their	250 5 O
adverse	256 7 O
reactions	264 9 O
subsided	274 8 O
,	282 1 O
seven	284 5 O
of	290 2 O
these	293 5 O
15	299 2 O
patients	302 8 O
were	311 4 O
rechallenged	316 12 O
with	329 4 O
inhaled	334 7 O
beclomethasone	342 14 B-Chemical
.	356 1 O

These	358 5 O
included	364 8 O
five	373 4 O
cases	378 5 O
who	384 3 O
developed	388 9 O
hoarseness	398 10 B-Disease
and	409 3 O
three	413 5 O
who	419 3 O
developed	423 9 O
Candidiasis	433 11 B-Disease
.	444 1 O

One	446 3 O
patient	450 7 O
had	458 3 O
both	462 4 O
.	466 1 O

Oral	468 4 O
thrush	473 6 B-Disease
did	480 3 O
not	484 3 O
recur	488 5 O
,	493 1 O
but	495 3 O
60	499 2 O
%	501 1 O
(	503 1 O
3	504 1 O
/	505 1 O
5	506 1 O
)	507 1 O
of	509 2 O
patients	512 8 O
with	521 4 O
hoarseness	526 10 B-Disease
had	537 3 O
recurrence	541 10 O
.	551 1 O

We	553 2 O
conclude	556 8 O
that	565 4 O
patients	570 8 O
may	579 3 O
be	583 2 O
restarted	586 9 O
on	596 2 O
inhaled	599 7 O
beclomethasone	607 14 B-Chemical
when	622 4 O
clinically	627 10 O
indicated	638 9 O
;	647 1 O
however	649 7 O
,	656 1 O
because	658 7 O
of	666 2 O
the	669 3 O
high	673 4 O
recurrence	678 10 O
rate	689 4 O
,	693 1 O
patients	695 8 O
who	704 3 O
develop	708 7 O
hoarseness	716 10 B-Disease
should	727 6 O
not	734 3 O
be	738 2 O
re	741 2 O
-	743 1 O
challenged	744 10 O
.	754 1 O

Concomitant	756 11 O
use	768 3 O
of	772 2 O
oral	775 4 O
prednisone	780 10 B-Chemical
and	791 3 O
topical	795 7 O
beclomethasone	803 14 B-Chemical
may	818 3 O
increase	822 8 O
the	831 3 O
risk	835 4 O
of	840 2 O
developing	843 10 O
hoarseness	854 10 B-Disease
or	865 2 O
candidiasis	868 11 B-Disease
.	879 1 O

Cyclophosphamide	0 16 B-Chemical
cardiotoxicity	17 14 B-Disease
:	31 1 O
an	33 2 O
analysis	36 8 O
of	45 2 O
dosing	48 6 O
as	55 2 O
a	58 1 O
risk	60 4 O
factor	65 6 O
.	71 1 O

Patients	73 8 O
who	82 3 O
undergo	86 7 O
bone	94 4 O
marrow	99 6 O
transplantation	106 15 O
are	122 3 O
generally	126 9 O
immunosuppressed	136 16 O
with	153 4 O
a	158 1 O
dose	160 4 O
of	165 2 O
cyclophosphamide	168 16 B-Chemical
(	185 1 O
CYA	186 3 B-Chemical
)	189 1 O
which	191 5 O
is	197 2 O
usually	200 7 O
calculated	208 10 O
based	219 5 O
on	225 2 O
the	228 3 O
patient	232 7 O
'	239 1 O
s	240 1 O
weight	242 6 O
.	248 1 O

At	250 2 O
these	253 5 O
high	259 4 O
doses	264 5 O
of	270 2 O
CYA	273 3 B-Chemical
,	276 1 O
serious	278 7 O
cardiotoxicity	286 14 B-Disease
may	301 3 O
occur	305 5 O
,	310 1 O
but	312 3 O
definitive	316 10 O
risk	327 4 O
factors	332 7 O
for	340 3 O
the	344 3 O
development	348 11 O
of	360 2 O
such	363 4 O
cardiotoxicity	368 14 B-Disease
have	383 4 O
not	388 3 O
been	392 4 O
described	397 9 O
.	406 1 O

Since	408 5 O
chemotherapeutic	414 16 O
agent	431 5 O
toxicity	437 8 B-Disease
generally	446 9 O
correlates	456 10 O
with	467 4 O
dose	472 4 O
per	477 3 O
body	481 4 O
surface	486 7 O
area	494 4 O
,	498 1 O
we	500 2 O
retrospectively	503 15 O
calculated	519 10 O
the	530 3 O
dose	534 4 O
of	539 2 O
CYA	542 3 B-Chemical
in	546 2 O
patients	549 8 O
transplanted	558 12 O
at	571 2 O
our	574 3 O
institution	578 11 O
to	590 2 O
determine	593 9 O
whether	603 7 O
the	611 3 O
incidence	615 9 O
of	625 2 O
CYA	628 3 B-Chemical
cardiotoxicity	632 14 B-Disease
correlated	647 10 O
with	658 4 O
the	663 3 O
dose	667 4 O
per	672 3 O
body	676 4 O
surface	681 7 O
area	689 4 O
.	693 1 O

Eighty	695 6 O
patients	702 8 O
who	711 3 O
were	715 4 O
to	720 2 O
receive	723 7 O
CYA	731 3 B-Chemical
50	735 2 O
mg	738 2 O
/	740 1 O
kg	741 2 O
/	743 1 O
d	744 1 O
for	746 3 O
four	750 4 O
days	755 4 O
as	760 2 O
preparation	763 11 O
for	775 3 O
marrow	779 6 O
grafting	786 8 O
underwent	795 9 O
a	805 1 O
total	807 5 O
of	813 2 O
84	816 2 O
transplants	819 11 O
for	831 3 O
aplastic	835 8 B-Disease
anemia	844 6 I-Disease
,	850 1 O
Wiskott	852 7 B-Disease
-	859 1 I-Disease
Aldrich	860 7 I-Disease
syndrome	868 8 I-Disease
,	876 1 O
or	878 2 O
severe	881 6 B-Disease
combined	888 8 I-Disease
immunodeficiency	897 16 I-Disease
syndrome	914 8 I-Disease
.	922 1 O

Fourteen	924 8 O
of	933 2 O
84	936 2 O
(	939 1 O
17	940 2 O
%	942 1 O
)	943 1 O
patients	945 8 O
had	954 3 O
symptoms	958 8 O
and	967 3 O
signs	971 5 O
consistent	977 10 O
with	988 4 O
CYA	993 3 B-Chemical
cardiotoxicity	997 14 B-Disease
within	1012 6 O
ten	1019 3 O
days	1023 4 O
of	1028 2 O
receiving	1031 9 O
1	1041 1 O
to	1043 2 O
4	1046 1 O
doses	1048 5 O
of	1054 2 O
CYA	1057 3 B-Chemical
.	1060 1 O

Six	1062 3 O
of	1066 2 O
the	1069 3 O
14	1073 2 O
patients	1076 8 O
died	1085 4 O
with	1090 4 O
congestive	1095 10 B-Disease
heart	1106 5 I-Disease
failure	1112 7 I-Disease
.	1119 1 O

The	1121 3 O
dose	1125 4 O
of	1130 2 O
CYA	1133 3 B-Chemical
per	1137 3 O
body	1141 4 O
surface	1146 7 O
area	1154 4 O
was	1159 3 O
calculated	1163 10 O
for	1174 3 O
all	1178 3 O
patients	1182 8 O
and	1191 3 O
the	1195 3 O
patients	1199 8 O
were	1208 4 O
divided	1213 7 O
into	1221 4 O
two	1226 3 O
groups	1230 6 O
based	1237 5 O
on	1243 2 O
daily	1246 5 O
CYA	1252 3 B-Chemical
dose	1256 4 O
:	1260 1 O
Group	1262 5 O
1	1268 1 O
,	1269 1 O
CYA	1271 3 B-Chemical
less	1275 4 O
than	1280 4 O
or	1285 2 O
equal	1288 5 O
to	1294 2 O
1	1297 1 O
.	1298 1 O
55	1299 2 O
g	1302 1 O
/	1303 1 O
m2	1304 2 O
/	1306 1 O
d	1307 1 O
;	1308 1 O
Group	1310 5 O
2	1316 1 O
,	1317 1 O
CYA	1319 3 B-Chemical
greater	1323 7 O
than	1331 4 O
1	1336 1 O
.	1337 1 O
55	1338 2 O
g	1341 1 O
/	1342 1 O
m2	1343 2 O
/	1345 1 O
d	1346 1 O
.	1347 1 O

Cardiotoxicity	1349 14 B-Disease
that	1364 4 O
was	1369 3 O
thought	1373 7 O
to	1381 2 O
be	1384 2 O
related	1387 7 O
to	1395 2 O
CYA	1398 3 B-Chemical
occurred	1402 8 O
in	1411 2 O
1	1414 1 O
/	1415 1 O
32	1416 2 O
(	1419 1 O
3	1420 1 O
%	1421 1 O
)	1422 1 O
of	1424 2 O
patients	1427 8 O
in	1436 2 O
Group	1439 5 O
1	1445 1 O
and	1447 3 O
in	1451 2 O
13	1454 2 O
/	1456 1 O
52	1457 2 O
(	1460 1 O
25	1461 2 O
%	1463 1 O
)	1464 1 O
patients	1466 8 O
in	1475 2 O
Group	1478 5 O
2	1484 1 O
(	1486 1 O
P	1487 1 O
less	1489 4 O
than	1494 4 O
0	1499 1 O
.	1500 1 O
025	1501 3 O
)	1504 1 O
.	1505 1 O

Congestive	1507 10 B-Disease
heart	1518 5 I-Disease
failure	1524 7 I-Disease
caused	1532 6 O
or	1539 2 O
contributed	1542 11 O
to	1554 2 O
death	1557 5 O
in	1563 2 O
0	1566 1 O
/	1567 1 O
32	1568 2 O
patients	1571 8 O
in	1580 2 O
Group	1583 5 O
1	1589 1 O
v	1591 1 O
6	1593 1 O
/	1594 1 O
52	1595 2 O
(	1598 1 O
12	1599 2 O
%	1601 1 O
)	1602 1 O
of	1604 2 O
patients	1607 8 O
in	1616 2 O
Group	1619 5 O
2	1625 1 O
(	1627 1 O
P	1628 1 O
less	1630 4 O
than	1635 4 O
0	1640 1 O
.	1641 1 O
25	1642 2 O
)	1644 1 O
.	1645 1 O

There	1647 5 O
was	1653 3 O
no	1657 2 O
difference	1660 10 O
in	1671 2 O
the	1674 3 O
rate	1678 4 O
of	1683 2 O
engraftment	1686 11 O
of	1698 2 O
evaluable	1701 9 O
patients	1711 8 O
in	1720 2 O
the	1723 3 O
two	1727 3 O
groups	1731 6 O
(	1738 1 O
P	1739 1 O
greater	1741 7 O
than	1749 4 O
0	1754 1 O
.	1755 1 O
5	1756 1 O
)	1757 1 O
.	1758 1 O

We	1760 2 O
conclude	1763 8 O
that	1772 4 O
the	1777 3 O
CYA	1781 3 B-Chemical
cardiotoxicity	1785 14 B-Disease
correlates	1800 10 O
with	1811 4 O
CYA	1816 3 B-Chemical
dosage	1820 6 O
as	1827 2 O
calculated	1830 10 O
by	1841 2 O
body	1844 4 O
surface	1849 7 O
area	1857 4 O
,	1861 1 O
and	1863 3 O
that	1867 4 O
patients	1872 8 O
with	1881 4 O
aplastic	1886 8 B-Disease
anemia	1895 6 I-Disease
and	1902 3 O
immunodeficiencies	1906 18 B-Disease
can	1925 3 O
be	1929 2 O
effectively	1932 11 O
prepared	1944 8 O
for	1953 3 O
bone	1957 4 O
marrow	1962 6 O
grafting	1969 8 O
at	1978 2 O
a	1981 1 O
CYA	1983 3 B-Chemical
dose	1987 4 O
of	1992 2 O
1	1995 1 O
.	1996 1 O
55	1997 2 O
g	2000 1 O
/	2001 1 O
m2	2002 2 O
/	2004 1 O
d	2005 1 O
for	2007 3 O
four	2011 4 O
days	2016 4 O
with	2021 4 O
a	2026 1 O
lower	2028 5 O
incidence	2034 9 O
of	2044 2 O
cardiotoxicity	2047 14 B-Disease
than	2062 4 O
patients	2067 8 O
whose	2076 5 O
CYA	2082 3 B-Chemical
dosage	2086 6 O
is	2093 2 O
calculated	2096 10 O
based	2107 5 O
on	2113 2 O
weight	2116 6 O
.	2122 1 O

This	2124 4 O
study	2129 5 O
reaffirms	2135 9 O
the	2145 3 O
principle	2149 9 O
that	2159 4 O
drug	2164 4 O
toxicity	2169 8 B-Disease
correlates	2178 10 O
with	2189 4 O
dose	2194 4 O
per	2199 3 O
body	2203 4 O
surface	2208 7 O
area	2216 4 O
.	2220 1 O

Studies	0 7 O
of	8 2 O
risk	11 4 O
factors	16 7 O
for	24 3 O
aminoglycoside	28 14 B-Chemical
nephrotoxicity	43 14 B-Disease
.	57 1 O

The	59 3 O
epidemiology	63 12 O
of	76 2 O
aminoglycoside	79 14 B-Chemical
-	93 1 O
induced	94 7 O
nephrotoxicity	102 14 B-Disease
is	117 2 O
not	120 3 O
fully	124 5 O
understood	130 10 O
.	140 1 O

Experimental	142 12 O
studies	155 7 O
in	163 2 O
healthy	166 7 O
human	174 5 O
volunteers	180 10 O
indicate	191 8 O
aminoglycosides	200 15 B-Chemical
cause	216 5 O
proximal	222 8 O
tubular	231 7 O
damage	239 6 O
in	246 2 O
most	249 4 O
patients	254 8 O
,	262 1 O
but	264 3 O
rarely	268 6 O
,	274 1 O
if	276 2 O
ever	279 4 O
,	283 1 O
cause	285 5 O
glomerular	291 10 B-Disease
or	302 2 I-Disease
tubular	305 7 I-Disease
dysfunction	313 11 I-Disease
.	324 1 O

Clinical	326 8 O
trials	335 6 O
of	342 2 O
aminoglycosides	345 15 B-Chemical
in	361 2 O
seriously	364 9 O
ill	374 3 O
patients	378 8 O
indicate	387 8 O
that	396 4 O
the	401 3 O
relative	405 8 O
risk	414 4 O
for	419 3 O
developing	423 10 O
acute	434 5 B-Disease
renal	440 5 I-Disease
failure	446 7 I-Disease
during	454 6 O
therapy	461 7 O
ranges	469 6 O
from	476 4 O
8	481 1 O
to	483 2 O
10	486 2 O
and	489 3 O
that	493 4 O
the	498 3 O
attributable	502 12 O
risk	515 4 O
is	520 2 O
70	523 2 O
%	525 1 O
to	527 2 O
80	530 2 O
%	532 1 O
.	533 1 O

Further	535 7 O
analysis	543 8 O
of	552 2 O
these	555 5 O
data	561 4 O
suggests	566 8 O
that	575 4 O
the	580 3 O
duration	584 8 O
of	593 2 O
therapy	596 7 O
,	603 1 O
plasma	605 6 O
aminoglycoside	612 14 B-Chemical
levels	627 6 O
,	633 1 O
liver	635 5 B-Disease
disease	641 7 I-Disease
,	648 1 O
advanced	650 8 O
age	659 3 O
,	662 1 O
high	664 4 O
initial	669 7 O
estimated	677 9 O
creatinine	687 10 B-Chemical
clearance	698 9 O
and	708 3 O
,	711 1 O
possibly	713 8 O
,	721 1 O
female	723 6 O
gender	730 6 O
all	737 3 O
increase	741 8 O
the	750 3 O
risk	754 4 O
for	759 3 O
nephrotoxicity	763 14 B-Disease
.	777 1 O

Other	779 5 O
causes	785 6 O
of	792 2 O
acute	795 5 B-Disease
renal	801 5 I-Disease
failure	807 7 I-Disease
,	814 1 O
such	816 4 O
as	821 2 O
shock	824 5 B-Disease
,	829 1 O
appear	831 6 O
to	838 2 O
have	841 4 O
an	846 2 O
additive	849 8 O
effect	858 6 O
.	864 1 O

Predictive	866 10 O
models	877 6 O
have	884 4 O
been	889 4 O
developed	894 9 O
from	904 4 O
these	909 5 O
analyses	915 8 O
that	924 4 O
should	929 6 O
be	936 2 O
useful	939 6 O
for	946 3 O
identifying	950 11 O
patients	962 8 O
at	971 2 O
high	974 4 O
risk	979 4 O
.	983 1 O

These	985 5 O
models	991 6 O
may	998 3 O
also	1002 4 O
be	1007 2 O
useful	1010 6 O
in	1017 2 O
developing	1020 10 O
insights	1031 8 O
into	1040 4 O
the	1045 3 O
pathophysiology	1049 15 O
of	1065 2 O
aminoglycoside	1068 14 B-Chemical
-	1082 1 O
induced	1083 7 O
nephrotoxicity	1091 14 B-Disease
.	1105 1 O

Flurothyl	0 9 B-Chemical
seizure	10 7 B-Disease
thresholds	18 10 O
in	29 2 O
mice	32 4 O
treated	37 7 O
neonatally	45 10 O
with	56 4 O
a	61 1 O
single	63 6 O
injection	70 9 O
of	80 2 O
monosodium	83 10 B-Chemical
glutamate	94 9 I-Chemical
(	104 1 O
MSG	105 3 B-Chemical
)	108 1 O
:	109 1 O
evaluation	111 10 O
of	122 2 O
experimental	125 12 O
parameters	138 10 O
in	149 2 O
flurothyl	152 9 B-Chemical
seizure	162 7 B-Disease
testing	170 7 O
.	177 1 O

Monosodium	179 10 B-Chemical
glutamate	190 9 I-Chemical
(	200 1 O
MSG	201 3 B-Chemical
)	204 1 O
administration	206 14 O
to	221 2 O
neonatal	224 8 O
rodents	233 7 O
produces	241 8 O
convulsions	250 11 B-Disease
and	262 3 O
results	266 7 O
in	274 2 O
numerous	277 8 O
biochemical	286 11 O
and	298 3 O
behavioral	302 10 O
deficits	313 8 O
.	321 1 O

These	323 5 O
studies	329 7 O
were	337 4 O
undertaken	342 10 O
to	353 2 O
determine	356 9 O
if	366 2 O
neonatal	369 8 O
administration	378 14 O
of	393 2 O
MSG	396 3 B-Chemical
produced	400 8 O
permanent	409 9 O
alterations	419 11 O
in	431 2 O
seizure	434 7 B-Disease
susceptibility	442 14 O
,	456 1 O
since	458 5 O
previous	464 8 O
investigations	473 14 O
were	488 4 O
inconclusive	493 12 O
.	505 1 O

A	507 1 O
flurothyl	509 9 B-Chemical
ether	519 5 B-Chemical
seizure	525 7 B-Disease
screening	533 9 O
technique	543 9 O
was	553 3 O
used	557 4 O
to	562 2 O
evaluate	565 8 O
seizure	574 7 B-Disease
susceptibility	582 14 O
in	597 2 O
adult	600 5 O
mice	606 4 O
that	611 4 O
received	616 8 O
neonatal	625 8 O
injections	634 10 O
of	645 2 O
MSG	648 3 B-Chemical
(	652 1 O
4	653 1 O
mg	655 2 O
/	657 1 O
g	658 1 O
and	660 3 O
1	664 1 O
mg	666 2 O
/	668 1 O
g	669 1 O
)	670 1 O
.	671 1 O

MSG	673 3 B-Chemical
treatment	677 9 O
resulted	687 8 O
in	696 2 O
significant	699 11 O
reductions	711 10 O
in	722 2 O
whole	725 5 O
brain	731 5 O
weight	737 6 O
but	744 3 O
did	748 3 O
not	752 3 O
alter	756 5 O
seizure	762 7 B-Disease
threshold	770 9 O
.	779 1 O

A	781 1 O
naloxone	783 8 B-Chemical
(	792 1 O
5	793 1 O
mg	795 2 O
/	797 1 O
kg	798 2 O
)	800 1 O
challenge	802 9 O
was	812 3 O
also	816 4 O
ineffective	821 11 O
in	833 2 O
altering	836 8 O
the	845 3 O
seizure	849 7 B-Disease
thresholds	857 10 O
of	868 2 O
either	871 6 O
control	878 7 O
of	886 2 O
MSG	889 3 B-Chemical
-	892 1 O
treated	893 7 O
mice	901 4 O
.	905 1 O

Flurothyl	907 9 B-Chemical
ether	917 5 B-Chemical
produced	923 8 O
hypothermia	932 11 B-Disease
which	944 5 O
was	950 3 O
correlated	954 10 O
with	965 4 O
the	970 3 O
duration	974 8 O
of	983 2 O
flurothyl	986 9 B-Chemical
exposure	996 8 O
;	1004 1 O
however	1006 7 O
,	1013 1 O
the	1015 3 O
relationship	1019 12 O
of	1032 2 O
hypothermia	1035 11 B-Disease
to	1047 2 O
seizure	1050 7 B-Disease
induction	1058 9 O
was	1068 3 O
unclear	1072 7 O
.	1079 1 O

Flurothyl	1081 9 B-Chemical
seizure	1091 7 B-Disease
testing	1099 7 O
proved	1107 6 O
to	1114 2 O
be	1117 2 O
a	1120 1 O
rapid	1122 5 O
and	1128 3 O
reliable	1132 8 O
technique	1141 9 O
with	1151 4 O
which	1156 5 O
to	1162 2 O
evaluate	1165 8 O
seizure	1174 7 B-Disease
susceptibility	1182 14 O
.	1196 1 O

Susceptibility	0 14 O
to	15 2 O
seizures	18 8 B-Disease
produced	27 8 O
by	36 2 O
pilocarpine	39 11 B-Chemical
in	51 2 O
rats	54 4 O
after	59 5 O
microinjection	65 14 O
of	80 2 O
isoniazid	83 9 B-Chemical
or	93 2 O
gamma	96 5 B-Chemical
-	101 1 I-Chemical
vinyl	102 5 I-Chemical
-	107 1 I-Chemical
GABA	108 4 I-Chemical
into	113 4 O
the	118 3 O
substantia	122 10 O
nigra	133 5 O
.	138 1 O

Pilocarpine	140 11 B-Chemical
,	151 1 O
given	153 5 O
intraperitoneally	159 17 O
to	177 2 O
rats	180 4 O
,	184 1 O
reproduces	186 10 O
the	197 3 O
neuropathological	201 17 O
sequelae	219 8 O
of	228 2 O
temporal	231 8 B-Disease
lobe	240 4 I-Disease
epilepsy	245 8 I-Disease
and	254 3 O
provides	258 8 O
a	267 1 O
relevant	269 8 O
animal	278 6 O
model	285 5 O
for	291 3 O
studying	295 8 O
mechanisms	304 10 O
of	315 2 O
buildup	318 7 O
of	326 2 O
convulsive	329 10 B-Disease
activity	340 8 O
and	349 3 O
pathways	353 8 O
operative	362 9 O
in	372 2 O
the	375 3 O
generalization	379 14 O
and	394 3 O
propagation	398 11 O
of	410 2 O
seizures	413 8 B-Disease
within	422 6 O
the	429 3 O
forebrain	433 9 O
.	442 1 O

In	444 2 O
the	447 3 O
present	451 7 O
study	459 5 O
,	464 1 O
the	466 3 O
effects	470 7 O
of	478 2 O
manipulating	481 12 O
the	494 3 O
activity	498 8 O
of	507 2 O
the	510 3 O
gamma	514 5 B-Chemical
-	519 1 I-Chemical
aminobutyric	520 12 I-Chemical
acid	533 4 I-Chemical
(	538 1 O
GABA	539 4 B-Chemical
)	543 1 O
-	544 1 O
mediated	545 8 O
synaptic	554 8 O
inhibition	563 10 O
within	574 6 O
the	581 3 O
substantia	585 10 O
nigra	596 5 O
on	602 2 O
seizures	605 8 B-Disease
produced	614 8 O
by	623 2 O
pilocarpine	626 11 B-Chemical
in	638 2 O
rats	641 4 O
,	645 1 O
were	647 4 O
investigated	652 12 O
.	664 1 O

In	666 2 O
animals	669 7 O
pretreated	677 10 O
with	688 4 O
microinjections	693 15 O
of	709 2 O
isoniazid	712 9 B-Chemical
,	721 1 O
150	723 3 O
micrograms	727 10 O
,	737 1 O
an	739 2 O
inhibitor	742 9 O
of	752 2 O
activity	755 8 O
of	764 2 O
the	767 3 O
GABA	771 4 B-Chemical
-	775 1 O
synthesizing	776 12 O
enzyme	789 6 O
,	795 1 O
L	797 1 B-Chemical
-	798 1 I-Chemical
glutamic	799 8 I-Chemical
acid	808 4 I-Chemical
decarboxylase	813 13 O
,	826 1 O
into	828 4 O
the	833 3 O
substantia	837 10 O
nigra	848 5 O
pars	854 4 O
reticulata	859 10 O
(	870 1 O
SNR	871 3 O
)	874 1 O
,	875 1 O
bilaterally	877 11 O
,	888 1 O
non	890 3 O
-	893 1 O
convulsant	894 10 O
doses	905 5 O
of	911 2 O
pilocarpine	914 11 B-Chemical
,	925 1 O
100	927 3 O
and	931 3 O
200	935 3 O
mg	939 2 O
/	941 1 O
kg	942 2 O
,	944 1 O
resulted	946 8 O
in	955 2 O
severe	958 6 O
motor	965 5 O
limbic	971 6 O
seizures	978 8 B-Disease
and	987 3 O
status	991 6 B-Disease
epilepticus	998 11 I-Disease
.	1009 1 O

Electroencephalographic	1011 23 O
and	1035 3 O
behavioral	1039 10 O
monitoring	1050 10 O
revealed	1061 8 O
a	1070 1 O
profound	1072 8 O
reduction	1081 9 O
of	1091 2 O
the	1094 3 O
threshold	1098 9 O
for	1108 3 O
pilocarpine	1112 11 B-Chemical
-	1123 1 O
induced	1124 7 O
convulsions	1132 11 B-Disease
.	1143 1 O

Morphological	1145 13 O
analysis	1159 8 O
of	1168 2 O
frontal	1171 7 O
forebrain	1179 9 O
sections	1189 8 O
with	1198 4 O
light	1203 5 O
microscopy	1209 10 O
revealed	1220 8 O
seizure	1229 7 B-Disease
-	1236 1 O
related	1237 7 O
damage	1245 6 O
to	1252 2 O
the	1255 3 O
hippocampal	1259 11 O
formation	1271 9 O
,	1280 1 O
thalamus	1282 8 O
,	1290 1 O
amygdala	1292 8 O
,	1300 1 O
olfactory	1302 9 O
cortex	1312 6 O
,	1318 1 O
substantia	1320 10 O
nigra	1331 5 O
and	1337 3 O
neocortex	1341 9 O
,	1350 1 O
which	1352 5 O
is	1358 2 O
typically	1361 9 O
observed	1371 8 O
with	1380 4 O
pilocarpine	1385 11 B-Chemical
in	1397 2 O
doses	1400 5 O
exceeding	1406 9 O
350	1416 3 O
mg	1420 2 O
/	1422 1 O
kg	1423 2 O
.	1425 1 O

Bilateral	1427 9 O
intrastriatal	1437 13 O
injections	1451 10 O
of	1462 2 O
isoniazid	1465 9 B-Chemical
did	1475 3 O
not	1479 3 O
augment	1483 7 O
seizures	1491 8 B-Disease
produced	1500 8 O
by	1509 2 O
pilocarpine	1512 11 B-Chemical
,	1523 1 O
200	1525 3 O
mg	1529 2 O
/	1531 1 O
kg	1532 2 O
.	1534 1 O

Application	1536 11 O
of	1548 2 O
an	1551 2 O
irreversible	1554 12 O
inhibitor	1567 9 O
of	1577 2 O
GABA	1580 4 B-Chemical
transaminase	1585 12 O
,	1597 1 O
gamma	1599 5 B-Chemical
-	1604 1 I-Chemical
vinyl	1605 5 I-Chemical
-	1610 1 I-Chemical
GABA	1611 4 I-Chemical
(	1616 1 O
D	1617 1 B-Chemical
,	1618 1 I-Chemical
L	1619 1 I-Chemical
-	1620 1 I-Chemical
4	1621 1 I-Chemical
-	1622 1 I-Chemical
amino	1623 5 I-Chemical
-	1628 1 I-Chemical
hex	1629 3 I-Chemical
-	1632 1 I-Chemical
5	1633 1 I-Chemical
-	1634 1 I-Chemical
enoic	1635 5 I-Chemical
acid	1641 4 I-Chemical
)	1645 1 O
,	1646 1 O
5	1648 1 O
micrograms	1650 10 O
,	1660 1 O
into	1662 4 O
the	1667 3 O
SNR	1671 3 O
,	1674 1 O
bilaterally	1676 11 O
,	1687 1 O
suppressed	1689 10 O
the	1700 3 O
appearance	1704 10 O
of	1715 2 O
electrographic	1718 14 O
and	1733 3 O
behavioral	1737 10 O
seizures	1748 8 B-Disease
produced	1757 8 O
by	1766 2 O
pilocarpine	1769 11 B-Chemical
,	1780 1 O
380	1782 3 O
mg	1786 2 O
/	1788 1 O
kg	1789 2 O
.	1791 1 O

This	1793 4 O
treatment	1798 9 O
was	1808 3 O
also	1812 4 O
sufficient	1817 10 O
to	1828 2 O
protect	1831 7 O
animals	1839 7 O
from	1847 4 O
the	1852 3 O
occurrence	1856 10 O
of	1867 2 O
brain	1870 5 B-Disease
damage	1876 6 I-Disease
.	1882 1 O

Microinjections	1884 15 O
of	1900 2 O
gamma	1903 5 B-Chemical
-	1908 1 I-Chemical
vinyl	1909 5 I-Chemical
-	1914 1 I-Chemical
GABA	1915 4 I-Chemical
,	1919 1 O
5	1921 1 O
micrograms	1923 10 O
,	1933 1 O
into	1935 4 O
the	1940 3 O
dorsal	1944 6 O
striatum	1951 8 O
,	1959 1 O
bilaterally	1961 11 O
,	1972 1 O
failed	1974 6 O
to	1981 2 O
prevent	1984 7 O
the	1992 3 O
development	1996 11 O
of	2008 2 O
convulsions	2011 11 B-Disease
produced	2023 8 O
by	2032 2 O
pilocarpine	2035 11 B-Chemical
,	2046 1 O
380	2048 3 O
mg	2052 2 O
/	2054 1 O
kg	2055 2 O
.	2057 1 O

The	2059 3 O
results	2063 7 O
demonstrate	2071 11 O
that	2083 4 O
the	2088 3 O
threshold	2092 9 O
for	2102 3 O
pilocarpine	2106 11 B-Chemical
-	2117 1 O
induced	2118 7 O
seizures	2126 8 B-Disease
in	2135 2 O
rats	2138 4 O
is	2143 2 O
subjected	2146 9 O
to	2156 2 O
the	2159 3 O
regulation	2163 10 O
of	2174 2 O
the	2177 3 O
GABA	2181 4 B-Chemical
-	2185 1 O
mediated	2186 8 O
synaptic	2195 8 O
inhibition	2204 10 O
within	2215 6 O
the	2222 3 O
substantia	2226 10 O
nigra	2237 5 O
.	2242 1 O

Non	0 3 O
-	3 1 O
invasive	4 8 O
detection	13 9 O
of	23 2 O
coronary	26 8 B-Disease
artery	35 6 I-Disease
disease	42 7 I-Disease
by	50 2 O
body	53 4 O
surface	58 7 O
electrocardiographic	66 20 O
mapping	87 7 O
after	95 5 O
dipyridamole	101 12 B-Chemical
infusion	114 8 O
.	122 1 O

Electrocardiographic	124 20 O
changes	145 7 O
after	153 5 O
dipyridamole	159 12 B-Chemical
infusion	172 8 O
(	181 1 O
0	182 1 O
.	183 1 O
568	184 3 O
mg	188 2 O
/	190 1 O
kg	191 2 O
/	193 1 O
4	194 1 O
min	196 3 O
)	199 1 O
were	201 4 O
studied	206 7 O
in	214 2 O
41	217 2 O
patients	220 8 O
with	229 4 O
coronary	234 8 B-Disease
artery	243 6 I-Disease
disease	250 7 I-Disease
and	258 3 O
compared	262 8 O
with	271 4 O
those	276 5 O
after	282 5 O
submaximal	288 10 O
treadmill	299 9 O
exercise	309 8 O
by	318 2 O
use	321 3 O
of	325 2 O
the	328 3 O
body	332 4 O
surface	337 7 O
mapping	345 7 O
technique	353 9 O
.	362 1 O

Patients	364 8 O
were	373 4 O
divided	378 7 O
into	386 4 O
three	391 5 O
groups	397 6 O
;	403 1 O
19	405 2 O
patients	408 8 O
without	417 7 O
myocardial	425 10 B-Disease
infarction	436 10 I-Disease
(	447 1 O
non	448 3 O
-	451 1 O
MI	452 2 B-Disease
group	455 5 O
)	460 1 O
,	461 1 O
14	463 2 O
with	466 4 O
anterior	471 8 B-Disease
infarction	480 10 I-Disease
(	491 1 O
ANT	492 3 B-Disease
-	495 1 I-Disease
MI	496 2 I-Disease
)	498 1 O
and	500 3 O
eight	504 5 O
with	510 4 O
inferior	515 8 B-Disease
infarction	524 10 I-Disease
(	535 1 O
INF	536 3 B-Disease
-	539 1 I-Disease
MI	540 2 I-Disease
)	542 1 O
.	543 1 O

Eighty	545 6 O
-	551 1 O
seven	552 5 O
unipolar	558 8 O
electrocardiograms	567 18 O
(	586 1 O
ECGs	587 4 O
)	591 1 O
distributed	593 11 O
over	605 4 O
the	610 3 O
entire	614 6 O
thoracic	621 8 O
surface	630 7 O
were	638 4 O
simultaneously	643 14 O
recorded	658 8 O
.	666 1 O

After	668 5 O
dipyridamole	674 12 B-Chemical
,	686 1 O
ischemic	688 8 B-Disease
ST	697 2 O
-	699 1 O
segment	700 7 O
depression	708 10 B-Disease
(	719 1 O
0	720 1 O
.	721 1 O
05	722 2 O
mV	725 2 O
or	728 2 O
more	731 4 O
)	735 1 O
was	737 3 O
observed	741 8 O
in	750 2 O
84	753 2 O
%	755 1 O
of	757 2 O
the	760 3 O
non	764 3 O
-	767 1 O
MI	768 2 B-Disease
group	771 5 O
,	776 1 O
29	778 2 O
%	780 1 O
of	782 2 O
the	785 3 O
ANT	789 3 B-Disease
-	792 1 I-Disease
MI	793 2 I-Disease
group	796 5 O
,	801 1 O
63	803 2 O
%	805 1 O
of	807 2 O
the	810 3 O
INF	814 3 B-Disease
-	817 1 I-Disease
MI	818 2 I-Disease
group	821 5 O
and	827 3 O
61	831 2 O
%	833 1 O
of	835 2 O
the	838 3 O
total	842 5 O
population	848 10 O
.	858 1 O

Exercise	860 8 O
-	868 1 O
induced	869 7 O
ST	877 2 O
depression	880 10 B-Disease
was	891 3 O
observed	895 8 O
in	904 2 O
84	907 2 O
%	909 1 O
of	911 2 O
the	914 3 O
non	918 3 O
-	921 1 O
MI	922 2 B-Disease
group	925 5 O
,	930 1 O
43	932 2 O
%	934 1 O
of	936 2 O
the	939 3 O
ANT	943 3 B-Disease
-	946 1 I-Disease
MI	947 2 I-Disease
group	950 5 O
,	955 1 O
38	957 2 O
%	959 1 O
of	961 2 O
the	964 3 O
INF	968 3 B-Disease
-	971 1 I-Disease
MI	972 2 I-Disease
group	975 5 O
and	981 3 O
61	985 2 O
%	987 1 O
of	989 2 O
the	992 3 O
total	996 5 O
.	1001 1 O

For	1003 3 O
individual	1007 10 O
patients	1018 8 O
,	1026 1 O
there	1028 5 O
were	1034 4 O
no	1039 2 O
obvious	1042 7 O
differences	1050 11 O
between	1062 7 O
the	1070 3 O
body	1074 4 O
surface	1079 7 O
distribution	1087 12 O
of	1100 2 O
ST	1103 2 O
depression	1106 10 B-Disease
in	1117 2 O
both	1120 4 O
tests	1125 5 O
.	1130 1 O

The	1132 3 O
increase	1136 8 O
in	1145 2 O
pressure	1148 8 O
rate	1157 4 O
product	1162 7 O
after	1170 5 O
dipyridamole	1176 12 B-Chemical
was	1189 3 O
significantly	1193 13 O
less	1207 4 O
than	1212 4 O
that	1217 4 O
during	1222 6 O
the	1229 3 O
treadmill	1233 9 O
exercise	1243 8 O
.	1251 1 O

The	1253 3 O
data	1257 4 O
suggest	1262 7 O
that	1270 4 O
the	1275 3 O
dipyridamole	1279 12 B-Chemical
-	1291 1 O
induced	1292 7 O
myocardial	1300 10 B-Disease
ischemia	1311 8 I-Disease
is	1320 2 O
caused	1323 6 O
by	1330 2 O
the	1333 3 O
inhomogenous	1337 12 O
distribution	1350 12 O
of	1363 2 O
myocardial	1366 10 O
blood	1377 5 O
flow	1383 4 O
.	1387 1 O

We	1389 2 O
conclude	1392 8 O
that	1401 4 O
the	1406 3 O
dipyridamole	1410 12 B-Chemical
ECG	1423 3 O
test	1427 4 O
is	1432 2 O
as	1435 2 O
useful	1438 6 O
as	1445 2 O
the	1448 3 O
exercise	1452 8 O
ECG	1461 3 O
test	1465 4 O
for	1470 3 O
the	1474 3 O
assessment	1478 10 O
of	1489 2 O
coronary	1492 8 B-Disease
artery	1501 6 I-Disease
disease	1508 7 I-Disease
.	1515 1 O

Bradycardia	0 11 B-Disease
after	12 5 O
high	18 4 O
-	22 1 O
dose	23 4 O
intravenous	28 11 O
methylprednisolone	40 18 B-Chemical
therapy	59 7 O
.	66 1 O

In	68 2 O
5	71 1 O
consecutive	73 11 O
patients	85 8 O
with	94 4 O
rheumatoid	99 10 B-Disease
arthritis	110 9 I-Disease
who	120 3 O
received	124 8 O
intravenous	133 11 O
high	145 4 O
-	149 1 O
dose	150 4 O
methylprednisolone	155 18 B-Chemical
(	174 1 O
MP	175 2 B-Chemical
)	177 1 O
therapy	179 7 O
(	187 1 O
1	188 1 O
g	190 1 O
daily	192 5 O
for	198 3 O
2	202 1 O
or	204 2 O
3	207 1 O
consecutive	209 11 O
days	221 4 O
)	225 1 O
,	226 1 O
a	228 1 O
decline	230 7 O
in	238 2 O
pulse	241 5 O
rate	247 4 O
was	252 3 O
observed	256 8 O
,	264 1 O
most	266 4 O
pronounced	271 10 O
on	282 2 O
day	285 3 O
4	289 1 O
.	290 1 O

In	292 2 O
one	295 3 O
of	299 2 O
the	302 3 O
5	306 1 O
patients	308 8 O
the	317 3 O
bradycardia	321 11 B-Disease
was	333 3 O
associated	337 10 O
with	348 4 O
complaints	353 10 O
of	364 2 O
substernal	367 10 O
pressure	378 8 O
.	386 1 O

Reversal	388 8 O
to	397 2 O
normal	400 6 O
heart	407 5 O
rate	413 4 O
was	418 3 O
found	422 5 O
on	428 2 O
day	431 3 O
7	435 1 O
.	436 1 O

Electrocardiographic	438 20 O
registrations	459 13 O
showed	473 6 O
sinus	480 5 B-Disease
bradycardia	486 11 I-Disease
in	498 2 O
all	501 3 O
cases	505 5 O
.	510 1 O

No	512 2 O
significant	515 11 O
changes	527 7 O
in	535 2 O
plasma	538 6 O
concentrations	545 14 O
of	560 2 O
electrolytes	563 12 O
were	576 4 O
found	581 5 O
.	586 1 O

Careful	588 7 O
observation	596 11 O
of	608 2 O
patients	611 8 O
receiving	620 9 O
high	630 4 O
-	634 1 O
dose	635 4 O
MP	640 2 B-Chemical
is	643 2 O
recommended	646 11 O
.	657 1 O

High	659 4 O
-	663 1 O
dose	664 4 O
MP	669 2 B-Chemical
may	672 3 O
be	676 2 O
contraindicated	679 15 O
in	695 2 O
patients	698 8 O
with	707 4 O
known	712 5 O
heart	718 5 B-Disease
disease	724 7 I-Disease
.	731 1 O

Two	0 3 O
cases	4 5 O
of	10 2 O
downbeat	13 8 B-Disease
nystagmus	22 9 I-Disease
and	32 3 O
oscillopsia	36 11 B-Disease
associated	48 10 O
with	59 4 O
carbamazepine	64 13 B-Chemical
.	77 1 O

Downbeat	79 8 B-Disease
nystagmus	88 9 I-Disease
is	98 2 O
often	101 5 O
associated	107 10 O
with	118 4 O
structural	123 10 O
lesions	134 7 O
at	142 2 O
the	145 3 O
craniocervical	149 14 O
junction	164 8 O
,	172 1 O
but	174 3 O
has	178 3 O
occasionally	182 12 O
been	195 4 O
reported	200 8 O
as	209 2 O
a	212 1 O
manifestation	214 13 O
of	228 2 O
metabolic	231 9 O
imbalance	241 9 O
or	251 2 O
drug	254 4 O
intoxication	259 12 O
.	271 1 O

We	273 2 O
recorded	276 8 O
the	285 3 O
eye	289 3 O
movements	293 9 O
of	303 2 O
two	306 3 O
patients	310 8 O
with	319 4 O
reversible	324 10 O
downbeat	335 8 B-Disease
nystagmus	344 9 I-Disease
related	354 7 O
to	362 2 O
carbamazepine	365 13 B-Chemical
therapy	379 7 O
.	386 1 O

The	388 3 O
nystagmus	392 9 B-Disease
of	402 2 O
both	405 4 O
patients	410 8 O
resolved	419 8 O
after	428 5 O
reduction	434 9 O
of	444 2 O
the	447 3 O
serum	451 5 O
carbamazepine	457 13 B-Chemical
levels	471 6 O
.	477 1 O

Neuroradiologic	479 15 O
investigations	495 14 O
including	510 9 O
magnetic	520 8 O
resonance	529 9 O
imaging	539 7 O
scans	547 5 O
in	553 2 O
both	556 4 O
patients	561 8 O
showed	570 6 O
no	577 2 O
evidence	580 8 O
of	589 2 O
intracranial	592 12 O
abnormality	605 11 O
.	616 1 O

In	618 2 O
patients	621 8 O
with	630 4 O
downbeat	635 8 B-Disease
nystagmus	644 9 I-Disease
who	654 3 O
are	658 3 O
taking	662 6 O
anticonvulsant	669 14 O
medications	684 11 O
,	695 1 O
consideration	697 13 O
should	711 6 O
be	718 2 O
given	721 5 O
to	727 2 O
reduction	730 9 O
in	740 2 O
dose	743 4 O
before	748 6 O
further	755 7 O
investigation	763 13 O
is	777 2 O
undertaken	780 10 O
.	790 1 O

Improvement	0 11 O
by	12 2 O
denopamine	15 10 B-Chemical
(	26 1 O
TA	27 2 B-Chemical
-	29 1 I-Chemical
064	30 3 I-Chemical
)	33 1 O
of	35 2 O
pentobarbital	38 13 B-Chemical
-	51 1 O
induced	52 7 O
cardiac	60 7 B-Disease
failure	68 7 I-Disease
in	76 2 O
the	79 3 O
dog	83 3 O
heart	87 5 O
-	92 1 O
lung	93 4 O
preparation	98 11 O
.	109 1 O

The	111 3 O
efficacy	115 8 O
of	124 2 O
denopamine	127 10 B-Chemical
,	137 1 O
an	139 2 O
orally	142 6 O
active	149 6 O
beta	156 4 O
1	161 1 O
-	162 1 O
adrenoceptor	163 12 O
agonist	176 7 O
,	183 1 O
in	185 2 O
improving	188 9 O
cardiac	198 7 B-Disease
failure	206 7 I-Disease
was	214 3 O
assessed	218 8 O
in	227 2 O
dog	230 3 O
heart	234 5 O
-	239 1 O
lung	240 4 O
preparations	245 12 O
.	257 1 O

Cardiac	259 7 O
functions	267 9 O
depressed	277 9 O
by	287 2 O
pentobarbital	290 13 B-Chemical
(	304 1 O
118	305 3 O
+	309 1 O
/	310 1 O
-	311 1 O
28	313 2 O
mg	316 2 O
;	318 1 O
mean	320 4 O
value	325 5 O
+	331 1 O
/	332 1 O
-	333 1 O
SD	335 2 O
)	337 1 O
such	339 4 O
that	344 4 O
cardiac	349 7 O
output	357 6 O
and	364 3 O
maximum	368 7 O
rate	376 4 O
of	381 2 O
rise	384 4 O
of	389 2 O
left	392 4 O
ventricular	397 11 O
pressure	409 8 O
(	418 1 O
LV	419 2 O
dP	422 2 O
/	424 1 O
dt	425 2 O
max	428 3 O
)	431 1 O
had	433 3 O
been	437 4 O
reduced	442 7 O
by	450 2 O
about	453 5 O
35	459 2 O
%	461 1 O
and	463 3 O
26	467 2 O
%	469 1 O
of	471 2 O
the	474 3 O
respective	478 10 O
controls	489 8 O
were	498 4 O
improved	503 8 O
by	512 2 O
denopamine	515 10 B-Chemical
(	526 1 O
10	527 2 O
-	529 1 O
300	530 3 O
micrograms	534 10 O
)	544 1 O
in	546 2 O
a	549 1 O
dose	551 4 O
-	555 1 O
dependent	556 9 O
manner	566 6 O
.	572 1 O

With	574 4 O
100	579 3 O
micrograms	583 10 O
denopamine	594 10 B-Chemical
,	604 1 O
almost	606 6 O
complete	613 8 O
restoration	622 11 O
of	634 2 O
cardiac	637 7 O
performance	645 11 O
was	657 3 O
attained	661 8 O
,	669 1 O
associated	671 10 O
with	682 4 O
a	687 1 O
slight	689 6 O
increase	696 8 O
in	705 2 O
heart	708 5 O
rate	714 4 O
.	718 1 O

No	720 2 O
arrhythmias	723 11 B-Disease
were	735 4 O
induced	740 7 O
by	748 2 O
these	751 5 O
doses	757 5 O
of	763 2 O
denopamine	766 10 B-Chemical
.	776 1 O

The	778 3 O
results	782 7 O
warrant	790 7 O
clinical	798 8 O
trials	807 6 O
of	814 2 O
denopamine	817 10 B-Chemical
in	828 2 O
the	831 3 O
treatment	835 9 O
of	845 2 O
cardiac	848 7 B-Disease
failure	856 7 I-Disease
.	863 1 O

Clonazepam	0 10 B-Chemical
monotherapy	11 11 O
for	23 3 O
epilepsy	27 8 B-Disease
in	36 2 O
childhood	39 9 O
.	48 1 O

Sixty	50 5 O
patients	56 8 O
(	65 1 O
age	66 3 O
-	69 1 O
range	70 5 O
one	76 3 O
month	80 5 O
to	86 2 O
14	89 2 O
years	92 5 O
)	97 1 O
with	99 4 O
other	104 5 O
types	110 5 O
of	116 2 O
epilepsy	119 8 B-Disease
than	128 4 O
infantile	133 9 B-Disease
spasms	143 6 I-Disease
were	150 4 O
treated	155 7 O
with	163 4 O
clonazepam	168 10 B-Chemical
.	178 1 O

Disappearance	180 13 O
of	194 2 O
seizures	197 8 B-Disease
and	206 3 O
normalization	210 13 O
of	224 2 O
abnormal	227 8 O
EEG	236 3 O
with	240 4 O
disappearance	245 13 O
of	259 2 O
seizures	262 8 B-Disease
were	271 4 O
recognized	276 10 O
in	287 2 O
77	290 2 O
%	292 1 O
and	294 3 O
50	298 2 O
%	300 1 O
,	301 1 O
respectively	303 12 O
.	315 1 O

Seizures	317 8 B-Disease
disappeared	326 11 O
in	338 2 O
71	341 2 O
%	343 1 O
of	345 2 O
the	348 3 O
patients	352 8 O
with	361 4 O
generalized	366 11 O
seizures	378 8 B-Disease
and	387 3 O
89	391 2 O
%	393 1 O
of	395 2 O
partial	398 7 O
seizures	406 8 B-Disease
.	414 1 O

Improvement	416 11 O
of	428 2 O
abnormal	431 8 O
EEG	440 3 O
was	444 3 O
noticed	448 7 O
in	456 2 O
76	459 2 O
%	461 1 O
of	463 2 O
diffuse	466 7 O
paroxysms	474 9 O
and	484 3 O
in	488 2 O
67	491 2 O
%	493 1 O
of	495 2 O
focal	498 5 O
paroxysms	504 9 O
.	513 1 O

In	515 2 O
excellent	518 9 O
cases	528 5 O
,	533 1 O
mean	535 4 O
effective	540 9 O
dosages	550 7 O
were	558 4 O
0	563 1 O
.	564 1 O
086	565 3 O
+	569 1 O
/	570 1 O
-	571 1 O
0	573 1 O
.	574 1 O
021	575 3 O
mg	579 2 O
/	581 1 O
kg	582 2 O
/	584 1 O
day	585 3 O
in	589 2 O
infants	592 7 O
and	600 3 O
0	604 1 O
.	605 1 O
057	606 3 O
+	610 1 O
/	611 1 O
-	612 1 O
0	614 1 O
.	615 1 O
022	616 3 O
mg	620 2 O
/	622 1 O
kg	623 2 O
/	625 1 O
day	626 3 O
in	630 2 O
schoolchildren	633 14 O
,	647 1 O
this	649 4 O
difference	654 10 O
was	665 3 O
statistically	669 13 O
significant	683 11 O
(	695 1 O
p	696 1 O
less	698 4 O
than	703 4 O
0	708 1 O
.	709 1 O
005	710 3 O
)	713 1 O
.	714 1 O

The	716 3 O
incidence	720 9 O
of	730 2 O
side	733 4 O
effects	738 7 O
such	746 4 O
as	751 2 O
drowsiness	754 10 B-Disease
and	765 3 O
ataxia	769 6 B-Disease
was	776 3 O
only	780 4 O
5	785 1 O
%	786 1 O
.	787 1 O

Postmarketing	0 13 O
study	14 5 O
of	20 2 O
timolol	23 7 B-Chemical
-	30 1 O
hydrochlorothiazide	31 19 B-Chemical
antihypertensive	51 16 O
therapy	68 7 O
.	75 1 O

A	77 1 O
postmarketing	79 13 O
surveillance	93 12 O
study	106 5 O
was	112 3 O
conducted	116 9 O
to	126 2 O
determine	129 9 O
the	139 3 O
safety	143 6 O
and	150 3 O
efficacy	154 8 O
of	163 2 O
a	166 1 O
fixed	168 5 O
-	173 1 O
ratio	174 5 O
combination	180 11 O
containing	192 10 O
10	203 2 O
mg	206 2 O
of	209 2 O
timolol	212 7 B-Chemical
maleate	220 7 I-Chemical
and	228 3 O
25	232 2 O
mg	235 2 O
of	238 2 O
hydrochlorothiazide	241 19 B-Chemical
,	260 1 O
administered	262 12 O
twice	275 5 O
daily	281 5 O
for	287 3 O
one	291 3 O
month	295 5 O
to	301 2 O
hypertensive	304 12 B-Disease
patients	317 8 O
.	325 1 O

Data	327 4 O
on	332 2 O
9	335 1 O
,	336 1 O
037	337 3 O
patients	341 8 O
were	350 4 O
collected	355 9 O
by	365 2 O
1	368 1 O
,	369 1 O
455	370 3 O
participating	374 13 O
physicians	388 10 O
.	398 1 O

Mean	400 4 O
systolic	405 8 O
blood	414 5 O
pressure	420 8 O
decreased	429 9 O
25	439 2 O
mmHg	442 4 O
and	447 3 O
mean	451 4 O
diastolic	456 9 O
blood	466 5 O
pressure	472 8 O
declined	481 8 O
15	490 2 O
mmHg	493 4 O
after	498 5 O
one	504 3 O
month	508 5 O
of	514 2 O
timolol	517 7 B-Chemical
-	524 1 O
hydrochlorothiazide	525 19 B-Chemical
therapy	545 7 O
(	553 1 O
P	554 1 O
less	556 4 O
than	561 4 O
0	566 1 O
.	567 1 O
01	568 2 O
,	570 1 O
both	572 4 O
comparisons	577 11 O
)	588 1 O
.	589 1 O

Age	591 3 O
,	594 1 O
race	596 4 O
,	600 1 O
and	602 3 O
sex	606 3 O
appeared	610 8 O
to	619 2 O
have	622 4 O
no	627 2 O
influence	630 9 O
on	640 2 O
the	643 3 O
decrease	647 8 O
in	656 2 O
blood	659 5 O
pressure	665 8 O
.	673 1 O

The	675 3 O
antihypertensive	679 16 O
effect	696 6 O
of	703 2 O
the	706 3 O
drug	710 4 O
was	715 3 O
greater	719 7 O
in	727 2 O
patients	730 8 O
with	739 4 O
more	744 4 O
severe	749 6 O
hypertension	756 12 B-Disease
.	768 1 O

Overall	770 7 O
,	777 1 O
1	779 1 O
,	780 1 O
453	781 3 O
patients	785 8 O
experienced	794 11 O
a	806 1 O
total	808 5 O
of	814 2 O
2	817 1 O
,	818 1 O
658	819 3 O
adverse	823 7 O
events	831 6 O
,	837 1 O
the	839 3 O
most	843 4 O
common	848 6 O
being	855 5 O
fatigue	861 7 B-Disease
,	868 1 O
dizziness	870 9 B-Disease
,	879 1 O
and	881 3 O
weakness	885 8 B-Disease
.	893 1 O

Treatment	895 9 O
in	905 2 O
590	908 3 O
patients	912 8 O
was	921 3 O
discontinued	925 12 O
because	938 7 O
of	946 2 O
adverse	949 7 O
events	957 6 O
.	963 1 O

Salicylate	0 10 B-Chemical
nephropathy	11 11 B-Disease
in	23 2 O
the	26 3 O
Gunn	30 4 O
rat	35 3 O
:	38 1 O
potential	40 9 O
role	50 4 O
of	55 2 O
prostaglandins	58 14 B-Chemical
.	72 1 O

We	74 2 O
examined	77 8 O
the	86 3 O
potential	90 9 O
role	100 4 O
of	105 2 O
prostaglandins	108 14 B-Chemical
in	123 2 O
the	126 3 O
development	130 11 O
of	142 2 O
analgesic	145 9 O
nephropathy	155 11 B-Disease
in	167 2 O
the	170 3 O
Gunn	174 4 O
strain	179 6 O
of	186 2 O
rat	189 3 O
.	192 1 O

The	194 3 O
homozygous	198 10 O
Gunn	209 4 O
rats	214 4 O
have	219 4 O
unconjugated	224 12 O
hyperbilirubinemia	237 18 B-Disease
due	256 3 O
to	260 2 O
the	263 3 O
absence	267 7 O
of	275 2 O
glucuronyl	278 10 B-Chemical
transferase	289 11 O
,	300 1 O
leading	302 7 O
to	310 2 O
marked	313 6 O
bilirubin	320 9 B-Chemical
deposition	330 10 O
in	341 2 O
renal	344 5 O
medulla	350 7 O
and	358 3 O
papilla	362 7 O
.	369 1 O

These	371 5 O
rats	377 4 O
are	382 3 O
also	386 4 O
highly	391 6 O
susceptible	398 11 O
to	410 2 O
develop	413 7 O
papillary	421 9 B-Disease
necrosis	431 8 I-Disease
with	440 4 O
analgesic	445 9 O
administration	455 14 O
.	469 1 O

We	471 2 O
used	474 4 O
homozygous	479 10 O
(	490 1 O
jj	491 2 O
)	493 1 O
and	495 3 O
phenotypically	499 14 O
normal	514 6 O
heterozygous	521 12 O
(	534 1 O
jJ	535 2 O
)	537 1 O
animals	539 7 O
.	546 1 O

Four	548 4 O
groups	553 6 O
of	560 2 O
rats	563 4 O
(	568 1 O
n	569 1 O
=	571 1 O
7	573 1 O
)	574 1 O
were	576 4 O
studied	581 7 O
:	588 1 O
jj	590 2 O
and	593 3 O
jJ	597 2 O
rats	600 4 O
treated	605 7 O
either	613 6 O
with	620 4 O
aspirin	625 7 B-Chemical
300	633 3 O
mg	637 2 O
/	639 1 O
kg	640 2 O
every	643 5 O
other	649 5 O
day	655 3 O
or	659 2 O
sham	662 4 O
-	666 1 O
treated	667 7 O
.	674 1 O

After	676 5 O
one	682 3 O
week	686 4 O
,	690 1 O
slices	692 6 O
of	699 2 O
cortex	702 6 O
,	708 1 O
outer	710 5 O
and	716 3 O
inner	720 5 O
medulla	726 7 O
from	734 4 O
one	739 3 O
kidney	743 6 O
were	750 4 O
incubated	755 9 O
in	765 2 O
buffer	768 6 O
and	775 3 O
prostaglandin	779 13 B-Chemical
synthesis	793 9 O
was	803 3 O
determined	807 10 O
by	818 2 O
radioimmunoassay	821 16 O
.	837 1 O

The	839 3 O
other	843 5 O
kidney	849 6 O
was	856 3 O
examined	860 8 O
histologically	869 14 O
.	883 1 O

A	885 1 O
marked	887 6 O
corticomedullary	894 16 O
gradient	911 8 O
of	920 2 O
prostaglandin	923 13 B-Chemical
synthesis	937 9 O
was	947 3 O
observed	951 8 O
in	960 2 O
all	963 3 O
groups	967 6 O
.	973 1 O

PGE2	975 4 B-Chemical
synthesis	980 9 O
was	990 3 O
significantly	994 13 O
higher	1008 6 O
in	1015 2 O
outer	1018 5 O
medulla	1024 7 O
,	1031 1 O
but	1033 3 O
not	1037 3 O
cortex	1041 6 O
or	1048 2 O
inner	1051 5 O
medulla	1057 7 O
,	1064 1 O
of	1066 2 O
jj	1069 2 O
(	1072 1 O
38	1073 2 O
+	1076 1 O
/	1077 1 O
-	1078 1 O
6	1080 1 O
ng	1082 2 O
/	1084 1 O
mg	1085 2 O
prot	1088 4 O
)	1092 1 O
than	1094 4 O
jJ	1099 2 O
rats	1102 4 O
(	1107 1 O
15	1108 2 O
+	1111 1 O
/	1112 1 O
-	1113 1 O
3	1115 1 O
)	1116 1 O
(	1118 1 O
p	1119 1 O
less	1121 4 O
than	1126 4 O
0	1131 1 O
.	1132 1 O
01	1133 2 O
)	1135 1 O
.	1136 1 O

Aspirin	1138 7 B-Chemical
treatment	1146 9 O
reduced	1156 7 O
PGE2	1164 4 B-Chemical
synthesis	1169 9 O
in	1179 2 O
all	1182 3 O
regions	1186 7 O
,	1193 1 O
but	1195 3 O
outer	1199 5 O
medullary	1205 9 O
PGE2	1215 4 B-Chemical
remained	1220 8 O
higher	1229 6 O
in	1236 2 O
jj	1239 2 O
(	1242 1 O
18	1243 2 O
+	1246 1 O
/	1247 1 O
-	1248 1 O
3	1250 1 O
)	1251 1 O
than	1253 4 O
jJ	1258 2 O
rats	1261 4 O
(	1266 1 O
9	1267 1 O
+	1269 1 O
/	1270 1 O
-	1271 1 O
2	1273 1 O
)	1274 1 O
(	1276 1 O
p	1277 1 O
less	1279 4 O
than	1284 4 O
0	1289 1 O
.	1290 1 O
05	1291 2 O
)	1293 1 O
.	1294 1 O

PGF2	1296 4 B-Chemical
alpha	1301 5 I-Chemical
was	1307 3 O
also	1311 4 O
significantly	1316 13 O
higher	1330 6 O
in	1337 2 O
the	1340 3 O
outer	1344 5 O
medulla	1350 7 O
of	1358 2 O
jj	1361 2 O
rats	1364 4 O
with	1369 4 O
and	1374 3 O
without	1378 7 O
aspirin	1386 7 B-Chemical
administration	1394 14 O
(	1409 1 O
p	1410 1 O
less	1412 4 O
than	1417 4 O
0	1422 1 O
.	1423 1 O
05	1424 2 O
)	1426 1 O
.	1427 1 O

The	1429 3 O
changes	1433 7 O
in	1441 2 O
renal	1444 5 O
prostaglandin	1450 13 B-Chemical
synthesis	1464 9 O
were	1474 4 O
accompanied	1479 11 O
by	1491 2 O
evidence	1494 8 O
of	1503 2 O
renal	1506 5 B-Disease
damage	1512 6 I-Disease
in	1519 2 O
aspirin	1522 7 B-Chemical
-	1529 1 O
treated	1530 7 O
jj	1538 2 O
but	1541 3 O
not	1545 3 O
jJ	1549 2 O
rats	1552 4 O
as	1557 2 O
evidenced	1560 9 O
by	1570 2 O
:	1572 1 O
increased	1574 9 O
incidence	1584 9 O
and	1594 3 O
severity	1598 8 O
of	1607 2 O
hematuria	1610 9 B-Disease
(	1620 1 O
p	1621 1 O
less	1623 4 O
than	1628 4 O
0	1633 1 O
.	1634 1 O
01	1635 2 O
)	1637 1 O
;	1638 1 O
increased	1640 9 O
serum	1650 5 O
creatinine	1656 10 B-Chemical
(	1667 1 O
p	1668 1 O
less	1670 4 O
than	1675 4 O
0	1680 1 O
.	1681 1 O
05	1682 2 O
)	1684 1 O
;	1685 1 O
and	1687 3 O
increase	1691 8 O
in	1700 2 O
outer	1703 5 O
medullary	1709 9 O
histopathologic	1719 15 O
lesions	1735 7 O
(	1743 1 O
p	1744 1 O
less	1746 4 O
than	1751 4 O
0	1756 1 O
.	1757 1 O
005	1758 3 O
compared	1762 8 O
to	1771 2 O
either	1774 6 O
sham	1781 4 O
-	1785 1 O
treated	1786 7 O
jj	1794 2 O
or	1797 2 O
aspirin	1800 7 B-Chemical
-	1807 1 O
treated	1808 7 O
jJ	1816 2 O
)	1818 1 O
.	1819 1 O

These	1821 5 O
results	1827 7 O
suggest	1835 7 O
that	1843 4 O
enhanced	1848 8 O
prostaglandin	1857 13 B-Chemical
synthesis	1871 9 O
contributes	1881 11 O
to	1893 2 O
maintenance	1896 11 O
of	1908 2 O
renal	1911 5 O
function	1917 8 O
and	1926 3 O
morphological	1930 13 O
integrity	1944 9 O
,	1953 1 O
and	1955 3 O
that	1959 4 O
inhibition	1964 10 O
of	1975 2 O
prostaglandin	1978 13 B-Chemical
synthesis	1992 9 O
may	2002 3 O
lead	2006 4 O
to	2011 2 O
pathological	2014 12 B-Disease
renal	2027 5 I-Disease
medullary	2033 9 I-Disease
lesions	2043 7 I-Disease
and	2051 3 O
deterioration	2055 13 B-Disease
of	2069 2 I-Disease
renal	2072 5 I-Disease
function	2078 8 I-Disease
.	2086 1 O

Prophylactic	0 12 O
lidocaine	13 9 B-Chemical
in	23 2 O
the	26 3 O
early	30 5 O
phase	36 5 O
of	42 2 O
suspected	45 9 O
myocardial	55 10 B-Disease
infarction	66 10 I-Disease
.	76 1 O

Four	78 4 O
hundred	83 7 O
two	91 3 O
patients	95 8 O
with	104 4 O
suspected	109 9 O
myocardial	119 10 B-Disease
infarction	130 10 I-Disease
seen	141 4 O
within	146 6 O
6	153 1 O
hours	155 5 O
of	161 2 O
the	164 3 O
onset	168 5 O
of	174 2 O
symptoms	177 8 O
entered	186 7 O
a	194 1 O
double	196 6 O
-	202 1 O
blind	203 5 O
randomized	209 10 O
trial	220 5 O
of	226 2 O
lidocaine	229 9 B-Chemical
vs	239 2 O
placebo	242 7 O
.	249 1 O

During	251 6 O
the	258 3 O
1	262 1 O
hour	264 4 O
after	269 5 O
administration	275 14 O
of	290 2 O
the	293 3 O
drug	297 4 O
the	302 3 O
incidence	306 9 O
of	316 2 O
ventricular	319 11 B-Disease
fibrillation	331 12 I-Disease
or	344 2 O
sustained	347 9 O
ventricular	357 11 B-Disease
tachycardia	369 11 I-Disease
among	381 5 O
the	387 3 O
204	391 3 O
patients	395 8 O
with	404 4 O
acute	409 5 O
myocardial	415 10 B-Disease
infarction	426 10 I-Disease
was	437 3 O
low	441 3 O
,	444 1 O
1	446 1 O
.	447 1 O
5	448 1 O
%	449 1 O
.	450 1 O

Lidocaine	452 9 B-Chemical
,	461 1 O
given	463 5 O
in	469 2 O
a	472 1 O
300	474 3 O
mg	478 2 O
dose	481 4 O
intramuscularly	486 15 O
followed	502 8 O
by	511 2 O
100	514 3 O
mg	518 2 O
intravenously	521 13 O
,	534 1 O
did	536 3 O
not	540 3 O
prevent	544 7 O
sustained	552 9 O
ventricular	562 11 B-Disease
tachycardia	574 11 I-Disease
,	585 1 O
although	587 8 O
there	596 5 O
was	602 3 O
a	606 1 O
significant	608 11 O
reduction	620 9 O
in	630 2 O
the	633 3 O
number	637 6 O
of	644 2 O
patients	647 8 O
with	656 4 O
warning	661 7 O
arrhythmias	669 11 B-Disease
between	681 7 O
15	689 2 O
and	692 3 O
45	696 2 O
minutes	699 7 O
after	707 5 O
the	713 3 O
administration	717 14 O
of	732 2 O
lidocaine	735 9 B-Chemical
(	745 1 O
p	746 1 O
less	748 4 O
than	753 4 O
0	758 1 O
.	759 1 O
05	760 2 O
)	762 1 O
.	763 1 O

The	765 3 O
average	769 7 O
plasma	777 6 O
lidocaine	784 9 B-Chemical
level	794 5 O
10	800 2 O
minutes	803 7 O
after	811 5 O
administration	817 14 O
for	832 3 O
patients	836 8 O
without	845 7 O
a	853 1 O
myocardial	855 10 B-Disease
infarction	866 10 I-Disease
was	877 3 O
significantly	881 13 O
higher	895 6 O
than	902 4 O
that	907 4 O
for	912 3 O
patients	916 8 O
with	925 4 O
an	930 2 O
acute	933 5 O
infarction	939 10 B-Disease
.	949 1 O

The	951 3 O
mean	955 4 O
plasma	960 6 O
lidocaine	967 9 B-Chemical
level	977 5 O
of	983 2 O
patients	986 8 O
on	995 2 O
beta	998 4 O
-	1002 1 O
blocking	1003 8 O
agents	1012 6 O
was	1019 3 O
no	1023 2 O
different	1026 9 O
from	1036 4 O
that	1041 4 O
in	1046 2 O
patients	1049 8 O
not	1058 3 O
on	1062 2 O
beta	1065 4 O
blocking	1070 8 O
agents	1079 6 O
.	1085 1 O

During	1087 6 O
the	1094 3 O
1	1098 1 O
-	1099 1 O
hour	1100 4 O
study	1105 5 O
period	1111 6 O
,	1117 1 O
the	1119 3 O
incidence	1123 9 O
of	1133 2 O
central	1136 7 O
nervous	1144 7 O
system	1152 6 O
side	1159 4 O
effects	1164 7 O
was	1172 3 O
significantly	1176 13 O
greater	1190 7 O
in	1198 2 O
the	1201 3 O
lidocaine	1205 9 B-Chemical
group	1215 5 O
,	1220 1 O
hypotension	1222 11 B-Disease
occurred	1234 8 O
in	1243 2 O
11	1246 2 O
patients	1249 8 O
,	1257 1 O
nine	1259 4 O
of	1264 2 O
whom	1267 4 O
had	1272 3 O
received	1276 8 O
lidocaine	1285 9 B-Chemical
,	1294 1 O
and	1296 3 O
four	1300 4 O
patients	1305 8 O
died	1314 4 O
from	1319 4 O
asystole	1324 8 B-Disease
,	1332 1 O
three	1334 5 O
of	1340 2 O
whom	1343 4 O
had	1348 3 O
had	1352 3 O
lidocaine	1356 9 B-Chemical
.	1365 1 O

We	1367 2 O
cannot	1370 6 O
advocate	1377 8 O
the	1386 3 O
administration	1390 14 O
of	1405 2 O
lidocaine	1408 9 B-Chemical
prophylactically	1418 16 O
in	1435 2 O
the	1438 3 O
early	1442 5 O
hours	1448 5 O
of	1454 2 O
suspected	1457 9 O
myocardial	1467 10 B-Disease
infarction	1478 10 I-Disease
.	1488 1 O

Evidence	0 8 O
for	9 3 O
a	13 1 O
cholinergic	15 11 O
role	27 4 O
in	32 2 O
haloperidol	35 11 B-Chemical
-	46 1 O
induced	47 7 O
catalepsy	55 9 B-Disease
.	64 1 O

Experiments	66 11 O
in	78 2 O
mice	81 4 O
tested	86 6 O
previous	93 8 O
evidence	102 8 O
that	111 4 O
activation	116 10 O
of	127 2 O
cholinergic	130 11 O
systems	142 7 O
promotes	150 8 O
catalepsy	159 9 B-Disease
and	169 3 O
that	173 4 O
cholinergic	178 11 O
mechanisms	190 10 O
need	201 4 O
to	206 2 O
be	209 2 O
intact	212 6 O
for	219 3 O
full	223 4 O
expression	228 10 O
of	239 2 O
neuroleptic	242 11 B-Chemical
-	253 1 O
induced	254 7 O
catalepsy	262 9 B-Disease
.	271 1 O

Large	273 5 O
doses	279 5 O
of	285 2 O
the	288 3 O
cholinomimetic	292 14 O
,	306 1 O
pilocarpine	308 11 B-Chemical
,	319 1 O
could	321 5 O
induce	327 6 O
catalepsy	334 9 B-Disease
when	344 4 O
peripheral	349 10 O
cholinergic	360 11 O
receptors	372 9 O
were	382 4 O
blocked	387 7 O
.	394 1 O

Low	396 3 O
doses	400 5 O
of	406 2 O
pilocarpine	409 11 B-Chemical
caused	421 6 O
a	428 1 O
pronounced	430 10 O
enhancement	441 11 O
of	453 2 O
the	456 3 O
catalepsy	460 9 B-Disease
that	470 4 O
was	475 3 O
induced	479 7 O
by	487 2 O
the	490 3 O
dopaminergic	494 12 O
blocker	507 7 O
,	514 1 O
haloperidol	516 11 B-Chemical
.	527 1 O

A	529 1 O
muscarinic	531 10 O
receptor	542 8 O
blocker	551 7 O
,	558 1 O
atropine	560 8 B-Chemical
,	568 1 O
disrupted	570 9 O
haloperidol	580 11 B-Chemical
-	591 1 O
induced	592 7 O
catalepsy	600 9 B-Disease
.	609 1 O

Intracranial	611 12 O
injection	624 9 O
of	634 2 O
an	637 2 O
acetylcholine	640 13 B-Chemical
-	653 1 O
synthesis	654 9 O
inhibitor	664 9 O
,	673 1 O
hemicholinium	675 13 B-Chemical
,	688 1 O
prevented	690 9 O
the	700 3 O
catalepsy	704 9 B-Disease
that	714 4 O
is	719 2 O
usually	722 7 O
induced	730 7 O
by	738 2 O
haloperidol	741 11 B-Chemical
.	752 1 O

These	754 5 O
findings	760 8 O
suggest	769 7 O
the	777 3 O
hypothesis	781 10 O
that	792 4 O
the	797 3 O
catalepsy	801 9 B-Disease
that	811 4 O
is	816 2 O
produced	819 8 O
by	828 2 O
neuroleptics	831 12 B-Chemical
such	844 4 O
as	849 2 O
haloperidol	852 11 B-Chemical
is	864 2 O
actually	867 8 O
mediated	876 8 O
by	885 2 O
intrinsic	888 9 O
central	898 7 O
cholinergic	906 11 O
systems	918 7 O
.	925 1 O

Alternatively	927 13 O
,	940 1 O
activation	942 10 O
of	953 2 O
central	956 7 O
cholinergic	964 11 O
systems	976 7 O
could	984 5 O
promote	990 7 O
catalepsy	998 9 B-Disease
by	1008 2 O
suppression	1011 11 O
of	1023 2 O
dopaminergic	1026 12 O
systems	1039 7 O
.	1046 1 O

Cardiovascular	0 14 B-Disease
dysfunction	15 11 I-Disease
and	27 3 O
hypersensitivity	31 16 B-Disease
to	48 2 O
sodium	51 6 B-Chemical
pentobarbital	58 13 I-Chemical
induced	72 7 O
by	80 2 O
chronic	83 7 O
barium	91 6 B-Chemical
chloride	98 8 I-Chemical
ingestion	107 9 O
.	116 1 O

Barium	118 6 B-Chemical
-	124 1 O
supplemented	125 12 O
Long	138 4 O
-	142 1 O
Evans	143 5 O
hooded	149 6 O
rats	156 4 O
were	161 4 O
characterized	166 13 O
by	180 2 O
a	183 1 O
persistent	185 10 O
hypertension	196 12 B-Disease
that	209 4 O
was	214 3 O
evident	218 7 O
after	226 5 O
1	232 1 O
month	234 5 O
of	240 2 O
barium	243 6 B-Chemical
(	250 1 O
100	251 3 O
micrograms	255 10 O
/	265 1 O
ml	266 2 O
mineral	269 7 O
fortified	277 9 O
water	287 5 O
)	292 1 O
treatment	294 9 O
.	303 1 O

Analysis	305 8 O
of	314 2 O
in	317 2 O
vivo	320 4 O
myocardial	325 10 O
excitability	336 12 O
,	348 1 O
contractility	350 13 O
,	363 1 O
and	365 3 O
metabolic	369 9 O
characteristics	379 15 O
at	395 2 O
16	398 2 O
months	401 6 O
revealed	408 8 O
other	417 5 O
significant	423 11 O
barium	435 6 B-Chemical
-	441 1 O
induced	442 7 O
disturbances	450 12 B-Disease
within	463 6 I-Disease
the	470 3 I-Disease
cardiovascular	474 14 I-Disease
system	489 6 I-Disease
.	495 1 O

The	497 3 O
most	501 4 O
distinctive	506 11 O
aspect	518 6 O
of	525 2 O
the	528 3 O
barium	532 6 B-Chemical
effect	539 6 O
was	546 3 O
a	550 1 O
demonstrated	552 12 O
hypersensitivity	565 16 B-Disease
of	582 2 O
the	585 3 O
cardiovascular	589 14 O
system	604 6 O
to	611 2 O
sodium	614 6 B-Chemical
pentobarbital	621 13 I-Chemical
.	634 1 O

Under	636 5 O
barbiturate	642 11 B-Chemical
anesthesia	654 10 O
,	664 1 O
virtually	666 9 O
all	676 3 O
of	680 2 O
the	683 3 O
myocardial	687 10 O
contractile	698 11 O
indices	710 7 O
were	718 4 O
depressed	723 9 O
significantly	733 13 O
in	747 2 O
barium	750 6 B-Chemical
-	756 1 O
exposed	757 7 O
rats	765 4 O
relative	770 8 O
to	779 2 O
the	782 3 O
corresponding	786 13 O
control	800 7 O
-	807 1 O
fed	808 3 O
rats	812 4 O
.	816 1 O

The	818 3 O
lack	822 4 O
of	827 2 O
a	830 1 O
similar	832 7 O
response	840 8 O
to	849 2 O
ketamine	852 8 B-Chemical
and	861 3 O
xylazine	865 8 B-Chemical
anesthesia	874 10 O
revealed	885 8 O
that	894 4 O
the	899 3 O
cardiovascular	903 14 O
actions	918 7 O
of	926 2 O
sodium	929 6 B-Chemical
pentobarbital	936 13 I-Chemical
in	950 2 O
barium	953 6 B-Chemical
-	959 1 O
treated	960 7 O
rats	968 4 O
were	973 4 O
linked	978 6 O
specifically	985 12 O
to	998 2 O
this	1001 4 O
anesthetic	1006 10 O
,	1016 1 O
and	1018 3 O
were	1022 4 O
not	1027 3 O
representative	1031 14 O
of	1046 2 O
a	1049 1 O
generalized	1051 11 O
anesthetic	1063 10 O
response	1074 8 O
.	1082 1 O

Other	1084 5 O
myocardial	1090 10 O
pathophysiologic	1101 16 O
and	1118 3 O
metabolic	1122 9 O
changes	1132 7 O
induced	1140 7 O
by	1148 2 O
barium	1151 6 B-Chemical
were	1158 4 O
manifest	1163 8 O
,	1171 1 O
irrespective	1173 12 O
of	1186 2 O
the	1189 3 O
anesthetic	1193 10 O
employed	1204 8 O
.	1212 1 O

The	1214 3 O
contractile	1218 11 O
element	1230 7 O
shortening	1238 10 O
velocity	1249 8 O
of	1258 2 O
the	1261 3 O
cardiac	1265 7 O
muscle	1273 6 O
fibers	1280 6 O
was	1287 3 O
significantly	1291 13 O
slower	1305 6 O
in	1312 2 O
both	1315 4 O
groups	1320 6 O
of	1327 2 O
barium	1330 6 B-Chemical
-	1336 1 O
treated	1337 7 O
rats	1345 4 O
relative	1350 8 O
to	1359 2 O
the	1362 3 O
control	1366 7 O
groups	1374 6 O
,	1380 1 O
irrespective	1382 12 O
of	1395 2 O
the	1398 3 O
anesthetic	1402 10 O
regimen	1413 7 O
.	1420 1 O

Similarly	1422 9 O
,	1431 1 O
significant	1433 11 O
disturbances	1445 12 O
in	1458 2 O
myocardial	1461 10 O
energy	1472 6 O
metabolism	1479 10 O
were	1490 4 O
detected	1495 8 O
in	1504 2 O
the	1507 3 O
barium	1511 6 B-Chemical
-	1517 1 O
exposed	1518 7 O
rats	1526 4 O
which	1531 5 O
were	1537 4 O
consistent	1542 10 O
with	1553 4 O
the	1558 3 O
reduced	1562 7 O
contractile	1570 11 O
element	1582 7 O
shortening	1590 10 O
velocity	1601 8 O
.	1609 1 O

In	1611 2 O
addition	1614 8 O
,	1622 1 O
the	1624 3 O
excitability	1628 12 O
of	1641 2 O
the	1644 3 O
cardiac	1648 7 O
conduction	1656 10 O
system	1667 6 O
was	1674 3 O
depressed	1678 9 O
preferentially	1688 14 O
in	1703 2 O
the	1706 3 O
atrioventricular	1710 16 O
nodal	1727 5 O
region	1733 6 O
of	1740 2 O
hearts	1743 6 O
from	1750 4 O
barium	1755 6 B-Chemical
-	1761 1 O
exposed	1762 7 O
rats	1770 4 O
.	1774 1 O

Overall	1776 7 O
,	1783 1 O
the	1785 3 O
altered	1789 7 O
cardiac	1797 7 O
contractility	1805 13 O
and	1819 3 O
excitability	1823 12 O
characteristics	1836 15 O
,	1851 1 O
the	1853 3 O
myocardial	1857 10 O
metabolic	1868 9 B-Disease
disturbances	1878 12 I-Disease
,	1890 1 O
and	1892 3 O
the	1896 3 O
hypersensitivity	1900 16 B-Disease
of	1917 2 O
the	1920 3 O
cardiovascular	1924 14 O
system	1939 6 O
to	1946 2 O
sodium	1949 6 B-Chemical
pentobarbital	1956 13 I-Chemical
suggest	1970 7 O
the	1978 3 O
existence	1982 9 O
of	1992 2 O
a	1995 1 O
heretofore	1997 10 O
undescribed	2008 11 O
cardiomyopathic	2020 15 B-Disease
disorder	2036 8 I-Disease
induced	2045 7 O
by	2053 2 O
chronic	2056 7 O
barium	2064 6 B-Chemical
exposure	2071 8 O
.	2079 1 O

These	2081 5 O
experimental	2087 12 O
findings	2100 8 O
represent	2109 9 O
the	2119 3 O
first	2123 5 O
indication	2129 10 O
that	2140 4 O
life	2145 4 O
-	2149 1 O
long	2150 4 O
barium	2155 6 B-Chemical
ingestion	2162 9 O
may	2172 3 O
have	2176 4 O
significant	2181 11 O
adverse	2193 7 O
effects	2201 7 O
on	2209 2 O
the	2212 3 O
mammalian	2216 9 O
cardiovascular	2226 14 O
system	2241 6 O
.	2247 1 O

Propranolol	0 11 B-Chemical
antagonism	12 10 O
of	23 2 O
phenylpropanolamine	26 19 B-Chemical
-	45 1 O
induced	46 7 O
hypertension	54 12 B-Disease
.	66 1 O

Phenylpropanolamine	68 19 B-Chemical
(	88 1 O
PPA	89 3 B-Chemical
)	92 1 O
overdose	94 8 B-Disease
can	103 3 O
cause	107 5 O
severe	113 6 O
hypertension	120 12 B-Disease
,	132 1 O
intracerebral	134 13 B-Disease
hemorrhage	148 10 I-Disease
,	158 1 O
and	160 3 O
death	164 5 O
.	169 1 O

We	171 2 O
studied	174 7 O
the	182 3 O
efficacy	186 8 O
and	195 3 O
safety	199 6 O
of	206 2 O
propranolol	209 11 B-Chemical
in	221 2 O
the	224 3 O
treatment	228 9 O
of	238 2 O
PPA	241 3 B-Chemical
-	244 1 O
induced	245 7 O
hypertension	253 12 B-Disease
.	265 1 O

Subjects	267 8 O
received	276 8 O
propranolol	285 11 B-Chemical
either	297 6 O
by	304 2 O
mouth	307 5 O
for	313 3 O
48	317 2 O
hours	320 5 O
before	326 6 O
PPA	333 3 B-Chemical
or	337 2 O
as	340 2 O
a	343 1 O
rapid	345 5 O
intravenous	351 11 O
infusion	363 8 O
after	372 5 O
PPA	378 3 B-Chemical
.	381 1 O

PPA	383 3 B-Chemical
,	386 1 O
75	388 2 O
mg	391 2 O
alone	394 5 O
,	399 1 O
increased	401 9 O
blood	411 5 O
pressure	417 8 O
(	426 1 O
31	427 2 O
+	430 1 O
/	431 1 O
-	432 1 O
14	434 2 O
mm	437 2 O
Hg	440 2 O
systolic	443 8 O
,	451 1 O
20	453 2 O
+	456 1 O
/	457 1 O
-	458 1 O
5	460 1 O
mm	462 2 O
Hg	465 2 O
diastolic	468 9 O
)	477 1 O
,	478 1 O
and	480 3 O
propranolol	484 11 B-Chemical
pretreatment	496 12 O
antagonized	509 11 O
this	521 4 O
increase	526 8 O
(	535 1 O
12	536 2 O
+	539 1 O
/	540 1 O
-	541 1 O
10	543 2 O
mm	546 2 O
Hg	549 2 O
systolic	552 8 O
,	560 1 O
10	562 2 O
+	565 1 O
/	566 1 O
-	567 1 O
7	569 1 O
mm	571 2 O
Hg	574 2 O
diastolic	577 9 O
)	586 1 O
.	587 1 O

Intravenous	589 11 O
propranolol	601 11 B-Chemical
after	613 5 O
PPA	619 3 B-Chemical
also	623 4 O
decreased	628 9 O
blood	638 5 O
pressure	644 8 O
.	652 1 O

Left	654 4 O
ventricular	659 11 O
function	671 8 O
(	680 1 O
assessed	681 8 O
by	690 2 O
echocardiography	693 16 O
)	709 1 O
showed	711 6 O
that	718 4 O
PPA	723 3 B-Chemical
increased	727 9 O
the	737 3 O
stroke	741 6 B-Disease
volume	748 6 O
30	755 2 O
%	757 1 O
(	759 1 O
from	760 4 O
62	765 2 O
.	767 1 O
5	768 1 O
+	770 1 O
/	771 1 O
-	772 1 O
20	774 2 O
.	776 1 O
9	777 1 O
to	779 2 O
80	782 2 O
.	784 1 O
8	785 1 O
+	787 1 O
/	788 1 O
-	789 1 O
22	791 2 O
.	793 1 O
4	794 1 O
ml	796 2 O
)	798 1 O
,	799 1 O
the	801 3 O
ejection	805 8 O
fraction	814 8 O
9	823 1 O
%	824 1 O
(	826 1 O
from	827 4 O
64	832 2 O
%	834 1 O
+	836 1 O
/	837 1 O
-	838 1 O
10	840 2 O
%	842 1 O
to	844 2 O
70	847 2 O
%	849 1 O
+	851 1 O
/	852 1 O
-	853 1 O
7	855 1 O
%	856 1 O
)	857 1 O
,	858 1 O
and	860 3 O
cardiac	864 7 O
output	872 6 O
14	879 2 O
%	881 1 O
(	883 1 O
from	884 4 O
3	889 1 O
.	890 1 O
6	891 1 O
+	893 1 O
/	894 1 O
-	895 1 O
0	897 1 O
.	898 1 O
6	899 1 O
to	901 2 O
4	904 1 O
.	905 1 O
1	906 1 O
+	908 1 O
/	909 1 O
-	910 1 O
1	912 1 O
.	913 1 O
0	914 1 O
L	916 1 O
/	917 1 O
min	918 3 O
)	921 1 O
.	922 1 O

Intravenous	924 11 O
propranolol	936 11 B-Chemical
reversed	948 8 O
these	957 5 O
effects	963 7 O
.	970 1 O

Systemic	972 8 O
vascular	981 8 O
resistance	990 10 O
was	1001 3 O
increased	1005 9 O
by	1015 2 O
PPA	1018 3 B-Chemical
28	1022 2 O
%	1024 1 O
(	1026 1 O
from	1027 4 O
1710	1032 4 O
+	1037 1 O
/	1038 1 O
-	1039 1 O
200	1041 3 O
to	1045 2 O
2190	1048 4 O
+	1053 1 O
/	1054 1 O
-	1055 1 O
700	1057 3 O
dyne	1061 4 O
X	1066 1 O
sec	1068 3 O
/	1071 1 O
cm5	1072 3 O
)	1075 1 O
and	1077 3 O
was	1081 3 O
further	1085 7 O
increased	1093 9 O
by	1103 2 O
propranolol	1106 11 B-Chemical
22	1118 2 O
%	1120 1 O
(	1122 1 O
to	1123 2 O
2660	1126 4 O
+	1131 1 O
/	1132 1 O
-	1133 1 O
1200	1135 4 O
dyne	1140 4 O
X	1145 1 O
sec	1147 3 O
/	1150 1 O
cm5	1151 3 O
)	1154 1 O
.	1155 1 O

We	1157 2 O
conclude	1160 8 O
that	1169 4 O
PPA	1174 3 B-Chemical
increases	1178 9 O
blood	1188 5 O
pressure	1194 8 O
by	1203 2 O
increasing	1206 10 O
systemic	1217 8 O
vascular	1226 8 O
resistance	1235 10 O
and	1246 3 O
cardiac	1250 7 O
output	1258 6 O
,	1264 1 O
and	1266 3 O
that	1270 4 O
propranolol	1275 11 B-Chemical
antagonizes	1287 11 O
this	1299 4 O
increase	1304 8 O
by	1313 2 O
reversing	1316 9 O
the	1326 3 O
effect	1330 6 O
of	1337 2 O
PPA	1340 3 B-Chemical
on	1344 2 O
cardiac	1347 7 O
output	1355 6 O
.	1361 1 O

That	1363 4 O
propranolol	1368 11 B-Chemical
antagonizes	1380 11 O
the	1392 3 O
pressor	1396 7 O
effect	1404 6 O
of	1411 2 O
PPA	1414 3 B-Chemical
is	1418 2 O
in	1421 2 O
contrast	1424 8 O
to	1433 2 O
the	1436 3 O
interaction	1440 11 O
in	1452 2 O
which	1455 5 O
propranolol	1461 11 B-Chemical
enhances	1473 8 O
the	1482 3 O
pressor	1486 7 O
effect	1494 6 O
of	1501 2 O
norepinephrine	1504 14 B-Chemical
.	1518 1 O

This	1520 4 O
is	1525 2 O
probably	1528 8 O
because	1537 7 O
PPA	1545 3 B-Chemical
has	1549 3 O
less	1553 4 O
beta	1558 4 O
2	1563 1 O
activity	1565 8 O
than	1574 4 O
does	1579 4 O
norepinephrine	1584 14 B-Chemical
.	1598 1 O

Mesangial	0 9 O
function	10 8 O
and	19 3 O
glomerular	23 10 B-Disease
sclerosis	34 9 I-Disease
in	44 2 O
rats	47 4 O
with	52 4 O
aminonucleoside	57 15 B-Chemical
nephrosis	73 9 B-Disease
.	82 1 O

The	84 3 O
possible	88 8 O
relationship	97 12 O
between	110 7 O
mesangial	118 9 B-Disease
dysfunction	128 11 I-Disease
and	140 3 O
development	144 11 O
of	156 2 O
glomerular	159 10 B-Disease
sclerosis	170 9 I-Disease
was	180 3 O
studied	184 7 O
in	192 2 O
the	195 3 O
puromycin	199 9 B-Chemical
aminonucleoside	209 15 I-Chemical
(	225 1 O
PAN	226 3 B-Chemical
)	229 1 O
model	231 5 O
.	236 1 O

Five	238 4 O
male	243 4 O
Wistar	248 6 O
rats	255 4 O
received	260 8 O
repeated	269 8 O
subcutaneous	278 12 O
PAN	291 3 B-Chemical
injections	295 10 O
;	305 1 O
five	307 4 O
controls	312 8 O
received	321 8 O
saline	330 6 O
only	337 4 O
.	341 1 O

After	343 5 O
4	349 1 O
weeks	351 5 O
the	357 3 O
PAN	361 3 B-Chemical
rats	365 4 O
were	370 4 O
severely	375 8 O
proteinuric	384 11 B-Disease
(	396 1 O
190	397 3 O
+	401 1 O
/	402 1 O
-	403 1 O
80	405 2 O
mg	408 2 O
/	410 1 O
24	411 2 O
hr	414 2 O
)	416 1 O
,	417 1 O
and	419 3 O
all	423 3 O
rats	427 4 O
were	432 4 O
given	437 5 O
colloidal	443 9 O
carbon	453 6 B-Chemical
(	460 1 O
CC	461 2 O
)	463 1 O
intravenously	465 13 O
.	478 1 O

At	480 2 O
5	483 1 O
months	485 6 O
glomerular	492 10 B-Disease
sclerosis	503 9 I-Disease
was	513 3 O
found	517 5 O
in	523 2 O
7	526 1 O
.	527 1 O
6	528 1 O
+	530 1 O
/	531 1 O
-	532 1 O
3	534 1 O
.	535 1 O
4	536 1 O
%	537 1 O
of	539 2 O
the	542 3 O
glomeruli	546 9 O
of	556 2 O
PAN	559 3 B-Chemical
rats	563 4 O
;	567 1 O
glomeruli	569 9 O
of	579 2 O
the	582 3 O
controls	586 8 O
were	595 4 O
normal	600 6 O
.	606 1 O

Glomeruli	608 9 O
of	618 2 O
PAN	621 3 B-Chemical
rats	625 4 O
contained	630 9 O
significantly	640 13 O
more	654 4 O
CC	659 2 O
than	662 4 O
glomeruli	667 9 O
of	677 2 O
controls	680 8 O
.	688 1 O

Glomeruli	690 9 O
with	700 4 O
sclerosis	705 9 B-Disease
contained	715 9 O
significantly	725 13 O
more	739 4 O
CC	744 2 O
than	747 4 O
non	752 3 O
-	755 1 O
sclerotic	756 9 O
glomeruli	766 9 O
in	776 2 O
the	779 3 O
same	783 4 O
kidneys	788 7 O
.	795 1 O

CC	797 2 O
was	800 3 O
preferentially	804 14 O
localized	819 9 O
within	829 6 O
the	836 3 O
sclerotic	840 9 O
areas	850 5 O
of	856 2 O
the	859 3 O
affected	863 8 O
glomeruli	872 9 O
.	881 1 O

Since	883 5 O
mesangial	889 9 O
CC	899 2 O
clearance	902 9 O
from	912 4 O
the	917 3 O
mesangium	921 9 O
did	931 3 O
not	935 3 O
change	939 6 O
during	946 6 O
chronic	953 7 O
PAN	961 3 B-Chemical
treatment	965 9 O
,	974 1 O
we	976 2 O
conclude	979 8 O
that	988 4 O
this	993 4 O
preferential	998 12 O
CC	1011 2 O
localization	1014 12 O
within	1027 6 O
the	1034 3 O
lesions	1038 7 O
is	1046 2 O
caused	1049 6 O
by	1056 2 O
an	1059 2 O
increased	1062 9 O
CC	1072 2 O
uptake	1075 6 O
shortly	1082 7 O
after	1090 5 O
injection	1096 9 O
in	1106 2 O
apparent	1109 8 O
vulnerable	1118 10 O
areas	1129 5 O
where	1135 5 O
sclerosis	1141 9 B-Disease
will	1151 4 O
develop	1156 7 O
subsequently	1164 12 O
.	1176 1 O

Cluster	1178 7 O
analysis	1186 8 O
showed	1195 6 O
a	1202 1 O
random	1204 6 O
distribution	1211 12 O
of	1224 2 O
lesions	1227 7 O
in	1235 2 O
the	1238 3 O
PAN	1242 3 B-Chemical
glomeruli	1246 9 O
in	1256 2 O
concordance	1259 11 O
with	1271 4 O
the	1276 3 O
random	1280 6 O
localization	1287 12 O
of	1300 2 O
mesangial	1303 9 O
areas	1313 5 O
with	1319 4 O
dysfunction	1324 11 O
in	1336 2 O
this	1339 4 O
model	1344 5 O
.	1349 1 O

Similar	1351 7 O
to	1359 2 O
the	1362 3 O
remnant	1366 7 O
kidney	1374 6 O
model	1381 5 O
in	1387 2 O
PAN	1390 3 B-Chemical
nephrosis	1394 9 B-Disease
the	1404 3 O
development	1408 11 O
of	1420 2 O
glomerular	1423 10 B-Disease
sclerosis	1434 9 I-Disease
may	1444 3 O
be	1448 2 O
related	1451 7 O
to	1459 2 O
"	1462 1 O
mesangial	1463 9 O
overloading	1473 11 O
.	1484 1 O
"	1485 1 O

Relationship	0 12 O
between	13 7 O
nicotine	21 8 B-Chemical
-	29 1 O
induced	30 7 O
seizures	38 8 B-Disease
and	47 3 O
hippocampal	51 11 O
nicotinic	63 9 O
receptors	73 9 O
.	82 1 O

A	84 1 O
controversy	86 11 O
has	98 3 O
existed	102 7 O
for	110 3 O
several	114 7 O
years	122 5 O
concerning	128 10 O
the	139 3 O
physiological	143 13 O
relevance	157 9 O
of	167 2 O
the	170 3 O
nicotinic	174 9 O
receptor	184 8 O
measured	193 8 O
by	202 2 O
alpha	205 5 O
-	210 1 O
bungarotoxin	211 12 O
binding	224 7 O
.	231 1 O

Using	233 5 O
mice	239 4 O
derived	244 7 O
from	252 4 O
a	257 1 O
classical	259 9 O
F2	269 2 O
and	272 3 O
backcross	276 9 O
genetic	286 7 O
design	294 6 O
,	300 1 O
a	302 1 O
relationship	304 12 O
between	317 7 O
nicotine	325 8 B-Chemical
-	333 1 O
induced	334 7 O
seizures	342 8 B-Disease
and	351 3 O
alpha	355 5 O
-	360 1 O
bungarotoxin	361 12 O
nicotinic	374 9 O
receptor	384 8 O
concentration	393 13 O
was	407 3 O
found	411 5 O
.	416 1 O

Mice	418 4 O
sensitive	423 9 O
to	433 2 O
the	436 3 O
convulsant	440 10 O
effects	451 7 O
of	459 2 O
nicotine	462 8 B-Chemical
had	471 3 O
greater	475 7 O
alpha	483 5 O
-	488 1 O
bungarotoxin	489 12 O
binding	502 7 O
in	510 2 O
the	513 3 O
hippocampus	517 11 O
than	529 4 O
seizure	534 7 B-Disease
insensitive	542 11 O
mice	554 4 O
.	558 1 O

The	560 3 O
binding	564 7 O
sites	572 5 O
from	578 4 O
seizure	583 7 B-Disease
sensitive	591 9 O
and	601 3 O
resistant	605 9 O
mice	615 4 O
were	620 4 O
equally	625 7 O
affected	633 8 O
by	642 2 O
treatment	645 9 O
with	655 4 O
dithiothreitol	660 14 B-Chemical
,	674 1 O
trypsin	676 7 O
or	684 2 O
heat	687 4 O
.	691 1 O

Thus	693 4 O
it	698 2 O
appears	701 7 O
that	709 4 O
the	714 3 O
difference	718 10 O
between	729 7 O
seizure	737 7 B-Disease
sensitive	745 9 O
and	755 3 O
insensitive	759 11 O
animals	771 7 O
may	779 3 O
be	783 2 O
due	786 3 O
to	790 2 O
a	793 1 O
difference	795 10 O
in	806 2 O
hippocampal	809 11 O
nicotinic	821 9 O
receptor	831 8 O
concentration	840 13 O
as	854 2 O
measured	857 8 O
with	866 4 O
alpha	871 5 O
-	876 1 O
bungarotoxin	877 12 O
binding	890 7 O
.	897 1 O

The	0 3 O
role	4 4 O
of	9 2 O
p	12 1 B-Chemical
-	13 1 I-Chemical
aminophenol	14 11 I-Chemical
in	26 2 O
acetaminophen	29 13 B-Chemical
-	42 1 O
induced	43 7 O
nephrotoxicity	51 14 B-Disease
:	65 1 O
effect	67 6 O
of	74 2 O
bis	77 3 B-Chemical
(	80 1 I-Chemical
p	81 1 I-Chemical
-	82 1 I-Chemical
nitrophenyl	83 11 I-Chemical
)	94 1 I-Chemical
phosphate	96 9 I-Chemical
on	106 2 O
acetaminophen	109 13 B-Chemical
and	123 3 O
p	127 1 B-Chemical
-	128 1 I-Chemical
aminophenol	129 11 I-Chemical
nephrotoxicity	141 14 B-Disease
and	156 3 O
metabolism	160 10 O
in	171 2 O
Fischer	174 7 O
344	182 3 O
rats	186 4 O
.	190 1 O

Acetaminophen	192 13 B-Chemical
(	206 1 O
APAP	207 4 B-Chemical
)	211 1 O
produces	213 8 O
proximal	222 8 O
tubular	231 7 B-Disease
necrosis	239 8 I-Disease
in	248 2 O
Fischer	251 7 O
344	259 3 O
(	263 1 O
F344	264 4 O
)	268 1 O
rats	270 4 O
.	274 1 O

Recently	276 8 O
,	284 1 O
p	286 1 B-Chemical
-	287 1 I-Chemical
aminophenol	288 11 I-Chemical
(	300 1 O
PAP	301 3 B-Chemical
)	304 1 O
,	305 1 O
a	307 1 O
known	309 5 O
potent	315 6 O
nephrotoxicant	322 14 O
,	336 1 O
was	338 3 O
identified	342 10 O
as	353 2 O
a	356 1 O
metabolite	358 10 O
of	369 2 O
APAP	372 4 B-Chemical
in	377 2 O
F344	380 4 O
rats	385 4 O
.	389 1 O

The	391 3 O
purpose	395 7 O
of	403 2 O
this	406 4 O
study	411 5 O
was	417 3 O
to	421 2 O
determine	424 9 O
if	434 2 O
PAP	437 3 B-Chemical
formation	441 9 O
is	451 2 O
a	454 1 O
requisite	456 9 O
step	466 4 O
in	471 2 O
APAP	474 4 B-Chemical
-	478 1 O
induced	479 7 O
nephrotoxicity	487 14 B-Disease
.	501 1 O

Therefore	503 9 O
,	512 1 O
the	514 3 O
effect	518 6 O
of	525 2 O
bis	528 3 B-Chemical
(	531 1 I-Chemical
p	532 1 I-Chemical
-	533 1 I-Chemical
nitrophenyl	534 11 I-Chemical
)	545 1 I-Chemical
phosphate	547 9 I-Chemical
(	557 1 O
BNPP	558 4 B-Chemical
)	562 1 O
,	563 1 O
an	565 2 O
acylamidase	568 11 O
inhibitor	580 9 O
,	589 1 O
on	591 2 O
APAP	594 4 B-Chemical
and	599 3 O
PAP	603 3 B-Chemical
nephrotoxicity	607 14 B-Disease
and	622 3 O
metabolism	626 10 O
was	637 3 O
determined	641 10 O
.	651 1 O

BNPP	653 4 B-Chemical
(	658 1 O
1	659 1 O
to	661 2 O
8	664 1 O
mM	666 2 O
)	668 1 O
reduced	670 7 O
APAP	678 4 B-Chemical
deacetylation	683 13 O
and	697 3 O
covalent	701 8 O
binding	710 7 O
in	718 2 O
F344	721 4 O
renal	726 5 O
cortical	732 8 O
homogenates	741 11 O
in	753 2 O
a	756 1 O
concentration	758 13 O
-	771 1 O
dependent	772 9 O
manner	782 6 O
.	788 1 O

Pretreatment	790 12 O
of	803 2 O
animals	806 7 O
with	814 4 O
BNPP	819 4 B-Chemical
prior	824 5 O
to	830 2 O
APAP	833 4 B-Chemical
or	838 2 O
PAP	841 3 B-Chemical
administration	845 14 O
resulted	860 8 O
in	869 2 O
marked	872 6 O
reduction	879 9 O
of	889 2 O
APAP	892 4 B-Chemical
(	897 1 O
900	898 3 O
mg	902 2 O
/	904 1 O
kg	905 2 O
)	907 1 O
nephrotoxicity	909 14 B-Disease
but	924 3 O
not	928 3 O
PAP	932 3 B-Chemical
nephrotoxicity	936 14 B-Disease
.	950 1 O

This	952 4 O
result	957 6 O
was	964 3 O
not	968 3 O
due	972 3 O
to	976 2 O
altered	979 7 O
disposition	987 11 O
of	999 2 O
either	1002 6 O
APAP	1009 4 B-Chemical
or	1014 2 O
acetylated	1017 10 O
metabolites	1028 11 O
in	1040 2 O
plasma	1043 6 O
or	1050 2 O
renal	1053 5 O
cortical	1059 8 O
and	1068 3 O
hepatic	1072 7 O
tissue	1080 6 O
.	1086 1 O

Rather	1088 6 O
,	1094 1 O
BNPP	1096 4 B-Chemical
pretreatment	1101 12 O
reduced	1114 7 O
the	1122 3 O
fraction	1126 8 O
of	1135 2 O
APAP	1138 4 B-Chemical
excreted	1143 8 O
as	1152 2 O
PAP	1155 3 B-Chemical
by	1159 2 O
64	1162 2 O
and	1165 3 O
75	1169 2 O
%	1171 1 O
after	1173 5 O
APAP	1179 4 B-Chemical
doses	1184 5 O
of	1190 2 O
750	1193 3 O
and	1197 3 O
900	1201 3 O
mg	1205 2 O
/	1207 1 O
kg	1208 2 O
.	1210 1 O

BNPP	1212 4 B-Chemical
did	1217 3 O
not	1221 3 O
alter	1225 5 O
the	1231 3 O
excretion	1235 9 O
of	1245 2 O
APAP	1248 4 B-Chemical
or	1253 2 O
any	1256 3 O
of	1260 2 O
its	1263 3 O
non	1267 3 O
-	1270 1 O
deacetylated	1271 12 O
metabolites	1284 11 O
nor	1296 3 O
did	1300 3 O
BNPP	1304 4 B-Chemical
alter	1309 5 O
excretion	1315 9 O
of	1325 2 O
PAP	1328 3 B-Chemical
or	1332 2 O
its	1335 3 O
metabolites	1339 11 O
after	1351 5 O
PAP	1357 3 B-Chemical
doses	1361 5 O
of	1367 2 O
150	1370 3 O
and	1374 3 O
300	1378 3 O
mg	1382 2 O
/	1384 1 O
kg	1385 2 O
.	1387 1 O

Therefore	1389 9 O
,	1398 1 O
the	1400 3 O
BNPP	1404 4 B-Chemical
-	1408 1 O
induced	1409 7 O
reduction	1417 9 O
in	1427 2 O
APAP	1430 4 B-Chemical
-	1434 1 O
induced	1435 7 O
nephrotoxicity	1443 14 B-Disease
appears	1458 7 O
to	1466 2 O
be	1469 2 O
due	1472 3 O
to	1476 2 O
inhibition	1479 10 O
of	1490 2 O
APAP	1493 4 B-Chemical
deacetylation	1498 13 O
.	1511 1 O

It	1513 2 O
is	1516 2 O
concluded	1519 9 O
that	1529 4 O
PAP	1534 3 B-Chemical
formation	1538 9 O
,	1547 1 O
in	1549 2 O
vivo	1552 4 O
,	1556 1 O
accounts	1558 8 O
,	1566 1 O
at	1568 2 O
least	1571 5 O
in	1577 2 O
part	1580 4 O
,	1584 1 O
for	1586 3 O
APAP	1590 4 B-Chemical
-	1594 1 O
induced	1595 7 O
renal	1603 5 B-Disease
tubular	1609 7 I-Disease
necrosis	1617 8 I-Disease
.	1625 1 O

Morphine	0 8 B-Chemical
-	8 1 O
induced	9 7 O
seizures	17 8 B-Disease
in	26 2 O
newborn	29 7 O
infants	37 7 O
.	44 1 O

Two	46 3 O
neonates	50 8 O
suffered	59 8 O
from	68 4 O
generalized	73 11 O
seizures	85 8 B-Disease
during	94 6 O
the	101 3 O
course	105 6 O
of	112 2 O
intravenous	115 11 O
morphine	127 8 B-Chemical
sulfate	136 7 I-Chemical
for	144 3 O
post	148 4 O
-	152 1 O
operative	153 9 O
analgesia	163 9 O
.	172 1 O

They	174 4 O
received	179 8 O
morphine	188 8 B-Chemical
in	197 2 O
doses	200 5 O
of	206 2 O
32	209 2 O
micrograms	212 10 O
/	222 1 O
kg	223 2 O
/	225 1 O
hr	226 2 O
and	229 3 O
40	233 2 O
micrograms	236 10 O
/	246 1 O
kg	247 2 O
/	249 1 O
hr	250 2 O
larger	253 6 O
than	260 4 O
a	265 1 O
group	267 5 O
of	273 2 O
10	276 2 O
neonates	279 8 O
who	288 3 O
received	292 8 O
6	301 1 O
-	302 1 O
24	303 2 O
micrograms	306 10 O
/	316 1 O
kg	317 2 O
/	319 1 O
hr	320 2 O
and	323 3 O
had	327 3 O
no	331 2 O
seizures	334 8 B-Disease
.	342 1 O

Plasma	344 6 O
concentrations	351 14 O
of	366 2 O
morphine	369 8 B-Chemical
in	378 2 O
these	381 5 O
neonates	387 8 O
was	396 3 O
excessive	400 9 O
(	410 1 O
60	411 2 O
and	414 3 O
90	418 2 O
mg	421 2 O
/	423 1 O
ml	424 2 O
)	426 1 O
.	427 1 O

Other	429 5 O
known	435 5 O
reasons	441 7 O
for	449 3 O
seizures	453 8 B-Disease
were	462 4 O
ruled	467 5 O
out	473 3 O
and	477 3 O
the	481 3 O
convulsions	485 11 B-Disease
stopped	497 7 O
a	505 1 O
few	507 3 O
hours	511 5 O
after	517 5 O
cessation	523 9 O
of	533 2 O
morphine	536 8 B-Chemical
and	545 3 O
did	549 3 O
not	553 3 O
reoccur	557 7 O
in	565 2 O
the	568 3 O
subsequent	572 10 O
8	583 1 O
months	585 6 O
.	591 1 O

It	593 2 O
is	596 2 O
suggested	599 9 O
that	609 4 O
post	614 4 O
-	618 1 O
operative	619 9 O
intravenous	629 11 O
morphine	641 8 B-Chemical
should	650 6 O
not	657 3 O
exceed	661 6 O
20	668 2 O
micrograms	671 10 O
/	681 1 O
kg	682 2 O
/	684 1 O
ml	685 2 O
in	688 2 O
neonates	691 8 O
.	699 1 O

Effect	0 6 O
of	7 2 O
vincristine	10 11 B-Chemical
sulfate	22 7 I-Chemical
on	30 2 O
Pseudomonas	33 11 B-Disease
infections	45 10 I-Disease
in	56 2 O
monkeys	59 7 O
.	66 1 O

In	68 2 O
rhesus	71 6 O
monkeys	78 7 O
,	85 1 O
intravenous	87 11 O
challenge	99 9 O
with	109 4 O
0	114 1 O
.	115 1 O
6	116 1 O
x	118 1 O
10	120 2 O
(	122 1 O
10	123 2 O
)	125 1 O
to	127 2 O
2	130 1 O
.	131 1 O
2	132 1 O
x	134 1 O
10	136 2 O
(	138 1 O
10	139 2 O
)	141 1 O
Pseudomonas	142 11 O
aeruginosa	154 10 O
organisms	165 9 O
caused	175 6 O
acute	182 5 O
illness	188 7 O
of	196 2 O
4	199 1 O
to	201 2 O
5	204 1 O
days	206 4 O
'	210 1 O
duration	212 8 O
with	221 4 O
spontaneous	226 11 O
recovery	238 8 O
in	247 2 O
13	250 2 O
of	253 2 O
15	256 2 O
monkeys	259 7 O
;	266 1 O
blood	268 5 O
cultures	274 8 O
became	283 6 O
negative	290 8 O
3	299 1 O
to	301 2 O
17	304 2 O
days	307 4 O
after	312 5 O
challenge	318 9 O
.	327 1 O

Leukocytosis	329 12 B-Disease
was	342 3 O
observed	346 8 O
in	355 2 O
all	358 3 O
monkeys	362 7 O
.	369 1 O

Intravenous	371 11 O
or	383 2 O
intratracheal	386 13 O
inoculation	400 11 O
of	412 2 O
2	415 1 O
.	416 1 O
0	417 1 O
to	419 2 O
2	422 1 O
.	423 1 O
5	424 1 O
mg	426 2 O
of	429 2 O
vincristine	432 11 B-Chemical
sulfate	444 7 I-Chemical
was	452 3 O
followed	456 8 O
by	465 2 O
leukopenia	468 10 B-Disease
in	479 2 O
4	482 1 O
to	484 2 O
5	487 1 O
days	489 4 O
.	493 1 O

Intravenous	495 11 O
inoculation	507 11 O
of	519 2 O
4	522 1 O
.	523 1 O
2	524 1 O
x	526 1 O
10	528 2 O
(	530 1 O
10	531 2 O
)	533 1 O
to	535 2 O
7	538 1 O
.	539 1 O
8	540 1 O
x	542 1 O
10	544 2 O
(	546 1 O
10	547 2 O
)	549 1 O
pyocin	551 6 O
type	558 4 O
6	563 1 O
Pseudomonas	565 11 O
organisms	577 9 O
in	587 2 O
monkeys	590 7 O
given	598 5 O
vincristine	604 11 B-Chemical
sulfate	616 7 I-Chemical
4	624 1 O
days	626 4 O
previously	631 10 O
resulted	642 8 O
in	651 2 O
fatal	654 5 O
infection	660 9 B-Disease
in	670 2 O
11	673 2 O
of	676 2 O
14	679 2 O
monkeys	682 7 O
,	689 1 O
whereas	691 7 O
none	699 4 O
of	704 2 O
four	707 4 O
receiving	712 9 O
Pseudomonas	722 11 O
alone	734 5 O
died	740 4 O
.	744 1 O

These	746 5 O
studies	752 7 O
suggest	760 7 O
that	768 4 O
an	773 2 O
antimetabolite	776 14 O
-	790 1 O
induced	791 7 O
leukopenia	799 10 B-Disease
predisposes	810 11 O
to	822 2 O
severe	825 6 O
Pseudomonas	832 11 O
sepsis	844 6 B-Disease
and	851 3 O
that	855 4 O
such	860 4 O
monkeys	865 7 O
may	873 3 O
serve	877 5 O
as	883 2 O
a	886 1 O
biological	888 10 O
model	899 5 O
for	905 3 O
study	909 5 O
of	915 2 O
comparative	918 11 O
efficacy	930 8 O
of	939 2 O
antimicrobial	942 13 O
agents	956 6 O
.	962 1 O

Central	0 7 O
excitatory	8 10 O
actions	19 7 O
of	27 2 O
flurazepam	30 10 B-Chemical
.	40 1 O

Toxic	42 5 O
actions	48 7 O
of	56 2 O
flurazepam	59 10 B-Chemical
(	70 1 O
FZP	71 3 B-Chemical
)	74 1 O
were	76 4 O
studied	81 7 O
in	89 2 O
cats	92 4 O
,	96 1 O
mice	98 4 O
and	103 3 O
rats	107 4 O
.	111 1 O

High	113 4 O
doses	118 5 O
caused	124 6 O
an	131 2 O
apparent	134 8 O
central	143 7 O
excitation	151 10 O
,	161 1 O
most	163 4 O
clearly	168 7 O
seen	176 4 O
as	181 2 O
clonic	184 6 O
convulsions	191 11 B-Disease
,	202 1 O
superimposed	204 12 O
on	217 2 O
general	220 7 O
depression	228 10 B-Disease
.	238 1 O

Following	240 9 O
a	250 1 O
lethal	252 6 O
dose	259 4 O
,	263 1 O
death	265 5 O
was	271 3 O
always	275 6 O
associated	282 10 O
with	293 4 O
convulsions	298 11 B-Disease
.	309 1 O

Comparing	311 9 O
the	321 3 O
relative	325 8 O
sensitivity	334 11 O
to	346 2 O
central	349 7 O
depression	357 10 B-Disease
and	368 3 O
excitation	372 10 O
revealed	383 8 O
that	392 4 O
rats	397 4 O
were	402 4 O
least	407 5 O
likely	413 6 O
to	420 2 O
have	423 4 O
convulsions	428 11 B-Disease
at	440 2 O
doses	443 5 O
that	449 4 O
did	454 3 O
not	458 3 O
first	462 5 O
cause	468 5 O
loss	474 4 B-Disease
of	479 2 I-Disease
consciousness	482 13 I-Disease
,	495 1 O
while	497 5 O
cats	503 4 O
most	508 4 O
clearly	513 7 O
showed	521 6 O
marked	528 6 O
central	535 7 O
excitatory	543 10 O
actions	554 7 O
.	561 1 O

Signs	563 5 O
of	569 2 O
FZP	572 3 B-Chemical
toxocity	576 8 B-Disease
in	585 2 O
cats	588 4 O
included	593 8 O
excessive	602 9 O
salivation	612 10 B-Disease
,	622 1 O
extreme	624 7 O
apprehensive	632 12 O
behavior	645 8 O
,	653 1 O
retching	655 8 O
,	663 1 O
muscle	665 6 B-Disease
tremors	672 7 I-Disease
and	680 3 O
convulsions	684 11 B-Disease
.	695 1 O

An	697 2 O
interaction	700 11 O
between	712 7 O
FZP	720 3 B-Chemical
and	724 3 O
pentylenetetrazol	728 17 B-Chemical
(	746 1 O
PTZ	747 3 B-Chemical
)	750 1 O
was	752 3 O
shown	756 5 O
by	762 2 O
pretreating	765 11 O
mice	777 4 O
with	782 4 O
FZP	787 3 B-Chemical
before	791 6 O
PTZ	798 3 B-Chemical
challenge	802 9 O
.	811 1 O

As	813 2 O
a	816 1 O
function	818 8 O
of	827 2 O
dose	830 4 O
,	834 1 O
FZP	836 3 B-Chemical
first	840 5 O
protected	846 9 O
against	856 7 O
convulsions	864 11 B-Disease
and	876 3 O
death	880 5 O
.	885 1 O

At	887 2 O
higher	890 6 O
doses	897 5 O
,	902 1 O
however	904 7 O
,	911 1 O
convulsions	913 11 B-Disease
again	925 5 O
emerged	931 7 O
.	938 1 O

These	940 5 O
doses	946 5 O
of	952 2 O
FZP	955 3 B-Chemical
were	959 4 O
lower	964 5 O
than	970 4 O
those	975 5 O
that	981 4 O
would	986 5 O
alone	992 5 O
cause	998 5 O
convulsions	1004 11 B-Disease
.	1015 1 O

These	1017 5 O
results	1023 7 O
may	1031 3 O
be	1035 2 O
relevant	1038 8 O
to	1047 2 O
the	1050 3 O
use	1054 3 O
of	1058 2 O
FZP	1061 3 B-Chemical
in	1065 2 O
clinical	1068 8 O
situations	1077 10 O
in	1088 2 O
which	1091 5 O
there	1097 5 O
is	1103 2 O
increased	1106 9 O
neural	1116 6 O
excitability	1123 12 O
,	1135 1 O
such	1137 4 O
as	1142 2 O
epilepsy	1145 8 B-Disease
or	1154 2 O
sedative	1157 8 O
-	1165 1 O
hypnotic	1166 8 O
drug	1175 4 O
withdrawal	1180 10 O
.	1190 1 O

Evidence	0 8 O
for	9 3 O
cardiac	13 7 O
beta	21 4 O
2	26 1 O
-	27 1 O
adrenoceptors	28 13 O
in	42 2 O
man	45 3 O
.	48 1 O

We	50 2 O
compared	53 8 O
the	62 3 O
effects	66 7 O
of	74 2 O
single	77 6 O
doses	84 5 O
of	90 2 O
50	93 2 O
mg	96 2 O
atenolol	99 8 B-Chemical
(	108 1 O
cardioselective	109 15 O
)	124 1 O
,	125 1 O
40	127 2 O
mg	130 2 O
propranolol	133 11 B-Chemical
(	145 1 O
nonselective	146 12 O
)	158 1 O
,	159 1 O
and	161 3 O
placebo	165 7 O
on	173 2 O
both	176 4 O
exercise	181 8 O
-	189 1 O
and	191 3 O
isoproterenol	195 13 B-Chemical
-	208 1 O
induced	209 7 O
tachycardia	217 11 B-Disease
in	229 2 O
two	232 3 O
experiments	236 11 O
involving	248 9 O
nine	258 4 O
normal	263 6 O
subjects	270 8 O
.	278 1 O

Maximal	280 7 O
exercise	288 8 O
heart	297 5 O
rate	303 4 O
was	308 3 O
reduced	312 7 O
from	320 4 O
187	325 3 O
+	329 1 O
/	330 1 O
-	331 1 O
4	333 1 O
(	334 1 O
SEM	335 3 O
)	338 1 O
after	340 5 O
placebo	346 7 O
to	354 2 O
146	357 3 O
+	361 1 O
/	362 1 O
-	363 1 O
7	365 1 O
bpm	367 3 O
after	371 5 O
atenolol	377 8 B-Chemical
and	386 3 O
138	390 3 O
+	394 1 O
/	395 1 O
-	396 1 O
6	398 1 O
bpm	400 3 O
after	404 5 O
propranolol	410 11 B-Chemical
,	421 1 O
but	423 3 O
there	427 5 O
were	433 4 O
no	438 2 O
differences	441 11 O
between	453 7 O
the	461 3 O
drugs	465 5 O
.	470 1 O

The	472 3 O
effects	476 7 O
on	484 2 O
isoproterenol	487 13 B-Chemical
tachycardia	501 11 B-Disease
were	513 4 O
determined	518 10 O
before	529 6 O
and	536 3 O
after	540 5 O
atropine	546 8 B-Chemical
(	555 1 O
0	556 1 O
.	557 1 O
04	558 2 O
mg	561 2 O
/	563 1 O
kg	564 2 O
IV	567 2 O
)	569 1 O
.	570 1 O

Isoproterenol	572 13 B-Chemical
sensitivity	586 11 O
was	598 3 O
determined	602 10 O
as	613 2 O
the	616 3 O
intravenous	620 11 O
dose	632 4 O
that	637 4 O
increased	642 9 O
heart	652 5 O
rate	658 4 O
by	663 2 O
25	666 2 O
bpm	669 3 O
(	673 1 O
CD25	674 4 O
)	678 1 O
and	680 3 O
this	684 4 O
was	689 3 O
increased	693 9 O
from	703 4 O
1	708 1 O
.	709 1 O
8	710 1 O
+	712 1 O
/	713 1 O
-	714 1 O
0	716 1 O
.	717 1 O
3	718 1 O
micrograms	720 10 O
after	731 5 O
placebo	737 7 O
to	745 2 O
38	748 2 O
.	750 1 O
9	751 1 O
+	753 1 O
/	754 1 O
-	755 1 O
8	757 1 O
.	758 1 O
3	759 1 O
micrograms	761 10 O
after	772 5 O
propranolol	778 11 B-Chemical
and	790 3 O
8	794 1 O
.	795 1 O
3	796 1 O
+	798 1 O
/	799 1 O
-	800 1 O
1	802 1 O
.	803 1 O
7	804 1 O
micrograms	806 10 O
after	817 5 O
atenolol	823 8 B-Chemical
.	831 1 O

The	833 3 O
difference	837 10 O
in	848 2 O
the	851 3 O
effects	855 7 O
of	863 2 O
the	866 3 O
two	870 3 O
was	874 3 O
significant	878 11 O
.	889 1 O

After	891 5 O
atropine	897 8 B-Chemical
the	906 3 O
CD25	910 4 O
was	915 3 O
unchanged	919 9 O
after	929 5 O
placebo	935 7 O
(	943 1 O
2	944 1 O
.	945 1 O
3	946 1 O
+	948 1 O
/	949 1 O
-	950 1 O
0	952 1 O
.	953 1 O
3	954 1 O
micrograms	956 10 O
)	966 1 O
and	968 3 O
atenolol	972 8 B-Chemical
(	981 1 O
7	982 1 O
.	983 1 O
7	984 1 O
+	986 1 O
/	987 1 O
-	988 1 O
1	990 1 O
.	991 1 O
3	992 1 O
micrograms	994 10 O
)	1004 1 O
;	1005 1 O
it	1007 2 O
was	1010 3 O
reduced	1014 7 O
after	1022 5 O
propranolol	1028 11 B-Chemical
(	1040 1 O
24	1041 2 O
.	1043 1 O
8	1044 1 O
+	1046 1 O
/	1047 1 O
-	1048 1 O
5	1050 1 O
.	1051 1 O
0	1052 1 O
micrograms	1054 10 O
)	1064 1 O
,	1065 1 O
but	1067 3 O
remained	1071 8 O
different	1080 9 O
from	1090 4 O
atenolol	1095 8 B-Chemical
.	1103 1 O

This	1105 4 O
change	1110 6 O
with	1117 4 O
propranolol	1122 11 B-Chemical
sensitivity	1134 11 O
was	1146 3 O
calculated	1150 10 O
as	1161 2 O
the	1164 3 O
apparent	1168 8 O
Ka	1177 2 O
,	1179 1 O
this	1181 4 O
was	1186 3 O
unchanged	1190 9 O
by	1200 2 O
atropine	1203 8 B-Chemical
(	1212 1 O
11	1213 2 O
.	1215 1 O
7	1216 1 O
+	1218 1 O
/	1219 1 O
-	1220 1 O
2	1222 1 O
.	1223 1 O
1	1224 1 O
and	1226 3 O
10	1230 2 O
.	1232 1 O
1	1233 1 O
+	1235 1 O
/	1236 1 O
-	1237 1 O
2	1239 1 O
.	1240 1 O
5	1241 1 O
ml	1243 2 O
/	1245 1 O
ng	1246 2 O
)	1248 1 O
.	1249 1 O

These	1251 5 O
data	1257 4 O
are	1262 3 O
consistent	1266 10 O
with	1277 4 O
the	1282 3 O
hypothesis	1286 10 O
that	1297 4 O
exercise	1302 8 O
-	1310 1 O
induced	1311 7 O
tachycardia	1319 11 B-Disease
results	1331 7 O
largely	1339 7 O
from	1347 4 O
beta	1352 4 O
1	1357 1 O
-	1358 1 O
receptor	1359 8 O
activation	1368 10 O
that	1379 4 O
is	1384 2 O
blocked	1387 7 O
by	1395 2 O
both	1398 4 O
cardioselective	1403 15 O
and	1419 3 O
nonselective	1423 12 O
drugs	1436 5 O
,	1441 1 O
whereas	1443 7 O
isoproterenol	1451 13 B-Chemical
activates	1465 9 O
both	1475 4 O
beta	1480 4 O
1	1485 1 O
-	1486 1 O
and	1488 3 O
beta	1492 4 O
2	1497 1 O
-	1498 1 O
receptors	1499 9 O
so	1509 2 O
that	1512 4 O
after	1517 5 O
cardioselective	1523 15 O
blockade	1539 8 O
there	1548 5 O
remains	1554 7 O
a	1562 1 O
beta	1564 4 O
2	1569 1 O
-	1570 1 O
component	1571 9 O
that	1581 4 O
can	1586 3 O
be	1590 2 O
blocked	1593 7 O
with	1601 4 O
a	1606 1 O
nonselective	1608 12 O
drug	1621 4 O
.	1625 1 O

While	1627 5 O
there	1633 5 O
appear	1639 6 O
to	1646 2 O
be	1649 2 O
beta	1652 4 O
2	1657 1 O
-	1658 1 O
receptors	1659 9 O
in	1669 2 O
the	1672 3 O
human	1676 5 O
heart	1682 5 O
,	1687 1 O
their	1689 5 O
physiologic	1695 11 O
or	1707 2 O
pathologic	1710 10 O
roles	1721 5 O
remain	1727 6 O
to	1734 2 O
be	1737 2 O
defined	1740 7 O
.	1747 1 O

Hormones	0 8 O
and	9 3 O
risk	13 4 O
of	18 2 O
breast	21 6 B-Disease
cancer	28 6 I-Disease
.	34 1 O

This	36 4 O
paper	41 5 O
reports	47 7 O
the	55 3 O
results	59 7 O
of	67 2 O
a	70 1 O
study	72 5 O
of	78 2 O
50	81 2 O
menopausal	84 10 O
women	95 5 O
receiving	101 9 O
hormonal	111 8 O
replacement	120 11 O
therapy	132 7 O
.	139 1 O

The	141 3 O
majority	145 8 O
(	154 1 O
29	155 2 O
)	157 1 O
had	159 3 O
surgical	163 8 O
menopause	172 9 O
;	181 1 O
their	183 5 O
mean	189 4 O
age	194 3 O
was	198 3 O
45	202 2 O
.	204 1 O
7	205 1 O
years	207 5 O
.	212 1 O

It	214 2 O
was	217 3 O
hypothesized	221 12 O
that	234 4 O
progestins	239 10 B-Chemical
could	250 5 O
equilibrate	256 11 O
the	268 3 O
effects	272 7 O
of	280 2 O
the	283 3 O
estrogenic	287 10 O
stimulation	298 11 O
on	310 2 O
the	313 3 O
mammary	317 7 O
and	325 3 O
endometrial	329 11 O
target	341 6 O
tissues	348 7 O
of	356 2 O
women	359 5 O
on	365 2 O
hormonal	368 8 O
replacement	377 11 O
therapy	389 7 O
.	396 1 O

The	398 3 O
treatment	402 9 O
schedule	412 8 O
consisted	421 9 O
of	431 2 O
conjugated	434 10 B-Chemical
estrogens	445 9 I-Chemical
(	455 1 O
Premarin	456 8 B-Chemical
)	464 1 O
1	466 1 O
.	467 1 O
25	468 2 O
mg	471 2 O
/	473 1 O
day	474 3 O
for	478 3 O
21	482 2 O
days	485 4 O
and	490 3 O
Medroxyprogesterone	494 19 B-Chemical
acetate	514 7 I-Chemical
10	522 2 O
mg	525 2 O
/	527 1 O
day	528 3 O
for	532 3 O
10	536 2 O
days	539 4 O
in	544 2 O
each	547 4 O
month	552 5 O
.	557 1 O

The	559 3 O
mean	563 4 O
treatment	568 9 O
period	578 6 O
was	585 3 O
18	589 2 O
months	592 6 O
.	598 1 O

During	600 6 O
the	607 3 O
follow	611 6 O
-	617 1 O
up	618 2 O
period	621 6 O
,	627 1 O
attention	629 9 O
was	639 3 O
paid	643 4 O
to	648 2 O
breast	651 6 O
modifications	658 13 O
as	672 2 O
evidenced	675 9 O
by	685 2 O
symptomatology	688 14 O
,	702 1 O
physical	704 8 O
examination	713 11 O
,	724 1 O
and	726 3 O
plate	730 5 O
thermography	736 12 O
.	748 1 O

Mastodynia	750 10 B-Disease
was	761 3 O
reported	765 8 O
by	774 2 O
21	777 2 O
patients	780 8 O
,	788 1 O
and	790 3 O
physical	794 8 O
examination	803 11 O
revealed	815 8 O
a	824 1 O
light	826 5 O
increase	832 8 O
in	841 2 O
breast	844 6 O
firmness	851 8 O
in	860 2 O
12	863 2 O
women	866 5 O
and	872 3 O
a	876 1 O
moderate	878 8 O
increase	887 8 O
in	896 2 O
breast	899 6 O
nodularity	906 10 O
in	917 2 O
2	920 1 O
women	922 5 O
.	927 1 O

Themography	929 11 O
confirmed	941 9 O
the	951 3 O
existence	955 9 O
of	965 2 O
an	968 2 O
excessive	971 9 O
breast	981 6 O
stimulation	988 11 O
in	1000 2 O
1	1003 1 O
women	1005 5 O
who	1011 3 O
complained	1015 10 O
of	1026 2 O
moderate	1029 8 O
mastodynia	1038 10 B-Disease
and	1049 3 O
in	1053 2 O
5	1056 1 O
of	1058 2 O
the	1061 3 O
7	1065 1 O
women	1067 5 O
who	1073 3 O
complained	1077 10 O
of	1088 2 O
severe	1091 6 O
mastodynia	1098 10 B-Disease
.	1108 1 O

Normalization	1110 13 O
was	1124 3 O
obtained	1128 8 O
by	1137 2 O
halving	1140 7 O
the	1148 3 O
estrogen	1152 8 B-Chemical
dose	1161 4 O
.	1165 1 O

These	1167 5 O
results	1173 7 O
suggest	1181 7 O
that	1189 4 O
hormonal	1194 8 O
replacement	1203 11 O
therapy	1215 7 O
can	1223 3 O
be	1227 2 O
safely	1230 6 O
prescribed	1237 10 O
if	1248 2 O
the	1251 3 O
following	1255 9 O
criteria	1265 8 O
are	1274 3 O
satisfied	1278 9 O
:	1287 1 O
1	1289 1 O
)	1290 1 O
preliminary	1292 11 O
evaluation	1304 10 O
of	1315 2 O
patients	1318 8 O
from	1327 4 O
a	1332 1 O
clinical	1334 8 O
,	1342 1 O
metabolic	1344 9 O
,	1353 1 O
cytologic	1355 9 O
,	1364 1 O
and	1366 3 O
mammographic	1370 12 O
perspective	1383 11 O
;	1394 1 O
2	1396 1 O
)	1397 1 O
cyclic	1399 6 O
treatment	1406 9 O
schedule	1416 8 O
,	1424 1 O
with	1426 4 O
a	1431 1 O
progestative	1433 12 O
phase	1446 5 O
of	1452 2 O
10	1455 2 O
days	1458 4 O
;	1462 1 O
and	1464 3 O
3	1468 1 O
)	1469 1 O
periodic	1471 8 O
complete	1480 8 O
follow	1489 6 O
-	1495 1 O
up	1496 2 O
,	1498 1 O
with	1500 4 O
accurate	1505 8 O
thermographic	1514 13 O
evaluation	1528 10 O
of	1539 2 O
the	1542 3 O
breast	1546 6 O
target	1553 6 O
tissues	1560 7 O
.	1567 1 O

Early	0 5 O
infections	6 10 B-Disease
in	17 2 O
kidney	20 6 O
,	26 1 O
heart	28 5 O
,	33 1 O
and	35 3 O
liver	39 5 O
transplant	45 10 O
recipients	56 10 O
on	67 2 O
cyclosporine	70 12 B-Chemical
.	82 1 O

Eighty	84 6 O
-	90 1 O
one	91 3 O
renal	95 5 O
,	100 1 O
seventeen	102 9 O
heart	112 5 O
,	117 1 O
and	119 3 O
twenty	123 6 O
-	129 1 O
four	130 4 O
liver	135 5 O
transplant	141 10 O
patients	152 8 O
were	161 4 O
followed	166 8 O
for	175 3 O
infection	179 9 B-Disease
.	188 1 O

Seventeen	190 9 O
renal	200 5 O
patients	206 8 O
received	215 8 O
azathioprine	224 12 B-Chemical
(	237 1 O
Aza	238 3 B-Chemical
)	241 1 O
and	243 3 O
prednisone	247 10 B-Chemical
as	258 2 O
part	261 4 O
of	266 2 O
a	269 1 O
randomized	271 10 O
trial	282 5 O
of	288 2 O
immunosuppression	291 17 O
with	309 4 O
21	314 2 O
cyclosporine	317 12 B-Chemical
-	329 1 O
and	330 3 O
-	333 1 O
prednisone	334 10 B-Chemical
-	344 1 O
treated	345 7 O
renal	353 5 O
transplant	359 10 O
patients	370 8 O
.	378 1 O

All	380 3 O
others	384 6 O
received	391 8 O
cyclosporine	400 12 B-Chemical
and	413 3 O
prednisone	417 10 B-Chemical
.	427 1 O

The	429 3 O
randomized	433 10 O
Aza	444 3 B-Chemical
patients	448 8 O
had	457 3 O
more	461 4 O
overall	466 7 O
infections	474 10 B-Disease
(	485 1 O
P	486 1 O
less	488 4 O
than	493 4 O
0	498 1 O
.	499 1 O
05	500 2 O
)	502 1 O
and	504 3 O
more	508 4 O
nonviral	513 8 O
infections	522 10 B-Disease
(	533 1 O
P	534 1 O
less	536 4 O
than	541 4 O
0	546 1 O
.	547 1 O
02	548 2 O
)	550 1 O
than	552 4 O
the	557 3 O
randomized	561 10 O
cyclosporine	572 12 B-Chemical
patients	585 8 O
.	593 1 O

Heart	595 5 O
and	601 3 O
liver	605 5 O
patients	611 8 O
had	620 3 O
more	624 4 O
infections	629 10 B-Disease
than	640 4 O
cyclosporine	645 12 B-Chemical
renal	658 5 O
patients	664 8 O
but	673 3 O
fewer	677 5 O
infections	683 10 B-Disease
than	694 4 O
the	699 3 O
Aza	703 3 B-Chemical
renal	707 5 O
patients	713 8 O
.	721 1 O

There	723 5 O
were	729 4 O
no	734 2 O
infectious	737 10 O
deaths	748 6 O
in	755 2 O
renal	758 5 O
transplant	764 10 O
patients	775 8 O
on	784 2 O
cyclosporine	787 12 B-Chemical
or	800 2 O
Aza	803 3 B-Chemical
,	806 1 O
but	808 3 O
infection	812 9 B-Disease
played	822 6 O
a	829 1 O
major	831 5 O
role	837 4 O
in	842 2 O
3	845 1 O
out	847 3 O
of	851 2 O
6	854 1 O
cardiac	856 7 O
transplant	864 10 O
deaths	875 6 O
and	882 3 O
in	886 2 O
8	889 1 O
out	891 3 O
of	895 2 O
9	898 1 O
liver	900 5 O
transplant	906 10 O
deaths	917 6 O
.	923 1 O

Renal	925 5 O
patients	931 8 O
on	940 2 O
cyclosporine	943 12 B-Chemical
had	956 3 O
the	960 3 O
fewest	964 6 O
bacteremias	971 11 B-Disease
.	982 1 O

Analysis	984 8 O
of	993 2 O
site	996 4 O
of	1001 2 O
infection	1004 9 B-Disease
showed	1014 6 O
a	1021 1 O
preponderance	1023 13 O
of	1037 2 O
abdominal	1040 9 B-Disease
infections	1050 10 I-Disease
in	1061 2 O
liver	1064 5 O
patients	1070 8 O
,	1078 1 O
intrathoracic	1080 13 O
infections	1094 10 B-Disease
in	1105 2 O
heart	1108 5 O
patients	1114 8 O
,	1122 1 O
and	1124 3 O
urinary	1128 7 B-Disease
tract	1136 5 I-Disease
infections	1142 10 I-Disease
in	1153 2 O
renal	1156 5 O
patients	1162 8 O
.	1170 1 O

Pulmonary	1172 9 O
infections	1182 10 B-Disease
were	1193 4 O
less	1198 4 O
common	1203 6 O
in	1210 2 O
cyclosporine	1213 12 B-Chemical
-	1225 1 O
treated	1226 7 O
renal	1234 5 O
patients	1240 8 O
than	1249 4 O
in	1254 2 O
Aza	1257 3 B-Chemical
-	1260 1 O
treated	1261 7 O
patients	1269 8 O
(	1278 1 O
P	1279 1 O
less	1281 4 O
than	1286 4 O
0	1291 1 O
.	1292 1 O
05	1293 2 O
)	1295 1 O
.	1296 1 O

Aza	1298 3 B-Chemical
patients	1302 8 O
had	1311 3 O
significantly	1315 13 O
more	1329 4 O
staphylococcal	1334 14 B-Disease
infections	1349 10 I-Disease
than	1360 4 O
all	1365 3 O
other	1369 5 O
transplant	1375 10 O
groups	1386 6 O
(	1393 1 O
P	1394 1 O
less	1396 4 O
than	1401 4 O
0	1406 1 O
.	1407 1 O
005	1408 3 O
)	1411 1 O
,	1412 1 O
and	1414 3 O
systemic	1418 8 O
fungal	1427 6 B-Disease
infections	1434 10 I-Disease
occurred	1445 8 O
only	1454 4 O
in	1459 2 O
the	1462 3 O
liver	1466 5 O
transplant	1472 10 O
group	1483 5 O
.	1488 1 O

Cytomegalovirus	1490 15 O
(	1506 1 O
CMV	1507 3 O
)	1510 1 O
shedding	1512 8 O
or	1521 2 O
serological	1524 11 O
rises	1536 5 O
in	1542 2 O
antibody	1545 8 O
titer	1554 5 O
,	1559 1 O
or	1561 2 O
both	1564 4 O
occurred	1569 8 O
in	1578 2 O
78	1581 2 O
%	1583 1 O
of	1585 2 O
cyclosporine	1588 12 B-Chemical
patients	1601 8 O
and	1610 3 O
76	1614 2 O
%	1616 1 O
of	1618 2 O
Aza	1621 3 B-Chemical
patients	1625 8 O
.	1633 1 O

Of	1635 2 O
the	1638 3 O
cyclosporine	1642 12 B-Chemical
patients	1655 8 O
,	1663 1 O
15	1665 2 O
%	1667 1 O
had	1669 3 O
symptoms	1673 8 O
related	1682 7 O
to	1690 2 O
CMV	1693 3 B-Disease
infection	1697 9 I-Disease
.	1706 1 O

Serological	1708 11 O
evidence	1720 8 O
for	1729 3 O
Epstein	1733 7 B-Disease
Barr	1741 4 I-Disease
Virus	1746 5 I-Disease
infection	1752 9 I-Disease
was	1762 3 O
found	1766 5 O
in	1772 2 O
20	1775 2 O
%	1777 1 O
of	1779 2 O
65	1782 2 O
cyclosporine	1785 12 B-Chemical
patients	1798 8 O
studied	1807 7 O
.	1814 1 O

Three	1816 5 O
had	1822 3 O
associated	1826 10 O
symptoms	1837 8 O
,	1845 1 O
and	1847 3 O
one	1851 3 O
developed	1855 9 O
a	1865 1 O
lymphoma	1867 8 B-Disease
.	1875 1 O

Structure	0 9 O
-	9 1 O
activity	10 8 O
and	19 3 O
dose	23 4 O
-	27 1 O
effect	28 6 O
relationships	35 13 O
of	49 2 O
the	52 3 O
antagonism	56 10 O
of	67 2 O
picrotoxin	70 10 B-Chemical
-	80 1 O
induced	81 7 O
seizures	89 8 B-Disease
by	98 2 O
cholecystokinin	101 15 B-Chemical
,	116 1 O
fragments	118 9 O
and	128 3 O
analogues	132 9 O
of	142 2 O
cholecystokinin	145 15 B-Chemical
in	161 2 O
mice	164 4 O
.	168 1 O

Intraperitoneal	170 15 O
administration	186 14 O
of	201 2 O
cholecystokinin	204 15 B-Chemical
octapeptide	220 11 I-Chemical
sulphate	232 8 O
ester	241 5 O
(	247 1 O
CCK	248 3 B-Chemical
-	251 1 I-Chemical
8	252 1 I-Chemical
-	253 1 O
SE	254 2 O
)	256 1 O
and	258 3 O
nonsulphated	262 12 O
cholecystokinin	275 15 B-Chemical
octapeptide	291 11 I-Chemical
(	303 1 O
CCK	304 3 B-Chemical
-	307 1 I-Chemical
8	308 1 I-Chemical
-	309 1 O
NS	310 2 O
)	312 1 O
enhanced	314 8 O
the	323 3 O
latency	327 7 O
of	335 2 O
seizures	338 8 B-Disease
induced	347 7 O
by	355 2 O
picrotoxin	358 10 B-Chemical
in	369 2 O
mice	372 4 O
.	376 1 O

Experiments	378 11 O
with	390 4 O
N	395 1 O
-	396 1 O
and	398 3 O
C	402 1 O
-	403 1 O
terminal	404 8 O
fragments	413 9 O
revealed	423 8 O
that	432 4 O
the	437 3 O
C	441 1 O
-	442 1 O
terminal	443 8 O
tetrapeptide	452 12 O
(	465 1 O
CCK	466 3 O
-	469 1 O
5	470 1 O
-	471 1 O
8	472 1 O
)	473 1 O
was	475 3 O
the	479 3 O
active	483 6 O
centre	490 6 O
of	497 2 O
the	500 3 O
CCK	504 3 O
octapeptide	508 11 O
molecule	520 8 O
.	528 1 O

The	530 3 O
analogues	534 9 O
CCK	544 3 B-Chemical
-	547 1 I-Chemical
8	548 1 I-Chemical
-	549 1 O
SE	550 2 O
and	553 3 O
CCK	557 3 B-Chemical
-	560 1 I-Chemical
8	561 1 I-Chemical
-	562 1 O
NS	563 2 O
(	566 1 O
dose	567 4 O
range	572 5 O
0	578 1 O
.	579 1 O
2	580 1 O
-	581 1 O
6	582 1 O
.	583 1 O
4	584 1 O
mumol	586 5 O
/	591 1 O
kg	592 2 O
)	594 1 O
and	596 3 O
caerulein	600 9 B-Chemical
dose	610 4 O
range	615 5 O
0	621 1 O
.	622 1 O
1	623 1 O
-	624 1 O
0	625 1 O
.	626 1 O
8	627 1 O
mumol	629 5 O
/	634 1 O
kg	635 2 O
)	637 1 O
showed	639 6 O
bell	646 4 O
-	650 1 O
shaped	651 6 O
dose	658 4 O
-	662 1 O
effect	663 6 O
curves	670 6 O
,	676 1 O
with	678 4 O
the	683 3 O
greatest	687 8 O
maximum	696 7 O
inhibition	704 10 O
for	715 3 O
CCK	719 3 B-Chemical
-	722 1 I-Chemical
8	723 1 I-Chemical
-	724 1 O
NS	725 2 O
.	727 1 O

The	729 3 O
peptide	733 7 O
CCK	741 3 O
-	744 1 O
5	745 1 O
-	746 1 O
8	747 1 O
had	749 3 O
weak	753 4 O
anticonvulsant	758 14 O
activity	773 8 O
in	782 2 O
comparison	785 10 O
to	796 2 O
the	799 3 O
octapeptides	803 12 O
,	815 1 O
3	817 1 O
.	818 1 O
2	819 1 O
mumol	821 5 O
/	826 1 O
kg	827 2 O
and	830 3 O
larger	834 6 O
doses	841 5 O
of	847 2 O
the	850 3 O
reference	854 9 O
drug	864 4 O
,	868 1 O
diazepam	870 8 B-Chemical
,	878 1 O
totally	880 7 O
prevented	888 9 O
picrotoxin	898 10 B-Chemical
-	908 1 O
induced	909 7 O
seizures	917 8 B-Disease
and	926 3 O
mortality	930 9 O
.	939 1 O

The	941 3 O
maximum	945 7 O
effect	953 6 O
of	960 2 O
the	963 3 O
peptides	967 8 O
tested	976 6 O
was	983 3 O
less	987 4 O
than	992 4 O
that	997 4 O
of	1002 2 O
diazepam	1005 8 B-Chemical
.	1013 1 O

Experiments	1015 11 O
with	1027 4 O
analogues	1032 9 O
and	1042 3 O
derivatives	1046 11 O
of	1058 2 O
CCK	1061 3 O
-	1064 1 O
5	1065 1 O
-	1066 1 O
8	1067 1 O
demonstrated	1069 12 O
that	1082 4 O
the	1087 3 O
effectiveness	1091 13 O
of	1105 2 O
the	1108 3 O
beta	1112 4 O
-	1116 1 O
alanyl	1117 6 O
derivatives	1124 11 O
of	1136 2 O
CCK	1139 3 O
-	1142 1 O
5	1143 1 O
-	1144 1 O
8	1145 1 O
were	1147 4 O
enhanced	1152 8 O
and	1161 3 O
that	1165 4 O
they	1170 4 O
were	1175 4 O
equipotent	1180 10 O
with	1191 4 O
CCK	1196 3 B-Chemical
-	1199 1 I-Chemical
8	1200 1 I-Chemical
-	1201 1 O
SE	1202 2 O
.	1204 1 O

Of	1206 2 O
the	1209 3 O
CCK	1213 3 O
-	1216 1 O
2	1217 1 O
-	1218 1 O
8	1219 1 O
analogues	1221 9 O
,	1230 1 O
Ser	1232 3 O
(	1235 1 O
SO3H	1236 4 O
)	1240 1 O
7	1241 1 O
-	1242 1 O
Ac	1243 2 O
-	1245 1 O
CCK	1246 3 O
-	1249 1 O
2	1250 1 O
-	1251 1 O
8	1252 1 O
-	1253 1 O
SE	1254 2 O
and	1257 3 O
Thr	1261 3 O
(	1264 1 O
SO3H	1265 4 O
)	1269 1 O
7	1270 1 O
-	1271 1 O
Ac	1272 2 O
-	1274 1 O
CCK	1275 3 O
-	1278 1 O
2	1279 1 O
-	1280 1 O
8	1281 1 O
-	1282 1 O
SE	1283 2 O
and	1286 3 O
Hyp	1290 3 O
(	1293 1 O
SO3H	1294 4 O
)	1298 1 O
-	1299 1 O
Ac	1300 2 O
-	1302 1 O
CCK	1303 3 O
-	1306 1 O
2	1307 1 O
-	1308 1 O
8	1309 1 O
-	1310 1 O
SE	1311 2 O
were	1314 4 O
slightly	1319 8 O
more	1328 4 O
active	1333 6 O
than	1340 4 O
CCK	1345 3 B-Chemical
-	1348 1 I-Chemical
8	1349 1 I-Chemical
-	1350 1 O
SE	1351 2 O
.	1353 1 O

Vasopressin	0 11 B-Chemical
as	12 2 O
a	15 1 O
possible	17 8 O
contributor	26 11 O
to	38 2 O
hypertension	41 12 B-Disease
.	53 1 O

The	55 3 O
role	59 4 O
of	64 2 O
vasopressin	67 11 B-Chemical
as	79 2 O
a	82 1 O
pressor	84 7 O
agent	92 5 O
to	98 2 O
the	101 3 O
hypertensive	105 12 B-Disease
process	118 7 O
was	126 3 O
examined	130 8 O
.	138 1 O

Vasopressin	140 11 B-Chemical
plays	152 5 O
a	158 1 O
major	160 5 O
role	166 4 O
in	171 2 O
the	174 3 O
pathogenesis	178 12 O
of	191 2 O
DOCA	194 4 B-Chemical
-	198 1 O
salt	199 4 O
hypertension	204 12 B-Disease
,	216 1 O
since	218 5 O
the	224 3 O
elevation	228 9 O
of	238 2 O
blood	241 5 O
pressure	247 8 O
was	256 3 O
not	260 3 O
substantial	264 11 O
in	276 2 O
the	279 3 O
rats	283 4 O
with	288 4 O
lithium	293 7 B-Chemical
-	300 1 O
treated	301 7 O
diabetes	309 8 B-Disease
insipidus	318 9 I-Disease
after	328 5 O
DOCA	334 4 B-Chemical
-	338 1 O
salt	339 4 O
treatment	344 9 O
.	353 1 O

Administration	355 14 O
of	370 2 O
DDAVP	373 5 B-Chemical
which	379 5 O
has	385 3 O
antidiuretic	389 12 O
action	402 6 O
but	409 3 O
minimal	413 7 O
vasopressor	421 11 O
effect	433 6 O
failed	440 6 O
to	447 2 O
increase	450 8 O
blood	459 5 O
pressure	465 8 O
to	474 2 O
the	477 3 O
levels	481 6 O
observed	488 8 O
after	497 5 O
administration	503 14 O
of	518 2 O
AVP	521 3 O
.	524 1 O

Furthermore	526 11 O
,	537 1 O
the	539 3 O
pressor	543 7 O
action	551 6 O
of	558 2 O
vasopressin	561 11 B-Chemical
appears	573 7 O
to	581 2 O
be	584 2 O
important	587 9 O
in	597 2 O
the	600 3 O
development	604 11 O
of	616 2 O
this	619 4 O
model	624 5 O
of	630 2 O
hypertension	633 12 B-Disease
,	645 1 O
since	647 5 O
the	653 3 O
enhanced	657 8 O
pressor	666 7 O
responsiveness	674 14 O
to	689 2 O
the	692 3 O
hormone	696 7 O
was	704 3 O
observed	708 8 O
in	717 2 O
the	720 3 O
initial	724 7 O
stage	732 5 O
of	738 2 O
hypertension	741 12 B-Disease
.	753 1 O

Increased	755 9 O
secretion	765 9 O
of	775 2 O
vasopressin	778 11 B-Chemical
from	790 4 O
neurohypophysis	795 15 O
also	811 4 O
promotes	816 8 O
the	825 3 O
function	829 8 O
of	838 2 O
the	841 3 O
hormone	845 7 O
as	853 2 O
a	856 1 O
pathogenetic	858 12 O
factor	871 6 O
in	878 2 O
hypertension	881 12 B-Disease
.	893 1 O

An	895 2 O
unproportional	898 14 O
release	913 7 O
of	921 2 O
vasopressin	924 11 B-Chemical
compared	936 8 O
to	945 2 O
plasma	948 6 O
osmolality	955 10 O
may	966 3 O
be	970 2 O
induced	973 7 O
by	981 2 O
the	984 3 O
absence	988 7 O
of	996 2 O
an	999 2 O
adjusting	1002 9 O
control	1012 7 O
of	1020 2 O
angiotensin	1023 11 B-Chemical
II	1035 2 O
forming	1038 7 O
and	1046 3 O
receptor	1050 8 O
binding	1059 7 O
capacity	1067 8 O
for	1076 3 O
sodium	1080 6 B-Chemical
balance	1087 7 O
in	1095 2 O
the	1098 3 O
brain	1102 5 O
.	1107 1 O

However	1109 7 O
,	1116 1 O
the	1118 3 O
role	1122 4 O
of	1127 2 O
vasopressin	1130 11 B-Chemical
remains	1142 7 O
to	1150 2 O
be	1153 2 O
determined	1156 10 O
in	1167 2 O
human	1170 5 O
essential	1176 9 O
hypertension	1186 12 B-Disease
.	1198 1 O

Toxic	0 5 B-Disease
hepatitis	6 9 I-Disease
induced	16 7 O
by	24 2 O
disulfiram	27 10 B-Chemical
in	38 2 O
a	41 1 O
non	43 3 O
-	46 1 O
alcoholic	47 9 O
.	56 1 O

A	58 1 O
reversible	60 10 O
toxic	71 5 B-Disease
liver	77 5 I-Disease
damage	83 6 I-Disease
was	90 3 O
observed	94 8 O
in	103 2 O
a	106 1 O
non	108 3 O
-	111 1 O
alcoholic	112 9 O
woman	122 5 O
treated	128 7 O
with	136 4 O
disulfiram	141 10 B-Chemical
.	151 1 O

The	153 3 O
causative	157 9 O
relationship	167 12 O
was	180 3 O
proven	184 6 O
by	191 2 O
challenge	194 9 O
.	203 1 O

Atrial	0 6 B-Disease
thrombosis	7 10 I-Disease
involving	18 9 O
the	28 3 O
heart	32 5 O
of	38 2 O
F	41 1 O
-	42 1 O
344	43 3 O
rats	47 4 O
ingesting	52 9 O
quinacrine	62 10 B-Chemical
hydrochloride	73 13 I-Chemical
.	86 1 O

Quinacrine	88 10 B-Chemical
hydrochloride	99 13 I-Chemical
is	113 2 O
toxic	116 5 O
for	122 3 O
the	126 3 O
heart	130 5 O
of	136 2 O
F	139 1 O
-	140 1 O
344	141 3 O
rats	145 4 O
.	149 1 O

Rats	151 4 O
treated	156 7 O
with	164 4 O
500	169 3 O
ppm	173 3 O
quinacrine	177 10 B-Chemical
hydrochloride	188 13 I-Chemical
in	202 2 O
the	205 3 O
diet	209 4 O
all	214 3 O
developed	218 9 O
a	228 1 O
high	230 4 O
incidence	235 9 O
of	245 2 O
left	248 4 O
atrial	253 6 B-Disease
thrombosis	260 10 I-Disease
.	270 1 O

The	272 3 O
lesion	276 6 O
was	283 3 O
associated	287 10 O
with	298 4 O
cardiac	303 7 B-Disease
hypertrophy	311 11 I-Disease
and	323 3 O
dilatation	327 10 O
and	338 3 O
focal	342 5 O
myocardial	348 10 B-Disease
degeneration	359 12 I-Disease
.	371 1 O

Rats	373 4 O
died	378 4 O
from	383 4 O
cardiac	388 7 B-Disease
hypertrophy	396 11 I-Disease
with	408 4 O
severe	413 6 O
acute	420 5 O
and	426 3 O
chronic	430 7 O
congestion	438 10 O
of	449 2 O
the	452 3 O
lungs	456 5 O
,	461 1 O
liver	463 5 O
,	468 1 O
and	470 3 O
other	474 5 O
organs	480 6 O
.	486 1 O

Seventy	488 7 O
percent	496 7 O
of	504 2 O
rats	507 4 O
given	512 5 O
250	518 3 O
ppm	522 3 O
quinacrine	526 10 B-Chemical
hydrochloride	537 13 I-Chemical
and	551 3 O
1	555 1 O
,	556 1 O
000	557 3 O
ppm	561 3 O
sodium	565 6 B-Chemical
nitrite	572 7 I-Chemical
simultaneously	580 14 O
in	595 2 O
the	598 3 O
diet	602 4 O
had	607 3 O
thrombosis	611 10 B-Disease
of	622 2 O
the	625 3 O
atria	629 5 O
of	635 2 O
the	638 3 O
heart	642 5 O
,	647 1 O
while	649 5 O
untreated	655 9 O
control	665 7 O
rats	673 4 O
in	678 2 O
this	681 4 O
laboratory	686 10 O
did	697 3 O
not	701 3 O
have	705 4 O
atrial	710 6 B-Disease
thrombosis	717 10 I-Disease
.	727 1 O

Sodium	729 6 B-Chemical
nitrite	736 7 I-Chemical
in	744 2 O
combination	747 11 O
with	759 4 O
quinacrine	764 10 B-Chemical
hydrochloride	775 13 I-Chemical
appeared	789 8 O
to	798 2 O
have	801 4 O
no	806 2 O
additional	809 10 O
effect	820 6 O
.	826 1 O

Alternating	0 11 B-Disease
sinus	12 5 I-Disease
rhythm	18 6 I-Disease
and	25 3 O
intermittent	29 12 O
sinoatrial	42 10 B-Disease
block	53 5 I-Disease
induced	59 7 O
by	67 2 O
propranolol	70 11 B-Chemical
.	81 1 O

Alternating	83 11 B-Disease
sinus	95 5 I-Disease
rhythm	101 6 I-Disease
and	108 3 O
intermittent	112 12 O
sinoatrial	125 10 B-Disease
(	136 1 I-Disease
S	137 1 I-Disease
-	138 1 I-Disease
A	139 1 I-Disease
)	140 1 I-Disease
block	142 5 I-Disease
was	148 3 O
observed	152 8 O
in	161 2 O
a	164 1 O
57	166 2 O
-	168 1 O
year	169 4 O
-	173 1 O
old	174 3 O
woman	178 5 O
,	183 1 O
under	185 5 O
treatment	191 9 O
for	201 3 O
angina	205 6 B-Disease
with	212 4 O
80	217 2 O
mg	220 2 O
propranolol	223 11 B-Chemical
daily	235 5 O
.	240 1 O

The	242 3 O
electrocardiogram	246 17 O
showed	264 6 O
alternation	271 11 O
of	283 2 O
long	286 4 O
and	291 3 O
short	295 5 O
P	301 1 O
-	302 1 O
P	303 1 O
intervals	305 9 O
and	315 3 O
occasional	319 10 O
pauses	330 6 O
.	336 1 O

These	338 5 O
pauses	344 6 O
were	351 4 O
always	356 6 O
preceded	363 8 O
by	372 2 O
the	375 3 O
short	379 5 O
P	385 1 O
-	386 1 O
P	387 1 O
intervals	389 9 O
and	399 3 O
were	403 4 O
usually	408 7 O
followed	416 8 O
by	425 2 O
one	428 3 O
or	432 2 O
two	435 3 O
P	439 1 O
-	440 1 O
P	441 1 O
intervals	443 9 O
of	453 2 O
0	456 1 O
.	457 1 O
92	458 2 O
-	460 1 O
0	461 1 O
.	462 1 O
95	463 2 O
s	466 1 O
representing	468 12 O
the	481 3 O
basic	485 5 O
sinus	491 5 O
cycle	497 5 O
.	502 1 O

Following	504 9 O
these	514 5 O
basic	520 5 O
sinus	526 5 O
cycles	532 6 O
,	538 1 O
alternating	540 11 B-Disease
rhythm	552 6 I-Disease
started	559 7 O
with	567 4 O
the	572 3 O
longer	576 6 O
P	583 1 O
-	584 1 O
P	585 1 O
interval	587 8 O
.	595 1 O

The	597 3 O
long	601 4 O
P	606 1 O
-	607 1 O
P	608 1 O
intervals	610 9 O
ranged	620 6 O
between	627 7 O
1	635 1 O
.	636 1 O
04	637 2 O
-	639 1 O
1	640 1 O
.	641 1 O
12	642 2 O
s	645 1 O
and	647 3 O
the	651 3 O
short	655 5 O
P	661 1 O
-	662 1 O
P	663 1 O
intervals	665 9 O
between	675 7 O
0	683 1 O
.	684 1 O
80	685 2 O
-	687 1 O
0	688 1 O
.	689 1 O
84	690 2 O
s	693 1 O
,	694 1 O
respectively	696 12 O
.	708 1 O

The	710 3 O
duration	714 8 O
of	723 2 O
the	726 3 O
pauses	730 6 O
were	737 4 O
equal	742 5 O
or	748 2 O
almost	751 6 O
equal	758 5 O
to	764 2 O
one	767 3 O
short	771 5 O
plus	777 4 O
one	782 3 O
long	786 4 O
P	791 1 O
-	792 1 O
P	793 1 O
interval	795 8 O
or	804 2 O
to	807 2 O
twice	810 5 O
the	816 3 O
basic	820 5 O
sinus	826 5 O
cycle	832 5 O
.	837 1 O

In	839 2 O
one	842 3 O
recording	846 9 O
a	856 1 O
short	858 5 O
period	864 6 O
of	871 2 O
regular	874 7 O
sinus	882 5 O
rhythm	888 6 O
with	895 4 O
intermittent	900 12 O
2	913 1 O
/	914 1 O
1	915 1 O
S	917 1 B-Disease
-	918 1 I-Disease
A	919 1 I-Disease
block	921 5 I-Disease
was	927 3 O
observed	931 8 O
.	939 1 O

This	941 4 O
short	946 5 O
period	952 6 O
of	959 2 O
sinus	962 5 O
rhythm	968 6 O
was	975 3 O
interrupted	979 11 O
by	991 2 O
sudden	994 6 O
prolongation	1001 12 O
of	1014 2 O
the	1017 3 O
P	1021 1 O
-	1022 1 O
P	1023 1 O
interval	1025 8 O
starting	1034 8 O
the	1043 3 O
alternative	1047 11 O
rhythm	1059 6 O
.	1065 1 O

There	1067 5 O
were	1073 4 O
small	1078 5 O
changes	1084 7 O
in	1092 2 O
the	1095 3 O
shape	1099 5 O
of	1105 2 O
the	1108 3 O
P	1112 1 O
waves	1114 5 O
and	1120 3 O
P	1124 1 O
-	1125 1 O
R	1126 1 O
intervals	1128 9 O
.	1137 1 O

S	1139 1 O
-	1140 1 O
A	1141 1 O
conduction	1143 10 O
through	1154 7 O
two	1162 3 O
pathways	1166 8 O
,	1174 1 O
the	1176 3 O
first	1180 5 O
with	1186 4 O
2	1191 1 O
/	1192 1 O
1	1193 1 O
block	1195 5 O
the	1201 3 O
second	1205 6 O
having	1212 6 O
0	1219 1 O
.	1220 1 O
12	1221 2 O
-	1223 1 O
0	1224 1 O
.	1225 1 O
14	1226 2 O
s	1229 1 O
longer	1231 6 O
conduction	1238 10 O
time	1249 4 O
and	1254 3 O
with	1258 4 O
occasional	1263 10 O
2	1274 1 O
/	1275 1 O
1	1276 1 O
block	1278 5 O
was	1284 3 O
proposed	1288 8 O
for	1297 3 O
the	1301 3 O
explanation	1305 11 O
of	1317 2 O
the	1320 3 O
alternating	1324 11 O
P	1336 1 O
-	1337 1 O
P	1338 1 O
interval	1340 8 O
and	1349 3 O
other	1353 5 O
electrocardiographic	1359 20 O
features	1380 8 O
seen	1389 4 O
.	1393 1 O

Atropine	1395 8 B-Chemical
1	1404 1 O
mg	1406 2 O
given	1409 5 O
intravenously	1415 13 O
resulted	1429 8 O
in	1438 2 O
shortening	1441 10 O
of	1452 2 O
all	1455 3 O
P	1459 1 O
-	1460 1 O
P	1461 1 O
intervals	1463 9 O
without	1473 7 O
changing	1481 8 O
the	1490 3 O
rhythm	1494 6 O
.	1500 1 O

The	1502 3 O
abnormal	1506 8 O
rhythm	1515 6 O
disappeared	1522 11 O
with	1534 4 O
the	1539 3 O
withdrawal	1543 10 O
of	1554 2 O
propranolol	1557 11 B-Chemical
and	1569 3 O
when	1573 4 O
the	1578 3 O
drug	1582 4 O
was	1587 3 O
restarted	1591 9 O
a	1601 1 O
2	1603 1 O
/	1604 1 O
1	1605 1 O
S	1607 1 B-Disease
-	1608 1 I-Disease
A	1609 1 I-Disease
block	1611 5 I-Disease
was	1617 3 O
seen	1621 4 O
.	1625 1 O

This	1627 4 O
was	1632 3 O
accepted	1636 8 O
as	1645 2 O
evidence	1648 8 O
for	1657 3 O
propranolol	1661 11 B-Chemical
being	1673 5 O
the	1679 3 O
cause	1683 5 O
of	1689 2 O
this	1692 4 O
conduction	1697 10 B-Disease
disorder	1708 8 I-Disease
.	1716 1 O

Antitumor	0 9 O
effect	10 6 O
,	16 1 O
cardiotoxicity	18 14 B-Disease
,	32 1 O
and	34 3 O
nephrotoxicity	38 14 B-Disease
of	53 2 O
doxorubicin	56 11 B-Chemical
in	68 2 O
the	71 3 O
IgM	75 3 O
solid	79 5 O
immunocytoma	85 12 B-Disease
-	97 1 O
bearing	98 7 O
LOU	106 3 O
/	109 1 O
M	110 1 O
/	111 1 O
WSL	112 3 O
rat	116 3 O
.	119 1 O

Antitumor	121 9 O
activity	131 8 O
,	139 1 O
cardiotoxicity	141 14 B-Disease
,	155 1 O
and	157 3 O
nephrotoxicity	161 14 B-Disease
induced	176 7 O
by	184 2 O
doxorubicin	187 11 B-Chemical
were	199 4 O
studied	204 7 O
in	212 2 O
LOU	215 3 O
/	218 1 O
M	219 1 O
/	220 1 O
WSL	221 3 O
inbred	225 6 O
rats	232 4 O
each	237 4 O
bearing	242 7 O
a	250 1 O
transplantable	252 14 O
solid	267 5 O
IgM	273 3 O
immunocytoma	277 12 B-Disease
.	289 1 O

Animals	291 7 O
with	299 4 O
a	304 1 O
tumor	306 5 B-Disease
(	312 1 O
diameter	313 8 O
,	321 1 O
15	323 2 O
.	325 1 O
8	326 1 O
+	328 1 O
/	329 1 O
-	330 1 O
3	332 1 O
.	333 1 O
3	334 1 O
mm	336 2 O
)	338 1 O
were	340 4 O
treated	345 7 O
with	353 4 O
iv	358 2 O
injections	361 10 O
of	372 2 O
doxorubicin	375 11 B-Chemical
on	387 2 O
5	390 1 O
consecutive	392 11 O
days	404 4 O
,	408 1 O
followed	410 8 O
by	419 2 O
1	422 1 O
weekly	424 6 O
injection	431 9 O
for	441 3 O
7	445 1 O
weeks	447 5 O
(	453 1 O
dose	454 4 O
range	459 5 O
,	464 1 O
0	466 1 O
.	467 1 O
015	468 3 O
-	471 1 O
4	472 1 O
.	473 1 O
0	474 1 O
mg	476 2 O
/	478 1 O
kg	479 2 O
body	482 4 O
wt	487 2 O
)	489 1 O
.	490 1 O

Tumor	492 5 B-Disease
regression	498 10 O
was	509 3 O
observed	513 8 O
with	522 4 O
0	527 1 O
.	528 1 O
5	529 1 O
mg	531 2 O
doxorubicin	534 11 B-Chemical
/	545 1 O
kg	546 2 O
.	548 1 O

Complete	550 8 O
disappearance	559 13 O
of	573 2 O
the	576 3 O
tumor	580 5 B-Disease
was	586 3 O
induced	590 7 O
with	598 4 O
1	603 1 O
.	604 1 O
0	605 1 O
mg	607 2 O
doxorubicin	610 11 B-Chemical
/	621 1 O
kg	622 2 O
.	624 1 O

Histologic	626 10 O
evidence	637 8 O
of	646 2 O
cardiotoxicity	649 14 B-Disease
scored	664 6 O
as	671 2 O
grade	674 5 O
III	680 3 O
was	684 3 O
only	688 4 O
observed	693 8 O
at	702 2 O
a	705 1 O
dose	707 4 O
of	712 2 O
1	715 1 O
.	716 1 O
0	717 1 O
mg	719 2 O
doxorubicin	722 11 B-Chemical
/	733 1 O
kg	734 2 O
.	736 1 O

Light	738 5 O
microscopic	744 11 O
evidence	756 8 O
of	765 2 O
renal	768 5 B-Disease
damage	774 6 I-Disease
was	781 3 O
seen	785 4 O
above	790 5 O
a	796 1 O
dose	798 4 O
of	803 2 O
0	806 1 O
.	807 1 O
5	808 1 O
mg	810 2 O
doxorubicin	813 11 B-Chemical
/	824 1 O
kg	825 2 O
,	827 1 O
which	829 5 O
resulted	835 8 O
in	844 2 O
albuminuria	847 11 B-Disease
and	859 3 O
very	863 4 O
low	868 3 O
serum	872 5 O
albumin	878 7 O
levels	886 6 O
.	892 1 O

In	894 2 O
the	897 3 O
group	901 5 O
that	907 4 O
received	912 8 O
1	921 1 O
.	922 1 O
0	923 1 O
mg	925 2 O
doxorubicin	928 11 B-Chemical
/	939 1 O
kg	940 2 O
,	942 1 O
the	944 3 O
serum	948 5 O
albumin	954 7 O
level	962 5 O
decreased	968 9 O
from	978 4 O
33	983 2 O
.	985 1 O
6	986 1 O
+	988 1 O
/	989 1 O
-	990 1 O
4	992 1 O
.	993 1 O
1	994 1 O
to	996 2 O
1	999 1 O
.	1000 1 O
5	1001 1 O
+	1003 1 O
/	1004 1 O
-	1005 1 O
0	1007 1 O
.	1008 1 O
5	1009 1 O
g	1011 1 O
/	1012 1 O
liter	1013 5 O
.	1018 1 O

Ascites	1020 7 B-Disease
and	1028 3 O
hydrothorax	1032 11 B-Disease
were	1044 4 O
observed	1049 8 O
simultaneously	1058 14 O
.	1072 1 O

The	1074 3 O
same	1078 4 O
experiments	1083 11 O
were	1095 4 O
performed	1100 9 O
with	1110 4 O
non	1115 3 O
-	1118 1 O
tumor	1119 5 B-Disease
-	1124 1 O
bearing	1125 7 O
rats	1133 4 O
,	1137 1 O
in	1139 2 O
which	1142 5 O
no	1148 2 O
major	1151 5 O
differences	1157 11 O
were	1169 4 O
observed	1174 8 O
.	1182 1 O

In	1184 2 O
conclusion	1187 10 O
,	1197 1 O
antitumor	1199 9 O
activity	1209 8 O
,	1217 1 O
cardiotoxicity	1219 14 B-Disease
,	1233 1 O
and	1235 3 O
nephrotoxicity	1239 14 B-Disease
were	1254 4 O
studied	1259 7 O
simultaneously	1267 14 O
in	1282 2 O
the	1285 3 O
same	1289 4 O
LOU	1294 3 O
/	1297 1 O
M	1298 1 O
/	1299 1 O
WSL	1300 3 O
rat	1304 3 O
.	1307 1 O

Albuminuria	1309 11 B-Disease
due	1321 3 O
to	1325 2 O
renal	1328 5 B-Disease
damage	1334 6 I-Disease
led	1341 3 O
to	1345 2 O
extremely	1348 9 O
low	1358 3 O
serum	1362 5 O
albumin	1368 7 O
levels	1376 6 O
,	1382 1 O
so	1384 2 O
ascites	1387 7 B-Disease
and	1395 3 O
hydrothorax	1399 11 B-Disease
were	1411 4 O
not	1416 3 O
necessarily	1420 11 O
a	1432 1 O
consequence	1434 11 O
of	1446 2 O
the	1449 3 O
observed	1453 8 O
cardiomyopathy	1462 14 B-Disease
.	1476 1 O

Intraoperative	0 14 O
bradycardia	15 11 B-Disease
and	27 3 O
hypotension	31 11 B-Disease
associated	43 10 O
with	54 4 O
timolol	59 7 B-Chemical
and	67 3 O
pilocarpine	71 11 B-Chemical
eye	83 3 O
drops	87 5 O
.	92 1 O

A	94 1 O
69	96 2 O
-	98 1 O
yr	99 2 O
-	101 1 O
old	102 3 O
man	106 3 O
,	109 1 O
who	111 3 O
was	115 3 O
concurrently	119 12 O
being	132 5 O
treated	138 7 O
with	146 4 O
pilocarpine	151 11 B-Chemical
nitrate	163 7 I-Chemical
and	171 3 O
timolol	175 7 B-Chemical
maleate	183 7 I-Chemical
eye	191 3 O
drops	195 5 O
,	200 1 O
developed	202 9 O
a	212 1 O
bradycardia	214 11 B-Disease
and	226 3 O
became	230 6 O
hypotensive	237 11 B-Disease
during	249 6 O
halothane	256 9 B-Chemical
anaesthesia	266 11 O
.	277 1 O

Both	279 4 O
timolol	284 7 B-Chemical
and	292 3 O
pilocarpine	296 11 B-Chemical
were	308 4 O
subsequently	313 12 O
identified	326 10 O
in	337 2 O
a	340 1 O
24	342 2 O
-	344 1 O
h	345 1 O
collection	347 10 O
of	358 2 O
urine	361 5 O
.	366 1 O

Timolol	368 7 B-Chemical
(	376 1 O
but	377 3 O
not	381 3 O
pilocarpine	385 11 B-Chemical
)	396 1 O
was	398 3 O
detected	402 8 O
in	411 2 O
a	414 1 O
sample	416 6 O
of	423 2 O
plasma	426 6 O
removed	433 7 O
during	441 6 O
surgery	448 7 O
;	455 1 O
the	457 3 O
plasma	461 6 O
concentration	468 13 O
of	482 2 O
timolol	485 7 B-Chemical
(	493 1 O
2	494 1 O
.	495 1 O
6	496 1 O
ng	498 2 O
ml	501 2 O
-	503 1 O
1	504 1 O
)	505 1 O
was	507 3 O
consistent	511 10 O
with	522 4 O
partial	527 7 O
beta	535 4 O
-	539 1 O
adrenoceptor	540 12 O
blockade	553 8 O
.	561 1 O

It	563 2 O
is	566 2 O
postulated	569 10 O
that	580 4 O
this	585 4 O
action	590 6 O
may	597 3 O
have	601 4 O
been	606 4 O
enhanced	611 8 O
during	620 6 O
halothane	627 9 B-Chemical
anaesthesia	637 11 O
with	649 4 O
resultant	654 9 O
bradycardia	664 11 B-Disease
and	676 3 O
hypotension	680 11 B-Disease
.	691 1 O

Pilocarpine	693 11 B-Chemical
may	705 3 O
have	709 4 O
had	714 3 O
a	718 1 O
contributory	720 12 O
effect	733 6 O
.	739 1 O

Succinylcholine	0 15 B-Chemical
apnoea	16 6 B-Disease
:	22 1 O
attempted	24 9 O
reversal	34 8 O
with	43 4 O
anticholinesterases	48 19 O
.	67 1 O

Anticholinesterases	69 19 O
were	89 4 O
administered	94 12 O
in	107 2 O
an	110 2 O
attempt	113 7 O
to	121 2 O
antagonize	124 10 O
prolonged	135 9 O
neuromuscular	145 13 B-Disease
blockade	159 8 I-Disease
following	168 9 O
the	178 3 O
administration	182 14 O
of	197 2 O
succinylcholine	200 15 B-Chemical
in	216 2 O
a	219 1 O
patient	221 7 O
later	229 5 O
found	235 5 O
to	241 2 O
be	244 2 O
homozygous	247 10 O
for	258 3 O
atypical	262 8 O
plasma	271 6 O
cholinesterase	278 14 O
.	292 1 O

Edrophonium	294 11 B-Chemical
10	306 2 O
mg	309 2 O
,	311 1 O
given	313 5 O
74	319 2 O
min	322 3 O
after	326 5 O
succinylcholine	332 15 B-Chemical
,	347 1 O
when	349 4 O
train	354 5 O
-	359 1 O
of	360 2 O
-	362 1 O
four	363 4 O
stimulation	368 11 O
was	380 3 O
characteristic	384 14 O
of	399 2 O
phase	402 5 O
II	408 2 O
block	411 5 O
,	416 1 O
produced	418 8 O
partial	427 7 O
antagonism	435 10 O
which	446 5 O
was	452 3 O
not	456 3 O
sustained	460 9 O
.	469 1 O

Repeated	471 8 O
doses	480 5 O
of	486 2 O
edrophonium	489 11 B-Chemical
to	501 2 O
70	504 2 O
mg	507 2 O
and	510 3 O
neostigmine	514 11 B-Chemical
to	526 2 O
2	529 1 O
.	530 1 O
5	531 1 O
mg	533 2 O
did	536 3 O
not	540 3 O
antagonize	544 10 O
or	555 2 O
augment	558 7 O
the	566 3 O
block	570 5 O
.	575 1 O

Spontaneous	577 11 O
respiration	589 11 O
recommenced	601 11 O
200	613 3 O
min	617 3 O
after	621 5 O
succinylcholine	627 15 B-Chemical
administration	643 14 O
.	657 1 O

It	659 2 O
is	662 2 O
concluded	665 9 O
that	675 4 O
anticholinesterases	680 19 O
are	700 3 O
only	704 4 O
partially	709 9 O
effective	719 9 O
in	729 2 O
restoring	732 9 O
neuromuscular	742 13 O
function	756 8 O
in	765 2 O
succinylcholine	768 15 B-Chemical
apnoea	784 6 B-Disease
despite	791 7 O
muscle	799 6 O
twitch	806 6 O
activity	813 8 O
typical	822 7 O
of	830 2 O
phase	833 5 O
II	839 2 O
block	842 5 O
.	847 1 O

Effect	0 6 O
of	7 2 O
doxorubicin	10 11 B-Chemical
on	22 2 O
[	25 1 B-Chemical
omega	26 5 I-Chemical
-	31 1 I-Chemical
I	32 1 I-Chemical
-	33 1 I-Chemical
131	34 3 I-Chemical
]	37 1 I-Chemical
heptadecanoic	38 13 I-Chemical
acid	52 4 I-Chemical
myocardial	57 10 O
scintigraphy	68 12 O
and	81 3 O
echocardiography	85 16 O
in	102 2 O
dogs	105 4 O
.	109 1 O

The	111 3 O
effects	115 7 O
of	123 2 O
serial	126 6 O
treatment	133 9 O
with	143 4 O
doxorubicin	148 11 B-Chemical
on	160 2 O
dynamic	163 7 O
myocardial	171 10 O
scintigraphy	182 12 O
with	195 4 O
[	200 1 B-Chemical
omega	201 5 I-Chemical
-	206 1 I-Chemical
I	207 1 I-Chemical
-	208 1 I-Chemical
131	209 3 I-Chemical
]	212 1 I-Chemical
heptadecanoic	213 13 I-Chemical
acid	227 4 I-Chemical
(	232 1 O
I	233 1 B-Chemical
-	234 1 I-Chemical
131	235 3 I-Chemical
HA	239 2 I-Chemical
)	241 1 O
,	242 1 O
and	244 3 O
on	248 2 O
global	251 6 O
left	258 4 O
-	262 1 O
ventricular	263 11 O
function	275 8 O
determined	284 10 O
echocardiographically	295 21 O
,	316 1 O
were	318 4 O
studied	323 7 O
in	331 2 O
a	334 1 O
group	336 5 O
of	342 2 O
nine	345 4 O
mongrel	350 7 O
dogs	358 4 O
.	362 1 O

Total	364 5 O
extractable	370 11 O
myocardial	382 10 O
lipid	393 5 O
was	399 3 O
compared	403 8 O
postmortem	412 10 O
between	423 7 O
a	431 1 O
group	433 5 O
of	439 2 O
control	442 7 O
dogs	450 4 O
and	455 3 O
doxorubicin	459 11 B-Chemical
-	470 1 O
treated	471 7 O
dogs	479 4 O
.	483 1 O

A	485 1 O
significant	487 11 O
and	499 3 O
then	503 4 O
progressive	508 11 O
fall	520 4 O
in	525 2 O
global	528 6 O
LV	535 2 O
function	538 8 O
was	547 3 O
observed	551 8 O
at	560 2 O
a	563 1 O
cumulative	565 10 O
doxorubicin	576 11 B-Chemical
dose	588 4 O
of	593 2 O
4	596 1 O
mg	598 2 O
/	600 1 O
kg	601 2 O
.	603 1 O

A	605 1 O
significant	607 11 O
increase	619 8 O
in	628 2 O
the	631 3 O
myocardial	635 10 O
t1	646 2 O
/	648 1 O
2	649 1 O
of	651 2 O
the	654 3 O
I	658 1 B-Chemical
-	659 1 I-Chemical
131	660 3 I-Chemical
HA	664 2 I-Chemical
was	667 3 O
observed	671 8 O
only	680 4 O
at	685 2 O
a	688 1 O
higher	690 6 O
cumulative	697 10 O
dose	708 4 O
,	712 1 O
10	714 2 O
mg	717 2 O
/	719 1 O
kg	720 2 O
.	722 1 O

No	724 2 O
significant	727 11 O
alteration	739 10 O
in	750 2 O
total	753 5 O
extractable	759 11 O
myocardial	771 10 O
lipids	782 6 O
was	789 3 O
observed	793 8 O
between	802 7 O
control	810 7 O
dogs	818 4 O
and	823 3 O
those	827 5 O
treated	833 7 O
with	841 4 O
doxorubicin	846 11 B-Chemical
.	857 1 O

Our	859 3 O
findings	863 8 O
suggest	872 7 O
that	880 4 O
the	885 3 O
changes	889 7 O
leading	897 7 O
to	905 2 O
an	908 2 O
alteration	911 10 O
of	922 2 O
myocardial	925 10 O
dynamic	936 7 O
imaging	944 7 O
with	952 4 O
I	957 1 B-Chemical
-	958 1 I-Chemical
131	959 3 I-Chemical
HA	963 2 I-Chemical
are	966 3 O
not	970 3 O
the	974 3 O
initiating	978 10 O
factor	989 6 O
in	996 2 O
doxorubicin	999 11 B-Chemical
cardiotoxicity	1011 14 B-Disease
.	1025 1 O

Hemodynamics	0 12 O
and	13 3 O
myocardial	17 10 O
metabolism	28 10 O
under	39 5 O
deliberate	45 10 O
hypotension	56 11 B-Disease
.	67 1 O

An	69 2 O
experimental	72 12 O
study	85 5 O
in	91 2 O
dogs	94 4 O
.	98 1 O

Coronary	100 8 O
blood	109 5 O
flow	115 4 O
,	119 1 O
cardiac	121 7 O
work	129 4 O
and	134 3 O
metabolism	138 10 O
were	149 4 O
studied	154 7 O
in	162 2 O
dogs	165 4 O
under	170 5 O
sodium	176 6 B-Chemical
nitroprusside	183 13 I-Chemical
(	197 1 O
SNP	198 3 B-Chemical
)	201 1 O
and	203 3 O
trimetaphan	207 11 B-Chemical
(	219 1 O
TMP	220 3 B-Chemical
)	223 1 O
deliberate	225 10 O
hypotension	236 11 B-Disease
(	248 1 O
20	249 2 O
%	251 1 O
and	253 3 O
40	257 2 O
%	259 1 O
mean	261 4 O
pressure	266 8 O
decrease	275 8 O
from	284 4 O
baseline	289 8 O
)	297 1 O
.	298 1 O

Regarding	300 9 O
the	310 3 O
effects	314 7 O
of	322 2 O
drug	325 4 O
-	329 1 O
induced	330 7 O
hypotension	338 11 B-Disease
on	350 2 O
coronary	353 8 O
blood	362 5 O
flow	368 4 O
,	372 1 O
aortic	374 6 O
and	381 3 O
coronary	385 8 O
sinus	394 5 O
metabolic	400 9 O
data	410 4 O
(	415 1 O
pH	416 2 O
,	418 1 O
pO2	420 3 O
,	423 1 O
pCO2	425 4 O
)	429 1 O
we	431 2 O
could	434 5 O
confirm	440 7 O
that	448 4 O
nitroprusside	453 13 B-Chemical
hypotension	467 11 B-Disease
could	479 5 O
be	485 2 O
safely	488 6 O
used	495 4 O
to	500 2 O
30	503 2 O
%	505 1 O
mean	507 4 O
blood	512 5 O
pressure	518 8 O
decrease	527 8 O
from	536 4 O
control	541 7 O
,	548 1 O
trimetaphan	550 11 B-Chemical
hypotension	562 11 B-Disease
to	574 2 O
20	577 2 O
%	579 1 O
mean	581 4 O
blood	586 5 O
pressure	592 8 O
decrease	601 8 O
.	609 1 O

Cardiac	611 7 O
work	619 4 O
was	624 3 O
significantly	628 13 O
reduced	642 7 O
during	650 6 O
SNP	657 3 B-Chemical
hypotension	661 11 B-Disease
.	672 1 O

Myocardial	674 10 O
O2	685 2 B-Chemical
consumption	688 11 O
and	700 3 O
O2	704 2 B-Chemical
availability	707 12 O
were	720 4 O
directly	725 8 O
dependent	734 9 O
on	744 2 O
the	747 3 O
coronary	751 8 O
perfusion	760 9 O
.	769 1 O

Careful	771 7 O
invasive	779 8 O
monitoring	788 10 O
of	799 2 O
the	802 3 O
blood	806 5 O
pressure	812 8 O
,	820 1 O
blood	822 5 O
gases	828 5 O
and	834 3 O
of	838 2 O
the	841 3 O
ECG	845 3 O
ST	849 2 O
-	851 1 O
T	852 1 O
segment	854 7 O
is	862 2 O
mandatory	865 9 O
.	874 1 O

Evidence	0 8 O
for	9 3 O
a	13 1 O
selective	15 9 O
brain	25 5 O
noradrenergic	31 13 O
involvement	45 11 O
in	57 2 O
the	60 3 O
locomotor	64 9 O
stimulant	74 9 O
effects	84 7 O
of	92 2 O
amphetamine	95 11 B-Chemical
in	107 2 O
the	110 3 O
rat	114 3 O
.	117 1 O

Male	119 4 O
rats	124 4 O
received	129 8 O
the	138 3 O
noradrenaline	142 13 B-Chemical
neurotoxin	156 10 O
DSP4	167 4 B-Chemical
(	172 1 O
50	173 2 O
mg	176 2 O
/	178 1 O
kg	179 2 O
)	181 1 O
7	183 1 O
days	185 4 O
prior	190 5 O
to	196 2 O
injection	199 9 O
of	209 2 O
D	212 1 B-Chemical
-	213 1 I-Chemical
amphetamine	214 11 I-Chemical
(	226 1 O
10	227 2 O
or	230 2 O
40	233 2 O
mumol	236 5 O
/	241 1 O
kg	242 2 O
i	245 1 O
.	246 1 O
p	247 1 O
.	248 1 O
)	249 1 O
.	250 1 O

The	252 3 O
hyperactivity	256 13 B-Disease
induced	270 7 O
by	278 2 O
D	281 1 B-Chemical
-	282 1 I-Chemical
amphetamine	283 11 I-Chemical
(	295 1 O
10	296 2 O
mumol	299 5 O
/	304 1 O
kg	305 2 O
)	307 1 O
was	309 3 O
significantly	313 13 O
reduced	327 7 O
by	335 2 O
DSP4	338 4 B-Chemical
pretreatment	343 12 O
.	355 1 O

However	357 7 O
,	364 1 O
the	366 3 O
increased	370 9 O
rearings	380 8 O
and	389 3 O
the	393 3 O
amphetamine	397 11 B-Chemical
-	408 1 O
induced	409 7 O
stereotypies	417 12 B-Disease
were	430 4 O
not	435 3 O
blocked	439 7 O
by	447 2 O
pretreatment	450 12 O
with	463 4 O
DSP4	468 4 B-Chemical
.	472 1 O

The	474 3 O
reduction	478 9 O
of	488 2 O
amphetamine	491 11 B-Chemical
hyperactivity	503 13 B-Disease
induced	517 7 O
by	525 2 O
DSP4	528 4 B-Chemical
was	533 3 O
blocked	537 7 O
by	545 2 O
pretreatment	548 12 O
with	561 4 O
the	566 3 O
noradrenaline	570 13 B-Chemical
-	583 1 O
uptake	584 6 O
blocking	591 8 O
agent	600 5 O
,	605 1 O
desipramine	607 11 B-Chemical
,	618 1 O
which	620 5 O
prevents	626 8 O
the	635 3 O
neurotoxic	639 10 B-Disease
action	650 6 O
of	657 2 O
DSP4	660 4 B-Chemical
.	664 1 O

The	666 3 O
present	670 7 O
results	678 7 O
suggest	686 7 O
a	694 1 O
selective	696 9 O
involvement	706 11 O
of	718 2 O
central	721 7 O
noradrenergic	729 13 O
neurones	743 8 O
in	752 2 O
the	755 3 O
locomotor	759 9 O
stimulant	769 9 O
effect	779 6 O
of	786 2 O
amphetamine	789 11 B-Chemical
in	801 2 O
the	804 3 O
rat	808 3 O
.	811 1 O

Accelerated	0 11 B-Disease
junctional	12 10 I-Disease
rhythms	23 7 I-Disease
during	31 6 O
oral	38 4 O
verapamil	43 9 B-Chemical
therapy	53 7 O
.	60 1 O

This	62 4 O
study	67 5 O
examined	73 8 O
the	82 3 O
frequency	86 9 O
of	96 2 O
atrioventricular	99 16 O
(	116 1 O
AV	117 2 O
)	119 1 O
dissociation	121 12 O
and	134 3 O
accelerated	138 11 B-Disease
junctional	150 10 I-Disease
rhythms	161 7 I-Disease
in	169 2 O
59	172 2 O
patients	175 8 O
receiving	184 9 O
oral	194 4 O
verapamil	199 9 B-Chemical
.	208 1 O

Accelerated	210 11 B-Disease
junctional	222 10 I-Disease
rhythms	233 7 I-Disease
and	241 3 O
AV	245 2 O
dissociation	248 12 O
were	261 4 O
frequent	266 8 O
in	275 2 O
patients	278 8 O
with	287 4 O
supraventricular	292 16 B-Disease
tachyarrhythmias	309 16 I-Disease
,	325 1 O
particularly	327 12 O
AV	340 2 O
nodal	343 5 O
reentry	349 7 O
.	356 1 O

Verapamil	358 9 B-Chemical
administration	368 14 O
to	383 2 O
these	386 5 O
patients	392 8 O
led	401 3 O
to	405 2 O
an	408 2 O
asymptomatic	411 12 O
increase	424 8 O
in	433 2 O
activity	436 8 O
of	445 2 O
these	448 5 O
junctional	454 10 O
pacemakers	465 10 O
.	475 1 O

In	477 2 O
patients	480 8 O
with	489 4 O
various	494 7 O
chest	502 5 B-Disease
pain	508 4 I-Disease
syndromes	513 9 O
,	522 1 O
verapamil	524 9 B-Chemical
neither	534 7 O
increased	542 9 O
the	552 3 O
frequency	556 9 O
of	566 2 O
junctional	569 10 O
rhythms	580 7 O
nor	588 3 O
suppressed	592 10 O
their	603 5 O
role	609 4 O
as	614 2 O
escape	617 6 O
rhythms	624 7 O
under	632 5 O
physiologically	638 15 O
appropriate	654 11 O
circumstances	666 13 O
.	679 1 O

Treatment	0 9 O
of	10 2 O
ovarian	13 7 B-Disease
cancer	21 6 I-Disease
with	28 4 O
a	33 1 O
combination	35 11 O
of	47 2 O
cis	50 3 B-Chemical
-	53 1 I-Chemical
platinum	54 8 I-Chemical
,	62 1 O
adriamycin	64 10 B-Chemical
,	74 1 O
cyclophosphamide	76 16 B-Chemical
and	93 3 O
hexamethylmelamine	97 18 B-Chemical
.	115 1 O

During	117 6 O
the	124 3 O
last	128 4 O
2	133 1 O
1	135 1 O
/	136 1 O
2	137 1 O
years	139 5 O
,	144 1 O
38	146 2 O
patients	149 8 O
with	158 4 O
ovarian	163 7 B-Disease
cancer	171 6 I-Disease
were	178 4 O
treated	183 7 O
with	191 4 O
a	196 1 O
combination	198 11 O
of	210 2 O
cisplatinum	213 11 B-Chemical
(	225 1 O
CPDD	226 4 B-Chemical
)	230 1 O
,	231 1 O
50	233 2 O
mg	236 2 O
/	238 1 O
m2	239 2 O
,	241 1 O
adriamycin	243 10 B-Chemical
,	253 1 O
30	255 2 O
mg	258 2 O
/	260 1 O
m2	261 2 O
,	263 1 O
cyclophosphamide	265 16 B-Chemical
,	281 1 O
300	283 3 O
mg	287 2 O
/	289 1 O
m2	290 2 O
,	292 1 O
on	294 2 O
day	297 3 O
1	301 1 O
;	302 1 O
and	304 3 O
hexamethylmelamine	308 18 B-Chemical
(	327 1 O
HMM	328 3 B-Chemical
)	331 1 O
,	332 1 O
6	334 1 O
mg	336 2 O
/	338 1 O
kg	339 2 O
daily	342 5 O
,	347 1 O
for	349 3 O
14	353 2 O
days	356 4 O
.	360 1 O

Each	362 4 O
course	367 6 O
was	374 3 O
repeated	378 8 O
monthly	387 7 O
.	394 1 O

2	396 1 O
patients	398 8 O
had	407 3 O
stage	411 5 O
II	417 2 O
,	419 1 O
14	421 2 O
stage	424 5 O
III	430 3 O
and	434 3 O
22	438 2 O
stage	441 5 O
IV	447 2 O
disease	450 7 O
.	457 1 O

14	459 2 O
of	462 2 O
the	465 3 O
38	469 2 O
patients	472 8 O
were	481 4 O
previously	486 10 O
treated	497 7 O
with	505 4 O
chemotherapy	510 12 O
,	522 1 O
1	524 1 O
with	526 4 O
radiation	531 9 O
,	540 1 O
6	542 1 O
with	544 4 O
both	549 4 O
chemotherapy	554 12 O
and	567 3 O
radiation	571 9 O
,	580 1 O
and	582 3 O
17	586 2 O
did	589 3 O
not	593 3 O
have	597 4 O
any	602 3 O
treatment	606 9 O
before	616 6 O
CPDD	623 4 B-Chemical
combination	628 11 O
.	639 1 O

31	641 2 O
of	644 2 O
the	647 3 O
38	651 2 O
cases	654 5 O
(	660 1 O
81	661 2 O
.	663 1 O
5	664 1 O
%	665 1 O
)	666 1 O
demonstrated	668 12 O
objective	681 9 O
responses	691 9 O
lasting	701 7 O
for	709 3 O
2	713 1 O
months	715 6 O
or	722 2 O
more	725 4 O
.	729 1 O

These	731 5 O
responses	737 9 O
were	747 4 O
partial	752 7 O
in	760 2 O
19	763 2 O
and	766 3 O
complete	770 8 O
in	779 2 O
12	782 2 O
cases	785 5 O
.	790 1 O

Hematologic	792 11 B-Disease
toxicity	804 8 I-Disease
was	813 3 O
moderate	817 8 O
and	826 3 O
with	830 4 O
reversible	835 10 O
anemia	846 6 B-Disease
developing	853 10 O
in	864 2 O
71	867 2 O
%	869 1 O
of	871 2 O
patients	874 8 O
.	882 1 O

Gastrointestinal	884 16 O
side	901 4 O
effects	906 7 O
from	914 4 O
CPDD	919 4 B-Chemical
were	924 4 O
universal	929 9 O
.	938 1 O

HMM	940 3 B-Chemical
gastrointestinal	944 16 B-Disease
toxicity	961 8 I-Disease
necessitated	970 12 O
discontinuation	983 15 O
of	999 2 O
the	1002 3 O
drug	1006 4 O
in	1011 2 O
5	1014 1 O
patients	1016 8 O
.	1024 1 O

Severe	1026 6 O
nephrotoxicity	1033 14 B-Disease
was	1048 3 O
observed	1052 8 O
in	1061 2 O
2	1064 1 O
patients	1066 8 O
but	1075 3 O
was	1079 3 O
reversible	1083 10 O
.	1093 1 O

There	1095 5 O
were	1101 4 O
no	1106 2 O
drug	1109 4 O
-	1113 1 O
related	1114 7 O
deaths	1122 6 O
.	1128 1 O

Nontraumatic	0 12 O
dissecting	13 10 B-Disease
aneurysm	24 8 I-Disease
of	33 2 O
the	36 3 O
basilar	40 7 O
artery	48 6 O
.	54 1 O

A	56 1 O
case	58 4 O
of	63 2 O
nontraumatic	66 12 O
dissecting	79 10 B-Disease
aneurysm	90 8 I-Disease
of	99 2 O
the	102 3 O
basilar	106 7 O
artery	114 6 O
in	121 2 O
association	124 11 O
with	136 4 O
hypertension	141 12 B-Disease
,	153 1 O
smoke	155 5 O
,	160 1 O
and	162 3 O
oral	166 4 B-Chemical
contraceptives	171 14 I-Chemical
is	186 2 O
reported	189 8 O
in	198 2 O
a	201 1 O
young	203 5 O
female	209 6 O
patient	216 7 O
with	224 4 O
a	229 1 O
locked	231 6 B-Disease
-	237 1 I-Disease
in	238 2 I-Disease
syndrome	241 8 I-Disease
.	249 1 O

Propylthiouracil	0 16 B-Chemical
-	16 1 O
induced	17 7 O
hepatic	25 7 B-Disease
damage	33 6 I-Disease
.	39 1 O

Two	41 3 O
cases	45 5 O
of	51 2 O
propylthiouracil	54 16 B-Chemical
-	70 1 O
induced	71 7 O
liver	79 5 B-Disease
damage	85 6 I-Disease
have	92 4 O
been	97 4 O
observed	102 8 O
.	110 1 O

The	112 3 O
first	116 5 O
case	122 4 O
is	127 2 O
of	130 2 O
an	133 2 O
acute	136 5 O
type	142 4 O
of	147 2 O
damage	150 6 O
,	156 1 O
proven	158 6 O
by	165 2 O
rechallenge	168 11 O
;	179 1 O
the	181 3 O
second	185 6 O
presents	192 8 O
a	201 1 O
clinical	203 8 O
and	212 3 O
histologic	216 10 O
picture	227 7 O
resembling	235 10 O
chronic	246 7 B-Disease
active	254 6 I-Disease
hepatitis	261 9 I-Disease
,	270 1 O
with	272 4 O
spontaneous	277 11 O
remission	289 9 O
.	298 1 O

Studies	0 7 O
on	8 2 O
the	11 3 O
bradycardia	15 11 B-Disease
induced	27 7 O
by	35 2 O
bepridil	38 8 B-Chemical
.	46 1 O

Bepridil	48 8 B-Chemical
,	56 1 O
a	58 1 O
novel	60 5 O
active	66 6 O
compound	73 8 O
for	82 3 O
prophylactic	86 12 O
treatment	99 9 O
of	109 2 O
anginal	112 7 B-Disease
attacks	120 7 I-Disease
,	127 1 O
induced	129 7 O
persistent	137 10 O
bradycardia	148 11 B-Disease
and	160 3 O
a	164 1 O
non	166 3 O
-	169 1 O
specific	170 8 O
anti	179 4 O
-	183 1 O
tachycardial	184 12 B-Disease
effect	197 6 O
,	203 1 O
the	205 3 O
mechanisms	209 10 O
of	220 2 O
which	223 5 O
were	229 4 O
investigated	234 12 O
in	247 2 O
vitro	250 5 O
and	256 3 O
in	260 2 O
vivo	263 4 O
.	267 1 O

In	269 2 O
vitro	272 5 O
perfusion	278 9 O
of	288 2 O
bepridil	291 8 B-Chemical
in	300 2 O
the	303 3 O
life	307 4 O
-	311 1 O
support	312 7 O
medium	320 6 O
for	327 3 O
isolated	331 8 O
sino	340 4 O
-	344 1 O
atrial	345 6 O
tissue	352 6 O
from	359 4 O
rabbit	364 6 O
heart	371 5 O
,	376 1 O
caused	378 6 O
a	385 1 O
reduction	387 9 O
in	397 2 O
action	400 6 O
potential	407 9 O
(	417 1 O
AP	418 2 O
)	420 1 O
spike	422 5 O
frequency	428 9 O
(	438 1 O
recorded	439 8 O
by	448 2 O
KCl	451 3 B-Chemical
microelectrodes	455 15 O
)	470 1 O
starting	472 8 O
at	481 2 O
doses	484 5 O
of	490 2 O
5	493 1 O
X	495 1 O
10	497 2 O
(	499 1 O
-	500 1 O
6	501 1 O
)	502 1 O
M	504 1 O
.	505 1 O

This	507 4 O
effect	512 6 O
was	519 3 O
dose	523 4 O
-	527 1 O
dependent	528 9 O
up	538 2 O
to	541 2 O
concentrations	544 14 O
of	559 2 O
5	562 1 O
X	564 1 O
10	566 2 O
(	568 1 O
-	569 1 O
5	570 1 O
)	571 1 O
M	573 1 O
,	574 1 O
whereupon	576 9 O
blockade	586 8 O
of	595 2 O
sinus	598 5 O
activity	604 8 O
set	613 3 O
in	617 2 O
.	619 1 O

Bepridil	621 8 B-Chemical
at	630 2 O
a	633 1 O
dose	635 4 O
of	640 2 O
5	643 1 O
X	645 1 O
10	647 2 O
(	649 1 O
-	650 1 O
6	651 1 O
)	652 1 O
M	654 1 O
,	655 1 O
induced	657 7 O
a	665 1 O
concomitant	667 11 O
reduction	679 9 O
in	689 2 O
AP	692 2 O
amplitude	695 9 O
(	705 1 O
falling	706 7 O
from	714 4 O
71	719 2 O
+	722 1 O
/	723 1 O
-	724 1 O
8	726 1 O
mV	728 2 O
to	731 2 O
47	734 2 O
+	737 1 O
/	738 1 O
-	739 1 O
6	741 1 O
mV	743 2 O
)	745 1 O
,	746 1 O
maximum	748 7 O
systolic	756 8 O
depolarization	765 14 O
velocity	780 8 O
(	789 1 O
phase	790 5 O
0	796 1 O
)	797 1 O
which	799 5 O
fell	805 4 O
from	810 4 O
1	815 1 O
.	816 1 O
85	817 2 O
+	820 1 O
/	821 1 O
-	822 1 O
0	824 1 O
.	825 1 O
35	826 2 O
V	829 1 O
/	830 1 O
s	831 1 O
to	833 2 O
0	836 1 O
.	837 1 O
84	838 2 O
+	841 1 O
/	842 1 O
-	843 1 O
0	845 1 O
.	846 1 O
28	847 2 O
V	850 1 O
/	851 1 O
s	852 1 O
,	853 1 O
together	855 8 O
with	864 4 O
maximum	869 7 O
diastolic	877 9 O
depolarization	887 14 O
velocity	902 8 O
(	911 1 O
phase	912 5 O
4	918 1 O
)	919 1 O
which	921 5 O
fell	927 4 O
from	932 4 O
38	937 2 O
+	940 1 O
/	941 1 O
-	942 1 O
3	944 1 O
mV	946 2 O
/	948 1 O
s	949 1 O
to	951 2 O
24	954 2 O
+	957 1 O
/	958 1 O
-	959 1 O
5	961 1 O
mV	963 2 O
/	965 1 O
s	966 1 O
.	967 1 O

In	969 2 O
vivo	972 4 O
injection	977 9 O
of	987 2 O
bepridil	990 8 B-Chemical
at	999 2 O
a	1002 1 O
dose	1004 4 O
of	1009 2 O
5	1012 1 O
mg	1014 2 O
/	1016 1 O
kg	1017 2 O
(	1020 1 O
i	1021 1 O
.	1022 1 O
v	1023 1 O
.	1024 1 O
)	1025 1 O
into	1027 4 O
6	1032 1 O
anaesthetized	1034 13 O
dogs	1048 4 O
which	1053 5 O
had	1059 3 O
undergone	1063 9 O
ablation	1073 8 O
of	1082 2 O
all	1085 3 O
the	1089 3 O
extrinsic	1093 9 O
cardiac	1103 7 O
afferent	1111 8 O
nerve	1120 5 O
supply	1126 6 O
,	1132 1 O
together	1134 8 O
with	1143 4 O
a	1148 1 O
bilateral	1150 9 O
medullo	1160 7 O
-	1167 1 O
adrenalectomy	1168 13 O
,	1181 1 O
caused	1183 6 O
a	1190 1 O
marked	1192 6 O
reduction	1199 9 O
in	1209 2 O
heart	1212 5 O
rate	1218 4 O
which	1223 5 O
fell	1229 4 O
from	1234 4 O
98	1239 2 O
.	1241 1 O
7	1242 1 O
+	1244 1 O
/	1245 1 O
-	1246 1 O
4	1248 1 O
.	1249 1 O
2	1250 1 O
beats	1252 5 O
/	1257 1 O
min	1258 3 O
to	1262 2 O
76	1265 2 O
+	1268 1 O
/	1269 1 O
-	1270 1 O
5	1272 1 O
.	1273 1 O
3	1274 1 O
beats	1276 5 O
/	1281 1 O
min	1282 3 O
sustained	1286 9 O
for	1296 3 O
more	1300 4 O
than	1305 4 O
45	1310 2 O
min	1313 3 O
.	1316 1 O

It	1318 2 O
is	1321 2 O
concluded	1324 9 O
that	1334 4 O
bepridil	1339 8 B-Chemical
reduces	1348 7 O
heart	1356 5 O
rate	1362 4 O
by	1367 2 O
acting	1370 6 O
directly	1377 8 O
on	1386 2 O
the	1389 3 O
sinus	1393 5 O
node	1399 4 O
.	1403 1 O

This	1405 4 O
effect	1410 6 O
,	1416 1 O
which	1418 5 O
results	1424 7 O
in	1432 2 O
a	1435 1 O
flattening	1437 10 O
of	1448 2 O
the	1451 3 O
phase	1455 5 O
0	1461 1 O
and	1463 3 O
phase	1467 5 O
4	1473 1 O
slope	1475 5 O
,	1480 1 O
together	1482 8 O
with	1491 4 O
a	1496 1 O
longer	1498 6 O
AP	1505 2 O
duration	1508 8 O
,	1516 1 O
may	1518 3 O
be	1522 2 O
due	1525 3 O
to	1529 2 O
an	1532 2 O
increase	1535 8 O
in	1544 2 O
the	1547 3 O
time	1551 4 O
constants	1556 9 O
of	1566 2 O
slow	1569 4 O
inward	1574 6 O
ionic	1581 5 O
currents	1587 8 O
(	1596 1 O
already	1597 7 O
demonstrated	1605 12 O
elsewhere	1618 9 O
)	1627 1 O
,	1628 1 O
but	1630 3 O
also	1634 4 O
to	1639 2 O
an	1642 2 O
increased	1645 9 O
time	1655 4 O
constant	1660 8 O
for	1669 3 O
deactivation	1673 12 O
of	1686 2 O
the	1689 3 O
outward	1693 7 O
potassium	1701 9 B-Chemical
current	1711 7 O
(	1719 1 O
Ip	1720 2 O
)	1722 1 O
.	1723 1 O

Hepatitis	0 9 B-Disease
and	10 3 O
renal	14 5 B-Disease
tubular	20 7 I-Disease
acidosis	28 8 I-Disease
after	37 5 O
anesthesia	43 10 O
with	54 4 O
methoxyflurane	59 14 B-Chemical
.	73 1 O

A	75 1 O
69	77 2 O
-	79 1 O
year	80 4 O
-	84 1 O
old	85 3 O
man	89 3 O
operated	93 8 O
for	102 3 O
acute	106 5 B-Disease
cholecystitis	112 13 I-Disease
under	126 5 O
methoxyflurane	132 14 B-Chemical
anesthesia	147 10 O
developed	158 9 O
postoperatively	168 15 O
a	184 1 O
hepatic	186 7 B-Disease
insufficiency	194 13 I-Disease
syndrome	208 8 I-Disease
and	217 3 O
renal	221 5 B-Disease
tubular	227 7 I-Disease
acidosis	235 8 I-Disease
.	243 1 O

Massive	245 7 O
bleeding	253 8 B-Disease
appeared	262 8 O
during	271 6 O
surgery	278 7 O
which	286 5 O
lasted	292 6 O
for	299 3 O
six	303 3 O
hours	307 5 O
.	312 1 O

Postoperative	314 13 O
evolution	328 9 O
under	338 5 O
supportive	344 10 O
therapy	355 7 O
was	363 3 O
favourable	367 10 O
.	377 1 O

Complete	379 8 O
recovery	388 8 O
was	397 3 O
confirmed	401 9 O
by	411 2 O
repeated	414 8 O
controls	423 8 O
performed	432 9 O
over	442 4 O
a	447 1 O
period	449 6 O
of	456 2 O
one	459 3 O
year	463 4 O
after	468 5 O
surgery	474 7 O
.	481 1 O

Pituitary	0 9 O
response	10 8 O
to	19 2 O
luteinizing	22 11 O
hormone	34 7 O
-	41 1 O
releasing	42 9 O
hormone	52 7 O
during	60 6 O
haloperidol	67 11 B-Chemical
-	78 1 O
induced	79 7 O
hyperprolactinemia	87 18 B-Disease
.	105 1 O

The	107 3 O
effects	111 7 O
of	119 2 O
a	122 1 O
6	124 1 O
-	125 1 O
hour	126 4 O
infusion	131 8 O
with	140 4 O
haloperidol	145 11 B-Chemical
on	157 2 O
serum	160 5 O
prolactin	166 9 O
and	176 3 O
luteinizing	180 11 O
hormone	192 7 O
(	200 1 O
LH	201 2 O
)	203 1 O
levels	205 6 O
was	212 3 O
studied	216 7 O
in	224 2 O
a	227 1 O
group	229 5 O
of	235 2 O
male	238 4 O
subjects	243 8 O
.	251 1 O

Five	253 4 O
hours	258 5 O
after	264 5 O
starting	270 8 O
the	279 3 O
infusions	283 9 O
,	292 1 O
a	294 1 O
study	296 5 O
of	302 2 O
the	305 3 O
pituitary	309 9 O
responses	319 9 O
to	329 2 O
LH	332 2 O
-	334 1 O
releasing	335 9 O
hormone	345 7 O
(	353 1 O
LH	354 2 O
-	356 1 O
RH	357 2 O
)	359 1 O
was	361 3 O
carried	365 7 O
out	373 3 O
.	376 1 O

Control	378 7 O
patients	386 8 O
received	395 8 O
infusions	404 9 O
of	414 2 O
0	417 1 O
.	418 1 O
9	419 1 O
%	420 1 O
NaCl	422 4 B-Chemical
solution	427 8 O
.	435 1 O

During	437 6 O
the	444 3 O
course	448 6 O
of	455 2 O
haloperidol	458 11 B-Chemical
infusions	470 9 O
,	479 1 O
significant	481 11 O
hyperprolactinemia	493 18 B-Disease
was	512 3 O
found	516 5 O
,	521 1 O
together	523 8 O
with	532 4 O
an	537 2 O
abolished	540 9 O
pituitary	550 9 O
response	560 8 O
to	569 2 O
LH	572 2 O
-	574 1 O
RH	575 2 O
,	577 1 O
as	579 2 O
compared	582 8 O
with	591 4 O
responses	596 9 O
of	606 2 O
control	609 7 O
subjects	617 8 O
.	625 1 O

Antirifampicin	0 14 O
antibodies	15 10 O
in	26 2 O
acute	29 5 O
rifampicin	35 10 B-Chemical
-	45 1 O
associated	46 10 O
renal	57 5 B-Disease
failure	63 7 I-Disease
.	70 1 O

5	72 1 O
patients	74 8 O
with	83 4 O
acute	88 5 B-Disease
renal	94 5 I-Disease
failure	100 7 I-Disease
(	108 1 O
3	109 1 O
with	111 4 O
thrombopenia	116 12 B-Disease
and	129 3 O
hemolysis	133 9 B-Disease
)	142 1 O
induced	144 7 O
by	152 2 O
the	155 3 O
reintroduction	159 14 O
of	174 2 O
rifampicin	177 10 B-Chemical
are	188 3 O
described	192 9 O
.	201 1 O

No	203 2 O
correlation	206 11 O
was	218 3 O
found	222 5 O
between	228 7 O
the	236 3 O
severity	240 8 O
of	249 2 O
clinical	252 8 O
manifestations	261 14 O
and	276 3 O
the	280 3 O
total	284 5 O
dose	290 4 O
taken	295 5 O
by	301 2 O
the	304 3 O
patients	308 8 O
.	316 1 O

In	318 2 O
all	321 3 O
but	325 3 O
1	329 1 O
patient	331 7 O
,	338 1 O
antirifampicin	340 14 O
antibodies	355 10 O
were	366 4 O
detected	371 8 O
.	379 1 O

Antibodies	381 10 O
suggested	392 9 O
to	402 2 O
be	405 2 O
of	408 2 O
the	411 3 O
IgM	415 3 O
class	419 5 O
were	425 4 O
detected	430 8 O
in	439 2 O
all	442 3 O
3	446 1 O
patients	448 8 O
with	457 4 O
hematological	462 13 B-Disease
disorders	476 9 I-Disease
.	485 1 O

The	487 3 O
pattern	491 7 O
of	499 2 O
non	502 3 O
-	505 1 O
specific	506 8 O
acute	515 5 B-Disease
tubular	521 7 I-Disease
necrosis	529 8 I-Disease
found	538 5 O
in	544 2 O
the	547 3 O
2	551 1 O
biopsied	553 8 O
patients	562 8 O
,	570 1 O
indistinguishable	572 17 O
from	590 4 O
that	595 4 O
of	600 2 O
ischemic	603 8 O
origin	612 6 O
,	618 1 O
raised	620 6 O
the	627 3 O
possibility	631 11 O
of	643 2 O
a	646 1 O
vascular	648 8 O
-	656 1 O
mediated	657 8 O
damage	666 6 O
.	672 1 O

In	674 2 O
3	677 1 O
patients	679 8 O
,	687 1 O
the	689 3 O
possibility	693 11 O
of	705 2 O
a	708 1 O
triggering	710 10 O
immunoallergic	721 14 O
mechanism	736 9 O
is	746 2 O
discussed	749 9 O
.	758 1 O

Cardiovascular	0 14 O
effects	15 7 O
of	23 2 O
hypotension	26 11 B-Disease
induced	38 7 O
by	46 2 O
adenosine	49 9 B-Chemical
triphosphate	59 12 I-Chemical
and	72 3 O
sodium	76 6 B-Chemical
nitroprusside	83 13 I-Chemical
on	97 2 O
dogs	100 4 O
with	105 4 O
denervated	110 10 O
hearts	121 6 O
.	127 1 O

Adenosine	129 9 B-Chemical
triphosphate	139 12 I-Chemical
(	152 1 O
ATP	153 3 B-Chemical
)	156 1 O
and	158 3 O
sodium	162 6 B-Chemical
nitroprusside	169 13 I-Chemical
(	183 1 O
SNP	184 3 B-Chemical
)	187 1 O
are	189 3 O
administered	193 12 O
to	206 2 O
patients	209 8 O
to	218 2 O
induce	221 6 O
and	228 3 O
control	232 7 O
hypotension	240 11 B-Disease
during	252 6 O
anesthesia	259 10 O
.	269 1 O

SNP	271 3 B-Chemical
is	275 2 O
authorized	278 10 O
for	289 3 O
clinical	293 8 O
use	302 3 O
in	306 2 O
USA	309 3 O
and	313 3 O
UK	317 2 O
,	319 1 O
and	321 3 O
ATP	325 3 B-Chemical
is	329 2 O
clinically	332 10 O
used	343 4 O
in	348 2 O
other	351 5 O
countries	357 9 O
such	367 4 O
as	372 2 O
Japan	375 5 O
.	380 1 O

We	382 2 O
investigated	385 12 O
how	398 3 O
these	402 5 O
two	408 3 O
drugs	412 5 O
act	418 3 O
on	422 2 O
the	425 3 O
cardiovascular	429 14 O
systems	444 7 O
of	452 2 O
20	455 2 O
dogs	458 4 O
whose	463 5 O
hearts	469 6 O
had	476 3 O
been	480 4 O
denervated	485 10 O
by	496 2 O
a	499 1 O
procedure	501 9 O
we	511 2 O
had	514 3 O
devised	518 7 O
.	525 1 O

ATP	527 3 B-Chemical
(	531 1 O
10	532 2 O
dogs	535 4 O
)	539 1 O
or	541 2 O
SNP	544 3 B-Chemical
(	548 1 O
10	549 2 O
dogs	552 4 O
)	556 1 O
was	558 3 O
administered	562 12 O
to	575 2 O
reduce	578 6 O
mean	585 4 O
arterial	590 8 O
pressure	599 8 O
by	608 2 O
30	611 2 O
%	613 1 O
to	615 2 O
70	618 2 O
%	620 1 O
of	622 2 O
control	625 7 O
.	632 1 O

Before	634 6 O
,	640 1 O
during	642 6 O
and	649 3 O
after	653 5 O
induced	659 7 O
hypotension	667 11 B-Disease
,	678 1 O
we	680 2 O
measured	683 8 O
major	692 5 O
cardiovascular	698 14 O
parameters	713 10 O
.	723 1 O

Hypotension	725 11 B-Disease
induced	737 7 O
by	745 2 O
ATP	748 3 B-Chemical
was	752 3 O
accompanied	756 11 O
by	768 2 O
significant	771 11 O
decreases	783 9 O
in	793 2 O
mean	796 4 O
pulmonary	801 9 O
arterial	811 8 O
pressure	820 8 O
(	829 1 O
p	830 1 O
less	832 4 O
than	837 4 O
0	842 1 O
.	843 1 O
001	844 3 O
)	847 1 O
,	848 1 O
central	850 7 O
venous	858 6 O
pressure	865 8 O
(	874 1 O
p	875 1 O
less	877 4 O
than	882 4 O
0	887 1 O
.	888 1 O
001	889 3 O
)	892 1 O
,	893 1 O
left	895 4 O
ventricular	900 11 O
end	912 3 O
-	915 1 O
diastolic	916 9 O
pressure	926 8 O
(	935 1 O
p	936 1 O
less	938 4 O
than	943 4 O
0	948 1 O
.	949 1 O
001	950 3 O
)	953 1 O
,	954 1 O
total	956 5 O
peripheral	962 10 O
resistance	973 10 O
(	984 1 O
p	985 1 O
less	987 4 O
than	992 4 O
0	997 1 O
.	998 1 O
001	999 3 O
)	1002 1 O
,	1003 1 O
rate	1005 4 O
pressure	1010 8 O
product	1019 7 O
(	1027 1 O
p	1028 1 O
less	1030 4 O
than	1035 4 O
0	1040 1 O
.	1041 1 O
001	1042 3 O
)	1045 1 O
,	1046 1 O
total	1048 5 O
body	1054 4 O
oxygen	1059 6 B-Chemical
consumption	1066 11 O
(	1078 1 O
p	1079 1 O
less	1081 4 O
than	1086 4 O
0	1091 1 O
.	1092 1 O
05	1093 2 O
)	1095 1 O
,	1096 1 O
and	1098 3 O
heart	1102 5 O
rate	1108 4 O
(	1113 1 O
p	1114 1 O
less	1116 4 O
than	1121 4 O
0	1126 1 O
.	1127 1 O
001	1128 3 O
)	1131 1 O
;	1132 1 O
all	1134 3 O
these	1138 5 O
variables	1144 9 O
returned	1154 8 O
normal	1163 6 O
within	1170 6 O
30	1177 2 O
min	1180 3 O
after	1184 5 O
ATP	1190 3 B-Chemical
was	1194 3 O
stopped	1198 7 O
.	1205 1 O

Cardiac	1207 7 O
output	1215 6 O
did	1222 3 O
not	1226 3 O
change	1230 6 O
.	1236 1 O

During	1238 6 O
hypotension	1245 11 B-Disease
produced	1257 8 O
by	1266 2 O
SNP	1269 3 B-Chemical
similar	1273 7 O
decreases	1281 9 O
were	1291 4 O
observed	1296 8 O
in	1305 2 O
mean	1308 4 O
pulmonary	1313 9 O
arterial	1323 8 O
pressure	1332 8 O
(	1341 1 O
p	1342 1 O
less	1344 4 O
than	1349 4 O
0	1354 1 O
.	1355 1 O
01	1356 2 O
)	1358 1 O
,	1359 1 O
central	1361 7 O
venous	1369 6 O
pressure	1376 8 O
(	1385 1 O
p	1386 1 O
less	1388 4 O
than	1393 4 O
0	1398 1 O
.	1399 1 O
001	1400 3 O
)	1403 1 O
,	1404 1 O
left	1406 4 O
ventricular	1411 11 O
end	1423 3 O
-	1426 1 O
diastolic	1427 9 O
pressure	1437 8 O
(	1446 1 O
p	1447 1 O
less	1449 4 O
than	1454 4 O
0	1459 1 O
.	1460 1 O
01	1461 2 O
)	1463 1 O
,	1464 1 O
total	1466 5 O
peripheral	1472 10 O
resistance	1483 10 O
(	1494 1 O
p	1495 1 O
less	1497 4 O
than	1502 4 O
0	1507 1 O
.	1508 1 O
001	1509 3 O
)	1512 1 O
,	1513 1 O
rate	1515 4 O
pressure	1520 8 O
product	1529 7 O
(	1537 1 O
p	1538 1 O
less	1540 4 O
than	1545 4 O
0	1550 1 O
.	1551 1 O
001	1552 3 O
)	1555 1 O
,	1556 1 O
and	1558 3 O
oxygen	1562 6 B-Chemical
content	1569 7 O
difference	1577 10 O
between	1588 7 O
arterial	1596 8 O
and	1605 3 O
mixed	1609 5 O
venous	1615 6 O
blood	1622 5 O
(	1628 1 O
p	1629 1 O
less	1631 4 O
than	1636 4 O
0	1641 1 O
.	1642 1 O
05	1643 2 O
)	1645 1 O
,	1646 1 O
while	1648 5 O
heart	1654 5 O
rate	1660 4 O
(	1665 1 O
p	1666 1 O
less	1668 4 O
than	1673 4 O
0	1678 1 O
.	1679 1 O
001	1680 3 O
)	1683 1 O
and	1685 3 O
cardiac	1689 7 O
output	1697 6 O
(	1704 1 O
p	1705 1 O
less	1707 4 O
than	1712 4 O
0	1717 1 O
.	1718 1 O
05	1719 2 O
)	1721 1 O
were	1723 4 O
increased	1728 9 O
.	1737 1 O

Recoveries	1739 10 O
of	1750 2 O
heart	1753 5 O
rate	1759 4 O
and	1764 3 O
left	1768 4 O
ventricular	1773 11 O
end	1785 3 O
-	1788 1 O
diastolic	1789 9 O
pressure	1799 8 O
were	1808 4 O
not	1813 3 O
shown	1817 5 O
within	1823 6 O
60	1830 2 O
min	1833 3 O
after	1837 5 O
SNP	1843 3 B-Chemical
had	1847 3 O
been	1851 4 O
stopped	1856 7 O
.	1863 1 O

Both	1865 4 O
ATP	1870 3 B-Chemical
and	1874 3 O
SNP	1878 3 B-Chemical
should	1882 6 O
act	1889 3 O
on	1893 2 O
the	1896 3 O
pacemaker	1900 9 O
tissue	1910 6 O
of	1917 2 O
the	1920 3 O
heart	1924 5 O
.	1929 1 O

Comparative	0 11 O
study	12 5 O
:	17 1 O
Endografine	19 11 B-Chemical
(	31 1 O
diatrizoate	32 11 B-Chemical
)	43 1 O
,	44 1 O
Vasurix	46 7 B-Chemical
polyvidone	54 10 I-Chemical
(	65 1 O
acetrizoate	66 11 B-Chemical
)	77 1 O
,	78 1 O
Dimer	80 5 B-Chemical
-	85 1 I-Chemical
X	86 1 I-Chemical
(	88 1 O
iocarmate	89 9 B-Chemical
)	98 1 O
and	100 3 O
Hexabrix	104 8 B-Chemical
(	113 1 O
ioxaglate	114 9 B-Chemical
)	123 1 O
in	125 2 O
hysterosalpingography	128 21 O
.	149 1 O

Side	151 4 O
effects	156 7 O
of	164 2 O
hysterosalpingography	167 21 O
with	189 4 O
Dimer	194 5 B-Chemical
-	199 1 I-Chemical
X	200 1 I-Chemical
,	201 1 O
Hexabrix	203 8 B-Chemical
,	211 1 O
Vasurix	213 7 B-Chemical
polyvidone	221 10 I-Chemical
and	232 3 O
Endografine	236 11 B-Chemical
in	248 2 O
142	251 3 O
consecutive	255 11 O
patients	267 8 O
,	275 1 O
receiving	277 9 O
one	287 3 O
of	291 2 O
the	294 3 O
four	298 4 O
tested	303 6 O
media	310 5 O
were	316 4 O
evaluated	321 9 O
from	331 4 O
replies	336 7 O
to	344 2 O
postal	347 6 O
questionnaires	354 14 O
.	368 1 O

The	370 3 O
Dimer	374 5 B-Chemical
-	379 1 I-Chemical
X	380 1 I-Chemical
group	382 5 O
had	388 3 O
a	392 1 O
higher	394 6 O
incidence	401 9 O
of	411 2 O
nausea	414 6 B-Disease
and	421 3 O
dizziness	425 9 B-Disease
.	434 1 O

The	436 3 O
Endografine	440 11 B-Chemical
group	452 5 O
had	458 3 O
a	462 1 O
higher	464 6 O
incidence	471 9 O
of	481 2 O
abdominal	484 9 B-Disease
pain	494 4 I-Disease
.	498 1 O

These	500 5 O
differences	506 11 O
occur	518 5 O
especially	524 10 O
in	535 2 O
the	538 3 O
age	542 3 O
groups	546 6 O
under	553 5 O
30	559 2 O
years	562 5 O
.	567 1 O

Hexabrix	569 8 B-Chemical
and	578 3 O
Vasurix	582 7 B-Chemical
polyvidone	590 10 I-Chemical
are	601 3 O
considered	605 10 O
the	616 3 O
best	620 4 O
contrast	625 8 B-Chemical
media	634 5 I-Chemical
for	640 3 O
hysterosalpingography	644 21 O
and	666 3 O
perhaps	670 7 O
because	678 7 O
of	686 2 O
its	689 3 O
low	693 3 O
toxicity	697 8 B-Disease
Hexabrix	706 8 B-Chemical
should	715 6 O
be	722 2 O
preferred	725 9 O
.	734 1 O

Post	0 4 O
-	4 1 O
suxamethonium	5 13 B-Chemical
pains	19 5 B-Disease
in	25 2 O
Nigerian	28 8 O
surgical	37 8 O
patients	46 8 O
.	54 1 O

Contrary	56 8 O
to	65 2 O
an	68 2 O
earlier	71 7 O
report	79 6 O
by	86 2 O
Coxon	89 5 O
,	94 1 O
scoline	96 7 B-Chemical
pain	104 4 B-Disease
occurs	109 6 O
in	116 2 O
African	119 7 O
negroes	127 7 O
.	134 1 O

Its	136 3 O
incidence	140 9 O
was	150 3 O
determined	154 10 O
in	165 2 O
a	168 1 O
prospective	170 11 O
study	182 5 O
involving	188 9 O
a	198 1 O
total	200 5 O
of	206 2 O
100	209 3 O
Nigerian	213 8 O
patients	222 8 O
(	231 1 O
50	232 2 O
out	235 3 O
-	238 1 O
patients	239 8 O
and	248 3 O
50	252 2 O
in	255 2 O
-	257 1 O
patients	258 8 O
)	266 1 O
.	267 1 O

About	269 5 O
62	275 2 O
%	277 1 O
of	279 2 O
the	282 3 O
out	286 3 O
-	289 1 O
patients	290 8 O
developed	299 9 O
scoline	309 7 B-Chemical
pain	317 4 B-Disease
as	322 2 O
compared	325 8 O
with	334 4 O
about	339 5 O
26	345 2 O
%	347 1 O
among	349 5 O
the	355 3 O
in	359 2 O
-	361 1 O
patients	362 8 O
.	370 1 O

The	372 3 O
abolition	376 9 O
of	386 2 O
muscle	389 6 O
fasciculations	396 14 B-Disease
(	411 1 O
by	412 2 O
0	415 1 O
.	416 1 O
075mg	417 5 O
/	422 1 O
kg	423 2 O
dose	426 4 O
of	431 2 O
Fazadinium	434 10 B-Chemical
)	444 1 O
did	446 3 O
not	450 3 O
influence	454 9 O
the	464 3 O
occurrence	468 10 O
of	479 2 O
scoline	482 7 B-Chemical
pain	490 4 B-Disease
.	494 1 O

Neither	496 7 O
the	504 3 O
type	508 4 O
of	513 2 O
induction	516 9 O
agent	526 5 O
(	532 1 O
Althesin	533 8 B-Chemical
or	542 2 O
Thiopentone	545 11 B-Chemical
)	556 1 O
nor	558 3 O
the	562 3 O
salt	566 4 O
preparation	571 11 O
of	583 2 O
suxamethonium	586 13 B-Chemical
used	600 4 O
(	605 1 O
chloride	606 8 B-Chemical
or	615 2 O
bromide	618 7 B-Chemical
)	625 1 O
,	626 1 O
affected	628 8 O
the	637 3 O
incidence	641 9 O
of	651 2 O
scoline	654 7 B-Chemical
pain	662 4 B-Disease
.	666 1 O

Medial	0 6 O
changes	7 7 O
in	15 2 O
arterial	18 8 O
spasm	27 5 B-Disease
induced	33 7 O
by	41 2 O
L	44 1 B-Chemical
-	45 1 I-Chemical
norepinephrine	46 14 I-Chemical
.	60 1 O

In	62 2 O
normal	65 6 O
rats	72 4 O
,	76 1 O
the	78 3 O
media	82 5 O
of	88 2 O
small	91 5 O
arteries	97 8 O
(	106 1 O
0	107 1 O
.	108 1 O
4	109 1 O
-	110 1 O
-	111 1 O
0	112 1 O
.	113 1 O
2	114 1 O
mm	116 2 O
in	119 2 O
diameter	122 8 O
)	130 1 O
previously	132 10 O
was	143 3 O
shown	147 5 O
to	153 2 O
contain	156 7 O
intracellular	164 13 O
vacuoles	178 8 O
,	186 1 O
identified	188 10 O
ultrastructurally	199 17 O
as	217 2 O
herniations	220 11 O
of	232 2 O
one	235 3 O
smooth	239 6 O
muscle	246 6 O
cell	253 4 O
into	258 4 O
another	263 7 O
.	270 1 O

The	272 3 O
hypothesis	276 10 O
that	287 4 O
intense	292 7 O
vasoconstriction	300 16 O
would	317 5 O
increase	323 8 O
the	332 3 O
number	336 6 O
of	343 2 O
such	346 4 O
vacuoles	351 8 O
has	360 3 O
been	364 4 O
tested	369 6 O
.	375 1 O

In	377 2 O
the	380 3 O
media	384 5 O
of	390 2 O
the	393 3 O
saphenous	397 9 O
artery	407 6 O
and	414 3 O
its	418 3 O
distal	422 6 O
branch	429 6 O
,	435 1 O
vasoconstriction	437 16 O
induced	454 7 O
by	462 2 O
L	465 1 B-Chemical
-	466 1 I-Chemical
norepinephrine	467 14 I-Chemical
produced	482 8 O
many	491 4 O
cell	496 4 O
-	500 1 O
to	501 2 O
-	503 1 O
cell	504 4 O
hernias	509 7 B-Disease
within	517 6 O
15	524 2 O
minutes	527 7 O
.	534 1 O

At	536 2 O
1	539 1 O
day	541 3 O
their	545 5 O
number	551 6 O
was	558 3 O
reduced	562 7 O
to	570 2 O
about	573 5 O
1	579 1 O
/	580 1 O
10	581 2 O
of	584 2 O
the	587 3 O
original	591 8 O
number	600 6 O
.	606 1 O

By	608 2 O
7	611 1 O
days	613 4 O
the	618 3 O
vessel	622 6 O
was	629 3 O
almost	633 6 O
restored	640 8 O
to	649 2 O
normal	652 6 O
.	658 1 O

Triple	660 6 O
stimulation	667 11 O
over	679 4 O
1	684 1 O
day	686 3 O
induced	690 7 O
more	698 4 O
severe	703 6 O
changes	710 7 O
in	718 2 O
the	721 3 O
media	725 5 O
.	730 1 O

These	732 5 O
findings	738 8 O
suggest	747 7 O
that	755 4 O
smooth	760 6 O
muscle	767 6 O
cells	774 5 O
are	780 3 O
susceptible	784 11 O
to	796 2 O
damage	799 6 O
in	806 2 O
the	809 3 O
course	813 6 O
of	820 2 O
their	823 5 O
specific	829 8 O
function	838 8 O
.	846 1 O

The	848 3 O
experimental	852 12 O
data	865 4 O
are	870 3 O
discussed	874 9 O
in	884 2 O
relation	887 8 O
to	896 2 O
medial	899 6 O
changes	906 7 O
observed	914 8 O
in	923 2 O
other	926 5 O
instances	932 9 O
of	942 2 O
arterial	945 8 O
spasm	954 5 B-Disease
.	959 1 O

Endothelial	961 11 O
changes	973 7 O
that	981 4 O
developed	986 9 O
in	996 2 O
the	999 3 O
same	1003 4 O
experimental	1008 12 O
model	1021 5 O
were	1027 4 O
described	1032 9 O
in	1042 2 O
a	1045 1 O
previous	1047 8 O
paper	1056 5 O
.	1061 1 O

Abnormalities	0 13 O
of	14 2 O
the	17 3 O
pupil	21 5 O
and	27 3 O
visual	31 6 O
-	37 1 O
evoked	38 6 O
potential	45 9 O
in	55 2 O
quinine	58 7 B-Chemical
amblyopia	66 9 B-Disease
.	75 1 O

Total	77 5 O
blindness	83 9 B-Disease
with	93 4 O
a	98 1 O
transient	100 9 O
tonic	110 5 B-Disease
pupillary	116 9 I-Disease
response	126 8 O
,	134 1 O
denervation	136 11 O
supersensitivity	148 16 O
,	164 1 O
and	166 3 O
abnormal	170 8 O
visual	179 6 O
-	185 1 O
evoked	186 6 O
potentials	193 10 O
developed	204 9 O
in	214 2 O
a	217 1 O
54	219 2 O
-	221 1 O
year	222 4 O
-	226 1 O
old	227 3 O
man	231 3 O
after	235 5 O
the	241 3 O
use	245 3 O
of	249 2 O
quinine	252 7 B-Chemical
sulfate	260 7 I-Chemical
for	268 3 O
leg	272 3 B-Disease
cramps	276 6 I-Disease
.	282 1 O

He	284 2 O
later	287 5 O
recovered	293 9 O
normal	303 6 O
visual	310 6 O
acuity	317 6 O
.	323 1 O

A	325 1 O
transient	327 9 O
tonic	337 5 B-Disease
pupillary	343 9 I-Disease
response	353 8 O
,	361 1 O
denervation	363 11 O
supersensitivity	375 16 O
,	391 1 O
and	393 3 O
abnormal	397 8 O
visual	406 6 O
-	412 1 O
evoked	413 6 O
potentials	420 10 O
in	431 2 O
quinine	434 7 B-Chemical
toxicity	442 8 B-Disease
,	450 1 O
to	452 2 O
our	455 3 O
knowledge	459 9 O
,	468 1 O
have	470 4 O
not	475 3 O
been	479 4 O
previously	484 10 O
reported	495 8 O
.	503 1 O

Suxamethonium	0 13 B-Chemical
-	13 1 O
induced	14 7 O
jaw	22 3 B-Disease
stiffness	26 9 I-Disease
and	36 3 O
myalgia	40 7 B-Disease
associated	48 10 O
with	59 4 O
atypical	64 8 O
cholinesterase	73 14 O
:	87 1 O
case	89 4 O
report	94 6 O
.	100 1 O

An	102 2 O
11	105 2 O
-	107 1 O
year	108 4 O
-	112 1 O
old	113 3 O
boy	117 3 O
was	121 3 O
given	125 5 O
halothane	131 9 B-Chemical
,	140 1 O
nitrous	142 7 B-Chemical
oxide	150 5 I-Chemical
and	156 3 O
oxygen	160 6 B-Chemical
,	166 1 O
pancuronium	168 11 B-Chemical
0	180 1 O
.	181 1 O
4	182 1 O
mg	184 2 O
and	187 3 O
suxamethonium	191 13 B-Chemical
100	205 3 O
mg	209 2 O
for	212 3 O
induction	216 9 O
of	226 2 O
anaesthesia	229 11 O
.	240 1 O

In	242 2 O
response	245 8 O
to	254 2 O
this	257 4 O
a	262 1 O
marked	264 6 O
jaw	271 3 B-Disease
stiffness	275 9 I-Disease
occurred	285 8 O
which	294 5 O
lasted	300 6 O
for	307 3 O
two	311 3 O
minutes	315 7 O
and	323 3 O
the	327 3 O
anaesthesia	331 11 O
were	343 4 O
terminated	348 10 O
.	358 1 O

Four	360 4 O
hours	365 5 O
of	371 2 O
apnoea	374 6 B-Disease
ensued	381 6 O
and	388 3 O
he	392 2 O
suffered	395 8 O
generalized	404 11 O
severe	416 6 O
myalgia	423 7 B-Disease
lasting	431 7 O
for	439 3 O
one	443 3 O
week	447 4 O
.	451 1 O

He	453 2 O
was	456 3 O
found	460 5 O
to	466 2 O
have	469 4 O
atypical	474 8 O
plasma	483 6 O
cholinesterase	490 14 O
with	505 4 O
a	510 1 O
dibucaine	512 9 B-Chemical
number	522 6 O
of	529 2 O
12	532 2 O
,	534 1 O
indicating	536 10 O
homozygocity	547 12 O
.	559 1 O

This	561 4 O
was	566 3 O
verified	570 8 O
by	579 2 O
study	582 5 O
of	588 2 O
the	591 3 O
family	595 6 O
.	601 1 O

The	603 3 O
case	607 4 O
shows	612 5 O
that	618 4 O
prolonged	623 9 B-Disease
jaw	633 3 I-Disease
rigidity	637 8 I-Disease
and	646 3 O
myalgia	650 7 B-Disease
may	658 3 O
occur	662 5 O
after	668 5 O
suxamethonium	674 13 B-Chemical
in	688 2 O
patients	691 8 O
with	700 4 O
atypical	705 8 O
cholinesterase	714 14 O
despite	729 7 O
pretreatment	737 12 O
with	750 4 O
pancuronium	755 11 B-Chemical
.	766 1 O

Indomethacin	0 12 B-Chemical
-	12 1 O
induced	13 7 O
hyperkalemia	21 12 B-Disease
in	34 2 O
three	37 5 O
patients	43 8 O
with	52 4 O
gouty	57 5 B-Disease
arthritis	63 9 I-Disease
.	72 1 O

We	74 2 O
describe	77 8 O
three	86 5 O
patients	92 8 O
in	101 2 O
whom	104 4 O
severe	109 6 O
,	115 1 O
life	117 4 O
-	121 1 O
threatening	122 11 O
hyperkalemia	134 12 B-Disease
and	147 3 O
renal	151 5 B-Disease
insufficiency	157 13 I-Disease
developed	171 9 O
after	181 5 O
treatment	187 9 O
of	197 2 O
acute	200 5 O
gouty	206 5 B-Disease
arthritis	212 9 I-Disease
with	222 4 O
indomethacin	227 12 B-Chemical
.	239 1 O

This	241 4 O
complication	246 12 O
may	259 3 O
result	263 6 O
from	270 4 O
an	275 2 O
inhibition	278 10 O
of	289 2 O
prostaglandin	292 13 B-Chemical
synthesis	306 9 O
and	316 3 O
consequent	320 10 O
hyporeninemic	331 13 B-Disease
hypoaidosteronism	345 17 I-Disease
.	362 1 O

Careful	364 7 O
attention	372 9 O
to	382 2 O
renal	385 5 O
function	391 8 O
and	400 3 O
potassium	404 9 B-Chemical
balance	414 7 O
in	422 2 O
patients	425 8 O
receiving	434 9 O
indomethacin	444 12 B-Chemical
or	457 2 O
other	460 5 O
nonsteroidal	466 12 O
anti	479 4 O
-	483 1 O
inflammatory	484 12 O
agents	497 6 O
,	503 1 O
particularly	505 12 O
in	518 2 O
those	521 5 O
patients	527 8 O
with	536 4 O
diabetes	541 8 B-Disease
mellitus	550 8 I-Disease
or	559 2 O
preexisting	562 11 O
renal	574 5 B-Disease
disease	580 7 I-Disease
,	587 1 O
will	589 4 O
help	594 4 O
prevent	599 7 O
this	607 4 O
potentially	612 11 O
serious	624 7 O
complication	632 12 O
.	644 1 O

Etomidate	0 9 B-Chemical
:	9 1 O
a	11 1 O
foreshortened	13 13 O
clinical	27 8 O
trial	36 5 O
.	41 1 O

A	43 1 O
clinical	45 8 O
evaluation	54 10 O
of	65 2 O
etomidate	68 9 B-Chemical
for	78 3 O
outpatient	82 10 O
cystoscopy	93 10 O
was	104 3 O
embarked	108 8 O
upon	117 4 O
.	121 1 O

Unpremedicated	123 14 O
patients	138 8 O
were	147 4 O
given	152 5 O
fentanyl	158 8 B-Chemical
1	167 1 O
microgram	169 9 O
/	178 1 O
kg	179 2 O
followed	182 8 O
by	191 2 O
etomidate	194 9 B-Chemical
0	204 1 O
.	205 1 O
3	206 1 O
mg	208 2 O
/	210 1 O
kg	211 2 O
.	213 1 O

Anaesthesia	215 11 O
was	227 3 O
maintained	231 10 O
with	242 4 O
intermittent	247 12 O
etomidate	260 9 B-Chemical
in	270 2 O
2	273 1 O
-	274 1 O
4	275 1 O
mg	277 2 O
doses	280 5 O
.	285 1 O

Patients	287 8 O
were	296 4 O
interviewed	301 11 O
personally	313 10 O
later	324 5 O
the	330 3 O
same	334 4 O
day	339 3 O
,	342 1 O
and	344 3 O
by	348 2 O
questionnaire	351 13 O
three	365 5 O
to	371 2 O
four	374 4 O
weeks	379 5 O
later	385 5 O
.	390 1 O

The	392 3 O
trial	396 5 O
was	402 3 O
discontinued	406 12 O
after	419 5 O
20	425 2 O
cases	428 5 O
because	434 7 O
of	442 2 O
an	445 2 O
unacceptable	448 12 O
incidence	461 9 O
of	471 2 O
side	474 4 O
effects	479 7 O
.	486 1 O

Venous	488 6 O
pain	495 4 B-Disease
occurred	500 8 O
in	509 2 O
68	512 2 O
%	514 1 O
of	516 2 O
patients	519 8 O
and	528 3 O
50	532 2 O
%	534 1 O
had	536 3 O
redness	540 7 O
,	547 1 O
pain	549 4 B-Disease
or	554 2 O
swelling	557 8 B-Disease
related	566 7 O
to	574 2 O
the	577 3 O
injection	581 9 O
site	591 4 O
,	595 1 O
in	597 2 O
some	600 4 O
cases	605 5 O
lasting	611 7 O
up	619 2 O
to	622 2 O
three	625 5 O
weeks	631 5 O
after	637 5 O
anaesthesia	643 11 O
.	654 1 O

Skeletal	656 8 O
movements	665 9 O
occurred	675 8 O
in	684 2 O
50	687 2 O
%	689 1 O
of	691 2 O
patients	694 8 O
;	702 1 O
30	704 2 O
%	706 1 O
experienced	708 11 O
respiratory	720 11 B-Disease
upset	732 5 I-Disease
,	737 1 O
one	739 3 O
sufficiently	743 12 O
severe	756 6 O
to	763 2 O
necessitate	766 11 O
abandoning	778 10 O
the	789 3 O
technique	793 9 O
.	802 1 O

Nausea	804 6 B-Disease
and	811 3 O
vomiting	815 8 B-Disease
occurred	824 8 O
in	833 2 O
40	836 2 O
%	838 1 O
and	840 3 O
25	844 2 O
%	846 1 O
had	848 3 O
disturbing	852 10 O
emergence	863 9 O
psychoses	873 9 B-Disease
.	882 1 O

Levodopa	0 8 B-Chemical
-	8 1 O
induced	9 7 O
dyskinesias	17 11 B-Disease
are	29 3 O
improved	33 8 O
by	42 2 O
fluoxetine	45 10 B-Chemical
.	55 1 O

We	57 2 O
evaluated	60 9 O
the	70 3 O
severity	74 8 O
of	83 2 O
motor	86 5 B-Disease
disability	92 10 I-Disease
and	103 3 O
dyskinesias	107 11 B-Disease
in	119 2 O
seven	122 5 O
levodopa	128 8 B-Chemical
-	136 1 O
responsive	137 10 O
patients	148 8 O
with	157 4 O
Parkinson	162 9 B-Disease
'	171 1 I-Disease
s	172 1 I-Disease
disease	174 7 I-Disease
after	182 5 O
an	188 2 O
acute	191 5 O
challenge	197 9 O
with	207 4 O
the	212 3 O
mixed	216 5 O
dopamine	222 8 B-Chemical
agonist	231 7 O
,	238 1 O
apomorphine	240 11 B-Chemical
,	251 1 O
before	253 6 O
and	260 3 O
after	264 5 O
the	270 3 O
administration	274 14 O
of	289 2 O
fluoxetine	292 10 B-Chemical
(	303 1 O
20	304 2 O
mg	307 2 O
twice	310 5 O
per	316 3 O
day	320 3 O
)	323 1 O
for	325 3 O
11	329 2 O
+	332 1 O
/	333 1 O
-	334 1 O
1	336 1 O
days	338 4 O
.	342 1 O

After	344 5 O
fluoxetine	350 10 B-Chemical
treatment	361 9 O
,	370 1 O
there	372 5 O
was	378 3 O
a	382 1 O
significant	384 11 O
47	396 2 O
%	398 1 O
improvement	400 11 O
(	412 1 O
p	413 1 O
<	415 1 O
0	417 1 O
.	418 1 O
05	419 2 O
)	421 1 O
of	423 2 O
apomorphine	426 11 B-Chemical
-	437 1 O
induced	438 7 O
dyskinesias	446 11 B-Disease
without	458 7 O
modification	466 12 O
of	479 2 O
parkinsonian	482 12 B-Disease
motor	495 5 B-Disease
disability	501 10 I-Disease
.	511 1 O

The	513 3 O
dyskinesias	517 11 B-Disease
were	529 4 O
reduced	534 7 O
predominantly	542 13 O
in	556 2 O
the	559 3 O
lower	563 5 O
limbs	569 5 O
during	575 6 O
the	582 3 O
onset	586 5 O
and	592 3 O
disappearance	596 13 O
of	610 2 O
dystonic	613 8 B-Disease
dyskinesias	622 11 I-Disease
(	634 1 O
onset	635 5 O
-	640 1 O
and	642 3 O
end	646 3 O
-	649 1 O
of	650 2 O
-	652 1 O
dose	653 4 O
dyskinesias	658 11 B-Disease
)	669 1 O
and	671 3 O
in	675 2 O
the	678 3 O
upper	682 5 O
limbs	688 5 O
during	694 6 O
choreic	701 7 B-Disease
mid	709 3 I-Disease
-	712 1 I-Disease
dose	713 4 I-Disease
dyskinesias	718 11 I-Disease
.	729 1 O

The	731 3 O
results	735 7 O
suggest	743 7 O
that	751 4 O
increased	756 9 O
brain	766 5 O
serotoninergic	772 14 O
transmission	787 12 O
with	800 4 O
fluoxetine	805 10 B-Chemical
may	816 3 O
reduce	820 6 O
levodopa	827 8 B-Chemical
-	835 1 O
or	837 2 O
dopamine	840 8 B-Chemical
agonist	849 7 O
-	856 1 O
induced	857 7 O
dyskinesias	865 11 B-Disease
without	877 7 O
aggravating	885 11 O
parkinsonian	897 12 B-Disease
motor	910 5 B-Disease
disability	916 10 I-Disease
.	926 1 O

A	0 1 O
large	2 5 O
population	8 10 O
-	18 1 O
based	19 5 O
follow	25 6 O
-	31 1 O
up	32 2 O
study	35 5 O
of	41 2 O
trimethoprim	44 12 B-Chemical
-	56 1 I-Chemical
sulfamethoxazole	57 16 I-Chemical
,	73 1 O
trimethoprim	75 12 B-Chemical
,	87 1 O
and	89 3 O
cephalexin	93 10 B-Chemical
for	104 3 O
uncommon	108 8 O
serious	117 7 O
drug	125 4 B-Disease
toxicity	130 8 I-Disease
.	138 1 O

We	140 2 O
conducted	143 9 O
a	153 1 O
population	155 10 O
-	165 1 O
based	166 5 O
45	172 2 O
-	174 1 O
day	175 3 O
follow	179 6 O
-	185 1 O
up	186 2 O
study	189 5 O
of	195 2 O
232	198 3 O
,	201 1 O
390	202 3 O
people	206 6 O
who	213 3 O
were	217 4 O
prescribed	222 10 O
trimethoprim	233 12 B-Chemical
-	245 1 I-Chemical
sulfamethoxazole	246 16 I-Chemical
(	263 1 O
TMP	264 3 B-Chemical
-	267 1 I-Chemical
SMZ	268 3 I-Chemical
)	271 1 O
,	272 1 O
266	274 3 O
,	277 1 O
951	278 3 O
prescribed	282 10 O
trimethoprim	293 12 B-Chemical
alone	306 5 O
,	311 1 O
and	313 3 O
196	317 3 O
,	320 1 O
397	321 3 O
prescribed	325 10 O
cephalexin	336 10 B-Chemical
,	346 1 O
to	348 2 O
estimate	351 8 O
the	360 3 O
risk	364 4 O
of	369 2 O
serious	372 7 O
liver	380 5 B-Disease
,	385 1 I-Disease
blood	387 5 I-Disease
,	392 1 I-Disease
skin	394 4 I-Disease
,	398 1 I-Disease
and	400 3 I-Disease
renal	404 5 I-Disease
disorders	410 9 I-Disease
resulting	420 9 O
in	430 2 O
referral	433 8 O
or	442 2 O
hospitalization	445 15 O
associated	461 10 O
with	472 4 O
these	477 5 O
drugs	483 5 O
.	488 1 O

The	490 3 O
results	494 7 O
were	502 4 O
based	507 5 O
on	513 2 O
information	516 11 O
recorded	528 8 O
on	537 2 O
office	540 6 O
computers	547 9 O
by	557 2 O
selected	560 8 O
general	569 7 O
practitioners	577 13 O
in	591 2 O
the	594 3 O
United	598 6 O
Kingdom	605 7 O
,	612 1 O
together	614 8 O
with	623 4 O
a	628 1 O
review	630 6 O
of	637 2 O
clinical	640 8 O
records	649 7 O
.	656 1 O

The	658 3 O
risk	662 4 O
of	667 2 O
clinically	670 10 O
important	681 9 O
idiopathic	691 10 O
liver	702 5 B-Disease
disease	708 7 I-Disease
was	716 3 O
similar	720 7 O
for	728 3 O
persons	732 7 O
prescribed	740 10 O
TMP	751 3 B-Chemical
-	754 1 I-Chemical
SMZ	755 3 I-Chemical
(	759 1 O
5	760 1 O
.	761 1 O
2	762 1 O
/	763 1 O
100	764 3 O
,	767 1 O
000	768 3 O
)	771 1 O
and	773 3 O
those	777 5 O
prescribed	783 10 O
trimethoprim	794 12 B-Chemical
alone	807 5 O
(	813 1 O
3	814 1 O
.	815 1 O
8	816 1 O
/	817 1 O
100	818 3 O
,	821 1 O
000	822 3 O
)	825 1 O
.	826 1 O

The	828 3 O
risk	832 4 O
for	837 3 O
those	841 5 O
prescribed	847 10 O
cephalexin	858 10 B-Chemical
was	869 3 O
somewhat	873 8 O
lower	882 5 O
(	888 1 O
2	889 1 O
.	890 1 O
0	891 1 O
/	892 1 O
100	893 3 O
,	896 1 O
000	897 3 O
)	900 1 O
.	901 1 O

Only	903 4 O
five	908 4 O
patients	913 8 O
experienced	922 11 O
blood	934 5 O
disorders	940 9 O
,	949 1 O
one	951 3 O
of	955 2 O
whom	958 4 O
was	963 3 O
exposed	967 7 O
to	975 2 O
TMP	978 3 B-Chemical
-	981 1 I-Chemical
SMZ	982 3 I-Chemical
;	985 1 O
of	987 2 O
seven	990 5 O
with	996 4 O
erythema	1001 8 B-Disease
multiforme	1010 10 I-Disease
and	1021 3 O
Stevens	1025 7 B-Disease
-	1032 1 I-Disease
Johnson	1033 7 I-Disease
syndrome	1041 8 I-Disease
,	1049 1 O
four	1051 4 O
were	1056 4 O
exposed	1061 7 O
to	1069 2 O
TMP	1072 3 B-Chemical
-	1075 1 I-Chemical
SMZ	1076 3 I-Chemical
.	1079 1 O

The	1081 3 O
one	1085 3 O
case	1089 4 O
of	1094 2 O
toxic	1097 5 B-Disease
epidermal	1103 9 I-Disease
necrolysis	1113 10 I-Disease
occurred	1124 8 O
in	1133 2 O
a	1136 1 O
patient	1138 7 O
who	1146 3 O
took	1150 4 O
cephalexin	1155 10 B-Chemical
.	1165 1 O

Finally	1167 7 O
,	1174 1 O
only	1176 4 O
five	1181 4 O
cases	1186 5 O
of	1192 2 O
acute	1195 5 O
parenchymal	1201 11 O
renal	1213 5 B-Disease
disease	1219 7 I-Disease
occurred	1227 8 O
,	1235 1 O
none	1237 4 O
likely	1242 6 O
to	1249 2 O
be	1252 2 O
caused	1255 6 O
by	1262 2 O
a	1265 1 O
study	1267 5 O
drug	1273 4 O
.	1277 1 O

We	1279 2 O
conclude	1282 8 O
that	1291 4 O
the	1296 3 O
risk	1300 4 O
of	1305 2 O
the	1308 3 O
serious	1312 7 O
diseases	1320 8 O
studied	1329 7 O
is	1337 2 O
small	1340 5 O
for	1346 3 O
the	1350 3 O
three	1354 5 O
agents	1360 6 O
,	1366 1 O
and	1368 3 O
compares	1372 8 O
reasonably	1381 10 O
with	1392 4 O
the	1397 3 O
risk	1401 4 O
for	1406 3 O
many	1410 4 O
other	1415 5 O
antibiotics	1421 11 O
.	1432 1 O

Clinical	0 8 O
safety	9 6 O
of	16 2 O
lidocaine	19 9 B-Chemical
in	29 2 O
patients	32 8 O
with	41 4 O
cocaine	46 7 B-Chemical
-	53 1 O
associated	54 10 O
myocardial	65 10 B-Disease
infarction	76 10 I-Disease
.	86 1 O

STUDY	88 5 O
OBJECTIVE	94 9 O
:	103 1 O
To	105 2 O
evaluate	108 8 O
the	117 3 O
safety	121 6 O
of	128 2 O
lidocaine	131 9 B-Chemical
in	141 2 O
the	144 3 O
setting	148 7 O
of	156 2 O
cocaine	159 7 B-Chemical
-	166 1 O
induced	167 7 O
myocardial	175 10 B-Disease
infarction	186 10 I-Disease
(	197 1 O
MI	198 2 B-Disease
)	200 1 O
.	201 1 O

DESIGN	203 6 O
:	209 1 O
A	211 1 O
retrospective	213 13 O
,	226 1 O
multicenter	228 11 O
study	240 5 O
.	245 1 O

SETTING	247 7 O
:	254 1 O
Twenty	256 6 O
-	262 1 O
nine	263 4 O
university	268 10 O
,	278 1 O
university	280 10 O
-	290 1 O
affiliated	291 10 O
,	301 1 O
or	303 2 O
community	306 9 O
hospitals	316 9 O
during	326 6 O
a	333 1 O
6	335 1 O
-	336 1 O
year	337 4 O
period	342 6 O
(	349 1 O
total	350 5 O
of	356 2 O
117	359 3 O
cumulative	363 10 O
hospital	374 8 O
-	382 1 O
years	383 5 O
)	388 1 O
.	389 1 O

PARTICIPANTS	391 12 O
:	403 1 O
Patients	405 8 O
with	414 4 O
cocaine	419 7 B-Chemical
-	426 1 O
associated	427 10 O
MI	438 2 B-Disease
who	441 3 O
received	445 8 O
lidocaine	454 9 B-Chemical
in	464 2 O
the	467 3 O
emergency	471 9 O
department	481 10 O
.	491 1 O

RESULTS	493 7 O
:	500 1 O
Of	502 2 O
29	505 2 O
patients	508 8 O
who	517 3 O
received	521 8 O
lidocaine	530 9 B-Chemical
in	540 2 O
the	543 3 O
setting	547 7 O
of	555 2 O
cocaine	558 7 B-Chemical
-	565 1 O
associated	566 10 O
MI	577 2 B-Disease
,	579 1 O
no	581 2 O
patient	584 7 O
died	592 4 O
;	596 1 O
exhibited	598 9 O
bradydysrhythmias	608 17 B-Disease
,	625 1 O
ventricular	627 11 B-Disease
tachycardia	639 11 I-Disease
,	650 1 O
or	652 2 O
ventricular	655 11 B-Disease
fibrillation	667 12 I-Disease
;	679 1 O
or	681 2 O
experienced	684 11 O
seizures	696 8 B-Disease
after	705 5 O
administration	711 14 O
of	726 2 O
lidocaine	729 9 B-Chemical
(	739 1 O
95	740 2 O
%	742 1 O
confidence	744 10 O
interval	755 8 O
,	763 1 O
0	765 1 O
%	766 1 O
to	768 2 O
11	771 2 O
%	773 1 O
)	774 1 O
.	775 1 O

CONCLUSION	777 10 O
:	787 1 O
Despite	789 7 O
theoretical	797 11 O
concerns	809 8 O
that	818 4 O
lidocaine	823 9 B-Chemical
may	833 3 O
enhance	837 7 O
cocaine	845 7 B-Chemical
toxicity	853 8 B-Disease
,	861 1 O
the	863 3 O
use	867 3 O
of	871 2 O
lidocaine	874 9 B-Chemical
in	884 2 O
patients	887 8 O
with	896 4 O
cocaine	901 7 B-Chemical
-	908 1 O
associated	909 10 O
MI	920 2 B-Disease
was	923 3 O
not	927 3 O
associated	931 10 O
with	942 4 O
significant	947 11 O
cardiovascular	959 14 B-Disease
or	974 2 I-Disease
central	977 7 I-Disease
nervous	985 7 I-Disease
system	993 6 I-Disease
toxicity	1000 8 I-Disease
.	1008 1 O

Paclitaxel	0 10 B-Chemical
3	11 1 O
-	12 1 O
hour	13 4 O
infusion	18 8 O
given	27 5 O
alone	33 5 O
and	39 3 O
combined	43 8 O
with	52 4 O
carboplatin	57 11 B-Chemical
:	68 1 O
preliminary	70 11 O
results	82 7 O
of	90 2 O
dose	93 4 O
-	97 1 O
escalation	98 10 O
trials	109 6 O
.	115 1 O

Paclitaxel	117 10 B-Chemical
(	128 1 O
Taxol	129 5 B-Chemical
;	134 1 O
Bristol	136 7 O
-	143 1 O
Myers	144 5 O
Squibb	150 6 O
Company	157 7 O
,	164 1 O
Princeton	166 9 O
,	175 1 O
NJ	177 2 O
)	179 1 O
by	181 2 O
3	184 1 O
-	185 1 O
hour	186 4 O
infusion	191 8 O
was	200 3 O
combined	204 8 O
with	213 4 O
carboplatin	218 11 B-Chemical
in	230 2 O
a	233 1 O
phase	235 5 O
I	241 1 O
/	242 1 O
II	243 2 O
study	246 5 O
directed	252 8 O
to	261 2 O
patients	264 8 O
with	273 4 O
non	278 3 B-Disease
-	281 1 I-Disease
small	282 5 I-Disease
cell	288 4 I-Disease
lung	293 4 I-Disease
cancer	298 6 I-Disease
.	304 1 O

Carboplatin	306 11 B-Chemical
was	318 3 O
given	322 5 O
at	328 2 O
a	331 1 O
fixed	333 5 O
target	339 6 O
area	346 4 O
under	351 5 O
the	357 3 O
concentration	361 13 O
-	374 1 O
time	375 4 O
curve	380 5 O
of	386 2 O
6	389 1 O
.	390 1 O
0	391 1 O
by	393 2 O
the	396 3 O
Calvert	400 7 O
formula	408 7 O
,	415 1 O
whereas	417 7 O
paclitaxel	425 10 B-Chemical
was	436 3 O
escalated	440 9 O
in	450 2 O
patient	453 7 O
cohorts	461 7 O
from	469 4 O
150	474 3 O
mg	478 2 O
/	480 1 O
m2	481 2 O
(	484 1 O
dose	485 4 O
level	490 5 O
I	496 1 O
)	497 1 O
to	499 2 O
175	502 3 O
,	505 1 O
200	507 3 O
,	510 1 O
225	512 3 O
,	515 1 O
and	517 3 O
250	521 3 O
mg	525 2 O
/	527 1 O
m2	528 2 O
.	530 1 O

The	532 3 O
225	536 3 O
mg	540 2 O
/	542 1 O
m2	543 2 O
level	546 5 O
was	552 3 O
expanded	556 8 O
for	565 3 O
the	569 3 O
phase	573 5 O
II	579 2 O
study	582 5 O
since	588 5 O
the	594 3 O
highest	598 7 O
level	606 5 O
achieved	612 8 O
(	621 1 O
250	622 3 O
mg	626 2 O
/	628 1 O
m2	629 2 O
)	631 1 O
required	633 8 O
modification	642 12 O
because	655 7 O
of	663 2 O
nonhematologic	666 14 O
toxicities	681 10 B-Disease
(	692 1 O
arthralgia	693 10 B-Disease
and	704 3 O
sensory	708 7 B-Disease
neuropathy	716 10 I-Disease
)	726 1 O
.	727 1 O

Therapeutic	729 11 O
effects	741 7 O
were	749 4 O
noted	754 5 O
at	760 2 O
all	763 3 O
dose	767 4 O
levels	772 6 O
,	778 1 O
with	780 4 O
objective	785 9 O
responses	795 9 O
in	805 2 O
17	808 2 O
(	811 1 O
two	812 3 O
complete	816 8 O
and	825 3 O
15	829 2 O
partial	832 7 O
regressions	840 11 O
)	851 1 O
of	853 2 O
41	856 2 O
previously	859 10 O
untreated	870 9 O
patients	880 8 O
.	888 1 O

Toxicities	890 10 B-Disease
were	901 4 O
compared	906 8 O
with	915 4 O
a	920 1 O
cohort	922 6 O
of	929 2 O
patients	932 8 O
in	941 2 O
a	944 1 O
phase	946 5 O
I	952 1 O
trial	954 5 O
of	960 2 O
paclitaxel	963 10 B-Chemical
alone	974 5 O
at	980 2 O
identical	983 9 O
dose	993 4 O
levels	998 6 O
.	1004 1 O

Carboplatin	1006 11 B-Chemical
did	1018 3 O
not	1022 3 O
appear	1026 6 O
to	1033 2 O
add	1036 3 O
to	1040 2 O
the	1043 3 O
hematologic	1047 11 B-Disease
toxicities	1059 10 I-Disease
observed	1070 8 O
,	1078 1 O
and	1080 3 O
the	1084 3 O
paclitaxel	1088 10 B-Chemical
/	1098 1 O
carboplatin	1099 11 B-Chemical
combination	1111 11 O
could	1123 5 O
be	1129 2 O
dosed	1132 5 O
every	1138 5 O
3	1144 1 O
weeks	1146 5 O
.	1151 1 O

The	0 3 O
dose	4 4 O
-	8 1 O
dependent	9 9 O
effect	19 6 O
of	26 2 O
misoprostol	29 11 B-Chemical
on	41 2 O
indomethacin	44 12 B-Chemical
-	56 1 O
induced	57 7 O
renal	65 5 B-Disease
dysfunction	71 11 I-Disease
in	83 2 O
well	86 4 O
compensated	91 11 O
cirrhosis	103 9 B-Disease
.	112 1 O

Misoprostol	114 11 B-Chemical
(	126 1 O
200	127 3 O
micrograms	131 10 O
)	141 1 O
has	143 3 O
been	147 4 O
shown	152 5 O
to	158 2 O
acutely	161 7 O
counteract	169 10 O
the	180 3 O
indomethacin	184 12 B-Chemical
-	196 1 O
induced	197 7 O
renal	205 5 B-Disease
dysfunction	211 11 I-Disease
in	223 2 O
well	226 4 O
compensated	231 11 O
cirrhotic	243 9 B-Disease
patients	253 8 O
.	261 1 O

The	263 3 O
aim	267 3 O
of	271 2 O
this	274 4 O
study	279 5 O
was	285 3 O
to	289 2 O
determine	292 9 O
if	302 2 O
the	305 3 O
prophylactic	309 12 O
value	322 5 O
of	328 2 O
misoprostol	331 11 B-Chemical
was	343 3 O
dose	347 4 O
-	351 1 O
dependent	352 9 O
.	361 1 O

Parameters	363 10 O
of	374 2 O
renal	377 5 O
hemodynamics	383 12 O
and	396 3 O
tubular	400 7 O
sodium	408 6 B-Chemical
and	415 3 O
water	419 5 O
handling	425 8 O
were	434 4 O
assessed	439 8 O
by	448 2 O
clearance	451 9 O
techniques	461 10 O
in	472 2 O
26	475 2 O
well	478 4 O
compensated	483 11 O
cirrhotic	495 9 B-Disease
patients	505 8 O
before	514 6 O
and	521 3 O
after	525 5 O
an	531 2 O
oral	534 4 O
combination	539 11 O
of	551 2 O
50	554 2 O
mg	557 2 O
of	560 2 O
indomethacin	563 12 B-Chemical
and	576 3 O
various	580 7 O
doses	588 5 O
of	594 2 O
misoprostol	597 11 B-Chemical
.	608 1 O

The	610 3 O
200	614 3 O
-	617 1 O
micrograms	618 10 O
dose	629 4 O
was	634 3 O
able	638 4 O
to	643 2 O
totally	646 7 O
abolish	654 7 O
the	662 3 O
deleterious	666 11 O
renal	678 5 O
effects	684 7 O
of	692 2 O
indomethacin	695 12 B-Chemical
,	707 1 O
whereas	709 7 O
the	717 3 O
800	721 3 O
-	724 1 O
micrograms	725 10 O
dose	736 4 O
resulted	741 8 O
in	750 2 O
significant	753 11 O
worsening	765 9 O
of	775 2 O
renal	778 5 O
hemodynamics	784 12 O
and	797 3 O
sodium	801 6 B-Chemical
retention	808 9 O
.	817 1 O

These	819 5 O
changes	825 7 O
were	833 4 O
maximal	838 7 O
in	846 2 O
the	849 3 O
hour	853 4 O
immediately	858 11 O
after	870 5 O
medications	876 11 O
and	888 3 O
slowly	892 6 O
returned	899 8 O
toward	908 6 O
base	915 4 O
-	919 1 O
line	920 4 O
levels	925 6 O
thereafter	932 10 O
.	942 1 O

These	944 5 O
results	950 7 O
suggest	958 7 O
that	966 4 O
the	971 3 O
renal	975 5 O
protective	981 10 O
effects	992 7 O
of	1000 2 O
misoprostol	1003 11 B-Chemical
is	1015 2 O
dose	1018 4 O
-	1022 1 O
dependent	1023 9 O
.	1032 1 O

However	1034 7 O
,	1041 1 O
until	1043 5 O
this	1049 4 O
apparent	1054 8 O
ability	1063 7 O
of	1071 2 O
200	1074 3 O
micrograms	1078 10 O
of	1089 2 O
misoprostol	1092 11 B-Chemical
to	1104 2 O
prevent	1107 7 O
the	1115 3 O
adverse	1119 7 O
effects	1127 7 O
of	1135 2 O
indomethacin	1138 12 B-Chemical
on	1151 2 O
renal	1154 5 O
function	1160 8 O
is	1169 2 O
confirmed	1172 9 O
with	1182 4 O
chronic	1187 7 O
frequent	1195 8 O
dosing	1204 6 O
,	1210 1 O
it	1212 2 O
would	1215 5 O
be	1221 2 O
prudent	1224 7 O
to	1232 2 O
avoid	1235 5 O
nonsteroidal	1241 12 O
anti	1254 4 O
-	1258 1 O
inflammatory	1259 12 O
therapy	1272 7 O
in	1280 2 O
patients	1283 8 O
with	1292 4 O
cirrhosis	1297 9 B-Disease
.	1306 1 O

Increased	0 9 O
frequency	10 9 O
and	20 3 O
severity	24 8 O
of	33 2 O
angio	36 5 B-Disease
-	41 1 I-Disease
oedema	42 6 I-Disease
related	49 7 O
to	57 2 O
long	60 4 O
-	64 1 O
term	65 4 O
therapy	70 7 O
with	78 4 O
angiotensin	83 11 B-Chemical
-	94 1 I-Chemical
converting	95 10 I-Chemical
enzyme	106 6 I-Chemical
inhibitor	113 9 I-Chemical
in	123 2 O
two	126 3 O
patients	130 8 O
.	138 1 O

Adverse	140 7 O
reactions	148 9 O
to	158 2 O
drugs	161 5 O
are	167 3 O
well	171 4 O
recognized	176 10 O
as	187 2 O
a	190 1 O
cause	192 5 O
of	198 2 O
acute	201 5 O
or	207 2 O
chronic	210 7 O
urticaria	218 9 B-Disease
,	227 1 O
and	229 3 O
angio	233 5 B-Disease
-	238 1 I-Disease
oedema	239 6 I-Disease
.	245 1 O

Angiotensin	247 11 B-Chemical
-	258 1 I-Chemical
converting	259 10 I-Chemical
enzyme	270 6 I-Chemical
(	277 1 I-Chemical
ACE	278 3 I-Chemical
)	281 1 I-Chemical
inhibitors	283 10 I-Chemical
,	293 1 O
used	295 4 O
to	300 2 O
treat	303 5 O
hypertension	309 12 B-Disease
and	322 3 O
congestive	326 10 B-Disease
heart	337 5 I-Disease
failure	343 7 I-Disease
,	350 1 O
were	352 4 O
introduced	357 10 O
in	368 2 O
Europe	371 6 O
in	378 2 O
the	381 3 O
middle	385 6 O
of	392 2 O
the	395 3 O
eighties	399 8 O
,	407 1 O
and	409 3 O
the	413 3 O
use	417 3 O
of	421 2 O
these	424 5 O
drugs	430 5 O
has	436 3 O
increased	440 9 O
progressively	450 13 O
.	463 1 O

Soon	465 4 O
after	470 5 O
the	476 3 O
introduction	480 12 O
of	493 2 O
ACE	496 3 B-Chemical
inhibitors	500 10 I-Chemical
,	510 1 O
acute	512 5 O
bouts	518 5 O
of	524 2 O
angio	527 5 B-Disease
-	532 1 I-Disease
oedema	533 6 I-Disease
were	540 4 O
reported	545 8 O
in	554 2 O
association	557 11 O
with	569 4 O
the	574 3 O
use	578 3 O
of	582 2 O
these	585 5 O
drugs	591 5 O
.	596 1 O

We	598 2 O
wish	601 4 O
to	606 2 O
draw	609 4 O
attention	614 9 O
to	624 2 O
the	627 3 O
possibility	631 11 O
of	643 2 O
adverse	646 7 O
reactions	654 9 O
to	664 2 O
ACE	667 3 B-Chemical
inhibitors	671 10 I-Chemical
after	682 5 O
long	688 4 O
-	692 1 O
term	693 4 O
use	698 3 O
and	702 3 O
in	706 2 O
patients	709 8 O
with	718 4 O
pre	723 3 O
-	726 1 O
existing	727 8 O
angio	736 5 B-Disease
-	741 1 I-Disease
oedema	742 6 I-Disease
.	748 1 O

Myoclonus	0 9 B-Disease
associated	10 10 O
with	21 4 O
lorazepam	26 9 B-Chemical
therapy	36 7 O
in	44 2 O
very	47 4 O
-	51 1 O
low	52 3 O
-	55 1 O
birth	56 5 O
-	61 1 O
weight	62 6 O
infants	69 7 O
.	76 1 O

Lorazepam	78 9 B-Chemical
is	88 2 O
being	91 5 O
used	97 4 O
with	102 4 O
increasing	107 10 O
frequency	118 9 O
as	128 2 O
a	131 1 O
sedative	133 8 O
in	142 2 O
the	145 3 O
newborn	149 7 O
and	157 3 O
the	161 3 O
young	165 5 O
infant	171 6 O
.	177 1 O

Concern	179 7 O
has	187 3 O
been	191 4 O
raised	196 6 O
with	203 4 O
regard	208 6 O
to	215 2 O
the	218 3 O
safety	222 6 O
of	229 2 O
lorazepam	232 9 B-Chemical
in	242 2 O
this	245 4 O
age	250 3 O
group	254 5 O
,	259 1 O
especially	261 10 O
in	272 2 O
very	275 4 O
-	279 1 O
low	280 3 O
-	283 1 O
birth	284 5 O
-	289 1 O
weight	290 6 O
(	297 1 O
VLBW	298 4 O
;	302 1 O
<	304 1 O
1	306 1 O
,	307 1 O
500	308 3 O
g	312 1 O
)	313 1 O
infants	315 7 O
.	322 1 O

Three	324 5 O
young	330 5 O
infants	336 7 O
,	343 1 O
all	345 3 O
of	349 2 O
birth	352 5 O
weight	358 6 O
<	365 1 O
1	367 1 O
,	368 1 O
500	369 3 O
g	373 1 O
,	374 1 O
experienced	376 11 O
myoclonus	388 9 B-Disease
following	398 9 O
the	408 3 O
intravenous	412 11 O
administration	424 14 O
of	439 2 O
lorazepam	442 9 B-Chemical
.	451 1 O

The	453 3 O
potential	457 9 O
neurotoxic	467 10 B-Disease
effects	478 7 O
of	486 2 O
the	489 3 O
drug	493 4 O
(	498 1 O
and	499 3 O
its	503 3 O
vehicle	507 7 O
)	514 1 O
in	516 2 O
this	519 4 O
population	524 10 O
are	535 3 O
discussed	539 9 O
.	548 1 O

Injectable	550 10 O
lorazepam	561 9 B-Chemical
should	571 6 O
be	578 2 O
used	581 4 O
with	586 4 O
caution	591 7 O
in	599 2 O
VLBW	602 4 O
infants	607 7 O
.	614 1 O

Transvenous	0 11 O
right	12 5 O
ventricular	18 11 O
pacing	30 6 O
during	37 6 O
cardiopulmonary	44 15 O
resuscitation	60 13 O
of	74 2 O
pediatric	77 9 O
patients	87 8 O
with	96 4 O
acute	101 5 O
cardiomyopathy	107 14 B-Disease
.	121 1 O

We	123 2 O
describe	126 8 O
the	135 3 O
cardiopulmonary	139 15 O
resuscitation	155 13 O
efforts	169 7 O
on	177 2 O
five	180 4 O
patients	185 8 O
who	194 3 O
presented	198 9 O
in	208 2 O
acute	211 5 O
circulatory	217 11 B-Disease
failure	229 7 I-Disease
from	237 4 O
myocardial	242 10 B-Disease
dysfunction	253 11 I-Disease
.	264 1 O

Three	266 5 O
patients	272 8 O
had	281 3 O
acute	285 5 O
viral	291 5 O
myocarditis	297 11 B-Disease
,	308 1 O
one	310 3 O
had	314 3 O
a	318 1 O
carbamazepine	320 13 B-Chemical
-	333 1 O
induced	334 7 O
acute	342 5 O
eosinophilic	348 12 B-Disease
myocarditis	361 11 I-Disease
,	372 1 O
and	374 3 O
one	378 3 O
had	382 3 O
cardiac	386 7 O
hemosiderosis	394 13 O
resulting	408 9 O
in	418 2 O
acute	421 5 O
cardiogenic	427 11 B-Disease
shock	439 5 I-Disease
.	444 1 O

All	446 3 O
patients	450 8 O
were	459 4 O
continuously	464 12 O
monitored	477 9 O
with	487 4 O
central	492 7 O
venous	500 6 O
and	507 3 O
arterial	511 8 O
catheters	520 9 O
in	530 2 O
addition	533 8 O
to	542 2 O
routine	545 7 O
noninvasive	553 11 O
monitoring	565 10 O
.	575 1 O

An	577 2 O
introducer	580 10 O
sheath	591 6 O
,	597 1 O
a	599 1 O
pacemaker	601 9 O
,	610 1 O
and	612 3 O
sterile	616 7 O
pacing	624 6 O
wires	631 5 O
were	637 4 O
made	642 4 O
readily	647 7 O
available	655 9 O
for	665 3 O
the	669 3 O
patients	673 8 O
,	681 1 O
should	683 6 O
the	690 3 O
need	694 4 O
arise	699 5 O
to	705 2 O
terminate	708 9 O
resistant	718 9 O
cardiac	728 7 O
dysrhythmias	736 12 B-Disease
.	748 1 O

All	750 3 O
patients	754 8 O
developed	763 9 O
cardiocirculatory	773 17 O
arrest	791 6 O
associated	798 10 O
with	809 4 O
extreme	814 7 O
hypotension	822 11 B-Disease
and	834 3 O
dysrhythmias	838 12 B-Disease
within	851 6 O
the	858 3 O
first	862 5 O
48	868 2 O
hours	871 5 O
of	877 2 O
their	880 5 O
admission	886 9 O
to	896 2 O
the	899 3 O
pediatric	903 9 O
intensive	913 9 O
care	923 4 O
unit	928 4 O
(	933 1 O
PICU	934 4 O
)	938 1 O
.	939 1 O

Right	941 5 O
ventricular	947 11 O
pacemaker	959 9 O
wires	969 5 O
were	975 4 O
inserted	980 8 O
in	989 2 O
all	992 3 O
of	996 2 O
them	999 4 O
during	1004 6 O
cardiopulmonary	1011 15 O
resuscitation	1027 13 O
(	1041 1 O
CPR	1042 3 O
)	1045 1 O
.	1046 1 O

In	1048 2 O
four	1051 4 O
patients	1056 8 O
,	1064 1 O
cardiac	1066 7 O
pacing	1074 6 O
was	1081 3 O
used	1085 4 O
,	1089 1 O
resulting	1091 9 O
in	1101 2 O
a	1104 1 O
temporary	1106 9 O
captured	1116 8 O
rhythm	1125 6 O
and	1132 3 O
restoration	1136 11 O
of	1148 2 O
their	1151 5 O
cardiac	1157 7 O
output	1165 6 O
.	1171 1 O

These	1173 5 O
patients	1179 8 O
had	1188 3 O
a	1192 1 O
second	1194 6 O
event	1201 5 O
of	1207 2 O
cardiac	1210 7 B-Disease
arrest	1218 6 I-Disease
,	1224 1 O
resulting	1226 9 O
in	1236 2 O
death	1239 5 O
,	1244 1 O
within	1246 6 O
10	1253 2 O
to	1256 2 O
60	1259 2 O
minutes	1262 7 O
.	1269 1 O

In	1271 2 O
one	1274 3 O
patient	1278 7 O
,	1285 1 O
cardiac	1287 7 O
pacing	1295 6 O
was	1302 3 O
not	1306 3 O
used	1310 4 O
,	1314 1 O
because	1316 7 O
he	1324 2 O
converted	1327 9 O
to	1337 2 O
normal	1340 6 O
sinus	1347 5 O
rhythm	1353 6 O
by	1360 2 O
electrical	1363 10 O
defibrillation	1374 14 O
within	1389 6 O
three	1396 5 O
minutes	1402 7 O
of	1410 2 O
initiating	1413 10 O
CPR	1424 3 O
.	1427 1 O

We	1429 2 O
conclude	1432 8 O
that	1441 4 O
cardiac	1446 7 O
pacing	1454 6 O
during	1461 6 O
resuscitative	1468 13 O
efforts	1482 7 O
in	1490 2 O
pediatric	1493 9 O
patients	1503 8 O
suffering	1512 9 O
from	1522 4 O
acute	1527 5 O
myocardial	1533 10 B-Disease
dysfunction	1544 11 I-Disease
may	1556 3 O
not	1560 3 O
have	1564 4 O
long	1569 4 O
-	1573 1 O
term	1574 4 O
value	1579 5 O
in	1585 2 O
and	1588 3 O
of	1592 2 O
itself	1595 6 O
;	1601 1 O
however	1603 7 O
,	1610 1 O
if	1612 2 O
temporary	1615 9 O
hemodynamic	1625 11 O
stability	1637 9 O
is	1647 2 O
achieved	1650 8 O
by	1659 2 O
this	1662 4 O
procedure	1667 9 O
,	1676 1 O
it	1678 2 O
may	1681 3 O
provide	1685 7 O
additional	1693 10 O
time	1704 4 O
needed	1709 6 O
to	1716 2 O
institute	1719 9 O
other	1729 5 O
therapeutic	1735 11 O
modalities	1747 10 O
.	1757 1 O

Efficacy	0 8 O
and	9 3 O
safety	13 6 O
of	20 2 O
granisetron	23 11 B-Chemical
,	34 1 O
a	36 1 O
selective	38 9 O
5	48 1 B-Chemical
-	49 1 I-Chemical
hydroxytryptamine	50 17 I-Chemical
-	67 1 O
3	68 1 O
receptor	70 8 O
antagonist	79 10 O
,	89 1 O
in	91 2 O
the	94 3 O
prevention	98 10 O
of	109 2 O
nausea	112 6 B-Disease
and	119 3 O
vomiting	123 8 B-Disease
induced	132 7 O
by	140 2 O
high	143 4 O
-	147 1 O
dose	148 4 O
cisplatin	153 9 B-Chemical
.	162 1 O

PURPOSE	164 7 O
:	171 1 O
To	173 2 O
assess	176 6 O
the	183 3 O
antiemetic	187 10 O
effects	198 7 O
and	206 3 O
safety	210 6 O
profile	217 7 O
of	225 2 O
four	228 4 O
different	233 9 O
doses	243 5 O
of	249 2 O
granisetron	252 11 B-Chemical
(	264 1 O
Kytril	265 6 B-Chemical
;	271 1 O
SmithKline	273 10 O
Beecham	284 7 O
Pharmaceuticals	292 15 O
,	307 1 O
Philadelphia	309 12 O
,	321 1 O
PA	323 2 O
)	325 1 O
when	327 4 O
administered	332 12 O
as	345 2 O
a	348 1 O
single	350 6 O
intravenous	357 11 O
(	369 1 O
IV	370 2 O
)	372 1 O
dose	374 4 O
for	379 3 O
prophylaxis	383 11 O
of	395 2 O
cisplatin	398 9 B-Chemical
-	407 1 O
induced	408 7 O
nausea	416 6 B-Disease
and	423 3 O
vomiting	427 8 B-Disease
.	435 1 O

PATIENTS	437 8 O
AND	446 3 O
METHODS	450 7 O
:	457 1 O
One	459 3 O
hundred	463 7 O
eighty	471 6 O
-	477 1 O
four	478 4 O
chemotherapy	483 12 O
-	495 1 O
naive	496 5 O
patients	502 8 O
receiving	511 9 O
high	521 4 O
-	525 1 O
dose	526 4 O
cisplatin	531 9 B-Chemical
(	541 1 O
81	542 2 O
to	545 2 O
120	548 3 O
mg	552 2 O
/	554 1 O
m2	555 2 O
)	557 1 O
were	559 4 O
randomized	564 10 O
to	575 2 O
receive	578 7 O
one	586 3 O
of	590 2 O
four	593 4 O
granisetron	598 11 B-Chemical
doses	610 5 O
(	616 1 O
5	617 1 O
,	618 1 O
10	620 2 O
,	622 1 O
20	624 2 O
,	626 1 O
or	628 2 O
40	631 2 O
micrograms	634 10 O
/	644 1 O
kg	645 2 O
)	647 1 O
administered	649 12 O
before	662 6 O
chemotherapy	669 12 O
.	681 1 O

Patients	683 8 O
were	692 4 O
observed	697 8 O
on	706 2 O
an	709 2 O
inpatient	712 9 O
basis	722 5 O
for	728 3 O
18	732 2 O
to	735 2 O
24	738 2 O
hours	741 5 O
,	746 1 O
and	748 3 O
vital	752 5 O
signs	758 5 O
,	763 1 O
nausea	765 6 B-Disease
,	771 1 O
vomiting	773 8 B-Disease
,	781 1 O
retching	783 8 O
,	791 1 O
and	793 3 O
appetite	797 8 O
were	806 4 O
assessed	811 8 O
.	819 1 O

Safety	821 6 O
analyses	828 8 O
included	837 8 O
incidence	846 9 O
of	856 2 O
adverse	859 7 O
experiences	867 11 O
and	879 3 O
laboratory	883 10 O
parameter	894 9 O
changes	904 7 O
.	911 1 O

RESULTS	913 7 O
:	920 1 O
After	922 5 O
granisetron	928 11 B-Chemical
doses	940 5 O
of	946 2 O
5	949 1 O
,	950 1 O
10	952 2 O
,	954 1 O
20	956 2 O
,	958 1 O
and	960 3 O
40	964 2 O
micrograms	967 10 O
/	977 1 O
kg	978 2 O
,	980 1 O
a	982 1 O
major	984 5 O
response	990 8 O
(	999 1 O
<	1000 1 O
or	1002 2 O
=	1005 1 O
two	1007 3 O
vomiting	1011 8 B-Disease
or	1020 2 O
retching	1023 8 O
episodes	1032 8 O
,	1040 1 O
and	1042 3 O
no	1046 2 O
antiemetic	1049 10 O
rescue	1060 6 O
)	1066 1 O
was	1068 3 O
recorded	1072 8 O
in	1081 2 O
23	1084 2 O
%	1086 1 O
,	1087 1 O
57	1089 2 O
%	1091 1 O
,	1092 1 O
58	1094 2 O
%	1096 1 O
,	1097 1 O
and	1099 3 O
60	1103 2 O
%	1105 1 O
of	1107 2 O
patients	1110 8 O
,	1118 1 O
respectively	1120 12 O
,	1132 1 O
and	1134 3 O
a	1138 1 O
complete	1140 8 O
response	1149 8 O
(	1158 1 O
no	1159 2 O
vomiting	1162 8 B-Disease
or	1171 2 O
retching	1174 8 O
,	1182 1 O
and	1184 3 O
no	1188 2 O
antiemetic	1191 10 O
rescue	1202 6 O
)	1208 1 O
in	1210 2 O
18	1213 2 O
%	1215 1 O
,	1216 1 O
41	1218 2 O
%	1220 1 O
,	1221 1 O
40	1223 2 O
%	1225 1 O
,	1226 1 O
and	1228 3 O
47	1232 2 O
%	1234 1 O
of	1236 2 O
patients	1239 8 O
,	1247 1 O
respectively	1249 12 O
.	1261 1 O

There	1263 5 O
was	1269 3 O
a	1273 1 O
statistically	1275 13 O
longer	1289 6 O
time	1296 4 O
to	1301 2 O
first	1304 5 O
episode	1310 7 O
of	1318 2 O
nausea	1321 6 B-Disease
(	1328 1 O
P	1329 1 O
=	1331 1 O
.	1333 1 O
0015	1334 4 O
)	1338 1 O
and	1340 3 O
vomiting	1344 8 B-Disease
(	1353 1 O
P	1354 1 O
=	1356 1 O
.	1358 1 O
0001	1359 4 O
)	1363 1 O
,	1364 1 O
and	1366 3 O
fewer	1370 5 O
patients	1376 8 O
were	1385 4 O
administered	1390 12 O
additional	1403 10 O
antiemetic	1414 10 O
medication	1425 10 O
in	1436 2 O
the	1439 3 O
10	1443 2 O
-	1445 1 O
micrograms	1446 10 O
/	1456 1 O
kg	1457 2 O
dosing	1460 6 O
groups	1467 6 O
than	1474 4 O
in	1479 2 O
the	1482 3 O
5	1486 1 O
-	1487 1 O
micrograms	1488 10 O
/	1498 1 O
kg	1499 2 O
dosing	1502 6 O
group	1509 5 O
.	1514 1 O

As	1516 2 O
granisetron	1519 11 B-Chemical
dose	1531 4 O
increased	1536 9 O
,	1545 1 O
appetite	1547 8 O
return	1556 6 O
increased	1563 9 O
(	1573 1 O
P	1574 1 O
=	1576 1 O
.	1578 1 O
040	1579 3 O
)	1582 1 O
.	1583 1 O

Headache	1585 8 B-Disease
was	1594 3 O
the	1598 3 O
most	1602 4 O
frequently	1607 10 O
reported	1618 8 O
adverse	1627 7 O
event	1635 5 O
(	1641 1 O
20	1642 2 O
%	1644 1 O
)	1645 1 O
.	1646 1 O

CONCLUSION	1648 10 O
:	1658 1 O
A	1660 1 O
single	1662 6 O
10	1669 2 O
-	1671 1 O
,	1672 1 O
20	1674 2 O
-	1676 1 O
,	1677 1 O
or	1679 2 O
40	1682 2 O
-	1684 1 O
micrograms	1685 10 O
/	1695 1 O
kg	1696 2 O
dose	1699 4 O
of	1704 2 O
granisetron	1707 11 B-Chemical
was	1719 3 O
effective	1723 9 O
in	1733 2 O
controlling	1736 11 O
vomiting	1748 8 B-Disease
in	1757 2 O
57	1760 2 O
%	1762 1 O
to	1764 2 O
60	1767 2 O
%	1769 1 O
of	1771 2 O
patients	1774 8 O
who	1783 3 O
received	1787 8 O
cisplatin	1796 9 B-Chemical
at	1806 2 O
doses	1809 5 O
greater	1815 7 O
than	1823 4 O
81	1828 2 O
mg	1831 2 O
/	1833 1 O
m2	1834 2 O
and	1837 3 O
totally	1841 7 O
prevented	1849 9 O
vomiting	1859 8 B-Disease
in	1868 2 O
40	1871 2 O
%	1873 1 O
to	1875 2 O
47	1878 2 O
%	1880 1 O
of	1882 2 O
patients	1885 8 O
.	1893 1 O

There	1895 5 O
were	1901 4 O
no	1906 2 O
statistically	1909 13 O
significant	1923 11 O
differences	1935 11 O
in	1947 2 O
efficacy	1950 8 O
between	1959 7 O
the	1967 3 O
10	1971 2 O
-	1973 1 O
micrograms	1974 10 O
/	1984 1 O
kg	1985 2 O
dose	1988 4 O
and	1993 3 O
the	1997 3 O
20	2001 2 O
-	2003 1 O
and	2005 3 O
40	2009 2 O
-	2011 1 O
micrograms	2012 10 O
/	2022 1 O
kg	2023 2 O
doses	2026 5 O
.	2031 1 O

Granisetron	2033 11 B-Chemical
was	2045 3 O
well	2049 4 O
tolerated	2054 9 O
at	2064 2 O
all	2067 3 O
doses	2071 5 O
.	2076 1 O

Adverse	0 7 O
interaction	8 11 O
between	20 7 O
clonidine	28 9 B-Chemical
and	38 3 O
verapamil	42 9 B-Chemical
.	51 1 O

OBJECTIVE	53 9 O
:	62 1 O
To	64 2 O
report	67 6 O
two	74 3 O
cases	78 5 O
of	84 2 O
a	87 1 O
possible	89 8 O
adverse	98 7 O
interaction	106 11 O
between	118 7 O
clonidine	126 9 B-Chemical
and	136 3 O
verapamil	140 9 B-Chemical
resulting	150 9 O
in	160 2 O
atrioventricular	163 16 B-Disease
(	180 1 I-Disease
AV	181 2 I-Disease
)	183 1 I-Disease
block	185 5 I-Disease
in	191 2 O
both	194 4 O
patients	199 8 O
and	208 3 O
severe	212 6 O
hypotension	219 11 B-Disease
in	231 2 O
one	234 3 O
patient	238 7 O
.	245 1 O

CASE	247 4 O
SUMMARIES	252 9 O
:	261 1 O
A	263 1 O
54	265 2 O
-	267 1 O
year	268 4 O
-	272 1 O
old	273 3 O
woman	277 5 O
with	283 4 O
hyperaldosteronism	288 18 B-Disease
was	307 3 O
treated	311 7 O
with	319 4 O
verapamil	324 9 B-Chemical
480	334 3 O
mg	338 2 O
/	340 1 O
d	341 1 O
and	343 3 O
spironolactone	347 14 B-Chemical
100	362 3 O
mg	366 2 O
/	368 1 O
d	369 1 O
.	370 1 O

After	372 5 O
the	378 3 O
addition	382 8 O
of	391 2 O
a	394 1 O
minimal	396 7 O
dose	404 4 O
of	409 2 O
clonidine	412 9 B-Chemical
(	422 1 O
0	423 1 O
.	424 1 O
15	425 2 O
mg	428 2 O
bid	431 3 O
)	434 1 O
,	435 1 O
she	437 3 O
developed	441 9 O
complete	451 8 O
AV	460 2 B-Disease
block	463 5 I-Disease
and	469 3 O
severe	473 6 O
hypotension	480 11 B-Disease
,	491 1 O
which	493 5 O
resolved	499 8 O
upon	508 4 O
cessation	513 9 O
of	523 2 O
all	526 3 O
medications	530 11 O
.	541 1 O

A	543 1 O
65	545 2 O
-	547 1 O
year	548 4 O
-	552 1 O
old	553 3 O
woman	557 5 O
was	563 3 O
treated	567 7 O
with	575 4 O
extended	580 8 O
-	588 1 O
release	589 7 O
verapamil	597 9 B-Chemical
240	607 3 O
mg	611 2 O
/	613 1 O
d	614 1 O
.	615 1 O

After	617 5 O
the	623 3 O
addition	627 8 O
of	636 2 O
clonidine	639 9 B-Chemical
0	649 1 O
.	650 1 O
15	651 2 O
mg	654 2 O
bid	657 3 O
she	661 3 O
developed	665 9 O
complete	675 8 O
AV	684 2 B-Disease
block	687 5 I-Disease
,	692 1 O
which	694 5 O
resolved	700 8 O
after	709 5 O
all	715 3 O
therapy	719 7 O
was	727 3 O
stopped	731 7 O
.	738 1 O

DISCUSSION	740 10 O
:	750 1 O
An	752 2 O
adverse	755 7 O
interaction	763 11 O
between	775 7 O
clonidine	783 9 B-Chemical
and	793 3 O
verapamil	797 9 B-Chemical
has	807 3 O
not	811 3 O
been	815 4 O
reported	820 8 O
previously	829 10 O
.	839 1 O

We	841 2 O
describe	844 8 O
two	853 3 O
such	857 4 O
cases	862 5 O
and	868 3 O
discuss	872 7 O
the	880 3 O
various	884 7 O
mechanisms	892 10 O
that	903 4 O
might	908 5 O
cause	914 5 O
such	920 4 O
an	925 2 O
interaction	928 11 O
.	939 1 O

Clinicians	941 10 O
should	952 6 O
be	959 2 O
acquainted	962 10 O
with	973 4 O
this	978 4 O
possibly	983 8 O
fatal	992 5 O
interaction	998 11 O
between	1010 7 O
two	1018 3 O
commonly	1022 8 O
used	1031 4 O
antihypertensive	1036 16 O
drugs	1053 5 O
.	1058 1 O

CONCLUSIONS	1060 11 O
:	1071 1 O
Caution	1073 7 O
is	1081 2 O
recommended	1084 11 O
in	1096 2 O
combining	1099 9 O
clonidine	1109 9 B-Chemical
and	1119 3 O
verapamil	1123 9 B-Chemical
therapy	1133 7 O
,	1140 1 O
even	1142 4 O
in	1147 2 O
patients	1150 8 O
who	1159 3 O
do	1163 2 O
not	1166 3 O
have	1170 4 O
sinus	1175 5 O
or	1181 2 O
AV	1184 2 O
node	1187 4 O
dysfunction	1192 11 O
.	1203 1 O

The	1205 3 O
two	1209 3 O
drugs	1213 5 O
may	1219 3 O
act	1223 3 O
synergistically	1227 15 O
on	1243 2 O
both	1246 4 O
the	1251 3 O
AV	1255 2 O
node	1258 4 O
and	1263 3 O
the	1267 3 O
peripheral	1271 10 O
circulation	1282 11 O
.	1293 1 O

Pharmacological	0 15 O
studies	16 7 O
on	24 2 O
a	27 1 O
new	29 3 O
dihydrothienopyridine	33 21 B-Chemical
calcium	55 7 I-Chemical
antagonist	63 10 O
,	73 1 O
S	75 1 B-Chemical
-	76 1 I-Chemical
312	77 3 I-Chemical
-	80 1 I-Chemical
d	81 1 I-Chemical
.	82 1 O

5th	84 3 O
communication	88 13 O
:	101 1 O
anticonvulsant	103 14 O
effects	118 7 O
in	126 2 O
mice	129 4 O
.	133 1 O

S	135 1 B-Chemical
-	136 1 I-Chemical
312	137 3 I-Chemical
,	140 1 O
S	142 1 B-Chemical
-	143 1 I-Chemical
312	144 3 I-Chemical
-	147 1 I-Chemical
d	148 1 I-Chemical
,	149 1 O
but	151 3 O
not	155 3 O
S	159 1 B-Chemical
-	160 1 I-Chemical
312	161 3 I-Chemical
-	164 1 I-Chemical
l	165 1 I-Chemical
,	166 1 O
L	168 1 O
-	169 1 O
type	170 4 O
calcium	175 7 B-Chemical
channel	183 7 O
antagonists	191 11 O
,	202 1 O
showed	204 6 O
anticonvulsant	211 14 O
effects	226 7 O
on	234 2 O
the	237 3 O
audiogenic	241 10 B-Disease
tonic	252 5 I-Disease
convulsions	258 11 I-Disease
in	270 2 O
DBA	273 3 O
/	276 1 O
2	277 1 O
mice	279 4 O
;	283 1 O
and	285 3 O
their	289 5 O
ED50	295 4 O
values	300 6 O
were	307 4 O
18	312 2 O
.	314 1 O
4	315 1 O
(	317 1 O
12	318 2 O
.	320 1 O
8	321 1 O
-	322 1 O
27	323 2 O
.	325 1 O
1	326 1 O
)	327 1 O
mg	329 2 O
/	331 1 O
kg	332 2 O
,	334 1 O
p	336 1 O
.	337 1 O
o	338 1 O
.	339 1 O
and	341 3 O
15	345 2 O
.	347 1 O
0	348 1 O
(	350 1 O
10	351 2 O
.	353 1 O
2	354 1 O
-	355 1 O
23	356 2 O
.	358 1 O
7	359 1 O
)	360 1 O
mg	362 2 O
/	364 1 O
kg	365 2 O
,	367 1 O
p	369 1 O
.	370 1 O
o	371 1 O
.	372 1 O
,	373 1 O
respectively	375 12 O
,	387 1 O
while	389 5 O
that	395 4 O
of	400 2 O
flunarizine	403 11 B-Chemical
was	415 3 O
34	419 2 O
.	421 1 O
0	422 1 O
(	424 1 O
26	425 2 O
.	427 1 O
0	428 1 O
-	429 1 O
44	430 2 O
.	432 1 O
8	433 1 O
)	434 1 O
mg	436 2 O
/	438 1 O
kg	439 2 O
,	441 1 O
p	443 1 O
.	444 1 O
o	445 1 O
.	446 1 O

Although	448 8 O
moderate	457 8 O
anticonvulsant	466 14 O
effects	481 7 O
of	489 2 O
S	492 1 B-Chemical
-	493 1 I-Chemical
312	494 3 I-Chemical
-	497 1 I-Chemical
d	498 1 I-Chemical
in	500 2 O
higher	503 6 O
doses	510 5 O
were	516 4 O
observed	521 8 O
against	530 7 O
the	538 3 O
clonic	542 6 O
convulsions	549 11 B-Disease
induced	561 7 O
by	569 2 O
pentylenetetrazole	572 18 B-Chemical
(	591 1 O
85	592 2 O
mg	595 2 O
/	597 1 O
kg	598 2 O
,	600 1 O
s	602 1 O
.	603 1 O
c	604 1 O
.	605 1 O
)	606 1 O
or	608 2 O
bemegride	611 9 B-Chemical
(	621 1 O
40	622 2 O
mg	625 2 O
/	627 1 O
kg	628 2 O
,	630 1 O
s	632 1 O
.	633 1 O
c	634 1 O
.	635 1 O
)	636 1 O
,	637 1 O
no	639 2 O
effects	642 7 O
were	650 4 O
observed	655 8 O
in	664 2 O
convulsions	667 11 B-Disease
induced	679 7 O
by	687 2 O
N	690 1 B-Chemical
-	691 1 I-Chemical
methyl	692 6 I-Chemical
-	698 1 I-Chemical
D	699 1 I-Chemical
-	700 1 I-Chemical
aspartate	701 9 I-Chemical
,	710 1 O
picrotoxin	712 10 B-Chemical
,	722 1 O
or	724 2 O
electroshock	727 12 O
in	740 2 O
Slc	743 3 O
:	746 1 O
ddY	747 3 O
mice	751 4 O
.	755 1 O

S	757 1 B-Chemical
-	758 1 I-Chemical
312	759 3 I-Chemical
-	762 1 I-Chemical
d	763 1 I-Chemical
may	765 3 O
be	769 2 O
useful	772 6 O
in	779 2 O
the	782 3 O
therapy	786 7 O
of	794 2 O
certain	797 7 O
types	805 5 O
of	811 2 O
human	814 5 O
epilepsy	820 8 B-Disease
.	828 1 O

Transmural	0 10 O
myocardial	11 10 B-Disease
infarction	22 10 I-Disease
with	33 4 O
sumatriptan	38 11 B-Chemical
.	49 1 O

For	51 3 O
sumatriptan	55 11 B-Chemical
,	66 1 O
tightness	68 9 O
in	78 2 O
the	81 3 O
chest	85 5 O
caused	91 6 O
by	98 2 O
an	101 2 O
unknown	104 7 O
mechanism	112 9 O
has	122 3 O
been	126 4 O
reported	131 8 O
in	140 2 O
3	143 1 O
-	144 1 O
5	145 1 O
%	146 1 O
of	148 2 O
users	151 5 O
.	156 1 O

We	158 2 O
describe	161 8 O
a	170 1 O
47	172 2 O
-	174 1 O
year	175 4 O
-	179 1 O
old	180 3 O
woman	184 5 O
with	190 4 O
an	195 2 O
acute	198 5 O
myocardial	204 10 B-Disease
infarction	215 10 I-Disease
after	226 5 O
administration	232 14 O
of	247 2 O
sumatriptan	250 11 B-Chemical
6	262 1 O
mg	264 2 O
subcutaneously	267 14 O
for	282 3 O
cluster	286 7 B-Disease
headache	294 8 I-Disease
.	302 1 O

The	304 3 O
patient	308 7 O
had	316 3 O
no	320 2 O
history	323 7 O
of	331 2 O
underlying	334 10 O
ischaemic	345 9 B-Disease
heart	355 5 I-Disease
disease	361 7 I-Disease
or	369 2 O
Prinzmetal	372 10 B-Disease
'	382 1 I-Disease
s	383 1 I-Disease
angina	385 6 I-Disease
.	391 1 O

She	393 3 O
recovered	397 9 O
without	407 7 O
complications	415 13 O
.	428 1 O

Flumazenil	0 10 B-Chemical
induces	11 7 O
seizures	19 8 B-Disease
and	28 3 O
death	32 5 O
in	38 2 O
mixed	41 5 O
cocaine	47 7 B-Chemical
-	54 1 O
diazepam	55 8 B-Chemical
intoxications	64 13 O
.	77 1 O

STUDY	79 5 O
HYPOTHESIS	85 10 O
:	95 1 O
Administration	97 14 O
of	112 2 O
the	115 3 O
benzodiazepine	119 14 B-Chemical
antagonist	134 10 O
flumazenil	145 10 B-Chemical
may	156 3 O
unmask	160 6 O
seizures	167 8 B-Disease
in	176 2 O
mixed	179 5 O
cocaine	185 7 B-Chemical
-	192 1 O
benzodiazepine	193 14 B-Chemical
intoxication	208 12 O
.	220 1 O

DESIGN	222 6 O
:	228 1 O
Male	230 4 O
Sprague	235 7 O
-	242 1 O
Dawley	243 6 O
rats	250 4 O
received	255 8 O
100	264 3 O
mg	268 2 O
/	270 1 O
kg	271 2 O
cocaine	274 7 B-Chemical
IP	282 2 O
alone	285 5 O
,	290 1 O
5	292 1 O
mg	294 2 O
/	296 1 O
kg	297 2 O
diazepam	300 8 B-Chemical
alone	309 5 O
,	314 1 O
or	316 2 O
a	319 1 O
combination	321 11 O
of	333 2 O
diazepam	336 8 B-Chemical
and	345 3 O
cocaine	349 7 B-Chemical
.	356 1 O

Three	358 5 O
minutes	364 7 O
later	372 5 O
,	377 1 O
groups	379 6 O
were	386 4 O
challenged	391 10 O
with	402 4 O
vehicle	407 7 O
or	415 2 O
flumazenil	418 10 B-Chemical
5	429 1 O
or	431 2 O
10	434 2 O
mg	437 2 O
/	439 1 O
kg	440 2 O
IP	443 2 O
.	445 1 O

Animal	447 6 O
behavior	454 8 O
,	462 1 O
seizures	464 8 B-Disease
(	473 1 O
time	474 4 O
to	479 2 O
and	482 3 O
incidence	486 9 O
)	495 1 O
,	496 1 O
death	498 5 O
(	504 1 O
time	505 4 O
to	510 2 O
and	513 3 O
incidence	517 9 O
)	526 1 O
,	527 1 O
and	529 3 O
cortical	533 8 O
EEG	542 3 O
tracings	546 8 O
were	555 4 O
recorded	560 8 O
.	568 1 O

INTERVENTIONS	570 13 O
:	583 1 O
Administration	585 14 O
of	600 2 O
flumazenil	603 10 B-Chemical
to	614 2 O
animals	617 7 O
after	625 5 O
they	631 4 O
had	636 3 O
received	640 8 O
a	649 1 O
combination	651 11 O
dose	663 4 O
of	668 2 O
cocaine	671 7 B-Chemical
and	679 3 O
diazepam	683 8 B-Chemical
.	691 1 O

RESULTS	693 7 O
:	700 1 O
In	702 2 O
group	705 5 O
1	711 1 O
,	712 1 O
animals	714 7 O
received	722 8 O
cocaine	731 7 B-Chemical
followed	739 8 O
by	748 2 O
vehicle	751 7 O
.	758 1 O

This	760 4 O
resulted	765 8 O
in	774 2 O
100	777 3 O
%	780 1 O
developing	782 10 O
seizures	793 8 B-Disease
and	802 3 O
death	806 5 O
.	811 1 O

Group	813 5 O
2	819 1 O
received	821 8 O
diazepam	830 8 B-Chemical
alone	839 5 O
followed	845 8 O
by	854 2 O
vehicle	857 7 O
.	864 1 O

Animals	866 7 O
became	874 6 O
somnolent	881 9 O
and	891 3 O
none	895 4 O
died	900 4 O
.	904 1 O

Group	906 5 O
3	912 1 O
received	914 8 O
diazepam	923 8 B-Chemical
followed	932 8 O
by	941 2 O
5	944 1 O
mg	946 2 O
/	948 1 O
kg	949 2 O
flumazenil	952 10 B-Chemical
.	962 1 O

Animals	964 7 O
became	972 6 O
somnolent	979 9 O
after	989 5 O
diazepam	995 8 B-Chemical
and	1004 3 O
then	1008 4 O
active	1013 6 O
after	1020 5 O
flumazenil	1026 10 B-Chemical
administration	1037 14 O
.	1051 1 O

In	1053 2 O
group	1056 5 O
4	1062 1 O
,	1063 1 O
a	1065 1 O
combination	1067 11 O
of	1079 2 O
cocaine	1082 7 B-Chemical
and	1090 3 O
diazepam	1094 8 B-Chemical
was	1103 3 O
administered	1107 12 O
simultaneously	1120 14 O
.	1134 1 O

This	1136 4 O
resulted	1141 8 O
in	1150 2 O
no	1153 2 O
overt	1156 5 O
or	1162 2 O
EEG	1165 3 O
-	1168 1 O
detectable	1169 10 O
seizures	1180 8 B-Disease
and	1189 3 O
a	1193 1 O
50	1195 2 O
%	1197 1 O
incidence	1199 9 O
of	1209 2 O
death	1212 5 O
.	1217 1 O

Group	1219 5 O
5	1225 1 O
received	1227 8 O
a	1236 1 O
similar	1238 7 O
combination	1246 11 O
of	1258 2 O
cocaine	1261 7 B-Chemical
and	1269 3 O
diazepam	1273 8 B-Chemical
,	1281 1 O
followed	1283 8 O
later	1292 5 O
by	1298 2 O
5	1301 1 O
mg	1303 2 O
/	1305 1 O
kg	1306 2 O
flumazenil	1309 10 B-Chemical
.	1319 1 O

This	1321 4 O
resulted	1326 8 O
in	1335 2 O
an	1338 2 O
increased	1341 9 O
incidence	1351 9 O
of	1361 2 O
seizures	1364 8 B-Disease
,	1372 1 O
90	1374 2 O
%	1376 1 O
(	1378 1 O
P	1379 1 O
<	1381 1 O
.	1383 1 O
01	1384 2 O
)	1386 1 O
,	1387 1 O
and	1389 3 O
death	1393 5 O
,	1398 1 O
100	1400 3 O
%	1403 1 O
(	1405 1 O
P	1406 1 O
<	1408 1 O
or	1410 2 O
=	1413 1 O
.	1415 1 O
01	1416 2 O
)	1418 1 O
,	1419 1 O
compared	1421 8 O
with	1430 4 O
group	1435 5 O
4	1441 1 O
.	1442 1 O

Group	1444 5 O
6	1450 1 O
received	1452 8 O
cocaine	1461 7 B-Chemical
and	1469 3 O
diazepam	1473 8 B-Chemical
followed	1482 8 O
by	1491 2 O
10	1494 2 O
mg	1497 2 O
/	1499 1 O
kg	1500 2 O
flumazenil	1503 10 B-Chemical
.	1513 1 O

This	1515 4 O
also	1520 4 O
resulted	1525 8 O
in	1534 2 O
an	1537 2 O
increased	1540 9 O
incidence	1550 9 O
of	1560 2 O
seizures	1563 8 B-Disease
,	1571 1 O
90	1573 2 O
%	1575 1 O
(	1577 1 O
P	1578 1 O
<	1580 1 O
or	1582 2 O
=	1585 1 O
.	1587 1 O
01	1588 2 O
)	1590 1 O
,	1591 1 O
and	1593 3 O
death	1597 5 O
,	1602 1 O
90	1604 2 O
%	1606 1 O
(	1608 1 O
P	1609 1 O
<	1611 1 O
or	1613 2 O
=	1616 1 O
.	1618 1 O
05	1619 2 O
)	1621 1 O
,	1622 1 O
compared	1624 8 O
with	1633 4 O
group	1638 5 O
4	1644 1 O
.	1645 1 O

CONCLUSION	1647 10 O
:	1657 1 O
Flumazenil	1659 10 B-Chemical
can	1670 3 O
unmask	1674 6 O
seizures	1681 8 B-Disease
and	1690 3 O
increase	1694 8 O
the	1703 3 O
incidence	1707 9 O
of	1717 2 O
death	1720 5 O
in	1726 2 O
a	1729 1 O
model	1731 5 O
of	1737 2 O
combined	1740 8 O
cocaine	1749 7 B-Chemical
-	1756 1 O
diazepam	1757 8 B-Chemical
intoxications	1766 13 O
.	1779 1 O

Mechanisms	0 10 O
for	11 3 O
protective	15 10 O
effects	26 7 O
of	34 2 O
free	37 4 O
radical	42 7 O
scavengers	50 10 O
on	61 2 O
gentamicin	64 10 B-Chemical
-	74 1 O
mediated	75 8 O
nephropathy	84 11 B-Disease
in	96 2 O
rats	99 4 O
.	103 1 O

Studies	105 7 O
were	113 4 O
performed	118 9 O
to	128 2 O
examine	131 7 O
the	139 3 O
mechanisms	143 10 O
for	154 3 O
the	158 3 O
protective	162 10 O
effects	173 7 O
of	181 2 O
free	184 4 O
radical	189 7 O
scavengers	197 10 O
on	208 2 O
gentamicin	211 10 B-Chemical
(	222 1 O
GM	223 2 B-Chemical
)	225 1 O
-	226 1 O
mediated	227 8 O
nephropathy	236 11 B-Disease
.	247 1 O

Administration	249 14 O
of	264 2 O
GM	267 2 B-Chemical
at	270 2 O
40	273 2 O
mg	276 2 O
/	278 1 O
kg	279 2 O
sc	282 2 O
for	285 3 O
13	289 2 O
days	292 4 O
to	297 2 O
rats	300 4 O
induced	305 7 O
a	313 1 O
significant	315 11 O
reduction	327 9 O
in	337 2 O
renal	340 5 O
blood	346 5 O
flow	352 4 O
(	357 1 O
RBF	358 3 O
)	361 1 O
and	363 3 O
inulin	367 6 O
clearance	374 9 O
(	384 1 O
CIn	385 3 O
)	388 1 O
as	390 2 O
well	393 4 O
as	398 2 O
marked	401 6 O
tubular	408 7 B-Disease
damage	416 6 I-Disease
.	422 1 O

A	424 1 O
significant	426 11 O
reduction	438 9 O
in	448 2 O
urinary	451 7 O
guanosine	459 9 B-Chemical
3	469 1 I-Chemical
'	470 1 I-Chemical
,	471 1 I-Chemical
5	472 1 I-Chemical
'	473 1 I-Chemical
-	474 1 I-Chemical
cyclic	475 6 I-Chemical
monophosphate	482 13 I-Chemical
(	496 1 O
cGMP	497 4 B-Chemical
)	501 1 O
excretion	503 9 O
and	513 3 O
a	517 1 O
significant	519 11 O
increase	531 8 O
in	540 2 O
renal	543 5 O
cortical	549 8 O
renin	558 5 O
and	564 3 O
endothelin	568 10 O
-	578 1 O
1	579 1 O
contents	581 8 O
were	590 4 O
also	595 4 O
observed	600 8 O
in	609 2 O
GM	612 2 B-Chemical
-	614 1 O
mediated	615 8 O
nephropathy	624 11 B-Disease
.	635 1 O

Superoxide	637 10 B-Chemical
dismutase	648 9 O
(	658 1 O
SOD	659 3 O
)	662 1 O
or	664 2 O
dimethylthiourea	667 16 B-Chemical
(	684 1 O
DMTU	685 4 B-Chemical
)	689 1 O
significantly	691 13 O
lessened	705 8 O
the	714 3 O
GM	718 2 B-Chemical
-	720 1 O
induced	721 7 O
decrement	729 9 O
in	739 2 O
CIn	742 3 O
.	745 1 O

The	747 3 O
SOD	751 3 O
-	754 1 O
induced	755 7 O
increase	763 8 O
in	772 2 O
glomerular	775 10 O
filtration	786 10 O
rate	797 4 O
was	802 3 O
associated	806 10 O
with	817 4 O
a	822 1 O
marked	824 6 O
improvement	831 11 O
in	843 2 O
RBF	846 3 O
,	849 1 O
an	851 2 O
increase	854 8 O
in	863 2 O
urinary	866 7 O
cGMP	874 4 B-Chemical
excretion	879 9 O
,	888 1 O
and	890 3 O
a	894 1 O
decrease	896 8 O
in	905 2 O
renal	908 5 O
renin	914 5 O
and	920 3 O
endothelin	924 10 O
-	934 1 O
1	935 1 O
content	937 7 O
.	944 1 O

SOD	946 3 O
did	950 3 O
not	954 3 O
attenuate	958 9 O
the	968 3 O
tubular	972 7 B-Disease
damage	980 6 I-Disease
.	986 1 O

In	988 2 O
contrast	991 8 O
,	999 1 O
DMTU	1001 4 B-Chemical
significantly	1006 13 O
reduced	1020 7 O
the	1028 3 O
tubular	1032 7 B-Disease
damage	1040 6 I-Disease
and	1047 3 O
lipid	1051 5 O
peroxidation	1057 12 O
,	1069 1 O
but	1071 3 O
it	1075 2 O
did	1078 3 O
not	1082 3 O
affect	1086 6 O
renal	1093 5 O
hemodynamics	1099 12 O
and	1112 3 O
vasoactive	1116 10 O
substances	1127 10 O
.	1137 1 O

Neither	1139 7 O
SOD	1147 3 O
nor	1151 3 O
DMTU	1155 4 B-Chemical
affected	1160 8 O
the	1169 3 O
renal	1173 5 O
cortical	1179 8 O
GM	1188 2 B-Chemical
content	1191 7 O
in	1199 2 O
GM	1202 2 B-Chemical
-	1204 1 O
treated	1205 7 O
rats	1213 4 O
.	1217 1 O

These	1219 5 O
results	1225 7 O
suggest	1233 7 O
that	1241 4 O
1	1246 1 O
)	1247 1 O
both	1249 4 O
SOD	1254 3 O
and	1258 3 O
DMTU	1262 4 B-Chemical
have	1267 4 O
protective	1272 10 O
effects	1283 7 O
on	1291 2 O
GM	1294 2 B-Chemical
-	1296 1 O
mediated	1297 8 O
nephropathy	1306 11 B-Disease
,	1317 1 O
2	1319 1 O
)	1320 1 O
the	1322 3 O
mechanisms	1326 10 O
for	1337 3 O
the	1341 3 O
protective	1345 10 O
effects	1356 7 O
differ	1364 6 O
for	1371 3 O
SOD	1375 3 O
and	1379 3 O
DMTU	1383 4 B-Chemical
,	1387 1 O
and	1389 3 O
3	1393 1 O
)	1394 1 O
superoxide	1396 10 B-Chemical
anions	1407 6 O
play	1414 4 O
a	1419 1 O
critical	1421 8 O
role	1430 4 O
in	1435 2 O
GM	1438 2 B-Chemical
-	1440 1 O
induced	1441 7 O
renal	1449 5 O
vasoconstriction	1455 16 O
.	1471 1 O

Assessment	0 10 O
of	11 2 O
cardiomyocyte	14 13 O
DNA	28 3 O
synthesis	32 9 O
during	42 6 O
hypertrophy	49 11 B-Disease
in	61 2 O
adult	64 5 O
mice	70 4 O
.	74 1 O

The	76 3 O
ability	80 7 O
of	88 2 O
cardiomyocytes	91 14 O
to	106 2 O
synthesize	109 10 O
DNA	120 3 O
in	124 2 O
response	127 8 O
to	136 2 O
experimentally	139 14 O
induced	154 7 O
cardiac	162 7 B-Disease
hypertrophy	170 11 I-Disease
was	182 3 O
assessed	186 8 O
in	195 2 O
adult	198 5 O
mice	204 4 O
.	208 1 O

Isoproterenol	210 13 B-Chemical
delivered	224 9 O
by	234 2 O
osmotic	237 7 O
minipump	245 8 O
implantation	254 12 O
in	267 2 O
adult	270 5 O
C3Heb	276 5 O
/	281 1 O
FeJ	282 3 O
mice	286 4 O
resulted	291 8 O
in	300 2 O
a	303 1 O
46	305 2 O
%	307 1 O
increase	309 8 O
in	318 2 O
heart	321 5 O
weight	327 6 O
and	334 3 O
a	338 1 O
19	340 2 O
.	342 1 O
3	343 1 O
%	344 1 O
increase	346 8 O
in	355 2 O
cardiomyocyte	358 13 O
area	372 4 O
.	376 1 O

No	378 2 O
DNA	381 3 O
synthesis	385 9 O
,	394 1 O
as	396 2 O
assessed	399 8 O
by	408 2 O
autoradiographic	411 16 O
analysis	428 8 O
of	437 2 O
isolated	440 8 O
cardiomyocytes	449 14 O
,	463 1 O
was	465 3 O
observed	469 8 O
in	478 2 O
control	481 7 O
or	489 2 O
hypertrophic	492 12 B-Disease
hearts	505 6 I-Disease
.	511 1 O

A	513 1 O
survey	515 6 O
of	522 2 O
15	525 2 O
independent	528 11 O
inbred	540 6 O
strains	547 7 O
of	555 2 O
mice	558 4 O
revealed	563 8 O
that	572 4 O
ventricular	577 11 O
cardiomyocyte	589 13 O
nuclear	603 7 O
number	611 6 O
ranged	618 6 O
from	625 4 O
3	630 1 O
to	632 2 O
13	635 2 O
%	637 1 O
mononucleate	639 12 O
,	651 1 O
suggesting	653 10 O
that	664 4 O
cardiomyocyte	669 13 O
terminal	683 8 O
differentiation	692 15 O
is	708 2 O
influenced	711 10 O
directly	722 8 O
or	731 2 O
indirectly	734 10 O
by	745 2 O
genetic	748 7 O
background	756 10 O
.	766 1 O

To	768 2 O
determine	771 9 O
whether	781 7 O
the	789 3 O
capacity	793 8 O
for	802 3 O
reactive	806 8 O
DNA	815 3 O
synthesis	819 9 O
was	829 3 O
also	833 4 O
subject	838 7 O
to	846 2 O
genetic	849 7 O
regulation	857 10 O
,	867 1 O
cardiac	869 7 B-Disease
hypertrophy	877 11 I-Disease
was	889 3 O
induced	893 7 O
in	901 2 O
the	904 3 O
strains	908 7 O
of	916 2 O
mice	919 4 O
comprising	924 10 O
the	935 3 O
extremes	939 8 O
of	948 2 O
the	951 3 O
nuclear	955 7 O
number	963 6 O
survey	970 6 O
.	976 1 O

These	978 5 O
data	984 4 O
indicate	989 8 O
that	998 4 O
adult	1003 5 O
mouse	1009 5 O
atrial	1015 6 O
and	1022 3 O
ventricular	1026 11 O
cardiomyocytes	1038 14 O
do	1053 2 O
not	1056 3 O
synthesize	1060 10 O
DNA	1071 3 O
in	1075 2 O
response	1078 8 O
to	1087 2 O
isoproterenol	1090 13 B-Chemical
-	1103 1 O
induced	1104 7 O
cardiac	1112 7 B-Disease
hypertrophy	1120 11 I-Disease
.	1131 1 O

Central	0 7 O
cardiovascular	8 14 O
effects	23 7 O
of	31 2 O
AVP	34 3 B-Chemical
and	38 3 O
ANP	42 3 O
in	46 2 O
normotensive	49 12 O
and	62 3 O
spontaneously	66 13 O
hypertensive	80 12 B-Disease
rats	93 4 O
.	97 1 O

The	99 3 O
purpose	103 7 O
of	111 2 O
the	114 3 O
present	118 7 O
study	126 5 O
was	132 3 O
to	136 2 O
compare	139 7 O
influence	147 9 O
of	157 2 O
central	160 7 O
arginine	168 8 B-Chemical
vasopressin	177 11 I-Chemical
(	189 1 O
AVP	190 3 B-Chemical
)	193 1 O
and	195 3 O
of	199 2 O
atrial	202 6 O
natriuretic	209 11 O
peptide	221 7 O
(	229 1 O
ANP	230 3 O
)	233 1 O
on	235 2 O
control	238 7 O
of	246 2 O
arterial	249 8 O
blood	258 5 O
pressure	264 8 O
(	273 1 O
MAP	274 3 O
)	277 1 O
and	279 3 O
heart	283 5 O
rate	289 4 O
(	294 1 O
HR	295 2 O
)	297 1 O
in	299 2 O
normotensive	302 12 O
(	315 1 O
WKY	316 3 O
)	319 1 O
and	321 3 O
spontaneously	325 13 O
hypertensive	339 12 B-Disease
(	352 1 O
SHR	353 3 O
)	356 1 O
rats	358 4 O
.	362 1 O

Three	364 5 O
series	370 6 O
of	377 2 O
experiments	380 11 O
were	392 4 O
performed	397 9 O
on	407 2 O
30	410 2 O
WKY	413 3 O
and	417 3 O
30	421 2 O
SHR	424 3 O
,	427 1 O
chronically	429 11 O
instrumented	441 12 O
with	454 4 O
guide	459 5 O
tubes	465 5 O
in	471 2 O
the	474 3 O
lateral	478 7 O
ventricle	486 9 O
(	496 1 O
LV	497 2 O
)	499 1 O
and	501 3 O
arterial	505 8 O
and	514 3 O
venous	518 6 O
catheters	525 9 O
.	534 1 O

MAP	536 3 O
and	540 3 O
HR	544 2 O
were	547 4 O
monitored	552 9 O
before	562 6 O
and	569 3 O
after	573 5 O
i	579 1 O
.	580 1 O
v	581 1 O
.	582 1 O
injections	584 10 O
of	595 2 O
either	598 6 O
vehicle	605 7 O
or	613 2 O
1	616 1 O
,	617 1 O
10	619 2 O
and	622 3 O
50	626 2 O
ng	629 2 O
of	632 2 O
AVP	635 3 B-Chemical
and	639 3 O
25	643 2 O
,	645 1 O
125	647 3 O
and	651 3 O
500	655 3 O
ng	659 2 O
of	662 2 O
ANP	665 3 O
.	668 1 O

Sensitivity	670 11 O
of	682 2 O
cardiac	685 7 O
component	693 9 O
of	703 2 O
baroreflex	706 10 O
(	717 1 O
CCB	718 3 O
)	721 1 O
,	722 1 O
expressed	724 9 O
as	734 2 O
a	737 1 O
slope	739 5 O
of	745 2 O
the	748 3 O
regression	752 10 O
line	763 4 O
was	768 3 O
determined	772 10 O
from	783 4 O
relationships	788 13 O
between	802 7 O
systolic	810 8 O
arterial	819 8 O
pressure	828 8 O
(	837 1 O
SAP	838 3 O
)	841 1 O
and	843 3 O
HR	847 2 O
period	850 6 O
(	857 1 O
HRp	858 3 O
)	861 1 O
during	863 6 O
phenylephrine	870 13 B-Chemical
(	884 1 O
Phe	885 3 B-Chemical
)	888 1 O
-	889 1 O
induced	890 7 O
hypertension	898 12 B-Disease
and	911 3 O
sodium	915 6 B-Chemical
nitroprusside	922 13 I-Chemical
(	936 1 O
SN	937 2 B-Chemical
)	939 1 O
-	940 1 O
induced	941 7 O
hypotension	949 11 B-Disease
.	960 1 O

CCB	962 3 O
was	966 3 O
measured	970 8 O
before	979 6 O
and	986 3 O
after	990 5 O
administration	996 14 O
of	1011 2 O
either	1014 6 O
vehicle	1021 7 O
,	1028 1 O
AVP	1030 3 B-Chemical
,	1033 1 O
ANP	1035 3 O
,	1038 1 O
or	1040 2 O
both	1043 4 O
peptides	1048 8 O
together	1057 8 O
.	1065 1 O

Increases	1067 9 O
of	1077 2 O
MAP	1080 3 O
occurred	1084 8 O
after	1093 5 O
LV	1099 2 O
administration	1102 14 O
of	1117 2 O
1	1120 1 O
,	1121 1 O
10	1123 2 O
and	1126 3 O
50	1130 2 O
ng	1133 2 O
of	1136 2 O
AVP	1139 3 B-Chemical
in	1143 2 O
WKY	1146 3 O
and	1150 3 O
of	1154 2 O
10	1157 2 O
and	1160 3 O
50	1164 2 O
ng	1167 2 O
in	1170 2 O
SHR	1173 3 O
.	1176 1 O

ANP	1178 3 O
did	1182 3 O
not	1186 3 O
cause	1190 5 O
significant	1196 11 O
changes	1208 7 O
in	1216 2 O
MAP	1219 3 O
in	1223 2 O
both	1226 4 O
strains	1231 7 O
as	1239 2 O
compared	1242 8 O
to	1251 2 O
vehicle	1254 7 O
,	1261 1 O
but	1263 3 O
it	1267 2 O
abolished	1270 9 O
AVP	1280 3 B-Chemical
-	1283 1 O
induced	1284 7 O
MAP	1292 3 O
increase	1296 8 O
in	1305 2 O
WKY	1308 3 O
and	1312 3 O
SHR	1316 3 O
.	1319 1 O

CCB	1321 3 O
was	1325 3 O
reduced	1329 7 O
in	1337 2 O
WKY	1340 3 O
and	1344 3 O
SHR	1348 3 O
after	1352 5 O
LV	1358 2 O
administration	1361 14 O
of	1376 2 O
AVP	1379 3 B-Chemical
during	1383 6 O
SN	1390 2 B-Chemical
-	1392 1 O
induced	1393 7 O
hypotension	1401 11 B-Disease
.	1412 1 O

In	1414 2 O
SHR	1417 3 O
but	1421 3 O
not	1425 3 O
in	1429 2 O
WKY	1432 3 O
administration	1436 14 O
of	1451 2 O
ANP	1454 3 O
,	1457 1 O
AVP	1459 3 B-Chemical
and	1463 3 O
ANP	1467 3 O
+	1471 1 O
AVP	1473 3 B-Chemical
decreased	1477 9 O
CCB	1487 3 O
during	1491 6 O
Phe	1498 3 B-Chemical
-	1501 1 O
induced	1502 7 O
MAP	1510 3 O
elevation	1514 9 O
.	1523 1 O

The	1525 3 O
results	1529 7 O
indicate	1537 8 O
that	1546 4 O
centrally	1551 9 O
applied	1561 7 O
AVP	1569 3 B-Chemical
and	1573 3 O
ANP	1577 3 O
exert	1581 5 O
differential	1587 12 O
effects	1600 7 O
on	1608 2 O
blood	1611 5 O
pressure	1617 8 O
and	1626 3 O
baroreflex	1630 10 O
control	1641 7 O
of	1649 2 O
heart	1652 5 O
rate	1658 4 O
in	1663 2 O
WKY	1666 3 O
and	1670 3 O
SHR	1674 3 O
and	1678 3 O
suggest	1682 7 O
interaction	1690 11 O
of	1702 2 O
these	1705 5 O
two	1711 3 O
peptides	1715 8 O
in	1724 2 O
blood	1727 5 O
pressure	1733 8 O
regulation	1742 10 O
at	1753 2 O
the	1756 3 O
level	1760 5 O
of	1766 2 O
central	1769 7 O
nervous	1777 7 O
system	1785 6 O
.	1791 1 O

Cutaneous	0 9 O
exposure	10 8 O
to	19 2 O
warfarin	22 8 B-Chemical
-	30 1 O
like	31 4 O
anticoagulant	36 13 O
causing	50 7 O
an	58 2 O
intracerebral	61 13 B-Disease
hemorrhage	75 10 I-Disease
:	85 1 O
a	87 1 O
case	89 4 O
report	94 6 O
.	100 1 O

A	102 1 O
case	104 4 O
of	109 2 O
intercerebral	112 13 O
hematoma	126 8 B-Disease
due	135 3 O
to	139 2 O
warfarin	142 8 B-Chemical
-	150 1 O
induced	151 7 O
coagulopathy	159 12 B-Disease
is	172 2 O
presented	175 9 O
.	184 1 O

The	186 3 O
39	190 2 O
-	192 1 O
year	193 4 O
-	197 1 O
old	198 3 O
woman	202 5 O
had	208 3 O
spread	212 6 O
a	219 1 O
warfarin	221 8 B-Chemical
-	229 1 O
type	230 4 O
rat	235 3 O
poison	239 6 O
around	246 6 O
her	253 3 O
house	257 5 O
weekly	263 6 O
using	270 5 O
her	276 3 O
bare	280 4 O
hands	285 5 O
,	290 1 O
with	292 4 O
no	297 2 O
washing	300 7 O
post	308 4 O
application	313 11 O
.	324 1 O

Percutaneous	326 12 O
absorption	339 10 O
of	350 2 O
warfarin	353 8 B-Chemical
causing	362 7 O
coagulopathy	370 12 B-Disease
,	382 1 O
reported	384 8 O
three	393 5 O
times	399 5 O
in	405 2 O
the	408 3 O
past	412 4 O
,	416 1 O
is	418 2 O
a	421 1 O
significant	423 11 O
risk	435 4 O
if	440 2 O
protective	443 10 O
measures	454 8 O
,	462 1 O
such	464 4 O
as	469 2 O
gloves	472 6 O
,	478 1 O
are	480 3 O
not	484 3 O
used	488 4 O
.	492 1 O

An	494 2 O
adverse	497 7 O
drug	505 4 O
interaction	510 11 O
with	522 4 O
piroxicam	527 9 B-Chemical
,	536 1 O
which	538 5 O
she	544 3 O
took	548 4 O
occasionally	553 12 O
,	565 1 O
may	567 3 O
have	571 4 O
exacerbated	576 11 O
the	588 3 O
coagulopathy	592 12 B-Disease
.	604 1 O

Pediatric	0 9 O
heart	10 5 O
transplantation	16 15 O
without	32 7 O
chronic	40 7 O
maintenance	48 11 O
steroids	60 8 B-Chemical
.	68 1 O

From	70 4 O
1986	75 4 O
to	80 2 O
February	83 8 O
1993	92 4 O
,	96 1 O
40	98 2 O
children	101 8 O
aged	110 4 O
2	115 1 O
months	117 6 O
to	124 2 O
18	127 2 O
years	130 5 O
(	136 1 O
average	137 7 O
age	145 3 O
10	149 2 O
.	151 1 O
4	152 1 O
+	154 1 O
/	155 1 O
-	156 1 O
5	158 1 O
.	159 1 O
8	160 1 O
years	162 5 O
)	167 1 O
underwent	169 9 O
heart	179 5 O
transplantation	185 15 O
.	200 1 O

Indications	202 11 O
for	214 3 O
transplantation	218 15 O
were	234 4 O
idiopathic	239 10 B-Disease
cardiomyopathy	250 14 I-Disease
(	265 1 O
52	266 2 O
%	268 1 O
)	269 1 O
,	270 1 O
congenital	272 10 B-Disease
heart	283 5 I-Disease
disease	289 7 I-Disease
(	297 1 O
35	298 2 O
%	300 1 O
)	301 1 O
with	303 4 O
and	308 3 O
without	312 7 O
prior	320 5 O
repair	326 6 O
(	333 1 O
71	334 2 O
%	336 1 O
and	338 3 O
29	342 2 O
%	344 1 O
,	345 1 O
respectively	347 12 O
)	359 1 O
,	360 1 O
hypertrophic	362 12 B-Disease
cardiomyopathy	375 14 I-Disease
(	390 1 O
5	391 1 O
%	392 1 O
)	393 1 O
,	394 1 O
valvular	396 8 B-Disease
heart	405 5 I-Disease
disease	411 7 I-Disease
(	419 1 O
3	420 1 O
%	421 1 O
)	422 1 O
,	423 1 O
and	425 3 O
doxorubicin	429 11 B-Chemical
cardiomyopathy	441 14 B-Disease
(	456 1 O
5	457 1 O
%	458 1 O
)	459 1 O
.	460 1 O

Patients	462 8 O
were	471 4 O
managed	476 7 O
with	484 4 O
cyclosporine	489 12 B-Chemical
and	502 3 O
azathioprine	506 12 B-Chemical
.	518 1 O

No	520 2 O
prophylaxis	523 11 O
with	535 4 O
antilymphocyte	540 14 O
globulin	555 8 O
was	564 3 O
used	568 4 O
.	572 1 O

Steroids	574 8 B-Chemical
were	583 4 O
given	588 5 O
to	594 2 O
39	597 2 O
%	599 1 O
of	601 2 O
patients	604 8 O
for	613 3 O
refractory	617 10 O
rejection	628 9 O
,	637 1 O
but	639 3 O
weaning	643 7 O
was	651 3 O
always	655 6 O
attempted	662 9 O
and	672 3 O
generally	676 9 O
successful	686 10 O
(	697 1 O
64	698 2 O
%	700 1 O
)	701 1 O
.	702 1 O

Five	704 4 O
patients	709 8 O
(	718 1 O
14	719 2 O
%	721 1 O
)	722 1 O
received	724 8 O
maintenance	733 11 O
steroids	745 8 B-Chemical
.	753 1 O

Four	755 4 O
patients	760 8 O
died	769 4 O
in	774 2 O
the	777 3 O
perioperative	781 13 O
period	795 6 O
and	802 3 O
one	806 3 O
died	810 4 O
4	815 1 O
months	817 6 O
later	824 5 O
.	829 1 O

There	831 5 O
have	837 4 O
been	842 4 O
no	847 2 O
deaths	850 6 O
related	857 7 O
to	865 2 O
rejection	868 9 O
or	878 2 O
infection	881 9 B-Disease
.	890 1 O

Average	892 7 O
follow	900 6 O
-	906 1 O
up	907 2 O
was	910 3 O
36	914 2 O
+	917 1 O
/	918 1 O
-	919 1 O
19	921 2 O
months	924 6 O
(	931 1 O
range	932 5 O
1	938 1 O
to	940 2 O
65	943 2 O
months	946 6 O
)	952 1 O
.	953 1 O

Cumulative	955 10 O
survival	966 8 O
is	975 2 O
88	978 2 O
%	980 1 O
at	982 2 O
5	985 1 O
years	987 5 O
.	992 1 O

In	994 2 O
patients	997 8 O
less	1006 4 O
than	1011 4 O
7	1016 1 O
years	1018 5 O
of	1024 2 O
age	1027 3 O
,	1030 1 O
rejection	1032 9 O
was	1042 3 O
monitored	1046 9 O
noninvasively	1056 13 O
.	1069 1 O

In	1071 2 O
the	1074 3 O
first	1078 5 O
postoperative	1084 13 O
month	1098 5 O
,	1103 1 O
89	1105 2 O
%	1107 1 O
of	1109 2 O
patients	1112 8 O
were	1121 4 O
treated	1126 7 O
for	1134 3 O
rejection	1138 9 O
.	1147 1 O

Freedom	1149 7 O
from	1157 4 O
serious	1162 7 O
infections	1170 10 B-Disease
was	1181 3 O
83	1185 2 O
%	1187 1 O
at	1189 2 O
1	1192 1 O
month	1194 5 O
and	1200 3 O
65	1204 2 O
%	1206 1 O
at	1208 2 O
1	1211 1 O
year	1213 4 O
.	1217 1 O

Cytomegalovirus	1219 15 B-Disease
infections	1235 10 I-Disease
were	1246 4 O
treated	1251 7 O
successfully	1259 12 O
with	1272 4 O
ganciclovir	1277 11 B-Chemical
in	1289 2 O
11	1292 2 O
patients	1295 8 O
.	1303 1 O

No	1305 2 O
impairment	1308 10 O
of	1319 2 O
growth	1322 6 O
was	1329 3 O
observed	1333 8 O
in	1342 2 O
children	1345 8 O
who	1354 3 O
underwent	1358 9 O
transplantation	1368 15 O
compared	1384 8 O
with	1393 4 O
a	1398 1 O
control	1400 7 O
population	1408 10 O
.	1418 1 O

Twenty	1420 6 O
-	1426 1 O
one	1427 3 O
patients	1431 8 O
(	1440 1 O
60	1441 2 O
%	1443 1 O
)	1444 1 O
have	1446 4 O
undergone	1451 9 O
annual	1461 6 O
catheterizations	1468 16 O
and	1485 3 O
no	1489 2 O
sign	1492 4 O
of	1497 2 O
graft	1500 5 O
atherosclerosis	1506 15 B-Disease
has	1522 3 O
been	1526 4 O
observed	1531 8 O
.	1539 1 O

Seizures	1541 8 B-Disease
occurred	1550 8 O
in	1559 2 O
five	1562 4 O
patients	1567 8 O
(	1576 1 O
14	1577 2 O
%	1579 1 O
)	1580 1 O
and	1582 3 O
hypertension	1586 12 B-Disease
was	1599 3 O
treated	1603 7 O
in	1611 2 O
10	1614 2 O
patients	1617 8 O
(	1626 1 O
28	1627 2 O
%	1629 1 O
)	1630 1 O
.	1631 1 O

No	1633 2 O
patient	1636 7 O
was	1644 3 O
disabled	1648 8 O
and	1657 3 O
no	1661 2 O
lymphoproliferative	1664 19 B-Disease
disorder	1684 8 I-Disease
was	1693 3 O
observed	1697 8 O
.	1705 1 O
(	1706 1 O
ABSTRACT	1707 8 O
TRUNCATED	1716 9 O
AT	1726 2 O
250	1729 3 O
WORDS	1733 5 O
)	1738 1 O

Delirium	0 8 B-Disease
during	9 6 O
fluoxetine	16 10 B-Chemical
treatment	27 9 O
.	36 1 O

A	38 1 O
case	40 4 O
report	45 6 O
.	51 1 O

The	53 3 O
correlation	57 11 O
between	69 7 O
high	77 4 O
serum	82 5 O
tricyclic	88 9 O
antidepressant	98 14 O
concentrations	113 14 O
and	128 3 O
central	132 7 O
nervous	140 7 O
system	148 6 O
side	155 4 O
effects	160 7 O
has	168 3 O
been	172 4 O
well	177 4 O
established	182 11 O
.	193 1 O

Only	195 4 O
a	200 1 O
few	202 3 O
reports	206 7 O
exist	214 5 O
,	219 1 O
however	221 7 O
,	228 1 O
on	230 2 O
the	233 3 O
relationship	237 12 O
between	250 7 O
the	258 3 O
serum	262 5 O
concentrations	268 14 O
of	283 2 O
selective	286 9 O
serotonin	296 9 B-Chemical
reuptake	306 8 O
inhibitors	315 10 O
(	326 1 O
SSRIs	327 5 O
)	332 1 O
and	334 3 O
their	338 5 O
toxic	344 5 O
effects	350 7 O
.	357 1 O

In	359 2 O
some	362 4 O
cases	367 5 O
,	372 1 O
a	374 1 O
high	376 4 O
serum	381 5 O
concentration	387 13 O
of	401 2 O
citalopram	404 10 B-Chemical
(	415 1 O
>	416 1 O
600	418 3 O
nmol	422 4 O
/	426 1 O
L	427 1 O
)	428 1 O
in	430 2 O
elderly	433 7 O
patients	441 8 O
has	450 3 O
been	454 4 O
associated	459 10 O
with	470 4 O
increased	475 9 O
somnolence	485 10 B-Disease
and	496 3 O
movement	500 8 B-Disease
difficulties	509 12 I-Disease
.	521 1 O

Widespread	523 10 O
cognitive	534 9 B-Disease
disorders	544 9 I-Disease
,	553 1 O
such	555 4 O
as	560 2 O
delirium	563 8 B-Disease
,	571 1 O
have	573 4 O
not	578 3 O
been	582 4 O
previously	587 10 O
linked	598 6 O
with	605 4 O
high	610 4 O
blood	615 5 O
levels	621 6 O
of	628 2 O
SSRIs	631 5 O
.	636 1 O

In	638 2 O
this	641 4 O
report	646 6 O
,	652 1 O
we	654 2 O
describe	657 8 O
a	666 1 O
patient	668 7 O
with	676 4 O
acute	681 5 O
hyperkinetic	687 12 B-Disease
delirium	700 8 B-Disease
connected	709 9 O
with	719 4 O
a	724 1 O
high	726 4 O
serum	731 5 O
total	737 5 O
fluoxetine	743 10 B-Chemical
(	754 1 O
fluoxetine	755 10 B-Chemical
plus	766 4 O
desmethylfluoxetine	771 19 B-Chemical
)	790 1 O
concentration	792 13 O
.	805 1 O

Pulmonary	0 9 B-Disease
edema	10 5 I-Disease
and	16 3 O
shock	20 5 B-Disease
after	26 5 O
high	32 4 O
-	36 1 O
dose	37 4 O
aracytine	42 9 B-Chemical
-	51 1 I-Chemical
C	52 1 I-Chemical
for	54 3 O
lymphoma	58 8 B-Disease
;	66 1 O
possible	68 8 O
role	77 4 O
of	82 2 O
TNF	85 3 O
-	88 1 O
alpha	89 5 O
and	95 3 O
PAF	99 3 O
.	102 1 O

Four	104 4 O
out	109 3 O
of	113 2 O
23	116 2 O
consecutive	119 11 O
patients	131 8 O
treated	140 7 O
with	148 4 O
high	153 4 O
-	157 1 O
dose	158 4 O
Ara	163 3 B-Chemical
-	166 1 I-Chemical
C	167 1 I-Chemical
for	169 3 O
lymphomas	173 9 B-Disease
in	183 2 O
our	186 3 O
institution	190 11 O
developed	202 9 O
a	212 1 O
strikingly	214 10 O
similar	225 7 O
syndrome	233 8 O
during	242 6 O
the	249 3 O
perfusion	253 9 O
.	262 1 O

It	264 2 O
was	267 3 O
characterized	271 13 O
by	285 2 O
the	288 3 O
onset	292 5 O
of	298 2 O
fever	301 5 B-Disease
,	306 1 O
diarrhea	308 8 B-Disease
,	316 1 O
shock	318 5 B-Disease
,	323 1 O
pulmonary	325 9 B-Disease
edema	335 5 I-Disease
,	340 1 O
acute	342 5 B-Disease
renal	348 5 I-Disease
failure	354 7 I-Disease
,	361 1 O
metabolic	363 9 B-Disease
acidosis	373 8 I-Disease
,	381 1 O
weight	383 6 B-Disease
gain	390 4 I-Disease
and	395 3 O
leukocytosis	399 12 B-Disease
.	411 1 O

Thorough	413 8 O
bacteriological	422 15 O
screening	438 9 O
failed	448 6 O
to	455 2 O
provide	458 7 O
evidence	466 8 O
of	475 2 O
infection	478 9 B-Disease
.	487 1 O

Sequential	489 10 O
biological	500 10 O
assays	511 6 O
of	518 2 O
IL	521 2 O
-	523 1 O
1	524 1 O
,	525 1 O
IL	527 2 O
-	529 1 O
2	530 1 O
,	531 1 O
TNF	533 3 O
and	537 3 O
PAF	541 3 O
were	545 4 O
performed	550 9 O
during	560 6 O
Ara	567 3 B-Chemical
-	570 1 I-Chemical
C	571 1 I-Chemical
infusion	573 8 O
to	582 2 O
ten	585 3 O
patients	589 8 O
,	597 1 O
including	599 9 O
the	609 3 O
four	613 4 O
who	618 3 O
developed	622 9 O
the	632 3 O
syndrome	636 8 O
.	644 1 O

TNF	646 3 O
and	650 3 O
PAF	654 3 O
activity	658 8 O
was	667 3 O
found	671 5 O
in	677 2 O
the	680 3 O
serum	684 5 O
of	690 2 O
respectively	693 12 O
two	706 3 O
and	710 3 O
four	714 4 O
of	719 2 O
the	722 3 O
cases	726 5 O
,	731 1 O
but	733 3 O
not	737 3 O
in	741 2 O
the	744 3 O
six	748 3 O
controls	752 8 O
.	760 1 O

As	762 2 O
TNF	765 3 O
and	769 3 O
PAF	773 3 O
are	777 3 O
thought	781 7 O
to	789 2 O
be	792 2 O
involved	795 8 O
in	804 2 O
the	807 3 O
development	811 11 O
of	823 2 O
septic	826 6 O
shock	833 5 B-Disease
and	839 3 O
adult	843 5 B-Disease
respiratory	849 11 I-Disease
distress	861 8 I-Disease
syndrome	870 8 I-Disease
,	878 1 O
we	880 2 O
hypothesize	883 11 O
that	895 4 O
high	900 4 O
-	904 1 O
dose	905 4 O
Ara	910 3 B-Chemical
-	913 1 I-Chemical
C	914 1 I-Chemical
may	916 3 O
be	920 2 O
associated	923 10 O
with	934 4 O
cytokine	939 8 O
release	948 7 O
.	955 1 O

Protective	0 10 O
effect	11 6 O
of	18 2 O
clentiazem	21 10 B-Chemical
against	32 7 O
epinephrine	40 11 B-Chemical
-	51 1 O
induced	52 7 O
cardiac	60 7 B-Disease
injury	68 6 I-Disease
in	75 2 O
rats	78 4 O
.	82 1 O

We	84 2 O
investigated	87 12 O
the	100 3 O
effects	104 7 O
of	112 2 O
clentiazem	115 10 B-Chemical
,	125 1 O
a	127 1 O
1	129 1 B-Chemical
,	130 1 I-Chemical
5	131 1 I-Chemical
-	132 1 I-Chemical
benzothiazepine	133 15 I-Chemical
calcium	149 7 B-Chemical
antagonist	157 10 O
,	167 1 O
on	169 2 O
epinephrine	172 11 B-Chemical
-	183 1 O
induced	184 7 O
cardiomyopathy	192 14 B-Disease
in	207 2 O
rats	210 4 O
.	214 1 O

With	216 4 O
2	221 1 O
-	222 1 O
week	223 4 O
chronic	228 7 O
epinephrine	236 11 B-Chemical
infusion	248 8 O
,	256 1 O
16	258 2 O
of	261 2 O
30	264 2 O
rats	267 4 O
died	272 4 O
within	277 6 O
4	284 1 O
days	286 4 O
,	290 1 O
and	292 3 O
severe	296 6 O
ischemic	303 8 B-Disease
lesions	312 7 I-Disease
and	320 3 O
fibrosis	324 8 B-Disease
of	333 2 O
the	336 3 O
left	340 4 O
ventricles	345 10 O
were	356 4 O
observed	361 8 O
.	369 1 O

In	371 2 O
epinephrine	374 11 B-Chemical
-	385 1 O
treated	386 7 O
rats	394 4 O
,	398 1 O
left	400 4 O
atrial	405 6 O
and	412 3 O
left	416 4 O
ventricular	421 11 O
papillary	433 9 O
muscle	443 6 O
contractile	450 11 O
responses	462 9 O
to	472 2 O
isoproterenol	475 13 B-Chemical
were	489 4 O
reduced	494 7 O
,	501 1 O
but	503 3 O
responses	507 9 O
to	517 2 O
calcium	520 7 B-Chemical
were	528 4 O
normal	533 6 O
or	540 2 O
enhanced	543 8 O
compared	552 8 O
to	561 2 O
controls	564 8 O
.	572 1 O

Left	574 4 O
ventricular	579 11 O
alpha	591 5 O
and	597 3 O
beta	601 4 O
adrenoceptor	606 12 O
densities	619 9 O
were	629 4 O
also	634 4 O
reduced	639 7 O
compared	647 8 O
to	656 2 O
controls	659 8 O
.	667 1 O

Treatment	669 9 O
with	679 4 O
clentiazem	684 10 B-Chemical
prevented	695 9 O
epinephrine	705 11 B-Chemical
-	716 1 O
induced	717 7 O
death	725 5 O
(	731 1 O
P	732 1 O
<	734 1 O
.	736 1 O
05	737 2 O
)	739 1 O
,	740 1 O
and	742 3 O
attenuated	746 10 O
the	757 3 O
ventricular	761 11 O
ischemic	773 8 B-Disease
lesions	782 7 I-Disease
and	790 3 O
fibrosis	794 8 B-Disease
,	802 1 O
in	804 2 O
a	807 1 O
dose	809 4 O
-	813 1 O
dependent	814 9 O
manner	824 6 O
.	830 1 O

Left	832 4 O
atrial	837 6 O
and	844 3 O
left	848 4 O
ventricular	853 11 O
papillary	865 9 O
muscle	875 6 O
contractile	882 11 O
responses	894 9 O
to	904 2 O
isoproterenol	907 13 B-Chemical
were	921 4 O
reduced	926 7 O
compared	934 8 O
to	943 2 O
controls	946 8 O
in	955 2 O
groups	958 6 O
treated	965 7 O
with	973 4 O
clentiazem	978 10 B-Chemical
alone	989 5 O
,	994 1 O
but	996 3 O
combined	1000 8 O
with	1009 4 O
epinephrine	1014 11 B-Chemical
,	1025 1 O
clentiazem	1027 10 B-Chemical
restored	1038 8 O
left	1047 4 O
atrial	1052 6 O
responses	1059 9 O
and	1069 3 O
enhanced	1073 8 O
left	1082 4 O
ventricular	1087 11 O
papillary	1099 9 O
responses	1109 9 O
to	1119 2 O
isoproterenol	1122 13 B-Chemical
.	1135 1 O

On	1137 2 O
the	1140 3 O
other	1144 5 O
hand	1150 4 O
clentiazem	1155 10 B-Chemical
did	1166 3 O
not	1170 3 O
prevent	1174 7 O
epinephrine	1182 11 B-Chemical
-	1193 1 O
induced	1194 7 O
down	1202 4 O
-	1206 1 O
regulation	1207 10 O
of	1218 2 O
alpha	1221 5 O
and	1227 3 O
beta	1231 4 O
adrenoceptors	1236 13 O
.	1249 1 O

Interestingly	1251 13 O
,	1264 1 O
clentiazem	1266 10 B-Chemical
,	1276 1 O
infused	1278 7 O
alone	1286 5 O
,	1291 1 O
resulted	1293 8 O
in	1302 2 O
decreased	1305 9 O
adrenergic	1315 10 O
receptor	1326 8 O
densities	1335 9 O
in	1345 2 O
the	1348 3 O
left	1352 4 O
ventricle	1357 9 O
.	1366 1 O

Clentiazem	1368 10 B-Chemical
also	1379 4 O
did	1384 3 O
not	1388 3 O
prevent	1392 7 O
the	1400 3 O
enhanced	1404 8 O
responses	1413 9 O
to	1423 2 O
calcium	1426 7 B-Chemical
seen	1434 4 O
in	1439 2 O
the	1442 3 O
epinephrine	1446 11 B-Chemical
-	1457 1 O
treated	1458 7 O
animals	1466 7 O
,	1473 1 O
although	1475 8 O
the	1484 3 O
high	1488 4 O
dose	1493 4 O
of	1498 2 O
clentiazem	1501 10 B-Chemical
partially	1512 9 O
attenuated	1522 10 O
the	1533 3 O
maximal	1537 7 O
response	1545 8 O
to	1554 2 O
calcium	1557 7 B-Chemical
compared	1565 8 O
to	1574 2 O
epinephrine	1577 11 B-Chemical
-	1588 1 O
treated	1589 7 O
animals	1597 7 O
.	1604 1 O

In	1606 2 O
conclusion	1609 10 O
,	1619 1 O
clentiazem	1621 10 B-Chemical
attenuated	1632 10 O
epinephrine	1643 11 B-Chemical
-	1654 1 O
induced	1655 7 O
cardiac	1663 7 B-Disease
injury	1671 6 I-Disease
,	1677 1 O
possibly	1679 8 O
through	1688 7 O
its	1696 3 O
effect	1700 6 O
on	1707 2 O
the	1710 3 O
adrenergic	1714 10 O
pathway	1725 7 O
.	1732 1 O

Cocaine	0 7 B-Chemical
induced	8 7 O
myocardial	16 10 B-Disease
ischemia	27 8 I-Disease
.	35 1 O

We	37 2 O
report	40 6 O
a	47 1 O
case	49 4 O
of	54 2 O
myocardial	57 10 B-Disease
ischemia	68 8 I-Disease
induced	77 7 O
by	85 2 O
cocaine	88 7 B-Chemical
.	95 1 O

The	97 3 O
ischemia	101 8 B-Disease
probably	110 8 O
induced	119 7 O
by	127 2 O
coronary	130 8 B-Disease
artery	139 6 I-Disease
spasm	146 5 I-Disease
was	152 3 O
reversed	156 8 O
by	165 2 O
nitroglycerin	168 13 B-Chemical
and	182 3 O
calcium	186 7 B-Chemical
blocking	194 8 O
agents	203 6 O
.	209 1 O

Doxorubicin	0 11 B-Chemical
-	11 1 O
induced	12 7 O
cardiotoxicity	20 14 B-Disease
monitored	35 9 O
by	45 2 O
ECG	48 3 O
in	52 2 O
freely	55 6 O
moving	62 6 O
mice	69 4 O
.	73 1 O

A	75 1 O
new	77 3 O
model	81 5 O
to	87 2 O
test	90 4 O
potential	95 9 O
protectors	105 10 O
.	115 1 O

In	117 2 O
laboratory	120 10 O
animals	131 7 O
,	138 1 O
histology	140 9 O
is	150 2 O
most	153 4 O
commonly	158 8 O
used	167 4 O
to	172 2 O
study	175 5 O
doxorubicin	181 11 B-Chemical
-	192 1 O
induced	193 7 O
cardiotoxicity	201 14 B-Disease
.	215 1 O

However	217 7 O
,	224 1 O
for	226 3 O
monitoring	230 10 O
during	241 6 O
treatment	248 9 O
,	257 1 O
large	259 5 O
numbers	265 7 O
of	273 2 O
animals	276 7 O
are	284 3 O
needed	288 6 O
.	294 1 O

Recently	296 8 O
we	305 2 O
developed	308 9 O
a	318 1 O
new	320 3 O
method	324 6 O
to	331 2 O
measure	334 7 O
ECG	342 3 O
values	346 6 O
in	353 2 O
freely	356 6 O
moving	363 6 O
mice	370 4 O
by	375 2 O
telemetry	378 9 O
.	387 1 O

With	389 4 O
this	394 4 O
model	399 5 O
we	405 2 O
investigated	408 12 O
the	421 3 O
effect	425 6 O
of	432 2 O
chronic	435 7 O
doxorubicin	443 11 B-Chemical
administration	455 14 O
on	470 2 O
the	473 3 O
ECG	477 3 O
of	481 2 O
freely	484 6 O
moving	491 6 O
BALB	498 4 O
/	502 1 O
c	503 1 O
mice	505 4 O
and	510 3 O
the	514 3 O
efficacy	518 8 O
of	527 2 O
ICRF	530 4 B-Chemical
-	534 1 I-Chemical
187	535 3 I-Chemical
as	539 2 O
a	542 1 O
protective	544 10 O
agent	555 5 O
.	560 1 O

The	562 3 O
ST	566 2 O
interval	569 8 O
significantly	578 13 O
widened	592 7 O
from	600 4 O
15	605 2 O
.	607 1 O
0	608 1 O
+	610 1 O
/	611 1 O
-	612 1 O
1	614 1 O
.	615 1 O
5	616 1 O
to	618 2 O
56	621 2 O
.	623 1 O
8	624 1 O
+	626 1 O
/	627 1 O
-	628 1 O
11	630 2 O
.	632 1 O
8	633 1 O
ms	635 2 O
in	638 2 O
week	641 4 O
10	646 2 O
(	649 1 O
7	650 1 O
weekly	652 6 O
doses	659 5 O
of	665 2 O
4	668 1 O
mg	670 2 O
/	672 1 O
kg	673 2 O
doxorubicin	676 11 B-Chemical
given	688 5 O
i	694 1 O
.	695 1 O
v	696 1 O
.	697 1 O
plus	699 4 O
3	704 1 O
weeks	706 5 O
of	712 2 O
observation	715 11 O
)	726 1 O
.	727 1 O

The	729 3 O
ECG	733 3 O
of	737 2 O
the	740 3 O
control	744 7 O
animals	752 7 O
did	760 3 O
not	764 3 O
change	768 6 O
during	775 6 O
the	782 3 O
entire	786 6 O
study	793 5 O
.	798 1 O

After	800 5 O
sacrifice	806 9 O
the	816 3 O
hearts	820 6 O
of	827 2 O
doxorubicin	830 11 B-Chemical
-	841 1 O
treated	842 7 O
animals	850 7 O
were	858 4 O
enlarged	863 8 O
and	872 3 O
the	876 3 O
atria	880 5 O
were	886 4 O
hypertrophic	891 12 B-Disease
.	903 1 O

As	905 2 O
this	908 4 O
schedule	913 8 O
exerted	922 7 O
more	930 4 O
toxicity	935 8 B-Disease
than	944 4 O
needed	949 6 O
to	956 2 O
investigate	959 11 O
protective	971 10 O
agents	982 6 O
,	988 1 O
the	990 3 O
protection	994 10 O
of	1005 2 O
ICRF	1008 4 B-Chemical
-	1012 1 I-Chemical
187	1013 3 I-Chemical
was	1017 3 O
determined	1021 10 O
using	1032 5 O
a	1038 1 O
dose	1040 4 O
schedule	1045 8 O
with	1054 4 O
lower	1059 5 O
general	1065 7 O
toxicity	1073 8 B-Disease
(	1082 1 O
6	1083 1 O
weekly	1085 6 O
doses	1092 5 O
of	1098 2 O
4	1101 1 O
mg	1103 2 O
/	1105 1 O
kg	1106 2 O
doxorubicin	1109 11 B-Chemical
given	1121 5 O
i	1127 1 O
.	1128 1 O
v	1129 1 O
.	1130 1 O
plus	1132 4 O
2	1137 1 O
weeks	1139 5 O
of	1145 2 O
observation	1148 11 O
)	1159 1 O
.	1160 1 O

On	1162 2 O
this	1165 4 O
schedule	1170 8 O
,	1178 1 O
the	1180 3 O
animals	1184 7 O
'	1191 1 O
hearts	1193 6 O
appeared	1200 8 O
normal	1209 6 O
after	1216 5 O
sacrifice	1222 9 O
and	1232 3 O
ICRF	1236 4 B-Chemical
-	1240 1 I-Chemical
187	1241 3 I-Chemical
(	1245 1 O
50	1246 2 O
mg	1249 2 O
/	1251 1 O
kg	1252 2 O
given	1255 5 O
i	1261 1 O
.	1262 1 O
p	1263 1 O
.	1264 1 O
1	1266 1 O
h	1268 1 O
before	1270 6 O
doxorubicin	1277 11 B-Chemical
)	1288 1 O
provided	1290 8 O
almost	1299 6 O
full	1306 4 O
protection	1311 10 O
.	1321 1 O

These	1323 5 O
data	1329 4 O
were	1334 4 O
confirmed	1339 9 O
by	1349 2 O
histology	1352 9 O
.	1361 1 O

The	1363 3 O
results	1367 7 O
indicate	1375 8 O
that	1384 4 O
this	1389 4 O
new	1394 3 O
model	1398 5 O
is	1404 2 O
very	1407 4 O
sensitive	1412 9 O
and	1422 3 O
enables	1426 7 O
monitoring	1434 10 O
of	1445 2 O
the	1448 3 O
development	1452 11 O
of	1464 2 O
cardiotoxicity	1467 14 B-Disease
with	1482 4 O
time	1487 4 O
.	1491 1 O

These	1493 5 O
findings	1499 8 O
result	1508 6 O
in	1515 2 O
a	1518 1 O
model	1520 5 O
that	1526 4 O
allows	1531 6 O
the	1538 3 O
testing	1542 7 O
of	1550 2 O
protectors	1553 10 O
against	1564 7 O
doxorubicin	1572 11 B-Chemical
-	1583 1 O
induced	1584 7 O
cardiotoxicity	1592 14 B-Disease
as	1607 2 O
demonstrated	1610 12 O
by	1623 2 O
the	1626 3 O
protection	1630 10 O
provided	1641 8 O
by	1650 2 O
ICRF	1653 4 B-Chemical
-	1657 1 I-Chemical
187	1658 3 I-Chemical
.	1661 1 O

Epinephrine	0 11 B-Chemical
dysrhythmogenicity	12 18 O
is	31 2 O
not	34 3 O
enhanced	38 8 O
by	47 2 O
subtoxic	50 8 O
bupivacaine	59 11 B-Chemical
in	71 2 O
dogs	74 4 O
.	78 1 O

Since	80 5 O
bupivacaine	86 11 B-Chemical
and	98 3 O
epinephrine	102 11 B-Chemical
may	114 3 O
both	118 4 O
precipitate	123 11 O
dysrhythmias	135 12 B-Disease
,	147 1 O
circulating	149 11 O
bupivacaine	161 11 B-Chemical
during	173 6 O
regional	180 8 O
anesthesia	189 10 O
could	200 5 O
potentiate	206 10 O
dysrhythmogenic	217 15 O
effects	233 7 O
of	241 2 O
epinephrine	244 11 B-Chemical
.	255 1 O

We	257 2 O
therefore	260 9 O
examined	270 8 O
whether	279 7 O
bupivacaine	287 11 B-Chemical
alters	299 6 O
the	306 3 O
dysrhythmogenicity	310 18 O
of	329 2 O
subsequent	332 10 O
administration	343 14 O
of	358 2 O
epinephrine	361 11 B-Chemical
in	373 2 O
conscious	376 9 O
,	385 1 O
healthy	387 7 O
dogs	395 4 O
and	400 3 O
in	404 2 O
anesthetized	407 12 O
dogs	420 4 O
with	425 4 O
myocardial	430 10 B-Disease
infarction	441 10 I-Disease
.	451 1 O

Forty	453 5 O
-	458 1 O
one	459 3 O
conscious	463 9 O
dogs	473 4 O
received	478 8 O
10	487 2 O
micrograms	490 10 O
.	500 1 O
kg	501 2 O
-	503 1 O
1	504 1 O
.	505 1 O
min	506 3 O
-	509 1 O
1	510 1 O
epinephrine	512 11 B-Chemical
.	523 1 O

Seventeen	525 9 O
animals	535 7 O
responded	543 9 O
with	553 4 O
ventricular	558 11 B-Disease
tachycardia	570 11 I-Disease
(	582 1 O
VT	583 2 B-Disease
)	585 1 O
within	587 6 O
3	594 1 O
min	596 3 O
.	599 1 O

After	601 5 O
3	607 1 O
h	609 1 O
,	610 1 O
these	612 5 O
responders	618 10 O
randomly	629 8 O
received	638 8 O
1	647 1 O
or	649 2 O
2	652 1 O
mg	654 2 O
/	656 1 O
kg	657 2 O
bupivacaine	660 11 B-Chemical
or	672 2 O
saline	675 6 O
over	682 4 O
5	687 1 O
min	689 3 O
,	692 1 O
followed	694 8 O
by	703 2 O
10	706 2 O
micrograms	709 10 O
.	719 1 O
kg	720 2 O
-	722 1 O
1	723 1 O
.	724 1 O
min	725 3 O
-	728 1 O
1	729 1 O
epinephrine	731 11 B-Chemical
.	742 1 O

In	744 2 O
the	747 3 O
bupivacaine	751 11 B-Chemical
groups	763 6 O
,	769 1 O
epinephrine	771 11 B-Chemical
caused	783 6 O
fewer	790 5 O
prodysrhythmic	796 14 O
effects	811 7 O
than	819 4 O
without	824 7 O
bupivacaine	832 11 B-Chemical
.	843 1 O

VT	845 2 B-Disease
appeared	848 8 O
in	857 2 O
fewer	860 5 O
dogs	866 4 O
and	871 3 O
at	875 2 O
a	878 1 O
later	880 5 O
time	886 4 O
,	890 1 O
and	892 3 O
there	896 5 O
were	902 4 O
more	907 4 O
sinoatrial	912 10 O
beats	923 5 O
and	929 3 O
less	933 4 O
ectopies	938 8 O
.	946 1 O

Epinephrine	948 11 B-Chemical
shortened	960 9 O
QT	970 2 O
less	973 4 O
after	978 5 O
bupivacaine	984 11 B-Chemical
than	996 4 O
in	1001 2 O
control	1004 7 O
animals	1012 7 O
.	1019 1 O

One	1021 3 O
day	1025 3 O
after	1029 5 O
experimental	1035 12 O
myocardial	1048 10 B-Disease
infarction	1059 10 I-Disease
,	1069 1 O
six	1071 3 O
additional	1075 10 O
halothane	1086 9 B-Chemical
-	1095 1 O
anesthetized	1096 12 O
dogs	1109 4 O
received	1114 8 O
4	1123 1 O
micrograms	1125 10 O
.	1135 1 O
kg	1136 2 O
-	1138 1 O
1	1139 1 O
.	1140 1 O
min	1141 3 O
-	1144 1 O
1	1145 1 O
epinephrine	1147 11 B-Chemical
until	1159 5 O
VT	1165 2 B-Disease
appeared	1168 8 O
.	1176 1 O

After	1178 5 O
45	1184 2 O
min	1187 3 O
,	1190 1 O
1	1192 1 O
mg	1194 2 O
/	1196 1 O
kg	1197 2 O
bupivacaine	1200 11 B-Chemical
was	1212 3 O
injected	1216 8 O
over	1225 4 O
5	1230 1 O
min	1232 3 O
,	1235 1 O
again	1237 5 O
followed	1243 8 O
by	1252 2 O
4	1255 1 O
micrograms	1257 10 O
.	1267 1 O
kg	1268 2 O
-	1270 1 O
1	1271 1 O
.	1272 1 O
min	1273 3 O
-	1276 1 O
1	1277 1 O
epinephrine	1279 11 B-Chemical
.	1290 1 O

In	1292 2 O
these	1295 5 O
dogs	1301 4 O
,	1305 1 O
the	1307 3 O
prodysrhythmic	1311 14 O
response	1326 8 O
to	1335 2 O
epinephrine	1338 11 B-Chemical
was	1350 3 O
also	1354 4 O
mitigated	1359 9 O
by	1369 2 O
preceding	1372 9 O
bupivacaine	1382 11 B-Chemical
.	1393 1 O

Bupivacaine	1395 11 B-Chemical
antagonizes	1407 11 O
epinephrine	1419 11 B-Chemical
dysrhythmogenicity	1431 18 O
in	1450 2 O
conscious	1453 9 O
dogs	1463 4 O
susceptible	1468 11 O
to	1480 2 O
VT	1483 2 B-Disease
and	1486 3 O
in	1490 2 O
anesthetized	1493 12 O
dogs	1506 4 O
with	1511 4 O
spontaneous	1516 11 O
postinfarct	1528 11 O
dysrhythmias	1540 12 B-Disease
.	1552 1 O

There	1554 5 O
is	1560 2 O
no	1563 2 O
evidence	1566 8 O
that	1575 4 O
systemic	1580 8 O
subtoxic	1589 8 O
bupivacaine	1598 11 B-Chemical
administration	1610 14 O
enhances	1625 8 O
the	1634 3 O
dysrhythmogenicity	1638 18 O
of	1657 2 O
subsequent	1660 10 O
epinephrine	1671 11 B-Chemical
.	1682 1 O

Milk	0 4 B-Disease
-	4 1 I-Disease
alkali	5 6 I-Disease
syndrome	12 8 I-Disease
induced	21 7 O
by	29 2 O
1	32 1 B-Chemical
,	33 1 I-Chemical
25	34 2 I-Chemical
(	36 1 I-Chemical
OH	37 2 I-Chemical
)	39 1 I-Chemical
2D	40 2 I-Chemical
in	43 2 O
a	46 1 O
patient	48 7 O
with	56 4 O
hypoparathyroidism	61 18 B-Disease
.	79 1 O

Milk	81 4 B-Disease
-	85 1 I-Disease
alkali	86 6 I-Disease
syndrome	93 8 I-Disease
was	102 3 O
first	106 5 O
described	112 9 O
70	122 2 O
years	125 5 O
ago	131 3 O
in	135 2 O
the	138 3 O
context	142 7 O
of	150 2 O
the	153 3 O
treatment	157 9 O
of	167 2 O
peptic	170 6 B-Disease
ulcer	177 5 I-Disease
disease	183 7 I-Disease
with	191 4 O
large	196 5 O
amounts	202 7 O
of	210 2 O
calcium	213 7 B-Chemical
and	221 3 O
alkali	225 6 B-Chemical
.	231 1 O

Although	233 8 O
with	242 4 O
current	247 7 O
ulcer	255 5 B-Disease
therapy	261 7 O
(	269 1 O
H	270 1 O
-	271 1 O
2	272 1 O
blockers	274 8 O
,	282 1 O
omeprazole	284 10 B-Chemical
,	294 1 O
and	296 3 O
sucralfate	300 10 B-Chemical
)	310 1 O
,	311 1 O
the	313 3 O
frequency	317 9 O
of	327 2 O
milk	330 4 B-Disease
-	334 1 I-Disease
alkali	335 6 I-Disease
syndrome	342 8 I-Disease
has	351 3 O
decreased	355 9 O
significantly	365 13 O
,	378 1 O
the	380 3 O
classic	384 7 O
triad	392 5 O
of	398 2 O
hypercalcemia	401 13 B-Disease
,	414 1 O
alkalosis	416 9 B-Disease
,	425 1 O
and	427 3 O
renal	431 5 B-Disease
impairment	437 10 I-Disease
remains	448 7 O
the	456 3 O
hallmark	460 8 O
of	469 2 O
the	472 3 O
syndrome	476 8 O
.	484 1 O

Milk	486 4 B-Disease
-	490 1 I-Disease
alkali	491 6 I-Disease
syndrome	498 8 I-Disease
can	507 3 O
present	511 7 O
serious	519 7 O
and	527 3 O
occasionally	531 12 O
life	544 4 O
-	548 1 O
threatening	549 11 O
illness	561 7 O
unless	569 6 O
diagnosed	576 9 O
and	586 3 O
treated	590 7 O
appropriately	598 13 O
.	611 1 O

This	613 4 O
article	618 7 O
presents	626 8 O
a	635 1 O
patient	637 7 O
with	645 4 O
hypoparathyroidism	650 18 B-Disease
who	669 3 O
was	673 3 O
treated	677 7 O
with	685 4 O
calcium	690 7 B-Chemical
carbonate	698 9 I-Chemical
and	708 3 O
calcitriol	712 10 B-Chemical
resulting	723 9 O
in	733 2 O
two	736 3 O
admissions	740 10 O
to	751 2 O
the	754 3 O
hospital	758 8 O
for	767 3 O
milk	771 4 B-Disease
-	775 1 I-Disease
alkali	776 6 I-Disease
syndrome	783 8 I-Disease
.	791 1 O

The	793 3 O
patient	797 7 O
was	805 3 O
successfully	809 12 O
treated	822 7 O
with	830 4 O
intravenous	835 11 O
pamidronate	847 11 B-Chemical
on	859 2 O
his	862 3 O
first	866 5 O
admission	872 9 O
and	882 3 O
with	886 4 O
hydrocortisone	891 14 B-Chemical
on	906 2 O
the	909 3 O
second	913 6 O
.	919 1 O

This	921 4 O
illustrates	926 11 O
intravenous	938 11 O
pamidronate	950 11 B-Chemical
as	962 2 O
a	965 1 O
valuable	967 8 O
therapeutic	976 11 O
tool	988 4 O
when	993 4 O
milk	998 4 B-Disease
-	1002 1 I-Disease
alkali	1003 6 I-Disease
syndrome	1010 8 I-Disease
presents	1019 8 O
as	1028 2 O
hypercalcemic	1031 13 B-Disease
emergency	1045 9 I-Disease
.	1054 1 O

Encephalopathy	0 14 B-Disease
during	15 6 O
amitriptyline	22 13 B-Chemical
therapy	36 7 O
:	43 1 O
are	45 3 O
neuroleptic	49 11 B-Disease
malignant	61 9 I-Disease
syndrome	71 8 I-Disease
and	80 3 O
serotonin	84 9 B-Disease
syndrome	94 8 I-Disease
spectrum	103 8 O
disorders	112 9 O
?	121 1 O

This	123 4 O
report	128 6 O
describes	135 9 O
a	145 1 O
case	147 4 O
of	152 2 O
encephalopathy	155 14 B-Disease
developed	170 9 O
in	180 2 O
the	183 3 O
course	187 6 O
of	194 2 O
amitriptyline	197 13 B-Chemical
therapy	211 7 O
,	218 1 O
during	220 6 O
a	227 1 O
remission	229 9 O
of	239 2 O
unipolar	242 8 B-Disease
depression	251 10 I-Disease
.	261 1 O

This	263 4 O
patient	268 7 O
could	276 5 O
have	282 4 O
been	287 4 O
diagnosed	292 9 O
as	302 2 O
having	305 6 O
either	312 6 O
neuroleptic	319 11 B-Disease
malignant	331 9 I-Disease
syndrome	341 8 I-Disease
(	350 1 O
NMS	351 3 B-Disease
)	354 1 O
or	356 2 O
serotonin	359 9 B-Disease
syndrome	369 8 I-Disease
(	378 1 O
SS	379 2 B-Disease
)	381 1 O
.	382 1 O

The	384 3 O
major	388 5 O
determinant	394 11 O
of	406 2 O
the	409 3 O
symptoms	413 8 O
may	422 3 O
have	426 4 O
been	431 4 O
dopamine	436 8 B-Chemical
/	444 1 O
serotonin	445 9 B-Chemical
imbalance	455 9 O
in	465 2 O
the	468 3 O
central	472 7 O
nervous	480 7 O
system	488 6 O
.	494 1 O

The	496 3 O
NMS	500 3 B-Disease
-	503 1 O
like	504 4 O
encephalopathy	509 14 B-Disease
that	524 4 O
develops	529 8 O
in	538 2 O
association	541 11 O
with	553 4 O
the	558 3 O
use	562 3 O
of	566 2 O
antidepressants	569 15 O
indicates	585 9 O
that	595 4 O
NMS	600 3 B-Disease
and	604 3 O
SS	608 2 B-Disease
are	611 3 O
spectrum	615 8 O
disorders	624 9 O
induced	634 7 O
by	642 2 O
drugs	645 5 O
with	651 4 O
both	656 4 O
antidopaminergic	661 16 O
and	678 3 O
serotonergic	682 12 O
effects	695 7 O
.	702 1 O

Genetic	0 7 O
separation	8 10 O
of	19 2 O
tumor	22 5 B-Disease
growth	28 6 O
and	35 3 O
hemorrhagic	39 11 B-Disease
phenotypes	51 10 O
in	62 2 O
an	65 2 O
estrogen	68 8 B-Chemical
-	76 1 O
induced	77 7 O
tumor	85 5 B-Disease
.	90 1 O

Chronic	92 7 O
administration	100 14 O
of	115 2 O
estrogen	118 8 B-Chemical
to	127 2 O
the	130 3 O
Fischer	134 7 O
344	142 3 O
(	146 1 O
F344	147 4 O
)	151 1 O
rat	153 3 O
induces	157 7 O
growth	165 6 O
of	172 2 O
large	175 5 O
,	180 1 O
hemorrhagic	182 11 B-Disease
pituitary	194 9 B-Disease
tumors	204 6 I-Disease
.	210 1 O

Ten	212 3 O
weeks	216 5 O
of	222 2 O
diethylstilbestrol	225 18 B-Chemical
(	244 1 O
DES	245 3 B-Chemical
)	248 1 O
treatment	250 9 O
caused	260 6 O
female	267 6 O
F344	274 4 O
rat	279 3 O
pituitaries	283 11 O
to	295 2 O
grow	298 4 O
to	303 2 O
an	306 2 O
average	309 7 O
of	317 2 O
109	320 3 O
.	323 1 O
2	324 1 O
+	326 1 O
/	327 1 O
-	328 1 O
6	330 1 O
.	331 1 O
3	332 1 O
mg	334 2 O
(	337 1 O
mean	338 4 O
+	343 1 O
/	344 1 O
-	345 1 O
SE	347 2 O
)	349 1 O
versus	351 6 O
11	358 2 O
.	360 1 O
3	361 1 O
+	363 1 O
/	364 1 O
-	365 1 O
1	367 1 O
.	368 1 O
4	369 1 O
mg	371 2 O
for	374 3 O
untreated	378 9 O
rats	388 4 O
,	392 1 O
and	394 3 O
to	398 2 O
become	401 6 O
highly	408 6 O
hemorrhagic	415 11 B-Disease
.	426 1 O

The	428 3 O
same	432 4 O
DES	437 3 B-Chemical
treatment	441 9 O
produced	451 8 O
no	460 2 O
significant	463 11 O
growth	475 6 O
(	482 1 O
8	483 1 O
.	484 1 O
9	485 1 O
+	487 1 O
/	488 1 O
-	489 1 O
0	491 1 O
.	492 1 O
5	493 1 O
mg	495 2 O
for	498 3 O
treated	502 7 O
females	510 7 O
versus	518 6 O
8	525 1 O
.	526 1 O
7	527 1 O
+	529 1 O
/	530 1 O
-	531 1 O
1	533 1 O
.	534 1 O
1	535 1 O
for	537 3 O
untreated	541 9 O
females	551 7 O
)	558 1 O
or	560 2 O
morphological	563 13 O
changes	577 7 O
in	585 2 O
Brown	588 5 O
Norway	594 6 O
(	601 1 O
BN	602 2 O
)	604 1 O
rat	606 3 O
pituitaries	610 11 O
.	621 1 O

An	623 2 O
F1	626 2 O
hybrid	629 6 O
of	636 2 O
F344	639 4 O
and	644 3 O
BN	648 2 O
exhibited	651 9 O
significant	661 11 O
pituitary	673 9 O
growth	683 6 O
after	690 5 O
10	696 2 O
weeks	699 5 O
of	705 2 O
DES	708 3 B-Chemical
treatment	712 9 O
with	722 4 O
an	727 2 O
average	730 7 O
mass	738 4 O
of	743 2 O
26	746 2 O
.	748 1 O
3	749 1 O
+	751 1 O
/	752 1 O
-	753 1 O
0	755 1 O
.	756 1 O
7	757 1 O
mg	759 2 O
compared	762 8 O
with	771 4 O
8	776 1 O
.	777 1 O
6	778 1 O
+	780 1 O
/	781 1 O
-	782 1 O
0	784 1 O
.	785 1 O
9	786 1 O
mg	788 2 O
for	791 3 O
untreated	795 9 O
rats	805 4 O
.	809 1 O

Surprisingly	811 12 O
,	823 1 O
the	825 3 O
F1	829 2 O
hybrid	832 6 O
tumors	839 6 B-Disease
were	846 4 O
not	851 3 O
hemorrhagic	855 11 B-Disease
and	867 3 O
had	871 3 O
hemoglobin	875 10 O
content	886 7 O
and	894 3 O
outward	898 7 O
appearance	906 10 O
identical	917 9 O
to	927 2 O
that	930 4 O
of	935 2 O
BN	938 2 O
.	940 1 O

Expression	942 10 O
of	953 2 O
both	956 4 O
growth	961 6 O
and	968 3 O
morphological	972 13 O
changes	986 7 O
is	994 2 O
due	997 3 O
to	1001 2 O
multiple	1004 8 O
genes	1013 5 O
.	1018 1 O

However	1020 7 O
,	1027 1 O
while	1029 5 O
DES	1035 3 B-Chemical
-	1038 1 O
induced	1039 7 O
pituitary	1047 9 O
growth	1057 6 O
exhibited	1064 9 O
quantitative	1074 12 O
,	1086 1 O
additive	1088 8 O
inheritance	1097 11 O
,	1108 1 O
the	1110 3 O
hemorrhagic	1114 11 B-Disease
phenotype	1126 9 O
exhibited	1136 9 O
recessive	1146 9 O
,	1155 1 O
epistatic	1157 9 O
inheritance	1167 11 O
.	1178 1 O

Only	1180 4 O
5	1185 1 O
of	1187 2 O
the	1190 3 O
160	1194 3 O
F2	1198 2 O
pituitaries	1201 11 O
exhibited	1213 9 O
the	1223 3 O
hemorrhagic	1227 11 B-Disease
phenotype	1239 9 O
;	1248 1 O
36	1250 2 O
of	1253 2 O
the	1256 3 O
160	1260 3 O
F2	1264 2 O
pituitaries	1267 11 O
were	1279 4 O
in	1284 2 O
the	1287 3 O
F344	1291 4 O
range	1296 5 O
of	1302 2 O
mass	1305 4 O
,	1309 1 O
but	1311 3 O
31	1315 2 O
of	1318 2 O
these	1321 5 O
were	1327 4 O
not	1332 3 O
hemorrhagic	1336 11 B-Disease
,	1347 1 O
indicating	1349 10 O
that	1360 4 O
the	1365 3 O
hemorrhagic	1369 11 B-Disease
phenotype	1381 9 O
is	1391 2 O
not	1394 3 O
merely	1398 6 O
a	1405 1 O
consequence	1407 11 O
of	1419 2 O
extensive	1422 9 O
growth	1432 6 O
.	1438 1 O

The	1440 3 O
hemorrhagic	1444 11 B-Disease
F2	1456 2 O
pituitaries	1459 11 O
were	1471 4 O
all	1476 3 O
among	1480 5 O
the	1486 3 O
most	1490 4 O
massive	1495 7 O
,	1502 1 O
indicating	1504 10 O
that	1515 4 O
some	1520 4 O
of	1525 2 O
the	1528 3 O
genes	1532 5 O
regulate	1538 8 O
both	1547 4 O
phenotypes	1552 10 O
.	1562 1 O

Increased	0 9 O
expression	10 10 O
of	21 2 O
neuronal	24 8 O
nitric	33 6 B-Chemical
oxide	40 5 I-Chemical
synthase	46 8 O
in	55 2 O
bladder	58 7 O
afferent	66 8 O
pathways	75 8 O
following	84 9 O
chronic	94 7 O
bladder	102 7 B-Disease
irritation	110 10 I-Disease
.	120 1 O

Immunocytochemical	122 18 O
techniques	141 10 O
were	152 4 O
used	157 4 O
to	162 2 O
examine	165 7 O
alterations	173 11 O
in	185 2 O
the	188 3 O
expression	192 10 O
of	203 2 O
neuronal	206 8 O
nitric	215 6 B-Chemical
oxide	222 5 I-Chemical
synthase	228 8 O
(	237 1 O
NOS	238 3 O
)	241 1 O
in	243 2 O
bladder	246 7 O
pathways	254 8 O
following	263 9 O
acute	273 5 O
and	279 3 O
chronic	283 7 O
irritation	291 10 B-Disease
of	302 2 I-Disease
the	305 3 I-Disease
urinary	309 7 I-Disease
tract	317 5 I-Disease
of	323 2 O
the	326 3 O
rat	330 3 O
.	333 1 O

Chemical	335 8 O
cystitis	344 8 B-Disease
was	353 3 O
induced	357 7 O
by	365 2 O
cyclophosphamide	368 16 B-Chemical
(	385 1 O
CYP	386 3 B-Chemical
)	389 1 O
which	391 5 O
is	397 2 O
metabolized	400 11 O
to	412 2 O
acrolein	415 8 B-Chemical
,	423 1 O
an	425 2 O
irritant	428 8 O
eliminated	437 10 O
in	448 2 O
the	451 3 O
urine	455 5 O
.	460 1 O

Injection	462 9 O
of	472 2 O
CYP	475 3 B-Chemical
(	479 1 O
n	480 1 O
=	482 1 O
10	484 2 O
,	486 1 O
75	488 2 O
mg	491 2 O
/	493 1 O
kg	494 2 O
,	496 1 O
i	498 1 O
.	499 1 O
p	500 1 O
.	501 1 O
)	502 1 O
2	504 1 O
hours	506 5 O
prior	512 5 O
to	518 2 O
perfusion	521 9 O
(	531 1 O
acute	532 5 O
treatment	538 9 O
)	547 1 O
of	549 2 O
the	552 3 O
animals	556 7 O
increased	564 9 O
Fos	574 3 O
-	577 1 O
immunoreactivity	578 16 O
(	595 1 O
IR	596 2 O
)	598 1 O
in	600 2 O
neurons	603 7 O
in	611 2 O
the	614 3 O
dorsal	618 6 O
commissure	625 10 O
,	635 1 O
dorsal	637 6 O
horn	644 4 O
,	648 1 O
and	650 3 O
autonomic	654 9 O
regions	664 7 O
of	672 2 O
spinal	675 6 O
segments	682 8 O
(	691 1 O
L1	692 2 O
-	694 1 O
L2	695 2 O
and	698 3 O
L6	702 2 O
-	704 1 O
S1	705 2 O
)	707 1 O
which	709 5 O
receive	715 7 O
afferent	723 8 O
inputs	732 6 O
from	739 4 O
the	744 3 O
bladder	748 7 O
,	755 1 O
urethra	757 7 O
,	764 1 O
and	766 3 O
ureter	770 6 O
.	776 1 O

Fos	778 3 O
-	781 1 O
IR	782 2 O
in	785 2 O
the	788 3 O
spinal	792 6 O
cord	799 4 O
was	804 3 O
not	808 3 O
changed	812 7 O
in	820 2 O
rats	823 4 O
receiving	828 9 O
chronic	838 7 O
CYP	846 3 B-Chemical
treatment	850 9 O
(	860 1 O
n	861 1 O
=	863 1 O
15	865 2 O
,	867 1 O
75	869 2 O
mg	872 2 O
/	874 1 O
kg	875 2 O
,	877 1 O
i	879 1 O
.	880 1 O
p	881 1 O
.	882 1 O
,	883 1 O
every	885 5 O
3rd	891 3 O
day	895 3 O
for	899 3 O
2	903 1 O
weeks	905 5 O
)	910 1 O
.	911 1 O

In	913 2 O
control	916 7 O
animals	924 7 O
and	932 3 O
in	936 2 O
animals	939 7 O
treated	947 7 O
acutely	955 7 O
with	963 4 O
CYP	968 3 B-Chemical
,	971 1 O
only	973 4 O
small	978 5 O
numbers	984 7 O
of	992 2 O
NOS	995 3 O
-	998 1 O
IR	999 2 O
cells	1002 5 O
(	1008 1 O
0	1009 1 O
.	1010 1 O
5	1011 1 O
-	1012 1 O
0	1013 1 O
.	1014 1 O
7	1015 1 O
cell	1017 4 O
profiles	1022 8 O
/	1030 1 O
sections	1031 8 O
)	1039 1 O
were	1041 4 O
detected	1046 8 O
in	1055 2 O
the	1058 3 O
L6	1062 2 O
-	1064 1 O
S1	1065 2 O
dorsal	1068 6 O
root	1075 4 O
ganglia	1080 7 O
(	1088 1 O
DRG	1089 3 O
)	1092 1 O
.	1093 1 O

Chronic	1095 7 O
CYP	1103 3 B-Chemical
administration	1107 14 O
significantly	1122 13 O
(	1136 1 O
P	1137 1 O
<	1139 1 O
or	1141 2 O
=	1144 1 O
.	1146 1 O
002	1147 3 O
)	1150 1 O
increased	1152 9 O
bladder	1162 7 O
weight	1170 6 O
by	1177 2 O
60	1180 2 O
%	1182 1 O
and	1184 3 O
increased	1188 9 O
(	1198 1 O
7	1199 1 O
-	1200 1 O
to	1202 2 O
11	1205 2 O
-	1207 1 O
fold	1208 4 O
)	1212 1 O
the	1214 3 O
numbers	1218 7 O
of	1226 2 O
NOS	1229 3 O
-	1232 1 O
immunoreactive	1233 14 O
(	1248 1 O
IR	1249 2 O
)	1251 1 O
afferent	1253 8 O
neurons	1262 7 O
in	1270 2 O
the	1273 3 O
L6	1277 2 O
-	1279 1 O
S1	1280 2 O
DRG	1283 3 O
.	1286 1 O

A	1288 1 O
small	1290 5 O
increase	1296 8 O
(	1305 1 O
1	1306 1 O
.	1307 1 O
5	1308 1 O
-	1309 1 O
fold	1310 4 O
)	1314 1 O
also	1316 4 O
occurred	1321 8 O
in	1330 2 O
the	1333 3 O
L1	1337 2 O
DRG	1340 3 O
,	1343 1 O
but	1345 3 O
no	1349 2 O
change	1352 6 O
was	1359 3 O
detected	1363 8 O
in	1372 2 O
the	1375 3 O
L2	1379 2 O
and	1382 3 O
L5	1386 2 O
DRG	1389 3 O
.	1392 1 O

Bladder	1394 7 O
afferent	1402 8 O
cells	1411 5 O
in	1417 2 O
the	1420 3 O
L6	1424 2 O
-	1426 1 O
S1	1427 2 O
DRG	1430 3 O
labeled	1434 7 O
by	1442 2 O
Fluorogold	1445 10 O
(	1456 1 O
40	1457 2 O
microliters	1460 11 O
)	1471 1 O
injected	1473 8 O
into	1482 4 O
the	1487 3 O
bladder	1491 7 O
wall	1499 4 O
did	1504 3 O
not	1508 3 O
exhibit	1512 7 O
NOS	1520 3 O
-	1523 1 O
IR	1524 2 O
in	1527 2 O
control	1530 7 O
animals	1538 7 O
;	1545 1 O
however	1547 7 O
,	1554 1 O
following	1556 9 O
chronic	1566 7 O
CYP	1574 3 B-Chemical
administration	1578 14 O
,	1592 1 O
a	1594 1 O
significant	1596 11 O
percentage	1608 10 O
of	1619 2 O
bladder	1622 7 O
afferent	1630 8 O
neurons	1639 7 O
were	1647 4 O
NOS	1652 3 O
-	1655 1 O
IR	1656 2 O
:	1658 1 O
L6	1660 2 O
(	1663 1 O
19	1664 2 O
.	1666 1 O
8	1667 1 O
+	1669 1 O
/	1670 1 O
-	1671 1 O
4	1673 1 O
.	1674 1 O
6	1675 1 O
%	1676 1 O
)	1677 1 O
and	1679 3 O
S1	1683 2 O
(	1686 1 O
25	1687 2 O
.	1689 1 O
3	1690 1 O
+	1692 1 O
/	1693 1 O
-	1694 1 O
2	1696 1 O
.	1697 1 O
9	1698 1 O
%	1699 1 O
)	1700 1 O
.	1701 1 O

These	1703 5 O
results	1709 7 O
indicate	1717 8 O
that	1726 4 O
neuronal	1731 8 O
gene	1740 4 O
expression	1745 10 O
in	1756 2 O
visceral	1759 8 O
sensory	1768 7 O
pathways	1776 8 O
can	1785 3 O
be	1789 2 O
upregulated	1792 11 O
by	1804 2 O
chemical	1807 8 O
irritation	1816 10 O
of	1827 2 O
afferent	1830 8 O
receptors	1839 9 O
in	1849 2 O
the	1852 3 O
urinary	1856 7 O
tract	1864 5 O
and	1870 3 O
/	1873 1 O
or	1874 2 O
that	1877 4 O
pathological	1882 12 O
changes	1895 7 O
in	1903 2 O
the	1906 3 O
urinary	1910 7 O
tract	1918 5 O
can	1924 3 O
initiate	1928 8 O
chemical	1937 8 O
signals	1946 7 O
that	1954 4 O
alter	1959 5 O
the	1965 3 O
chemical	1969 8 O
properties	1978 10 O
of	1989 2 O
visceral	1992 8 O
afferent	2001 8 O
neurons	2010 7 O
.	2017 1 O

Effects	0 7 O
of	8 2 O
a	11 1 O
new	13 3 O
calcium	17 7 B-Chemical
antagonist	25 10 O
,	35 1 O
CD	37 2 B-Chemical
-	39 1 I-Chemical
832	40 3 I-Chemical
,	43 1 O
on	45 2 O
isoproterenol	48 13 B-Chemical
-	61 1 O
induced	62 7 O
myocardial	70 10 B-Disease
ischemia	81 8 I-Disease
in	90 2 O
dogs	93 4 O
with	98 4 O
partial	103 7 O
coronary	111 8 B-Disease
stenosis	120 8 I-Disease
.	128 1 O

Effects	130 7 O
of	138 2 O
CD	141 2 B-Chemical
-	143 1 I-Chemical
832	144 3 I-Chemical
on	148 2 O
isoproterenol	151 13 B-Chemical
(	165 1 O
ISO	166 3 B-Chemical
)	169 1 O
-	170 1 O
induced	171 7 O
myocardial	179 10 B-Disease
ischemia	190 8 I-Disease
were	199 4 O
studied	204 7 O
in	212 2 O
dogs	215 4 O
with	220 4 O
partial	225 7 O
coronary	233 8 B-Disease
stenosis	242 8 I-Disease
of	251 2 O
the	254 3 O
left	258 4 O
circumflex	263 10 O
coronary	274 8 O
artery	283 6 O
and	290 3 O
findings	294 8 O
were	303 4 O
compared	308 8 O
with	317 4 O
those	322 5 O
for	328 3 O
nifedipine	332 10 B-Chemical
or	343 2 O
diltiazem	346 9 B-Chemical
.	355 1 O

In	357 2 O
the	360 3 O
presence	364 8 O
of	373 2 O
coronary	376 8 B-Disease
artery	385 6 I-Disease
stenosis	392 8 I-Disease
,	400 1 O
3	402 1 O
-	403 1 O
min	404 3 O
periods	408 7 O
of	416 2 O
intracoronary	419 13 O
ISO	433 3 B-Chemical
infusion	437 8 O
(	446 1 O
10	447 2 O
ng	450 2 O
/	452 1 O
kg	453 2 O
/	455 1 O
min	456 3 O
)	459 1 O
increased	461 9 O
heart	471 5 O
rate	477 4 O
and	482 3 O
maximal	486 7 O
rate	494 4 O
of	499 2 O
left	502 4 O
ventricular	507 11 O
pressure	519 8 O
rise	528 4 O
,	532 1 O
which	534 5 O
resulted	540 8 O
in	549 2 O
a	552 1 O
decrease	554 8 O
in	563 2 O
percentage	566 10 O
segmental	577 9 O
shortening	587 10 O
and	598 3 O
ST	602 2 O
-	604 1 O
segment	605 7 O
elevation	613 9 O
of	623 2 O
the	626 3 O
epicardial	630 10 O
electrocardiogram	641 17 O
.	658 1 O

After	660 5 O
the	666 3 O
control	670 7 O
ISO	678 3 B-Chemical
infusion	682 8 O
with	691 4 O
stenosis	696 8 B-Disease
was	705 3 O
performed	709 9 O
,	718 1 O
equihypotensive	720 15 O
doses	736 5 O
of	742 2 O
CD	745 2 B-Chemical
-	747 1 I-Chemical
832	748 3 I-Chemical
(	752 1 O
3	753 1 O
and	755 3 O
10	759 2 O
micrograms	762 10 O
/	772 1 O
kg	773 2 O
/	775 1 O
min	776 3 O
,	779 1 O
n	781 1 O
=	783 1 O
7	785 1 O
)	786 1 O
,	787 1 O
nifedipine	789 10 B-Chemical
(	800 1 O
1	801 1 O
and	803 3 O
3	807 1 O
micrograms	809 10 O
/	819 1 O
kg	820 2 O
/	822 1 O
min	823 3 O
,	826 1 O
n	828 1 O
=	830 1 O
9	832 1 O
)	833 1 O
or	835 2 O
diltiazem	838 9 B-Chemical
(	848 1 O
10	849 2 O
and	852 3 O
30	856 2 O
micrograms	859 10 O
/	869 1 O
kg	870 2 O
/	872 1 O
min	873 3 O
,	876 1 O
n	878 1 O
=	880 1 O
7	882 1 O
)	883 1 O
were	885 4 O
infused	890 7 O
5	898 1 O
min	900 3 O
before	904 6 O
and	911 3 O
during	915 6 O
the	922 3 O
second	926 6 O
and	933 3 O
third	937 5 O
ISO	943 3 B-Chemical
infusion	947 8 O
.	955 1 O

Both	957 4 O
CD	962 2 B-Chemical
-	964 1 I-Chemical
832	965 3 I-Chemical
and	969 3 O
diltiazem	973 9 B-Chemical
,	982 1 O
but	984 3 O
not	988 3 O
nifedipine	992 10 B-Chemical
,	1002 1 O
significantly	1004 13 O
reduced	1018 7 O
the	1026 3 O
increase	1030 8 O
in	1039 2 O
heart	1042 5 O
rate	1048 4 O
induced	1053 7 O
by	1061 2 O
ISO	1064 3 B-Chemical
infusion	1068 8 O
.	1076 1 O

In	1078 2 O
contrast	1081 8 O
to	1090 2 O
nifedipine	1093 10 B-Chemical
,	1103 1 O
CD	1105 2 B-Chemical
-	1107 1 I-Chemical
832	1108 3 I-Chemical
(	1112 1 O
10	1113 2 O
micrograms	1116 10 O
/	1126 1 O
kg	1127 2 O
/	1129 1 O
min	1130 3 O
)	1133 1 O
prevented	1135 9 O
the	1145 3 O
decrease	1149 8 O
in	1158 2 O
percentage	1161 10 O
segmental	1172 9 O
shortening	1182 10 O
from	1193 4 O
32	1198 2 O
+	1201 1 O
/	1202 1 O
-	1203 1 O
12	1205 2 O
%	1207 1 O
to	1209 2 O
115	1212 3 O
+	1216 1 O
/	1217 1 O
-	1218 1 O
26	1220 2 O
%	1222 1 O
of	1224 2 O
the	1227 3 O
control	1231 7 O
value	1239 5 O
(	1245 1 O
P	1246 1 O
<	1248 1 O
.	1250 1 O
01	1251 2 O
)	1253 1 O
and	1255 3 O
ST	1259 2 O
-	1261 1 O
segment	1262 7 O
elevation	1270 9 O
from	1280 4 O
5	1285 1 O
.	1286 1 O
6	1287 1 O
+	1289 1 O
/	1290 1 O
-	1291 1 O
1	1293 1 O
.	1294 1 O
0	1295 1 O
mV	1297 2 O
to	1300 2 O
1	1303 1 O
.	1304 1 O
6	1305 1 O
+	1307 1 O
/	1308 1 O
-	1309 1 O
1	1311 1 O
.	1312 1 O
3	1313 1 O
mV	1315 2 O
(	1318 1 O
P	1319 1 O
<	1321 1 O
.	1323 1 O
01	1324 2 O
)	1326 1 O
at	1328 2 O
3	1331 1 O
min	1333 3 O
after	1337 5 O
ISO	1343 3 B-Chemical
infusion	1347 8 O
with	1356 4 O
stenosis	1361 8 B-Disease
.	1369 1 O

Diltiazem	1371 9 B-Chemical
(	1381 1 O
30	1382 2 O
micrograms	1385 10 O
/	1395 1 O
kg	1396 2 O
/	1398 1 O
min	1399 3 O
)	1402 1 O
also	1404 4 O
prevented	1409 9 O
the	1419 3 O
decrease	1423 8 O
in	1432 2 O
percentage	1435 10 O
segmental	1446 9 O
shortening	1456 10 O
from	1467 4 O
34	1472 2 O
+	1475 1 O
/	1476 1 O
-	1477 1 O
14	1479 2 O
%	1481 1 O
to	1483 2 O
63	1486 2 O
+	1489 1 O
/	1490 1 O
-	1491 1 O
18	1493 2 O
%	1495 1 O
of	1497 2 O
the	1500 3 O
control	1504 7 O
value	1512 5 O
(	1518 1 O
P	1519 1 O
<	1521 1 O
.	1523 1 O
05	1524 2 O
)	1526 1 O
and	1528 3 O
ST	1532 2 O
-	1534 1 O
segment	1535 7 O
elevation	1543 9 O
from	1553 4 O
4	1558 1 O
.	1559 1 O
7	1560 1 O
+	1562 1 O
/	1563 1 O
-	1564 1 O
0	1566 1 O
.	1567 1 O
7	1568 1 O
mV	1570 2 O
to	1573 2 O
2	1576 1 O
.	1577 1 O
1	1578 1 O
+	1580 1 O
/	1581 1 O
-	1582 1 O
0	1584 1 O
.	1585 1 O
7	1586 1 O
mV	1588 2 O
(	1591 1 O
P	1592 1 O
<	1594 1 O
.	1596 1 O
01	1597 2 O
)	1599 1 O
at	1601 2 O
3	1604 1 O
min	1606 3 O
after	1610 5 O
ISO	1616 3 B-Chemical
infusion	1620 8 O
with	1629 4 O
stenosis	1634 8 B-Disease
.	1642 1 O

These	1644 5 O
data	1650 4 O
show	1655 4 O
that	1660 4 O
CD	1665 2 B-Chemical
-	1667 1 I-Chemical
832	1668 3 I-Chemical
improves	1672 8 O
myocardial	1681 10 B-Disease
ischemia	1692 8 I-Disease
during	1701 6 O
ISO	1708 3 B-Chemical
infusion	1712 8 O
with	1721 4 O
stenosis	1726 8 B-Disease
and	1735 3 O
suggest	1739 7 O
that	1747 4 O
the	1752 3 O
negative	1756 8 O
chronotropic	1765 12 O
property	1778 8 O
of	1787 2 O
CD	1790 2 B-Chemical
-	1792 1 I-Chemical
832	1793 3 I-Chemical
plays	1797 5 O
a	1803 1 O
major	1805 5 O
role	1811 4 O
in	1816 2 O
the	1819 3 O
beneficial	1823 10 O
effects	1834 7 O
of	1842 2 O
CD	1845 2 B-Chemical
-	1847 1 I-Chemical
832	1848 3 I-Chemical
.	1851 1 O

The	0 3 O
effect	4 6 O
of	11 2 O
recombinant	14 11 O
human	26 5 O
insulin	32 7 O
-	39 1 O
like	40 4 O
growth	45 6 O
factor	52 6 O
-	58 1 O
I	59 1 O
on	61 2 O
chronic	64 7 O
puromycin	72 9 B-Chemical
aminonucleoside	82 15 I-Chemical
nephropathy	98 11 B-Disease
in	110 2 O
rats	113 4 O
.	117 1 O

We	119 2 O
recently	122 8 O
demonstrated	131 12 O
that	144 4 O
recombinant	149 11 O
hGH	161 3 O
exacerbates	165 11 O
renal	177 5 O
functional	183 10 O
and	194 3 O
structural	198 10 O
injury	209 6 O
in	216 2 O
chronic	219 7 O
puromycin	227 9 B-Chemical
aminonucleoside	237 15 I-Chemical
(	253 1 O
PAN	254 3 B-Chemical
)	257 1 O
nephropathy	259 11 B-Disease
,	270 1 O
an	272 2 O
experimental	275 12 O
model	288 5 O
of	294 2 O
glomerular	297 10 B-Disease
disease	308 7 I-Disease
.	315 1 O

Therefore	317 9 O
,	326 1 O
we	328 2 O
examined	331 8 O
whether	340 7 O
recombinant	348 11 O
human	360 5 O
(	366 1 O
rh	367 2 O
)	369 1 O
IGF	371 3 O
-	374 1 O
I	375 1 O
is	377 2 O
a	380 1 O
safer	382 5 O
alternative	388 11 O
for	400 3 O
the	404 3 O
treatment	408 9 O
of	418 2 O
growth	421 6 B-Disease
failure	428 7 I-Disease
in	436 2 O
rats	439 4 O
with	444 4 O
chronic	449 7 O
PAN	457 3 B-Chemical
nephropathy	461 11 B-Disease
.	472 1 O

The	474 3 O
glomerulopathy	478 14 B-Disease
was	493 3 O
induced	497 7 O
by	505 2 O
seven	508 5 O
serial	514 6 O
injections	521 10 O
of	532 2 O
PAN	535 3 B-Chemical
over	539 4 O
12	544 2 O
wk	547 2 O
.	549 1 O

Experimental	551 12 O
animals	564 7 O
(	572 1 O
n	573 1 O
=	575 1 O
6	577 1 O
)	578 1 O
received	580 8 O
rhIGF	589 5 O
-	594 1 O
I	595 1 O
,	596 1 O
400	598 3 O
micrograms	602 10 O
/	612 1 O
d	613 1 O
,	614 1 O
whereas	616 7 O
control	624 7 O
rats	632 4 O
(	637 1 O
n	638 1 O
=	640 1 O
6	642 1 O
)	643 1 O
received	645 8 O
the	654 3 O
vehicle	658 7 O
.	665 1 O

rhIGF	667 5 O
-	672 1 O
I	673 1 O
improved	675 8 O
weight	684 6 O
gain	691 4 O
by	696 2 O
14	699 2 O
%	701 1 O
(	703 1 O
p	704 1 O
<	706 1 O
0	708 1 O
.	709 1 O
05	710 2 O
)	712 1 O
,	713 1 O
without	715 7 O
altering	723 8 O
hematocrit	732 10 O
or	743 2 O
blood	746 5 O
pressure	752 8 O
in	761 2 O
rats	764 4 O
with	769 4 O
renal	774 5 B-Disease
disease	780 7 I-Disease
.	787 1 O

Urinary	789 7 O
protein	797 7 O
excretion	805 9 O
was	815 3 O
unaltered	819 9 O
by	829 2 O
rhIGF	832 5 O
-	837 1 O
I	838 1 O
treatment	840 9 O
in	850 2 O
rats	853 4 O
with	858 4 O
chronic	863 7 O
PAN	871 3 B-Chemical
nephropathy	875 11 B-Disease
.	886 1 O

After	888 5 O
12	894 2 O
wk	897 2 O
,	899 1 O
the	901 3 O
inulin	905 6 O
clearance	912 9 O
was	922 3 O
higher	926 6 O
in	933 2 O
rhIGF	936 5 O
-	941 1 O
I	942 1 O
-	943 1 O
treated	944 7 O
rats	952 4 O
,	956 1 O
0	958 1 O
.	959 1 O
48	960 2 O
+	963 1 O
/	964 1 O
-	965 1 O
0	967 1 O
.	968 1 O
08	969 2 O
versus	972 6 O
0	979 1 O
.	980 1 O
24	981 2 O
+	984 1 O
/	985 1 O
-	986 1 O
0	988 1 O
.	989 1 O
06	990 2 O
mL	993 2 O
/	995 1 O
min	996 3 O
/	999 1 O
100	1000 3 O
g	1004 1 O
of	1006 2 O
body	1009 4 O
weight	1014 6 O
in	1021 2 O
untreated	1024 9 O
PAN	1034 3 B-Chemical
nephropathy	1038 11 B-Disease
animals	1050 7 O
,	1057 1 O
p	1059 1 O
<	1061 1 O
0	1063 1 O
.	1064 1 O
05	1065 2 O
.	1067 1 O

The	1069 3 O
improvement	1073 11 O
in	1085 2 O
GFR	1088 3 O
was	1092 3 O
not	1096 3 O
associated	1100 10 O
with	1111 4 O
enhanced	1116 8 O
glomerular	1125 10 B-Disease
hypertrophy	1136 11 I-Disease
or	1148 2 O
increased	1151 9 O
segmental	1161 9 O
glomerulosclerosis	1171 18 B-Disease
,	1189 1 O
tubulointerstitial	1191 18 B-Disease
injury	1210 6 I-Disease
,	1216 1 O
or	1218 2 O
renal	1221 5 O
cortical	1227 8 O
malondialdehyde	1236 15 B-Chemical
content	1252 7 O
.	1259 1 O

In	1261 2 O
rats	1264 4 O
with	1269 4 O
PAN	1274 3 B-Chemical
nephropathy	1278 11 B-Disease
,	1289 1 O
administration	1291 14 O
of	1306 2 O
rhIGF	1309 5 O
-	1314 1 O
I	1315 1 O
increased	1317 9 O
IGF	1327 3 O
-	1330 1 O
I	1331 1 O
and	1333 3 O
GH	1337 2 O
receptor	1340 8 O
gene	1349 4 O
expression	1354 10 O
,	1364 1 O
without	1366 7 O
altering	1374 8 O
the	1383 3 O
steady	1387 6 O
state	1394 5 O
level	1400 5 O
of	1406 2 O
IGF	1409 3 O
-	1412 1 O
I	1413 1 O
receptor	1415 8 O
mRNA	1424 4 O
.	1428 1 O

In	1430 2 O
normal	1433 6 O
rats	1440 4 O
with	1445 4 O
intact	1450 6 O
kidneys	1457 7 O
,	1464 1 O
rhIGF	1466 5 O
-	1471 1 O
I	1472 1 O
administration	1474 14 O
(	1489 1 O
n	1490 1 O
=	1492 1 O
4	1494 1 O
)	1495 1 O
did	1497 3 O
not	1501 3 O
alter	1505 5 O
weight	1511 6 O
gain	1518 4 O
,	1522 1 O
blood	1524 5 O
pressure	1530 8 O
,	1538 1 O
proteinuria	1540 11 B-Disease
,	1551 1 O
GFR	1553 3 O
,	1556 1 O
glomerular	1558 10 O
planar	1569 6 O
area	1576 4 O
,	1580 1 O
renal	1582 5 O
cortical	1588 8 O
malondialdehyde	1597 15 B-Chemical
content	1613 7 O
,	1620 1 O
or	1622 2 O
glomerular	1625 10 O
or	1636 2 O
tubulointerstitial	1639 18 B-Disease
damage	1658 6 I-Disease
,	1664 1 O
compared	1666 8 O
with	1675 4 O
untreated	1680 9 O
animals	1690 7 O
(	1698 1 O
n	1699 1 O
=	1701 1 O
4	1703 1 O
)	1704 1 O
.	1705 1 O

rhIGF	1707 5 O
-	1712 1 O
I	1713 1 O
treatment	1715 9 O
reduced	1725 7 O
the	1733 3 O
steady	1737 6 O
state	1744 5 O
renal	1750 5 O
IGF	1756 3 O
-	1759 1 O
I	1760 1 O
mRNA	1762 4 O
level	1767 5 O
but	1773 3 O
did	1777 3 O
not	1781 3 O
modify	1785 6 O
gene	1792 4 O
expression	1797 10 O
of	1808 2 O
the	1811 3 O
IGF	1815 3 O
-	1818 1 O
I	1819 1 O
or	1821 2 O
GH	1824 2 O
receptors	1827 9 O
.	1836 1 O

We	1838 2 O
conclude	1841 8 O
that	1850 4 O
:	1854 1 O
1	1856 1 O
)	1857 1 O
administration	1859 14 O
of	1874 2 O
rhIGF	1877 5 O
-	1882 1 O
I	1883 1 O
improves	1885 8 O
growth	1894 6 O
and	1901 3 O
GFR	1905 3 O
in	1909 2 O
rats	1912 4 O
with	1917 4 O
chronic	1922 7 O
PAN	1930 3 B-Chemical
nephropathy	1934 11 B-Disease
and	1946 3 O
2	1950 1 O
)	1951 1 O
unlike	1953 6 O
rhGH	1960 4 O
,	1964 1 O
long	1966 4 O
-	1970 1 O
term	1971 4 O
use	1976 3 O
of	1980 2 O
rhIGF	1983 5 O
-	1988 1 O
I	1989 1 O
does	1991 4 O
not	1996 3 O
worsen	2000 6 O
renal	2007 5 O
functional	2013 10 O
and	2024 3 O
structural	2028 10 O
injury	2039 6 O
in	2046 2 O
this	2049 4 O
disease	2054 7 O
model	2062 5 O
.	2067 1 O

Nefiracetam	0 11 B-Chemical
(	12 1 O
DM	13 2 B-Chemical
-	15 1 I-Chemical
9384	16 4 I-Chemical
)	20 1 O
reverses	22 8 O
apomorphine	31 11 B-Chemical
-	42 1 O
induced	43 7 O
amnesia	51 7 B-Disease
of	59 2 O
a	62 1 O
passive	64 7 O
avoidance	72 9 O
response	82 8 O
:	90 1 O
delayed	92 7 O
emergence	100 9 O
of	110 2 O
the	113 3 O
memory	117 6 O
retention	124 9 O
effects	134 7 O
.	141 1 O

Nefiracetam	143 11 B-Chemical
is	155 2 O
a	158 1 O
novel	160 5 O
pyrrolidone	166 11 B-Chemical
derivative	178 10 O
which	189 5 O
attenuates	195 10 O
scopolamine	206 11 B-Chemical
-	217 1 O
induced	218 7 O
learning	226 8 B-Disease
and	235 3 I-Disease
post	239 4 I-Disease
-	243 1 I-Disease
training	244 8 I-Disease
consolidation	253 13 I-Disease
deficits	267 8 I-Disease
.	275 1 O

Given	277 5 O
that	283 4 O
apomorphine	288 11 B-Chemical
inhibits	300 8 O
passive	309 7 O
avoidance	317 9 O
retention	327 9 O
when	337 4 O
given	342 5 O
during	348 6 O
training	355 8 O
or	364 2 O
in	367 2 O
a	370 1 O
defined	372 7 O
10	380 2 O
-	382 1 O
12h	383 3 O
post	387 4 O
-	391 1 O
training	392 8 O
period	401 6 O
,	407 1 O
we	409 2 O
evaluated	412 9 O
the	422 3 O
ability	426 7 O
of	434 2 O
nefiracetam	437 11 B-Chemical
to	449 2 O
attenuate	452 9 O
amnesia	462 7 B-Disease
induced	470 7 O
by	478 2 O
dopaminergic	481 12 O
agonism	494 7 O
.	501 1 O

A	503 1 O
step	505 4 O
-	509 1 O
down	510 4 O
passive	515 7 O
avoidance	523 9 O
paradigm	533 8 O
was	542 3 O
employed	546 8 O
and	555 3 O
nefiracetam	559 11 B-Chemical
(	571 1 O
3	572 1 O
mg	574 2 O
/	576 1 O
kg	577 2 O
)	579 1 O
and	581 3 O
apomorphine	585 11 B-Chemical
(	597 1 O
0	598 1 O
.	599 1 O
5	600 1 O
mg	602 2 O
/	604 1 O
kg	605 2 O
)	607 1 O
were	609 4 O
given	614 5 O
alone	620 5 O
or	626 2 O
in	629 2 O
combination	632 11 O
during	644 6 O
training	651 8 O
and	660 3 O
at	664 2 O
the	667 3 O
10	671 2 O
-	673 1 O
12h	674 3 O
post	678 4 O
-	682 1 O
training	683 8 O
period	692 6 O
of	699 2 O
consolidation	702 13 O
.	715 1 O

Co	717 2 O
-	719 1 O
administration	720 14 O
of	735 2 O
nefiracetam	738 11 B-Chemical
and	750 3 O
apomorphine	754 11 B-Chemical
during	766 6 O
training	773 8 O
or	782 2 O
10h	785 3 O
thereafter	789 10 O
produced	800 8 O
no	809 2 O
significant	812 11 O
anti	824 4 O
-	828 1 O
amnesic	829 7 O
effect	837 6 O
.	843 1 O

However	845 7 O
,	852 1 O
administration	854 14 O
of	869 2 O
nefiracetam	872 11 B-Chemical
during	884 6 O
training	891 8 O
completely	900 10 O
reversed	911 8 O
the	920 3 O
amnesia	924 7 B-Disease
induced	932 7 O
by	940 2 O
apomorphine	943 11 B-Chemical
at	955 2 O
the	958 3 O
10h	962 3 O
post	966 4 O
-	970 1 O
training	971 8 O
time	980 4 O
and	985 3 O
the	989 3 O
converse	993 8 O
was	1002 3 O
also	1006 4 O
true	1011 4 O
.	1015 1 O

These	1017 5 O
effects	1023 7 O
were	1031 4 O
not	1036 3 O
mediated	1040 8 O
by	1049 2 O
a	1052 1 O
dopaminergic	1054 12 O
mechanism	1067 9 O
as	1077 2 O
nefiracetam	1080 11 B-Chemical
,	1091 1 O
at	1093 2 O
millimolar	1096 10 O
concentrations	1107 14 O
,	1121 1 O
failed	1123 6 O
to	1130 2 O
displace	1133 8 O
either	1142 6 O
[	1149 1 O
3H	1150 2 O
]	1152 1 O
SCH	1153 3 B-Chemical
23390	1157 5 I-Chemical
or	1163 2 O
[	1166 1 O
3H	1167 2 O
]	1169 1 O
spiperone	1170 9 B-Chemical
binding	1180 7 O
from	1188 4 O
D1	1193 2 O
or	1196 2 O
D2	1199 2 O
dopamine	1202 8 B-Chemical
receptor	1211 8 O
subtypes	1220 8 O
,	1228 1 O
respectively	1230 12 O
.	1242 1 O

It	1244 2 O
is	1247 2 O
suggested	1250 9 O
that	1260 4 O
nefiracetam	1265 11 B-Chemical
augments	1277 8 O
molecular	1286 9 O
processes	1296 9 O
in	1306 2 O
the	1309 3 O
early	1313 5 O
stages	1319 6 O
of	1326 2 O
events	1329 6 O
which	1336 5 O
ultimately	1342 10 O
lead	1353 4 O
to	1358 2 O
consolidation	1361 13 O
of	1375 2 O
memory	1378 6 O
.	1384 1 O

Human	0 5 O
corticotropin	6 13 B-Chemical
-	19 1 O
releasing	20 9 O
hormone	30 7 O
and	38 3 O
thyrotropin	42 11 B-Chemical
-	53 1 O
releasing	54 9 O
hormone	64 7 O
modulate	72 8 O
the	81 3 O
hypercapnic	85 11 B-Disease
ventilatory	97 11 O
response	109 8 O
in	118 2 O
humans	121 6 O
.	127 1 O

Human	129 5 O
corticotropin	135 13 B-Chemical
-	148 1 O
releasing	149 9 O
hormone	159 7 O
(	167 1 O
hCRH	168 4 O
)	172 1 O
and	174 3 O
thyrotropin	178 11 B-Chemical
-	189 1 O
releasing	190 9 O
hormone	200 7 O
(	208 1 O
TRH	209 3 O
)	212 1 O
are	214 3 O
known	218 5 O
to	224 2 O
stimulate	227 9 O
ventilation	237 11 O
after	249 5 O
i	255 1 O
.	256 1 O
v	257 1 O
.	258 1 O
administration	260 14 O
in	275 2 O
humans	278 6 O
.	284 1 O

In	286 2 O
a	289 1 O
placebo	291 7 O
-	298 1 O
controlled	299 10 O
,	309 1 O
single	311 6 O
-	317 1 O
blind	318 5 O
study	324 5 O
we	330 2 O
aimed	333 5 O
to	339 2 O
clarify	342 7 O
if	350 2 O
both	353 4 O
peptides	358 8 O
act	367 3 O
by	371 2 O
altering	374 8 O
central	383 7 O
chemosensitivity	391 16 O
.	407 1 O

Two	409 3 O
subsequent	413 10 O
CO2	424 3 B-Chemical
-	427 1 O
rebreathing	428 11 O
tests	440 5 O
were	446 4 O
performed	451 9 O
in	461 2 O
healthy	464 7 O
young	472 5 O
volunteers	478 10 O
.	488 1 O

During	490 6 O
the	497 3 O
first	501 5 O
test	507 4 O
0	512 1 O
.	513 1 O
9	514 1 O
%	515 1 O
NaCl	517 4 B-Chemical
was	522 3 O
given	526 5 O
i	532 1 O
.	533 1 O
v	534 1 O
.	535 1 O
;	536 1 O
during	538 6 O
the	545 3 O
second	549 6 O
test	556 4 O
200	561 3 O
micrograms	565 10 O
of	576 2 O
hCRH	579 4 O
(	584 1 O
n	585 1 O
=	587 1 O
12	589 2 O
)	591 1 O
or	593 2 O
400	596 3 O
micrograms	600 10 O
of	611 2 O
TRH	614 3 O
(	618 1 O
n	619 1 O
=	621 1 O
6	623 1 O
)	624 1 O
was	626 3 O
administered	630 12 O
i	643 1 O
.	644 1 O
v	645 1 O
.	646 1 O
Nine	648 4 O
subjects	653 8 O
received	662 8 O
0	671 1 O
.	672 1 O
9	673 1 O
%	674 1 O
NaCl	676 4 B-Chemical
i	681 1 O
.	682 1 O
v	683 1 O
.	684 1 O
during	686 6 O
both	693 4 O
rebreathing	698 11 O
manoeuvres	710 10 O
.	720 1 O

The	722 3 O
CO2	726 3 B-Chemical
-	729 1 O
response	730 8 O
curves	739 6 O
for	746 3 O
the	750 3 O
two	754 3 O
tests	758 5 O
were	764 4 O
compared	769 8 O
within	778 6 O
the	785 3 O
same	789 4 O
subject	794 7 O
.	801 1 O

In	803 2 O
the	806 3 O
hCRH	810 4 O
group	815 5 O
a	821 1 O
marked	823 6 O
parallel	830 8 O
shift	839 5 O
of	845 2 O
the	848 3 O
CO2	852 3 B-Chemical
-	855 1 O
response	856 8 O
curve	865 5 O
to	871 2 O
the	874 3 O
left	878 4 O
was	883 3 O
observed	887 8 O
after	896 5 O
hCRH	902 4 O
(	907 1 O
P	908 1 O
<	910 1 O
0	912 1 O
.	913 1 O
01	914 2 O
)	916 1 O
.	917 1 O

The	919 3 O
same	923 4 O
effect	928 6 O
occurred	935 8 O
following	944 9 O
TRH	954 3 O
but	958 3 O
was	962 3 O
less	966 4 O
striking	971 8 O
(	980 1 O
P	981 1 O
=	983 1 O
0	985 1 O
.	986 1 O
05	987 2 O
)	989 1 O
.	990 1 O

hCRH	992 4 O
and	997 3 O
TRH	1001 3 O
caused	1005 6 O
a	1012 1 O
reduction	1014 9 O
in	1024 2 O
the	1027 3 O
CO2	1031 3 B-Chemical
threshold	1035 9 O
.	1044 1 O

The	1046 3 O
CO2	1050 3 B-Chemical
-	1053 1 O
response	1054 8 O
curves	1063 6 O
in	1070 2 O
the	1073 3 O
control	1077 7 O
group	1085 5 O
were	1091 4 O
nearly	1096 6 O
identical	1103 9 O
.	1112 1 O

The	1114 3 O
results	1118 7 O
indicate	1126 8 O
an	1135 2 O
additive	1138 8 O
effect	1147 6 O
of	1154 2 O
both	1157 4 O
releasing	1162 9 O
hormones	1172 8 O
on	1181 2 O
the	1184 3 O
hypercapnic	1188 11 B-Disease
ventilatory	1200 11 O
response	1212 8 O
in	1221 2 O
humans	1224 6 O
,	1230 1 O
presumably	1232 10 O
independent	1243 11 O
of	1255 2 O
central	1258 7 O
chemosensitivity	1266 16 O
.	1282 1 O

Lamivudine	0 10 B-Chemical
is	11 2 O
effective	14 9 O
in	24 2 O
suppressing	27 11 O
hepatitis	39 9 B-Disease
B	49 1 I-Disease
virus	51 5 O
DNA	57 3 O
in	61 2 O
Chinese	64 7 O
hepatitis	72 9 B-Chemical
B	82 1 I-Chemical
surface	84 7 I-Chemical
antigen	92 7 I-Chemical
carriers	100 8 O
:	108 1 O
a	110 1 O
placebo	112 7 O
-	119 1 O
controlled	120 10 O
trial	131 5 O
.	136 1 O

Lamivudine	138 10 B-Chemical
is	149 2 O
a	152 1 O
novel	154 5 O
2	160 1 B-Chemical
'	161 1 I-Chemical
,	162 1 I-Chemical
3	163 1 I-Chemical
'	164 1 I-Chemical
-	165 1 I-Chemical
dideoxy	166 7 I-Chemical
cytosine	174 8 I-Chemical
analogue	183 8 O
that	192 4 O
has	197 3 O
potent	201 6 O
inhibitory	208 10 O
effects	219 7 O
on	227 2 O
hepatitis	230 9 B-Disease
B	240 1 I-Disease
virus	242 5 O
replication	248 11 O
in	260 2 O
vitro	263 5 O
and	269 3 O
in	273 2 O
vivo	276 4 O
.	280 1 O

We	282 2 O
performed	285 9 O
a	295 1 O
single	297 6 O
-	303 1 O
blind	304 5 O
,	309 1 O
placebo	311 7 O
-	318 1 O
controlled	319 10 O
study	330 5 O
to	336 2 O
assess	339 6 O
its	346 3 O
effectiveness	350 13 O
and	364 3 O
safety	368 6 O
in	375 2 O
Chinese	378 7 O
hepatitis	386 9 B-Chemical
B	396 1 I-Chemical
surface	398 7 I-Chemical
antigen	406 7 I-Chemical
(	414 1 O
HBsAg	415 5 B-Chemical
)	420 1 O
carriers	422 8 O
.	430 1 O

Forty	432 5 O
-	437 1 O
two	438 3 O
Chinese	442 7 O
HBsAg	450 5 B-Chemical
carriers	456 8 O
were	465 4 O
randomized	470 10 O
to	481 2 O
receive	484 7 O
placebo	492 7 O
(	500 1 O
6	501 1 O
patients	503 8 O
)	511 1 O
or	513 2 O
lamivudine	516 10 B-Chemical
orally	527 6 O
in	534 2 O
dosages	537 7 O
of	545 2 O
25	548 2 O
mg	551 2 O
,	553 1 O
100	555 3 O
mg	559 2 O
,	561 1 O
or	563 2 O
300	566 3 O
mg	570 2 O
daily	573 5 O
(	579 1 O
12	580 2 O
patients	583 8 O
for	592 3 O
each	596 4 O
dosage	601 6 O
)	607 1 O
.	608 1 O

The	610 3 O
drug	614 4 O
was	619 3 O
given	623 5 O
for	629 3 O
4	633 1 O
weeks	635 5 O
.	640 1 O

The	642 3 O
patients	646 8 O
were	655 4 O
closely	660 7 O
monitored	668 9 O
clinically	678 10 O
,	688 1 O
biochemically	690 13 O
,	703 1 O
and	705 3 O
serologically	709 13 O
up	723 2 O
to	726 2 O
4	729 1 O
weeks	731 5 O
after	737 5 O
drug	743 4 O
treatment	748 9 O
.	757 1 O

All	759 3 O
36	763 2 O
patients	766 8 O
receiving	775 9 O
lamivudine	785 10 B-Chemical
had	796 3 O
a	800 1 O
decrease	802 8 O
in	811 2 O
hepatitis	814 9 B-Disease
B	824 1 I-Disease
virus	826 5 O
(	832 1 O
HBV	833 3 O
)	836 1 O
DNA	838 3 O
values	842 6 O
of	849 2 O
>	852 1 O
90	853 2 O
%	855 1 O
(	857 1 O
P	858 1 O
<	860 1 O
.	862 1 O
001	863 3 O
compared	867 8 O
with	876 4 O
placebo	881 7 O
)	888 1 O
.	889 1 O

Although	891 8 O
25	900 2 O
mg	903 2 O
of	906 2 O
lamivudine	909 10 B-Chemical
was	920 3 O
slightly	924 8 O
less	933 4 O
effective	938 9 O
than	948 4 O
100	953 3 O
mg	957 2 O
(	960 1 O
P	961 1 O
=	963 1 O
.	965 1 O
011	966 3 O
)	969 1 O
and	971 3 O
300	975 3 O
mg	979 2 O
(	982 1 O
P	983 1 O
=	985 1 O
.	987 1 O
005	988 3 O
)	991 1 O
,	992 1 O
it	994 2 O
still	997 5 O
induced	1003 7 O
94	1011 2 O
%	1013 1 O
suppression	1015 11 O
of	1027 2 O
HBV	1030 3 O
DNA	1034 3 O
after	1038 5 O
the	1044 3 O
fourth	1048 6 O
week	1055 4 O
of	1060 2 O
therapy	1063 7 O
.	1070 1 O

HBV	1072 3 O
DNA	1076 3 O
values	1080 6 O
returned	1087 8 O
to	1096 2 O
pretreatment	1099 12 O
levels	1112 6 O
within	1119 6 O
4	1126 1 O
weeks	1128 5 O
of	1134 2 O
cessation	1137 9 O
of	1147 2 O
therapy	1150 7 O
.	1157 1 O

There	1159 5 O
was	1165 3 O
no	1169 2 O
change	1172 6 O
in	1179 2 O
the	1182 3 O
hepatitis	1186 9 B-Disease
B	1196 1 I-Disease
e	1198 1 O
antigen	1200 7 O
status	1208 6 O
or	1215 2 O
in	1218 2 O
aminotransferase	1221 16 O
levels	1238 6 O
.	1244 1 O

No	1246 2 O
serious	1249 7 O
adverse	1257 7 O
events	1265 6 O
were	1272 4 O
observed	1277 8 O
.	1285 1 O

In	1287 2 O
conclusion	1290 10 O
,	1300 1 O
a	1302 1 O
4	1304 1 O
-	1305 1 O
week	1306 4 O
course	1311 6 O
of	1318 2 O
lamivudine	1321 10 B-Chemical
was	1332 3 O
safe	1336 4 O
and	1341 3 O
effective	1345 9 O
in	1355 2 O
suppression	1358 11 O
of	1370 2 O
HBV	1373 3 O
DNA	1377 3 O
in	1381 2 O
Chinese	1384 7 O
HBsAg	1392 5 B-Chemical
carriers	1398 8 O
.	1406 1 O

The	1408 3 O
suppression	1412 11 O
was	1424 3 O
>	1428 1 O
90	1429 2 O
%	1431 1 O
but	1433 3 O
reversible	1437 10 O
.	1447 1 O

Studies	1449 7 O
with	1457 4 O
long	1462 4 O
-	1466 1 O
term	1467 4 O
lamivudine	1472 10 B-Chemical
administration	1483 14 O
should	1498 6 O
be	1505 2 O
performed	1508 9 O
to	1518 2 O
determine	1521 9 O
if	1531 2 O
prolonged	1534 9 O
suppression	1544 11 O
of	1556 2 O
HBV	1559 3 O
DNA	1563 3 O
can	1567 3 O
be	1571 2 O
achieved	1574 8 O
.	1582 1 O

Population	0 10 O
-	10 1 O
based	11 5 O
study	17 5 O
of	23 2 O
risk	26 4 O
of	31 2 O
venous	34 6 B-Disease
thromboembolism	41 15 I-Disease
associated	57 10 O
with	68 4 O
various	73 7 O
oral	81 4 B-Chemical
contraceptives	86 14 I-Chemical
.	100 1 O

BACKGROUND	102 10 O
:	112 1 O
Four	114 4 O
studies	119 7 O
published	127 9 O
since	137 5 O
December	143 8 O
,	151 1 O
1995	153 4 O
,	157 1 O
reported	159 8 O
that	168 4 O
the	173 3 O
incidence	177 9 O
of	187 2 O
venous	190 6 B-Disease
thromboembolism	197 15 I-Disease
(	213 1 O
VTE	214 3 B-Disease
)	217 1 O
was	219 3 O
higher	223 6 O
in	230 2 O
women	233 5 O
who	239 3 O
used	243 4 O
oral	248 4 B-Chemical
contraceptives	253 14 I-Chemical
(	268 1 O
OCs	269 3 B-Chemical
)	272 1 O
containing	274 10 O
the	285 3 O
third	289 5 O
-	294 1 O
generation	295 10 O
progestagens	306 12 B-Chemical
gestodene	319 9 B-Chemical
or	329 2 O
desogestrel	332 11 B-Chemical
than	344 4 O
in	349 2 O
users	352 5 O
of	358 2 O
OCs	361 3 B-Chemical
containing	365 10 O
second	376 6 O
-	382 1 O
generation	383 10 O
progestagens	394 12 B-Chemical
.	406 1 O

However	408 7 O
,	415 1 O
confounding	417 11 O
and	429 3 O
bias	433 4 O
in	438 2 O
the	441 3 O
design	445 6 O
of	452 2 O
these	455 5 O
studies	461 7 O
may	469 3 O
have	473 4 O
affected	478 8 O
the	487 3 O
findings	491 8 O
.	499 1 O

The	501 3 O
aim	505 3 O
of	509 2 O
our	512 3 O
study	516 5 O
was	522 3 O
to	526 2 O
re	529 2 O
-	531 1 O
examine	532 7 O
the	540 3 O
association	544 11 O
between	556 7 O
risk	564 4 O
of	569 2 O
VTE	572 3 B-Disease
and	576 3 O
OC	580 2 B-Chemical
use	583 3 O
with	587 4 O
a	592 1 O
different	594 9 O
study	604 5 O
design	610 6 O
and	617 3 O
analysis	621 8 O
to	630 2 O
avoid	633 5 O
some	639 4 O
of	644 2 O
the	647 3 O
bias	651 4 O
and	656 3 O
confounding	660 11 O
of	672 2 O
the	675 3 O
earlier	679 7 O
studies	687 7 O
.	694 1 O

METHODS	696 7 O
:	703 1 O
We	705 2 O
used	708 4 O
computer	713 8 O
records	722 7 O
of	730 2 O
patients	733 8 O
from	742 4 O
143	747 3 O
general	751 7 O
practices	759 9 O
in	769 2 O
the	772 3 O
UK	776 2 O
.	778 1 O

The	780 3 O
study	784 5 O
was	790 3 O
based	794 5 O
on	800 2 O
the	803 3 O
medical	807 7 O
records	815 7 O
of	823 2 O
about	826 5 O
540	832 3 O
,	835 1 O
000	836 3 O
women	840 5 O
born	846 4 O
between	851 7 O
1941	859 4 O
and	864 3 O
1981	868 4 O
.	872 1 O

All	874 3 O
women	878 5 O
who	884 3 O
had	888 3 O
a	892 1 O
recorded	894 8 O
diagnosis	903 9 O
of	913 2 O
deep	916 4 B-Disease
-	920 1 I-Disease
vein	921 4 I-Disease
thrombosis	926 10 I-Disease
,	936 1 O
venous	938 6 B-Disease
thrombosis	945 10 I-Disease
not	956 3 O
otherwise	960 9 O
specified	970 9 O
,	979 1 O
or	981 2 O
pulmonary	984 9 O
embolus	994 7 O
during	1002 6 O
the	1009 3 O
study	1013 5 O
period	1019 6 O
,	1025 1 O
and	1027 3 O
who	1031 3 O
had	1035 3 O
been	1039 4 O
treated	1044 7 O
with	1052 4 O
an	1057 2 O
anticoagulant	1060 13 O
were	1074 4 O
identified	1079 10 O
as	1090 2 O
potential	1093 9 O
cases	1103 5 O
of	1109 2 O
VTE	1112 3 B-Disease
.	1115 1 O

We	1117 2 O
did	1120 3 O
a	1124 1 O
cohort	1126 6 O
analysis	1133 8 O
to	1142 2 O
estimate	1145 8 O
and	1154 3 O
compare	1158 7 O
incidence	1166 9 O
of	1176 2 O
VTE	1179 3 B-Disease
in	1183 2 O
users	1186 5 O
of	1192 2 O
the	1195 3 O
main	1199 4 O
OC	1204 2 B-Chemical
preparations	1207 12 O
,	1219 1 O
and	1221 3 O
a	1225 1 O
nested	1227 6 O
case	1234 4 O
-	1238 1 O
control	1239 7 O
study	1247 5 O
to	1253 2 O
calculate	1256 9 O
the	1266 3 O
odds	1270 4 O
ratios	1275 6 O
of	1282 2 O
VTE	1285 3 B-Disease
associated	1289 10 O
with	1300 4 O
use	1305 3 O
of	1309 2 O
different	1312 9 O
types	1322 5 O
of	1328 2 O
OC	1331 2 B-Chemical
,	1333 1 O
after	1335 5 O
adjustment	1341 10 O
for	1352 3 O
potential	1356 9 O
confounding	1366 11 O
factors	1378 7 O
.	1385 1 O

In	1387 2 O
the	1390 3 O
case	1394 4 O
-	1398 1 O
control	1399 7 O
study	1407 5 O
,	1412 1 O
we	1414 2 O
matched	1417 7 O
cases	1425 5 O
to	1431 2 O
controls	1434 8 O
by	1443 2 O
exact	1446 5 O
year	1452 4 O
of	1457 2 O
birth	1460 5 O
,	1465 1 O
practice	1467 8 O
,	1475 1 O
and	1477 3 O
current	1481 7 O
use	1489 3 O
of	1493 2 O
OCs	1496 3 B-Chemical
.	1499 1 O

We	1501 2 O
used	1504 4 O
a	1509 1 O
multiple	1511 8 O
logistic	1520 8 O
regression	1529 10 O
model	1540 5 O
that	1546 4 O
included	1551 8 O
body	1560 4 O
-	1564 1 O
mass	1565 4 O
index	1570 5 O
,	1575 1 O
number	1577 6 O
of	1584 2 O
cycles	1587 6 O
,	1593 1 O
change	1595 6 O
in	1602 2 O
type	1605 4 O
of	1610 2 O
OC	1613 2 B-Chemical
prescribed	1616 10 O
within	1627 6 O
3	1634 1 O
months	1636 6 O
of	1643 2 O
the	1646 3 O
event	1650 5 O
,	1655 1 O
previous	1657 8 O
pregnancy	1666 9 O
,	1675 1 O
and	1677 3 O
concurrent	1681 10 O
disease	1692 7 O
.	1699 1 O

FINDINGS	1701 8 O
:	1709 1 O
85	1711 2 O
women	1714 5 O
met	1720 3 O
the	1724 3 O
inclusion	1728 9 O
criteria	1738 8 O
for	1747 3 O
VTE	1751 3 B-Disease
,	1754 1 O
two	1756 3 O
of	1760 2 O
whom	1763 4 O
were	1768 4 O
users	1773 5 O
of	1779 2 O
progestagen	1782 11 B-Chemical
-	1793 1 O
only	1794 4 O
OCs	1799 3 B-Chemical
.	1802 1 O

Of	1804 2 O
the	1807 3 O
83	1811 2 O
cases	1814 5 O
of	1820 2 O
VTE	1823 3 B-Disease
associated	1827 10 O
with	1838 4 O
use	1843 3 O
of	1847 2 O
combined	1850 8 O
OCs	1859 3 B-Chemical
,	1862 1 O
43	1864 2 O
were	1867 4 O
recorded	1872 8 O
as	1881 2 O
deep	1884 4 B-Disease
-	1888 1 I-Disease
vein	1889 4 I-Disease
thrombosis	1894 10 I-Disease
,	1904 1 O
35	1906 2 O
as	1909 2 O
pulmonary	1912 9 O
thrombosis	1922 10 B-Disease
,	1932 1 O
and	1934 3 O
five	1938 4 O
as	1943 2 O
venous	1946 6 B-Disease
thrombosis	1953 10 I-Disease
not	1964 3 O
otherwise	1968 9 O
specified	1978 9 O
.	1987 1 O

The	1989 3 O
crude	1993 5 O
rate	1999 4 O
of	2004 2 O
VTE	2007 3 B-Disease
per	2011 3 O
10	2015 2 O
,	2017 1 O
000	2018 3 O
woman	2022 5 O
-	2027 1 O
years	2028 5 O
was	2034 3 O
4	2038 1 O
.	2039 1 O
10	2040 2 O
in	2043 2 O
current	2046 7 O
users	2054 5 O
of	2060 2 O
any	2063 3 O
OC	2067 2 B-Chemical
,	2069 1 O
3	2071 1 O
.	2072 1 O
10	2073 2 O
in	2076 2 O
users	2079 5 O
of	2085 2 O
second	2088 6 O
-	2094 1 O
generation	2095 10 O
OCs	2106 3 B-Chemical
,	2109 1 O
and	2111 3 O
4	2115 1 O
.	2116 1 O
96	2117 2 O
in	2120 2 O
users	2123 5 O
of	2129 2 O
third	2132 5 O
-	2137 1 O
generation	2138 10 O
preparations	2149 12 O
.	2161 1 O

After	2163 5 O
adjustment	2169 10 O
for	2180 3 O
age	2184 3 O
,	2187 1 O
the	2189 3 O
rate	2193 4 O
ratio	2198 5 O
of	2204 2 O
VTE	2207 3 B-Disease
in	2211 2 O
users	2214 5 O
of	2220 2 O
third	2223 5 O
-	2228 1 O
generation	2229 10 O
relative	2240 8 O
to	2249 2 O
second	2252 6 O
-	2258 1 O
generation	2259 10 O
OCs	2270 3 B-Chemical
was	2274 3 O
1	2278 1 O
.	2279 1 O
68	2280 2 O
(	2283 1 O
95	2284 2 O
%	2286 1 O
CI	2288 2 O
1	2291 1 O
.	2292 1 O
04	2293 2 O
-	2295 1 O
2	2296 1 O
.	2297 1 O
75	2298 2 O
)	2300 1 O
.	2301 1 O

Logistic	2303 8 O
regression	2312 10 O
showed	2323 6 O
no	2330 2 O
significant	2333 11 O
difference	2345 10 O
in	2356 2 O
the	2359 3 O
risk	2363 4 O
of	2368 2 O
VTE	2371 3 B-Disease
between	2375 7 O
users	2383 5 O
of	2389 2 O
third	2392 5 O
-	2397 1 O
generation	2398 10 O
and	2409 3 O
second	2413 6 O
-	2419 1 O
generation	2420 10 O
OCs	2431 3 B-Chemical
.	2434 1 O

Among	2436 5 O
users	2442 5 O
of	2448 2 O
third	2451 5 O
-	2456 1 O
generation	2457 10 O
progestagens	2468 12 B-Chemical
,	2480 1 O
the	2482 3 O
risk	2486 4 O
of	2491 2 O
VTE	2494 3 B-Disease
was	2498 3 O
higher	2502 6 O
in	2509 2 O
users	2512 5 O
of	2518 2 O
desogestrel	2521 11 B-Chemical
with	2533 4 O
20	2538 2 O
g	2541 1 O
ethinyloestradiol	2543 17 B-Chemical
than	2561 4 O
in	2566 2 O
users	2569 5 O
of	2575 2 O
gestodene	2578 9 B-Chemical
or	2588 2 O
desogestrel	2591 11 B-Chemical
with	2603 4 O
30	2608 2 O
g	2611 1 O
ethinyloestradiol	2613 17 B-Chemical
.	2630 1 O

With	2632 4 O
all	2637 3 O
second	2641 6 O
-	2647 1 O
generation	2648 10 O
OCs	2659 3 B-Chemical
as	2663 2 O
the	2666 3 O
reference	2670 9 O
,	2679 1 O
the	2681 3 O
odds	2685 4 O
ratios	2690 6 O
for	2697 3 O
VTE	2701 3 B-Disease
were	2705 4 O
3	2710 1 O
.	2711 1 O
49	2712 2 O
(	2715 1 O
1	2716 1 O
.	2717 1 O
21	2718 2 O
-	2720 1 O
10	2721 2 O
.	2723 1 O
12	2724 2 O
)	2726 1 O
for	2728 3 O
desogestrel	2732 11 B-Chemical
plus	2744 4 O
20	2749 2 O
g	2752 1 O
ethinyloestradiol	2754 17 B-Chemical
and	2772 3 O
1	2776 1 O
.	2777 1 O
18	2778 2 O
(	2781 1 O
0	2782 1 O
.	2783 1 O
66	2784 2 O
-	2786 1 O
2	2787 1 O
.	2788 1 O
17	2789 2 O
)	2791 1 O
for	2793 3 O
the	2797 3 O
other	2801 5 O
third	2807 5 O
-	2812 1 O
generation	2813 10 O
progestagens	2824 12 B-Chemical
.	2836 1 O

INTERPRETATION	2838 14 O
:	2852 1 O
The	2854 3 O
previously	2858 10 O
reported	2869 8 O
increase	2878 8 O
in	2887 2 O
odds	2890 4 O
ratio	2895 5 O
associated	2901 10 O
with	2912 4 O
third	2917 5 O
-	2922 1 O
generation	2923 10 O
OCs	2934 3 B-Chemical
when	2938 4 O
compared	2943 8 O
with	2952 4 O
second	2957 6 O
-	2963 1 O
generation	2964 10 O
products	2975 8 O
is	2984 2 O
likely	2987 6 O
to	2994 2 O
have	2997 4 O
been	3002 4 O
the	3007 3 O
result	3011 6 O
of	3018 2 O
residual	3021 8 O
confounding	3030 11 O
by	3042 2 O
age	3045 3 O
.	3048 1 O

The	3050 3 O
increased	3054 9 O
odds	3064 4 O
ratio	3069 5 O
associated	3075 10 O
with	3086 4 O
products	3091 8 O
containing	3100 10 O
20	3111 2 O
micrograms	3114 10 O
ethinyloestradiol	3125 17 B-Chemical
and	3143 3 O
desogestrel	3147 11 B-Chemical
compared	3159 8 O
with	3168 4 O
the	3173 3 O
30	3177 2 O
micrograms	3180 10 O
product	3191 7 O
is	3199 2 O
biologically	3202 12 O
implausible	3215 11 O
,	3226 1 O
and	3228 3 O
is	3232 2 O
likely	3235 6 O
to	3242 2 O
be	3245 2 O
the	3248 3 O
result	3252 6 O
of	3259 2 O
preferential	3262 12 O
prescribing	3275 11 O
and	3287 3 O
,	3290 1 O
thus	3292 4 O
,	3296 1 O
confounding	3298 11 O
.	3309 1 O

MK	0 2 B-Chemical
-	2 1 I-Chemical
801	3 3 I-Chemical
augments	7 8 O
pilocarpine	16 11 B-Chemical
-	27 1 O
induced	28 7 O
electrographic	36 14 O
seizure	51 7 B-Disease
but	59 3 O
protects	63 8 O
against	72 7 O
brain	80 5 B-Disease
damage	86 6 I-Disease
in	93 2 O
rats	96 4 O
.	100 1 O

1	102 1 O
.	103 1 O

The	105 3 O
authors	109 7 O
examined	117 8 O
the	126 3 O
anticonvulsant	130 14 O
effects	145 7 O
of	153 2 O
MK	156 2 B-Chemical
-	158 1 I-Chemical
801	159 3 I-Chemical
on	163 2 O
the	166 3 O
pilocarpine	170 11 B-Chemical
-	181 1 O
induced	182 7 O
seizure	190 7 B-Disease
model	198 5 O
.	203 1 O

Intraperitoneal	205 15 O
injection	221 9 O
of	231 2 O
pilocarpine	234 11 B-Chemical
(	246 1 O
400	247 3 O
mg	251 2 O
/	253 1 O
kg	254 2 O
)	256 1 O
induced	258 7 O
tonic	266 5 B-Disease
and	272 3 I-Disease
clonic	276 6 I-Disease
seizure	283 7 I-Disease
.	290 1 O

Scopolamine	292 11 B-Chemical
(	304 1 O
10	305 2 O
mg	308 2 O
/	310 1 O
kg	311 2 O
)	313 1 O
and	315 3 O
pentobarbital	319 13 B-Chemical
(	333 1 O
5	334 1 O
mg	336 2 O
/	338 1 O
kg	339 2 O
)	341 1 O
prevented	343 9 O
development	353 11 O
of	365 2 O
pilocarpine	368 11 B-Chemical
-	379 1 O
induced	380 7 O
behavioral	388 10 O
seizure	399 7 B-Disease
but	407 3 O
MK	411 2 B-Chemical
-	413 1 I-Chemical
801	414 3 I-Chemical
(	418 1 O
0	419 1 O
.	420 1 O
5	421 1 O
mg	423 2 O
/	425 1 O
kg	426 2 O
)	428 1 O
did	430 3 O
not	434 3 O
.	437 1 O

2	439 1 O
.	440 1 O

An	442 2 O
electrical	445 10 O
seizure	456 7 B-Disease
measured	464 8 O
with	473 4 O
hippocampal	478 11 O
EEG	490 3 O
appeared	494 8 O
in	503 2 O
the	506 3 O
pilocarpine	510 11 B-Chemical
-	521 1 O
treated	522 7 O
group	530 5 O
.	535 1 O

Scopolamine	537 11 B-Chemical
and	549 3 O
pentobarbital	553 13 B-Chemical
blocked	567 7 O
the	575 3 O
pilocarpine	579 11 B-Chemical
-	590 1 O
induced	591 7 O
electrographic	599 14 O
seizure	614 7 B-Disease
,	621 1 O
MK	623 2 B-Chemical
-	625 1 I-Chemical
801	626 3 I-Chemical
treatment	630 9 O
augmented	640 9 O
the	650 3 O
electrographic	654 14 O
seizure	669 7 B-Disease
induced	677 7 O
by	685 2 O
pilocarpine	688 11 B-Chemical
.	699 1 O

3	701 1 O
.	702 1 O

Brain	704 5 B-Disease
damage	710 6 I-Disease
was	717 3 O
assessed	721 8 O
by	730 2 O
examining	733 9 O
the	743 3 O
hippocampus	747 11 O
microscopically	759 15 O
.	774 1 O

Pilocarpine	776 11 B-Chemical
produced	788 8 O
neuronal	797 8 B-Disease
death	806 5 I-Disease
in	812 2 O
the	815 3 O
hippocampus	819 11 O
,	830 1 O
which	832 5 O
showed	838 6 O
pyknotic	845 8 O
changes	854 7 O
.	861 1 O

Pentobarbital	863 13 B-Chemical
,	876 1 O
scopolamine	878 11 B-Chemical
and	890 3 O
MK	894 2 B-Chemical
-	896 1 I-Chemical
801	897 3 I-Chemical
protected	901 9 O
the	911 3 O
brain	915 5 B-Disease
damage	921 6 I-Disease
by	928 2 O
pilocarpine	931 11 B-Chemical
,	942 1 O
though	944 6 O
in	951 2 O
the	954 3 O
MK	958 2 B-Chemical
-	960 1 I-Chemical
801	961 3 I-Chemical
-	964 1 O
treated	965 7 O
group	973 5 O
,	978 1 O
the	980 3 O
pyramidal	984 9 O
cells	994 5 O
of	1000 2 O
hippocampus	1003 11 O
appeared	1015 8 O
darker	1024 6 O
than	1031 4 O
normal	1036 6 O
.	1042 1 O

In	1044 2 O
all	1047 3 O
treatments	1051 10 O
,	1061 1 O
granule	1063 7 O
cells	1071 5 O
of	1077 2 O
the	1080 3 O
dentate	1084 7 O
gyrus	1092 5 O
were	1098 4 O
not	1103 3 O
affected	1107 8 O
.	1115 1 O

4	1117 1 O
.	1118 1 O

These	1120 5 O
results	1126 7 O
indicate	1134 8 O
that	1143 4 O
status	1148 6 B-Disease
epilepticus	1155 11 I-Disease
induced	1167 7 O
by	1175 2 O
pilocarpine	1178 11 B-Chemical
is	1190 2 O
initiated	1193 9 O
by	1203 2 O
cholinergic	1206 11 O
overstimulation	1218 15 O
and	1234 3 O
propagated	1238 10 O
by	1249 2 O
glutamatergic	1252 13 O
transmission	1266 12 O
,	1278 1 O
the	1280 3 O
elevation	1284 9 O
of	1294 2 O
which	1297 5 O
may	1303 3 O
cause	1307 5 O
brain	1313 5 B-Disease
damage	1319 6 I-Disease
through	1326 7 O
an	1334 2 O
excitatory	1337 10 O
NMDA	1348 4 B-Chemical
receptor	1353 8 O
-	1361 1 O
mediated	1362 8 O
mechanism	1371 9 O
.	1380 1 O

Paclitaxel	0 10 B-Chemical
,	10 1 O
5	12 1 B-Chemical
-	13 1 I-Chemical
fluorouracil	14 12 I-Chemical
,	26 1 O
and	28 3 O
folinic	32 7 B-Chemical
acid	40 4 I-Chemical
in	45 2 O
metastatic	48 10 O
breast	59 6 B-Disease
cancer	66 6 I-Disease
:	72 1 O
BRE	74 3 O
-	77 1 O
26	78 2 O
,	80 1 O
a	82 1 O
phase	84 5 O
II	90 2 O
trial	93 5 O
.	98 1 O

5	100 1 B-Chemical
-	101 1 I-Chemical
Fluorouracil	102 12 I-Chemical
plus	115 4 O
folinic	120 7 B-Chemical
acid	128 4 I-Chemical
and	133 3 O
paclitaxel	137 10 B-Chemical
(	148 1 O
Taxol	149 5 B-Chemical
;	154 1 O
Bristol	156 7 O
-	163 1 O
Myers	164 5 O
Squibb	170 6 O
Company	177 7 O
,	184 1 O
Princeton	186 9 O
,	195 1 O
NJ	197 2 O
)	199 1 O
are	201 3 O
effective	205 9 O
salvage	215 7 O
therapies	223 9 O
for	233 3 O
metastatic	237 10 O
breast	248 6 B-Disease
cancer	255 6 I-Disease
patients	262 8 O
.	270 1 O

Paclitaxel	272 10 B-Chemical
and	283 3 O
5	287 1 B-Chemical
-	288 1 I-Chemical
fluorouracil	289 12 I-Chemical
have	302 4 O
additive	307 8 O
cytotoxicity	316 12 B-Disease
in	329 2 O
MCF	332 3 O
-	335 1 O
7	336 1 O
cell	338 4 O
lines	343 5 O
.	348 1 O

We	350 2 O
performed	353 9 O
a	363 1 O
phase	365 5 O
II	371 2 O
trial	374 5 O
of	380 2 O
paclitaxel	383 10 B-Chemical
175	394 3 O
mg	398 2 O
/	400 1 O
m2	401 2 O
over	404 4 O
3	409 1 O
hours	411 5 O
on	417 2 O
day	420 3 O
I	424 1 O
followed	426 8 O
by	435 2 O
folinic	438 7 B-Chemical
acid	446 4 I-Chemical
300	451 3 O
mg	455 2 O
over	458 4 O
1	463 1 O
hour	465 4 O
before	470 6 O
5	477 1 B-Chemical
-	478 1 I-Chemical
fluorouracil	479 12 I-Chemical
350	492 3 O
mg	496 2 O
/	498 1 O
m2	499 2 O
on	502 2 O
days	505 4 O
1	510 1 O
to	512 2 O
3	515 1 O
every	517 5 O
28	523 2 O
days	526 4 O
(	531 1 O
TFL	532 3 O
)	535 1 O
in	537 2 O
women	540 5 O
with	546 4 O
metastatic	551 10 O
breast	562 6 B-Disease
cancer	569 6 I-Disease
.	575 1 O

Analysis	577 8 O
is	586 2 O
reported	589 8 O
on	598 2 O
37	601 2 O
patients	604 8 O
with	613 4 O
a	618 1 O
minimum	620 7 O
of	628 2 O
6	631 1 O
months	633 6 O
follow	640 6 O
-	646 1 O
up	647 2 O
who	650 3 O
received	654 8 O
a	663 1 O
total	665 5 O
of	671 2 O
192	674 3 O
cycles	678 6 O
of	685 2 O
TFL	688 3 O
:	691 1 O
nine	693 4 O
cycles	698 6 O
(	705 1 O
5	706 1 O
%	707 1 O
)	708 1 O
were	710 4 O
associated	715 10 O
with	726 4 O
grade	731 5 O
3	737 1 O
/	738 1 O
4	739 1 O
neutropenia	741 11 B-Disease
requiring	753 9 O
hospitalization	763 15 O
;	778 1 O
seven	780 5 O
(	786 1 O
4	787 1 O
%	788 1 O
)	789 1 O
cycles	791 6 O
in	798 2 O
two	801 3 O
patients	805 8 O
required	814 8 O
granulocyte	823 11 B-Chemical
colony	835 6 I-Chemical
-	841 1 I-Chemical
stimulating	842 11 I-Chemical
factor	854 6 I-Chemical
due	861 3 O
to	865 2 O
neutropenia	868 11 B-Disease
;	879 1 O
no	881 2 O
patient	884 7 O
required	892 8 O
platelet	901 8 O
transfusions	910 12 O
.	922 1 O

Grade	924 5 O
3	930 1 O
/	931 1 O
4	932 1 O
nonhematologic	934 14 O
toxicities	949 10 B-Disease
were	960 4 O
uncommon	965 8 O
.	973 1 O

Among	975 5 O
the	981 3 O
34	985 2 O
patients	988 8 O
evaluable	997 9 O
for	1007 3 O
response	1011 8 O
,	1019 1 O
there	1021 5 O
were	1027 4 O
three	1032 5 O
complete	1038 8 O
responses	1047 9 O
(	1057 1 O
9	1058 1 O
%	1059 1 O
)	1060 1 O
and	1062 3 O
18	1066 2 O
partial	1069 7 O
responses	1077 9 O
(	1087 1 O
53	1088 2 O
%	1090 1 O
)	1091 1 O
for	1093 3 O
an	1097 2 O
overall	1100 7 O
response	1108 8 O
rate	1117 4 O
of	1122 2 O
62	1125 2 O
%	1127 1 O
.	1128 1 O

Of	1130 2 O
the	1133 3 O
19	1137 2 O
evaluable	1140 9 O
patients	1150 8 O
with	1159 4 O
prior	1164 5 O
doxorubicin	1170 11 B-Chemical
exposure	1182 8 O
,	1190 1 O
11	1192 2 O
(	1195 1 O
58	1196 2 O
%	1198 1 O
)	1199 1 O
responded	1201 9 O
compared	1211 8 O
with	1220 4 O
nine	1225 4 O
of	1230 2 O
15	1233 2 O
(	1236 1 O
60	1237 2 O
%	1239 1 O
)	1240 1 O
without	1242 7 O
prior	1250 5 O
doxorubicin	1256 11 B-Chemical
.	1267 1 O

Plasma	1269 6 O
paclitaxel	1276 10 B-Chemical
concentrations	1287 14 O
were	1302 4 O
measured	1307 8 O
at	1316 2 O
the	1319 3 O
completion	1323 10 O
of	1334 2 O
paclitaxel	1337 10 B-Chemical
infusion	1348 8 O
and	1357 3 O
at	1361 2 O
24	1364 2 O
hours	1367 5 O
in	1373 2 O
19	1376 2 O
patients	1379 8 O
.	1387 1 O

TFL	1389 3 O
is	1393 2 O
an	1396 2 O
active	1399 6 O
,	1405 1 O
well	1407 4 O
-	1411 1 O
tolerated	1412 9 O
regimen	1422 7 O
in	1430 2 O
metastatic	1433 10 O
breast	1444 6 B-Disease
cancer	1451 6 I-Disease
.	1457 1 O

Efficacy	0 8 O
and	9 3 O
proarrhythmia	13 13 B-Disease
with	27 4 O
the	32 3 O
use	36 3 O
of	40 2 O
d	43 1 B-Chemical
,	44 1 I-Chemical
l	45 1 I-Chemical
-	46 1 I-Chemical
sotalol	47 7 I-Chemical
for	55 3 O
sustained	59 9 O
ventricular	69 11 B-Disease
tachyarrhythmias	81 16 I-Disease
.	97 1 O

This	99 4 O
study	104 5 O
prospectively	110 13 O
evaluated	124 9 O
the	134 3 O
clinical	138 8 O
efficacy	147 8 O
,	155 1 O
the	157 3 O
incidence	161 9 O
of	171 2 O
torsades	174 8 B-Disease
de	183 2 I-Disease
pointes	186 7 I-Disease
,	193 1 O
and	195 3 O
the	199 3 O
presumable	203 10 O
risk	214 4 O
factors	219 7 O
for	227 3 O
torsades	231 8 B-Disease
de	240 2 I-Disease
pointes	243 7 I-Disease
in	251 2 O
patients	254 8 O
treated	263 7 O
with	271 4 O
d	276 1 B-Chemical
,	277 1 I-Chemical
l	278 1 I-Chemical
-	279 1 I-Chemical
sotalol	280 7 I-Chemical
for	288 3 O
sustained	292 9 O
ventricular	302 11 B-Disease
tachyarrhythmias	314 16 I-Disease
.	330 1 O

Eighty	332 6 O
-	338 1 O
one	339 3 O
consecutive	343 11 O
patients	355 8 O
(	364 1 O
54	365 2 O
with	368 4 O
coronary	373 8 B-Disease
artery	382 6 I-Disease
disease	389 7 I-Disease
,	396 1 O
and	398 3 O
20	402 2 O
with	405 4 O
dilated	410 7 B-Disease
cardiomyopathy	418 14 I-Disease
)	432 1 O
with	434 4 O
inducible	439 9 O
sustained	449 9 O
ventricular	459 11 B-Disease
tachycardia	471 11 I-Disease
or	483 2 O
ventricular	486 11 B-Disease
fibrillation	498 12 I-Disease
received	511 8 O
oral	520 4 O
d	525 1 B-Chemical
,	526 1 I-Chemical
l	527 1 I-Chemical
-	528 1 I-Chemical
sotalol	529 7 I-Chemical
to	537 2 O
prevent	540 7 O
induction	548 9 O
of	558 2 O
the	561 3 O
ventricular	565 11 B-Disease
tachyarrhythmia	577 15 I-Disease
.	592 1 O

During	594 6 O
oral	601 4 O
loading	606 7 O
with	614 4 O
d	619 1 B-Chemical
,	620 1 I-Chemical
l	621 1 I-Chemical
-	622 1 I-Chemical
sotalol	623 7 I-Chemical
,	630 1 O
continuous	632 10 O
electrocardiographic	643 20 O
(	664 1 O
ECG	665 3 O
)	668 1 O
monitoring	670 10 O
was	681 3 O
performed	685 9 O
.	694 1 O

Those	696 5 O
patients	702 8 O
in	711 2 O
whom	714 4 O
d	719 1 B-Chemical
,	720 1 I-Chemical
l	721 1 I-Chemical
-	722 1 I-Chemical
sotalol	723 7 I-Chemical
prevented	731 9 O
induction	741 9 O
of	751 2 O
ventricular	754 11 B-Disease
tachycardia	766 11 I-Disease
or	778 2 O
ventricular	781 11 B-Disease
fibrillation	793 12 I-Disease
were	806 4 O
discharged	811 10 O
with	822 4 O
the	827 3 O
drug	831 4 O
and	836 3 O
followed	840 8 O
up	849 2 O
on	852 2 O
an	855 2 O
outpatient	858 10 O
basis	869 5 O
for	875 3 O
21	879 2 O
+	882 1 O
/	883 1 O
-	884 1 O
18	886 2 O
months	889 6 O
.	895 1 O

Induction	897 9 O
of	907 2 O
the	910 3 O
ventricular	914 11 B-Disease
tachyarrhythmia	926 15 I-Disease
was	942 3 O
prevented	946 9 O
by	956 2 O
oral	959 4 O
d	964 1 B-Chemical
,	965 1 I-Chemical
l	966 1 I-Chemical
-	967 1 I-Chemical
sotalol	968 7 I-Chemical
in	976 2 O
35	979 2 O
(	982 1 O
43	983 2 O
%	985 1 O
)	986 1 O
patients	988 8 O
;	996 1 O
the	998 3 O
ventricular	1002 11 B-Disease
tachyarrhythmia	1014 15 I-Disease
remained	1030 8 O
inducible	1039 9 O
in	1049 2 O
40	1052 2 O
(	1055 1 O
49	1056 2 O
%	1058 1 O
)	1059 1 O
patients	1061 8 O
;	1069 1 O
and	1071 3 O
two	1075 3 O
(	1079 1 O
2	1080 1 O
.	1081 1 O
5	1082 1 O
%	1083 1 O
)	1084 1 O
patients	1086 8 O
did	1095 3 O
not	1099 3 O
tolerate	1103 8 O
even	1112 4 O
40	1117 2 O
mg	1120 2 O
of	1123 2 O
d	1126 1 B-Chemical
,	1127 1 I-Chemical
l	1128 1 I-Chemical
-	1129 1 I-Chemical
sotalol	1130 7 I-Chemical
once	1138 4 O
daily	1143 5 O
.	1148 1 O

Four	1150 4 O
(	1155 1 O
5	1156 1 O
%	1157 1 O
)	1158 1 O
patients	1160 8 O
had	1169 3 O
from	1173 4 O
torsades	1178 8 B-Disease
de	1187 2 I-Disease
pointes	1190 7 I-Disease
during	1198 6 O
the	1205 3 O
initial	1209 7 O
oral	1217 4 O
treatment	1222 9 O
with	1232 4 O
d	1237 1 B-Chemical
,	1238 1 I-Chemical
l	1239 1 I-Chemical
-	1240 1 I-Chemical
sotalol	1241 7 I-Chemical
.	1248 1 O

Neither	1250 7 O
ECG	1258 3 O
[	1262 1 O
sinus	1263 5 O
-	1268 1 O
cycle	1269 5 O
length	1275 6 O
(	1282 1 O
SCL	1283 3 O
)	1286 1 O
,	1287 1 O
QT	1289 2 O
or	1292 2 O
QTc	1295 3 O
interval	1299 8 O
,	1307 1 O
or	1309 2 O
U	1312 1 O
wave	1314 4 O
]	1318 1 O
nor	1320 3 O
clinical	1324 8 O
parameters	1333 10 O
identified	1344 10 O
patients	1355 8 O
at	1364 2 O
risk	1367 4 O
for	1372 3 O
torsades	1376 8 B-Disease
de	1385 2 I-Disease
pointes	1388 7 I-Disease
.	1395 1 O

However	1397 7 O
,	1404 1 O
the	1406 3 O
oral	1410 4 O
dose	1415 4 O
of	1420 2 O
d	1423 1 B-Chemical
,	1424 1 I-Chemical
l	1425 1 I-Chemical
-	1426 1 I-Chemical
sotalol	1427 7 I-Chemical
was	1435 3 O
significantly	1439 13 O
lower	1453 5 O
in	1459 2 O
patients	1462 8 O
with	1471 4 O
torsades	1476 8 B-Disease
de	1485 2 I-Disease
pointes	1488 7 I-Disease
(	1496 1 O
200	1497 3 O
+	1501 1 O
/	1502 1 O
-	1503 1 O
46	1505 2 O
vs	1508 2 O
.	1510 1 O
328	1512 3 O
+	1516 1 O
/	1517 1 O
-	1518 1 O
53	1520 2 O
mg	1523 2 O
/	1525 1 O
day	1526 3 O
;	1529 1 O
p	1531 1 O
=	1533 1 O
0	1535 1 O
.	1536 1 O
0017	1537 4 O
)	1541 1 O
.	1542 1 O

Risk	1544 4 O
factors	1549 7 O
associated	1557 10 O
with	1568 4 O
the	1573 3 O
development	1577 11 O
of	1589 2 O
torsades	1592 8 B-Disease
de	1601 2 I-Disease
pointes	1604 7 I-Disease
were	1612 4 O
the	1617 3 O
appearance	1621 10 O
of	1632 2 O
an	1635 2 O
U	1638 1 O
wave	1640 4 O
(	1645 1 O
p	1646 1 O
=	1648 1 O
0	1650 1 O
.	1651 1 O
049	1652 3 O
)	1655 1 O
,	1656 1 O
female	1658 6 O
gender	1665 6 O
(	1672 1 O
p	1673 1 O
=	1675 1 O
0	1677 1 O
.	1678 1 O
015	1679 3 O
)	1682 1 O
,	1683 1 O
and	1685 3 O
significant	1689 11 O
dose	1701 4 O
-	1705 1 O
corrected	1706 9 O
changes	1716 7 O
of	1724 2 O
SCL	1727 3 O
,	1730 1 O
QT	1732 2 O
interval	1735 8 O
,	1743 1 O
and	1745 3 O
QTc	1749 3 O
interval	1753 8 O
(	1762 1 O
p	1763 1 O
<	1765 1 O
0	1767 1 O
.	1768 1 O
05	1769 2 O
)	1771 1 O
.	1772 1 O

During	1774 6 O
follow	1781 6 O
-	1787 1 O
up	1788 2 O
,	1790 1 O
seven	1792 5 O
(	1798 1 O
20	1799 2 O
%	1801 1 O
)	1802 1 O
patients	1804 8 O
had	1813 3 O
a	1817 1 O
nonfatal	1819 8 O
ventricular	1828 11 B-Disease
tachycardia	1840 11 I-Disease
recurrence	1852 10 O
,	1862 1 O
and	1864 3 O
two	1868 3 O
(	1872 1 O
6	1873 1 O
%	1874 1 O
)	1875 1 O
patients	1877 8 O
died	1886 4 O
suddenly	1891 8 O
.	1899 1 O

One	1901 3 O
female	1905 6 O
patient	1912 7 O
with	1920 4 O
stable	1925 6 O
cardiac	1932 7 B-Disease
disease	1940 7 I-Disease
had	1948 3 O
recurrent	1952 9 O
torsades	1962 8 B-Disease
de	1971 2 I-Disease
pointes	1974 7 I-Disease
after	1982 5 O
2	1988 1 O
years	1990 5 O
of	1996 2 O
successful	1999 10 O
treatment	2010 9 O
with	2020 4 O
d	2025 1 B-Chemical
,	2026 1 I-Chemical
l	2027 1 I-Chemical
-	2028 1 I-Chemical
sotalol	2029 7 I-Chemical
.	2036 1 O

Torsades	2038 8 B-Disease
de	2047 2 I-Disease
pointes	2050 7 I-Disease
occurred	2058 8 O
early	2067 5 O
during	2073 6 O
treatment	2080 9 O
even	2090 4 O
with	2095 4 O
low	2100 3 O
doses	2104 5 O
of	2110 2 O
oral	2113 4 O
d	2118 1 B-Chemical
,	2119 1 I-Chemical
l	2120 1 I-Chemical
-	2121 1 I-Chemical
sotalol	2122 7 I-Chemical
.	2129 1 O

Pronounced	2131 10 O
changes	2142 7 O
in	2150 2 O
the	2153 3 O
surface	2157 7 O
ECG	2165 3 O
(	2169 1 O
cycle	2170 5 O
length	2176 6 O
,	2182 1 O
QT	2184 2 O
,	2186 1 O
and	2188 3 O
QTc	2192 3 O
)	2195 1 O
in	2197 2 O
relation	2200 8 O
to	2209 2 O
the	2212 3 O
dose	2216 4 O
of	2221 2 O
oral	2224 4 O
d	2229 1 B-Chemical
,	2230 1 I-Chemical
l	2231 1 I-Chemical
-	2232 1 I-Chemical
sotalol	2233 7 I-Chemical
might	2241 5 O
identify	2247 8 O
a	2256 1 O
subgroup	2258 8 O
of	2267 2 O
patients	2270 8 O
with	2279 4 O
an	2284 2 O
increased	2287 9 O
risk	2297 4 O
for	2302 3 O
torsades	2306 8 B-Disease
de	2315 2 I-Disease
pointes	2318 7 I-Disease
.	2325 1 O

Other	2327 5 O
ECG	2333 3 O
parameters	2337 10 O
before	2348 6 O
the	2355 3 O
application	2359 11 O
of	2371 2 O
d	2374 1 B-Chemical
,	2375 1 I-Chemical
l	2376 1 I-Chemical
-	2377 1 I-Chemical
sotalol	2378 7 I-Chemical
did	2386 3 O
not	2390 3 O
identify	2394 8 O
patients	2403 8 O
at	2412 2 O
increased	2415 9 O
risk	2425 4 O
for	2430 3 O
torsades	2434 8 B-Disease
de	2443 2 I-Disease
pointes	2446 7 I-Disease
.	2453 1 O

Recurrence	2455 10 O
rates	2466 5 O
of	2472 2 O
ventricular	2475 11 B-Disease
tachyarrhythmias	2487 16 I-Disease
are	2504 3 O
high	2508 4 O
despite	2513 7 O
complete	2521 8 O
suppression	2530 11 O
of	2542 2 O
the	2545 3 O
arrhythmia	2549 10 B-Disease
during	2560 6 O
programmed	2567 10 O
stimulation	2578 11 O
.	2589 1 O

Therefore	2591 9 O
programmed	2601 10 O
electrical	2612 10 O
stimulation	2623 11 O
in	2635 2 O
the	2638 3 O
case	2642 4 O
of	2647 2 O
d	2650 1 B-Chemical
,	2651 1 I-Chemical
l	2652 1 I-Chemical
-	2653 1 I-Chemical
sotalol	2654 7 I-Chemical
seems	2662 5 O
to	2668 2 O
be	2671 2 O
of	2674 2 O
limited	2677 7 O
prognostic	2685 10 O
value	2696 5 O
.	2701 1 O

Chronic	0 7 O
hyperprolactinemia	8 18 B-Disease
and	27 3 O
changes	31 7 O
in	39 2 O
dopamine	42 8 B-Chemical
neurons	51 7 O
.	58 1 O

The	60 3 O
tuberoinfundibular	64 18 O
dopaminergic	83 12 O
(	96 1 O
TIDA	97 4 O
)	101 1 O
system	103 6 O
is	110 2 O
known	113 5 O
to	119 2 O
inhibit	122 7 O
prolactin	130 9 O
(	140 1 O
PRL	141 3 O
)	144 1 O
secretion	146 9 O
.	155 1 O

In	157 2 O
young	160 5 O
animals	166 7 O
this	174 4 O
system	179 6 O
responds	186 8 O
to	195 2 O
acute	198 5 O
elevations	204 10 O
in	215 2 O
serum	218 5 O
PRL	224 3 O
by	228 2 O
increasing	231 10 O
its	242 3 O
activity	246 8 O
.	254 1 O

However	256 7 O
,	263 1 O
this	265 4 O
responsiveness	270 14 O
is	285 2 O
lost	288 4 O
in	293 2 O
aging	296 5 O
rats	302 4 O
with	307 4 O
chronically	312 11 O
high	324 4 O
serum	329 5 O
PRL	335 3 O
levels	339 6 O
.	345 1 O

The	347 3 O
purpose	351 7 O
of	359 2 O
this	362 4 O
study	367 5 O
was	373 3 O
to	377 2 O
induce	380 6 O
hyperprolactinemia	387 18 B-Disease
in	406 2 O
rats	409 4 O
for	414 3 O
extended	418 8 O
periods	427 7 O
of	435 2 O
time	438 4 O
and	443 3 O
examine	447 7 O
its	455 3 O
effects	459 7 O
on	467 2 O
dopaminergic	470 12 O
systems	483 7 O
in	491 2 O
the	494 3 O
brain	498 5 O
.	503 1 O

Hyperprolactinemia	505 18 B-Disease
was	524 3 O
induced	528 7 O
by	536 2 O
treatment	539 9 O
with	549 4 O
haloperidol	554 11 B-Chemical
,	565 1 O
a	567 1 O
dopamine	569 8 B-Chemical
receptor	578 8 O
antagonist	587 10 O
,	597 1 O
and	599 3 O
Palkovits	603 9 O
'	612 1 O
microdissection	614 15 O
technique	630 9 O
in	640 2 O
combination	643 11 O
with	655 4 O
high	660 4 O
-	664 1 O
performance	665 11 O
liquid	677 6 O
chromatography	684 14 O
was	699 3 O
used	703 4 O
to	708 2 O
measure	711 7 O
neurotransmitter	719 16 O
concentrations	736 14 O
in	751 2 O
several	754 7 O
areas	762 5 O
of	768 2 O
the	771 3 O
brain	775 5 O
.	780 1 O

After	782 5 O
6	788 1 O
months	790 6 O
of	797 2 O
hyperprolactinemia	800 18 B-Disease
,	818 1 O
dopamine	820 8 B-Chemical
(	829 1 O
DA	830 2 B-Chemical
)	832 1 O
concentrations	834 14 O
in	849 2 O
the	852 3 O
median	856 6 O
eminence	863 8 O
(	872 1 O
ME	873 2 O
)	875 1 O
increased	877 9 O
by	887 2 O
84	890 2 O
%	892 1 O
over	894 4 O
the	899 3 O
control	903 7 O
group	911 5 O
.	916 1 O

Nine	918 4 O
months	923 6 O
of	930 2 O
hyperprolactinemia	933 18 B-Disease
produced	952 8 O
a	961 1 O
50	963 2 O
%	965 1 O
increase	967 8 O
in	976 2 O
DA	979 2 B-Chemical
concentrations	982 14 O
in	997 2 O
the	1000 3 O
ME	1004 2 O
over	1007 4 O
the	1012 3 O
control	1016 7 O
group	1024 5 O
.	1029 1 O

However	1031 7 O
,	1038 1 O
DA	1040 2 B-Chemical
response	1043 8 O
was	1052 3 O
lost	1056 4 O
if	1061 2 O
a	1064 1 O
9	1066 1 O
-	1067 1 O
month	1068 5 O
long	1074 4 O
haloperidol	1079 11 B-Chemical
-	1090 1 O
induced	1091 7 O
hyperprolactinemia	1099 18 B-Disease
was	1118 3 O
followed	1122 8 O
by	1131 2 O
a	1134 1 O
1	1136 1 O
1	1138 1 O
/	1139 1 O
2	1140 1 O
month	1142 5 O
-	1147 1 O
long	1148 4 O
extremely	1153 9 O
high	1163 4 O
increase	1168 8 O
in	1177 2 O
serum	1180 5 O
PRL	1186 3 O
levels	1190 6 O
produced	1197 8 O
by	1206 2 O
implantation	1209 12 O
of	1222 2 O
MMQ	1225 3 O
cells	1229 5 O
under	1235 5 O
the	1241 3 O
kidney	1245 6 O
capsule	1252 7 O
.	1259 1 O

There	1261 5 O
was	1267 3 O
no	1271 2 O
change	1274 6 O
in	1281 2 O
the	1284 3 O
levels	1288 6 O
of	1295 2 O
DA	1298 2 B-Chemical
,	1300 1 O
norepinephrine	1302 14 B-Chemical
(	1317 1 O
NE	1318 2 B-Chemical
)	1320 1 O
,	1321 1 O
serotonin	1323 9 B-Chemical
(	1333 1 O
5	1334 1 B-Chemical
-	1335 1 I-Chemical
HT	1336 2 I-Chemical
)	1338 1 O
,	1339 1 O
or	1341 2 O
their	1344 5 O
metabolites	1350 11 O
in	1362 2 O
the	1365 3 O
arcuate	1369 7 O
nucleus	1377 7 O
(	1385 1 O
AN	1386 2 O
)	1388 1 O
,	1389 1 O
medial	1391 6 O
preoptic	1398 8 O
area	1407 4 O
(	1412 1 O
MPA	1413 3 O
)	1416 1 O
,	1417 1 O
caudate	1419 7 O
putamen	1427 7 O
(	1435 1 O
CP	1436 2 O
)	1438 1 O
,	1439 1 O
substantia	1441 10 O
nigra	1452 5 O
(	1458 1 O
SN	1459 2 O
)	1461 1 O
,	1462 1 O
and	1464 3 O
zona	1468 4 O
incerta	1473 7 O
(	1481 1 O
ZI	1482 2 O
)	1484 1 O
,	1485 1 O
except	1487 6 O
for	1494 3 O
a	1498 1 O
decrease	1500 8 O
in	1509 2 O
5	1512 1 B-Chemical
-	1513 1 I-Chemical
hydroxyindoleacetic	1514 19 I-Chemical
acid	1534 4 I-Chemical
(	1539 1 O
5	1540 1 B-Chemical
-	1541 1 I-Chemical
HIAA	1542 4 I-Chemical
)	1546 1 O
in	1548 2 O
the	1551 3 O
AN	1555 2 O
after	1558 5 O
6	1564 1 O
-	1565 1 O
months	1566 6 O
of	1573 2 O
hyperprolactinemia	1576 18 B-Disease
and	1595 3 O
an	1599 2 O
increase	1602 8 O
in	1611 2 O
DA	1614 2 B-Chemical
concentrations	1617 14 O
in	1632 2 O
the	1635 3 O
AN	1639 2 O
after	1642 5 O
9	1648 1 O
-	1649 1 O
months	1650 6 O
of	1657 2 O
hyperprolactinemia	1660 18 B-Disease
.	1678 1 O

These	1680 5 O
results	1686 7 O
demonstrate	1694 11 O
that	1706 4 O
hyperprolactinemia	1711 18 B-Disease
specifically	1730 12 O
affects	1743 7 O
TIDA	1751 4 O
neurons	1756 7 O
and	1764 3 O
these	1768 5 O
effects	1774 7 O
vary	1782 4 O
,	1786 1 O
depending	1788 9 O
on	1798 2 O
the	1801 3 O
duration	1805 8 O
and	1814 3 O
intensity	1818 9 O
of	1828 2 O
hyperprolactinemia	1831 18 B-Disease
.	1849 1 O

The	1851 3 O
age	1855 3 O
-	1858 1 O
related	1859 7 O
decrease	1867 8 O
in	1876 2 O
hypothalamic	1879 12 O
dopamine	1892 8 B-Chemical
function	1901 8 O
may	1910 3 O
be	1914 2 O
associated	1917 10 O
with	1928 4 O
increases	1933 9 O
in	1943 2 O
PRL	1946 3 O
secretion	1950 9 O
.	1959 1 O

Treatment	0 9 O
-	9 1 O
related	10 7 O
disseminated	18 12 O
necrotizing	31 11 O
leukoencephalopathy	43 19 B-Disease
with	63 4 O
characteristic	68 14 O
contrast	83 8 O
enhancement	92 11 O
of	104 2 O
the	107 3 O
white	111 5 O
matter	117 6 O
.	123 1 O

This	125 4 O
report	130 6 O
describes	137 9 O
unique	147 6 O
contrast	154 8 O
enhancement	163 11 O
of	175 2 O
the	178 3 O
white	182 5 O
matter	188 6 O
on	195 2 O
T1	198 2 O
-	200 1 O
weighted	201 8 O
magnetic	210 8 O
resonance	219 9 O
images	229 6 O
of	236 2 O
two	239 3 O
patients	243 8 O
with	252 4 O
disseminated	257 12 O
necrotizing	270 11 O
leukoencephalopathy	282 19 B-Disease
,	301 1 O
which	303 5 O
developed	309 9 O
from	319 4 O
acute	324 5 B-Disease
lymphoblastic	330 13 I-Disease
leukemia	344 8 I-Disease
treated	353 7 O
with	361 4 O
high	366 4 O
-	370 1 O
dose	371 4 O
methotrexate	376 12 B-Chemical
.	388 1 O

In	390 2 O
both	393 4 O
patients	398 8 O
,	406 1 O
the	408 3 O
enhancement	412 11 O
was	424 3 O
more	428 4 O
pronounced	433 10 O
near	444 4 O
the	449 3 O
base	453 4 O
of	458 2 O
the	461 3 O
brain	465 5 O
than	471 4 O
at	476 2 O
the	479 3 O
vertex	483 6 O
.	489 1 O

Necropsy	491 8 O
of	500 2 O
the	503 3 O
first	507 5 O
case	513 4 O
revealed	518 8 O
loss	527 4 B-Disease
of	532 2 I-Disease
myelination	535 11 I-Disease
and	547 3 O
necrosis	551 8 B-Disease
of	560 2 O
the	563 3 O
white	567 5 O
matter	573 6 O
.	579 1 O

Possible	581 8 O
mechanisms	590 10 O
causing	601 7 O
such	609 4 O
a	614 1 O
leukoencephalopathy	616 19 B-Disease
are	636 3 O
discussed	640 9 O
.	649 1 O

Thrombotic	0 10 B-Disease
complications	11 13 O
in	25 2 O
acute	28 5 B-Disease
promyelocytic	34 13 I-Disease
leukemia	48 8 I-Disease
during	57 6 O
all	64 3 B-Chemical
-	67 1 I-Chemical
trans	68 5 I-Chemical
-	73 1 I-Chemical
retinoic	74 8 I-Chemical
acid	83 4 I-Chemical
therapy	88 7 O
.	95 1 O

A	97 1 O
case	99 4 O
of	104 2 O
acute	107 5 B-Disease
renal	113 5 I-Disease
failure	119 7 I-Disease
,	126 1 O
due	128 3 O
to	132 2 O
occlusion	135 9 B-Disease
of	145 2 I-Disease
renal	148 5 I-Disease
vessels	154 7 I-Disease
in	162 2 O
a	165 1 O
patient	167 7 O
with	175 4 O
acute	180 5 B-Disease
promyelocytic	186 13 I-Disease
leukemia	200 8 I-Disease
(	209 1 O
APL	210 3 B-Disease
)	213 1 O
treated	215 7 O
with	223 4 O
all	228 3 B-Chemical
-	231 1 I-Chemical
trans	232 5 I-Chemical
-	237 1 I-Chemical
retinoic	238 8 I-Chemical
acid	247 4 I-Chemical
(	252 1 O
ATRA	253 4 B-Chemical
)	257 1 O
and	259 3 O
tranexamic	263 10 B-Chemical
acid	274 4 I-Chemical
has	279 3 O
been	283 4 O
described	288 9 O
recently	298 8 O
.	306 1 O

We	308 2 O
report	311 6 O
a	318 1 O
case	320 4 O
of	325 2 O
acute	328 5 B-Disease
renal	334 5 I-Disease
failure	340 7 I-Disease
in	348 2 O
an	351 2 O
APL	354 3 B-Disease
patient	358 7 O
treated	366 7 O
with	374 4 O
ATRA	379 4 B-Chemical
alone	384 5 O
.	389 1 O

This	391 4 O
case	396 4 O
further	401 7 O
supports	409 8 O
the	418 3 O
concern	422 7 O
about	430 5 O
thromboembolic	436 14 B-Disease
complications	451 13 O
associated	465 10 O
with	476 4 O
ATRA	481 4 B-Chemical
therapy	486 7 O
in	494 2 O
APL	497 3 B-Disease
patients	501 8 O
.	509 1 O

The	511 3 O
patients	515 8 O
,	523 1 O
a	525 1 O
43	527 2 O
-	529 1 O
year	530 4 O
-	534 1 O
old	535 3 O
man	539 3 O
,	542 1 O
presented	544 9 O
all	554 3 O
the	558 3 O
signs	562 5 O
and	568 3 O
symptoms	572 8 O
of	581 2 O
APL	584 3 B-Disease
and	588 3 O
was	592 3 O
included	596 8 O
in	605 2 O
a	608 1 O
treatment	610 9 O
protocol	620 8 O
with	629 4 O
ATRA	634 4 B-Chemical
.	638 1 O

After	640 5 O
10	646 2 O
days	649 4 O
of	654 2 O
treatment	657 9 O
,	666 1 O
he	668 2 O
developed	671 9 O
acute	681 5 B-Disease
renal	687 5 I-Disease
failure	693 7 I-Disease
that	701 4 O
was	706 3 O
completely	710 10 O
reversible	721 10 O
after	732 5 O
complete	738 8 O
remission	747 9 O
of	757 2 O
APL	760 3 B-Disease
was	764 3 O
achieved	768 8 O
and	777 3 O
therapy	781 7 O
discontinued	789 12 O
.	801 1 O

We	803 2 O
conclude	806 8 O
that	815 4 O
ATRA	820 4 B-Chemical
is	825 2 O
a	828 1 O
valid	830 5 O
therapeutic	836 11 O
choice	848 6 O
for	855 3 O
patients	859 8 O
with	868 4 O
APL	873 3 B-Disease
,	876 1 O
although	878 8 O
the	887 3 O
procoagulant	891 12 O
tendency	904 8 O
is	913 2 O
not	916 3 O
completely	920 10 O
corrected	931 9 O
.	940 1 O

Thrombotic	942 10 B-Disease
events	953 6 O
,	959 1 O
however	961 7 O
,	968 1 O
could	970 5 O
be	976 2 O
avoided	979 7 O
by	987 2 O
using	990 5 O
low	996 3 O
-	999 1 O
dose	1000 4 O
heparin	1005 7 B-Chemical
.	1012 1 O

Pupillary	0 9 O
changes	10 7 O
associated	18 10 O
with	29 4 O
the	34 3 O
development	38 11 O
of	50 2 O
stimulant	53 9 O
-	62 1 O
induced	63 7 O
mania	71 5 B-Disease
:	76 1 O
a	78 1 O
case	80 4 O
report	85 6 O
.	91 1 O

A	93 1 O
30	95 2 O
-	97 1 O
year	98 4 O
-	102 1 O
old	103 3 O
cocaine	107 7 B-Chemical
-	114 1 O
dependent	115 9 O
man	125 3 O
who	129 3 O
was	133 3 O
a	137 1 O
subject	139 7 O
in	147 2 O
a	150 1 O
study	152 5 O
evaluating	158 10 O
the	169 3 O
anticraving	173 11 O
efficacy	185 8 O
of	194 2 O
the	197 3 O
stimulant	201 9 O
medication	211 10 O
diethylpropion	222 14 B-Chemical
(	237 1 O
DEP	238 3 B-Chemical
)	241 1 O
became	243 6 O
manic	250 5 B-Disease
during	256 6 O
his	263 3 O
second	267 6 O
week	274 4 O
on	279 2 O
the	282 3 O
study	286 5 O
drug	292 4 O
.	296 1 O

Pupillometric	298 13 O
changes	312 7 O
while	320 5 O
on	326 2 O
DEP	329 3 B-Chemical
,	332 1 O
especially	334 10 O
changes	345 7 O
in	353 2 O
the	356 3 O
total	360 5 O
power	366 5 O
of	372 2 O
pupillary	375 9 B-Disease
oscillation	385 11 I-Disease
,	396 1 O
were	398 4 O
dramatically	403 12 O
different	416 9 O
than	426 4 O
those	431 5 O
observed	437 8 O
in	446 2 O
the	449 3 O
eight	453 5 O
other	459 5 O
study	465 5 O
subjects	471 8 O
who	480 3 O
did	484 3 O
not	488 3 O
become	492 6 O
manic	499 5 B-Disease
.	504 1 O

The	506 3 O
large	510 5 O
changes	516 7 O
in	524 2 O
total	527 5 O
power	533 5 O
of	539 2 O
pupillary	542 9 B-Disease
oscillation	552 11 I-Disease
occurred	564 8 O
a	573 1 O
few	575 3 O
days	579 4 O
before	584 6 O
the	591 3 O
patient	595 7 O
became	603 6 O
fully	610 5 O
manic	616 5 B-Disease
.	621 1 O

Such	623 4 O
medication	628 10 O
-	638 1 O
associated	639 10 O
changes	650 7 O
in	658 2 O
the	661 3 O
total	665 5 O
power	671 5 O
of	677 2 O
pupillary	680 9 B-Disease
oscillation	690 11 I-Disease
might	702 5 O
be	708 2 O
of	711 2 O
utility	714 7 O
in	722 2 O
identifying	725 11 O
persons	737 7 O
at	745 2 O
risk	748 4 O
for	753 3 O
manic	757 5 B-Disease
-	762 1 O
like	763 4 O
adverse	768 7 O
effects	776 7 O
during	784 6 O
the	791 3 O
medical	795 7 O
use	803 3 O
of	807 2 O
psychomotor	810 11 O
stimulants	822 10 O
or	833 2 O
sympathomimetic	836 15 O
agents	852 6 O
.	858 1 O

The	0 3 O
negative	4 8 O
mucosal	13 7 O
potential	21 9 O
:	30 1 O
separating	32 10 O
central	43 7 O
and	51 3 O
peripheral	55 10 O
effects	66 7 O
of	74 2 O
NSAIDs	77 6 O
in	84 2 O
man	87 3 O
.	90 1 O

OBJECTIVE	92 9 O
:	101 1 O
We	103 2 O
wanted	106 6 O
to	113 2 O
test	116 4 O
whether	121 7 O
assessment	129 10 O
of	140 2 O
both	143 4 O
a	148 1 O
central	150 7 O
pain	158 4 B-Disease
-	162 1 O
related	163 7 O
signal	171 6 O
(	178 1 O
chemo	179 5 O
-	184 1 O
somatosensory	185 13 O
evoked	199 6 O
potential	206 9 O
,	215 1 O
CSSEP	217 5 O
)	222 1 O
and	224 3 O
a	228 1 O
concomitantly	230 13 O
recorded	244 8 O
peripheral	253 10 O
signal	264 6 O
(	271 1 O
negative	272 8 O
mucosal	281 7 O
potential	289 9 O
,	298 1 O
NMP	300 3 O
)	303 1 O
allows	305 6 O
for	312 3 O
separation	316 10 O
of	327 2 O
central	330 7 O
and	338 3 O
peripheral	342 10 O
effects	353 7 O
of	361 2 O
NSAIDs	364 6 O
.	370 1 O

For	372 3 O
this	376 4 O
purpose	381 7 O
,	388 1 O
experimental	390 12 O
conditions	403 10 O
were	414 4 O
created	419 7 O
in	427 2 O
which	430 5 O
NSAIDs	436 6 O
had	443 3 O
previously	447 10 O
been	458 4 O
observed	463 8 O
to	472 2 O
produce	475 7 O
effects	483 7 O
on	491 2 O
phasic	494 6 O
and	501 3 O
tonic	505 5 O
pain	511 4 B-Disease
by	516 2 O
either	519 6 O
central	526 7 O
or	534 2 O
peripheral	537 10 O
mechanisms	548 10 O
.	558 1 O

METHODS	560 7 O
:	567 1 O
According	569 9 O
to	579 2 O
a	582 1 O
double	584 6 O
-	590 1 O
blind	591 5 O
,	596 1 O
randomised	598 10 O
,	608 1 O
controlled	610 10 O
,	620 1 O
threefold	622 9 O
cross	632 5 O
-	637 1 O
over	638 4 O
design	643 6 O
,	649 1 O
18	651 2 O
healthy	654 7 O
subjects	662 8 O
(	671 1 O
11	672 2 O
males	675 5 O
,	680 1 O
7	682 1 O
females	684 7 O
;	691 1 O
mean	693 4 O
age	698 3 O
26	702 2 O
years	705 5 O
)	710 1 O
received	712 8 O
either	721 6 O
placebo	728 7 O
,	735 1 O
400	737 3 O
mg	741 2 O
ibuprofen	744 9 B-Chemical
,	753 1 O
or	755 2 O
800	758 3 O
mg	762 2 O
ibuprofen	765 9 B-Chemical
.	774 1 O

Phasic	776 6 O
pain	783 4 B-Disease
was	788 3 O
applied	792 7 O
by	800 2 O
means	803 5 O
of	809 2 O
short	812 5 O
pulses	818 6 O
of	825 2 O
CO2	828 3 B-Chemical
to	832 2 O
the	835 3 O
nasal	839 5 O
mucosa	845 6 O
(	852 1 O
stimulus	853 8 O
duration	862 8 O
500	871 3 O
ms	875 2 O
,	877 1 O
interval	879 8 O
approximately	888 13 O
60	902 2 O
s	905 1 O
)	906 1 O
,	907 1 O
and	909 3 O
tonic	913 5 O
pain	919 4 B-Disease
was	924 3 O
induced	928 7 O
in	936 2 O
the	939 3 O
nasal	943 5 O
cavity	949 6 O
by	956 2 O
means	959 5 O
of	965 2 O
dry	968 3 O
air	972 3 O
of	976 2 O
controlled	979 10 O
temperature	990 11 O
,	1001 1 O
humidity	1003 8 O
and	1012 3 O
flow	1016 4 O
rate	1021 4 O
(	1026 1 O
22	1027 2 O
degrees	1030 7 O
C	1038 1 O
,	1039 1 O
0	1041 1 O
%	1042 1 O
relative	1044 8 O
humidity	1053 8 O
,	1061 1 O
145	1063 3 O
ml	1067 2 O
.	1069 1 O
s	1070 1 O
-	1071 1 O
1	1072 1 O
)	1073 1 O
.	1074 1 O

Both	1076 4 O
CSSEPs	1081 6 O
as	1088 2 O
central	1091 7 O
and	1099 3 O
NMPs	1103 4 O
as	1108 2 O
peripheral	1111 10 O
correlates	1122 10 O
of	1133 2 O
pain	1136 4 B-Disease
were	1141 4 O
obtained	1146 8 O
in	1155 2 O
response	1158 8 O
to	1167 2 O
the	1170 3 O
CO2	1174 3 B-Chemical
stimuli	1178 7 O
.	1185 1 O

Additionally	1187 12 O
,	1199 1 O
the	1201 3 O
subjects	1205 8 O
rated	1214 5 O
the	1220 3 O
intensity	1224 9 O
of	1234 2 O
both	1237 4 O
phasic	1242 6 O
and	1249 3 O
tonic	1253 5 O
pain	1259 4 B-Disease
by	1264 2 O
means	1267 5 O
of	1273 2 O
visual	1276 6 O
analogue	1283 8 O
scales	1292 6 O
.	1298 1 O

RESULTS	1300 7 O
:	1307 1 O
As	1309 2 O
described	1312 9 O
earlier	1322 7 O
,	1329 1 O
administration	1331 14 O
of	1346 2 O
ibuprofen	1349 9 B-Chemical
was	1359 3 O
followed	1363 8 O
by	1372 2 O
a	1375 1 O
decrease	1377 8 O
in	1386 2 O
tonic	1389 5 O
pain	1395 4 B-Disease
but	1400 3 O
-	1403 1 O
relative	1404 8 O
to	1413 2 O
placebo	1416 7 O
-	1423 1 O
an	1424 2 O
increase	1427 8 O
in	1436 2 O
correlates	1439 10 O
of	1450 2 O
phasic	1453 6 O
pain	1460 4 B-Disease
,	1464 1 O
indicating	1466 10 O
a	1477 1 O
specific	1479 8 O
effect	1488 6 O
of	1495 2 O
ibuprofen	1498 9 B-Chemical
on	1508 2 O
the	1511 3 O
interaction	1515 11 O
between	1527 7 O
the	1535 3 O
pain	1539 4 B-Disease
stimuli	1544 7 O
under	1552 5 O
these	1558 5 O
special	1564 7 O
experimental	1572 12 O
conditions	1585 10 O
.	1595 1 O

Based	1597 5 O
on	1603 2 O
the	1606 3 O
similar	1610 7 O
behaviour	1618 9 O
of	1628 2 O
CSSEP	1631 5 O
and	1637 3 O
NMP	1641 3 O
,	1644 1 O
it	1646 2 O
was	1649 3 O
concluded	1653 9 O
that	1663 4 O
the	1668 3 O
pharmacological	1672 15 O
process	1688 7 O
underlying	1696 10 O
this	1707 4 O
phenomenon	1712 10 O
was	1723 3 O
localised	1727 9 O
in	1737 2 O
the	1740 3 O
periphery	1744 9 O
.	1753 1 O

By	1755 2 O
means	1758 5 O
of	1764 2 O
the	1767 3 O
simultaneous	1771 12 O
recording	1784 9 O
of	1794 2 O
interrelated	1797 12 O
peripheral	1810 10 O
and	1821 3 O
central	1825 7 O
electrophysiologic	1833 18 O
correlates	1852 10 O
of	1863 2 O
nociception	1866 11 O
,	1877 1 O
it	1879 2 O
was	1882 3 O
possible	1886 8 O
to	1895 2 O
separate	1898 8 O
central	1907 7 O
and	1915 3 O
peripheral	1919 10 O
effects	1930 7 O
of	1938 2 O
an	1941 2 O
NSAID	1944 5 O
.	1949 1 O

The	1951 3 O
major	1955 5 O
advantage	1961 9 O
of	1971 2 O
this	1974 4 O
pain	1979 4 B-Disease
model	1984 5 O
is	1990 2 O
the	1993 3 O
possibility	1997 11 O
of	2009 2 O
obtaining	2012 9 O
peripheral	2022 10 O
pain	2033 4 B-Disease
-	2037 1 O
related	2038 7 O
activity	2046 8 O
directly	2055 8 O
using	2064 5 O
a	2070 1 O
non	2072 3 O
-	2075 1 O
invasive	2076 8 O
technique	2085 9 O
in	2095 2 O
humans	2098 6 O
.	2104 1 O

Acute	0 5 O
severe	6 6 O
depression	13 10 B-Disease
following	24 9 O
peri	34 4 O
-	38 1 O
operative	39 9 O
ondansetron	49 11 B-Chemical
.	60 1 O

A	62 1 O
41	64 2 O
-	66 1 O
year	67 4 O
-	71 1 O
old	72 3 O
woman	76 5 O
with	82 4 O
a	87 1 O
strong	89 6 O
history	96 7 O
of	104 2 O
postoperative	107 13 B-Disease
nausea	121 6 I-Disease
and	128 3 I-Disease
vomiting	132 8 I-Disease
presented	141 9 O
for	151 3 O
abdominal	155 9 O
hysterectomy	165 12 O
3	178 1 O
months	180 6 O
after	187 5 O
a	193 1 O
previous	195 8 O
anaesthetic	204 11 O
where	216 5 O
ondansetron	222 11 B-Chemical
prophylaxis	234 11 O
had	246 3 O
been	250 4 O
used	255 4 O
.	259 1 O

She	261 3 O
had	265 3 O
developed	269 9 O
a	279 1 O
severe	281 6 O
acute	288 5 O
major	294 5 B-Disease
depression	300 10 I-Disease
disorder	311 8 I-Disease
almost	320 6 O
immediately	327 11 O
thereafter	339 10 O
,	349 1 O
possibly	351 8 O
related	360 7 O
to	368 2 O
the	371 3 O
use	375 3 O
of	379 2 O
a	382 1 O
serotonin	384 9 B-Chemical
antagonist	394 10 O
.	404 1 O

Nine	406 4 O
years	411 5 O
before	417 6 O
she	424 3 O
had	428 3 O
experienced	432 11 O
a	444 1 O
self	446 4 O
-	450 1 O
limited	451 7 O
puerperal	459 9 O
depressive	469 10 B-Disease
episode	480 7 I-Disease
.	487 1 O

Anaesthesia	489 11 O
with	501 4 O
a	506 1 O
propofol	508 8 B-Chemical
infusion	517 8 O
and	526 3 O
avoidance	530 9 O
of	540 2 O
serotonin	543 9 B-Chemical
antagonists	553 11 O
provided	565 8 O
a	574 1 O
nausea	576 6 B-Disease
-	582 1 O
free	583 4 O
postoperative	588 13 O
course	602 6 O
without	609 7 O
exacerbation	617 12 O
of	630 2 O
the	633 3 O
depression	637 10 B-Disease
disorder	648 8 I-Disease
.	656 1 O

Hypertensive	0 12 B-Disease
response	13 8 O
during	22 6 O
dobutamine	29 10 B-Chemical
stress	40 6 O
echocardiography	47 16 O
.	63 1 O

Among	65 5 O
3	71 1 O
,	72 1 O
129	73 3 O
dobutamine	77 10 B-Chemical
stress	88 6 O
echocardiographic	95 17 O
studies	113 7 O
,	120 1 O
a	122 1 O
hypertensive	124 12 B-Disease
response	137 8 O
,	145 1 O
defined	147 7 O
as	155 2 O
systolic	158 8 O
blood	167 5 O
pressure	173 8 O
(	182 1 O
BP	183 2 O
)	185 1 O
>	187 1 O
or	189 2 O
=	192 1 O
220	194 3 O
mm	198 2 O
Hg	201 2 O
and	204 3 O
/	207 1 O
or	208 2 O
diastolic	211 9 O
BP	221 2 O
>	224 1 O
or	226 2 O
=	229 1 O
110	231 3 O
mm	235 2 O
Hg	238 2 O
,	240 1 O
occurred	242 8 O
in	251 2 O
30	254 2 O
patients	257 8 O
(	266 1 O
1	267 1 O
%	268 1 O
)	269 1 O
.	270 1 O

Patients	272 8 O
with	281 4 O
this	286 4 O
response	291 8 O
more	300 4 O
often	305 5 O
had	311 3 O
a	315 1 O
history	317 7 O
of	325 2 O
hypertension	328 12 B-Disease
and	341 3 O
had	345 3 O
higher	349 6 O
resting	356 7 O
systolic	364 8 O
and	373 3 O
diastolic	377 9 O
BP	387 2 O
before	390 6 O
dobutamine	397 10 B-Chemical
infusion	408 8 O
.	416 1 O

Continuously	0 12 O
nebulized	13 9 O
albuterol	23 9 B-Chemical
in	33 2 O
severe	36 6 O
exacerbations	43 13 O
of	57 2 O
asthma	60 6 B-Disease
in	67 2 O
adults	70 6 O
:	76 1 O
a	78 1 O
case	80 4 O
-	84 1 O
controlled	85 10 O
study	96 5 O
.	101 1 O

A	103 1 O
retrospective	105 13 O
,	118 1 O
case	120 4 O
-	124 1 O
controlled	125 10 O
analysis	136 8 O
comparing	145 9 O
patients	155 8 O
admitted	164 8 O
to	173 2 O
a	176 1 O
medical	178 7 O
intensive	186 9 O
care	196 4 O
unit	201 4 O
with	206 4 O
severe	211 6 O
exacerbations	218 13 O
of	232 2 O
asthma	235 6 B-Disease
who	242 3 O
received	246 8 O
continuously	255 12 O
nebulized	268 9 O
albuterol	278 9 B-Chemical
(	288 1 O
CNA	289 3 O
)	292 1 O
versus	294 6 O
intermittent	301 12 O
albuterol	314 9 B-Chemical
(	324 1 O
INA	325 3 O
)	328 1 O
treatments	330 10 O
is	341 2 O
reported	344 8 O
.	352 1 O

Forty	354 5 O
matched	360 7 O
pairs	368 5 O
of	374 2 O
patients	377 8 O
with	386 4 O
asthma	391 6 B-Disease
are	398 3 O
compared	402 8 O
.	410 1 O

CNA	412 3 O
was	416 3 O
administered	420 12 O
for	433 3 O
a	437 1 O
mean	439 4 O
of	444 2 O
11	447 2 O
+	450 1 O
/	451 1 O
-	452 1 O
10	454 2 O
hr	457 2 O
.	459 1 O

The	461 3 O
incidence	465 9 O
of	475 2 O
cardiac	478 7 B-Disease
dysrhythmias	486 12 I-Disease
was	499 3 O
similar	503 7 O
between	511 7 O
groups	519 6 O
.	525 1 O

Symptomatic	527 11 O
hypokalemia	539 11 B-Disease
did	551 3 O
not	555 3 O
occur	559 5 O
.	564 1 O

CNA	566 3 O
patients	570 8 O
had	579 3 O
higher	583 6 O
heart	590 5 O
rates	596 5 O
during	602 6 O
treatment	609 9 O
,	618 1 O
which	620 5 O
may	626 3 O
reflect	630 7 O
severity	638 8 O
of	647 2 O
illness	650 7 O
.	657 1 O

The	659 3 O
incidence	663 9 O
of	673 2 O
intubation	676 10 O
was	687 3 O
similar	691 7 O
.	698 1 O

We	700 2 O
conclude	703 8 O
that	712 4 O
CNA	717 3 O
and	721 3 O
INA	725 3 O
demonstrated	729 12 O
similar	742 7 O
profiles	750 8 O
with	759 4 O
regard	764 6 O
to	771 2 O
safety	774 6 O
,	780 1 O
morbidity	782 9 O
,	791 1 O
and	793 3 O
mortality	797 9 O
.	806 1 O

Hyperosmolar	0 12 B-Disease
nonketotic	13 10 I-Disease
coma	24 4 I-Disease
precipitated	29 12 O
by	42 2 O
lithium	45 7 B-Chemical
-	52 1 O
induced	53 7 O
nephrogenic	61 11 B-Disease
diabetes	73 8 I-Disease
insipidus	82 9 I-Disease
.	91 1 O

A	93 1 O
45	95 2 O
-	97 1 O
year	98 4 O
-	102 1 O
old	103 3 O
man	107 3 O
,	110 1 O
with	112 4 O
a	117 1 O
10	119 2 O
-	121 1 O
year	122 4 O
history	127 7 O
of	135 2 O
manic	138 5 B-Disease
depression	144 10 I-Disease
treated	155 7 O
with	163 4 O
lithium	168 7 B-Chemical
,	175 1 O
was	177 3 O
admitted	181 8 O
with	190 4 O
hyperosmolar	195 12 B-Disease
,	207 1 I-Disease
nonketotic	209 10 I-Disease
coma	220 4 I-Disease
.	224 1 O

He	226 2 O
gave	229 4 O
a	234 1 O
five	236 4 O
-	240 1 O
year	241 4 O
history	246 7 O
of	254 2 O
polyuria	257 8 B-Disease
and	266 3 O
polydipsia	270 10 B-Disease
,	280 1 O
during	282 6 O
which	289 5 O
time	295 4 O
urinalysis	300 10 O
had	311 3 O
been	315 4 O
negative	320 8 O
for	329 3 O
glucose	333 7 B-Chemical
.	340 1 O

After	342 5 O
recovery	348 8 O
from	357 4 O
hyperglycaemia	362 14 B-Disease
,	376 1 O
he	378 2 O
remained	381 8 O
polyuric	390 8 B-Disease
despite	399 7 O
normal	407 6 O
blood	414 5 O
glucose	420 7 B-Chemical
concentrations	428 14 O
;	442 1 O
water	444 5 O
deprivation	450 11 O
testing	462 7 O
indicated	470 9 O
nephrogenic	480 11 B-Disease
diabetes	492 8 I-Disease
insipidus	501 9 I-Disease
,	510 1 O
likely	512 6 O
to	519 2 O
be	522 2 O
lithium	525 7 B-Chemical
-	532 1 O
induced	533 7 O
.	540 1 O

We	542 2 O
hypothesize	545 11 O
that	557 4 O
when	562 4 O
this	567 4 O
man	572 3 O
developed	576 9 O
type	586 4 B-Disease
2	591 1 I-Disease
diabetes	593 8 I-Disease
,	601 1 O
chronic	603 7 O
polyuria	611 8 B-Disease
due	620 3 O
to	624 2 O
nephrogenic	627 11 B-Disease
diabetes	639 8 I-Disease
insipidus	648 9 I-Disease
was	658 3 O
sufficient	662 10 O
to	673 2 O
precipitate	676 11 O
hyperosmolar	688 12 O
dehydration	701 11 B-Disease
.	712 1 O

Effects	0 7 O
of	8 2 O
the	11 3 O
intracoronary	15 13 O
infusion	29 8 O
of	38 2 O
cocaine	41 7 B-Chemical
on	49 2 O
left	52 4 O
ventricular	57 11 O
systolic	69 8 O
and	78 3 O
diastolic	82 9 O
function	92 8 O
in	101 2 O
humans	104 6 O
.	110 1 O

BACKGROUND	112 10 O
:	122 1 O
In	124 2 O
dogs	127 4 O
,	131 1 O
a	133 1 O
large	135 5 O
amount	141 6 O
of	148 2 O
intravenous	151 11 O
cocaine	163 7 B-Chemical
causes	171 6 O
a	178 1 O
profound	180 8 O
deterioration	189 13 B-Disease
of	203 2 I-Disease
left	206 4 I-Disease
ventricular	211 11 I-Disease
(	223 1 I-Disease
LV	224 2 I-Disease
)	226 1 I-Disease
systolic	228 8 I-Disease
function	237 8 I-Disease
and	246 3 O
an	250 2 O
increase	253 8 O
in	262 2 O
LV	265 2 O
end	268 3 O
-	271 1 O
diastolic	272 9 O
pressure	282 8 O
.	290 1 O

This	292 4 O
study	297 5 O
was	303 3 O
done	307 4 O
to	312 2 O
assess	315 6 O
the	322 3 O
influence	326 9 O
of	336 2 O
a	339 1 O
high	341 4 O
intracoronary	346 13 O
cocaine	360 7 B-Chemical
concentration	368 13 O
on	382 2 O
LV	385 2 O
systolic	388 8 O
and	397 3 O
diastolic	401 9 O
function	411 8 O
in	420 2 O
humans	423 6 O
.	429 1 O

METHODS	431 7 O
AND	439 3 O
RESULTS	443 7 O
:	450 1 O
In	452 2 O
20	455 2 O
patients	458 8 O
(	467 1 O
14	468 2 O
men	471 3 O
and	475 3 O
6	479 1 O
women	481 5 O
aged	487 4 O
39	492 2 O
to	495 2 O
72	498 2 O
years	501 5 O
)	506 1 O
referred	508 8 O
for	517 3 O
cardiac	521 7 O
catheterization	529 15 O
for	545 3 O
the	549 3 O
evaluation	553 10 O
of	564 2 O
chest	567 5 B-Disease
pain	573 4 I-Disease
,	577 1 O
we	579 2 O
measured	582 8 O
heart	591 5 O
rate	597 4 O
,	601 1 O
systemic	603 8 O
arterial	612 8 O
pressure	621 8 O
,	629 1 O
LV	631 2 O
pressure	634 8 O
and	643 3 O
its	647 3 O
first	651 5 O
derivative	657 10 O
(	668 1 O
dP	669 2 O
/	671 1 O
dt	672 2 O
)	674 1 O
,	675 1 O
and	677 3 O
LV	681 2 O
volumes	684 7 O
and	692 3 O
ejection	696 8 O
fraction	705 8 O
before	714 6 O
and	721 3 O
during	725 6 O
the	732 3 O
final	736 5 O
2	742 1 O
to	744 2 O
3	747 1 O
minutes	749 7 O
of	757 2 O
a	760 1 O
15	762 2 O
-	764 1 O
minute	765 6 O
intracoronary	772 13 O
infusion	786 8 O
of	795 2 O
saline	798 6 O
(	805 1 O
n	806 1 O
=	807 1 O
10	808 2 O
,	810 1 O
control	812 7 O
subjects	820 8 O
)	828 1 O
or	830 2 O
cocaine	833 7 B-Chemical
hydrochloride	841 13 I-Chemical
1	855 1 O
mg	857 2 O
/	859 1 O
min	860 3 O
(	864 1 O
n	865 1 O
=	866 1 O
10	867 2 O
)	869 1 O
.	870 1 O

No	872 2 O
variable	875 8 O
changed	884 7 O
with	892 4 O
saline	897 6 O
.	903 1 O

With	905 4 O
cocaine	910 7 B-Chemical
,	917 1 O
the	919 3 O
drug	923 4 O
concentration	928 13 O
in	942 2 O
blood	945 5 O
obtained	951 8 O
from	960 4 O
the	965 3 O
coronary	969 8 O
sinus	978 5 O
was	984 3 O
3	988 1 O
.	989 1 O
0	990 1 O
+	991 1 O
/	992 1 O
-	993 1 O
0	994 1 O
.	995 1 O
4	996 1 O
(	998 1 O
mean	999 4 O
+	1003 1 O
/	1004 1 O
-	1005 1 O
SD	1006 2 O
)	1008 1 O
mg	1010 2 O
/	1012 1 O
L	1013 1 O
,	1014 1 O
similar	1016 7 O
in	1024 2 O
magnitude	1027 9 O
to	1037 2 O
the	1040 3 O
blood	1044 5 O
cocaine	1050 7 B-Chemical
concentration	1058 13 O
reported	1072 8 O
in	1081 2 O
abusers	1084 7 O
dying	1092 5 O
of	1098 2 O
cocaine	1101 7 B-Chemical
intoxication	1109 12 O
.	1121 1 O

Cocaine	1123 7 B-Chemical
induced	1131 7 O
no	1139 2 O
significant	1142 11 O
change	1154 6 O
in	1161 2 O
heart	1164 5 O
rate	1170 4 O
,	1174 1 O
LV	1176 2 O
dP	1179 2 O
/	1181 1 O
dt	1182 2 O
(	1185 1 O
positive	1186 8 O
or	1195 2 O
negative	1198 8 O
)	1206 1 O
,	1207 1 O
or	1209 2 O
LV	1212 2 O
end	1215 3 O
-	1218 1 O
diastolic	1219 9 O
volume	1229 6 O
,	1235 1 O
but	1237 3 O
it	1241 2 O
caused	1244 6 O
an	1251 2 O
increase	1254 8 O
in	1263 2 O
systolic	1266 8 O
and	1275 3 O
mean	1279 4 O
arterial	1284 8 O
pressures	1293 9 O
,	1302 1 O
LV	1304 2 O
end	1307 3 O
-	1310 1 O
diastolic	1311 9 O
pressure	1321 8 O
,	1329 1 O
and	1331 3 O
LV	1335 2 O
end	1338 3 O
-	1341 1 O
systolic	1342 8 O
volume	1351 6 O
,	1357 1 O
as	1359 2 O
well	1362 4 O
as	1367 2 O
a	1370 1 O
decrease	1372 8 O
in	1381 2 O
LV	1384 2 O
ejection	1387 8 O
fraction	1396 8 O
.	1404 1 O

CONCLUSIONS	1406 11 O
:	1417 1 O
In	1419 2 O
humans	1422 6 O
,	1428 1 O
the	1430 3 O
intracoronary	1434 13 O
infusion	1448 8 O
of	1457 2 O
cocaine	1460 7 B-Chemical
sufficient	1468 10 O
in	1479 2 O
amount	1482 6 O
to	1489 2 O
achieve	1492 7 O
a	1500 1 O
high	1502 4 O
drug	1507 4 O
concentration	1512 13 O
in	1526 2 O
coronary	1529 8 O
sinus	1538 5 O
blood	1544 5 O
causes	1550 6 O
a	1557 1 O
deterioration	1559 13 B-Disease
of	1573 2 I-Disease
LV	1576 2 I-Disease
systolic	1579 8 I-Disease
and	1588 3 I-Disease
diastolic	1592 9 I-Disease
performance	1602 11 I-Disease
.	1613 1 O

Heparin	0 7 B-Chemical
-	7 1 O
induced	8 7 O
thrombocytopenia	16 16 B-Disease
,	32 1 O
paradoxical	34 11 O
thromboembolism	46 15 B-Disease
,	61 1 O
and	63 3 O
other	67 5 O
side	73 4 O
effects	78 7 O
of	86 2 O
heparin	89 7 B-Chemical
therapy	97 7 O
.	104 1 O

Although	106 8 O
several	115 7 O
new	123 3 O
anticoagulant	127 13 O
drugs	141 5 O
are	147 3 O
in	151 2 O
development	154 11 O
,	165 1 O
heparin	167 7 B-Chemical
remains	175 7 O
the	183 3 O
drug	187 4 O
of	192 2 O
choice	195 6 O
for	202 3 O
most	206 4 O
anticoagulation	211 15 O
needs	227 5 O
.	232 1 O

The	234 3 O
clinical	238 8 O
effects	247 7 O
of	255 2 O
heparin	258 7 B-Chemical
are	266 3 O
meritorious	270 11 O
,	281 1 O
but	283 3 O
side	287 4 O
effects	292 7 O
do	300 2 O
exist	303 5 O
.	308 1 O

Important	310 9 O
untoward	320 8 O
effects	329 7 O
of	337 2 O
heparin	340 7 B-Chemical
therapy	348 7 O
including	356 9 O
heparin	366 7 B-Chemical
-	373 1 O
induced	374 7 O
thrombocytopenia	382 16 B-Disease
,	398 1 O
heparin	400 7 B-Chemical
-	407 1 O
associated	408 10 O
osteoporosis	419 12 B-Disease
,	431 1 O
eosinophilia	433 12 B-Disease
,	445 1 O
skin	447 4 B-Disease
reactions	452 9 I-Disease
,	461 1 O
allergic	463 8 B-Disease
reactions	472 9 I-Disease
other	482 5 O
than	488 4 O
thrombocytopenia	493 16 B-Disease
and	510 3 O
alopecia	514 8 B-Disease
will	523 4 O
be	528 2 O
discussed	531 9 O
in	541 2 O
this	544 4 O
article	549 7 O
.	556 1 O

Nonopaque	0 9 O
crystal	10 7 O
deposition	18 10 O
causing	29 7 O
ureteric	37 8 B-Disease
obstruction	46 11 I-Disease
in	58 2 O
patients	61 8 O
with	70 4 O
HIV	75 3 O
undergoing	79 10 O
indinavir	90 9 B-Chemical
therapy	100 7 O
.	107 1 O

OBJECTIVE	109 9 O
:	118 1 O
We	120 2 O
describe	123 8 O
the	132 3 O
unique	136 6 O
CT	143 2 O
features	146 8 O
of	155 2 O
ureteric	158 8 B-Disease
calculi	167 7 I-Disease
in	175 2 O
six	178 3 O
HIV	182 3 B-Disease
-	185 1 I-Disease
infected	186 8 I-Disease
patients	195 8 O
receiving	204 9 O
indinavir	214 9 B-Chemical
,	223 1 O
the	225 3 O
most	229 4 O
commonly	234 8 O
used	243 4 O
HIV	248 3 O
protease	252 8 O
inhibitor	261 9 O
,	270 1 O
which	272 5 O
is	278 2 O
associated	281 10 O
with	292 4 O
an	297 2 O
increased	300 9 O
incidence	310 9 O
of	320 2 O
urolithiasis	323 12 B-Disease
.	335 1 O

CONCLUSION	337 10 O
:	347 1 O
Ureteric	349 8 B-Disease
obstruction	358 11 I-Disease
caused	370 6 O
by	377 2 O
precipitated	380 12 O
indinavir	393 9 B-Chemical
crystals	403 8 O
may	412 3 O
be	416 2 O
difficult	419 9 O
to	429 2 O
diagnose	432 8 O
with	441 4 O
unenhanced	446 10 O
CT	457 2 O
.	459 1 O

The	461 3 O
calculi	465 7 O
are	473 3 O
not	477 3 O
opaque	481 6 O
,	487 1 O
and	489 3 O
secondary	493 9 O
signs	503 5 O
of	509 2 O
obstruction	512 11 O
may	524 3 O
be	528 2 O
absent	531 6 O
or	538 2 O
minimal	541 7 O
and	549 3 O
should	553 6 O
be	560 2 O
sought	563 6 O
carefully	570 9 O
.	579 1 O

Images	581 6 O
may	588 3 O
need	592 4 O
to	597 2 O
be	600 2 O
obtained	603 8 O
using	612 5 O
i	618 1 O
.	619 1 O
v	620 1 O
.	621 1 O
contrast	623 8 O
material	632 8 O
to	641 2 O
enable	644 6 O
diagnosis	651 9 O
of	661 2 O
ureteric	664 8 B-Disease
stones	673 6 I-Disease
or	680 2 I-Disease
obstruction	683 11 I-Disease
in	695 2 O
patients	698 8 O
with	707 4 O
HIV	712 3 B-Disease
infection	716 9 I-Disease
who	726 3 O
receive	730 7 O
indinavir	738 9 B-Chemical
therapy	748 7 O
.	755 1 O

Ischemic	0 8 B-Disease
colitis	9 7 I-Disease
and	17 3 O
sumatriptan	21 11 B-Chemical
use	33 3 O
.	36 1 O

Sumatriptan	38 11 B-Chemical
succinate	50 9 I-Chemical
,	59 1 O
a	61 1 O
serotonin	63 9 B-Chemical
-	72 1 O
1	73 1 O
(	75 1 O
5	76 1 B-Chemical
-	77 1 I-Chemical
hydroxytryptamine	78 17 I-Chemical
-	95 1 O
1	96 1 O
)	97 1 O
receptor	99 8 O
agonist	108 7 O
,	115 1 O
is	117 2 O
an	120 2 O
antimigraine	123 12 O
drug	136 4 O
that	141 4 O
is	146 2 O
reported	149 8 O
to	158 2 O
act	161 3 O
by	165 2 O
selectively	168 11 O
constricting	180 12 O
intracranial	193 12 O
arteries	206 8 O
.	214 1 O

Recently	216 8 O
,	224 1 O
vasopressor	226 11 O
responses	238 9 O
that	248 4 O
are	253 3 O
distinct	257 8 O
from	266 4 O
the	271 3 O
cranial	275 7 O
circulation	283 11 O
have	295 4 O
been	300 4 O
demonstrated	305 12 O
to	318 2 O
occur	321 5 O
in	327 2 O
the	330 3 O
systemic	334 8 O
,	342 1 O
pulmonary	344 9 O
,	353 1 O
and	355 3 O
coronary	359 8 O
circulations	368 12 O
.	380 1 O

Cases	382 5 O
have	388 4 O
been	393 4 O
published	398 9 O
of	408 2 O
coronary	411 8 B-Disease
vasospasm	420 9 I-Disease
,	429 1 O
myocardial	431 10 B-Disease
ischemia	442 8 I-Disease
,	450 1 O
and	452 3 O
myocardial	456 10 B-Disease
infarction	467 10 I-Disease
occurring	478 9 O
after	488 5 O
sumatriptan	494 11 B-Chemical
use	506 3 O
.	509 1 O

We	511 2 O
report	514 6 O
on	521 2 O
the	524 3 O
development	528 11 O
of	540 2 O
8	543 1 O
serious	545 7 O
cases	553 5 O
of	559 2 O
ischemic	562 8 B-Disease
colitis	571 7 I-Disease
in	579 2 O
patients	582 8 O
with	591 4 O
migraine	596 8 B-Disease
treated	605 7 O
with	613 4 O
sumatriptan	618 11 B-Chemical
.	629 1 O

Pallidotomy	0 11 O
with	12 4 O
the	17 3 O
gamma	21 5 O
knife	27 5 O
:	32 1 O
a	34 1 O
positive	36 8 O
experience	45 10 O
.	55 1 O

51	57 2 O
patients	60 8 O
with	69 4 O
medically	74 9 O
refractory	84 10 O
Parkinson	95 9 B-Disease
'	104 1 I-Disease
s	105 1 I-Disease
disease	107 7 I-Disease
underwent	115 9 O
stereotactic	125 12 O
posteromedial	138 13 O
pallidotomy	152 11 O
between	164 7 O
August	172 6 O
1993	179 4 O
and	184 3 O
February	188 8 O
1997	197 4 O
for	202 3 O
treatment	206 9 O
of	216 2 O
bradykinesia	219 12 B-Disease
,	231 1 O
rigidity	233 8 B-Disease
,	241 1 O
and	243 3 O
L	247 1 B-Chemical
-	248 1 I-Chemical
DOPA	249 4 I-Chemical
-	253 1 O
induced	254 7 O
dyskinesias	262 11 B-Disease
.	273 1 O

In	275 2 O
29	278 2 O
patients	281 8 O
,	289 1 O
the	291 3 O
pallidotomies	295 13 O
were	309 4 O
performed	314 9 O
with	324 4 O
the	329 3 O
Leksell	333 7 O
Gamma	341 5 O
Knife	347 5 O
and	353 3 O
in	357 2 O
22	360 2 O
they	363 4 O
were	368 4 O
performed	373 9 O
with	383 4 O
the	388 3 O
standard	392 8 O
radiofrequency	401 14 O
(	416 1 O
RF	417 2 O
)	419 1 O
method	421 6 O
.	427 1 O

Clinical	429 8 O
assessment	438 10 O
as	449 2 O
well	452 4 O
as	457 2 O
blinded	460 7 O
ratings	468 7 O
of	476 2 O
Unified	479 7 O
Parkinson	487 9 B-Disease
'	496 1 I-Disease
s	497 1 I-Disease
Disease	499 7 I-Disease
Rating	507 6 O
Scale	514 5 O
(	520 1 O
UPDRS	521 5 O
)	526 1 O
scores	528 6 O
were	535 4 O
carried	540 7 O
out	548 3 O
pre	552 3 O
-	555 1 O
and	557 3 O
postoperatively	561 15 O
.	576 1 O

Mean	578 4 O
follow	583 6 O
-	589 1 O
up	590 2 O
time	593 4 O
is	598 2 O
20	601 2 O
.	603 1 O
6	604 1 O
months	606 6 O
(	613 1 O
range	614 5 O
6	620 1 O
-	621 1 O
48	622 2 O
)	624 1 O
and	626 3 O
all	630 3 O
except	634 6 O
4	641 1 O
patients	643 8 O
have	652 4 O
been	657 4 O
followed	662 8 O
more	671 4 O
than	676 4 O
one	681 3 O
year	685 4 O
.	689 1 O

85	691 2 O
percent	694 7 O
of	702 2 O
patients	705 8 O
with	714 4 O
dyskinesias	719 11 B-Disease
were	731 4 O
relieved	736 8 O
of	745 2 O
symptoms	748 8 O
,	756 1 O
regardless	758 10 O
of	769 2 O
whether	772 7 O
the	780 3 O
pallidotomies	784 13 O
were	798 4 O
performed	803 9 O
with	813 4 O
the	818 3 O
Gamma	822 5 O
Knife	828 5 O
or	834 2 O
radiofrequency	837 14 O
methods	852 7 O
.	859 1 O

About	861 5 O
2	867 1 O
/	868 1 O
3	869 1 O
of	871 2 O
the	874 3 O
patients	878 8 O
in	887 2 O
both	890 4 O
Gamma	895 5 O
Knife	901 5 O
and	907 3 O
radiofrequency	911 14 O
groups	926 6 O
showed	933 6 O
improvements	940 12 O
in	953 2 O
bradykinesia	956 12 B-Disease
and	969 3 O
rigidity	973 8 B-Disease
,	981 1 O
although	983 8 O
when	992 4 O
considered	997 10 O
as	1008 2 O
a	1011 1 O
group	1013 5 O
neither	1019 7 O
the	1027 3 O
Gamma	1031 5 O
Knife	1037 5 O
nor	1043 3 O
the	1047 3 O
radiofrequency	1051 14 O
group	1066 5 O
showed	1072 6 O
statistically	1079 13 O
significant	1093 11 O
improvements	1105 12 O
in	1118 2 O
UPDRS	1121 5 O
scores	1127 6 O
.	1133 1 O

One	1135 3 O
patient	1139 7 O
in	1147 2 O
the	1150 3 O
Gamma	1154 5 O
Knife	1160 5 O
group	1166 5 O
(	1172 1 O
3	1173 1 O
.	1174 1 O
4	1175 1 O
%	1176 1 O
)	1177 1 O
developed	1179 9 O
a	1189 1 O
homonymous	1191 10 B-Disease
hemianopsia	1202 11 I-Disease
9	1214 1 O
months	1216 6 O
following	1223 9 O
treatment	1233 9 O
and	1243 3 O
5	1247 1 O
patients	1249 8 O
(	1258 1 O
27	1259 2 O
.	1261 1 O
7	1262 1 O
%	1263 1 O
)	1264 1 O
in	1266 2 O
the	1269 3 O
radiofrequency	1273 14 O
group	1288 5 O
became	1294 6 O
transiently	1301 11 O
confused	1313 8 O
postoperatively	1322 15 O
.	1337 1 O

No	1339 2 O
other	1342 5 O
complications	1348 13 O
were	1362 4 O
seen	1367 4 O
.	1371 1 O

Gamma	1373 5 O
Knife	1379 5 O
pallidotomy	1385 11 O
is	1397 2 O
as	1400 2 O
effective	1403 9 O
as	1413 2 O
radiofrequency	1416 14 O
pallidotomy	1431 11 O
in	1443 2 O
controlling	1446 11 O
certain	1458 7 O
of	1466 2 O
the	1469 3 O
symptoms	1473 8 O
of	1482 2 O
Parkinson	1485 9 B-Disease
'	1494 1 I-Disease
s	1495 1 I-Disease
disease	1497 7 I-Disease
.	1504 1 O

It	1506 2 O
may	1509 3 O
be	1513 2 O
the	1516 3 O
only	1520 4 O
practical	1525 9 O
technique	1535 9 O
available	1545 9 O
in	1555 2 O
certain	1558 7 O
patients	1566 8 O
,	1574 1 O
such	1576 4 O
as	1581 2 O
those	1584 5 O
who	1590 3 O
take	1594 4 O
anticoagulants	1599 14 O
,	1613 1 O
have	1615 4 O
bleeding	1620 8 B-Disease
diatheses	1629 9 O
or	1639 2 O
serious	1642 7 O
systemic	1650 8 O
medical	1659 7 O
illnesses	1667 9 O
.	1676 1 O

It	1678 2 O
is	1681 2 O
a	1684 1 O
viable	1686 6 O
option	1693 6 O
for	1700 3 O
other	1704 5 O
patients	1710 8 O
as	1719 2 O
well	1722 4 O
.	1726 1 O

Neuroleptic	0 11 B-Disease
malignant	12 9 I-Disease
syndrome	22 8 I-Disease
and	31 3 O
methylphenidate	35 15 B-Chemical
.	50 1 O

A	52 1 O
1	54 1 O
-	55 1 O
year	56 4 O
-	60 1 O
old	61 3 O
female	65 6 O
presented	72 9 O
with	82 4 O
neuroleptic	87 11 B-Disease
malignant	99 9 I-Disease
syndrome	109 8 I-Disease
probably	118 8 O
caused	127 6 O
by	134 2 O
methylphenidate	137 15 B-Chemical
.	152 1 O

She	154 3 O
had	158 3 O
defects	162 7 O
in	170 2 O
the	173 3 O
supratentorial	177 14 O
brain	192 5 O
including	198 9 O
the	208 3 O
basal	212 5 O
ganglia	218 7 O
and	226 3 O
the	230 3 O
striatum	234 8 O
(	243 1 O
multicystic	244 11 B-Disease
encephalomalacia	256 16 I-Disease
)	272 1 O
due	274 3 O
to	278 2 O
severe	281 6 O
perinatal	288 9 O
hypoxic	298 7 B-Disease
-	305 1 I-Disease
ischemic	306 8 I-Disease
encephalopathy	315 14 I-Disease
,	329 1 O
which	331 5 O
was	337 3 O
considered	341 10 O
to	352 2 O
be	355 2 O
a	358 1 O
possible	360 8 O
predisposing	369 12 O
factor	382 6 O
causing	389 7 O
neuroleptic	397 11 B-Disease
malignant	409 9 I-Disease
syndrome	419 8 I-Disease
.	427 1 O

A	429 1 O
dopaminergic	431 12 O
blockade	444 8 O
mechanism	453 9 O
generally	463 9 O
is	473 2 O
accepted	476 8 O
as	485 2 O
the	488 3 O
pathogenesis	492 12 O
of	505 2 O
this	508 4 O
syndrome	513 8 O
.	521 1 O

However	523 7 O
,	530 1 O
methylphenidate	532 15 B-Chemical
is	548 2 O
a	551 1 O
dopamine	553 8 B-Chemical
agonist	562 7 O
via	570 3 O
the	574 3 O
inhibition	578 10 O
of	589 2 O
uptake	592 6 O
of	599 2 O
dopamine	602 8 B-Chemical
,	610 1 O
and	612 3 O
therefore	616 9 O
dopaminergic	626 12 O
systems	639 7 O
in	647 2 O
the	650 3 O
brainstem	654 9 O
(	664 1 O
mainly	665 6 O
the	672 3 O
midbrain	676 8 O
)	684 1 O
and	686 3 O
the	690 3 O
spinal	694 6 O
cord	701 4 O
were	706 4 O
unlikely	711 8 O
to	720 2 O
participate	723 11 O
in	735 2 O
the	738 3 O
onset	742 5 O
of	748 2 O
this	751 4 O
syndrome	756 8 O
.	764 1 O

A	766 1 O
relative	768 8 O
gamma	777 5 B-Chemical
-	782 1 I-Chemical
aminobutyric	783 12 I-Chemical
acid	796 4 I-Chemical
-	800 1 O
ergic	801 5 O
deficiency	807 10 O
might	818 5 O
occur	824 5 O
because	830 7 O
diazepam	838 8 B-Chemical
,	846 1 O
a	848 1 O
gamma	850 5 B-Chemical
-	855 1 I-Chemical
aminobutyric	856 12 I-Chemical
acid	869 4 I-Chemical
-	873 1 O
mimetic	874 7 O
agent	882 5 O
,	887 1 O
was	889 3 O
strikingly	893 10 O
effective	904 9 O
.	913 1 O

This	915 4 O
is	920 2 O
the	923 3 O
first	927 5 O
reported	933 8 O
patient	942 7 O
with	950 4 O
neuroleptic	955 11 B-Disease
malignant	967 9 I-Disease
syndrome	977 8 I-Disease
probably	986 8 O
caused	995 6 O
by	1002 2 O
methylphenidate	1005 15 B-Chemical
.	1020 1 O

Differential	0 12 O
effects	13 7 O
of	21 2 O
17alpha	24 7 B-Chemical
-	31 1 I-Chemical
ethinylestradiol	32 16 I-Chemical
on	49 2 O
the	52 3 O
neutral	56 7 O
and	64 3 O
acidic	68 6 O
pathways	75 8 O
of	84 2 O
bile	87 4 B-Chemical
salt	92 4 I-Chemical
synthesis	97 9 O
in	107 2 O
the	110 3 O
rat	114 3 O
.	117 1 O

Effects	119 7 O
of	127 2 O
17alpha	130 7 B-Chemical
-	137 1 I-Chemical
ethinylestradiol	138 16 I-Chemical
(	155 1 O
EE	156 2 B-Chemical
)	158 1 O
on	160 2 O
the	163 3 O
neutral	167 7 O
and	175 3 O
acidic	179 6 O
biosynthetic	186 12 O
pathways	199 8 O
of	208 2 O
bile	211 4 B-Chemical
salt	216 4 I-Chemical
(	221 1 O
BS	222 2 B-Chemical
)	224 1 O
synthesis	226 9 O
were	236 4 O
evaluated	241 9 O
in	251 2 O
rats	254 4 O
with	259 4 O
an	264 2 O
intact	267 6 O
enterohepatic	274 13 O
circulation	288 11 O
and	300 3 O
in	304 2 O
rats	307 4 O
with	312 4 O
long	317 4 O
-	321 1 O
term	322 4 O
bile	327 4 O
diversion	332 9 O
to	342 2 O
induce	345 6 O
BS	352 2 B-Chemical
synthesis	355 9 O
.	364 1 O

For	366 3 O
this	370 4 O
purpose	375 7 O
,	382 1 O
bile	384 4 B-Chemical
salt	389 4 I-Chemical
pool	394 4 O
composition	399 11 O
,	410 1 O
synthesis	412 9 O
of	422 2 O
individual	425 10 O
BS	436 2 B-Chemical
in	439 2 O
vivo	442 4 O
,	446 1 O
hepatic	448 7 O
activities	456 10 O
,	466 1 O
and	468 3 O
expression	472 10 O
levels	483 6 O
of	490 2 O
cholesterol	493 11 B-Chemical
7alpha	505 6 O
-	511 1 O
hydroxylase	512 11 O
(	524 1 O
CYP7A	525 5 O
)	530 1 O
,	531 1 O
and	533 3 O
sterol	537 6 B-Chemical
27	544 2 O
-	546 1 O
hydroxylase	547 11 O
(	559 1 O
CYP27	560 5 O
)	565 1 O
,	566 1 O
as	568 2 O
well	571 4 O
as	576 2 O
of	579 2 O
other	582 5 O
enzymes	588 7 O
involved	596 8 O
in	605 2 O
BS	608 2 B-Chemical
synthesis	611 9 O
,	620 1 O
were	622 4 O
analyzed	627 8 O
in	636 2 O
rats	639 4 O
treated	644 7 O
with	652 4 O
EE	657 2 B-Chemical
(	660 1 O
5	661 1 O
mg	663 2 O
/	665 1 O
kg	666 2 O
,	668 1 O
3	670 1 O
days	672 4 O
)	676 1 O
or	678 2 O
its	681 3 O
vehicle	685 7 O
.	692 1 O

BS	694 2 B-Chemical
pool	697 4 O
size	702 4 O
was	707 3 O
decreased	711 9 O
by	721 2 O
27	724 2 O
%	726 1 O
but	728 3 O
total	732 5 O
BS	738 2 B-Chemical
synthesis	741 9 O
was	751 3 O
not	755 3 O
affected	759 8 O
by	768 2 O
EE	771 2 B-Chemical
in	774 2 O
intact	777 6 O
rats	784 4 O
.	788 1 O

Synthesis	790 9 O
of	800 2 O
cholate	803 7 B-Chemical
was	811 3 O
reduced	815 7 O
by	823 2 O
68	826 2 O
%	828 1 O
in	830 2 O
EE	833 2 B-Chemical
-	835 1 O
treated	836 7 O
rats	844 4 O
,	848 1 O
while	850 5 O
that	856 4 O
of	861 2 O
chenodeoxycholate	864 17 B-Chemical
was	882 3 O
increased	886 9 O
by	896 2 O
60	899 2 O
%	901 1 O
.	902 1 O

The	904 3 O
recently	908 8 O
identified	917 10 O
Delta22	928 7 O
-	935 1 O
isomer	936 6 O
of	943 2 O
beta	946 4 O
-	950 1 O
muricholate	951 11 O
contributed	963 11 O
for	975 3 O
5	979 1 O
.	980 1 O
4	981 1 O
%	982 1 O
and	984 3 O
18	988 2 O
.	990 1 O
3	991 1 O
%	993 1 O
(	995 1 O
P	996 1 O
<	998 1 O
0	1000 1 O
.	1001 1 O
01	1002 2 O
)	1004 1 O
to	1006 2 O
the	1009 3 O
pool	1013 4 O
in	1018 2 O
control	1021 7 O
and	1029 3 O
EE	1033 2 B-Chemical
-	1035 1 O
treated	1036 7 O
rats	1044 4 O
,	1048 1 O
respectively	1050 12 O
,	1062 1 O
but	1064 3 O
could	1068 5 O
not	1074 3 O
be	1078 2 O
detected	1081 8 O
in	1090 2 O
bile	1093 4 O
after	1098 5 O
exhaustion	1104 10 O
of	1115 2 O
the	1118 3 O
pool	1122 4 O
.	1126 1 O

A	1128 1 O
clear	1130 5 O
reduction	1136 9 O
of	1146 2 O
BS	1149 2 B-Chemical
synthesis	1152 9 O
was	1162 3 O
found	1166 5 O
in	1172 2 O
bile	1175 4 O
-	1179 1 O
diverted	1180 8 O
rats	1189 4 O
treated	1194 7 O
with	1202 4 O
EE	1207 2 B-Chemical
,	1209 1 O
yet	1211 3 O
biliary	1215 7 O
BS	1223 2 B-Chemical
composition	1226 11 O
was	1238 3 O
only	1242 4 O
minimally	1247 9 O
affected	1257 8 O
.	1265 1 O

Activity	1267 8 O
of	1276 2 O
CYP7A	1279 5 O
was	1285 3 O
decreased	1289 9 O
by	1299 2 O
EE	1302 2 B-Chemical
in	1305 2 O
both	1308 4 O
intact	1313 6 O
and	1320 3 O
bile	1324 4 O
-	1328 1 O
diverted	1329 8 O
rats	1338 4 O
,	1342 1 O
whereas	1344 7 O
the	1352 3 O
activity	1356 8 O
of	1365 2 O
the	1368 3 O
CYP27	1372 5 O
was	1378 3 O
not	1382 3 O
affected	1386 8 O
.	1394 1 O

Hepatic	1396 7 O
mRNA	1404 4 O
levels	1409 6 O
of	1416 2 O
CYP7A	1419 5 O
were	1425 4 O
significantly	1430 13 O
reduced	1444 7 O
by	1452 2 O
EE	1455 2 B-Chemical
in	1458 2 O
bile	1461 4 O
-	1465 1 O
diverted	1466 8 O
rats	1475 4 O
only	1480 4 O
;	1484 1 O
CYP27	1486 5 O
mRNA	1492 4 O
levels	1497 6 O
were	1504 4 O
not	1509 3 O
affected	1513 8 O
by	1522 2 O
EE	1525 2 B-Chemical
.	1527 1 O

In	1529 2 O
addition	1532 8 O
,	1540 1 O
mRNA	1542 4 O
levels	1547 6 O
of	1554 2 O
sterol	1557 6 B-Chemical
12alpha	1564 7 O
-	1571 1 O
hydroxylase	1572 11 O
and	1584 3 O
lithocholate	1588 12 O
6beta	1601 5 O
-	1606 1 O
hydroxylase	1607 11 O
were	1619 4 O
increased	1624 9 O
by	1634 2 O
bile	1637 4 O
diversion	1642 9 O
and	1652 3 O
suppressed	1656 10 O
by	1667 2 O
EE	1670 2 B-Chemical
.	1672 1 O

This	1674 4 O
study	1679 5 O
shows	1685 5 O
that	1691 4 O
17alpha	1696 7 B-Chemical
-	1703 1 I-Chemical
ethinylestradiol	1704 16 I-Chemical
(	1721 1 O
EE	1722 2 B-Chemical
)	1724 1 O
-	1725 1 O
induced	1726 7 O
intrahepatic	1734 12 B-Disease
cholestasis	1747 11 I-Disease
in	1759 2 O
rats	1762 4 O
is	1767 2 O
associated	1770 10 O
with	1781 4 O
selective	1786 9 O
inhibition	1796 10 O
of	1807 2 O
the	1810 3 O
neutral	1814 7 O
pathway	1822 7 O
of	1830 2 O
bile	1833 4 B-Chemical
salt	1838 4 I-Chemical
(	1843 1 O
BS	1844 2 B-Chemical
)	1846 1 O
synthesis	1848 9 O
.	1857 1 O

Simultaneous	1859 12 O
impairment	1872 10 O
of	1883 2 O
other	1886 5 O
enzymes	1892 7 O
in	1900 2 O
the	1903 3 O
BS	1907 2 B-Chemical
biosynthetic	1910 12 O
pathways	1923 8 O
may	1932 3 O
contribute	1936 10 O
to	1947 2 O
overall	1950 7 O
effects	1958 7 O
of	1966 2 O
EE	1969 2 B-Chemical
on	1972 2 O
BS	1975 2 B-Chemical
synthesis	1978 9 O
.	1987 1 O

Glibenclamide	0 13 B-Chemical
-	13 1 O
sensitive	14 9 O
hypotension	24 11 B-Disease
produced	36 8 O
by	45 2 O
helodermin	48 10 B-Chemical
assessed	59 8 O
in	68 2 O
the	71 3 O
rat	75 3 O
.	78 1 O

The	80 3 O
effects	84 7 O
of	92 2 O
helodermin	95 10 B-Chemical
,	105 1 O
a	107 1 O
basic	109 5 O
35	115 2 O
-	117 1 O
amino	118 5 B-Chemical
acid	124 4 I-Chemical
peptide	129 7 O
isolated	137 8 O
from	146 4 O
the	151 3 O
venom	155 5 O
of	161 2 O
a	164 1 O
lizard	166 6 O
salivary	173 8 O
gland	182 5 O
,	187 1 O
on	189 2 O
arterial	192 8 O
blood	201 5 O
pressure	207 8 O
and	216 3 O
heart	220 5 O
rate	226 4 O
were	231 4 O
examined	236 8 O
in	245 2 O
the	248 3 O
rat	252 3 O
,	255 1 O
focusing	257 8 O
on	266 2 O
the	269 3 O
possibility	273 11 O
that	285 4 O
activation	290 10 O
of	301 2 O
ATP	304 3 B-Chemical
sensitive	308 9 O
K	318 1 B-Chemical
+	319 1 O
(	321 1 O
K	322 1 B-Chemical
(	323 1 O
ATP	324 3 B-Chemical
)	327 1 O
)	328 1 O
channels	330 8 O
is	339 2 O
involved	342 8 O
in	351 2 O
the	354 3 O
responses	358 9 O
.	367 1 O

The	369 3 O
results	373 7 O
were	381 4 O
also	386 4 O
compared	391 8 O
with	400 4 O
those	405 5 O
of	411 2 O
vasoactive	414 10 O
intestinal	425 10 O
polypeptide	436 11 O
(	448 1 O
VIP	449 3 O
)	452 1 O
.	453 1 O

Helodermin	455 10 B-Chemical
produced	466 8 O
hypotension	475 11 B-Disease
in	487 2 O
a	490 1 O
dose	492 4 O
-	496 1 O
dependent	497 9 O
manner	507 6 O
with	514 4 O
approximately	519 13 O
similar	533 7 O
potency	541 7 O
and	549 3 O
duration	553 8 O
to	562 2 O
VIP	565 3 O
.	568 1 O

Hypotension	570 11 B-Disease
induced	582 7 O
by	590 2 O
both	593 4 O
peptides	598 8 O
was	607 3 O
significantly	611 13 O
attenuated	625 10 O
by	636 2 O
glibenclamide	639 13 B-Chemical
,	652 1 O
which	654 5 O
abolished	660 9 O
a	670 1 O
levcromakalim	672 13 B-Chemical
-	685 1 O
produced	686 8 O
decrease	695 8 O
in	704 2 O
arterial	707 8 O
blood	716 5 O
pressure	722 8 O
.	730 1 O

Oxyhemoglobin	732 13 O
did	746 3 O
not	750 3 O
affect	754 6 O
helodermin	761 10 B-Chemical
-	771 1 O
induced	772 7 O
hypotension	780 11 B-Disease
,	791 1 O
whereas	793 7 O
it	801 2 O
shortened	804 9 O
the	814 3 O
duration	818 8 O
of	827 2 O
acetylcholine	830 13 B-Chemical
(	844 1 O
ACh	845 3 B-Chemical
)	848 1 O
-	849 1 O
produced	850 8 O
hypotension	859 11 B-Disease
.	870 1 O

These	872 5 O
findings	878 8 O
suggest	887 7 O
that	895 4 O
helodermin	900 10 B-Chemical
-	910 1 O
produced	911 8 O
hypotension	920 11 B-Disease
is	932 2 O
partly	935 6 O
attributable	942 12 O
to	955 2 O
the	958 3 O
activation	962 10 O
of	973 2 O
glibenclamide	976 13 B-Chemical
-	989 1 O
sensitive	990 9 O
K	1000 1 B-Chemical
+	1001 1 O
channels	1003 8 O
(	1012 1 O
K	1013 1 B-Chemical
(	1014 1 O
ATP	1015 3 B-Chemical
)	1018 1 O
channels	1020 8 O
)	1028 1 O
,	1029 1 O
which	1031 5 O
presumably	1037 10 O
exist	1048 5 O
on	1054 2 O
arterial	1057 8 O
smooth	1066 6 O
muscle	1073 6 O
cells	1080 5 O
.	1085 1 O

EDRF	1087 4 O
(	1092 1 O
endothelium	1093 11 O
-	1104 1 O
derived	1105 7 O
relaxing	1113 8 O
factor	1122 6 O
)	1128 1 O
/	1129 1 O
nitric	1130 6 B-Chemical
oxide	1137 5 I-Chemical
does	1143 4 O
not	1148 3 O
seem	1152 4 O
to	1157 2 O
play	1160 4 O
an	1165 2 O
important	1168 9 O
role	1178 4 O
in	1183 2 O
the	1186 3 O
peptide	1190 7 O
-	1197 1 O
produced	1198 8 O
hypotension	1207 11 B-Disease
.	1218 1 O

Long	0 4 O
-	4 1 O
term	5 4 O
efficacy	10 8 O
and	19 3 O
adverse	23 7 O
event	31 5 O
of	37 2 O
nifedipine	40 10 B-Chemical
sustained	51 9 O
-	60 1 O
release	61 7 O
tablets	69 7 O
for	77 3 O
cyclosporin	81 11 B-Chemical
A	93 1 I-Chemical
-	94 1 O
induced	95 7 O
hypertension	103 12 B-Disease
in	116 2 O
patients	119 8 O
with	128 4 O
psoriasis	133 9 B-Disease
.	142 1 O

Thirteen	144 8 O
psoriatic	153 9 B-Disease
patients	163 8 O
with	172 4 O
hypertension	177 12 B-Disease
during	190 6 O
the	197 3 O
course	201 6 O
of	208 2 O
cyclosporin	211 11 B-Chemical
A	223 1 I-Chemical
therapy	225 7 O
were	233 4 O
treated	238 7 O
for	246 3 O
25	250 2 O
months	253 6 O
with	260 4 O
a	265 1 O
calcium	267 7 B-Chemical
channel	275 7 O
blocker	283 7 O
,	290 1 O
sustained	292 9 O
-	301 1 O
release	302 7 O
nifedipine	310 10 B-Chemical
,	320 1 O
to	322 2 O
study	325 5 O
the	331 3 O
clinical	335 8 O
antihypertensive	344 16 O
effects	361 7 O
and	369 3 O
adverse	373 7 O
events	381 6 O
during	388 6 O
treatment	395 9 O
with	405 4 O
both	410 4 O
drugs	415 5 O
.	420 1 O

Seven	422 5 O
of	428 2 O
the	431 3 O
13	435 2 O
patients	438 8 O
had	447 3 O
exhibited	451 9 O
a	461 1 O
subclinical	463 11 O
hypertensive	475 12 B-Disease
state	488 5 O
before	494 6 O
cyclosporin	501 11 B-Chemical
A	513 1 I-Chemical
therapy	515 7 O
.	522 1 O

Both	524 4 O
systolic	529 8 O
and	538 3 O
diastolic	542 9 O
blood	552 5 O
pressures	558 9 O
of	568 2 O
these	571 5 O
13	577 2 O
patients	580 8 O
were	589 4 O
decreased	594 9 O
significantly	604 13 O
after	618 5 O
4	624 1 O
weeks	626 5 O
of	632 2 O
nifedipine	635 10 B-Chemical
therapy	646 7 O
,	653 1 O
and	655 3 O
blood	659 5 O
pressure	665 8 O
was	674 3 O
maintained	678 10 O
within	689 6 O
the	696 3 O
normal	700 6 O
range	707 5 O
thereafter	713 10 O
for	724 3 O
25	728 2 O
months	731 6 O
.	737 1 O

The	739 3 O
adverse	743 7 O
events	751 6 O
during	758 6 O
combined	765 8 O
therapy	774 7 O
with	782 4 O
cyclosporin	787 11 B-Chemical
A	799 1 I-Chemical
and	801 3 O
nifedipine	805 10 B-Chemical
included	816 8 O
an	825 2 O
increase	828 8 O
in	837 2 O
blood	840 5 B-Chemical
urea	846 4 I-Chemical
nitrogen	851 8 I-Chemical
levels	860 6 O
in	867 2 O
9	870 1 O
of	872 2 O
the	875 3 O
13	879 2 O
patients	882 8 O
and	891 3 O
development	895 11 O
of	907 2 O
gingival	910 8 B-Disease
hyperplasia	919 11 I-Disease
in	931 2 O
2	934 1 O
of	936 2 O
the	939 3 O
13	943 2 O
patients	946 8 O
.	954 1 O

Our	956 3 O
findings	960 8 O
indicate	969 8 O
that	978 4 O
sustained	983 9 O
-	992 1 O
release	993 7 O
nifedipine	1001 10 B-Chemical
is	1012 2 O
useful	1015 6 O
for	1022 3 O
hypertensive	1026 12 B-Disease
psoriatic	1039 9 B-Disease
patients	1049 8 O
under	1058 5 O
long	1064 4 O
-	1068 1 O
term	1069 4 O
treatment	1074 9 O
with	1084 4 O
cyclosporin	1089 11 B-Chemical
A	1101 1 I-Chemical
,	1102 1 O
but	1104 3 O
that	1108 4 O
these	1113 5 O
patients	1119 8 O
should	1128 6 O
be	1135 2 O
monitored	1138 9 O
for	1148 3 O
gingival	1152 8 B-Disease
hyperplasia	1161 11 I-Disease
.	1172 1 O

Torsade	0 7 B-Disease
de	8 2 I-Disease
pointes	11 7 I-Disease
ventricular	19 11 B-Disease
tachycardia	31 11 I-Disease
during	43 6 O
low	50 3 O
dose	54 4 O
intermittent	59 12 O
dobutamine	72 10 B-Chemical
treatment	83 9 O
in	93 2 O
a	96 1 O
patient	98 7 O
with	106 4 O
dilated	111 7 B-Disease
cardiomyopathy	119 14 I-Disease
and	134 3 O
congestive	138 10 B-Disease
heart	149 5 I-Disease
failure	155 7 I-Disease
.	162 1 O

The	164 3 O
authors	168 7 O
describe	176 8 O
the	185 3 O
case	189 4 O
of	194 2 O
a	197 1 O
56	199 2 O
-	201 1 O
year	202 4 O
-	206 1 O
old	207 3 O
woman	211 5 O
with	217 4 O
chronic	222 7 O
,	229 1 O
severe	231 6 O
heart	238 5 B-Disease
failure	244 7 I-Disease
secondary	252 9 O
to	262 2 O
dilated	265 7 B-Disease
cardiomyopathy	273 14 I-Disease
and	288 3 O
absence	292 7 O
of	300 2 O
significant	303 11 O
ventricular	315 11 B-Disease
arrhythmias	327 11 I-Disease
who	339 3 O
developed	343 9 O
QT	353 2 B-Disease
prolongation	356 12 I-Disease
and	369 3 O
torsade	373 7 B-Disease
de	381 2 I-Disease
pointes	384 7 I-Disease
ventricular	392 11 B-Disease
tachycardia	404 11 I-Disease
during	416 6 O
one	423 3 O
cycle	427 5 O
of	433 2 O
intermittent	436 12 O
low	449 3 O
dose	453 4 O
(	458 1 O
2	459 1 O
.	460 1 O
5	461 1 O
mcg	463 3 O
/	466 1 O
kg	467 2 O
per	470 3 O
min	474 3 O
)	477 1 O
dobutamine	479 10 B-Chemical
.	489 1 O

This	491 4 O
report	496 6 O
of	503 2 O
torsade	506 7 B-Disease
de	514 2 I-Disease
pointes	517 7 I-Disease
ventricular	525 11 B-Disease
tachycardia	537 11 I-Disease
during	549 6 O
intermittent	556 12 O
dobutamine	569 10 B-Chemical
supports	580 8 O
the	589 3 O
hypothesis	593 10 O
that	604 4 O
unpredictable	609 13 O
fatal	623 5 O
arrhythmias	629 11 B-Disease
may	641 3 O
occur	645 5 O
even	651 4 O
with	656 4 O
low	661 3 O
doses	665 5 O
and	671 3 O
in	675 2 O
patients	678 8 O
with	687 4 O
no	692 2 O
history	695 7 O
of	703 2 O
significant	706 11 O
rhythm	718 6 O
disturbances	725 12 O
.	737 1 O

The	739 3 O
mechanisms	743 10 O
of	754 2 O
proarrhythmic	757 13 O
effects	771 7 O
of	779 2 O
Dubutamine	782 10 B-Chemical
are	793 3 O
discussed	797 9 O
.	806 1 O

Positive	0 8 O
skin	9 4 O
tests	14 5 O
in	20 2 O
late	23 4 O
reactions	28 9 O
to	38 2 O
radiographic	41 12 O
contrast	54 8 B-Chemical
media	63 5 I-Chemical
.	68 1 O

In	70 2 O
the	73 3 O
last	77 4 O
few	82 3 O
years	86 5 O
delayed	92 7 O
reactions	100 9 O
several	110 7 O
hours	118 5 O
after	124 5 O
the	130 3 O
injection	134 9 O
of	144 2 O
radiographic	147 12 O
and	160 3 O
contrast	164 8 B-Chemical
materials	173 9 I-Chemical
(	183 1 O
PRC	184 3 B-Chemical
)	187 1 O
have	189 4 O
been	194 4 O
described	199 9 O
with	209 4 O
increasing	214 10 O
frequency	225 9 O
.	234 1 O

The	236 3 O
authors	240 7 O
report	248 6 O
two	255 3 O
observations	259 12 O
on	272 2 O
patients	275 8 O
with	284 4 O
delayed	289 7 O
reactions	297 9 O
in	307 2 O
whom	310 4 O
intradermoreactions	315 19 O
(	335 1 O
IDR	336 3 O
)	339 1 O
and	341 3 O
patch	345 5 O
tests	351 5 O
to	357 2 O
a	360 1 O
series	362 6 O
of	369 2 O
ionic	372 5 O
and	378 3 O
non	382 3 O
ionic	386 5 O
PRC	392 3 B-Chemical
were	396 4 O
studied	401 7 O
.	408 1 O

After	410 5 O
angiography	416 11 O
by	428 2 O
the	431 3 O
venous	435 6 O
route	442 5 O
in	448 2 O
patient	451 7 O
n	459 1 O
degree	461 6 O
1	468 1 O
a	470 1 O
biphasic	472 8 O
reaction	481 8 O
with	490 4 O
an	495 2 O
immediate	498 9 O
reaction	508 8 O
(	517 1 O
dyspnea	518 7 B-Disease
,	525 1 O
loss	527 4 B-Disease
of	532 2 I-Disease
consciousness	535 13 I-Disease
)	548 1 O
and	550 3 O
delayed	554 7 O
macro	562 5 B-Disease
-	567 1 I-Disease
papular	568 7 I-Disease
rash	576 4 I-Disease
appeared	581 8 O
,	589 1 O
whilst	591 6 O
patient	598 7 O
n	606 1 O
degree	608 6 O
2	615 1 O
developed	617 9 O
a	627 1 O
generalised	629 11 O
sensation	641 9 O
of	651 2 O
heat	654 4 O
,	658 1 O
persistent	660 10 O
pain	671 4 B-Disease
at	676 2 O
the	679 3 O
site	683 4 O
of	688 2 O
injection	691 9 O
immediately	701 11 O
and	713 3 O
a	717 1 O
generalised	719 11 O
macro	731 5 O
-	736 1 O
papular	737 7 O
reaction	745 8 O
after	754 5 O
24	760 2 O
hours	763 5 O
.	768 1 O

The	770 3 O
skin	774 4 O
tests	779 5 O
revealed	785 8 O
positive	794 8 O
delayed	803 7 O
reactions	811 9 O
of	821 2 O
24	824 2 O
hours	827 5 O
and	833 3 O
48	837 2 O
hours	840 5 O
by	846 2 O
IDR	849 3 O
and	853 3 O
patch	857 5 O
tests	863 5 O
to	869 2 O
only	872 4 O
some	877 4 O
PRC	882 3 B-Chemical
with	886 4 O
common	891 6 O
chains	898 6 O
in	905 2 O
their	908 5 O
structures	914 10 O
.	924 1 O

The	926 3 O
positive	930 8 O
skin	939 4 O
tests	944 5 O
are	950 3 O
in	954 2 O
favour	957 6 O
of	964 2 O
immunological	967 13 O
reactions	981 9 O
and	991 3 O
may	995 3 O
help	999 4 O
in	1004 2 O
diagnosis	1007 9 O
of	1017 2 O
allergy	1020 7 B-Disease
in	1028 2 O
the	1031 3 O
patients	1035 8 O
.	1043 1 O

Risk	0 4 O
of	5 2 O
transient	8 9 O
hyperammonemic	18 14 B-Disease
encephalopathy	33 14 I-Disease
in	48 2 O
cancer	51 6 B-Disease
patients	58 8 O
who	67 3 O
received	71 8 O
continuous	80 10 O
infusion	91 8 O
of	100 2 O
5	103 1 B-Chemical
-	104 1 I-Chemical
fluorouracil	105 12 I-Chemical
with	118 4 O
the	123 3 O
complication	127 12 O
of	140 2 O
dehydration	143 11 B-Disease
and	155 3 O
infection	159 9 B-Disease
.	168 1 O

From	170 4 O
1986	175 4 O
to	180 2 O
1998	183 4 O
,	187 1 O
29	189 2 O
cancer	192 6 B-Disease
patients	199 8 O
who	208 3 O
had	212 3 O
32	216 2 O
episodes	219 8 O
of	228 2 O
transient	231 9 O
hyperammonemic	241 14 B-Disease
encephalopathy	256 14 I-Disease
related	271 7 O
to	279 2 O
continuous	282 10 O
infusion	293 8 O
of	302 2 O
5	305 1 B-Chemical
-	306 1 I-Chemical
fluorouracil	307 12 I-Chemical
(	320 1 O
5	321 1 B-Chemical
-	322 1 I-Chemical
FU	323 2 I-Chemical
)	325 1 O
were	327 4 O
identified	332 10 O
.	342 1 O

None	344 4 O
of	349 2 O
the	352 3 O
patients	356 8 O
had	365 3 O
decompensated	369 13 O
liver	383 5 B-Disease
disease	389 7 I-Disease
.	396 1 O

Onset	398 5 O
of	404 2 O
hyperammonemic	407 14 B-Disease
encephalopathy	422 14 I-Disease
varied	437 6 O
from	444 4 O
0	449 1 O
.	450 1 O
5	451 1 O
to	453 2 O
5	456 1 O
days	458 4 O
(	463 1 O
mean	464 4 O
:	468 1 O
2	470 1 O
.	471 1 O
6	472 1 O
+	474 1 O
/	475 1 O
-	476 1 O
1	478 1 O
.	479 1 O
3	480 1 O
days	482 4 O
)	486 1 O
after	488 5 O
the	494 3 O
initiation	498 10 O
of	509 2 O
chemotherapy	512 12 O
.	524 1 O

Plasma	526 6 O
ammonium	533 8 B-Chemical
level	542 5 O
ranged	548 6 O
from	555 4 O
248	560 3 O
to	564 2 O
2387	567 4 O
microg	572 6 O
%	578 1 O
(	580 1 O
mean	581 4 O
:	585 1 O
626	587 3 O
+	591 1 O
/	592 1 O
-	593 1 O
431	595 3 O
microg	599 6 O
%	605 1 O
)	606 1 O
.	607 1 O

Among	609 5 O
the	615 3 O
32	619 2 O
episodes	622 8 O
,	630 1 O
26	632 2 O
(	635 1 O
81	636 2 O
%	638 1 O
)	639 1 O
had	641 3 O
various	645 7 O
degrees	653 7 O
of	661 2 O
azotemia	664 8 B-Disease
,	672 1 O
18	674 2 O
(	677 1 O
56	678 2 O
%	680 1 O
)	681 1 O
occurred	683 8 O
during	692 6 O
bacterial	699 9 B-Disease
infections	709 10 I-Disease
and	720 3 O
14	724 2 O
(	727 1 O
44	728 2 O
%	730 1 O
)	731 1 O
without	733 7 O
infection	741 9 B-Disease
occurred	751 8 O
during	760 6 O
periods	767 7 O
of	775 2 O
dehydration	778 11 B-Disease
.	789 1 O

Higher	791 6 O
plasma	798 6 O
ammonium	805 8 B-Chemical
levels	814 6 O
and	821 3 O
more	825 4 O
rapid	830 5 O
onset	836 5 O
of	842 2 O
hyperammonemia	845 14 B-Disease
were	860 4 O
seen	865 4 O
in	870 2 O
18	873 2 O
patients	876 8 O
with	885 4 O
bacterial	890 9 B-Disease
infections	900 10 I-Disease
(	911 1 O
p	912 1 O
=	913 1 O
0	914 1 O
.	915 1 O
003	916 3 O
and	920 3 O
0	924 1 O
.	925 1 O
0006	926 4 O
,	930 1 O
respectively	932 12 O
)	944 1 O
and	946 3 O
in	950 2 O
nine	953 4 O
patients	958 8 O
receiving	967 9 O
high	977 4 O
daily	982 5 O
doses	988 5 O
(	994 1 O
2600	995 4 O
or	1000 2 O
1800	1003 4 O
mg	1008 2 O
/	1010 1 O
m2	1011 2 O
)	1013 1 O
of	1015 2 O
5	1018 1 B-Chemical
-	1019 1 I-Chemical
FU	1020 2 I-Chemical
(	1023 1 O
p	1024 1 O
=	1025 1 O
0	1026 1 O
.	1027 1 O
0001	1028 4 O
and	1033 3 O
<	1037 1 O
0	1039 1 O
.	1040 1 O
0001	1041 4 O
,	1045 1 O
respectively	1047 12 O
)	1059 1 O
.	1060 1 O

In	1062 2 O
25	1065 2 O
out	1068 3 O
of	1072 2 O
32	1075 2 O
episodes	1078 8 O
(	1087 1 O
78	1088 2 O
%	1090 1 O
)	1091 1 O
,	1092 1 O
plasma	1094 6 O
ammonium	1101 8 B-Chemical
levels	1110 6 O
and	1117 3 O
mental	1121 6 O
status	1128 6 O
returned	1135 8 O
to	1144 2 O
normal	1147 6 O
within	1154 6 O
2	1161 1 O
days	1163 4 O
after	1168 5 O
adequate	1174 8 O
management	1183 10 O
.	1193 1 O

In	1195 2 O
conclusion	1198 10 O
,	1208 1 O
hyperammonemic	1210 14 B-Disease
encephalopathy	1225 14 I-Disease
can	1240 3 O
occur	1244 5 O
in	1250 2 O
patients	1253 8 O
receiving	1262 9 O
continuous	1272 10 O
infusion	1283 8 O
of	1292 2 O
5	1295 1 B-Chemical
-	1296 1 I-Chemical
FU	1297 2 I-Chemical
.	1299 1 O

Azotemia	1301 8 B-Disease
,	1309 1 O
body	1311 4 O
fluid	1316 5 O
insufficiency	1322 13 O
and	1336 3 O
bacterial	1340 9 B-Disease
infections	1350 10 I-Disease
were	1361 4 O
frequently	1366 10 O
found	1377 5 O
in	1383 2 O
these	1386 5 O
patients	1392 8 O
.	1400 1 O

It	1402 2 O
is	1405 2 O
therefore	1408 9 O
important	1418 9 O
to	1428 2 O
recognize	1431 9 O
this	1441 4 O
condition	1446 9 O
in	1456 2 O
patients	1459 8 O
receiving	1468 9 O
continuous	1478 10 O
infusion	1489 8 O
of	1498 2 O
5	1501 1 B-Chemical
-	1502 1 I-Chemical
FU	1503 2 I-Chemical
.	1505 1 O

The	0 3 O
effects	4 7 O
of	12 2 O
quinine	15 7 B-Chemical
and	23 3 O
4	27 1 B-Chemical
-	28 1 I-Chemical
aminopyridine	29 13 I-Chemical
on	43 2 O
conditioned	46 11 O
place	58 5 O
preference	64 10 O
and	75 3 O
changes	79 7 O
in	87 2 O
motor	90 5 O
activity	96 8 O
induced	105 7 O
by	113 2 O
morphine	116 8 B-Chemical
in	125 2 O
rats	128 4 O
.	132 1 O

1	134 1 O
.	135 1 O

The	137 3 O
effects	141 7 O
of	149 2 O
two	152 3 O
unselective	156 11 O
potassium	168 9 B-Chemical
(	178 1 O
K	179 1 B-Chemical
(	180 1 O
+	181 1 O
)	182 1 O
-	183 1 O
)	184 1 O
channel	186 7 O
blockers	194 8 O
,	202 1 O
quinine	204 7 B-Chemical
(	212 1 O
12	213 2 O
.	215 1 O
5	216 1 O
,	217 1 O
25	219 2 O
and	222 3 O
50	226 2 O
mg	229 2 O
/	231 1 O
kg	232 2 O
)	234 1 O
and	236 3 O
4	240 1 B-Chemical
-	241 1 I-Chemical
aminopyridine	242 13 I-Chemical
(	256 1 O
1	257 1 O
and	259 3 O
2	263 1 O
mg	265 2 O
/	267 1 O
kg	268 2 O
)	270 1 O
,	271 1 O
on	273 2 O
conditioned	276 11 O
place	288 5 O
preference	294 10 O
and	305 3 O
biphasic	309 8 O
changes	318 7 O
in	326 2 O
motor	329 5 O
activity	335 8 O
induced	344 7 O
by	352 2 O
morphine	355 8 B-Chemical
(	364 1 O
10	365 2 O
mg	368 2 O
/	370 1 O
kg	371 2 O
)	373 1 O
were	375 4 O
tested	380 6 O
in	387 2 O
Wistar	390 6 O
rats	397 4 O
.	401 1 O

Quinine	403 7 B-Chemical
is	411 2 O
known	414 5 O
to	420 2 O
block	423 5 O
voltage	429 7 O
-	436 1 O
,	437 1 O
calcium	439 7 B-Chemical
-	446 1 O
and	448 3 O
ATP	452 3 B-Chemical
-	455 1 O
sensitive	456 9 O
K	466 1 B-Chemical
(	467 1 O
+	468 1 O
)	469 1 O
-	470 1 O
channels	471 8 O
while	480 5 O
4	486 1 B-Chemical
-	487 1 I-Chemical
aminopyridine	488 13 I-Chemical
is	502 2 O
known	505 5 O
to	511 2 O
block	514 5 O
voltage	520 7 O
-	527 1 O
sensitive	528 9 O
K	538 1 B-Chemical
(	539 1 O
+	540 1 O
)	541 1 O
-	542 1 O
channels	543 8 O
.	551 1 O

2	553 1 O
.	554 1 O

In	556 2 O
the	559 3 O
counterbalanced	563 15 O
method	579 6 O
,	585 1 O
quinine	587 7 B-Chemical
attenuated	595 10 O
morphine	606 8 B-Chemical
-	614 1 O
induced	615 7 O
place	623 5 O
preference	629 10 O
,	639 1 O
whereas	641 7 O
4	649 1 B-Chemical
-	650 1 I-Chemical
aminopyridine	651 13 I-Chemical
was	665 3 O
ineffective	669 11 O
.	680 1 O

In	682 2 O
the	685 3 O
motor	689 5 O
activity	695 8 O
test	704 4 O
measured	709 8 O
with	718 4 O
an	723 2 O
Animex	726 6 O
-	732 1 O
activity	733 8 O
meter	742 5 O
neither	748 7 O
of	756 2 O
the	759 3 O
K	763 1 B-Chemical
(	764 1 O
+	765 1 O
)	766 1 O
-	767 1 O
channel	768 7 O
blockers	776 8 O
affected	785 8 O
morphine	794 8 B-Chemical
-	802 1 O
induced	803 7 O
hypoactivity	811 12 B-Disease
,	823 1 O
but	825 3 O
both	829 4 O
K	834 1 B-Chemical
(	835 1 O
+	836 1 O
)	837 1 O
-	838 1 O
channel	839 7 O
blockers	847 8 O
prevented	856 9 O
morphine	866 8 B-Chemical
-	874 1 O
induced	875 7 O
secondary	883 9 O
hyperactivity	893 13 B-Disease
.	906 1 O

3	908 1 O
.	909 1 O

These	911 5 O
results	917 7 O
suggest	925 7 O
the	933 3 O
involvement	937 11 O
of	949 2 O
quinine	952 7 B-Chemical
-	959 1 O
sensitive	960 9 O
but	970 3 O
not	974 3 O
4	978 1 B-Chemical
-	979 1 I-Chemical
aminopyridine	980 13 I-Chemical
-	993 1 O
sensitive	994 9 O
K	1004 1 B-Chemical
(	1005 1 O
+	1006 1 O
)	1007 1 O
-	1008 1 O
channels	1009 8 O
in	1018 2 O
morphine	1021 8 B-Chemical
reward	1030 6 O
.	1036 1 O

It	1038 2 O
is	1041 2 O
also	1044 4 O
suggested	1049 9 O
that	1059 4 O
the	1064 3 O
blockade	1068 8 O
of	1077 2 O
K	1080 1 B-Chemical
(	1081 1 O
+	1082 1 O
)	1083 1 O
-	1084 1 O
channels	1085 8 O
sensitive	1094 9 O
to	1104 2 O
these	1107 5 O
blockers	1113 8 O
is	1122 2 O
not	1125 3 O
sufficient	1129 10 O
to	1140 2 O
prevent	1143 7 O
morphine	1151 8 B-Chemical
-	1159 1 O
induced	1160 7 O
hypoactivity	1168 12 B-Disease
whereas	1181 7 O
morphine	1189 8 B-Chemical
-	1197 1 O
induced	1198 7 O
hyperactivity	1206 13 B-Disease
seems	1220 5 O
to	1226 2 O
be	1229 2 O
connected	1232 9 O
to	1242 2 O
both	1245 4 O
quinine	1250 7 B-Chemical
-	1257 1 O
and	1259 3 O
4	1263 1 B-Chemical
-	1264 1 I-Chemical
aminopyridine	1265 13 I-Chemical
-	1278 1 O
sensitive	1279 9 O
K	1289 1 B-Chemical
(	1290 1 O
+	1291 1 O
)	1292 1 O
-	1293 1 O
channels	1294 8 O
.	1302 1 O

Nociceptin	0 10 B-Chemical
/	10 1 O
orphanin	11 8 B-Chemical
FQ	20 2 I-Chemical
and	23 3 O
nocistatin	27 10 B-Chemical
on	38 2 O
learning	41 8 B-Disease
and	50 3 I-Disease
memory	54 6 I-Disease
impairment	61 10 I-Disease
induced	72 7 O
by	80 2 O
scopolamine	83 11 B-Chemical
in	95 2 O
mice	98 4 O
.	102 1 O

1	104 1 O
.	105 1 O

Nociceptin	107 10 B-Chemical
,	117 1 O
also	119 4 O
known	124 5 O
as	130 2 O
orphanin	133 8 B-Chemical
FQ	142 2 I-Chemical
,	144 1 O
is	146 2 O
an	149 2 O
endogenous	152 10 O
ligand	163 6 O
for	170 3 O
the	174 3 O
orphan	178 6 O
opioid	185 6 O
receptor	192 8 O
-	200 1 O
like	201 4 O
receptor	206 8 O
1	215 1 O
(	217 1 O
ORL1	218 4 O
)	222 1 O
and	224 3 O
involves	228 8 O
in	237 2 O
various	240 7 O
functions	248 9 O
in	258 2 O
the	261 3 O
central	265 7 O
nervous	273 7 O
system	281 6 O
(	288 1 O
CNS	289 3 O
)	292 1 O
.	293 1 O

On	295 2 O
the	298 3 O
other	302 5 O
hand	308 4 O
,	312 1 O
nocistatin	314 10 B-Chemical
is	325 2 O
recently	328 8 O
isolated	337 8 O
from	346 4 O
the	351 3 O
same	355 4 O
precursor	360 9 O
as	370 2 O
nociceptin	373 10 B-Chemical
and	384 3 O
blocks	388 6 O
nociceptin	395 10 B-Chemical
-	405 1 O
induced	406 7 O
allodynia	414 9 B-Disease
and	424 3 O
hyperalgesia	428 12 B-Disease
.	440 1 O

2	442 1 O
.	443 1 O

Although	445 8 O
ORL1	454 4 O
receptors	459 9 O
which	469 5 O
display	475 7 O
a	483 1 O
high	485 4 O
degree	490 6 O
of	497 2 O
sequence	500 8 O
homology	509 8 O
with	518 4 O
classical	523 9 O
opioid	533 6 O
receptors	540 9 O
are	550 3 O
abundant	554 8 O
in	563 2 O
the	566 3 O
hippocampus	570 11 O
,	581 1 O
little	583 6 O
is	590 2 O
known	593 5 O
regarding	599 9 O
their	609 5 O
role	615 4 O
in	620 2 O
learning	623 8 O
and	632 3 O
memory	636 6 O
.	642 1 O

3	644 1 O
.	645 1 O

The	647 3 O
present	651 7 O
study	659 5 O
was	665 3 O
designed	669 8 O
to	678 2 O
investigate	681 11 O
whether	693 7 O
nociceptin	701 10 B-Chemical
/	711 1 O
orphanin	712 8 B-Chemical
FQ	721 2 I-Chemical
and	724 3 O
nocistatin	728 10 B-Chemical
could	739 5 O
modulate	745 8 O
impairment	754 10 B-Disease
of	765 2 I-Disease
learning	768 8 I-Disease
and	777 3 I-Disease
memory	781 6 I-Disease
induced	788 7 O
by	796 2 O
scopolamine	799 11 B-Chemical
,	810 1 O
a	812 1 O
muscarinic	814 10 O
cholinergic	825 11 O
receptor	837 8 O
antagonist	846 10 O
,	856 1 O
using	858 5 O
spontaneous	864 11 O
alternation	876 11 O
of	888 2 O
Y	891 1 O
-	892 1 O
maze	893 4 O
and	898 3 O
step	902 4 O
-	906 1 O
down	907 4 O
type	912 4 O
passive	917 7 O
avoidance	925 9 O
tasks	935 5 O
in	941 2 O
mice	944 4 O
.	948 1 O

4	950 1 O
.	951 1 O

While	953 5 O
nocistatin	959 10 B-Chemical
(	970 1 O
0	971 1 O
.	972 1 O
5	973 1 O
-	974 1 O
5	975 1 O
.	976 1 O
0	977 1 O
nmol	979 4 O
mouse	984 5 O
-	989 1 O
1	990 1 O
,	991 1 O
i	993 1 O
.	994 1 O
c	995 1 O
.	996 1 O
v	997 1 O
.	998 1 O
)	999 1 O
administered	1001 12 O
30	1014 2 O
min	1017 3 O
before	1021 6 O
spontaneous	1028 11 O
alternation	1040 11 O
performance	1052 11 O
or	1064 2 O
the	1067 3 O
training	1071 8 O
session	1080 7 O
of	1088 2 O
the	1091 3 O
passive	1095 7 O
avoidance	1103 9 O
task	1113 4 O
,	1117 1 O
had	1119 3 O
no	1123 2 O
effect	1126 6 O
on	1133 2 O
spontaneous	1136 11 O
alternation	1148 11 O
or	1160 2 O
passive	1163 7 O
avoidance	1171 9 O
behaviours	1181 10 O
,	1191 1 O
a	1193 1 O
lower	1195 5 O
per	1201 3 O
cent	1205 4 O
alternation	1210 11 O
and	1222 3 O
shorter	1226 7 O
median	1234 6 O
step	1241 4 O
-	1245 1 O
down	1246 4 O
latency	1251 7 O
in	1259 2 O
the	1262 3 O
retention	1266 9 O
test	1276 4 O
were	1281 4 O
obtained	1286 8 O
in	1295 2 O
nociceptin	1298 10 B-Chemical
(	1309 1 O
1	1310 1 O
.	1311 1 O
5	1312 1 O
and	1314 3 O
/	1317 1 O
or	1318 2 O
5	1321 1 O
.	1322 1 O
0	1323 1 O
nmol	1325 4 O
mouse	1330 5 O
-	1335 1 O
1	1336 1 O
,	1337 1 O
i	1339 1 O
.	1340 1 O
c	1341 1 O
.	1342 1 O
v	1343 1 O
.	1344 1 O
)	1345 1 O
-	1346 1 O
treated	1347 7 O
normal	1355 6 O
mice	1362 4 O
.	1366 1 O

5	1368 1 O
.	1369 1 O

Administration	1371 14 O
of	1386 2 O
nocistatin	1389 10 B-Chemical
(	1400 1 O
1	1401 1 O
.	1402 1 O
5	1403 1 O
and	1405 3 O
/	1408 1 O
or	1409 2 O
5	1412 1 O
.	1413 1 O
0	1414 1 O
nmol	1416 4 O
mouse	1421 5 O
-	1426 1 O
1	1427 1 O
,	1428 1 O
i	1430 1 O
.	1431 1 O
c	1432 1 O
.	1433 1 O
v	1434 1 O
.	1435 1 O
)	1436 1 O
30	1438 2 O
min	1441 3 O
before	1445 6 O
spontaneous	1452 11 O
alternation	1464 11 O
performance	1476 11 O
or	1488 2 O
the	1491 3 O
training	1495 8 O
session	1504 7 O
of	1512 2 O
the	1515 3 O
passive	1519 7 O
avoidance	1527 9 O
task	1537 4 O
,	1541 1 O
attenuated	1543 10 O
the	1554 3 O
scopolamine	1558 11 B-Chemical
-	1569 1 O
induced	1570 7 O
impairment	1578 10 O
of	1589 2 O
spontaneous	1592 11 O
alternation	1604 11 O
and	1616 3 O
passive	1620 7 O
avoidance	1628 9 O
behaviours	1638 10 O
.	1648 1 O

6	1650 1 O
.	1651 1 O

These	1653 5 O
results	1659 7 O
indicated	1667 9 O
that	1677 4 O
nocistatin	1682 10 B-Chemical
,	1692 1 O
a	1694 1 O
new	1696 3 O
biologically	1700 12 O
active	1713 6 O
peptide	1720 7 O
,	1727 1 O
ameliorates	1729 11 O
impairments	1741 11 O
of	1753 2 O
spontaneous	1756 11 O
alternation	1768 11 O
and	1780 3 O
passive	1784 7 O
avoidance	1792 9 O
induced	1802 7 O
by	1810 2 O
scopolamine	1813 11 B-Chemical
,	1824 1 O
and	1826 3 O
suggested	1830 9 O
that	1840 4 O
these	1845 5 O
peptides	1851 8 O
play	1860 4 O
opposite	1865 8 O
roles	1874 5 O
in	1880 2 O
learning	1883 8 O
and	1892 3 O
memory	1896 6 O
.	1902 1 O

Meloxicam	0 9 B-Chemical
-	9 1 O
induced	10 7 O
liver	18 5 B-Disease
toxicity	24 8 I-Disease
.	32 1 O

We	34 2 O
report	37 6 O
the	44 3 O
case	48 4 O
of	53 2 O
a	56 1 O
female	58 6 O
patient	65 7 O
with	73 4 O
rheumatoid	78 10 B-Disease
arthritis	89 9 I-Disease
who	99 3 O
developed	103 9 O
acute	113 5 O
cytolytic	119 9 O
hepatitis	129 9 B-Disease
due	139 3 O
to	143 2 O
meloxicam	146 9 B-Chemical
.	155 1 O

Recently	157 8 O
introduced	166 10 O
in	177 2 O
Belgium	180 7 O
,	187 1 O
meloxicam	189 9 B-Chemical
is	199 2 O
the	202 3 O
first	206 5 O
nonsteroidal	212 12 O
antiinflammatory	225 16 O
drug	242 4 O
with	247 4 O
selective	252 9 O
action	262 6 O
on	269 2 O
the	272 3 O
inducible	276 9 O
form	286 4 O
of	291 2 O
cyclooxygenase	294 14 O
2	309 1 O
.	310 1 O

The	312 3 O
acute	316 5 O
cytolytic	322 9 O
hepatitis	332 9 B-Disease
occurred	342 8 O
rapidly	351 7 O
after	359 5 O
meloxicam	365 9 B-Chemical
administration	375 14 O
and	390 3 O
was	394 3 O
associated	398 10 O
with	409 4 O
the	414 3 O
development	418 11 O
of	430 2 O
antinuclear	433 11 O
antibodies	445 10 O
suggesting	456 10 O
a	467 1 O
hypersensitivity	469 16 B-Disease
mechanism	486 9 O
.	495 1 O

This	497 4 O
first	502 5 O
case	508 4 O
of	513 2 O
meloxicam	516 9 B-Chemical
related	526 7 O
liver	534 5 B-Disease
toxicity	540 8 I-Disease
demonstrates	549 12 O
the	562 3 O
potential	566 9 O
of	576 2 O
this	579 4 O
drug	584 4 O
to	589 2 O
induce	592 6 O
hepatic	599 7 B-Disease
damage	607 6 I-Disease
.	613 1 O

Induction	0 9 O
of	10 2 O
apoptosis	13 9 O
by	23 2 O
remoxipride	26 11 B-Chemical
metabolites	38 11 O
in	50 2 O
HL60	53 4 O
and	58 3 O
CD34	62 4 O
+	66 1 O
/	67 1 O
CD19	68 4 O
-	72 1 O
human	74 5 O
bone	80 4 O
marrow	85 6 O
progenitor	92 10 O
cells	103 5 O
:	108 1 O
potential	110 9 O
relevance	120 9 O
to	130 2 O
remoxipride	133 11 B-Chemical
-	144 1 O
induced	145 7 O
aplastic	153 8 B-Disease
anemia	162 6 I-Disease
.	168 1 O

The	170 3 O
antipsychotic	174 13 O
agent	188 5 O
,	193 1 O
remoxipride	195 11 B-Chemical
[	207 1 O
(	208 1 B-Chemical
S	209 1 I-Chemical
)	210 1 I-Chemical
-	211 1 I-Chemical
(	212 1 I-Chemical
-	213 1 I-Chemical
)	214 1 I-Chemical
-	215 1 I-Chemical
3	216 1 I-Chemical
-	217 1 I-Chemical
bromo	218 5 I-Chemical
-	223 1 I-Chemical
N	224 1 I-Chemical
-	225 1 I-Chemical
[	226 1 I-Chemical
(	227 1 I-Chemical
1	228 1 I-Chemical
-	229 1 I-Chemical
ethyl	230 5 I-Chemical
-	235 1 I-Chemical
2	236 1 I-Chemical
-	237 1 I-Chemical
pyrrolidinyl	238 12 I-Chemical
)	250 1 I-Chemical
methyl	251 6 I-Chemical
]	257 1 I-Chemical
-	258 1 I-Chemical
2	259 1 I-Chemical
,	260 1 I-Chemical
6	261 1 I-Chemical
-	262 1 I-Chemical
dimethoxybenz	263 13 I-Chemical
amide	277 5 I-Chemical
]	282 1 O
has	284 3 O
been	288 4 O
associated	293 10 O
with	304 4 O
acquired	309 8 O
aplastic	318 8 B-Disease
anemia	327 6 I-Disease
.	333 1 O

We	335 2 O
have	338 4 O
examined	343 8 O
the	352 3 O
ability	356 7 O
of	364 2 O
remoxipride	367 11 B-Chemical
,	378 1 O
three	380 5 O
pyrrolidine	386 11 B-Chemical
ring	398 4 O
metabolites	403 11 O
and	415 3 O
five	419 4 O
aromatic	424 8 O
ring	433 4 O
metabolites	438 11 O
of	450 2 O
the	453 3 O
parent	457 6 O
compound	464 8 O
to	473 2 O
induce	476 6 O
apoptosis	483 9 O
in	493 2 O
HL60	496 4 O
cells	501 5 O
and	507 3 O
human	511 5 O
bone	517 4 O
marrow	522 6 O
progenitor	529 10 O
(	540 1 O
HBMP	541 4 O
)	545 1 O
cells	547 5 O
.	552 1 O

Cells	554 5 O
were	560 4 O
treated	565 7 O
for	573 3 O
0	577 1 O
-	578 1 O
24	579 2 O
h	582 1 O
with	584 4 O
each	589 4 O
compound	594 8 O
(	603 1 O
0	604 1 O
-	605 1 O
200	606 3 O
microM	610 6 O
)	616 1 O
.	617 1 O

Apoptosis	619 9 O
was	629 3 O
assessed	633 8 O
by	642 2 O
fluorescence	645 12 O
microscopy	658 10 O
in	669 2 O
Hoechst	672 7 B-Chemical
33342	680 5 I-Chemical
-	685 1 O
and	687 3 O
propidium	691 9 B-Chemical
iodide	701 6 I-Chemical
stained	708 7 O
cell	716 4 O
samples	721 7 O
.	728 1 O

Results	730 7 O
were	738 4 O
confirmed	743 9 O
by	753 2 O
determination	756 13 O
of	770 2 O
internucleosomal	773 16 O
DNA	790 3 O
fragmentation	794 13 O
using	808 5 O
gel	814 3 O
electrophoresis	818 15 O
for	834 3 O
HL60	838 4 O
cell	843 4 O
samples	848 7 O
and	856 3 O
terminal	860 8 O
deoxynucleotidyl	869 16 O
transferase	886 11 O
assay	898 5 O
in	904 2 O
HBMP	907 4 O
cells	912 5 O
.	917 1 O

The	919 3 O
catechol	923 8 B-Chemical
and	932 3 O
hydroquinone	936 12 B-Chemical
metabolites	949 11 O
,	960 1 O
NCQ436	962 6 B-Chemical
and	969 3 O
NCQ344	973 6 B-Chemical
,	979 1 O
induced	981 7 O
apoptosis	989 9 O
in	999 2 O
HL60	1002 4 O
and	1007 3 O
HBMP	1011 4 O
cells	1016 5 O
in	1022 2 O
a	1025 1 O
time	1027 4 O
-	1031 1 O
and	1033 3 O
concentration	1037 13 O
dependent	1051 9 O
manner	1061 6 O
,	1067 1 O
while	1069 5 O
the	1075 3 O
phenols	1079 7 B-Chemical
,	1086 1 O
NCR181	1088 6 O
,	1094 1 O
FLA873	1096 6 O
,	1102 1 O
and	1104 3 O
FLA797	1108 6 B-Chemical
,	1114 1 O
and	1116 3 O
the	1120 3 O
derivatives	1124 11 O
formed	1136 6 O
by	1143 2 O
oxidation	1146 9 O
of	1156 2 O
the	1159 3 O
pyrrolidine	1163 11 B-Chemical
ring	1175 4 O
,	1179 1 O
FLA838	1181 6 O
,	1187 1 O
NCM001	1189 6 O
,	1195 1 O
and	1197 3 O
NCL118	1201 6 O
,	1207 1 O
had	1209 3 O
no	1213 2 O
effect	1216 6 O
.	1222 1 O

No	1224 2 O
necrosis	1227 8 B-Disease
was	1236 3 O
observed	1240 8 O
in	1249 2 O
cells	1252 5 O
treated	1258 7 O
with	1266 4 O
NCQ436	1271 6 B-Chemical
but	1278 3 O
NCQ344	1282 6 B-Chemical
had	1289 3 O
a	1293 1 O
biphasic	1295 8 O
effect	1304 6 O
in	1311 2 O
both	1314 4 O
cell	1319 4 O
types	1324 5 O
,	1329 1 O
inducing	1331 8 O
apoptosis	1340 9 O
at	1350 2 O
lower	1353 5 O
concentrations	1359 14 O
and	1374 3 O
necrosis	1378 8 B-Disease
at	1387 2 O
higher	1390 6 O
concentrations	1397 14 O
.	1411 1 O

These	1413 5 O
data	1419 4 O
show	1424 4 O
that	1429 4 O
the	1434 3 O
catechol	1438 8 B-Chemical
and	1447 3 O
hydroquinone	1451 12 B-Chemical
metabolites	1464 11 O
of	1476 2 O
remoxipride	1479 11 B-Chemical
have	1491 4 O
direct	1496 6 O
toxic	1503 5 O
effects	1509 7 O
in	1517 2 O
HL60	1520 4 O
and	1525 3 O
HBMP	1529 4 O
cells	1534 5 O
,	1539 1 O
leading	1541 7 O
to	1549 2 O
apoptosis	1552 9 O
,	1561 1 O
while	1563 5 O
the	1569 3 O
phenol	1573 6 B-Chemical
metabolites	1580 11 O
were	1592 4 O
inactive	1597 8 O
.	1605 1 O

Similarly	1607 9 O
,	1616 1 O
benzene	1618 7 B-Chemical
-	1625 1 O
derived	1626 7 O
catechol	1634 8 B-Chemical
and	1643 3 O
hydroquinone	1647 12 B-Chemical
,	1659 1 O
but	1661 3 O
not	1665 3 O
phenol	1669 6 B-Chemical
,	1675 1 O
induce	1677 6 O
apoptosis	1684 9 O
in	1694 2 O
HBMP	1697 4 O
cells	1702 5 O
[	1708 1 O
Moran	1709 5 O
et	1715 2 O
al	1718 2 O
.	1720 1 O
,	1721 1 O
Mol	1723 3 O
.	1726 1 O
Pharmacol	1728 9 O
.	1737 1 O
,	1738 1 O
50	1740 2 O
(	1743 1 O
1996	1744 4 O
)	1748 1 O
610	1750 3 O
-	1753 1 O
615	1754 3 O
]	1757 1 O
.	1758 1 O

We	1760 2 O
propose	1763 7 O
that	1771 4 O
remoxipride	1776 11 B-Chemical
and	1788 3 O
benzene	1792 7 B-Chemical
may	1800 3 O
induce	1804 6 O
aplastic	1811 8 B-Disease
anemia	1820 6 I-Disease
via	1827 3 O
production	1831 10 O
of	1842 2 O
similar	1845 7 O
reactive	1853 8 O
metabolites	1862 11 O
and	1874 3 O
that	1878 4 O
the	1883 3 O
ability	1887 7 O
of	1895 2 O
NCQ436	1898 6 B-Chemical
and	1905 3 O
NCQ344	1909 6 B-Chemical
to	1916 2 O
induce	1919 6 O
apoptosis	1926 9 O
in	1936 2 O
HBMP	1939 4 O
cells	1944 5 O
may	1950 3 O
contribute	1954 10 O
to	1965 2 O
the	1968 3 O
mechanism	1972 9 O
underlying	1982 10 O
acquired	1993 8 O
aplastic	2002 8 B-Disease
anemia	2011 6 I-Disease
that	2018 4 O
has	2023 3 O
been	2027 4 O
associated	2032 10 O
with	2043 4 O
remoxipride	2048 11 B-Chemical
.	2059 1 O

Synthesis	0 9 O
and	10 3 O
preliminary	14 11 O
pharmacological	26 15 O
investigations	42 14 O
of	57 2 O
1	60 1 B-Chemical
-	61 1 I-Chemical
(	62 1 I-Chemical
1	63 1 I-Chemical
,	64 1 I-Chemical
2	65 1 I-Chemical
-	66 1 I-Chemical
dihydro	67 7 I-Chemical
-	74 1 I-Chemical
2	75 1 I-Chemical
-	76 1 I-Chemical
acenaphthylenyl	77 15 I-Chemical
)	92 1 I-Chemical
piperazine	93 10 I-Chemical
derivatives	104 11 O
as	116 2 O
potential	119 9 O
atypical	129 8 O
antipsychotic	138 13 O
agents	152 6 O
in	159 2 O
mice	162 4 O
.	166 1 O

In	168 2 O
research	171 8 O
towards	180 7 O
the	188 3 O
development	192 11 O
of	204 2 O
new	207 3 O
atypical	211 8 O
antipsychotic	220 13 O
agents	234 6 O
,	240 1 O
one	242 3 O
strategy	246 8 O
is	255 2 O
that	258 4 O
the	263 3 O
dopaminergic	267 12 O
system	280 6 O
can	287 3 O
be	291 2 O
modulated	294 9 O
through	304 7 O
manipulation	312 12 O
of	325 2 O
the	328 3 O
serotonergic	332 12 O
system	345 6 O
.	351 1 O

The	353 3 O
synthesis	357 9 O
and	367 3 O
preliminary	371 11 O
pharmacological	383 15 O
evaluation	399 10 O
of	410 2 O
a	413 1 O
series	415 6 O
of	422 2 O
potential	425 9 O
atypical	435 8 O
antipsychotic	444 13 O
agents	458 6 O
based	465 5 O
on	471 2 O
the	474 3 O
structure	478 9 O
of	488 2 O
1	491 1 B-Chemical
-	492 1 I-Chemical
(	493 1 I-Chemical
1	494 1 I-Chemical
,	495 1 I-Chemical
2	496 1 I-Chemical
-	497 1 I-Chemical
dihydro	498 7 I-Chemical
-	505 1 I-Chemical
2	506 1 I-Chemical
-	507 1 I-Chemical
acenaphthylenyl	508 15 I-Chemical
)	523 1 I-Chemical
piperazine	524 10 I-Chemical
(	535 1 O
7	536 1 O
)	537 1 O
is	539 2 O
described	542 9 O
.	551 1 O

Compound	553 8 O
7e	562 2 O
,	564 1 O
5	566 1 B-Chemical
-	567 1 I-Chemical
{	568 1 I-Chemical
2	569 1 I-Chemical
-	570 1 I-Chemical
[	571 1 I-Chemical
4	572 1 I-Chemical
-	573 1 I-Chemical
(	574 1 I-Chemical
1	575 1 I-Chemical
,	576 1 I-Chemical
2	577 1 I-Chemical
-	578 1 I-Chemical
dihydro	579 7 I-Chemical
-	586 1 I-Chemical
2	587 1 I-Chemical
-	588 1 I-Chemical
acenaphthylenyl	589 15 I-Chemical
)	604 1 I-Chemical
piperazinyl	605 11 I-Chemical
]	616 1 I-Chemical
ethyl	617 5 I-Chemical
}	622 1 I-Chemical
-	623 1 I-Chemical
2	624 1 I-Chemical
,	625 1 I-Chemical
3	626 1 I-Chemical
-	627 1 I-Chemical
dihy	628 4 I-Chemical
dro	633 3 I-Chemical
-	636 1 I-Chemical
1H	637 2 I-Chemical
-	639 1 I-Chemical
indol	641 5 I-Chemical
-	646 1 I-Chemical
2	647 1 I-Chemical
-	648 1 I-Chemical
one	649 3 I-Chemical
,	652 1 O
from	654 4 O
this	659 4 O
series	664 6 O
showed	671 6 O
significant	678 11 O
affinities	690 10 O
at	701 2 O
the	704 3 O
5	708 1 O
-	709 1 O
HT1A	710 4 O
and	715 3 O
5	719 1 O
-	720 1 O
HT2A	721 4 O
receptors	726 9 O
and	736 3 O
moderate	740 8 O
affinity	749 8 O
at	758 2 O
the	761 3 O
D2	765 2 O
receptor	768 8 O
.	776 1 O

7e	778 2 O
exhibits	781 8 O
a	790 1 O
high	792 4 O
reversal	797 8 O
of	806 2 O
catalepsy	809 9 B-Disease
induced	819 7 O
by	827 2 O
haloperidol	830 11 B-Chemical
indicating	842 10 O
its	853 3 O
atypical	857 8 O
antipsychotic	866 13 O
nature	880 6 O
.	886 1 O

Sub	0 3 O
-	3 1 O
chronic	4 7 O
inhibition	12 10 O
of	23 2 O
nitric	26 6 B-Chemical
-	32 1 I-Chemical
oxide	33 5 I-Chemical
synthesis	39 9 O
modifies	49 8 O
haloperidol	58 11 B-Chemical
-	69 1 O
induced	70 7 O
catalepsy	78 9 B-Disease
and	88 3 O
the	92 3 O
number	96 6 O
of	103 2 O
NADPH	106 5 B-Chemical
-	111 1 O
diaphorase	112 10 O
neurons	123 7 O
in	131 2 O
mice	134 4 O
.	138 1 O

RATIONALE	140 9 O
:	149 1 O
NG	151 2 B-Chemical
-	153 1 I-Chemical
nitro	154 5 I-Chemical
-	159 1 I-Chemical
L	160 1 I-Chemical
-	161 1 I-Chemical
arginine	162 8 I-Chemical
(	171 1 O
L	172 1 B-Chemical
-	173 1 I-Chemical
NOARG	174 5 I-Chemical
)	179 1 O
,	180 1 O
an	182 2 O
inhibitor	185 9 O
of	195 2 O
nitric	198 6 B-Chemical
-	204 1 I-Chemical
oxide	205 5 I-Chemical
synthase	211 8 O
(	220 1 O
NOS	221 3 O
)	224 1 O
,	225 1 O
induces	227 7 O
catalepsy	235 9 B-Disease
in	245 2 O
mice	248 4 O
.	252 1 O

This	254 4 O
effect	259 6 O
undergoes	266 9 O
rapid	276 5 O
tolerance	282 9 O
,	291 1 O
showing	293 7 O
a	301 1 O
significant	303 11 O
decrease	315 8 O
after	324 5 O
2	330 1 O
days	332 4 O
of	337 2 O
sub	340 3 O
-	343 1 O
chronic	344 7 O
L	352 1 B-Chemical
-	353 1 I-Chemical
NOARG	354 5 I-Chemical
treatment	360 9 O
.	369 1 O

Nitric	371 6 B-Chemical
oxide	378 5 I-Chemical
(	384 1 O
NO	385 2 B-Chemical
)	387 1 O
has	389 3 O
been	393 4 O
shown	398 5 O
to	404 2 O
influence	407 9 O
dopaminergic	417 12 O
neurotransmission	430 17 O
in	448 2 O
the	451 3 O
striatum	455 8 O
.	463 1 O

Neuroleptic	465 11 O
drugs	477 5 O
such	483 4 O
as	488 2 O
haloperidol	491 11 B-Chemical
,	502 1 O
which	504 5 O
block	510 5 O
dopamine	516 8 B-Chemical
receptors	525 9 O
,	534 1 O
also	536 4 O
cause	541 5 O
catalepsy	547 9 B-Disease
in	557 2 O
rodents	560 7 O
.	567 1 O

OBJECTIVES	569 10 O
:	579 1 O
To	581 2 O
investigate	584 11 O
the	596 3 O
effects	600 7 O
of	608 2 O
subchronic	611 10 O
L	622 1 B-Chemical
-	623 1 I-Chemical
NOARG	624 5 I-Chemical
treatment	630 9 O
in	640 2 O
haloperidol	643 11 B-Chemical
-	654 1 O
induced	655 7 O
catalepsy	663 9 B-Disease
and	673 3 O
the	677 3 O
number	681 6 O
of	688 2 O
NOS	691 3 O
neurons	695 7 O
in	703 2 O
areas	706 5 O
related	712 7 O
to	720 2 O
motor	723 5 O
control	729 7 O
.	736 1 O

METHODS	738 7 O
:	745 1 O
Male	747 4 O
albino	752 6 O
Swiss	759 5 O
mice	765 4 O
were	770 4 O
treated	775 7 O
sub	783 3 O
-	786 1 O
chronically	787 11 O
(	799 1 O
twice	800 5 O
a	806 1 O
day	808 3 O
for	812 3 O
4	816 1 O
days	818 4 O
)	822 1 O
with	824 4 O
L	829 1 B-Chemical
-	830 1 I-Chemical
NOARG	831 5 I-Chemical
(	837 1 O
40	838 2 O
mg	841 2 O
/	843 1 O
kg	844 2 O
i	847 1 O
.	848 1 O
p	849 1 O
.	850 1 O
)	851 1 O
or	853 2 O
haloperidol	856 11 B-Chemical
(	868 1 O
1	869 1 O
mg	871 2 O
/	873 1 O
kg	874 2 O
i	877 1 O
.	878 1 O
p	879 1 O
.	880 1 O
)	881 1 O
.	882 1 O

Catalepsy	884 9 B-Disease
was	894 3 O
evaluated	898 9 O
at	908 2 O
the	911 3 O
beginning	915 9 O
and	925 3 O
the	929 3 O
end	933 3 O
of	937 2 O
the	940 3 O
treatments	944 10 O
.	954 1 O

Reduced	956 7 O
nicotinamide	964 12 B-Chemical
adenine	977 7 I-Chemical
dinucleotide	985 12 I-Chemical
phosphate	998 9 I-Chemical
-	1007 1 O
diaphorase	1008 10 O
(	1019 1 O
NADPH	1020 5 B-Chemical
-	1025 1 O
d	1026 1 O
)	1027 1 O
histochemistry	1029 14 O
was	1044 3 O
also	1048 4 O
employed	1053 8 O
to	1062 2 O
visualize	1065 9 O
NOS	1075 3 O
as	1079 2 O
an	1082 2 O
index	1085 5 O
of	1091 2 O
enzyme	1094 6 O
expression	1101 10 O
in	1112 2 O
mice	1115 4 O
brain	1120 5 O
regions	1126 7 O
related	1134 7 O
to	1142 2 O
motor	1145 5 O
control	1151 7 O
.	1158 1 O

RESULTS	1160 7 O
:	1167 1 O
L	1169 1 B-Chemical
-	1170 1 I-Chemical
NOARG	1171 5 I-Chemical
sub	1177 3 O
-	1180 1 O
chronic	1181 7 O
administration	1189 14 O
produced	1204 8 O
tolerance	1213 9 O
of	1223 2 O
L	1226 1 B-Chemical
-	1227 1 I-Chemical
NOARG	1228 5 I-Chemical
and	1234 3 O
of	1238 2 O
haloperidol	1241 11 B-Chemical
-	1252 1 O
induced	1253 7 O
catalepsy	1261 9 B-Disease
.	1270 1 O

It	1272 2 O
also	1275 4 O
induced	1280 7 O
an	1288 2 O
increase	1291 8 O
in	1300 2 O
the	1303 3 O
number	1307 6 O
of	1314 2 O
NADPH	1317 5 B-Chemical
-	1322 1 O
d	1323 1 O
-	1324 1 O
positive	1325 8 O
cells	1334 5 O
in	1340 2 O
the	1343 3 O
dorsal	1347 6 O
part	1354 4 O
of	1359 2 O
the	1362 3 O
caudate	1366 7 O
and	1374 3 O
accumbens	1378 9 O
nuclei	1388 6 O
compared	1395 8 O
with	1404 4 O
haloperidol	1409 11 B-Chemical
and	1421 3 O
in	1425 2 O
the	1428 3 O
pedunculopontine	1432 16 O
tegmental	1449 9 O
nucleus	1459 7 O
compared	1467 8 O
with	1476 4 O
saline	1481 6 O
.	1487 1 O

In	1489 2 O
contrast	1492 8 O
,	1500 1 O
there	1502 5 O
was	1508 3 O
a	1512 1 O
decrease	1514 8 O
in	1523 2 O
NADPH	1526 5 B-Chemical
-	1531 1 O
d	1532 1 O
neuron	1534 6 O
number	1541 6 O
in	1548 2 O
the	1551 3 O
substantia	1555 10 O
nigra	1566 5 O
,	1571 1 O
pars	1573 4 O
compacta	1578 8 O
in	1587 2 O
both	1590 4 O
haloperidol	1595 11 B-Chemical
-	1606 1 O
treated	1607 7 O
and	1615 3 O
L	1619 1 B-Chemical
-	1620 1 I-Chemical
NOARG	1621 5 I-Chemical
-	1626 1 O
treated	1627 7 O
animals	1635 7 O
.	1642 1 O

CONCLUSIONS	1644 11 O
:	1655 1 O
The	1657 3 O
results	1661 7 O
give	1669 4 O
further	1674 7 O
support	1682 7 O
to	1690 2 O
the	1693 3 O
hypothesis	1697 10 O
that	1708 4 O
NO	1713 2 B-Chemical
plays	1716 5 O
a	1722 1 O
role	1724 4 O
in	1729 2 O
motor	1732 5 O
behavior	1738 8 O
control	1747 7 O
and	1755 3 O
suggest	1759 7 O
that	1767 4 O
it	1772 2 O
may	1775 3 O
take	1779 4 O
part	1784 4 O
in	1789 2 O
the	1792 3 O
synaptic	1796 8 O
changes	1805 7 O
produced	1813 8 O
by	1822 2 O
antipsychotic	1825 13 O
treatment	1839 9 O
.	1848 1 O

Prolonged	0 9 O
left	10 4 B-Disease
ventricular	15 11 I-Disease
dysfunction	27 11 I-Disease
occurs	39 6 O
in	46 2 O
patients	49 8 O
with	58 4 O
coronary	63 8 B-Disease
artery	72 6 I-Disease
disease	79 7 I-Disease
after	87 5 O
both	93 4 O
dobutamine	98 10 B-Chemical
and	109 3 O
exercise	113 8 O
induced	122 7 O
myocardial	130 10 B-Disease
ischaemia	141 9 I-Disease
.	150 1 O

OBJECTIVE	152 9 O
:	161 1 O
To	163 2 O
determine	166 9 O
whether	176 7 O
pharmacological	184 15 O
stress	200 6 O
leads	207 5 O
to	213 2 O
prolonged	216 9 O
but	226 3 O
reversible	230 10 O
left	241 4 B-Disease
ventricular	246 11 I-Disease
dysfunction	258 11 I-Disease
in	270 2 O
patients	273 8 O
with	282 4 O
coronary	287 8 B-Disease
artery	296 6 I-Disease
disease	303 7 I-Disease
,	310 1 O
similar	312 7 O
to	320 2 O
that	323 4 O
seen	328 4 O
after	333 5 O
exercise	339 8 O
.	347 1 O

DESIGN	349 6 O
:	355 1 O
A	357 1 O
randomised	359 10 O
crossover	370 9 O
study	380 5 O
of	386 2 O
recovery	389 8 O
time	398 4 O
of	403 2 O
systolic	406 8 O
and	415 3 O
diastolic	419 9 O
left	429 4 O
ventricular	434 11 O
function	446 8 O
after	455 5 O
exercise	461 8 O
and	470 3 O
dobutamine	474 10 B-Chemical
induced	485 7 O
ischaemia	493 9 B-Disease
.	502 1 O

SUBJECTS	504 8 O
:	512 1 O
10	514 2 O
patients	517 8 O
with	526 4 O
stable	531 6 B-Disease
angina	538 6 I-Disease
,	544 1 O
angiographically	546 16 O
proven	563 6 O
coronary	570 8 B-Disease
artery	579 6 I-Disease
disease	586 7 I-Disease
,	593 1 O
and	595 3 O
normal	599 6 O
left	606 4 O
ventricular	611 11 O
function	623 8 O
.	631 1 O

INTERVENTIONS	633 13 O
:	646 1 O
Treadmill	648 9 O
exercise	658 8 O
and	667 3 O
dobutamine	671 10 B-Chemical
stress	682 6 O
were	689 4 O
performed	694 9 O
on	704 2 O
different	707 9 O
days	717 4 O
.	721 1 O

Quantitative	723 12 O
assessment	736 10 O
of	747 2 O
systolic	750 8 O
and	759 3 O
diastolic	763 9 O
left	773 4 O
ventricular	778 11 O
function	790 8 O
was	799 3 O
performed	803 9 O
using	813 5 O
transthoracic	819 13 O
echocardiography	833 16 O
at	850 2 O
baseline	853 8 O
and	862 3 O
at	866 2 O
regular	869 7 O
intervals	877 9 O
after	887 5 O
each	893 4 O
test	898 4 O
.	902 1 O

RESULTS	904 7 O
:	911 1 O
Both	913 4 O
forms	918 5 O
of	924 2 O
stress	927 6 O
led	934 3 O
to	938 2 O
prolonged	941 9 O
but	951 3 O
reversible	955 10 O
systolic	966 8 O
and	975 3 O
diastolic	979 9 O
dysfunction	989 11 O
.	1000 1 O

There	1002 5 O
was	1008 3 O
no	1012 2 O
difference	1015 10 O
in	1026 2 O
the	1029 3 O
maximum	1033 7 O
double	1041 6 O
product	1048 7 O
(	1056 1 O
p	1057 1 O
=	1059 1 O
0	1061 1 O
.	1062 1 O
53	1063 2 O
)	1065 1 O
or	1067 2 O
ST	1070 2 O
depression	1073 10 B-Disease
(	1084 1 O
p	1085 1 O
=	1087 1 O
0	1089 1 O
.	1090 1 O
63	1091 2 O
)	1093 1 O
with	1095 4 O
either	1100 6 O
form	1107 4 O
of	1112 2 O
stress	1115 6 O
.	1121 1 O

After	1123 5 O
exercise	1129 8 O
,	1137 1 O
ejection	1139 8 O
fraction	1148 8 O
was	1157 3 O
reduced	1161 7 O
at	1169 2 O
15	1172 2 O
and	1175 3 O
30	1179 2 O
minutes	1182 7 O
compared	1190 8 O
with	1199 4 O
baseline	1204 8 O
(	1213 1 O
mean	1214 4 O
(	1219 1 O
SEM	1220 3 O
)	1223 1 O
,	1224 1 O
-	1226 1 O
5	1227 1 O
.	1228 1 O
6	1229 1 O
(	1231 1 O
1	1232 1 O
.	1233 1 O
5	1234 1 O
)	1235 1 O
%	1236 1 O
,	1237 1 O
p	1239 1 O
<	1241 1 O
0	1243 1 O
.	1244 1 O
05	1245 2 O
;	1247 1 O
and	1249 3 O
-	1253 1 O
6	1254 1 O
.	1255 1 O
1	1256 1 O
(	1258 1 O
2	1259 1 O
.	1260 1 O
2	1261 1 O
)	1262 1 O
%	1263 1 O
,	1264 1 O
p	1266 1 O
<	1268 1 O
0	1270 1 O
.	1271 1 O
01	1273 2 O
)	1275 1 O
,	1276 1 O
and	1278 3 O
at	1282 2 O
30	1285 2 O
and	1288 3 O
45	1292 2 O
minutes	1295 7 O
after	1303 5 O
dobutamine	1309 10 B-Chemical
(	1320 1 O
-	1321 1 O
10	1322 2 O
.	1324 1 O
8	1325 1 O
(	1327 1 O
1	1328 1 O
.	1329 1 O
8	1330 1 O
)	1331 1 O
%	1332 1 O
and	1334 3 O
-	1338 1 O
5	1339 1 O
.	1340 1 O
5	1342 1 O
(	1344 1 O
1	1345 1 O
.	1346 1 O
8	1347 1 O
)	1348 1 O
%	1349 1 O
,	1350 1 O
both	1352 4 O
p	1357 1 O
<	1359 1 O
0	1361 1 O
.	1362 1 O
01	1363 2 O
)	1365 1 O
.	1366 1 O

Regional	1368 8 O
analysis	1377 8 O
showed	1386 6 O
a	1393 1 O
reduction	1395 9 O
in	1405 2 O
the	1408 3 O
worst	1412 5 O
affected	1418 8 O
segment	1427 7 O
15	1435 2 O
and	1438 3 O
30	1442 2 O
minutes	1445 7 O
after	1453 5 O
exercise	1459 8 O
(	1468 1 O
-	1469 1 O
27	1470 2 O
.	1472 1 O
9	1473 1 O
(	1475 1 O
7	1476 1 O
.	1477 1 O
2	1478 1 O
)	1479 1 O
%	1480 1 O
and	1482 3 O
-	1486 1 O
28	1487 2 O
.	1489 1 O
6	1490 1 O
(	1492 1 O
5	1493 1 O
.	1494 1 O
7	1495 1 O
)	1496 1 O
%	1497 1 O
,	1498 1 O
both	1500 4 O
p	1505 1 O
<	1507 1 O
0	1509 1 O
.	1510 1 O
01	1511 2 O
)	1513 1 O
,	1514 1 O
and	1516 3 O
at	1520 2 O
30	1523 2 O
minutes	1526 7 O
after	1534 5 O
dobutamine	1540 10 B-Chemical
(	1551 1 O
-	1552 1 O
32	1553 2 O
(	1556 1 O
5	1557 1 O
.	1558 1 O
3	1559 1 O
)	1560 1 O
%	1561 1 O
,	1562 1 O
p	1564 1 O
<	1566 1 O
0	1568 1 O
.	1569 1 O
01	1570 2 O
)	1572 1 O
.	1573 1 O

The	1575 3 O
isovolumic	1579 10 O
relaxation	1590 10 O
period	1601 6 O
was	1608 3 O
prolonged	1612 9 O
45	1622 2 O
minutes	1625 7 O
after	1633 5 O
each	1639 4 O
form	1644 4 O
of	1649 2 O
stress	1652 6 O
(	1659 1 O
p	1660 1 O
<	1662 1 O
0	1664 1 O
.	1665 1 O
05	1666 2 O
)	1668 1 O
.	1669 1 O

CONCLUSIONS	1671 11 O
:	1682 1 O
In	1684 2 O
patients	1687 8 O
with	1696 4 O
coronary	1701 8 B-Disease
artery	1710 6 I-Disease
disease	1717 7 I-Disease
,	1724 1 O
dobutamine	1726 10 B-Chemical
induced	1737 7 O
ischaemia	1745 9 B-Disease
results	1755 7 O
in	1763 2 O
prolonged	1766 9 O
reversible	1776 10 O
left	1787 4 B-Disease
ventricular	1792 11 I-Disease
dysfunction	1804 11 I-Disease
,	1815 1 O
presumed	1817 8 O
to	1826 2 O
be	1829 2 O
myocardial	1832 10 B-Disease
stunning	1843 8 I-Disease
,	1851 1 O
similar	1853 7 O
to	1861 2 O
that	1864 4 O
seen	1869 4 O
after	1874 5 O
exercise	1880 8 O
.	1888 1 O

Dobutamine	1890 10 B-Chemical
induced	1901 7 O
ischaemia	1909 9 B-Disease
could	1919 5 O
therefore	1925 9 O
be	1935 2 O
used	1938 4 O
to	1943 2 O
study	1946 5 O
the	1952 3 O
pathophysiology	1956 15 O
of	1972 2 O
this	1975 4 O
phenomenon	1980 10 O
further	1991 7 O
in	1999 2 O
patients	2002 8 O
with	2011 4 O
coronary	2016 8 B-Disease
artery	2025 6 I-Disease
disease	2032 7 I-Disease
.	2039 1 O

Anorexigens	0 11 O
and	12 3 O
pulmonary	16 9 B-Disease
hypertension	26 12 I-Disease
in	39 2 O
the	42 3 O
United	46 6 O
States	53 6 O
:	59 1 O
results	61 7 O
from	69 4 O
the	74 3 O
surveillance	78 12 O
of	91 2 O
North	94 5 O
American	100 8 O
pulmonary	109 9 B-Disease
hypertension	119 12 I-Disease
.	131 1 O

BACKGROUND	133 10 O
:	143 1 O
The	145 3 O
use	149 3 O
of	153 2 O
appetite	156 8 O
suppressants	165 12 O
in	178 2 O
Europe	181 6 O
has	188 3 O
been	192 4 O
associated	197 10 O
with	208 4 O
the	213 3 O
development	217 11 O
of	229 2 O
primary	232 7 B-Disease
pulmonary	240 9 I-Disease
hypertension	250 12 I-Disease
(	263 1 O
PPH	264 3 B-Disease
)	267 1 O
.	268 1 O

Recently	270 8 O
,	278 1 O
fenfluramine	280 12 B-Chemical
appetite	293 8 O
suppressants	302 12 O
became	315 6 O
widely	322 6 O
used	329 4 O
in	334 2 O
the	337 3 O
United	341 6 O
States	348 6 O
but	355 3 O
were	359 4 O
withdrawn	364 9 O
in	374 2 O
September	377 9 O
1997	387 4 O
because	392 7 O
of	400 2 O
concerns	403 8 O
over	412 4 O
adverse	417 7 O
effects	425 7 O
.	432 1 O

MATERIALS	434 9 O
AND	444 3 O
METHODS	448 7 O
:	455 1 O
We	457 2 O
conducted	460 9 O
a	470 1 O
prospective	472 11 O
surveillance	484 12 O
study	497 5 O
on	503 2 O
patients	506 8 O
diagnosed	515 9 O
with	525 4 O
pulmonary	530 9 B-Disease
hypertension	540 12 I-Disease
at	553 2 O
12	556 2 O
large	559 5 O
referral	565 8 O
centers	574 7 O
in	582 2 O
North	585 5 O
America	591 7 O
.	598 1 O

Data	600 4 O
collected	605 9 O
on	615 2 O
patients	618 8 O
seen	627 4 O
from	632 4 O
September	637 9 O
1	647 1 O
,	648 1 O
1996	650 4 O
,	654 1 O
to	656 2 O
December	659 8 O
31	668 2 O
,	670 1 O
1997	672 4 O
,	676 1 O
included	678 8 O
the	687 3 O
cause	691 5 O
of	697 2 O
the	700 3 O
pulmonary	704 9 B-Disease
hypertension	714 12 I-Disease
and	727 3 O
its	731 3 O
severity	735 8 O
.	743 1 O

Patients	745 8 O
with	754 4 O
no	759 2 O
identifiable	762 12 O
cause	775 5 O
of	781 2 O
pulmonary	784 9 B-Disease
hypertension	794 12 I-Disease
were	807 4 O
classed	812 7 O
as	820 2 O
PPH	823 3 B-Disease
.	826 1 O

A	828 1 O
history	830 7 O
of	838 2 O
drug	841 4 O
exposure	846 8 O
also	855 4 O
was	860 3 O
taken	864 5 O
with	870 4 O
special	875 7 O
attention	883 9 O
on	893 2 O
the	896 3 O
use	900 3 O
of	904 2 O
antidepressants	907 15 O
,	922 1 O
anorexigens	924 11 O
,	935 1 O
and	937 3 O
amphetamines	941 12 B-Chemical
.	953 1 O

RESULTS	955 7 O
:	962 1 O
Five	964 4 O
hundred	969 7 O
seventy	977 7 O
-	984 1 O
nine	985 4 O
patients	990 8 O
were	999 4 O
studied	1004 7 O
,	1011 1 O
205	1013 3 O
with	1017 4 O
PPH	1022 3 B-Disease
and	1026 3 O
374	1030 3 O
with	1034 4 O
pulmonary	1039 9 B-Disease
hypertension	1049 12 I-Disease
from	1062 4 O
other	1067 5 O
causes	1073 6 O
(	1080 1 O
secondary	1081 9 O
pulmonary	1091 9 B-Disease
hypertension	1101 12 I-Disease
[	1114 1 O
SPH	1115 3 O
]	1118 1 O
)	1119 1 O
.	1120 1 O

The	1122 3 O
use	1126 3 O
of	1130 2 O
anorexigens	1133 11 O
was	1145 3 O
common	1149 6 O
in	1156 2 O
both	1159 4 O
groups	1164 6 O
.	1170 1 O

However	1172 7 O
,	1179 1 O
of	1181 2 O
the	1184 3 O
medications	1188 11 O
surveyed	1200 8 O
,	1208 1 O
only	1210 4 O
the	1215 3 O
fenfluramines	1219 13 B-Chemical
had	1233 3 O
a	1237 1 O
significant	1239 11 O
preferential	1251 12 O
association	1264 11 O
with	1276 4 O
PPH	1281 3 B-Disease
as	1285 2 O
compared	1288 8 O
with	1297 4 O
SPH	1302 3 O
(	1306 1 O
adjusted	1307 8 O
odds	1316 4 O
ratio	1321 5 O
for	1327 3 O
use	1331 3 O
>	1335 1 O
6	1337 1 O
months	1339 6 O
,	1345 1 O
7	1347 1 O
.	1348 1 O
5	1349 1 O
;	1350 1 O
95	1352 2 O
%	1354 1 O
confidence	1356 10 O
interval	1367 8 O
,	1375 1 O
1	1377 1 O
.	1378 1 O
7	1379 1 O
to	1381 2 O
32	1384 2 O
.	1386 1 O
4	1387 1 O
)	1388 1 O
.	1389 1 O

The	1391 3 O
association	1395 11 O
was	1407 3 O
stronger	1411 8 O
with	1420 4 O
longer	1425 6 O
duration	1432 8 O
of	1441 2 O
use	1444 3 O
when	1448 4 O
compared	1453 8 O
to	1462 2 O
shorter	1465 7 O
duration	1473 8 O
of	1482 2 O
use	1485 3 O
and	1489 3 O
was	1493 3 O
more	1497 4 O
pronounced	1502 10 O
in	1513 2 O
recent	1516 6 O
users	1523 5 O
than	1529 4 O
in	1534 2 O
remote	1537 6 O
users	1544 5 O
.	1549 1 O

An	1551 2 O
unexpectedly	1554 12 O
high	1567 4 O
(	1572 1 O
11	1573 2 O
.	1575 1 O
4	1576 1 O
%	1577 1 O
)	1578 1 O
number	1580 6 O
of	1587 2 O
patients	1590 8 O
with	1599 4 O
SPH	1604 3 O
had	1608 3 O
used	1612 4 O
anorexigens	1617 11 O
.	1628 1 O

CONCLUSION	1630 10 O
:	1640 1 O
The	1642 3 O
magnitude	1646 9 O
of	1656 2 O
the	1659 3 O
association	1663 11 O
with	1675 4 O
PPH	1680 3 B-Disease
,	1683 1 O
the	1685 3 O
increase	1689 8 O
of	1698 2 O
association	1701 11 O
with	1713 4 O
increasing	1718 10 O
duration	1729 8 O
of	1738 2 O
use	1741 3 O
,	1744 1 O
and	1746 3 O
the	1750 3 O
specificity	1754 11 O
for	1766 3 O
fenfluramines	1770 13 B-Chemical
are	1784 3 O
consistent	1788 10 O
with	1799 4 O
previous	1804 8 O
studies	1813 7 O
indicating	1821 10 O
that	1832 4 O
fenfluramines	1837 13 B-Chemical
are	1851 3 O
causally	1855 8 O
related	1864 7 O
to	1872 2 O
PPH	1875 3 B-Disease
.	1878 1 O

The	1880 3 O
high	1884 4 O
prevalence	1889 10 O
of	1900 2 O
anorexigen	1903 10 O
use	1914 3 O
in	1918 2 O
patients	1921 8 O
with	1930 4 O
SPH	1935 3 O
also	1939 4 O
raises	1944 6 O
the	1951 3 O
possibility	1955 11 O
that	1967 4 O
these	1972 5 O
drugs	1978 5 O
precipitate	1984 11 O
pulmonary	1996 9 B-Disease
hypertension	2006 12 I-Disease
in	2019 2 O
patients	2022 8 O
with	2031 4 O
underlying	2036 10 O
conditions	2047 10 O
associated	2058 10 O
with	2069 4 O
SPH	2074 3 O
.	2077 1 O

Clinical	0 8 O
aspects	9 7 O
of	17 2 O
heparin	20 7 B-Chemical
-	27 1 O
induced	28 7 O
thrombocytopenia	36 16 B-Disease
and	53 3 O
thrombosis	57 10 B-Disease
and	68 3 O
other	72 5 O
side	78 4 O
effects	83 7 O
of	91 2 O
heparin	94 7 B-Chemical
therapy	102 7 O
.	109 1 O

Heparin	111 7 B-Chemical
,	118 1 O
first	120 5 O
used	126 4 O
to	131 2 O
prevent	134 7 O
the	142 3 O
clotting	146 8 O
of	155 2 O
blood	158 5 O
in	164 2 O
vitro	167 5 O
,	172 1 O
has	174 3 O
been	178 4 O
clinically	183 10 O
used	194 4 O
to	199 2 O
treat	202 5 O
thrombosis	208 10 B-Disease
for	219 3 O
more	223 4 O
than	228 4 O
50	233 2 O
years	236 5 O
.	241 1 O

Although	243 8 O
several	252 7 O
new	260 3 O
anticoagulant	264 13 O
drugs	278 5 O
are	284 3 O
in	288 2 O
development	291 11 O
,	302 1 O
heparin	304 7 B-Chemical
remains	312 7 O
the	320 3 O
anticoagulant	324 13 O
of	338 2 O
choice	341 6 O
to	348 2 O
treat	351 5 O
acute	357 5 O
thrombotic	363 10 B-Disease
episodes	374 8 O
.	382 1 O

The	384 3 O
clinical	388 8 O
effects	397 7 O
of	405 2 O
heparin	408 7 B-Chemical
are	416 3 O
meritorious	420 11 O
,	431 1 O
but	433 3 O
side	437 4 O
effects	442 7 O
do	450 2 O
exist	453 5 O
.	458 1 O

Bleeding	460 8 B-Disease
is	469 2 O
the	472 3 O
primary	476 7 O
untoward	484 8 O
effect	493 6 O
of	500 2 O
heparin	503 7 B-Chemical
.	510 1 O

Major	512 5 O
bleeding	518 8 B-Disease
is	527 2 O
of	530 2 O
primary	533 7 O
concern	541 7 O
in	549 2 O
patients	552 8 O
receiving	561 9 O
heparin	571 7 B-Chemical
therapy	579 7 O
.	586 1 O

However	588 7 O
,	595 1 O
additional	597 10 O
important	608 9 O
untoward	618 8 O
effects	627 7 O
of	635 2 O
heparin	638 7 B-Chemical
therapy	646 7 O
include	654 7 O
heparin	662 7 B-Chemical
-	669 1 O
induced	670 7 O
thrombocytopenia	678 16 B-Disease
,	694 1 O
heparin	696 7 B-Chemical
-	703 1 O
associated	704 10 O
osteoporosis	715 12 B-Disease
,	727 1 O
eosinophilia	729 12 B-Disease
,	741 1 O
skin	743 4 B-Disease
reactions	748 9 I-Disease
,	757 1 O
allergic	759 8 B-Disease
reactions	768 9 I-Disease
other	778 5 O
than	784 4 O
thrombocytopenia	789 16 B-Disease
,	805 1 O
alopecia	807 8 B-Disease
,	815 1 O
transaminasemia	817 15 O
,	832 1 O
hyperkalemia	834 12 B-Disease
,	846 1 O
hypoaldosteronism	848 17 B-Disease
,	865 1 O
and	867 3 O
priapism	871 8 B-Disease
.	879 1 O

These	881 5 O
side	887 4 O
effects	892 7 O
are	900 3 O
relatively	904 10 O
rare	915 4 O
in	920 2 O
a	923 1 O
given	925 5 O
individual	931 10 O
,	941 1 O
but	943 3 O
given	947 5 O
the	953 3 O
extremely	957 9 O
widespread	967 10 O
use	978 3 O
of	982 2 O
heparin	985 7 B-Chemical
,	992 1 O
some	994 4 O
are	999 3 O
quite	1003 5 O
common	1009 6 O
,	1015 1 O
particularly	1017 12 O
HITT	1030 4 B-Disease
and	1035 3 O
osteoporosis	1039 12 B-Disease
.	1051 1 O

Although	1053 8 O
reasonable	1062 10 O
incidences	1073 10 O
of	1084 2 O
many	1087 4 O
of	1092 2 O
these	1095 5 O
side	1101 4 O
effects	1106 7 O
can	1114 3 O
be	1118 2 O
"	1121 1 O
softly	1122 6 O
"	1128 1 O
deduced	1130 7 O
from	1138 4 O
current	1143 7 O
reports	1151 7 O
dealing	1159 7 O
with	1167 4 O
unfractionated	1172 14 O
heparin	1187 7 B-Chemical
,	1194 1 O
at	1196 2 O
present	1199 7 O
the	1207 3 O
incidences	1211 10 O
of	1222 2 O
these	1225 5 O
side	1231 4 O
effects	1236 7 O
with	1244 4 O
newer	1249 5 O
low	1255 3 O
molecular	1259 9 O
weight	1269 6 O
heparins	1276 8 B-Chemical
appear	1285 6 O
to	1292 2 O
be	1295 2 O
much	1298 4 O
less	1303 4 O
common	1308 6 O
.	1314 1 O

However	1316 7 O
,	1323 1 O
only	1325 4 O
longer	1330 6 O
experience	1337 10 O
will	1348 4 O
more	1353 4 O
clearly	1358 7 O
define	1366 6 O
the	1373 3 O
incidence	1377 9 O
of	1387 2 O
each	1390 4 O
side	1395 4 O
effect	1400 6 O
with	1407 4 O
low	1412 3 O
molecular	1416 9 O
weight	1426 6 O
preparations	1433 12 O
.	1445 1 O

A	0 1 O
case	2 4 O
of	7 2 O
bilateral	10 9 O
optic	20 5 B-Disease
neuropathy	26 10 I-Disease
in	37 2 O
a	40 1 O
patient	42 7 O
on	50 2 O
tacrolimus	53 10 B-Chemical
(	64 1 O
FK506	65 5 B-Chemical
)	70 1 O
therapy	72 7 O
after	80 5 O
liver	86 5 O
transplantation	92 15 O
.	107 1 O

PURPOSE	109 7 O
:	116 1 O
To	118 2 O
report	121 6 O
a	128 1 O
case	130 4 O
of	135 2 O
bilateral	138 9 O
optic	148 5 B-Disease
neuropathy	154 10 I-Disease
in	165 2 O
a	168 1 O
patient	170 7 O
receiving	178 9 O
tacrolimus	188 10 B-Chemical
(	199 1 O
FK	200 2 B-Chemical
506	203 3 I-Chemical
,	206 1 O
Prograf	208 7 O
;	215 1 O
Fujisawa	217 8 O
USA	226 3 O
,	229 1 O
Inc	231 3 O
,	234 1 O
Deerfield	236 9 O
,	245 1 O
Illinois	247 8 O
)	255 1 O
for	257 3 O
immunosuppression	261 17 O
after	279 5 O
orthotropic	285 11 O
liver	297 5 O
transplantation	303 15 O
.	318 1 O

METHOD	320 6 O
:	326 1 O
Case	328 4 O
report	333 6 O
.	339 1 O

In	341 2 O
a	344 1 O
58	346 2 O
-	348 1 O
year	349 4 O
-	353 1 O
old	354 3 O
man	358 3 O
receiving	362 9 O
tacrolimus	372 10 B-Chemical
after	383 5 O
orthotropic	389 11 O
liver	401 5 O
transplantation	407 15 O
,	422 1 O
serial	424 6 O
neuro	431 5 O
-	436 1 O
ophthalmologic	437 14 O
examinations	452 12 O
and	465 3 O
laboratory	469 10 O
studies	480 7 O
were	488 4 O
performed	493 9 O
.	502 1 O

RESULTS	504 7 O
:	511 1 O
The	513 3 O
patient	517 7 O
had	525 3 O
episodic	529 8 O
deterioration	538 13 O
of	552 2 O
vision	555 6 O
in	562 2 O
both	565 4 O
eyes	570 4 O
,	574 1 O
with	576 4 O
clinical	581 8 O
features	590 8 O
resembling	599 10 O
ischemic	610 8 B-Disease
optic	619 5 I-Disease
neuropathies	625 12 I-Disease
.	637 1 O

Deterioration	639 13 B-Disease
of	653 2 I-Disease
vision	656 6 I-Disease
occurred	663 8 O
despite	672 7 O
discontinuation	680 15 O
of	696 2 O
the	699 3 O
tacrolimus	703 10 B-Chemical
.	713 1 O

CONCLUSION	715 10 O
:	725 1 O
Tacrolimus	727 10 B-Chemical
and	738 3 O
other	742 5 O
immunosuppressive	748 17 O
agents	766 6 O
may	773 3 O
be	777 2 O
associated	780 10 O
with	791 4 O
optic	796 5 B-Disease
nerve	802 5 I-Disease
toxicity	808 8 I-Disease
.	816 1 O

Hypercalcemia	0 13 B-Disease
,	13 1 O
arrhythmia	15 10 B-Disease
,	25 1 O
and	27 3 O
mood	31 4 O
stabilizers	36 11 O
.	47 1 O

Recent	49 6 O
findings	56 8 O
in	65 2 O
a	68 1 O
bipolar	70 7 B-Disease
patient	78 7 O
receiving	86 9 O
maintenance	96 11 O
lithium	108 7 B-Chemical
therapy	116 7 O
who	124 3 O
developed	128 9 O
hypercalcemia	138 13 B-Disease
and	152 3 O
severe	156 6 O
bradyarrhythmia	163 15 B-Disease
prompted	179 8 O
the	188 3 O
authors	192 7 O
to	200 2 O
conduct	203 7 O
a	211 1 O
retrospective	213 13 O
study	227 5 O
of	233 2 O
bipolar	236 7 B-Disease
patients	244 8 O
with	253 4 O
lithium	258 7 B-Chemical
-	265 1 O
associated	266 10 O
hypercalcemia	277 13 B-Disease
.	290 1 O

A	292 1 O
printout	294 8 O
of	303 2 O
all	306 3 O
cases	310 5 O
of	316 2 O
hypercalcemia	319 13 B-Disease
that	333 4 O
presented	338 9 O
during	348 6 O
a	355 1 O
1	357 1 O
-	358 1 O
year	359 4 O
period	364 6 O
was	371 3 O
generated	375 9 O
.	384 1 O

After	386 5 O
eliminating	392 11 O
spurious	404 8 O
hypercalcemias	413 14 B-Disease
or	428 2 O
those	431 5 O
associated	437 10 O
with	448 4 O
intravenous	453 11 O
fluids	465 6 O
,	471 1 O
the	473 3 O
authors	477 7 O
identified	485 10 O
18	496 2 O
non	499 3 O
-	502 1 O
lithium	503 7 B-Chemical
-	510 1 O
treated	511 7 O
patients	519 8 O
with	528 4 O
hypercalcemias	533 14 B-Disease
related	548 7 O
to	556 2 O
malignancies	559 12 B-Disease
and	572 3 O
other	576 5 O
medical	582 7 O
conditions	590 10 O
(	601 1 O
group	602 5 O
A	608 1 O
)	609 1 O
and	611 3 O
12	615 2 O
patients	618 8 O
with	627 4 O
lithium	632 7 B-Chemical
-	639 1 O
associated	640 10 O
hypercalcemia	651 13 B-Disease
(	665 1 O
group	666 5 O
B	672 1 O
)	673 1 O
.	674 1 O

Patients	676 8 O
in	685 2 O
group	688 5 O
B	694 1 O
were	696 4 O
not	701 3 O
comparable	705 10 O
to	716 2 O
those	719 5 O
in	725 2 O
group	728 5 O
A	734 1 O
,	735 1 O
as	737 2 O
the	740 3 O
latter	744 6 O
were	751 4 O
medically	756 9 O
compromised	766 11 O
and	778 3 O
were	782 4 O
receiving	787 9 O
multiple	797 8 O
pharmacotherapies	806 17 O
.	823 1 O

Thus	825 4 O
,	829 1 O
two	831 3 O
control	835 7 O
groups	843 6 O
were	850 4 O
generated	855 9 O
:	864 1 O
group	866 5 O
C1	872 2 O
,	874 1 O
which	876 5 O
included	882 8 O
age	891 3 O
-	894 1 O
and	896 3 O
sex	900 3 O
-	903 1 O
comparable	904 10 O
lithium	915 7 B-Chemical
-	922 1 O
treated	923 7 O
bipolar	931 7 B-Disease
normocalcemic	939 13 O
patients	953 8 O
,	961 1 O
and	963 3 O
group	967 5 O
C2	973 2 O
,	975 1 O
which	977 5 O
included	983 8 O
bipolar	992 7 B-Disease
normocalcemic	1000 13 O
patients	1014 8 O
treated	1023 7 O
with	1031 4 O
anticonvulsant	1036 14 O
mood	1051 4 O
stabilizers	1056 11 O
.	1067 1 O

The	1069 3 O
electrocardiographic	1073 20 O
(	1094 1 O
ECG	1095 3 O
)	1098 1 O
findings	1100 8 O
for	1109 3 O
patients	1113 8 O
in	1122 2 O
group	1125 5 O
B	1131 1 O
were	1133 4 O
compared	1138 8 O
with	1147 4 O
those	1152 5 O
of	1158 2 O
patients	1161 8 O
in	1170 2 O
groups	1173 6 O
C1	1180 2 O
and	1183 3 O
C2	1187 2 O
.	1189 1 O

It	1191 2 O
was	1194 3 O
found	1198 5 O
that	1204 4 O
these	1209 5 O
groups	1215 6 O
did	1222 3 O
not	1226 3 O
differ	1230 6 O
in	1237 2 O
their	1240 5 O
overall	1246 7 O
frequency	1254 9 O
of	1264 2 O
ECG	1267 3 O
abnormalities	1271 13 O
;	1284 1 O
however	1286 7 O
,	1293 1 O
there	1295 5 O
were	1301 4 O
significant	1306 11 O
differences	1318 11 O
in	1330 2 O
the	1333 3 O
frequency	1337 9 O
of	1347 2 O
conduction	1350 10 O
defects	1361 7 O
.	1368 1 O

Patients	1370 8 O
with	1379 4 O
hypercalcemia	1384 13 B-Disease
resulting	1398 9 O
from	1408 4 O
medical	1413 7 O
diseases	1421 8 O
and	1430 3 O
bipolar	1434 7 B-Disease
patients	1442 8 O
with	1451 4 O
lithium	1456 7 B-Chemical
-	1463 1 O
associated	1464 10 O
hypercalcemia	1475 13 B-Disease
had	1489 3 O
significantly	1493 13 O
higher	1507 6 O
frequencies	1514 11 O
of	1526 2 O
conduction	1529 10 O
defects	1540 7 O
.	1547 1 O

Patients	1549 8 O
in	1558 2 O
group	1561 5 O
A	1567 1 O
had	1569 3 O
significant	1573 11 O
mortality	1585 9 O
at	1595 2 O
2	1598 1 O
-	1599 1 O
year	1600 4 O
follow	1605 6 O
-	1611 1 O
up	1612 2 O
(	1615 1 O
28	1616 2 O
%	1618 1 O
)	1619 1 O
,	1620 1 O
in	1622 2 O
contrast	1625 8 O
to	1634 2 O
zero	1637 4 O
mortality	1642 9 O
in	1652 2 O
the	1655 3 O
other	1659 5 O
three	1665 5 O
groups	1671 6 O
.	1677 1 O

The	1679 3 O
clinical	1683 8 O
implications	1692 12 O
of	1705 2 O
these	1708 5 O
findings	1714 8 O
are	1723 3 O
discussed	1727 9 O
.	1736 1 O

Attenuation	0 11 O
of	12 2 O
nephrotoxicity	15 14 B-Disease
by	30 2 O
a	33 1 O
novel	35 5 O
lipid	41 5 O
nanosphere	47 10 O
(	58 1 O
NS	59 2 O
-	61 1 O
718	62 3 O
)	65 1 O
incorporating	67 13 O
amphotericin	81 12 B-Chemical
B	94 1 I-Chemical
.	95 1 O

NS	97 2 O
-	99 1 O
718	100 3 O
,	103 1 O
a	105 1 O
lipid	107 5 O
nanosphere	113 10 O
incorporating	124 13 O
amphotericin	138 12 B-Chemical
B	151 1 I-Chemical
,	152 1 O
is	154 2 O
effective	157 9 O
against	167 7 O
pathogenic	175 10 O
fungi	186 5 O
and	192 3 O
has	196 3 O
low	200 3 O
toxicity	204 8 B-Disease
.	212 1 O

We	214 2 O
compared	217 8 O
the	226 3 O
toxicity	230 8 B-Disease
of	239 2 O
NS	242 2 O
-	244 1 O
718	245 3 O
with	249 4 O
that	254 4 O
of	259 2 O
Fungizone	262 9 B-Chemical
(	272 1 O
amphotericin	273 12 B-Chemical
B	286 1 I-Chemical
-	287 1 I-Chemical
sodium	288 6 I-Chemical
deoxycholate	295 12 I-Chemical
;	307 1 O
D	309 1 B-Chemical
-	310 1 I-Chemical
AmB	311 3 I-Chemical
)	314 1 O
in	316 2 O
vitro	319 5 O
using	325 5 O
renal	331 5 O
cell	337 4 O
cultures	342 8 O
and	351 3 O
in	355 2 O
vivo	358 4 O
by	363 2 O
biochemical	366 11 O
analysis	378 8 O
,	386 1 O
histopathological	388 17 O
study	406 5 O
of	412 2 O
the	415 3 O
kidney	419 6 O
and	426 3 O
pharmacokinetic	430 15 O
study	446 5 O
of	452 2 O
amphotericin	455 12 B-Chemical
B	468 1 I-Chemical
following	470 9 O
intravenous	480 11 O
infusion	492 8 O
of	501 2 O
the	504 3 O
formulation	508 11 O
in	520 2 O
rats	523 4 O
.	527 1 O

Incubation	529 10 O
with	540 4 O
NS	545 2 O
-	547 1 O
718	548 3 O
resulted	552 8 O
in	561 2 O
significantly	564 13 O
less	578 4 O
damage	583 6 O
of	590 2 O
cultured	593 8 O
human	602 5 O
renal	608 5 O
proximal	614 8 O
tubular	623 7 O
epithelial	631 10 O
cells	642 5 O
compared	648 8 O
with	657 4 O
D	662 1 B-Chemical
-	663 1 I-Chemical
AmB	664 3 I-Chemical
.	667 1 O

Serum	669 5 O
blood	675 5 O
urea	681 4 B-Chemical
and	686 3 O
creatinine	690 10 B-Chemical
concentrations	701 14 O
increased	716 9 O
significantly	726 13 O
in	740 2 O
rats	743 4 O
given	748 5 O
an	754 2 O
iv	757 2 O
infusion	760 8 O
of	769 2 O
D	772 1 B-Chemical
-	773 1 I-Chemical
AmB	774 3 I-Chemical
3	778 1 O
mg	780 2 O
/	782 1 O
kg	783 2 O
but	786 3 O
not	790 3 O
in	794 2 O
those	797 5 O
given	803 5 O
the	809 3 O
same	813 4 O
dose	818 4 O
of	823 2 O
NS	826 2 O
-	828 1 O
718	829 3 O
.	832 1 O

Histopathological	834 17 O
examination	852 11 O
of	864 2 O
the	867 3 O
kidney	871 6 O
showed	878 6 O
tubular	885 7 B-Disease
necrosis	893 8 I-Disease
in	902 2 O
D	905 1 B-Chemical
-	906 1 I-Chemical
AmB	907 3 I-Chemical
-	910 1 O
treated	911 7 O
rats	919 4 O
but	924 3 O
no	928 2 O
change	931 6 O
in	938 2 O
NS	941 2 O
-	943 1 O
718	944 3 O
-	947 1 O
treated	948 7 O
rats	956 4 O
.	960 1 O

Amphotericin	962 12 B-Chemical
B	975 1 I-Chemical
concentrations	977 14 O
in	992 2 O
the	995 3 O
kidney	999 6 O
in	1006 2 O
NS	1009 2 O
-	1011 1 O
718	1012 3 O
-	1015 1 O
treated	1016 7 O
rats	1024 4 O
were	1029 4 O
higher	1034 6 O
than	1041 4 O
those	1046 5 O
in	1052 2 O
D	1055 1 B-Chemical
-	1056 1 I-Chemical
AmB	1057 3 I-Chemical
-	1060 1 O
treated	1061 7 O
rats	1069 4 O
.	1073 1 O

Our	1075 3 O
in	1079 2 O
vitro	1082 5 O
and	1088 3 O
in	1092 2 O
vivo	1095 4 O
results	1100 7 O
suggest	1108 7 O
that	1116 4 O
incorporation	1121 13 O
of	1135 2 O
amphotericin	1138 12 B-Chemical
B	1151 1 I-Chemical
into	1153 4 O
lipid	1158 5 O
nanospheres	1164 11 O
of	1176 2 O
NS	1179 2 O
-	1181 1 O
718	1182 3 O
attenuates	1186 10 O
the	1197 3 O
nephrotoxicity	1201 14 B-Disease
of	1216 2 O
amphotericin	1219 12 B-Chemical
B	1232 1 I-Chemical
.	1233 1 O

Patterns	0 8 O
of	9 2 O
sulfadiazine	12 12 B-Chemical
acute	25 5 B-Disease
nephrotoxicity	31 14 I-Disease
.	45 1 O

Sulfadiazine	47 12 B-Chemical
acute	60 5 B-Disease
nephrotoxicity	66 14 I-Disease
is	81 2 O
reviving	84 8 O
specially	93 9 O
because	103 7 O
of	111 2 O
its	114 3 O
use	118 3 O
in	122 2 O
toxoplasmosis	125 13 B-Disease
in	139 2 O
HIV	142 3 O
-	145 1 O
positive	146 8 O
patients	155 8 O
.	163 1 O

We	165 2 O
report	168 6 O
4	175 1 O
cases	177 5 O
,	182 1 O
one	184 3 O
of	188 2 O
them	191 4 O
in	196 2 O
a	199 1 O
previously	201 10 O
healthy	212 7 O
person	220 6 O
.	226 1 O

Under	228 5 O
treatment	234 9 O
with	244 4 O
sulfadiazine	249 12 B-Chemical
they	262 4 O
developed	267 9 O
oliguria	277 8 B-Disease
,	285 1 O
abdominal	287 9 B-Disease
pain	297 4 I-Disease
,	301 1 O
renal	303 5 B-Disease
failure	309 7 I-Disease
and	317 3 O
showed	321 6 O
multiple	328 8 O
radiolucent	337 11 O
renal	349 5 B-Disease
calculi	355 7 I-Disease
in	363 2 O
echography	366 10 O
.	376 1 O

All	378 3 O
patients	382 8 O
recovered	391 9 O
their	401 5 O
previous	407 8 O
normal	416 6 O
renal	423 5 O
function	429 8 O
after	438 5 O
adequate	444 8 O
hydration	453 9 O
and	463 3 O
alcalinization	467 14 O
.	481 1 O

A	483 1 O
nephrostomy	485 11 O
tube	497 4 O
had	502 3 O
to	506 2 O
be	509 2 O
placed	512 6 O
in	519 2 O
one	522 3 O
of	526 2 O
the	529 3 O
patients	533 8 O
for	542 3 O
ureteral	546 8 B-Disease
lithiasis	555 9 I-Disease
in	565 2 O
a	568 1 O
single	570 6 O
functional	577 10 O
kidney	588 6 O
.	594 1 O

None	596 4 O
of	601 2 O
them	604 4 O
needed	609 6 O
dialysis	616 8 O
or	625 2 O
a	628 1 O
renal	630 5 O
biopsy	636 6 O
because	643 7 O
of	651 2 O
a	654 1 O
typical	656 7 O
benign	664 6 O
course	671 6 O
.	677 1 O

Treatment	679 9 O
with	689 4 O
sulfadiazine	694 12 B-Chemical
requires	707 8 O
exquisite	716 9 O
control	726 7 O
of	734 2 O
renal	737 5 O
function	743 8 O
,	751 1 O
an	753 2 O
increase	756 8 O
in	765 2 O
water	768 5 O
ingestion	774 9 O
and	784 3 O
possibly	788 8 O
the	797 3 O
alcalinization	801 14 O
of	816 2 O
the	819 3 O
urine	823 5 O
.	828 1 O

We	830 2 O
communicate	833 11 O
a	845 1 O
case	847 4 O
in	852 2 O
a	855 1 O
previously	857 10 O
healthy	868 7 O
person	876 6 O
,	882 1 O
a	884 1 O
fact	886 4 O
not	891 3 O
found	895 5 O
in	901 2 O
the	904 3 O
recent	908 6 O
literature	915 10 O
.	925 1 O

Probably	927 8 O
many	936 4 O
more	941 4 O
cases	946 5 O
are	952 3 O
not	956 3 O
detected	960 8 O
.	968 1 O

We	970 2 O
think	973 5 O
that	979 4 O
a	984 1 O
prospective	986 11 O
study	998 5 O
would	1004 5 O
be	1010 2 O
useful	1013 6 O
.	1019 1 O

Downbeat	0 8 B-Disease
nystagmus	9 9 I-Disease
associated	19 10 O
with	30 4 O
intravenous	35 11 O
patient	47 7 O
-	54 1 O
controlled	55 10 O
administration	66 14 O
of	81 2 O
morphine	84 8 B-Chemical
.	92 1 O

IMPLICATIONS	94 12 O
:	106 1 O
This	108 4 O
case	113 4 O
documents	118 9 O
a	128 1 O
patient	130 7 O
who	138 3 O
developed	142 9 O
dizziness	152 9 B-Disease
with	162 4 O
downbeating	167 11 B-Disease
nystagmus	179 9 I-Disease
while	189 5 O
receiving	195 9 O
a	205 1 O
relatively	207 10 O
large	218 5 O
dose	224 4 O
of	229 2 O
IV	232 2 O
patient	235 7 O
-	242 1 O
controlled	243 10 O
analgesia	254 9 O
morphine	264 8 B-Chemical
.	272 1 O

Although	274 8 O
there	283 5 O
have	289 4 O
been	294 4 O
case	299 4 O
reports	304 7 O
of	312 2 O
epidural	315 8 O
morphine	324 8 B-Chemical
with	333 4 O
these	338 5 O
symptoms	344 8 O
and	353 3 O
signs	357 5 O
,	362 1 O
this	364 4 O
has	369 3 O
not	373 3 O
been	377 4 O
previously	382 10 O
documented	393 10 O
with	404 4 O
IV	409 2 O
or	412 2 O
patient	415 7 O
-	422 1 O
controlled	423 10 O
analgesia	434 9 O
morphine	444 8 B-Chemical
.	452 1 O

Hemodynamic	0 11 O
and	12 3 O
antiadrenergic	16 14 O
effects	31 7 O
of	39 2 O
dronedarone	42 11 B-Chemical
and	54 3 O
amiodarone	58 10 B-Chemical
in	69 2 O
animals	72 7 O
with	80 4 O
a	85 1 O
healed	87 6 O
myocardial	94 10 B-Disease
infarction	105 10 I-Disease
.	115 1 O

The	117 3 O
hemodynamic	121 11 O
and	133 3 O
antiadrenergic	137 14 O
effects	152 7 O
of	160 2 O
dronedarone	163 11 B-Chemical
,	174 1 O
a	176 1 O
noniodinated	178 12 O
compound	191 8 O
structurally	200 12 O
related	213 7 O
to	221 2 O
amiodarone	224 10 B-Chemical
,	234 1 O
were	236 4 O
compared	241 8 O
with	250 4 O
those	255 5 O
of	261 2 O
amiodarone	264 10 B-Chemical
after	275 5 O
prolonged	281 9 O
oral	291 4 O
administration	296 14 O
,	310 1 O
both	312 4 O
at	317 2 O
rest	320 4 O
and	325 3 O
during	329 6 O
sympathetic	336 11 O
stimulation	348 11 O
in	360 2 O
conscious	363 9 O
dogs	373 4 O
with	378 4 O
a	383 1 O
healed	385 6 O
myocardial	392 10 B-Disease
infarction	403 10 I-Disease
.	413 1 O

All	415 3 O
dogs	419 4 O
(	424 1 O
n	425 1 O
=	427 1 O
6	429 1 O
)	430 1 O
randomly	432 8 O
received	441 8 O
orally	450 6 O
dronedarone	457 11 B-Chemical
(	469 1 O
10	470 2 O
and	473 3 O
30	477 2 O
mg	480 2 O
/	482 1 O
kg	483 2 O
)	485 1 O
,	486 1 O
amiodarone	488 10 B-Chemical
(	499 1 O
10	500 2 O
and	503 3 O
30	507 2 O
mg	510 2 O
/	512 1 O
kg	513 2 O
)	515 1 O
,	516 1 O
and	518 3 O
placebo	522 7 O
twice	530 5 O
daily	536 5 O
for	542 3 O
7	546 1 O
days	548 4 O
,	552 1 O
with	554 4 O
a	559 1 O
3	561 1 O
-	562 1 O
week	563 4 O
washout	568 7 O
between	576 7 O
consecutive	584 11 O
treatments	596 10 O
.	606 1 O

Heart	608 5 O
rate	614 4 O
(	619 1 O
HR	620 2 O
)	622 1 O
,	623 1 O
mean	625 4 O
arterial	630 8 O
pressure	639 8 O
(	648 1 O
MBP	649 3 O
)	652 1 O
,	653 1 O
positive	655 8 O
rate	664 4 O
of	669 2 O
increase	672 8 O
of	681 2 O
left	684 4 O
ventricular	689 11 O
pressure	701 8 O
(	710 1 O
+	711 1 O
LVdP	712 4 O
/	716 1 O
dt	717 2 O
)	719 1 O
,	720 1 O
echocardiographically	722 21 O
assessed	744 8 O
left	753 4 O
ventricular	758 11 O
ejection	770 8 O
fraction	779 8 O
(	788 1 O
LVEF	789 4 O
)	793 1 O
,	794 1 O
and	796 3 O
fractional	800 10 O
shortening	811 10 O
(	822 1 O
FS	823 2 O
)	825 1 O
,	826 1 O
as	828 2 O
well	831 4 O
as	836 2 O
chronotropic	839 12 O
response	852 8 O
to	861 2 O
isoproterenol	864 13 B-Chemical
and	878 3 O
exercise	882 8 O
-	890 1 O
induced	891 7 O
sympathetic	899 11 O
stimulation	911 11 O
were	923 4 O
evaluated	928 9 O
under	938 5 O
baseline	944 8 O
and	953 3 O
posttreatment	957 13 O
conditions	971 10 O
.	981 1 O

Resting	983 7 O
values	991 6 O
of	998 2 O
LVEF	1001 4 O
,	1005 1 O
FS	1007 2 O
,	1009 1 O
+	1011 1 O
LVdP	1012 4 O
/	1016 1 O
dt	1017 2 O
,	1019 1 O
and	1021 3 O
MBP	1025 3 O
remained	1029 8 O
unchanged	1038 9 O
whatever	1048 8 O
the	1057 3 O
drug	1061 4 O
and	1066 3 O
the	1070 3 O
dosing	1074 6 O
regimen	1081 7 O
,	1088 1 O
whereas	1090 7 O
resting	1098 7 O
HR	1106 2 O
was	1109 3 O
significantly	1113 13 O
and	1127 3 O
dose	1131 4 O
-	1135 1 O
dependently	1136 11 O
lowered	1148 7 O
after	1156 5 O
dronedarone	1162 11 B-Chemical
and	1174 3 O
to	1178 2 O
a	1181 1 O
lesser	1183 6 O
extent	1190 6 O
after	1197 5 O
amiodarone	1203 10 B-Chemical
.	1213 1 O

Both	1215 4 O
dronedarone	1220 11 B-Chemical
and	1232 3 O
amiodarone	1236 10 B-Chemical
significantly	1247 13 O
reduced	1261 7 O
the	1269 3 O
exercise	1273 8 O
-	1281 1 O
induced	1282 7 O
tachycardia	1290 11 B-Disease
and	1302 3 O
,	1305 1 O
at	1307 2 O
the	1310 3 O
highest	1314 7 O
dose	1322 4 O
,	1326 1 O
decreased	1328 9 O
the	1338 3 O
isoproterenol	1342 13 B-Chemical
-	1355 1 O
induced	1356 7 O
tachycardia	1364 11 B-Disease
.	1375 1 O

Thus	1377 4 O
,	1381 1 O
dronedarone	1383 11 B-Chemical
and	1395 3 O
amiodarone	1399 10 B-Chemical
displayed	1410 9 O
a	1420 1 O
similar	1422 7 O
level	1430 5 O
of	1436 2 O
antiadrenergic	1439 14 O
effect	1454 6 O
and	1461 3 O
did	1465 3 O
not	1469 3 O
impair	1473 6 O
the	1480 3 O
resting	1484 7 O
left	1492 4 O
ventricular	1497 11 O
function	1509 8 O
.	1517 1 O

Consequently	1519 12 O
,	1531 1 O
dronedarone	1533 11 B-Chemical
might	1545 5 O
be	1551 2 O
particularly	1554 12 O
suitable	1567 8 O
for	1576 3 O
the	1580 3 O
treatment	1584 9 O
and	1594 3 O
prevention	1598 10 O
of	1609 2 O
various	1612 7 O
clinical	1620 8 O
arrhythmias	1629 11 B-Disease
,	1640 1 O
without	1642 7 O
compromising	1650 12 O
the	1663 3 O
left	1667 4 O
ventricular	1672 11 O
function	1684 8 O
.	1692 1 O

Phase	0 5 O
2	6 1 O
trial	8 5 O
of	14 2 O
liposomal	17 9 O
doxorubicin	27 11 B-Chemical
(	39 1 O
40	40 2 O
mg	43 2 O
/	45 1 O
m	46 1 O
(	47 1 O
2	48 1 O
)	49 1 O
)	50 1 O
in	52 2 O
platinum	55 8 B-Chemical
/	63 1 O
paclitaxel	64 10 B-Chemical
-	74 1 O
refractory	75 10 O
ovarian	86 7 B-Disease
and	94 3 I-Disease
fallopian	98 9 I-Disease
tube	108 4 I-Disease
cancers	113 7 I-Disease
and	121 3 O
primary	125 7 O
carcinoma	133 9 B-Disease
of	143 2 I-Disease
the	146 3 I-Disease
peritoneum	150 10 I-Disease
.	160 1 O

BACKGROUND	162 10 O
:	172 1 O
Several	174 7 O
studies	182 7 O
have	190 4 O
demonstrated	195 12 O
liposomal	208 9 O
doxorubicin	218 11 B-Chemical
(	230 1 O
Doxil	231 5 B-Chemical
)	236 1 O
to	238 2 O
be	241 2 O
an	244 2 O
active	247 6 O
antineoplastic	254 14 O
agent	269 5 O
in	275 2 O
platinum	278 8 B-Chemical
-	286 1 O
resistant	287 9 O
ovarian	297 7 B-Disease
cancer	305 6 I-Disease
,	311 1 O
with	313 4 O
dose	318 4 O
limiting	323 8 O
toxicity	332 8 B-Disease
of	341 2 O
the	344 3 O
standard	348 8 O
dosing	357 6 O
regimen	364 7 O
(	372 1 O
50	373 2 O
mg	376 2 O
/	378 1 O
m	379 1 O
(	380 1 O
2	381 1 O
)	382 1 O
q	384 1 O
4	386 1 O
weeks	388 5 O
)	393 1 O
being	395 5 O
severe	401 6 O
erythrodysesthesia	408 18 B-Disease
(	427 1 O
"	428 1 O
hand	429 4 B-Disease
-	433 1 I-Disease
foot	434 4 I-Disease
syndrome	439 8 I-Disease
"	447 1 O
)	448 1 O
and	450 3 O
stomatitis	454 10 B-Disease
.	464 1 O

We	466 2 O
wished	469 6 O
to	476 2 O
develop	479 7 O
a	487 1 O
more	489 4 O
tolerable	494 9 O
liposomal	504 9 O
doxorubicin	514 11 B-Chemical
treatment	526 9 O
regimen	536 7 O
and	544 3 O
document	548 8 O
its	557 3 O
level	561 5 O
of	567 2 O
activity	570 8 O
in	579 2 O
a	582 1 O
well	584 4 O
-	588 1 O
defined	589 7 O
patient	597 7 O
population	605 10 O
with	616 4 O
platinum	621 8 B-Chemical
/	629 1 O
paclitaxel	630 10 B-Chemical
-	640 1 O
refractory	641 10 O
disease	652 7 O
.	659 1 O

METHODS	661 7 O
AND	669 3 O
MATERIALS	673 9 O
:	682 1 O
Patients	684 8 O
with	693 4 O
ovarian	698 7 B-Disease
or	706 2 I-Disease
fallopian	709 9 I-Disease
tube	719 4 I-Disease
cancers	724 7 I-Disease
or	732 2 O
primary	735 7 O
peritoneal	743 10 B-Disease
carcinoma	754 9 I-Disease
with	764 4 O
platinum	769 8 B-Chemical
/	777 1 O
paclitaxel	778 10 B-Chemical
-	788 1 O
refractory	789 10 O
disease	800 7 O
(	808 1 O
stable	809 6 O
or	816 2 O
progressive	819 11 O
disease	831 7 O
following	839 9 O
treatment	849 9 O
with	859 4 O
these	864 5 O
agents	870 6 O
or	877 2 O
previous	880 8 O
objective	889 9 O
response	899 8 O
<	908 1 O
3	909 1 O
months	911 6 O
in	918 2 O
duration	921 8 O
)	929 1 O
were	931 4 O
treated	936 7 O
with	944 4 O
liposomal	949 9 O
doxorubicin	959 11 B-Chemical
at	971 2 O
a	974 1 O
dose	976 4 O
of	981 2 O
40	984 2 O
mg	987 2 O
/	989 1 O
m	990 1 O
(	991 1 O
2	992 1 O
)	993 1 O
q	995 1 O
4	997 1 O
weeks	999 5 O
.	1004 1 O

RESULTS	1006 7 O
:	1013 1 O
A	1015 1 O
total	1017 5 O
of	1023 2 O
49	1026 2 O
patients	1029 8 O
(	1038 1 O
median	1039 6 O
age	1046 3 O
:	1049 1 O
60	1051 2 O
;	1053 1 O
range	1055 5 O
41	1061 2 O
-	1063 1 O
81	1064 2 O
)	1066 1 O
entered	1068 7 O
this	1076 4 O
phase	1081 5 O
2	1087 1 O
trial	1089 5 O
.	1094 1 O

The	1096 3 O
median	1100 6 O
number	1107 6 O
of	1114 2 O
prior	1117 5 O
regimens	1123 8 O
was	1132 3 O
2	1136 1 O
(	1138 1 O
range	1139 5 O
:	1144 1 O
1	1146 1 O
-	1147 1 O
6	1148 1 O
)	1149 1 O
.	1150 1 O

Six	1152 3 O
(	1156 1 O
12	1157 2 O
%	1159 1 O
)	1160 1 O
and	1162 3 O
4	1166 1 O
(	1168 1 O
8	1169 1 O
%	1170 1 O
)	1171 1 O
patients	1173 8 O
experienced	1182 11 O
grade	1194 5 O
2	1200 1 O
hand	1202 4 B-Disease
-	1206 1 I-Disease
foot	1207 4 I-Disease
syndrome	1212 8 I-Disease
and	1221 3 O
stomatitis	1225 10 B-Disease
,	1235 1 O
respectively	1237 12 O
(	1250 1 O
no	1251 2 O
episodes	1254 8 O
of	1263 2 O
grade	1266 5 O
3	1272 1 O
)	1273 1 O
.	1274 1 O

One	1276 3 O
patient	1280 7 O
developed	1288 9 O
grade	1298 5 O
3	1304 1 O
diarrhea	1306 8 B-Disease
requiring	1315 9 O
hospitalization	1325 15 O
for	1341 3 O
hydration	1345 9 O
.	1354 1 O

Six	1356 3 O
(	1360 1 O
12	1361 2 O
%	1363 1 O
)	1364 1 O
individuals	1366 11 O
required	1378 8 O
dose	1387 4 O
reductions	1392 10 O
.	1402 1 O

The	1404 3 O
median	1408 6 O
number	1415 6 O
of	1422 2 O
courses	1425 7 O
of	1433 2 O
liposomal	1436 9 O
doxorubicin	1446 11 B-Chemical
administered	1458 12 O
on	1471 2 O
this	1474 4 O
protocol	1479 8 O
was	1488 3 O
2	1492 1 O
(	1494 1 O
range	1495 5 O
:	1500 1 O
1	1502 1 O
-	1503 1 O
12	1504 2 O
)	1506 1 O
.	1507 1 O

Four	1509 4 O
of	1514 2 O
44	1517 2 O
patients	1520 8 O
(	1529 1 O
9	1530 1 O
%	1531 1 O
)	1532 1 O
evaluable	1534 9 O
for	1544 3 O
response	1548 8 O
exhibited	1557 9 O
objective	1567 9 O
and	1577 3 O
subjective	1581 10 O
evidence	1592 8 O
of	1601 2 O
an	1604 2 O
antineoplastic	1607 14 O
effect	1622 6 O
of	1629 2 O
therapy	1632 7 O
.	1639 1 O

CONCLUSION	1641 10 O
:	1651 1 O
This	1653 4 O
modified	1658 8 O
liposomal	1667 9 O
doxorubicin	1677 11 B-Chemical
regimen	1689 7 O
results	1697 7 O
in	1705 2 O
less	1708 4 O
toxicity	1713 8 B-Disease
(	1722 1 O
stomatitis	1723 10 B-Disease
,	1733 1 O
hand	1735 4 B-Disease
-	1739 1 I-Disease
foot	1740 4 I-Disease
syndrome	1745 8 I-Disease
)	1753 1 O
than	1755 4 O
the	1760 3 O
standard	1764 8 O
FDA	1773 3 O
-	1776 1 O
approved	1777 8 O
dose	1786 4 O
schedule	1791 8 O
.	1799 1 O

Definite	1801 8 O
,	1809 1 O
although	1811 8 O
limited	1820 7 O
,	1827 1 O
antineoplastic	1829 14 O
activity	1844 8 O
is	1853 2 O
observed	1856 8 O
in	1865 2 O
patients	1868 8 O
with	1877 4 O
well	1882 4 O
-	1886 1 O
defined	1887 7 O
platinum	1895 8 B-Chemical
-	1903 1 O
and	1905 3 O
paclitaxel	1909 10 B-Chemical
-	1919 1 O
refractory	1920 10 O
ovarian	1931 7 B-Disease
cancer	1939 6 I-Disease
.	1945 1 O

Efficacy	0 8 O
of	9 2 O
olanzapine	12 10 B-Chemical
in	23 2 O
acute	26 5 O
bipolar	32 7 B-Disease
mania	40 5 I-Disease
:	45 1 O
a	47 1 O
double	49 6 O
-	55 1 O
blind	56 5 O
,	61 1 O
placebo	63 7 O
-	70 1 O
controlled	71 10 O
study	82 5 O
.	87 1 O

The	89 3 O
Olanzipine	93 10 B-Chemical
HGGW	104 4 O
Study	109 5 O
Group	115 5 O
.	120 1 O

BACKGROUND	122 10 O
:	132 1 O
We	134 2 O
compared	137 8 O
the	146 3 O
efficacy	150 8 O
and	159 3 O
safety	163 6 O
of	170 2 O
olanzapine	173 10 B-Chemical
vs	184 2 O
placebo	187 7 O
for	195 3 O
the	199 3 O
treatment	203 9 O
of	213 2 O
acute	216 5 O
bipolar	222 7 B-Disease
mania	230 5 I-Disease
.	235 1 O

METHODS	237 7 O
:	244 1 O
Four	246 4 O
-	250 1 O
week	251 4 O
,	255 1 O
randomized	257 10 O
,	267 1 O
double	269 6 O
-	275 1 O
blind	276 5 O
,	281 1 O
parallel	283 8 O
study	292 5 O
.	297 1 O

A	299 1 O
total	301 5 O
of	307 2 O
115	310 3 O
patients	314 8 O
with	323 4 O
a	328 1 O
DSM	330 3 O
-	333 1 O
IV	334 2 O
diagnosis	337 9 O
of	347 2 O
bipolar	350 7 B-Disease
disorder	358 8 I-Disease
,	366 1 O
manic	368 5 B-Disease
or	374 2 O
mixed	377 5 O
,	382 1 O
were	384 4 O
randomized	389 10 O
to	400 2 O
olanzapine	403 10 B-Chemical
,	413 1 O
5	415 1 O
to	417 2 O
20	420 2 O
mg	423 2 O
/	425 1 O
d	426 1 O
(	428 1 O
n	429 1 O
=	431 1 O
55	433 2 O
)	435 1 O
,	436 1 O
or	438 2 O
placebo	441 7 O
(	449 1 O
n	450 1 O
=	452 1 O
60	454 2 O
)	456 1 O
.	457 1 O

The	459 3 O
primary	463 7 O
efficacy	471 8 O
measure	480 7 O
was	488 3 O
the	492 3 O
Young	496 5 O
-	501 1 O
Mania	502 5 B-Disease
Rating	508 6 O
Scale	515 5 O
(	521 1 O
Y	522 1 O
-	523 1 O
MRS	524 3 O
)	527 1 O
total	529 5 O
score	535 5 O
.	540 1 O

Response	542 8 O
and	551 3 O
euthymia	555 8 O
were	564 4 O
defined	569 7 O
,	576 1 O
a	578 1 O
priori	580 6 O
,	586 1 O
as	588 2 O
at	591 2 O
least	594 5 O
a	600 1 O
50	602 2 O
%	604 1 O
improvement	606 11 O
from	618 4 O
baseline	623 8 O
to	632 2 O
end	635 3 O
point	639 5 O
and	645 3 O
as	649 2 O
a	652 1 O
score	654 5 O
of	660 2 O
no	663 2 O
less	666 4 O
than	671 4 O
12	676 2 O
at	679 2 O
end	682 3 O
point	686 5 O
in	692 2 O
the	695 3 O
Y	699 1 O
-	700 1 O
MRS	701 3 O
total	705 5 O
score	711 5 O
,	716 1 O
respectively	718 12 O
.	730 1 O

Safety	732 6 O
was	739 3 O
assessed	743 8 O
using	752 5 O
adverse	758 7 O
events	766 6 O
,	772 1 O
Extrapyramidal	774 14 B-Disease
Symptom	789 7 I-Disease
(	797 1 O
EPS	798 3 B-Disease
)	801 1 O
rating	803 6 O
scales	810 6 O
,	816 1 O
laboratory	818 10 O
values	829 6 O
,	835 1 O
electrocardiograms	837 18 O
,	855 1 O
vital	857 5 O
signs	863 5 O
,	868 1 O
and	870 3 O
weight	874 6 O
change	881 6 O
.	887 1 O

RESULTS	889 7 O
:	896 1 O
Olanzapine	898 10 B-Chemical
-	908 1 O
treated	909 7 O
patients	917 8 O
demonstrated	926 12 O
a	939 1 O
statistically	941 13 O
significant	955 11 O
greater	967 7 O
mean	975 4 O
(	980 1 O
+	981 1 O
/	982 1 O
-	983 1 O
SD	985 2 O
)	987 1 O
improvement	989 11 O
in	1001 2 O
Y	1004 1 O
-	1005 1 O
MRS	1006 3 O
total	1010 5 O
score	1016 5 O
than	1022 4 O
placebo	1027 7 O
-	1034 1 O
treated	1035 7 O
patients	1043 8 O
(	1052 1 O
-	1053 1 O
14	1054 2 O
.	1056 1 O
8	1057 1 O
+	1059 1 O
/	1060 1 O
-	1061 1 O
12	1063 2 O
.	1065 1 O
5	1066 1 O
and	1068 3 O
-	1072 1 O
8	1073 1 O
.	1074 1 O
1	1075 1 O
+	1077 1 O
/	1078 1 O
-	1079 1 O
12	1081 2 O
.	1083 1 O
7	1084 1 O
,	1085 1 O
respectively	1087 12 O
;	1099 1 O
P	1101 1 O
<	1102 1 O
.	1103 1 O
001	1104 3 O
)	1107 1 O
,	1108 1 O
which	1110 5 O
was	1116 3 O
evident	1120 7 O
at	1128 2 O
the	1131 3 O
first	1135 5 O
postbaseline	1141 12 O
observation	1154 11 O
1	1166 1 O
week	1168 4 O
after	1173 5 O
randomization	1179 13 O
and	1193 3 O
was	1197 3 O
maintained	1201 10 O
throughout	1212 10 O
the	1223 3 O
study	1227 5 O
(	1233 1 O
last	1234 4 O
observation	1239 11 O
carried	1251 7 O
forward	1259 7 O
)	1266 1 O
.	1267 1 O

Olanzapine	1269 10 B-Chemical
-	1279 1 O
treated	1280 7 O
patients	1288 8 O
demonstrated	1297 12 O
a	1310 1 O
higher	1312 6 O
rate	1319 4 O
of	1324 2 O
response	1327 8 O
(	1336 1 O
65	1337 2 O
%	1339 1 O
vs	1341 2 O
43	1344 2 O
%	1346 1 O
,	1347 1 O
respectively	1349 12 O
;	1361 1 O
P	1363 1 O
=	1365 1 O
.	1366 1 O
02	1367 2 O
)	1369 1 O
and	1371 3 O
euthymia	1375 8 O
(	1384 1 O
61	1385 2 O
%	1387 1 O
vs	1389 2 O
36	1392 2 O
%	1394 1 O
,	1395 1 O
respectively	1397 12 O
;	1409 1 O
P	1411 1 O
=	1413 1 O
.	1414 1 O
01	1416 2 O
)	1418 1 O
than	1420 4 O
placebo	1425 7 O
-	1432 1 O
treated	1433 7 O
patients	1441 8 O
.	1449 1 O

There	1451 5 O
were	1457 4 O
no	1462 2 O
statistically	1465 13 O
significant	1479 11 O
differences	1491 11 O
in	1503 2 O
EPSs	1506 4 B-Disease
between	1511 7 O
groups	1519 6 O
.	1525 1 O

However	1527 7 O
,	1534 1 O
olanzapine	1536 10 B-Chemical
-	1546 1 O
treated	1547 7 O
patients	1555 8 O
had	1564 3 O
a	1568 1 O
statistically	1570 13 O
significant	1584 11 O
greater	1596 7 O
mean	1604 4 O
(	1609 1 O
+	1610 1 O
/	1611 1 O
-	1612 1 O
SD	1614 2 O
)	1616 1 O
weight	1618 6 B-Disease
gain	1625 4 I-Disease
than	1630 4 O
placebo	1635 7 O
-	1642 1 O
treated	1643 7 O
patients	1651 8 O
(	1660 1 O
2	1661 1 O
.	1662 1 O
1	1663 1 O
+	1665 1 O
/	1666 1 O
-	1667 1 O
2	1669 1 O
.	1670 1 O
8	1671 1 O
vs	1673 2 O
0	1676 1 O
.	1677 1 O
45	1678 2 O
+	1681 1 O
/	1682 1 O
-	1683 1 O
2	1685 1 O
.	1686 1 O
3	1687 1 O
kg	1689 2 O
,	1691 1 O
respectively	1693 12 O
)	1705 1 O
and	1707 3 O
also	1711 4 O
experienced	1716 11 O
more	1728 4 O
treatment	1733 9 O
-	1742 1 O
emergent	1743 8 O
somnolence	1752 10 B-Disease
(	1763 1 O
21	1764 2 O
patients	1767 8 O
[	1776 1 O
38	1777 2 O
.	1779 1 O
2	1780 1 O
%	1781 1 O
]	1782 1 O
vs	1784 2 O
5	1787 1 O
[	1789 1 O
8	1790 1 O
.	1791 1 O
3	1792 1 O
%	1793 1 O
]	1795 1 O
,	1796 1 O
respectively	1798 12 O
)	1810 1 O
.	1811 1 O

CONCLUSION	1813 10 O
:	1823 1 O
Olanzapine	1825 10 B-Chemical
demonstrated	1836 12 O
greater	1849 7 O
efficacy	1857 8 O
than	1866 4 O
placebo	1871 7 O
in	1879 2 O
the	1882 3 O
treatment	1886 9 O
of	1896 2 O
acute	1899 5 O
bipolar	1905 7 B-Disease
mania	1913 5 I-Disease
and	1919 3 O
was	1923 3 O
generally	1927 9 O
well	1937 4 O
tolerated	1942 9 O
.	1951 1 O

The	0 3 O
effect	4 6 O
of	11 2 O
pupil	14 5 B-Disease
dilation	20 8 I-Disease
with	29 4 O
tropicamide	34 11 B-Chemical
on	46 2 O
vision	49 6 O
and	56 3 O
driving	60 7 O
simulator	68 9 O
performance	78 11 O
.	89 1 O

PURPOSE	91 7 O
:	98 1 O
To	100 2 O
assess	103 6 O
the	110 3 O
effect	114 6 O
of	121 2 O
pupil	124 5 B-Disease
dilation	130 8 I-Disease
on	139 2 O
vision	142 6 O
and	149 3 O
driving	153 7 O
ability	161 7 O
.	168 1 O

METHODS	170 7 O
:	177 1 O
A	179 1 O
series	181 6 O
of	188 2 O
tests	191 5 O
on	197 2 O
various	200 7 O
parameters	208 10 O
of	219 2 O
visual	222 6 O
function	229 8 O
and	238 3 O
driving	242 7 O
simulator	250 9 O
performance	260 11 O
were	272 4 O
performed	277 9 O
on	287 2 O
12	290 2 O
healthy	293 7 O
drivers	301 7 O
,	308 1 O
before	310 6 O
and	317 3 O
after	321 5 O
pupil	327 5 B-Disease
dilation	333 8 I-Disease
using	342 5 O
guttae	348 6 O
tropicamide	355 11 B-Chemical
1	367 1 O
%	368 1 O
.	369 1 O

A	371 1 O
driving	373 7 O
simulator	381 9 O
(	391 1 O
Transport	392 9 O
Research	402 8 O
Laboratory	411 10 O
)	421 1 O
was	423 3 O
used	427 4 O
to	432 2 O
measure	435 7 O
reaction	443 8 O
time	452 4 O
(	457 1 O
RT	458 2 O
)	460 1 O
,	461 1 O
speed	463 5 O
maintenance	469 11 O
and	481 3 O
steering	485 8 O
accuracy	494 8 O
.	502 1 O

Tests	504 5 O
of	510 2 O
basic	513 5 O
visual	519 6 O
function	526 8 O
included	535 8 O
high	544 4 O
-	548 1 O
and	550 3 O
low	554 3 O
-	557 1 O
contrast	558 8 O
visual	567 6 O
acuity	574 6 O
(	581 1 O
HCVA	582 4 O
and	587 3 O
LCVA	591 4 O
)	595 1 O
,	596 1 O
Pelli	598 5 O
-	603 1 O
Robson	604 6 O
contrast	611 8 O
threshold	620 9 O
(	630 1 O
CT	631 2 O
)	633 1 O
and	635 3 O
Goldmann	639 8 O
perimetry	648 9 O
(	658 1 O
FIELDS	659 6 O
)	665 1 O
.	666 1 O

Useful	668 6 O
Field	675 5 O
of	681 2 O
View	684 4 O
(	689 1 O
UFOV	690 4 O
-	694 1 O
-	695 1 O
a	696 1 O
test	698 4 O
of	703 2 O
visual	706 6 O
attention	713 9 O
)	722 1 O
was	724 3 O
also	728 4 O
undertaken	733 10 O
.	743 1 O

The	745 3 O
mean	749 4 O
differences	754 11 O
in	766 2 O
the	769 3 O
pre	773 3 O
-	776 1 O
and	778 3 O
post	782 4 O
-	786 1 O
dilatation	787 10 O
measurements	798 12 O
were	811 4 O
tested	816 6 O
for	823 3 O
statistical	827 11 O
significance	839 12 O
at	852 2 O
the	855 3 O
95	859 2 O
%	861 1 O
level	863 5 O
using	869 5 O
one	875 3 O
-	878 1 O
tail	879 4 O
paired	884 6 O
t	891 1 O
-	892 1 O
tests	893 5 O
.	898 1 O

RESULTS	900 7 O
:	907 1 O
Pupillary	909 9 B-Disease
dilation	919 8 I-Disease
resulted	928 8 O
in	937 2 O
a	940 1 O
statistically	942 13 O
significant	956 11 O
deterioration	968 13 O
in	982 2 O
CT	985 2 O
and	988 3 O
HCVA	992 4 O
only	997 4 O
.	1001 1 O

Five	1003 4 O
of	1008 2 O
12	1011 2 O
drivers	1014 7 O
also	1022 4 O
exhibited	1027 9 O
deterioration	1037 13 O
in	1051 2 O
LCVA	1054 4 O
,	1058 1 O
CT	1060 2 O
and	1063 3 O
RT	1067 2 O
.	1069 1 O

Little	1071 6 O
evidence	1078 8 O
emerged	1087 7 O
for	1095 3 O
deterioration	1099 13 O
in	1113 2 O
FIELDS	1116 6 O
and	1123 3 O
UFOV	1127 4 O
.	1131 1 O

Also	1133 4 O
,	1137 1 O
7	1139 1 O
of	1141 2 O
12	1144 2 O
drivers	1147 7 O
appeared	1155 8 O
to	1164 2 O
adjust	1167 6 O
their	1174 5 O
driving	1180 7 O
behaviour	1188 9 O
by	1198 2 O
reducing	1201 8 O
their	1210 5 O
speed	1216 5 O
on	1222 2 O
the	1225 3 O
driving	1229 7 O
simulator	1237 9 O
,	1246 1 O
leading	1248 7 O
to	1256 2 O
improved	1259 8 O
steering	1268 8 O
accuracy	1277 8 O
.	1285 1 O

CONCLUSIONS	1287 11 O
:	1298 1 O
Pupillary	1300 9 B-Disease
dilation	1310 8 I-Disease
may	1319 3 O
lead	1323 4 O
to	1328 2 O
a	1331 1 O
decrease	1333 8 O
in	1342 2 O
vision	1345 6 O
and	1352 3 O
daylight	1356 8 O
driving	1365 7 O
performance	1373 11 O
in	1385 2 O
young	1388 5 O
people	1394 6 O
.	1400 1 O

A	1402 1 O
larger	1404 6 O
study	1411 5 O
,	1416 1 O
including	1418 9 O
a	1428 1 O
broader	1430 7 O
spectrum	1438 8 O
of	1447 2 O
subjects	1450 8 O
,	1458 1 O
is	1460 2 O
warranted	1463 9 O
before	1473 6 O
guidelines	1480 10 O
can	1491 3 O
be	1495 2 O
recommended	1498 11 O
.	1509 1 O

A	0 1 O
case	2 4 O
of	7 2 O
isotretinoin	10 12 B-Disease
embryopathy	23 11 I-Disease
with	35 4 O
bilateral	40 9 O
anotia	50 6 B-Disease
and	57 3 O
Taussig	61 7 B-Disease
-	68 1 I-Disease
Bing	69 4 I-Disease
malformation	74 12 I-Disease
.	86 1 O

We	88 2 O
report	91 6 O
a	98 1 O
newborn	100 7 O
infant	108 6 O
with	115 4 O
multiple	120 8 O
congenital	129 10 O
anomalies	140 9 O
(	150 1 O
anotia	151 6 B-Disease
and	158 3 O
Taussig	162 7 B-Disease
-	169 1 I-Disease
Bing	170 4 I-Disease
malformation	175 12 I-Disease
)	187 1 O
due	189 3 O
to	193 2 O
exposure	196 8 O
to	205 2 O
isotretinoin	208 12 B-Chemical
within	221 6 O
the	228 3 O
first	232 5 O
trimester	238 9 O
.	247 1 O

In	249 2 O
this	252 4 O
paper	257 5 O
we	263 2 O
aim	266 3 O
to	270 2 O
draw	273 4 O
to	278 2 O
the	281 3 O
fact	285 4 O
that	290 4 O
caution	295 7 O
is	303 2 O
needed	306 6 O
when	313 4 O
prescribing	318 11 O
vitamin	330 7 B-Chemical
A	338 1 I-Chemical
-	339 1 O
containing	340 10 O
drugs	351 5 O
to	357 2 O
women	360 5 O
of	366 2 O
childbearing	369 12 O
years	382 5 O
.	387 1 O

Effect	0 6 O
of	7 2 O
methoxamine	10 11 B-Chemical
on	22 2 O
maximum	25 7 O
urethral	33 8 O
pressure	42 8 O
in	51 2 O
women	54 5 O
with	60 4 O
genuine	65 7 O
stress	73 6 B-Disease
incontinence	80 12 I-Disease
:	92 1 O
a	94 1 O
placebo	96 7 O
-	103 1 O
controlled	104 10 O
,	114 1 O
double	116 6 O
-	122 1 O
blind	123 5 O
crossover	129 9 O
study	139 5 O
.	144 1 O

The	146 3 O
aim	150 3 O
of	154 2 O
the	157 3 O
study	161 5 O
was	167 3 O
to	171 2 O
evaluate	174 8 O
the	183 3 O
potential	187 9 O
role	197 4 O
for	202 3 O
a	206 1 O
selective	208 9 O
alpha1	218 6 O
-	224 1 O
adrenoceptor	225 12 O
agonist	238 7 O
in	246 2 O
the	249 3 O
treatment	253 9 O
of	263 2 O
urinary	266 7 B-Disease
stress	274 6 I-Disease
incontinence	281 12 I-Disease
.	293 1 O

A	295 1 O
randomised	297 10 O
,	307 1 O
double	309 6 O
-	315 1 O
blind	316 5 O
,	321 1 O
placebo	323 7 O
-	330 1 O
controlled	331 10 O
,	341 1 O
crossover	343 9 O
study	353 5 O
design	359 6 O
was	366 3 O
employed	370 8 O
.	378 1 O

Half	380 4 O
log	385 3 O
incremental	389 11 O
doses	401 5 O
of	407 2 O
intravenous	410 11 O
methoxamine	422 11 B-Chemical
or	434 2 O
placebo	437 7 O
(	445 1 O
saline	446 6 O
)	452 1 O
were	454 4 O
administered	459 12 O
to	472 2 O
a	475 1 O
group	477 5 O
of	483 2 O
women	486 5 O
with	492 4 O
genuine	497 7 O
stress	505 6 B-Disease
incontinence	512 12 I-Disease
while	525 5 O
measuring	531 9 O
maximum	541 7 O
urethral	549 8 O
pressure	558 8 O
(	567 1 O
MUP	568 3 O
)	571 1 O
,	572 1 O
blood	574 5 O
pressure	580 8 O
,	588 1 O
heart	590 5 O
rate	596 4 O
,	600 1 O
and	602 3 O
symptomatic	606 11 O
side	618 4 O
effects	623 7 O
.	630 1 O

Methoxamine	632 11 B-Chemical
evoked	644 6 O
non	651 3 O
-	654 1 O
significant	655 11 O
increases	667 9 O
in	677 2 O
MUP	680 3 O
and	684 3 O
diastolic	688 9 O
blood	698 5 O
pressure	704 8 O
but	713 3 O
caused	717 6 O
a	724 1 B-Disease
significant	726 11 I-Disease
rise	738 4 I-Disease
in	743 2 I-Disease
systolic	746 8 I-Disease
blood	755 5 I-Disease
pressure	761 8 I-Disease
and	770 3 O
significant	774 11 O
fall	786 4 O
in	791 2 O
heart	794 5 O
rate	800 4 O
at	805 2 O
maximum	808 7 O
dosage	816 6 O
.	822 1 O

Systemic	824 8 O
side	833 4 O
effects	838 7 O
including	846 9 O
piloerection	856 12 O
,	868 1 O
headache	870 8 B-Disease
,	878 1 O
and	880 3 O
cold	884 4 O
extremities	889 11 O
were	901 4 O
experienced	906 11 O
in	918 2 O
all	921 3 O
subjects	925 8 O
.	933 1 O

The	935 3 O
results	939 7 O
indicate	947 8 O
that	956 4 O
the	961 3 O
clinical	965 8 O
usefulness	974 10 O
of	985 2 O
direct	988 6 O
,	994 1 O
peripherally	996 12 O
acting	1009 6 O
sub	1016 3 O
-	1019 1 O
type	1020 4 O
-	1024 1 O
selective	1025 9 O
alpha1	1035 6 O
-	1041 1 O
adrenoceptor	1042 12 O
agonists	1055 8 O
in	1064 2 O
the	1067 3 O
medical	1071 7 O
treatment	1079 9 O
of	1089 2 O
stress	1092 6 B-Disease
incontinence	1099 12 I-Disease
may	1112 3 O
be	1116 2 O
limited	1119 7 O
by	1127 2 O
associated	1130 10 O
piloerection	1141 12 O
and	1154 3 O
cardiovascular	1158 14 O
side	1173 4 O
effects	1178 7 O
.	1185 1 O

Toleration	0 10 O
of	11 2 O
high	14 4 O
doses	19 5 O
of	25 2 O
angiotensin	28 11 B-Chemical
-	39 1 I-Chemical
converting	40 10 I-Chemical
enzyme	51 6 I-Chemical
inhibitors	58 10 I-Chemical
in	69 2 O
patients	72 8 O
with	81 4 O
chronic	86 7 O
heart	94 5 B-Disease
failure	100 7 I-Disease
:	107 1 O
results	109 7 O
from	117 4 O
the	122 3 O
ATLAS	126 5 O
trial	132 5 O
.	137 1 O

The	139 3 O
Assessment	143 10 O
of	154 2 O
Treatment	157 9 O
with	167 4 O
Lisinopril	172 10 B-Chemical
and	183 3 O
Survival	187 8 O
.	195 1 O

BACKGROUND	197 10 O
:	207 1 O
Treatment	209 9 O
with	219 4 O
angiotensin	224 11 B-Chemical
-	235 1 I-Chemical
converting	236 10 I-Chemical
enzyme	247 6 I-Chemical
(	254 1 I-Chemical
ACE	255 3 I-Chemical
)	258 1 I-Chemical
inhibitors	260 10 I-Chemical
reduces	271 7 O
mortality	279 9 O
and	289 3 O
morbidity	293 9 O
in	303 2 O
patients	306 8 O
with	315 4 O
chronic	320 7 O
heart	328 5 B-Disease
failure	334 7 I-Disease
(	342 1 O
CHF	343 3 B-Disease
)	346 1 O
,	347 1 O
but	349 3 O
most	353 4 O
affected	358 8 O
patients	367 8 O
are	376 3 O
not	380 3 O
receiving	384 9 O
these	394 5 O
agents	400 6 O
or	407 2 O
are	410 3 O
being	414 5 O
treated	420 7 O
with	428 4 O
doses	433 5 O
lower	439 5 O
than	445 4 O
those	450 5 O
found	456 5 O
to	462 2 O
be	465 2 O
efficacious	468 11 O
in	480 2 O
trials	483 6 O
,	489 1 O
primarily	491 9 O
because	501 7 O
of	509 2 O
concerns	512 8 O
about	521 5 O
the	527 3 O
safety	531 6 O
and	538 3 O
tolerability	542 12 O
of	555 2 O
these	558 5 O
agents	564 6 O
,	570 1 O
especially	572 10 O
at	583 2 O
the	586 3 O
recommended	590 11 O
doses	602 5 O
.	607 1 O

The	609 3 O
present	613 7 O
study	621 5 O
examines	627 8 O
the	636 3 O
safety	640 6 O
and	647 3 O
tolerability	651 12 O
of	664 2 O
high	667 4 O
-	671 1 O
compared	673 8 O
with	682 4 O
low	687 3 O
-	690 1 O
dose	691 4 O
lisinopril	696 10 B-Chemical
in	707 2 O
CHF	710 3 B-Disease
.	713 1 O

METHODS	715 7 O
:	722 1 O
The	724 3 O
Assessment	728 10 O
of	739 2 O
Lisinopril	742 10 B-Chemical
and	753 3 O
Survival	757 8 O
study	766 5 O
was	772 3 O
a	776 1 O
multicenter	778 11 O
,	789 1 O
randomized	791 10 O
,	801 1 O
double	803 6 O
-	809 1 O
blind	810 5 O
trial	816 5 O
in	822 2 O
which	825 5 O
patients	831 8 O
with	840 4 O
or	845 2 O
without	848 7 O
previous	856 8 O
ACE	865 3 B-Chemical
inhibitor	869 9 I-Chemical
treatment	879 9 O
were	889 4 O
stabilized	894 10 O
receiving	905 9 O
medium	915 6 O
-	921 1 O
dose	922 4 O
lisinopril	927 10 B-Chemical
(	938 1 O
12	939 2 O
.	941 1 O
5	942 1 O
or	944 2 O
15	947 2 O
.	949 1 O
0	950 1 O
mg	952 2 O
once	955 4 O
daily	960 5 O
[	966 1 O
OD	967 2 O
]	969 1 O
)	970 1 O
for	972 3 O
2	976 1 O
to	978 2 O
4	981 1 O
weeks	983 5 O
and	989 3 O
then	993 4 O
randomized	998 10 O
to	1009 2 O
high	1012 4 O
-	1016 1 O
(	1018 1 O
35	1019 2 O
.	1021 1 O
0	1022 1 O
or	1024 2 O
32	1027 2 O
.	1029 1 O
5	1030 1 O
mg	1032 2 O
OD	1035 2 O
)	1037 1 O
or	1039 2 O
low	1042 3 O
-	1045 1 O
dose	1046 4 O
(	1051 1 O
5	1052 1 O
.	1053 1 O
0	1054 1 O
or	1056 2 O
2	1059 1 O
.	1060 1 O
5	1061 1 O
mg	1063 2 O
OD	1066 2 O
)	1068 1 O
groups	1070 6 O
.	1076 1 O

Patients	1078 8 O
with	1087 4 O
New	1092 3 O
York	1096 4 O
Heart	1101 5 O
Association	1107 11 O
classes	1119 7 O
II	1127 2 O
to	1130 2 O
IV	1133 2 O
CHF	1136 3 B-Disease
and	1140 3 O
left	1144 4 O
ventricular	1149 11 O
ejection	1161 8 O
fractions	1170 9 O
of	1180 2 O
no	1183 2 O
greater	1186 7 O
than	1194 4 O
0	1199 1 O
.	1200 1 O
30	1201 2 O
(	1204 1 O
n	1205 1 O
=	1207 1 O
3164	1209 4 O
)	1213 1 O
were	1215 4 O
randomized	1220 10 O
and	1231 3 O
followed	1235 8 O
up	1244 2 O
for	1247 3 O
a	1251 1 O
median	1253 6 O
of	1260 2 O
46	1263 2 O
months	1266 6 O
.	1272 1 O

We	1274 2 O
examined	1277 8 O
the	1286 3 O
occurrence	1290 10 O
of	1301 2 O
adverse	1304 7 O
events	1312 6 O
and	1319 3 O
the	1323 3 O
need	1327 4 O
for	1332 3 O
discontinuation	1336 15 O
and	1352 3 O
dose	1356 4 O
reduction	1361 9 O
during	1371 6 O
treatment	1378 9 O
,	1387 1 O
with	1389 4 O
a	1394 1 O
focus	1396 5 O
on	1402 2 O
hypotension	1405 11 B-Disease
and	1417 3 O
renal	1421 5 B-Disease
dysfunction	1427 11 I-Disease
.	1438 1 O

RESULTS	1440 7 O
:	1447 1 O
Of	1449 2 O
405	1452 3 O
patients	1456 8 O
not	1465 3 O
previously	1469 10 O
receiving	1480 9 O
an	1490 2 O
ACE	1493 3 B-Chemical
inhibitor	1497 9 I-Chemical
,	1506 1 O
doses	1508 5 O
in	1514 2 O
only	1517 4 O
4	1522 1 O
.	1523 1 O
2	1524 1 O
%	1525 1 O
could	1527 5 O
not	1533 3 O
be	1537 2 O
titrated	1540 8 O
to	1549 2 O
the	1552 3 O
medium	1556 6 O
doses	1563 5 O
required	1569 8 O
for	1578 3 O
randomization	1582 13 O
because	1596 7 O
of	1604 2 O
symptoms	1607 8 O
possibly	1616 8 O
related	1625 7 O
to	1633 2 O
hypotension	1636 11 B-Disease
(	1648 1 O
2	1649 1 O
.	1650 1 O
0	1651 1 O
%	1652 1 O
)	1653 1 O
or	1655 2 O
because	1658 7 O
of	1666 2 O
renal	1669 5 B-Disease
dysfunction	1675 11 I-Disease
or	1687 2 O
hyperkalemia	1690 12 B-Disease
(	1703 1 O
2	1704 1 O
.	1705 1 O
3	1706 1 O
%	1707 1 O
)	1708 1 O
.	1709 1 O

Doses	1711 5 O
in	1717 2 O
more	1720 4 O
than	1725 4 O
90	1730 2 O
%	1732 1 O
of	1734 2 O
randomized	1737 10 O
patients	1748 8 O
in	1757 2 O
the	1760 3 O
high	1764 4 O
-	1768 1 O
and	1770 3 O
low	1774 3 O
-	1777 1 O
dose	1778 4 O
groups	1783 6 O
were	1790 4 O
titrated	1795 8 O
to	1804 2 O
their	1807 5 O
assigned	1813 8 O
target	1822 6 O
,	1828 1 O
and	1830 3 O
the	1834 3 O
mean	1838 4 O
doses	1843 5 O
of	1849 2 O
blinded	1852 7 O
medication	1860 10 O
in	1871 2 O
both	1874 4 O
groups	1879 6 O
remained	1886 8 O
similar	1895 7 O
throughout	1903 10 O
the	1914 3 O
study	1918 5 O
.	1923 1 O

Withdrawals	1925 11 O
occurred	1937 8 O
in	1946 2 O
27	1949 2 O
.	1951 1 O
1	1952 1 O
%	1953 1 O
of	1955 2 O
the	1958 3 O
high	1962 4 O
-	1966 1 O
and	1968 3 O
30	1972 2 O
.	1974 1 O
7	1975 1 O
%	1976 1 O
of	1978 2 O
the	1981 3 O
low	1985 3 O
-	1988 1 O
dose	1989 4 O
groups	1994 6 O
.	2000 1 O

Subgroups	2002 9 O
presumed	2012 8 O
to	2021 2 O
be	2024 2 O
at	2027 2 O
higher	2030 6 O
risk	2037 4 O
for	2042 3 O
ACE	2046 3 B-Chemical
inhibitor	2050 9 I-Chemical
intolerance	2060 11 O
(	2072 1 O
blood	2073 5 O
pressure	2079 8 O
,	2087 1 O
<	2089 1 O
120	2090 3 O
mm	2094 2 O
Hg	2097 2 O
;	2099 1 O
creatinine	2101 10 B-Chemical
,	2111 1 O
>	2113 1 O
or	2115 2 O
=	2118 1 O
132	2119 3 O
.	2122 1 O
6	2123 1 O
micromol	2125 8 O
/	2133 1 O
L	2134 1 O
[	2136 1 O
>	2137 1 O
or	2139 2 O
=	2142 1 O
1	2143 1 O
.	2144 1 O
5	2145 1 O
mg	2147 2 O
/	2149 1 O
dL	2150 2 O
]	2152 1 O
;	2153 1 O
age	2155 3 O
,	2158 1 O
>	2160 1 O
or	2162 2 O
=	2165 1 O
70	2166 2 O
years	2169 5 O
;	2174 1 O
and	2176 3 O
patients	2180 8 O
with	2189 4 O
diabetes	2194 8 B-Disease
)	2202 1 O
generally	2204 9 O
tolerated	2214 9 O
the	2224 3 O
high	2228 4 O
-	2232 1 O
dose	2233 4 O
strategy	2238 8 O
.	2246 1 O

CONCLUSIONS	2248 11 O
:	2259 1 O
These	2261 5 O
findings	2267 8 O
demonstrate	2276 11 O
that	2288 4 O
ACE	2293 3 B-Chemical
inhibitor	2297 9 I-Chemical
therapy	2307 7 O
in	2315 2 O
most	2318 4 O
patients	2323 8 O
with	2332 4 O
CHF	2337 3 B-Disease
can	2341 3 O
be	2345 2 O
successfully	2348 12 O
titrated	2361 8 O
to	2370 2 O
and	2373 3 O
maintained	2377 10 O
at	2388 2 O
high	2391 4 O
doses	2396 5 O
,	2401 1 O
and	2403 3 O
that	2407 4 O
more	2412 4 O
aggressive	2417 10 O
use	2428 3 O
of	2432 2 O
these	2435 5 O
agents	2441 6 O
is	2448 2 O
warranted	2451 9 O
.	2460 1 O

Cocaine	0 7 B-Chemical
,	7 1 O
ethanol	9 7 B-Chemical
,	16 1 O
and	18 3 O
cocaethylene	22 12 B-Chemical
cardiotoxity	35 12 B-Disease
in	48 2 O
an	51 2 O
animal	54 6 O
model	61 5 O
of	67 2 O
cocaine	70 7 B-Disease
and	78 3 I-Disease
ethanol	82 7 I-Disease
abuse	90 5 I-Disease
.	95 1 O

OBJECTIVES	97 10 O
:	107 1 O
Simultaneous	109 12 O
abuse	122 5 B-Disease
of	128 2 I-Disease
cocaine	131 7 I-Disease
and	139 3 I-Disease
ethanol	143 7 I-Disease
affects	151 7 O
12	159 2 O
million	162 7 O
Americans	170 9 O
annually	180 8 O
.	188 1 O

In	190 2 O
combination	193 11 O
,	204 1 O
these	206 5 O
substances	212 10 O
are	223 3 O
substantially	227 13 O
more	241 4 O
toxic	246 5 O
than	252 4 O
either	257 6 O
drug	264 4 O
alone	269 5 O
.	274 1 O

Their	276 5 O
combined	282 8 O
cardiac	291 7 B-Disease
toxicity	299 8 I-Disease
may	308 3 O
be	312 2 O
due	315 3 O
to	319 2 O
independent	322 11 O
effects	334 7 O
of	342 2 O
each	345 4 O
drug	350 4 O
;	354 1 O
however	356 7 O
,	363 1 O
they	365 4 O
may	370 3 O
also	374 4 O
be	379 2 O
due	382 3 O
to	386 2 O
cocaethylene	389 12 B-Chemical
(	402 1 O
CE	403 2 B-Chemical
)	405 1 O
,	406 1 O
a	408 1 O
cocaine	410 7 B-Chemical
metabolite	418 10 O
formed	429 6 O
only	436 4 O
in	441 2 O
the	444 3 O
presence	448 8 O
of	457 2 O
ethanol	460 7 B-Chemical
.	467 1 O

The	469 3 O
purpose	473 7 O
of	481 2 O
this	484 4 O
study	489 5 O
was	495 3 O
to	499 2 O
delineate	502 9 O
the	512 3 O
role	516 4 O
of	521 2 O
CE	524 2 B-Chemical
in	527 2 O
the	530 3 O
combined	534 8 O
cardiotoxicity	543 14 B-Disease
of	558 2 O
cocaine	561 7 B-Chemical
and	569 3 O
ethanol	573 7 B-Chemical
in	581 2 O
a	584 1 O
model	586 5 O
simulating	592 10 O
their	603 5 O
abuse	609 5 O
.	614 1 O

METHODS	616 7 O
:	623 1 O
Twenty	625 6 O
-	631 1 O
three	632 5 O
dogs	638 4 O
were	643 4 O
randomized	648 10 O
to	659 2 O
receive	662 7 O
either	670 6 O
1	677 1 O
)	678 1 O
three	680 5 O
intravenous	686 11 O
(	698 1 O
IV	699 2 O
)	701 1 O
boluses	703 7 O
of	711 2 O
cocaine	714 7 B-Chemical
7	722 1 O
.	723 1 O
5	724 1 O
mg	726 2 O
/	728 1 O
kg	729 2 O
with	732 4 O
ethanol	737 7 B-Chemical
(	745 1 O
1	746 1 O
g	748 1 O
/	749 1 O
kg	750 2 O
)	752 1 O
as	754 2 O
an	757 2 O
IV	760 2 O
infusion	763 8 O
(	772 1 O
C	773 1 O
+	774 1 O
E	775 1 O
,	776 1 O
n	778 1 O
=	780 1 O
8	782 1 O
)	783 1 O
,	784 1 O
2	786 1 O
)	787 1 O
three	789 5 O
cocaine	795 7 B-Chemical
boluses	803 7 O
only	811 4 O
(	816 1 O
C	817 1 O
,	818 1 O
n	820 1 O
=	822 1 O
6	824 1 O
)	825 1 O
,	826 1 O
3	828 1 O
)	829 1 O
ethanol	831 7 B-Chemical
infusion	839 8 O
only	848 4 O
(	853 1 O
E	854 1 O
,	855 1 O
n	857 1 O
=	859 1 O
5	861 1 O
)	862 1 O
,	863 1 O
or	865 2 O
4	868 1 O
)	869 1 O
placebo	871 7 O
boluses	879 7 O
and	887 3 O
infusion	891 8 O
(	900 1 O
n	901 1 O
=	903 1 O
4	905 1 O
)	906 1 O
.	907 1 O

Hemodynamic	909 11 O
measurements	921 12 O
,	933 1 O
electrocardiograms	935 18 O
,	953 1 O
and	955 3 O
serum	959 5 O
drug	965 4 O
concentrations	970 14 O
were	985 4 O
obtained	990 8 O
at	999 2 O
baseline	1002 8 O
,	1010 1 O
and	1012 3 O
then	1016 4 O
at	1021 2 O
fixed	1024 5 O
time	1030 4 O
intervals	1035 9 O
after	1045 5 O
each	1051 4 O
drug	1056 4 O
was	1061 3 O
administered	1065 12 O
.	1077 1 O

RESULTS	1079 7 O
:	1086 1 O
Two	1088 3 O
of	1092 2 O
eight	1095 5 O
dogs	1101 4 O
in	1106 2 O
the	1109 3 O
C	1113 1 O
+	1114 1 O
E	1115 1 O
group	1117 5 O
experienced	1123 11 O
cardiovascular	1135 14 B-Disease
collapse	1150 8 I-Disease
.	1158 1 O

The	1160 3 O
most	1164 4 O
dramatic	1169 8 O
hemodynamic	1178 11 O
changes	1190 7 O
occurred	1198 8 O
after	1207 5 O
each	1213 4 O
cocaine	1218 7 B-Chemical
bolus	1226 5 O
in	1232 2 O
the	1235 3 O
C	1239 1 O
+	1240 1 O
E	1241 1 O
and	1243 3 O
C	1247 1 O
only	1249 4 O
groups	1254 6 O
;	1260 1 O
however	1262 7 O
,	1269 1 O
persistent	1271 10 O
hemodynamic	1282 11 O
changes	1294 7 O
occurred	1302 8 O
in	1311 2 O
the	1314 3 O
C	1318 1 O
+	1319 1 O
E	1320 1 O
group	1322 5 O
.	1327 1 O

Peak	1329 4 O
CE	1334 2 B-Chemical
levels	1337 6 O
were	1344 4 O
associated	1349 10 O
with	1360 4 O
a	1365 1 O
45	1367 2 O
%	1369 1 O
(	1371 1 O
SD	1372 2 O
+	1375 1 O
/	1376 1 O
-	1377 1 O
22	1379 2 O
%	1381 1 O
,	1382 1 O
95	1384 2 O
%	1386 1 O
CI	1388 2 O
=	1391 1 O
22	1393 2 O
%	1395 1 O
to	1397 2 O
69	1400 2 O
%	1402 1 O
)	1403 1 O
decrease	1405 8 B-Disease
in	1414 2 I-Disease
cardiac	1417 7 I-Disease
output	1425 6 I-Disease
(	1432 1 O
p	1433 1 O
<	1435 1 O
0	1437 1 O
.	1438 1 O
05	1439 2 O
)	1441 1 O
,	1442 1 O
a	1444 1 O
56	1446 2 O
%	1448 1 O
(	1450 1 O
SD	1451 2 O
+	1454 1 O
/	1455 1 O
-	1456 1 O
23	1458 2 O
%	1460 1 O
,	1461 1 O
95	1463 2 O
%	1465 1 O
CI	1467 2 O
=	1470 1 O
32	1472 2 O
%	1474 1 O
to	1476 2 O
80	1479 2 O
%	1481 1 O
)	1482 1 O
decrease	1484 8 O
in	1493 2 O
dP	1496 2 O
/	1498 1 O
dt	1499 2 O
(	1501 1 O
max	1502 3 O
)	1505 1 O
(	1507 1 O
p	1508 1 O
<	1510 1 O
.	1511 1 O
006	1512 3 O
)	1515 1 O
,	1516 1 O
and	1518 3 O
a	1522 1 O
23	1524 2 O
%	1526 1 O
(	1528 1 O
SD	1529 2 O
+	1532 1 O
/	1533 1 O
-	1534 1 O
15	1536 2 O
%	1538 1 O
,	1539 1 O
95	1541 2 O
%	1543 1 O
CI	1545 2 O
=	1548 1 O
7	1550 1 O
%	1551 1 O
to	1553 2 O
49	1556 2 O
%	1558 1 O
)	1559 1 O
decrease	1561 8 O
in	1570 2 O
SVO	1573 3 O
(	1576 1 O
2	1577 1 O
)	1578 1 O
(	1580 1 O
p	1581 1 O
<	1583 1 O
0	1585 1 O
.	1586 1 O
025	1587 3 O
)	1590 1 O
.	1591 1 O

Ventricular	1593 11 B-Disease
arrhythmias	1605 11 I-Disease
were	1617 4 O
primarily	1622 9 O
observed	1632 8 O
in	1641 2 O
the	1644 3 O
C	1648 1 O
+	1649 1 O
E	1650 1 O
group	1652 5 O
,	1657 1 O
in	1659 2 O
which	1662 5 O
four	1668 4 O
of	1673 2 O
eight	1676 5 O
dogs	1682 4 O
experienced	1687 11 O
ventricular	1699 11 B-Disease
tachycardia	1711 11 I-Disease
.	1722 1 O

CONCLUSIONS	1724 11 O
:	1735 1 O
Cocaine	1737 7 B-Chemical
and	1745 3 O
ethanol	1749 7 B-Chemical
in	1757 2 O
combination	1760 11 O
were	1772 4 O
more	1777 4 O
toxic	1782 5 O
than	1788 4 O
either	1793 6 O
substance	1800 9 O
alone	1810 5 O
.	1815 1 O

Co	1817 2 O
-	1819 1 O
administration	1820 14 O
resulted	1835 8 O
in	1844 2 O
prolonged	1847 9 O
cardiac	1857 7 B-Disease
toxicity	1865 8 I-Disease
and	1874 3 O
was	1878 3 O
dysrhythmogenic	1882 15 O
.	1897 1 O

Peak	1899 4 O
serum	1904 5 O
cocaethylene	1910 12 B-Chemical
concentrations	1923 14 O
were	1938 4 O
associated	1943 10 O
with	1954 4 O
prolonged	1959 9 O
myocardial	1969 10 B-Disease
depression	1980 10 I-Disease
.	1990 1 O

Worsening	0 9 O
of	10 2 O
Parkinsonism	13 12 B-Disease
after	26 5 O
the	32 3 O
use	36 3 O
of	40 2 O
veralipride	43 11 B-Chemical
for	55 3 O
treatment	59 9 O
of	69 2 O
menopause	72 9 O
:	81 1 O
case	83 4 O
report	88 6 O
.	94 1 O

We	96 2 O
describe	99 8 O
a	108 1 O
female	110 6 O
patient	117 7 O
with	125 4 O
stable	130 6 O
Parkinson	137 9 B-Disease
'	146 1 I-Disease
s	147 1 I-Disease
disease	149 7 I-Disease
who	157 3 O
has	161 3 O
shown	165 5 O
a	171 1 O
marked	173 6 O
worsening	180 9 O
of	190 2 O
her	193 3 O
motor	197 5 O
functions	203 9 O
following	213 9 O
therapy	223 7 O
of	231 2 O
menopause	234 9 O
related	244 7 O
symptoms	252 8 O
with	261 4 O
veralipride	266 11 B-Chemical
,	277 1 O
as	279 2 O
well	282 4 O
as	287 2 O
the	290 3 O
improvement	294 11 O
of	306 2 O
her	309 3 O
symptoms	313 8 O
back	322 4 O
to	327 2 O
baseline	330 8 O
after	339 5 O
discontinuation	345 15 O
of	361 2 O
the	364 3 O
drug	368 4 O
.	372 1 O

We	374 2 O
emphasize	377 9 O
the	387 3 O
anti	391 4 O
-	395 1 O
dopaminergic	396 12 O
effect	409 6 O
of	416 2 O
veralipride	419 11 B-Chemical
.	430 1 O

Viracept	0 8 B-Chemical
and	9 3 O
irregular	13 9 B-Disease
heartbeat	23 9 I-Disease
warning	33 7 O
.	40 1 O

A	42 1 O
group	44 5 O
of	50 2 O
doctors	53 7 O
in	61 2 O
Boston	64 6 O
warn	71 4 O
that	76 4 O
the	81 3 O
protease	85 8 O
inhibitor	94 9 O
Viracept	104 8 B-Chemical
may	113 3 O
cause	117 5 O
an	123 2 O
irregular	126 9 B-Disease
heart	136 5 I-Disease
beat	142 4 I-Disease
,	146 1 O
known	148 5 O
as	154 2 O
bradycardia	157 11 B-Disease
,	168 1 O
in	170 2 O
people	173 6 O
with	180 4 O
HIV	185 3 O
.	188 1 O

Bradycardia	190 11 B-Disease
occurred	202 8 O
in	211 2 O
a	214 1 O
45	216 2 O
-	218 1 O
year	219 4 O
-	223 1 O
old	224 3 O
male	228 4 O
patient	233 7 O
who	241 3 O
was	245 3 O
Viracept	249 8 B-Chemical
in	258 2 O
combination	261 11 O
with	273 4 O
other	278 5 O
anti	284 4 O
-	288 1 O
HIV	289 3 O
drugs	293 5 O
.	298 1 O

The	300 3 O
symptoms	304 8 O
ceased	313 6 O
after	320 5 O
switching	326 9 O
to	336 2 O
another	339 7 O
drug	347 4 O
combination	352 11 O
.	363 1 O

Frequency	0 9 O
of	10 2 O
appearance	13 10 O
of	24 2 O
myeloperoxidase	27 15 O
-	42 1 O
antineutrophil	43 14 O
cytoplasmic	58 11 O
antibody	70 8 O
(	79 1 O
MPO	80 3 O
-	83 1 O
ANCA	84 4 O
)	88 1 O
in	90 2 O
Graves	93 6 B-Disease
'	99 1 I-Disease
disease	101 7 I-Disease
patients	109 8 O
treated	118 7 O
with	126 4 O
propylthiouracil	131 16 B-Chemical
and	148 3 O
the	152 3 O
relationship	156 12 O
between	169 7 O
MPO	177 3 O
-	180 1 O
ANCA	181 4 O
and	186 3 O
clinical	190 8 O
manifestations	199 14 O
.	213 1 O

OBJECTIVE	215 9 O
:	224 1 O
Myeloperoxidase	226 15 O
antineutrophil	242 14 O
cytoplasmic	257 11 O
antibody	269 8 O
(	278 1 O
MPO	279 3 O
-	282 1 O
ANCA	283 4 O
)	287 1 O
-	288 1 O
positive	289 8 O
vasculitis	298 10 B-Disease
has	309 3 O
been	313 4 O
reported	318 8 O
in	327 2 O
patients	330 8 O
with	339 4 O
Graves	344 6 B-Disease
'	350 1 I-Disease
disease	352 7 I-Disease
who	360 3 O
were	364 4 O
treated	369 7 O
with	377 4 O
propylthiouracil	382 16 B-Chemical
(	399 1 O
PTU	400 3 B-Chemical
)	403 1 O
.	404 1 O

The	406 3 O
appearance	410 10 O
of	421 2 O
MPO	424 3 O
-	427 1 O
ANCA	428 4 O
in	433 2 O
these	436 5 O
cases	442 5 O
was	448 3 O
suspected	452 9 O
of	462 2 O
being	465 5 O
related	471 7 O
to	479 2 O
PTU	482 3 B-Chemical
because	486 7 O
the	494 3 O
titres	498 6 O
of	505 2 O
MPO	508 3 O
-	511 1 O
ANCA	512 4 O
decreased	517 9 O
when	527 4 O
PTU	532 3 B-Chemical
was	536 3 O
stopped	540 7 O
.	547 1 O

Nevertheless	549 12 O
,	561 1 O
there	563 5 O
have	569 4 O
been	574 4 O
no	579 2 O
studies	582 7 O
on	590 2 O
the	593 3 O
temporal	597 8 O
relationship	606 12 O
between	619 7 O
the	627 3 O
appearance	631 10 O
of	642 2 O
MPO	645 3 O
-	648 1 O
ANCA	649 4 O
and	654 3 O
vasculitis	658 10 B-Disease
during	669 6 O
PTU	676 3 B-Chemical
therapy	680 7 O
,	687 1 O
or	689 2 O
on	692 2 O
the	695 3 O
incidence	699 9 O
of	709 2 O
MPO	712 3 O
-	715 1 O
ANCA	716 4 O
in	721 2 O
untreated	724 9 O
Graves	734 6 B-Disease
'	740 1 I-Disease
disease	742 7 I-Disease
patients	750 8 O
.	758 1 O

Therefore	760 9 O
,	769 1 O
we	771 2 O
sought	774 6 O
to	781 2 O
address	784 7 O
these	792 5 O
parameters	798 10 O
in	809 2 O
patients	812 8 O
with	821 4 O
Graves	826 6 B-Disease
'	832 1 I-Disease
disease	834 7 I-Disease
.	841 1 O

PATIENTS	843 8 O
:	851 1 O
We	853 2 O
investigated	856 12 O
102	869 3 O
untreated	873 9 O
patients	883 8 O
with	892 4 O
hyperthyroidism	897 15 B-Disease
due	913 3 O
to	917 2 O
Graves	920 6 B-Disease
'	926 1 I-Disease
disease	928 7 I-Disease
for	936 3 O
the	940 3 O
presence	944 8 O
of	953 2 O
MPO	956 3 O
-	959 1 O
ANCA	960 4 O
,	964 1 O
and	966 3 O
for	970 3 O
the	974 3 O
development	978 11 O
vasculitis	990 10 B-Disease
after	1001 5 O
starting	1007 8 O
PTU	1016 3 B-Chemical
therapy	1020 7 O
.	1027 1 O

Twenty	1029 6 O
-	1035 1 O
nine	1036 4 O
of	1041 2 O
them	1044 4 O
were	1049 4 O
later	1054 5 O
excluded	1060 8 O
because	1069 7 O
of	1077 2 O
adverse	1080 7 O
effects	1088 7 O
of	1096 2 O
PTU	1099 3 B-Chemical
or	1103 2 O
because	1106 7 O
the	1114 3 O
observation	1118 11 O
period	1130 6 O
was	1137 3 O
less	1141 4 O
than	1146 4 O
3	1151 1 O
months	1153 6 O
.	1159 1 O

The	1161 3 O
remaining	1165 9 O
73	1175 2 O
patients	1178 8 O
(	1187 1 O
55	1188 2 O
women	1191 5 O
and	1197 3 O
18	1201 2 O
men	1204 3 O
)	1207 1 O
,	1208 1 O
all	1210 3 O
of	1214 2 O
whom	1217 4 O
were	1222 4 O
examined	1227 8 O
for	1236 3 O
more	1240 4 O
than	1245 4 O
3	1250 1 O
months	1252 6 O
,	1258 1 O
were	1260 4 O
adopted	1265 7 O
as	1273 2 O
the	1276 3 O
subjects	1280 8 O
of	1289 2 O
the	1292 3 O
investigation	1296 13 O
.	1309 1 O

The	1311 3 O
median	1315 6 O
observation	1322 11 O
period	1334 6 O
was	1341 3 O
23	1345 2 O
.	1347 1 O
6	1348 1 O
months	1350 6 O
(	1357 1 O
range	1358 5 O
:	1363 1 O
3	1365 1 O
-	1366 1 O
37	1367 2 O
months	1370 6 O
)	1376 1 O
.	1377 1 O

MEASUREMENTS	1379 12 O
:	1391 1 O
MPO	1393 3 O
-	1396 1 O
ANCA	1397 4 O
was	1402 3 O
measured	1406 8 O
at	1415 2 O
intervals	1418 9 O
of	1428 2 O
2	1431 1 O
-	1432 1 O
6	1433 1 O
months	1435 6 O
.	1441 1 O

RESULTS	1443 7 O
:	1450 1 O
Before	1452 6 O
treatment	1459 9 O
,	1468 1 O
the	1470 3 O
MPO	1474 3 O
-	1477 1 O
ANCA	1478 4 O
titres	1483 6 O
of	1490 2 O
all	1493 3 O
102	1497 3 O
untreated	1501 9 O
Graves	1511 6 B-Disease
'	1517 1 I-Disease
disease	1519 7 I-Disease
patients	1527 8 O
were	1536 4 O
within	1541 6 O
the	1548 3 O
reference	1552 9 O
range	1562 5 O
(	1568 1 O
below	1569 5 O
10	1575 2 O
U	1578 1 O
/	1579 1 O
ml	1580 2 O
)	1582 1 O
.	1583 1 O

Three	1585 5 O
(	1591 1 O
4	1592 1 O
.	1593 1 O
1	1594 1 O
%	1595 1 O
)	1596 1 O
of	1598 2 O
the	1601 3 O
73	1605 2 O
patients	1608 8 O
were	1617 4 O
positive	1622 8 O
for	1631 3 O
MPO	1635 3 O
-	1638 1 O
ANCA	1639 4 O
at	1644 2 O
13	1647 2 O
,	1649 1 O
16	1651 2 O
and	1654 3 O
17	1658 2 O
months	1661 6 O
,	1667 1 O
respectively	1669 12 O
,	1681 1 O
after	1683 5 O
the	1689 3 O
start	1693 5 O
of	1699 2 O
PTU	1702 3 B-Chemical
therapy	1706 7 O
.	1713 1 O

In	1715 2 O
two	1718 3 O
of	1722 2 O
them	1725 4 O
,	1729 1 O
the	1731 3 O
MPO	1735 3 O
-	1738 1 O
ANCA	1739 4 O
titres	1744 6 O
transiently	1751 11 O
increased	1763 9 O
to	1773 2 O
12	1776 2 O
.	1778 1 O
8	1779 1 O
and	1781 3 O
15	1785 2 O
.	1787 1 O
0	1788 1 O
U	1790 1 O
/	1791 1 O
ml	1792 2 O
,	1794 1 O
respectively	1796 12 O
,	1808 1 O
despite	1810 7 O
continued	1818 9 O
PTU	1828 3 B-Chemical
therapy	1832 7 O
,	1839 1 O
but	1841 3 O
no	1845 2 O
vasculitic	1848 10 B-Disease
disorders	1859 9 I-Disease
developed	1869 9 O
.	1878 1 O

In	1880 2 O
the	1883 3 O
third	1887 5 O
patient	1893 7 O
,	1900 1 O
the	1902 3 O
MPO	1906 3 O
-	1909 1 O
ANCA	1910 4 O
titre	1915 5 O
increased	1921 9 O
to	1931 2 O
204	1934 3 O
U	1938 1 O
/	1939 1 O
ml	1940 2 O
and	1943 3 O
she	1947 3 O
developed	1951 9 O
a	1961 1 O
higher	1963 6 O
fever	1970 5 B-Disease
,	1975 1 O
oral	1977 4 B-Disease
ulcers	1982 6 I-Disease
and	1989 3 O
polyarthralgia	1993 14 B-Disease
,	2007 1 O
but	2009 3 O
the	2013 3 O
symptoms	2017 8 O
resolved	2026 8 O
2	2035 1 O
weeks	2037 5 O
after	2043 5 O
stopping	2049 8 O
PTU	2058 3 B-Chemical
therapy	2062 7 O
,	2069 1 O
and	2071 3 O
the	2075 3 O
MPO	2079 3 O
-	2082 1 O
ANCA	2083 4 O
titre	2088 5 O
decreased	2094 9 O
to	2104 2 O
20	2107 2 O
.	2109 1 O
7	2110 1 O
U	2112 1 O
/	2113 1 O
ml	2114 2 O
by	2117 2 O
4	2120 1 O
months	2122 6 O
after	2129 5 O
discontinuing	2135 13 O
PTU	2149 3 B-Chemical
.	2152 1 O

CONCLUSIONS	2154 11 O
:	2165 1 O
PTU	2167 3 B-Chemical
therapy	2171 7 O
may	2179 3 O
be	2183 2 O
related	2186 7 O
to	2194 2 O
the	2197 3 O
appearance	2201 10 O
of	2212 2 O
MPO	2215 3 O
-	2218 1 O
ANCA	2219 4 O
,	2223 1 O
but	2225 3 O
MPO	2229 3 O
-	2232 1 O
ANCA	2233 4 O
does	2238 4 O
not	2243 3 O
appear	2247 6 O
to	2254 2 O
be	2257 2 O
closely	2260 7 O
related	2268 7 O
to	2276 2 O
vasculitis	2279 10 B-Disease
.	2289 1 O

Prevalence	0 10 O
of	11 2 O
heart	14 5 B-Disease
disease	20 7 I-Disease
in	28 2 O
asymptomatic	31 12 O
chronic	44 7 O
cocaine	52 7 B-Chemical
users	60 5 O
.	65 1 O

To	67 2 O
determine	70 9 O
the	80 3 O
prevalence	84 10 O
of	95 2 O
heart	98 5 B-Disease
disease	104 7 I-Disease
in	112 2 O
outpatient	115 10 O
young	126 5 O
asymptomatic	132 12 O
chronic	145 7 O
cocaine	153 7 B-Chemical
users	161 5 O
,	166 1 O
35	168 2 O
cocaine	171 7 B-Chemical
users	179 5 O
and	185 3 O
32	189 2 O
age	192 3 O
-	195 1 O
matched	196 7 O
controls	204 8 O
underwent	213 9 O
resting	223 7 O
and	231 3 O
exercise	235 8 O
electrocardiography	244 19 O
(	264 1 O
ECG	265 3 O
)	268 1 O
and	270 3 O
Doppler	274 7 O
echocardiography	282 16 O
.	298 1 O

Findings	300 8 O
consistent	309 10 O
with	320 4 O
coronary	325 8 B-Disease
artery	334 6 I-Disease
disease	341 7 I-Disease
were	349 4 O
detected	354 8 O
in	363 2 O
12	366 2 O
(	369 1 O
34	370 2 O
%	372 1 O
)	373 1 O
patients	375 8 O
and	384 3 O
3	388 1 O
(	390 1 O
9	391 1 O
%	392 1 O
)	393 1 O
controls	395 8 O
(	404 1 O
p	405 1 O
=	407 1 O
0	409 1 O
.	410 1 O
01	411 2 O
)	413 1 O
.	414 1 O

Decreased	416 9 O
left	426 4 O
ventricular	431 11 O
systolic	443 8 O
function	452 8 O
was	461 3 O
demonstrated	465 12 O
in	478 2 O
5	481 1 O
(	483 1 O
14	484 2 O
%	486 1 O
)	487 1 O
patients	489 8 O
,	497 1 O
but	499 3 O
in	503 2 O
none	506 4 O
of	511 2 O
the	514 3 O
controls	518 8 O
(	527 1 O
p	528 1 O
=	530 1 O
0	532 1 O
.	533 1 O
055	534 3 O
)	537 1 O
.	538 1 O

Finally	540 7 O
,	547 1 O
resting	549 7 O
and	557 3 O
peak	561 4 O
exercise	566 8 O
abnormal	575 8 B-Disease
left	584 4 I-Disease
ventricular	589 11 I-Disease
filling	601 7 I-Disease
was	609 3 O
detected	613 8 O
in	622 2 O
38	625 2 O
and	628 3 O
35	632 2 O
%	634 1 O
of	636 2 O
patients	639 8 O
as	648 2 O
compared	651 8 O
to	660 2 O
19	663 2 O
and	666 3 O
9	670 1 O
%	671 1 O
of	673 2 O
controls	676 8 O
,	684 1 O
respectively	686 12 O
(	699 1 O
p	700 1 O
=	702 1 O
0	704 1 O
.	705 1 O
11	706 2 O
and	709 3 O
0	713 1 O
.	714 1 O
02	715 2 O
,	717 1 O
respectively	719 12 O
)	731 1 O
.	732 1 O

We	734 2 O
conclude	737 8 O
that	746 4 O
coronary	751 8 B-Disease
artery	760 6 I-Disease
or	767 2 I-Disease
myocardial	770 10 I-Disease
disease	781 7 I-Disease
is	789 2 O
common	792 6 O
(	799 1 O
38	800 2 O
%	802 1 O
)	803 1 O
in	805 2 O
young	808 5 O
asymptomatic	814 12 O
chronic	827 7 O
cocaine	835 7 B-Chemical
users	843 5 O
.	848 1 O

Therefore	850 9 O
,	859 1 O
screening	861 9 O
ECG	871 3 O
and	875 3 O
echocardiography	879 16 O
may	896 3 O
be	900 2 O
warranted	903 9 O
in	913 2 O
these	916 5 O
patients	922 8 O
.	930 1 O

Cardioprotective	0 16 O
effects	17 7 O
of	25 2 O
Picrorrhiza	28 11 O
kurroa	40 6 O
against	47 7 O
isoproterenol	55 13 B-Chemical
-	68 1 O
induced	69 7 O
myocardial	77 10 O
stress	88 6 O
in	95 2 O
rats	98 4 O
.	102 1 O

The	104 3 O
cardioprotective	108 16 O
effect	125 6 O
of	132 2 O
the	135 3 O
ethanol	139 7 B-Chemical
extract	147 7 O
of	155 2 O
Picrorrhiza	158 11 O
kurroa	170 6 O
rhizomes	177 8 O
and	186 3 O
roots	190 5 O
(	196 1 O
PK	197 2 O
)	199 1 O
on	201 2 O
isoproterenol	204 13 B-Chemical
-	217 1 O
induced	218 7 O
myocardial	226 10 B-Disease
infarction	237 10 I-Disease
in	248 2 O
rats	251 4 O
with	256 4 O
respect	261 7 O
to	269 2 O
lipid	272 5 O
metabolism	278 10 O
in	289 2 O
serum	292 5 O
and	298 3 O
heart	302 5 O
tissue	308 6 O
has	315 3 O
been	319 4 O
investigated	324 12 O
.	336 1 O

Oral	338 4 O
pre	343 3 O
-	346 1 O
treatment	347 9 O
with	357 4 O
PK	362 2 O
(	365 1 O
80	366 2 O
mg	369 2 O
kg	372 2 O
(	374 1 O
-	375 1 O
1	376 1 O
)	377 1 O
day	379 3 O
(	382 1 O
-	383 1 O
1	384 1 O
)	385 1 O
for	387 3 O
15	391 2 O
days	394 4 O
)	398 1 O
significantly	400 13 O
prevented	414 9 O
the	424 3 O
isoproterenol	428 13 B-Chemical
-	441 1 O
induced	442 7 O
myocardial	450 10 B-Disease
infarction	461 10 I-Disease
and	472 3 O
maintained	476 10 O
the	487 3 O
rats	491 4 O
at	496 2 O
near	499 4 O
normal	504 6 O
status	511 6 O
.	517 1 O

Phase	0 5 O
2	6 1 O
early	8 5 O
afterdepolarization	14 19 O
as	34 2 O
a	37 1 O
trigger	39 7 O
of	47 2 O
polymorphic	50 11 O
ventricular	62 11 B-Disease
tachycardia	74 11 I-Disease
in	86 2 O
acquired	89 8 O
long	98 4 B-Disease
-	102 1 I-Disease
QT	103 2 I-Disease
syndrome	106 8 I-Disease
:	115 1 O
direct	117 6 O
evidence	124 8 O
from	133 4 O
intracellular	138 13 O
recordings	152 10 O
in	163 2 O
the	166 3 O
intact	170 6 O
left	177 4 O
ventricular	182 11 O
wall	194 4 O
.	198 1 O

BACKGROUND	200 10 O
:	210 1 O
This	212 4 O
study	217 5 O
examined	223 8 O
the	232 3 O
role	236 4 O
of	241 2 O
phase	244 5 O
2	250 1 O
early	252 5 O
afterdepolarization	258 19 O
(	278 1 O
EAD	279 3 O
)	282 1 O
in	284 2 O
producing	287 9 O
a	297 1 O
trigger	299 7 O
to	307 2 O
initiate	310 8 O
torsade	319 7 B-Disease
de	327 2 I-Disease
pointes	330 7 I-Disease
(	338 1 O
TdP	339 3 B-Disease
)	342 1 O
with	344 4 O
QT	349 2 B-Disease
prolongation	352 12 I-Disease
induced	365 7 O
by	373 2 O
dl	376 2 O
-	378 1 O
sotalol	379 7 B-Chemical
and	387 3 O
azimilide	391 9 B-Chemical
.	400 1 O

The	402 3 O
contribution	406 12 O
of	419 2 O
transmural	422 10 O
dispersion	433 10 O
of	444 2 O
repolarization	447 14 O
(	462 1 O
TDR	463 3 O
)	466 1 O
to	468 2 O
transmural	471 10 O
propagation	482 11 O
of	494 2 O
EAD	497 3 O
and	501 3 O
the	505 3 O
maintenance	509 11 O
of	521 2 O
TdP	524 3 B-Disease
was	528 3 O
also	532 4 O
evaluated	537 9 O
.	546 1 O

METHODS	548 7 O
AND	556 3 O
RESULTS	560 7 O
:	567 1 O
Transmembrane	569 13 O
action	583 6 O
potentials	590 10 O
from	601 4 O
epicardium	606 10 O
,	616 1 O
midmyocardium	618 13 O
,	631 1 O
and	633 3 O
endocardium	637 11 O
were	649 4 O
recorded	654 8 O
simultaneously	663 14 O
,	677 1 O
together	679 8 O
with	688 4 O
a	693 1 O
transmural	695 10 O
ECG	706 3 O
,	709 1 O
in	711 2 O
arterially	714 10 O
perfused	725 8 O
canine	734 6 O
and	741 3 O
rabbit	745 6 O
left	752 4 O
ventricular	757 11 O
preparations	769 12 O
.	781 1 O

dl	783 2 O
-	785 1 O
Sotalol	786 7 B-Chemical
preferentially	794 14 O
prolonged	809 9 O
action	819 6 O
potential	826 9 O
duration	836 8 O
(	845 1 O
APD	846 3 O
)	849 1 O
in	851 2 O
M	854 1 O
cells	856 5 O
dose	862 4 O
-	866 1 O
dependently	867 11 O
(	879 1 O
1	880 1 O
to	882 2 O
100	885 3 O
micromol	889 8 O
/	897 1 O
L	898 1 O
)	899 1 O
,	900 1 O
leading	902 7 O
to	910 2 O
QT	913 2 B-Disease
prolongation	916 12 I-Disease
and	929 3 O
an	933 2 O
increase	936 8 O
in	945 2 O
TDR	948 3 O
.	951 1 O

Azimilide	953 9 B-Chemical
,	962 1 O
however	964 7 O
,	971 1 O
significantly	973 13 O
prolonged	987 9 O
APD	997 3 O
and	1001 3 O
QT	1005 2 O
interval	1008 8 O
at	1017 2 O
concentrations	1020 14 O
from	1035 4 O
0	1040 1 O
.	1041 1 O
1	1042 1 O
to	1044 2 O
10	1047 2 O
micromol	1050 8 O
/	1058 1 O
L	1059 1 O
but	1061 3 O
shortened	1065 9 O
them	1075 4 O
at	1080 2 O
30	1083 2 O
micromol	1086 8 O
/	1094 1 O
L	1095 1 O
.	1096 1 O

Unlike	1098 6 O
dl	1105 2 O
-	1107 1 O
sotalol	1108 7 B-Chemical
,	1115 1 O
azimilide	1117 9 B-Chemical
(	1127 1 O
>	1128 1 O
3	1129 1 O
micromol	1131 8 O
/	1139 1 O
L	1140 1 O
)	1141 1 O
increased	1143 9 O
epicardial	1153 10 O
APD	1164 3 O
markedly	1168 8 O
,	1176 1 O
causing	1178 7 O
a	1186 1 O
diminished	1188 10 O
TDR	1199 3 O
.	1202 1 O

Although	1204 8 O
both	1213 4 O
dl	1218 2 O
-	1220 1 O
sotalol	1221 7 B-Chemical
and	1229 3 O
azimilide	1233 9 B-Chemical
rarely	1243 6 O
induced	1250 7 O
EADs	1258 4 O
in	1263 2 O
canine	1266 6 O
left	1273 4 O
ventricles	1278 10 O
,	1288 1 O
they	1290 4 O
produced	1295 8 O
frequent	1304 8 O
EADs	1313 4 O
in	1318 2 O
rabbits	1321 7 O
,	1328 1 O
in	1330 2 O
which	1333 5 O
more	1339 4 O
pronounced	1344 10 O
QT	1355 2 B-Disease
prolongation	1358 12 I-Disease
was	1371 3 O
seen	1375 4 O
.	1379 1 O

An	1381 2 O
increase	1384 8 O
in	1393 2 O
TDR	1396 3 O
by	1400 2 O
dl	1403 2 O
-	1405 1 O
sotalol	1406 7 B-Chemical
facilitated	1414 11 O
transmural	1426 10 O
propagation	1437 11 O
of	1449 2 O
EADs	1452 4 O
that	1457 4 O
initiated	1462 9 O
multiple	1472 8 O
episodes	1481 8 O
of	1490 2 O
spontaneous	1493 11 O
TdP	1505 3 B-Disease
in	1509 2 O
3	1512 1 O
of	1514 2 O
6	1517 1 O
rabbit	1519 6 O
left	1526 4 O
ventricles	1531 10 O
.	1541 1 O

Of	1543 2 O
note	1546 4 O
,	1550 1 O
although	1552 8 O
azimilide	1561 9 B-Chemical
(	1571 1 O
3	1572 1 O
to	1574 2 O
10	1577 2 O
micromol	1580 8 O
/	1588 1 O
L	1589 1 O
)	1590 1 O
increased	1592 9 O
APD	1602 3 O
more	1606 4 O
than	1611 4 O
dl	1616 2 O
-	1618 1 O
sotalol	1619 7 B-Chemical
,	1626 1 O
its	1628 3 O
EADs	1632 4 O
often	1637 5 O
failed	1643 6 O
to	1650 2 O
propagate	1653 9 O
transmurally	1663 12 O
,	1675 1 O
probably	1677 8 O
because	1686 7 O
of	1694 2 O
a	1697 1 O
diminished	1699 10 O
TDR	1710 3 O
.	1713 1 O

CONCLUSIONS	1715 11 O
:	1726 1 O
This	1728 4 O
study	1733 5 O
provides	1739 8 O
the	1748 3 O
first	1752 5 O
direct	1758 6 O
evidence	1765 8 O
from	1774 4 O
intracellular	1779 13 O
action	1793 6 O
potential	1800 9 O
recordings	1810 10 O
that	1821 4 O
phase	1826 5 O
2	1832 1 O
EAD	1834 3 O
can	1838 3 O
be	1842 2 O
generated	1845 9 O
from	1855 4 O
intact	1860 6 O
ventricular	1867 11 O
wall	1879 4 O
and	1884 3 O
produce	1888 7 O
a	1896 1 O
trigger	1898 7 O
to	1906 2 O
initiate	1909 8 O
the	1918 3 O
onset	1922 5 O
of	1928 2 O
TdP	1931 3 B-Disease
under	1935 5 O
QT	1941 2 B-Disease
prolongation	1944 12 I-Disease
.	1956 1 O

Prenatal	0 8 O
cocaine	9 7 B-Chemical
exposure	17 8 O
and	26 3 O
cranial	30 7 O
sonographic	38 11 O
findings	50 8 O
in	59 2 O
preterm	62 7 B-Disease
infants	70 7 I-Disease
.	77 1 O

PURPOSE	79 7 O
:	86 1 O
Prenatal	88 8 O
cocaine	97 7 B-Chemical
exposure	105 8 O
has	114 3 O
been	118 4 O
linked	123 6 O
with	130 4 O
subependymal	135 12 O
hemorrhage	148 10 B-Disease
and	159 3 O
the	163 3 O
formation	167 9 O
of	177 2 O
cysts	180 5 B-Disease
that	186 4 O
are	191 3 O
detectable	195 10 O
on	206 2 O
cranial	209 7 O
sonography	217 10 O
in	228 2 O
neonates	231 8 O
born	240 4 O
at	245 2 O
term	248 4 O
.	252 1 O

We	254 2 O
sought	257 6 O
to	264 2 O
determine	267 9 O
if	277 2 O
prenatal	280 8 O
cocaine	289 7 B-Chemical
exposure	297 8 O
increases	306 9 O
the	316 3 O
incidence	320 9 O
of	330 2 O
subependymal	333 12 B-Disease
cysts	346 5 I-Disease
in	352 2 O
preterm	355 7 B-Disease
infants	363 7 I-Disease
.	370 1 O

METHODS	372 7 O
:	379 1 O
We	381 2 O
retrospectively	384 15 O
reviewed	400 8 O
the	409 3 O
medical	413 7 O
records	421 7 O
and	429 3 O
cranial	433 7 O
sonograms	441 9 O
obtained	451 8 O
during	460 6 O
a	467 1 O
1	469 1 O
-	470 1 O
year	471 4 O
period	476 6 O
on	483 2 O
122	486 3 O
premature	490 9 B-Disease
(	500 1 I-Disease
<	501 1 I-Disease
36	503 2 I-Disease
weeks	506 5 I-Disease
of	512 2 I-Disease
gestation	515 9 I-Disease
)	524 1 I-Disease
infants	526 7 I-Disease
.	533 1 O

Infants	535 7 O
were	543 4 O
categorized	548 11 O
into	560 4 O
1	565 1 O
of	567 2 O
2	570 1 O
groups	572 6 O
:	578 1 O
those	580 5 O
exposed	586 7 O
to	594 2 O
cocaine	597 7 B-Chemical
and	605 3 O
those	609 5 O
not	615 3 O
exposed	619 7 O
to	627 2 O
cocaine	630 7 B-Chemical
.	637 1 O

Infants	639 7 O
were	647 4 O
assigned	652 8 O
to	661 2 O
the	664 3 O
cocaine	668 7 B-Chemical
-	675 1 O
exposed	676 7 O
group	684 5 O
if	690 2 O
there	693 5 O
was	699 3 O
a	703 1 O
maternal	705 8 O
history	714 7 O
of	722 2 O
cocaine	725 7 B-Disease
abuse	733 5 I-Disease
during	739 6 O
pregnancy	746 9 O
or	756 2 O
if	759 2 O
maternal	762 8 O
or	771 2 O
neonatal	774 8 O
urine	783 5 O
toxicology	789 10 O
results	800 7 O
were	808 4 O
positive	813 8 O
at	822 2 O
the	825 3 O
time	829 4 O
of	834 2 O
delivery	837 8 O
.	845 1 O

RESULTS	847 7 O
:	854 1 O
Five	856 4 O
of	861 2 O
the	864 3 O
122	868 3 O
infants	872 7 O
were	880 4 O
excluded	885 8 O
from	894 4 O
the	899 3 O
study	903 5 O
because	909 7 O
of	917 2 O
insufficient	920 12 O
medical	933 7 O
and	941 3 O
drug	945 4 O
histories	950 9 O
.	959 1 O

The	961 3 O
incidence	965 9 O
of	975 2 O
subependymal	978 12 B-Disease
cysts	991 5 I-Disease
in	997 2 O
the	1000 3 O
117	1004 3 O
remaining	1008 9 O
infants	1018 7 O
was	1026 3 O
14	1030 2 O
%	1032 1 O
(	1034 1 O
16	1035 2 O
of	1038 2 O
117	1041 3 O
)	1044 1 O
.	1045 1 O

The	1047 3 O
incidence	1051 9 O
of	1061 2 O
subependymal	1064 12 B-Disease
cysts	1077 5 I-Disease
in	1083 2 O
infants	1086 7 O
exposed	1094 7 O
to	1102 2 O
cocaine	1105 7 B-Chemical
prenatally	1113 10 O
was	1124 3 O
44	1128 2 O
%	1130 1 O
(	1132 1 O
8	1133 1 O
of	1135 2 O
18	1138 2 O
)	1140 1 O
compared	1142 8 O
with	1151 4 O
8	1156 1 O
%	1157 1 O
(	1159 1 O
8	1160 1 O
of	1162 2 O
99	1165 2 O
)	1167 1 O
in	1169 2 O
the	1172 3 O
unexposed	1176 9 O
group	1186 5 O
(	1192 1 O
p	1193 1 O
<	1195 1 O
0	1197 1 O
.	1198 1 O
01	1199 2 O
)	1201 1 O
.	1202 1 O

CONCLUSIONS	1204 11 O
:	1215 1 O
We	1217 2 O
found	1220 5 O
an	1226 2 O
increased	1229 9 O
incidence	1239 9 O
of	1249 2 O
subependymal	1252 12 B-Disease
cyst	1265 4 I-Disease
formation	1270 9 O
in	1280 2 O
preterm	1283 7 B-Disease
infants	1291 7 I-Disease
who	1299 3 O
were	1303 4 O
exposed	1308 7 O
to	1316 2 O
cocaine	1319 7 B-Chemical
prenatally	1327 10 O
.	1337 1 O

This	1339 4 O
result	1344 6 O
is	1351 2 O
consistent	1354 10 O
with	1365 4 O
results	1370 7 O
of	1378 2 O
similar	1381 7 O
studies	1389 7 O
in	1397 2 O
term	1400 4 O
infants	1405 7 O
.	1412 1 O

Thalidomide	0 11 B-Chemical
neuropathy	12 10 B-Disease
in	23 2 O
patients	26 8 O
treated	35 7 O
for	43 3 O
metastatic	47 10 O
prostate	58 8 B-Disease
cancer	67 6 I-Disease
.	73 1 O

We	75 2 O
prospectively	78 13 O
evaluated	92 9 O
thalidomide	102 11 B-Chemical
-	113 1 O
induced	114 7 O
neuropathy	122 10 B-Disease
using	133 5 O
electrodiagnostic	139 17 O
studies	157 7 O
.	164 1 O

Sixty	166 5 O
-	171 1 O
seven	172 5 O
men	178 3 O
with	182 4 O
metastatic	187 10 O
androgen	198 8 B-Chemical
-	206 1 O
independent	207 11 O
prostate	219 8 B-Disease
cancer	228 6 I-Disease
in	235 2 O
an	238 2 O
open	241 4 O
-	245 1 O
label	246 5 O
trial	252 5 O
of	258 2 O
oral	261 4 O
thalidomide	266 11 B-Chemical
underwent	278 9 O
neurologic	288 10 O
examinations	299 12 O
and	312 3 O
nerve	316 5 O
conduction	322 10 O
studies	333 7 O
(	341 1 O
NCS	342 3 O
)	345 1 O
prior	347 5 O
to	353 2 O
and	356 3 O
at	360 2 O
3	363 1 O
-	364 1 O
month	365 5 O
intervals	371 9 O
during	381 6 O
treatment	388 9 O
.	397 1 O

NCS	399 3 O
included	403 8 O
recording	412 9 O
of	422 2 O
sensory	425 7 O
nerve	433 5 O
action	439 6 O
potentials	446 10 O
(	457 1 O
SNAPs	458 5 O
)	463 1 O
from	465 4 O
median	470 6 O
,	476 1 O
radial	478 6 O
,	484 1 O
ulnar	486 5 O
,	491 1 O
and	493 3 O
sural	497 5 O
nerves	503 6 O
.	509 1 O

SNAP	511 4 O
amplitudes	516 10 O
for	527 3 O
each	531 4 O
nerve	536 5 O
were	542 4 O
expressed	547 9 O
as	557 2 O
the	560 3 O
percentage	564 10 O
of	575 2 O
its	578 3 O
baseline	582 8 O
,	590 1 O
and	592 3 O
the	596 3 O
mean	600 4 O
of	605 2 O
the	608 3 O
four	612 4 O
was	617 3 O
termed	621 6 O
the	628 3 O
SNAP	632 4 O
index	637 5 O
.	642 1 O

A	644 1 O
40	646 2 O
%	648 1 O
decline	650 7 O
in	658 2 O
the	661 3 O
SNAP	665 4 O
index	670 5 O
was	676 3 O
considered	680 10 O
clinically	691 10 O
significant	702 11 O
.	713 1 O

Thalidomide	715 11 B-Chemical
was	727 3 O
discontinued	731 12 O
in	744 2 O
55	747 2 O
patients	750 8 O
for	759 3 O
lack	763 4 O
of	768 2 O
therapeutic	771 11 O
response	783 8 O
.	791 1 O

Of	793 2 O
67	796 2 O
patients	799 8 O
initially	808 9 O
enrolled	818 8 O
,	826 1 O
24	828 2 O
remained	831 8 O
on	840 2 O
thalidomide	843 11 B-Chemical
for	855 3 O
3	859 1 O
months	861 6 O
,	867 1 O
8	869 1 O
remained	871 8 O
at	880 2 O
6	883 1 O
months	885 6 O
,	891 1 O
and	893 3 O
3	897 1 O
remained	899 8 O
at	908 2 O
9	911 1 O
months	913 6 O
.	919 1 O

Six	921 3 O
patients	925 8 O
developed	934 9 O
neuropathy	944 10 B-Disease
.	954 1 O

Clinical	956 8 O
symptoms	965 8 O
and	974 3 O
a	978 1 O
decline	980 7 O
in	988 2 O
the	991 3 O
SNAP	995 4 O
index	1000 5 O
occurred	1006 8 O
concurrently	1015 12 O
.	1027 1 O

Older	1029 5 O
age	1035 3 O
and	1039 3 O
cumulative	1043 10 O
dose	1054 4 O
were	1059 4 O
possible	1064 8 O
contributing	1073 12 O
factors	1086 7 O
.	1093 1 O

Neuropathy	1095 10 B-Disease
may	1106 3 O
thus	1110 4 O
be	1115 2 O
a	1118 1 O
common	1120 6 O
complication	1127 12 O
of	1140 2 O
thalidomide	1143 11 B-Chemical
in	1155 2 O
older	1158 5 O
patients	1164 8 O
.	1172 1 O

The	1174 3 O
SNAP	1178 4 O
index	1183 5 O
can	1189 3 O
be	1193 2 O
used	1196 4 O
to	1201 2 O
monitor	1204 7 O
peripheral	1212 10 B-Disease
neuropathy	1223 10 I-Disease
,	1233 1 O
but	1235 3 O
not	1239 3 O
for	1243 3 O
early	1247 5 O
detection	1253 9 O
.	1262 1 O

Overexpression	0 14 O
of	15 2 O
copper	18 6 B-Chemical
/	24 1 O
zinc	25 4 B-Chemical
-	29 1 O
superoxide	30 10 B-Chemical
dismutase	41 9 O
protects	51 8 O
from	60 4 O
kanamycin	65 9 B-Chemical
-	74 1 O
induced	75 7 O
hearing	83 7 B-Disease
loss	91 4 I-Disease
.	95 1 O

The	97 3 O
participation	101 13 O
of	115 2 O
reactive	118 8 O
oxygen	127 6 B-Chemical
species	134 7 O
in	142 2 O
aminoglycoside	145 14 B-Chemical
-	159 1 O
induced	160 7 O
ototoxicity	168 11 B-Disease
has	180 3 O
been	184 4 O
deduced	189 7 O
from	197 4 O
observations	202 12 O
that	215 4 O
aminoglycoside	220 14 B-Chemical
-	234 1 O
iron	235 4 B-Chemical
complexes	240 9 O
catalyze	250 8 O
the	259 3 O
formation	263 9 O
of	273 2 O
superoxide	276 10 B-Chemical
radicals	287 8 O
in	296 2 O
vitro	299 5 O
and	305 3 O
that	309 4 O
antioxidants	314 12 O
attenuate	327 9 O
ototoxicity	337 11 B-Disease
in	349 2 O
vivo	352 4 O
.	356 1 O

We	358 2 O
therefore	361 9 O
hypothesized	371 12 O
that	384 4 O
overexpression	389 14 O
of	404 2 O
Cu	407 2 B-Chemical
/	409 1 O
Zn	410 2 B-Chemical
-	412 1 O
superoxide	413 10 B-Chemical
dismutase	424 9 O
(	434 1 O
h	435 1 O
-	436 1 O
SOD1	437 4 O
)	441 1 O
should	443 6 O
protect	450 7 O
transgenic	458 10 O
mice	469 4 O
from	474 4 O
ototoxicity	479 11 B-Disease
.	490 1 O

Immunocytochemistry	492 19 O
confirmed	512 9 O
expression	522 10 O
of	533 2 O
h	536 1 O
-	537 1 O
SOD1	538 4 O
in	543 2 O
inner	546 5 O
ear	552 3 O
tissues	556 7 O
of	564 2 O
transgenic	567 10 O
C57BL	578 5 O
/	583 1 O
6	584 1 O
-	585 1 O
TgN	586 3 O
[	589 1 O
SOD1	590 4 O
]	594 1 O
3Cje	595 4 O
mice	600 4 O
.	604 1 O

Transgenic	606 10 O
and	617 3 O
nontransgenic	621 13 O
littermates	635 11 O
received	647 8 O
kanamycin	656 9 B-Chemical
(	666 1 O
400	667 3 O
mg	671 2 O
/	673 1 O
kg	674 2 O
body	677 4 O
weight	682 6 O
/	688 1 O
day	689 3 O
)	692 1 O
for	694 3 O
10	698 2 O
days	701 4 O
beginning	706 9 O
on	716 2 O
day	719 3 O
10	723 2 O
after	726 5 O
birth	732 5 O
.	737 1 O

Auditory	739 8 O
thresholds	748 10 O
were	759 4 O
tested	764 6 O
by	771 2 O
evoked	774 6 O
auditory	781 8 O
brain	790 5 O
stem	796 4 O
responses	801 9 O
at	811 2 O
1	814 1 O
month	816 5 O
after	822 5 O
birth	828 5 O
.	833 1 O

In	835 2 O
nontransgenic	838 13 O
animals	852 7 O
,	859 1 O
the	861 3 O
threshold	865 9 O
in	875 2 O
the	878 3 O
kanamycin	882 9 B-Chemical
-	891 1 O
treated	892 7 O
group	900 5 O
was	906 3 O
45	910 2 O
-	912 1 O
50	913 2 O
dB	916 2 O
higher	919 6 O
than	926 4 O
in	931 2 O
saline	934 6 O
-	940 1 O
injected	941 8 O
controls	950 8 O
.	958 1 O

In	960 2 O
the	963 3 O
transgenic	967 10 O
group	978 5 O
,	983 1 O
kanamycin	985 9 B-Chemical
increased	995 9 O
the	1005 3 O
threshold	1009 9 O
by	1019 2 O
only	1022 4 O
15	1027 2 O
dB	1030 2 O
over	1033 4 O
the	1038 3 O
respective	1042 10 O
controls	1053 8 O
.	1061 1 O

The	1063 3 O
effects	1067 7 O
were	1075 4 O
similar	1080 7 O
at	1088 2 O
12	1091 2 O
and	1094 3 O
24	1098 2 O
kHz	1101 3 O
.	1104 1 O

The	1106 3 O
protection	1110 10 O
by	1121 2 O
overexpression	1124 14 O
of	1139 2 O
superoxide	1142 10 B-Chemical
dismutase	1153 9 O
supports	1163 8 O
the	1172 3 O
hypothesis	1176 10 O
that	1187 4 O
oxidant	1192 7 O
stress	1200 6 O
plays	1207 5 O
a	1213 1 O
significant	1215 11 O
role	1227 4 O
in	1232 2 O
aminoglycoside	1235 14 B-Chemical
-	1249 1 O
induced	1250 7 O
ototoxicity	1258 11 B-Disease
.	1269 1 O

The	1271 3 O
results	1275 7 O
also	1283 4 O
suggest	1288 7 O
transgenic	1296 10 O
animals	1307 7 O
as	1315 2 O
suitable	1318 8 O
models	1327 6 O
to	1334 2 O
investigate	1337 11 O
the	1349 3 O
underlying	1353 10 O
mechanisms	1364 10 O
and	1375 3 O
possible	1379 8 O
strategies	1388 10 O
for	1399 3 O
prevention	1403 10 O
.	1413 1 O

Prednisone	0 10 B-Chemical
induces	11 7 O
anxiety	19 7 B-Disease
and	27 3 O
glial	31 5 O
cerebral	37 8 O
changes	46 7 O
in	54 2 O
rats	57 4 O
.	61 1 O

OBJECTIVE	63 9 O
:	72 1 O
To	74 2 O
assess	77 6 O
whether	84 7 O
prednisone	92 10 B-Chemical
(	103 1 O
PDN	104 3 B-Chemical
)	107 1 O
produces	109 8 O
anxiety	118 7 B-Disease
and	126 3 O
/	129 1 O
or	130 2 O
cerebral	133 8 O
glial	142 5 O
changes	148 7 O
in	156 2 O
rats	159 4 O
.	163 1 O

METHODS	165 7 O
:	172 1 O
Male	174 4 O
Wistar	179 6 O
rats	186 4 O
were	191 4 O
studied	196 7 O
and	204 3 O
3	208 1 O
groups	210 6 O
were	217 4 O
formed	222 6 O
(	229 1 O
8	230 1 O
rats	232 4 O
per	237 3 O
group	241 5 O
)	246 1 O
.	247 1 O

The	249 3 O
moderate	253 8 O
-	261 1 O
dose	262 4 O
group	267 5 O
received	273 8 O
5	282 1 O
mg	284 2 O
/	286 1 O
kg	287 2 O
/	289 1 O
day	290 3 O
PDN	294 3 B-Chemical
released	298 8 O
from	307 4 O
a	312 1 O
subcutaneous	314 12 O
implant	327 7 O
.	334 1 O

In	336 2 O
the	339 3 O
high	343 4 O
-	347 1 O
dose	348 4 O
group	353 5 O
,	358 1 O
implants	360 8 O
containing	369 10 O
PDN	380 3 B-Chemical
equivalent	384 10 O
to	395 2 O
60	398 2 O
mg	401 2 O
/	403 1 O
kg	404 2 O
/	406 1 O
day	407 3 O
were	411 4 O
applied	416 7 O
.	423 1 O

In	425 2 O
the	428 3 O
control	432 7 O
group	440 5 O
implants	446 8 O
contained	455 9 O
no	465 2 O
PDN	468 3 B-Chemical
.	471 1 O

Anxiety	473 7 B-Disease
was	481 3 O
assessed	485 8 O
using	494 5 O
an	500 2 O
open	503 4 O
field	508 5 O
and	514 3 O
elevated	518 8 O
plus	527 4 O
-	531 1 O
maze	532 4 O
devices	537 7 O
.	544 1 O

The	546 3 O
number	550 6 O
of	557 2 O
cells	560 5 O
and	566 3 O
cytoplasmic	570 11 O
transformation	582 14 O
of	597 2 O
astrocytes	600 10 O
and	611 3 O
microglia	615 9 O
cells	625 5 O
were	631 4 O
assessed	636 8 O
by	645 2 O
immunohistochemical	648 19 O
analyses	668 8 O
.	676 1 O

RESULTS	678 7 O
:	685 1 O
Anxiety	687 7 B-Disease
was	695 3 O
documented	699 10 O
in	710 2 O
both	713 4 O
groups	718 6 O
of	725 2 O
PDN	728 3 B-Chemical
treated	732 7 O
rats	740 4 O
compared	745 8 O
with	754 4 O
controls	759 8 O
.	767 1 O

The	769 3 O
magnitude	773 9 O
of	783 2 O
transformation	786 14 O
of	801 2 O
the	804 3 O
microglia	808 9 O
assessed	818 8 O
by	827 2 O
the	830 3 O
number	834 6 O
of	841 2 O
intersections	844 13 O
was	858 3 O
significantly	862 13 O
higher	876 6 O
in	883 2 O
the	886 3 O
PDN	890 3 B-Chemical
groups	894 6 O
than	901 4 O
in	906 2 O
controls	909 8 O
in	918 2 O
the	921 3 O
prefrontal	925 10 O
cortex	936 6 O
(	943 1 O
moderate	944 8 O
-	952 1 O
dose	953 4 O
,	957 1 O
24	959 2 O
.	961 1 O
1	962 1 O
;	963 1 O
high	965 4 O
-	969 1 O
dose	970 4 O
,	974 1 O
23	976 2 O
.	978 1 O
6	979 1 O
;	980 1 O
controls	982 8 O
18	991 2 O
.	993 1 O
7	994 1 O
;	995 1 O
p	997 1 O
<	999 1 O
0	1001 1 O
.	1002 1 O
01	1003 2 O
)	1005 1 O
and	1007 3 O
striatum	1011 8 O
(	1020 1 O
moderate	1021 8 O
-	1029 1 O
dose	1030 4 O
25	1035 2 O
.	1037 1 O
6	1038 1 O
;	1039 1 O
high	1041 4 O
-	1045 1 O
dose	1046 4 O
26	1051 2 O
.	1053 1 O
3	1054 1 O
;	1055 1 O
controls	1057 8 O
18	1066 2 O
.	1068 1 O
9	1069 1 O
;	1070 1 O
p	1072 1 O
<	1074 1 O
0	1076 1 O
.	1077 1 O
01	1078 2 O
)	1080 1 O
,	1081 1 O
but	1083 3 O
not	1087 3 O
in	1091 2 O
hippocampus	1094 11 O
.	1105 1 O

The	1107 3 O
number	1111 6 O
of	1118 2 O
stained	1121 7 O
microglia	1129 9 O
cells	1139 5 O
was	1145 3 O
significantly	1149 13 O
higher	1163 6 O
in	1170 2 O
the	1173 3 O
PDN	1177 3 B-Chemical
treated	1181 7 O
groups	1189 6 O
in	1196 2 O
the	1199 3 O
prefrontal	1203 10 O
cortex	1214 6 O
than	1221 4 O
in	1226 2 O
controls	1229 8 O
(	1238 1 O
moderate	1239 8 O
-	1247 1 O
dose	1248 4 O
,	1252 1 O
29	1254 2 O
.	1256 1 O
1	1257 1 O
;	1258 1 O
high	1260 4 O
-	1264 1 O
dose	1265 4 O
,	1269 1 O
28	1271 2 O
.	1273 1 O
4	1274 1 O
;	1275 1 O
control	1277 7 O
,	1284 1 O
17	1286 2 O
.	1288 1 O
7	1289 1 O
cells	1291 5 O
per	1297 3 O
field	1301 5 O
;	1306 1 O
p	1308 1 O
<	1310 1 O
0	1312 1 O
.	1313 1 O
01	1314 2 O
)	1316 1 O
.	1317 1 O

Stained	1319 7 O
microglia	1327 9 O
cells	1337 5 O
were	1343 4 O
significantly	1348 13 O
more	1362 4 O
numerous	1367 8 O
striatum	1376 8 O
and	1385 3 O
hippocampus	1389 11 O
in	1401 2 O
the	1404 3 O
high	1408 4 O
-	1412 1 O
dose	1413 4 O
group	1418 5 O
compared	1424 8 O
to	1433 2 O
controls	1436 8 O
.	1444 1 O

CONCLUSION	1446 10 O
:	1456 1 O
Subacute	1458 8 O
exposure	1467 8 O
to	1476 2 O
PDN	1479 3 B-Chemical
induced	1483 7 O
anxiety	1491 7 B-Disease
and	1499 3 O
reactivity	1503 10 O
of	1514 2 O
microglia	1517 9 O
.	1526 1 O

The	1528 3 O
relevance	1532 9 O
of	1542 2 O
these	1545 5 O
features	1551 8 O
for	1560 3 O
patients	1564 8 O
using	1573 5 O
PDN	1579 3 B-Chemical
remains	1583 7 O
to	1591 2 O
be	1594 2 O
elucidated	1597 10 O
.	1607 1 O

Phase	0 5 O
II	6 2 O
study	9 5 O
of	15 2 O
carboplatin	18 11 B-Chemical
and	30 3 O
liposomal	34 9 O
doxorubicin	44 11 B-Chemical
in	56 2 O
patients	59 8 O
with	68 4 O
recurrent	73 9 O
squamous	83 8 B-Disease
cell	92 4 I-Disease
carcinoma	97 9 I-Disease
of	107 2 I-Disease
the	110 3 I-Disease
cervix	114 6 I-Disease
.	120 1 O

BACKGROUND	122 10 O
:	132 1 O
The	134 3 O
activity	138 8 O
of	147 2 O
the	150 3 O
combination	154 11 O
of	166 2 O
carboplatin	169 11 B-Chemical
and	181 3 O
liposomal	185 9 O
doxorubicin	195 11 B-Chemical
was	207 3 O
tested	211 6 O
in	218 2 O
a	221 1 O
Phase	223 5 O
II	229 2 O
study	232 5 O
of	238 2 O
patients	241 8 O
with	250 4 O
recurrent	255 9 O
cervical	265 8 B-Disease
carcinoma	274 9 I-Disease
.	283 1 O

METHODS	285 7 O
:	292 1 O
The	294 3 O
combination	298 11 O
of	310 2 O
carboplatin	313 11 B-Chemical
(	325 1 O
area	326 4 O
under	331 5 O
the	337 3 O
concentration	341 13 O
curve	355 5 O
[	361 1 O
AUC	362 3 O
]	365 1 O
,	366 1 O
5	368 1 O
)	369 1 O
and	371 3 O
liposomal	375 9 O
doxorubicin	385 11 B-Chemical
(	397 1 O
Doxil	398 5 B-Chemical
;	403 1 O
starting	405 8 O
dose	414 4 O
,	418 1 O
40	420 2 O
mg	423 2 O
/	425 1 O
m	426 1 O
(	427 1 O
2	428 1 O
)	429 1 O
)	430 1 O
was	432 3 O
administered	436 12 O
intravenously	449 13 O
every	463 5 O
28	469 2 O
days	472 4 O
to	477 2 O
37	480 2 O
patients	483 8 O
with	492 4 O
recurrent	497 9 O
squamous	507 8 B-Disease
cell	516 4 I-Disease
cervical	521 8 I-Disease
carcinoma	530 9 I-Disease
to	540 2 O
determine	543 9 O
antitumor	553 9 O
activity	563 8 O
and	572 3 O
toxicity	576 8 B-Disease
profile	585 7 O
.	592 1 O

RESULTS	594 7 O
:	601 1 O
Twenty	603 6 O
-	609 1 O
nine	610 4 O
patients	615 8 O
were	624 4 O
assessable	629 10 O
for	640 3 O
response	644 8 O
,	652 1 O
and	654 3 O
35	658 2 O
patients	661 8 O
were	670 4 O
assessable	675 10 O
for	686 3 O
toxicity	690 8 B-Disease
.	698 1 O

The	700 3 O
overall	704 7 O
response	712 8 O
rate	721 4 O
was	726 3 O
38	730 2 O
%	732 1 O
,	733 1 O
the	735 3 O
median	739 6 O
time	746 4 O
to	751 2 O
response	754 8 O
was	763 3 O
10	767 2 O
weeks	770 5 O
,	775 1 O
the	777 3 O
median	781 6 O
duration	788 8 O
of	797 2 O
response	800 8 O
was	809 3 O
26	813 2 O
weeks	816 5 O
,	821 1 O
and	823 3 O
the	827 3 O
median	831 6 O
survival	838 8 O
was	847 3 O
37	851 2 O
weeks	854 5 O
.	859 1 O

The	861 3 O
main	865 4 O
toxic	870 5 O
effect	876 6 O
was	883 3 O
myelosuppression	887 16 B-Disease
,	903 1 O
with	905 4 O
Grade	910 5 O
3	916 1 O
and	918 3 O
4	922 1 O
neutropenia	924 11 B-Disease
in	936 2 O
16	939 2 O
patients	942 8 O
,	950 1 O
anemia	952 6 B-Disease
in	959 2 O
12	962 2 O
patients	965 8 O
,	973 1 O
thrombocytopenia	975 16 B-Disease
in	992 2 O
11	995 2 O
patients	998 8 O
,	1006 1 O
and	1008 3 O
neutropenic	1012 11 B-Disease
fever	1024 5 I-Disease
in	1030 2 O
3	1033 1 O
patients	1035 8 O
.	1043 1 O

Four	1045 4 O
patients	1050 8 O
had	1059 3 O
five	1063 4 O
infusion	1068 8 O
-	1076 1 O
related	1077 7 O
reactions	1085 9 O
during	1095 6 O
the	1102 3 O
infusion	1106 8 O
of	1115 2 O
liposomal	1118 9 O
doxorubicin	1128 11 B-Chemical
,	1139 1 O
leading	1141 7 O
to	1149 2 O
treatment	1152 9 O
discontinuation	1162 15 O
in	1178 2 O
three	1181 5 O
patients	1187 8 O
.	1195 1 O

Grade	1197 5 O
>	1203 1 O
or	1205 2 O
=	1208 1 O
2	1210 1 O
nonhematologic	1212 14 O
toxicity	1227 8 B-Disease
included	1236 8 O
nausea	1245 6 B-Disease
in	1252 2 O
17	1255 2 O
patients	1258 8 O
,	1266 1 O
emesis	1268 6 B-Disease
in	1275 2 O
14	1278 2 O
patients	1281 8 O
,	1289 1 O
fatigue	1291 7 B-Disease
in	1299 2 O
9	1302 1 O
patients	1304 8 O
,	1312 1 O
mucositis	1314 9 B-Disease
and	1324 3 O
/	1327 1 O
or	1328 2 O
stomatitis	1331 10 B-Disease
in	1342 2 O
8	1345 1 O
patients	1347 8 O
,	1355 1 O
constipation	1357 12 B-Disease
in	1370 2 O
6	1373 1 O
patients	1375 8 O
,	1383 1 O
weight	1385 6 B-Disease
loss	1392 4 I-Disease
in	1397 2 O
5	1400 1 O
patients	1402 8 O
,	1410 1 O
hand	1412 4 B-Disease
-	1416 1 I-Disease
foot	1417 4 I-Disease
syndrome	1422 8 I-Disease
in	1431 2 O
2	1434 1 O
patients	1436 8 O
,	1444 1 O
and	1446 3 O
skin	1450 4 B-Disease
reactions	1455 9 I-Disease
in	1465 2 O
3	1468 1 O
patients	1470 8 O
.	1478 1 O

CONCLUSIONS	1480 11 O
:	1491 1 O
The	1493 3 O
combination	1497 11 O
of	1509 2 O
carboplatin	1512 11 B-Chemical
and	1524 3 O
liposomal	1528 9 O
doxorubicin	1538 11 B-Chemical
has	1550 3 O
modest	1554 6 O
activity	1561 8 O
in	1570 2 O
patients	1573 8 O
with	1582 4 O
recurrent	1587 9 O
cervical	1597 8 B-Disease
carcinoma	1606 9 I-Disease
.	1615 1 O

Antimicrobial	0 13 O
-	13 1 O
induced	14 7 O
mania	22 5 B-Disease
(	28 1 O
antibiomania	29 12 B-Disease
)	41 1 O
:	42 1 O
a	44 1 O
review	46 6 O
of	53 2 O
spontaneous	56 11 O
reports	68 7 O
.	75 1 O

The	77 3 O
authors	81 7 O
reviewed	89 8 O
reported	98 8 O
cases	107 5 O
of	113 2 O
antibiotic	116 10 O
-	126 1 O
induced	127 7 O
manic	135 5 B-Disease
episodes	141 8 O
by	150 2 O
means	153 5 O
of	159 2 O
a	162 1 O
MEDLINE	164 7 O
and	172 3 O
PsychLit	176 8 O
search	185 6 O
for	192 3 O
reports	196 7 O
of	204 2 O
antibiotic	207 10 O
-	217 1 O
induced	218 7 O
mania	226 5 B-Disease
.	231 1 O

Unpublished	233 11 O
reports	245 7 O
were	253 4 O
requested	258 9 O
from	268 4 O
the	273 3 O
World	277 5 O
Health	283 6 O
Organization	290 12 O
(	303 1 O
WHO	304 3 O
)	307 1 O
and	309 3 O
the	313 3 O
Food	317 4 O
and	322 3 O
Drug	326 4 O
Administration	331 14 O
(	346 1 O
FDA	347 3 O
)	350 1 O
.	351 1 O

Twenty	353 6 O
-	359 1 O
one	360 3 O
reports	364 7 O
of	372 2 O
antimicrobial	375 13 O
-	388 1 O
induced	389 7 O
mania	397 5 B-Disease
were	403 4 O
found	408 5 O
in	414 2 O
the	417 3 O
literature	421 10 O
.	431 1 O

There	433 5 O
were	439 4 O
6	444 1 O
cases	446 5 O
implicating	452 11 O
clarithromycin	464 14 B-Chemical
,	478 1 O
13	480 2 O
implicating	483 11 O
isoniazid	495 9 B-Chemical
,	504 1 O
and	506 3 O
1	510 1 O
case	512 4 O
each	517 4 O
implicating	522 11 O
erythromycin	534 12 B-Chemical
and	547 3 O
amoxicillin	551 11 B-Chemical
.	562 1 O

The	564 3 O
WHO	568 3 O
reported	572 8 O
82	581 2 O
cases	584 5 O
.	589 1 O

Of	591 2 O
these	594 5 O
,	599 1 O
clarithromycin	601 14 B-Chemical
was	616 3 O
implicated	620 10 O
in	631 2 O
23	634 2 O
(	637 1 O
27	638 2 O
.	640 1 O
6	641 1 O
%	642 1 O
)	643 1 O
cases	645 5 O
,	650 1 O
ciprofloxacin	652 13 B-Chemical
in	666 2 O
12	669 2 O
(	672 1 O
14	673 2 O
.	675 1 O
4	676 1 O
%	677 1 O
)	678 1 O
cases	680 5 O
,	685 1 O
and	687 3 O
ofloxacin	691 9 B-Chemical
in	701 2 O
10	704 2 O
(	707 1 O
12	708 2 O
%	710 1 O
)	711 1 O
cases	713 5 O
.	718 1 O

Cotrimoxazole	720 13 B-Chemical
,	733 1 O
metronidazole	735 13 B-Chemical
,	748 1 O
and	750 3 O
erythromycin	754 12 B-Chemical
were	767 4 O
involved	772 8 O
in	781 2 O
15	784 2 O
reported	787 8 O
manic	796 5 B-Disease
episodes	802 8 O
.	810 1 O

Cases	812 5 O
reported	818 8 O
by	827 2 O
the	830 3 O
FDA	834 3 O
showed	838 6 O
clarithromycin	845 14 B-Chemical
and	860 3 O
ciprofloxacin	864 13 B-Chemical
to	878 2 O
be	881 2 O
the	884 3 O
most	888 4 O
frequently	893 10 O
associated	904 10 O
with	915 4 O
the	920 3 O
development	924 11 O
of	936 2 O
mania	939 5 B-Disease
.	944 1 O

Statistical	946 11 O
analysis	958 8 O
of	967 2 O
the	970 3 O
data	974 4 O
would	979 5 O
not	985 3 O
have	989 4 O
demonstrated	994 12 O
a	1007 1 O
significant	1009 11 O
statistical	1021 11 O
correlative	1033 11 O
risk	1045 4 O
and	1050 3 O
was	1054 3 O
therefore	1058 9 O
not	1068 3 O
undertaken	1072 10 O
.	1082 1 O

Patients	1084 8 O
have	1093 4 O
an	1098 2 O
increased	1101 9 O
risk	1111 4 O
of	1116 2 O
developing	1119 10 O
mania	1130 5 B-Disease
while	1136 5 O
being	1142 5 O
treated	1148 7 O
with	1156 4 O
antimicrobials	1161 14 O
.	1175 1 O

Although	1177 8 O
this	1186 4 O
is	1191 2 O
not	1194 3 O
a	1198 1 O
statistically	1200 13 O
significant	1214 11 O
risk	1226 4 O
,	1230 1 O
physicians	1232 10 O
must	1243 4 O
be	1248 2 O
aware	1251 5 O
of	1257 2 O
the	1260 3 O
effect	1264 6 O
and	1271 3 O
reversibility	1275 13 O
.	1288 1 O

Further	1290 7 O
research	1298 8 O
clearly	1307 7 O
is	1315 2 O
required	1318 8 O
to	1327 2 O
determine	1330 9 O
the	1340 3 O
incidence	1344 9 O
of	1354 2 O
antimicrobial	1357 13 O
-	1370 1 O
induced	1371 7 O
mania	1379 5 B-Disease
,	1384 1 O
the	1386 3 O
relative	1390 8 O
risk	1399 4 O
factors	1404 7 O
of	1412 2 O
developing	1415 10 O
an	1426 2 O
antimicrobial	1429 13 O
-	1442 1 O
induced	1443 7 O
manic	1451 5 B-Disease
episode	1457 7 O
among	1465 5 O
various	1471 7 O
demographic	1479 11 O
populations	1491 11 O
,	1502 1 O
and	1504 3 O
the	1508 3 O
incidence	1512 9 O
of	1522 2 O
patients	1525 8 O
who	1534 3 O
continue	1538 8 O
to	1547 2 O
have	1550 4 O
persistent	1555 10 O
affective	1566 9 O
disorders	1576 9 O
once	1586 4 O
the	1591 3 O
initial	1595 7 O
episode	1603 7 O
,	1610 1 O
which	1612 5 O
occurs	1618 6 O
while	1625 5 O
the	1631 3 O
patient	1635 7 O
is	1643 2 O
taking	1646 6 O
antibiotics	1653 11 O
,	1664 1 O
subsides	1666 8 O
.	1674 1 O

The	1676 3 O
authors	1680 7 O
elected	1688 7 O
to	1696 2 O
name	1699 4 O
this	1704 4 O
syndrome	1709 8 O
"	1718 1 O
antibiomania	1719 12 B-Disease
.	1731 1 O
"	1732 1 O

Levodopa	0 8 B-Chemical
-	8 1 O
induced	9 7 O
ocular	17 6 B-Disease
dyskinesias	24 11 I-Disease
in	36 2 O
Parkinson	39 9 B-Disease
'	48 1 I-Disease
s	49 1 I-Disease
disease	51 7 I-Disease
.	58 1 O

Levodopa	60 8 B-Chemical
-	68 1 O
induced	69 7 O
ocular	77 6 B-Disease
dyskinesias	84 11 I-Disease
are	96 3 O
very	100 4 O
uncommon	105 8 O
.	113 1 O

Usually	115 7 O
they	123 4 O
occur	128 5 O
simultaneously	134 14 O
with	149 4 O
limb	154 4 O
peak	159 4 O
-	163 1 O
dose	164 4 O
choreatic	169 9 B-Disease
dyskinesias	179 11 I-Disease
.	190 1 O

We	192 2 O
report	195 6 O
on	202 2 O
a	205 1 O
patient	207 7 O
with	215 4 O
leftward	220 8 O
and	229 3 O
upward	233 6 O
deviations	240 10 O
of	251 2 O
gaze	254 4 O
during	259 6 O
the	266 3 O
peak	270 4 O
effect	275 6 O
of	282 2 O
levodopa	285 8 B-Chemical
,	293 1 O
and	295 3 O
hypothesize	299 11 O
that	311 4 O
a	316 1 O
severe	318 6 O
dopaminergic	325 12 O
denervation	338 11 O
in	350 2 O
the	353 3 O
caudate	357 7 O
nucleus	365 7 O
is	373 2 O
needed	376 6 O
for	383 3 O
the	387 3 O
appearance	391 10 O
of	402 2 O
these	405 5 O
levodopa	411 8 B-Chemical
-	419 1 O
induce	420 6 O
ocular	427 6 B-Disease
dyskinesias	434 11 I-Disease
.	445 1 O

A	0 1 O
comparison	2 10 O
of	13 2 O
glyceryl	16 8 B-Chemical
trinitrate	25 10 I-Chemical
with	36 4 O
diclofenac	41 10 B-Chemical
for	52 3 O
the	56 3 O
treatment	60 9 O
of	70 2 O
primary	73 7 O
dysmenorrhea	81 12 B-Disease
:	93 1 O
an	95 2 O
open	98 4 O
,	102 1 O
randomized	104 10 O
,	114 1 O
cross	116 5 O
-	121 1 O
over	122 4 O
trial	127 5 O
.	132 1 O

Primary	134 7 O
dysmenorrhea	142 12 B-Disease
is	155 2 O
a	158 1 O
syndrome	160 8 O
characterized	169 13 O
by	183 2 O
painful	186 7 O
uterine	194 7 O
contractility	202 13 O
caused	216 6 O
by	223 2 O
a	226 1 O
hypersecretion	228 14 O
of	243 2 O
endometrial	246 11 O
prostaglandins	258 14 B-Chemical
;	272 1 O
non	274 3 O
-	277 1 O
steroidal	278 9 O
anti	288 4 O
-	292 1 O
inflammatory	293 12 O
drugs	306 5 O
are	312 3 O
the	316 3 O
first	320 5 O
choice	326 6 O
for	333 3 O
its	337 3 O
treatment	341 9 O
.	350 1 O

However	352 7 O
,	359 1 O
in	361 2 O
vivo	364 4 O
and	369 3 O
in	373 2 O
vitro	376 5 O
studies	382 7 O
have	390 4 O
demonstrated	395 12 O
that	408 4 O
myometrial	413 10 O
cells	424 5 O
are	430 3 O
also	434 4 O
targets	439 7 O
of	447 2 O
the	450 3 O
relaxant	454 8 O
effects	463 7 O
of	471 2 O
nitric	474 6 B-Chemical
oxide	481 5 I-Chemical
(	487 1 O
NO	488 2 B-Chemical
)	490 1 O
.	491 1 O

The	493 3 O
aim	497 3 O
of	501 2 O
the	504 3 O
present	508 7 O
study	516 5 O
was	522 3 O
to	526 2 O
determine	529 9 O
the	539 3 O
efficacy	543 8 O
of	552 2 O
glyceryl	555 8 B-Chemical
trinitrate	564 10 I-Chemical
(	575 1 O
GTN	576 3 B-Chemical
)	579 1 O
,	580 1 O
an	582 2 O
NO	585 2 B-Chemical
donor	588 5 O
,	593 1 O
in	595 2 O
the	598 3 O
resolution	602 10 O
of	613 2 O
primary	616 7 O
dysmenorrhea	624 12 B-Disease
in	637 2 O
comparison	640 10 O
with	651 4 O
diclofenac	656 10 B-Chemical
(	667 1 O
DCF	668 3 B-Chemical
)	671 1 O
.	672 1 O

A	674 1 O
total	676 5 O
of	682 2 O
24	685 2 O
patients	688 8 O
with	697 4 O
the	702 3 O
diagnosis	706 9 O
of	716 2 O
severe	719 6 O
primary	726 7 O
dysmenorrhea	734 12 B-Disease
were	747 4 O
studied	752 7 O
during	760 6 O
two	767 3 O
consecutive	771 11 O
menstrual	783 9 O
cycles	793 6 O
.	799 1 O

In	801 2 O
an	804 2 O
open	807 4 O
,	811 1 O
cross	813 5 O
-	818 1 O
over	819 4 O
,	823 1 O
controlled	825 10 O
design	836 6 O
,	842 1 O
patients	844 8 O
were	853 4 O
randomized	858 10 O
to	869 2 O
receive	872 7 O
either	880 6 O
DCF	887 3 B-Chemical
per	891 3 O
os	895 2 O
or	898 2 O
GTN	901 3 B-Chemical
patches	905 7 O
the	913 3 O
first	917 5 O
days	923 4 O
of	928 2 O
menses	931 6 O
,	937 1 O
when	939 4 O
menstrual	944 9 O
cramps	954 6 O
became	961 6 O
unendurable	968 11 O
.	979 1 O

In	981 2 O
the	984 3 O
subsequent	988 10 O
cycle	999 5 O
the	1005 3 O
other	1009 5 O
treatment	1015 9 O
was	1025 3 O
used	1029 4 O
.	1033 1 O

Patients	1035 8 O
received	1044 8 O
up	1053 2 O
to	1056 2 O
3	1059 1 O
doses	1061 5 O
/	1066 1 O
day	1067 3 O
of	1071 2 O
50	1074 2 O
mg	1077 2 O
DCF	1080 3 B-Chemical
or	1084 2 O
2	1087 1 O
.	1088 1 O
5	1089 1 O
mg	1091 2 O
/	1093 1 O
24	1094 2 O
h	1097 1 O
transdermal	1099 11 O
GTN	1111 3 B-Chemical
for	1115 3 O
the	1119 3 O
first	1123 5 O
3	1129 1 O
days	1131 4 O
of	1136 2 O
the	1139 3 O
cycle	1143 5 O
,	1148 1 O
according	1150 9 O
to	1160 2 O
their	1163 5 O
needs	1169 5 O
.	1174 1 O

The	1176 3 O
participants	1180 12 O
recorded	1193 8 O
menstrual	1202 9 O
symptoms	1212 8 O
and	1221 3 O
possible	1225 8 O
side	1234 4 O
-	1238 1 O
effects	1239 7 O
at	1247 2 O
different	1250 9 O
times	1260 5 O
(	1266 1 O
0	1267 1 O
,	1268 1 O
30	1270 2 O
,	1272 1 O
60	1274 2 O
,	1276 1 O
120	1278 3 O
minutes	1282 7 O
)	1289 1 O
after	1291 5 O
the	1297 3 O
first	1301 5 O
dose	1307 4 O
of	1312 2 O
medication	1315 10 O
on	1326 2 O
the	1329 3 O
first	1333 5 O
day	1339 3 O
of	1343 2 O
the	1346 3 O
cycle	1350 5 O
,	1355 1 O
with	1357 4 O
both	1362 4 O
drugs	1367 5 O
.	1372 1 O

The	1374 3 O
difference	1378 10 O
in	1389 2 O
pain	1392 4 B-Disease
intensity	1397 9 O
score	1407 5 O
(	1413 1 O
DPI	1414 3 O
)	1417 1 O
was	1419 3 O
the	1423 3 O
main	1427 4 O
outcome	1432 7 O
variable	1440 8 O
.	1448 1 O

Both	1450 4 O
treatments	1455 10 O
significantly	1466 13 O
reduced	1480 7 O
DPI	1488 3 O
by	1492 2 O
the	1495 3 O
30th	1499 4 O
minute	1504 6 O
(	1511 1 O
GTN	1512 3 B-Chemical
,	1515 1 O
-	1517 1 O
12	1518 2 O
.	1520 1 O
8	1521 1 O
+	1523 1 O
/	1524 1 O
-	1525 1 O
17	1527 2 O
.	1529 1 O
9	1530 1 O
;	1531 1 O
DCF	1533 3 B-Chemical
,	1536 1 O
-	1538 1 O
18	1539 2 O
.	1541 1 O
9	1542 1 O
+	1544 1 O
/	1545 1 O
-	1546 1 O
16	1548 2 O
.	1550 1 O
6	1551 1 O
)	1552 1 O
.	1553 1 O

However	1555 7 O
,	1562 1 O
DCF	1564 3 B-Chemical
continued	1568 9 O
to	1578 2 O
be	1581 2 O
effective	1584 9 O
in	1594 2 O
reducing	1597 8 O
pelvic	1606 6 B-Disease
pain	1613 4 I-Disease
for	1618 3 O
two	1622 3 O
hours	1626 5 O
,	1631 1 O
whereas	1633 7 O
GTN	1641 3 B-Chemical
scores	1645 6 O
remained	1652 8 O
more	1661 4 O
or	1666 2 O
less	1669 4 O
stable	1674 6 O
after	1681 5 O
30	1687 2 O
min	1690 3 O
and	1694 3 O
significantly	1698 13 O
higher	1712 6 O
than	1719 4 O
those	1724 5 O
for	1730 3 O
DFC	1734 3 O
(	1738 1 O
after	1739 5 O
one	1745 3 O
hour	1749 4 O
:	1753 1 O
GTN	1755 3 B-Chemical
,	1758 1 O
-	1760 1 O
12	1761 2 O
.	1763 1 O
8	1764 1 O
+	1766 1 O
/	1767 1 O
-	1768 1 O
17	1770 2 O
.	1772 1 O
9	1773 1 O
;	1774 1 O
DFC	1776 3 O
,	1779 1 O
-	1781 1 O
18	1782 2 O
.	1784 1 O
9	1785 1 O
+	1787 1 O
/	1788 1 O
-	1789 1 O
16	1791 2 O
.	1793 1 O
6	1794 1 O
and	1796 3 O
after	1800 5 O
two	1806 3 O
hours	1810 5 O
:	1815 1 O
GTN	1817 3 B-Chemical
,	1820 1 O
-	1822 1 O
23	1823 2 O
.	1825 1 O
7	1826 1 O
+	1828 1 O
/	1829 1 O
-	1830 1 O
20	1832 2 O
.	1834 1 O
5	1835 1 O
;	1836 1 O
DFC	1838 3 O
,	1841 1 O
-	1843 1 O
59	1844 2 O
.	1846 1 O
7	1847 1 O
+	1849 1 O
/	1850 1 O
-	1851 1 O
17	1853 2 O
.	1855 1 O
9	1856 1 O
,	1857 1 O
p	1859 1 O
=	1861 1 O
0	1863 1 O
.	1864 1 O
0001	1865 4 O
)	1869 1 O
.	1870 1 O

Low	1872 3 B-Disease
back	1876 4 I-Disease
pain	1881 4 I-Disease
was	1886 3 O
also	1890 4 O
relieved	1895 8 O
by	1904 2 O
both	1907 4 O
drugs	1912 5 O
.	1917 1 O

Headache	1919 8 B-Disease
was	1928 3 O
significantly	1932 13 O
increased	1946 9 O
by	1956 2 O
GTN	1959 3 B-Chemical
but	1963 3 O
not	1967 3 O
by	1971 2 O
DCF	1974 3 B-Chemical
.	1977 1 O

Eight	1979 5 O
patients	1985 8 O
stopped	1994 7 O
using	2002 5 O
GTN	2008 3 B-Chemical
because	2012 7 O
headache	2020 8 B-Disease
-	2028 1 O
-	2029 1 O
attributed	2030 10 O
to	2041 2 O
its	2044 3 O
use	2048 3 O
-	2051 1 O
-	2052 1 O
became	2053 6 O
intolerable	2060 11 O
.	2071 1 O

These	2073 5 O
findings	2079 8 O
indicate	2088 8 O
that	2097 4 O
GTN	2102 3 B-Chemical
has	2106 3 O
a	2110 1 O
reduced	2112 7 O
efficacy	2120 8 O
and	2129 3 O
tolerability	2133 12 O
by	2146 2 O
comparison	2149 10 O
with	2160 4 O
DCF	2165 3 B-Chemical
in	2169 2 O
the	2172 3 O
treatment	2176 9 O
of	2186 2 O
primary	2189 7 O
dysmenorrhea	2197 12 B-Disease
.	2209 1 O

Temocapril	0 10 B-Chemical
,	10 1 O
a	12 1 O
long	14 4 O
-	18 1 O
acting	19 6 O
non	26 3 O
-	29 1 O
SH	30 2 O
group	33 5 O
angiotensin	39 11 B-Chemical
converting	51 10 O
enzyme	62 6 O
inhibitor	69 9 O
,	78 1 O
modulates	80 9 O
glomerular	90 10 B-Disease
injury	101 6 I-Disease
in	108 2 O
chronic	111 7 O
puromycin	119 9 B-Chemical
aminonucleoside	129 15 I-Chemical
nephrosis	145 9 B-Disease
.	154 1 O

The	156 3 O
purpose	160 7 O
of	168 2 O
the	171 3 O
present	175 7 O
study	183 5 O
was	189 3 O
to	193 2 O
determine	196 9 O
whether	206 7 O
chronic	214 7 O
administration	222 14 O
of	237 2 O
temocapril	240 10 B-Chemical
,	250 1 O
a	252 1 O
long	254 4 O
-	258 1 O
acting	259 6 O
non	266 3 O
-	269 1 O
SH	270 2 O
group	273 5 O
angiotensin	279 11 B-Chemical
converting	291 10 O
enzyme	302 6 O
(	309 1 O
ACE	310 3 O
)	313 1 O
inhibitor	315 9 O
,	324 1 O
reduced	326 7 O
proteinuria	334 11 B-Disease
,	345 1 O
inhibited	347 9 O
glomerular	357 10 O
hypertrophy	368 11 B-Disease
and	380 3 O
prevented	384 9 O
glomerulosclerosis	394 18 B-Disease
in	413 2 O
chronic	416 7 O
puromycin	424 9 B-Chemical
aminonucleoside	434 15 I-Chemical
(	450 1 O
PAN	451 3 B-Chemical
)	454 1 O
-	456 1 O
induced	458 7 O
nephrotic	466 9 B-Disease
rats	476 4 O
.	480 1 O

Nephrosis	482 9 B-Disease
was	492 3 O
induced	496 7 O
by	504 2 O
injection	507 9 O
of	517 2 O
PAN	520 3 B-Chemical
(	524 1 O
15mg	525 4 O
/	529 1 O
100g	530 4 O
body	535 4 O
weight	540 6 O
)	546 1 O
in	548 2 O
male	551 4 O
Sprague	556 7 O
-	563 1 O
Dawley	564 6 O
(	571 1 O
SD	572 2 O
)	574 1 O
rats	576 4 O
.	580 1 O

Four	582 4 O
groups	587 6 O
were	594 4 O
used	599 4 O
,	603 1 O
i	605 1 O
)	606 1 O
the	608 3 O
PAN	612 3 B-Chemical
group	616 5 O
(	622 1 O
14	623 2 O
)	625 1 O
,	626 1 O
ii	628 2 O
)	630 1 O
PAN	632 3 B-Chemical
/	635 1 O
temocapril	636 10 B-Chemical
(	647 1 O
13	648 2 O
)	650 1 O
,	651 1 O
iii	653 3 O
)	656 1 O
temocapril	658 10 B-Chemical
(	669 1 O
14	670 2 O
)	672 1 O
and	674 3 O
iv	678 2 O
)	680 1 O
untreated	682 9 O
controls	692 8 O
(	701 1 O
15	702 2 O
)	704 1 O
.	705 1 O

Temocapril	707 10 B-Chemical
(	718 1 O
8	719 1 O
mg	721 2 O
/	723 1 O
kg	724 2 O
/	726 1 O
day	727 3 O
)	730 1 O
was	732 3 O
administered	736 12 O
to	749 2 O
the	752 3 O
rats	756 4 O
which	761 5 O
were	767 4 O
killed	772 6 O
at	779 2 O
weeks	782 5 O
4	788 1 O
,	789 1 O
14	791 2 O
or	794 2 O
20	797 2 O
.	799 1 O

At	801 2 O
each	804 4 O
time	809 4 O
point	814 5 O
,	819 1 O
systolic	821 8 O
blood	830 5 O
pressure	836 8 O
(	845 1 O
BP	846 2 O
)	848 1 O
,	849 1 O
urinary	851 7 O
protein	859 7 O
excretion	867 9 O
and	877 3 O
renal	881 5 O
histopathological	887 17 O
findings	905 8 O
were	914 4 O
evaluated	919 9 O
,	928 1 O
and	930 3 O
morphometric	934 12 O
image	947 5 O
analysis	953 8 O
was	962 3 O
done	966 4 O
.	970 1 O

Systolic	972 8 O
BP	981 2 O
in	984 2 O
the	987 3 O
PAN	991 3 B-Chemical
group	995 5 O
was	1001 3 O
significantly	1005 13 O
high	1019 4 O
at	1024 2 O
4	1027 1 O
,	1028 1 O
14	1030 2 O
and	1033 3 O
20	1037 2 O
weeks	1040 5 O
,	1045 1 O
but	1047 3 O
was	1051 3 O
normal	1055 6 O
in	1062 2 O
the	1065 3 O
PAN	1069 3 B-Chemical
/	1072 1 O
temocapril	1073 10 B-Chemical
group	1084 5 O
.	1089 1 O

Urinary	1091 7 O
protein	1099 7 O
excretion	1107 9 O
in	1117 2 O
the	1120 3 O
PAN	1124 3 B-Chemical
group	1128 5 O
increased	1134 9 O
significantly	1144 13 O
,	1157 1 O
peaking	1159 7 O
at	1167 2 O
8	1170 1 O
days	1172 4 O
,	1176 1 O
then	1178 4 O
decreased	1183 9 O
at	1193 2 O
4	1196 1 O
weeks	1198 5 O
,	1203 1 O
but	1205 3 O
rose	1209 4 O
again	1214 5 O
significantly	1220 13 O
at	1234 2 O
14	1237 2 O
and	1240 3 O
20	1244 2 O
weeks	1247 5 O
.	1252 1 O

Temocapril	1254 10 B-Chemical
did	1265 3 O
not	1269 3 O
attenuate	1273 9 O
proteinuria	1283 11 B-Disease
at	1295 2 O
8	1298 1 O
days	1300 4 O
,	1304 1 O
but	1306 3 O
it	1310 2 O
did	1313 3 O
markedly	1317 8 O
lower	1326 5 O
it	1332 2 O
from	1335 4 O
weeks	1340 5 O
4	1346 1 O
to	1348 2 O
20	1351 2 O
.	1353 1 O

The	1355 3 O
glomerulosclerosis	1359 18 B-Disease
index	1378 5 O
(	1384 1 O
GSI	1385 3 O
)	1388 1 O
was	1390 3 O
6	1394 1 O
.	1395 1 O
21	1396 2 O
%	1399 1 O
at	1401 2 O
4	1404 1 O
weeks	1406 5 O
and	1412 3 O
respectively	1416 12 O
25	1429 2 O
.	1431 1 O
35	1432 2 O
%	1435 1 O
and	1437 3 O
30	1441 2 O
.	1443 1 O
49	1444 2 O
%	1447 1 O
at	1449 2 O
14	1452 2 O
and	1455 3 O
20	1459 2 O
weeks	1462 5 O
in	1468 2 O
the	1471 3 O
PAN	1475 3 B-Chemical
group	1479 5 O
.	1484 1 O

There	1486 5 O
was	1492 3 O
a	1496 1 O
significant	1498 11 O
correlation	1510 11 O
between	1522 7 O
urinary	1530 7 O
protein	1538 7 O
excretion	1546 9 O
and	1556 3 O
GSI	1560 3 O
(	1564 1 O
r	1565 1 O
=	1567 1 O
0	1569 1 O
.	1570 1 O
808	1571 3 O
,	1574 1 O
p	1576 1 O
<	1578 1 O
0	1580 1 O
.	1581 1 O
0001	1582 4 O
)	1586 1 O
.	1587 1 O

The	1589 3 O
ratio	1593 5 O
of	1599 2 O
glomerular	1602 10 O
tuft	1613 4 O
area	1618 4 O
to	1623 2 O
the	1626 3 O
area	1630 4 O
of	1635 2 O
Bowman	1638 6 O
'	1644 1 O
s	1645 1 O
capsules	1647 8 O
(	1656 1 O
GT	1657 2 O
/	1659 1 O
BC	1660 2 O
)	1662 1 O
in	1664 2 O
the	1667 3 O
PAN	1671 3 B-Chemical
group	1675 5 O
was	1681 3 O
significantly	1685 13 O
increased	1699 9 O
,	1708 1 O
but	1710 3 O
it	1714 2 O
was	1717 3 O
significantly	1721 13 O
lower	1735 5 O
in	1741 2 O
the	1744 3 O
PAN	1748 3 B-Chemical
/	1751 1 O
temocapril	1752 10 B-Chemical
group	1763 5 O
.	1768 1 O

It	1770 2 O
appears	1773 7 O
that	1781 4 O
temocapril	1786 10 B-Chemical
was	1797 3 O
effective	1801 9 O
in	1811 2 O
retarding	1814 9 O
renal	1824 5 O
progression	1830 11 O
and	1842 3 O
protected	1846 9 O
renal	1856 5 O
function	1862 8 O
in	1871 2 O
PAN	1874 3 B-Chemical
neprotic	1878 8 B-Disease
rats	1887 4 O
.	1891 1 O

Pulmonary	0 9 B-Disease
hypertension	10 12 I-Disease
after	23 5 O
ibuprofen	29 9 B-Chemical
prophylaxis	39 11 O
in	51 2 O
very	54 4 O
preterm	59 7 O
infants	67 7 O
.	74 1 O

We	76 2 O
report	79 6 O
three	86 5 O
cases	92 5 O
of	98 2 O
severe	101 6 O
hypoxaemia	108 10 B-Disease
after	119 5 O
ibuprofen	125 9 B-Chemical
administration	135 14 O
during	150 6 O
a	157 1 O
randomised	159 10 O
controlled	170 10 O
trial	181 5 O
of	187 2 O
prophylactic	190 12 O
treatment	203 9 O
of	213 2 O
patent	216 6 B-Disease
ductus	223 6 I-Disease
arteriosus	230 10 I-Disease
with	241 4 O
ibuprofen	246 9 B-Chemical
in	256 2 O
premature	259 9 O
infants	269 7 O
born	277 4 O
at	282 2 O
less	285 4 O
than	290 4 O
28	295 2 O
weeks	298 5 O
of	304 2 O
gestation	307 9 O
.	316 1 O

Echocardiography	318 16 O
showed	335 6 O
severely	342 8 O
decreased	351 9 O
pulmonary	361 9 O
blood	371 5 O
flow	377 4 O
.	381 1 O

Hypoxaemia	383 10 B-Disease
resolved	394 8 O
quickly	403 7 O
on	411 2 O
inhaled	414 7 O
nitric	422 6 B-Chemical
oxide	429 5 I-Chemical
therapy	435 7 O
.	442 1 O

We	444 2 O
suggest	447 7 O
that	455 4 O
investigators	460 13 O
involved	474 8 O
in	483 2 O
similar	486 7 O
trials	494 6 O
pay	501 3 O
close	505 5 O
attention	511 9 O
to	521 2 O
pulmonary	524 9 O
pressure	534 8 O
if	543 2 O
hypoxaemia	546 10 B-Disease
occurs	557 6 O
after	564 5 O
prophylactic	570 12 O
administration	583 14 O
of	598 2 O
ibuprofen	601 9 B-Chemical
.	610 1 O

Hyponatremia	0 12 B-Disease
and	13 3 O
syndrome	17 8 B-Disease
of	26 2 I-Disease
inappropriate	29 13 I-Disease
anti	43 4 I-Disease
-	47 1 I-Disease
diuretic	48 8 I-Disease
hormone	57 7 I-Disease
reported	65 8 O
with	74 4 O
the	79 3 O
use	83 3 O
of	87 2 O
Vincristine	90 11 B-Chemical
:	101 1 O
an	103 2 O
over	106 4 O
-	110 1 O
representation	111 14 O
of	126 2 O
Asians	129 6 O
?	135 1 O

PURPOSE	137 7 O
:	144 1 O
This	146 4 O
retrospective	151 13 O
study	165 5 O
used	171 4 O
a	176 1 O
pharmaceutical	178 14 O
company	193 7 O
'	200 1 O
s	201 1 O
global	203 6 O
safety	210 6 O
database	217 8 O
to	226 2 O
determine	229 9 O
the	239 3 O
reporting	243 9 O
rate	253 4 O
of	258 2 O
hyponatremia	261 12 B-Disease
and	274 3 O
/	277 1 O
or	278 2 O
syndrome	281 8 B-Disease
of	290 2 I-Disease
inappropriate	293 13 I-Disease
secretion	307 9 I-Disease
of	317 2 I-Disease
anti	320 4 I-Disease
-	324 1 I-Disease
diuretic	325 8 I-Disease
hormone	334 7 I-Disease
(	342 1 O
SIADH	343 5 B-Disease
)	348 1 O
among	350 5 O
vincristine	356 11 B-Chemical
-	367 1 O
treated	368 7 O
patients	376 8 O
and	385 3 O
to	389 2 O
explore	392 7 O
the	400 3 O
possibility	404 11 O
of	416 2 O
at	419 2 O
-	421 1 O
risk	422 4 O
population	427 10 O
subgroups	438 9 O
.	447 1 O

METHOD	449 6 O
:	455 1 O
We	457 2 O
searched	460 8 O
the	469 3 O
Eli	473 3 O
Lilly	477 5 O
and	483 3 O
Company	487 7 O
'	494 1 O
s	495 1 O
computerized	497 12 O
adverse	510 7 O
event	518 5 O
database	524 8 O
for	533 3 O
all	537 3 O
reported	541 8 O
cases	550 5 O
of	556 2 O
hyponatremia	559 12 B-Disease
and	572 3 O
/	575 1 O
or	576 2 O
SIADH	579 5 B-Disease
as	585 2 O
of	588 2 O
1	591 1 O
November	593 8 O
1999	602 4 O
that	607 4 O
had	612 3 O
been	616 4 O
reported	621 8 O
during	630 6 O
the	637 3 O
use	641 3 O
of	645 2 O
vincristine	648 11 B-Chemical
.	659 1 O

RESULTS	661 7 O
:	668 1 O
A	670 1 O
total	672 5 O
of	678 2 O
76	681 2 O
cases	684 5 O
of	690 2 O
hyponatremia	693 12 B-Disease
and	706 3 O
/	709 1 O
or	710 2 O
SIADH	713 5 B-Disease
associated	719 10 O
with	730 4 O
vincristine	735 11 B-Chemical
use	747 3 O
were	751 4 O
identified	756 10 O
.	766 1 O

The	768 3 O
overall	772 7 O
reporting	780 9 O
rate	790 4 O
was	795 3 O
estimated	799 9 O
to	809 2 O
be	812 2 O
1	815 1 O
.	816 1 O
3	817 1 O
/	818 1 O
100	819 3 O
,	822 1 O
000	823 3 O
treated	827 7 O
patients	835 8 O
.	843 1 O

The	845 3 O
average	849 7 O
age	857 3 O
of	861 2 O
patients	864 8 O
was	873 3 O
35	877 2 O
.	879 1 O
6	880 1 O
+	882 1 O
/	883 1 O
-	884 1 O
28	886 2 O
.	888 1 O
3	889 1 O
years	891 5 O
,	896 1 O
and	898 3 O
62	902 2 O
%	904 1 O
were	906 4 O
males	911 5 O
.	916 1 O

Approximately	918 13 O
75	932 2 O
%	934 1 O
of	936 2 O
the	939 3 O
patients	943 8 O
were	952 4 O
receiving	957 9 O
treatment	967 9 O
for	977 3 O
leukemia	981 8 B-Disease
or	990 2 O
lymphoma	993 8 B-Disease
.	1001 1 O

Among	1003 5 O
the	1009 3 O
39	1013 2 O
reports	1016 7 O
that	1024 4 O
included	1029 8 O
information	1038 11 O
on	1050 2 O
race	1053 4 O
,	1057 1 O
the	1059 3 O
racial	1063 6 O
distribution	1070 12 O
was	1083 3 O
:	1086 1 O
1	1088 1 O
Black	1090 5 O
,	1095 1 O
3	1097 1 O
Caucasian	1099 9 O
,	1108 1 O
and	1110 3 O
35	1114 2 O
Asian	1117 5 O
.	1122 1 O

CONCLUSION	1124 10 O
:	1134 1 O
Our	1136 3 O
data	1140 4 O
suggest	1145 7 O
that	1153 4 O
Asian	1158 5 O
patients	1164 8 O
may	1173 3 O
be	1177 2 O
at	1180 2 O
increased	1183 9 O
risk	1193 4 O
of	1198 2 O
hyponatremia	1201 12 B-Disease
and	1214 3 O
/	1217 1 O
or	1218 2 O
SIADH	1221 5 B-Disease
associated	1227 10 O
with	1238 4 O
vincristine	1243 11 B-Chemical
use	1255 3 O
.	1258 1 O

Although	1260 8 O
the	1269 3 O
overall	1273 7 O
reported	1281 8 O
rate	1290 4 O
of	1295 2 O
SIADH	1298 5 B-Disease
associated	1304 10 O
with	1315 4 O
vincristine	1320 11 B-Chemical
is	1332 2 O
very	1335 4 O
low	1340 3 O
,	1343 1 O
physicians	1345 10 O
caring	1356 6 O
for	1363 3 O
Asian	1367 5 O
oncology	1373 8 O
patients	1382 8 O
should	1391 6 O
be	1398 2 O
aware	1401 5 O
of	1407 2 O
this	1410 4 O
potential	1415 9 O
serious	1425 7 O
but	1433 3 O
reversible	1437 10 O
adverse	1448 7 O
event	1456 5 O
.	1461 1 O

Delayed	0 7 O
toxicity	8 8 B-Disease
of	17 2 O
cyclophosphamide	20 16 B-Chemical
on	37 2 O
the	40 3 O
bladder	44 7 O
of	52 2 O
DBA	55 3 O
/	58 1 O
2	59 1 O
and	61 3 O
C57BL	65 5 O
/	70 1 O
6	71 1 O
female	73 6 O
mouse	80 5 O
.	85 1 O

The	87 3 O
present	91 7 O
study	99 5 O
describes	105 9 O
the	115 3 O
delayed	119 7 O
development	127 11 O
of	139 2 O
a	142 1 O
severe	144 6 O
bladder	151 7 O
pathology	159 9 O
in	169 2 O
a	172 1 O
susceptible	174 11 O
strain	186 6 O
of	193 2 O
mice	196 4 O
(	201 1 O
DBA	202 3 O
/	205 1 O
2	206 1 O
)	207 1 O
but	209 3 O
not	213 3 O
in	217 2 O
a	220 1 O
resistant	222 9 O
strain	232 6 O
(	239 1 O
C57BL	240 5 O
/	245 1 O
6	246 1 O
)	247 1 O
when	249 4 O
both	254 4 O
were	259 4 O
treated	264 7 O
with	272 4 O
a	277 1 O
single	279 6 O
300	286 3 O
mg	290 2 O
/	292 1 O
kg	293 2 O
dose	296 4 O
of	301 2 O
cyclophosphamide	304 16 B-Chemical
(	321 1 O
CY	322 2 B-Chemical
)	324 1 O
.	325 1 O

Inbred	327 6 O
DBA	334 3 O
/	337 1 O
2	338 1 O
and	340 3 O
C57BL	344 5 O
/	349 1 O
6	350 1 O
female	352 6 O
mice	359 4 O
were	364 4 O
injected	369 8 O
with	378 4 O
CY	383 2 B-Chemical
,	385 1 O
and	387 3 O
the	391 3 O
effect	395 6 O
of	402 2 O
the	405 3 O
drug	409 4 O
on	414 2 O
the	417 3 O
bladder	421 7 O
was	429 3 O
assessed	433 8 O
during	442 6 O
100	449 3 O
days	453 4 O
by	458 2 O
light	461 5 O
microscopy	467 10 O
using	478 5 O
different	484 9 O
staining	494 8 O
procedures	503 10 O
,	513 1 O
and	515 3 O
after	519 5 O
30	525 2 O
days	528 4 O
by	533 2 O
conventional	536 12 O
electron	549 8 O
microscopy	558 10 O
.	568 1 O

Early	570 5 O
CY	576 2 B-Chemical
toxicity	579 8 B-Disease
caused	588 6 O
a	595 1 O
typical	597 7 O
haemorrhagic	605 12 B-Disease
cystitis	618 8 B-Disease
in	627 2 O
both	630 4 O
strains	635 7 O
that	643 4 O
was	648 3 O
completely	652 10 O
repaired	663 8 O
in	672 2 O
about	675 5 O
7	681 1 O
-	682 1 O
10	683 2 O
days	686 4 O
.	690 1 O

After	692 5 O
30	698 2 O
days	701 4 O
of	706 2 O
CY	709 2 B-Chemical
injection	712 9 O
ulcerous	722 8 O
and	731 3 O
non	735 3 O
-	738 1 O
ulcerous	739 8 O
forms	748 5 O
of	754 2 O
chronic	757 7 O
cystitis	765 8 B-Disease
appeared	774 8 O
in	783 2 O
86	786 2 O
%	788 1 O
of	790 2 O
DBA	793 3 O
/	796 1 O
2	797 1 O
mice	799 4 O
but	804 3 O
only	808 4 O
in	813 2 O
4	816 1 O
%	817 1 O
of	819 2 O
C57BL	822 5 O
/	827 1 O
6	828 1 O
mice	830 4 O
.	834 1 O

Delayed	836 7 O
cystitis	844 8 B-Disease
was	853 3 O
characterized	857 13 O
by	871 2 O
infiltration	874 12 O
and	887 3 O
transepithelial	891 15 O
passage	907 7 O
into	915 4 O
the	920 3 O
lumen	924 5 O
of	930 2 O
inflammatory	933 12 O
cells	946 5 O
and	952 3 O
by	956 2 O
frequent	959 8 O
exfoliation	968 11 O
of	980 2 O
the	983 3 O
urothelium	987 10 O
.	997 1 O

Mast	999 4 O
cells	1004 5 O
appeared	1010 8 O
in	1019 2 O
the	1022 3 O
connective	1026 10 O
and	1037 3 O
muscular	1041 8 O
layers	1050 6 O
of	1057 2 O
the	1060 3 O
bladder	1064 7 O
at	1072 2 O
a	1075 1 O
much	1077 4 O
higher	1082 6 O
number	1089 6 O
in	1096 2 O
DBA	1099 3 O
/	1102 1 O
2	1103 1 O
mice	1105 4 O
than	1110 4 O
in	1115 2 O
C57BL	1118 5 O
/	1123 1 O
6	1124 1 O
mice	1126 4 O
or	1131 2 O
untreated	1134 9 O
controls	1144 8 O
.	1152 1 O

Electron	1154 8 O
microscopy	1163 10 O
disclosed	1174 9 O
the	1184 3 O
absence	1188 7 O
of	1196 2 O
the	1199 3 O
typical	1203 7 O
discoidal	1211 9 O
vesicles	1221 8 O
normally	1230 8 O
present	1239 7 O
in	1247 2 O
the	1250 3 O
cytoplasm	1254 9 O
of	1264 2 O
surface	1267 7 O
cells	1275 5 O
.	1280 1 O

Instead	1282 7 O
,	1289 1 O
numerous	1291 8 O
abnormal	1300 8 O
vesicles	1309 8 O
containing	1318 10 O
one	1329 3 O
or	1333 2 O
several	1336 7 O
dark	1344 4 O
granules	1349 8 O
were	1358 4 O
observed	1363 8 O
in	1372 2 O
the	1375 3 O
cytoplasm	1379 9 O
of	1389 2 O
cells	1392 5 O
from	1398 4 O
all	1403 3 O
the	1407 3 O
epithelial	1411 10 O
layers	1422 6 O
.	1428 1 O

Delayed	1430 7 O
cystitis	1438 8 B-Disease
still	1447 5 O
persisted	1453 9 O
in	1463 2 O
DBA	1466 3 O
/	1469 1 O
2	1470 1 O
mice	1472 4 O
100	1477 3 O
days	1481 4 O
after	1486 5 O
treatment	1492 9 O
.	1501 1 O

These	1503 5 O
results	1509 7 O
indicate	1517 8 O
that	1526 4 O
delayed	1531 7 O
toxicity	1539 8 B-Disease
of	1548 2 O
CY	1551 2 B-Chemical
in	1554 2 O
female	1557 6 O
DBA	1564 3 O
/	1567 1 O
2	1568 1 O
mice	1570 4 O
causes	1575 6 O
a	1582 1 O
bladder	1584 7 O
pathology	1592 9 O
that	1602 4 O
is	1607 2 O
not	1610 3 O
observed	1614 8 O
in	1623 2 O
C57BL	1626 5 O
/	1631 1 O
6	1632 1 O
mice	1634 4 O
.	1638 1 O

This	1640 4 O
pathology	1645 9 O
resembles	1655 9 O
interstitial	1665 12 B-Disease
cystitis	1678 8 I-Disease
in	1687 2 O
humans	1690 6 O
and	1697 3 O
could	1701 5 O
perhaps	1707 7 O
be	1715 2 O
used	1718 4 O
as	1723 2 O
an	1726 2 O
animal	1729 6 O
model	1736 5 O
for	1742 3 O
studies	1746 7 O
on	1754 2 O
the	1757 3 O
disease	1761 7 O
.	1768 1 O

High	0 4 O
-	4 1 O
dose	5 4 O
5	10 1 B-Chemical
-	11 1 I-Chemical
fluorouracil	12 12 I-Chemical
/	25 1 O
folinic	27 7 B-Chemical
acid	35 4 I-Chemical
in	40 2 O
combination	43 11 O
with	55 4 O
three	60 5 O
-	65 1 O
weekly	66 6 O
mitomycin	73 9 B-Chemical
C	83 1 I-Chemical
in	85 2 O
the	88 3 O
treatment	92 9 O
of	102 2 O
advanced	105 8 O
gastric	114 7 B-Disease
cancer	122 6 I-Disease
.	128 1 O

A	130 1 O
phase	132 5 O
II	138 2 O
study	141 5 O
.	146 1 O

BACKGROUND	148 10 O
:	158 1 O
The	160 3 O
24	164 2 O
-	166 1 O
hour	167 4 O
continuous	172 10 O
infusion	183 8 O
of	192 2 O
5	195 1 B-Chemical
-	196 1 I-Chemical
fluorouracil	197 12 I-Chemical
(	210 1 O
5	211 1 B-Chemical
-	212 1 I-Chemical
FU	213 2 I-Chemical
)	215 1 O
and	217 3 O
folinic	221 7 B-Chemical
acid	229 4 I-Chemical
(	234 1 O
FA	235 2 B-Chemical
)	237 1 O
as	239 2 O
part	242 4 O
of	247 2 O
several	250 7 O
new	258 3 O
multidrug	262 9 O
chemotherapy	272 12 O
regimens	285 8 O
in	294 2 O
advanced	297 8 O
gastric	306 7 B-Disease
cancer	314 6 I-Disease
(	321 1 O
AGC	322 3 B-Disease
)	325 1 O
has	327 3 O
shown	331 5 O
to	337 2 O
be	340 2 O
effective	343 9 O
,	352 1 O
with	354 4 O
low	359 3 O
toxicity	363 8 B-Disease
.	371 1 O

In	373 2 O
a	376 1 O
previous	378 8 O
phase	387 5 O
II	393 2 O
study	396 5 O
with	402 4 O
3	407 1 O
-	408 1 O
weekly	409 6 O
bolus	416 5 O
5	422 1 B-Chemical
-	423 1 I-Chemical
FU	424 2 I-Chemical
,	426 1 O
FA	428 2 B-Chemical
and	431 3 O
mitomycin	435 9 B-Chemical
C	445 1 I-Chemical
(	447 1 O
MMC	448 3 B-Chemical
)	451 1 O
we	453 2 O
found	456 5 O
a	462 1 O
low	464 3 O
toxicity	468 8 B-Disease
rate	477 4 O
and	482 3 O
response	486 8 O
rates	495 5 O
comparable	501 10 O
to	512 2 O
those	515 5 O
of	521 2 O
regimens	524 8 O
such	533 4 O
as	538 2 O
ELF	541 3 O
,	544 1 O
FAM	546 3 O
or	550 2 O
FAMTX	553 5 O
,	558 1 O
and	560 3 O
a	564 1 O
promising	566 9 O
median	576 6 O
overall	583 7 O
survival	591 8 O
.	599 1 O

In	601 2 O
order	604 5 O
to	610 2 O
improve	613 7 O
this	621 4 O
MMC	626 3 B-Chemical
-	629 1 O
dependent	630 9 O
schedule	640 8 O
we	649 2 O
initiated	652 9 O
a	662 1 O
phase	664 5 O
II	670 2 O
study	673 5 O
with	679 4 O
high	684 4 O
-	688 1 O
dose	689 4 O
5	694 1 B-Chemical
-	695 1 I-Chemical
FU	696 2 I-Chemical
/	698 1 O
FA	699 2 B-Chemical
and	702 3 O
3	706 1 O
-	707 1 O
weekly	708 6 O
bolus	715 5 O
MMC	721 3 B-Chemical
.	724 1 O

PATIENTS	726 8 O
AND	735 3 O
METHODS	739 7 O
:	746 1 O
From	748 4 O
February	753 8 O
,	761 1 O
1998	763 4 O
to	768 2 O
September	771 9 O
,	780 1 O
2000	782 4 O
we	787 2 O
recruited	790 9 O
33	800 2 O
patients	803 8 O
with	812 4 O
AGC	817 3 B-Disease
to	821 2 O
receive	824 7 O
weekly	832 6 O
24	839 2 O
-	841 1 O
hour	842 4 O
5	847 1 B-Chemical
-	848 1 I-Chemical
FU	849 2 I-Chemical
2	852 1 O
,	853 1 O
600	854 3 O
mg	858 2 O
/	860 1 O
m	861 1 O
(	862 1 O
2	863 1 O
)	864 1 O
preceded	866 8 O
by	875 2 O
2	878 1 O
-	879 1 O
hour	880 4 O
FA	885 2 B-Chemical
500	888 3 O
mg	892 2 O
/	894 1 O
m	895 1 O
(	896 1 O
2	897 1 O
)	898 1 O
for	900 3 O
6	904 1 O
weeks	906 5 O
,	911 1 O
followed	913 8 O
by	922 2 O
a	925 1 O
2	927 1 O
-	928 1 O
week	929 4 O
rest	934 4 O
period	939 6 O
.	945 1 O

Bolus	947 5 O
MMC	953 3 B-Chemical
10	957 2 O
mg	960 2 O
/	962 1 O
m	963 1 O
(	964 1 O
2	965 1 O
)	966 1 O
was	968 3 O
added	972 5 O
in	978 2 O
3	981 1 O
-	982 1 O
weekly	983 6 O
intervals	990 9 O
.	999 1 O

Treatment	1001 9 O
given	1011 5 O
on	1017 2 O
an	1020 2 O
outpatient	1023 10 O
basis	1034 5 O
,	1039 1 O
using	1041 5 O
portable	1047 8 O
pump	1056 4 O
systems	1061 7 O
,	1068 1 O
was	1070 3 O
repeated	1074 8 O
on	1083 2 O
day	1086 3 O
57	1090 2 O
.	1092 1 O

Patients	1094 8 O
'	1102 1 O
characteristics	1104 15 O
were	1120 4 O
:	1124 1 O
male	1126 4 O
/	1130 1 O
female	1131 6 O
ratio	1138 5 O
20	1144 2 O
/	1146 1 O
13	1147 2 O
;	1149 1 O
median	1151 6 O
age	1158 3 O
57	1162 2 O
(	1165 1 O
27	1166 2 O
-	1168 1 O
75	1169 2 O
)	1171 1 O
years	1173 5 O
;	1178 1 O
median	1180 6 O
WHO	1187 3 O
status	1191 6 O
1	1198 1 O
(	1200 1 O
0	1201 1 O
-	1202 1 O
2	1203 1 O
)	1204 1 O
.	1205 1 O

18	1207 2 O
patients	1210 8 O
had	1219 3 O
a	1223 1 O
primary	1225 7 O
AGC	1233 3 B-Disease
,	1236 1 O
and	1238 3 O
15	1242 2 O
showed	1245 6 O
a	1252 1 O
relapsed	1254 8 O
AGC	1263 3 B-Disease
.	1266 1 O

Median	1268 6 O
follow	1275 6 O
-	1281 1 O
up	1282 2 O
was	1285 3 O
11	1289 2 O
.	1291 1 O
8	1292 1 O
months	1294 6 O
(	1301 1 O
range	1302 5 O
of	1308 2 O
those	1311 5 O
surviving	1317 9 O
:	1326 1 O
2	1328 1 O
.	1329 1 O
7	1330 1 O
-	1331 1 O
11	1332 2 O
.	1334 1 O
8	1335 1 O
months	1337 6 O
)	1343 1 O
.	1344 1 O

RESULTS	1346 7 O
:	1353 1 O
32	1355 2 O
patients	1358 8 O
were	1367 4 O
evaluable	1372 9 O
for	1382 3 O
response	1386 8 O
-	1395 1 O
complete	1397 8 O
remission	1406 9 O
9	1416 1 O
.	1417 1 O
1	1418 1 O
%	1419 1 O
(	1421 1 O
n	1422 1 O
=	1424 1 O
3	1426 1 O
)	1427 1 O
,	1428 1 O
partial	1430 7 O
remission	1438 9 O
45	1448 2 O
.	1450 1 O
5	1451 1 O
%	1452 1 O
(	1454 1 O
n	1455 1 O
=	1457 1 O
15	1459 2 O
)	1461 1 O
,	1462 1 O
no	1464 2 O
change	1467 6 O
27	1474 2 O
.	1476 1 O
3	1477 1 O
%	1478 1 O
(	1480 1 O
n	1481 1 O
=	1483 1 O
9	1485 1 O
)	1486 1 O
,	1487 1 O
progressive	1489 11 O
disease	1501 7 O
15	1509 2 O
.	1511 1 O
1	1512 1 O
%	1513 1 O
(	1515 1 O
n	1516 1 O
=	1518 1 O
5	1520 1 O
)	1521 1 O
.	1522 1 O

Median	1524 6 O
overall	1531 7 O
survival	1539 8 O
time	1548 4 O
was	1553 3 O
10	1557 2 O
.	1559 1 O
2	1560 1 O
months	1562 6 O
[	1569 1 O
95	1570 2 O
%	1572 1 O
confidence	1574 10 O
interval	1585 8 O
(	1594 1 O
CI	1595 2 O
)	1597 1 O
:	1598 1 O
8	1600 1 O
.	1601 1 O
7	1602 1 O
-	1603 1 O
11	1604 2 O
.	1606 1 O
6	1607 1 O
]	1608 1 O
,	1609 1 O
and	1611 3 O
median	1615 6 O
progression	1622 11 O
-	1633 1 O
free	1634 4 O
survival	1639 8 O
time	1648 4 O
was	1653 3 O
7	1657 1 O
.	1658 1 O
6	1659 1 O
months	1661 6 O
(	1668 1 O
95	1669 2 O
%	1671 1 O
CI	1673 2 O
:	1675 1 O
4	1677 1 O
.	1678 1 O
4	1679 1 O
-	1680 1 O
10	1681 2 O
.	1683 1 O
9	1684 1 O
)	1685 1 O
.	1686 1 O

The	1688 3 O
worst	1692 5 O
toxicities	1698 10 B-Disease
(	1709 1 O
%	1710 1 O
)	1711 1 O
observed	1713 8 O
were	1722 4 O
(	1727 1 O
CTC	1728 3 O
-	1731 1 O
NCI	1732 3 O
1	1736 1 O
/	1737 1 O
2	1738 1 O
/	1739 1 O
3	1740 1 O
)	1741 1 O
:	1742 1 O
leukopenia	1744 10 B-Disease
45	1755 2 O
.	1757 1 O
5	1758 1 O
/	1759 1 O
18	1760 2 O
.	1762 1 O
2	1763 1 O
/	1764 1 O
6	1765 1 O
.	1766 1 O
1	1767 1 O
,	1768 1 O
thrombocytopenia	1770 16 B-Disease
33	1787 2 O
.	1789 1 O
3	1790 1 O
/	1791 1 O
9	1792 1 O
.	1793 1 O
1	1794 1 O
/	1795 1 O
6	1796 1 O
.	1797 1 O
1	1798 1 O
,	1799 1 O
vomitus	1801 7 B-Disease
24	1809 2 O
.	1811 1 O
2	1812 1 O
/	1813 1 O
9	1814 1 O
.	1815 1 O
1	1816 1 O
/	1817 1 O
0	1818 1 O
,	1819 1 O
diarrhea	1821 8 B-Disease
36	1830 2 O
.	1832 1 O
4	1833 1 O
/	1834 1 O
6	1835 1 O
.	1836 1 O
1	1837 1 O
/	1838 1 O
3	1839 1 O
.	1840 1 O
0	1841 1 O
,	1842 1 O
stomatitis	1844 10 B-Disease
18	1855 2 O
.	1857 1 O
2	1858 1 O
/	1859 1 O
9	1860 1 O
.	1861 1 O
1	1862 1 O
/	1863 1 O
0	1864 1 O
,	1865 1 O
hand	1867 4 B-Disease
-	1871 1 I-Disease
foot	1872 4 I-Disease
syndrome	1877 8 I-Disease
12	1886 2 O
.	1888 1 O
1	1889 1 O
/	1890 1 O
0	1891 1 O
/	1892 1 O
0	1893 1 O
.	1894 1 O

Two	1896 3 O
patients	1900 8 O
developed	1909 9 O
hemolytic	1919 9 B-Disease
-	1928 1 I-Disease
uremic	1929 6 I-Disease
syndrome	1936 8 I-Disease
(	1945 1 O
HUS	1946 3 B-Disease
)	1949 1 O
.	1950 1 O

CONCLUSIONS	1952 11 O
:	1963 1 O
High	1965 4 O
-	1969 1 O
dose	1970 4 O
5	1975 1 B-Chemical
-	1976 1 I-Chemical
FU	1977 2 I-Chemical
/	1979 1 O
FA	1980 2 B-Chemical
/	1982 1 O
MMC	1983 3 B-Chemical
is	1987 2 O
an	1990 2 O
effective	1993 9 O
and	2003 3 O
well	2007 4 O
-	2011 1 O
tolerated	2012 9 O
outpatient	2022 10 O
regimen	2033 7 O
for	2041 3 O
AGC	2045 3 B-Disease
(	2049 1 O
objective	2050 9 O
response	2060 8 O
rate	2069 4 O
54	2074 2 O
.	2076 1 O
6	2077 1 O
%	2078 1 O
)	2079 1 O
.	2080 1 O

It	2082 2 O
may	2085 3 O
serve	2089 5 O
as	2095 2 O
an	2098 2 O
alternative	2101 11 O
to	2113 2 O
cisplatin	2116 9 B-Chemical
-	2125 1 O
containing	2126 10 O
regimens	2137 8 O
;	2145 1 O
however	2147 7 O
,	2154 1 O
it	2156 2 O
has	2159 3 O
to	2163 2 O
be	2166 2 O
considered	2169 10 O
that	2180 4 O
possibly	2185 8 O
HUS	2194 3 B-Disease
may	2198 3 O
occur	2202 5 O
.	2207 1 O

Persistent	0 10 O
sterile	11 7 O
leukocyturia	19 12 B-Disease
is	32 2 O
associated	35 10 O
with	46 4 O
impaired	51 8 B-Disease
renal	60 5 I-Disease
function	66 8 I-Disease
in	75 2 O
human	78 5 B-Disease
immunodeficiency	84 16 I-Disease
virus	101 5 I-Disease
type	107 4 I-Disease
1	112 1 I-Disease
-	113 1 I-Disease
infected	114 8 I-Disease
children	123 8 O
treated	132 7 O
with	140 4 O
indinavir	145 9 B-Chemical
.	154 1 O

BACKGROUND	156 10 O
:	166 1 O
Prolonged	168 9 O
administration	178 14 O
of	193 2 O
indinavir	196 9 B-Chemical
is	206 2 O
associated	209 10 O
with	220 4 O
the	225 3 O
occurrence	229 10 O
of	240 2 O
a	243 1 O
variety	245 7 O
of	253 2 O
renal	256 5 O
complications	262 13 O
in	276 2 O
adults	279 6 O
.	285 1 O

These	287 5 O
well	293 4 O
-	297 1 O
documented	298 10 O
side	309 4 O
effects	314 7 O
have	322 4 O
restricted	327 10 O
the	338 3 O
use	342 3 O
of	346 2 O
this	349 4 O
potent	354 6 O
protease	361 8 O
inhibitor	370 9 O
in	380 2 O
children	383 8 O
.	391 1 O

DESIGN	393 6 O
:	399 1 O
A	401 1 O
prospective	403 11 O
study	415 5 O
to	421 2 O
monitor	424 7 O
indinavir	432 9 B-Chemical
-	441 1 O
related	442 7 O
nephrotoxicity	450 14 B-Disease
in	465 2 O
a	468 1 O
cohort	470 6 O
of	477 2 O
30	480 2 O
human	483 5 B-Disease
immunodeficiency	489 16 I-Disease
virus	506 5 I-Disease
type	512 4 I-Disease
1	517 1 I-Disease
-	518 1 I-Disease
infected	519 8 I-Disease
children	528 8 O
treated	537 7 O
with	545 4 O
indinavir	550 9 B-Chemical
.	559 1 O

METHODS	561 7 O
:	568 1 O
Urinary	570 7 O
pH	578 2 O
,	580 1 O
albumin	582 7 O
,	589 1 O
creatinine	591 10 B-Chemical
,	601 1 O
the	603 3 O
presence	607 8 O
of	616 2 O
erythrocytes	619 12 O
,	631 1 O
leukocytes	633 10 O
,	643 1 O
bacteria	645 8 O
and	654 3 O
crystals	658 8 O
,	666 1 O
and	668 3 O
culture	672 7 O
were	680 4 O
analyzed	685 8 O
every	694 5 O
3	700 1 O
months	702 6 O
for	709 3 O
96	713 2 O
weeks	716 5 O
.	721 1 O

Serum	723 5 O
creatinine	729 10 B-Chemical
levels	740 6 O
were	747 4 O
routinely	752 9 O
determined	762 10 O
at	773 2 O
the	776 3 O
same	780 4 O
time	785 4 O
points	790 6 O
.	796 1 O

Steady	798 6 O
-	804 1 O
state	805 5 O
pharmacokinetics	811 16 O
of	828 2 O
indinavir	831 9 B-Chemical
were	841 4 O
done	846 4 O
at	851 2 O
week	854 4 O
4	859 1 O
after	861 5 O
the	867 3 O
initiation	871 10 O
of	882 2 O
indinavir	885 9 B-Chemical
.	894 1 O

RESULTS	896 7 O
:	903 1 O
The	905 3 O
cumulative	909 10 O
incidence	920 9 O
of	930 2 O
persistent	933 10 O
sterile	944 7 O
leukocyturia	952 12 B-Disease
(	965 1 O
>	966 1 O
or	968 2 O
=	971 1 O
75	972 2 O
cells	975 5 O
/	980 1 O
micro	982 5 O
L	988 1 O
in	990 2 O
at	993 2 O
least	996 5 O
2	1002 1 O
consecutive	1004 11 O
visits	1016 6 O
)	1022 1 O
after	1024 5 O
96	1030 2 O
weeks	1033 5 O
was	1039 3 O
53	1043 2 O
%	1045 1 O
.	1046 1 O

Persistent	1048 10 O
sterile	1059 7 O
leukocyturia	1067 12 B-Disease
was	1080 3 O
frequently	1084 10 O
associated	1095 10 O
with	1106 4 O
a	1111 1 O
mild	1113 4 O
increase	1118 8 O
in	1127 2 O
the	1130 3 O
urine	1134 5 O
albumin	1140 7 O
/	1147 1 O
creatinine	1148 10 B-Chemical
ratio	1159 5 O
and	1165 3 O
by	1169 2 O
microscopic	1172 11 O
hematuria	1184 9 B-Disease
.	1193 1 O

The	1195 3 O
cumulative	1199 10 O
incidence	1210 9 O
of	1220 2 O
serum	1223 5 O
creatinine	1229 10 B-Chemical
levels	1240 6 O
>	1247 1 O
50	1248 2 O
%	1250 1 O
above	1252 5 O
normal	1258 6 O
was	1265 3 O
33	1269 2 O
%	1271 1 O
after	1273 5 O
96	1279 2 O
weeks	1282 5 O
.	1287 1 O

Children	1289 8 O
with	1298 4 O
persistent	1303 10 O
sterile	1314 7 O
leukocyturia	1322 12 B-Disease
more	1335 4 O
frequently	1340 10 O
had	1351 3 O
serum	1355 5 O
creatinine	1361 10 B-Chemical
levels	1372 6 O
of	1379 2 O
50	1382 2 O
%	1384 1 O
above	1386 5 O
normal	1392 6 O
than	1399 4 O
those	1404 5 O
children	1410 8 O
without	1419 7 O
persistent	1427 10 O
sterile	1438 7 O
leukocyturia	1446 12 B-Disease
.	1458 1 O

In	1460 2 O
children	1463 8 O
younger	1472 7 O
than	1480 4 O
5	1485 1 O
.	1486 1 O
6	1487 1 O
years	1489 5 O
,	1494 1 O
persistent	1496 10 O
sterile	1507 7 O
leukocyturia	1515 12 B-Disease
was	1528 3 O
significantly	1532 13 O
more	1546 4 O
frequent	1551 8 O
than	1560 4 O
in	1565 2 O
older	1568 5 O
children	1574 8 O
.	1582 1 O

A	1584 1 O
higher	1586 6 O
cumulative	1593 10 O
incidence	1604 9 O
of	1614 2 O
persistent	1617 10 O
leukocyturia	1628 12 B-Disease
was	1641 3 O
found	1645 5 O
in	1651 2 O
children	1654 8 O
with	1663 4 O
an	1668 2 O
area	1671 4 O
under	1676 5 O
the	1682 3 O
curve	1686 5 O
>	1692 1 O
19	1693 2 O
mg	1696 2 O
/	1698 1 O
L	1699 1 O
x	1701 1 O
h	1703 1 O
or	1705 2 O
a	1708 1 O
peak	1710 4 O
serum	1715 5 O
level	1721 5 O
of	1727 2 O
indinavir	1730 9 B-Chemical
>	1740 1 O
12	1741 2 O
mg	1744 2 O
/	1746 1 O
L	1747 1 O
.	1748 1 O

In	1750 2 O
4	1753 1 O
children	1755 8 O
,	1763 1 O
indinavir	1765 9 B-Chemical
was	1775 3 O
discontinued	1779 12 O
because	1792 7 O
of	1800 2 O
nephrotoxicity	1803 14 B-Disease
.	1817 1 O

Subsequently	1819 12 O
,	1831 1 O
the	1833 3 O
serum	1837 5 O
creatinine	1843 10 B-Chemical
levels	1854 6 O
decreased	1861 9 O
,	1870 1 O
the	1872 3 O
urine	1876 5 O
albumin	1882 7 O
/	1889 1 O
creatinine	1890 10 B-Chemical
ratios	1901 6 O
returned	1908 8 O
to	1917 2 O
zero	1920 4 O
,	1924 1 O
and	1926 3 O
the	1930 3 O
leukocyturia	1934 12 B-Disease
disappeared	1947 11 O
within	1959 6 O
3	1966 1 O
months	1968 6 O
.	1974 1 O

CONCLUSIONS	1976 11 O
:	1987 1 O
Children	1989 8 O
treated	1998 7 O
with	2006 4 O
indinavir	2011 9 B-Chemical
have	2021 4 O
a	2026 1 O
high	2028 4 O
cumulative	2033 10 O
incidence	2044 9 O
of	2054 2 O
persistent	2057 10 O
sterile	2068 7 O
leukocyturia	2076 12 B-Disease
.	2088 1 O

Children	2090 8 O
with	2099 4 O
persistent	2104 10 O
sterile	2115 7 O
leukocyturia	2123 12 B-Disease
more	2136 4 O
frequently	2141 10 O
had	2152 3 O
an	2156 2 O
increase	2159 8 O
in	2168 2 O
serum	2171 5 O
creatinine	2177 10 B-Chemical
levels	2188 6 O
of	2195 2 O
>	2198 1 O
50	2199 2 O
%	2201 1 O
above	2203 5 O
normal	2209 6 O
.	2215 1 O

Younger	2217 7 O
children	2225 8 O
have	2234 4 O
an	2239 2 O
additional	2242 10 O
risk	2253 4 O
for	2258 3 O
renal	2262 5 O
complications	2268 13 O
.	2281 1 O

The	2283 3 O
impairment	2287 10 B-Disease
of	2298 2 I-Disease
the	2301 3 I-Disease
renal	2305 5 I-Disease
function	2311 8 I-Disease
in	2320 2 O
these	2323 5 O
children	2329 8 O
occurred	2338 8 O
in	2347 2 O
the	2350 3 O
absence	2354 7 O
of	2362 2 O
clinical	2365 8 O
symptoms	2374 8 O
of	2383 2 O
nephrolithiasis	2386 15 B-Disease
.	2401 1 O

Indinavir	2403 9 B-Chemical
-	2412 1 O
associated	2413 10 O
nephrotoxicity	2424 14 B-Disease
must	2439 4 O
be	2444 2 O
monitored	2447 9 O
closely	2457 7 O
,	2464 1 O
especially	2466 10 O
in	2477 2 O
children	2480 8 O
with	2489 4 O
risk	2494 4 O
factors	2499 7 O
such	2507 4 O
as	2512 2 O
persistent	2515 10 O
sterile	2526 7 O
leukocyturia	2534 12 B-Disease
,	2546 1 O
age	2548 3 O
<	2552 1 O
5	2553 1 O
.	2554 1 O
6	2555 1 O
years	2557 5 O
,	2562 1 O
an	2564 2 O
area	2567 4 O
under	2572 5 O
the	2578 3 O
curve	2582 5 O
of	2588 2 O
indinavir	2591 9 B-Chemical
>	2601 1 O
19	2602 2 O
mg	2605 2 O
/	2607 1 O
L	2608 1 O
x	2610 1 O
h	2612 1 O
,	2613 1 O
and	2615 3 O
a	2619 1 O
C	2621 1 O
(	2622 1 O
max	2623 3 O
)	2626 1 O
>	2628 1 O
12	2629 2 O
mg	2632 2 O
/	2634 1 O
L	2635 1 O
.	2636 1 O

Utility	0 7 O
of	8 2 O
troponin	11 8 O
I	20 1 O
in	22 2 O
patients	25 8 O
with	34 4 O
cocaine	39 7 B-Chemical
-	46 1 O
associated	47 10 O
chest	58 5 B-Disease
pain	64 4 I-Disease
.	68 1 O

Baseline	70 8 O
electrocardiogram	79 17 O
abnormalities	97 13 O
and	111 3 O
market	115 6 O
elevations	122 10 O
not	133 3 O
associated	137 10 O
with	148 4 O
myocardial	153 10 B-Disease
necrosis	164 8 I-Disease
make	173 4 O
accurate	178 8 O
diagnosis	187 9 O
of	197 2 O
myocardial	200 10 B-Disease
infarction	211 10 I-Disease
(	222 1 O
MI	223 2 B-Disease
)	225 1 O
difficult	227 9 O
in	237 2 O
patients	240 8 O
with	249 4 O
cocaine	254 7 B-Chemical
-	261 1 O
associated	262 10 O
chest	273 5 B-Disease
pain	279 4 I-Disease
.	283 1 O

Troponin	285 8 O
sampling	294 8 O
may	303 3 O
offer	307 5 O
greater	313 7 O
diagnostic	321 10 O
utility	332 7 O
in	340 2 O
these	343 5 O
patients	349 8 O
.	357 1 O

OBJECTIVE	359 9 O
:	368 1 O
To	370 2 O
assess	373 6 O
outcomes	380 8 O
based	389 5 O
on	395 2 O
troponin	398 8 O
positivity	407 10 O
in	418 2 O
patients	421 8 O
with	430 4 O
cocaine	435 7 B-Chemical
chest	443 5 B-Disease
pain	449 4 I-Disease
admitted	454 8 O
for	463 3 O
exclusion	467 9 O
of	477 2 O
MI	480 2 B-Disease
.	482 1 O

METHODS	484 7 O
:	491 1 O
Outcomes	493 8 O
were	502 4 O
examined	507 8 O
in	516 2 O
patients	519 8 O
admitted	528 8 O
for	537 3 O
possible	541 8 O
MI	550 2 B-Disease
after	553 5 O
cocaine	559 7 B-Chemical
use	567 3 O
.	570 1 O

All	572 3 O
patients	576 8 O
underwent	585 9 O
a	595 1 O
rapid	597 5 O
rule	603 4 O
-	607 1 O
in	608 2 O
protocol	611 8 O
that	620 4 O
included	625 8 O
serial	634 6 O
sampling	641 8 O
of	650 2 O
creatine	653 8 B-Chemical
kinase	662 6 O
(	669 1 O
CK	670 2 O
)	672 1 O
,	673 1 O
CK	675 2 O
-	677 1 O
MB	678 2 O
,	680 1 O
and	682 3 O
cardiac	686 7 O
troponin	694 8 O
I	703 1 O
(	705 1 O
cTnI	706 4 O
)	710 1 O
over	712 4 O
eight	717 5 O
hours	723 5 O
.	728 1 O

Outcomes	730 8 O
included	739 8 O
CK	748 2 O
-	750 1 O
MB	751 2 O
MI	754 2 B-Disease
(	757 1 O
CK	758 2 O
-	760 1 O
MB	761 2 O
>	764 1 O
or	765 2 O
=	767 1 O
8	769 1 O
ng	771 2 O
/	773 1 O
mL	774 2 O
with	777 4 O
a	782 1 O
relative	784 8 O
index	793 5 O
[	799 1 O
(	800 1 O
CK	801 2 O
-	803 1 O
MB	804 2 O
x	807 1 O
100	809 3 O
)	812 1 O
/	813 1 O
total	814 5 O
CK	820 2 O
]	822 1 O
>	824 1 O
or	825 2 O
=	827 1 O
4	829 1 O
,	830 1 O
cardiac	832 7 B-Disease
death	840 5 I-Disease
,	845 1 O
and	847 3 O
significant	851 11 O
coronary	863 8 B-Disease
disease	872 7 I-Disease
(	880 1 O
>	881 1 O
or	882 2 O
=	884 1 O
50	885 2 O
%	887 1 O
)	888 1 O
.	889 1 O

RESULTS	891 7 O
:	898 1 O
Of	900 2 O
the	903 3 O
246	907 3 O
admitted	911 8 O
patients	920 8 O
,	928 1 O
34	930 2 O
(	933 1 O
14	934 2 O
%	936 1 O
)	937 1 O
met	939 3 O
CK	943 2 O
-	945 1 O
MB	946 2 O
criteria	949 8 O
for	958 3 O
MI	962 2 B-Disease
and	965 3 O
38	969 2 O
(	972 1 O
16	973 2 O
%	975 1 O
)	976 1 O
had	978 3 O
cTnI	982 4 O
elevations	987 10 O
.	997 1 O

Angiography	999 11 O
was	1011 3 O
performed	1015 9 O
in	1025 2 O
29	1028 2 O
of	1031 2 O
38	1034 2 O
patients	1037 8 O
who	1046 3 O
were	1050 4 O
cTnI	1055 4 O
-	1059 1 O
positive	1060 8 O
,	1068 1 O
with	1070 4 O
significant	1075 11 O
disease	1087 7 O
present	1095 7 O
in	1103 2 O
25	1106 2 O
(	1109 1 O
86	1110 2 O
%	1112 1 O
)	1113 1 O
.	1114 1 O

Three	1116 5 O
of	1122 2 O
the	1125 3 O
four	1129 4 O
patients	1134 8 O
without	1143 7 O
significant	1151 11 O
disease	1163 7 O
who	1171 3 O
had	1175 3 O
cTnI	1179 4 O
elevations	1184 10 O
met	1195 3 O
CK	1199 2 O
-	1201 1 O
MB	1202 2 O
criteria	1205 8 O
for	1214 3 O
MI	1218 2 B-Disease
,	1220 1 O
and	1222 3 O
the	1226 3 O
other	1230 5 O
had	1236 3 O
a	1240 1 O
peak	1242 4 O
CK	1247 2 O
-	1249 1 O
MB	1250 2 O
level	1253 5 O
of	1259 2 O
13	1262 2 O
ng	1265 2 O
/	1267 1 O
mL	1268 2 O
.	1270 1 O

Sensitivities	1272 13 O
,	1285 1 O
specificities	1287 13 O
,	1300 1 O
and	1302 3 O
positive	1306 8 O
and	1315 3 O
negative	1319 8 O
likelihood	1328 10 O
ratios	1339 6 O
for	1346 3 O
predicting	1350 10 O
cardiac	1361 7 B-Disease
death	1369 5 I-Disease
or	1375 2 O
significant	1378 11 O
disease	1390 7 O
were	1398 4 O
high	1403 4 O
for	1408 3 O
both	1412 4 O
CK	1417 2 O
-	1419 1 O
MB	1420 2 O
MI	1423 2 B-Disease
and	1426 3 O
cTnI	1430 4 O
and	1435 3 O
were	1439 4 O
not	1444 3 O
significantly	1448 13 O
different	1462 9 O
.	1471 1 O

CONCLUSIONS	1473 11 O
:	1484 1 O
Most	1486 4 O
patients	1491 8 O
with	1500 4 O
cTnI	1505 4 O
elevations	1510 10 O
meet	1521 4 O
CK	1526 2 O
-	1528 1 O
MB	1529 2 O
criteria	1532 8 O
for	1541 3 O
MI	1545 2 B-Disease
,	1547 1 O
as	1549 2 O
well	1552 4 O
as	1557 2 O
have	1560 4 O
a	1565 1 O
high	1567 4 O
incidence	1572 9 O
of	1582 2 O
underlying	1585 10 O
significant	1596 11 O
disease	1608 7 O
.	1615 1 O

Troponin	1617 8 O
appears	1626 7 O
to	1634 2 O
have	1637 4 O
an	1642 2 O
equivalent	1645 10 O
diagnostic	1656 10 O
accuracy	1667 8 O
compared	1676 8 O
with	1685 4 O
CK	1690 2 O
-	1692 1 O
MB	1693 2 O
for	1696 3 O
diagnosing	1700 10 O
necrosis	1711 8 B-Disease
in	1720 2 O
patients	1723 8 O
with	1732 4 O
cocaine	1737 7 B-Chemical
-	1744 1 O
associated	1745 10 O
chest	1756 5 B-Disease
pain	1762 4 I-Disease
and	1767 3 O
suspected	1771 9 O
MI	1781 2 B-Disease
.	1783 1 O

Acute	0 5 O
interstitial	6 12 B-Disease
nephritis	19 9 I-Disease
due	29 3 O
to	33 2 O
nicergoline	36 11 B-Chemical
(	48 1 O
Sermion	49 7 B-Chemical
)	56 1 O
.	57 1 O

We	59 2 O
report	62 6 O
a	69 1 O
case	71 4 O
of	76 2 O
acute	79 5 O
interstitial	85 12 B-Disease
nephritis	98 9 I-Disease
(	108 1 O
AIN	109 3 B-Disease
)	112 1 O
due	114 3 O
to	118 2 O
nicergoline	121 11 B-Chemical
(	133 1 O
Sermion	134 7 B-Chemical
)	141 1 O
.	142 1 O

A	144 1 O
50	146 2 O
-	148 1 O
year	149 4 O
-	153 1 O
old	154 3 O
patient	158 7 O
admitted	166 8 O
to	175 2 O
our	178 3 O
hospital	182 8 O
for	191 3 O
fever	195 5 B-Disease
and	201 3 O
acute	205 5 B-Disease
renal	211 5 I-Disease
failure	217 7 I-Disease
.	224 1 O

Before	226 6 O
admission	233 9 O
,	242 1 O
he	244 2 O
had	247 3 O
been	251 4 O
taking	256 6 O
nicergoline	263 11 B-Chemical
and	275 3 O
bendazac	279 8 B-Chemical
lysine	288 6 I-Chemical
due	295 3 O
to	299 2 O
retinal	302 7 B-Disease
vein	310 4 I-Disease
occlusion	315 9 I-Disease
at	325 2 O
ophthalmologic	328 14 O
department	343 10 O
.	353 1 O

Thereafter	355 10 O
,	365 1 O
he	367 2 O
experienced	370 11 O
intermittent	382 12 O
fever	395 5 B-Disease
and	401 3 O
skin	405 4 B-Disease
rash	410 4 I-Disease
.	414 1 O

On	416 2 O
admission	419 9 O
,	428 1 O
clinical	430 8 O
symptoms	439 8 O
(	448 1 O
i	449 1 O
.	450 1 O
e	451 1 O
.	452 1 O
arthralgia	454 10 B-Disease
and	465 3 O
fever	469 5 B-Disease
)	474 1 O
and	476 3 O
laboratory	480 10 O
findings	491 8 O
(	500 1 O
i	501 1 O
.	502 1 O
e	503 1 O
.	504 1 O
eosinophilia	506 12 B-Disease
and	519 3 O
renal	523 5 B-Disease
failure	529 7 I-Disease
)	536 1 O
suggested	538 9 O
AIN	548 3 B-Disease
,	551 1 O
and	553 3 O
which	557 5 O
was	563 3 O
confirmed	567 9 O
by	577 2 O
pathologic	580 10 O
findings	591 8 O
on	600 2 O
renal	603 5 O
biopsy	609 6 O
.	615 1 O

A	617 1 O
lymphocyte	619 10 O
transformation	630 14 O
test	645 4 O
demonstrated	650 12 O
a	663 1 O
positive	665 8 O
result	674 6 O
against	681 7 O
nicergoline	689 11 B-Chemical
.	700 1 O

Treatment	702 9 O
was	712 3 O
consisted	716 9 O
of	726 2 O
withdrawal	729 10 O
of	740 2 O
nicergoline	743 11 B-Chemical
and	755 3 O
intravenous	759 11 O
methylprednisolone	771 18 B-Chemical
,	789 1 O
and	791 3 O
his	795 3 O
renal	799 5 O
function	805 8 O
was	814 3 O
completely	818 10 O
recovered	829 9 O
.	838 1 O

To	840 2 O
our	843 3 O
knowledge	847 9 O
,	856 1 O
this	858 4 O
is	863 2 O
the	866 3 O
first	870 5 O
report	876 6 O
of	883 2 O
nicergoline	886 11 B-Chemical
-	897 1 O
associated	898 10 O
AIN	909 3 B-Disease
.	912 1 O

Neuroleptic	0 11 B-Disease
malignant	12 9 I-Disease
syndrome	22 8 I-Disease
complicated	31 11 O
by	43 2 O
massive	46 7 O
intestinal	54 10 O
bleeding	65 8 B-Disease
in	74 2 O
a	77 1 O
patient	79 7 O
with	87 4 O
chronic	92 7 B-Disease
renal	100 5 I-Disease
failure	106 7 I-Disease
.	113 1 O

A	115 1 O
patient	117 7 O
with	125 4 O
chronic	130 7 B-Disease
renal	138 5 I-Disease
failure	144 7 I-Disease
(	152 1 O
CRF	153 3 B-Disease
)	156 1 O
developed	158 9 O
neuroleptic	168 11 B-Disease
malignant	180 9 I-Disease
syndrome	190 8 I-Disease
(	199 1 O
NMS	200 3 B-Disease
)	203 1 O
after	205 5 O
administration	211 14 O
of	226 2 O
risperidone	229 11 B-Chemical
and	241 3 O
levomepromazine	245 15 B-Chemical
.	260 1 O

In	262 2 O
addition	265 8 O
to	274 2 O
the	277 3 O
typical	281 7 O
symptoms	289 8 O
of	298 2 O
NMS	301 3 B-Disease
,	304 1 O
massive	306 7 O
intestinal	314 10 O
bleeding	325 8 B-Disease
was	334 3 O
observed	338 8 O
during	347 6 O
the	354 3 O
episode	358 7 O
.	365 1 O

This	367 4 O
report	372 6 O
suggests	379 8 O
that	388 4 O
NMS	393 3 B-Disease
in	397 2 O
a	400 1 O
patient	402 7 O
with	410 4 O
CRF	415 3 B-Disease
may	419 3 O
be	423 2 O
complicated	426 11 O
by	438 2 O
intestinal	441 10 O
bleeding	452 8 B-Disease
and	461 3 O
needs	465 5 O
special	471 7 O
caution	479 7 O
for	487 3 O
this	491 4 O
complication	496 12 O
.	508 1 O

Blood	0 5 O
brain	6 5 O
barrier	12 7 O
in	20 2 O
right	23 5 O
-	28 1 O
and	30 3 O
left	34 4 O
-	38 1 O
pawed	39 5 O
female	45 6 O
rats	52 4 O
assessed	57 8 O
by	66 2 O
a	69 1 O
new	71 3 O
staining	75 8 O
method	84 6 O
.	90 1 O

The	92 3 O
asymmetrical	96 12 O
breakdown	109 9 O
of	119 2 O
the	122 3 O
blood	126 5 O
-	131 1 O
brain	132 5 O
barrier	138 7 O
(	146 1 O
BBB	147 3 O
)	150 1 O
was	152 3 O
studied	156 7 O
in	164 2 O
female	167 6 O
rats	174 4 O
.	178 1 O

Paw	180 3 O
preference	184 10 O
was	195 3 O
assessed	199 8 O
by	208 2 O
a	211 1 O
food	213 4 O
reaching	218 8 O
test	227 4 O
.	231 1 O

Adrenaline	233 10 B-Chemical
-	243 1 O
induced	244 7 O
hypertension	252 12 B-Disease
was	265 3 O
used	269 4 O
to	274 2 O
destroy	277 7 O
the	285 3 O
BBB	289 3 O
,	292 1 O
which	294 5 O
was	300 3 O
evaluated	304 9 O
using	314 5 O
triphenyltetrazolium	320 20 B-Chemical
(	341 1 O
TTC	342 3 B-Chemical
)	345 1 O
staining	347 8 O
of	356 2 O
the	359 3 O
brain	363 5 O
slices	369 6 O
just	376 4 O
after	381 5 O
giving	387 6 O
adrenaline	394 10 B-Chemical
for	405 3 O
30	409 2 O
s	412 1 O
.	413 1 O

In	415 2 O
normal	418 6 O
rats	425 4 O
,	429 1 O
the	431 3 O
whole	435 5 O
brain	441 5 O
sections	447 8 O
exhibited	456 9 O
complete	466 8 O
staining	475 8 O
with	484 4 O
TTC	489 3 B-Chemical
.	492 1 O

After	494 5 O
adrenaline	500 10 B-Chemical
infusion	511 8 O
for	520 3 O
30	524 2 O
s	527 1 O
,	528 1 O
there	530 5 O
were	536 4 O
large	541 5 O
unstained	547 9 O
areas	557 5 O
in	563 2 O
the	566 3 O
left	570 4 O
brain	575 5 O
in	581 2 O
right	584 5 O
-	589 1 O
pawed	590 5 O
animals	596 7 O
,	603 1 O
and	605 3 O
vice	609 4 O
versa	614 5 O
in	620 2 O
left	623 4 O
-	627 1 O
pawed	628 5 O
animals	634 7 O
.	641 1 O

Similar	643 7 O
results	651 7 O
were	659 4 O
obtained	664 8 O
in	673 2 O
seizure	676 7 B-Disease
-	683 1 O
induced	684 7 O
breakdown	692 9 O
of	702 2 O
BBB	705 3 O
.	708 1 O

These	710 5 O
results	716 7 O
were	724 4 O
explained	729 9 O
by	739 2 O
an	742 2 O
asymmetric	745 10 O
cerebral	756 8 O
blood	765 5 O
flow	771 4 O
depending	776 9 O
upon	786 4 O
the	791 3 O
paw	795 3 O
preference	799 10 O
in	810 2 O
rats	813 4 O
.	817 1 O

It	819 2 O
was	822 3 O
suggested	826 9 O
that	836 4 O
this	841 4 O
new	846 3 O
method	850 6 O
and	857 3 O
the	861 3 O
results	865 7 O
are	873 3 O
consistent	877 10 O
with	888 4 O
contralateral	893 13 O
motor	907 5 O
control	913 7 O
that	921 4 O
may	926 3 O
be	930 2 O
important	933 9 O
in	943 2 O
determining	946 11 O
the	958 3 O
dominant	962 8 O
cerebral	971 8 O
hemisphere	980 10 O
in	991 2 O
animals	994 7 O
.	1001 1 O

Carvedilol	0 10 B-Chemical
protects	11 8 O
against	20 7 O
doxorubicin	28 11 B-Chemical
-	39 1 O
induced	40 7 O
mitochondrial	48 13 O
cardiomyopathy	62 14 B-Disease
.	76 1 O

Several	78 7 O
cytopathic	86 10 O
mechanisms	97 10 O
have	108 4 O
been	113 4 O
suggested	118 9 O
to	128 2 O
mediate	131 7 O
the	139 3 O
dose	143 4 O
-	147 1 O
limiting	148 8 O
cumulative	157 10 O
and	168 3 O
irreversible	172 12 O
cardiomyopathy	185 14 B-Disease
caused	200 6 O
by	207 2 O
doxorubicin	210 11 B-Chemical
.	221 1 O

Recent	223 6 O
evidence	230 8 O
indicates	239 9 O
that	249 4 O
oxidative	254 9 O
stress	264 6 O
and	271 3 O
mitochondrial	275 13 B-Disease
dysfunction	289 11 I-Disease
are	301 3 O
key	305 3 O
factors	309 7 O
in	317 2 O
the	320 3 O
pathogenic	324 10 O
process	335 7 O
.	342 1 O

The	344 3 O
objective	348 9 O
of	358 2 O
this	361 4 O
investigation	366 13 O
was	380 3 O
to	384 2 O
test	387 4 O
the	392 3 O
hypothesis	396 10 O
that	407 4 O
carvedilol	412 10 B-Chemical
,	422 1 O
a	424 1 O
nonselective	426 12 O
beta	439 4 O
-	443 1 O
adrenergic	444 10 O
receptor	455 8 O
antagonist	464 10 O
with	475 4 O
potent	480 6 O
antioxidant	487 11 O
properties	499 10 O
,	509 1 O
protects	511 8 O
against	520 7 O
the	528 3 O
cardiac	532 7 O
and	540 3 O
hepatic	544 7 O
mitochondrial	552 13 O
bioenergetic	566 12 O
dysfunction	579 11 O
associated	591 10 O
with	602 4 O
subchronic	607 10 O
doxorubicin	618 11 B-Chemical
toxicity	630 8 B-Disease
.	638 1 O

Heart	640 5 O
and	646 3 O
liver	650 5 O
mitochondria	656 12 O
were	669 4 O
isolated	674 8 O
from	683 4 O
rats	688 4 O
treated	693 7 O
for	701 3 O
7	705 1 O
weeks	707 5 O
with	713 4 O
doxorubicin	718 11 B-Chemical
(	730 1 O
2	731 1 O
mg	733 2 O
/	735 1 O
kg	736 2 O
sc	739 2 O
/	741 1 O
week	742 4 O
)	746 1 O
,	747 1 O
carvedilol	749 10 B-Chemical
(	760 1 O
1	761 1 O
mg	763 2 O
/	765 1 O
kg	766 2 O
ip	769 2 O
/	771 1 O
week	772 4 O
)	776 1 O
,	777 1 O
or	779 2 O
the	782 3 O
combination	786 11 O
of	798 2 O
the	801 3 O
two	805 3 O
drugs	809 5 O
.	814 1 O

Heart	816 5 O
mitochondria	822 12 O
isolated	835 8 O
from	844 4 O
doxorubicin	849 11 B-Chemical
-	860 1 O
treated	861 7 O
rats	869 4 O
exhibited	874 9 O
depressed	884 9 O
rates	894 5 O
for	900 3 O
state	904 5 O
3	910 1 O
respiration	912 11 O
(	924 1 O
336	925 3 O
+	929 1 O
/	930 1 O
-	931 1 O
26	933 2 O
versus	936 6 O
425	943 3 O
+	947 1 O
/	948 1 O
-	949 1 O
53	951 2 O
natom	954 5 O
O	960 1 O
/	961 1 O
min	962 3 O
/	965 1 O
mg	966 2 O
protein	969 7 O
)	976 1 O
and	978 3 O
a	982 1 O
lower	984 5 O
respiratory	990 11 O
control	1002 7 O
ratio	1010 5 O
(	1016 1 O
RCR	1017 3 O
)	1020 1 O
(	1022 1 O
4	1023 1 O
.	1024 1 O
3	1025 1 O
+	1027 1 O
/	1028 1 O
-	1029 1 O
0	1031 1 O
.	1032 1 O
6	1033 1 O
versus	1035 6 O
5	1042 1 O
.	1043 1 O
8	1044 1 O
+	1046 1 O
/	1047 1 O
-	1048 1 O
0	1050 1 O
.	1051 1 O
4	1052 1 O
)	1053 1 O
compared	1055 8 O
with	1064 4 O
cardiac	1069 7 O
mitochondria	1077 12 O
isolated	1090 8 O
from	1099 4 O
saline	1104 6 O
-	1110 1 O
treated	1111 7 O
rats	1119 4 O
.	1123 1 O

Mitochondrial	1125 13 O
calcium	1139 7 B-Chemical
-	1146 1 O
loading	1147 7 O
capacity	1155 8 O
and	1164 3 O
the	1168 3 O
activity	1172 8 O
of	1181 2 O
NADH	1184 4 O
-	1188 1 O
dehydrogenase	1189 13 O
were	1203 4 O
also	1208 4 O
suppressed	1213 10 O
in	1224 2 O
cardiac	1227 7 O
mitochondria	1235 12 O
from	1248 4 O
doxorubicin	1253 11 B-Chemical
-	1264 1 O
treated	1265 7 O
rats	1273 4 O
.	1277 1 O

Doxorubicin	1279 11 B-Chemical
treatment	1291 9 O
also	1301 4 O
caused	1306 6 O
a	1313 1 O
decrease	1315 8 O
in	1324 2 O
RCR	1327 3 O
for	1331 3 O
liver	1335 5 O
mitochondria	1341 12 O
(	1354 1 O
3	1355 1 O
.	1356 1 O
9	1357 1 O
+	1359 1 O
/	1360 1 O
-	1361 1 O
0	1363 1 O
.	1364 1 O
9	1365 1 O
versus	1367 6 O
5	1374 1 O
.	1375 1 O
6	1376 1 O
+	1378 1 O
/	1379 1 O
-	1380 1 O
0	1382 1 O
.	1383 1 O
7	1384 1 O
for	1386 3 O
control	1390 7 O
rats	1398 4 O
)	1402 1 O
and	1404 3 O
inhibition	1408 10 O
of	1419 2 O
hepatic	1422 7 O
cytochrome	1430 10 O
oxidase	1441 7 O
activity	1449 8 O
.	1457 1 O

Coadministration	1459 16 O
of	1476 2 O
carvedilol	1479 10 B-Chemical
decreased	1490 9 O
the	1500 3 O
extent	1504 6 O
of	1511 2 O
cellular	1514 8 O
vacuolization	1523 13 O
in	1537 2 O
cardiac	1540 7 O
myocytes	1548 8 O
and	1557 3 O
prevented	1561 9 O
the	1571 3 O
inhibitory	1575 10 O
effect	1586 6 O
of	1593 2 O
doxorubicin	1596 11 B-Chemical
on	1608 2 O
mitochondrial	1611 13 O
respiration	1625 11 O
in	1637 2 O
both	1640 4 O
heart	1645 5 O
and	1651 3 O
liver	1655 5 O
.	1660 1 O

Carvedilol	1662 10 B-Chemical
also	1673 4 O
prevented	1678 9 O
the	1688 3 O
decrease	1692 8 O
in	1701 2 O
mitochondrial	1704 13 O
Ca	1718 2 B-Chemical
(	1720 1 O
2	1721 1 O
+	1722 1 O
)	1723 1 O
loading	1725 7 O
capacity	1733 8 O
and	1742 3 O
the	1746 3 O
inhibition	1750 10 O
of	1761 2 O
the	1764 3 O
respiratory	1768 11 O
complexes	1780 9 O
of	1790 2 O
heart	1793 5 O
mitochondria	1799 12 O
caused	1812 6 O
by	1819 2 O
doxorubicin	1822 11 B-Chemical
.	1833 1 O

Carvedilol	1835 10 B-Chemical
by	1846 2 O
itself	1849 6 O
did	1856 3 O
not	1860 3 O
affect	1864 6 O
any	1871 3 O
of	1875 2 O
the	1878 3 O
parameters	1882 10 O
measured	1893 8 O
for	1902 3 O
heart	1906 5 O
or	1912 2 O
liver	1915 5 O
mitochondria	1921 12 O
.	1933 1 O

It	1935 2 O
is	1938 2 O
concluded	1941 9 O
that	1951 4 O
this	1956 4 O
protection	1961 10 O
by	1972 2 O
carvedilol	1975 10 B-Chemical
against	1986 7 O
both	1994 4 O
the	1999 3 O
structural	2003 10 O
and	2014 3 O
functional	2018 10 O
cardiac	2029 7 O
tissue	2037 6 O
damage	2044 6 O
may	2051 3 O
afford	2055 6 O
significant	2062 11 O
clinical	2074 8 O
advantage	2083 9 O
in	2093 2 O
minimizing	2096 10 O
the	2107 3 O
dose	2111 4 O
-	2115 1 O
limiting	2116 8 O
mitochondrial	2125 13 B-Disease
dysfunction	2139 11 I-Disease
and	2151 3 O
cardiomyopathy	2155 14 B-Disease
that	2170 4 O
accompanies	2175 11 O
long	2187 4 O
-	2191 1 O
term	2192 4 O
doxorubicin	2197 11 B-Chemical
therapy	2209 7 O
in	2217 2 O
cancer	2220 6 B-Disease
patients	2227 8 O
.	2235 1 O

Cocaine	0 7 B-Chemical
-	7 1 O
induced	8 7 O
hyperactivity	16 13 B-Disease
is	30 2 O
more	33 4 O
influenced	38 10 O
by	49 2 O
adenosine	52 9 B-Chemical
receptor	62 8 O
agonists	71 8 O
than	80 4 O
amphetamine	85 11 B-Chemical
-	96 1 O
induced	97 7 O
hyperactivity	105 13 B-Disease
.	118 1 O

The	120 3 O
influence	124 9 O
of	134 2 O
adenosine	137 9 B-Chemical
receptor	147 8 O
agonists	156 8 O
and	165 3 O
antagonists	169 11 O
on	181 2 O
cocaine	184 7 B-Chemical
-	191 1 O
and	192 3 O
amphetamine	196 11 B-Chemical
-	207 1 O
induced	208 7 O
hyperactivity	216 13 B-Disease
was	230 3 O
examined	234 8 O
in	243 2 O
mice	246 4 O
.	250 1 O

All	252 3 O
adenosine	256 9 B-Chemical
receptor	266 8 O
agonists	275 8 O
significantly	284 13 O
decreased	298 9 B-Disease
the	308 3 I-Disease
locomotor	312 9 I-Disease
activity	322 8 I-Disease
in	331 2 O
mice	334 4 O
,	338 1 O
and	340 3 O
the	344 3 O
effects	348 7 O
were	356 4 O
dose	361 4 O
-	365 1 O
dependent	366 9 O
.	375 1 O

It	377 2 O
seems	380 5 O
that	386 4 O
adenosine	391 9 B-Chemical
A1	401 2 O
and	404 3 O
A2	408 2 O
receptors	411 9 O
might	421 5 O
be	427 2 O
involved	430 8 O
in	439 2 O
this	442 4 O
reaction	447 8 O
.	455 1 O

Moreover	457 8 O
,	465 1 O
all	467 3 O
adenosine	471 9 B-Chemical
receptor	481 8 O
agonists	490 8 O
:	498 1 O
2	500 1 B-Chemical
-	501 1 I-Chemical
p	502 1 I-Chemical
-	503 1 I-Chemical
(	504 1 I-Chemical
2	505 1 I-Chemical
-	506 1 I-Chemical
carboxyethyl	507 12 I-Chemical
)	519 1 I-Chemical
phenethylamino	520 14 I-Chemical
-	534 1 I-Chemical
5	535 1 I-Chemical
'	536 1 I-Chemical
-	537 1 I-Chemical
N	538 1 I-Chemical
-	539 1 I-Chemical
ethylcarboxamidoadenosine	540 25 I-Chemical
(	566 1 O
CGS	567 3 B-Chemical
21680	571 5 I-Chemical
)	576 1 O
,	577 1 O
A2A	579 3 O
receptor	583 8 O
agonist	592 7 O
,	599 1 O
N6	601 2 B-Chemical
-	603 1 I-Chemical
cyclopentyladenosine	604 20 I-Chemical
(	625 1 O
CPA	626 3 B-Chemical
)	629 1 O
,	630 1 O
A1	632 2 O
receptor	635 8 O
agonist	644 7 O
,	651 1 O
and	653 3 O
5	657 1 B-Chemical
'	658 1 I-Chemical
-	659 1 I-Chemical
N	660 1 I-Chemical
-	661 1 I-Chemical
ethylcarboxamidoadenosine	662 25 I-Chemical
(	688 1 O
NECA	689 4 B-Chemical
)	693 1 O
,	694 1 O
A2	696 2 O
/	698 1 O
A1	699 2 O
receptor	702 8 O
agonist	711 7 O
significantly	719 13 O
and	733 3 O
dose	737 4 O
-	741 1 O
dependently	742 11 O
decreased	754 9 O
cocaine	764 7 B-Chemical
-	771 1 O
induced	772 7 O
locomotor	780 9 O
activity	790 8 O
.	798 1 O

CPA	800 3 B-Chemical
reduced	804 7 O
cocaine	812 7 B-Chemical
action	820 6 O
at	827 2 O
the	830 3 O
doses	834 5 O
which	840 5 O
,	845 1 O
given	847 5 O
alone	853 5 O
,	858 1 O
did	860 3 O
not	864 3 O
influence	868 9 O
motility	878 8 O
,	886 1 O
while	888 5 O
CGS	894 3 B-Chemical
21680	898 5 I-Chemical
and	904 3 O
NECA	908 4 B-Chemical
decreased	913 9 O
the	923 3 O
action	927 6 O
of	934 2 O
cocaine	937 7 B-Chemical
at	945 2 O
the	948 3 O
doses	952 5 O
which	958 5 O
,	963 1 O
given	965 5 O
alone	971 5 O
,	976 1 O
decreased	978 9 O
locomotor	988 9 O
activity	998 8 O
in	1007 2 O
animals	1010 7 O
.	1017 1 O

These	1019 5 O
results	1025 7 O
suggest	1033 7 O
the	1041 3 O
involvement	1045 11 O
of	1057 2 O
both	1060 4 O
adenosine	1065 9 B-Chemical
receptors	1075 9 O
in	1085 2 O
the	1088 3 O
action	1092 6 O
of	1099 2 O
cocaine	1102 7 B-Chemical
although	1110 8 O
agonists	1119 8 O
of	1128 2 O
A1	1131 2 O
receptors	1134 9 O
seem	1144 4 O
to	1149 2 O
have	1152 4 O
stronger	1157 8 O
influence	1166 9 O
on	1176 2 O
it	1179 2 O
.	1181 1 O

The	1183 3 O
selective	1187 9 O
blockade	1197 8 O
of	1206 2 O
A2	1209 2 O
adenosine	1212 9 B-Chemical
receptor	1222 8 O
by	1231 2 O
DMPX	1234 4 B-Chemical
(	1239 1 O
3	1240 1 B-Chemical
,	1241 1 I-Chemical
7	1242 1 I-Chemical
-	1243 1 I-Chemical
dimethyl	1244 8 I-Chemical
-	1252 1 I-Chemical
1	1253 1 I-Chemical
-	1254 1 I-Chemical
propargylxanthine	1255 17 I-Chemical
)	1272 1 O
significantly	1274 13 O
enhanced	1288 8 O
cocaine	1297 7 B-Chemical
-	1304 1 O
induced	1305 7 O
locomotor	1313 9 O
activity	1323 8 O
of	1332 2 O
animals	1335 7 O
.	1342 1 O

Caffeine	1344 8 B-Chemical
had	1353 3 O
similar	1357 7 O
action	1365 6 O
but	1372 3 O
the	1376 3 O
effect	1380 6 O
was	1387 3 O
not	1391 3 O
significant	1395 11 O
.	1406 1 O

CPT	1408 3 B-Chemical
(	1412 1 O
8	1413 1 B-Chemical
-	1414 1 I-Chemical
cyclopentyltheophylline	1415 23 I-Chemical
)	1438 1 O
-	1439 1 O
-	1440 1 O
A1	1441 2 O
receptor	1444 8 O
antagonist	1453 10 O
,	1463 1 O
did	1465 3 O
not	1469 3 O
show	1473 4 O
any	1478 3 O
influence	1482 9 O
in	1492 2 O
this	1495 4 O
test	1500 4 O
.	1504 1 O

Similarly	1506 9 O
,	1515 1 O
all	1517 3 O
adenosine	1521 9 B-Chemical
receptor	1531 8 O
agonists	1540 8 O
decreased	1549 9 O
amphetamine	1559 11 B-Chemical
-	1570 1 O
induced	1571 7 O
hyperactivity	1579 13 B-Disease
,	1592 1 O
but	1594 3 O
at	1598 2 O
the	1601 3 O
higher	1605 6 O
doses	1612 5 O
than	1618 4 O
those	1623 5 O
which	1629 5 O
were	1635 4 O
active	1640 6 O
in	1647 2 O
cocaine	1650 7 B-Chemical
-	1657 1 O
induced	1658 7 O
hyperactivity	1666 13 B-Disease
.	1679 1 O

The	1681 3 O
selective	1685 9 O
blockade	1695 8 O
of	1704 2 O
A2	1707 2 O
adenosine	1710 9 B-Chemical
receptors	1720 9 O
(	1730 1 O
DMPX	1731 4 B-Chemical
)	1735 1 O
and	1737 3 O
non	1741 3 O
-	1744 1 O
selective	1745 9 O
blockade	1755 8 O
of	1764 2 O
adenosine	1767 9 B-Chemical
receptors	1777 9 O
(	1787 1 O
caffeine	1788 8 B-Chemical
)	1796 1 O
significantly	1798 13 O
increased	1812 9 O
the	1822 3 O
action	1826 6 O
of	1833 2 O
amphetamine	1836 11 B-Chemical
in	1848 2 O
the	1851 3 O
locomotor	1855 9 O
activity	1865 8 O
test	1874 4 O
.	1878 1 O

Our	1880 3 O
results	1884 7 O
have	1892 4 O
shown	1897 5 O
that	1903 4 O
all	1908 3 O
adenosine	1912 9 B-Chemical
receptor	1922 8 O
agonists	1931 8 O
(	1940 1 O
A1	1941 2 O
and	1944 3 O
A2	1948 2 O
)	1950 1 O
reduce	1952 6 O
cocaine	1959 7 B-Chemical
-	1966 1 O
and	1968 3 O
amphetamine	1972 11 B-Chemical
-	1983 1 O
induced	1984 7 O
locomotor	1992 9 O
activity	2002 8 O
and	2011 3 O
indicate	2015 8 O
that	2024 4 O
cocaine	2029 7 B-Chemical
-	2036 1 O
induced	2037 7 O
hyperactivity	2045 13 B-Disease
is	2059 2 O
more	2062 4 O
influenced	2067 10 O
by	2078 2 O
adenosine	2081 9 B-Chemical
receptor	2091 8 O
agonists	2100 8 O
(	2109 1 O
particularly	2110 12 O
A1	2123 2 O
receptors	2126 9 O
)	2135 1 O
than	2137 4 O
amphetamine	2142 11 B-Chemical
-	2153 1 O
induced	2154 7 O
hyperactivity	2162 13 B-Disease
.	2175 1 O

Amiodarone	0 10 B-Chemical
and	11 3 O
the	15 3 O
risk	19 4 O
of	24 2 O
bradyarrhythmia	27 15 B-Disease
requiring	43 9 O
permanent	53 9 O
pacemaker	63 9 O
in	73 2 O
elderly	76 7 O
patients	84 8 O
with	93 4 O
atrial	98 6 B-Disease
fibrillation	105 12 I-Disease
and	118 3 O
prior	122 5 O
myocardial	128 10 B-Disease
infarction	139 10 I-Disease
.	149 1 O

OBJECTIVES	151 10 O
:	161 1 O
The	163 3 O
aim	167 3 O
of	171 2 O
this	174 4 O
study	179 5 O
was	185 3 O
to	189 2 O
determine	192 9 O
whether	202 7 O
the	210 3 O
use	214 3 O
of	218 2 O
amiodarone	221 10 B-Chemical
in	232 2 O
patients	235 8 O
with	244 4 O
atrial	249 6 B-Disease
fibrillation	256 12 I-Disease
(	269 1 O
AF	270 2 B-Disease
)	272 1 O
increases	274 9 O
the	284 3 O
risk	288 4 O
of	293 2 O
bradyarrhythmia	296 15 B-Disease
requiring	312 9 O
a	322 1 O
permanent	324 9 O
pacemaker	334 9 O
.	343 1 O

BACKGROUND	345 10 O
:	355 1 O
Reports	357 7 O
of	365 2 O
severe	368 6 O
bradyarrhythmia	375 15 B-Disease
during	391 6 O
amiodarone	398 10 B-Chemical
therapy	409 7 O
are	417 3 O
infrequent	421 10 O
and	432 3 O
limited	436 7 O
to	444 2 O
studies	447 7 O
assessing	455 9 O
the	465 3 O
therapy	469 7 O
'	476 1 O
s	477 1 O
use	479 3 O
in	483 2 O
the	486 3 O
management	490 10 O
of	501 2 O
patients	504 8 O
with	513 4 O
ventricular	518 11 B-Disease
arrhythmias	530 11 I-Disease
.	541 1 O

METHODS	543 7 O
:	550 1 O
A	552 1 O
study	554 5 O
cohort	560 6 O
of	567 2 O
8	570 1 O
,	571 1 O
770	572 3 O
patients	576 8 O
age	585 3 O
>	589 1 O
or	591 2 O
=	594 1 O
65	595 2 O
years	598 5 O
with	604 4 O
a	609 1 O
new	611 3 O
diagnosis	615 9 O
of	625 2 O
AF	628 2 B-Disease
was	631 3 O
identified	635 10 O
from	646 4 O
a	651 1 O
provincewide	653 12 O
database	666 8 O
of	675 2 O
Quebec	678 6 O
residents	685 9 O
with	695 4 O
a	700 1 O
myocardial	702 10 B-Disease
infarction	713 10 I-Disease
(	724 1 O
MI	725 2 B-Disease
)	727 1 O
between	729 7 O
1991	737 4 O
and	742 3 O
1999	746 4 O
.	750 1 O

Using	752 5 O
a	758 1 O
nested	760 6 O
case	767 4 O
-	771 1 O
control	772 7 O
design	780 6 O
,	786 1 O
477	788 3 O
cases	792 5 O
of	798 2 O
bradyarrhythmia	801 15 B-Disease
requiring	817 9 O
a	827 1 O
permanent	829 9 O
pacemaker	839 9 O
were	849 4 O
matched	854 7 O
(	862 1 O
1	863 1 O
:	864 1 O
4	865 1 O
)	866 1 O
to	868 2 O
1	871 1 O
,	872 1 O
908	873 3 O
controls	877 8 O
.	885 1 O

Multivariable	887 13 O
logistic	901 8 O
regression	910 10 O
was	921 3 O
used	925 4 O
to	930 2 O
estimate	933 8 O
the	942 3 O
odds	946 4 O
ratio	951 5 O
(	957 1 O
OR	958 2 O
)	960 1 O
of	962 2 O
pacemaker	965 9 O
insertion	975 9 O
associated	985 10 O
with	996 4 O
amiodarone	1001 10 B-Chemical
use	1012 3 O
,	1015 1 O
controlling	1017 11 O
for	1029 3 O
baseline	1033 8 O
risk	1042 4 O
factors	1047 7 O
and	1055 3 O
exposure	1059 8 O
to	1068 2 O
sotalol	1071 7 B-Chemical
,	1078 1 O
Class	1080 5 O
I	1086 1 O
antiarrhythmic	1088 14 O
agents	1103 6 O
,	1109 1 O
beta	1111 4 O
-	1115 1 O
blockers	1116 8 O
,	1124 1 O
calcium	1126 7 B-Chemical
channel	1134 7 O
blockers	1142 8 O
,	1150 1 O
and	1152 3 O
digoxin	1156 7 B-Chemical
.	1163 1 O

RESULTS	1165 7 O
:	1172 1 O
amiodarone	1174 10 B-Chemical
use	1185 3 O
was	1189 3 O
associated	1193 10 O
with	1204 4 O
an	1209 2 O
increased	1212 9 O
risk	1222 4 O
of	1227 2 O
pacemaker	1230 9 O
insertion	1240 9 O
(	1250 1 O
OR	1251 2 O
:	1253 1 O
2	1255 1 O
.	1256 1 O
14	1257 2 O
,	1259 1 O
95	1261 2 O
%	1263 1 O
confidence	1265 10 O
interval	1276 8 O
[	1285 1 O
CI	1286 2 O
]	1288 1 O
:	1289 1 O
1	1291 1 O
.	1292 1 O
30	1293 2 O
to	1296 2 O
3	1299 1 O
.	1300 1 O
54	1301 2 O
)	1303 1 O
.	1304 1 O

This	1306 4 O
effect	1311 6 O
was	1318 3 O
modified	1322 8 O
by	1331 2 O
gender	1334 6 O
,	1340 1 O
with	1342 4 O
a	1347 1 O
greater	1349 7 O
risk	1357 4 O
in	1362 2 O
women	1365 5 O
versus	1371 6 O
men	1378 3 O
(	1382 1 O
OR	1383 2 O
:	1385 1 O
3	1387 1 O
.	1388 1 O
86	1389 2 O
,	1391 1 O
95	1393 2 O
%	1395 1 O
CI	1397 2 O
:	1399 1 O
1	1401 1 O
.	1402 1 O
70	1403 2 O
to	1406 2 O
8	1409 1 O
.	1410 1 O
75	1411 2 O
vs	1414 2 O
.	1416 1 O
OR	1418 2 O
:	1420 1 O
1	1422 1 O
.	1423 1 O
52	1424 2 O
,	1426 1 O
95	1428 2 O
%	1430 1 O
CI	1432 2 O
:	1434 1 O
0	1436 1 O
.	1437 1 O
80	1438 2 O
to	1441 2 O
2	1444 1 O
.	1445 1 O
89	1446 2 O
)	1448 1 O
.	1449 1 O

Digoxin	1451 7 B-Chemical
was	1459 3 O
the	1463 3 O
only	1467 4 O
other	1472 5 O
medication	1478 10 O
associated	1489 10 O
with	1500 4 O
an	1505 2 O
increased	1508 9 O
risk	1518 4 O
of	1523 2 O
pacemaker	1526 9 O
insertion	1536 9 O
(	1546 1 O
OR	1547 2 O
:	1549 1 O
1	1551 1 O
.	1552 1 O
78	1553 2 O
,	1555 1 O
95	1557 2 O
%	1559 1 O
CI	1561 2 O
:	1563 1 O
1	1565 1 O
.	1566 1 O
37	1567 2 O
to	1570 2 O
2	1573 1 O
.	1574 1 O
31	1575 2 O
)	1577 1 O
.	1578 1 O

CONCLUSIONS	1580 11 O
:	1591 1 O
This	1593 4 O
study	1598 5 O
suggests	1604 8 O
that	1613 4 O
the	1618 3 O
use	1622 3 O
of	1626 2 O
amiodarone	1629 10 B-Chemical
in	1640 2 O
elderly	1643 7 O
patients	1651 8 O
with	1660 4 O
AF	1665 2 B-Disease
and	1668 3 O
a	1672 1 O
previous	1674 8 O
MI	1683 2 B-Disease
increases	1686 9 O
the	1696 3 O
risk	1700 4 O
of	1705 2 O
bradyarrhythmia	1708 15 B-Disease
requiring	1724 9 O
a	1734 1 O
permanent	1736 9 O
pacemaker	1746 9 O
.	1755 1 O

The	1757 3 O
finding	1761 7 O
of	1769 2 O
an	1772 2 O
augmented	1775 9 O
risk	1785 4 O
of	1790 2 O
pacemaker	1793 9 O
insertion	1803 9 O
in	1813 2 O
elderly	1816 7 O
women	1824 5 O
receiving	1830 9 O
amiodarone	1840 10 B-Chemical
requires	1851 8 O
further	1860 7 O
investigation	1868 13 O
.	1881 1 O

Indomethacin	0 12 B-Chemical
-	12 1 O
induced	13 7 O
morphologic	21 11 O
changes	33 7 O
in	41 2 O
the	44 3 O
rat	48 3 O
urinary	52 7 O
bladder	60 7 O
epithelium	68 10 O
.	78 1 O

OBJECTIVES	80 10 O
:	90 1 O
To	92 2 O
evaluate	95 8 O
the	104 3 O
morphologic	108 11 O
changes	120 7 O
in	128 2 O
rat	131 3 O
urothelium	135 10 O
induced	146 7 O
by	154 2 O
indomethacin	157 12 B-Chemical
.	169 1 O

Nonsteroidal	171 12 O
anti	184 4 O
-	188 1 O
inflammatory	189 12 O
drug	202 4 O
-	206 1 O
induced	207 7 O
cystitis	215 8 B-Disease
is	224 2 O
a	227 1 O
poorly	229 6 O
recognized	236 10 O
and	247 3 O
under	251 5 O
-	256 1 O
reported	257 8 O
condition	266 9 O
.	275 1 O

In	277 2 O
addition	280 8 O
to	289 2 O
tiaprofenic	292 11 B-Chemical
acid	304 4 I-Chemical
,	308 1 O
indomethacin	310 12 B-Chemical
has	323 3 O
been	327 4 O
reported	332 8 O
to	341 2 O
be	344 2 O
associated	347 10 O
with	358 4 O
this	363 4 O
condition	368 9 O
.	377 1 O

METHODS	379 7 O
:	386 1 O
Three	388 5 O
groups	394 6 O
were	401 4 O
established	406 11 O
:	417 1 O
a	419 1 O
control	421 7 O
group	429 5 O
(	435 1 O
n	436 1 O
=	438 1 O
10	440 2 O
)	442 1 O
,	443 1 O
a	445 1 O
high	447 4 O
-	451 1 O
dose	452 4 O
group	457 5 O
(	463 1 O
n	464 1 O
=	466 1 O
10	468 2 O
)	470 1 O
,	471 1 O
treated	473 7 O
with	481 4 O
one	486 3 O
intraperitoneal	490 15 O
injection	506 9 O
of	516 2 O
indomethacin	519 12 B-Chemical
20	532 2 O
mg	535 2 O
/	537 1 O
kg	538 2 O
,	540 1 O
and	542 3 O
a	546 1 O
therapeutic	548 11 O
dose	560 4 O
group	565 5 O
(	571 1 O
n	572 1 O
=	574 1 O
10	576 2 O
)	578 1 O
in	580 2 O
which	583 5 O
oral	589 4 O
indomethacin	594 12 B-Chemical
was	607 3 O
administered	611 12 O
3	624 1 O
.	625 1 O
25	626 2 O
mg	629 2 O
/	631 1 O
kg	632 2 O
body	635 4 O
weight	640 6 O
daily	647 5 O
for	653 3 O
3	657 1 O
weeks	659 5 O
.	664 1 O

The	666 3 O
animals	670 7 O
were	678 4 O
then	683 4 O
killed	688 6 O
and	695 3 O
the	699 3 O
bladders	703 8 O
removed	712 7 O
for	720 3 O
light	724 5 O
and	730 3 O
electron	734 8 O
microscopic	743 11 O
studies	755 7 O
.	762 1 O

RESULTS	764 7 O
:	771 1 O
The	773 3 O
light	777 5 O
microscopic	783 11 O
findings	795 8 O
showed	804 6 O
some	811 4 O
focal	816 5 O
epithelial	822 10 O
degeneration	833 12 O
that	846 4 O
was	851 3 O
more	855 4 O
prominent	860 9 O
in	870 2 O
the	873 3 O
high	877 4 O
-	881 1 O
dose	882 4 O
group	887 5 O
.	892 1 O

When	894 4 O
compared	899 8 O
with	908 4 O
the	913 3 O
control	917 7 O
group	925 5 O
,	930 1 O
both	932 4 O
indomethacin	937 12 B-Chemical
groups	950 6 O
revealed	957 8 O
statistically	966 13 O
increased	980 9 O
numbers	990 7 O
of	998 2 O
mast	1001 4 O
cells	1006 5 O
in	1012 2 O
the	1015 3 O
mucosa	1019 6 O
(	1026 1 O
P	1027 1 O
<	1029 1 O
0	1030 1 O
.	1031 1 O
0001	1032 4 O
)	1036 1 O
and	1038 3 O
penetration	1042 11 O
of	1054 2 O
lanthanum	1057 9 B-Chemical
nitrate	1067 7 I-Chemical
through	1075 7 O
intercellular	1083 13 O
areas	1097 5 O
of	1103 2 O
the	1106 3 O
epithelium	1110 10 O
.	1120 1 O

Furthermore	1122 11 O
,	1133 1 O
the	1135 3 O
difference	1139 10 O
in	1150 2 O
mast	1153 4 O
cell	1158 4 O
counts	1163 6 O
between	1170 7 O
the	1178 3 O
high	1182 4 O
and	1187 3 O
therapeutic	1191 11 O
dose	1203 4 O
groups	1208 6 O
was	1215 3 O
also	1219 4 O
statistically	1224 13 O
significant	1238 11 O
(	1250 1 O
P	1251 1 O
<	1253 1 O
0	1254 1 O
.	1255 1 O
0001	1256 4 O
)	1260 1 O
.	1261 1 O

CONCLUSIONS	1263 11 O
:	1274 1 O
Indomethacin	1276 12 B-Chemical
resulted	1289 8 O
in	1298 2 O
histopathologic	1301 15 O
findings	1317 8 O
typical	1326 7 O
of	1334 2 O
interstitial	1337 12 B-Disease
cystitis	1350 8 I-Disease
,	1358 1 O
such	1360 4 O
as	1365 2 O
leaky	1368 5 O
bladder	1374 7 O
epithelium	1382 10 O
and	1393 3 O
mucosal	1397 7 O
mastocytosis	1405 12 B-Disease
.	1417 1 O

The	1419 3 O
true	1423 4 O
incidence	1428 9 O
of	1438 2 O
nonsteroidal	1441 12 O
anti	1454 4 O
-	1458 1 O
inflammatory	1459 12 O
drug	1472 4 O
-	1476 1 O
induced	1477 7 O
cystitis	1485 8 B-Disease
in	1494 2 O
humans	1497 6 O
must	1504 4 O
be	1509 2 O
clarified	1512 9 O
by	1522 2 O
prospective	1525 11 O
clinical	1537 8 O
trials	1546 6 O
.	1552 1 O

An	0 2 O
open	3 4 O
-	7 1 O
label	8 5 O
phase	14 5 O
II	20 2 O
study	23 5 O
of	29 2 O
low	32 3 O
-	35 1 O
dose	36 4 O
thalidomide	41 11 B-Chemical
in	53 2 O
androgen	56 8 B-Chemical
-	64 1 O
independent	65 11 O
prostate	77 8 B-Disease
cancer	86 6 I-Disease
.	92 1 O

The	94 3 O
antiangiogenic	98 14 O
effects	113 7 O
of	121 2 O
thalidomide	124 11 B-Chemical
have	136 4 O
been	141 4 O
assessed	146 8 O
in	155 2 O
clinical	158 8 O
trials	167 6 O
in	174 2 O
patients	177 8 O
with	186 4 O
various	191 7 O
solid	199 5 O
and	205 3 O
haematological	209 14 B-Disease
malignancies	224 12 I-Disease
.	236 1 O

Thalidomide	238 11 B-Chemical
blocks	250 6 O
the	257 3 O
activity	261 8 O
of	270 2 O
angiogenic	273 10 O
agents	284 6 O
including	291 9 O
bFGF	301 4 O
,	305 1 O
VEGF	307 4 O
and	312 3 O
IL	316 2 O
-	318 1 O
6	319 1 O
.	320 1 O

We	322 2 O
undertook	325 9 O
an	335 2 O
open	338 4 O
-	342 1 O
label	343 5 O
study	349 5 O
using	355 5 O
thalidomide	361 11 B-Chemical
100	373 3 O
mg	377 2 O
once	380 4 O
daily	385 5 O
for	391 3 O
up	395 2 O
to	398 2 O
6	401 1 O
months	403 6 O
in	410 2 O
20	413 2 O
men	416 3 O
with	420 4 O
androgen	425 8 B-Chemical
-	433 1 O
independent	434 11 O
prostate	446 8 B-Disease
cancer	455 6 I-Disease
.	461 1 O

The	463 3 O
mean	467 4 O
time	472 4 O
of	477 2 O
study	480 5 O
was	486 3 O
109	490 3 O
days	494 4 O
(	499 1 O
median	500 6 O
107	507 3 O
,	510 1 O
range	512 5 O
4	518 1 O
-	519 1 O
184	520 3 O
days	524 4 O
)	528 1 O
.	529 1 O

Patients	531 8 O
underwent	540 9 O
regular	550 7 O
measurement	558 11 O
of	570 2 O
prostate	573 8 O
-	581 1 O
specific	582 8 O
antigen	591 7 O
(	599 1 O
PSA	600 3 O
)	603 1 O
,	604 1 O
urea	606 4 B-Chemical
and	611 3 O
electrolytes	615 12 O
,	627 1 O
serum	629 5 O
bFGF	635 4 O
and	640 3 O
VEGF	644 4 O
.	648 1 O

Three	650 5 O
men	656 3 O
(	660 1 O
15	661 2 O
%	663 1 O
)	664 1 O
showed	666 6 O
a	673 1 O
decline	675 7 O
in	683 2 O
serum	686 5 O
PSA	692 3 O
of	696 2 O
at	699 2 O
least	702 5 O
50	708 2 O
%	710 1 O
,	711 1 O
sustained	713 9 O
throughout	723 10 O
treatment	734 9 O
.	743 1 O

Of	745 2 O
16	748 2 O
men	751 3 O
treated	755 7 O
for	763 3 O
at	767 2 O
least	770 5 O
2	776 1 O
months	778 6 O
,	784 1 O
six	786 3 O
(	790 1 O
37	791 2 O
.	793 1 O
5	794 1 O
%	795 1 O
)	796 1 O
showed	798 6 O
a	805 1 O
fall	807 4 O
in	812 2 O
absolute	815 8 O
PSA	824 3 O
by	828 2 O
a	831 1 O
median	833 6 O
of	840 2 O
48	843 2 O
%	845 1 O
.	846 1 O

Increasing	848 10 O
levels	859 6 O
of	866 2 O
serum	869 5 O
bFGF	875 4 O
and	880 3 O
VEGF	884 4 O
were	889 4 O
associated	894 10 O
with	905 4 O
progressive	910 11 O
disease	922 7 O
;	929 1 O
five	931 4 O
of	936 2 O
six	939 3 O
men	943 3 O
who	947 3 O
demonstrated	951 12 O
a	964 1 O
fall	966 4 O
in	971 2 O
PSA	974 3 O
also	978 4 O
showed	983 6 O
a	990 1 O
decline	992 7 O
in	1000 2 O
bFGF	1003 4 O
and	1008 3 O
VEGF	1012 4 O
levels	1017 6 O
,	1023 1 O
and	1025 3 O
three	1029 5 O
of	1035 2 O
four	1038 4 O
men	1043 3 O
with	1047 4 O
a	1052 1 O
rising	1054 6 O
PSA	1061 3 O
showed	1065 6 O
an	1072 2 O
increase	1075 8 O
in	1084 2 O
both	1087 4 O
growth	1092 6 O
factors	1099 7 O
.	1106 1 O

Adverse	1108 7 O
effects	1116 7 O
included	1124 8 O
constipation	1133 12 B-Disease
,	1145 1 O
morning	1147 7 O
drowsiness	1155 10 B-Disease
,	1165 1 O
dizziness	1167 9 B-Disease
and	1177 3 O
rash	1181 4 B-Disease
,	1185 1 O
and	1187 3 O
resulted	1191 8 O
in	1200 2 O
withdrawal	1203 10 O
from	1214 4 O
the	1219 3 O
study	1223 5 O
by	1229 2 O
three	1232 5 O
men	1238 3 O
.	1241 1 O

Evidence	1243 8 O
of	1252 2 O
peripheral	1255 10 B-Disease
sensory	1266 7 I-Disease
neuropathy	1274 10 I-Disease
was	1285 3 O
found	1289 5 O
in	1295 2 O
nine	1298 4 O
of	1303 2 O
13	1306 2 O
men	1309 3 O
before	1313 6 O
treatment	1320 9 O
.	1329 1 O

In	1331 2 O
the	1334 3 O
seven	1338 5 O
men	1344 3 O
who	1348 3 O
completed	1352 9 O
six	1362 3 O
months	1366 6 O
on	1373 2 O
thalidomide	1376 11 B-Chemical
,	1387 1 O
subclinical	1389 11 O
evidence	1401 8 O
of	1410 2 O
peripheral	1413 10 B-Disease
neuropathy	1424 10 I-Disease
was	1435 3 O
found	1439 5 O
in	1445 2 O
four	1448 4 O
before	1453 6 O
treatment	1460 9 O
,	1469 1 O
but	1471 3 O
in	1475 2 O
all	1478 3 O
seven	1482 5 O
at	1488 2 O
repeat	1491 6 O
testing	1498 7 O
.	1505 1 O

The	1507 3 O
findings	1511 8 O
indicate	1520 8 O
that	1529 4 O
thalidomide	1534 11 B-Chemical
may	1546 3 O
be	1550 2 O
an	1553 2 O
option	1556 6 O
for	1563 3 O
patients	1567 8 O
who	1576 3 O
have	1580 4 O
failed	1585 6 O
other	1592 5 O
forms	1598 5 O
of	1604 2 O
therapy	1607 7 O
,	1614 1 O
provided	1616 8 O
close	1625 5 O
follow	1631 6 O
-	1637 1 O
up	1638 2 O
is	1641 2 O
maintained	1644 10 O
for	1655 3 O
development	1659 11 O
of	1671 2 O
peripheral	1674 10 B-Disease
neuropathy	1685 10 I-Disease
.	1695 1 O

Central	0 7 B-Disease
nervous	8 7 I-Disease
system	16 6 I-Disease
toxicity	23 8 I-Disease
following	32 9 O
the	42 3 O
administration	46 14 O
of	61 2 O
levobupivacaine	64 15 B-Chemical
for	80 3 O
lumbar	84 6 O
plexus	91 6 O
block	98 5 O
:	103 1 O
A	105 1 O
report	107 6 O
of	114 2 O
two	117 3 O
cases	121 5 O
.	126 1 O

BACKGROUND	128 10 O
AND	139 3 O
OBJECTIVES	143 10 O
:	153 1 O
Central	155 7 B-Disease
nervous	163 7 I-Disease
system	171 6 I-Disease
and	178 3 I-Disease
cardiac	182 7 I-Disease
toxicity	190 8 I-Disease
following	199 9 O
the	209 3 O
administration	213 14 O
of	228 2 O
local	231 5 O
anesthetics	237 11 O
is	249 2 O
a	252 1 O
recognized	254 10 O
complication	265 12 O
of	278 2 O
regional	281 8 O
anesthesia	290 10 O
.	300 1 O

Levobupivacaine	302 15 B-Chemical
,	317 1 O
the	319 3 O
pure	323 4 O
S	328 1 O
(	329 1 O
-	330 1 O
)	331 1 O
enantiomer	333 10 O
of	344 2 O
bupivacaine	347 11 B-Chemical
,	358 1 O
was	360 3 O
developed	364 9 O
to	374 2 O
improve	377 7 O
the	385 3 O
cardiac	389 7 O
safety	397 6 O
profile	404 7 O
of	412 2 O
bupivacaine	415 11 B-Chemical
.	426 1 O

We	428 2 O
describe	431 8 O
2	440 1 O
cases	442 5 O
of	448 2 O
grand	451 5 B-Disease
mal	457 3 I-Disease
seizures	461 8 I-Disease
following	470 9 O
accidental	480 10 O
intravascular	491 13 O
injection	505 9 O
of	515 2 O
levobupivacaine	518 15 B-Chemical
.	533 1 O

CASE	535 4 O
REPORT	540 6 O
:	546 1 O
Two	548 3 O
patients	552 8 O
presenting	561 10 O
for	572 3 O
elective	576 8 O
orthopedic	585 10 O
surgery	596 7 O
of	604 2 O
the	607 3 O
lower	611 5 O
limb	617 4 O
underwent	622 9 O
blockade	632 8 O
of	641 2 O
the	644 3 O
lumbar	648 6 O
plexus	655 6 O
via	662 3 O
the	666 3 O
posterior	670 9 O
approach	680 8 O
.	688 1 O

Immediately	690 11 O
after	702 5 O
the	708 3 O
administration	712 14 O
of	727 2 O
levobupivacaine	730 15 B-Chemical
0	746 1 O
.	747 1 O
5	748 1 O
%	749 1 O
with	751 4 O
epinephrine	756 11 B-Chemical
2	768 1 O
.	769 1 O
5	770 1 O
microgram	772 9 O
/	781 1 O
mL	782 2 O
,	784 1 O
the	786 3 O
patients	790 8 O
developed	799 9 O
grand	809 5 B-Disease
mal	815 3 I-Disease
seizures	819 8 I-Disease
,	827 1 O
despite	829 7 O
negative	837 8 O
aspiration	846 10 O
for	857 3 O
blood	861 5 O
and	867 3 O
no	871 2 O
clinical	874 8 O
signs	883 5 O
of	889 2 O
intravenous	892 11 O
epinephrine	904 11 B-Chemical
administration	916 14 O
.	930 1 O

The	932 3 O
seizures	936 8 B-Disease
were	945 4 O
successfully	950 12 O
treated	963 7 O
with	971 4 O
sodium	976 6 B-Chemical
thiopental	983 10 I-Chemical
in	994 2 O
addition	997 8 O
to	1006 2 O
succinylcholine	1009 15 B-Chemical
in	1025 2 O
1	1028 1 O
patient	1030 7 O
.	1037 1 O

Neither	1039 7 O
patient	1047 7 O
developed	1055 9 O
signs	1065 5 O
of	1071 2 O
cardiovascular	1074 14 B-Disease
toxicity	1089 8 I-Disease
.	1097 1 O

Both	1099 4 O
patients	1104 8 O
were	1113 4 O
treated	1118 7 O
preoperatively	1126 14 O
with	1141 4 O
beta	1146 4 O
-	1150 1 O
adrenergic	1151 10 O
antagonist	1162 10 O
medications	1173 11 O
,	1184 1 O
which	1186 5 O
may	1192 3 O
have	1196 4 O
masked	1201 6 O
the	1208 3 O
cardiovascular	1212 14 O
signs	1227 5 O
of	1233 2 O
the	1236 3 O
unintentional	1240 13 O
intravascular	1254 13 O
administration	1268 14 O
of	1283 2 O
levobupivacaine	1286 15 B-Chemical
with	1302 4 O
epinephrine	1307 11 B-Chemical
.	1318 1 O

CONCLUSIONS	1320 11 O
:	1331 1 O
Although	1333 8 O
levobupivacaine	1342 15 B-Chemical
may	1358 3 O
have	1362 4 O
a	1367 1 O
safer	1369 5 O
cardiac	1375 7 B-Disease
toxicity	1383 8 I-Disease
profile	1392 7 O
than	1400 4 O
racemic	1405 7 O
bupivacaine	1413 11 B-Chemical
,	1424 1 O
if	1426 2 O
adequate	1429 8 O
amounts	1438 7 O
of	1446 2 O
levobupivacaine	1449 15 B-Chemical
reach	1465 5 O
the	1471 3 O
circulation	1475 11 O
,	1486 1 O
it	1488 2 O
will	1491 4 O
result	1496 6 O
in	1503 2 O
convulsions	1506 11 B-Disease
.	1517 1 O

Plasma	1519 6 O
concentrations	1526 14 O
sufficient	1541 10 O
to	1552 2 O
result	1555 6 O
in	1562 2 O
central	1565 7 B-Disease
nervous	1573 7 I-Disease
system	1581 6 I-Disease
toxicity	1588 8 I-Disease
did	1597 3 O
not	1601 3 O
produce	1605 7 O
manifestations	1613 14 O
of	1628 2 O
cardiac	1631 7 B-Disease
toxicity	1639 8 I-Disease
in	1648 2 O
these	1651 5 O
2	1657 1 O
patients	1659 8 O
.	1667 1 O

Anaesthetic	0 11 O
complications	12 13 O
associated	26 10 O
with	37 4 O
myotonia	42 8 B-Disease
congenita	51 9 I-Disease
:	60 1 O
case	62 4 O
study	67 5 O
and	73 3 O
comparison	77 10 O
with	88 4 O
other	93 5 O
myotonic	99 8 B-Disease
disorders	108 9 I-Disease
.	117 1 O

Myotonia	119 8 B-Disease
congenita	128 9 I-Disease
(	138 1 O
MC	139 2 B-Disease
)	141 1 O
is	143 2 O
caused	146 6 O
by	153 2 O
a	156 1 O
defect	158 6 O
in	165 2 O
the	168 3 O
skeletal	172 8 O
muscle	181 6 O
chloride	188 8 B-Chemical
channel	197 7 O
function	205 8 O
,	213 1 O
which	215 5 O
may	221 3 O
cause	225 5 O
sustained	231 9 B-Disease
membrane	241 8 I-Disease
depolarisation	250 14 I-Disease
.	264 1 O

We	266 2 O
describe	269 8 O
a	278 1 O
previously	280 10 O
healthy	291 7 O
32	299 2 O
-	301 1 O
year	302 4 O
-	306 1 O
old	307 3 O
woman	311 5 O
who	317 3 O
developed	321 9 O
a	331 1 O
life	333 4 O
-	337 1 O
threatening	338 11 O
muscle	350 6 B-Disease
spasm	357 5 I-Disease
and	363 3 O
secondary	367 9 O
ventilation	377 11 O
difficulties	389 12 O
following	402 9 O
a	412 1 O
preoperative	414 12 O
injection	427 9 O
of	437 2 O
suxamethonium	440 13 B-Chemical
.	453 1 O

The	455 3 O
muscle	459 6 B-Disease
spasms	466 6 I-Disease
disappeared	473 11 O
spontaneously	485 13 O
and	499 3 O
the	503 3 O
surgery	507 7 O
proceeded	515 9 O
without	525 7 O
further	533 7 O
problems	541 8 O
.	549 1 O

When	551 4 O
subsequently	556 12 O
questioned	569 10 O
,	579 1 O
she	581 3 O
reported	585 8 O
minor	594 5 O
symptoms	600 8 O
suggesting	609 10 O
a	620 1 O
myotonic	622 8 B-Disease
condition	631 9 I-Disease
.	640 1 O

Myotonia	642 8 B-Disease
was	651 3 O
found	655 5 O
on	661 2 O
clinical	664 8 O
examination	673 11 O
and	685 3 O
EMG	689 3 O
.	692 1 O

The	694 3 O
diagnosis	698 9 O
MC	708 2 B-Disease
was	711 3 O
confirmed	715 9 O
genetically	725 11 O
.	736 1 O

Neither	738 7 O
the	746 3 O
patient	750 7 O
nor	758 3 O
the	762 3 O
anaesthetist	766 12 O
were	779 4 O
aware	784 5 O
of	790 2 O
the	793 3 O
diagnosis	797 9 O
before	807 6 O
this	814 4 O
potentially	819 11 O
lethal	831 6 O
complication	838 12 O
occurred	851 8 O
.	859 1 O

We	861 2 O
give	864 4 O
a	869 1 O
brief	871 5 O
overview	877 8 O
of	886 2 O
ion	889 3 B-Disease
channel	893 7 I-Disease
disorders	901 9 I-Disease
including	911 9 O
malignant	921 9 B-Disease
hyperthermia	931 12 I-Disease
and	944 3 O
their	948 5 O
anaesthetic	954 11 O
considerations	966 14 O
.	980 1 O

Respiratory	0 11 O
pattern	12 7 O
in	20 2 O
a	23 1 O
rat	25 3 O
model	29 5 O
of	35 2 O
epilepsy	38 8 B-Disease
.	46 1 O

PURPOSE	48 7 O
:	55 1 O
Apnea	57 5 B-Disease
is	63 2 O
known	66 5 O
to	72 2 O
occur	75 5 O
during	81 6 O
seizures	88 8 B-Disease
,	96 1 O
but	98 3 O
systematic	102 10 O
studies	113 7 O
of	121 2 O
ictal	124 5 O
respiratory	130 11 O
changes	142 7 O
in	150 2 O
adults	153 6 O
are	160 3 O
few	164 3 O
.	167 1 O

Data	169 4 O
regarding	174 9 O
respiratory	184 11 O
pattern	196 7 O
defects	204 7 O
during	212 6 O
interictal	219 10 O
periods	230 7 O
also	238 4 O
are	243 3 O
scarce	247 6 O
.	253 1 O

Here	255 4 O
we	260 2 O
sought	263 6 O
to	270 2 O
generate	273 8 O
information	282 11 O
with	294 4 O
regard	299 6 O
to	306 2 O
the	309 3 O
interictal	313 10 O
period	324 6 O
in	331 2 O
animals	334 7 O
with	342 4 O
pilocarpine	347 11 B-Chemical
-	358 1 O
induced	359 7 O
epilepsy	367 8 B-Disease
.	375 1 O

METHODS	377 7 O
:	384 1 O
Twelve	386 6 O
rats	393 4 O
(	398 1 O
six	399 3 O
chronically	403 11 O
epileptic	415 9 B-Disease
animals	425 7 O
and	433 3 O
six	437 3 O
controls	441 8 O
)	449 1 O
were	451 4 O
anesthetized	456 12 O
,	468 1 O
given	470 5 O
tracheotomies	476 13 O
,	489 1 O
and	491 3 O
subjected	495 9 O
to	505 2 O
hyperventilation	508 16 B-Disease
or	525 2 O
hypoventilation	528 15 O
conditions	544 10 O
.	554 1 O

Breathing	556 9 O
movements	566 9 O
caused	576 6 O
changes	583 7 O
in	591 2 O
thoracic	594 8 O
volume	603 6 O
and	610 3 O
forced	614 6 O
air	621 3 O
to	625 2 O
flow	628 4 O
tidally	633 7 O
through	641 7 O
a	649 1 O
pneumotachograph	651 16 O
.	667 1 O

This	669 4 O
flow	674 4 O
was	679 3 O
measured	683 8 O
by	692 2 O
using	695 5 O
a	701 1 O
differential	703 12 O
pressure	716 8 O
transducer	725 10 O
,	735 1 O
passed	737 6 O
through	744 7 O
a	752 1 O
polygraph	754 9 O
,	763 1 O
and	765 3 O
from	769 4 O
this	774 4 O
to	779 2 O
a	782 1 O
computer	784 8 O
with	793 4 O
custom	798 6 O
software	805 8 O
that	814 4 O
derived	819 7 O
ventilation	827 11 O
(	839 1 O
VE	840 2 O
)	842 1 O
,	843 1 O
tidal	845 5 O
volume	851 6 O
(	858 1 O
VT	859 2 O
)	861 1 O
,	862 1 O
inspiratory	864 11 O
time	876 4 O
(	881 1 O
TI	882 2 O
)	884 1 O
,	885 1 O
expiratory	887 10 O
time	898 4 O
(	903 1 O
TE	904 2 O
)	906 1 O
,	907 1 O
breathing	909 9 O
frequency	919 9 O
(	929 1 O
f	930 1 O
)	931 1 O
,	932 1 O
and	934 3 O
mean	938 4 O
inspiratory	943 11 O
flow	955 4 O
(	960 1 O
VT	961 2 O
/	963 1 O
TI	964 2 O
)	966 1 O
on	968 2 O
a	971 1 O
breath	973 6 O
-	979 1 O
by	980 2 O
-	982 1 O
breath	983 6 O
basis	990 5 O
.	995 1 O

RESULTS	997 7 O
:	1004 1 O
The	1006 3 O
hyperventilation	1010 16 B-Disease
maneuver	1027 8 O
caused	1036 6 O
a	1043 1 O
decrease	1045 8 O
in	1054 2 O
spontaneous	1057 11 O
ventilation	1069 11 O
in	1081 2 O
pilocarpine	1084 11 B-Chemical
-	1095 1 O
treated	1096 7 O
and	1104 3 O
control	1108 7 O
rats	1116 4 O
.	1120 1 O

Although	1122 8 O
VE	1131 2 O
had	1134 3 O
a	1138 1 O
similar	1140 7 O
decrease	1148 8 O
in	1157 2 O
both	1160 4 O
groups	1165 6 O
,	1171 1 O
in	1173 2 O
the	1176 3 O
epileptic	1180 9 B-Disease
group	1190 5 O
,	1195 1 O
the	1197 3 O
decrease	1201 8 O
in	1210 2 O
VE	1213 2 O
was	1216 3 O
due	1220 3 O
to	1224 2 O
a	1227 1 O
significant	1229 11 O
(	1241 1 O
p	1242 1 O
<	1244 1 O
0	1246 1 O
.	1247 1 O
05	1248 2 O
)	1250 1 O
increase	1252 8 O
in	1261 2 O
TE	1264 2 O
peak	1267 4 O
in	1272 2 O
relation	1275 8 O
to	1284 2 O
that	1287 4 O
of	1292 2 O
the	1295 3 O
control	1299 7 O
animals	1307 7 O
.	1314 1 O

The	1316 3 O
hypoventilation	1320 15 O
maneuver	1336 8 O
led	1345 3 O
to	1349 2 O
an	1352 2 O
increase	1355 8 O
in	1364 2 O
the	1367 3 O
arterial	1371 8 O
Paco2	1380 5 O
,	1385 1 O
followed	1387 8 O
by	1396 2 O
an	1399 2 O
increase	1402 8 O
in	1411 2 O
VE	1414 2 O
.	1416 1 O

In	1418 2 O
the	1421 3 O
epileptic	1425 9 B-Disease
group	1435 5 O
,	1440 1 O
the	1442 3 O
increase	1446 8 O
in	1455 2 O
VE	1458 2 O
was	1461 3 O
mediated	1465 8 O
by	1474 2 O
a	1477 1 O
significant	1479 11 O
(	1491 1 O
p	1492 1 O
<	1494 1 O
0	1496 1 O
.	1497 1 O
05	1498 2 O
)	1500 1 O
decrease	1502 8 O
in	1511 2 O
TE	1514 2 O
peak	1517 4 O
compared	1522 8 O
with	1531 4 O
the	1536 3 O
control	1540 7 O
group	1548 5 O
.	1553 1 O

Systemic	1555 8 O
application	1564 11 O
of	1576 2 O
KCN	1579 3 O
,	1582 1 O
to	1584 2 O
evaluate	1587 8 O
the	1596 3 O
effects	1600 7 O
of	1608 2 O
peripheral	1611 10 O
chemoreception	1622 14 O
activation	1637 10 O
on	1648 2 O
ventilation	1651 11 O
,	1662 1 O
led	1664 3 O
to	1668 2 O
a	1671 1 O
similar	1673 7 O
increase	1681 8 O
in	1690 2 O
VE	1693 2 O
for	1696 3 O
both	1700 4 O
groups	1705 6 O
.	1711 1 O

CONCLUSIONS	1713 11 O
:	1724 1 O
The	1726 3 O
data	1730 4 O
indicate	1735 8 O
that	1744 4 O
pilocarpine	1749 11 B-Chemical
-	1760 1 O
treated	1761 7 O
animals	1769 7 O
have	1777 4 O
an	1782 2 O
altered	1785 7 O
ability	1793 7 O
to	1801 2 O
react	1804 5 O
to	1810 2 O
(	1813 1 O
or	1814 2 O
compensate	1817 10 O
for	1828 3 O
)	1831 1 O
blood	1833 5 O
gas	1839 3 O
changes	1843 7 O
with	1851 4 O
changes	1856 7 O
in	1864 2 O
ventilation	1867 11 O
and	1879 3 O
suggest	1883 7 O
that	1891 4 O
it	1896 2 O
is	1899 2 O
centrally	1902 9 O
determined	1912 10 O
.	1922 1 O

We	1924 2 O
speculate	1927 9 O
on	1937 2 O
the	1940 3 O
possible	1944 8 O
relation	1953 8 O
of	1962 2 O
the	1965 3 O
current	1969 7 O
findings	1977 8 O
on	1986 2 O
treating	1989 8 O
different	1998 9 O
epilepsy	2008 8 B-Disease
-	2016 1 O
associated	2017 10 O
conditions	2028 10 O
.	2038 1 O

Increased	0 9 O
serum	10 5 O
soluble	16 7 O
Fas	24 3 O
in	28 2 O
patients	31 8 O
with	40 4 O
acute	45 5 B-Disease
liver	51 5 I-Disease
failure	57 7 I-Disease
due	65 3 O
to	69 2 O
paracetamol	72 11 B-Chemical
overdose	84 8 B-Disease
.	92 1 O

BACKGROUND	94 10 O
/	104 1 O
AIMS	105 4 O
:	109 1 O
Experimental	111 12 O
studies	124 7 O
have	132 4 O
suggested	137 9 O
that	147 4 O
apoptosis	152 9 O
via	162 3 O
the	166 3 O
Fas	170 3 O
/	173 1 O
Fas	174 3 O
Ligand	178 6 O
signaling	185 9 O
system	195 6 O
may	202 3 O
play	206 4 O
an	211 2 O
important	214 9 O
role	224 4 O
in	229 2 O
the	232 3 O
development	236 11 O
of	248 2 O
acute	251 5 B-Disease
liver	257 5 I-Disease
failure	263 7 I-Disease
.	270 1 O

The	272 3 O
aim	276 3 O
of	280 2 O
the	283 3 O
study	287 5 O
was	293 3 O
to	297 2 O
investigate	300 11 O
the	312 3 O
soluble	316 7 O
form	324 4 O
of	329 2 O
Fas	332 3 O
in	336 2 O
patients	339 8 O
with	348 4 O
acute	353 5 B-Disease
liver	359 5 I-Disease
failure	365 7 I-Disease
.	372 1 O

METHODOLOGY	374 11 O
:	385 1 O
Serum	387 5 O
levels	393 6 O
of	400 2 O
sFas	403 4 O
(	408 1 O
soluble	409 7 O
Fas	417 3 O
)	420 1 O
were	422 4 O
measured	427 8 O
by	436 2 O
ELISA	439 5 O
in	445 2 O
24	448 2 O
patients	451 8 O
with	460 4 O
acute	465 5 B-Disease
liver	471 5 I-Disease
failure	477 7 I-Disease
and	485 3 O
10	489 2 O
normal	492 6 O
control	499 7 O
subjects	507 8 O
.	515 1 O

Serum	517 5 O
levels	523 6 O
of	530 2 O
tumor	533 5 B-Disease
necrosis	539 8 B-Disease
factor	548 6 O
-	554 1 O
alpha	555 5 O
and	561 3 O
interferon	565 10 O
-	575 1 O
gamma	576 5 O
were	582 4 O
also	587 4 O
determined	592 10 O
by	603 2 O
ELISA	606 5 O
.	611 1 O

RESULTS	613 7 O
:	620 1 O
Serum	622 5 O
sFas	628 4 O
was	633 3 O
significantly	637 13 O
increased	651 9 O
in	661 2 O
patients	664 8 O
with	673 4 O
acute	678 5 B-Disease
liver	684 5 I-Disease
failure	690 7 I-Disease
(	698 1 O
median	699 6 O
,	705 1 O
26	707 2 O
.	709 1 O
8	710 1 O
U	712 1 O
/	713 1 O
mL	714 2 O
;	716 1 O
range	718 5 O
,	723 1 O
6	725 1 O
.	726 1 O
9	727 1 O
-	728 1 O
52	729 2 O
.	731 1 O
7	732 1 O
U	734 1 O
/	735 1 O
mL	736 2 O
)	738 1 O
compared	740 8 O
to	749 2 O
the	752 3 O
normal	756 6 O
controls	763 8 O
(	772 1 O
median	773 6 O
,	779 1 O
8	781 1 O
.	782 1 O
6	783 1 O
U	785 1 O
/	786 1 O
mL	787 2 O
;	789 1 O
range	791 5 O
,	796 1 O
6	798 1 O
.	799 1 O
5	800 1 O
-	801 1 O
12	802 2 O
.	804 1 O
0	805 1 O
U	807 1 O
/	808 1 O
mL	809 2 O
,	811 1 O
P	813 1 O
<	815 1 O
0	817 1 O
.	818 1 O
0001	819 4 O
)	823 1 O
.	824 1 O

Levels	826 6 O
were	833 4 O
significantly	838 13 O
greater	852 7 O
in	860 2 O
patients	863 8 O
with	872 4 O
acute	877 5 B-Disease
liver	883 5 I-Disease
failure	889 7 I-Disease
due	897 3 O
to	901 2 O
paracetamol	904 11 B-Chemical
overdose	916 8 B-Disease
(	925 1 O
median	926 6 O
,	932 1 O
28	934 2 O
.	936 1 O
7	937 1 O
U	939 1 O
/	940 1 O
mL	941 2 O
;	943 1 O
range	945 5 O
,	950 1 O
12	952 2 O
.	954 1 O
8	955 1 O
-	956 1 O
52	957 2 O
.	959 1 O
7	960 1 O
U	962 1 O
/	963 1 O
mL	964 2 O
,	966 1 O
n	968 1 O
=	970 1 O
17	972 2 O
)	974 1 O
than	976 4 O
those	981 5 O
due	987 3 O
to	991 2 O
non	994 3 O
-	997 1 O
A	998 1 O
to	1000 2 O
E	1003 1 O
hepatitis	1005 9 B-Disease
(	1015 1 O
median	1016 6 O
,	1022 1 O
12	1024 2 O
.	1026 1 O
5	1027 1 O
U	1029 1 O
/	1030 1 O
mL	1031 2 O
;	1033 1 O
range	1035 5 O
,	1040 1 O
6	1042 1 O
.	1043 1 O
9	1044 1 O
-	1045 1 O
46	1046 2 O
.	1048 1 O
0	1049 1 O
U	1051 1 O
/	1052 1 O
mL	1053 2 O
,	1055 1 O
n	1057 1 O
=	1059 1 O
7	1061 1 O
,	1062 1 O
P	1064 1 O
<	1066 1 O
0	1068 1 O
.	1069 1 O
01	1070 2 O
)	1072 1 O
.	1073 1 O

There	1075 5 O
was	1081 3 O
no	1085 2 O
relationship	1088 12 O
of	1101 2 O
sFas	1104 4 O
to	1109 2 O
eventual	1112 8 O
outcome	1121 7 O
in	1129 2 O
the	1132 3 O
patients	1136 8 O
.	1144 1 O

A	1146 1 O
significant	1148 11 O
correlation	1160 11 O
was	1172 3 O
observed	1176 8 O
between	1185 7 O
serum	1193 5 O
sFas	1199 4 O
levels	1204 6 O
and	1211 3 O
aspartate	1215 9 B-Chemical
aminotransferase	1225 16 O
(	1242 1 O
r	1243 1 O
=	1245 1 O
0	1247 1 O
.	1248 1 O
613	1249 3 O
,	1252 1 O
P	1254 1 O
<	1256 1 O
0	1258 1 O
.	1259 1 O
01	1260 2 O
)	1262 1 O
.	1263 1 O

CONCLUSIONS	1265 11 O
:	1276 1 O
The	1278 3 O
increased	1282 9 O
concentration	1292 13 O
of	1306 2 O
sFas	1309 4 O
in	1314 2 O
serum	1317 5 O
of	1323 2 O
patients	1326 8 O
with	1335 4 O
acute	1340 5 B-Disease
liver	1346 5 I-Disease
failure	1352 7 I-Disease
may	1360 3 O
reflect	1364 7 O
activation	1372 10 O
of	1383 2 O
Fas	1386 3 O
-	1389 1 O
mediated	1390 8 O
apoptosis	1399 9 O
in	1409 2 O
the	1412 3 O
liver	1416 5 O
and	1422 3 O
this	1426 4 O
together	1431 8 O
with	1440 4 O
increased	1445 9 O
tumor	1455 5 B-Disease
necrosis	1461 8 B-Disease
factor	1470 6 O
-	1476 1 O
alpha	1477 5 O
may	1483 3 O
be	1487 2 O
an	1490 2 O
important	1493 9 O
factor	1503 6 O
in	1510 2 O
liver	1513 5 O
cell	1519 4 O
loss	1524 4 O
.	1528 1 O

Bilateral	0 9 O
subthalamic	10 11 O
nucleus	22 7 O
stimulation	30 11 O
for	42 3 O
Parkinson	46 9 B-Disease
'	55 1 I-Disease
s	56 1 I-Disease
disease	58 7 I-Disease
.	65 1 O

High	67 4 O
frequency	72 9 O
stimulation	82 11 O
of	94 2 O
the	97 3 O
subthalamic	101 11 O
nucleus	113 7 O
(	121 1 O
STN	122 3 O
)	125 1 O
is	127 2 O
known	130 5 O
to	136 2 O
ameliorate	139 10 O
the	150 3 O
signs	154 5 O
and	160 3 O
symptoms	164 8 O
of	173 2 O
advanced	176 8 O
Parkinson	185 9 B-Disease
'	194 1 I-Disease
s	195 1 I-Disease
disease	197 7 I-Disease
.	204 1 O

AIM	206 3 O
:	209 1 O
We	211 2 O
studied	214 7 O
the	222 3 O
effect	226 6 O
of	233 2 O
high	236 4 O
frequency	241 9 O
STN	251 3 O
stimulation	255 11 O
in	267 2 O
23	270 2 O
patients	273 8 O
.	281 1 O

METHOD	283 6 O
:	289 1 O
Twenty	291 6 O
-	297 1 O
three	298 5 O
patients	304 8 O
suffering	313 9 O
from	323 4 O
severe	328 6 O
Parkinson	335 9 B-Disease
'	344 1 I-Disease
s	345 1 I-Disease
disease	347 7 I-Disease
(	355 1 O
Stages	356 6 O
III	363 3 O
-	366 1 O
V	367 1 O
on	369 2 O
Hoehn	372 5 O
and	378 3 O
Yahr	382 4 O
scale	387 5 O
)	392 1 O
and	394 3 O
,	397 1 O
particularly	399 12 O
bradykinesia	412 12 B-Disease
,	424 1 O
rigidity	426 8 B-Disease
,	434 1 O
and	436 3 O
levodopa	440 8 B-Chemical
-	448 1 O
induced	449 7 O
dyskinesias	457 11 B-Disease
underwent	469 9 O
bilateral	479 9 O
implantation	489 12 O
of	502 2 O
electrodes	505 10 O
in	516 2 O
the	519 3 O
STN	523 3 O
.	526 1 O

Preoperative	528 12 O
and	541 3 O
postoperative	545 13 O
assessments	559 11 O
of	571 2 O
these	574 5 O
patients	580 8 O
at	589 2 O
1	592 1 O
,	593 1 O
3	595 1 O
,	596 1 O
6	598 1 O
and	600 3 O
12	604 2 O
months	607 6 O
follow	614 6 O
-	620 1 O
up	621 2 O
,	623 1 O
in	625 2 O
"	628 1 O
on	629 2 O
"	631 1 O
and	633 3 O
"	637 1 O
off	638 3 O
"	641 1 O
drug	643 4 O
conditions	648 10 O
,	658 1 O
was	660 3 O
carried	664 7 O
out	672 3 O
using	676 5 O
Unified	682 7 O
Parkinson	690 9 B-Disease
'	699 1 I-Disease
s	700 1 I-Disease
Disease	702 7 I-Disease
Rating	710 6 O
Scale	717 5 O
,	722 1 O
Hoehn	724 5 O
and	730 3 O
Yahr	734 4 O
staging	739 7 O
,	746 1 O
England	748 7 O
activities	756 10 O
of	767 2 O
daily	770 5 O
living	776 6 O
score	783 5 O
and	789 3 O
video	793 5 O
recordings	799 10 O
.	809 1 O

RESULTS	811 7 O
:	818 1 O
After	820 5 O
one	826 3 O
year	830 4 O
of	835 2 O
electrical	838 10 O
stimulation	849 11 O
of	861 2 O
the	864 3 O
STN	868 3 O
,	871 1 O
the	873 3 O
patients	877 8 O
'	885 1 O
scores	887 6 O
for	894 3 O
activities	898 10 O
of	909 2 O
daily	912 5 O
living	918 6 O
and	925 3 O
motor	929 5 O
examination	935 11 O
scores	947 6 O
(	954 1 O
Unified	955 7 O
Parkinson	963 9 B-Disease
'	972 1 I-Disease
s	973 1 I-Disease
Disease	975 7 I-Disease
Rating	983 6 O
Scale	990 5 O
parts	996 5 O
II	1002 2 O
and	1005 3 O
III	1009 3 O
)	1012 1 O
off	1014 3 O
medication	1018 10 O
improved	1029 8 O
by	1038 2 O
62	1041 2 O
%	1043 1 O
and	1045 3 O
61	1049 2 O
%	1051 1 O
respectively	1053 12 O
(	1066 1 O
p	1067 1 O
<	1068 1 O
0	1069 1 O
.	1070 1 O
0005	1071 4 O
)	1075 1 O
.	1076 1 O

The	1078 3 O
subscores	1082 9 O
for	1092 3 O
the	1096 3 O
akinesia	1100 8 B-Disease
,	1108 1 O
rigidity	1110 8 B-Disease
,	1118 1 O
tremor	1120 6 B-Disease
and	1127 3 O
gait	1131 4 O
also	1136 4 O
improved	1141 8 O
.	1149 1 O

(	1151 1 O
p	1152 1 O
<	1153 1 O
0	1154 1 O
.	1155 1 O
0005	1156 4 O
)	1160 1 O
.	1161 1 O

The	1163 3 O
average	1167 7 O
levodopa	1175 8 B-Chemical
dose	1184 4 O
decreased	1189 9 O
from	1199 4 O
813	1204 3 O
mg	1208 2 O
to	1211 2 O
359	1214 3 O
mg	1218 2 O
.	1220 1 O

The	1222 3 O
cognitive	1226 9 O
functions	1236 9 O
remained	1246 8 O
unchanged	1255 9 O
.	1264 1 O

Two	1266 3 O
patients	1270 8 O
developed	1279 9 O
device	1289 6 O
-	1295 1 O
related	1296 7 O
complications	1304 13 O
and	1318 3 O
two	1322 3 O
patients	1326 8 O
experienced	1335 11 O
abnormal	1347 8 O
weight	1356 6 O
gain	1363 4 O
.	1367 1 O

CONCLUSION	1369 10 O
:	1379 1 O
Bilateral	1381 9 O
subthalamic	1391 11 O
nucleus	1403 7 O
stimulation	1411 11 O
is	1423 2 O
an	1426 2 O
effective	1429 9 O
treatment	1439 9 O
for	1449 3 O
advanced	1453 8 O
Parkinson	1462 9 B-Disease
'	1471 1 I-Disease
s	1472 1 I-Disease
disease	1474 7 I-Disease
.	1481 1 O

It	1483 2 O
reduces	1486 7 O
the	1494 3 O
severity	1498 8 O
of	1507 2 O
"	1510 1 O
off	1511 3 O
"	1514 1 O
phase	1516 5 O
symptoms	1522 8 O
,	1530 1 O
improves	1532 8 O
the	1541 3 O
axial	1545 5 O
symptoms	1551 8 O
and	1560 3 O
reduces	1564 7 O
levodopa	1572 8 B-Chemical
requirements	1581 12 O
.	1593 1 O

The	1595 3 O
reduction	1599 9 O
in	1609 2 O
the	1612 3 O
levodopa	1616 8 B-Chemical
dose	1625 4 O
is	1630 2 O
useful	1633 6 O
in	1640 2 O
controlling	1643 11 O
drug	1655 4 B-Disease
-	1659 1 I-Disease
induced	1660 7 I-Disease
dyskinesias	1668 11 I-Disease
.	1679 1 O

Ocular	0 6 O
motility	7 8 O
changes	16 7 O
after	24 5 O
subtenon	30 8 O
carboplatin	39 11 B-Chemical
chemotherapy	51 12 O
for	64 3 O
retinoblastoma	68 14 B-Disease
.	82 1 O

BACKGROUND	84 10 O
:	94 1 O
Focal	96 5 O
subtenon	102 8 O
carboplatin	111 11 B-Chemical
injections	123 10 O
have	134 4 O
recently	139 8 O
been	148 4 O
used	153 4 O
as	158 2 O
a	161 1 O
presumably	163 10 O
toxicity	174 8 B-Disease
-	182 1 O
free	183 4 O
adjunct	188 7 O
to	196 2 O
systemic	199 8 O
chemotherapy	208 12 O
for	221 3 O
intraocular	225 11 O
retinoblastoma	237 14 B-Disease
.	251 1 O

OBJECTIVE	253 9 O
:	262 1 O
To	264 2 O
report	267 6 O
our	274 3 O
clinical	278 8 O
experience	287 10 O
with	298 4 O
abnormal	303 8 B-Disease
ocular	312 6 I-Disease
motility	319 8 I-Disease
in	328 2 O
patients	331 8 O
treated	340 7 O
with	348 4 O
subtenon	353 8 O
carboplatin	362 11 B-Chemical
chemotherapy	374 12 O
.	386 1 O

METHODS	388 7 O
:	395 1 O
We	397 2 O
noted	400 5 O
abnormal	406 8 B-Disease
ocular	415 6 I-Disease
motility	422 8 I-Disease
in	431 2 O
10	434 2 O
consecutive	437 11 O
patients	449 8 O
with	458 4 O
retinoblastoma	463 14 B-Disease
who	478 3 O
had	482 3 O
received	486 8 O
subtenon	495 8 O
carboplatin	504 11 B-Chemical
.	515 1 O

During	517 6 O
ocular	524 6 O
manipulation	531 12 O
under	544 5 O
general	550 7 O
anesthesia	558 10 O
,	568 1 O
we	570 2 O
assessed	573 8 O
their	582 5 O
eyes	588 4 O
by	593 2 O
forced	596 6 O
duction	603 7 O
testing	611 7 O
,	618 1 O
comparing	620 9 O
ocular	630 6 O
motility	637 8 O
after	646 5 O
tumor	652 5 B-Disease
control	658 7 O
with	666 4 O
ocular	671 6 O
motility	678 8 O
at	687 2 O
diagnosis	690 9 O
.	699 1 O

Eyes	701 4 O
subsequently	706 12 O
enucleated	719 10 O
because	730 7 O
of	738 2 O
treatment	741 9 O
failure	751 7 O
(	759 1 O
n	760 1 O
=	762 1 O
4	764 1 O
)	765 1 O
were	767 4 O
examined	772 8 O
histologically	781 14 O
.	795 1 O

RESULTS	797 7 O
:	804 1 O
Limitation	806 10 O
of	817 2 O
ocular	820 6 O
motility	827 8 O
was	836 3 O
detected	840 8 O
in	849 2 O
all	852 3 O
12	856 2 O
eyes	859 4 O
of	864 2 O
10	867 2 O
patients	870 8 O
treated	879 7 O
for	887 3 O
intraocular	891 11 O
retinoblastoma	903 14 B-Disease
with	918 4 O
1	923 1 O
to	925 2 O
6	928 1 O
injections	930 10 O
of	941 2 O
subtenon	944 8 O
carboplatin	953 11 B-Chemical
as	965 2 O
part	968 4 O
of	973 2 O
multimodality	976 13 O
therapy	990 7 O
.	997 1 O

Histopathological	999 17 O
examination	1017 11 O
revealed	1029 8 O
many	1038 4 O
lipophages	1043 10 O
in	1054 2 O
the	1057 3 O
periorbital	1061 11 O
fat	1073 3 O
surrounding	1077 11 O
the	1089 3 O
optic	1093 5 O
nerve	1099 5 O
in	1105 2 O
1	1108 1 O
eye	1110 3 O
,	1113 1 O
indicative	1115 10 O
of	1126 2 O
phagocytosis	1129 12 O
of	1142 2 O
previously	1145 10 O
existing	1156 8 O
fat	1165 3 O
cells	1169 5 O
and	1175 3 O
suggesting	1179 10 O
prior	1190 5 O
fat	1196 3 O
necrosis	1200 8 B-Disease
.	1208 1 O

The	1210 3 O
enucleations	1214 12 O
were	1227 4 O
technically	1232 11 O
difficult	1244 9 O
and	1254 3 O
hazardous	1258 9 O
for	1268 3 O
globe	1272 5 O
rupture	1278 7 B-Disease
because	1286 7 O
of	1294 2 O
extensive	1297 9 O
orbital	1307 7 O
soft	1315 4 O
tissue	1320 6 O
adhesions	1327 9 O
.	1336 1 O

CONCLUSIONS	1338 11 O
:	1349 1 O
Subtenon	1351 8 O
carboplatin	1360 11 B-Chemical
chemotherapy	1372 12 O
is	1385 2 O
associated	1388 10 O
with	1399 4 O
significant	1404 11 O
fibrosis	1416 8 B-Disease
of	1425 2 O
orbital	1428 7 O
soft	1436 4 O
tissues	1441 7 O
,	1448 1 O
leading	1450 7 O
to	1458 2 O
mechanical	1461 10 O
restriction	1472 11 O
of	1484 2 O
eye	1487 3 O
movements	1491 9 O
and	1501 3 O
making	1505 6 O
subsequent	1512 10 O
enucleation	1523 11 O
difficult	1535 9 O
.	1544 1 O

Subtenon	1546 8 O
carboplatin	1555 11 B-Chemical
is	1567 2 O
not	1570 3 O
free	1574 4 O
of	1579 2 O
toxicity	1582 8 B-Disease
,	1590 1 O
and	1592 3 O
its	1596 3 O
use	1600 3 O
is	1604 2 O
best	1607 4 O
restricted	1612 10 O
to	1623 2 O
specific	1626 8 O
indications	1635 11 O
.	1646 1 O

Ethambutol	0 10 B-Chemical
and	11 3 O
optic	15 5 B-Disease
neuropathy	21 10 I-Disease
.	31 1 O

PURPOSE	33 7 O
:	40 1 O
To	42 2 O
demonstrate	45 11 O
the	57 3 O
association	61 11 O
between	73 7 O
ethambutol	81 10 B-Chemical
and	92 3 O
optic	96 5 B-Disease
neuropathy	102 10 I-Disease
.	112 1 O

METHOD	114 6 O
:	120 1 O
Thirteen	122 8 O
patients	131 8 O
who	140 3 O
developed	144 9 O
optic	154 5 B-Disease
neuropathy	160 10 I-Disease
after	171 5 O
being	177 5 O
treated	183 7 O
with	191 4 O
ethambutol	196 10 B-Chemical
for	207 3 O
tuberculosis	211 12 B-Disease
of	224 2 I-Disease
the	227 3 I-Disease
lung	231 4 I-Disease
or	236 2 I-Disease
lymph	239 5 I-Disease
node	245 4 I-Disease
at	250 2 O
Siriraj	253 7 O
Hospital	261 8 O
between	270 7 O
1997	278 4 O
and	283 3 O
2001	287 4 O
were	292 4 O
retrospectively	297 15 O
reviewed	313 8 O
.	321 1 O

The	323 3 O
clinical	327 8 O
characteristics	336 15 O
and	352 3 O
initial	356 7 O
and	364 3 O
final	368 5 O
visual	374 6 O
acuity	381 6 O
were	388 4 O
analyzed	393 8 O
to	402 2 O
determine	405 9 O
visual	415 6 O
outcome	422 7 O
.	429 1 O

RESULTS	431 7 O
:	438 1 O
All	440 3 O
patients	444 8 O
had	453 3 O
optic	457 5 B-Disease
neuropathy	463 10 I-Disease
between	474 7 O
1	482 1 O
to	484 2 O
6	487 1 O
months	489 6 O
(	496 1 O
mean	497 4 O
=	502 1 O
2	504 1 O
.	505 1 O
9	506 1 O
months	508 6 O
)	514 1 O
after	516 5 O
starting	522 8 O
ethambutol	531 10 B-Chemical
therapy	542 7 O
at	550 2 O
a	553 1 O
dosage	555 6 O
ranging	562 7 O
from	570 4 O
13	575 2 O
to	578 2 O
20	581 2 O
mg	584 2 O
/	586 1 O
kg	587 2 O
/	589 1 O
day	590 3 O
(	594 1 O
mean	595 4 O
=	600 1 O
17	602 2 O
mg	605 2 O
/	607 1 O
kg	608 2 O
/	610 1 O
day	611 3 O
)	614 1 O
.	615 1 O

Seven	617 5 O
(	623 1 O
54	624 2 O
%	626 1 O
)	627 1 O
of	629 2 O
the	632 3 O
13	636 2 O
patients	639 8 O
experienced	648 11 O
visual	660 6 O
recovery	667 8 O
after	676 5 O
stopping	682 8 O
the	691 3 O
drug	695 4 O
.	699 1 O

Of	701 2 O
6	704 1 O
patients	706 8 O
with	715 4 O
irreversible	720 12 O
visual	733 6 B-Disease
impairment	740 10 I-Disease
,	750 1 O
4	752 1 O
patients	754 8 O
had	763 3 O
diabetes	767 8 B-Disease
mellitus	776 8 I-Disease
,	784 1 O
glaucoma	786 8 B-Disease
and	795 3 O
a	799 1 O
history	801 7 O
of	809 2 O
heavy	812 5 O
smoking	818 7 O
.	825 1 O

CONCLUSION	827 10 O
:	837 1 O
Early	839 5 O
recognition	845 11 O
of	857 2 O
optic	860 5 B-Disease
neuropathy	866 10 I-Disease
should	877 6 O
be	884 2 O
considered	887 10 O
in	898 2 O
patients	901 8 O
with	910 4 O
ethambutol	915 10 B-Chemical
therapy	926 7 O
.	933 1 O

A	935 1 O
low	937 3 O
dose	941 4 O
and	946 3 O
prompt	950 6 O
discontinuation	957 15 O
of	973 2 O
the	976 3 O
drug	980 4 O
is	985 2 O
recommended	988 11 O
particularly	1000 12 O
in	1013 2 O
individuals	1016 11 O
with	1028 4 O
diabetes	1033 8 B-Disease
mellitus	1042 8 I-Disease
,	1050 1 O
glaucoma	1052 8 B-Disease
or	1061 2 O
who	1064 3 O
are	1068 3 O
heavy	1072 5 O
smokers	1078 7 O
.	1085 1 O

Treatment	0 9 O
of	10 2 O
compensatory	13 12 O
gustatory	26 9 B-Disease
hyperhidrosis	36 13 I-Disease
with	50 4 O
topical	55 7 O
glycopyrrolate	63 14 B-Chemical
.	77 1 O

Gustatory	79 9 B-Disease
hyperhidrosis	89 13 I-Disease
is	103 2 O
facial	106 6 O
sweating	113 8 B-Disease
usually	122 7 O
associated	130 10 O
with	141 4 O
the	146 3 O
eating	150 6 O
of	157 2 O
hot	160 3 O
spicy	164 5 O
food	170 4 O
or	175 2 O
even	178 4 O
smelling	183 8 O
this	192 4 O
food	197 4 O
.	201 1 O

Current	203 7 O
options	211 7 O
of	219 2 O
treatment	222 9 O
include	232 7 O
oral	240 4 O
anticholinergic	245 15 O
drugs	261 5 O
,	266 1 O
the	268 3 O
topical	272 7 O
application	280 11 O
of	292 2 O
anticholinergics	295 16 O
or	312 2 O
aluminum	315 8 B-Chemical
chloride	324 8 I-Chemical
,	332 1 O
and	334 3 O
the	338 3 O
injection	342 9 O
of	352 2 O
botulinum	355 9 O
toxin	365 5 O
.	370 1 O

Thirteen	372 8 O
patients	381 8 O
have	390 4 O
been	395 4 O
treated	400 7 O
to	408 2 O
date	411 4 O
with	416 4 O
1	421 1 O
.	422 1 O
5	423 1 O
%	424 1 O
or	426 2 O
2	429 1 O
%	430 1 O
topical	432 7 O
glycopyrrolate	440 14 B-Chemical
.	454 1 O

All	456 3 O
patients	460 8 O
had	469 3 O
gustatory	473 9 B-Disease
hyperhidrosis	483 13 I-Disease
,	496 1 O
which	498 5 O
interfered	504 10 O
with	515 4 O
their	520 5 O
social	526 6 O
activities	533 10 O
,	543 1 O
after	545 5 O
transthroacic	551 13 O
endoscopic	565 10 O
sympathectomy	576 13 O
,	589 1 O
and	591 3 O
which	595 5 O
was	601 3 O
associated	605 10 O
with	616 4 O
compensatory	621 12 O
focal	634 5 O
hyperhidrosis	640 13 B-Disease
.	653 1 O

After	655 5 O
applying	661 8 O
topical	670 7 O
glycopyrrolate	678 14 B-Chemical
,	692 1 O
the	694 3 O
subjective	698 10 O
effect	709 6 O
was	716 3 O
excellent	720 9 O
(	730 1 O
no	731 2 O
sweating	734 8 B-Disease
after	743 5 O
eating	749 6 O
hot	756 3 O
spicy	760 5 O
food	766 4 O
)	770 1 O
in	772 2 O
10	775 2 O
patients	778 8 O
(	787 1 O
77	788 2 O
%	790 1 O
)	791 1 O
,	792 1 O
and	794 3 O
fair	798 4 O
(	803 1 O
clearly	804 7 O
reduced	812 7 O
sweating	820 8 B-Disease
)	828 1 O
in	830 2 O
3	833 1 O
patients	835 8 O
(	844 1 O
23	845 2 O
%	847 1 O
)	848 1 O
.	849 1 O

All	851 3 O
had	855 3 O
reported	859 8 O
incidents	868 9 O
of	878 2 O
being	881 5 O
very	887 4 O
embarrassed	892 11 O
whilst	904 6 O
eating	911 6 O
hot	918 3 O
spicy	922 5 O
foods	928 5 O
.	933 1 O

Adverse	935 7 O
effects	943 7 O
included	951 8 O
a	960 1 O
mildly	962 6 O
dry	969 3 B-Disease
mouth	973 5 I-Disease
and	979 3 O
a	983 1 O
sore	985 4 B-Disease
throat	990 6 I-Disease
in	997 2 O
2	1000 1 O
patients	1002 8 O
(	1011 1 O
2	1012 1 O
%	1013 1 O
glycopyrrolate	1015 14 B-Chemical
)	1029 1 O
,	1030 1 O
a	1032 1 O
light	1034 5 O
headache	1040 8 B-Disease
in	1049 2 O
1	1052 1 O
patient	1054 7 O
(	1062 1 O
1	1063 1 O
.	1064 1 O
5	1065 1 O
%	1066 1 O
glycopyrrolate	1068 14 B-Chemical
)	1082 1 O
.	1083 1 O

The	1085 3 O
topical	1089 7 O
application	1097 11 O
of	1109 2 O
a	1112 1 O
glycopyrrolate	1114 14 B-Chemical
pad	1129 3 O
appeared	1133 8 O
to	1142 2 O
be	1145 2 O
safe	1148 4 O
,	1152 1 O
efficacious	1154 11 O
,	1165 1 O
well	1167 4 O
tolerated	1172 9 O
,	1181 1 O
and	1183 3 O
a	1187 1 O
convenient	1189 10 O
method	1200 6 O
of	1207 2 O
treatment	1210 9 O
for	1220 3 O
moderate	1224 8 O
to	1233 2 O
severe	1236 6 O
symptoms	1243 8 O
of	1252 2 O
gustatory	1255 9 B-Disease
hyperhidrosis	1265 13 I-Disease
in	1279 2 O
post	1282 4 O
transthoracic	1287 13 O
endoscopic	1301 10 O
sympathectomy	1312 13 O
or	1326 2 O
sympathicotomy	1329 14 O
patients	1344 8 O
,	1352 1 O
with	1354 4 O
few	1359 3 O
side	1363 4 O
effects	1368 7 O
.	1375 1 O

Pharmacological	0 15 O
characteristics	16 15 O
and	32 3 O
side	36 4 O
effects	41 7 O
of	49 2 O
a	52 1 O
new	54 3 O
galenic	58 7 O
formulation	66 11 O
of	78 2 O
propofol	81 8 B-Chemical
without	90 7 O
soyabean	98 8 O
oil	107 3 O
.	110 1 O

We	112 2 O
compared	115 8 O
the	124 3 O
pharmacokinetics	128 16 O
,	144 1 O
pharmacodynamics	146 16 O
and	163 3 O
safety	167 6 O
profile	174 7 O
of	182 2 O
a	185 1 O
new	187 3 O
galenic	191 7 O
formulation	199 11 O
of	211 2 O
propofol	214 8 B-Chemical
(	223 1 O
AM149	224 5 O
1	230 1 O
%	231 1 O
)	232 1 O
,	233 1 O
which	235 5 O
does	241 4 O
not	246 3 O
contain	250 7 O
soyabean	258 8 O
oil	267 3 O
,	270 1 O
with	272 4 O
a	277 1 O
standard	279 8 O
formulation	288 11 O
of	300 2 O
propofol	303 8 B-Chemical
(	312 1 O
Disoprivan	313 10 B-Chemical
1	324 1 O
%	325 1 O
)	326 1 O
.	327 1 O

In	329 2 O
a	332 1 O
randomised	334 10 O
,	344 1 O
double	346 6 O
-	352 1 O
blind	353 5 O
,	358 1 O
cross	360 5 O
-	365 1 O
over	366 4 O
study	371 5 O
,	376 1 O
30	378 2 O
healthy	381 7 O
volunteers	389 10 O
received	400 8 O
a	409 1 O
single	411 6 O
intravenous	418 11 O
bolus	430 5 O
injection	436 9 O
of	446 2 O
2	449 1 O
.	450 1 O
5	451 1 O
mg	453 2 O
.	455 1 O
kg	456 2 O
-	458 1 O
1	459 1 O
propofol	461 8 B-Chemical
.	469 1 O

Plasma	471 6 O
propofol	478 8 B-Chemical
levels	487 6 O
were	494 4 O
measured	499 8 O
for	508 3 O
48	512 2 O
h	515 1 O
following	517 9 O
drug	527 4 O
administration	532 14 O
and	547 3 O
evaluated	551 9 O
according	561 9 O
to	571 2 O
a	574 1 O
three	576 5 O
-	581 1 O
compartment	582 11 O
model	594 5 O
.	599 1 O

The	601 3 O
pharmacodynamic	605 15 O
parameters	621 10 O
assessed	632 8 O
included	641 8 O
induction	650 9 O
and	660 3 O
emergence	664 9 O
times	674 5 O
,	679 1 O
respiratory	681 11 O
and	693 3 O
cardiovascular	697 14 O
effects	712 7 O
,	719 1 O
and	721 3 O
pain	725 4 B-Disease
on	730 2 O
injection	733 9 O
.	742 1 O

Patients	744 8 O
were	753 4 O
monitored	758 9 O
for	768 3 O
side	772 4 O
effects	777 7 O
over	785 4 O
48	790 2 O
h	793 1 O
.	794 1 O

Owing	796 5 O
to	802 2 O
a	805 1 O
high	807 4 O
incidence	812 9 O
of	822 2 O
thrombophlebitis	825 16 B-Disease
,	841 1 O
the	843 3 O
study	847 5 O
was	853 3 O
terminated	857 10 O
prematurely	868 11 O
and	880 3 O
only	884 4 O
the	889 3 O
data	893 4 O
of	898 2 O
the	901 3 O
two	905 3 O
parallel	909 8 O
treatment	918 9 O
groups	928 6 O
(	935 1 O
15	936 2 O
patients	939 8 O
in	948 2 O
each	951 4 O
group	956 5 O
)	961 1 O
were	963 4 O
analysed	968 8 O
.	976 1 O

Plasma	978 6 O
concentrations	985 14 O
did	1000 3 O
not	1004 3 O
differ	1008 6 O
significantly	1015 13 O
between	1029 7 O
the	1037 3 O
two	1041 3 O
formulations	1045 12 O
.	1057 1 O

Anaesthesia	1059 11 O
induction	1071 9 O
and	1081 3 O
emergence	1085 9 O
times	1095 5 O
,	1100 1 O
respiratory	1102 11 O
and	1114 3 O
cardiovascular	1118 14 O
variables	1133 9 O
showed	1143 6 O
no	1150 2 O
significant	1153 11 O
differences	1165 11 O
between	1177 7 O
the	1185 3 O
two	1189 3 O
treatment	1193 9 O
groups	1203 6 O
.	1209 1 O

Pain	1211 4 B-Disease
on	1216 2 O
injection	1219 9 O
(	1229 1 O
80	1230 2 O
vs	1233 2 O
.	1235 1 O
20	1237 2 O
%	1239 1 O
,	1240 1 O
p	1242 1 O
<	1244 1 O
0	1246 1 O
.	1247 1 O
01	1248 2 O
)	1250 1 O
and	1252 3 O
thrombophlebitis	1256 16 B-Disease
(	1273 1 O
93	1274 2 O
.	1276 1 O
3	1277 1 O
vs	1279 2 O
.	1281 1 O
6	1283 1 O
.	1284 1 O
6	1285 1 O
%	1286 1 O
,	1287 1 O
p	1289 1 O
<	1291 1 O
0	1293 1 O
.	1294 1 O
001	1295 3 O
)	1298 1 O
occurred	1300 8 O
more	1309 4 O
frequently	1314 10 O
with	1325 4 O
AM149	1330 5 O
than	1336 4 O
with	1341 4 O
Disoprivan	1346 10 B-Chemical
.	1356 1 O

Although	1358 8 O
both	1367 4 O
formulations	1372 12 O
had	1385 3 O
similar	1389 7 O
pharmacokinetic	1397 15 O
and	1413 3 O
pharmacodynamic	1417 15 O
profiles	1433 8 O
the	1442 3 O
new	1446 3 O
formulation	1450 11 O
is	1462 2 O
not	1465 3 O
suitable	1469 8 O
for	1478 3 O
clinical	1482 8 O
use	1491 3 O
due	1495 3 O
to	1499 2 O
the	1502 3 O
high	1506 4 O
incidence	1511 9 O
of	1521 2 O
thrombophlebitis	1524 16 B-Disease
produced	1541 8 O
.	1549 1 O

Vinorelbine	0 11 B-Chemical
-	11 1 O
related	12 7 O
cardiac	20 7 O
events	28 6 O
:	34 1 O
a	36 1 O
meta	38 4 O
-	42 1 O
analysis	43 8 O
of	52 2 O
randomized	55 10 O
clinical	66 8 O
trials	75 6 O
.	81 1 O

Several	83 7 O
cases	91 5 O
of	97 2 O
cardiac	100 7 O
adverse	108 7 O
reactions	116 9 O
related	126 7 O
to	134 2 O
vinorelbine	137 11 B-Chemical
(	149 1 O
VNR	150 3 B-Chemical
)	153 1 O
have	155 4 O
been	160 4 O
reported	165 8 O
in	174 2 O
the	177 3 O
literature	181 10 O
.	191 1 O

In	193 2 O
order	196 5 O
to	202 2 O
quantify	205 8 O
the	214 3 O
incidence	218 9 O
of	228 2 O
these	231 5 O
cardiac	237 7 O
events	245 6 O
,	251 1 O
we	253 2 O
performed	256 9 O
a	266 1 O
meta	268 4 O
-	272 1 O
analysis	273 8 O
of	282 2 O
clinical	285 8 O
trials	294 6 O
comparing	301 9 O
VNR	311 3 B-Chemical
with	315 4 O
other	320 5 O
chemotherapeutic	326 16 O
agents	343 6 O
in	350 2 O
the	353 3 O
treatment	357 9 O
of	367 2 O
various	370 7 O
malignancies	378 12 B-Disease
.	390 1 O

Randomized	392 10 O
clinical	403 8 O
trials	412 6 O
comparing	419 9 O
VNR	429 3 B-Chemical
with	433 4 O
other	438 5 O
drugs	444 5 O
in	450 2 O
the	453 3 O
treatment	457 9 O
of	467 2 O
cancer	470 6 B-Disease
were	477 4 O
searched	482 8 O
in	491 2 O
Medline	494 7 O
,	501 1 O
Embase	503 6 O
,	509 1 O
Evidence	511 8 O
-	519 1 O
based	520 5 O
Medicine	526 8 O
Reviews	535 7 O
databases	543 9 O
and	553 3 O
the	557 3 O
Cochrane	561 8 O
library	570 7 O
from	578 4 O
1987	583 4 O
to	588 2 O
2002	591 4 O
.	595 1 O

Outcomes	597 8 O
of	606 2 O
interest	609 8 O
were	618 4 O
severe	623 6 O
cardiac	630 7 O
events	638 6 O
,	644 1 O
toxic	646 5 O
deaths	652 6 O
and	659 3 O
cardiac	663 7 O
event	671 5 O
-	676 1 O
related	677 7 O
deaths	685 6 O
reported	692 8 O
in	701 2 O
each	704 4 O
publication	709 11 O
.	720 1 O

We	722 2 O
found	725 5 O
19	731 2 O
trials	734 6 O
,	740 1 O
involving	742 9 O
2441	752 4 O
patients	757 8 O
treated	766 7 O
by	774 2 O
VNR	777 3 B-Chemical
and	781 3 O
2050	785 4 O
control	790 7 O
patients	798 8 O
.	806 1 O

The	808 3 O
incidence	812 9 O
of	822 2 O
cardiac	825 7 O
events	833 6 O
with	840 4 O
VNR	845 3 B-Chemical
was	849 3 O
1	853 1 O
.	854 1 O
19	855 2 O
%	857 1 O
[	859 1 O
95	860 2 O
%	862 1 O
confidence	864 10 O
interval	875 8 O
(	884 1 O
CI	885 2 O
)	887 1 O
(	889 1 O
0	890 1 O
.	891 1 O
75	892 2 O
;	894 1 O
1	896 1 O
.	897 1 O
67	898 2 O
)	900 1 O
]	901 1 O
.	902 1 O

There	904 5 O
was	910 3 O
no	914 2 O
difference	917 10 O
in	928 2 O
the	931 3 O
risk	935 4 O
of	940 2 O
cardiac	943 7 O
events	951 6 O
between	958 7 O
VNR	966 3 B-Chemical
and	970 3 O
other	974 5 O
drugs	980 5 O
[	986 1 O
odds	987 4 O
ratio	992 5 O
:	997 1 O
0	999 1 O
.	1000 1 O
92	1001 2 O
,	1003 1 O
95	1005 2 O
%	1007 1 O
CI	1009 2 O
(	1012 1 O
0	1013 1 O
.	1014 1 O
54	1015 2 O
;	1017 1 O
1	1019 1 O
.	1020 1 O
55	1021 2 O
)	1023 1 O
]	1024 1 O
.	1025 1 O

The	1027 3 O
risk	1031 4 O
of	1036 2 O
VNR	1039 3 B-Chemical
cardiac	1043 7 O
events	1051 6 O
was	1058 3 O
similar	1062 7 O
to	1070 2 O
vindesine	1073 9 B-Chemical
(	1083 1 O
VDS	1084 3 B-Chemical
)	1087 1 O
and	1089 3 O
other	1093 5 O
cardiotoxic	1099 11 B-Disease
drugs	1111 5 O
[	1117 1 O
fluorouracil	1118 12 B-Chemical
,	1130 1 O
anthracyclines	1132 14 B-Chemical
,	1146 1 O
gemcitabine	1148 11 B-Chemical
(	1160 1 O
GEM	1161 3 B-Chemical
)	1164 1 O
em	1166 2 O
leader	1169 6 O
]	1176 1 O
.	1177 1 O

Even	1179 4 O
if	1184 2 O
it	1187 2 O
did	1190 3 O
not	1194 3 O
reach	1198 5 O
statistical	1204 11 O
significance	1216 12 O
because	1229 7 O
of	1237 2 O
a	1240 1 O
few	1242 3 O
number	1246 6 O
of	1253 2 O
cases	1256 5 O
,	1261 1 O
the	1263 3 O
risk	1267 4 O
was	1272 3 O
lower	1276 5 O
in	1282 2 O
trials	1285 6 O
excluding	1292 9 O
patients	1302 8 O
with	1311 4 O
cardiac	1316 7 O
history	1324 7 O
,	1331 1 O
and	1333 3 O
seemed	1337 6 O
to	1344 2 O
be	1347 2 O
higher	1350 6 O
in	1357 2 O
trials	1360 6 O
including	1367 9 O
patients	1377 8 O
with	1386 4 O
pre	1391 3 O
-	1394 1 O
existing	1395 8 O
cardiac	1404 7 B-Disease
diseases	1412 8 I-Disease
.	1420 1 O

Vinorelbine	1422 11 B-Chemical
-	1433 1 O
related	1434 7 O
cardiac	1442 7 O
events	1450 6 O
concern	1457 7 O
about	1465 5 O
1	1471 1 O
%	1472 1 O
of	1474 2 O
treated	1477 7 O
patients	1485 8 O
in	1494 2 O
clinical	1497 8 O
trials	1506 6 O
.	1512 1 O

However	1514 7 O
,	1521 1 O
the	1523 3 O
risk	1527 4 O
associated	1532 10 O
with	1543 4 O
VNR	1548 3 B-Chemical
seems	1552 5 O
to	1558 2 O
be	1561 2 O
similar	1564 7 O
to	1572 2 O
that	1575 4 O
of	1580 2 O
other	1583 5 O
chemotherapeutic	1589 16 O
agents	1606 6 O
in	1613 2 O
the	1616 3 O
same	1620 4 O
indications	1625 11 O
.	1636 1 O

MRI	0 3 O
findings	4 8 O
of	13 2 O
hypoxic	16 7 O
cortical	24 8 O
laminar	33 7 O
necrosis	41 8 B-Disease
in	50 2 O
a	53 1 O
child	55 5 O
with	61 4 O
hemolytic	66 9 B-Disease
anemia	76 6 I-Disease
crisis	83 6 O
.	89 1 O

We	91 2 O
present	94 7 O
magnetic	102 8 O
resonance	111 9 O
imaging	121 7 O
findings	129 8 O
of	138 2 O
a	141 1 O
5	143 1 O
-	144 1 O
year	145 4 O
-	149 1 O
old	150 3 O
girl	154 4 O
who	159 3 O
had	163 3 O
a	167 1 O
rapidly	169 7 O
installing	177 10 O
hemolytic	188 9 B-Disease
anemia	198 6 I-Disease
crisis	205 6 O
induced	212 7 O
by	220 2 O
trimethoprim	223 12 B-Chemical
-	235 1 I-Chemical
sulfomethoxazole	236 16 I-Chemical
,	252 1 O
resulting	254 9 O
in	264 2 O
cerebral	267 8 B-Disease
anoxia	276 6 I-Disease
leading	283 7 O
to	291 2 O
permanent	294 9 O
damage	304 6 O
.	310 1 O

Magnetic	312 8 O
Resonance	321 9 O
imaging	331 7 O
revealed	339 8 O
cortical	348 8 O
laminar	357 7 O
necrosis	365 8 B-Disease
in	374 2 O
arterial	377 8 O
border	386 6 O
zones	393 5 O
in	399 2 O
both	402 4 O
cerebral	407 8 O
hemispheres	416 11 O
,	427 1 O
ischemic	429 8 O
changes	438 7 O
in	446 2 O
subcortical	449 11 O
white	461 5 O
matter	467 6 O
of	474 2 O
left	477 4 O
cerebral	482 8 O
hemisphere	491 10 O
,	501 1 O
and	503 3 O
in	507 2 O
the	510 3 O
left	514 4 O
putamen	519 7 O
.	526 1 O

Although	528 8 O
cortical	537 8 O
laminar	546 7 O
necrosis	554 8 B-Disease
is	563 2 O
a	566 1 O
classic	568 7 O
entity	576 6 O
in	583 2 O
adulthood	586 9 O
related	596 7 O
to	604 2 O
conditions	607 10 O
of	618 2 O
energy	621 6 O
depletions	628 10 O
,	638 1 O
there	640 5 O
are	646 3 O
few	650 3 O
reports	654 7 O
available	662 9 O
in	672 2 O
children	675 8 O
.	683 1 O

A	685 1 O
wide	687 4 O
review	692 6 O
of	699 2 O
the	702 3 O
literature	706 10 O
is	717 2 O
also	720 4 O
presented	725 9 O
.	734 1 O

The	0 3 O
natural	4 7 O
history	12 7 O
of	20 2 O
Vigabatrin	23 10 B-Chemical
associated	34 10 O
visual	45 6 B-Disease
field	52 5 I-Disease
defects	58 7 I-Disease
in	66 2 O
patients	69 8 O
electing	78 8 O
to	87 2 O
continue	90 8 O
their	99 5 O
medication	105 10 O
.	115 1 O

PURPOSE	117 7 O
:	124 1 O
To	126 2 O
determine	129 9 O
the	139 3 O
natural	143 7 O
history	151 7 O
of	159 2 O
visual	162 6 B-Disease
field	169 5 I-Disease
defects	175 7 I-Disease
in	183 2 O
a	186 1 O
group	188 5 O
of	194 2 O
patients	197 8 O
known	206 5 O
to	212 2 O
have	215 4 O
Vigabatrin	220 10 B-Chemical
-	230 1 O
associated	231 10 O
changes	242 7 O
who	250 3 O
elected	254 7 O
to	262 2 O
continue	265 8 O
the	274 3 O
medication	278 10 O
because	289 7 O
of	297 2 O
good	300 4 O
seizure	305 7 B-Disease
control	313 7 O
.	320 1 O

METHODS	322 7 O
:	329 1 O
All	331 3 O
patients	335 8 O
taking	344 6 O
Vigabatrin	351 10 B-Chemical
alone	362 5 O
or	368 2 O
in	371 2 O
combination	374 11 O
with	386 4 O
other	391 5 O
antiepileptic	397 13 O
drugs	411 5 O
for	417 3 O
at	421 2 O
least	424 5 O
5	430 1 O
years	432 5 O
(	438 1 O
range	439 5 O
5	445 1 O
-	446 1 O
12	447 2 O
years	450 5 O
)	455 1 O
were	457 4 O
entered	462 7 O
into	470 4 O
a	475 1 O
visual	477 6 O
surveillance	484 12 O
programme	497 9 O
.	506 1 O

Patients	508 8 O
were	517 4 O
followed	522 8 O
up	531 2 O
at	534 2 O
6	537 1 O
-	538 1 O
monthly	539 7 O
intervals	547 9 O
for	557 3 O
not	561 3 O
less	565 4 O
than	570 4 O
18	575 2 O
months	578 6 O
(	585 1 O
range	586 5 O
18	592 2 O
-	594 1 O
43	595 2 O
months	598 6 O
)	604 1 O
.	605 1 O

In	607 2 O
all	610 3 O
,	613 1 O
16	615 2 O
patients	618 8 O
with	627 4 O
unequivocal	632 11 O
defects	644 7 O
continued	652 9 O
the	662 3 O
medication	666 10 O
.	676 1 O

Following	678 9 O
already	688 7 O
published	696 9 O
methodology	706 11 O
(	718 1 O
Eye	719 3 O
2002	723 4 O
;	727 1 O
16	729 2 O
;	731 1 O
567	732 3 O
-	735 1 O
571	736 3 O
)	739 1 O
monocular	741 9 O
mean	751 4 O
radial	756 6 O
degrees	763 7 O
(	771 1 O
MRDs	772 4 O
)	776 1 O
to	778 2 O
the	781 3 O
I	785 1 O
/	786 1 O
4e	787 2 O
isopter	790 7 O
on	798 2 O
Goldmann	801 8 O
perimetry	810 9 O
was	820 3 O
calculated	824 10 O
for	835 3 O
the	839 3 O
right	843 5 O
eye	849 3 O
at	853 2 O
the	856 3 O
time	860 4 O
of	865 2 O
discovery	868 9 O
of	878 2 O
a	881 1 O
visual	883 6 B-Disease
field	890 5 I-Disease
defect	896 6 I-Disease
and	903 3 O
again	907 5 O
after	913 5 O
not	919 3 O
less	923 4 O
than	928 4 O
18	933 2 O
months	936 6 O
follow	943 6 O
-	949 1 O
up	950 2 O
.	952 1 O

RESULTS	954 7 O
:	961 1 O
Mean	963 4 O
right	968 5 O
eye	974 3 O
MRD	978 3 O
at	982 2 O
presentation	985 12 O
was	998 3 O
36	1002 2 O
.	1004 1 O
98	1005 2 O
degrees	1008 7 O
(	1016 1 O
range	1017 5 O
22	1023 2 O
.	1025 1 O
25	1026 2 O
-	1028 1 O
51	1029 2 O
.	1031 1 O
0	1032 1 O
)	1033 1 O
,	1034 1 O
compared	1036 8 O
to	1045 2 O
38	1048 2 O
.	1050 1 O
40	1051 2 O
degrees	1054 7 O
(	1062 1 O
range	1063 5 O
22	1069 2 O
.	1071 1 O
5	1072 1 O
-	1073 1 O
49	1074 2 O
.	1076 1 O
75	1077 2 O
)	1079 1 O
after	1081 5 O
follow	1087 6 O
-	1093 1 O
up	1094 2 O
;	1096 1 O
P	1098 1 O
=	1099 1 O
0	1100 1 O
.	1101 1 O
338	1102 3 O
unpaired	1106 8 O
t	1115 1 O
-	1116 1 O
test	1117 4 O
.	1121 1 O

Only	1123 4 O
one	1128 3 O
patient	1132 7 O
demonstrated	1140 12 O
a	1153 1 O
deterioration	1155 13 B-Disease
in	1169 2 I-Disease
visual	1172 6 I-Disease
field	1179 5 I-Disease
during	1185 6 O
the	1192 3 O
study	1196 5 O
period	1202 6 O
and	1209 3 O
discontinued	1213 12 O
treatment	1226 9 O
.	1235 1 O

CONCLUSION	1237 10 O
:	1247 1 O
Established	1249 11 O
visual	1261 6 B-Disease
field	1268 5 I-Disease
defects	1274 7 I-Disease
presumed	1282 8 O
to	1291 2 O
be	1294 2 O
due	1297 3 O
to	1301 2 O
Vigabatrin	1304 10 B-Chemical
therapy	1315 7 O
did	1323 3 O
not	1327 3 O
usually	1331 7 O
progress	1339 8 O
in	1348 2 O
spite	1351 5 O
of	1357 2 O
continuing	1360 10 O
use	1371 3 O
of	1375 2 O
the	1378 3 O
medication	1382 10 O
.	1392 1 O

These	1394 5 O
data	1400 4 O
give	1405 4 O
support	1410 7 O
to	1418 2 O
the	1421 3 O
hypothesis	1425 10 O
that	1436 4 O
the	1441 3 O
pathogenesis	1445 12 O
of	1458 2 O
Vigabatrin	1461 10 B-Chemical
-	1471 1 O
associated	1472 10 O
visual	1483 6 B-Disease
field	1490 5 I-Disease
defects	1496 7 I-Disease
may	1504 3 O
be	1508 2 O
an	1511 2 O
idiosyncratic	1514 13 O
adverse	1528 7 O
drug	1536 4 O
reaction	1541 8 O
rather	1550 6 O
than	1557 4 O
dose	1562 4 O
-	1566 1 O
dependent	1567 9 O
toxicity	1577 8 B-Disease
.	1585 1 O

Induction	0 9 O
of	10 2 O
rosaceiform	13 11 O
dermatitis	25 10 B-Disease
during	36 6 O
treatment	43 9 O
of	53 2 O
facial	56 6 B-Disease
inflammatory	63 12 I-Disease
dermatoses	76 10 I-Disease
with	87 4 O
tacrolimus	92 10 B-Chemical
ointment	103 8 O
.	111 1 O

BACKGROUND	113 10 O
:	123 1 O
Tacrolimus	125 10 B-Chemical
ointment	136 8 O
is	145 2 O
increasingly	148 12 O
used	161 4 O
for	166 3 O
anti	170 4 O
-	174 1 O
inflammatory	175 12 O
treatment	188 9 O
of	198 2 O
sensitive	201 9 O
areas	211 5 O
such	217 4 O
as	222 2 O
the	225 3 O
face	229 4 O
,	233 1 O
and	235 3 O
recent	239 6 O
observations	246 12 O
indicate	259 8 O
that	268 4 O
the	273 3 O
treatment	277 9 O
is	287 2 O
effective	290 9 O
in	300 2 O
steroid	303 7 B-Chemical
-	310 1 O
aggravated	311 10 O
rosacea	322 7 B-Disease
and	330 3 O
perioral	334 8 B-Disease
dermatitis	343 10 I-Disease
.	353 1 O

We	355 2 O
report	358 6 O
on	365 2 O
rosaceiform	368 11 O
dermatitis	380 10 B-Disease
as	391 2 O
a	394 1 O
complication	396 12 O
of	409 2 O
treatment	412 9 O
with	422 4 O
tacrolimus	427 10 B-Chemical
ointment	438 8 O
.	446 1 O

OBSERVATIONS	448 12 O
:	460 1 O
Six	462 3 O
adult	466 5 O
patients	472 8 O
with	481 4 O
inflammatory	486 12 B-Disease
facial	499 6 I-Disease
dermatoses	506 10 I-Disease
were	517 4 O
treated	522 7 O
with	530 4 O
tacrolimus	535 10 B-Chemical
ointment	546 8 O
because	555 7 O
of	563 2 O
the	566 3 O
ineffectiveness	570 15 O
of	586 2 O
standard	589 8 O
treatments	598 10 O
.	608 1 O

Within	610 6 O
2	617 1 O
to	619 2 O
3	622 1 O
weeks	624 5 O
of	630 2 O
initially	633 9 O
effective	643 9 O
and	653 3 O
well	657 4 O
-	661 1 O
tolerated	662 9 O
treatment	672 9 O
,	681 1 O
3	683 1 O
patients	685 8 O
with	694 4 O
a	699 1 O
history	701 7 O
of	709 2 O
rosacea	712 7 B-Disease
and	720 3 O
1	724 1 O
with	726 4 O
a	731 1 O
history	733 7 O
of	741 2 O
acne	744 4 B-Disease
experienced	749 11 O
sudden	761 6 O
worsening	768 9 O
with	778 4 O
pustular	783 8 O
rosaceiform	792 11 O
lesions	804 7 O
.	811 1 O

Biopsy	813 6 O
revealed	820 8 O
an	829 2 O
abundance	832 9 O
of	842 2 O
Demodex	845 7 O
mites	853 5 O
in	859 2 O
2	862 1 O
of	864 2 O
these	867 5 O
patients	873 8 O
.	881 1 O

In	883 2 O
1	886 1 O
patient	888 7 O
with	896 4 O
eyelid	901 6 O
eczema	908 6 B-Disease
,	914 1 O
rosaceiform	916 11 O
periocular	928 10 B-Disease
dermatitis	939 10 I-Disease
gradually	950 9 O
appeared	960 8 O
after	969 5 O
3	975 1 O
weeks	977 5 O
of	983 2 O
treatment	986 9 O
.	995 1 O

In	997 2 O
1	1000 1 O
patient	1002 7 O
with	1010 4 O
atopic	1015 6 B-Disease
dermatitis	1022 10 I-Disease
,	1032 1 O
telangiectatic	1034 14 O
and	1049 3 O
papular	1053 7 B-Disease
rosacea	1061 7 I-Disease
insidiously	1069 11 O
appeared	1081 8 O
after	1090 5 O
5	1096 1 O
months	1098 6 O
of	1105 2 O
treatment	1108 9 O
.	1117 1 O

CONCLUSIONS	1119 11 O
:	1130 1 O
Our	1132 3 O
observations	1136 12 O
suggest	1149 7 O
that	1157 4 O
the	1162 3 O
spectrum	1166 8 O
of	1175 2 O
rosaceiform	1178 11 O
dermatitis	1190 10 B-Disease
as	1201 2 O
a	1204 1 O
complication	1206 12 O
of	1219 2 O
treatment	1222 9 O
with	1232 4 O
tacrolimus	1237 10 B-Chemical
ointment	1248 8 O
is	1257 2 O
heterogeneous	1260 13 O
.	1273 1 O

A	1275 1 O
variety	1277 7 O
of	1285 2 O
factors	1288 7 O
,	1295 1 O
such	1297 4 O
as	1302 2 O
vasoactive	1305 10 O
properties	1316 10 O
of	1327 2 O
tacrolimus	1330 10 B-Chemical
,	1340 1 O
proliferation	1342 13 O
of	1356 2 O
Demodex	1359 7 O
due	1367 3 O
to	1371 2 O
local	1374 5 O
immunosuppression	1380 17 O
,	1397 1 O
and	1399 3 O
the	1403 3 O
occlusive	1407 9 O
properties	1417 10 O
of	1428 2 O
the	1431 3 O
ointment	1435 8 O
,	1443 1 O
may	1445 3 O
be	1449 2 O
involved	1452 8 O
in	1461 2 O
the	1464 3 O
observed	1468 8 O
phenomena	1477 9 O
.	1486 1 O

Future	1488 6 O
studies	1495 7 O
are	1503 3 O
needed	1507 6 O
to	1514 2 O
identify	1517 8 O
individual	1526 10 O
risk	1537 4 O
factors	1542 7 O
.	1549 1 O

Structural	0 10 O
abnormalities	11 13 O
in	25 2 O
the	28 3 O
brains	32 6 O
of	39 2 O
human	42 5 O
subjects	48 8 O
who	57 3 O
use	61 3 O
methamphetamine	65 15 B-Chemical
.	80 1 O

We	82 2 O
visualize	85 9 O
,	94 1 O
for	96 3 O
the	100 3 O
first	104 5 O
time	110 4 O
,	114 1 O
the	116 3 O
profile	120 7 O
of	128 2 O
structural	131 10 B-Disease
deficits	142 8 I-Disease
in	151 2 I-Disease
the	154 3 I-Disease
human	158 5 I-Disease
brain	164 5 I-Disease
associated	170 10 O
with	181 4 O
chronic	186 7 O
methamphetamine	194 15 B-Chemical
(	210 1 O
MA	211 2 B-Chemical
)	213 1 O
abuse	215 5 O
.	220 1 O

Studies	222 7 O
of	230 2 O
human	233 5 O
subjects	239 8 O
who	248 3 O
have	252 4 O
used	257 4 O
MA	262 2 B-Chemical
chronically	265 11 O
have	277 4 O
revealed	282 8 O
deficits	291 8 O
in	300 2 O
dopaminergic	303 12 O
and	316 3 O
serotonergic	320 12 O
systems	333 7 O
and	341 3 O
cerebral	345 8 O
metabolic	354 9 B-Disease
abnormalities	364 13 I-Disease
.	377 1 O

Using	379 5 O
magnetic	385 8 O
resonance	394 9 O
imaging	404 7 O
(	412 1 O
MRI	413 3 O
)	416 1 O
and	418 3 O
new	422 3 O
computational	426 13 O
brain	440 5 O
-	445 1 O
mapping	446 7 O
techniques	454 10 O
,	464 1 O
we	466 2 O
determined	469 10 O
the	480 3 O
pattern	484 7 O
of	492 2 O
structural	495 10 O
brain	506 5 O
alterations	512 11 O
associated	524 10 O
with	535 4 O
chronic	540 7 O
MA	548 2 B-Chemical
abuse	551 5 O
in	557 2 O
human	560 5 O
subjects	566 8 O
and	575 3 O
related	579 7 O
these	587 5 O
deficits	593 8 O
to	602 2 O
cognitive	605 9 B-Disease
impairment	615 10 I-Disease
.	625 1 O

We	627 2 O
used	630 4 O
high	635 4 O
-	639 1 O
resolution	640 10 O
MRI	651 3 O
and	655 3 O
surface	659 7 O
-	666 1 O
based	667 5 O
computational	673 13 O
image	687 5 O
analyses	693 8 O
to	702 2 O
map	705 3 O
regional	709 8 O
abnormalities	718 13 B-Disease
in	732 2 I-Disease
the	735 3 I-Disease
cortex	739 6 I-Disease
,	745 1 I-Disease
hippocampus	747 11 I-Disease
,	758 1 I-Disease
white	760 5 I-Disease
matter	766 6 I-Disease
,	772 1 I-Disease
and	774 3 I-Disease
ventricles	778 10 I-Disease
in	789 2 O
22	792 2 O
human	795 5 O
subjects	801 8 O
who	810 3 O
used	814 4 O
MA	819 2 B-Chemical
and	822 3 O
21	826 2 O
age	829 3 O
-	832 1 O
matched	833 7 O
,	840 1 O
healthy	842 7 O
controls	850 8 O
.	858 1 O

Cortical	860 8 O
maps	869 4 O
revealed	874 8 O
severe	883 6 O
gray	890 4 O
-	894 1 O
matter	895 6 O
deficits	902 8 O
in	911 2 O
the	914 3 O
cingulate	918 9 O
,	927 1 O
limbic	929 6 O
,	935 1 O
and	937 3 O
paralimbic	941 10 O
cortices	952 8 O
of	961 2 O
MA	964 2 B-Chemical
abusers	967 7 O
(	975 1 O
averaging	976 9 O
11	986 2 O
.	988 1 O
3	989 1 O
%	990 1 O
below	992 5 O
control	998 7 O
;	1005 1 O
p	1007 1 O
<	1009 1 O
0	1011 1 O
.	1012 1 O
05	1013 2 O
)	1015 1 O
.	1016 1 O

On	1018 2 O
average	1021 7 O
,	1028 1 O
MA	1030 2 B-Chemical
abusers	1033 7 O
had	1041 3 O
7	1045 1 O
.	1046 1 O
8	1047 1 O
%	1048 1 O
smaller	1050 7 O
hippocampal	1058 11 O
volumes	1070 7 O
than	1078 4 O
control	1083 7 O
subjects	1091 8 O
(	1100 1 O
p	1101 1 O
<	1103 1 O
0	1105 1 O
.	1106 1 O
01	1107 2 O
;	1109 1 O
left	1111 4 O
,	1115 1 O
p	1117 1 O
=	1119 1 O
0	1121 1 O
.	1122 1 O
01	1123 2 O
;	1125 1 O
right	1127 5 O
,	1132 1 O
p	1134 1 O
<	1136 1 O
0	1138 1 O
.	1139 1 O
05	1140 2 O
)	1142 1 O
and	1144 3 O
significant	1148 11 O
white	1160 5 O
-	1165 1 O
matter	1166 6 O
hypertrophy	1173 11 B-Disease
(	1185 1 O
7	1186 1 O
.	1187 1 O
0	1188 1 O
%	1189 1 O
;	1190 1 O
p	1192 1 O
<	1194 1 O
0	1196 1 O
.	1197 1 O
01	1198 2 O
)	1200 1 O
.	1201 1 O

Hippocampal	1203 11 O
deficits	1215 8 O
were	1224 4 O
mapped	1229 6 O
and	1236 3 O
correlated	1240 10 O
with	1251 4 O
memory	1256 6 O
performance	1263 11 O
on	1275 2 O
a	1278 1 O
word	1280 4 O
-	1284 1 O
recall	1285 6 O
test	1292 4 O
(	1297 1 O
p	1298 1 O
<	1300 1 O
0	1302 1 O
.	1303 1 O
05	1304 2 O
)	1306 1 O
.	1307 1 O

MRI	1309 3 O
-	1312 1 O
based	1313 5 O
maps	1319 4 O
suggest	1324 7 O
that	1332 4 O
chronic	1337 7 O
methamphetamine	1345 15 B-Chemical
abuse	1361 5 O
causes	1367 6 O
a	1374 1 O
selective	1376 9 O
pattern	1386 7 O
of	1394 2 O
cerebral	1397 8 O
deterioration	1406 13 O
that	1420 4 O
contributes	1425 11 O
to	1437 2 O
impaired	1440 8 B-Disease
memory	1449 6 I-Disease
performance	1456 11 I-Disease
.	1467 1 O

MA	1469 2 B-Chemical
may	1472 3 O
selectively	1476 11 O
damage	1488 6 O
the	1495 3 O
medial	1499 6 O
temporal	1506 8 O
lobe	1515 4 O
and	1520 3 O
,	1523 1 O
consistent	1525 10 O
with	1536 4 O
metabolic	1541 9 O
studies	1551 7 O
,	1558 1 O
the	1560 3 O
cingulate	1564 9 O
-	1573 1 O
limbic	1574 6 O
cortex	1581 6 O
,	1587 1 O
inducing	1589 8 O
neuroadaptation	1598 15 O
,	1613 1 O
neuropil	1615 8 O
reduction	1624 9 O
,	1633 1 O
or	1635 2 O
cell	1638 4 O
death	1643 5 O
.	1648 1 O

Prominent	1650 9 O
white	1660 5 O
-	1665 1 O
matter	1666 6 O
hypertrophy	1673 11 B-Disease
may	1685 3 O
result	1689 6 O
from	1696 4 O
altered	1701 7 O
myelination	1709 11 O
and	1721 3 O
adaptive	1725 8 O
glial	1734 5 O
changes	1740 7 O
,	1747 1 O
including	1749 9 O
gliosis	1759 7 B-Disease
secondary	1767 9 O
to	1777 2 O
neuronal	1780 8 B-Disease
damage	1789 6 I-Disease
.	1795 1 O

These	1797 5 O
brain	1803 5 O
substrates	1809 10 O
may	1820 3 O
help	1824 4 O
account	1829 7 O
for	1837 3 O
the	1841 3 O
symptoms	1845 8 O
of	1854 2 O
MA	1857 2 B-Chemical
abuse	1860 5 O
,	1865 1 O
providing	1867 9 O
therapeutic	1877 11 O
targets	1889 7 O
for	1897 3 O
drug	1901 4 O
-	1905 1 O
induced	1906 7 O
brain	1914 5 B-Disease
injury	1920 6 I-Disease
.	1926 1 O

Disruption	0 10 O
of	11 2 O
hepatic	14 7 O
lipid	22 5 O
homeostasis	28 11 O
in	40 2 O
mice	43 4 O
after	48 5 O
amiodarone	54 10 B-Chemical
treatment	65 9 O
is	75 2 O
associated	78 10 O
with	89 4 O
peroxisome	94 10 O
proliferator	105 12 O
-	117 1 O
activated	118 9 O
receptor	128 8 O
-	136 1 O
alpha	137 5 O
target	143 6 O
gene	150 4 O
activation	155 10 O
.	165 1 O

Amiodarone	167 10 B-Chemical
,	177 1 O
an	179 2 O
efficacious	182 11 O
and	194 3 O
widely	198 6 O
used	205 4 O
antiarrhythmic	210 14 O
agent	225 5 O
,	230 1 O
has	232 3 O
been	236 4 O
reported	241 8 O
to	250 2 O
cause	253 5 O
hepatotoxicity	259 14 B-Disease
in	274 2 O
some	277 4 O
patients	282 8 O
.	290 1 O

To	292 2 O
gain	295 4 O
insight	300 7 O
into	308 4 O
the	313 3 O
mechanism	317 9 O
of	327 2 O
this	330 4 O
unwanted	335 8 O
effect	344 6 O
,	350 1 O
mice	352 4 O
were	357 4 O
administered	362 12 O
various	375 7 O
doses	383 5 O
of	389 2 O
amiodarone	392 10 B-Chemical
and	403 3 O
examined	407 8 O
for	416 3 O
changes	420 7 O
in	428 2 O
hepatic	431 7 O
histology	439 9 O
and	449 3 O
gene	453 4 O
regulation	458 10 O
.	468 1 O

Amiodarone	470 10 B-Chemical
induced	481 7 O
hepatomegaly	489 12 B-Disease
,	501 1 O
hepatocyte	503 10 O
microvesicular	514 14 O
lipid	529 5 O
accumulation	535 12 O
,	547 1 O
and	549 3 O
a	553 1 O
significant	555 11 O
decrease	567 8 O
in	576 2 O
serum	579 5 O
triglycerides	585 13 B-Chemical
and	599 3 O
glucose	603 7 B-Chemical
.	610 1 O

Northern	612 8 O
blot	621 4 O
analysis	626 8 O
of	635 2 O
hepatic	638 7 O
RNA	646 3 O
revealed	650 8 O
a	659 1 O
dose	661 4 O
-	665 1 O
dependent	666 9 O
increase	676 8 O
in	685 2 O
the	688 3 O
expression	692 10 O
of	703 2 O
a	706 1 O
number	708 6 O
of	715 2 O
genes	718 5 O
critical	724 8 O
for	733 3 O
fatty	737 5 B-Chemical
acid	743 4 I-Chemical
oxidation	748 9 O
,	757 1 O
lipoprotein	759 11 O
assembly	771 8 O
,	779 1 O
and	781 3 O
lipid	785 5 O
transport	791 9 O
.	800 1 O

Many	802 4 O
of	807 2 O
these	810 5 O
genes	816 5 O
are	822 3 O
regulated	826 9 O
by	836 2 O
the	839 3 O
peroxisome	843 10 O
proliferator	854 12 O
-	866 1 O
activated	867 9 O
receptor	877 8 O
-	885 1 O
alpha	886 5 O
(	892 1 O
PPARalpha	893 9 O
)	902 1 O
,	903 1 O
a	905 1 O
ligand	907 6 O
-	913 1 O
activated	914 9 O
nuclear	924 7 O
hormone	932 7 O
receptor	940 8 O
transcription	949 13 O
factor	963 6 O
.	969 1 O

The	971 3 O
absence	975 7 O
of	983 2 O
induction	986 9 O
of	996 2 O
these	999 5 O
genes	1005 5 O
as	1011 2 O
well	1014 4 O
as	1019 2 O
hepatomegaly	1022 12 B-Disease
in	1035 2 O
PPARalpha	1038 9 O
knockout	1048 8 O
[	1057 1 O
PPARalpha	1058 9 O
-	1067 1 O
/	1068 1 O
-	1069 1 O
]	1070 1 O
mice	1072 4 O
indicated	1077 9 O
that	1087 4 O
the	1092 3 O
effects	1096 7 O
of	1104 2 O
amiodarone	1107 10 B-Chemical
were	1118 4 O
dependent	1123 9 O
upon	1133 4 O
the	1138 3 O
presence	1142 8 O
of	1151 2 O
a	1154 1 O
functional	1156 10 O
PPARalpha	1167 9 O
gene	1177 4 O
.	1181 1 O

Compared	1183 8 O
to	1192 2 O
wild	1195 4 O
-	1199 1 O
type	1200 4 O
mice	1205 4 O
,	1209 1 O
treatment	1211 9 O
of	1221 2 O
PPARalpha	1224 9 O
-	1233 1 O
/	1234 1 O
-	1235 1 O
mice	1237 4 O
with	1242 4 O
amiodarone	1247 10 B-Chemical
resulted	1258 8 O
in	1267 2 O
an	1270 2 O
increased	1273 9 O
rate	1283 4 O
and	1288 3 O
extent	1292 6 O
of	1299 2 O
total	1302 5 O
body	1308 4 O
weight	1313 6 B-Disease
loss	1320 4 I-Disease
.	1324 1 O

The	1326 3 O
inability	1330 9 O
of	1340 2 O
amiodarone	1343 10 B-Chemical
to	1354 2 O
directly	1357 8 O
activate	1366 8 O
either	1375 6 O
human	1382 5 O
or	1388 2 O
mouse	1391 5 O
PPARalpha	1397 9 O
transiently	1407 11 O
expressed	1419 9 O
in	1429 2 O
human	1432 5 O
HepG2	1438 5 O
hepatoma	1444 8 B-Disease
cells	1453 5 O
indicates	1459 9 O
that	1469 4 O
the	1474 3 O
effects	1478 7 O
of	1486 2 O
amiodarone	1489 10 B-Chemical
on	1500 2 O
the	1503 3 O
function	1507 8 O
of	1516 2 O
this	1519 4 O
receptor	1524 8 O
were	1533 4 O
indirect	1538 8 O
.	1546 1 O

Based	1548 5 O
upon	1554 4 O
these	1559 5 O
results	1565 7 O
,	1572 1 O
we	1574 2 O
conclude	1577 8 O
that	1586 4 O
amiodarone	1591 10 B-Chemical
disrupts	1602 8 O
hepatic	1611 7 O
lipid	1619 5 O
homeostasis	1625 11 O
and	1637 3 O
that	1641 4 O
the	1646 3 O
increased	1650 9 O
expression	1660 10 O
of	1671 2 O
PPARalpha	1674 9 O
target	1684 6 O
genes	1691 5 O
is	1697 2 O
secondary	1700 9 O
to	1710 2 O
this	1713 4 O
toxic	1718 5 O
effect	1724 6 O
.	1730 1 O

These	1732 5 O
results	1738 7 O
provide	1746 7 O
important	1754 9 O
new	1764 3 O
mechanistic	1768 11 O
information	1780 11 O
regarding	1792 9 O
the	1802 3 O
hepatotoxic	1806 11 B-Disease
effects	1818 7 O
of	1826 2 O
amiodarone	1829 10 B-Chemical
and	1840 3 O
indicate	1844 8 O
that	1853 4 O
PPARalpha	1858 9 O
protects	1868 8 O
against	1877 7 O
amiodarone	1885 10 B-Chemical
-	1895 1 O
induced	1896 7 O
hepatotoxicity	1904 14 B-Disease
.	1918 1 O

Safety	0 6 O
and	7 3 O
compliance	11 10 O
with	22 4 O
once	27 4 O
-	31 1 O
daily	32 5 O
niacin	38 6 B-Chemical
extended	45 8 I-Chemical
-	53 1 I-Chemical
release	54 7 I-Chemical
/	61 1 I-Chemical
lovastatin	62 10 I-Chemical
as	73 2 O
initial	76 7 O
therapy	84 7 O
in	92 2 O
the	95 3 O
Impact	99 6 O
of	106 2 O
Medical	109 7 O
Subspecialty	117 12 O
on	130 2 O
Patient	133 7 O
Compliance	141 10 O
to	152 2 O
Treatment	155 9 O
(	165 1 O
IMPACT	166 6 O
)	172 1 O
study	174 5 O
.	179 1 O

Niacin	181 6 B-Chemical
extended	188 8 I-Chemical
-	196 1 I-Chemical
release	197 7 I-Chemical
/	204 1 I-Chemical
lovastatin	205 10 I-Chemical
is	216 2 O
a	219 1 O
new	221 3 O
combination	225 11 O
product	237 7 O
approved	245 8 O
for	254 3 O
treatment	258 9 O
of	268 2 O
primary	271 7 O
hypercholesterolemia	279 20 B-Disease
and	300 3 O
mixed	304 5 O
dyslipidemia	310 12 B-Disease
.	322 1 O

This	324 4 O
open	329 4 O
-	333 1 O
labeled	334 7 O
,	341 1 O
multicenter	343 11 O
study	355 5 O
evaluated	361 9 O
the	371 3 O
safety	375 6 O
of	382 2 O
bedtime	385 7 O
niacin	393 6 B-Chemical
extended	400 8 I-Chemical
-	408 1 I-Chemical
release	409 7 I-Chemical
/	416 1 I-Chemical
lovastatin	417 10 I-Chemical
when	428 4 O
dosed	433 5 O
as	439 2 O
initial	442 7 O
therapy	450 7 O
and	458 3 O
patient	462 7 O
compliance	470 10 O
to	481 2 O
treatment	484 9 O
in	494 2 O
various	497 7 O
clinical	505 8 O
practice	514 8 O
settings	523 8 O
.	531 1 O

A	533 1 O
total	535 5 O
of	541 2 O
4	544 1 O
,	545 1 O
499	546 3 O
patients	550 8 O
with	559 4 O
dyslipidemia	564 12 B-Disease
requiring	577 9 O
drug	587 4 O
intervention	592 12 O
was	605 3 O
enrolled	609 8 O
at	618 2 O
1	621 1 O
,	622 1 O
081	623 3 O
sites	627 5 O
.	632 1 O

Patients	634 8 O
were	643 4 O
treated	648 7 O
with	656 4 O
1	661 1 O
tablet	663 6 O
(	670 1 O
500	671 3 O
mg	675 2 O
of	678 2 O
niacin	681 6 B-Chemical
extended	688 8 O
-	696 1 O
release	697 7 O
/	704 1 O
20	705 2 O
mg	708 2 O
of	711 2 O
lovastatin	714 10 B-Chemical
)	724 1 O
once	726 4 O
nightly	731 7 O
for	739 3 O
4	743 1 O
weeks	745 5 O
and	751 3 O
then	755 4 O
2	760 1 O
tablets	762 7 O
for	770 3 O
8	774 1 O
weeks	776 5 O
.	781 1 O

Patients	783 8 O
also	792 4 O
received	797 8 O
dietary	806 7 O
counseling	814 10 O
,	824 1 O
educational	826 11 O
materials	838 9 O
,	847 1 O
and	849 3 O
reminders	853 9 O
to	863 2 O
call	866 4 O
a	871 1 O
toll	873 4 O
-	877 1 O
free	878 4 O
number	883 6 O
that	890 4 O
provided	895 8 O
further	904 7 O
education	912 9 O
about	922 5 O
dyslipidemia	928 12 B-Disease
and	941 3 O
niacin	945 6 B-Chemical
extended	952 8 I-Chemical
-	960 1 I-Chemical
release	961 7 I-Chemical
/	968 1 I-Chemical
lovastatin	969 10 I-Chemical
.	979 1 O

Primary	981 7 O
end	989 3 O
points	993 6 O
were	1000 4 O
study	1005 5 O
compliance	1011 10 O
,	1021 1 O
increases	1023 9 O
in	1033 2 O
liver	1036 5 O
transaminases	1042 13 O
to	1056 2 O
>	1059 1 O
3	1060 1 O
times	1062 5 O
the	1068 3 O
upper	1072 5 O
limit	1078 5 O
of	1084 2 O
normal	1087 6 O
,	1093 1 O
and	1095 3 O
clinical	1099 8 O
myopathy	1108 8 B-Disease
.	1116 1 O

Final	1118 5 O
study	1124 5 O
status	1130 6 O
was	1137 3 O
available	1141 9 O
for	1151 3 O
4	1155 1 O
,	1156 1 O
217	1157 3 O
patients	1161 8 O
(	1170 1 O
94	1171 2 O
%	1173 1 O
)	1174 1 O
.	1175 1 O

Compliance	1177 10 O
to	1188 2 O
niacin	1191 6 B-Chemical
extended	1198 8 I-Chemical
-	1206 1 I-Chemical
release	1207 7 I-Chemical
/	1214 1 I-Chemical
lovastatin	1215 10 I-Chemical
was	1226 3 O
77	1230 2 O
%	1232 1 O
,	1233 1 O
with	1235 4 O
3	1240 1 O
,	1241 1 O
245	1242 3 O
patients	1246 8 O
completing	1255 10 O
the	1266 3 O
study	1270 5 O
.	1275 1 O

Patients	1277 8 O
in	1286 2 O
the	1289 3 O
southeast	1293 9 O
and	1303 3 O
those	1307 5 O
enrolled	1313 8 O
by	1322 2 O
endocrinologists	1325 16 O
had	1342 3 O
the	1346 3 O
lowest	1350 6 O
compliance	1357 10 O
and	1368 3 O
highest	1372 7 O
adverse	1380 7 O
event	1388 5 O
rates	1394 5 O
.	1399 1 O

Flushing	1401 8 B-Disease
was	1410 3 O
the	1414 3 O
most	1418 4 O
common	1423 6 O
adverse	1430 7 O
event	1438 5 O
,	1443 1 O
reported	1445 8 O
by	1454 2 O
18	1457 2 O
%	1459 1 O
of	1461 2 O
patients	1464 8 O
and	1473 3 O
leading	1477 7 O
to	1485 2 O
discontinuation	1488 15 O
by	1504 2 O
6	1507 1 O
%	1508 1 O
.	1509 1 O

Incidence	1511 9 O
of	1521 2 O
increased	1524 9 O
aspartate	1534 9 B-Chemical
aminotransferase	1544 16 O
and	1561 3 O
/	1564 1 O
or	1565 2 O
alanine	1568 7 B-Chemical
aminotransferase	1576 16 O
>	1593 1 O
3	1594 1 O
times	1596 5 O
the	1602 3 O
upper	1606 5 O
limit	1612 5 O
of	1618 2 O
normal	1621 6 O
was	1628 3 O
<	1632 1 O
0	1633 1 O
.	1634 1 O
3	1635 1 O
%	1636 1 O
.	1637 1 O

An	1639 2 O
increase	1642 8 O
of	1651 2 O
creatine	1654 8 B-Chemical
phosphokinase	1663 13 O
to	1677 2 O
>	1680 1 O
5	1681 1 O
times	1683 5 O
the	1689 3 O
upper	1693 5 O
limit	1699 5 O
of	1705 2 O
normal	1708 6 O
occurred	1715 8 O
in	1724 2 O
0	1727 1 O
.	1728 1 O
24	1729 2 O
%	1731 1 O
of	1733 2 O
patients	1736 8 O
,	1744 1 O
and	1746 3 O
no	1750 2 O
cases	1753 5 O
of	1759 2 O
drug	1762 4 O
-	1766 1 O
induced	1767 7 O
myopathy	1775 8 B-Disease
were	1784 4 O
observed	1789 8 O
.	1797 1 O

Niacin	1799 6 B-Chemical
extended	1806 8 I-Chemical
-	1814 1 I-Chemical
release	1815 7 I-Chemical
/	1822 1 I-Chemical
lovastatin	1823 10 I-Chemical
1	1834 1 O
,	1835 1 O
000	1836 3 O
/	1839 1 O
40	1840 2 O
mg	1843 2 O
,	1845 1 O
dosed	1847 5 O
as	1853 2 O
initial	1856 7 O
therapy	1864 7 O
,	1871 1 O
was	1873 3 O
associated	1877 10 O
with	1888 4 O
good	1893 4 O
compliance	1898 10 O
and	1909 3 O
safety	1913 6 O
and	1920 3 O
had	1924 3 O
very	1928 4 O
low	1933 3 O
incidences	1937 10 O
of	1948 2 O
increased	1951 9 O
liver	1961 5 O
and	1967 3 O
muscle	1971 6 O
enzymes	1978 7 O
.	1985 1 O

Protective	0 10 O
effect	11 6 O
of	18 2 O
Terminalia	21 10 B-Chemical
chebula	32 7 I-Chemical
against	40 7 O
experimental	48 12 O
myocardial	61 10 B-Disease
injury	72 6 I-Disease
induced	79 7 O
by	87 2 O
isoproterenol	90 13 B-Chemical
.	103 1 O

Cardioprotective	105 16 O
effect	122 6 O
of	129 2 O
ethanolic	132 9 B-Chemical
extract	142 7 I-Chemical
of	150 2 I-Chemical
Terminalia	153 10 I-Chemical
chebula	164 7 I-Chemical
fruits	172 6 I-Chemical
(	179 1 O
500	180 3 O
mg	184 2 O
/	186 1 O
kg	187 2 O
body	190 4 O
wt	195 2 O
)	197 1 O
was	199 3 O
examined	203 8 O
in	212 2 O
isoproterenol	215 13 B-Chemical
(	229 1 O
200	230 3 O
mg	234 2 O
/	236 1 O
kg	237 2 O
body	240 4 O
wt	245 2 O
)	247 1 O
induced	249 7 O
myocardial	257 10 B-Disease
damage	268 6 I-Disease
in	275 2 O
rats	278 4 O
.	282 1 O

In	284 2 O
isoproterenol	287 13 B-Chemical
administered	301 12 O
rats	314 4 O
,	318 1 O
the	320 3 O
level	324 5 O
of	330 2 O
lipid	333 5 O
peroxides	339 9 B-Chemical
increased	349 9 O
significantly	359 13 O
in	373 2 O
the	376 3 O
serum	380 5 O
and	386 3 O
heart	390 5 O
.	395 1 O

A	397 1 O
significant	399 11 O
decrease	411 8 O
was	420 3 O
observed	424 8 O
in	433 2 O
the	436 3 O
activity	440 8 O
of	449 2 O
the	452 3 O
myocardial	456 10 O
marker	467 6 O
enzymes	474 7 O
with	482 4 O
a	487 1 O
concomitant	489 11 O
increase	501 8 O
in	510 2 O
their	513 5 O
activity	519 8 O
in	528 2 O
serum	531 5 O
.	536 1 O

Histopathological	538 17 O
examination	556 11 O
was	568 3 O
carried	572 7 O
out	580 3 O
to	584 2 O
confirm	587 7 O
the	595 3 O
myocardial	599 10 O
necrosis	610 8 B-Disease
.	618 1 O

T	620 1 B-Chemical
.	621 1 I-Chemical
chebula	623 7 I-Chemical
extract	631 7 I-Chemical
pretreatment	639 12 O
was	652 3 O
found	656 5 O
to	662 2 O
ameliorate	665 10 O
the	676 3 O
effect	680 6 O
of	687 2 O
isoproterenol	690 13 B-Chemical
on	704 2 O
lipid	707 5 O
peroxide	713 8 B-Chemical
formation	722 9 O
and	732 3 O
retained	736 8 O
the	745 3 O
activities	749 10 O
of	760 2 O
the	763 3 O
diagnostic	767 10 O
marker	778 6 O
enzymes	785 7 O
.	792 1 O

A	0 1 O
case	2 4 O
of	7 2 O
postoperative	10 13 O
anxiety	24 7 B-Disease
due	32 3 O
to	36 2 O
low	39 3 O
dose	43 4 O
droperidol	48 10 B-Chemical
used	59 4 O
with	64 4 O
patient	69 7 O
-	76 1 O
controlled	77 10 O
analgesia	88 9 O
.	97 1 O

A	99 1 O
multiparous	101 11 O
woman	113 5 O
in	119 2 O
good	122 4 O
psychological	127 13 O
health	141 6 O
underwent	148 9 O
urgent	158 6 O
caesarean	165 9 O
section	175 7 O
in	183 2 O
labour	186 6 O
.	192 1 O

Postoperatively	194 15 O
,	209 1 O
she	211 3 O
was	215 3 O
given	219 5 O
a	225 1 O
patient	227 7 O
-	234 1 O
controlled	235 10 O
analgesia	246 9 O
device	256 6 O
delivering	263 10 O
boluses	274 7 O
of	282 2 O
diamorphine	285 11 B-Chemical
0	297 1 O
.	298 1 O
5	299 1 O
mg	301 2 O
and	304 3 O
droperidol	308 10 B-Chemical
0	319 1 O
.	320 1 O
025	321 3 O
mg	325 2 O
.	327 1 O

Whilst	329 6 O
using	336 5 O
the	342 3 O
device	346 6 O
she	353 3 O
gradually	357 9 O
became	367 6 O
anxious	374 7 O
,	381 1 O
the	383 3 O
feeling	387 7 O
worsening	395 9 O
after	405 5 O
each	411 4 O
bolus	416 5 O
.	421 1 O

The	423 3 O
diagnosis	427 9 O
of	437 2 O
droperidol	440 10 B-Chemical
-	450 1 O
induced	451 7 O
psychological	459 13 B-Disease
disturbance	473 11 I-Disease
was	485 3 O
not	489 3 O
made	493 4 O
straight	498 8 O
away	507 4 O
although	512 8 O
on	521 2 O
subsequent	524 10 O
close	535 5 O
questioning	541 11 O
the	553 3 O
patient	557 7 O
gave	565 4 O
a	570 1 O
very	572 4 O
clear	577 5 O
history	583 7 O
.	590 1 O

After	592 5 O
she	598 3 O
had	602 3 O
received	606 8 O
a	615 1 O
total	617 5 O
of	623 2 O
only	626 4 O
0	631 1 O
.	632 1 O
9	633 1 O
mg	635 2 O
droperidol	638 10 B-Chemical
,	648 1 O
a	650 1 O
syringe	652 7 O
containing	660 10 O
diamorphine	671 11 B-Chemical
only	683 4 O
was	688 3 O
substituted	692 11 O
and	704 3 O
her	708 3 O
unease	712 6 O
resolved	719 8 O
completely	728 10 O
.	738 1 O

We	740 2 O
feel	743 4 O
that	748 4 O
,	752 1 O
although	754 8 O
the	763 3 O
dramatic	767 8 O
extrapyramidal	776 14 O
side	791 4 O
effects	796 7 O
of	804 2 O
dopaminergic	807 12 O
antiemetics	820 11 O
are	832 3 O
well	836 4 O
known	841 5 O
,	846 1 O
more	848 4 O
subtle	853 6 O
manifestations	860 14 O
may	875 3 O
easily	879 6 O
be	886 2 O
overlooked	889 10 O
.	899 1 O

Accurate	0 8 O
patient	9 7 O
history	17 7 O
contributes	25 11 O
to	37 2 O
differentiating	40 15 O
diabetes	56 8 B-Disease
insipidus	65 9 I-Disease
:	74 1 O
a	76 1 O
case	78 4 O
study	83 5 O
.	88 1 O

This	90 4 O
case	95 4 O
study	100 5 O
highlights	106 10 O
the	117 3 O
important	121 9 O
contribution	131 12 O
of	144 2 O
nursing	147 7 O
in	155 2 O
obtaining	158 9 O
an	168 2 O
accurate	171 8 O
health	180 6 O
history	187 7 O
.	194 1 O

The	196 3 O
case	200 4 O
discussed	205 9 O
herein	215 6 O
initially	222 9 O
appeared	232 8 O
to	241 2 O
be	244 2 O
neurogenic	247 10 B-Disease
diabetes	258 8 I-Disease
insipidus	267 9 I-Disease
(	277 1 O
DI	278 2 B-Disease
)	280 1 O
secondary	282 9 O
to	292 2 O
a	295 1 O
traumatic	297 9 B-Disease
brain	307 5 I-Disease
injury	313 6 I-Disease
.	319 1 O

The	321 3 O
nursing	325 7 O
staff	333 5 O
,	338 1 O
by	340 2 O
reviewing	343 9 O
the	353 3 O
patient	357 7 O
'	364 1 O
s	365 1 O
health	367 6 O
history	374 7 O
with	382 4 O
his	387 3 O
family	391 6 O
,	397 1 O
discovered	399 10 O
a	410 1 O
history	412 7 O
of	420 2 O
polydipsia	423 10 B-Disease
and	434 3 O
long	438 4 O
-	442 1 O
standing	443 8 O
lithium	452 7 B-Chemical
use	460 3 O
.	463 1 O

Lithium	465 7 B-Chemical
is	473 2 O
implicated	476 10 O
in	487 2 O
drug	490 4 O
-	494 1 O
induced	495 7 O
nephrogenic	503 11 B-Disease
DI	515 2 I-Disease
,	517 1 O
and	519 3 O
because	523 7 O
the	531 3 O
patient	535 7 O
had	543 3 O
not	547 3 O
received	551 8 O
lithium	560 7 B-Chemical
since	568 5 O
being	574 5 O
admitted	580 8 O
to	589 2 O
the	592 3 O
hospital	596 8 O
,	604 1 O
his	606 3 O
treatment	610 9 O
changed	620 7 O
to	628 2 O
focus	631 5 O
on	637 2 O
nephrogenic	640 11 B-Disease
DI	652 2 I-Disease
.	654 1 O

By	656 2 O
combining	659 9 O
information	669 11 O
from	681 4 O
the	686 3 O
patient	690 7 O
history	698 7 O
,	705 1 O
the	707 3 O
physical	711 8 O
examination	720 11 O
,	731 1 O
and	733 3 O
radiologic	737 10 O
and	748 3 O
laboratory	752 10 O
studies	763 7 O
,	770 1 O
the	772 3 O
critical	776 8 O
care	785 4 O
team	790 4 O
demonstrated	795 12 O
that	808 4 O
the	813 3 O
patient	817 7 O
had	825 3 O
been	829 4 O
self	834 4 O
-	838 1 O
treating	839 8 O
his	848 3 O
lithium	852 7 B-Chemical
-	859 1 O
induced	860 7 O
nephrogenic	868 11 B-Disease
DI	880 2 I-Disease
and	883 3 O
developed	887 9 O
neurogenic	897 10 B-Disease
DI	908 2 I-Disease
secondary	911 9 O
to	921 2 O
brain	924 5 B-Disease
trauma	930 6 I-Disease
.	936 1 O

Thus	938 4 O
successful	943 10 O
treatment	954 9 O
required	964 8 O
that	973 4 O
nephrogenic	978 11 O
and	990 3 O
neurogenic	994 10 B-Disease
DI	1005 2 I-Disease
be	1008 2 O
treated	1011 7 O
concomitantly	1019 13 O
.	1032 1 O

Factors	0 7 O
contributing	8 12 O
to	21 2 O
ribavirin	24 9 B-Chemical
-	33 1 O
induced	34 7 O
anemia	42 6 B-Disease
.	48 1 O

BACKGROUND	50 10 O
AND	61 3 O
AIM	65 3 O
:	68 1 O
Interferon	70 10 B-Chemical
and	81 3 O
ribavirin	85 9 B-Chemical
combination	95 11 O
therapy	107 7 O
for	115 3 O
chronic	119 7 B-Disease
hepatitis	127 9 I-Disease
C	137 1 I-Disease
produces	139 8 O
hemolytic	148 9 B-Disease
anemia	158 6 I-Disease
.	164 1 O

This	166 4 O
study	171 5 O
was	177 3 O
conducted	181 9 O
to	191 2 O
identify	194 8 O
the	203 3 O
factors	207 7 O
contributing	215 12 O
to	228 2 O
ribavirin	231 9 B-Chemical
-	240 1 O
induced	241 7 O
anemia	249 6 B-Disease
.	255 1 O

METHODS	257 7 O
:	264 1 O
Eighty	266 6 O
-	272 1 O
eight	273 5 O
patients	279 8 O
with	288 4 O
chronic	293 7 B-Disease
hepatitis	301 9 I-Disease
C	311 1 I-Disease
who	313 3 O
received	317 8 O
interferon	326 10 B-Chemical
-	336 1 I-Chemical
alpha	337 5 I-Chemical
-	342 1 I-Chemical
2b	343 2 I-Chemical
at	346 2 O
a	349 1 O
dose	351 4 O
of	356 2 O
6	359 1 O
MU	361 2 O
administered	364 12 O
intramuscularly	377 15 O
for	393 3 O
24	397 2 O
weeks	400 5 O
in	406 2 O
combination	409 11 O
with	421 4 O
ribavirin	426 9 B-Chemical
administered	436 12 O
orally	449 6 O
at	456 2 O
a	459 1 O
dose	461 4 O
of	466 2 O
600	469 3 O
mg	473 2 O
or	476 2 O
800	479 3 O
mg	483 2 O
participated	486 12 O
in	499 2 O
the	502 3 O
study	506 5 O
.	511 1 O

A	513 1 O
hemoglobin	515 10 O
concentration	526 13 O
of	540 2 O
<	543 1 O
10	544 2 O
g	547 1 O
/	548 1 O
dL	549 2 O
was	552 3 O
defined	556 7 O
as	564 2 O
ribavirin	567 9 B-Chemical
-	576 1 O
induced	577 7 O
anemia	585 6 B-Disease
.	591 1 O

RESULTS	593 7 O
:	600 1 O
Ribavirin	602 9 B-Chemical
-	611 1 O
induced	612 7 O
anemia	620 6 B-Disease
occurred	627 8 O
in	636 2 O
18	639 2 O
(	642 1 O
20	643 2 O
.	645 1 O
5	646 1 O
%	647 1 O
)	648 1 O
patients	650 8 O
during	659 6 O
treatment	666 9 O
.	675 1 O

A	677 1 O
2	679 1 O
g	681 1 O
/	682 1 O
dL	683 2 O
decrease	686 8 O
in	695 2 O
hemoglobin	698 10 O
concentrations	709 14 O
in	724 2 O
patients	727 8 O
with	736 4 O
anemia	741 6 B-Disease
was	748 3 O
observed	752 8 O
at	761 2 O
week	764 4 O
2	769 1 O
after	771 5 O
the	777 3 O
start	781 5 O
of	787 2 O
treatment	790 9 O
.	799 1 O

The	801 3 O
hemoglobin	805 10 O
concentration	816 13 O
in	830 2 O
patients	833 8 O
with	842 4 O
>	847 1 O
or	849 2 O
=	852 1 O
2	853 1 O
g	855 1 O
/	856 1 O
dL	857 2 O
decrease	860 8 O
at	869 2 O
week	872 4 O
2	877 1 O
was	879 3 O
observed	883 8 O
to	892 2 O
be	895 2 O
significantly	898 13 O
lower	912 5 O
even	918 4 O
after	923 5 O
week	929 4 O
2	934 1 O
than	936 4 O
in	941 2 O
patients	944 8 O
with	953 4 O
<	958 1 O
2	959 1 O
g	961 1 O
/	962 1 O
dL	963 2 O
decrease	966 8 O
(	975 1 O
P	976 1 O
<	978 1 O
0	980 1 O
.	981 1 O
01	982 2 O
)	984 1 O
.	985 1 O

A	987 1 O
significant	989 11 O
relationship	1001 12 O
was	1014 3 O
observed	1018 8 O
between	1027 7 O
the	1035 3 O
rate	1039 4 O
of	1044 2 O
reduction	1047 9 O
of	1057 2 O
hemoglobin	1060 10 O
concentrations	1071 14 O
at	1086 2 O
week	1089 4 O
2	1094 1 O
and	1096 3 O
the	1100 3 O
severity	1104 8 O
of	1113 2 O
anemia	1116 6 B-Disease
(	1123 1 O
P	1124 1 O
<	1126 1 O
0	1128 1 O
.	1129 1 O
01	1130 2 O
)	1132 1 O
.	1133 1 O

Such	1135 4 O
factors	1140 7 O
as	1148 2 O
sex	1151 3 O
(	1155 1 O
female	1156 6 O
)	1162 1 O
,	1163 1 O
age	1165 3 O
(	1169 1 O
>	1170 1 O
or	1172 2 O
=	1175 1 O
60	1176 2 O
years	1179 5 O
old	1185 3 O
)	1188 1 O
,	1189 1 O
and	1191 3 O
the	1195 3 O
ribavirin	1199 9 B-Chemical
dose	1209 4 O
by	1214 2 O
body	1217 4 O
weight	1222 6 O
(	1229 1 O
12	1230 2 O
mg	1233 2 O
/	1235 1 O
kg	1236 2 O
or	1239 2 O
more	1242 4 O
)	1246 1 O
were	1248 4 O
significant	1253 11 O
by	1265 2 O
univariate	1268 10 O
analysis	1279 8 O
.	1287 1 O

CONCLUSIONS	1289 11 O
:	1300 1 O
Careful	1302 7 O
administration	1310 14 O
is	1325 2 O
necessary	1328 9 O
in	1338 2 O
patients	1341 8 O
>	1350 1 O
or	1352 2 O
=	1355 1 O
60	1356 2 O
years	1359 5 O
old	1365 3 O
,	1368 1 O
in	1370 2 O
female	1373 6 O
patients	1380 8 O
,	1388 1 O
and	1390 3 O
in	1394 2 O
patients	1397 8 O
receiving	1406 9 O
a	1416 1 O
ribavirin	1418 9 B-Chemical
dose	1428 4 O
of	1433 2 O
12	1436 2 O
mg	1439 2 O
/	1441 1 O
kg	1442 2 O
or	1445 2 O
more	1448 4 O
.	1452 1 O

Patients	1454 8 O
who	1463 3 O
experience	1467 10 O
a	1478 1 O
fall	1480 4 O
in	1485 2 O
hemoglobin	1488 10 O
concentrations	1499 14 O
of	1514 2 O
2	1517 1 O
g	1519 1 O
/	1520 1 O
dL	1521 2 O
or	1524 2 O
more	1527 4 O
at	1532 2 O
week	1535 4 O
2	1540 1 O
after	1542 5 O
the	1548 3 O
start	1552 5 O
of	1558 2 O
treatment	1561 9 O
should	1571 6 O
be	1578 2 O
monitored	1581 9 O
with	1591 4 O
particular	1596 10 O
care	1607 4 O
.	1611 1 O

Oxidative	0 9 O
damage	10 6 O
precedes	17 8 O
nitrative	26 9 O
damage	36 6 O
in	43 2 O
adriamycin	46 10 B-Chemical
-	56 1 O
induced	57 7 O
cardiac	65 7 O
mitochondrial	73 13 B-Disease
injury	87 6 I-Disease
.	93 1 O

The	95 3 O
purpose	99 7 O
of	107 2 O
the	110 3 O
present	114 7 O
study	122 5 O
was	128 3 O
to	132 2 O
determine	135 9 O
if	145 2 O
elevated	148 8 O
reactive	157 8 O
oxygen	166 6 B-Chemical
(	173 1 O
ROS	174 3 O
)	177 1 O
/	178 1 O
nitrogen	179 8 B-Chemical
species	188 7 O
(	196 1 O
RNS	197 3 O
)	200 1 O
reported	202 8 O
to	211 2 O
be	214 2 O
present	217 7 O
in	225 2 O
adriamycin	228 10 B-Chemical
(	239 1 O
ADR	240 3 B-Chemical
)	243 1 O
-	244 1 O
induced	245 7 O
cardiotoxicity	253 14 B-Disease
actually	268 8 O
resulted	277 8 O
in	286 2 O
cardiomyocyte	289 13 O
oxidative	303 9 O
/	312 1 O
nitrative	313 9 O
damage	323 6 O
,	329 1 O
and	331 3 O
to	335 2 O
quantitatively	338 14 O
determine	353 9 O
the	363 3 O
time	367 4 O
course	372 6 O
and	379 3 O
subcellular	383 11 O
localization	395 12 O
of	408 2 O
these	411 5 O
postulated	417 10 O
damage	428 6 O
products	435 8 O
using	444 5 O
an	450 2 O
in	453 2 O
vivo	456 4 O
approach	461 8 O
.	469 1 O

B6C3	471 4 O
mice	476 4 O
were	481 4 O
treated	486 7 O
with	494 4 O
a	499 1 O
single	501 6 O
dose	508 4 O
of	513 2 O
20	516 2 O
mg	519 2 O
/	521 1 O
kg	522 2 O
ADR	525 3 B-Chemical
.	528 1 O

Ultrastructural	530 15 O
damage	546 6 O
and	553 3 O
levels	557 6 O
of	564 2 O
4	567 1 B-Chemical
-	568 1 I-Chemical
hydroxy	569 7 I-Chemical
-	576 1 I-Chemical
2	577 1 I-Chemical
-	578 1 I-Chemical
nonenal	579 7 I-Chemical
(	587 1 O
4HNE	588 4 B-Chemical
)	592 1 O
-	593 1 O
protein	594 7 O
adducts	602 7 O
and	610 3 O
3	614 1 B-Chemical
-	615 1 I-Chemical
nitrotyrosine	616 13 I-Chemical
(	630 1 O
3NT	631 3 B-Chemical
)	634 1 O
were	636 4 O
analyzed	641 8 O
.	649 1 O

Quantitative	651 12 O
ultrastructural	664 15 O
damage	680 6 O
using	687 5 O
computerized	693 12 O
image	706 5 O
techniques	712 10 O
showed	723 6 O
cardiomyocyte	730 13 O
injury	744 6 O
as	751 2 O
early	754 5 O
as	760 2 O
3	763 1 O
hours	765 5 O
,	770 1 O
with	772 4 O
mitochondria	777 12 O
being	790 5 O
the	796 3 O
most	800 4 O
extensively	805 11 O
and	817 3 O
progressively	821 13 O
injured	835 7 O
subcellular	843 11 O
organelle	855 9 O
.	864 1 O

Analysis	866 8 O
of	875 2 O
4HNE	878 4 B-Chemical
protein	883 7 O
adducts	891 7 O
by	899 2 O
immunogold	902 10 O
electron	913 8 O
microscopy	922 10 O
showed	933 6 O
appearance	940 10 O
of	951 2 O
4HNE	954 4 B-Chemical
protein	959 7 O
adducts	967 7 O
in	975 2 O
mitochondria	978 12 O
as	991 2 O
early	994 5 O
as	1000 2 O
3	1003 1 O
hours	1005 5 O
,	1010 1 O
with	1012 4 O
a	1017 1 O
peak	1019 4 O
at	1024 2 O
6	1027 1 O
hours	1029 5 O
and	1035 3 O
subsequent	1039 10 O
decline	1050 7 O
at	1058 2 O
24	1061 2 O
hours	1064 5 O
.	1069 1 O

3NT	1071 3 B-Chemical
levels	1075 6 O
were	1082 4 O
significantly	1087 13 O
increased	1101 9 O
in	1111 2 O
all	1114 3 O
subcellular	1118 11 O
compartments	1130 12 O
at	1143 2 O
6	1146 1 O
hours	1148 5 O
and	1154 3 O
subsequently	1158 12 O
declined	1171 8 O
at	1180 2 O
24	1183 2 O
hours	1186 5 O
.	1191 1 O

Our	1193 3 O
data	1197 4 O
showed	1202 6 O
ADR	1209 3 B-Chemical
induced	1213 7 O
4HNE	1221 4 B-Chemical
-	1225 1 O
protein	1226 7 O
adducts	1234 7 O
in	1242 2 O
mitochondria	1245 12 O
at	1258 2 O
the	1261 3 O
same	1265 4 O
time	1270 4 O
point	1275 5 O
as	1281 2 O
when	1284 4 O
mitochondrial	1289 13 B-Disease
injury	1303 6 I-Disease
initially	1310 9 O
appeared	1320 8 O
.	1328 1 O

These	1330 5 O
results	1336 7 O
document	1344 8 O
for	1353 3 O
the	1357 3 O
first	1361 5 O
time	1367 4 O
in	1372 2 O
vivo	1375 4 O
that	1380 4 O
mitochondrial	1385 13 B-Disease
oxidative	1399 9 I-Disease
damage	1409 6 I-Disease
precedes	1416 8 O
nitrative	1425 9 O
damage	1435 6 O
.	1441 1 O

The	1443 3 O
progressive	1447 11 O
nature	1459 6 O
of	1466 2 O
mitochondrial	1469 13 B-Disease
injury	1483 6 I-Disease
suggests	1490 8 O
that	1499 4 O
mitochondria	1504 12 O
,	1516 1 O
not	1518 3 O
other	1522 5 O
subcellular	1528 11 O
organelles	1540 10 O
,	1550 1 O
are	1552 3 O
the	1556 3 O
major	1560 5 O
site	1566 4 O
of	1571 2 O
intracellular	1574 13 O
injury	1588 6 O
.	1594 1 O

Sotalol	0 7 B-Chemical
-	7 1 O
induced	8 7 O
coronary	16 8 B-Disease
spasm	25 5 I-Disease
in	31 2 O
a	34 1 O
patient	36 7 O
with	44 4 O
dilated	49 7 B-Disease
cardiomyopathy	57 14 I-Disease
associated	72 10 O
with	83 4 O
sustained	88 9 O
ventricular	98 11 B-Disease
tachycardia	110 11 I-Disease
.	121 1 O

A	123 1 O
54	125 2 O
-	127 1 O
year	128 4 O
-	132 1 O
old	133 3 O
man	137 3 O
with	141 4 O
severe	146 6 O
left	153 4 O
ventricular	158 11 B-Disease
dysfunction	170 11 I-Disease
due	182 3 O
to	186 2 O
dilated	189 7 B-Disease
cardiomyopathy	197 14 I-Disease
was	212 3 O
referred	216 8 O
to	225 2 O
our	228 3 O
hospital	232 8 O
for	241 3 O
symptomatic	245 11 O
incessant	257 9 O
sustained	267 9 O
ventricular	277 11 B-Disease
tachycardia	289 11 I-Disease
(	301 1 O
VT	302 2 B-Disease
)	304 1 O
.	305 1 O

After	307 5 O
the	313 3 O
administration	317 14 O
of	332 2 O
nifekalant	335 10 B-Chemical
hydrochloride	346 13 I-Chemical
,	359 1 O
sustained	361 9 O
VT	371 2 B-Disease
was	374 3 O
terminated	378 10 O
.	388 1 O

An	390 2 O
alternate	393 9 O
class	403 5 O
III	409 3 O
agent	413 5 O
,	418 1 O
sotalol	420 7 B-Chemical
,	427 1 O
was	429 3 O
also	433 4 O
effective	438 9 O
for	448 3 O
the	452 3 O
prevention	456 10 O
of	467 2 O
VT	470 2 B-Disease
.	472 1 O

However	474 7 O
,	481 1 O
one	483 3 O
month	487 5 O
after	493 5 O
switching	499 9 O
over	509 4 O
nifekalant	514 10 B-Chemical
to	525 2 O
sotalol	528 7 B-Chemical
,	535 1 O
a	537 1 O
short	539 5 O
duration	545 8 O
of	554 2 O
ST	557 2 O
elevation	560 9 O
was	570 3 O
documented	574 10 O
in	585 2 O
ECG	588 3 O
monitoring	592 10 O
at	603 2 O
almost	606 6 O
the	613 3 O
same	617 4 O
time	622 4 O
for	627 3 O
three	631 5 O
consecutive	637 11 O
days	649 4 O
.	653 1 O

ST	655 2 O
elevation	658 9 O
with	668 4 O
chest	673 5 O
discomfort	679 10 O
disappeared	690 11 O
since	702 5 O
he	708 2 O
began	711 5 O
taking	717 6 O
long	724 4 O
-	728 1 O
acting	729 6 O
diltiazem	736 9 B-Chemical
.	745 1 O

Coronary	747 8 B-Disease
vasospasm	756 9 I-Disease
may	766 3 O
be	770 2 O
induced	773 7 O
by	781 2 O
the	784 3 O
non	788 3 O
-	791 1 O
selective	792 9 O
beta	802 4 O
-	806 1 O
blocking	807 8 O
properties	816 10 O
of	827 2 O
sotalol	830 7 B-Chemical
.	837 1 O

Effects	0 7 O
of	8 2 O
the	11 3 O
antidepressant	15 14 O
trazodone	30 9 B-Chemical
,	39 1 O
a	41 1 O
5	43 1 B-Chemical
-	44 1 I-Chemical
HT	45 2 I-Chemical
2A	48 2 O
/	50 1 O
2C	51 2 O
receptor	54 8 O
antagonist	63 10 O
,	73 1 O
on	75 2 O
dopamine	78 8 B-Chemical
-	86 1 O
dependent	87 9 O
behaviors	97 9 O
in	107 2 O
rats	110 4 O
.	114 1 O

RATIONALE	116 9 O
:	125 1 O
5	127 1 B-Chemical
-	128 1 I-Chemical
Hydroxytryptamine	129 17 I-Chemical
,	146 1 O
via	148 3 O
stimulation	152 11 O
of	164 2 O
5	167 1 B-Chemical
-	168 1 I-Chemical
HT	169 2 I-Chemical
2C	172 2 O
receptors	175 9 O
,	184 1 O
exerts	186 6 O
a	193 1 O
tonic	195 5 O
inhibitory	201 10 O
influence	212 9 O
on	222 2 O
dopaminergic	225 12 O
neurotransmission	238 17 O
,	255 1 O
whereas	257 7 O
activation	265 10 O
of	276 2 O
5	279 1 B-Chemical
-	280 1 I-Chemical
HT	281 2 I-Chemical
2A	284 2 O
receptors	287 9 O
enhances	297 8 O
stimulated	306 10 O
DAergic	317 7 O
neurotransmission	325 17 O
.	342 1 O

The	344 3 O
antidepressant	348 14 O
trazodone	363 9 B-Chemical
is	373 2 O
a	376 1 O
5	378 1 B-Chemical
-	379 1 I-Chemical
HT	380 2 I-Chemical
2A	383 2 O
/	385 1 O
2C	386 2 O
receptor	389 8 O
antagonist	398 10 O
.	408 1 O

OBJECTIVES	410 10 O
:	420 1 O
To	422 2 O
evaluate	425 8 O
the	434 3 O
effect	438 6 O
of	445 2 O
trazodone	448 9 B-Chemical
treatment	458 9 O
on	468 2 O
behaviors	471 9 O
dependent	481 9 O
on	491 2 O
the	494 3 O
functional	498 10 O
status	509 6 O
of	516 2 O
the	519 3 O
nigrostriatal	523 13 O
DAergic	537 7 O
system	545 6 O
.	551 1 O

METHODS	553 7 O
:	560 1 O
The	562 3 O
effect	566 6 O
of	573 2 O
pretreatment	576 12 O
with	589 4 O
trazodone	594 9 B-Chemical
on	604 2 O
dexamphetamine	607 14 B-Chemical
-	621 1 O
and	623 3 O
apomorphine	627 11 B-Chemical
-	638 1 O
induced	639 7 O
oral	647 4 B-Disease
stereotypies	652 12 I-Disease
,	664 1 O
on	666 2 O
catalepsy	669 9 B-Disease
induced	679 7 O
by	687 2 O
haloperidol	690 11 B-Chemical
and	702 3 O
apomorphine	706 11 B-Chemical
(	718 1 O
0	719 1 O
.	720 1 O
05	721 2 O
mg	724 2 O
/	726 1 O
kg	727 2 O
,	729 1 O
i	731 1 O
.	732 1 O
p	733 1 O
.	734 1 O
)	735 1 O
,	736 1 O
on	738 2 O
ergometrine	741 11 B-Chemical
-	752 1 O
induced	753 7 O
wet	761 3 O
dog	765 3 O
shake	769 5 O
(	775 1 O
WDS	776 3 O
)	779 1 O
behavior	781 8 O
and	790 3 O
fluoxetine	794 10 B-Chemical
-	804 1 O
induced	805 7 O
penile	813 6 O
erections	820 9 O
was	830 3 O
studied	834 7 O
in	842 2 O
rats	845 4 O
.	849 1 O

We	851 2 O
also	854 4 O
investigated	859 12 O
whether	872 7 O
trazodone	880 9 B-Chemical
induces	890 7 O
catalepsy	898 9 B-Disease
in	908 2 O
rats	911 4 O
.	915 1 O

RESULTS	917 7 O
:	924 1 O
Trazodone	926 9 B-Chemical
at	936 2 O
2	939 1 O
.	940 1 O
5	941 1 O
-	942 1 O
20	943 2 O
mg	946 2 O
/	948 1 O
kg	949 2 O
i	952 1 O
.	953 1 O
p	954 1 O
.	955 1 O
did	957 3 O
not	961 3 O
induce	965 6 O
catalepsy	972 9 B-Disease
,	981 1 O
and	983 3 O
did	987 3 O
not	991 3 O
antagonize	995 10 O
apomorphine	1006 11 B-Chemical
(	1018 1 O
1	1019 1 O
.	1020 1 O
5	1021 1 O
and	1023 3 O
3	1027 1 O
mg	1029 2 O
/	1031 1 O
kg	1032 2 O
)	1034 1 O
stereotypy	1036 10 O
and	1047 3 O
apomorphine	1051 11 B-Chemical
(	1063 1 O
0	1064 1 O
.	1065 1 O
05	1066 2 O
mg	1069 2 O
/	1071 1 O
kg	1072 2 O
)	1074 1 O
-	1075 1 O
induced	1076 7 O
catalepsy	1084 9 B-Disease
.	1093 1 O

However	1095 7 O
,	1102 1 O
pretreatment	1104 12 O
with	1117 4 O
5	1122 1 O
,	1123 1 O
10	1125 2 O
and	1128 3 O
20	1132 2 O
mg	1135 2 O
/	1137 1 O
kg	1138 2 O
i	1141 1 O
.	1142 1 O
p	1143 1 O
.	1144 1 O
trazodone	1146 9 B-Chemical
enhanced	1156 8 O
dexamphetamine	1165 14 B-Chemical
stereotypy	1180 10 O
,	1190 1 O
and	1192 3 O
antagonized	1196 11 O
haloperidol	1208 11 B-Chemical
catalepsy	1220 9 B-Disease
,	1229 1 O
ergometrine	1231 11 B-Chemical
-	1242 1 O
induced	1243 7 O
WDS	1251 3 O
behavior	1255 8 O
and	1264 3 O
fluoxetine	1268 10 B-Chemical
-	1278 1 O
induced	1279 7 O
penile	1287 6 O
erections	1294 9 O
.	1303 1 O

Trazodone	1305 9 B-Chemical
at	1315 2 O
30	1318 2 O
,	1320 1 O
40	1322 2 O
and	1325 3 O
50	1329 2 O
mg	1332 2 O
/	1334 1 O
kg	1335 2 O
i	1338 1 O
.	1339 1 O
p	1340 1 O
.	1341 1 O
induced	1343 7 O
catalepsy	1351 9 B-Disease
and	1361 3 O
antagonized	1365 11 O
apomorphine	1377 11 B-Chemical
and	1389 3 O
dexamphetamine	1393 14 B-Chemical
stereotypies	1408 12 O
.	1420 1 O

CONCLUSIONS	1422 11 O
:	1433 1 O
Our	1435 3 O
results	1439 7 O
indicate	1447 8 O
that	1456 4 O
trazodone	1461 9 B-Chemical
at	1471 2 O
2	1474 1 O
.	1475 1 O
5	1476 1 O
-	1477 1 O
20	1478 2 O
mg	1481 2 O
/	1483 1 O
kg	1484 2 O
does	1487 4 O
not	1492 3 O
block	1496 5 O
pre	1502 3 O
-	1505 1 O
and	1507 3 O
postsynaptic	1511 12 O
striatal	1524 8 O
D2	1533 2 O
DA	1536 2 O
receptors	1539 9 O
,	1548 1 O
while	1550 5 O
at	1556 2 O
30	1559 2 O
,	1561 1 O
40	1563 2 O
and	1566 3 O
50	1570 2 O
mg	1573 2 O
/	1575 1 O
kg	1576 2 O
it	1579 2 O
blocks	1582 6 O
postsynaptic	1589 12 O
striatal	1602 8 O
D2	1611 2 O
DA	1614 2 O
receptors	1617 9 O
.	1626 1 O

Furthermore	1628 11 O
,	1639 1 O
at	1641 2 O
5	1644 1 O
,	1645 1 O
10	1647 2 O
and	1650 3 O
20	1654 2 O
mg	1657 2 O
/	1659 1 O
kg	1660 2 O
,	1662 1 O
trazodone	1664 9 B-Chemical
blocks	1674 6 O
5	1681 1 B-Chemical
-	1682 1 I-Chemical
HT	1683 2 I-Chemical
2A	1686 2 O
and	1689 3 O
5	1693 1 B-Chemical
-	1694 1 I-Chemical
HT	1695 2 I-Chemical
2C	1698 2 O
receptors	1701 9 O
.	1710 1 O

We	1712 2 O
suggest	1715 7 O
that	1723 4 O
trazodone	1728 9 B-Chemical
(	1738 1 O
5	1739 1 O
,	1740 1 O
10	1742 2 O
and	1745 3 O
20	1749 2 O
mg	1752 2 O
/	1754 1 O
kg	1755 2 O
)	1757 1 O
,	1758 1 O
by	1760 2 O
blocking	1763 8 O
the	1772 3 O
5	1776 1 B-Chemical
-	1777 1 I-Chemical
HT	1778 2 I-Chemical
2C	1781 2 O
receptors	1784 9 O
,	1793 1 O
releases	1795 8 O
the	1804 3 O
nigrostriatal	1808 13 O
DAergic	1822 7 O
neurons	1830 7 O
from	1838 4 O
tonic	1843 5 O
inhibition	1849 10 O
caused	1860 6 O
by	1867 2 O
5	1870 1 B-Chemical
-	1871 1 I-Chemical
HT	1872 2 I-Chemical
,	1874 1 O
and	1876 3 O
thereby	1880 7 O
potentiates	1888 11 O
dexamphetamine	1900 14 B-Chemical
stereotypy	1915 10 O
and	1926 3 O
antagonizes	1930 11 O
haloperidol	1942 11 B-Chemical
catalepsy	1954 9 B-Disease
.	1963 1 O

Swallowing	0 10 B-Disease
abnormalities	11 13 I-Disease
and	25 3 O
dyskinesia	29 10 B-Disease
in	40 2 O
Parkinson	43 9 B-Disease
'	52 1 I-Disease
s	53 1 I-Disease
disease	55 7 I-Disease
.	62 1 O

Gastrointestinal	64 16 B-Disease
abnormalities	81 13 I-Disease
in	95 2 O
Parkinson	98 9 B-Disease
'	107 1 I-Disease
s	108 1 I-Disease
disease	110 7 I-Disease
(	118 1 O
PD	119 2 B-Disease
)	121 1 O
have	123 4 O
been	128 4 O
known	133 5 O
for	139 3 O
almost	143 6 O
two	150 3 O
centuries	154 9 O
,	163 1 O
but	165 3 O
many	169 4 O
aspects	174 7 O
concerning	182 10 O
their	193 5 O
pathophysiology	199 15 O
have	215 4 O
not	220 3 O
been	224 4 O
completely	229 10 O
clarified	240 9 O
.	249 1 O

The	251 3 O
aim	255 3 O
of	259 2 O
this	262 4 O
study	267 5 O
was	273 3 O
to	277 2 O
characterize	280 12 O
the	293 3 O
oropharyngeal	297 13 O
dynamics	311 8 O
in	320 2 O
PD	323 2 B-Disease
patients	326 8 O
with	335 4 O
and	340 3 O
without	344 7 O
levodopa	352 8 B-Chemical
-	360 1 O
induced	361 7 O
dyskinesia	369 10 B-Disease
.	379 1 O

Fifteen	381 7 O
dyskinetic	389 10 B-Disease
,	399 1 O
12	401 2 O
nondyskinetic	404 13 O
patients	418 8 O
,	426 1 O
and	428 3 O
a	432 1 O
control	434 7 O
group	442 5 O
were	448 4 O
included	453 8 O
.	461 1 O

Patients	463 8 O
were	472 4 O
asked	477 5 O
about	483 5 O
dysphagia	489 9 B-Disease
and	499 3 O
evaluated	503 9 O
with	513 4 O
the	518 3 O
Unified	522 7 O
Parkinson	530 9 B-Disease
'	539 1 I-Disease
s	540 1 I-Disease
Disease	542 7 I-Disease
Rating	550 6 O
Scale	557 5 O
Parts	563 5 O
II	569 2 O
and	572 3 O
III	576 3 O
and	580 3 O
the	584 3 O
Hoehn	588 5 O
and	594 3 O
Yahr	598 4 O
scale	603 5 O
.	608 1 O

Deglutition	610 11 O
was	622 3 O
assessed	626 8 O
using	635 5 O
modified	641 8 O
barium	650 6 B-Chemical
swallow	657 7 O
with	665 4 O
videofluoroscopy	670 16 O
.	686 1 O

Nondyskinetic	688 13 O
patients	702 8 O
,	710 1 O
but	712 3 O
not	716 3 O
the	720 3 O
dyskinetic	724 10 B-Disease
ones	735 4 O
,	739 1 O
showed	741 6 O
less	748 4 O
oropharyngeal	753 13 O
swallowing	767 10 O
efficiency	778 10 O
(	789 1 O
OPSE	790 4 O
)	794 1 O
for	796 3 O
liquid	800 6 O
food	807 4 O
than	812 4 O
controls	817 8 O
(	826 1 O
Dunnett	827 7 O
,	834 1 O
P	836 1 O
=	838 1 O
0	840 1 O
.	841 1 O
02	842 2 O
)	844 1 O
.	845 1 O

Dyskinetic	847 10 B-Disease
patients	858 8 O
tended	867 6 O
to	874 2 O
have	877 4 O
a	882 1 O
greater	884 7 O
OPSE	892 4 O
than	897 4 O
nondyskinetic	902 13 O
(	916 1 O
Dunnett	917 7 O
,	924 1 O
P	926 1 O
=	928 1 O
0	930 1 O
.	931 1 O
06	932 2 O
)	934 1 O
.	935 1 O

Patients	937 8 O
who	946 3 O
were	950 4 O
using	955 5 O
a	961 1 O
higher	963 6 O
dose	970 4 O
of	975 2 O
levodopa	978 8 B-Chemical
had	987 3 O
a	991 1 O
greater	993 7 O
OPSE	1001 4 O
and	1006 3 O
a	1010 1 O
trend	1012 5 O
toward	1018 6 O
a	1025 1 O
smaller	1027 7 O
oral	1035 4 O
transit	1040 7 O
time	1048 4 O
(	1053 1 O
Pearson	1054 7 O
'	1061 1 O
s	1062 1 O
correlation	1064 11 O
,	1075 1 O
P	1077 1 O
=	1079 1 O
0	1081 1 O
.	1082 1 O
01	1083 2 O
and	1086 3 O
0	1090 1 O
.	1091 1 O
08	1092 2 O
,	1094 1 O
respectively	1096 12 O
)	1108 1 O
.	1109 1 O

Neither	1111 7 O
the	1119 3 O
report	1123 6 O
of	1130 2 O
dysphagia	1133 9 B-Disease
nor	1143 3 O
any	1147 3 O
of	1151 2 O
the	1154 3 O
PD	1158 2 B-Disease
severity	1161 8 O
parameters	1170 10 O
correlated	1181 10 O
to	1192 2 O
the	1195 3 O
videofluoroscopic	1199 17 O
variables	1217 9 O
.	1226 1 O

In	1228 2 O
the	1231 3 O
current	1235 7 O
study	1243 5 O
,	1248 1 O
dyskinetic	1250 10 B-Disease
patients	1261 8 O
performed	1270 9 O
better	1280 6 O
in	1287 2 O
swallowing	1290 10 O
function	1301 8 O
,	1309 1 O
which	1311 5 O
could	1317 5 O
be	1323 2 O
explained	1326 9 O
on	1336 2 O
the	1339 3 O
basis	1343 5 O
of	1349 2 O
a	1352 1 O
greater	1354 7 O
levodopa	1362 8 B-Chemical
dose	1371 4 O
.	1375 1 O

Our	1377 3 O
results	1381 7 O
suggest	1389 7 O
a	1397 1 O
role	1399 4 O
for	1404 3 O
levodopa	1408 8 B-Chemical
in	1417 2 O
the	1420 3 O
oral	1424 4 O
phase	1429 5 O
of	1435 2 O
deglutition	1438 11 O
and	1450 3 O
confirm	1454 7 O
that	1462 4 O
dysphagia	1467 9 B-Disease
is	1477 2 O
not	1480 3 O
a	1484 1 O
good	1486 4 O
predictor	1491 9 O
of	1501 2 O
deglutition	1504 11 O
alterations	1516 11 O
in	1528 2 O
PD	1531 2 B-Disease
.	1533 1 O

Inhibition	0 10 O
of	11 2 O
nuclear	14 7 O
factor	22 6 O
-	28 1 O
kappaB	29 6 O
activation	36 10 O
attenuates	47 10 O
tubulointerstitial	58 18 B-Disease
nephritis	77 9 I-Disease
induced	87 7 O
by	95 2 O
gentamicin	98 10 B-Chemical
.	108 1 O

BACKGROUND	110 10 O
:	120 1 O
Animals	122 7 O
treated	130 7 O
with	138 4 O
gentamicin	143 10 B-Chemical
can	154 3 O
show	158 4 O
residual	163 8 O
areas	172 5 O
of	178 2 O
interstitial	181 12 O
fibrosis	194 8 B-Disease
in	203 2 O
the	206 3 O
renal	210 5 O
cortex	216 6 O
.	222 1 O

This	224 4 O
study	229 5 O
investigated	235 12 O
the	248 3 O
expression	252 10 O
of	263 2 O
nuclear	266 7 O
factor	274 6 O
-	280 1 O
kappaB	281 6 O
(	288 1 O
NF	289 2 O
-	291 1 O
kappaB	292 6 O
)	298 1 O
,	299 1 O
mitogen	301 7 O
-	308 1 O
activated	309 9 O
protein	319 7 O
(	327 1 O
MAP	328 3 O
)	331 1 O
kinases	333 7 O
and	341 3 O
macrophages	345 11 O
in	357 2 O
the	360 3 O
renal	364 5 O
cortex	370 6 O
and	377 3 O
structural	381 10 O
and	392 3 O
functional	396 10 O
renal	407 5 O
changes	413 7 O
of	421 2 O
rats	424 4 O
treated	429 7 O
with	437 4 O
gentamicin	442 10 B-Chemical
or	453 2 O
gentamicin	456 10 B-Chemical
+	467 1 O
pyrrolidine	469 11 B-Chemical
dithiocarbamate	481 15 I-Chemical
(	497 1 O
PDTC	498 4 B-Chemical
)	502 1 O
,	503 1 O
an	505 2 O
NF	508 2 O
-	510 1 O
kappaB	511 6 O
inhibitor	518 9 O
.	527 1 O

METHODS	529 7 O
:	536 1 O
38	538 2 O
female	541 6 O
Wistar	548 6 O
rats	555 4 O
were	560 4 O
injected	565 8 O
with	574 4 O
gentamicin	579 10 B-Chemical
,	589 1 O
40	591 2 O
mg	594 2 O
/	596 1 O
kg	597 2 O
,	599 1 O
twice	601 5 O
a	607 1 O
day	609 3 O
for	613 3 O
9	617 1 O
days	619 4 O
,	623 1 O
38	625 2 O
with	628 4 O
gentamicin	633 10 B-Chemical
+	644 1 O
PDTC	646 4 B-Chemical
,	650 1 O
and	652 3 O
28	656 2 O
with	659 4 O
0	664 1 O
.	665 1 O
15	666 2 O
M	669 1 O
NaCl	671 4 B-Chemical
solution	676 8 O
.	684 1 O

The	686 3 O
animals	690 7 O
were	698 4 O
killed	703 6 O
5	710 1 O
and	712 3 O
30	716 2 O
days	719 4 O
after	724 5 O
these	730 5 O
injections	736 10 O
and	747 3 O
the	751 3 O
kidneys	755 7 O
were	763 4 O
removed	768 7 O
for	776 3 O
histological	780 12 O
and	793 3 O
immunohistochemical	797 19 O
studies	817 7 O
.	824 1 O

The	826 3 O
results	830 7 O
of	838 2 O
the	841 3 O
immunohistochemical	845 19 O
studies	865 7 O
were	873 4 O
scored	878 6 O
according	885 9 O
to	895 2 O
the	898 3 O
extent	902 6 O
of	909 2 O
staining	912 8 O
.	920 1 O

The	922 3 O
fractional	926 10 O
interstitial	937 12 O
area	950 4 O
was	955 3 O
determined	959 10 O
by	970 2 O
morphometry	973 11 O
.	984 1 O

RESULTS	986 7 O
:	993 1 O
Gentamicin	995 10 B-Chemical
-	1005 1 O
treated	1006 7 O
rats	1014 4 O
presented	1019 9 O
a	1029 1 O
transitory	1031 10 O
increase	1042 8 O
in	1051 2 O
plasma	1054 6 O
creatinine	1061 10 B-Chemical
levels	1072 6 O
.	1078 1 O

Increased	1080 9 O
ED	1090 2 O
-	1092 1 O
1	1093 1 O
,	1094 1 O
MAP	1096 3 O
kinases	1100 7 O
and	1108 3 O
NF	1112 2 O
-	1114 1 O
kappaB	1115 6 O
staining	1122 8 O
were	1131 4 O
also	1136 4 O
observed	1141 8 O
in	1150 2 O
the	1153 3 O
renal	1157 5 O
cortex	1163 6 O
from	1170 4 O
all	1175 3 O
gentamicin	1179 10 B-Chemical
-	1189 1 O
treated	1190 7 O
rats	1198 4 O
compared	1203 8 O
to	1212 2 O
control	1215 7 O
(	1223 1 O
p	1224 1 O
<	1226 1 O
0	1228 1 O
.	1229 1 O
05	1230 2 O
)	1232 1 O
.	1233 1 O

The	1235 3 O
animals	1239 7 O
killed	1247 6 O
on	1254 2 O
day	1257 3 O
30	1261 2 O
also	1264 4 O
presented	1269 9 O
fibrosis	1279 8 B-Disease
in	1288 2 O
the	1291 3 O
renal	1295 5 O
cortex	1301 6 O
despite	1308 7 O
the	1316 3 O
recovery	1320 8 O
of	1329 2 O
renal	1332 5 O
function	1338 8 O
.	1346 1 O

Treatment	1348 9 O
with	1358 4 O
PDTC	1363 4 B-Chemical
reduced	1368 7 O
the	1376 3 O
functional	1380 10 O
and	1391 3 O
structural	1395 10 O
changes	1406 7 O
induced	1414 7 O
by	1422 2 O
gentamicin	1425 10 B-Chemical
.	1435 1 O

CONCLUSIONS	1437 11 O
:	1448 1 O
These	1450 5 O
data	1456 4 O
show	1461 4 O
that	1466 4 O
inhibition	1471 10 O
of	1482 2 O
NF	1485 2 O
-	1487 1 O
kappaB	1488 6 O
activation	1495 10 O
attenuates	1506 10 O
tubulointerstitial	1517 18 B-Disease
nephritis	1536 9 I-Disease
induced	1546 7 O
by	1554 2 O
gentamicin	1557 10 B-Chemical
.	1567 1 O

Glucose	0 7 B-Chemical
metabolism	8 10 O
in	19 2 O
patients	22 8 O
with	31 4 O
schizophrenia	36 13 B-Disease
treated	50 7 O
with	58 4 O
atypical	63 8 O
antipsychotic	72 13 O
agents	86 6 O
:	92 1 O
a	94 1 O
frequently	96 10 O
sampled	107 7 O
intravenous	115 11 O
glucose	127 7 B-Chemical
tolerance	135 9 O
test	145 4 O
and	150 3 O
minimal	154 7 O
model	162 5 O
analysis	168 8 O
.	176 1 O

BACKGROUND	178 10 O
:	188 1 O
While	190 5 O
the	196 3 O
incidence	200 9 O
of	210 2 O
new	213 3 O
-	216 1 O
onset	217 5 O
diabetes	223 8 B-Disease
mellitus	232 8 I-Disease
may	241 3 O
be	245 2 O
increasing	248 10 O
in	259 2 O
patients	262 8 O
with	271 4 O
schizophrenia	276 13 B-Disease
treated	290 7 O
with	298 4 O
certain	303 7 O
atypical	311 8 O
antipsychotic	320 13 O
agents	334 6 O
,	340 1 O
it	342 2 O
remains	345 7 O
unclear	353 7 O
whether	361 7 O
atypical	369 8 O
agents	378 6 O
are	385 3 O
directly	389 8 O
affecting	398 9 O
glucose	408 7 B-Chemical
metabolism	416 10 O
or	427 2 O
simply	430 6 O
increasing	437 10 O
known	448 5 O
risk	454 4 O
factors	459 7 O
for	467 3 O
diabetes	471 8 B-Disease
.	479 1 O

OBJECTIVE	481 9 O
:	490 1 O
To	492 2 O
study	495 5 O
the	501 3 O
2	505 1 O
drugs	507 5 O
most	513 4 O
clearly	518 7 O
implicated	526 10 O
(	537 1 O
clozapine	538 9 B-Chemical
and	548 3 O
olanzapine	552 10 B-Chemical
)	562 1 O
and	564 3 O
risperidone	568 11 B-Chemical
using	580 5 O
a	586 1 O
frequently	588 10 O
sampled	599 7 O
intravenous	607 11 O
glucose	619 7 B-Chemical
tolerance	627 9 O
test	637 4 O
.	641 1 O

DESIGN	643 6 O
:	649 1 O
A	651 1 O
cross	653 5 O
-	658 1 O
sectional	659 9 O
design	669 6 O
in	676 2 O
stable	679 6 O
,	685 1 O
treated	687 7 O
patients	695 8 O
with	704 4 O
schizophrenia	709 13 B-Disease
evaluated	723 9 O
using	733 5 O
a	739 1 O
frequently	741 10 O
sampled	752 7 O
intravenous	760 11 O
glucose	772 7 B-Chemical
tolerance	780 9 O
test	790 4 O
and	795 3 O
the	799 3 O
Bergman	803 7 O
minimal	811 7 O
model	819 5 O
analysis	825 8 O
.	833 1 O

SETTING	835 7 O
:	842 1 O
Subjects	844 8 O
were	853 4 O
recruited	858 9 O
from	868 4 O
an	873 2 O
urban	876 5 O
community	882 9 O
mental	892 6 O
health	899 6 O
clinic	906 6 O
and	913 3 O
were	917 4 O
studied	922 7 O
at	930 2 O
a	933 1 O
general	935 7 O
clinical	943 8 O
research	952 8 O
center	961 6 O
.	967 1 O

Patients	969 8 O
Fifty	978 5 O
subjects	984 8 O
signed	993 6 O
informed	1000 8 O
consent	1009 7 O
and	1017 3 O
41	1021 2 O
underwent	1024 9 O
the	1034 3 O
frequently	1038 10 O
sampled	1049 7 O
intravenous	1057 11 O
glucose	1069 7 B-Chemical
tolerance	1077 9 O
test	1087 4 O
.	1091 1 O

Thirty	1093 6 O
-	1099 1 O
six	1100 3 O
nonobese	1104 8 O
subjects	1113 8 O
with	1122 4 O
schizophrenia	1127 13 B-Disease
or	1141 2 O
schizoaffective	1144 15 B-Disease
disorder	1160 8 I-Disease
,	1168 1 O
matched	1170 7 O
by	1178 2 O
body	1181 4 O
mass	1186 4 O
index	1191 5 O
and	1197 3 O
treated	1201 7 O
with	1209 4 O
either	1214 6 O
clozapine	1221 9 B-Chemical
,	1230 1 O
olanzapine	1232 10 B-Chemical
,	1242 1 O
or	1244 2 O
risperidone	1247 11 B-Chemical
,	1258 1 O
were	1260 4 O
included	1265 8 O
in	1274 2 O
the	1277 3 O
analysis	1281 8 O
.	1289 1 O

MAIN	1291 4 O
OUTCOME	1296 7 O
MEASURES	1304 8 O
:	1312 1 O
Fasting	1314 7 O
plasma	1322 6 O
glucose	1329 7 B-Chemical
and	1337 3 O
fasting	1341 7 O
serum	1349 5 O
insulin	1355 7 O
levels	1363 6 O
,	1369 1 O
insulin	1371 7 B-Disease
sensitivity	1379 11 I-Disease
index	1391 5 O
,	1396 1 O
homeostasis	1398 11 O
model	1410 5 O
assessment	1416 10 O
of	1427 2 O
insulin	1430 7 B-Disease
resistance	1438 10 I-Disease
,	1448 1 O
and	1450 3 O
glucose	1454 7 B-Chemical
effectiveness	1462 13 O
.	1475 1 O

RESULTS	1477 7 O
:	1484 1 O
The	1486 3 O
mean	1490 4 O
+	1495 1 O
/	1496 1 O
-	1497 1 O
SD	1499 2 O
duration	1502 8 O
of	1511 2 O
treatment	1514 9 O
with	1524 4 O
the	1529 3 O
identified	1533 10 O
atypical	1544 8 O
antipsychotic	1553 13 O
agent	1567 5 O
was	1573 3 O
68	1577 2 O
.	1579 1 O
3	1580 1 O
+	1582 1 O
/	1583 1 O
-	1584 1 O
28	1586 2 O
.	1588 1 O
9	1589 1 O
months	1591 6 O
(	1598 1 O
clozapine	1599 9 B-Chemical
)	1608 1 O
,	1609 1 O
29	1611 2 O
.	1613 1 O
5	1614 1 O
+	1616 1 O
/	1617 1 O
-	1618 1 O
17	1620 2 O
.	1622 1 O
5	1623 1 O
months	1625 6 O
(	1632 1 O
olanzapine	1633 10 B-Chemical
)	1643 1 O
,	1644 1 O
and	1646 3 O
40	1650 2 O
.	1652 1 O
9	1653 1 O
+	1655 1 O
/	1656 1 O
-	1657 1 O
33	1659 2 O
.	1661 1 O
7	1662 1 O
(	1664 1 O
risperidone	1665 11 B-Chemical
)	1676 1 O
.	1677 1 O

Fasting	1679 7 O
serum	1687 5 O
insulin	1693 7 O
concentrations	1701 14 O
differed	1716 8 O
among	1725 5 O
groups	1731 6 O
(	1738 1 O
F	1739 1 O
(	1740 1 O
33	1741 2 O
)	1743 1 O
=	1745 1 O
3	1747 1 O
.	1748 1 O
35	1749 2 O
;	1751 1 O
P	1753 1 O
=	1755 1 O
.	1757 1 O
047	1758 3 O
)	1761 1 O
(	1763 1 O
clozapine	1764 9 B-Chemical
>	1773 1 O
olanzapine	1774 10 B-Chemical
>	1784 1 O
risperidone	1785 11 B-Chemical
)	1796 1 O
with	1798 4 O
significant	1803 11 O
differences	1815 11 O
between	1827 7 O
clozapine	1835 9 B-Chemical
and	1845 3 O
risperidone	1849 11 B-Chemical
(	1861 1 O
t	1862 1 O
(	1863 1 O
33	1864 2 O
)	1866 1 O
=	1868 1 O
2	1870 1 O
.	1871 1 O
32	1872 2 O
;	1874 1 O
P	1876 1 O
=	1878 1 O
.	1880 1 O
03	1881 2 O
)	1883 1 O
and	1885 3 O
olanzapine	1889 10 B-Chemical
and	1900 3 O
risperidone	1904 11 B-Chemical
(	1916 1 O
t	1917 1 O
(	1918 1 O
33	1919 2 O
)	1921 1 O
=	1923 1 O
2	1925 1 O
.	1926 1 O
15	1927 2 O
;	1929 1 O
P	1931 1 O
=	1933 1 O
.	1935 1 O
04	1936 2 O
)	1938 1 O
.	1939 1 O

There	1941 5 O
was	1947 3 O
a	1951 1 O
significant	1953 11 O
difference	1965 10 O
in	1976 2 O
insulin	1979 7 B-Disease
sensitivity	1987 11 I-Disease
index	1999 5 O
among	2005 5 O
groups	2011 6 O
(	2018 1 O
F	2019 1 O
(	2020 1 O
33	2021 2 O
)	2023 1 O
=	2025 1 O
10	2027 2 O
.	2029 1 O
66	2030 2 O
;	2032 1 O
P	2034 1 O
<	2035 1 O
.	2036 1 O
001	2037 3 O
)	2040 1 O
(	2042 1 O
clozapine	2043 9 B-Chemical
<	2052 1 O
olanzapine	2053 10 B-Chemical
<	2063 1 O
risperidone	2064 11 B-Chemical
)	2075 1 O
,	2076 1 O
with	2078 4 O
subjects	2083 8 O
who	2092 3 O
received	2096 8 O
clozapine	2105 9 B-Chemical
and	2115 3 O
olanzapine	2119 10 B-Chemical
exhibiting	2130 10 O
significant	2141 11 O
insulin	2153 7 B-Disease
resistance	2161 10 I-Disease
compared	2172 8 O
with	2181 4 O
subjects	2186 8 O
who	2195 3 O
were	2199 4 O
treated	2204 7 O
with	2212 4 O
risperidone	2217 11 B-Chemical
(	2229 1 O
clozapine	2230 9 B-Chemical
vs	2240 2 O
risperidone	2243 11 B-Chemical
,	2254 1 O
t	2256 1 O
(	2257 1 O
33	2258 2 O
)	2260 1 O
=	2262 1 O
-	2264 1 O
4	2265 1 O
.	2266 1 O
29	2267 2 O
;	2269 1 O
P	2271 1 O
<	2272 1 O
.	2273 1 O
001	2274 3 O
;	2277 1 O
olanzapine	2279 10 B-Chemical
vs	2290 2 O
risperidone	2293 11 B-Chemical
,	2304 1 O
t	2306 1 O
(	2307 1 O
33	2308 2 O
)	2310 1 O
=	2312 1 O
-	2314 1 O
3	2315 1 O
.	2316 1 O
62	2317 2 O
;	2319 1 O
P	2321 1 O
=	2323 1 O
.	2325 1 O
001	2326 3 O
[	2330 1 O
P	2331 1 O
<	2332 1 O
.	2333 1 O
001	2334 3 O
]	2337 1 O
)	2338 1 O
.	2339 1 O

The	2341 3 O
homeostasis	2345 11 O
model	2357 5 O
assessment	2363 10 O
of	2374 2 O
insulin	2377 7 B-Disease
resistance	2385 10 I-Disease
also	2396 4 O
differed	2401 8 O
significantly	2410 13 O
among	2424 5 O
groups	2430 6 O
(	2437 1 O
F	2438 1 O
(	2439 1 O
33	2440 2 O
)	2442 1 O
=	2444 1 O
4	2446 1 O
.	2447 1 O
92	2448 2 O
;	2450 1 O
P	2452 1 O
=	2454 1 O
.	2456 1 O
01	2457 2 O
)	2459 1 O
(	2461 1 O
clozapine	2462 9 B-Chemical
>	2471 1 O
olanzapine	2472 10 B-Chemical
>	2482 1 O
risperidone	2483 11 B-Chemical
)	2494 1 O
(	2496 1 O
clozapine	2497 9 B-Chemical
vs	2507 2 O
risperidone	2510 11 B-Chemical
,	2521 1 O
t	2523 1 O
(	2524 1 O
33	2525 2 O
)	2527 1 O
=	2529 1 O
2	2531 1 O
.	2532 1 O
94	2533 2 O
;	2535 1 O
P	2537 1 O
=	2539 1 O
.	2541 1 O
006	2542 3 O
;	2545 1 O
olanzapine	2547 10 B-Chemical
vs	2558 2 O
risperidone	2561 11 B-Chemical
,	2572 1 O
t	2574 1 O
(	2575 1 O
33	2576 2 O
)	2578 1 O
=	2580 1 O
2	2582 1 O
.	2583 1 O
42	2584 2 O
;	2586 1 O
P	2588 1 O
=	2590 1 O
.	2592 1 O
02	2593 2 O
)	2595 1 O
.	2596 1 O

There	2598 5 O
was	2604 3 O
a	2608 1 O
significant	2610 11 O
difference	2622 10 O
among	2633 5 O
groups	2639 6 O
in	2646 2 O
glucose	2649 7 B-Chemical
effectiveness	2657 13 O
(	2671 1 O
F	2672 1 O
(	2673 1 O
30	2674 2 O
)	2676 1 O
=	2678 1 O
4	2680 1 O
.	2681 1 O
18	2682 2 O
;	2684 1 O
P	2686 1 O
=	2688 1 O
.	2690 1 O
02	2691 2 O
)	2693 1 O
(	2695 1 O
clozapine	2696 9 B-Chemical
<	2705 1 O
olanzapine	2706 10 B-Chemical
<	2716 1 O
risperidone	2717 11 B-Chemical
)	2728 1 O
with	2730 4 O
significant	2735 11 O
differences	2747 11 O
between	2759 7 O
clozapine	2767 9 B-Chemical
and	2777 3 O
risperidone	2781 11 B-Chemical
(	2793 1 O
t	2794 1 O
(	2795 1 O
30	2796 2 O
)	2798 1 O
=	2800 1 O
-	2802 1 O
2	2803 1 O
.	2804 1 O
59	2805 2 O
;	2807 1 O
P	2809 1 O
=	2811 1 O
.	2813 1 O
02	2814 2 O
)	2816 1 O
and	2818 3 O
olanzapine	2822 10 B-Chemical
and	2833 3 O
risperidone	2837 11 B-Chemical
(	2849 1 O
t	2850 1 O
(	2851 1 O
30	2852 2 O
)	2854 1 O
=	2856 1 O
-	2858 1 O
2	2859 1 O
.	2860 1 O
34	2861 2 O
,	2863 1 O
P	2865 1 O
=	2867 1 O
.	2869 1 O
03	2870 2 O
)	2872 1 O
.	2873 1 O

CONCLUSIONS	2875 11 O
:	2886 1 O
Both	2888 4 O
nonobese	2893 8 O
clozapine	2902 9 B-Chemical
-	2911 1 O
and	2913 3 O
olanzapine	2917 10 B-Chemical
-	2927 1 O
treated	2928 7 O
groups	2936 6 O
displayed	2943 9 O
significant	2953 11 O
insulin	2965 7 B-Disease
resistance	2973 10 I-Disease
and	2984 3 O
impairment	2988 10 O
of	2999 2 O
glucose	3002 7 B-Chemical
effectiveness	3010 13 O
compared	3024 8 O
with	3033 4 O
risperidone	3038 11 B-Chemical
-	3049 1 O
treated	3050 7 O
subjects	3058 8 O
.	3066 1 O

Patients	3068 8 O
taking	3077 6 O
clozapine	3084 9 B-Chemical
and	3094 3 O
olanzapine	3098 10 B-Chemical
must	3109 4 O
be	3114 2 O
examined	3117 8 O
for	3126 3 O
insulin	3130 7 B-Disease
resistance	3138 10 I-Disease
and	3149 3 O
its	3153 3 O
consequences	3157 12 O
.	3169 1 O

Focal	0 5 O
cerebral	6 8 B-Disease
ischemia	15 8 I-Disease
in	24 2 O
rats	27 4 O
:	31 1 O
effect	33 6 O
of	40 2 O
phenylephrine	43 13 B-Chemical
-	56 1 O
induced	57 7 O
hypertension	65 12 B-Disease
during	78 6 O
reperfusion	85 11 O
.	96 1 O

After	98 5 O
180	104 3 O
min	108 3 O
of	112 2 O
temporary	115 9 O
middle	125 6 B-Disease
cerebral	132 8 I-Disease
artery	141 6 I-Disease
occlusion	148 9 I-Disease
in	158 2 O
spontaneously	161 13 O
hypertensive	175 12 B-Disease
rats	188 4 O
,	192 1 O
the	194 3 O
effect	198 6 O
of	205 2 O
phenylephrine	208 13 B-Chemical
-	221 1 O
induced	222 7 O
hypertension	230 12 B-Disease
on	243 2 O
ischemic	246 8 B-Disease
brain	255 5 I-Disease
injury	261 6 I-Disease
and	268 3 O
blood	272 5 O
-	277 1 O
brain	278 5 O
barrier	284 7 O
permeability	292 12 O
was	305 3 O
determined	309 10 O
.	319 1 O

Blood	321 5 O
pressure	327 8 O
was	336 3 O
manipulated	340 11 O
by	352 2 O
one	355 3 O
of	359 2 O
the	362 3 O
following	366 9 O
schedules	376 9 O
during	386 6 O
120	393 3 O
min	397 3 O
of	401 2 O
reperfusion	404 11 O
:	415 1 O
Control	417 7 O
,	424 1 O
normotensive	426 12 O
reperfusion	439 11 O
;	450 1 O
90	452 2 O
/	454 1 O
hypertension	455 12 B-Disease
(	468 1 O
90	469 2 O
/	471 1 O
HTN	472 3 B-Disease
)	475 1 O
,	476 1 O
blood	478 5 O
pressure	484 8 O
was	493 3 O
increased	497 9 O
by	507 2 O
35	510 2 O
mm	513 2 O
Hg	516 2 O
during	519 6 O
the	526 3 O
initial	530 7 O
90	538 2 O
min	541 3 O
of	545 2 O
reperfusion	548 11 O
only	560 4 O
;	564 1 O
15	566 2 O
/	568 1 O
hypertension	569 12 B-Disease
(	582 1 O
15	583 2 O
/	585 1 O
HTN	586 3 B-Disease
)	589 1 O
,	590 1 O
normotensive	592 12 O
reperfusion	605 11 O
for	617 3 O
30	621 2 O
min	624 3 O
followed	628 8 O
by	637 2 O
15	640 2 O
min	643 3 O
of	647 2 O
hypertension	650 12 B-Disease
and	663 3 O
75	667 2 O
min	670 3 O
of	674 2 O
normotension	677 12 O
.	689 1 O

Part	691 4 O
A	696 1 O
,	697 1 O
for	699 3 O
eight	703 5 O
rats	709 4 O
in	714 2 O
each	717 4 O
group	722 5 O
brain	728 5 B-Disease
injury	734 6 I-Disease
was	741 3 O
evaluated	745 9 O
by	755 2 O
staining	758 8 O
tissue	767 6 O
using	774 5 O
2	780 1 B-Chemical
,	781 1 I-Chemical
3	782 1 I-Chemical
,	783 1 I-Chemical
5	784 1 I-Chemical
-	785 1 I-Chemical
triphenyltetrazolium	786 20 I-Chemical
chloride	807 8 I-Chemical
and	816 3 O
edema	820 5 B-Disease
was	826 3 O
evaluated	830 9 O
by	840 2 O
microgravimetry	843 15 O
.	858 1 O

Part	860 4 O
B	865 1 O
,	866 1 O
for	868 3 O
eight	872 5 O
different	878 9 O
rats	888 4 O
in	893 2 O
each	896 4 O
group	901 5 O
blood	907 5 O
-	912 1 O
brain	913 5 O
barrier	919 7 O
permeability	927 12 O
was	940 3 O
evaluated	944 9 O
by	954 2 O
measuring	957 9 O
the	967 3 O
amount	971 6 O
and	978 3 O
extent	982 6 O
of	989 2 O
extravasation	992 13 O
of	1006 2 O
Evans	1009 5 O
Blue	1015 4 O
dye	1020 3 O
.	1023 1 O

Brain	1025 5 B-Disease
injury	1031 6 I-Disease
(	1038 1 O
percentage	1039 10 O
of	1050 2 O
the	1053 3 O
ischemic	1057 8 B-Disease
hemisphere	1066 10 I-Disease
)	1076 1 O
was	1078 3 O
less	1082 4 O
in	1087 2 O
the	1090 3 O
15	1094 2 O
/	1096 1 O
HTN	1097 3 B-Disease
group	1101 5 O
(	1107 1 O
16	1108 2 O
+	1111 1 O
/	1112 1 O
-	1113 1 O
6	1115 1 O
,	1116 1 O
mean	1118 4 O
+	1123 1 O
/	1124 1 O
-	1125 1 O
SD	1127 2 O
)	1129 1 O
versus	1131 6 O
the	1138 3 O
90	1142 2 O
/	1144 1 O
HTN	1145 3 B-Disease
group	1149 5 O
(	1155 1 O
30	1156 2 O
+	1159 1 O
/	1160 1 O
-	1161 1 O
6	1163 1 O
)	1164 1 O
,	1165 1 O
which	1167 5 O
was	1173 3 O
in	1177 2 O
turn	1180 4 O
less	1185 4 O
than	1190 4 O
the	1195 3 O
control	1199 7 O
group	1207 5 O
(	1213 1 O
42	1214 2 O
+	1217 1 O
/	1218 1 O
-	1219 1 O
5	1221 1 O
)	1222 1 O
.	1223 1 O

Specific	1225 8 O
gravity	1234 7 O
was	1242 3 O
greater	1246 7 O
in	1254 2 O
the	1257 3 O
15	1261 2 O
/	1263 1 O
HTN	1264 3 B-Disease
group	1268 5 O
(	1274 1 O
1	1275 1 O
.	1276 1 O
043	1277 3 O
+	1281 1 O
/	1282 1 O
-	1283 1 O
0	1285 1 O
.	1286 1 O
002	1287 3 O
)	1290 1 O
versus	1292 6 O
the	1299 3 O
90	1303 2 O
/	1305 1 O
HTN	1306 3 B-Disease
(	1310 1 O
1	1311 1 O
.	1312 1 O
036	1313 3 O
+	1317 1 O
/	1318 1 O
-	1319 1 O
0	1321 1 O
.	1322 1 O
003	1323 3 O
)	1326 1 O
and	1328 3 O
control	1332 7 O
(	1340 1 O
1	1341 1 O
.	1342 1 O
037	1343 3 O
+	1347 1 O
/	1348 1 O
-	1349 1 O
0	1351 1 O
.	1352 1 O
003	1353 3 O
)	1356 1 O
groups	1358 6 O
.	1364 1 O

Evans	1366 5 B-Chemical
Blue	1372 4 I-Chemical
(	1377 1 O
mug	1378 3 O
g	1382 1 O
-	1383 1 O
1	1384 1 O
of	1386 2 O
brain	1389 5 O
tissue	1395 6 O
)	1401 1 O
was	1403 3 O
greater	1407 7 O
in	1415 2 O
the	1418 3 O
90	1422 2 O
/	1424 1 O
HTN	1425 3 B-Disease
group	1429 5 O
(	1435 1 O
24	1436 2 O
.	1438 1 O
4	1439 1 O
+	1441 1 O
/	1442 1 O
-	1443 1 O
6	1445 1 O
.	1446 1 O
0	1447 1 O
)	1448 1 O
versus	1450 6 O
the	1457 3 O
control	1461 7 O
group	1469 5 O
(	1475 1 O
12	1476 2 O
.	1478 1 O
3	1479 1 O
+	1481 1 O
/	1482 1 O
-	1483 1 O
4	1485 1 O
.	1486 1 O
1	1487 1 O
)	1488 1 O
,	1489 1 O
which	1491 5 O
was	1497 3 O
in	1501 2 O
turn	1504 4 O
greater	1509 7 O
than	1517 4 O
the	1522 3 O
15	1526 2 O
/	1528 1 O
HTN	1529 3 B-Disease
group	1533 5 O
(	1539 1 O
7	1540 1 O
.	1541 1 O
3	1542 1 O
+	1544 1 O
/	1545 1 O
-	1546 1 O
3	1548 1 O
.	1549 1 O
2	1550 1 O
)	1551 1 O
.	1552 1 O

This	1554 4 O
study	1559 5 O
supports	1565 8 O
a	1574 1 O
hypothesis	1576 10 O
that	1587 4 O
during	1592 6 O
reperfusion	1599 11 O
,	1610 1 O
a	1612 1 O
short	1614 5 O
interval	1620 8 O
of	1629 2 O
hypertension	1632 12 B-Disease
decreases	1645 9 O
brain	1655 5 B-Disease
injury	1661 6 I-Disease
and	1668 3 O
edema	1672 5 B-Disease
;	1677 1 O
and	1679 3 O
that	1683 4 O
sustained	1688 9 O
hypertension	1698 12 B-Disease
increases	1711 9 O
the	1721 3 O
risk	1725 4 O
of	1730 2 O
vasogenic	1733 9 B-Disease
edema	1743 5 I-Disease
.	1748 1 O

People	0 6 O
aged	7 4 O
over	12 4 O
75	17 2 O
in	20 2 O
atrial	23 6 B-Disease
fibrillation	30 12 I-Disease
on	43 2 O
warfarin	46 8 B-Chemical
:	54 1 O
the	56 3 O
rate	60 4 O
of	65 2 O
major	68 5 O
hemorrhage	74 10 B-Disease
and	85 3 O
stroke	89 6 B-Disease
in	96 2 O
more	99 4 O
than	104 4 O
500	109 3 O
patient	113 7 O
-	120 1 O
years	121 5 O
of	127 2 O
follow	130 6 O
-	136 1 O
up	137 2 O
.	139 1 O

OBJECTIVES	141 10 O
:	151 1 O
To	153 2 O
determine	156 9 O
the	166 3 O
incidence	170 9 O
of	180 2 O
major	183 5 O
hemorrhage	189 10 B-Disease
and	200 3 O
stroke	204 6 B-Disease
in	211 2 O
people	214 6 O
aged	221 4 O
76	226 2 O
and	229 3 O
older	233 5 O
with	239 4 O
atrial	244 6 B-Disease
fibrillation	251 12 I-Disease
on	264 2 O
adjusted	267 8 O
-	275 1 O
dose	276 4 O
warfarin	281 8 B-Chemical
who	290 3 O
had	294 3 O
been	298 4 O
recently	303 8 O
been	312 4 O
admitted	317 8 O
to	326 2 O
hospital	329 8 O
.	337 1 O

DESIGN	339 6 O
:	345 1 O
A	347 1 O
retrospective	349 13 O
observational	363 13 O
cohort	377 6 O
study	384 5 O
.	389 1 O

SETTING	391 7 O
:	398 1 O
A	400 1 O
major	402 5 O
healthcare	408 10 O
network	419 7 O
involving	427 9 O
four	437 4 O
tertiary	442 8 O
hospitals	451 9 O
.	460 1 O

PARTICIPANTS	462 12 O
:	474 1 O
Two	476 3 O
hundred	480 7 O
thirty	488 6 O
-	494 1 O
five	495 4 O
patients	500 8 O
aged	509 4 O
76	514 2 O
and	517 3 O
older	521 5 O
admitted	527 8 O
to	536 2 O
a	539 1 O
major	541 5 O
healthcare	547 10 O
network	558 7 O
between	566 7 O
July	574 4 O
1	579 1 O
,	580 1 O
2001	582 4 O
,	586 1 O
and	588 3 O
June	592 4 O
30	597 2 O
,	599 1 O
2002	601 4 O
,	605 1 O
with	607 4 O
atrial	612 6 B-Disease
fibrillation	619 12 I-Disease
on	632 2 O
warfarin	635 8 B-Chemical
were	644 4 O
enrolled	649 8 O
.	657 1 O

MEASUREMENTS	659 12 O
:	671 1 O
Information	673 11 O
regarding	685 9 O
major	695 5 O
bleeding	701 8 B-Disease
episodes	710 8 O
,	718 1 O
strokes	720 7 B-Disease
,	727 1 O
and	729 3 O
warfarin	733 8 B-Chemical
use	742 3 O
was	746 3 O
obtained	750 8 O
from	759 4 O
patients	764 8 O
,	772 1 O
relatives	774 9 O
,	783 1 O
primary	785 7 O
physicians	793 10 O
,	803 1 O
and	805 3 O
medical	809 7 O
records	817 7 O
.	824 1 O

RESULTS	826 7 O
:	833 1 O
Two	835 3 O
hundred	839 7 O
twenty	847 6 O
-	853 1 O
eight	854 5 O
patients	860 8 O
(	869 1 O
42	870 2 O
%	872 1 O
men	874 3 O
)	877 1 O
with	879 4 O
a	884 1 O
mean	886 4 O
age	891 3 O
of	895 2 O
81	898 2 O
.	900 1 O
1	901 1 O
(	903 1 O
range	904 5 O
76	910 2 O
-	912 1 O
94	913 2 O
)	915 1 O
were	917 4 O
included	922 8 O
in	931 2 O
the	934 3 O
analysis	938 8 O
.	946 1 O

Total	948 5 O
follow	954 6 O
-	960 1 O
up	961 2 O
on	964 2 O
warfarin	967 8 B-Chemical
was	976 3 O
530	980 3 O
years	984 5 O
(	990 1 O
mean	991 4 O
28	996 2 O
months	999 6 O
)	1005 1 O
.	1006 1 O

There	1008 5 O
were	1014 4 O
53	1019 2 O
major	1022 5 O
hemorrhages	1028 11 B-Disease
,	1039 1 O
for	1041 3 O
an	1045 2 O
annual	1048 6 O
rate	1055 4 O
of	1060 2 O
10	1063 2 O
.	1065 1 O
0	1066 1 O
%	1067 1 O
,	1068 1 O
including	1070 9 O
24	1080 2 O
(	1083 1 O
45	1084 2 O
.	1086 1 O
3	1087 1 O
%	1088 1 O
)	1089 1 O
life	1091 4 O
-	1095 1 O
threatening	1096 11 O
and	1108 3 O
five	1112 4 O
(	1117 1 O
9	1118 1 O
.	1119 1 O
4	1120 1 O
%	1121 1 O
)	1122 1 O
fatal	1124 5 O
bleeds	1130 6 O
.	1136 1 O

The	1138 3 O
annual	1142 6 O
stroke	1149 6 B-Disease
rate	1156 4 O
after	1161 5 O
initiation	1167 10 O
of	1178 2 O
warfarin	1181 8 B-Chemical
was	1190 3 O
2	1194 1 O
.	1195 1 O
6	1196 1 O
%	1197 1 O
.	1198 1 O

CONCLUSION	1200 10 O
:	1210 1 O
The	1212 3 O
rate	1216 4 O
of	1221 2 O
major	1224 5 O
hemorrhage	1230 10 B-Disease
was	1241 3 O
high	1245 4 O
in	1250 2 O
this	1253 4 O
old	1258 3 O
,	1261 1 O
frail	1263 5 O
group	1269 5 O
,	1274 1 O
but	1276 3 O
excluding	1280 9 O
fatalities	1290 10 O
,	1300 1 O
resulted	1302 8 O
in	1311 2 O
no	1314 2 O
long	1317 4 O
-	1321 1 O
term	1322 4 O
sequelae	1327 8 O
,	1335 1 O
and	1337 3 O
the	1341 3 O
stroke	1345 6 B-Disease
rate	1352 4 O
on	1357 2 O
warfarin	1360 8 B-Chemical
was	1369 3 O
low	1373 3 O
,	1376 1 O
demonstrating	1378 13 O
how	1392 3 O
effective	1396 9 O
warfarin	1406 8 B-Chemical
treatment	1415 9 O
is	1425 2 O
.	1427 1 O

Safety	0 6 O
of	7 2 O
celecoxib	10 9 B-Chemical
in	20 2 O
patients	23 8 O
with	32 4 O
adverse	37 7 O
skin	45 4 B-Disease
reactions	50 9 I-Disease
to	60 2 O
acetaminophen	63 13 B-Chemical
(	77 1 O
paracetamol	78 11 B-Chemical
)	89 1 O
and	91 3 O
nimesulide	95 10 B-Chemical
associated	106 10 O
or	117 2 O
not	120 3 O
with	124 4 O
common	129 6 O
non	136 3 O
-	139 1 O
steroidal	140 9 O
anti	150 4 O
-	154 1 O
inflammatory	155 12 O
drugs	168 5 O
.	173 1 O

BACKGROUND	175 10 O
:	185 1 O
Acetaminophen	187 13 B-Chemical
(	201 1 O
paracetamol	202 11 B-Chemical
-	213 1 O
-	214 1 O
P	215 1 B-Chemical
)	216 1 O
and	218 3 O
Nimesulide	222 10 B-Chemical
(	233 1 O
N	234 1 B-Chemical
)	235 1 O
are	237 3 O
widely	241 6 O
used	248 4 O
analgesic	253 9 O
-	262 1 O
antipyretic	263 11 O
/	274 1 O
anti	275 4 O
-	279 1 O
inflammatory	280 12 O
drugs	293 5 O
.	298 1 O

The	300 3 O
rate	304 4 O
of	309 2 O
adverse	312 7 O
hypersensitivity	320 16 B-Disease
reactions	337 9 O
to	347 2 O
these	350 5 O
agents	356 6 O
is	363 2 O
generally	366 9 O
low	376 3 O
.	379 1 O

On	381 2 O
the	384 3 O
contrary	388 8 O
non	397 3 O
-	400 1 O
steroidal	401 9 O
anti	411 4 O
-	415 1 O
inflammatory	416 12 O
drugs	429 5 O
(	435 1 O
NSAIDs	436 6 O
)	442 1 O
are	444 3 O
commonly	448 8 O
involved	457 8 O
in	466 2 O
such	469 4 O
reactions	474 9 O
.	483 1 O

Celecoxib	485 9 B-Chemical
(	495 1 O
CE	496 2 B-Chemical
)	498 1 O
is	500 2 O
a	503 1 O
novel	505 5 O
drug	511 4 O
,	515 1 O
with	517 4 O
high	522 4 O
selectivity	527 11 O
and	539 3 O
affinity	543 8 O
for	552 3 O
COX	556 3 O
-	559 1 O
2	560 1 O
enzyme	562 6 O
.	568 1 O

OBJECTIVE	570 9 O
:	579 1 O
We	581 2 O
evaluated	584 9 O
the	594 3 O
tolerability	598 12 O
of	611 2 O
CE	614 2 B-Chemical
in	617 2 O
a	620 1 O
group	622 5 O
of	628 2 O
patients	631 8 O
with	640 4 O
documented	645 10 O
history	656 7 O
of	664 2 O
adverse	667 7 O
cutaneous	675 9 B-Disease
reactions	685 9 I-Disease
to	695 2 O
P	698 1 B-Chemical
and	700 3 O
N	704 1 B-Chemical
associated	706 10 O
or	717 2 O
not	720 3 O
to	724 2 O
classic	727 7 O
NSAIDs	735 6 O
.	741 1 O

METHODS	743 7 O
:	750 1 O
We	752 2 O
studied	755 7 O
9	763 1 O
patients	765 8 O
with	774 4 O
hypersensitivity	779 16 B-Disease
to	796 2 O
P	799 1 B-Chemical
and	801 3 O
N	805 1 B-Chemical
with	807 4 O
or	812 2 O
without	815 7 O
associated	823 10 O
reactions	834 9 O
to	844 2 O
classic	847 7 O
NSAIDs	855 6 O
.	861 1 O

The	863 3 O
diagnosis	867 9 O
of	877 2 O
P	880 1 B-Chemical
and	882 3 O
N	886 1 B-Chemical
-	887 1 O
induced	888 7 O
skin	896 4 B-Disease
reactions	901 9 I-Disease
was	911 3 O
based	915 5 O
in	921 2 O
vivo	924 4 O
challenge	929 9 O
.	938 1 O

The	940 3 O
placebo	944 7 O
was	952 3 O
blindly	956 7 O
administered	964 12 O
at	977 2 O
the	980 3 O
beginning	984 9 O
of	994 2 O
each	997 4 O
challenge	1002 9 O
.	1011 1 O

After	1013 5 O
three	1019 5 O
days	1025 4 O
,	1029 1 O
a	1031 1 O
cumulative	1033 10 O
dosage	1044 6 O
of	1051 2 O
200	1054 3 O
mg	1058 2 O
of	1061 2 O
CE	1064 2 B-Chemical
in	1067 2 O
refracted	1070 9 O
doses	1080 5 O
were	1086 4 O
given	1091 5 O
.	1096 1 O

After	1098 5 O
2	1104 1 O
-	1105 1 O
3	1106 1 O
days	1108 4 O
,	1112 1 O
a	1114 1 O
single	1116 6 O
dose	1123 4 O
of	1128 2 O
200	1131 3 O
mg	1135 2 O
was	1138 3 O
administered	1142 12 O
.	1154 1 O

All	1156 3 O
patients	1160 8 O
were	1169 4 O
observed	1174 8 O
for	1183 3 O
6	1187 1 O
hours	1189 5 O
after	1195 5 O
each	1201 4 O
challenge	1206 9 O
,	1215 1 O
and	1217 3 O
controlled	1221 10 O
again	1232 5 O
after	1238 5 O
24	1244 2 O
hours	1247 5 O
to	1253 2 O
exclude	1256 7 O
delayed	1264 7 O
reactions	1272 9 O
.	1281 1 O

The	1283 3 O
challenge	1287 9 O
was	1297 3 O
considered	1301 10 O
positive	1312 8 O
if	1321 2 O
one	1324 3 O
or	1328 2 O
more	1331 4 O
of	1336 2 O
the	1339 3 O
following	1343 9 O
appeared	1353 8 O
:	1361 1 O
erythema	1363 8 B-Disease
,	1371 1 O
rush	1373 4 O
or	1378 2 O
urticaria	1381 9 B-Disease
-	1390 1 O
angioedema	1391 10 B-Disease
.	1401 1 O

RESULTS	1403 7 O
:	1410 1 O
No	1412 2 O
reaction	1415 8 O
was	1424 3 O
observed	1428 8 O
with	1437 4 O
placebo	1442 7 O
and	1450 3 O
eight	1454 5 O
patients	1460 8 O
(	1469 1 O
88	1470 2 O
.	1472 1 O
8	1473 1 O
%	1474 1 O
)	1475 1 O
tolerated	1477 9 O
CE	1487 2 B-Chemical
.	1489 1 O

Only	1491 4 O
one	1496 3 O
patient	1500 7 O
developed	1508 9 O
a	1518 1 O
moderate	1520 8 O
angioedema	1529 10 B-Disease
of	1540 2 O
the	1543 3 O
lips	1547 4 O
.	1551 1 O

CONCLUSION	1553 10 O
:	1563 1 O
Only	1565 4 O
one	1570 3 O
hypersensitivity	1574 16 B-Disease
reaction	1591 8 O
to	1600 2 O
CE	1603 2 B-Chemical
was	1606 3 O
documented	1610 10 O
among	1621 5 O
9	1627 1 O
P	1629 1 B-Chemical
and	1631 3 O
N	1635 1 B-Chemical
-	1636 1 O
highly	1637 6 O
NSAIDs	1644 6 O
intolerant	1651 10 O
patients	1662 8 O
.	1670 1 O

Thus	1672 4 O
,	1676 1 O
we	1678 2 O
conclude	1681 8 O
that	1690 4 O
CE	1695 2 B-Chemical
is	1698 2 O
a	1701 1 O
reasonably	1703 10 O
safe	1714 4 O
alternative	1719 11 O
to	1731 2 O
be	1734 2 O
used	1737 4 O
in	1742 2 O
subjects	1745 8 O
who	1754 3 O
do	1758 2 O
not	1761 3 O
tolerate	1765 8 O
P	1774 1 B-Chemical
and	1776 3 O
N	1780 1 B-Chemical
.	1781 1 O

Case	0 4 O
-	4 1 O
control	5 7 O
study	13 5 O
of	19 2 O
regular	22 7 O
analgesic	30 9 O
and	40 3 O
nonsteroidal	44 12 O
anti	57 4 O
-	61 1 O
inflammatory	62 12 O
use	75 3 O
and	79 3 O
end	83 3 B-Disease
-	86 1 I-Disease
stage	87 5 I-Disease
renal	93 5 I-Disease
disease	99 7 I-Disease
.	106 1 O

BACKGROUND	108 10 O
:	118 1 O
Studies	120 7 O
on	128 2 O
the	131 3 O
association	135 11 O
between	147 7 O
the	155 3 O
long	159 4 O
-	163 1 O
term	164 4 O
use	169 3 O
of	173 2 O
aspirin	176 7 B-Chemical
and	184 3 O
other	188 5 O
analgesic	194 9 O
and	204 3 O
nonsteroidal	208 12 O
anti	221 4 O
-	225 1 O
inflammatory	226 12 O
drugs	239 5 O
(	245 1 O
NSAIDs	246 6 O
)	252 1 O
and	254 3 O
end	258 3 B-Disease
-	261 1 I-Disease
stage	262 5 I-Disease
renal	268 5 I-Disease
disease	274 7 I-Disease
(	282 1 O
ESRD	283 4 B-Disease
)	287 1 O
have	289 4 O
given	294 5 O
conflicting	300 11 O
results	312 7 O
.	319 1 O

In	321 2 O
order	324 5 O
to	330 2 O
examine	333 7 O
this	341 4 O
association	346 11 O
,	357 1 O
a	359 1 O
case	361 4 O
-	365 1 O
control	366 7 O
study	374 5 O
with	380 4 O
incident	385 8 O
cases	394 5 O
of	400 2 O
ESRD	403 4 B-Disease
was	408 3 O
carried	412 7 O
out	420 3 O
.	423 1 O

METHODS	425 7 O
:	432 1 O
The	434 3 O
cases	438 5 O
were	444 4 O
all	449 3 O
patients	453 8 O
entering	462 8 O
the	471 3 O
local	475 5 O
dialysis	481 8 O
program	490 7 O
because	498 7 O
of	506 2 O
ESRD	509 4 B-Disease
in	514 2 O
the	517 3 O
study	521 5 O
area	527 4 O
between	532 7 O
June	540 4 O
1	545 1 O
,	546 1 O
1995	548 4 O
and	553 3 O
November	557 8 O
30	566 2 O
,	568 1 O
1997	570 4 O
.	574 1 O

They	576 4 O
were	581 4 O
classified	586 10 O
according	597 9 O
to	607 2 O
the	610 3 O
underlying	614 10 O
disease	625 7 O
,	632 1 O
which	634 5 O
had	640 3 O
presumably	644 10 O
led	655 3 O
them	659 4 O
to	664 2 O
ESRD	667 4 B-Disease
.	671 1 O

Controls	673 8 O
were	682 4 O
patients	687 8 O
admitted	696 8 O
to	705 2 O
the	708 3 O
same	712 4 O
hospitals	717 9 O
from	727 4 O
where	732 5 O
the	738 3 O
cases	742 5 O
arose	748 5 O
,	753 1 O
also	755 4 O
matched	760 7 O
by	768 2 O
age	771 3 O
and	775 3 O
sex	779 3 O
.	782 1 O

Odds	784 4 O
ratios	789 6 O
were	796 4 O
calculated	801 10 O
using	812 5 O
a	818 1 O
conditional	820 11 O
logistic	832 8 O
model	841 5 O
,	846 1 O
including	848 9 O
potential	858 9 O
confounding	868 11 O
factors	880 7 O
,	887 1 O
both	889 4 O
for	894 3 O
the	898 3 O
whole	902 5 O
study	908 5 O
population	914 10 O
and	925 3 O
for	929 3 O
the	933 3 O
various	937 7 O
underlying	945 10 O
diseases	956 8 O
.	964 1 O

RESULTS	966 7 O
:	973 1 O
Five	975 4 O
hundred	980 7 O
and	988 3 O
eighty	992 6 O
-	998 1 O
three	999 5 O
cases	1005 5 O
and	1011 3 O
1190	1015 4 O
controls	1020 8 O
were	1029 4 O
included	1034 8 O
in	1043 2 O
the	1046 3 O
analysis	1050 8 O
.	1058 1 O

Long	1060 4 O
-	1064 1 O
term	1065 4 O
use	1070 3 O
of	1074 2 O
any	1077 3 O
analgesic	1081 9 O
was	1091 3 O
associated	1095 10 O
with	1106 4 O
an	1111 2 O
overall	1114 7 O
odds	1122 4 O
ratio	1127 5 O
of	1133 2 O
1	1136 1 O
.	1137 1 O
22	1138 2 O
(	1141 1 O
95	1142 2 O
%	1144 1 O
CI	1146 2 O
,	1148 1 O
0	1150 1 O
.	1151 1 O
89	1152 2 O
-	1154 1 O
1	1155 1 O
.	1156 1 O
66	1157 2 O
)	1159 1 O
.	1160 1 O

For	1162 3 O
specific	1166 8 O
groups	1175 6 O
of	1182 2 O
drugs	1185 5 O
,	1190 1 O
the	1192 3 O
risks	1196 5 O
were	1202 4 O
1	1207 1 O
.	1208 1 O
56	1209 2 O
(	1212 1 O
1	1213 1 O
.	1214 1 O
05	1215 2 O
-	1217 1 O
2	1218 1 O
.	1219 1 O
30	1220 2 O
)	1222 1 O
for	1224 3 O
aspirin	1228 7 B-Chemical
,	1235 1 O
1	1237 1 O
.	1238 1 O
03	1239 2 O
(	1242 1 O
0	1243 1 O
.	1244 1 O
60	1245 2 O
-	1247 1 O
1	1248 1 O
.	1249 1 O
76	1250 2 O
)	1252 1 O
for	1254 3 O
pyrazolones	1258 11 B-Chemical
,	1269 1 O
0	1271 1 O
.	1272 1 O
80	1273 2 O
(	1276 1 O
0	1277 1 O
.	1278 1 O
39	1279 2 O
-	1281 1 O
1	1282 1 O
.	1283 1 O
63	1284 2 O
)	1286 1 O
for	1288 3 O
paracetamol	1292 11 B-Chemical
,	1303 1 O
and	1305 3 O
0	1309 1 O
.	1310 1 O
94	1311 2 O
(	1314 1 O
0	1315 1 O
.	1316 1 O
57	1317 2 O
-	1319 1 O
1	1320 1 O
.	1321 1 O
56	1322 2 O
)	1324 1 O
for	1326 3 O
nonaspirin	1330 10 O
NSAIDs	1341 6 O
.	1347 1 O

The	1349 3 O
risk	1353 4 O
of	1358 2 O
ESRD	1361 4 B-Disease
associated	1366 10 O
with	1377 4 O
aspirin	1382 7 B-Chemical
was	1390 3 O
related	1394 7 O
to	1402 2 O
the	1405 3 O
cumulated	1409 9 O
dose	1419 4 O
and	1424 3 O
duration	1428 8 O
of	1437 2 O
use	1440 3 O
,	1443 1 O
and	1445 3 O
it	1449 2 O
was	1452 3 O
particularly	1456 12 O
high	1469 4 O
among	1474 5 O
the	1480 3 O
subset	1484 6 O
of	1491 2 O
patients	1494 8 O
with	1503 4 O
vascular	1508 8 O
nephropathy	1517 11 B-Disease
as	1529 2 O
underlying	1532 10 O
disease	1543 7 O
[	1551 1 O
2	1552 1 O
.	1553 1 O
35	1554 2 O
(	1557 1 O
1	1558 1 O
.	1559 1 O
17	1560 2 O
-	1562 1 O
4	1563 1 O
.	1564 1 O
72	1565 2 O
)	1567 1 O
]	1568 1 O
.	1569 1 O

CONCLUSION	1571 10 O
:	1581 1 O
Our	1583 3 O
data	1587 4 O
indicate	1592 8 O
that	1601 4 O
long	1606 4 O
-	1610 1 O
term	1611 4 O
use	1616 3 O
of	1620 2 O
nonaspirin	1623 10 O
analgesic	1634 9 O
drugs	1644 5 O
and	1650 3 O
NSAIDs	1654 6 O
is	1661 2 O
not	1664 3 O
associated	1668 10 O
with	1679 4 O
an	1684 2 O
increased	1687 9 O
risk	1697 4 O
of	1702 2 O
ESRD	1705 4 B-Disease
.	1709 1 O

However	1711 7 O
,	1718 1 O
the	1720 3 O
chronic	1724 7 O
use	1732 3 O
of	1736 2 O
aspirin	1739 7 B-Chemical
may	1747 3 O
increase	1751 8 O
the	1760 3 O
risk	1764 4 O
of	1769 2 O
ESRD	1772 4 B-Disease
.	1776 1 O

Two	0 3 O
cases	4 5 O
of	10 2 O
amisulpride	13 11 B-Chemical
overdose	25 8 B-Disease
:	33 1 O
a	35 1 O
cause	37 5 O
for	43 3 O
prolonged	47 9 B-Disease
QT	57 2 I-Disease
syndrome	60 8 I-Disease
.	68 1 O

Two	70 3 O
cases	74 5 O
of	80 2 O
deliberate	83 10 O
self	94 4 O
-	98 1 O
poisoning	99 9 B-Disease
with	109 4 O
5	114 1 O
g	116 1 O
and	118 3 O
3	122 1 O
.	123 1 O
6	124 1 O
g	126 1 O
of	128 2 O
amisulpride	131 11 B-Chemical
,	142 1 O
respectively	144 12 O
,	156 1 O
are	158 3 O
reported	162 8 O
.	170 1 O

In	172 2 O
both	175 4 O
cases	180 5 O
,	185 1 O
QT	187 2 B-Disease
prolongation	190 12 I-Disease
and	203 3 O
hypocalcaemia	207 13 B-Disease
were	221 4 O
noted	226 5 O
.	231 1 O

The	233 3 O
QT	237 2 B-Disease
prolongation	240 12 I-Disease
appeared	253 8 O
to	262 2 O
respond	265 7 O
to	273 2 O
administration	276 14 O
of	291 2 O
i	294 1 O
.	295 1 O
v	296 1 O
.	297 1 O
calcium	299 7 B-Chemical
gluconate	307 9 I-Chemical
.	316 1 O

Growth	0 6 O
-	6 1 O
associated	7 10 O
protein	18 7 O
43	26 2 O
expression	29 10 O
in	40 2 O
hippocampal	43 11 O
molecular	55 9 O
layer	65 5 O
of	71 2 O
chronic	74 7 O
epileptic	82 9 B-Disease
rats	92 4 O
treated	97 7 O
with	105 4 O
cycloheximide	110 13 B-Chemical
.	123 1 O

PURPOSE	125 7 O
:	132 1 O
GAP43	134 5 O
has	140 3 O
been	144 4 O
thought	149 7 O
to	157 2 O
be	160 2 O
linked	163 6 O
with	170 4 O
mossy	175 5 O
fiber	181 5 O
sprouting	187 9 O
(	197 1 O
MFS	198 3 O
)	201 1 O
in	203 2 O
various	206 7 O
experimental	214 12 O
models	227 6 O
of	234 2 O
epilepsy	237 8 B-Disease
.	245 1 O

To	247 2 O
investigate	250 11 O
how	262 3 O
GAP43	266 5 O
expression	272 10 O
(	283 1 O
GAP43	284 5 O
-	289 1 O
ir	290 2 O
)	292 1 O
correlates	294 10 O
with	305 4 O
MFS	310 3 O
,	313 1 O
we	315 2 O
assessed	318 8 O
the	327 3 O
intensity	331 9 O
(	341 1 O
densitometry	342 12 O
)	354 1 O
and	356 3 O
extension	360 9 O
(	370 1 O
width	371 5 O
)	376 1 O
of	378 2 O
GAP43	381 5 O
-	386 1 O
ir	387 2 O
in	390 2 O
the	393 3 O
inner	397 5 O
molecular	403 9 O
layer	413 5 O
of	419 2 O
the	422 3 O
dentate	426 7 O
gyrus	434 5 O
(	440 1 O
IML	441 3 O
)	444 1 O
of	446 2 O
rats	449 4 O
subject	454 7 O
to	462 2 O
status	465 6 B-Disease
epilepticus	472 11 I-Disease
induced	484 7 O
by	492 2 O
pilocarpine	495 11 B-Chemical
(	507 1 O
Pilo	508 4 B-Chemical
)	512 1 O
,	513 1 O
previously	515 10 O
injected	526 8 O
or	535 2 O
not	538 3 O
with	542 4 O
cycloheximide	547 13 B-Chemical
(	561 1 O
CHX	562 3 B-Chemical
)	565 1 O
,	566 1 O
which	568 5 O
has	574 3 O
been	578 4 O
shown	583 5 O
to	589 2 O
inhibit	592 7 O
MFS	600 3 O
.	603 1 O

METHODS	605 7 O
:	612 1 O
CHX	614 3 B-Chemical
was	618 3 O
injected	622 8 O
before	631 6 O
the	638 3 O
Pilo	642 4 B-Chemical
injection	647 9 O
in	657 2 O
adult	660 5 O
Wistar	666 6 O
rats	673 4 O
.	677 1 O

The	679 3 O
Pilo	683 4 B-Chemical
group	688 5 O
was	694 3 O
injected	698 8 O
with	707 4 O
the	712 3 O
same	716 4 O
drugs	721 5 O
,	726 1 O
except	728 6 O
for	735 3 O
CHX	739 3 B-Chemical
.	742 1 O

Animals	744 7 O
were	752 4 O
killed	757 6 O
between	764 7 O
30	772 2 O
and	775 3 O
60	779 2 O
days	782 4 O
later	787 5 O
,	792 1 O
and	794 3 O
brain	798 5 O
sections	804 8 O
were	813 4 O
processed	818 9 O
for	828 3 O
GAP43	832 5 O
immunohistochemistry	838 20 O
.	858 1 O

RESULTS	860 7 O
:	867 1 O
Densitometry	869 12 O
showed	882 6 O
no	889 2 O
significant	892 11 O
difference	904 10 O
regarding	915 9 O
GAP43	925 5 O
-	930 1 O
ir	931 2 O
in	934 2 O
the	937 3 O
IML	941 3 O
between	945 7 O
Pilo	953 4 B-Chemical
,	957 1 O
CHX	959 3 B-Chemical
+	962 1 O
Pilo	963 4 B-Chemical
,	967 1 O
and	969 3 O
control	973 7 O
groups	981 6 O
.	987 1 O

However	989 7 O
,	996 1 O
the	998 3 O
results	1002 7 O
of	1010 2 O
the	1013 3 O
width	1017 5 O
of	1023 2 O
the	1026 3 O
GAP43	1030 5 O
-	1035 1 O
ir	1036 2 O
band	1039 4 O
in	1044 2 O
the	1047 3 O
IML	1051 3 O
showed	1055 6 O
that	1062 4 O
CHX	1067 3 B-Chemical
+	1070 1 O
Pilo	1071 4 B-Chemical
and	1076 3 O
control	1080 7 O
animals	1088 7 O
had	1096 3 O
a	1100 1 O
significantly	1102 13 O
larger	1116 6 O
band	1123 4 O
(	1128 1 O
p	1129 1 O
=	1131 1 O
0	1133 1 O
.	1134 1 O
03	1135 2 O
)	1137 1 O
as	1139 2 O
compared	1142 8 O
with	1151 4 O
that	1156 4 O
in	1161 2 O
the	1164 3 O
Pilo	1168 4 B-Chemical
group	1173 5 O
.	1178 1 O

CONCLUSIONS	1180 11 O
:	1191 1 O
Our	1193 3 O
current	1197 7 O
finding	1205 7 O
that	1213 4 O
animals	1218 7 O
in	1226 2 O
the	1229 3 O
CHX	1233 3 B-Chemical
+	1236 1 O
Pilo	1237 4 B-Chemical
group	1242 5 O
have	1248 4 O
a	1253 1 O
GAP43	1255 5 O
-	1260 1 O
ir	1261 2 O
band	1264 4 O
in	1269 2 O
the	1272 3 O
IML	1276 3 O
,	1279 1 O
similar	1281 7 O
to	1289 2 O
that	1292 4 O
of	1297 2 O
controls	1300 8 O
,	1308 1 O
reinforces	1310 10 O
prior	1321 5 O
data	1327 4 O
on	1332 2 O
the	1335 3 O
blockade	1339 8 O
of	1348 2 O
MFS	1351 3 O
in	1355 2 O
these	1358 5 O
animals	1364 7 O
.	1371 1 O

The	1373 3 O
change	1377 6 O
in	1384 2 O
GAP43	1387 5 O
-	1392 1 O
ir	1393 2 O
present	1396 7 O
in	1404 2 O
Pilo	1407 4 B-Chemical
-	1411 1 O
treated	1412 7 O
animals	1420 7 O
was	1428 3 O
a	1432 1 O
thinning	1434 8 O
of	1443 2 O
the	1446 3 O
band	1450 4 O
to	1455 2 O
a	1458 1 O
very	1460 4 O
narrow	1465 6 O
layer	1472 5 O
just	1478 4 O
above	1483 5 O
the	1489 3 O
granule	1493 7 O
cell	1501 4 O
layer	1506 5 O
that	1512 4 O
is	1517 2 O
likely	1520 6 O
to	1527 2 O
be	1530 2 O
associated	1533 10 O
with	1544 4 O
the	1549 3 O
loss	1553 4 O
of	1558 2 O
hilar	1561 5 O
cell	1567 4 O
projections	1572 11 O
that	1584 4 O
express	1589 7 O
GAP	1597 3 O
-	1600 1 O
43	1601 2 O
.	1603 1 O

Nicotine	0 8 B-Chemical
antagonizes	9 11 O
caffeine	21 8 B-Chemical
-	29 1 O
but	31 3 O
not	35 3 O
pentylenetetrazole	39 18 B-Chemical
-	57 1 O
induced	58 7 O
anxiogenic	66 10 O
effect	77 6 O
in	84 2 O
mice	87 4 O
.	91 1 O

RATIONALE	93 9 O
:	102 1 O
Nicotine	104 8 B-Chemical
and	113 3 O
caffeine	117 8 B-Chemical
are	126 3 O
widely	130 6 O
consumed	137 8 O
licit	146 5 O
psychoactive	152 12 O
drugs	165 5 O
worldwide	171 9 O
.	180 1 O

Epidemiological	182 15 O
studies	198 7 O
showed	206 6 O
that	213 4 O
they	218 4 O
were	223 4 O
generally	228 9 O
used	238 4 O
concurrently	243 12 O
.	255 1 O

Although	257 8 O
some	266 4 O
studies	271 7 O
in	279 2 O
experimental	282 12 O
animals	295 7 O
indicate	303 8 O
clear	312 5 O
pharmacological	318 15 O
interactions	334 12 O
between	347 7 O
them	355 4 O
,	359 1 O
no	361 2 O
studies	364 7 O
have	372 4 O
shown	377 5 O
a	383 1 O
specific	385 8 O
interaction	394 11 O
on	406 2 O
anxiety	409 7 B-Disease
responses	417 9 O
.	426 1 O

OBJECTIVES	428 10 O
:	438 1 O
The	440 3 O
present	444 7 O
study	452 5 O
investigates	458 12 O
the	471 3 O
effects	475 7 O
of	483 2 O
nicotine	486 8 B-Chemical
on	495 2 O
anxiety	498 7 B-Disease
induced	506 7 O
by	514 2 O
caffeine	517 8 B-Chemical
and	526 3 O
another	530 7 O
anxiogenic	538 10 O
drug	549 4 O
,	553 1 O
pentylenetetrazole	555 18 B-Chemical
,	573 1 O
in	575 2 O
mice	578 4 O
.	582 1 O

The	584 3 O
elevated	588 8 O
plus	597 4 O
-	601 1 O
maze	602 4 O
(	607 1 O
EPM	608 3 O
)	611 1 O
test	613 4 O
was	618 3 O
used	622 4 O
to	627 2 O
evaluate	630 8 O
the	639 3 O
effects	643 7 O
of	651 2 O
drugs	654 5 O
on	660 2 O
anxiety	663 7 B-Disease
.	670 1 O

METHODS	672 7 O
:	679 1 O
Adult	681 5 O
male	687 4 O
Swiss	692 5 O
Webster	698 7 O
mice	706 4 O
(	711 1 O
25	712 2 O
-	714 1 O
32	715 2 O
g	718 1 O
)	719 1 O
were	721 4 O
given	726 5 O
nicotine	732 8 B-Chemical
(	741 1 O
0	742 1 O
.	743 1 O
05	744 2 O
-	746 1 O
0	747 1 O
.	748 1 O
25	749 2 O
mg	752 2 O
/	754 1 O
kg	755 2 O
s	758 1 O
.	759 1 O
c	760 1 O
.	761 1 O
)	762 1 O
or	764 2 O
saline	767 6 O
10	774 2 O
min	777 3 O
before	781 6 O
caffeine	788 8 B-Chemical
(	797 1 O
70	798 2 O
mg	801 2 O
/	803 1 O
kg	804 2 O
i	807 1 O
.	808 1 O
p	809 1 O
.	810 1 O
)	811 1 O
or	813 2 O
pentylenetetrazole	816 18 B-Chemical
(	835 1 O
15	836 2 O
and	839 3 O
30	843 2 O
mg	846 2 O
/	848 1 O
kg	849 2 O
i	852 1 O
.	853 1 O
p	854 1 O
.	855 1 O
)	856 1 O
injections	858 10 O
.	868 1 O

After	870 5 O
15	876 2 O
min	879 3 O
,	882 1 O
mice	884 4 O
were	889 4 O
evaluated	894 9 O
for	904 3 O
their	908 5 O
open	914 4 O
-	918 1 O
and	920 3 O
closed	924 6 O
-	930 1 O
arm	931 3 O
time	935 4 O
and	940 3 O
entries	944 7 O
on	952 2 O
the	955 3 O
EPM	959 3 O
for	963 3 O
a	967 1 O
10	969 2 O
-	971 1 O
min	972 3 O
session	976 7 O
.	983 1 O

Locomotor	985 9 O
activity	995 8 O
was	1004 3 O
recorded	1008 8 O
for	1017 3 O
individual	1021 10 O
groups	1032 6 O
by	1039 2 O
using	1042 5 O
the	1048 3 O
same	1052 4 O
treatment	1057 9 O
protocol	1067 8 O
with	1076 4 O
the	1081 3 O
EPM	1085 3 O
test	1089 4 O
.	1093 1 O

RESULTS	1095 7 O
:	1102 1 O
Nicotine	1104 8 B-Chemical
(	1113 1 O
0	1114 1 O
.	1115 1 O
05	1116 2 O
-	1118 1 O
0	1119 1 O
.	1120 1 O
25	1121 2 O
mg	1124 2 O
/	1126 1 O
kg	1127 2 O
)	1129 1 O
itself	1131 6 O
did	1138 3 O
not	1142 3 O
produce	1146 7 O
any	1154 3 O
significant	1158 11 O
effect	1170 6 O
in	1177 2 O
the	1180 3 O
EPM	1184 3 O
test	1188 4 O
,	1192 1 O
whereas	1194 7 O
caffeine	1202 8 B-Chemical
(	1211 1 O
70	1212 2 O
mg	1215 2 O
/	1217 1 O
kg	1218 2 O
)	1220 1 O
and	1222 3 O
pentylenetetrazole	1226 18 B-Chemical
(	1245 1 O
30	1246 2 O
mg	1249 2 O
/	1251 1 O
kg	1252 2 O
)	1254 1 O
produced	1256 8 O
an	1265 2 O
anxiogenic	1268 10 O
effect	1279 6 O
,	1285 1 O
apparent	1287 8 O
with	1296 4 O
decreases	1301 9 O
in	1311 2 O
open	1314 4 O
-	1318 1 O
arm	1319 3 O
time	1323 4 O
and	1328 3 O
entry	1332 5 O
.	1337 1 O

Nicotine	1339 8 B-Chemical
(	1348 1 O
0	1349 1 O
.	1350 1 O
25	1351 2 O
mg	1354 2 O
/	1356 1 O
kg	1357 2 O
)	1359 1 O
pretreatment	1361 12 O
blocked	1374 7 O
the	1382 3 O
caffeine	1386 8 B-Chemical
-	1394 1 O
but	1396 3 O
not	1400 3 O
pentylenetetrazole	1404 18 B-Chemical
-	1422 1 O
induced	1423 7 O
anxiety	1431 7 B-Disease
.	1438 1 O

Administration	1440 14 O
of	1455 2 O
each	1458 4 O
drug	1463 4 O
and	1468 3 O
their	1472 5 O
combinations	1478 12 O
did	1491 3 O
not	1495 3 O
produce	1499 7 O
any	1507 3 O
effect	1511 6 O
on	1518 2 O
locomotor	1521 9 O
activity	1531 8 O
.	1539 1 O

CONCLUSIONS	1541 11 O
:	1552 1 O
Our	1554 3 O
results	1558 7 O
suggest	1566 7 O
that	1574 4 O
the	1579 3 O
antagonistic	1583 12 O
effect	1596 6 O
of	1603 2 O
nicotine	1606 8 B-Chemical
on	1615 2 O
caffeine	1618 8 B-Chemical
-	1626 1 O
induced	1627 7 O
anxiety	1635 7 B-Disease
is	1643 2 O
specific	1646 8 O
to	1655 2 O
caffeine	1658 8 B-Chemical
,	1666 1 O
instead	1668 7 O
of	1676 2 O
a	1679 1 O
non	1681 3 O
-	1684 1 O
specific	1685 8 O
anxiolytic	1694 10 O
effect	1705 6 O
.	1711 1 O

Thus	1713 4 O
,	1717 1 O
it	1719 2 O
may	1722 3 O
extend	1726 6 O
the	1733 3 O
current	1737 7 O
findings	1745 8 O
on	1754 2 O
the	1757 3 O
interaction	1761 11 O
between	1773 7 O
nicotine	1781 8 B-Chemical
and	1790 3 O
caffeine	1794 8 B-Chemical
.	1802 1 O

Long	0 4 O
term	5 4 O
hormone	10 7 O
therapy	18 7 O
for	26 3 O
perimenopausal	30 14 O
and	45 3 O
postmenopausal	49 14 O
women	64 5 O
.	69 1 O

BACKGROUND	71 10 O
:	81 1 O
Hormone	83 7 O
therapy	91 7 O
(	99 1 O
HT	100 2 O
)	102 1 O
is	104 2 O
widely	107 6 O
used	114 4 O
for	119 3 O
controlling	123 11 O
menopausal	135 10 B-Disease
symptoms	146 8 I-Disease
.	154 1 O

It	156 2 O
has	159 3 O
also	163 4 O
been	168 4 O
used	173 4 O
for	178 3 O
the	182 3 O
management	186 10 O
and	197 3 O
prevention	201 10 O
of	212 2 O
cardiovascular	215 14 B-Disease
disease	230 7 I-Disease
,	237 1 O
osteoporosis	239 12 B-Disease
and	252 3 O
dementia	256 8 B-Disease
in	265 2 O
older	268 5 O
women	274 5 O
but	280 3 O
the	284 3 O
evidence	288 8 O
supporting	297 10 O
its	308 3 O
use	312 3 O
for	316 3 O
these	320 5 O
indications	326 11 O
is	338 2 O
largely	341 7 O
observational	349 13 O
.	362 1 O

OBJECTIVES	364 10 O
:	374 1 O
To	376 2 O
assess	379 6 O
the	386 3 O
effect	390 6 O
of	397 2 O
long	400 4 O
-	404 1 O
term	405 4 O
HT	410 2 O
on	413 2 O
mortality	416 9 O
,	425 1 O
heart	427 5 B-Disease
disease	433 7 I-Disease
,	440 1 O
venous	442 6 B-Disease
thromboembolism	449 15 I-Disease
,	464 1 O
stroke	466 6 B-Disease
,	472 1 O
transient	474 9 B-Disease
ischaemic	484 9 I-Disease
attacks	494 7 I-Disease
,	501 1 O
breast	503 6 B-Disease
cancer	510 6 I-Disease
,	516 1 O
colorectal	518 10 B-Disease
cancer	529 6 I-Disease
,	535 1 O
ovarian	537 7 B-Disease
cancer	545 6 I-Disease
,	551 1 O
endometrial	553 11 B-Disease
cancer	565 6 I-Disease
,	571 1 O
gallbladder	573 11 B-Disease
disease	585 7 I-Disease
,	592 1 O
cognitive	594 9 O
function	604 8 O
,	612 1 O
dementia	614 8 B-Disease
,	622 1 O
fractures	624 9 B-Disease
and	634 3 O
quality	638 7 O
of	646 2 O
life	649 4 O
.	653 1 O

SEARCH	655 6 O
STRATEGY	662 8 O
:	670 1 O
We	672 2 O
searched	675 8 O
the	684 3 O
following	688 9 O
databases	698 9 O
up	708 2 O
to	711 2 O
November	714 8 O
2004	723 4 O
:	727 1 O
the	729 3 O
Cochrane	733 8 O
Menstrual	742 9 O
Disorders	752 9 O
and	762 3 O
Subfertility	766 12 O
Group	779 5 O
Trials	785 6 O
Register	792 8 O
,	800 1 O
Cochrane	802 8 O
Central	811 7 O
Register	819 8 O
of	828 2 O
Controlled	831 10 O
Trials	842 6 O
(	849 1 O
CENTRAL	850 7 O
)	857 1 O
,	858 1 O
MEDLINE	860 7 O
,	867 1 O
EMBASE	869 6 O
,	875 1 O
Biological	877 10 O
Abstracts	888 9 O
.	897 1 O

Relevant	899 8 O
non	908 3 O
-	911 1 O
indexed	912 7 O
journals	920 8 O
and	929 3 O
conference	933 10 O
abstracts	944 9 O
were	954 4 O
also	959 4 O
searched	964 8 O
.	972 1 O

SELECTION	974 9 O
CRITERIA	984 8 O
:	992 1 O
Randomised	994 10 O
double	1005 6 O
-	1011 1 O
blind	1012 5 O
trials	1018 6 O
of	1025 2 O
HT	1028 2 O
(	1031 1 O
oestrogens	1032 10 B-Chemical
with	1043 4 O
or	1048 2 O
without	1051 7 O
progestogens	1059 12 B-Chemical
)	1071 1 O
versus	1073 6 O
placebo	1080 7 O
,	1087 1 O
taken	1089 5 O
for	1095 3 O
at	1099 2 O
least	1102 5 O
one	1108 3 O
year	1112 4 O
by	1117 2 O
perimenopausal	1120 14 O
or	1135 2 O
postmenopausal	1138 14 O
women	1153 5 O
.	1158 1 O

DATA	1160 4 O
COLLECTION	1165 10 O
AND	1176 3 O
ANALYSIS	1180 8 O
:	1188 1 O
Fifteen	1190 7 O
RCTs	1198 4 O
were	1203 4 O
included	1208 8 O
.	1216 1 O

Trials	1218 6 O
were	1225 4 O
assessed	1230 8 O
for	1239 3 O
quality	1243 7 O
and	1251 3 O
two	1255 3 O
review	1259 6 O
authors	1266 7 O
extracted	1274 9 O
data	1284 4 O
independently	1289 13 O
.	1302 1 O

They	1304 4 O
calculated	1309 10 O
risk	1320 4 O
ratios	1325 6 O
for	1332 3 O
dichotomous	1336 11 O
outcomes	1348 8 O
and	1357 3 O
weighted	1361 8 O
mean	1370 4 O
differences	1375 11 O
for	1387 3 O
continuous	1391 10 O
outcomes	1402 8 O
.	1410 1 O

Clinical	1412 8 O
heterogeneity	1421 13 O
precluded	1435 9 O
meta	1445 4 O
-	1449 1 O
analysis	1450 8 O
for	1459 3 O
most	1463 4 O
outcomes	1468 8 O
.	1476 1 O

MAIN	1478 4 O
RESULTS	1483 7 O
:	1490 1 O
All	1492 3 O
the	1496 3 O
statistically	1500 13 O
significant	1514 11 O
results	1526 7 O
were	1534 4 O
derived	1539 7 O
from	1547 4 O
the	1552 3 O
two	1556 3 O
biggest	1560 7 O
trials	1568 6 O
.	1574 1 O

In	1576 2 O
relatively	1579 10 O
healthy	1590 7 O
women	1598 5 O
,	1603 1 O
combined	1605 8 O
continuous	1614 10 O
HT	1625 2 O
significantly	1628 13 O
increased	1642 9 O
the	1652 3 O
risk	1656 4 O
of	1661 2 O
venous	1664 6 B-Disease
thromboembolism	1671 15 I-Disease
or	1687 2 O
coronary	1690 8 O
event	1699 5 O
(	1705 1 O
after	1706 5 O
one	1712 3 O
year	1716 4 O
'	1720 1 O
s	1721 1 O
use	1723 3 O
)	1726 1 O
,	1727 1 O
stroke	1729 6 B-Disease
(	1736 1 O
after	1737 5 O
3	1743 1 O
years	1745 5 O
)	1750 1 O
,	1751 1 O
breast	1753 6 B-Disease
cancer	1760 6 I-Disease
(	1767 1 O
after	1768 5 O
5	1774 1 O
years	1776 5 O
)	1781 1 O
and	1783 3 O
gallbladder	1787 11 B-Disease
disease	1799 7 I-Disease
.	1806 1 O

Long	1808 4 O
-	1812 1 O
term	1813 4 O
oestrogen	1818 9 B-Chemical
-	1827 1 O
only	1828 4 O
HT	1833 2 O
also	1836 4 O
significantly	1841 13 O
increased	1855 9 O
the	1865 3 O
risk	1869 4 O
of	1874 2 O
stroke	1877 6 B-Disease
and	1884 3 O
gallbladder	1888 11 B-Disease
disease	1900 7 I-Disease
.	1907 1 O

Overall	1909 7 O
,	1916 1 O
the	1918 3 O
only	1922 4 O
statistically	1927 13 O
significant	1941 11 O
benefits	1953 8 O
of	1962 2 O
HT	1965 2 O
were	1968 4 O
a	1973 1 O
decreased	1975 9 O
incidence	1985 9 O
of	1995 2 O
fractures	1998 9 B-Disease
and	2008 3 O
colon	2012 5 B-Disease
cancer	2018 6 I-Disease
with	2025 4 O
long	2030 4 O
-	2034 1 O
term	2035 4 O
use	2040 3 O
.	2043 1 O

Among	2045 5 O
relatively	2051 10 O
healthy	2062 7 O
women	2070 5 O
over	2076 4 O
65	2081 2 O
years	2084 5 O
taking	2090 6 O
continuous	2097 10 O
combined	2108 8 O
HT	2117 2 O
,	2119 1 O
there	2121 5 O
was	2127 3 O
a	2131 1 O
statistically	2133 13 O
significant	2147 11 O
increase	2159 8 O
in	2168 2 O
the	2171 3 O
incidence	2175 9 O
of	2185 2 O
dementia	2188 8 B-Disease
.	2196 1 O

Among	2198 5 O
women	2204 5 O
with	2210 4 O
cardiovascular	2215 14 B-Disease
disease	2230 7 I-Disease
,	2237 1 O
long	2239 4 O
-	2243 1 O
term	2244 4 O
use	2249 3 O
of	2253 2 O
combined	2256 8 O
continuous	2265 10 O
HT	2276 2 O
significantly	2279 13 O
increased	2293 9 O
the	2303 3 O
risk	2307 4 O
of	2312 2 O
venous	2315 6 B-Disease
thromboembolism	2322 15 I-Disease
.	2337 1 O

No	2339 2 O
trials	2342 6 O
focussed	2349 8 O
specifically	2358 12 O
on	2371 2 O
younger	2374 7 O
women	2382 5 O
.	2387 1 O

However	2389 7 O
,	2396 1 O
one	2398 3 O
trial	2402 5 O
analysed	2408 8 O
subgroups	2417 9 O
of	2427 2 O
2839	2430 4 O
relatively	2435 10 O
healthy	2446 7 O
50	2454 2 O
to	2457 2 O
59	2460 2 O
year	2463 4 O
-	2467 1 O
old	2468 3 O
women	2472 5 O
taking	2478 6 O
combined	2485 8 O
continuous	2494 10 O
HT	2505 2 O
and	2508 3 O
1637	2512 4 O
taking	2517 6 O
oestrogen	2524 9 B-Chemical
-	2533 1 O
only	2534 4 O
HT	2539 2 O
,	2541 1 O
versus	2543 6 O
similar	2550 7 O
-	2557 1 O
sized	2558 5 O
placebo	2564 7 O
groups	2572 6 O
.	2578 1 O

The	2580 3 O
only	2584 4 O
significantly	2589 13 O
increased	2603 9 O
risk	2613 4 O
reported	2618 8 O
was	2627 3 O
for	2631 3 O
venous	2635 6 B-Disease
thromboembolism	2642 15 I-Disease
in	2658 2 O
women	2661 5 O
taking	2667 6 O
combined	2674 8 O
continuous	2683 10 O
HT	2694 2 O
;	2696 1 O
their	2698 5 O
absolute	2704 8 O
risk	2713 4 O
remained	2718 8 O
very	2727 4 O
low	2732 3 O
.	2735 1 O

AUTHORS	2737 7 O
'	2744 1 O
CONCLUSIONS	2746 11 O
:	2757 1 O
HT	2759 2 O
is	2762 2 O
not	2765 3 O
indicated	2769 9 O
for	2779 3 O
the	2783 3 O
routine	2787 7 O
management	2795 10 O
of	2806 2 O
chronic	2809 7 B-Disease
disease	2817 7 I-Disease
.	2824 1 O

We	2826 2 O
need	2829 4 O
more	2834 4 O
evidence	2839 8 O
on	2848 2 O
the	2851 3 O
safety	2855 6 O
of	2862 2 O
HT	2865 2 O
for	2868 3 O
menopausal	2872 10 O
symptom	2883 7 O
control	2891 7 O
,	2898 1 O
though	2900 6 O
short	2907 5 O
-	2912 1 O
term	2913 4 O
use	2918 3 O
appears	2922 7 O
to	2930 2 O
be	2933 2 O
relatively	2936 10 O
safe	2947 4 O
for	2952 3 O
healthy	2956 7 O
younger	2964 7 O
women	2972 5 O
.	2977 1 O

Drug	0 4 B-Disease
-	4 1 I-Disease
induced	5 7 I-Disease
liver	13 5 I-Disease
injury	19 6 I-Disease
:	25 1 O
an	27 2 O
analysis	30 8 O
of	39 2 O
461	42 3 O
incidences	46 10 O
submitted	57 9 O
to	67 2 O
the	70 3 O
Spanish	74 7 O
registry	82 8 O
over	91 4 O
a	96 1 O
10	98 2 O
-	100 1 O
year	101 4 O
period	106 6 O
.	112 1 O

BACKGROUND	114 10 O
&	125 1 O
AIMS	127 4 O
:	131 1 O
Progress	133 8 O
in	142 2 O
the	145 3 O
understanding	149 13 O
of	163 2 O
susceptibility	166 14 O
factors	181 7 O
to	189 2 O
drug	192 4 B-Disease
-	196 1 I-Disease
induced	197 7 I-Disease
liver	205 5 I-Disease
injury	211 6 I-Disease
(	218 1 O
DILI	219 4 B-Disease
)	223 1 O
and	225 3 O
outcome	229 7 O
predictability	237 14 O
are	252 3 O
hampered	256 8 O
by	265 2 O
the	268 3 O
lack	272 4 O
of	277 2 O
systematic	280 10 O
programs	291 8 O
to	300 2 O
detect	303 6 O
bona	310 4 O
fide	315 4 O
cases	320 5 O
.	325 1 O

METHODS	327 7 O
:	334 1 O
A	336 1 O
cooperative	338 11 O
network	350 7 O
was	358 3 O
created	362 7 O
in	370 2 O
1994	373 4 O
in	378 2 O
Spain	381 5 O
to	387 2 O
identify	390 8 O
all	399 3 O
suspicions	403 10 O
of	414 2 O
DILI	417 4 B-Disease
following	422 9 O
a	432 1 O
prospective	434 11 O
structured	446 10 O
report	457 6 O
form	464 4 O
.	468 1 O

The	470 3 O
liver	474 5 B-Disease
damage	480 6 I-Disease
was	487 3 O
characterized	491 13 O
according	505 9 O
to	515 2 O
hepatocellular	518 14 O
,	532 1 O
cholestatic	534 11 B-Disease
,	545 1 O
and	547 3 O
mixed	551 5 O
laboratory	557 10 O
criteria	568 8 O
and	577 3 O
to	581 2 O
histologic	584 10 O
criteria	595 8 O
when	604 4 O
available	609 9 O
.	618 1 O

Further	620 7 O
evaluation	628 10 O
of	639 2 O
causality	642 9 O
assessment	652 10 O
was	663 3 O
centrally	667 9 O
performed	677 9 O
.	686 1 O

RESULTS	688 7 O
:	695 1 O
Since	697 5 O
April	703 5 O
1994	709 4 O
to	714 2 O
August	717 6 O
2004	724 4 O
,	728 1 O
461	730 3 O
out	734 3 O
of	738 2 O
570	741 3 O
submitted	745 9 O
cases	755 5 O
,	760 1 O
involving	762 9 O
505	772 3 O
drugs	776 5 O
,	781 1 O
were	783 4 O
deemed	788 6 O
to	795 2 O
be	798 2 O
related	801 7 O
to	809 2 O
DILI	812 4 B-Disease
.	816 1 O

The	818 3 O
antiinfective	822 13 O
group	836 5 O
of	842 2 O
drugs	845 5 O
was	851 3 O
the	855 3 O
more	859 4 O
frequently	864 10 O
incriminated	875 12 O
,	887 1 O
amoxicillin	889 11 B-Chemical
-	900 1 I-Chemical
clavulanate	901 11 I-Chemical
accounting	913 10 O
for	924 3 O
the	928 3 O
12	932 2 O
.	934 1 O
8	935 1 O
%	936 1 O
of	938 2 O
the	941 3 O
whole	945 5 O
series	951 6 O
.	957 1 O

The	959 3 O
hepatocellular	963 14 O
pattern	978 7 O
of	986 2 O
damage	989 6 O
was	996 3 O
the	1000 3 O
most	1004 4 O
common	1009 6 O
(	1016 1 O
58	1017 2 O
%	1019 1 O
)	1020 1 O
,	1021 1 O
was	1023 3 O
inversely	1027 9 O
correlated	1037 10 O
with	1048 4 O
age	1053 3 O
(	1057 1 O
P	1058 1 O
<	1060 1 O
.	1062 1 O
0001	1063 4 O
)	1067 1 O
,	1068 1 O
and	1070 3 O
had	1074 3 O
the	1078 3 O
worst	1082 5 O
outcome	1088 7 O
(	1096 1 O
Cox	1097 3 O
regression	1101 10 O
,	1111 1 O
P	1113 1 O
<	1115 1 O
.	1117 1 O
034	1118 3 O
)	1121 1 O
.	1122 1 O

Indeed	1124 6 O
,	1130 1 O
the	1132 3 O
incidence	1136 9 O
of	1146 2 O
liver	1149 5 O
transplantation	1155 15 O
and	1171 3 O
death	1175 5 O
in	1181 2 O
this	1184 4 O
group	1189 5 O
was	1195 3 O
11	1199 2 O
.	1201 1 O
7	1202 1 O
%	1203 1 O
if	1205 2 O
patients	1208 8 O
had	1217 3 O
jaundice	1221 8 B-Disease
at	1230 2 O
presentation	1233 12 O
,	1245 1 O
whereas	1247 7 O
the	1255 3 O
corresponding	1259 13 O
figure	1273 6 O
was	1280 3 O
3	1284 1 O
.	1285 1 O
8	1286 1 O
%	1287 1 O
in	1289 2 O
nonjaundiced	1292 12 O
patients	1305 8 O
(	1314 1 O
P	1315 1 O
<	1317 1 O
.	1319 1 O
04	1320 2 O
)	1322 1 O
.	1323 1 O

Factors	1325 7 O
associated	1333 10 O
with	1344 4 O
the	1349 3 O
development	1353 11 O
of	1365 2 O
fulminant	1368 9 B-Disease
hepatic	1378 7 I-Disease
failure	1386 7 I-Disease
were	1394 4 O
female	1399 6 O
sex	1406 3 O
(	1410 1 O
OR	1411 2 O
=	1414 1 O
25	1416 2 O
;	1418 1 O
95	1420 2 O
%	1422 1 O
CI	1424 2 O
:	1426 1 O
4	1428 1 O
.	1429 1 O
1	1430 1 O
-	1431 1 O
151	1432 3 O
;	1435 1 O
P	1437 1 O
<	1439 1 O
.	1441 1 O
0001	1442 4 O
)	1446 1 O
,	1447 1 O
hepatocellular	1449 14 O
damage	1464 6 O
(	1471 1 O
OR	1472 2 O
=	1475 1 O
7	1477 1 O
.	1478 1 O
9	1479 1 O
;	1480 1 O
95	1482 2 O
%	1484 1 O
CI	1486 2 O
:	1488 1 O
1	1490 1 O
.	1491 1 O
6	1492 1 O
-	1493 1 O
37	1494 2 O
;	1496 1 O
P	1498 1 O
<	1500 1 O
.	1502 1 O
009	1503 3 O
)	1506 1 O
,	1507 1 O
and	1509 3 O
higher	1513 6 O
baseline	1520 8 O
plasma	1529 6 O
bilirubin	1536 9 B-Chemical
value	1546 5 O
(	1552 1 O
OR	1553 2 O
=	1556 1 O
1	1558 1 O
.	1559 1 O
15	1560 2 O
;	1562 1 O
95	1564 2 O
%	1566 1 O
CI	1568 2 O
:	1570 1 O
1	1572 1 O
.	1573 1 O
09	1574 2 O
-	1576 1 O
1	1577 1 O
.	1578 1 O
22	1579 2 O
;	1581 1 O
P	1583 1 O
<	1585 1 O
.	1587 1 O
0001	1588 4 O
)	1592 1 O
.	1593 1 O

CONCLUSIONS	1595 11 O
:	1606 1 O
Patients	1608 8 O
with	1617 4 O
drug	1622 4 O
-	1626 1 O
induced	1627 7 O
hepatocellular	1635 14 O
jaundice	1650 8 B-Disease
have	1659 4 O
11	1664 2 O
.	1666 1 O
7	1667 1 O
%	1668 1 O
chance	1670 6 O
of	1677 2 O
progressing	1680 11 O
to	1692 2 O
death	1695 5 O
or	1701 2 O
transplantation	1704 15 O
.	1719 1 O

Amoxicillin	1721 11 B-Chemical
-	1732 1 I-Chemical
clavulanate	1733 11 I-Chemical
stands	1745 6 O
out	1752 3 O
as	1756 2 O
the	1759 3 O
most	1763 4 O
common	1768 6 O
drug	1775 4 O
related	1780 7 O
to	1788 2 O
DILI	1791 4 B-Disease
.	1795 1 O

Morphological	0 13 O
evaluation	14 10 O
of	25 2 O
the	28 3 O
effect	32 6 O
of	39 2 O
d	42 1 B-Chemical
-	43 1 I-Chemical
ribose	44 6 I-Chemical
on	51 2 O
adriamycin	54 10 B-Chemical
-	64 1 O
evoked	65 6 O
cardiotoxicity	72 14 B-Disease
in	87 2 O
rats	90 4 O
.	94 1 O

The	96 3 O
influence	100 9 O
of	110 2 O
d	113 1 B-Chemical
-	114 1 I-Chemical
ribose	115 6 I-Chemical
on	122 2 O
adriamycin	125 10 B-Chemical
-	135 1 O
induced	136 7 O
myocardiopathy	144 14 B-Disease
in	159 2 O
rats	162 4 O
was	167 3 O
studied	171 7 O
.	178 1 O

Adriamycin	180 10 B-Chemical
in	191 2 O
the	194 3 O
cumulative	198 10 O
dose	209 4 O
of	214 2 O
25	217 2 O
mg	220 2 O
/	222 1 O
kg	223 2 O
evoked	226 6 O
fully	233 5 O
developed	239 9 O
cardiac	249 7 B-Disease
toxicity	257 8 I-Disease
.	265 1 O

D	267 1 B-Chemical
-	268 1 I-Chemical
ribose	269 6 I-Chemical
in	276 2 O
the	279 3 O
multiple	283 8 O
doses	292 5 O
of	298 2 O
200	301 3 O
mg	305 2 O
/	307 1 O
kg	308 2 O
did	311 3 O
not	315 3 O
influence	319 9 O
ADR	329 3 B-Chemical
cardiotoxicity	333 14 B-Disease
.	347 1 O

In	0 2 O
vivo	3 4 O
evidences	8 9 O
suggesting	18 10 O
the	29 3 O
role	33 4 O
of	38 2 O
oxidative	41 9 O
stress	51 6 O
in	58 2 O
pathogenesis	61 12 O
of	74 2 O
vancomycin	77 10 B-Chemical
-	87 1 O
induced	88 7 O
nephrotoxicity	96 14 B-Disease
:	110 1 O
protection	112 10 O
by	123 2 O
erdosteine	126 10 B-Chemical
.	136 1 O

The	138 3 O
aims	142 4 O
of	147 2 O
this	150 4 O
study	155 5 O
were	161 4 O
to	166 2 O
examine	169 7 O
vancomycin	177 10 B-Chemical
(	188 1 O
VCM	189 3 B-Chemical
)	192 1 O
-	193 1 O
induced	194 7 O
oxidative	202 9 O
stress	212 6 O
that	219 4 O
promotes	224 8 O
production	233 10 O
of	244 2 O
reactive	247 8 O
oxygen	256 6 B-Chemical
species	263 7 O
(	271 1 O
ROS	272 3 O
)	275 1 O
and	277 3 O
to	281 2 O
investigate	284 11 O
the	296 3 O
role	300 4 O
of	305 2 O
erdosteine	308 10 B-Chemical
,	318 1 O
an	320 2 O
expectorant	323 11 O
agent	335 5 O
,	340 1 O
which	342 5 O
has	348 3 O
also	352 4 O
antioxidant	357 11 O
properties	369 10 O
,	379 1 O
on	381 2 O
kidney	384 6 O
tissue	391 6 O
against	398 7 O
the	406 3 O
possible	410 8 O
VCM	419 3 B-Chemical
-	422 1 O
induced	423 7 O
renal	431 5 B-Disease
impairment	437 10 I-Disease
in	448 2 O
rats	451 4 O
.	455 1 O

Rats	457 4 O
were	462 4 O
divided	467 7 O
into	475 4 O
three	480 5 O
groups	486 6 O
:	492 1 O
sham	494 4 O
,	498 1 O
VCM	500 3 B-Chemical
and	504 3 O
VCM	508 3 B-Chemical
plus	512 4 O
erdosteine	517 10 B-Chemical
.	527 1 O

VCM	529 3 B-Chemical
was	533 3 O
administrated	537 13 O
intraperitoneally	551 17 O
(	569 1 O
i	570 1 O
.	571 1 O
p	572 1 O
.	573 1 O
)	574 1 O
with	576 4 O
200mgkg	581 7 O
(	588 1 O
-	589 1 O
1	590 1 O
)	591 1 O
twice	593 5 O
daily	599 5 O
for	605 3 O
7	609 1 O
days	611 4 O
.	615 1 O

Erdosteine	617 10 B-Chemical
was	628 3 O
administered	632 12 O
orally	645 6 O
.	651 1 O

VCM	653 3 B-Chemical
administration	657 14 O
to	672 2 O
control	675 7 O
rats	683 4 O
significantly	688 13 O
increased	702 9 O
renal	712 5 O
malondialdehyde	718 15 B-Chemical
(	734 1 O
MDA	735 3 B-Chemical
)	738 1 O
and	740 3 O
urinary	744 7 O
N	752 1 O
-	753 1 O
acetyl	754 6 O
-	760 1 O
beta	761 4 O
-	765 1 O
d	766 1 O
-	767 1 O
glucosaminidase	768 15 O
(	784 1 O
NAG	785 3 O
,	788 1 O
a	790 1 O
marker	792 6 O
of	799 2 O
renal	802 5 B-Disease
tubular	808 7 I-Disease
injury	816 6 I-Disease
)	822 1 O
excretion	824 9 O
but	834 3 O
decreased	838 9 O
superoxide	848 10 B-Chemical
dismutase	859 9 O
(	869 1 O
SOD	870 3 O
)	873 1 O
and	875 3 O
catalase	879 8 O
(	888 1 O
CAT	889 3 O
)	892 1 O
activities	894 10 O
.	904 1 O

Erdosteine	906 10 B-Chemical
administration	917 14 O
with	932 4 O
VCM	937 3 B-Chemical
injections	941 10 O
caused	952 6 O
significantly	959 13 O
decreased	973 9 O
renal	983 5 O
MDA	989 3 B-Chemical
and	993 3 O
urinary	997 7 O
NAG	1005 3 O
excretion	1009 9 O
,	1018 1 O
and	1020 3 O
increased	1024 9 O
SOD	1034 3 O
activity	1038 8 O
,	1046 1 O
but	1048 3 O
not	1052 3 O
CAT	1056 3 O
activity	1060 8 O
in	1069 2 O
renal	1072 5 O
tissue	1078 6 O
when	1085 4 O
compared	1090 8 O
with	1099 4 O
VCM	1104 3 B-Chemical
alone	1108 5 O
.	1113 1 O

Erdosteine	1115 10 B-Chemical
showed	1126 6 O
histopathological	1133 17 O
protection	1151 10 O
against	1162 7 O
VCM	1170 3 B-Chemical
-	1173 1 O
induced	1174 7 O
nephrotoxicity	1182 14 B-Disease
.	1196 1 O

There	1198 5 O
were	1204 4 O
a	1209 1 O
significant	1211 11 O
dilatation	1223 10 O
of	1234 2 O
tubular	1237 7 O
lumens	1245 6 O
,	1251 1 O
extensive	1253 9 O
epithelial	1263 10 O
cell	1274 4 O
vacuolization	1279 13 O
,	1292 1 O
atrophy	1294 7 B-Disease
,	1301 1 O
desquamation	1303 12 B-Disease
,	1315 1 O
and	1317 3 O
necrosis	1321 8 B-Disease
in	1330 2 O
VCM	1333 3 B-Chemical
-	1336 1 O
treated	1337 7 O
rats	1345 4 O
more	1350 4 O
than	1355 4 O
those	1360 5 O
of	1366 2 O
the	1369 3 O
control	1373 7 O
and	1381 3 O
the	1385 3 O
erdosteine	1389 10 B-Chemical
groups	1400 6 O
.	1406 1 O

Erdosteine	1408 10 B-Chemical
caused	1419 6 O
a	1426 1 O
marked	1428 6 O
reduction	1435 9 O
in	1445 2 O
the	1448 3 O
extent	1452 6 O
of	1459 2 O
tubular	1462 7 O
damage	1470 6 O
.	1476 1 O

It	1478 2 O
is	1481 2 O
concluded	1484 9 O
that	1494 4 O
oxidative	1499 9 O
tubular	1509 7 O
damage	1517 6 O
plays	1524 5 O
an	1530 2 O
important	1533 9 O
role	1543 4 O
in	1548 2 O
the	1551 3 O
VCM	1555 3 B-Chemical
-	1558 1 O
induced	1559 7 O
nephrotoxicity	1567 14 B-Disease
and	1582 3 O
the	1586 3 O
modulation	1590 10 O
of	1601 2 O
oxidative	1604 9 O
stress	1614 6 O
with	1621 4 O
erdosteine	1626 10 B-Chemical
reduces	1637 7 O
the	1645 3 O
VCM	1649 3 B-Chemical
-	1652 1 O
induced	1653 7 O
kidney	1661 6 B-Disease
damage	1668 6 I-Disease
both	1675 4 O
at	1680 2 O
the	1683 3 O
biochemical	1687 11 O
and	1699 3 O
histological	1703 12 O
levels	1716 6 O
.	1722 1 O

Does	0 4 O
domperidone	5 11 B-Chemical
potentiate	17 10 O
mirtazapine	28 11 B-Chemical
-	39 1 O
associated	40 10 O
restless	51 8 B-Disease
legs	60 4 I-Disease
syndrome	65 8 I-Disease
?	73 1 O

There	75 5 O
is	81 2 O
now	84 3 O
evidence	88 8 O
to	97 2 O
suggest	100 7 O
a	108 1 O
central	110 7 O
role	118 4 O
for	123 3 O
the	127 3 O
dopaminergic	131 12 O
system	144 6 O
in	151 2 O
restless	154 8 B-Disease
legs	163 4 I-Disease
syndrome	168 8 I-Disease
(	177 1 O
RLS	178 3 B-Disease
)	181 1 O
.	182 1 O

For	184 3 O
example	188 7 O
,	195 1 O
the	197 3 O
symptoms	201 8 O
of	210 2 O
RLS	213 3 B-Disease
can	217 3 O
be	221 2 O
dramatically	224 12 O
improved	237 8 O
by	246 2 O
levodopa	249 8 B-Chemical
and	258 3 O
dopamine	262 8 B-Chemical
agonists	271 8 O
,	279 1 O
whereas	281 7 O
central	289 7 O
dopamine	297 8 B-Chemical
D2	306 2 O
receptor	309 8 O
antagonists	318 11 O
can	330 3 O
induce	334 6 O
or	341 2 O
aggravate	344 9 O
RLS	354 3 B-Disease
symptoms	358 8 O
.	366 1 O

To	368 2 O
our	371 3 O
knowledge	375 9 O
,	384 1 O
there	386 5 O
is	392 2 O
no	395 2 O
previous	398 8 O
report	407 6 O
regarding	414 9 O
whether	424 7 O
domperidone	432 11 B-Chemical
,	443 1 O
a	445 1 O
peripheral	447 10 O
dopamine	458 8 B-Chemical
D2	467 2 O
receptor	470 8 O
antagonist	479 10 O
,	489 1 O
can	491 3 O
also	495 4 O
induce	500 6 O
or	507 2 O
aggravate	510 9 O
symptoms	520 8 O
of	529 2 O
RLS	532 3 B-Disease
.	535 1 O

Mirtazapine	537 11 B-Chemical
,	548 1 O
the	550 3 O
first	554 5 O
noradrenergic	560 13 O
and	574 3 O
specific	578 8 O
serotonergic	587 12 O
antidepressant	600 14 O
(	615 1 O
NaSSA	616 5 O
)	621 1 O
,	622 1 O
has	624 3 O
been	628 4 O
associated	633 10 O
with	644 4 O
RLS	649 3 B-Disease
in	653 2 O
several	656 7 O
recent	664 6 O
publications	671 12 O
.	683 1 O

The	685 3 O
authors	689 7 O
report	697 6 O
here	704 4 O
a	709 1 O
depressed	711 9 O
patient	721 7 O
comorbid	729 8 O
with	738 4 O
postprandial	743 12 B-Disease
dyspepsia	756 9 I-Disease
who	766 3 O
developed	770 9 O
RLS	780 3 B-Disease
after	784 5 O
mirtazapine	790 11 B-Chemical
had	802 3 O
been	806 4 O
added	811 5 O
to	817 2 O
his	820 3 O
domperidone	824 11 B-Chemical
therapy	836 7 O
.	843 1 O

Our	845 3 O
patient	849 7 O
started	857 7 O
to	865 2 O
have	868 4 O
symptoms	873 8 O
of	882 2 O
RLS	885 3 B-Disease
only	889 4 O
after	894 5 O
he	900 2 O
had	903 3 O
been	907 4 O
treated	912 7 O
with	920 4 O
mirtazapine	925 11 B-Chemical
,	936 1 O
and	938 3 O
his	942 3 O
RLS	946 3 B-Disease
symptoms	950 8 O
resolved	959 8 O
completely	968 10 O
upon	979 4 O
discontinuation	984 15 O
of	1000 2 O
his	1003 3 O
mirtazapine	1007 11 B-Chemical
.	1018 1 O

Such	1020 4 O
a	1025 1 O
temporal	1027 8 O
relationship	1036 12 O
between	1049 7 O
the	1057 3 O
use	1061 3 O
of	1065 2 O
mirtazapine	1068 11 B-Chemical
and	1080 3 O
the	1084 3 O
symptoms	1088 8 O
of	1097 2 O
RLS	1100 3 B-Disease
in	1104 2 O
our	1107 3 O
patient	1111 7 O
did	1119 3 O
not	1123 3 O
support	1127 7 O
a	1135 1 O
potentiating	1137 12 O
effect	1150 6 O
of	1157 2 O
domperione	1160 10 B-Chemical
on	1171 2 O
mirtazapine	1174 11 B-Chemical
-	1185 1 O
associated	1186 10 O
RLS	1197 3 B-Disease
.	1200 1 O

However	1202 7 O
,	1209 1 O
physicians	1211 10 O
should	1222 6 O
be	1229 2 O
aware	1232 5 O
of	1238 2 O
the	1241 3 O
possibility	1245 11 O
that	1257 4 O
mirtazapine	1262 11 B-Chemical
can	1274 3 O
be	1278 2 O
associated	1281 10 O
with	1292 4 O
RLS	1297 3 B-Disease
in	1301 2 O
some	1304 4 O
individuals	1309 11 O
,	1320 1 O
especially	1322 10 O
those	1333 5 O
receiving	1339 9 O
concomitant	1349 11 O
dopamine	1361 8 B-Chemical
D2	1370 2 O
receptor	1373 8 O
antagonists	1382 11 O
.	1393 1 O

Antiandrogenic	0 14 O
therapy	15 7 O
can	23 3 O
cause	27 5 O
coronary	33 8 B-Disease
arterial	42 8 I-Disease
disease	51 7 I-Disease
.	58 1 O

AIM	60 3 O
:	63 1 O
To	65 2 O
study	68 5 O
the	74 3 O
change	78 6 O
of	85 2 O
lipid	88 5 O
metabolism	94 10 O
by	105 2 O
antiandrogen	108 12 O
therapy	121 7 O
in	129 2 O
patients	132 8 O
with	141 4 O
prostate	146 8 B-Disease
cancer	155 6 I-Disease
.	161 1 O

MATERIALS	163 9 O
AND	173 3 O
METHODS	177 7 O
:	184 1 O
We	186 2 O
studied	189 7 O
with	197 4 O
a	202 1 O
2	204 1 O
.	205 1 O
5	206 1 O
years	208 5 O
follow	214 6 O
-	220 1 O
up	221 2 O
the	224 3 O
changes	228 7 O
in	236 2 O
plasma	239 6 O
cholesterols	246 12 B-Chemical
(	259 1 O
C	260 1 B-Chemical
)	261 1 O
,	262 1 O
triglycerides	264 13 B-Chemical
(	278 1 O
TG	279 2 B-Chemical
)	281 1 O
,	282 1 O
lipoproteins	284 12 O
(	297 1 O
LP	298 2 O
)	300 1 O
,	301 1 O
and	303 3 O
apolipoproteins	307 15 O
(	323 1 O
Apo	324 3 O
)	327 1 O
B	329 1 O
-	330 1 O
100	331 3 O
,	334 1 O
A	336 1 O
-	337 1 O
I	338 1 O
,	339 1 O
and	341 3 O
A	345 1 O
-	346 1 O
II	347 2 O
pro	350 3 O
fi	354 2 O
les	357 3 O
in	361 2 O
24	364 2 O
patients	367 8 O
of	376 2 O
mean	379 4 O
age	384 3 O
60	388 2 O
years	391 5 O
with	397 4 O
low	402 3 O
risk	406 4 O
prostate	411 8 B-Disease
cancer	420 6 I-Disease
(	427 1 O
stage	428 5 O
:	433 1 O
T1cN0M0	435 7 O
,	442 1 O
Gleason	444 7 O
score	452 5 O
:	457 1 O
2	459 1 O
-	460 1 O
5	461 1 O
)	462 1 O
during	464 6 O
treatment	471 9 O
with	481 4 O
cyproterone	486 11 B-Chemical
acetate	498 7 I-Chemical
(	506 1 O
CPA	507 3 B-Chemical
)	510 1 O
without	512 7 O
surgical	520 8 O
management	529 10 O
or	540 2 O
radiation	543 9 O
therapy	553 7 O
.	560 1 O

RESULTS	562 7 O
:	569 1 O
Significant	571 11 O
decreases	583 9 O
of	593 2 O
HDL	596 3 O
-	599 1 O
C	600 1 O
,	601 1 O
Apo	603 3 O
A	607 1 O
-	608 1 O
I	609 1 O
and	611 3 O
Apo	615 3 O
A	619 1 O
-	620 1 O
II	621 2 O
and	624 3 O
an	628 2 O
increase	631 8 O
of	640 2 O
triglyceride	643 12 B-Chemical
levels	656 6 O
in	663 2 O
VLDL	666 4 O
were	671 4 O
induced	676 7 O
by	684 2 O
CPA	687 3 B-Chemical
.	690 1 O

After	692 5 O
a	698 1 O
period	700 6 O
of	707 2 O
2	710 1 O
.	711 1 O
5	712 1 O
years	714 5 O
on	720 2 O
CPA	723 3 B-Chemical
treatment	727 9 O
,	736 1 O
four	738 4 O
patients	743 8 O
out	752 3 O
of	756 2 O
twenty	759 6 O
-	765 1 O
four	766 4 O
were	771 4 O
found	776 5 O
to	782 2 O
be	785 2 O
affected	788 8 O
by	797 2 O
coronary	800 8 B-Disease
heart	809 5 I-Disease
disease	815 7 I-Disease
.	822 1 O

CONCLUSIONS	824 11 O
:	835 1 O
Ischaemic	837 9 O
coronary	847 8 B-Disease
arteriosclerosis	856 16 I-Disease
with	873 4 O
an	878 2 O
incidence	881 9 O
rate	891 4 O
of	896 2 O
16	899 2 O
.	901 1 O
6	902 1 O
%	903 1 O
as	905 2 O
caused	908 6 O
by	915 2 O
prolonged	918 9 O
CPA	928 3 B-Chemical
therapy	932 7 O
is	940 2 O
mediated	943 8 O
through	952 7 O
changes	960 7 O
in	968 2 O
HDL	971 3 O
cholesterol	975 11 B-Chemical
,	986 1 O
Apo	988 3 O
A	992 1 O
-	993 1 O
I	994 1 O
and	996 3 O
Apo	1000 3 O
A	1004 1 O
-	1005 1 O
II	1006 2 O
pro	1009 3 O
fi	1013 2 O
les	1016 3 O
,	1019 1 O
other	1021 5 O
than	1027 4 O
the	1032 3 O
well	1036 4 O
-	1040 1 O
known	1041 5 O
hyperglyceridemic	1047 17 B-Disease
effect	1065 6 I-Disease
caused	1072 6 O
by	1079 2 O
estrogen	1082 8 B-Chemical
.	1090 1 O

5	0 1 B-Chemical
-	1 1 I-Chemical
Fluorouracil	2 12 I-Chemical
cardiotoxicity	15 14 B-Disease
induced	30 7 O
by	38 2 O
alpha	41 5 B-Chemical
-	46 1 I-Chemical
fluoro	47 6 I-Chemical
-	53 1 I-Chemical
beta	54 4 I-Chemical
-	58 1 I-Chemical
alanine	59 7 I-Chemical
.	66 1 O

Cardiotoxicity	68 14 B-Disease
is	83 2 O
a	86 1 O
rare	88 4 O
complication	93 12 O
occurring	106 9 O
during	116 6 O
5	123 1 B-Chemical
-	124 1 I-Chemical
fluorouracil	125 12 I-Chemical
(	138 1 O
5	139 1 B-Chemical
-	140 1 I-Chemical
FU	141 2 I-Chemical
)	143 1 O
treatment	145 9 O
for	155 3 O
malignancies	159 12 B-Disease
.	171 1 O

We	173 2 O
herein	176 6 O
report	183 6 O
the	190 3 O
case	194 4 O
of	199 2 O
a	202 1 O
70	204 2 O
-	206 1 O
year	207 4 O
-	211 1 O
old	212 3 O
man	216 3 O
with	220 4 O
5	225 1 B-Chemical
-	226 1 I-Chemical
FU	227 2 I-Chemical
-	229 1 O
induced	230 7 O
cardiotoxicity	238 14 B-Disease
,	252 1 O
in	254 2 O
whom	257 4 O
a	262 1 O
high	264 4 O
serum	269 5 O
level	275 5 O
of	281 2 O
alpha	284 5 B-Chemical
-	289 1 I-Chemical
fluoro	290 6 I-Chemical
-	296 1 I-Chemical
beta	297 4 I-Chemical
-	301 1 I-Chemical
alanine	302 7 I-Chemical
(	310 1 O
FBAL	311 4 B-Chemical
)	315 1 O
was	317 3 O
observed	321 8 O
.	329 1 O

The	331 3 O
patient	335 7 O
,	342 1 O
who	344 3 O
had	348 3 O
unresectable	352 12 O
colon	365 5 B-Disease
cancer	371 6 I-Disease
metastases	378 10 O
to	389 2 O
the	392 3 O
liver	396 5 O
and	402 3 O
lung	406 4 O
,	410 1 O
was	412 3 O
referred	416 8 O
to	425 2 O
us	428 2 O
for	431 3 O
chemotherapy	435 12 O
from	448 4 O
an	453 2 O
affiliated	456 10 O
hospital	467 8 O
;	475 1 O
he	477 2 O
had	480 3 O
no	484 2 O
cardiac	487 7 O
history	495 7 O
.	502 1 O

After	504 5 O
admission	510 9 O
,	519 1 O
the	521 3 O
patient	525 7 O
received	533 8 O
a	542 1 O
continuous	544 10 O
intravenous	555 11 O
infusion	567 8 O
of	576 2 O
5	579 1 B-Chemical
-	580 1 I-Chemical
FU	581 2 I-Chemical
(	584 1 O
1000	585 4 O
mg	590 2 O
/	592 1 O
day	593 3 O
)	596 1 O
,	597 1 O
during	599 6 O
which	606 5 O
precordial	612 10 B-Disease
pain	623 4 I-Disease
with	628 4 O
right	633 5 B-Disease
bundle	639 6 I-Disease
branch	646 6 I-Disease
block	653 5 I-Disease
occurred	659 8 O
concomitantly	668 13 O
with	682 4 O
a	687 1 O
high	689 4 O
serum	694 5 O
FBAL	700 4 B-Chemical
concentration	705 13 O
of	719 2 O
1955	722 4 O
ng	727 2 O
/	729 1 O
ml	730 2 O
.	732 1 O

Both	734 4 O
the	739 3 O
precordial	743 10 B-Disease
pain	754 4 I-Disease
and	759 3 O
the	763 3 O
electrocardiographic	767 20 O
changes	788 7 O
disappeared	796 11 O
spontaneously	808 13 O
after	822 5 O
the	828 3 O
discontinuation	832 15 O
of	848 2 O
5	851 1 B-Chemical
-	852 1 I-Chemical
FU	853 2 I-Chemical
.	855 1 O

As	857 2 O
the	860 3 O
precordial	864 10 B-Disease
pain	875 4 I-Disease
in	880 2 O
this	883 4 O
patient	888 7 O
was	896 3 O
considered	900 10 O
to	911 2 O
have	914 4 O
been	919 4 O
due	924 3 O
to	928 2 O
5	931 1 B-Chemical
-	932 1 I-Chemical
FU	933 2 I-Chemical
-	935 1 O
induced	936 7 O
cardiotoxicity	944 14 B-Disease
,	958 1 O
the	960 3 O
administration	964 14 O
of	979 2 O
5	982 1 B-Chemical
-	983 1 I-Chemical
FU	984 2 I-Chemical
was	987 3 O
abandoned	991 9 O
.	1000 1 O

Instead	1002 7 O
,	1009 1 O
oral	1011 4 O
administration	1016 14 O
of	1031 2 O
S	1034 1 O
-	1035 1 O
1	1036 1 O
(	1038 1 O
a	1039 1 O
derivative	1041 10 O
of	1052 2 O
5	1055 1 B-Chemical
-	1056 1 I-Chemical
FU	1057 2 I-Chemical
)	1059 1 O
,	1060 1 O
at	1062 2 O
200	1065 3 O
mg	1069 2 O
/	1071 1 O
day	1072 3 O
twice	1076 5 O
a	1082 1 O
week	1084 4 O
,	1088 1 O
was	1090 3 O
instituted	1094 10 O
,	1104 1 O
because	1106 7 O
S	1114 1 O
-	1115 1 O
1	1116 1 O
has	1118 3 O
a	1122 1 O
strong	1124 6 O
inhibitory	1131 10 O
effect	1142 6 O
on	1149 2 O
dihydropyrimidine	1152 17 B-Chemical
dehydrogenase	1170 13 O
,	1183 1 O
which	1185 5 O
catalyzes	1191 9 O
the	1201 3 O
degradative	1205 11 O
of	1217 2 O
5	1220 1 B-Chemical
-	1221 1 I-Chemical
FU	1222 2 I-Chemical
into	1225 4 O
FBAL	1230 4 B-Chemical
.	1234 1 O

The	1236 3 O
serum	1240 5 O
FBAL	1246 4 B-Chemical
concentration	1251 13 O
subsequently	1265 12 O
decreased	1278 9 O
to	1288 2 O
352	1291 3 O
ng	1295 2 O
/	1297 1 O
ml	1298 2 O
,	1300 1 O
the	1302 3 O
same	1306 4 O
as	1311 2 O
the	1314 3 O
value	1318 5 O
measured	1324 8 O
on	1333 2 O
the	1336 3 O
first	1340 5 O
day	1346 3 O
of	1350 2 O
S	1353 1 O
-	1354 1 O
1	1355 1 O
administration	1357 14 O
.	1371 1 O

Thereafter	1373 10 O
,	1383 1 O
no	1385 2 O
cardiac	1388 7 B-Disease
symptoms	1396 8 I-Disease
were	1405 4 O
observed	1410 8 O
.	1418 1 O

The	1420 3 O
patient	1424 7 O
achieved	1432 8 O
a	1441 1 O
partial	1443 7 O
response	1451 8 O
6	1460 1 O
months	1462 6 O
after	1469 5 O
the	1475 3 O
initiation	1479 10 O
of	1490 2 O
the	1493 3 O
S	1497 1 O
-	1498 1 O
1	1499 1 O
treatment	1501 9 O
.	1510 1 O

The	1512 3 O
experience	1516 10 O
of	1527 2 O
this	1530 4 O
case	1535 4 O
,	1539 1 O
together	1541 8 O
with	1550 4 O
a	1555 1 O
review	1557 6 O
of	1564 2 O
the	1567 3 O
literature	1571 10 O
,	1581 1 O
suggests	1583 8 O
that	1592 4 O
FBAL	1597 4 B-Chemical
is	1602 2 O
related	1605 7 O
to	1613 2 O
5	1616 1 B-Chemical
-	1617 1 I-Chemical
FU	1618 2 I-Chemical
-	1620 1 O
induced	1621 7 O
cardiotoxicity	1629 14 B-Disease
.	1643 1 O

S	1645 1 O
-	1646 1 O
1	1647 1 O
may	1649 3 O
be	1653 2 O
administered	1656 12 O
safely	1669 6 O
to	1676 2 O
patients	1679 8 O
with	1688 4 O
5	1693 1 B-Chemical
-	1694 1 I-Chemical
FU	1695 2 I-Chemical
-	1697 1 O
induced	1698 7 O
cardiotoxicity	1706 14 B-Disease
.	1720 1 O

The	0 3 O
influence	4 9 O
of	14 2 O
the	17 3 O
time	21 4 O
interval	26 8 O
between	35 7 O
monoHER	43 7 B-Chemical
and	51 3 O
doxorubicin	55 11 B-Chemical
administration	67 14 O
on	82 2 O
the	85 3 O
protection	89 10 O
against	100 7 O
doxorubicin	108 11 B-Chemical
-	119 1 O
induced	120 7 O
cardiotoxicity	128 14 B-Disease
in	143 2 O
mice	146 4 O
.	150 1 O

PURPOSE	152 7 O
:	159 1 O
Despite	161 7 O
its	169 3 O
well	173 4 O
-	177 1 O
known	178 5 O
cardiotoxicity	184 14 B-Disease
,	198 1 O
the	200 3 O
anthracyclin	204 12 O
doxorubicin	217 11 B-Chemical
(	229 1 O
DOX	230 3 B-Chemical
)	233 1 O
continues	235 9 O
to	245 2 O
be	248 2 O
an	251 2 O
effective	254 9 O
and	264 3 O
widely	268 6 O
used	275 4 O
chemotherapeutic	280 16 O
agent	297 5 O
.	302 1 O

DOX	304 3 B-Chemical
-	307 1 O
induced	308 7 O
cardiac	316 7 B-Disease
damage	324 6 I-Disease
presumably	331 10 O
results	342 7 O
from	350 4 O
the	355 3 O
formation	359 9 O
of	369 2 O
free	372 4 O
radicals	377 8 O
by	386 2 O
DOX	389 3 B-Chemical
.	392 1 O

Reactive	394 8 O
oxygen	403 6 B-Chemical
species	410 7 O
particularly	418 12 O
affect	431 6 O
the	438 3 O
cardiac	442 7 O
myocytes	450 8 O
because	459 7 O
these	467 5 O
cells	473 5 O
seem	479 4 O
to	484 2 O
have	487 4 O
a	492 1 O
relatively	494 10 O
poor	505 4 O
antioxidant	510 11 O
defense	522 7 O
system	530 6 O
.	536 1 O

The	538 3 O
semisynthetic	542 13 O
flavonoid	556 9 B-Chemical
monohydroxyethylrutoside	566 24 B-Chemical
(	591 1 O
monoHER	592 7 B-Chemical
)	599 1 O
showed	601 6 O
cardioprotection	608 16 O
against	625 7 O
DOX	633 3 B-Chemical
-	636 1 O
induced	637 7 O
cardiotoxicity	645 14 B-Disease
through	660 7 O
its	668 3 O
radical	672 7 O
scavenging	680 10 O
and	691 3 O
iron	695 4 B-Chemical
chelating	700 9 O
properties	710 10 O
.	720 1 O

Because	722 7 O
of	730 2 O
the	733 3 O
relatively	737 10 O
short	748 5 O
final	754 5 O
half	760 4 O
-	764 1 O
life	765 4 O
of	770 2 O
monoHER	773 7 B-Chemical
(	781 1 O
about	782 5 O
30	788 2 O
min	791 3 O
)	794 1 O
,	795 1 O
it	797 2 O
is	800 2 O
expected	803 8 O
that	812 4 O
the	817 3 O
time	821 4 O
interval	826 8 O
between	835 7 O
monoHER	843 7 B-Chemical
and	851 3 O
DOX	855 3 B-Chemical
might	859 5 O
be	865 2 O
of	868 2 O
influence	871 9 O
on	881 2 O
the	884 3 O
cardioprotective	888 16 O
effect	905 6 O
of	912 2 O
monoHER	915 7 B-Chemical
.	922 1 O

Therefore	924 9 O
,	933 1 O
the	935 3 O
aim	939 3 O
of	943 2 O
the	946 3 O
present	950 7 O
study	958 5 O
was	964 3 O
to	968 2 O
investigate	971 11 O
this	983 4 O
possible	988 8 O
effect	997 6 O
.	1003 1 O

METHODS	1005 7 O
:	1012 1 O
Six	1014 3 O
groups	1018 6 O
of	1025 2 O
6	1028 1 O
BALB	1030 4 O
/	1034 1 O
c	1035 1 O
mice	1037 4 O
were	1042 4 O
treated	1047 7 O
with	1055 4 O
saline	1060 6 O
,	1066 1 O
DOX	1068 3 B-Chemical
alone	1072 5 O
or	1078 2 O
DOX	1081 3 B-Chemical
(	1085 1 O
4	1086 1 O
mg	1088 2 O
/	1090 1 O
kg	1091 2 O
i	1094 1 O
.	1095 1 O
v	1096 1 O
.	1097 1 O
)	1098 1 O
preceded	1100 8 O
by	1109 2 O
monoHER	1112 7 B-Chemical
(	1120 1 O
500	1121 3 O
mg	1125 2 O
/	1127 1 O
kg	1128 2 O
i	1131 1 O
.	1132 1 O
p	1133 1 O
.	1134 1 O
)	1135 1 O
with	1137 4 O
an	1142 2 O
interval	1145 8 O
of	1154 2 O
10	1157 2 O
,	1159 1 O
30	1161 2 O
,	1163 1 O
60	1165 2 O
or	1168 2 O
120	1171 3 O
min	1175 3 O
.	1178 1 O

After	1180 5 O
a	1186 1 O
6	1188 1 O
-	1189 1 O
week	1190 4 O
treatment	1195 9 O
period	1205 6 O
and	1212 3 O
additional	1216 10 O
observation	1227 11 O
for	1239 3 O
2	1243 1 O
weeks	1245 5 O
,	1250 1 O
the	1252 3 O
mice	1256 4 O
were	1261 4 O
sacrificed	1266 10 O
.	1276 1 O

Their	1278 5 O
cardiac	1284 7 O
tissues	1292 7 O
were	1300 4 O
processed	1305 9 O
for	1315 3 O
light	1319 5 O
microscopy	1325 10 O
,	1335 1 O
after	1337 5 O
which	1343 5 O
cardiomyocyte	1349 13 B-Disease
damage	1363 6 I-Disease
was	1370 3 O
evaluated	1374 9 O
according	1384 9 O
to	1394 2 O
Billingham	1397 10 O
(	1408 1 O
in	1409 2 O
Cancer	1412 6 B-Disease
Treat	1419 5 O
Rep	1425 3 O
62	1429 2 O
(	1431 1 O
6	1432 1 O
)	1433 1 O
:	1434 1 O
865	1435 3 O
-	1438 1 O
872	1439 3 O
,	1442 1 O
1978	1444 4 O
)	1448 1 O
.	1449 1 O

Microscopic	1451 11 O
evaluation	1463 10 O
revealed	1474 8 O
that	1483 4 O
treatment	1488 9 O
with	1498 4 O
DOX	1503 3 B-Chemical
alone	1507 5 O
induced	1513 7 O
significant	1521 11 O
cardiac	1533 7 B-Disease
damage	1541 6 I-Disease
in	1548 2 O
comparison	1551 10 O
to	1562 2 O
the	1565 3 O
saline	1569 6 O
control	1576 7 O
group	1584 5 O
(	1590 1 O
P	1591 1 O
<	1592 1 O
0	1593 1 O
.	1594 1 O
001	1595 3 O
)	1598 1 O
.	1599 1 O

RESULTS	1601 7 O
:	1608 1 O
The	1610 3 O
number	1614 6 O
of	1621 2 O
damaged	1624 7 O
cardiomyocytes	1632 14 O
was	1647 3 O
9	1651 1 O
.	1652 1 O
6	1653 1 O
-	1654 1 O
fold	1655 4 O
(	1660 1 O
95	1661 2 O
%	1663 1 O
CI	1665 2 O
4	1668 1 O
.	1669 1 O
4	1670 1 O
-	1671 1 O
21	1672 2 O
.	1674 1 O
0	1675 1 O
)	1676 1 O
higher	1678 6 O
in	1685 2 O
mice	1688 4 O
treated	1693 7 O
with	1701 4 O
DOX	1706 3 B-Chemical
alone	1710 5 O
than	1716 4 O
that	1721 4 O
in	1726 2 O
animals	1729 7 O
of	1737 2 O
the	1740 3 O
control	1744 7 O
group	1752 5 O
.	1757 1 O

The	1759 3 O
ratio	1763 5 O
of	1769 2 O
aberrant	1772 8 O
cardiomyocytes	1781 14 O
in	1796 2 O
mice	1799 4 O
treated	1804 7 O
with	1812 4 O
DOX	1817 3 B-Chemical
preceded	1821 8 O
by	1830 2 O
monoHER	1833 7 B-Chemical
and	1841 3 O
those	1845 5 O
in	1851 2 O
mice	1854 4 O
treated	1859 7 O
with	1867 4 O
saline	1872 6 O
ranged	1879 6 O
from	1886 4 O
1	1891 1 O
.	1892 1 O
6	1893 1 O
to	1895 2 O
2	1898 1 O
.	1899 1 O
8	1900 1 O
(	1902 1 O
mean	1903 4 O
2	1908 1 O
.	1909 1 O
2	1910 1 O
,	1911 1 O
95	1913 2 O
%	1915 1 O
CI	1917 2 O
1	1920 1 O
.	1921 1 O
2	1922 1 O
-	1923 1 O
4	1924 1 O
.	1925 1 O
1	1926 1 O
,	1927 1 O
P	1929 1 O
=	1930 1 O
0	1931 1 O
.	1932 1 O
019	1933 3 O
)	1936 1 O
.	1937 1 O

The	1939 3 O
mean	1943 4 O
protective	1948 10 O
effect	1959 6 O
by	1966 2 O
adding	1969 6 O
monoHER	1976 7 B-Chemical
before	1984 6 O
DOX	1991 3 B-Chemical
led	1995 3 O
to	1999 2 O
a	2002 1 O
significant	2004 11 O
4	2016 1 O
.	2017 1 O
4	2018 1 O
-	2019 1 O
fold	2020 4 O
reduction	2025 9 O
(	2035 1 O
P	2036 1 O
<	2037 1 O
0	2038 1 O
.	2039 1 O
001	2040 3 O
,	2043 1 O
95	2045 2 O
%	2047 1 O
CI	2049 2 O
2	2052 1 O
.	2053 1 O
3	2054 1 O
-	2055 1 O
8	2056 1 O
.	2057 1 O
2	2058 1 O
)	2059 1 O
of	2061 2 O
abnormal	2064 8 O
cardiomyocytes	2073 14 O
.	2087 1 O

This	2089 4 O
protective	2094 10 O
effect	2105 6 O
did	2112 3 O
not	2116 3 O
depend	2120 6 O
on	2127 2 O
the	2130 3 O
time	2134 4 O
interval	2139 8 O
between	2148 7 O
monoHER	2156 7 B-Chemical
and	2164 3 O
DOX	2168 3 B-Chemical
administration	2172 14 O
(	2187 1 O
P	2188 1 O
=	2189 1 O
0	2190 1 O
.	2191 1 O
345	2192 3 O
)	2195 1 O
.	2196 1 O

CONCLUSION	2198 10 O
:	2208 1 O
The	2210 3 O
results	2214 7 O
indicate	2222 8 O
that	2231 4 O
in	2236 2 O
an	2239 2 O
outpatient	2242 10 O
clinical	2253 8 O
setting	2262 7 O
monoHER	2270 7 B-Chemical
may	2278 3 O
be	2282 2 O
administered	2285 12 O
shortly	2298 7 O
before	2306 6 O
DOX	2313 3 B-Chemical
.	2316 1 O

Clinical	0 8 O
evaluation	9 10 O
of	20 2 O
adverse	23 7 O
effects	31 7 O
during	39 6 O
bepridil	46 8 B-Chemical
administration	55 14 O
for	70 3 O
atrial	74 6 B-Disease
fibrillation	81 12 I-Disease
and	94 3 I-Disease
flutter	98 7 I-Disease
.	105 1 O

BACKGROUND	107 10 O
:	117 1 O
Bepridil	119 8 B-Chemical
hydrochloride	128 13 I-Chemical
(	142 1 O
Bpd	143 3 B-Chemical
)	146 1 O
has	148 3 O
attracted	152 9 O
attention	162 9 O
as	172 2 O
an	175 2 O
effective	178 9 O
drug	188 4 O
for	193 3 O
atrial	197 6 B-Disease
fibrillation	204 12 I-Disease
(	217 1 O
AF	218 2 B-Disease
)	220 1 O
and	222 3 O
atrial	226 6 B-Disease
flutter	233 7 I-Disease
(	241 1 O
AFL	242 3 B-Disease
)	245 1 O
.	246 1 O

However	248 7 O
,	255 1 O
serious	257 7 O
adverse	265 7 O
effects	273 7 O
,	280 1 O
including	282 9 O
torsade	292 7 B-Disease
de	300 2 I-Disease
pointes	303 7 I-Disease
(	311 1 O
Tdp	312 3 B-Disease
)	315 1 O
,	316 1 O
have	318 4 O
been	323 4 O
reported	328 8 O
.	336 1 O

METHODS	338 7 O
AND	346 3 O
RESULTS	350 7 O
:	357 1 O
Adverse	359 7 O
effects	367 7 O
of	375 2 O
Bpd	378 3 B-Chemical
requiring	382 9 O
discontinuation	392 15 O
of	408 2 O
treatment	411 9 O
were	421 4 O
evaluated	426 9 O
.	435 1 O

Bpd	437 3 B-Chemical
was	441 3 O
administered	445 12 O
to	458 2 O
459	461 3 O
patients	465 8 O
(	474 1 O
361	475 3 O
males	479 5 O
,	484 1 O
63	486 2 O
+	488 1 O
/	489 1 O
-	490 1 O
12	491 2 O
years	494 5 O
old	500 3 O
)	503 1 O
comprising	505 10 O
378	516 3 O
AF	520 2 B-Disease
and	523 3 O
81	527 2 O
AFL	530 3 B-Disease
cases	534 5 O
.	539 1 O

Mean	541 4 O
left	546 4 O
ventricular	551 11 O
ejection	563 8 O
fraction	572 8 O
and	581 3 O
atrial	585 6 O
dimension	592 9 O
(	602 1 O
LAD	603 3 O
)	606 1 O
were	608 4 O
66	613 2 O
+	615 1 O
/	616 1 O
-	617 1 O
11	618 2 O
%	620 1 O
and	622 3 O
40	626 2 O
+	628 1 O
/	629 1 O
-	630 1 O
6	631 1 O
mm	633 2 O
,	635 1 O
respectively	637 12 O
.	649 1 O

Adverse	651 7 O
effects	659 7 O
were	667 4 O
observed	672 8 O
in	681 2 O
19	684 2 O
patients	687 8 O
(	696 1 O
4	697 1 O
%	698 1 O
)	699 1 O
during	701 6 O
an	708 2 O
average	711 7 O
follow	719 6 O
-	725 1 O
up	726 2 O
of	729 2 O
20	732 2 O
months	735 6 O
.	741 1 O

There	743 5 O
was	749 3 O
marked	753 6 O
QT	760 2 B-Disease
prolongation	763 12 I-Disease
greater	776 7 O
than	784 4 O
0	789 1 O
.	790 1 O
55	791 2 O
s	794 1 O
in	796 2 O
13	799 2 O
patients	802 8 O
,	810 1 O
bradycardia	812 11 B-Disease
less	824 4 O
than	829 4 O
40	834 2 O
beats	837 5 O
/	842 1 O
min	843 3 O
in	847 2 O
6	850 1 O
patients	852 8 O
,	860 1 O
dizziness	862 9 B-Disease
and	872 3 O
general	876 7 O
fatigue	884 7 B-Disease
in	892 2 O
1	895 1 O
patient	897 7 O
each	905 4 O
.	909 1 O

In	911 2 O
4	914 1 O
of	916 2 O
13	919 2 O
patients	922 8 O
with	931 4 O
QT	936 2 B-Disease
prolongation	939 12 I-Disease
,	951 1 O
Tdp	953 3 B-Disease
occurred	957 8 O
.	965 1 O

The	967 3 O
major	971 5 O
triggering	977 10 O
factors	988 7 O
of	996 2 O
Tdp	999 3 B-Disease
were	1003 4 O
hypokalemia	1008 11 B-Disease
and	1020 3 O
sudden	1024 6 O
decrease	1031 8 O
in	1040 2 O
heart	1043 5 O
rate	1049 4 O
.	1053 1 O

There	1055 5 O
were	1061 4 O
no	1066 2 O
differences	1069 11 O
in	1081 2 O
the	1084 3 O
clinical	1088 8 O
backgrounds	1097 11 O
of	1109 2 O
the	1112 3 O
patients	1116 8 O
with	1125 4 O
and	1130 3 O
without	1134 7 O
Tdp	1142 3 B-Disease
other	1146 5 O
than	1152 4 O
LAD	1157 3 O
and	1161 3 O
age	1165 3 O
,	1168 1 O
which	1170 5 O
were	1176 4 O
larger	1181 6 O
and	1188 3 O
older	1192 5 O
in	1198 2 O
the	1201 3 O
patients	1205 8 O
with	1214 4 O
Tdp	1219 3 B-Disease
.	1222 1 O

CONCLUSION	1224 10 O
:	1234 1 O
Careful	1236 7 O
observation	1244 11 O
of	1256 2 O
serum	1259 5 O
potassium	1265 9 B-Chemical
concentration	1275 13 O
and	1289 3 O
the	1293 3 O
ECG	1297 3 O
should	1301 6 O
always	1308 6 O
be	1315 2 O
done	1318 4 O
during	1323 6 O
Bpd	1330 3 B-Chemical
administration	1334 14 O
,	1348 1 O
particularly	1350 12 O
in	1363 2 O
elderly	1366 7 O
patients	1374 8 O
.	1382 1 O

Enhanced	0 8 O
isoproterenol	9 13 B-Chemical
-	22 1 O
induced	23 7 O
cardiac	31 7 B-Disease
hypertrophy	39 11 I-Disease
in	51 2 O
transgenic	54 10 O
rats	65 4 O
with	70 4 O
low	75 3 O
brain	79 5 O
angiotensinogen	85 15 O
.	100 1 O

We	102 2 O
have	105 4 O
previously	110 10 O
shown	121 5 O
that	127 4 O
a	132 1 O
permanent	134 9 O
deficiency	144 10 O
in	155 2 O
the	158 3 O
brain	162 5 O
renin	168 5 O
-	173 1 O
angiotensin	174 11 B-Chemical
system	186 6 O
(	193 1 O
RAS	194 3 O
)	197 1 O
may	199 3 O
increase	203 8 O
the	212 3 O
sensitivity	216 11 O
of	228 2 O
the	231 3 O
baroreflex	235 10 O
control	246 7 O
of	254 2 O
heart	257 5 O
rate	263 4 O
.	267 1 O

In	269 2 O
this	272 4 O
study	277 5 O
we	283 2 O
aimed	286 5 O
at	292 2 O
studying	295 8 O
the	304 3 O
involvement	308 11 O
of	320 2 O
the	323 3 O
brain	327 5 O
RAS	333 3 O
in	337 2 O
the	340 3 O
cardiac	344 7 O
reactivity	352 10 O
to	363 2 O
the	366 3 O
beta	370 4 O
-	374 1 O
adrenoceptor	375 12 O
(	388 1 O
beta	389 4 O
-	393 1 O
AR	394 2 O
)	396 1 O
agonist	398 7 O
isoproterenol	406 13 B-Chemical
(	420 1 O
Iso	421 3 B-Chemical
)	424 1 O
.	425 1 O

Transgenic	427 10 O
rats	438 4 O
with	443 4 O
low	448 3 O
brain	452 5 O
angiotensinogen	458 15 O
(	474 1 O
TGR	475 3 O
)	478 1 O
were	480 4 O
used	485 4 O
.	489 1 O

In	491 2 O
isolated	494 8 O
hearts	503 6 O
,	509 1 O
Iso	511 3 B-Chemical
induced	515 7 O
a	523 1 O
significantly	525 13 O
greater	539 7 O
increase	547 8 O
in	556 2 O
left	559 4 O
ventricular	564 11 O
(	576 1 O
LV	577 2 O
)	579 1 O
pressure	581 8 O
and	590 3 O
maximal	594 7 O
contraction	602 11 O
(	614 1 O
+	615 1 O
dP	616 2 O
/	618 1 O
dt	619 2 O
(	621 1 O
max	622 3 O
)	625 1 O
)	626 1 O
in	628 2 O
the	631 3 O
TGR	635 3 O
than	639 4 O
in	644 2 O
the	647 3 O
Sprague	651 7 O
-	658 1 O
Dawley	659 6 O
(	666 1 O
SD	667 2 O
)	669 1 O
rats	671 4 O
.	675 1 O

LV	677 2 B-Disease
hypertrophy	680 11 I-Disease
induced	692 7 O
by	700 2 O
Iso	703 3 B-Chemical
treatment	707 9 O
was	717 3 O
significantly	721 13 O
higher	735 6 O
in	742 2 O
TGR	745 3 O
than	749 4 O
in	754 2 O
SD	757 2 O
rats	760 4 O
(	765 1 O
in	766 2 O
g	769 1 O
LV	771 2 O
wt	774 2 O
/	776 1 O
100	777 3 O
g	781 1 O
body	783 4 O
wt	788 2 O
,	790 1 O
0	792 1 O
.	793 1 O
28	794 2 O
+	797 1 O
/	798 1 O
-	799 1 O
0	801 1 O
.	802 1 O
004	803 3 O
vs	807 2 O
.	809 1 O
0	811 1 O
.	812 1 O
24	813 2 O
+	816 1 O
/	817 1 O
-	818 1 O
0	820 1 O
.	821 1 O
004	822 3 O
,	825 1 O
respectively	827 12 O
)	839 1 O
.	840 1 O

The	842 3 O
greater	846 7 O
LV	854 2 B-Disease
hypertrophy	857 11 I-Disease
in	869 2 O
TGR	872 3 O
rats	876 4 O
was	881 3 O
associated	885 10 O
with	896 4 O
more	901 4 O
pronounced	906 10 O
downregulation	917 14 O
of	932 2 O
beta	935 4 O
-	939 1 O
AR	940 2 O
and	943 3 O
upregulation	947 12 O
of	960 2 O
LV	963 2 O
beta	966 4 O
-	970 1 O
AR	971 2 O
kinase	974 6 O
-	980 1 O
1	981 1 O
mRNA	983 4 O
levels	988 6 O
compared	995 8 O
with	1004 4 O
those	1009 5 O
in	1015 2 O
SD	1018 2 O
rats	1021 4 O
.	1025 1 O

The	1027 3 O
decrease	1031 8 O
in	1040 2 O
the	1043 3 O
heart	1047 5 O
rate	1053 4 O
(	1058 1 O
HR	1059 2 O
)	1061 1 O
induced	1063 7 O
by	1071 2 O
the	1074 3 O
beta	1078 4 O
-	1082 1 O
AR	1083 2 O
antagonist	1086 10 O
metoprolol	1097 10 B-Chemical
in	1108 2 O
conscious	1111 9 O
rats	1121 4 O
was	1126 3 O
significantly	1130 13 O
attenuated	1144 10 O
in	1155 2 O
TGR	1158 3 O
compared	1162 8 O
with	1171 4 O
SD	1176 2 O
rats	1179 4 O
(	1184 1 O
-	1185 1 O
9	1186 1 O
.	1187 1 O
9	1188 1 O
+	1190 1 O
/	1191 1 O
-	1192 1 O
1	1194 1 O
.	1195 1 O
7	1196 1 O
%	1197 1 O
vs	1199 2 O
.	1201 1 O
-	1203 1 O
18	1204 2 O
.	1206 1 O
1	1207 1 O
+	1209 1 O
/	1210 1 O
-	1211 1 O
1	1213 1 O
.	1214 1 O
5	1215 1 O
%	1216 1 O
)	1217 1 O
,	1218 1 O
whereas	1220 7 O
the	1228 3 O
effect	1232 6 O
of	1239 2 O
parasympathetic	1242 15 O
blockade	1258 8 O
by	1267 2 O
atropine	1270 8 B-Chemical
on	1279 2 O
HR	1282 2 O
was	1285 3 O
similar	1289 7 O
in	1297 2 O
both	1300 4 O
strains	1305 7 O
.	1312 1 O

These	1314 5 O
results	1320 7 O
indicate	1328 8 O
that	1337 4 O
TGR	1342 3 O
are	1346 3 O
more	1350 4 O
sensitive	1355 9 O
to	1365 2 O
beta	1368 4 O
-	1372 1 O
AR	1373 2 O
agonist	1376 7 O
-	1383 1 O
induced	1384 7 O
cardiac	1392 7 B-Disease
inotropic	1400 9 I-Disease
response	1410 8 O
and	1419 3 O
hypertrophy	1423 11 B-Disease
,	1434 1 O
possibly	1436 8 O
due	1445 3 O
to	1449 2 O
chronically	1452 11 O
low	1464 3 O
sympathetic	1468 11 O
outflow	1480 7 O
directed	1488 8 O
to	1497 2 O
the	1500 3 O
heart	1504 5 O
.	1509 1 O

Drug	0 4 O
-	4 1 O
induced	5 7 O
long	13 4 B-Disease
QT	18 2 I-Disease
syndrome	21 8 I-Disease
in	30 2 O
injection	33 9 O
drug	43 4 O
users	48 5 O
receiving	54 9 O
methadone	64 9 B-Chemical
:	73 1 O
high	75 4 O
frequency	80 9 O
in	90 2 O
hospitalized	93 12 O
patients	106 8 O
and	115 3 O
risk	119 4 O
factors	124 7 O
.	131 1 O

BACKGROUND	133 10 O
:	143 1 O
Drug	145 4 O
-	149 1 O
induced	150 7 O
long	158 4 B-Disease
QT	163 2 I-Disease
syndrome	166 8 I-Disease
is	175 2 O
a	178 1 O
serious	180 7 O
adverse	188 7 O
drug	196 4 O
reaction	201 8 O
.	209 1 O

Methadone	211 9 B-Chemical
prolongs	221 8 O
the	230 3 O
QT	234 2 O
interval	237 8 O
in	246 2 O
vitro	249 5 O
in	255 2 O
a	258 1 O
dose	260 4 O
-	264 1 O
dependent	265 9 O
manner	275 6 O
.	281 1 O

In	283 2 O
the	286 3 O
inpatient	290 9 O
setting	300 7 O
,	307 1 O
the	309 3 O
frequency	313 9 O
of	323 2 O
QT	326 2 B-Disease
interval	329 8 I-Disease
prolongation	338 12 I-Disease
with	351 4 O
methadone	356 9 B-Chemical
treatment	366 9 O
,	375 1 O
its	377 3 O
dose	381 4 O
dependence	386 10 O
,	396 1 O
and	398 3 O
the	402 3 O
importance	406 10 O
of	417 2 O
cofactors	420 9 O
such	430 4 O
as	435 2 O
drug	438 4 O
-	442 1 O
drug	443 4 O
interactions	448 12 O
remain	461 6 O
unknown	468 7 O
.	475 1 O

METHODS	477 7 O
:	484 1 O
We	486 2 O
performed	489 9 O
a	499 1 O
systematic	501 10 O
,	511 1 O
retrospective	513 13 O
study	527 5 O
comparing	533 9 O
active	543 6 O
or	550 2 O
former	553 6 O
intravenous	560 11 O
drug	572 4 O
users	577 5 O
receiving	583 9 O
methadone	593 9 B-Chemical
and	603 3 O
those	607 5 O
not	613 3 O
receiving	617 9 O
methadone	627 9 B-Chemical
among	637 5 O
all	643 3 O
patients	647 8 O
hospitalized	656 12 O
over	669 4 O
a	674 1 O
5	676 1 O
-	677 1 O
year	678 4 O
period	683 6 O
in	690 2 O
a	693 1 O
tertiary	695 8 O
care	704 4 O
hospital	709 8 O
.	717 1 O

A	719 1 O
total	721 5 O
of	727 2 O
167	730 3 O
patients	734 8 O
receiving	743 9 O
methadone	753 9 B-Chemical
fulfilled	763 9 O
the	773 3 O
inclusion	777 9 O
criteria	787 8 O
and	796 3 O
were	800 4 O
compared	805 8 O
with	814 4 O
a	819 1 O
control	821 7 O
group	829 5 O
of	835 2 O
80	838 2 O
injection	841 9 O
drug	851 4 O
users	856 5 O
not	862 3 O
receiving	866 9 O
methadone	876 9 B-Chemical
.	885 1 O

In	887 2 O
addition	890 8 O
to	899 2 O
methadone	902 9 B-Chemical
dose	912 4 O
,	916 1 O
15	918 2 O
demographic	921 11 O
,	932 1 O
biological	934 10 O
,	944 1 O
and	946 3 O
pharmacological	950 15 O
variables	966 9 O
were	976 4 O
considered	981 10 O
as	992 2 O
potential	995 9 O
risk	1005 4 O
factors	1010 7 O
for	1018 3 O
QT	1022 2 B-Disease
prolongation	1025 12 I-Disease
.	1037 1 O

RESULTS	1039 7 O
:	1046 1 O
Among	1048 5 O
167	1054 3 O
methadone	1058 9 B-Chemical
maintenance	1068 11 O
patients	1080 8 O
,	1088 1 O
the	1090 3 O
prevalence	1094 10 O
of	1105 2 O
QTc	1108 3 O
prolongation	1112 12 O
to	1125 2 O
0	1128 1 O
.	1129 1 O
50	1130 2 O
second	1133 6 O
(	1139 1 O
(	1140 1 O
1	1141 1 O
/	1142 1 O
2	1143 1 O
)	1144 1 O
)	1145 1 O
or	1147 2 O
longer	1150 6 O
was	1157 3 O
16	1161 2 O
.	1163 1 O
2	1164 1 O
%	1165 1 O
compared	1167 8 O
with	1176 4 O
0	1181 1 O
%	1182 1 O
in	1184 2 O
80	1187 2 O
control	1190 7 O
subjects	1198 8 O
.	1206 1 O

Six	1208 3 O
patients	1212 8 O
(	1221 1 O
3	1222 1 O
.	1223 1 O
6	1224 1 O
%	1225 1 O
)	1226 1 O
in	1228 2 O
the	1231 3 O
methadone	1235 9 B-Chemical
group	1245 5 O
presented	1251 9 O
torsades	1261 8 B-Disease
de	1270 2 I-Disease
pointes	1273 7 I-Disease
.	1280 1 O

QTc	1282 3 O
length	1286 6 O
was	1293 3 O
weakly	1297 6 O
but	1304 3 O
significantly	1308 13 O
associated	1322 10 O
with	1333 4 O
methadone	1338 9 B-Chemical
daily	1348 5 O
dose	1354 4 O
(	1359 1 O
Spearman	1360 8 O
rank	1369 4 O
correlation	1374 11 O
coefficient	1386 11 O
,	1397 1 O
0	1399 1 O
.	1400 1 O
20	1401 2 O
;	1403 1 O
P	1405 1 O
<	1406 1 O
.	1407 1 O
01	1408 2 O
)	1410 1 O
.	1411 1 O

Multivariate	1413 12 O
regression	1426 10 O
analysis	1437 8 O
allowed	1446 7 O
attribution	1454 11 O
of	1466 2 O
31	1469 2 O
.	1471 1 O
8	1472 1 O
%	1473 1 O
of	1475 2 O
QTc	1478 3 O
variability	1482 11 O
to	1494 2 O
methadone	1497 9 B-Chemical
dose	1507 4 O
,	1511 1 O
cytochrome	1513 10 O
P	1524 1 O
-	1525 1 O
450	1526 3 O
3A4	1530 3 O
drug	1534 4 O
-	1538 1 O
drug	1539 4 O
interactions	1544 12 O
,	1556 1 O
hypokalemia	1558 11 B-Disease
,	1569 1 O
and	1571 3 O
altered	1575 7 O
liver	1583 5 O
function	1589 8 O
.	1597 1 O

CONCLUSIONS	1599 11 O
:	1610 1 O
QT	1612 2 B-Disease
interval	1615 8 I-Disease
prolongation	1624 12 I-Disease
in	1637 2 O
methadone	1640 9 B-Chemical
maintenance	1650 11 O
patients	1662 8 O
hospitalized	1671 12 O
in	1684 2 O
a	1687 1 O
tertiary	1689 8 O
care	1698 4 O
center	1703 6 O
is	1710 2 O
a	1713 1 O
frequent	1715 8 O
finding	1724 7 O
.	1731 1 O

Methadone	1733 9 B-Chemical
dose	1743 4 O
,	1747 1 O
presence	1749 8 O
of	1758 2 O
cytochrome	1761 10 O
P	1772 1 O
-	1773 1 O
450	1774 3 O
3A4	1778 3 O
inhibitors	1782 10 O
,	1792 1 O
potassium	1794 9 B-Chemical
level	1804 5 O
,	1809 1 O
and	1811 3 O
liver	1815 5 O
function	1821 8 O
contribute	1830 10 O
to	1841 2 O
QT	1844 2 B-Disease
prolongation	1847 12 I-Disease
.	1859 1 O

Long	1861 4 B-Disease
QT	1866 2 I-Disease
syndrome	1869 8 I-Disease
can	1878 3 O
occur	1882 5 O
with	1888 4 O
low	1893 3 O
doses	1897 5 O
of	1903 2 O
methadone	1906 9 B-Chemical
.	1915 1 O

Mechanisms	0 10 O
of	11 2 O
hypertension	14 12 B-Disease
induced	27 7 O
by	35 2 O
nitric	38 6 B-Chemical
oxide	45 5 I-Chemical
(	51 1 O
NO	52 2 B-Chemical
)	54 1 O
deficiency	56 10 O
:	66 1 O
focus	68 5 O
on	74 2 O
venous	77 6 O
function	84 8 O
.	92 1 O

Loss	94 4 O
of	99 2 O
endothelial	102 11 O
cell	114 4 O
-	118 1 O
derived	119 7 O
nitric	127 6 B-Chemical
oxide	134 5 I-Chemical
(	140 1 O
NO	141 2 B-Chemical
)	143 1 O
in	145 2 O
hypertension	148 12 B-Disease
is	161 2 O
a	164 1 O
hallmark	166 8 O
of	175 2 O
arterial	178 8 B-Disease
dysfunction	187 11 I-Disease
.	198 1 O

Experimental	200 12 O
hypertension	213 12 B-Disease
created	226 7 O
by	234 2 O
the	237 3 O
removal	241 7 O
of	249 2 O
NO	252 2 B-Chemical
,	254 1 O
however	256 7 O
,	263 1 O
involves	265 8 O
mechanisms	274 10 O
in	285 2 O
addition	288 8 O
to	297 2 O
decreased	300 9 O
arterial	310 8 O
vasodilator	319 11 O
activity	331 8 O
.	339 1 O

These	341 5 O
include	347 7 O
augmented	355 9 O
endothelin	365 10 O
-	375 1 O
1	376 1 O
(	378 1 O
ET	379 2 O
-	381 1 O
1	382 1 O
)	383 1 O
release	385 7 O
,	392 1 O
increased	394 9 O
sympathetic	404 11 O
nervous	416 7 O
system	424 6 O
activity	431 8 O
,	439 1 O
and	441 3 O
elevated	445 8 O
tissue	454 6 O
oxidative	461 9 O
stress	471 6 O
.	477 1 O

We	479 2 O
hypothesized	482 12 O
that	495 4 O
increased	500 9 O
venous	510 6 O
smooth	517 6 O
muscle	524 6 O
(	531 1 O
venomotor	532 9 O
)	541 1 O
tone	543 4 O
plays	548 5 O
a	554 1 O
role	556 4 O
in	561 2 O
Nomega	564 6 B-Chemical
-	570 1 I-Chemical
nitro	571 5 I-Chemical
-	576 1 I-Chemical
L	577 1 I-Chemical
-	578 1 I-Chemical
arginine	579 8 I-Chemical
(	588 1 O
LNNA	589 4 B-Chemical
)	593 1 O
hypertension	595 12 B-Disease
through	608 7 O
these	616 5 O
mechanisms	622 10 O
.	632 1 O

Rats	634 4 O
were	639 4 O
treated	644 7 O
with	652 4 O
the	657 3 O
NO	661 2 B-Chemical
synthase	664 8 O
inhibitor	673 9 O
LNNA	683 4 B-Chemical
(	688 1 O
0	689 1 O
.	690 1 O
5	691 1 O
g	693 1 O
/	694 1 O
L	695 1 O
in	697 2 O
drinking	700 8 O
water	709 5 O
)	714 1 O
for	716 3 O
2	720 1 O
weeks	722 5 O
.	727 1 O

Mean	729 4 O
arterial	734 8 O
pressure	743 8 O
of	752 2 O
conscious	755 9 O
rats	765 4 O
was	770 3 O
119	774 3 O
+	778 1 O
/	779 1 O
-	780 1 O
2	782 1 O
mm	784 2 O
Hg	787 2 O
in	790 2 O
control	793 7 O
and	801 3 O
194	805 3 O
+	809 1 O
/	810 1 O
-	811 1 O
5	813 1 O
mm	815 2 O
Hg	818 2 O
in	821 2 O
LNNA	824 4 B-Chemical
rats	829 4 O
(	834 1 O
P	835 1 O
<	836 1 O
0	837 1 O
.	838 1 O
05	839 2 O
)	841 1 O
.	842 1 O

Carotid	844 7 O
arteries	852 8 O
and	861 3 O
vena	865 4 O
cava	870 4 O
were	875 4 O
removed	880 7 O
for	888 3 O
measurement	892 11 O
of	904 2 O
isometric	907 9 O
contraction	917 11 O
.	928 1 O

Maximal	930 7 O
contraction	938 11 O
to	950 2 O
norepinephrine	953 14 B-Chemical
was	968 3 O
modestly	972 8 O
reduced	981 7 O
in	989 2 O
arteries	992 8 O
from	1001 4 O
LNNA	1006 4 B-Chemical
compared	1011 8 O
with	1020 4 O
control	1025 7 O
rats	1033 4 O
whereas	1038 7 O
the	1046 3 O
maximum	1050 7 O
contraction	1058 11 O
to	1070 2 O
ET	1073 2 O
-	1075 1 O
1	1076 1 O
was	1078 3 O
significantly	1082 13 O
reduced	1096 7 O
(	1104 1 O
54	1105 2 O
%	1107 1 O
control	1109 7 O
)	1116 1 O
.	1117 1 O

Maximum	1119 7 O
contraction	1127 11 O
of	1139 2 O
vena	1142 4 O
cava	1147 4 O
to	1152 2 O
norepinephrine	1155 14 B-Chemical
(	1170 1 O
37	1171 2 O
%	1173 1 O
control	1175 7 O
)	1182 1 O
also	1184 4 O
was	1189 3 O
reduced	1193 7 O
but	1201 3 O
no	1205 2 O
change	1208 6 O
in	1215 2 O
response	1218 8 O
to	1227 2 O
ET	1230 2 O
-	1232 1 O
1	1233 1 O
was	1235 3 O
observed	1239 8 O
.	1247 1 O

Mean	1249 4 O
circulatory	1254 11 O
filling	1266 7 O
pressure	1274 8 O
,	1282 1 O
an	1284 2 O
in	1287 2 O
vivo	1290 4 O
measure	1295 7 O
of	1303 2 O
venomotor	1306 9 O
tone	1316 4 O
,	1320 1 O
was	1322 3 O
not	1326 3 O
elevated	1330 8 O
in	1339 2 O
LNNA	1342 4 B-Chemical
hypertension	1347 12 B-Disease
at	1360 2 O
1	1363 1 O
or	1365 2 O
2	1368 1 O
weeks	1370 5 O
after	1376 5 O
LNNA	1382 4 B-Chemical
.	1386 1 O

The	1388 3 O
superoxide	1392 10 B-Chemical
scavenger	1403 9 O
tempol	1413 6 B-Chemical
(	1420 1 O
30	1421 2 O
,	1423 1 O
100	1425 3 O
,	1428 1 O
and	1430 3 O
300	1434 3 O
micromol	1438 8 O
kg	1447 2 O
(	1449 1 O
-	1450 1 O
1	1451 1 O
)	1452 1 O
,	1453 1 O
IV	1455 2 O
)	1457 1 O
did	1459 3 O
not	1463 3 O
change	1467 6 O
arterial	1474 8 O
pressure	1483 8 O
in	1492 2 O
control	1495 7 O
rats	1503 4 O
but	1508 3 O
caused	1512 6 O
a	1519 1 O
dose	1521 4 O
-	1525 1 O
dependent	1526 9 O
decrease	1536 8 O
in	1545 2 O
LNNA	1548 4 B-Chemical
rats	1553 4 O
(	1558 1 O
-	1559 1 O
18	1560 2 O
+	1563 1 O
/	1564 1 O
-	1565 1 O
8	1567 1 O
,	1568 1 O
-	1570 1 O
26	1571 2 O
+	1574 1 O
/	1575 1 O
-	1576 1 O
15	1578 2 O
,	1580 1 O
and	1582 3 O
-	1586 1 O
54	1587 2 O
+	1590 1 O
/	1591 1 O
-	1592 1 O
11	1594 2 O
mm	1597 2 O
Hg	1600 2 O
)	1602 1 O
.	1603 1 O

Similarly	1605 9 O
,	1614 1 O
ganglionic	1616 10 O
blockade	1627 8 O
with	1636 4 O
hexamethonium	1641 13 B-Chemical
caused	1655 6 O
a	1662 1 O
significantly	1664 13 O
greater	1678 7 O
fall	1686 4 O
in	1691 2 O
LNNA	1694 4 B-Chemical
hypertensive	1699 12 B-Disease
rats	1712 4 O
(	1717 1 O
76	1718 2 O
+	1721 1 O
/	1722 1 O
-	1723 1 O
9	1725 1 O
mm	1727 2 O
Hg	1730 2 O
)	1732 1 O
compared	1734 8 O
with	1743 4 O
control	1748 7 O
rats	1756 4 O
(	1761 1 O
35	1762 2 O
+	1765 1 O
/	1766 1 O
-	1767 1 O
10	1769 2 O
mm	1772 2 O
Hg	1775 2 O
)	1777 1 O
.	1778 1 O

Carotid	1780 7 O
arteries	1788 8 O
,	1796 1 O
vena	1798 4 O
cava	1803 4 O
,	1807 1 O
and	1809 3 O
sympathetic	1813 11 O
ganglia	1825 7 O
from	1833 4 O
LNNA	1838 4 B-Chemical
rats	1843 4 O
had	1848 3 O
higher	1852 6 O
basal	1859 5 O
levels	1865 6 O
of	1872 2 O
superoxide	1875 10 B-Chemical
compared	1886 8 O
with	1895 4 O
those	1900 5 O
from	1906 4 O
control	1911 7 O
rats	1919 4 O
.	1923 1 O

These	1925 5 O
data	1931 4 O
suggest	1936 7 O
that	1944 4 O
while	1949 5 O
NO	1955 2 B-Chemical
deficiency	1958 10 O
increases	1969 9 O
oxidative	1979 9 O
stress	1989 6 O
and	1996 3 O
sympathetic	2000 11 O
activity	2012 8 O
in	2021 2 O
both	2024 4 O
arterial	2029 8 O
and	2038 3 O
venous	2042 6 O
vessels	2049 7 O
,	2056 1 O
the	2058 3 O
impact	2062 6 O
on	2069 2 O
veins	2072 5 O
does	2078 4 O
not	2083 3 O
make	2087 4 O
a	2092 1 O
major	2094 5 O
contribution	2100 12 O
to	2113 2 O
this	2116 4 O
form	2121 4 O
of	2126 2 O
hypertension	2129 12 B-Disease
.	2141 1 O

Association	0 11 O
of	12 2 O
DRD2	15 4 O
polymorphisms	20 13 O
and	34 3 O
chlorpromazine	38 14 B-Chemical
-	52 1 O
induced	53 7 O
extrapyramidal	61 14 B-Disease
syndrome	76 8 I-Disease
in	85 2 O
Chinese	88 7 O
schizophrenic	96 13 B-Disease
patients	110 8 O
.	118 1 O

AIM	120 3 O
:	123 1 O
Extrapyramidal	125 14 B-Disease
syndrome	140 8 I-Disease
(	149 1 O
EPS	150 3 B-Disease
)	153 1 O
is	155 2 O
most	158 4 O
commonly	163 8 O
affected	172 8 O
by	181 2 O
typical	184 7 O
antipsychotic	192 13 O
drugs	206 5 O
that	212 4 O
have	217 4 O
a	222 1 O
high	224 4 O
affinity	229 8 O
with	238 4 O
the	243 3 O
D2	247 2 O
receptor	250 8 O
.	258 1 O

Recently	260 8 O
,	268 1 O
many	270 4 O
research	275 8 O
groups	284 6 O
have	291 4 O
reported	296 8 O
on	305 2 O
the	308 3 O
positive	312 8 O
relationship	321 12 O
between	334 7 O
the	342 3 O
genetic	346 7 O
variations	354 10 O
in	365 2 O
the	368 3 O
DRD2	372 4 O
gene	377 4 O
and	382 3 O
the	386 3 O
therapeutic	390 11 O
response	402 8 O
in	411 2 O
schizophrenia	414 13 B-Disease
patients	428 8 O
as	437 2 O
a	440 1 O
result	442 6 O
of	449 2 O
the	452 3 O
role	456 4 O
of	461 2 O
variations	464 10 O
in	475 2 O
the	478 3 O
receptor	482 8 O
in	491 2 O
modulating	494 10 O
receptor	505 8 O
expression	514 10 O
.	524 1 O

In	526 2 O
this	529 4 O
study	534 5 O
,	539 1 O
we	541 2 O
evaluate	544 8 O
the	553 3 O
role	557 4 O
DRD2	562 4 O
plays	567 5 O
in	573 2 O
chlorpromazine	576 14 B-Chemical
-	590 1 O
induced	591 7 O
EPS	599 3 B-Disease
in	603 2 O
schizophrenic	606 13 B-Disease
patients	620 8 O
.	628 1 O

METHODS	630 7 O
:	637 1 O
We	639 2 O
identified	642 10 O
seven	653 5 O
SNP	659 3 O
(	662 1 O
single	663 6 O
nucleotide	670 10 O
polymorphism	681 12 O
)	693 1 O
(	695 1 O
-	696 1 O
141Cins	697 7 O
>	704 1 O
del	705 3 O
,	708 1 O
TaqIB	710 5 O
,	715 1 O
TaqID	717 5 O
,	722 1 O
Ser311Cys	724 9 O
,	733 1 O
rs6275	735 6 O
,	741 1 O
rs6277	743 6 O
and	750 3 O
TaqIA	754 5 O
)	759 1 O
in	761 2 O
the	764 3 O
DRD2	768 4 O
gene	773 4 O
in	778 2 O
146	781 3 O
schizophrenic	785 13 B-Disease
inpatients	799 10 O
(	810 1 O
59	811 2 O
with	814 4 O
EPS	819 3 B-Disease
and	823 3 O
87	827 2 O
without	830 7 O
EPS	838 3 B-Disease
according	842 9 O
to	852 2 O
the	855 3 O
Simpson	859 7 O
-	866 1 O
Angus	867 5 O
Scale	873 5 O
)	878 1 O
treated	880 7 O
with	888 4 O
chlorpromazine	893 14 B-Chemical
after	908 5 O
8	914 1 O
weeks	916 5 O
.	921 1 O

The	923 3 O
alleles	927 7 O
of	935 2 O
all	938 3 O
loci	942 4 O
were	947 4 O
determined	952 10 O
by	963 2 O
PCR	966 3 O
(	970 1 O
polymerase	971 10 O
chain	982 5 O
reaction	988 8 O
)	996 1 O
.	997 1 O

RESULTS	999 7 O
:	1006 1 O
Polymorphisms	1008 13 O
TaqID	1022 5 O
,	1027 1 O
Ser311Cys	1029 9 O
and	1039 3 O
rs6277	1043 6 O
were	1050 4 O
not	1055 3 O
polymorphic	1059 11 O
in	1071 2 O
the	1074 3 O
population	1078 10 O
recruited	1089 9 O
in	1099 2 O
the	1102 3 O
present	1106 7 O
study	1114 5 O
.	1119 1 O

No	1121 2 O
statistical	1124 11 O
significance	1136 12 O
was	1149 3 O
found	1153 5 O
in	1159 2 O
the	1162 3 O
allele	1166 6 O
distribution	1173 12 O
of	1186 2 O
-	1189 1 O
141Cins	1190 7 O
>	1197 1 O
del	1198 3 O
,	1201 1 O
TaqIB	1203 5 O
,	1208 1 O
rs6275	1210 6 O
and	1217 3 O
TaqIA	1221 5 O
or	1227 2 O
in	1230 2 O
the	1233 3 O
estimated	1237 9 O
haplotypes	1247 10 O
(	1258 1 O
constituted	1259 11 O
by	1271 2 O
TaqIB	1274 5 O
,	1279 1 O
rs6275	1281 6 O
and	1288 3 O
TaqIA	1292 5 O
)	1297 1 O
in	1299 2 O
linkage	1302 7 O
disequilibrium	1310 14 O
between	1325 7 O
the	1333 3 O
two	1337 3 O
groups	1341 6 O
.	1347 1 O

CONCLUSION	1349 10 O
:	1359 1 O
Our	1361 3 O
results	1365 7 O
did	1373 3 O
not	1377 3 O
lend	1381 4 O
strong	1386 6 O
support	1393 7 O
to	1401 2 O
the	1404 3 O
view	1408 4 O
that	1413 4 O
the	1418 3 O
genetic	1422 7 O
variation	1430 9 O
of	1440 2 O
the	1443 3 O
DRD2	1447 4 O
gene	1452 4 O
plays	1457 5 O
a	1463 1 O
major	1465 5 O
role	1471 4 O
in	1476 2 O
the	1479 3 O
individually	1483 12 O
variable	1496 8 O
adverse	1505 7 O
effect	1513 6 O
induced	1520 7 O
by	1528 2 O
chlorpromazine	1531 14 B-Chemical
,	1545 1 O
at	1547 2 O
least	1550 5 O
in	1556 2 O
Chinese	1559 7 O
patients	1567 8 O
with	1576 4 O
schizophrenia	1581 13 B-Disease
.	1594 1 O

Our	1596 3 O
results	1600 7 O
confirmed	1608 9 O
a	1618 1 O
previous	1620 8 O
study	1629 5 O
on	1635 2 O
the	1638 3 O
relationship	1642 12 O
between	1655 7 O
DRD2	1663 4 O
and	1668 3 O
EPS	1672 3 B-Disease
in	1676 2 O
Caucasians	1679 10 O
.	1689 1 O

Physical	0 8 O
training	9 8 O
decreases	18 9 O
susceptibility	28 14 O
to	43 2 O
subsequent	46 10 O
pilocarpine	57 11 B-Chemical
-	68 1 O
induced	69 7 O
seizures	77 8 B-Disease
in	86 2 O
the	89 3 O
rat	93 3 O
.	96 1 O

Regular	98 7 O
motor	106 5 O
activity	112 8 O
has	121 3 O
many	125 4 O
benefits	130 8 O
for	139 3 O
mental	143 6 O
and	150 3 O
physical	154 8 O
condition	163 9 O
but	173 3 O
its	177 3 O
implications	181 12 O
for	194 3 O
epilepsy	198 8 B-Disease
are	207 3 O
still	211 5 O
controversial	217 13 O
.	230 1 O

In	232 2 O
order	235 5 O
to	241 2 O
elucidate	244 9 O
this	254 4 O
problem	259 7 O
,	266 1 O
we	268 2 O
have	271 4 O
studied	276 7 O
the	284 3 O
effect	288 6 O
of	295 2 O
long	298 4 O
-	302 1 O
term	303 4 O
physical	308 8 O
activity	317 8 O
on	326 2 O
susceptibility	329 14 O
to	344 2 O
subsequent	347 10 O
seizures	358 8 B-Disease
.	366 1 O

Male	368 4 O
Wistar	373 6 O
rats	380 4 O
were	385 4 O
subjected	390 9 O
to	400 2 O
repeated	403 8 O
training	412 8 O
sessions	421 8 O
in	430 2 O
a	433 1 O
treadmill	435 9 O
and	445 3 O
swimming	449 8 O
pool	458 4 O
.	462 1 O

Thereafter	464 10 O
,	474 1 O
seizures	476 8 B-Disease
were	485 4 O
induced	490 7 O
by	498 2 O
pilocarpine	501 11 B-Chemical
injections	513 10 O
in	524 2 O
trained	527 7 O
and	535 3 O
non	539 3 O
-	542 1 O
trained	543 7 O
control	551 7 O
groups	559 6 O
.	565 1 O

During	567 6 O
the	574 3 O
acute	578 5 O
period	584 6 O
of	591 2 O
status	594 6 B-Disease
epilepticus	601 11 I-Disease
,	612 1 O
we	614 2 O
measured	617 8 O
:	625 1 O
(	627 1 O
1	628 1 O
)	629 1 O
the	631 3 O
latency	635 7 O
of	643 2 O
the	646 3 O
first	650 5 O
motor	656 5 O
sign	662 4 O
,	666 1 O
(	668 1 O
2	669 1 O
)	670 1 O
the	672 3 O
intensity	676 9 O
of	686 2 O
seizures	689 8 B-Disease
,	697 1 O
(	699 1 O
3	700 1 O
)	701 1 O
the	703 3 O
time	707 4 O
when	712 4 O
it	717 2 O
occurred	720 8 O
within	729 6 O
the	736 3 O
6	740 1 O
-	741 1 O
h	742 1 O
observation	744 11 O
period	756 6 O
,	762 1 O
and	764 3 O
(	768 1 O
4	769 1 O
)	770 1 O
the	772 3 O
time	776 4 O
when	781 4 O
the	786 3 O
acute	790 5 O
period	796 6 O
ended	803 5 O
.	808 1 O

All	810 3 O
these	814 5 O
behavioral	820 10 O
parameters	831 10 O
showed	842 6 O
statistically	849 13 O
significant	863 11 O
changes	875 7 O
suggesting	883 10 O
that	894 4 O
regular	899 7 O
physical	907 8 O
exercises	916 9 O
decrease	926 8 O
susceptibility	935 14 O
to	950 2 O
subsequently	953 12 O
induced	966 7 O
seizures	974 8 B-Disease
and	983 3 O
ameliorate	987 10 O
the	998 3 O
course	1002 6 O
of	1009 2 O
experimentally	1012 14 O
induced	1027 7 O
status	1035 6 B-Disease
epilepticus	1042 11 I-Disease
.	1053 1 O

Tonic	0 5 O
dopaminergic	6 12 O
stimulation	19 11 O
impairs	31 7 B-Disease
associative	39 11 I-Disease
learning	51 8 I-Disease
in	60 2 O
healthy	63 7 O
subjects	71 8 O
.	79 1 O

Endogenous	81 10 O
dopamine	92 8 B-Chemical
plays	101 5 O
a	107 1 O
central	109 7 O
role	117 4 O
in	122 2 O
salience	125 8 O
coding	134 6 O
during	141 6 O
associative	148 11 O
learning	160 8 O
.	168 1 O

Administration	170 14 O
of	185 2 O
the	188 3 O
dopamine	192 8 B-Chemical
precursor	201 9 O
levodopa	211 8 B-Chemical
enhances	220 8 O
learning	229 8 O
in	238 2 O
healthy	241 7 O
subjects	249 8 O
and	258 3 O
stroke	262 6 B-Disease
patients	269 8 O
.	277 1 O

Because	279 7 O
levodopa	287 8 B-Chemical
increases	296 9 O
both	306 4 O
phasic	311 6 O
and	318 3 O
tonic	322 5 O
dopaminergic	328 12 O
neurotransmission	341 17 O
,	358 1 O
the	360 3 O
critical	364 8 O
mechanism	373 9 O
mediating	383 9 O
the	393 3 O
enhancement	397 11 O
of	409 2 O
learning	412 8 O
is	421 2 O
unresolved	424 10 O
.	434 1 O

We	436 2 O
here	439 4 O
probed	444 6 O
how	451 3 O
selective	455 9 O
tonic	465 5 O
dopaminergic	471 12 O
stimulation	484 11 O
affects	496 7 O
associative	504 11 O
learning	516 8 O
.	524 1 O

Forty	526 5 O
healthy	532 7 O
subjects	540 8 O
were	549 4 O
trained	554 7 O
in	562 2 O
a	565 1 O
novel	567 5 O
vocabulary	573 10 O
of	584 2 O
45	587 2 O
concrete	590 8 O
nouns	599 5 O
over	605 4 O
the	610 3 O
course	614 6 O
of	621 2 O
5	624 1 O
consecutive	626 11 O
training	638 8 O
days	647 4 O
in	652 2 O
a	655 1 O
prospective	657 11 O
,	668 1 O
randomized	670 10 O
,	680 1 O
double	682 6 O
-	688 1 O
blind	689 5 O
,	694 1 O
placebo	696 7 O
-	703 1 O
controlled	704 10 O
design	715 6 O
.	721 1 O

Subjects	723 8 O
received	732 8 O
the	741 3 O
tonically	745 9 O
stimulating	755 11 O
dopamine	767 8 B-Chemical
-	775 1 O
receptor	776 8 O
agonist	785 7 O
pergolide	793 9 B-Chemical
(	803 1 O
0	804 1 O
.	805 1 O
1	806 1 O
mg	808 2 O
)	810 1 O
vs	812 2 O
placebo	815 7 O
120	823 3 O
min	827 3 O
before	831 6 O
training	838 8 O
on	847 2 O
each	850 4 O
training	855 8 O
day	864 3 O
.	867 1 O

The	869 3 O
dopamine	873 8 B-Chemical
agonist	882 7 O
significantly	890 13 O
impaired	904 8 B-Disease
novel	913 5 I-Disease
word	919 4 I-Disease
learning	924 8 I-Disease
compared	933 8 O
to	942 2 O
placebo	945 7 O
.	952 1 O

This	954 4 O
learning	959 8 O
decrement	968 9 O
persisted	978 9 O
up	988 2 O
to	991 2 O
the	994 3 O
last	998 4 O
follow	1003 6 O
-	1009 1 O
up	1010 2 O
4	1013 1 O
weeks	1015 5 O
post	1021 4 O
-	1025 1 O
training	1026 8 O
.	1034 1 O

Subjects	1036 8 O
treated	1045 7 O
with	1053 4 O
pergolide	1058 9 B-Chemical
also	1068 4 O
showed	1073 6 O
restricted	1080 10 O
emotional	1091 9 O
responses	1101 9 O
compared	1111 8 O
to	1120 2 O
the	1123 3 O
PLACEBO	1127 7 O
group	1135 5 O
.	1140 1 O

The	1142 3 O
extent	1146 6 O
of	1153 2 O
'	1156 1 O
flattened	1157 9 O
'	1166 1 O
affect	1168 6 O
with	1175 4 O
pergolide	1180 9 B-Chemical
was	1190 3 O
related	1194 7 O
to	1202 2 O
the	1205 3 O
degree	1209 6 O
of	1216 2 O
learning	1219 8 O
inhibition	1228 10 O
.	1238 1 O

These	1240 5 O
findings	1246 8 O
suggest	1255 7 O
that	1263 4 O
tonic	1268 5 O
occupation	1274 10 O
of	1285 2 O
dopamine	1288 8 B-Chemical
receptors	1297 9 O
impairs	1307 7 O
learning	1315 8 O
by	1324 2 O
competition	1327 11 O
with	1339 4 O
phasic	1344 6 O
dopamine	1351 8 B-Chemical
signals	1360 7 O
.	1367 1 O

Thus	1369 4 O
,	1373 1 O
phasic	1375 6 O
signaling	1382 9 O
seems	1392 5 O
to	1398 2 O
be	1401 2 O
the	1404 3 O
critical	1408 8 O
mechanism	1417 9 O
by	1427 2 O
which	1430 5 O
dopamine	1436 8 B-Chemical
enhances	1445 8 O
associative	1454 11 O
learning	1466 8 O
in	1475 2 O
healthy	1478 7 O
subjects	1486 8 O
and	1495 3 O
stroke	1499 6 B-Disease
patients	1506 8 O
.	1514 1 O

Minocycline	0 11 B-Chemical
-	11 1 O
induced	12 7 O
vasculitis	20 10 B-Disease
fulfilling	31 10 O
the	42 3 O
criteria	46 8 O
of	55 2 O
polyarteritis	58 13 B-Disease
nodosa	72 6 I-Disease
.	78 1 O

A	80 1 O
47	82 2 O
-	84 1 O
year	85 4 O
-	89 1 O
old	90 3 O
man	94 3 O
who	98 3 O
had	102 3 O
been	106 4 O
taking	111 6 O
minocycline	118 11 B-Chemical
for	130 3 O
palmoplantar	134 12 B-Disease
pustulosis	147 10 I-Disease
developed	158 9 O
fever	168 5 B-Disease
,	173 1 O
myalgias	175 8 B-Disease
,	183 1 O
polyneuropathy	185 14 B-Disease
,	199 1 O
and	201 3 O
testicular	205 10 B-Disease
pain	216 4 I-Disease
,	220 1 O
with	222 4 O
elevated	227 8 O
C	236 1 O
-	237 1 O
reactive	238 8 O
protein	247 7 O
(	255 1 O
CRP	256 3 O
)	259 1 O
.	260 1 O

Neither	262 7 O
myeloperoxidase	270 15 O
-	285 1 O
nor	287 3 O
proteinase	291 10 O
-	301 1 O
3	302 1 O
-	303 1 O
antineutrophil	304 14 O
cytoplasmic	319 11 O
antibody	331 8 O
was	340 3 O
positive	344 8 O
.	352 1 O

These	354 5 O
manifestations	360 14 O
met	375 3 O
the	379 3 O
American	383 8 O
College	392 7 O
of	400 2 O
Rheumatology	403 12 O
1990	416 4 O
criteria	421 8 O
for	430 3 O
the	434 3 O
classification	438 14 O
of	453 2 O
polyarteritis	456 13 B-Disease
nodosa	470 6 I-Disease
.	476 1 O

Stopping	478 8 O
minocycline	487 11 B-Chemical
led	499 3 O
to	503 2 O
amelioration	506 12 O
of	519 2 O
symptoms	522 8 O
and	531 3 O
normalization	535 13 O
of	549 2 O
CRP	552 3 O
level	556 5 O
.	561 1 O

To	563 2 O
our	566 3 O
knowledge	570 9 O
,	579 1 O
this	581 4 O
is	586 2 O
the	589 3 O
second	593 6 O
case	600 4 O
of	605 2 O
minocycline	608 11 B-Chemical
-	619 1 O
induced	620 7 O
vasculitis	628 10 B-Disease
satisfying	639 10 O
the	650 3 O
criteria	654 8 O
.	662 1 O

Differential	664 12 O
diagnosis	677 9 O
for	687 3 O
drug	691 4 O
-	695 1 O
induced	696 7 O
disease	704 7 O
is	712 2 O
invaluable	715 10 O
even	726 4 O
for	731 3 O
patients	735 8 O
with	744 4 O
classical	749 9 O
polyarteritis	759 13 B-Disease
nodosa	773 6 I-Disease
.	779 1 O

Intramuscular	0 13 O
hepatitis	14 9 B-Disease
B	24 1 I-Disease
immune	26 6 O
globulin	33 8 O
combined	42 8 O
with	51 4 O
lamivudine	56 10 B-Chemical
in	67 2 O
prevention	70 10 O
of	81 2 O
hepatitis	84 9 B-Disease
B	94 1 I-Disease
recurrence	96 10 O
after	107 5 O
liver	113 5 O
transplantation	119 15 O
.	134 1 O

BACKGROUND	136 10 O
:	146 1 O
Combined	148 8 O
hepatitis	157 9 B-Disease
B	167 1 I-Disease
immune	169 6 O
globulin	176 8 O
(	185 1 O
HBIg	186 4 O
)	190 1 O
and	192 3 O
lamivudine	196 10 B-Chemical
in	207 2 O
prophylaxis	210 11 O
of	222 2 O
the	225 3 O
recurrence	229 10 O
of	240 2 O
hepatitis	243 9 B-Disease
B	253 1 I-Disease
after	255 5 O
liver	261 5 O
transplantation	267 15 O
has	283 3 O
significantly	287 13 O
improved	301 8 O
the	310 3 O
survival	314 8 O
of	323 2 O
HBsAg	326 5 B-Chemical
positive	332 8 O
patients	341 8 O
.	349 1 O

This	351 4 O
study	356 5 O
was	362 3 O
undertaken	366 10 O
to	377 2 O
evaluate	380 8 O
the	389 3 O
outcomes	393 8 O
of	402 2 O
liver	405 5 O
transplantation	411 15 O
for	427 3 O
patients	431 8 O
with	440 4 O
hepatitis	445 9 B-Disease
B	455 1 I-Disease
virus	457 5 O
(	463 1 O
HBV	464 3 O
)	467 1 O
.	468 1 O

METHODS	470 7 O
:	477 1 O
A	479 1 O
retrospective	481 13 O
chart	495 5 O
analysis	501 8 O
and	510 3 O
a	514 1 O
review	516 6 O
of	523 2 O
the	526 3 O
organ	530 5 O
transplant	536 10 O
database	547 8 O
identified	556 10 O
51	567 2 O
patients	570 8 O
(	579 1 O
43	580 2 O
men	583 3 O
and	587 3 O
8	591 1 O
women	593 5 O
)	598 1 O
transplanted	600 12 O
for	613 3 O
benign	617 6 O
HBV	624 3 O
-	627 1 O
related	628 7 O
cirrhotic	636 9 B-Disease
diseases	646 8 I-Disease
between	655 7 O
June	663 4 O
2002	668 4 O
and	673 3 O
December	677 8 O
2004	686 4 O
who	691 3 O
had	695 3 O
survived	699 8 O
more	708 4 O
than	713 4 O
3	718 1 O
months	720 6 O
.	726 1 O

HBIg	728 4 O
was	733 3 O
administered	737 12 O
intravenously	750 13 O
during	764 6 O
the	771 3 O
first	775 5 O
week	781 4 O
and	786 3 O
intramuscularly	790 15 O
thereafter	806 10 O
.	816 1 O

RESULTS	818 7 O
:	825 1 O
At	827 2 O
a	830 1 O
median	832 6 O
follow	839 6 O
-	845 1 O
up	846 2 O
of	849 2 O
14	852 2 O
.	854 1 O
1	855 1 O
months	857 6 O
,	863 1 O
the	865 3 O
overall	869 7 O
recurrence	877 10 O
rate	888 4 O
in	893 2 O
the	896 3 O
51	900 2 O
patients	903 8 O
was	912 3 O
3	916 1 O
.	917 1 O
9	918 1 O
%	919 1 O
(	921 1 O
2	922 1 O
/	923 1 O
51	924 2 O
)	926 1 O
.	927 1 O

The	929 3 O
overall	933 7 O
patient	941 7 O
survival	949 8 O
was	958 3 O
88	962 2 O
.	964 1 O
3	965 1 O
%	966 1 O
,	967 1 O
and	969 3 O
82	973 2 O
.	975 1 O
4	976 1 O
%	977 1 O
after	979 5 O
1	985 1 O
and	987 3 O
2	991 1 O
years	993 5 O
,	998 1 O
respectively	1000 12 O
.	1012 1 O

A	1014 1 O
daily	1016 5 O
oral	1022 4 O
dose	1027 4 O
of	1032 2 O
100	1035 3 O
mg	1039 2 O
lamivudine	1042 10 B-Chemical
for	1053 3 O
2	1057 1 O
weeks	1059 5 O
before	1065 6 O
transplantation	1072 15 O
for	1088 3 O
10	1092 2 O
patients	1095 8 O
enabled	1104 7 O
57	1112 2 O
.	1114 1 O
1	1115 1 O
%	1116 1 O
(	1118 1 O
4	1119 1 O
/	1120 1 O
7	1121 1 O
)	1122 1 O
and	1124 3 O
62	1128 2 O
.	1130 1 O
5	1131 1 O
%	1132 1 O
(	1134 1 O
5	1135 1 O
/	1136 1 O
8	1137 1 O
)	1138 1 O
of	1140 2 O
HBV	1143 3 O
-	1146 1 O
DNA	1147 3 O
and	1151 3 O
HBeAg	1155 5 B-Chemical
positive	1161 8 O
patients	1170 8 O
respectively	1179 12 O
to	1192 2 O
convert	1195 7 O
to	1203 2 O
be	1206 2 O
negative	1209 8 O
.	1217 1 O

Intramuscular	1219 13 O
HBIg	1233 4 O
was	1238 3 O
well	1242 4 O
tolerated	1247 9 O
in	1257 2 O
all	1260 3 O
patients	1264 8 O
.	1272 1 O

CONCLUSION	1274 10 O
:	1284 1 O
Lamivudine	1286 10 B-Chemical
combined	1297 8 O
with	1306 4 O
intramuscular	1311 13 O
HBIg	1325 4 O
can	1330 3 O
effectively	1334 11 O
prevent	1346 7 O
allograft	1354 9 O
from	1364 4 O
the	1369 3 O
recurrence	1373 10 O
of	1384 2 O
HBV	1387 3 O
after	1391 5 O
liver	1397 5 O
transplantation	1403 15 O
.	1418 1 O

Anticonvulsant	0 14 O
effect	15 6 O
of	22 2 O
eslicarbazepine	25 15 B-Chemical
acetate	41 7 I-Chemical
(	49 1 O
BIA	50 3 B-Chemical
2	54 1 I-Chemical
-	55 1 I-Chemical
093	56 3 I-Chemical
)	59 1 O
on	61 2 O
seizures	64 8 B-Disease
induced	73 7 O
by	81 2 O
microperfusion	84 14 O
of	99 2 O
picrotoxin	102 10 B-Chemical
in	113 2 O
the	116 3 O
hippocampus	120 11 O
of	132 2 O
freely	135 6 O
moving	142 6 O
rats	149 4 O
.	153 1 O

Eslicarbazepine	155 15 B-Chemical
acetate	171 7 I-Chemical
(	179 1 O
BIA	180 3 B-Chemical
2	184 1 I-Chemical
-	185 1 I-Chemical
093	186 3 I-Chemical
,	189 1 O
S	191 1 B-Chemical
-	192 1 I-Chemical
(	193 1 I-Chemical
-	194 1 I-Chemical
)	195 1 I-Chemical
-	196 1 I-Chemical
10	197 2 I-Chemical
-	199 1 I-Chemical
acetoxy	200 7 I-Chemical
-	207 1 I-Chemical
10	208 2 I-Chemical
,	210 1 I-Chemical
11	211 2 I-Chemical
-	213 1 I-Chemical
dihydro	214 7 I-Chemical
-	221 1 I-Chemical
5H	222 2 I-Chemical
-	224 1 I-Chemical
dibenzo	225 7 I-Chemical
/	232 1 I-Chemical
b	233 1 I-Chemical
,	234 1 I-Chemical
f	235 1 I-Chemical
/	236 1 I-Chemical
azepine	237 7 I-Chemical
-	244 1 I-Chemical
5	245 1 I-Chemical
-	246 1 I-Chemical
carboxamide	247 11 I-Chemical
)	258 1 O
is	260 2 O
a	263 1 O
novel	265 5 O
antiepileptic	271 13 O
drug	285 4 O
,	289 1 O
now	291 3 O
in	295 2 O
Phase	298 5 O
III	304 3 O
clinical	308 8 O
trials	317 6 O
,	323 1 O
designed	325 8 O
with	334 4 O
the	339 3 O
aim	343 3 O
of	347 2 O
improving	350 9 O
efficacy	360 8 O
and	369 3 O
safety	373 6 O
in	380 2 O
comparison	383 10 O
with	394 4 O
the	399 3 O
structurally	403 12 O
related	416 7 O
drugs	424 5 O
carbamazepine	430 13 B-Chemical
(	444 1 O
CBZ	445 3 B-Chemical
)	448 1 O
and	450 3 O
oxcarbazepine	454 13 B-Chemical
(	468 1 O
OXC	469 3 B-Chemical
)	472 1 O
.	473 1 O

We	475 2 O
have	478 4 O
studied	483 7 O
the	491 3 O
effects	495 7 O
of	503 2 O
oral	506 4 O
treatment	511 9 O
with	521 4 O
eslicarbazepine	526 15 B-Chemical
acetate	542 7 I-Chemical
on	550 2 O
a	553 1 O
whole	555 5 O
-	560 1 O
animal	561 6 O
model	568 5 O
in	574 2 O
which	577 5 O
partial	583 7 O
seizures	591 8 B-Disease
can	600 3 O
be	604 2 O
elicited	607 8 O
repeatedly	616 10 O
on	627 2 O
different	630 9 O
days	640 4 O
without	645 7 O
changes	653 7 O
in	661 2 O
threshold	664 9 O
or	674 2 O
seizure	677 7 B-Disease
patterns	685 8 O
.	693 1 O

In	695 2 O
the	698 3 O
animals	702 7 O
treated	710 7 O
with	718 4 O
threshold	723 9 O
doses	733 5 O
of	739 2 O
picrotoxin	742 10 B-Chemical
,	752 1 O
the	754 3 O
average	758 7 O
number	766 6 O
of	773 2 O
seizures	776 8 B-Disease
was	785 3 O
2	789 1 O
.	790 1 O
3	791 1 O
+	792 1 O
/	793 1 O
-	794 1 O
1	795 1 O
.	796 1 O
2	797 1 O
,	798 1 O
and	800 3 O
average	804 7 O
seizure	812 7 B-Disease
duration	820 8 O
was	829 3 O
39	833 2 O
.	835 1 O
5	836 1 O
+	837 1 O
/	838 1 O
-	839 1 O
8	840 1 O
.	841 1 O
4s	842 2 O
.	844 1 O

Pre	846 3 O
-	849 1 O
treatment	850 9 O
with	860 4 O
a	865 1 O
dose	867 4 O
of	872 2 O
30	875 2 O
mg	878 2 O
/	880 1 O
kg	881 2 O
2h	884 2 O
before	887 6 O
picrotoxin	894 10 B-Chemical
microperfusion	905 14 O
prevented	920 9 O
seizures	930 8 B-Disease
in	939 2 O
the	942 3 O
75	946 2 O
%	948 1 O
of	950 2 O
the	953 3 O
rats	957 4 O
.	961 1 O

Lower	963 5 O
doses	969 5 O
(	975 1 O
3	976 1 O
and	978 3 O
10mg	982 4 O
/	986 1 O
kg	987 2 O
)	989 1 O
did	991 3 O
not	995 3 O
suppress	999 8 O
seizures	1008 8 B-Disease
,	1016 1 O
however	1018 7 O
,	1025 1 O
after	1027 5 O
administration	1033 14 O
of	1048 2 O
10mg	1051 4 O
/	1055 1 O
kg	1056 2 O
,	1058 1 O
significant	1060 11 O
reductions	1072 10 O
in	1083 2 O
seizures	1086 8 B-Disease
duration	1095 8 O
(	1104 1 O
24	1105 2 O
.	1107 1 O
3	1108 1 O
+	1109 1 O
/	1110 1 O
-	1111 1 O
6	1112 1 O
.	1113 1 O
8s	1114 2 O
)	1116 1 O
and	1118 3 O
seizure	1122 7 B-Disease
number	1130 6 O
(	1137 1 O
1	1138 1 O
.	1139 1 O
6	1140 1 O
+	1141 1 O
/	1142 1 O
-	1143 1 O
0	1144 1 O
.	1145 1 O
34	1146 2 O
)	1148 1 O
were	1150 4 O
found	1155 5 O
.	1160 1 O

No	1162 2 O
adverse	1165 7 O
effects	1173 7 O
of	1181 2 O
eslicarbazepine	1184 15 B-Chemical
acetate	1200 7 I-Chemical
were	1208 4 O
observed	1213 8 O
in	1222 2 O
the	1225 3 O
behavioral	1229 10 O
/	1239 1 O
EEG	1240 3 O
patterns	1244 8 O
studied	1253 7 O
,	1260 1 O
including	1262 9 O
sleep	1272 5 O
/	1277 1 O
wakefulness	1278 11 O
cycle	1290 5 O
,	1295 1 O
at	1297 2 O
the	1300 3 O
doses	1304 5 O
studied	1310 7 O
.	1317 1 O

Acute	0 5 B-Disease
renal	6 5 I-Disease
failure	12 7 I-Disease
associated	20 10 O
with	31 4 O
prolonged	36 9 O
intake	46 6 O
of	53 2 O
slimming	56 8 O
pills	65 5 O
containing	71 10 O
anthraquinones	82 14 B-Chemical
.	96 1 O

Chinese	98 7 B-Chemical
herbal	106 6 I-Chemical
medicine	113 8 O
preparations	122 12 O
are	135 3 O
widely	139 6 O
available	146 9 O
and	156 3 O
often	160 5 O
regarded	166 8 O
by	175 2 O
the	178 3 O
public	182 6 O
as	189 2 O
natural	192 7 O
and	200 3 O
safe	204 4 O
remedies	209 8 O
for	218 3 O
a	222 1 O
variety	224 7 O
of	232 2 O
medical	235 7 O
conditions	243 10 O
.	253 1 O

Nephropathy	255 11 B-Disease
caused	267 6 O
by	274 2 O
Chinese	277 7 B-Chemical
herbs	285 5 I-Chemical
has	291 3 O
previously	295 10 O
been	306 4 O
reported	311 8 O
,	319 1 O
usually	321 7 O
involving	329 9 O
the	339 3 O
use	343 3 O
of	347 2 O
aristolochic	350 12 B-Chemical
acids	363 5 I-Chemical
.	368 1 O

We	370 2 O
report	373 6 O
a	380 1 O
23	382 2 O
-	384 1 O
year	385 4 O
-	389 1 O
old	390 3 O
woman	394 5 O
who	400 3 O
developed	404 9 O
acute	414 5 B-Disease
renal	420 5 I-Disease
failure	426 7 I-Disease
following	434 9 O
prolonged	444 9 O
use	454 3 O
of	458 2 O
a	461 1 O
proprietary	463 11 O
Chinese	475 7 B-Chemical
herbal	483 6 I-Chemical
slimming	490 8 O
pill	499 4 O
that	504 4 O
contained	509 9 O
anthraquinone	519 13 B-Chemical
derivatives	533 11 O
,	544 1 O
extracted	546 9 O
from	556 4 O
Rhizoma	561 7 O
Rhei	569 4 O
(	574 1 O
rhubarb	575 7 O
)	582 1 O
.	583 1 O

The	585 3 O
renal	589 5 B-Disease
injury	595 6 I-Disease
was	602 3 O
probably	606 8 O
aggravated	615 10 O
by	626 2 O
the	629 3 O
concomitant	633 11 O
intake	645 6 O
of	652 2 O
a	655 1 O
non	657 3 O
-	660 1 O
steroidal	661 9 O
anti	671 4 O
-	675 1 O
inflammatory	676 12 O
drug	689 4 O
,	693 1 O
diclofenac	695 10 B-Chemical
.	705 1 O

Renal	707 5 O
pathology	713 9 O
was	723 3 O
that	727 4 O
of	732 2 O
hypocellular	735 12 O
interstitial	748 12 O
fibrosis	761 8 B-Disease
.	769 1 O

Spontaneous	771 11 O
renal	783 5 O
recovery	789 8 O
occurred	798 8 O
upon	807 4 O
cessation	812 9 O
of	822 2 O
the	825 3 O
slimming	829 8 O
pills	838 5 O
,	843 1 O
but	845 3 O
mild	849 4 O
interstitial	854 12 O
fibrosis	867 8 B-Disease
and	876 3 O
tubular	880 7 O
atrophy	888 7 B-Disease
was	896 3 O
still	900 5 O
evident	906 7 O
histologically	914 14 O
4	929 1 O
months	931 6 O
later	938 5 O
.	943 1 O

Although	945 8 O
a	954 1 O
causal	956 6 O
relationship	963 12 O
between	976 7 O
the	984 3 O
use	988 3 O
of	992 2 O
an	995 2 O
anthraquinone	998 13 B-Chemical
-	1011 1 O
containing	1012 10 O
herbal	1023 6 O
agent	1030 5 O
and	1036 3 O
renal	1040 5 B-Disease
injury	1046 6 I-Disease
remains	1053 7 O
to	1061 2 O
be	1064 2 O
proven	1067 6 O
,	1073 1 O
phytotherapy	1075 12 O
-	1087 1 O
associated	1088 10 O
interstitial	1099 12 O
nephropathy	1112 11 B-Disease
should	1124 6 O
be	1131 2 O
considered	1134 10 O
in	1145 2 O
patients	1148 8 O
who	1157 3 O
present	1161 7 O
with	1169 4 O
unexplained	1174 11 O
renal	1186 5 B-Disease
failure	1192 7 I-Disease
.	1199 1 O

Chloroacetaldehyde	0 18 B-Chemical
as	19 2 O
a	22 1 O
sulfhydryl	24 10 B-Chemical
reagent	35 7 O
:	42 1 O
the	44 3 O
role	48 4 O
of	53 2 O
critical	56 8 O
thiol	65 5 B-Chemical
groups	71 6 O
in	78 2 O
ifosfamide	81 10 B-Chemical
nephropathy	92 11 B-Disease
.	103 1 O

Chloroacetaldehyde	105 18 B-Chemical
(	124 1 O
CAA	125 3 B-Chemical
)	128 1 O
is	130 2 O
a	133 1 O
metabolite	135 10 O
of	146 2 O
the	149 3 O
alkylating	153 10 O
agent	164 5 O
ifosfamide	170 10 B-Chemical
(	181 1 O
IFO	182 3 B-Chemical
)	185 1 O
and	187 3 O
putatively	191 10 O
responsible	202 11 O
for	214 3 O
renal	218 5 B-Disease
damage	224 6 I-Disease
following	231 9 O
anti	241 4 O
-	245 1 O
tumor	246 5 B-Disease
therapy	252 7 O
with	260 4 O
IFO	265 3 B-Chemical
.	268 1 O

Depletion	270 9 O
of	280 2 O
sulfhydryl	283 10 B-Chemical
(	294 1 O
SH	295 2 B-Chemical
)	297 1 O
groups	299 6 O
has	306 3 O
been	310 4 O
reported	315 8 O
from	324 4 O
cell	329 4 O
culture	334 7 O
,	341 1 O
animal	343 6 O
and	350 3 O
clinical	354 8 O
studies	363 7 O
.	370 1 O

In	372 2 O
this	375 4 O
work	380 4 O
the	385 3 O
effect	389 6 O
of	396 2 O
CAA	399 3 B-Chemical
on	403 2 O
human	406 5 O
proximal	412 8 O
tubule	421 6 O
cells	428 5 O
in	434 2 O
primary	437 7 O
culture	445 7 O
(	453 1 O
hRPTEC	454 6 O
)	460 1 O
was	462 3 O
investigated	466 12 O
.	478 1 O

Toxicity	480 8 B-Disease
of	489 2 O
CAA	492 3 B-Chemical
was	496 3 O
determined	500 10 O
by	511 2 O
protein	514 7 O
content	522 7 O
,	529 1 O
cell	531 4 O
number	536 6 O
,	542 1 O
LDH	544 3 O
release	548 7 O
,	555 1 O
trypan	557 6 B-Chemical
blue	564 4 I-Chemical
exclusion	569 9 O
assay	579 5 O
and	585 3 O
caspase	589 7 O
-	596 1 O
3	597 1 O
activity	599 8 O
.	607 1 O

Free	609 4 O
thiols	614 6 B-Chemical
were	621 4 O
measured	626 8 O
by	635 2 O
the	638 3 O
method	642 6 O
of	649 2 O
Ellman	652 6 O
.	658 1 O

CAA	660 3 B-Chemical
reduced	664 7 O
hRPTEC	672 6 O
cell	679 4 O
number	684 6 O
and	691 3 O
protein	695 7 O
,	702 1 O
induced	704 7 O
a	712 1 O
loss	714 4 O
in	719 2 O
free	722 4 O
intracellular	727 13 O
thiols	741 6 B-Chemical
and	748 3 O
an	752 2 O
increase	755 8 O
in	764 2 O
necrosis	767 8 B-Disease
markers	776 7 O
.	783 1 O

CAA	785 3 B-Chemical
but	789 3 O
not	793 3 O
acrolein	797 8 B-Chemical
inhibited	806 9 O
the	816 3 O
cysteine	820 8 B-Chemical
proteases	829 9 O
caspase	839 7 O
-	846 1 O
3	847 1 O
,	848 1 O
caspase	850 7 O
-	857 1 O
8	858 1 O
and	860 3 O
cathepsin	864 9 O
B	874 1 O
.	875 1 O

Caspase	877 7 O
activation	885 10 O
by	896 2 O
cisplatin	899 9 B-Chemical
was	909 3 O
inhibited	913 9 O
by	923 2 O
CAA	926 3 B-Chemical
.	929 1 O

In	931 2 O
cells	934 5 O
stained	940 7 O
with	948 4 O
fluorescent	953 11 O
dyes	965 4 O
targeting	970 9 O
lysosomes	980 9 O
,	989 1 O
CAA	991 3 B-Chemical
induced	995 7 O
an	1003 2 O
increase	1006 8 O
in	1015 2 O
lysosomal	1018 9 O
size	1028 4 O
and	1033 3 O
lysosomal	1037 9 O
leakage	1047 7 O
.	1054 1 O

The	1056 3 O
effects	1060 7 O
of	1068 2 O
CAA	1071 3 B-Chemical
on	1075 2 O
cysteine	1078 8 B-Chemical
protease	1087 8 O
activities	1096 10 O
and	1107 3 O
thiols	1111 6 B-Chemical
could	1118 5 O
be	1124 2 O
reproduced	1127 10 O
in	1138 2 O
cell	1141 4 O
lysate	1146 6 O
.	1152 1 O

Acidification	1154 13 O
,	1167 1 O
which	1169 5 O
slowed	1175 6 O
the	1182 3 O
reaction	1186 8 O
of	1195 2 O
CAA	1198 3 B-Chemical
with	1202 4 O
thiol	1207 5 B-Chemical
donors	1213 6 O
,	1219 1 O
could	1221 5 O
also	1227 4 O
attenuate	1232 9 O
effects	1242 7 O
of	1250 2 O
CAA	1253 3 B-Chemical
on	1257 2 O
necrosis	1260 8 B-Disease
markers	1269 7 O
,	1276 1 O
thiol	1278 5 B-Chemical
depletion	1284 9 O
and	1294 3 O
cysteine	1298 8 B-Chemical
protease	1307 8 O
inhibition	1316 10 O
in	1327 2 O
living	1330 6 O
cells	1337 5 O
.	1342 1 O

Thus	1344 4 O
,	1348 1 O
CAA	1350 3 B-Chemical
directly	1354 8 O
reacts	1363 6 O
with	1370 4 O
cellular	1375 8 O
protein	1384 7 O
and	1392 3 O
non	1396 3 O
-	1399 1 O
protein	1400 7 O
thiols	1408 6 B-Chemical
,	1414 1 O
mediating	1416 9 O
its	1426 3 O
toxicity	1430 8 B-Disease
on	1439 2 O
hRPTEC	1442 6 O
.	1448 1 O

This	1450 4 O
effect	1455 6 O
can	1462 3 O
be	1466 2 O
reduced	1469 7 O
by	1477 2 O
acidification	1480 13 O
.	1493 1 O

Therefore	1495 9 O
,	1504 1 O
urinary	1506 7 O
acidification	1514 13 O
could	1528 5 O
be	1534 2 O
an	1537 2 O
option	1540 6 O
to	1547 2 O
prevent	1550 7 O
IFO	1558 3 B-Chemical
nephropathy	1562 11 B-Disease
in	1574 2 O
patients	1577 8 O
.	1585 1 O

Stereological	0 13 O
methods	14 7 O
reveal	22 6 O
the	29 3 O
robust	33 6 O
size	40 4 O
and	45 3 O
stability	49 9 O
of	59 2 O
ectopic	62 7 O
hilar	70 5 O
granule	76 7 O
cells	84 5 O
after	90 5 O
pilocarpine	96 11 B-Chemical
-	107 1 O
induced	108 7 O
status	116 6 B-Disease
epilepticus	123 11 I-Disease
in	135 2 O
the	138 3 O
adult	142 5 O
rat	148 3 O
.	151 1 O

Following	153 9 O
status	163 6 B-Disease
epilepticus	170 11 I-Disease
in	182 2 O
the	185 3 O
rat	189 3 O
,	192 1 O
dentate	194 7 O
granule	202 7 O
cell	210 4 O
neurogenesis	215 12 O
increases	228 9 O
greatly	238 7 O
,	245 1 O
and	247 3 O
many	251 4 O
of	256 2 O
the	259 3 O
new	263 3 O
neurons	267 7 O
appear	275 6 O
to	282 2 O
develop	285 7 O
ectopically	293 11 O
,	304 1 O
in	306 2 O
the	309 3 O
hilar	313 5 O
region	319 6 O
of	326 2 O
the	329 3 O
hippocampal	333 11 O
formation	345 9 O
.	354 1 O

It	356 2 O
has	359 3 O
been	363 4 O
suggested	368 9 O
that	378 4 O
the	383 3 O
ectopic	387 7 O
hilar	395 5 O
granule	401 7 O
cells	409 5 O
could	415 5 O
contribute	421 10 O
to	432 2 O
the	435 3 O
spontaneous	439 11 O
seizures	451 8 B-Disease
that	460 4 O
ultimately	465 10 O
develop	476 7 O
after	484 5 O
status	490 6 B-Disease
epilepticus	497 11 I-Disease
.	508 1 O

However	510 7 O
,	517 1 O
the	519 3 O
population	523 10 O
has	534 3 O
never	538 5 O
been	544 4 O
quantified	549 10 O
,	559 1 O
so	561 2 O
it	564 2 O
is	567 2 O
unclear	570 7 O
whether	578 7 O
it	586 2 O
is	589 2 O
substantial	592 11 O
enough	604 6 O
to	611 2 O
have	614 4 O
a	619 1 O
strong	621 6 O
influence	628 9 O
on	638 2 O
epileptogenesis	641 15 O
.	656 1 O

To	658 2 O
quantify	661 8 O
this	670 4 O
population	675 10 O
,	685 1 O
the	687 3 O
total	691 5 O
number	697 6 O
of	704 2 O
ectopic	707 7 O
hilar	715 5 O
granule	721 7 O
cells	729 5 O
was	735 3 O
estimated	739 9 O
using	749 5 O
unbiased	755 8 O
stereology	764 10 O
at	775 2 O
different	778 9 O
times	788 5 O
after	794 5 O
pilocarpine	800 11 B-Chemical
-	811 1 O
induced	812 7 O
status	820 6 B-Disease
epilepticus	827 11 I-Disease
.	838 1 O

The	840 3 O
number	844 6 O
of	851 2 O
hilar	854 5 O
neurons	860 7 O
immunoreactive	868 14 O
for	883 3 O
Prox	887 4 O
-	891 1 O
1	892 1 O
,	893 1 O
a	895 1 O
granule	897 7 O
-	904 1 O
cell	905 4 O
-	909 1 O
specific	910 8 O
marker	919 6 O
,	925 1 O
was	927 3 O
estimated	931 9 O
using	941 5 O
the	947 3 O
optical	951 7 O
fractionator	959 12 O
method	972 6 O
.	978 1 O

The	980 3 O
results	984 7 O
indicate	992 8 O
that	1001 4 O
the	1006 3 O
size	1010 4 O
of	1015 2 O
the	1018 3 O
hilar	1022 5 O
ectopic	1028 7 O
granule	1036 7 O
cell	1044 4 O
population	1049 10 O
after	1060 5 O
status	1066 6 B-Disease
epilepticus	1073 11 I-Disease
is	1085 2 O
substantial	1088 11 O
,	1099 1 O
and	1101 3 O
stable	1105 6 O
over	1112 4 O
time	1117 4 O
.	1121 1 O

Interestingly	1123 13 O
,	1136 1 O
the	1138 3 O
size	1142 4 O
of	1147 2 O
the	1150 3 O
population	1154 10 O
appears	1165 7 O
to	1173 2 O
be	1176 2 O
correlated	1179 10 O
with	1190 4 O
the	1195 3 O
frequency	1199 9 O
of	1209 2 O
behavioral	1212 10 O
seizures	1223 8 B-Disease
,	1231 1 O
because	1233 7 O
animals	1241 7 O
with	1249 4 O
more	1254 4 O
ectopic	1259 7 O
granule	1267 7 O
cells	1275 5 O
in	1281 2 O
the	1284 3 O
hilus	1288 5 O
have	1294 4 O
more	1299 4 O
frequent	1304 8 O
behavioral	1313 10 O
seizures	1324 8 B-Disease
.	1332 1 O

The	1334 3 O
hilar	1338 5 O
ectopic	1344 7 O
granule	1352 7 O
cell	1360 4 O
population	1365 10 O
does	1376 4 O
not	1381 3 O
appear	1385 6 O
to	1392 2 O
vary	1395 4 O
systematically	1400 14 O
across	1415 6 O
the	1422 3 O
septotemporal	1426 13 O
axis	1440 4 O
,	1444 1 O
although	1446 8 O
it	1455 2 O
is	1458 2 O
associated	1461 10 O
with	1472 4 O
an	1477 2 O
increase	1480 8 O
in	1489 2 O
volume	1492 6 O
of	1499 2 O
the	1502 3 O
hilus	1506 5 O
.	1511 1 O

The	1513 3 O
results	1517 7 O
provide	1525 7 O
new	1533 3 O
insight	1537 7 O
into	1545 4 O
the	1550 3 O
potential	1554 9 O
role	1564 4 O
of	1569 2 O
ectopic	1572 7 O
hilar	1580 5 O
granule	1586 7 O
cells	1594 5 O
in	1600 2 O
the	1603 3 O
pilocarpine	1607 11 B-Chemical
model	1619 5 O
of	1625 2 O
temporal	1628 8 B-Disease
lobe	1637 4 I-Disease
epilepsy	1642 8 I-Disease
.	1650 1 O

A	0 1 O
prospective	2 11 O
,	13 1 O
open	15 4 O
-	19 1 O
label	20 5 O
trial	26 5 O
of	32 2 O
galantamine	35 11 B-Chemical
in	47 2 O
autistic	50 8 B-Disease
disorder	59 8 I-Disease
.	67 1 O

OBJECTIVE	69 9 O
:	78 1 O
Post	80 4 O
-	84 1 O
mortem	85 6 O
studies	92 7 O
have	100 4 O
reported	105 8 O
abnormalities	114 13 O
of	128 2 O
the	131 3 O
cholinergic	135 11 O
system	147 6 O
in	154 2 O
autism	157 6 B-Disease
.	163 1 O

The	165 3 O
purpose	169 7 O
of	177 2 O
this	180 4 O
study	185 5 O
was	191 3 O
to	195 2 O
assess	198 6 O
the	205 3 O
use	209 3 O
of	213 2 O
galantamine	216 11 B-Chemical
,	227 1 O
an	229 2 O
acetylcholinesterase	232 20 O
inhibitor	253 9 O
and	263 3 O
nicotinic	267 9 O
receptor	277 8 O
modulator	286 9 O
,	295 1 O
in	297 2 O
the	300 3 O
treatment	304 9 O
of	314 2 O
interfering	317 11 O
behaviors	329 9 O
in	339 2 O
children	342 8 O
with	351 4 O
autism	356 6 B-Disease
.	362 1 O

METHODS	364 7 O
:	371 1 O
Thirteen	373 8 O
medication	382 10 O
-	392 1 O
free	393 4 O
children	398 8 O
with	407 4 O
autism	412 6 B-Disease
(	419 1 O
mean	420 4 O
age	425 3 O
,	428 1 O
8	430 1 O
.	431 1 O
8	432 1 O
+	434 1 O
/	435 1 O
-	436 1 O
3	438 1 O
.	439 1 O
5	440 1 O
years	442 5 O
)	447 1 O
participated	449 12 O
in	462 2 O
a	465 1 O
12	467 2 O
-	469 1 O
week	470 4 O
,	474 1 O
open	476 4 O
-	480 1 O
label	481 5 O
trial	487 5 O
of	493 2 O
galantamine	496 11 B-Chemical
.	507 1 O

Patients	509 8 O
were	518 4 O
rated	523 5 O
monthly	529 7 O
by	537 2 O
parents	540 7 O
on	548 2 O
the	551 3 O
Aberrant	555 8 O
Behavior	564 8 O
Checklist	573 9 O
(	583 1 O
ABC	584 3 O
)	587 1 O
and	589 3 O
the	593 3 O
Conners	597 7 O
'	604 1 O
Parent	606 6 O
Rating	613 6 O
Scale	620 5 O
-	625 1 O
Revised	626 7 O
,	633 1 O
and	635 3 O
by	639 2 O
a	642 1 O
physician	644 9 O
using	654 5 O
the	660 3 O
Children	664 8 O
'	672 1 O
s	673 1 O
Psychiatric	675 11 O
Rating	687 6 O
Scale	694 5 O
and	700 3 O
the	704 3 O
Clinical	708 8 O
Global	717 6 O
Impressions	724 11 O
scale	736 5 O
.	741 1 O

RESULTS	743 7 O
:	750 1 O
Patients	752 8 O
showed	761 6 O
a	768 1 O
significant	770 11 O
reduction	782 9 O
in	792 2 O
parent	795 6 O
-	801 1 O
rated	802 5 O
irritability	808 12 B-Disease
and	821 3 O
social	825 6 O
withdrawal	832 10 O
on	843 2 O
the	846 3 O
ABC	850 3 O
as	854 2 O
well	857 4 O
as	862 2 O
significant	865 11 O
improvements	877 12 O
in	890 2 O
emotional	893 9 O
lability	903 8 O
and	912 3 O
inattention	916 11 O
on	928 2 O
the	931 3 O
Conners	935 7 O
'	942 1 O
Parent	944 6 O
Rating	951 6 O
Scale	958 5 O
-	963 1 O
-	964 1 O
Revised	965 7 O
.	972 1 O

Similarly	974 9 O
,	983 1 O
clinician	985 9 O
ratings	995 7 O
showed	1003 6 O
reductions	1010 10 O
in	1021 2 O
the	1024 3 O
anger	1028 5 O
subscale	1034 8 O
of	1043 2 O
the	1046 3 O
Children	1050 8 O
'	1058 1 O
s	1059 1 O
Psychiatric	1061 11 O
Rating	1073 6 O
Scale	1080 5 O
.	1085 1 O

Eight	1087 5 O
of	1093 2 O
13	1096 2 O
participants	1099 12 O
were	1112 4 O
rated	1117 5 O
as	1123 2 O
responders	1126 10 O
on	1137 2 O
the	1140 3 O
basis	1144 5 O
of	1150 2 O
their	1153 5 O
improvement	1159 11 O
scores	1171 6 O
on	1178 2 O
the	1181 3 O
Clinical	1185 8 O
Global	1194 6 O
Impressions	1201 11 O
scale	1213 5 O
.	1218 1 O

Overall	1220 7 O
,	1227 1 O
galantamine	1229 11 B-Chemical
was	1241 3 O
well	1245 4 O
-	1249 1 O
tolerated	1250 9 O
,	1259 1 O
with	1261 4 O
no	1266 2 O
significant	1269 11 O
adverse	1281 7 O
effects	1289 7 O
apart	1297 5 O
from	1303 4 O
headaches	1308 9 B-Disease
in	1318 2 O
one	1321 3 O
patient	1325 7 O
.	1332 1 O

CONCLUSION	1334 10 O
:	1344 1 O
In	1346 2 O
this	1349 4 O
open	1354 4 O
trial	1359 5 O
,	1364 1 O
galantamine	1366 11 B-Chemical
was	1378 3 O
well	1382 4 O
-	1386 1 O
tolerated	1387 9 O
and	1397 3 O
appeared	1401 8 O
to	1410 2 O
be	1413 2 O
beneficial	1416 10 O
for	1427 3 O
the	1431 3 O
treatment	1435 9 O
of	1445 2 O
interfering	1448 11 O
behaviors	1460 9 O
in	1470 2 O
children	1473 8 O
with	1482 4 O
autism	1487 6 B-Disease
,	1493 1 O
particularly	1495 12 O
aggression	1508 10 B-Disease
,	1518 1 O
behavioral	1520 10 B-Disease
dyscontrol	1531 10 I-Disease
,	1541 1 O
and	1543 3 O
inattention	1547 11 B-Disease
.	1558 1 O

Further	1560 7 O
controlled	1568 10 O
trials	1579 6 O
are	1586 3 O
warranted	1590 9 O
.	1599 1 O

Randomized	0 10 O
comparison	11 10 O
of	22 2 O
olanzapine	25 10 B-Chemical
versus	36 6 O
risperidone	43 11 B-Chemical
for	55 3 O
the	59 3 O
treatment	63 9 O
of	73 2 O
first	76 5 O
-	81 1 O
episode	82 7 O
schizophrenia	90 13 B-Disease
:	103 1 O
4	105 1 O
-	106 1 O
month	107 5 O
outcomes	113 8 O
.	121 1 O

OBJECTIVE	123 9 O
:	132 1 O
The	134 3 O
authors	138 7 O
compared	146 8 O
4	155 1 O
-	156 1 O
month	157 5 O
treatment	163 9 O
outcomes	173 8 O
for	182 3 O
olanzapine	186 10 B-Chemical
versus	197 6 O
risperidone	204 11 B-Chemical
in	216 2 O
patients	219 8 O
with	228 4 O
first	233 5 O
-	238 1 O
episode	239 7 O
schizophrenia	247 13 B-Disease
spectrum	261 8 O
disorders	270 9 O
.	279 1 O

METHOD	281 6 O
:	287 1 O
One	289 3 O
hundred	293 7 O
twelve	301 6 O
subjects	308 8 O
(	317 1 O
70	318 2 O
%	320 1 O
male	322 4 O
;	326 1 O
mean	328 4 O
age	333 3 O
=	336 1 O
23	337 2 O
.	339 1 O
3	340 1 O
years	342 5 O
[	348 1 O
SD	349 2 O
=	352 1 O
5	354 1 O
.	355 1 O
1	356 1 O
]	357 1 O
)	358 1 O
with	360 4 O
first	365 5 O
-	370 1 O
episode	371 7 O
schizophrenia	379 13 B-Disease
(	393 1 O
75	394 2 O
%	396 1 O
)	397 1 O
,	398 1 O
schizophreniform	400 16 B-Disease
disorder	417 8 I-Disease
(	426 1 O
17	427 2 O
%	429 1 O
)	430 1 O
,	431 1 O
or	433 2 O
schizoaffective	436 15 B-Disease
disorder	452 8 I-Disease
(	461 1 O
8	462 1 O
%	463 1 O
)	464 1 O
were	466 4 O
randomly	471 8 O
assigned	480 8 O
to	489 2 O
treatment	492 9 O
with	502 4 O
olanzapine	507 10 B-Chemical
(	518 1 O
2	519 1 O
.	520 1 O
5	521 1 O
-	522 1 O
20	523 2 O
mg	526 2 O
/	528 1 O
day	529 3 O
)	532 1 O
or	534 2 O
risperidone	537 11 B-Chemical
(	549 1 O
1	550 1 O
-	551 1 O
6	552 1 O
mg	554 2 O
/	556 1 O
day	557 3 O
)	560 1 O
.	561 1 O

RESULTS	563 7 O
:	570 1 O
Response	572 8 O
rates	581 5 O
did	587 3 O
not	591 3 O
significantly	595 13 O
differ	609 6 O
between	616 7 O
olanzapine	624 10 B-Chemical
(	635 1 O
43	636 2 O
.	638 1 O
7	639 1 O
%	640 1 O
,	641 1 O
95	643 2 O
%	645 1 O
CI	647 2 O
=	649 1 O
28	650 2 O
.	652 1 O
8	653 1 O
%	654 1 O
-	655 1 O
58	656 2 O
.	658 1 O
6	659 1 O
%	660 1 O
)	661 1 O
and	663 3 O
risperidone	667 11 B-Chemical
(	679 1 O
54	680 2 O
.	682 1 O
3	683 1 O
%	684 1 O
,	685 1 O
95	687 2 O
%	689 1 O
CI	691 2 O
=	693 1 O
39	694 2 O
.	696 1 O
9	697 1 O
%	698 1 O
-	699 1 O
68	700 2 O
.	702 1 O
7	703 1 O
%	704 1 O
)	705 1 O
.	706 1 O

Among	708 5 O
those	714 5 O
responding	720 10 O
to	731 2 O
treatment	734 9 O
,	743 1 O
more	745 4 O
subjects	750 8 O
in	759 2 O
the	762 3 O
olanzapine	766 10 B-Chemical
group	777 5 O
(	783 1 O
40	784 2 O
.	786 1 O
9	787 1 O
%	788 1 O
,	789 1 O
95	791 2 O
%	793 1 O
CI	795 2 O
=	797 1 O
16	798 2 O
.	800 1 O
8	801 1 O
%	802 1 O
-	803 1 O
65	804 2 O
.	806 1 O
0	807 1 O
%	808 1 O
)	809 1 O
than	811 4 O
in	816 2 O
the	819 3 O
risperidone	823 11 B-Chemical
group	835 5 O
(	841 1 O
18	842 2 O
.	844 1 O
9	845 1 O
%	846 1 O
,	847 1 O
95	849 2 O
%	851 1 O
CI	853 2 O
=	855 1 O
0	856 1 O
%	857 1 O
-	858 1 O
39	859 2 O
.	861 1 O
2	862 1 O
%	863 1 O
)	864 1 O
had	866 3 O
subsequent	870 10 O
ratings	881 7 O
not	889 3 O
meeting	893 7 O
response	901 8 O
criteria	910 8 O
.	918 1 O

Negative	920 8 O
symptom	929 7 O
outcomes	937 8 O
and	946 3 O
measures	950 8 O
of	959 2 O
parkinsonism	962 12 B-Disease
and	975 3 O
akathisia	979 9 B-Disease
did	989 3 O
not	993 3 O
differ	997 6 O
between	1004 7 O
medications	1012 11 O
.	1023 1 O

Extrapyramidal	1025 14 B-Disease
symptom	1040 7 I-Disease
severity	1048 8 O
scores	1057 6 O
were	1064 4 O
1	1069 1 O
.	1070 1 O
4	1071 1 O
(	1073 1 O
95	1074 2 O
%	1076 1 O
CI	1078 2 O
=	1080 1 O
1	1081 1 O
.	1082 1 O
2	1083 1 O
-	1084 1 O
1	1085 1 O
.	1086 1 O
6	1087 1 O
)	1088 1 O
with	1090 4 O
risperidone	1095 11 B-Chemical
and	1107 3 O
1	1111 1 O
.	1112 1 O
2	1113 1 O
(	1115 1 O
95	1116 2 O
%	1118 1 O
CI	1120 2 O
=	1122 1 O
1	1123 1 O
.	1124 1 O
0	1125 1 O
-	1126 1 O
1	1127 1 O
.	1128 1 O
4	1129 1 O
)	1130 1 O
with	1132 4 O
olanzapine	1137 10 B-Chemical
.	1147 1 O

Significantly	1149 13 O
more	1163 4 O
weight	1168 6 B-Disease
gain	1175 4 I-Disease
occurred	1180 8 O
with	1189 4 O
olanzapine	1194 10 B-Chemical
than	1205 4 O
with	1210 4 O
risperidone	1215 11 B-Chemical
:	1226 1 O
the	1228 3 O
increase	1232 8 O
in	1241 2 O
weight	1244 6 O
at	1251 2 O
4	1254 1 O
months	1256 6 O
relative	1263 8 O
to	1272 2 O
baseline	1275 8 O
weight	1284 6 O
was	1291 3 O
17	1295 2 O
.	1297 1 O
3	1298 1 O
%	1299 1 O
(	1301 1 O
95	1302 2 O
%	1304 1 O
CI	1306 2 O
=	1308 1 O
14	1309 2 O
.	1311 1 O
2	1312 1 O
%	1313 1 O
-	1314 1 O
20	1315 2 O
.	1317 1 O
5	1318 1 O
%	1319 1 O
)	1320 1 O
with	1322 4 O
olanzapine	1327 10 B-Chemical
and	1338 3 O
11	1342 2 O
.	1344 1 O
3	1345 1 O
%	1346 1 O
(	1348 1 O
95	1349 2 O
%	1351 1 O
CI	1353 2 O
=	1355 1 O
8	1356 1 O
.	1357 1 O
4	1358 1 O
%	1359 1 O
-	1360 1 O
14	1361 2 O
.	1363 1 O
3	1364 1 O
%	1365 1 O
)	1366 1 O
with	1368 4 O
risperidone	1373 11 B-Chemical
.	1384 1 O

Body	1386 4 O
mass	1391 4 O
index	1396 5 O
at	1402 2 O
baseline	1405 8 O
and	1414 3 O
at	1418 2 O
4	1421 1 O
months	1423 6 O
was	1430 3 O
24	1434 2 O
.	1436 1 O
3	1437 1 O
(	1439 1 O
95	1440 2 O
%	1442 1 O
CI	1444 2 O
=	1446 1 O
22	1447 2 O
.	1449 1 O
8	1450 1 O
-	1451 1 O
25	1452 2 O
.	1454 1 O
7	1455 1 O
)	1456 1 O
versus	1458 6 O
28	1465 2 O
.	1467 1 O
2	1468 1 O
(	1470 1 O
95	1471 2 O
%	1473 1 O
CI	1475 2 O
=	1477 1 O
26	1478 2 O
.	1480 1 O
7	1481 1 O
-	1482 1 O
29	1483 2 O
.	1485 1 O
7	1486 1 O
)	1487 1 O
with	1489 4 O
olanzapine	1494 10 B-Chemical
and	1505 3 O
23	1509 2 O
.	1511 1 O
9	1512 1 O
(	1514 1 O
95	1515 2 O
%	1517 1 O
CI	1519 2 O
=	1521 1 O
22	1522 2 O
.	1524 1 O
5	1525 1 O
-	1526 1 O
25	1527 2 O
.	1529 1 O
3	1530 1 O
)	1531 1 O
versus	1533 6 O
26	1540 2 O
.	1542 1 O
7	1543 1 O
(	1545 1 O
95	1546 2 O
%	1548 1 O
CI	1550 2 O
=	1552 1 O
25	1553 2 O
.	1555 1 O
2	1556 1 O
-	1557 1 O
28	1558 2 O
.	1560 1 O
2	1561 1 O
)	1562 1 O
with	1564 4 O
risperidone	1569 11 B-Chemical
.	1580 1 O

CONCLUSIONS	1582 11 O
:	1593 1 O
Clinical	1595 8 O
outcomes	1604 8 O
with	1613 4 O
risperidone	1618 11 B-Chemical
were	1630 4 O
equal	1635 5 O
to	1641 2 O
those	1644 5 O
with	1650 4 O
olanzapine	1655 10 B-Chemical
,	1665 1 O
and	1667 3 O
response	1671 8 O
may	1680 3 O
be	1684 2 O
more	1687 4 O
stable	1692 6 O
.	1698 1 O

Olanzapine	1700 10 B-Chemical
may	1711 3 O
have	1715 4 O
an	1720 2 O
advantage	1723 9 O
for	1733 3 O
motor	1737 5 O
side	1743 4 O
effects	1748 7 O
.	1755 1 O

Both	1757 4 O
medications	1762 11 O
caused	1774 6 O
substantial	1781 11 O
rapid	1793 5 O
weight	1799 6 B-Disease
gain	1806 4 I-Disease
,	1810 1 O
but	1812 3 O
weight	1816 6 B-Disease
gain	1823 4 I-Disease
was	1828 3 O
greater	1832 7 O
with	1840 4 O
olanzapine	1845 10 B-Chemical
.	1855 1 O

Early	0 5 O
paracentral	6 11 O
visual	18 6 B-Disease
field	25 5 I-Disease
loss	31 4 I-Disease
in	36 2 O
patients	39 8 O
taking	48 6 O
hydroxychloroquine	55 18 B-Chemical
.	73 1 O

OBJECTIVE	75 9 O
:	84 1 O
To	86 2 O
review	89 6 O
the	96 3 O
natural	100 7 O
history	108 7 O
and	116 3 O
ocular	120 6 O
and	127 3 O
systemic	131 8 O
adverse	140 7 O
effects	148 7 O
of	156 2 O
patients	159 8 O
taking	168 6 O
hydroxychloroquine	175 18 B-Chemical
sulfate	194 7 I-Chemical
who	202 3 O
attended	206 8 O
an	215 2 O
ophthalmic	218 10 O
screening	229 9 O
program	239 7 O
.	246 1 O

DESIGN	248 6 O
:	254 1 O
Retrospective	256 13 O
study	270 5 O
.	275 1 O

RESULTS	277 7 O
:	284 1 O
Records	286 7 O
of	294 2 O
262	297 3 O
patients	301 8 O
who	310 3 O
were	314 4 O
taking	319 6 O
hydroxychloroquine	326 18 B-Chemical
and	345 3 O
screened	349 8 O
in	358 2 O
the	361 3 O
Department	365 10 O
of	376 2 O
Ophthalmology	379 13 O
were	393 4 O
reviewed	398 8 O
.	406 1 O

Of	408 2 O
the	411 3 O
262	415 3 O
patients	419 8 O
,	427 1 O
14	429 2 O
(	432 1 O
18	433 2 O
%	435 1 O
)	436 1 O
of	438 2 O
76	441 2 O
who	444 3 O
had	448 3 O
stopped	452 7 O
treatment	460 9 O
at	470 2 O
the	473 3 O
time	477 4 O
of	482 2 O
the	485 3 O
study	489 5 O
experienced	495 11 O
documented	507 10 O
adverse	518 7 O
effects	526 7 O
.	533 1 O

Systemic	535 8 O
adverse	544 7 O
effects	552 7 O
occurred	560 8 O
in	569 2 O
8	572 1 O
patients	574 8 O
(	583 1 O
10	584 2 O
.	586 1 O
5	587 1 O
%	588 1 O
)	589 1 O
and	591 3 O
ocular	595 6 O
adverse	602 7 O
effects	610 7 O
,	617 1 O
in	619 2 O
5	622 1 O
(	624 1 O
6	625 1 O
.	626 1 O
5	627 1 O
%	628 1 O
)	629 1 O
.	630 1 O

Thirty	632 6 O
-	638 1 O
five	639 4 O
patients	644 8 O
(	653 1 O
13	654 2 O
.	656 1 O
4	657 1 O
%	658 1 O
)	659 1 O
had	661 3 O
visual	665 6 B-Disease
field	672 5 I-Disease
abnormalities	678 13 I-Disease
,	691 1 O
which	693 5 O
were	699 4 O
attributed	704 10 O
to	715 2 O
hydroxychloroquine	718 18 B-Chemical
treatment	737 9 O
in	747 2 O
4	750 1 O
patients	752 8 O
(	761 1 O
1	762 1 O
.	763 1 O
5	764 1 O
%	765 1 O
)	766 1 O
.	767 1 O

Three	769 5 O
of	775 2 O
the	778 3 O
4	782 1 O
patients	784 8 O
were	793 4 O
taking	798 6 O
less	805 4 O
than	810 4 O
6	815 1 O
.	816 1 O
5	817 1 O
mg	819 2 O
/	821 1 O
kg	822 2 O
per	825 3 O
day	829 3 O
and	833 3 O
all	837 3 O
patients	841 8 O
had	850 3 O
normal	854 6 O
renal	861 5 O
and	867 3 O
liver	871 5 O
function	877 8 O
test	886 4 O
results	891 7 O
.	898 1 O

CONCLUSIONS	900 11 O
:	911 1 O
The	913 3 O
current	917 7 O
study	925 5 O
used	931 4 O
a	936 1 O
protocol	938 8 O
of	947 2 O
visual	950 6 O
acuity	957 6 O
and	964 3 O
color	968 5 O
vision	974 6 O
assessment	981 10 O
,	991 1 O
funduscopy	993 10 O
,	1003 1 O
and	1005 3 O
Humphrey	1009 8 O
10	1018 2 O
-	1020 1 O
2	1021 1 O
visual	1023 6 O
field	1030 5 O
testing	1036 7 O
and	1044 3 O
shows	1048 5 O
that	1054 4 O
visual	1059 6 B-Disease
field	1066 5 I-Disease
defects	1072 7 I-Disease
appeared	1080 8 O
before	1089 6 O
any	1096 3 O
corresponding	1100 13 O
changes	1114 7 O
in	1122 2 O
any	1125 3 O
other	1129 5 O
tested	1135 6 O
clinical	1142 8 O
parameters	1151 10 O
;	1161 1 O
the	1163 3 O
defects	1167 7 O
were	1175 4 O
reproducible	1180 12 O
and	1193 3 O
the	1197 3 O
test	1201 4 O
parameters	1206 10 O
were	1217 4 O
reliable	1222 8 O
.	1230 1 O

Patients	1232 8 O
taking	1241 6 O
hydroxychloroquine	1248 18 B-Chemical
can	1267 3 O
demonstrate	1271 11 O
a	1283 1 O
toxic	1285 5 O
reaction	1291 8 O
in	1300 2 O
the	1303 3 O
retina	1307 6 O
despite	1314 7 O
the	1322 3 O
absence	1326 7 O
of	1334 2 O
known	1337 5 O
risk	1343 4 O
factors	1348 7 O
.	1355 1 O

Screening	1357 9 O
,	1366 1 O
including	1368 9 O
Humphrey	1378 8 O
10	1387 2 O
-	1389 1 O
2	1390 1 O
visual	1392 6 O
field	1399 5 O
assessment	1405 10 O
,	1415 1 O
is	1417 2 O
recommended	1420 11 O
2	1432 1 O
years	1434 5 O
after	1440 5 O
the	1446 3 O
initial	1450 7 O
baseline	1458 8 O
and	1467 3 O
yearly	1471 6 O
thereafter	1478 10 O
.	1488 1 O

Peri	0 4 O
-	4 1 O
operative	5 9 O
atrioventricular	15 16 B-Disease
block	32 5 I-Disease
as	38 2 O
a	41 1 O
result	43 6 O
of	50 2 O
chemotherapy	53 12 O
with	66 4 O
epirubicin	71 10 B-Chemical
and	82 3 O
paclitaxel	86 10 B-Chemical
.	96 1 O

A	98 1 O
47	100 2 O
-	102 1 O
year	103 4 O
-	107 1 O
old	108 3 O
woman	112 5 O
presented	118 9 O
for	128 3 O
mastectomy	132 10 O
and	143 3 O
immediate	147 9 O
latissimus	157 10 O
dorsi	168 5 O
flap	174 4 O
reconstruction	179 14 O
having	194 6 O
been	201 4 O
diagnosed	206 9 O
with	216 4 O
carcinoma	221 9 B-Disease
of	231 2 I-Disease
the	234 3 I-Disease
breast	238 6 I-Disease
6	245 1 O
months	247 6 O
previously	254 10 O
.	264 1 O

In	266 2 O
the	269 3 O
preceding	273 9 O
months	283 6 O
she	290 3 O
had	294 3 O
received	298 8 O
neo	307 3 O
-	310 1 O
adjuvant	311 8 O
chemotherapy	320 12 O
with	333 4 O
epirubicin	338 10 B-Chemical
,	348 1 O
paclitaxel	350 10 B-Chemical
(	361 1 O
Taxol	362 5 B-Chemical
)	367 1 O
and	369 3 O
cyclophosphamide	373 16 B-Chemical
.	389 1 O

This	391 4 O
had	396 3 O
been	400 4 O
apparently	405 10 O
uncomplicated	416 13 O
and	430 3 O
she	434 3 O
had	438 3 O
maintained	442 10 O
a	453 1 O
remarkably	455 10 O
high	466 4 O
level	471 5 O
of	477 2 O
physical	480 8 O
activity	489 8 O
.	497 1 O

She	499 3 O
was	503 3 O
found	507 5 O
to	513 2 O
be	516 2 O
bradycardic	519 11 B-Disease
at	531 2 O
pre	534 3 O
-	537 1 O
operative	538 9 O
assessment	548 10 O
but	559 3 O
had	563 3 O
no	567 2 O
cardiac	570 7 O
symptoms	578 8 O
.	586 1 O

Second	588 6 O
degree	595 6 O
Mobitz	602 6 O
type	609 4 O
II	614 2 O
atrioventricular	617 16 B-Disease
block	634 5 I-Disease
was	640 3 O
diagnosed	644 9 O
on	654 2 O
electrocardiogram	657 17 O
,	674 1 O
and	676 3 O
temporary	680 9 O
transvenous	690 11 O
ventricular	702 11 O
pacing	714 6 O
instituted	721 10 O
in	732 2 O
the	735 3 O
peri	739 4 O
-	743 1 O
operative	744 9 O
period	754 6 O
.	760 1 O

We	762 2 O
discuss	765 7 O
how	773 3 O
evidence	777 8 O
-	785 1 O
based	786 5 O
guidelines	792 10 O
would	803 5 O
not	809 3 O
have	813 4 O
been	818 4 O
helpful	823 7 O
in	831 2 O
this	834 4 O
case	839 4 O
,	843 1 O
and	845 3 O
how	849 3 O
chemotherapy	853 12 O
can	866 3 O
exhibit	870 7 O
substantial	878 11 O
cardiotoxicity	890 14 B-Disease
that	905 4 O
may	910 3 O
develop	914 7 O
over	922 4 O
many	927 4 O
years	932 5 O
.	937 1 O

We	939 2 O
suggest	942 7 O
that	950 4 O
patients	955 8 O
who	964 3 O
have	968 4 O
received	973 8 O
chemotherapy	982 12 O
at	995 2 O
any	998 3 O
time	1002 4 O
should	1007 6 O
have	1014 4 O
a	1019 1 O
pre	1021 3 O
-	1024 1 O
operative	1025 9 O
electrocardiogram	1035 17 O
even	1053 4 O
if	1058 2 O
they	1061 4 O
are	1066 3 O
asymptomatic	1070 12 O
.	1082 1 O

Risks	0 5 O
and	6 3 O
benefits	10 8 O
of	19 2 O
COX	22 3 B-Chemical
-	25 1 I-Chemical
2	26 1 I-Chemical
inhibitors	28 10 I-Chemical
vs	39 2 O
non	42 3 O
-	45 1 O
selective	46 9 O
NSAIDs	56 6 O
:	62 1 O
does	64 4 O
their	69 5 O
cardiovascular	75 14 O
risk	90 4 O
exceed	95 6 O
their	102 5 O
gastrointestinal	108 16 O
benefit	125 7 O
?	132 1 O

A	134 1 O
retrospective	136 13 O
cohort	150 6 O
study	157 5 O
.	162 1 O

OBJECTIVES	164 10 O
:	174 1 O
The	176 3 O
risk	180 4 O
of	185 2 O
acute	188 5 B-Disease
myocardial	194 10 I-Disease
infarction	205 10 I-Disease
(	216 1 O
AMI	217 3 B-Disease
)	220 1 O
with	222 4 O
COX	227 3 B-Chemical
-	230 1 I-Chemical
2	231 1 I-Chemical
inhibitors	233 10 I-Chemical
may	244 3 O
offset	248 6 O
their	255 5 O
gastrointestinal	261 16 O
(	278 1 O
GI	279 2 O
)	281 1 O
benefit	283 7 O
compared	291 8 O
with	300 4 O
non	305 3 O
-	308 1 O
selective	309 9 O
(	319 1 O
NS	320 2 O
)	322 1 O
non	324 3 B-Chemical
-	327 1 I-Chemical
steroidal	328 9 I-Chemical
anti	338 4 I-Chemical
-	342 1 I-Chemical
inflammatory	343 12 I-Chemical
drugs	356 5 I-Chemical
(	362 1 O
NSAIDs	363 6 O
)	369 1 O
.	370 1 O

We	372 2 O
aimed	375 5 O
to	381 2 O
compare	384 7 O
the	392 3 O
risks	396 5 O
of	402 2 O
hospitalization	405 15 O
for	421 3 O
AMI	425 3 B-Disease
and	429 3 O
GI	433 2 B-Disease
bleeding	436 8 I-Disease
among	445 5 O
elderly	451 7 O
patients	459 8 O
using	468 5 O
COX	474 3 B-Chemical
-	477 1 I-Chemical
2	478 1 I-Chemical
inhibitors	480 10 I-Chemical
,	490 1 O
NS	492 2 O
-	494 1 O
NSAIDs	495 6 O
and	502 3 O
acetaminophen	506 13 B-Chemical
.	519 1 O

METHODS	521 7 O
:	528 1 O
We	530 2 O
conducted	533 9 O
a	543 1 O
retrospective	545 13 O
cohort	559 6 O
study	566 5 O
using	572 5 O
administrative	578 14 O
data	593 4 O
of	598 2 O
patients	601 8 O
>	610 1 O
or	612 2 O
=	615 1 O
65	616 2 O
years	619 5 O
of	625 2 O
age	628 3 O
who	632 3 O
filled	636 6 O
a	643 1 O
prescription	645 12 O
for	658 3 O
NSAID	662 5 O
or	668 2 O
acetaminophen	671 13 B-Chemical
during	685 6 O
1999	692 4 O
-	696 1 O
2002	697 4 O
.	701 1 O

Outcomes	703 8 O
were	712 4 O
compared	717 8 O
using	726 5 O
Cox	732 3 O
regression	736 10 O
models	747 6 O
with	754 4 O
time	759 4 O
-	763 1 O
dependent	764 9 O
exposures	774 9 O
.	783 1 O

RESULTS	785 7 O
:	792 1 O
Person	794 6 O
-	800 1 O
years	801 5 O
of	807 2 O
exposure	810 8 O
among	819 5 O
non	825 3 O
-	828 1 O
users	829 5 O
of	835 2 O
aspirin	838 7 B-Chemical
were	846 4 O
:	850 1 O
75	852 2 O
,	854 1 O
761	855 3 O
to	859 2 O
acetaminophen	862 13 B-Chemical
,	875 1 O
42	877 2 O
,	879 1 O
671	880 3 O
to	884 2 O
rofecoxib	887 9 B-Chemical
65	897 2 O
,	899 1 O
860	900 3 O
to	904 2 O
celecoxib	907 9 B-Chemical
,	916 1 O
and	918 3 O
37	922 2 O
,	924 1 O
495	925 3 O
to	929 2 O
NS	932 2 O
-	934 1 O
NSAIDs	935 6 O
.	941 1 O

Among	943 5 O
users	949 5 O
of	955 2 O
aspirin	958 7 B-Chemical
,	965 1 O
they	967 4 O
were	972 4 O
:	976 1 O
14	978 2 O
,	980 1 O
671	981 3 O
to	985 2 O
rofecoxib	988 9 B-Chemical
,	997 1 O
22	999 2 O
,	1001 1 O
875	1002 3 O
to	1006 2 O
celecoxib	1009 9 B-Chemical
,	1018 1 O
9	1020 1 O
,	1021 1 O
832	1022 3 O
to	1026 2 O
NS	1029 2 O
-	1031 1 O
NSAIDs	1032 6 O
and	1039 3 O
38	1043 2 O
,	1045 1 O
048	1046 3 O
to	1050 2 O
acetaminophen	1053 13 B-Chemical
.	1066 1 O

Among	1068 5 O
non	1074 3 O
-	1077 1 O
users	1078 5 O
of	1084 2 O
aspirin	1087 7 B-Chemical
,	1094 1 O
the	1096 3 O
adjusted	1100 8 O
hazard	1109 6 O
ratios	1116 6 O
(	1123 1 O
95	1124 2 O
%	1126 1 O
confidence	1128 10 O
interval	1139 8 O
)	1147 1 O
of	1149 2 O
hospitalization	1152 15 O
for	1168 3 O
AMI	1172 3 B-Disease
/	1175 1 O
GI	1176 2 O
vs	1179 2 O
the	1182 3 O
acetaminophen	1186 13 B-Chemical
(	1200 1 O
with	1201 4 O
no	1206 2 O
aspirin	1209 7 B-Chemical
)	1216 1 O
group	1218 5 O
were	1224 4 O
:	1228 1 O
rofecoxib	1230 9 B-Chemical
1	1240 1 O
.	1241 1 O
27	1242 2 O
(	1245 1 O
1	1246 1 O
.	1247 1 O
13	1248 2 O
,	1250 1 O
1	1252 1 O
.	1253 1 O
42	1254 2 O
)	1256 1 O
,	1257 1 O
celecoxib	1259 9 B-Chemical
0	1269 1 O
.	1270 1 O
93	1271 2 O
(	1274 1 O
0	1275 1 O
.	1276 1 O
83	1277 2 O
,	1279 1 O
1	1281 1 O
.	1282 1 O
03	1283 2 O
)	1285 1 O
,	1286 1 O
naproxen	1288 8 B-Chemical
1	1297 1 O
.	1298 1 O
59	1299 2 O
(	1302 1 O
1	1303 1 O
.	1304 1 O
31	1305 2 O
,	1307 1 O
1	1309 1 O
.	1310 1 O
93	1311 2 O
)	1313 1 O
,	1314 1 O
diclofenac	1316 10 B-Chemical
1	1327 1 O
.	1328 1 O
17	1329 2 O
(	1332 1 O
0	1333 1 O
.	1334 1 O
99	1335 2 O
,	1337 1 O
1	1339 1 O
.	1340 1 O
38	1341 2 O
)	1343 1 O
and	1345 3 O
ibuprofen	1349 9 B-Chemical
1	1359 1 O
.	1360 1 O
05	1361 2 O
(	1364 1 O
0	1365 1 O
.	1366 1 O
74	1367 2 O
,	1369 1 O
1	1371 1 O
.	1372 1 O
51	1373 2 O
)	1375 1 O
.	1376 1 O

Among	1378 5 O
users	1384 5 O
of	1390 2 O
aspirin	1393 7 B-Chemical
,	1400 1 O
they	1402 4 O
were	1407 4 O
:	1411 1 O
rofecoxib	1413 9 B-Chemical
1	1423 1 O
.	1424 1 O
73	1425 2 O
(	1428 1 O
1	1429 1 O
.	1430 1 O
52	1431 2 O
,	1433 1 O
1	1435 1 O
.	1436 1 O
98	1437 2 O
)	1439 1 O
,	1440 1 O
celecoxib	1442 9 B-Chemical
1	1452 1 O
.	1453 1 O
34	1454 2 O
(	1457 1 O
1	1458 1 O
.	1459 1 O
19	1460 2 O
,	1462 1 O
1	1464 1 O
.	1465 1 O
52	1466 2 O
)	1468 1 O
,	1469 1 O
ibuprofen	1471 9 B-Chemical
1	1481 1 O
.	1482 1 O
51	1483 2 O
(	1486 1 O
0	1487 1 O
.	1488 1 O
95	1489 2 O
,	1491 1 O
2	1493 1 O
.	1494 1 O
41	1495 2 O
)	1497 1 O
,	1498 1 O
diclofenac	1500 10 B-Chemical
1	1511 1 O
.	1512 1 O
69	1513 2 O
(	1516 1 O
1	1517 1 O
.	1518 1 O
35	1519 2 O
,	1521 1 O
2	1523 1 O
.	1524 1 O
10	1525 2 O
)	1527 1 O
,	1528 1 O
naproxen	1530 8 B-Chemical
1	1539 1 O
.	1540 1 O
35	1541 2 O
(	1544 1 O
0	1545 1 O
.	1546 1 O
97	1547 2 O
,	1549 1 O
1	1551 1 O
.	1552 1 O
88	1553 2 O
)	1555 1 O
and	1557 3 O
acetaminophen	1561 13 B-Chemical
1	1575 1 O
.	1576 1 O
29	1577 2 O
(	1580 1 O
1	1581 1 O
.	1582 1 O
17	1583 2 O
,	1585 1 O
1	1587 1 O
.	1588 1 O
42	1589 2 O
)	1591 1 O
.	1592 1 O

CONCLUSION	1594 10 O
:	1604 1 O
Among	1606 5 O
non	1612 3 O
-	1615 1 O
users	1616 5 O
of	1622 2 O
aspirin	1625 7 B-Chemical
,	1632 1 O
naproxen	1634 8 B-Chemical
seemed	1643 6 O
to	1650 2 O
carry	1653 5 O
the	1659 3 O
highest	1663 7 O
risk	1671 4 O
for	1676 3 O
AMI	1680 3 B-Disease
/	1683 1 O
GI	1684 2 B-Disease
bleeding	1687 8 I-Disease
.	1695 1 O

The	1697 3 O
AMI	1701 3 B-Disease
/	1704 1 O
GI	1705 2 O
toxicity	1708 8 B-Disease
of	1717 2 O
celecoxib	1720 9 B-Chemical
was	1730 3 O
similar	1734 7 O
to	1742 2 O
that	1745 4 O
of	1750 2 O
acetaminophen	1753 13 B-Chemical
and	1767 3 O
seemed	1771 6 O
to	1778 2 O
be	1781 2 O
better	1784 6 O
than	1791 4 O
those	1796 5 O
of	1802 2 O
rofecoxib	1805 9 B-Chemical
and	1815 3 O
NS	1819 2 O
-	1821 1 O
NSAIDs	1822 6 O
.	1828 1 O

Among	1830 5 O
users	1836 5 O
of	1842 2 O
aspirin	1845 7 B-Chemical
,	1852 1 O
both	1854 4 O
celecoxib	1859 9 B-Chemical
and	1869 3 O
naproxen	1873 8 B-Chemical
seemed	1882 6 O
to	1889 2 O
be	1892 2 O
the	1895 3 O
least	1899 5 O
toxic	1905 5 O
.	1910 1 O

Quinine	0 7 B-Chemical
-	7 1 O
induced	8 7 O
arrhythmia	16 10 B-Disease
in	27 2 O
a	30 1 O
patient	32 7 O
with	40 4 O
severe	45 6 B-Disease
malaria	52 7 I-Disease
.	59 1 O

It	61 2 O
was	64 3 O
reported	68 8 O
that	77 4 O
there	82 5 O
was	88 3 O
a	92 1 O
case	94 4 O
of	99 2 O
severe	102 6 B-Disease
malaria	109 7 I-Disease
patient	117 7 O
with	125 4 O
jaundice	130 8 B-Disease
who	139 3 O
presented	143 9 O
with	153 4 O
arrhythmia	158 10 B-Disease
(	169 1 O
premature	170 9 B-Disease
ventricular	180 11 I-Disease
contraction	192 11 I-Disease
)	203 1 O
while	205 5 O
getting	211 7 O
quinine	219 7 B-Chemical
infusion	227 8 O
was	236 3 O
reported	240 8 O
.	248 1 O

A	250 1 O
man	252 3 O
,	255 1 O
25	257 2 O
years	260 5 O
old	266 3 O
,	269 1 O
was	271 3 O
admitted	275 8 O
to	284 2 O
hospital	287 8 O
with	296 4 O
high	301 4 O
fever	306 5 B-Disease
,	311 1 O
chill	313 5 B-Disease
,	318 1 O
vomiting	320 8 B-Disease
,	328 1 O
jaundice	330 8 B-Disease
.	338 1 O

The	340 3 O
patient	344 7 O
was	352 3 O
fully	356 5 O
conscious	362 9 O
,	371 1 O
blood	373 5 O
pressure	379 8 O
120	388 3 O
/	391 1 O
80	392 2 O
mmHg	395 4 O
,	399 1 O
pulse	401 5 O
rate	407 4 O
100	412 3 O
x	416 1 O
/	417 1 O
minute	418 6 O
,	424 1 O
regular	426 7 O
.	433 1 O

On	435 2 O
admission	438 9 O
,	447 1 O
laboratory	449 10 O
examination	460 11 O
showed	472 6 O
Plasmodium	479 10 O
falciparum	490 10 O
(	501 1 O
+	502 1 O
+	503 1 O
+	504 1 O
+	505 1 O
)	506 1 O
,	507 1 O
total	509 5 O
bilirubin	515 9 B-Chemical
8	525 1 O
.	526 1 O
25	527 2 O
mg	530 2 O
/	532 1 O
dL	533 2 O
,	535 1 O
conjugated	537 10 O
bilirubin	548 9 B-Chemical
4	558 1 O
.	559 1 O
36	560 2 O
mg	563 2 O
/	565 1 O
dL	566 2 O
,	568 1 O
unconjugated	570 12 O
bilirubin	583 9 B-Chemical
3	593 1 O
.	594 1 O
89	595 2 O
mg	598 2 O
/	600 1 O
dL	601 2 O
,	603 1 O
potassium	605 9 B-Chemical
3	615 1 O
.	616 1 O
52	617 2 O
meq	620 3 O
/	623 1 O
L	624 1 O
Patient	626 7 O
was	634 3 O
diagnosed	638 9 O
as	648 2 O
severe	651 6 B-Disease
malaria	658 7 I-Disease
with	666 4 O
jaundice	671 8 B-Disease
and	680 3 O
got	684 3 O
quinine	688 7 B-Chemical
infusion	696 8 O
in	705 2 O
dextrose	708 8 B-Chemical
5	717 1 O
%	718 1 O
500	720 3 O
mg	724 2 O
/	726 1 O
8	727 1 O
hour	729 4 O
.	733 1 O

On	735 2 O
the	738 3 O
second	742 6 O
day	749 3 O
the	753 3 O
patient	757 7 O
had	765 3 O
vomitus	769 7 B-Disease
,	776 1 O
diarrhea	778 8 B-Disease
,	786 1 O
tinnitus	788 8 B-Disease
,	796 1 O
loss	798 4 B-Disease
of	803 2 I-Disease
hearing	806 7 I-Disease
.	813 1 O

After	815 5 O
30	821 2 O
hours	824 5 O
of	830 2 O
quinine	833 7 B-Chemical
infusion	841 8 O
the	850 3 O
patient	854 7 O
felt	862 4 O
palpitation	867 11 B-Disease
and	879 3 O
electrocardiography	883 19 O
(	903 1 O
ECG	904 3 O
)	907 1 O
recording	909 9 O
showed	919 6 O
premature	926 9 B-Disease
ventricular	936 11 I-Disease
contraction	948 11 I-Disease
(	960 1 O
PVC	961 3 B-Disease
)	964 1 O
>	966 1 O
5	968 1 O
x	970 1 O
/	971 1 O
minute	972 6 O
,	978 1 O
trigemini	980 9 O
,	989 1 O
constant	991 8 O
type	1000 4 O
-	1004 1 O
-	1005 1 O
sinoatrial	1006 10 B-Disease
block	1017 5 I-Disease
,	1022 1 O
positive	1024 8 O
U	1033 1 O
wave	1035 4 O
.	1039 1 O

He	1041 2 O
was	1044 3 O
treated	1048 7 O
with	1056 4 O
lidocaine	1061 9 B-Chemical
50	1071 2 O
mg	1074 2 O
intravenously	1077 13 O
followed	1091 8 O
by	1100 2 O
infusion	1103 8 O
1500	1112 4 O
mg	1117 2 O
in	1120 2 O
dextrose	1123 8 B-Chemical
5	1132 1 O
%	1133 1 O
/	1134 1 O
24	1135 2 O
hour	1138 4 O
and	1143 3 O
potassium	1147 9 B-Chemical
aspartate	1157 9 I-Chemical
tablet	1167 6 O
.	1173 1 O

Quinine	1175 7 B-Chemical
infusion	1183 8 O
was	1192 3 O
discontinued	1196 12 O
and	1209 3 O
changed	1213 7 O
with	1221 4 O
sulfate	1226 7 O
quinine	1234 7 B-Chemical
tablets	1242 7 O
.	1249 1 O

Three	1251 5 O
hours	1257 5 O
later	1263 5 O
the	1269 3 O
patient	1273 7 O
felt	1281 4 O
better	1286 6 O
,	1292 1 O
the	1294 3 O
frequency	1298 9 O
of	1308 2 O
PVC	1311 3 B-Disease
reduced	1315 7 O
to	1323 2 O
4	1326 1 O
-	1328 1 O
5	1330 1 O
x	1332 1 O
/	1333 1 O
minute	1334 6 O
and	1341 3 O
on	1345 2 O
the	1348 3 O
third	1352 5 O
day	1358 3 O
ECG	1362 3 O
was	1366 3 O
normal	1370 6 O
,	1376 1 O
potassium	1378 9 B-Chemical
level	1388 5 O
was	1394 3 O
3	1398 1 O
.	1399 1 O
34	1400 2 O
meq	1403 3 O
/	1406 1 O
L	1407 1 O
.	1408 1 O

He	1410 2 O
was	1413 3 O
discharged	1417 10 O
on	1428 2 O
7th	1431 3 O
day	1435 3 O
in	1439 2 O
good	1442 4 O
condition	1447 9 O
.	1456 1 O

Quinine	1458 7 B-Chemical
,	1465 1 O
like	1467 4 O
quinidine	1472 9 B-Chemical
,	1481 1 O
is	1483 2 O
a	1486 1 O
chincona	1488 8 O
alkaloid	1497 8 O
that	1506 4 O
has	1511 3 O
anti	1515 4 O
-	1519 1 O
arrhythmic	1520 10 B-Disease
property	1531 8 O
,	1539 1 O
although	1541 8 O
it	1550 2 O
also	1553 4 O
pro	1558 3 O
-	1561 1 O
arrhythmic	1562 10 B-Disease
that	1573 4 O
can	1578 3 O
cause	1582 5 O
various	1588 7 O
arrhythmias	1596 11 B-Disease
,	1607 1 O
including	1609 9 O
severe	1619 6 O
arrhythmia	1626 10 B-Disease
such	1637 4 O
as	1642 2 O
multiple	1645 8 O
PVC	1654 3 B-Disease
.	1657 1 O

Administration	1659 14 O
of	1674 2 O
parenteral	1677 10 O
quinine	1688 7 B-Chemical
must	1696 4 O
be	1701 2 O
done	1704 4 O
carefully	1709 9 O
and	1719 3 O
with	1723 4 O
good	1728 4 O
observation	1733 11 O
because	1745 7 O
of	1753 2 O
its	1756 3 O
pro	1760 3 O
-	1763 1 O
arrhythmic	1764 10 B-Disease
effect	1775 6 O
,	1781 1 O
especially	1783 10 O
in	1794 2 O
older	1797 5 O
patients	1803 8 O
who	1812 3 O
have	1816 4 O
heart	1821 5 B-Disease
diseases	1827 8 I-Disease
or	1836 2 O
patients	1839 8 O
with	1848 4 O
electrolyte	1853 11 B-Disease
disorder	1865 8 I-Disease
(	1874 1 O
hypokalemia	1875 11 B-Disease
)	1886 1 O
which	1888 5 O
frequently	1894 10 O
occurs	1905 6 O
due	1912 3 O
to	1916 2 O
vomiting	1919 8 B-Disease
and	1928 3 O
or	1932 2 O
diarrhea	1935 8 B-Disease
in	1944 2 O
malaria	1947 7 B-Disease
cases	1955 5 O
.	1960 1 O

Penicillamine	0 13 B-Chemical
-	13 1 O
related	14 7 O
lichenoid	22 9 B-Disease
dermatitis	32 10 I-Disease
and	43 3 O
utility	47 7 O
of	55 2 O
zinc	58 4 B-Chemical
acetate	63 7 I-Chemical
in	71 2 O
a	74 1 O
Wilson	76 6 B-Disease
disease	83 7 I-Disease
patient	91 7 O
with	99 4 O
hepatic	104 7 O
presentation	112 12 O
,	124 1 O
anxiety	126 7 B-Disease
and	134 3 O
SPECT	138 5 O
abnormalities	144 13 O
.	157 1 O

Wilson	159 6 B-Disease
'	165 1 I-Disease
s	166 1 I-Disease
disease	168 7 I-Disease
is	176 2 O
an	179 2 O
autosomal	182 9 O
recessive	192 9 O
disorder	202 8 O
of	211 2 O
hepatic	214 7 O
copper	222 6 B-Chemical
metabolism	229 10 O
with	240 4 O
consequent	245 10 O
copper	256 6 B-Chemical
accumulation	263 12 O
and	276 3 O
toxicity	280 8 B-Disease
in	289 2 O
many	292 4 O
tissues	297 7 O
and	305 3 O
consequent	309 10 O
hepatic	320 7 B-Disease
,	327 1 I-Disease
neurologic	329 10 I-Disease
and	340 3 I-Disease
psychiatric	344 11 I-Disease
disorders	356 9 I-Disease
.	365 1 O

We	367 2 O
report	370 6 O
a	377 1 O
case	379 4 O
of	384 2 O
Wilson	387 6 B-Disease
'	393 1 I-Disease
s	394 1 I-Disease
disease	396 7 I-Disease
with	404 4 O
chronic	409 7 B-Disease
liver	417 5 I-Disease
disease	423 7 I-Disease
;	430 1 O
moreover	432 8 O
,	440 1 O
in	442 2 O
our	445 3 O
patient	449 7 O
,	456 1 O
presenting	458 10 O
also	469 4 O
with	474 4 O
high	479 4 O
levels	484 6 O
of	491 2 O
state	494 5 O
anxiety	500 7 B-Disease
without	508 7 O
depression	516 10 B-Disease
,	526 1 O
99mTc	528 5 O
-	533 1 O
ECD	534 3 O
-	537 1 O
SPECT	538 5 O
showed	544 6 O
cortical	551 8 O
hypoperfusion	560 13 O
in	574 2 O
frontal	577 7 O
lobes	585 5 O
,	590 1 O
more	592 4 O
marked	597 6 O
on	604 2 O
the	607 3 O
left	611 4 O
frontal	616 7 O
lobe	624 4 O
.	628 1 O

During	630 6 O
the	637 3 O
follow	641 6 O
-	647 1 O
up	648 2 O
of	651 2 O
our	654 3 O
patient	658 7 O
,	665 1 O
penicillamine	667 13 B-Chemical
was	681 3 O
interrupted	685 11 O
after	697 5 O
the	703 3 O
appearance	707 10 O
of	718 2 O
a	721 1 O
lichenoid	723 9 B-Disease
dermatitis	733 10 I-Disease
,	743 1 O
and	745 3 O
zinc	749 4 B-Chemical
acetate	754 7 I-Chemical
permitted	762 9 O
to	772 2 O
continue	775 8 O
the	784 3 O
successful	788 10 O
treatment	799 9 O
of	809 2 O
the	812 3 O
patient	816 7 O
without	824 7 O
side	832 4 O
-	836 1 O
effects	837 7 O
.	844 1 O

In	846 2 O
our	849 3 O
case	853 4 O
the	858 3 O
therapy	862 7 O
with	870 4 O
zinc	875 4 B-Chemical
acetate	880 7 I-Chemical
represented	888 11 O
an	900 2 O
effective	903 9 O
treatment	913 9 O
for	923 3 O
a	927 1 O
Wilson	929 6 B-Disease
'	935 1 I-Disease
s	936 1 I-Disease
disease	938 7 I-Disease
patient	946 7 O
in	954 2 O
which	957 5 O
penicillamine	963 13 B-Chemical
-	976 1 O
related	977 7 O
side	985 4 O
effects	990 7 O
appeared	998 8 O
.	1006 1 O

The	1008 3 O
safety	1012 6 O
of	1019 2 O
the	1022 3 O
zinc	1026 4 B-Chemical
acetate	1031 7 I-Chemical
allowed	1039 7 O
us	1047 2 O
to	1050 2 O
avoid	1053 5 O
other	1059 5 O
potentially	1065 11 O
toxic	1077 5 O
chelating	1083 9 O
drugs	1093 5 O
;	1098 1 O
this	1100 4 O
observation	1105 11 O
is	1117 2 O
in	1120 2 O
line	1123 4 O
with	1128 4 O
the	1133 3 O
growing	1137 7 O
evidence	1145 8 O
on	1154 2 O
the	1157 3 O
efficacy	1161 8 O
of	1170 2 O
the	1173 3 O
drug	1177 4 O
in	1182 2 O
the	1185 3 O
treatment	1189 9 O
of	1199 2 O
Wilson	1202 6 B-Disease
'	1208 1 I-Disease
s	1209 1 I-Disease
disease	1211 7 I-Disease
.	1218 1 O

Since	1220 5 O
most	1226 4 O
of	1231 2 O
Wilson	1234 6 B-Disease
'	1240 1 I-Disease
s	1241 1 I-Disease
disease	1243 7 I-Disease
penicillamine	1251 13 B-Chemical
-	1264 1 O
treated	1265 7 O
patients	1273 8 O
do	1282 2 O
not	1285 3 O
seem	1289 4 O
to	1294 2 O
develop	1297 7 O
this	1305 4 O
skin	1310 4 B-Disease
lesion	1315 6 I-Disease
,	1321 1 O
it	1323 2 O
could	1326 5 O
be	1332 2 O
conceivable	1335 11 O
that	1347 4 O
a	1352 1 O
specific	1354 8 O
genetic	1363 7 O
factor	1371 6 O
is	1378 2 O
involved	1381 8 O
in	1390 2 O
drug	1393 4 O
response	1398 8 O
.	1406 1 O

Further	1408 7 O
studies	1416 7 O
are	1424 3 O
needed	1428 6 O
for	1435 3 O
a	1439 1 O
better	1441 6 O
clarification	1448 13 O
of	1462 2 O
Wilson	1465 6 B-Disease
'	1471 1 I-Disease
s	1472 1 I-Disease
disease	1474 7 I-Disease
therapy	1482 7 O
,	1489 1 O
and	1491 3 O
in	1495 2 O
particular	1498 10 O
to	1509 2 O
differentiate	1512 13 O
specific	1526 8 O
therapies	1535 9 O
for	1545 3 O
different	1549 9 O
Wilson	1559 6 B-Disease
'	1565 1 I-Disease
s	1566 1 I-Disease
disease	1568 7 I-Disease
phenotypes	1576 10 O
.	1586 1 O

A	0 1 O
dramatic	2 8 O
drop	11 4 B-Disease
in	16 2 I-Disease
blood	19 5 I-Disease
pressure	25 8 I-Disease
following	34 9 O
prehospital	44 11 O
GTN	56 3 B-Chemical
administration	60 14 O
.	74 1 O

A	76 1 O
male	78 4 O
in	83 2 O
his	86 3 O
sixties	90 7 O
with	98 4 O
no	103 2 O
history	106 7 O
of	114 2 O
cardiac	117 7 O
chest	125 5 B-Disease
pain	131 4 I-Disease
awoke	136 5 O
with	142 4 O
chest	147 5 B-Disease
pain	153 4 I-Disease
following	158 9 O
an	168 2 O
afternoon	171 9 O
sleep	181 5 O
.	186 1 O

The	188 3 O
patient	192 7 O
did	200 3 O
not	204 3 O
self	208 4 O
medicate	213 8 O
.	221 1 O

The	223 3 O
patient	227 7 O
'	234 1 O
s	235 1 O
observations	237 12 O
were	250 4 O
within	255 6 O
normal	262 6 O
limits	269 6 O
,	275 1 O
he	277 2 O
was	280 3 O
administered	284 12 O
oxygen	297 6 B-Chemical
via	304 3 O
a	308 1 O
face	310 4 O
mask	315 4 O
and	320 3 O
glyceryl	324 8 B-Chemical
trinitrate	333 10 I-Chemical
(	344 1 O
GTN	345 3 B-Chemical
)	348 1 O
.	349 1 O

Several	351 7 O
minutes	359 7 O
after	367 5 O
the	373 3 O
GTN	377 3 B-Chemical
the	381 3 O
patient	385 7 O
experienced	393 11 O
a	405 1 O
sudden	407 6 O
drop	414 4 B-Disease
in	419 2 I-Disease
blood	422 5 I-Disease
pressure	428 8 I-Disease
and	437 3 O
heart	441 5 O
rate	447 4 O
,	451 1 O
this	453 4 O
was	458 3 O
rectified	462 9 O
by	472 2 O
atropine	475 8 B-Chemical
sulphate	484 8 I-Chemical
and	493 3 O
a	497 1 O
fluid	499 5 O
challenge	505 9 O
.	514 1 O

There	516 5 O
was	522 3 O
no	526 2 O
further	529 7 O
deterioration	537 13 O
in	551 2 O
the	554 3 O
patient	558 7 O
'	565 1 O
s	566 1 O
condition	568 9 O
during	578 6 O
transport	585 9 O
to	595 2 O
hospital	598 8 O
.	606 1 O

There	608 5 O
are	614 3 O
very	618 4 O
few	623 3 O
documented	627 10 O
case	638 4 O
like	643 4 O
this	648 4 O
in	653 2 O
the	656 3 O
prehospital	660 11 O
scientific	672 10 O
literature	683 10 O
.	693 1 O

The	695 3 O
cause	699 5 O
appears	705 7 O
to	713 2 O
be	716 2 O
the	719 3 O
Bezold	723 6 O
-	729 1 O
Jarish	730 6 O
reflex	737 6 O
,	743 1 O
stimulation	745 11 O
of	757 2 O
the	760 3 O
ventricular	764 11 O
walls	776 5 O
which	782 5 O
in	788 2 O
turn	791 4 O
decreases	796 9 O
sympathetic	806 11 O
outflow	818 7 O
from	826 4 O
the	831 3 O
vasomotor	835 9 O
centre	845 6 O
.	851 1 O

Prehospital	853 11 O
care	865 4 O
providers	870 9 O
who	880 3 O
are	884 3 O
managing	888 8 O
any	897 3 O
patient	901 7 O
with	909 4 O
a	914 1 O
syncopal	916 8 B-Disease
episode	925 7 I-Disease
that	933 4 O
fails	938 5 O
to	944 2 O
recover	947 7 O
within	955 6 O
a	962 1 O
reasonable	964 10 O
time	975 4 O
frame	980 5 O
should	986 6 O
consider	993 8 O
the	1002 3 O
Bezold	1006 6 O
-	1012 1 O
Jarisch	1013 7 O
reflex	1021 6 O
as	1028 2 O
the	1031 3 O
cause	1035 5 O
and	1041 3 O
manage	1045 6 O
the	1052 3 O
patient	1056 7 O
accordingly	1064 11 O
.	1075 1 O

Acute	0 5 B-Disease
encephalopathy	6 14 I-Disease
and	21 3 O
cerebral	25 8 B-Disease
vasospasm	34 9 I-Disease
after	44 5 O
multiagent	50 10 O
chemotherapy	61 12 O
including	74 9 O
PEG	84 3 B-Chemical
-	87 1 I-Chemical
asparaginase	88 12 I-Chemical
and	101 3 O
intrathecal	105 11 O
cytarabine	117 10 B-Chemical
for	128 3 O
the	132 3 O
treatment	136 9 O
of	146 2 O
acute	149 5 B-Disease
lymphoblastic	155 13 I-Disease
leukemia	169 8 I-Disease
.	177 1 O

A	179 1 O
7	181 1 O
-	182 1 O
year	183 4 O
-	187 1 O
old	188 3 O
girl	192 4 O
with	197 4 O
an	202 2 O
unusual	205 7 O
reaction	213 8 O
to	222 2 O
induction	225 9 O
chemotherapy	235 12 O
for	248 3 O
precursor	252 9 O
B	262 1 O
-	263 1 O
cell	264 4 O
acute	269 5 B-Disease
lymphoblastic	275 13 I-Disease
leukemia	289 8 I-Disease
(	298 1 O
ALL	299 3 B-Disease
)	302 1 O
is	304 2 O
described	307 9 O
.	316 1 O

The	318 3 O
patient	322 7 O
developed	330 9 O
acute	340 5 B-Disease
encephalopathy	346 14 I-Disease
evidenced	361 9 O
by	371 2 O
behavioral	374 10 O
changes	385 7 O
,	392 1 O
aphasia	394 7 B-Disease
,	401 1 O
incontinence	403 12 B-Disease
,	415 1 O
visual	417 6 B-Disease
hallucinations	424 14 I-Disease
,	438 1 O
and	440 3 O
right	444 5 O
-	449 1 O
sided	450 5 O
weakness	456 8 B-Disease
with	465 4 O
diffuse	470 7 O
cerebral	478 8 B-Disease
vasospasm	487 9 I-Disease
on	497 2 O
magnetic	500 8 O
resonance	509 9 O
angiography	519 11 O
after	531 5 O
the	537 3 O
administration	541 14 O
of	556 2 O
intrathecal	559 11 O
cytarabine	571 10 B-Chemical
.	581 1 O

Vincristine	583 11 B-Chemical
,	594 1 O
dexamethasone	596 13 B-Chemical
,	609 1 O
and	611 3 O
polyethylene	615 12 B-Chemical
glycol	628 6 I-Chemical
-	634 1 I-Chemical
asparaginase	635 12 I-Chemical
were	648 4 O
also	653 4 O
administered	658 12 O
before	671 6 O
the	678 3 O
episode	682 7 O
as	690 2 O
part	693 4 O
of	698 2 O
induction	701 9 O
therapy	711 7 O
.	718 1 O

Neurologic	720 10 O
status	731 6 O
returned	738 8 O
to	747 2 O
baseline	750 8 O
within	759 6 O
10	766 2 O
days	769 4 O
of	774 2 O
the	777 3 O
acute	781 5 O
event	787 5 O
,	792 1 O
and	794 3 O
magnetic	798 8 O
resonance	807 9 O
angiography	817 11 O
findings	829 8 O
returned	838 8 O
to	847 2 O
normal	850 6 O
4	857 1 O
months	859 6 O
later	866 5 O
.	871 1 O

Comparison	0 10 O
of	11 2 O
valsartan	14 9 B-Chemical
/	23 1 O
hydrochlorothiazide	24 19 B-Chemical
combination	44 11 O
therapy	56 7 O
at	64 2 O
doses	67 5 O
up	73 2 O
to	76 2 O
320	79 3 O
/	82 1 O
25	83 2 O
mg	86 2 O
versus	89 6 O
monotherapy	96 11 O
:	107 1 O
a	109 1 O
double	111 6 O
-	117 1 O
blind	118 5 O
,	123 1 O
placebo	125 7 O
-	132 1 O
controlled	133 10 O
study	144 5 O
followed	150 8 O
by	159 2 O
long	162 4 O
-	166 1 O
term	167 4 O
combination	172 11 O
therapy	184 7 O
in	192 2 O
hypertensive	195 12 B-Disease
adults	208 6 O
.	214 1 O

BACKGROUND	216 10 O
:	226 1 O
One	228 3 O
third	232 5 O
of	238 2 O
patients	241 8 O
treated	250 7 O
for	258 3 O
hypertension	262 12 B-Disease
attain	275 6 O
adequate	282 8 O
blood	291 5 O
pressure	297 8 O
(	306 1 O
BP	307 2 O
)	309 1 O
control	311 7 O
,	318 1 O
and	320 3 O
multidrug	324 9 O
regimens	334 8 O
are	343 3 O
often	347 5 O
required	353 8 O
.	361 1 O

Given	363 5 O
the	369 3 O
lifelong	373 8 O
nature	382 6 O
of	389 2 O
hypertension	392 12 B-Disease
,	404 1 O
there	406 5 O
is	412 2 O
a	415 1 O
need	417 4 O
to	422 2 O
evaluate	425 8 O
the	434 3 O
long	438 4 O
-	442 1 O
term	443 4 O
efficacy	448 8 O
and	457 3 O
tolerability	461 12 O
of	474 2 O
higher	477 6 O
doses	484 5 O
of	490 2 O
combination	493 11 O
anti	505 4 O
-	509 1 O
hypertensive	510 12 B-Disease
therapies	523 9 O
.	532 1 O

OBJECTIVE	534 9 O
:	543 1 O
This	545 4 O
study	550 5 O
investigated	556 12 O
the	569 3 O
efficacy	573 8 O
and	582 3 O
tolerability	586 12 O
of	599 2 O
valsartan	602 9 B-Chemical
(	612 1 O
VAL	613 3 B-Chemical
)	616 1 O
or	618 2 O
hydrochlorothiazide	621 19 B-Chemical
(	641 1 O
HCTZ	642 4 B-Chemical
)	646 1 O
-	647 1 O
monotherapy	648 11 O
and	660 3 O
higher	664 6 O
-	670 1 O
dose	671 4 O
combinations	676 12 O
in	689 2 O
patients	692 8 O
with	701 4 O
essential	706 9 B-Disease
hypertension	716 12 I-Disease
.	728 1 O

METHODS	730 7 O
:	737 1 O
The	739 3 O
first	743 5 O
part	749 4 O
of	754 2 O
this	757 4 O
study	762 5 O
was	768 3 O
an	772 2 O
8	775 1 O
-	776 1 O
week	777 4 O
,	781 1 O
multicenter	783 11 O
,	794 1 O
randomized	796 10 O
,	806 1 O
double	808 6 O
-	814 1 O
blind	815 5 O
,	820 1 O
placebo	822 7 O
controlled	830 10 O
,	840 1 O
parallel	842 8 O
-	850 1 O
group	851 5 O
trial	857 5 O
.	862 1 O

Patients	864 8 O
with	873 4 O
essential	878 9 B-Disease
hypertension	888 12 I-Disease
(	901 1 O
mean	902 4 O
sitting	907 7 O
diastolic	915 9 O
BP	925 2 O
[	928 1 O
MSDBP	929 5 O
]	934 1 O
,	935 1 O
>	937 1 O
or	939 2 O
=	942 1 O
95	943 2 O
mm	946 2 O
Hg	949 2 O
and	952 3 O
<	956 1 O
110	957 3 O
mm	961 2 O
Hg	964 2 O
)	966 1 O
were	968 4 O
randomized	973 10 O
to	984 2 O
1	987 1 O
of	989 2 O
8	992 1 O
treatment	994 9 O
groups	1004 6 O
:	1010 1 O
VAL	1012 3 B-Chemical
160	1016 3 O
or	1020 2 O
320	1023 3 O
mg	1027 2 O
;	1029 1 O
HCTZ	1031 4 B-Chemical
12	1036 2 O
.	1038 1 O
5	1039 1 O
or	1041 2 O
25	1044 2 O
mg	1047 2 O
;	1049 1 O
VAL	1051 3 B-Chemical
/	1054 1 O
HCTZ	1055 4 B-Chemical
160	1060 3 O
/	1063 1 O
12	1064 2 O
.	1066 1 O
5	1067 1 O
,	1068 1 O
320	1070 3 O
/	1073 1 O
12	1074 2 O
.	1076 1 O
5	1077 1 O
,	1078 1 O
or	1080 2 O
320	1083 3 O
/	1086 1 O
25	1087 2 O
mg	1090 2 O
;	1092 1 O
or	1094 2 O
placebo	1097 7 O
.	1104 1 O

Mean	1106 4 O
changes	1111 7 O
in	1119 2 O
MSDBP	1122 5 O
and	1128 3 O
mean	1132 4 O
sitting	1137 7 O
systolic	1145 8 O
BP	1154 2 O
(	1157 1 O
MSSBP	1158 5 O
)	1163 1 O
were	1165 4 O
analyzed	1170 8 O
at	1179 2 O
the	1182 3 O
8	1186 1 O
-	1187 1 O
week	1188 4 O
core	1193 4 O
study	1198 5 O
end	1204 3 O
point	1208 5 O
.	1213 1 O

VAL	1215 3 B-Chemical
/	1218 1 O
HCTZ	1219 4 B-Chemical
320	1224 3 O
/	1227 1 O
12	1228 2 O
.	1230 1 O
5	1231 1 O
and	1233 3 O
320	1237 3 O
/	1240 1 O
25	1241 2 O
mg	1244 2 O
were	1247 4 O
further	1252 7 O
investigated	1260 12 O
in	1273 2 O
a	1276 1 O
54	1278 2 O
-	1280 1 O
week	1281 4 O
,	1285 1 O
open	1287 4 O
-	1291 1 O
label	1292 5 O
extension	1298 9 O
.	1307 1 O

Response	1309 8 O
was	1318 3 O
defined	1322 7 O
as	1330 2 O
MSDBP	1333 5 O
<	1339 1 O
90	1340 2 O
mm	1343 2 O
Hg	1346 2 O
or	1349 2 O
a	1352 1 O
>	1354 1 O
or	1356 2 O
=	1359 1 O
10	1360 2 O
mm	1363 2 O
Hg	1366 2 O
decrease	1369 8 O
compared	1378 8 O
to	1387 2 O
baseline	1390 8 O
.	1398 1 O

Control	1400 7 O
was	1408 3 O
defined	1412 7 O
as	1420 2 O
MSDBP	1423 5 O
<	1429 1 O
90	1430 2 O
mm	1433 2 O
Hg	1436 2 O
compared	1439 8 O
with	1448 4 O
baseline	1453 8 O
.	1461 1 O

Tolerability	1463 12 O
was	1476 3 O
assessed	1480 8 O
by	1489 2 O
monitoring	1492 10 O
adverse	1503 7 O
events	1511 6 O
at	1518 2 O
randomization	1521 13 O
and	1535 3 O
all	1539 3 O
subsequent	1543 10 O
study	1554 5 O
visits	1560 6 O
and	1567 3 O
regular	1571 7 O
evaluation	1579 10 O
of	1590 2 O
hematology	1593 10 O
and	1604 3 O
blood	1608 5 O
chemistry	1614 9 O
.	1623 1 O

RESULTS	1625 7 O
:	1632 1 O
A	1634 1 O
total	1636 5 O
of	1642 2 O
1346	1645 4 O
patients	1650 8 O
were	1659 4 O
randomized	1664 10 O
into	1675 4 O
the	1680 3 O
8	1684 1 O
-	1685 1 O
week	1686 4 O
core	1691 4 O
study	1696 5 O
(	1702 1 O
734	1703 3 O
men	1707 3 O
,	1710 1 O
612	1712 3 O
women	1716 5 O
;	1721 1 O
924	1723 3 O
white	1727 5 O
,	1732 1 O
291	1734 3 O
black	1738 5 O
,	1743 1 O
23	1745 2 O
Asian	1748 5 O
,	1753 1 O
108	1755 3 O
other	1759 5 O
;	1764 1 O
mean	1766 4 O
age	1771 3 O
,	1774 1 O
52	1776 2 O
.	1778 1 O
7	1779 1 O
years	1781 5 O
;	1786 1 O
mean	1788 4 O
weight	1793 6 O
,	1799 1 O
92	1801 2 O
.	1803 1 O
6	1804 1 O
kg	1806 2 O
)	1808 1 O
.	1809 1 O

All	1811 3 O
active	1815 6 O
treatments	1822 10 O
were	1833 4 O
associated	1838 10 O
with	1849 4 O
significantly	1854 13 O
reduced	1868 7 O
MSSBP	1876 5 O
and	1882 3 O
MSDBP	1886 5 O
during	1892 6 O
the	1899 3 O
core	1903 4 O
8	1908 1 O
-	1909 1 O
week	1910 4 O
study	1915 5 O
,	1920 1 O
with	1922 4 O
each	1927 4 O
monotherapy	1932 11 O
significantly	1944 13 O
contributing	1958 12 O
to	1971 2 O
the	1974 3 O
overall	1978 7 O
effect	1986 6 O
of	1993 2 O
combination	1996 11 O
therapy	2008 7 O
(	2016 1 O
VAL	2017 3 B-Chemical
and	2021 3 O
HCTZ	2025 4 B-Chemical
,	2029 1 O
P	2031 1 O
<	2033 1 O
0	2035 1 O
.	2036 1 O
001	2037 3 O
)	2040 1 O
.	2041 1 O

Each	2043 4 O
combination	2048 11 O
was	2060 3 O
associated	2064 10 O
with	2075 4 O
significantly	2080 13 O
greater	2094 7 O
reductions	2102 10 O
in	2113 2 O
MSSBP	2116 5 O
and	2122 3 O
MSDBP	2126 5 O
compared	2132 8 O
with	2141 4 O
the	2146 3 O
monotherapies	2150 13 O
and	2164 3 O
placebo	2168 7 O
(	2176 1 O
all	2177 3 O
,	2180 1 O
P	2182 1 O
<	2184 1 O
0	2186 1 O
.	2187 1 O
001	2188 3 O
)	2191 1 O
.	2192 1 O

The	2194 3 O
mean	2198 4 O
reduction	2203 9 O
in	2213 2 O
MSSBP	2216 5 O
/	2221 1 O
MSDBP	2222 5 O
with	2228 4 O
VAL	2233 3 B-Chemical
/	2236 1 O
HCTZ	2237 4 B-Chemical
320	2242 3 O
/	2245 1 O
25	2246 2 O
mg	2249 2 O
was	2252 3 O
24	2256 2 O
.	2258 1 O
7	2259 1 O
/	2260 1 O
16	2261 2 O
.	2263 1 O
6	2264 1 O
mm	2266 2 O
Hg	2269 2 O
,	2271 1 O
compared	2273 8 O
with	2282 4 O
5	2287 1 O
.	2288 1 O
9	2289 1 O
/	2290 1 O
7	2291 1 O
.	2292 1 O
0	2293 1 O
mm	2295 2 O
Hg	2298 2 O
with	2301 4 O
placebo	2306 7 O
.	2313 1 O

The	2315 3 O
reduction	2319 9 O
in	2329 2 O
MSSBP	2332 5 O
was	2338 3 O
significantly	2342 13 O
greater	2356 7 O
with	2364 4 O
VAL	2369 3 B-Chemical
/	2372 1 O
HCTZ	2373 4 B-Chemical
320	2378 3 O
/	2381 1 O
25	2382 2 O
mg	2385 2 O
compared	2388 8 O
with	2397 4 O
VAL	2402 3 B-Chemical
/	2405 1 O
HCTZ	2406 4 B-Chemical
160	2411 3 O
/	2414 1 O
12	2415 2 O
.	2417 1 O
5	2418 1 O
mg	2420 2 O
(	2423 1 O
P	2424 1 O
<	2426 1 O
0	2428 1 O
.	2429 1 O
002	2430 3 O
)	2433 1 O
.	2434 1 O

Rates	2436 5 O
of	2442 2 O
response	2445 8 O
and	2454 3 O
BP	2458 2 O
control	2461 7 O
were	2469 4 O
significantly	2474 13 O
higher	2488 6 O
in	2495 2 O
the	2498 3 O
groups	2502 6 O
that	2509 4 O
received	2514 8 O
combination	2523 11 O
treatment	2535 9 O
compared	2545 8 O
with	2554 4 O
those	2559 5 O
that	2565 4 O
received	2570 8 O
monotherapy	2579 11 O
.	2590 1 O

The	2592 3 O
incidence	2596 9 O
of	2606 2 O
hypokalemia	2609 11 B-Disease
was	2621 3 O
lower	2625 5 O
with	2631 4 O
VAL	2636 3 B-Chemical
/	2639 1 O
HCTZ	2640 4 B-Chemical
combinations	2645 12 O
(	2658 1 O
1	2659 1 O
.	2660 1 O
8	2661 1 O
%	2662 1 O
-	2663 1 O
6	2664 1 O
.	2665 1 O
1	2666 1 O
%	2667 1 O
)	2668 1 O
than	2670 4 O
with	2675 4 O
HCTZ	2680 4 B-Chemical
monotherapies	2685 13 O
(	2699 1 O
7	2700 1 O
.	2701 1 O
1	2702 1 O
%	2703 1 O
-	2704 1 O
13	2705 2 O
.	2707 1 O
3	2708 1 O
%	2709 1 O
)	2710 1 O
.	2711 1 O

The	2713 3 O
majority	2717 8 O
of	2726 2 O
adverse	2729 7 O
events	2737 6 O
in	2744 2 O
the	2747 3 O
core	2751 4 O
study	2756 5 O
were	2762 4 O
of	2767 2 O
mild	2770 4 O
to	2775 2 O
moderate	2778 8 O
severity	2787 8 O
.	2795 1 O

The	2797 3 O
efficacy	2801 8 O
and	2810 3 O
tolerability	2814 12 O
of	2827 2 O
VAL	2830 3 B-Chemical
/	2833 1 O
HCTZ	2834 4 B-Chemical
combinations	2839 12 O
were	2852 4 O
maintained	2857 10 O
during	2868 6 O
the	2875 3 O
extension	2879 9 O
(	2889 1 O
797	2890 3 O
patients	2894 8 O
)	2902 1 O
.	2903 1 O

CONCLUSIONS	2905 11 O
:	2916 1 O
In	2918 2 O
this	2921 4 O
study	2926 5 O
population	2932 10 O
,	2942 1 O
combination	2944 11 O
therapies	2956 9 O
with	2966 4 O
VAL	2971 3 B-Chemical
/	2974 1 O
HCTZ	2975 4 B-Chemical
were	2980 4 O
associated	2985 10 O
with	2996 4 O
significantly	3001 13 O
greater	3015 7 O
BP	3023 2 O
reductions	3026 10 O
compared	3037 8 O
with	3046 4 O
either	3051 6 O
monotherapy	3058 11 O
,	3069 1 O
were	3071 4 O
well	3076 4 O
tolerated	3081 9 O
,	3090 1 O
and	3092 3 O
were	3096 4 O
associated	3101 10 O
with	3112 4 O
less	3117 4 O
hypokalemia	3122 11 B-Disease
than	3134 4 O
HCTZ	3139 4 B-Chemical
alone	3144 5 O
.	3149 1 O

Succimer	0 8 B-Chemical
chelation	9 9 O
improves	19 8 O
learning	28 8 O
,	36 1 O
attention	38 9 O
,	47 1 O
and	49 3 O
arousal	53 7 O
regulation	61 10 O
in	72 2 O
lead	75 4 B-Chemical
-	79 1 O
exposed	80 7 O
rats	88 4 O
but	93 3 O
produces	97 8 O
lasting	106 7 O
cognitive	114 9 B-Disease
impairment	124 10 I-Disease
in	135 2 O
the	138 3 O
absence	142 7 O
of	150 2 O
lead	153 4 B-Chemical
exposure	158 8 O
.	166 1 O

BACKGROUND	168 10 O
:	178 1 O
There	180 5 O
is	186 2 O
growing	189 7 O
pressure	197 8 O
for	206 3 O
clinicians	210 10 O
to	221 2 O
prescribe	224 9 O
chelation	234 9 O
therapy	244 7 O
at	252 2 O
only	255 4 O
slightly	260 8 O
elevated	269 8 O
blood	278 5 O
lead	284 4 B-Chemical
levels	289 6 O
.	295 1 O

However	297 7 O
,	304 1 O
very	306 4 O
few	311 3 O
studies	315 7 O
have	323 4 O
evaluated	328 9 O
whether	338 7 O
chelation	346 9 O
improves	356 8 O
cognitive	365 9 O
outcomes	375 8 O
in	384 2 O
Pb	387 2 B-Chemical
-	389 1 O
exposed	390 7 O
children	398 8 O
,	406 1 O
or	408 2 O
whether	411 7 O
these	419 5 O
agents	425 6 O
have	432 4 O
adverse	437 7 O
effects	445 7 O
that	453 4 O
may	458 3 O
affect	462 6 O
brain	469 5 O
development	475 11 O
in	487 2 O
the	490 3 O
absence	494 7 O
of	502 2 O
Pb	505 2 B-Chemical
exposure	508 8 O
.	516 1 O

OBJECTIVES	518 10 O
:	528 1 O
The	530 3 O
present	534 7 O
study	542 5 O
was	548 3 O
designed	552 8 O
to	561 2 O
answer	564 6 O
these	571 5 O
questions	577 9 O
,	586 1 O
using	588 5 O
a	594 1 O
rodent	596 6 O
model	603 5 O
of	609 2 O
early	612 5 O
childhood	618 9 O
Pb	628 2 B-Chemical
exposure	631 8 O
and	640 3 O
treatment	644 9 O
with	654 4 O
succimer	659 8 B-Chemical
,	667 1 O
a	669 1 O
widely	671 6 O
used	678 4 O
chelating	683 9 O
agent	693 5 O
for	699 3 O
the	703 3 O
treatment	707 9 O
of	717 2 O
Pb	720 2 B-Disease
poisoning	723 9 I-Disease
.	732 1 O

RESULTS	734 7 O
:	741 1 O
Pb	743 2 B-Chemical
exposure	746 8 O
produced	755 8 O
lasting	764 7 O
impairments	772 11 B-Disease
in	784 2 I-Disease
learning	787 8 I-Disease
,	795 1 I-Disease
attention	797 9 I-Disease
,	806 1 I-Disease
inhibitory	808 10 I-Disease
control	819 7 I-Disease
,	826 1 I-Disease
and	828 3 I-Disease
arousal	832 7 I-Disease
regulation	840 10 I-Disease
,	850 1 O
paralleling	852 11 O
the	864 3 O
areas	868 5 O
of	874 2 O
dysfunction	877 11 O
seen	889 4 O
in	894 2 O
Pb	897 2 B-Chemical
-	899 1 O
exposed	900 7 O
children	908 8 O
.	916 1 O

Succimer	918 8 B-Chemical
treatment	927 9 O
of	937 2 O
the	940 3 O
Pb	944 2 B-Chemical
-	946 1 O
exposed	947 7 O
rats	955 4 O
significantly	960 13 O
improved	974 8 O
learning	983 8 O
,	991 1 O
attention	993 9 O
,	1002 1 O
and	1004 3 O
arousal	1008 7 O
regulation	1016 10 O
,	1026 1 O
although	1028 8 O
the	1037 3 O
efficacy	1041 8 O
of	1050 2 O
the	1053 3 O
treatment	1057 9 O
varied	1067 6 O
as	1074 2 O
a	1077 1 O
function	1079 8 O
of	1088 2 O
the	1091 3 O
Pb	1095 2 B-Chemical
exposure	1098 8 O
level	1107 5 O
and	1113 3 O
the	1117 3 O
specific	1121 8 O
functional	1130 10 O
deficit	1141 7 O
.	1148 1 O

In	1150 2 O
contrast	1153 8 O
,	1161 1 O
succimer	1163 8 B-Chemical
treatment	1172 9 O
of	1182 2 O
rats	1185 4 O
not	1190 3 O
previously	1194 10 O
exposed	1205 7 O
to	1213 2 O
Pb	1216 2 B-Chemical
produced	1219 8 O
lasting	1228 7 O
and	1236 3 O
pervasive	1240 9 O
cognitive	1250 9 B-Disease
and	1260 3 I-Disease
affective	1264 9 I-Disease
dysfunction	1274 11 I-Disease
comparable	1286 10 O
in	1297 2 O
magnitude	1300 9 O
to	1310 2 O
that	1313 4 O
produced	1318 8 O
by	1327 2 O
the	1330 3 O
higher	1334 6 O
Pb	1341 2 B-Chemical
exposure	1344 8 O
regimen	1353 7 O
.	1360 1 O

CONCLUSIONS	1362 11 O
:	1373 1 O
These	1375 5 O
are	1381 3 O
the	1385 3 O
first	1389 5 O
data	1395 4 O
,	1399 1 O
to	1401 2 O
our	1404 3 O
knowledge	1408 9 O
,	1417 1 O
to	1419 2 O
show	1422 4 O
that	1427 4 O
treatment	1432 9 O
with	1442 4 O
any	1447 3 O
chelating	1451 9 O
agent	1461 5 O
can	1467 3 O
alleviate	1471 9 O
cognitive	1481 9 B-Disease
deficits	1491 8 I-Disease
due	1500 3 O
to	1504 2 O
Pb	1507 2 B-Chemical
exposure	1510 8 O
.	1518 1 O

These	1520 5 O
findings	1526 8 O
suggest	1535 7 O
that	1543 4 O
it	1548 2 O
may	1551 3 O
be	1555 2 O
possible	1558 8 O
to	1567 2 O
identify	1570 8 O
a	1579 1 O
succimer	1581 8 B-Chemical
treatment	1590 9 O
protocol	1600 8 O
that	1609 4 O
improves	1614 8 O
cognitive	1623 9 O
outcomes	1633 8 O
in	1642 2 O
Pb	1645 2 B-Chemical
-	1647 1 O
exposed	1648 7 O
children	1656 8 O
.	1664 1 O

However	1666 7 O
,	1673 1 O
they	1675 4 O
also	1680 4 O
suggest	1685 7 O
that	1693 4 O
succimer	1698 8 B-Chemical
treatment	1707 9 O
should	1717 6 O
be	1724 2 O
strongly	1727 8 O
discouraged	1736 11 O
for	1748 3 O
children	1752 8 O
who	1761 3 O
do	1765 2 O
not	1768 3 O
have	1772 4 O
elevated	1777 8 O
tissue	1786 6 O
levels	1793 6 O
of	1800 2 O
Pb	1803 2 B-Chemical
or	1806 2 O
other	1809 5 O
heavy	1815 5 O
metals	1821 6 O
.	1827 1 O

Caffeine	0 8 B-Chemical
challenge	9 9 O
test	19 4 O
in	24 2 O
panic	27 5 B-Disease
disorder	33 8 I-Disease
and	42 3 O
depression	46 10 B-Disease
with	57 4 O
panic	62 5 B-Disease
attacks	68 7 I-Disease
.	75 1 O

Our	77 3 O
aim	81 3 O
was	85 3 O
to	89 2 O
observe	92 7 O
if	100 2 O
patients	103 8 O
with	112 4 O
panic	117 5 B-Disease
disorder	123 8 I-Disease
(	132 1 O
PD	133 2 B-Disease
)	135 1 O
and	137 3 O
patients	141 8 O
with	150 4 O
major	155 5 B-Disease
depression	161 10 I-Disease
with	172 4 O
panic	177 5 B-Disease
attacks	183 7 I-Disease
(	191 1 O
MDP	192 3 B-Disease
)	195 1 O
(	197 1 O
Diagnostic	198 10 O
and	209 3 O
Statistical	213 11 O
Manual	225 6 O
of	232 2 O
Mental	235 6 B-Disease
Disorders	242 9 I-Disease
,	251 1 O
Fourth	253 6 O
Edition	260 7 O
criteria	268 8 O
)	276 1 O
respond	278 7 O
in	286 2 O
a	289 1 O
similar	291 7 O
way	299 3 O
to	303 2 O
the	306 3 O
induction	310 9 O
of	320 2 O
panic	323 5 B-Disease
attacks	329 7 I-Disease
by	337 2 O
an	340 2 O
oral	343 4 O
caffeine	348 8 B-Chemical
challenge	357 9 O
test	367 4 O
.	371 1 O

We	373 2 O
randomly	376 8 O
selected	385 8 O
29	394 2 O
patients	397 8 O
with	406 4 O
PD	411 2 B-Disease
,	413 1 O
27	415 2 O
with	418 4 O
MDP	423 3 B-Disease
,	426 1 O
25	428 2 O
with	431 4 O
major	436 5 B-Disease
depression	442 10 I-Disease
without	453 7 O
panic	461 5 B-Disease
attacks	467 7 I-Disease
(	475 1 O
MD	476 2 B-Disease
)	478 1 O
,	479 1 O
and	481 3 O
28	485 2 O
healthy	488 7 O
volunteers	496 10 O
.	506 1 O

The	508 3 O
patients	512 8 O
had	521 3 O
no	525 2 O
psychotropic	528 12 O
drug	541 4 O
for	546 3 O
at	550 2 O
least	553 5 O
a	559 1 O
4	561 1 O
-	562 1 O
week	563 4 O
period	568 6 O
.	574 1 O

In	576 2 O
a	579 1 O
randomized	581 10 O
double	592 6 O
-	598 1 O
blind	599 5 O
experiment	605 10 O
performed	616 9 O
in	626 2 O
2	629 1 O
occasions	631 9 O
7	641 1 O
days	643 4 O
apart	648 5 O
,	653 1 O
480	655 3 O
mg	659 2 O
caffeine	662 8 B-Chemical
and	671 3 O
a	675 1 O
caffeine	677 8 B-Chemical
-	685 1 O
free	686 4 O
(	691 1 O
placebo	692 7 O
)	699 1 O
solution	701 8 O
were	710 4 O
administered	715 12 O
in	728 2 O
a	731 1 O
coffee	733 6 O
form	740 4 O
and	745 3 O
anxiety	749 7 B-Disease
scales	757 6 O
were	764 4 O
applied	769 7 O
before	777 6 O
and	784 3 O
after	788 5 O
each	794 4 O
test	799 4 O
.	803 1 O

A	805 1 O
total	807 5 O
of	813 2 O
58	816 2 O
.	818 1 O
6	819 1 O
%	820 1 O
(	822 1 O
n	823 1 O
=	825 1 O
17	827 2 O
)	829 1 O
of	831 2 O
patients	834 8 O
with	843 4 O
PD	848 2 B-Disease
,	850 1 O
44	852 2 O
.	854 1 O
4	855 1 O
%	856 1 O
(	858 1 O
n	859 1 O
=	861 1 O
12	863 2 O
)	865 1 O
of	867 2 O
patients	870 8 O
with	879 4 O
MDP	884 3 B-Disease
,	887 1 O
12	889 2 O
.	891 1 O
0	892 1 O
%	893 1 O
(	895 1 O
n	896 1 O
=	898 1 O
3	900 1 O
)	901 1 O
of	903 2 O
patients	906 8 O
with	915 4 O
MD	920 2 B-Disease
,	922 1 O
and	924 3 O
7	928 1 O
.	929 1 O
1	930 1 O
%	931 1 O
(	933 1 O
n	934 1 O
=	935 1 O
2	937 1 O
)	938 1 O
of	940 2 O
control	943 7 O
subjects	951 8 O
had	960 3 O
a	964 1 O
panic	966 5 B-Disease
attack	972 6 I-Disease
after	979 5 O
the	985 3 O
480	989 3 O
-	992 1 O
mg	993 2 O
caffeine	996 8 B-Chemical
challenge	1005 9 O
test	1015 4 O
(	1020 1 O
chi	1021 3 O
(	1024 1 O
2	1025 1 O
)	1026 1 O
(	1027 1 O
3	1028 1 O
)	1029 1 O
=	1031 1 O
16	1033 2 O
.	1035 1 O
22	1036 2 O
,	1038 1 O
P	1040 1 O
=	1042 1 O
.	1044 1 O
001	1045 3 O
)	1048 1 O
.	1049 1 O

The	1051 3 O
patients	1055 8 O
with	1064 4 O
PD	1069 2 B-Disease
and	1072 3 O
MDP	1076 3 B-Disease
were	1080 4 O
more	1085 4 O
sensitive	1090 9 O
to	1100 2 O
caffeine	1103 8 B-Chemical
than	1112 4 O
were	1117 4 O
patients	1122 8 O
with	1131 4 O
MD	1136 2 B-Disease
and	1139 3 O
healthy	1143 7 O
volunteers	1151 10 O
.	1161 1 O

No	1163 2 O
panic	1166 5 B-Disease
attack	1172 6 I-Disease
was	1179 3 O
observed	1183 8 O
after	1192 5 O
the	1198 3 O
caffeine	1202 8 B-Chemical
-	1210 1 O
free	1211 4 O
solution	1216 8 O
intake	1225 6 O
.	1231 1 O

The	1233 3 O
patients	1237 8 O
with	1246 4 O
MD	1251 2 B-Disease
had	1254 3 O
a	1258 1 O
lower	1260 5 O
heart	1266 5 O
rate	1272 4 O
response	1277 8 O
to	1286 2 O
the	1289 3 O
test	1293 4 O
than	1298 4 O
all	1303 3 O
the	1307 3 O
other	1311 5 O
groups	1317 6 O
(	1324 1 O
2	1325 1 O
-	1326 1 O
way	1327 3 O
analysis	1331 8 O
of	1340 2 O
variance	1343 8 O
,	1351 1 O
group	1353 5 O
by	1359 2 O
time	1362 4 O
interaction	1367 11 O
with	1379 4 O
Greenhouse	1384 10 O
-	1394 1 O
Geisser	1395 7 O
correction	1403 10 O
:	1413 1 O
F	1415 1 O
(	1416 1 O
3	1417 1 O
,	1418 1 O
762	1419 3 O
)	1422 1 O
=	1424 1 O
2	1426 1 O
.	1427 1 O
85	1428 2 O
,	1430 1 O
P	1432 1 O
=	1434 1 O
.	1436 1 O
026	1437 3 O
)	1440 1 O
.	1441 1 O

Our	1443 3 O
data	1447 4 O
suggest	1452 7 O
that	1460 4 O
there	1465 5 O
is	1471 2 O
an	1474 2 O
association	1477 11 O
between	1489 7 O
panic	1497 5 B-Disease
attacks	1503 7 I-Disease
,	1510 1 O
no	1512 2 O
matter	1515 6 O
if	1522 2 O
associated	1525 10 O
with	1536 4 O
PD	1541 2 B-Disease
or	1544 2 O
MDP	1547 3 B-Disease
,	1550 1 O
and	1552 3 O
hyperreactivity	1556 15 O
to	1572 2 O
an	1575 2 O
oral	1578 4 O
caffeine	1583 8 B-Chemical
challenge	1592 9 O
test	1602 4 O
.	1606 1 O

Mitral	0 6 O
annuloplasty	7 12 O
as	20 2 O
a	23 1 O
ventricular	25 11 O
restoration	37 11 O
method	49 6 O
for	56 3 O
the	60 3 O
failing	64 7 B-Disease
left	72 4 I-Disease
ventricle	77 9 I-Disease
:	86 1 O
a	88 1 O
pilot	90 5 O
study	96 5 O
.	101 1 O

BACKGROUND	103 10 O
AND	114 3 O
AIM	118 3 O
OF	122 2 O
THE	125 3 O
STUDY	129 5 O
:	134 1 O
Undersized	136 10 O
mitral	147 6 O
annuloplasty	154 12 O
(	167 1 O
MAP	168 3 O
)	171 1 O
is	173 2 O
effective	176 9 O
in	186 2 O
patients	189 8 O
with	198 4 O
dilated	203 7 B-Disease
cardiomyopathy	211 14 I-Disease
and	226 3 O
functional	230 10 O
mitral	241 6 B-Disease
regurgitation	248 13 I-Disease
(	262 1 O
MR	263 2 B-Disease
)	265 1 O
since	267 5 O
,	272 1 O
as	274 2 O
well	277 4 O
as	282 2 O
addressing	285 10 O
the	296 3 O
MR	300 2 B-Disease
,	302 1 O
the	304 3 O
MAP	308 3 O
may	312 3 O
also	316 4 O
reshape	321 7 O
the	329 3 O
dilated	333 7 O
left	341 4 O
ventricular	346 11 O
(	358 1 O
LV	359 2 O
)	361 1 O
base	363 4 O
.	367 1 O

However	369 7 O
,	376 1 O
the	378 3 O
direct	382 6 O
benefits	389 8 O
of	398 2 O
this	401 4 O
possible	406 8 O
reshaping	415 9 O
on	425 2 O
LV	428 2 O
function	431 8 O
in	440 2 O
the	443 3 O
absence	447 7 O
of	455 2 O
underlying	458 10 O
MR	469 2 B-Disease
remain	472 6 O
incompletely	479 12 O
understood	492 10 O
.	502 1 O

The	504 3 O
study	508 5 O
aim	514 3 O
was	518 3 O
to	522 2 O
identify	525 8 O
these	534 5 O
benefits	540 8 O
in	549 2 O
a	552 1 O
canine	554 6 O
model	561 5 O
of	567 2 O
acute	570 5 O
heart	576 5 B-Disease
failure	582 7 I-Disease
.	589 1 O

METHODS	591 7 O
:	598 1 O
Six	600 3 O
dogs	604 4 O
underwent	609 9 O
MAP	619 3 O
with	623 4 O
a	628 1 O
prosthetic	630 10 O
band	641 4 O
on	646 2 O
the	649 3 O
posterior	653 9 O
mitral	663 6 O
annulus	670 7 O
,	677 1 O
using	679 5 O
four	685 4 O
mattress	690 8 O
sutures	699 7 O
.	706 1 O

The	708 3 O
sutures	712 7 O
were	720 4 O
passed	725 6 O
individually	732 12 O
through	745 7 O
four	753 4 O
tourniquets	758 11 O
and	770 3 O
exteriorized	774 12 O
untied	787 6 O
via	794 3 O
the	798 3 O
left	802 4 O
atriotomy	807 9 O
.	816 1 O

Sonomicrometry	818 14 O
crystals	833 8 O
were	842 4 O
implanted	847 9 O
around	857 6 O
the	864 3 O
mitral	868 6 O
annulus	875 7 O
and	883 3 O
left	887 4 O
ventricle	892 9 O
to	902 2 O
measure	905 7 O
geometry	913 8 O
and	922 3 O
regional	926 8 O
function	935 8 O
.	943 1 O

Acute	945 5 O
heart	951 5 B-Disease
failure	957 7 I-Disease
was	965 3 O
induced	969 7 O
by	977 2 O
propranolol	980 11 B-Chemical
and	992 3 O
volume	996 6 O
loading	1003 7 O
after	1011 5 O
weaning	1017 7 O
from	1025 4 O
cardiopulmonary	1030 15 O
bypass	1046 6 O
;	1052 1 O
an	1054 2 O
absence	1057 7 O
of	1065 2 O
MR	1068 2 B-Disease
was	1071 3 O
confirmed	1075 9 O
by	1085 2 O
echocardiography	1088 16 O
.	1104 1 O

MAP	1106 3 O
was	1110 3 O
accomplished	1114 12 O
by	1127 2 O
cinching	1130 8 O
the	1139 3 O
tourniquets	1143 11 O
.	1154 1 O

Data	1156 4 O
were	1161 4 O
acquired	1166 8 O
at	1175 2 O
baseline	1178 8 O
,	1186 1 O
after	1188 5 O
induction	1194 9 O
of	1204 2 O
acute	1207 5 O
heart	1213 5 B-Disease
failure	1219 7 I-Disease
,	1226 1 O
and	1228 3 O
after	1232 5 O
MAP	1238 3 O
.	1241 1 O

RESULTS	1243 7 O
:	1250 1 O
MAP	1252 3 O
decreased	1256 9 O
mitral	1266 6 O
annular	1273 7 O
dimensions	1281 10 O
in	1292 2 O
both	1295 4 O
commissure	1300 10 O
-	1310 1 O
commissure	1311 10 O
and	1322 3 O
septal	1326 6 O
-	1332 1 O
lateral	1333 7 O
directions	1341 10 O
.	1351 1 O

Concomitantly	1353 13 O
,	1366 1 O
the	1368 3 O
diastolic	1372 9 O
diameter	1382 8 O
of	1391 2 O
the	1394 3 O
LV	1398 2 O
base	1401 4 O
and	1406 3 O
LV	1410 2 O
sphericity	1413 10 O
decreased	1424 9 O
(	1434 1 O
i	1435 1 O
.	1436 1 O
e	1437 1 O
.	1438 1 O
,	1439 1 O
improved	1441 8 O
)	1449 1 O
from	1451 4 O
37	1456 2 O
.	1458 1 O
4	1459 1 O
+	1461 1 O
/	1462 1 O
-	1463 1 O
9	1465 1 O
.	1466 1 O
3	1467 1 O
to	1469 2 O
35	1472 2 O
.	1474 1 O
9	1475 1 O
+	1477 1 O
/	1478 1 O
-	1479 1 O
10	1481 2 O
mm	1484 2 O
(	1487 1 O
p	1488 1 O
=	1490 1 O
0	1492 1 O
.	1493 1 O
063	1494 3 O
)	1497 1 O
,	1498 1 O
and	1500 3 O
from	1504 4 O
67	1509 2 O
.	1511 1 O
9	1512 1 O
+	1514 1 O
/	1515 1 O
-	1516 1 O
18	1518 2 O
.	1520 1 O
6	1521 1 O
%	1522 1 O
to	1524 2 O
65	1527 2 O
.	1529 1 O
3	1530 1 O
+	1532 1 O
/	1533 1 O
-	1534 1 O
18	1536 2 O
.	1538 1 O
9	1539 1 O
%	1540 1 O
(	1542 1 O
p	1543 1 O
=	1545 1 O
0	1547 1 O
.	1548 1 O
016	1549 3 O
)	1552 1 O
,	1553 1 O
respectively	1555 12 O
.	1567 1 O

Decreases	1569 9 O
were	1579 4 O
evident	1584 7 O
in	1592 2 O
both	1595 4 O
LV	1600 2 O
end	1603 3 O
-	1606 1 O
diastolic	1607 9 O
pressure	1617 8 O
(	1626 1 O
from	1627 4 O
17	1632 2 O
+	1635 1 O
/	1636 1 O
-	1637 1 O
7	1639 1 O
to	1641 2 O
15	1644 2 O
+	1647 1 O
/	1648 1 O
-	1649 1 O
6	1651 1 O
mmHg	1653 4 O
,	1657 1 O
p	1659 1 O
=	1661 1 O
0	1663 1 O
.	1664 1 O
0480	1665 4 O
and	1670 3 O
Tau	1674 3 O
(	1678 1 O
from	1679 4 O
48	1684 2 O
+	1687 1 O
/	1688 1 O
-	1689 1 O
8	1691 1 O
to	1693 2 O
45	1696 2 O
+	1699 1 O
/	1700 1 O
-	1701 1 O
8	1703 1 O
ms	1705 2 O
,	1707 1 O
p	1709 1 O
<	1711 1 O
0	1712 1 O
.	1713 1 O
01	1714 2 O
)	1716 1 O
,	1717 1 O
while	1719 5 O
fractional	1725 10 O
shortening	1736 10 O
at	1747 2 O
the	1750 3 O
LV	1754 2 O
base	1757 4 O
increased	1762 9 O
from	1772 4 O
7	1777 1 O
.	1778 1 O
7	1779 1 O
+	1781 1 O
/	1782 1 O
-	1783 1 O
4	1785 1 O
.	1786 1 O
5	1787 1 O
%	1788 1 O
to	1790 2 O
9	1793 1 O
.	1794 1 O
4	1795 1 O
+	1797 1 O
/	1798 1 O
-	1799 1 O
4	1801 1 O
.	1802 1 O
5	1803 1 O
%	1804 1 O
(	1806 1 O
p	1807 1 O
=	1809 1 O
0	1811 1 O
.	1812 1 O
045	1813 3 O
)	1816 1 O
.	1817 1 O

After	1819 5 O
MAP	1825 3 O
,	1828 1 O
increases	1830 9 O
were	1840 4 O
identified	1845 10 O
in	1856 2 O
both	1859 4 O
cardiac	1864 7 O
output	1872 6 O
(	1879 1 O
from	1880 4 O
1	1885 1 O
.	1886 1 O
54	1887 2 O
+	1890 1 O
/	1891 1 O
-	1892 1 O
0	1894 1 O
.	1895 1 O
57	1896 2 O
to	1899 2 O
1	1902 1 O
.	1903 1 O
65	1904 2 O
+	1907 1 O
/	1908 1 O
-	1909 1 O
0	1911 1 O
.	1912 1 O
57	1913 2 O
1	1916 1 O
/	1917 1 O
min	1918 3 O
)	1921 1 O
and	1923 3 O
Emax	1927 4 O
(	1932 1 O
from	1933 4 O
1	1938 1 O
.	1939 1 O
86	1940 2 O
+	1943 1 O
/	1944 1 O
-	1945 1 O
0	1947 1 O
.	1948 1 O
9	1949 1 O
to	1951 2 O
2	1954 1 O
.	1955 1 O
41	1956 2 O
+	1959 1 O
/	1960 1 O
-	1961 1 O
1	1963 1 O
.	1964 1 O
31	1965 2 O
mmHg	1968 4 O
/	1972 1 O
ml	1973 2 O
)	1975 1 O
.	1976 1 O

CONCLUSION	1978 10 O
:	1988 1 O
The	1990 3 O
data	1994 4 O
acquired	1999 8 O
suggest	2008 7 O
that	2016 4 O
isolated	2021 8 O
MAP	2030 3 O
may	2034 3 O
have	2038 4 O
certain	2043 7 O
benefits	2051 8 O
on	2060 2 O
LV	2063 2 O
dimension	2066 9 O
/	2075 1 O
function	2076 8 O
in	2085 2 O
acute	2088 5 O
heart	2094 5 B-Disease
failure	2100 7 I-Disease
,	2107 1 O
even	2109 4 O
in	2114 2 O
the	2117 3 O
absence	2121 7 O
of	2129 2 O
MR	2132 2 B-Disease
.	2134 1 O

However	2136 7 O
,	2143 1 O
further	2145 7 O
investigations	2153 14 O
are	2168 3 O
warranted	2172 9 O
in	2182 2 O
a	2185 1 O
model	2187 5 O
of	2193 2 O
chronic	2196 7 O
heart	2204 5 B-Disease
failure	2210 7 I-Disease
.	2217 1 O

Piperacillin	0 12 B-Chemical
/	12 1 I-Chemical
tazobactam	13 10 I-Chemical
-	23 1 O
induced	24 7 O
seizure	32 7 B-Disease
rapidly	40 7 O
reversed	48 8 O
by	57 2 O
high	60 4 O
flux	65 4 O
hemodialysis	70 12 O
in	83 2 O
a	86 1 O
patient	88 7 O
on	96 2 O
peritoneal	99 10 O
dialysis	110 8 O
.	118 1 O

Despite	120 7 O
popular	128 7 O
use	136 3 O
of	140 2 O
piperacillin	143 12 B-Chemical
,	155 1 O
the	157 3 O
dire	161 4 O
neurotoxicity	166 13 B-Disease
associated	180 10 O
with	191 4 O
piperacillin	196 12 B-Chemical
still	209 5 O
goes	215 4 O
unrecognized	220 12 O
,	232 1 O
leading	234 7 O
to	242 2 O
a	245 1 O
delay	247 5 O
in	253 2 O
appropriate	256 11 O
management	268 10 O
.	278 1 O

We	280 2 O
report	283 6 O
a	290 1 O
57	292 2 O
-	294 1 O
year	295 4 O
-	299 1 O
old	300 3 O
woman	304 5 O
with	310 4 O
end	315 3 B-Disease
-	318 1 I-Disease
stage	319 5 I-Disease
renal	325 5 I-Disease
disease	331 7 I-Disease
receiving	339 9 O
continuous	349 10 O
ambulatory	360 10 O
peritoneal	371 10 O
dialysis	382 8 O
(	391 1 O
CAPD	392 4 O
)	396 1 O
,	397 1 O
who	399 3 O
developed	403 9 O
slurred	413 7 O
speech	421 6 O
,	427 1 O
tremor	429 6 B-Disease
,	435 1 O
bizarre	437 7 O
behavior	445 8 O
,	453 1 O
progressive	455 11 O
mental	467 6 O
confusion	474 9 B-Disease
,	483 1 O
and	485 3 O
2	489 1 O
episodes	491 8 O
of	500 2 O
generalized	503 11 O
tonic	515 5 B-Disease
-	520 1 I-Disease
clonic	521 6 I-Disease
seizure	528 7 I-Disease
(	536 1 O
GTCS	537 4 B-Disease
)	541 1 O
after	543 5 O
5	549 1 O
doses	551 5 O
of	557 2 O
piperacillin	560 12 B-Chemical
/	572 1 I-Chemical
tazobactam	573 10 I-Chemical
(	584 1 O
2	585 1 O
g	587 1 O
/	588 1 O
250	589 3 O
mg	593 2 O
)	595 1 O
were	597 4 O
given	602 5 O
for	608 3 O
bronchiectasis	612 14 B-Disease
with	627 4 O
secondary	632 9 B-Disease
infection	642 9 I-Disease
.	651 1 O

The	653 3 O
laboratory	657 10 O
data	668 4 O
revealed	673 8 O
normal	682 6 O
plasma	689 6 O
electrolyte	696 11 O
and	708 3 O
ammonia	712 7 B-Chemical
levels	720 6 O
but	727 3 O
leukocytosis	731 12 B-Disease
.	743 1 O

Neurologic	745 10 O
examinations	756 12 O
showed	769 6 O
dysarthria	776 10 B-Disease
and	787 3 O
bilateral	791 9 O
Babinski	801 8 O
sign	810 4 O
.	814 1 O

Computed	816 8 O
tomography	825 10 O
of	836 2 O
brain	839 5 O
and	845 3 O
electroencephalogram	849 20 O
were	870 4 O
unremarkable	875 12 O
.	887 1 O

Despite	889 7 O
the	897 3 O
use	901 3 O
of	905 2 O
antiepileptic	908 13 O
agents	922 6 O
,	928 1 O
another	930 7 O
GTCS	938 4 B-Disease
episode	943 7 O
recurred	951 8 O
after	960 5 O
the	966 3 O
sixth	970 5 O
dose	976 4 O
of	981 2 O
piperacillin	984 12 B-Chemical
/	996 1 I-Chemical
tazobactam	997 10 I-Chemical
.	1007 1 O

Brain	1009 5 O
magnetic	1015 8 O
resonance	1024 9 O
imaging	1034 7 O
did	1042 3 O
not	1046 3 O
demonstrate	1050 11 O
acute	1062 5 O
infarction	1068 10 B-Disease
and	1079 3 O
organic	1083 7 B-Disease
brain	1091 5 I-Disease
lesions	1097 7 I-Disease
.	1104 1 O

Initiation	1106 10 O
of	1117 2 O
high	1120 4 O
-	1124 1 O
flux	1125 4 O
hemodialysis	1130 12 O
rapidly	1143 7 O
reversed	1151 8 O
the	1160 3 O
neurologic	1164 10 O
symptoms	1175 8 O
within	1184 6 O
4	1191 1 O
hours	1193 5 O
.	1198 1 O

Piperacillin	1200 12 B-Chemical
-	1212 1 O
induced	1213 7 O
encephalopathy	1221 14 B-Disease
should	1236 6 O
be	1243 2 O
considered	1246 10 O
in	1257 2 O
any	1260 3 O
uremic	1264 6 B-Disease
patients	1271 8 O
with	1280 4 O
unexplained	1285 11 O
neurological	1297 12 O
manifestations	1310 14 O
.	1324 1 O

CAPD	1326 4 O
is	1331 2 O
inefficient	1334 11 O
in	1346 2 O
removing	1349 8 O
piperacillin	1358 12 B-Chemical
,	1370 1 O
whereas	1372 7 O
hemodialysis	1380 12 O
can	1393 3 O
rapidly	1397 7 O
terminate	1405 9 O
the	1415 3 O
piperacillin	1419 12 B-Chemical
-	1431 1 O
induced	1432 7 O
encephalopathy	1440 14 B-Disease
.	1454 1 O

Frequency	0 9 O
of	10 2 O
transient	13 9 O
ipsilateral	23 11 O
vocal	35 5 B-Disease
cord	41 4 I-Disease
paralysis	46 9 I-Disease
in	56 2 O
patients	59 8 O
undergoing	68 10 O
carotid	79 7 O
endarterectomy	87 14 O
under	102 5 O
local	108 5 O
anesthesia	114 10 O
.	124 1 O

BACKGROUND	126 10 O
:	136 1 O
Especially	138 10 O
because	149 7 O
of	157 2 O
improvements	160 12 O
in	173 2 O
clinical	176 8 O
neurologic	185 10 O
monitoring	196 10 O
,	206 1 O
carotid	208 7 O
endarterectomy	216 14 O
done	231 4 O
under	236 5 O
local	242 5 O
anesthesia	248 10 O
has	259 3 O
become	263 6 O
the	270 3 O
technique	274 9 O
of	284 2 O
choice	287 6 O
in	294 2 O
several	297 7 O
centers	305 7 O
.	312 1 O

Temporary	314 9 O
ipsilateral	324 11 O
vocal	336 5 B-Disease
nerve	342 5 I-Disease
palsies	348 7 I-Disease
due	356 3 O
to	360 2 O
local	363 5 O
anesthetics	369 11 O
have	381 4 O
been	386 4 O
described	391 9 O
,	400 1 O
however	402 7 O
.	409 1 O

Such	411 4 O
complications	416 13 O
are	430 3 O
most	434 4 O
important	439 9 O
in	449 2 O
situations	452 10 O
where	463 5 O
there	469 5 O
is	475 2 O
a	478 1 O
pre	480 3 O
-	483 1 O
existing	484 8 O
contralateral	493 13 O
paralysis	507 9 B-Disease
.	516 1 O

We	518 2 O
therefore	521 9 O
examined	531 8 O
the	540 3 O
effect	544 6 O
of	551 2 O
local	554 5 O
anesthesia	560 10 O
on	571 2 O
vocal	574 5 O
cord	580 4 O
function	585 8 O
to	594 2 O
better	597 6 O
understand	604 10 O
its	615 3 O
possible	619 8 O
consequences	628 12 O
.	640 1 O

METHODS	642 7 O
:	649 1 O
This	651 4 O
prospective	656 11 O
study	668 5 O
included	674 8 O
28	683 2 O
patients	686 8 O
undergoing	695 10 O
carotid	706 7 O
endarterectomy	714 14 O
under	729 5 O
local	735 5 O
anesthesia	741 10 O
.	751 1 O

Vocal	753 5 O
cord	759 4 O
function	764 8 O
was	773 3 O
evaluated	777 9 O
before	787 6 O
,	793 1 O
during	795 6 O
,	801 1 O
and	803 3 O
after	807 5 O
surgery	813 7 O
(	821 1 O
postoperative	822 13 O
day	836 3 O
1	840 1 O
)	841 1 O
using	843 5 O
flexible	849 8 O
laryngoscopy	858 12 O
.	870 1 O

Anesthesia	872 10 O
was	883 3 O
performed	887 9 O
by	897 2 O
injecting	900 9 O
20	910 2 O
to	913 2 O
40	916 2 O
mL	919 2 O
of	922 2 O
a	925 1 O
mixture	927 7 O
of	935 2 O
long	938 4 O
-	942 1 O
acting	943 6 O
(	950 1 O
ropivacaine	951 11 B-Chemical
)	962 1 O
and	964 3 O
short	968 5 O
-	973 1 O
acting	974 6 O
(	981 1 O
prilocaine	982 10 B-Chemical
)	992 1 O
anesthetic	994 10 O
.	1004 1 O

RESULTS	1006 7 O
:	1013 1 O
All	1015 3 O
patients	1019 8 O
had	1028 3 O
normal	1032 6 O
vocal	1039 5 O
cord	1045 4 O
function	1050 8 O
preoperatively	1059 14 O
.	1073 1 O

Twelve	1075 6 O
patients	1082 8 O
(	1091 1 O
43	1092 2 O
%	1094 1 O
)	1095 1 O
were	1097 4 O
found	1102 5 O
to	1108 2 O
have	1111 4 O
intraoperative	1116 14 O
ipsilateral	1131 11 O
vocal	1143 5 B-Disease
cord	1149 4 I-Disease
paralysis	1154 9 I-Disease
.	1163 1 O

It	1165 2 O
resolved	1168 8 O
in	1177 2 O
all	1180 3 O
cases	1184 5 O
<	1190 1 O
or	1192 2 O
=	1195 1 O
24	1196 2 O
hours	1199 5 O
.	1204 1 O

There	1206 5 O
were	1212 4 O
no	1217 2 O
significant	1220 11 O
differences	1232 11 O
in	1244 2 O
operating	1247 9 O
time	1257 4 O
or	1262 2 O
volume	1265 6 O
or	1272 2 O
frequency	1275 9 O
of	1285 2 O
anesthetic	1288 10 O
administration	1299 14 O
in	1314 2 O
patients	1317 8 O
with	1326 4 O
temporary	1331 9 O
vocal	1341 5 B-Disease
cord	1347 4 I-Disease
paralysis	1352 9 I-Disease
compared	1362 8 O
with	1371 4 O
those	1376 5 O
without	1382 7 O
.	1389 1 O

CONCLUSION	1391 10 O
:	1401 1 O
Local	1403 5 O
anesthesia	1409 10 O
led	1420 3 O
to	1424 2 O
temporary	1427 9 O
ipsilateral	1437 11 O
vocal	1449 5 B-Disease
cord	1455 4 I-Disease
paralysis	1460 9 I-Disease
in	1470 2 O
almost	1473 6 O
half	1480 4 O
of	1485 2 O
these	1488 5 O
patients	1494 8 O
.	1502 1 O

Because	1504 7 O
pre	1512 3 O
-	1515 1 O
existing	1516 8 O
paralysis	1525 9 B-Disease
is	1535 2 O
of	1538 2 O
a	1541 1 O
relevant	1543 8 O
frequency	1552 9 O
(	1562 1 O
up	1563 2 O
to	1566 2 O
3	1569 1 O
%	1570 1 O
)	1571 1 O
,	1572 1 O
a	1574 1 O
preoperative	1576 12 O
evaluation	1589 10 O
of	1600 2 O
vocal	1603 5 O
cord	1609 4 O
function	1614 8 O
before	1623 6 O
carotid	1630 7 O
endarterectomy	1638 14 O
under	1653 5 O
local	1659 5 O
anesthesia	1665 10 O
is	1676 2 O
recommended	1679 11 O
to	1691 2 O
avoid	1694 5 O
intraoperative	1700 14 O
bilateral	1715 9 O
paralysis	1725 9 B-Disease
.	1734 1 O

In	1736 2 O
patients	1739 8 O
with	1748 4 O
preoperative	1753 12 O
contralateral	1766 13 O
vocal	1780 5 B-Disease
cord	1786 4 I-Disease
paralysis	1791 9 I-Disease
,	1800 1 O
surgery	1802 7 O
under	1810 5 O
general	1816 7 O
anesthesia	1824 10 O
should	1835 6 O
be	1842 2 O
considered	1845 10 O
.	1855 1 O

Neuroprotective	0 15 O
effects	16 7 O
of	24 2 O
melatonin	27 9 B-Chemical
upon	37 4 O
the	42 3 O
offspring	46 9 O
cerebellar	56 10 O
cortex	67 6 O
in	74 2 O
the	77 3 O
rat	81 3 O
model	85 5 O
of	91 2 O
BCNU	94 4 B-Chemical
-	98 1 O
induced	99 7 O
cortical	107 8 B-Disease
dysplasia	116 9 I-Disease
.	125 1 O

Cortical	127 8 B-Disease
dysplasia	136 9 I-Disease
is	146 2 O
a	149 1 O
malformation	151 12 O
characterized	164 13 O
by	178 2 O
defects	181 7 O
in	189 2 O
proliferation	192 13 O
,	205 1 O
migration	207 9 O
and	217 3 O
maturation	221 10 O
.	231 1 O

This	233 4 O
study	238 5 O
was	244 3 O
designed	248 8 O
to	257 2 O
evaluate	260 8 O
the	269 3 O
alterations	273 11 O
in	285 2 O
offspring	288 9 O
rat	298 3 O
cerebellum	302 10 O
induced	313 7 O
by	321 2 O
maternal	324 8 O
exposure	333 8 O
to	342 2 O
carmustine	345 10 B-Chemical
-	355 1 O
[	356 1 O
1	357 1 B-Chemical
,	358 1 I-Chemical
3	359 1 I-Chemical
-	360 1 I-Chemical
bis	361 3 I-Chemical
(	365 1 I-Chemical
2	366 1 I-Chemical
-	367 1 I-Chemical
chloroethyl	368 11 I-Chemical
)	379 1 I-Chemical
-	380 1 I-Chemical
1	381 1 I-Chemical
-	382 1 I-Chemical
nitrosoure	383 10 I-Chemical
]	393 1 O
(	395 1 O
BCNU	396 4 B-Chemical
)	400 1 O
and	402 3 O
to	406 2 O
investigate	409 11 O
the	421 3 O
effects	425 7 O
of	433 2 O
exogenous	436 9 O
melatonin	446 9 B-Chemical
upon	456 4 O
cerebellar	461 10 O
BCNU	472 4 B-Chemical
-	476 1 O
induced	477 7 O
cortical	485 8 B-Disease
dysplasia	494 9 I-Disease
,	503 1 O
using	505 5 O
histological	511 12 O
and	524 3 O
biochemical	528 11 O
analyses	540 8 O
.	548 1 O

Pregnant	550 8 O
Wistar	559 6 O
rats	566 4 O
were	571 4 O
assigned	576 8 O
to	585 2 O
five	588 4 O
groups	593 6 O
:	599 1 O
intact	601 6 O
-	607 1 O
control	608 7 O
,	615 1 O
saline	617 6 O
-	623 1 O
control	624 7 O
,	631 1 O
melatonin	633 9 B-Chemical
-	642 1 O
treated	643 7 O
,	650 1 O
BCNU	652 4 B-Chemical
-	656 1 O
exposed	657 7 O
and	665 3 O
BCNU	669 4 B-Chemical
-	673 1 O
exposed	674 7 O
plus	682 4 O
melatonin	687 9 B-Chemical
.	696 1 O

Rats	698 4 O
were	703 4 O
exposed	708 7 O
to	716 2 O
BCNU	719 4 B-Chemical
on	724 2 O
embryonic	727 9 O
day	737 3 O
15	741 2 O
and	744 3 O
melatonin	748 9 B-Chemical
was	758 3 O
given	762 5 O
until	768 5 O
delivery	774 8 O
.	782 1 O

Immuno	784 6 O
/	790 1 O
histochemistry	791 14 O
and	806 3 O
electron	810 8 O
microscopy	819 10 O
were	830 4 O
carried	835 7 O
out	843 3 O
on	847 2 O
the	850 3 O
offspring	854 9 O
cerebellum	864 10 O
,	874 1 O
and	876 3 O
levels	880 6 O
of	887 2 O
malondialdehyde	890 15 B-Chemical
and	906 3 O
superoxide	910 10 B-Chemical
dismutase	921 9 O
were	931 4 O
determined	936 10 O
.	946 1 O

Histopathologically	948 19 O
,	967 1 O
typical	969 7 O
findings	977 8 O
were	986 4 O
observed	991 8 O
in	1000 2 O
the	1003 3 O
cerebella	1007 9 O
from	1017 4 O
the	1022 3 O
control	1026 7 O
groups	1034 6 O
,	1040 1 O
but	1042 3 O
the	1046 3 O
findings	1050 8 O
consistent	1059 10 O
with	1070 4 O
early	1075 5 O
embryonic	1081 9 O
development	1091 11 O
were	1103 4 O
noted	1108 5 O
in	1114 2 O
BCNU	1117 4 B-Chemical
-	1121 1 O
exposed	1122 7 O
cortical	1130 8 B-Disease
dysplasia	1139 9 I-Disease
group	1149 5 O
.	1154 1 O

There	1156 5 O
was	1162 3 O
a	1166 1 O
marked	1168 6 O
increase	1175 8 O
in	1184 2 O
the	1187 3 O
number	1191 6 O
of	1198 2 O
TUNEL	1201 5 O
positive	1207 8 O
cells	1216 5 O
and	1222 3 O
nestin	1226 6 O
positive	1233 8 O
cells	1242 5 O
in	1248 2 O
BCNU	1251 4 B-Chemical
-	1255 1 O
exposed	1256 7 O
group	1264 5 O
,	1269 1 O
but	1271 3 O
a	1275 1 O
decreased	1277 9 O
immunoreactivity	1287 16 O
to	1304 2 O
glial	1307 5 O
fibrillary	1313 10 O
acidic	1324 6 O
protein	1331 7 O
,	1338 1 O
synaptophysin	1340 13 O
and	1354 3 O
transforming	1358 12 O
growth	1371 6 O
factor	1378 6 O
beta1	1385 5 O
was	1391 3 O
observed	1395 8 O
,	1403 1 O
indicating	1405 10 O
a	1416 1 O
delayed	1418 7 O
maturation	1426 10 O
,	1436 1 O
and	1438 3 O
melatonin	1442 9 B-Chemical
significantly	1452 13 O
reversed	1466 8 O
these	1475 5 O
changes	1481 7 O
.	1488 1 O

Malondialdehyde	1490 15 B-Chemical
level	1506 5 O
in	1512 2 O
BCNU	1515 4 B-Chemical
-	1519 1 O
exposed	1520 7 O
group	1528 5 O
was	1534 3 O
higher	1538 6 O
than	1545 4 O
those	1550 5 O
in	1556 2 O
control	1559 7 O
groups	1567 6 O
and	1574 3 O
melatonin	1578 9 B-Chemical
decreased	1588 9 O
malondialdehyde	1598 15 B-Chemical
levels	1614 6 O
in	1621 2 O
BCNU	1624 4 B-Chemical
group	1629 5 O
(	1635 1 O
P	1636 1 O
<	1637 1 O
0	1638 1 O
.	1639 1 O
01	1640 2 O
)	1642 1 O
,	1643 1 O
while	1645 5 O
there	1651 5 O
were	1657 4 O
no	1662 2 O
significant	1665 11 O
differences	1677 11 O
in	1689 2 O
the	1692 3 O
superoxide	1696 10 B-Chemical
dismutase	1707 9 O
levels	1717 6 O
between	1724 7 O
these	1732 5 O
groups	1738 6 O
.	1744 1 O

These	1746 5 O
data	1752 4 O
suggest	1757 7 O
that	1765 4 O
exposure	1770 8 O
of	1779 2 O
animals	1782 7 O
to	1790 2 O
BCNU	1793 4 B-Chemical
during	1798 6 O
pregnancy	1805 9 O
leads	1815 5 O
to	1821 2 O
delayed	1824 7 O
maturation	1832 10 O
of	1843 2 O
offspring	1846 9 O
cerebellum	1856 10 O
and	1867 3 O
melatonin	1871 9 B-Chemical
protects	1881 8 O
the	1890 3 O
cerebellum	1894 10 O
against	1905 7 O
the	1913 3 O
effects	1917 7 O
of	1925 2 O
BCNU	1928 4 B-Chemical
.	1932 1 O

Myo	0 3 B-Chemical
-	3 1 I-Chemical
inositol	4 8 I-Chemical
-	12 1 I-Chemical
1	13 1 I-Chemical
-	14 1 I-Chemical
phosphate	15 9 I-Chemical
(	25 1 O
MIP	26 3 B-Chemical
)	29 1 O
synthase	31 8 O
inhibition	40 10 O
:	50 1 O
in	52 2 O
-	54 1 O
vivo	55 4 O
study	60 5 O
in	66 2 O
rats	69 4 O
.	73 1 O

Lithium	75 7 B-Chemical
and	83 3 O
valproate	87 9 B-Chemical
are	97 3 O
the	101 3 O
prototypic	105 10 O
mood	116 4 O
stabilizers	121 11 O
and	133 3 O
have	137 4 O
diverse	142 7 O
structures	150 10 O
and	161 3 O
targets	165 7 O
.	172 1 O

Both	174 4 O
drugs	179 5 O
influence	185 9 O
inositol	195 8 B-Chemical
metabolism	204 10 O
.	214 1 O

Lithium	216 7 B-Chemical
inhibits	224 8 O
IMPase	233 6 O
and	240 3 O
valproate	244 9 B-Chemical
inhibits	254 8 O
MIP	263 3 B-Chemical
synthase	267 8 O
.	275 1 O

This	277 4 O
study	282 5 O
shows	288 5 O
that	294 4 O
MIP	299 3 B-Chemical
synthase	303 8 O
inhibition	312 10 O
does	323 4 O
not	328 3 O
replicate	332 9 O
or	342 2 O
augment	345 7 O
the	353 3 O
effects	357 7 O
of	365 2 O
lithium	368 7 B-Chemical
in	376 2 O
the	379 3 O
inositol	383 8 B-Chemical
sensitive	392 9 O
pilocarpine	402 11 B-Chemical
-	413 1 O
induced	414 7 O
seizures	422 8 B-Disease
model	431 5 O
.	436 1 O

This	438 4 O
lack	443 4 O
of	448 2 O
effects	451 7 O
may	459 3 O
stem	463 4 O
from	468 4 O
the	473 3 O
low	477 3 O
contribution	481 12 O
of	494 2 O
de	497 2 O
-	499 1 O
novo	500 4 O
synthesis	505 9 O
to	515 2 O
cellular	518 8 O
inositol	527 8 B-Chemical
supply	536 6 O
or	543 2 O
to	546 2 O
the	549 3 O
inhibition	553 10 O
of	564 2 O
the	567 3 O
de	571 2 O
-	573 1 O
novo	574 4 O
synthesis	579 9 O
by	589 2 O
lithium	592 7 B-Chemical
itself	600 6 O
.	606 1 O

Non	0 3 O
-	3 1 O
steroidal	4 9 O
anti	14 4 O
-	18 1 O
inflammatory	19 12 O
drugs	32 5 O
-	37 1 O
associated	38 10 O
acute	49 5 O
interstitial	55 12 B-Disease
nephritis	68 9 I-Disease
with	78 4 O
granular	83 8 O
tubular	92 7 O
basement	100 8 O
membrane	109 8 O
deposits	118 8 O
.	126 1 O

Acute	128 5 B-Disease
tubulo	134 6 I-Disease
-	140 1 I-Disease
interstitial	141 12 I-Disease
nephritis	154 9 I-Disease
(	164 1 O
ATIN	165 4 B-Disease
)	169 1 O
is	171 2 O
an	174 2 O
important	177 9 O
cause	187 5 O
of	193 2 O
acute	196 5 B-Disease
renal	202 5 I-Disease
failure	208 7 I-Disease
resulting	216 9 O
from	226 4 O
a	231 1 O
variety	233 7 O
of	241 2 O
insults	244 7 O
,	251 1 O
including	253 9 O
immune	263 6 O
complex	270 7 O
-	277 1 O
mediated	278 8 O
tubulo	287 6 B-Disease
-	293 1 I-Disease
interstitial	294 12 I-Disease
injury	307 6 I-Disease
,	313 1 O
but	315 3 O
drugs	319 5 O
such	325 4 O
as	330 2 O
non	333 3 O
-	336 1 O
steroidal	337 9 O
anti	347 4 O
-	351 1 O
inflammatory	352 12 O
drugs	365 5 O
(	371 1 O
NSAIDs	372 6 O
)	378 1 O
are	380 3 O
a	384 1 O
far	386 3 O
more	390 4 O
frequent	395 8 O
cause	404 5 O
.	409 1 O

Overall	411 7 O
,	418 1 O
as	420 2 O
an	423 2 O
entity	426 6 O
,	432 1 O
ATIN	434 4 B-Disease
remains	439 7 O
under	447 5 O
-	452 1 O
diagnosed	453 9 O
,	462 1 O
as	464 2 O
symptoms	467 8 O
resolve	476 7 O
spontaneously	484 13 O
if	498 2 O
the	501 3 O
medication	505 10 O
is	516 2 O
stopped	519 7 O
.	526 1 O

We	528 2 O
report	531 6 O
on	538 2 O
a	541 1 O
14	543 2 O
-	545 1 O
year	546 4 O
-	550 1 O
old	551 3 O
boy	555 3 O
who	559 3 O
developed	563 9 O
acute	573 5 B-Disease
renal	579 5 I-Disease
failure	585 7 I-Disease
2	593 1 O
weeks	595 5 O
after	601 5 O
aortic	607 6 O
valve	614 5 O
surgery	620 7 O
.	627 1 O

He	629 2 O
was	632 3 O
put	636 3 O
on	640 2 O
aspirin	643 7 B-Chemical
following	651 9 O
surgery	661 7 O
and	669 3 O
took	673 4 O
ibuprofen	678 9 B-Chemical
for	688 3 O
fever	692 5 B-Disease
for	698 3 O
nearly	702 6 O
a	709 1 O
week	711 4 O
prior	716 5 O
to	722 2 O
presentation	725 12 O
.	737 1 O

He	739 2 O
then	742 4 O
presented	747 9 O
to	757 2 O
the	760 3 O
emergency	764 9 O
department	774 10 O
feeling	785 7 O
quite	793 5 O
ill	799 3 O
and	803 3 O
was	807 3 O
found	811 5 O
to	817 2 O
have	820 4 O
a	825 1 O
blood	827 5 B-Chemical
urea	833 4 I-Chemical
nitrogen	838 8 I-Chemical
(	847 1 O
BUN	848 3 B-Chemical
)	851 1 O
concentration	853 13 O
of	867 2 O
of	870 2 O
147	873 3 O
mg	877 2 O
/	879 1 O
dl	880 2 O
,	882 1 O
creatinine	884 10 B-Chemical
of	895 2 O
15	898 2 O
.	900 1 O
3	901 1 O
mg	903 2 O
/	905 1 O
dl	906 2 O
and	909 3 O
serum	913 5 O
potassium	919 9 B-Chemical
of	929 2 O
8	932 1 O
.	933 1 O
7	934 1 O
mEq	936 3 O
/	939 1 O
l	940 1 O
.	941 1 O

Dialysis	943 8 O
was	952 3 O
immediately	956 11 O
initiated	968 9 O
.	977 1 O

A	979 1 O
kidney	981 6 O
biopsy	988 6 O
showed	995 6 O
inflammatory	1002 12 O
infiltrate	1015 10 O
consistent	1026 10 O
with	1037 4 O
ATIN	1042 4 B-Disease
.	1046 1 O

However	1048 7 O
,	1055 1 O
in	1057 2 O
the	1060 3 O
tubular	1064 7 O
basement	1072 8 O
membrane	1081 8 O
(	1090 1 O
TBM	1091 3 O
)	1094 1 O
,	1095 1 O
very	1097 4 O
intense	1102 7 O
granular	1110 8 O
deposits	1119 8 O
of	1128 2 O
polyclonal	1131 10 O
IgG	1142 3 O
and	1146 3 O
C3	1150 2 O
were	1153 4 O
noted	1158 5 O
.	1163 1 O

He	1165 2 O
needed	1168 6 O
dialysis	1175 8 O
for	1184 3 O
2	1188 1 O
weeks	1190 5 O
and	1196 3 O
was	1200 3 O
treated	1204 7 O
successfully	1212 12 O
with	1225 4 O
steroids	1230 8 B-Chemical
for	1239 3 O
6	1243 1 O
months	1245 6 O
.	1251 1 O

His	1253 3 O
renal	1257 5 O
recovery	1263 8 O
and	1272 3 O
disappearance	1276 13 O
of	1290 2 O
proteinuria	1293 11 B-Disease
took	1305 4 O
a	1310 1 O
year	1312 4 O
.	1316 1 O

In	1318 2 O
conclusion	1321 10 O
,	1331 1 O
this	1333 4 O
is	1338 2 O
a	1341 1 O
first	1343 5 O
report	1349 6 O
of	1356 2 O
NSAIDs	1359 6 O
-	1365 1 O
associated	1366 10 O
ATIN	1377 4 B-Disease
,	1381 1 O
showing	1383 7 O
deposits	1391 8 O
of	1400 2 O
granular	1403 8 O
immune	1412 6 O
complex	1419 7 O
present	1427 7 O
only	1435 4 O
in	1440 2 O
the	1443 3 O
TBM	1447 3 O
and	1451 3 O
not	1455 3 O
in	1459 2 O
the	1462 3 O
glomeruli	1466 9 O
.	1475 1 O

Rifampicin	0 10 B-Chemical
-	10 1 O
associated	11 10 O
segmental	22 9 O
necrotizing	32 11 O
glomerulonephritis	44 18 B-Disease
in	63 2 O
staphylococcal	66 14 B-Disease
endocarditis	81 12 I-Disease
.	93 1 O

Segmental	95 9 O
necrotising	105 11 O
glomerulonephritis	117 18 B-Disease
has	136 3 O
been	140 4 O
reported	145 8 O
as	154 2 O
complication	157 12 O
of	170 2 O
rifampicin	173 10 B-Chemical
therapy	184 7 O
in	192 2 O
patients	195 8 O
receiving	204 9 O
treatment	214 9 O
for	224 3 O
tuberculosis	228 12 B-Disease
.	240 1 O

Changing	242 8 O
epidemiology	251 12 O
of	264 2 O
infections	267 10 B-Disease
such	278 4 O
as	283 2 O
infective	286 9 B-Disease
endocarditis	296 12 I-Disease
(	309 1 O
IE	310 2 B-Disease
)	312 1 O
has	314 3 O
led	318 3 O
to	322 2 O
an	325 2 O
increase	328 8 O
in	337 2 O
the	340 3 O
use	344 3 O
of	348 2 O
rifampicin	351 10 B-Chemical
for	362 3 O
Staphylococcal	366 14 B-Disease
infections	381 10 I-Disease
.	391 1 O

We	393 2 O
describe	396 8 O
a	405 1 O
case	407 4 O
of	412 2 O
a	415 1 O
patient	417 7 O
with	425 4 O
Staphylococcal	430 14 B-Disease
IE	445 2 I-Disease
who	448 3 O
developed	452 9 O
acute	462 5 B-Disease
renal	468 5 I-Disease
failure	474 7 I-Disease
secondary	482 9 O
to	492 2 O
a	495 1 O
segmental	497 9 O
necrotising	507 11 O
glomerulonephritis	519 18 B-Disease
while	538 5 O
being	544 5 O
treated	550 7 O
with	558 4 O
rifampicin	563 10 B-Chemical
,	573 1 O
and	575 3 O
review	579 6 O
the	586 3 O
literature	590 10 O
regarding	601 9 O
this	611 4 O
complication	616 12 O
of	629 2 O
rifampicin	632 10 B-Chemical
therapy	643 7 O
.	650 1 O

Rate	0 4 O
of	5 2 O
YMDD	8 4 O
motif	13 5 O
mutants	19 7 O
in	27 2 O
lamivudine	30 10 B-Chemical
-	40 1 O
untreated	41 9 O
Iranian	51 7 O
patients	59 8 O
with	68 4 O
chronic	73 7 B-Disease
hepatitis	81 9 I-Disease
B	91 1 I-Disease
virus	93 5 I-Disease
infection	99 9 I-Disease
.	108 1 O

BACKGROUND	110 10 O
:	120 1 O
Lamivudine	122 10 B-Chemical
is	133 2 O
used	136 4 O
for	141 3 O
the	145 3 O
treatment	149 9 O
of	159 2 O
chronic	162 7 B-Disease
hepatitis	170 9 I-Disease
B	180 1 I-Disease
patients	182 8 O
.	190 1 O

Recent	192 6 O
studies	199 7 O
show	207 4 O
that	212 4 O
the	217 3 O
YMDD	221 4 O
motif	226 5 O
mutants	232 7 O
(	240 1 O
resistant	241 9 O
hepatitis	251 9 B-Disease
B	261 1 I-Disease
virus	263 5 O
)	268 1 O
occur	270 5 O
as	276 2 O
natural	279 7 O
genome	287 6 O
variability	294 11 O
in	306 2 O
lamivudine	309 10 B-Chemical
-	319 1 O
untreated	320 9 O
chronic	330 7 B-Disease
hepatitis	338 9 I-Disease
B	348 1 I-Disease
patients	350 8 O
.	358 1 O

In	360 2 O
this	363 4 O
study	368 5 O
we	374 2 O
aimed	377 5 O
to	383 2 O
determine	386 9 O
the	396 3 O
rate	400 4 O
of	405 2 O
YMDD	408 4 O
motif	413 5 O
mutants	419 7 O
in	427 2 O
lamivudine	430 10 B-Chemical
-	440 1 O
untreated	441 9 O
chronic	451 7 B-Disease
hepatitis	459 9 I-Disease
B	469 1 I-Disease
patients	471 8 O
in	480 2 O
Iran	483 4 O
.	487 1 O

PATIENTS	489 8 O
AND	498 3 O
METHODS	502 7 O
:	509 1 O
A	511 1 O
total	513 5 O
of	519 2 O
77	522 2 O
chronic	525 7 B-Disease
hepatitis	533 9 I-Disease
B	543 1 I-Disease
patients	545 8 O
who	554 3 O
had	558 3 O
not	562 3 O
been	566 4 O
treated	571 7 O
with	579 4 O
lamivudine	584 10 B-Chemical
were	595 4 O
included	600 8 O
in	609 2 O
the	612 3 O
study	616 5 O
.	621 1 O

Serum	623 5 O
samples	629 7 O
from	637 4 O
patients	642 8 O
were	651 4 O
tested	656 6 O
by	663 2 O
polymerase	666 10 O
chain	677 5 O
reaction	683 8 O
-	691 1 O
restriction	692 11 O
fragment	704 8 O
length	713 6 O
polymorphism	720 12 O
(	733 1 O
PCR	734 3 O
-	737 1 O
RFLP	738 4 O
)	742 1 O
for	744 3 O
detection	748 9 O
of	758 2 O
YMDD	761 4 O
motif	766 5 O
mutants	772 7 O
.	779 1 O

All	781 3 O
patients	785 8 O
were	794 4 O
also	799 4 O
tested	804 6 O
for	811 3 O
liver	815 5 O
enzymes	821 7 O
,	828 1 O
anti	830 4 O
-	834 1 O
HCV	835 3 O
,	838 1 O
HBeAg	840 5 B-Chemical
,	845 1 O
and	847 3 O
anti	851 4 O
-	855 1 O
HBe	856 3 O
.	859 1 O

RESULTS	861 7 O
:	868 1 O
Of	870 2 O
the	873 3 O
77	877 2 O
patients	880 8 O
enrolled	889 8 O
in	898 2 O
the	901 3 O
study	905 5 O
,	910 1 O
73	912 2 O
%	914 1 O
were	916 4 O
male	921 4 O
and	926 3 O
27	930 2 O
%	932 1 O
were	934 4 O
female	939 6 O
.	945 1 O

Mean	947 4 O
ALT	952 3 O
and	956 3 O
AST	960 3 O
levels	964 6 O
were	971 4 O
124	976 3 O
.	979 1 O
4	980 1 O
+	981 1 O
/	982 1 O
-	983 1 O
73	984 2 O
.	986 1 O
4	987 1 O
and	989 3 O
103	993 3 O
.	996 1 O
1	997 1 O
+	998 1 O
/	999 1 O
-	1000 1 O
81	1001 2 O
IU	1004 2 O
/	1006 1 O
l	1007 1 O
,	1008 1 O
respectively	1010 12 O
.	1022 1 O

HBeAg	1024 5 B-Chemical
was	1030 3 O
positive	1034 8 O
in	1043 2 O
40	1046 2 O
%	1048 1 O
and	1050 3 O
anti	1054 4 O
-	1058 1 O
HBe	1059 3 O
in	1063 2 O
60	1066 2 O
%	1068 1 O
of	1070 2 O
the	1073 3 O
patients	1077 8 O
.	1085 1 O

Anti	1087 4 O
-	1091 1 O
HCV	1092 3 O
was	1096 3 O
negative	1100 8 O
in	1109 2 O
all	1112 3 O
of	1116 2 O
them	1119 4 O
.	1123 1 O

YMDD	1125 4 O
motif	1130 5 O
mutants	1136 7 O
were	1144 4 O
not	1149 3 O
detected	1153 8 O
in	1162 2 O
any	1165 3 O
of	1169 2 O
the	1172 3 O
patients	1176 8 O
despite	1185 7 O
the	1193 3 O
liver	1197 5 O
enzyme	1203 6 O
levels	1210 6 O
and	1217 3 O
the	1221 3 O
presence	1225 8 O
of	1234 2 O
HBeAg	1237 5 B-Chemical
or	1243 2 O
anti	1246 4 O
-	1250 1 O
HBe	1251 3 O
.	1254 1 O

CONCLUSION	1256 10 O
:	1266 1 O
Although	1268 8 O
the	1277 3 O
natural	1281 7 O
occurrence	1289 10 O
of	1300 2 O
YMDD	1303 4 O
motif	1308 5 O
mutants	1314 7 O
in	1322 2 O
lamivudine	1325 10 B-Chemical
-	1335 1 O
untreated	1336 9 O
patients	1346 8 O
with	1355 4 O
chronic	1360 7 B-Disease
hepatitis	1368 9 I-Disease
B	1378 1 I-Disease
has	1380 3 O
been	1384 4 O
reported	1389 8 O
,	1397 1 O
these	1399 5 O
mutants	1405 7 O
were	1413 4 O
not	1418 3 O
detected	1422 8 O
in	1431 2 O
Iranian	1434 7 O
lamivudine	1442 10 B-Chemical
-	1452 1 O
untreated	1453 9 O
chronic	1463 7 B-Disease
hepatitis	1471 9 I-Disease
B	1481 1 I-Disease
patients	1483 8 O
.	1491 1 O

Branch	0 6 O
retinal	7 7 B-Disease
vein	15 4 I-Disease
occlusion	20 9 I-Disease
and	30 3 O
fluoxetine	34 10 B-Chemical
.	44 1 O

A	46 1 O
case	48 4 O
of	53 2 O
branch	56 6 O
retinal	63 7 B-Disease
vein	71 4 I-Disease
occlusion	76 9 I-Disease
associated	86 10 O
with	97 4 O
fluoxetine	102 10 B-Chemical
-	112 1 O
induced	113 7 O
secondary	121 9 O
hypertension	131 12 B-Disease
is	144 2 O
described	147 9 O
.	156 1 O

Although	158 8 O
an	167 2 O
infrequent	170 10 O
complication	181 12 O
of	194 2 O
selective	197 9 O
serotonin	207 9 B-Chemical
reuptake	217 8 O
inhibitor	226 9 O
therapy	236 7 O
,	243 1 O
it	245 2 O
is	248 2 O
important	251 9 O
that	261 4 O
ophthalmologists	266 16 O
are	283 3 O
aware	287 5 O
that	293 4 O
these	298 5 O
agents	304 6 O
can	311 3 O
cause	315 5 O
hypertension	321 12 B-Disease
because	334 7 O
this	342 4 O
class	347 5 O
of	353 2 O
drugs	356 5 O
is	362 2 O
widely	365 6 O
prescribed	372 10 O
.	382 1 O

The	0 3 O
differential	4 12 O
effects	17 7 O
of	25 2 O
bupivacaine	28 11 B-Chemical
and	40 3 O
lidocaine	44 9 B-Chemical
on	54 2 O
prostaglandin	57 13 B-Chemical
E2	71 2 I-Chemical
release	74 7 O
,	81 1 O
cyclooxygenase	83 14 O
gene	98 4 O
expression	103 10 O
and	114 3 O
pain	118 4 B-Disease
in	123 2 O
a	126 1 O
clinical	128 8 O
pain	137 4 B-Disease
model	142 5 O
.	147 1 O

BACKGROUND	149 10 O
:	159 1 O
In	161 2 O
addition	164 8 O
to	173 2 O
blocking	176 8 O
nociceptive	185 11 O
input	197 5 O
from	203 4 O
surgical	208 8 O
sites	217 5 O
,	222 1 O
long	224 4 O
-	228 1 O
acting	229 6 O
local	236 5 O
anesthetics	242 11 O
might	254 5 O
directly	260 8 O
modulate	269 8 O
inflammation	278 12 B-Disease
.	290 1 O

In	292 2 O
the	295 3 O
present	299 7 O
study	307 5 O
,	312 1 O
we	314 2 O
describe	317 8 O
the	326 3 O
proinflammatory	330 15 O
effects	346 7 O
of	354 2 O
bupivacaine	357 11 B-Chemical
on	369 2 O
local	372 5 O
prostaglandin	378 13 B-Chemical
E2	392 2 I-Chemical
(	395 1 O
PGE2	396 4 B-Chemical
)	400 1 O
production	402 10 O
and	413 3 O
cyclooxygenase	417 14 O
(	432 1 O
COX	433 3 O
)	436 1 O
gene	438 4 O
expression	443 10 O
that	454 4 O
increases	459 9 O
postoperative	469 13 B-Disease
pain	483 4 I-Disease
in	488 2 O
human	491 5 O
subjects	497 8 O
.	505 1 O

METHODS	507 7 O
:	514 1 O
Subjects	516 8 O
(	525 1 O
n	526 1 O
=	528 1 O
114	530 3 O
)	533 1 O
undergoing	535 10 O
extraction	546 10 O
of	557 2 O
impacted	560 8 O
third	569 5 O
molars	575 6 O
received	582 8 O
either	591 6 O
2	598 1 O
%	599 1 O
lidocaine	601 9 B-Chemical
or	611 2 O
0	614 1 O
.	615 1 O
5	616 1 O
%	617 1 O
bupivacaine	619 11 B-Chemical
before	631 6 O
surgery	638 7 O
and	646 3 O
either	650 6 O
rofecoxib	657 9 B-Chemical
50	667 2 O
mg	670 2 O
or	673 2 O
placebo	676 7 O
orally	684 6 O
90	691 2 O
min	694 3 O
before	698 6 O
surgery	705 7 O
and	713 3 O
for	717 3 O
the	721 3 O
following	725 9 O
48	735 2 O
h	738 1 O
.	739 1 O

Oral	741 4 O
mucosal	746 7 O
biopsies	754 8 O
were	763 4 O
taken	768 5 O
before	774 6 O
surgery	781 7 O
and	789 3 O
48	793 2 O
h	796 1 O
after	798 5 O
surgery	804 7 O
.	811 1 O

After	813 5 O
extraction	819 10 O
,	829 1 O
a	831 1 O
microdialysis	833 13 O
probe	847 5 O
was	853 3 O
placed	857 6 O
at	864 2 O
the	867 3 O
surgical	871 8 O
site	880 4 O
for	885 3 O
PGE2	889 4 B-Chemical
and	894 3 O
thromboxane	898 11 B-Chemical
B2	910 2 I-Chemical
(	913 1 O
TXB2	914 4 B-Chemical
)	918 1 O
measurements	920 12 O
.	932 1 O

RESULTS	934 7 O
:	941 1 O
The	943 3 O
bupivacaine	947 11 B-Chemical
/	958 1 O
rofecoxib	959 9 B-Chemical
group	969 5 O
reported	975 8 O
significantly	984 13 O
less	998 4 O
pain	1003 4 B-Disease
,	1007 1 O
as	1009 2 O
assessed	1012 8 O
by	1021 2 O
a	1024 1 O
visual	1026 6 O
analog	1033 6 O
scale	1040 5 O
,	1045 1 O
compared	1047 8 O
with	1056 4 O
the	1061 3 O
other	1065 5 O
three	1071 5 O
treatment	1077 9 O
groups	1087 6 O
over	1094 4 O
the	1099 3 O
first	1103 5 O
4	1109 1 O
h	1111 1 O
.	1112 1 O

However	1114 7 O
,	1121 1 O
the	1123 3 O
bupivacaine	1127 11 B-Chemical
/	1138 1 O
placebo	1139 7 O
group	1147 5 O
reported	1153 8 O
significantly	1162 13 O
more	1176 4 O
pain	1181 4 B-Disease
at	1186 2 O
24	1189 2 O
h	1192 1 O
and	1194 3 O
PGE2	1198 4 B-Chemical
levels	1203 6 O
during	1210 6 O
the	1217 3 O
first	1221 5 O
4	1227 1 O
h	1229 1 O
were	1231 4 O
significantly	1236 13 O
higher	1250 6 O
than	1257 4 O
the	1262 3 O
other	1266 5 O
three	1272 5 O
treatment	1278 9 O
groups	1288 6 O
.	1294 1 O

Moreover	1296 8 O
,	1304 1 O
bupivacaine	1306 11 B-Chemical
significantly	1318 13 O
increased	1332 9 O
COX	1342 3 O
-	1345 1 O
2	1346 1 O
gene	1348 4 O
expression	1353 10 O
at	1364 2 O
48	1367 2 O
h	1370 1 O
as	1372 2 O
compared	1375 8 O
with	1384 4 O
the	1389 3 O
lidocaine	1393 9 B-Chemical
/	1402 1 O
placebo	1403 7 O
group	1411 5 O
.	1416 1 O

Thromboxane	1418 11 B-Chemical
levels	1430 6 O
were	1437 4 O
not	1442 3 O
significantly	1446 13 O
affected	1460 8 O
by	1469 2 O
any	1472 3 O
of	1476 2 O
the	1479 3 O
treatments	1483 10 O
,	1493 1 O
indicating	1495 10 O
that	1506 4 O
the	1511 3 O
effects	1515 7 O
seen	1523 4 O
were	1528 4 O
attributable	1533 12 O
to	1546 2 O
inhibition	1549 10 O
of	1560 2 O
COX	1563 3 O
-	1566 1 O
2	1567 1 O
,	1568 1 O
but	1570 3 O
not	1574 3 O
COX	1578 3 O
-	1581 1 O
1	1582 1 O
.	1583 1 O

CONCLUSIONS	1585 11 O
:	1596 1 O
These	1598 5 O
results	1604 7 O
suggest	1612 7 O
that	1620 4 O
bupivacaine	1625 11 B-Chemical
stimulates	1637 10 O
COX	1648 3 O
-	1651 1 O
2	1652 1 O
gene	1654 4 O
expression	1659 10 O
after	1670 5 O
tissue	1676 6 B-Disease
injury	1683 6 I-Disease
,	1689 1 O
which	1691 5 O
is	1697 2 O
associated	1700 10 O
with	1711 4 O
higher	1716 6 O
PGE2	1723 4 B-Chemical
production	1728 10 O
and	1739 3 O
pain	1743 4 B-Disease
after	1748 5 O
the	1754 3 O
local	1758 5 O
anesthetic	1764 10 O
effect	1775 6 O
dissipates	1782 10 O
.	1792 1 O

p75NTR	0 6 O
expression	7 10 O
in	18 2 O
rat	21 3 O
urinary	25 7 O
bladder	33 7 O
sensory	41 7 O
neurons	49 7 O
and	57 3 O
spinal	61 6 O
cord	68 4 O
with	73 4 O
cyclophosphamide	78 16 B-Chemical
-	94 1 O
induced	95 7 O
cystitis	103 8 B-Disease
.	111 1 O

A	113 1 O
role	115 4 O
for	120 3 O
nerve	124 5 O
growth	130 6 O
factor	137 6 O
(	144 1 O
NGF	145 3 O
)	148 1 O
in	150 2 O
contributing	153 12 O
to	166 2 O
increased	169 9 O
voiding	179 7 O
frequency	187 9 O
and	197 3 O
altered	201 7 O
sensation	209 9 O
from	219 4 O
the	224 3 O
urinary	228 7 O
bladder	236 7 O
has	244 3 O
been	248 4 O
suggested	253 9 O
.	262 1 O

Previous	264 8 O
studies	273 7 O
have	281 4 O
examined	286 8 O
the	295 3 O
expression	299 10 O
and	310 3 O
regulation	314 10 O
of	325 2 O
tyrosine	328 8 B-Chemical
kinase	337 6 O
receptors	344 9 O
(	354 1 O
Trks	355 4 O
)	359 1 O
in	361 2 O
micturition	364 11 O
reflexes	376 8 O
with	385 4 O
urinary	390 7 B-Disease
bladder	398 7 I-Disease
inflammation	406 12 I-Disease
.	418 1 O

The	420 3 O
present	424 7 O
studies	432 7 O
examine	440 7 O
the	448 3 O
expression	452 10 O
and	463 3 O
regulation	467 10 O
of	478 2 O
another	481 7 O
receptor	489 8 O
known	498 5 O
to	504 2 O
bind	507 4 O
NGF	512 3 O
,	515 1 O
p75	517 3 O
(	520 1 O
NTR	521 3 O
)	524 1 O
,	525 1 O
after	527 5 O
various	533 7 O
durations	541 9 O
of	551 2 O
bladder	554 7 B-Disease
inflammation	562 12 I-Disease
induced	575 7 O
by	583 2 O
cyclophosphamide	586 16 B-Chemical
(	603 1 O
CYP	604 3 B-Chemical
)	607 1 O
.	608 1 O

CYP	610 3 B-Chemical
-	613 1 O
induced	614 7 O
cystitis	622 8 B-Disease
increased	631 9 O
(	641 1 O
P	642 1 O
<	644 1 O
or	646 2 O
=	649 1 O
0	651 1 O
.	652 1 O
001	653 3 O
)	656 1 O
p75	658 3 O
(	661 1 O
NTR	662 3 O
)	665 1 O
expression	667 10 O
in	678 2 O
the	681 3 O
superficial	685 11 O
lateral	697 7 O
and	705 3 O
medial	709 6 O
dorsal	716 6 O
horn	723 4 O
in	728 2 O
L1	731 2 O
-	733 1 O
L2	734 2 O
and	737 3 O
L6	741 2 O
-	743 1 O
S1	744 2 O
spinal	747 6 O
segments	754 8 O
.	762 1 O

The	764 3 O
number	768 6 O
of	775 2 O
p75	778 3 O
(	781 1 O
NTR	782 3 O
)	785 1 O
-	786 1 O
immunoreactive	787 14 O
(	802 1 O
-	803 1 O
IR	804 2 O
)	806 1 O
cells	808 5 O
in	814 2 O
the	817 3 O
lumbosacral	821 11 O
dorsal	833 6 O
root	840 4 O
ganglia	845 7 O
(	853 1 O
DRG	854 3 O
)	857 1 O
also	859 4 O
increased	864 9 O
(	874 1 O
P	875 1 O
<	877 1 O
or	879 2 O
=	882 1 O
0	884 1 O
.	885 1 O
05	886 2 O
)	888 1 O
with	890 4 O
CYP	895 3 B-Chemical
-	898 1 O
induced	899 7 O
cystitis	907 8 B-Disease
(	916 1 O
acute	917 5 O
,	922 1 O
intermediate	924 12 O
,	936 1 O
and	938 3 O
chronic	942 7 O
)	949 1 O
.	950 1 O

Quantitative	952 12 O
,	964 1 O
real	966 4 O
-	970 1 O
time	971 4 O
polymerase	976 10 O
chain	987 5 O
reaction	993 8 O
also	1002 4 O
demonstrated	1007 12 O
significant	1020 11 O
increases	1032 9 O
(	1042 1 O
P	1043 1 O
<	1045 1 O
or	1047 2 O
=	1050 1 O
0	1052 1 O
.	1053 1 O
01	1054 2 O
)	1056 1 O
in	1058 2 O
p75	1061 3 O
(	1064 1 O
NTR	1065 3 O
)	1068 1 O
mRNA	1070 4 O
in	1075 2 O
DRG	1078 3 O
with	1082 4 O
intermediate	1087 12 O
and	1100 3 O
chronic	1104 7 O
CYP	1112 3 B-Chemical
-	1115 1 O
induced	1116 7 O
cystitis	1124 8 B-Disease
.	1132 1 O

Retrograde	1134 10 O
dye	1145 3 O
-	1148 1 O
tracing	1149 7 O
techniques	1157 10 O
with	1168 4 O
Fastblue	1173 8 O
were	1182 4 O
used	1187 4 O
to	1192 2 O
identify	1195 8 O
presumptive	1204 11 O
bladder	1216 7 O
afferent	1224 8 O
cells	1233 5 O
in	1239 2 O
the	1242 3 O
lumbosacral	1246 11 O
DRG	1258 3 O
.	1261 1 O

In	1263 2 O
bladder	1266 7 O
afferent	1274 8 O
cells	1283 5 O
in	1289 2 O
DRG	1292 3 O
,	1295 1 O
p75	1297 3 O
(	1300 1 O
NTR	1301 3 O
)	1304 1 O
-	1305 1 O
IR	1306 2 O
was	1309 3 O
also	1313 4 O
increased	1318 9 O
(	1328 1 O
P	1329 1 O
<	1331 1 O
or	1333 2 O
=	1336 1 O
0	1338 1 O
.	1339 1 O
01	1340 2 O
)	1342 1 O
with	1344 4 O
cystitis	1349 8 B-Disease
.	1357 1 O

In	1359 2 O
addition	1362 8 O
to	1371 2 O
increases	1374 9 O
in	1384 2 O
p75	1387 3 O
(	1390 1 O
NTR	1391 3 O
)	1394 1 O
-	1395 1 O
IR	1396 2 O
in	1399 2 O
DRG	1402 3 O
cell	1406 4 O
bodies	1411 6 O
,	1417 1 O
increases	1419 9 O
(	1429 1 O
P	1430 1 O
<	1432 1 O
or	1434 2 O
=	1437 1 O
0	1439 1 O
.	1440 1 O
001	1441 3 O
)	1444 1 O
in	1446 2 O
pericellular	1449 12 O
(	1462 1 O
encircling	1463 10 O
DRG	1474 3 O
cells	1478 5 O
)	1483 1 O
p75	1485 3 O
(	1488 1 O
NTR	1489 3 O
)	1492 1 O
-	1493 1 O
IR	1494 2 O
in	1497 2 O
DRG	1500 3 O
also	1504 4 O
increased	1509 9 O
.	1518 1 O

Confocal	1520 8 O
analyses	1529 8 O
demonstrated	1538 12 O
that	1551 4 O
pericellular	1556 12 O
p75	1569 3 O
(	1572 1 O
NTR	1573 3 O
)	1576 1 O
-	1577 1 O
IR	1578 2 O
was	1581 3 O
not	1585 3 O
colocalized	1589 11 O
with	1601 4 O
the	1606 3 O
glial	1610 5 O
marker	1616 6 O
,	1622 1 O
glial	1624 5 O
fibrillary	1630 10 O
acidic	1641 6 O
protein	1648 7 O
(	1656 1 O
GFAP	1657 4 O
)	1661 1 O
.	1662 1 O

These	1664 5 O
studies	1670 7 O
demonstrate	1678 11 O
that	1690 4 O
p75	1695 3 O
(	1698 1 O
NTR	1699 3 O
)	1702 1 O
expression	1704 10 O
in	1715 2 O
micturition	1718 11 O
reflexes	1730 8 O
is	1739 2 O
present	1742 7 O
constitutively	1750 14 O
and	1765 3 O
modified	1769 8 O
by	1778 2 O
bladder	1781 7 B-Disease
inflammation	1789 12 I-Disease
.	1801 1 O

The	1803 3 O
functional	1807 10 O
significance	1818 12 O
of	1831 2 O
p75	1834 3 O
(	1837 1 O
NTR	1838 3 O
)	1841 1 O
expression	1843 10 O
in	1854 2 O
micturition	1857 11 O
reflexes	1869 8 O
remains	1878 7 O
to	1886 2 O
be	1889 2 O
determined	1892 10 O
.	1902 1 O

Azathioprine	0 12 B-Chemical
-	12 1 O
induced	13 7 O
suicidal	21 8 O
erythrocyte	30 11 O
death	42 5 O
.	47 1 O

BACKGROUND	49 10 O
:	59 1 O
Azathioprine	61 12 B-Chemical
is	74 2 O
widely	77 6 O
used	84 4 O
as	89 2 O
an	92 2 O
immunosuppressive	95 17 O
drug	113 4 O
.	117 1 O

The	119 3 O
side	123 4 O
effects	128 7 O
of	136 2 O
azathioprine	139 12 B-Chemical
include	152 7 O
anemia	160 6 B-Disease
,	166 1 O
which	168 5 O
has	174 3 O
been	178 4 O
attributed	183 10 O
to	194 2 O
bone	197 4 O
marrow	202 6 O
suppression	209 11 O
.	220 1 O

Alternatively	222 13 O
,	235 1 O
anemia	237 6 B-Disease
could	244 5 O
result	250 6 O
from	257 4 O
accelerated	262 11 O
suicidal	274 8 O
erythrocyte	283 11 O
death	295 5 O
or	301 2 O
eryptosis	304 9 O
,	313 1 O
which	315 5 O
is	321 2 O
characterized	324 13 O
by	338 2 O
exposure	341 8 O
of	350 2 O
phosphatidylserine	353 18 B-Chemical
(	372 1 O
PS	373 2 B-Chemical
)	375 1 O
at	377 2 O
the	380 3 O
erythrocyte	384 11 O
surface	396 7 O
and	404 3 O
by	408 2 O
cell	411 4 O
shrinkage	416 9 O
.	425 1 O

METHODS	427 7 O
:	434 1 O
The	436 3 O
present	440 7 O
experiments	448 11 O
explored	460 8 O
whether	469 7 O
azathioprine	477 12 B-Chemical
influences	490 10 O
eryptosis	501 9 O
.	510 1 O

According	512 9 O
to	522 2 O
annexin	525 7 O
V	533 1 O
binding	535 7 O
,	542 1 O
erythrocytes	544 12 O
from	557 4 O
patients	562 8 O
indeed	571 6 O
showed	578 6 O
a	585 1 O
significant	587 11 O
increase	599 8 O
of	608 2 O
PS	611 2 B-Chemical
exposure	614 8 O
within	623 6 O
1	630 1 O
week	632 4 O
of	637 2 O
treatment	640 9 O
with	650 4 O
azathioprine	655 12 B-Chemical
.	667 1 O

In	669 2 O
a	672 1 O
second	674 6 O
series	681 6 O
,	687 1 O
cytosolic	689 9 O
Ca2	699 3 B-Chemical
+	702 1 O
activity	704 8 O
(	713 1 O
Fluo3	714 5 B-Chemical
fluorescence	720 12 O
)	732 1 O
,	733 1 O
cell	735 4 O
volume	740 6 O
(	747 1 O
forward	748 7 O
scatter	756 7 O
)	763 1 O
,	764 1 O
and	766 3 O
PS	770 2 B-Chemical
-	772 1 O
exposure	773 8 O
(	782 1 O
annexin	783 7 O
V	791 1 O
binding	793 7 O
)	800 1 O
were	802 4 O
determined	807 10 O
by	818 2 O
FACS	821 4 O
analysis	826 8 O
in	835 2 O
erythrocytes	838 12 O
from	851 4 O
healthy	856 7 O
volunteers	864 10 O
.	874 1 O

RESULTS	876 7 O
:	883 1 O
Exposure	885 8 O
to	894 2 O
azathioprine	897 12 B-Chemical
(	910 1 O
>	911 1 O
or	913 2 O
=	916 1 O
2	917 1 O
microg	919 6 O
/	925 1 O
mL	926 2 O
)	928 1 O
for	930 3 O
48	934 2 O
hours	937 5 O
increased	943 9 O
cytosolic	953 9 O
Ca2	963 3 B-Chemical
+	966 1 O
activity	968 8 O
and	977 3 O
annexin	981 7 O
V	989 1 O
binding	991 7 O
and	999 3 O
decreased	1003 9 O
forward	1013 7 O
scatter	1021 7 O
.	1028 1 O

The	1030 3 O
effect	1034 6 O
of	1041 2 O
azathioprine	1044 12 B-Chemical
on	1057 2 O
both	1060 4 O
annexin	1065 7 O
V	1073 1 O
binding	1075 7 O
and	1083 3 O
forward	1087 7 O
scatter	1095 7 O
was	1103 3 O
significantly	1107 13 O
blunted	1121 7 O
in	1129 2 O
the	1132 3 O
nominal	1136 7 O
absence	1144 7 O
of	1152 2 O
extracellular	1155 13 O
Ca2	1169 3 B-Chemical
+	1172 1 O
.	1173 1 O

CONCLUSIONS	1175 11 O
:	1186 1 O
Azathioprine	1188 12 B-Chemical
triggers	1201 8 O
suicidal	1210 8 O
erythrocyte	1219 11 O
death	1231 5 O
,	1236 1 O
an	1238 2 O
effect	1241 6 O
presumably	1248 10 O
contributing	1259 12 O
to	1272 2 O
azathioprine	1275 12 B-Chemical
-	1287 1 O
induced	1288 7 O
anemia	1296 6 B-Disease
.	1302 1 O

Clinical	0 8 O
comparison	9 10 O
of	20 2 O
cardiorespiratory	23 17 O
effects	41 7 O
during	49 6 O
unilateral	56 10 O
and	67 3 O
conventional	71 12 O
spinal	84 6 O
anaesthesia	91 11 O
.	102 1 O

BACKGROUND	104 10 O
:	114 1 O
Spinal	116 6 O
anaesthesia	123 11 O
is	135 2 O
widely	138 6 O
employed	145 8 O
in	154 2 O
clinical	157 8 O
practice	166 8 O
but	175 3 O
has	179 3 O
the	183 3 O
main	187 4 O
drawback	192 8 O
of	201 2 O
post	204 4 O
-	208 1 O
spinal	209 6 O
block	216 5 O
hypotension	222 11 B-Disease
.	233 1 O

Efforts	235 7 O
must	243 4 O
therefore	248 9 O
continue	258 8 O
to	267 2 O
be	270 2 O
made	273 4 O
to	278 2 O
obviate	281 7 O
this	289 4 O
setback	294 7 O
OBJECTIVE	302 9 O
:	311 1 O
To	313 2 O
evaluate	316 8 O
the	325 3 O
cardiovascular	329 14 O
and	344 3 O
respiratory	348 11 O
changes	360 7 O
during	368 6 O
unilateral	375 10 O
and	386 3 O
conventional	390 12 O
spinal	403 6 O
anaesthesia	410 11 O
.	421 1 O

METHODS	423 7 O
:	430 1 O
With	432 4 O
ethical	437 7 O
approval	445 8 O
,	453 1 O
we	455 2 O
studied	458 7 O
74	466 2 O
American	469 8 O
Society	478 7 O
of	486 2 O
Anesthesiologists	489 17 O
(	507 1 O
ASA	508 3 O
)	511 1 O
,	512 1 O
physical	514 8 O
status	523 6 O
class	530 5 O
1	536 1 O
and	538 3 O
2	542 1 O
patients	544 8 O
scheduled	553 9 O
for	563 3 O
elective	567 8 O
unilateral	576 10 O
lower	587 5 O
limb	593 4 O
surgery	598 7 O
.	605 1 O

Patients	607 8 O
were	616 4 O
randomly	621 8 O
allocated	630 9 O
into	640 4 O
one	645 3 O
of	649 2 O
two	652 3 O
groups	656 6 O
:	662 1 O
lateral	664 7 O
and	672 3 O
conventional	676 12 O
spinal	689 6 O
anaesthesia	696 11 O
groups	708 6 O
.	714 1 O

In	716 2 O
the	719 3 O
lateral	723 7 O
position	731 8 O
with	740 4 O
operative	745 9 O
side	755 4 O
down	760 4 O
,	764 1 O
patients	766 8 O
recived	775 7 O
10	783 2 O
mg	786 2 O
(	789 1 O
2mls	790 4 O
)	794 1 O
of	796 2 O
0	799 1 O
.	800 1 O
5	801 1 O
%	802 1 O
hyperbaric	804 10 O
bupivacaine	815 11 B-Chemical
through	827 7 O
a	835 1 O
25	837 2 O
-	839 1 O
gauge	840 5 O
spinal	846 6 O
needle	853 6 O
.	859 1 O

Patients	861 8 O
in	870 2 O
the	873 3 O
unilateral	877 10 O
group	888 5 O
were	894 4 O
maintained	899 10 O
in	910 2 O
the	913 3 O
lateral	917 7 O
position	925 8 O
for	934 3 O
15	938 2 O
minutes	941 7 O
following	949 9 O
spinal	959 6 O
injection	966 9 O
while	976 5 O
those	982 5 O
in	988 2 O
the	991 3 O
conventional	995 12 O
group	1008 5 O
were	1014 4 O
turned	1019 6 O
supine	1026 6 O
immediately	1033 11 O
after	1045 5 O
injection	1051 9 O
.	1060 1 O

Blood	1062 5 O
pressure	1068 8 O
,	1076 1 O
heart	1078 5 O
rate	1084 4 O
,	1088 1 O
respiratory	1090 11 O
rate	1102 4 O
and	1107 3 O
oxygen	1111 6 B-Chemical
saturation	1118 10 O
were	1129 4 O
monitored	1134 9 O
over	1144 4 O
1	1149 1 O
hour	1151 4 O
.	1155 1 O

RESULTS	1157 7 O
:	1164 1 O
Three	1166 5 O
patients	1172 8 O
(	1181 1 O
8	1182 1 O
.	1183 1 O
1	1184 1 O
%	1185 1 O
)	1186 1 O
in	1188 2 O
the	1191 3 O
unilateral	1195 10 O
group	1206 5 O
and	1212 3 O
5	1216 1 O
(	1218 1 O
13	1219 2 O
.	1221 1 O
5	1222 1 O
%	1223 1 O
)	1224 1 O
in	1226 2 O
the	1229 3 O
conventional	1233 12 O
group	1246 5 O
developed	1252 9 O
hypotension	1262 11 B-Disease
,	1273 1 O
P	1275 1 O
=	1276 1 O
0	1278 1 O
.	1279 1 O
71	1280 2 O
.	1282 1 O

Four	1284 4 O
(	1289 1 O
10	1290 2 O
.	1292 1 O
8	1293 1 O
%	1294 1 O
)	1295 1 O
patients	1297 8 O
in	1306 2 O
the	1309 3 O
conventional	1313 12 O
group	1326 5 O
and	1332 3 O
1	1336 1 O
(	1338 1 O
2	1339 1 O
.	1340 1 O
7	1341 1 O
%	1342 1 O
)	1343 1 O
in	1345 2 O
the	1348 3 O
unilateral	1352 10 O
group	1363 5 O
,	1368 1 O
P	1370 1 O
=	1371 1 O
0	1373 1 O
.	1374 1 O
17	1375 2 O
required	1378 8 O
epinephrine	1387 11 B-Chemical
infusion	1399 8 O
to	1408 2 O
treat	1411 5 O
hypotension	1417 11 B-Disease
.	1428 1 O

Patients	1430 8 O
in	1439 2 O
the	1442 3 O
conventional	1446 12 O
group	1459 5 O
had	1465 3 O
statistically	1469 13 O
significant	1483 11 O
greater	1495 7 O
fall	1503 4 O
in	1508 2 O
the	1511 3 O
systolic	1515 8 O
blood	1524 5 O
pressures	1530 9 O
at	1540 2 O
15	1543 2 O
,	1545 1 O
30	1547 2 O
and	1550 3 O
45	1554 2 O
minutes	1557 7 O
when	1565 4 O
compared	1570 8 O
to	1579 2 O
the	1582 3 O
baseline	1586 8 O
(	1595 1 O
P	1596 1 O
=	1597 1 O
0	1599 1 O
.	1600 1 O
003	1601 3 O
,	1604 1 O
0	1606 1 O
.	1607 1 O
001	1608 3 O
and	1612 3 O
0	1616 1 O
.	1617 1 O
004	1618 3 O
)	1621 1 O
.	1622 1 O

The	1624 3 O
mean	1628 4 O
respiratory	1633 11 O
rate	1645 4 O
and	1650 3 O
oxygen	1654 6 B-Chemical
saturations	1661 11 O
in	1673 2 O
the	1676 3 O
two	1680 3 O
groups	1684 6 O
were	1691 4 O
similar	1696 7 O
.	1703 1 O

CONCLUSION	1705 10 O
:	1715 1 O
Compared	1717 8 O
to	1726 2 O
conventional	1729 12 O
spinal	1742 6 O
anaesthesia	1749 11 O
,	1760 1 O
unilateral	1762 10 O
spinal	1773 6 O
anaesthesia	1780 11 O
was	1792 3 O
associated	1796 10 O
with	1807 4 O
fewer	1812 5 O
cardiovascular	1818 14 O
perturbations	1833 13 O
.	1846 1 O

Also	1848 4 O
,	1852 1 O
the	1854 3 O
type	1858 4 O
of	1863 2 O
spinal	1866 6 O
block	1873 5 O
instituted	1879 10 O
affected	1890 8 O
neither	1899 7 O
the	1907 3 O
respiratory	1911 11 O
rate	1923 4 O
nor	1928 3 O
the	1932 3 O
arterial	1936 8 O
oxygen	1945 6 B-Chemical
saturation	1952 10 O
.	1962 1 O

Spectrum	0 8 O
of	9 2 O
adverse	12 7 O
events	20 6 O
after	27 5 O
generic	33 7 O
HAART	41 5 O
in	47 2 O
southern	50 8 O
Indian	59 6 O
HIV	66 3 B-Disease
-	69 1 I-Disease
infected	70 8 I-Disease
patients	79 8 O
.	87 1 O

To	89 2 O
determine	92 9 O
the	102 3 O
incidence	106 9 O
of	116 2 O
clinically	119 10 O
significant	130 11 O
adverse	142 7 O
events	150 6 O
after	157 5 O
long	163 4 O
-	167 1 O
term	168 4 O
,	172 1 O
fixed	174 5 O
-	179 1 O
dose	180 4 O
,	184 1 O
generic	186 7 O
highly	194 6 O
active	201 6 O
antiretroviral	208 14 O
therapy	223 7 O
(	231 1 O
HAART	232 5 O
)	237 1 O
use	239 3 O
among	243 5 O
HIV	249 3 B-Disease
-	252 1 I-Disease
infected	253 8 I-Disease
individuals	262 11 O
in	274 2 O
South	277 5 O
India	283 5 O
,	288 1 O
we	290 2 O
examined	293 8 O
the	302 3 O
experiences	306 11 O
of	318 2 O
3154	321 4 O
HIV	326 3 B-Disease
-	329 1 I-Disease
infected	330 8 I-Disease
individuals	339 11 O
who	351 3 O
received	355 8 O
a	364 1 O
minimum	366 7 O
of	374 2 O
3	377 1 O
months	379 6 O
of	386 2 O
generic	389 7 O
HAART	397 5 O
between	403 7 O
February	411 8 O
1996	420 4 O
and	425 3 O
December	429 8 O
2006	438 4 O
at	443 2 O
a	446 1 O
tertiary	448 8 O
HIV	457 3 O
care	461 4 O
referral	466 8 O
center	475 6 O
in	482 2 O
South	485 5 O
India	491 5 O
.	496 1 O

The	498 3 O
most	502 4 O
common	507 6 O
regimens	514 8 O
were	523 4 O
3TC	528 3 B-Chemical
+	532 1 O
d4T	534 3 B-Chemical
+	538 1 O
nevirapine	540 10 B-Chemical
(	551 1 O
NVP	552 3 B-Chemical
)	555 1 O
(	557 1 O
54	558 2 O
.	560 1 O
8	561 1 O
%	562 1 O
)	563 1 O
,	564 1 O
zidovudine	566 10 B-Chemical
(	577 1 O
AZT	578 3 B-Chemical
)	581 1 O
+	583 1 O
3TC	585 3 B-Chemical
+	589 1 O
NVP	591 3 B-Chemical
(	595 1 O
14	596 2 O
.	598 1 O
5	599 1 O
%	600 1 O
)	601 1 O
,	602 1 O
3TC	604 3 B-Chemical
+	608 1 O
d4T	610 3 B-Chemical
+	614 1 O
efavirenz	616 9 B-Chemical
(	626 1 O
EFV	627 3 B-Chemical
)	630 1 O
(	632 1 O
20	633 2 O
.	635 1 O
1	636 1 O
%	637 1 O
)	638 1 O
,	639 1 O
and	641 3 O
AZT	645 3 B-Chemical
+	649 1 O
3TC	651 3 B-Chemical
+	655 1 O
EFV	657 3 B-Chemical
(	661 1 O
5	662 1 O
.	663 1 O
4	664 1 O
%	665 1 O
)	666 1 O
.	667 1 O

The	669 3 O
most	673 4 O
common	678 6 O
adverse	685 7 O
events	693 6 O
and	700 3 O
median	704 6 O
CD4	711 3 O
at	715 2 O
time	718 4 O
of	723 2 O
event	726 5 O
were	732 4 O
rash	737 4 B-Disease
(	742 1 O
15	743 2 O
.	745 1 O
2	746 1 O
%	747 1 O
;	748 1 O
CD4	750 3 O
,	753 1 O
285	755 3 O
cells	759 5 O
/	764 1 O
microL	765 6 O
)	771 1 O
and	773 3 O
peripheral	777 10 B-Disease
neuropathy	788 10 I-Disease
(	799 1 O
9	800 1 O
.	801 1 O
0	802 1 O
%	803 1 O
and	805 3 O
348	809 3 O
cells	813 5 O
/	818 1 O
microL	819 6 O
)	825 1 O
.	826 1 O

Clinically	828 10 O
significant	839 11 O
anemia	851 6 B-Disease
(	858 1 O
hemoglobin	859 10 O
<	870 1 O
7	871 1 O
g	873 1 O
/	874 1 O
dL	875 2 O
)	877 1 O
was	879 3 O
observed	883 8 O
in	892 2 O
5	895 1 O
.	896 1 O
4	897 1 O
%	898 1 O
of	900 2 O
patients	903 8 O
(	912 1 O
CD4	913 3 O
,	916 1 O
165	918 3 O
cells	922 5 O
/	927 1 O
microL	928 6 O
)	934 1 O
and	936 3 O
hepatitis	940 9 B-Disease
(	950 1 O
clinical	951 8 O
jaundice	960 8 B-Disease
with	969 4 O
alanine	974 7 B-Chemical
aminotransferase	982 16 O
>	999 1 O
5	1001 1 O
times	1003 5 O
upper	1009 5 O
limits	1015 6 O
of	1022 2 O
normal	1025 6 O
)	1031 1 O
in	1033 2 O
3	1036 1 O
.	1037 1 O
5	1038 1 O
%	1039 1 O
of	1041 2 O
patients	1044 8 O
(	1053 1 O
CD4	1054 3 O
,	1057 1 O
260	1059 3 O
cells	1063 5 O
/	1068 1 O
microL	1069 6 O
)	1075 1 O
.	1076 1 O

Women	1078 5 O
were	1084 4 O
significantly	1089 13 O
more	1103 4 O
likely	1108 6 O
to	1115 2 O
experience	1118 10 O
lactic	1129 6 B-Disease
acidosis	1136 8 I-Disease
,	1144 1 O
while	1146 5 O
men	1152 3 O
were	1156 4 O
significantly	1161 13 O
more	1175 4 O
likely	1180 6 O
to	1187 2 O
experience	1190 10 O
immune	1201 6 B-Disease
reconstitution	1208 14 I-Disease
syndrome	1223 8 I-Disease
(	1232 1 O
p	1233 1 O
<	1235 1 O
0	1237 1 O
.	1238 1 O
05	1239 2 O
)	1241 1 O
.	1242 1 O

Among	1244 5 O
the	1250 3 O
patients	1254 8 O
with	1263 4 O
1	1268 1 O
year	1270 4 O
of	1275 2 O
follow	1278 6 O
-	1284 1 O
up	1285 2 O
,	1287 1 O
NVP	1289 3 B-Chemical
therapy	1293 7 O
was	1301 3 O
significantly	1305 13 O
associated	1319 10 O
with	1330 4 O
developing	1335 10 O
rash	1346 4 B-Disease
and	1351 3 O
d4T	1355 3 B-Chemical
therapy	1359 7 O
with	1367 4 O
developing	1372 10 O
peripheral	1383 10 B-Disease
neuropathy	1394 10 I-Disease
(	1405 1 O
p	1406 1 O
<	1408 1 O
0	1410 1 O
.	1411 1 O
05	1412 2 O
)	1414 1 O
.	1415 1 O

Anemia	1417 6 B-Disease
and	1424 3 O
hepatitis	1428 9 B-Disease
often	1438 5 O
occur	1444 5 O
within	1450 6 O
12	1457 2 O
weeks	1460 5 O
of	1466 2 O
initiating	1469 10 O
generic	1480 7 O
HAART	1488 5 O
.	1493 1 O

Frequent	1495 8 O
and	1504 3 O
early	1508 5 O
monitoring	1514 10 O
for	1525 3 O
these	1529 5 O
toxicities	1535 10 B-Disease
is	1546 2 O
warranted	1549 9 O
in	1559 2 O
developing	1562 10 O
countries	1573 9 O
where	1583 5 O
generic	1589 7 O
HAART	1597 5 O
is	1603 2 O
increasingly	1606 12 O
available	1619 9 O
.	1628 1 O

Thalidomide	0 11 B-Chemical
and	12 3 O
sensory	16 7 B-Disease
neurotoxicity	24 13 I-Disease
:	37 1 O
a	39 1 O
neurophysiological	41 18 O
study	60 5 O
.	65 1 O

BACKGROUND	67 10 O
:	77 1 O
Recent	79 6 O
studies	86 7 O
confirmed	94 9 O
a	104 1 O
high	106 4 O
incidence	111 9 O
of	121 2 O
sensory	124 7 B-Disease
axonal	132 6 I-Disease
neuropathy	139 10 I-Disease
in	150 2 O
patients	153 8 O
treated	162 7 O
with	170 4 O
different	175 9 O
doses	185 5 O
of	191 2 O
thalidomide	194 11 B-Chemical
.	205 1 O

The	207 3 O
study	211 5 O
'	216 1 O
s	217 1 O
aims	219 4 O
were	224 4 O
to	229 2 O
measure	232 7 O
variations	240 10 O
in	251 2 O
sural	254 5 O
nerve	260 5 O
sensory	266 7 O
action	274 6 O
potential	281 9 O
(	291 1 O
SAP	292 3 O
)	295 1 O
amplitude	297 9 O
in	307 2 O
patients	310 8 O
with	319 4 O
refractory	324 10 O
cutaneous	335 9 B-Disease
lupus	345 5 I-Disease
erythematosus	351 13 I-Disease
(	365 1 O
CLE	366 3 B-Disease
)	369 1 O
treated	371 7 O
with	379 4 O
thalidomide	384 11 B-Chemical
and	396 3 O
use	400 3 O
these	404 5 O
findings	410 8 O
to	419 2 O
identify	422 8 O
the	431 3 O
neurotoxic	435 10 B-Disease
potential	446 9 O
of	456 2 O
thalidomide	459 11 B-Chemical
and	471 3 O
the	475 3 O
recovery	479 8 O
capacity	488 8 O
of	497 2 O
sensory	500 7 O
fibres	508 6 O
after	515 5 O
discontinuation	521 15 O
of	537 2 O
treatment	540 9 O
.	549 1 O

PATIENTS	551 8 O
AND	560 3 O
METHODS	564 7 O
:	571 1 O
Clinical	573 8 O
and	582 3 O
electrophysiological	586 20 O
data	607 4 O
in	612 2 O
12	615 2 O
female	618 6 O
patients	625 8 O
with	634 4 O
CLE	639 3 B-Disease
during	643 6 O
treatment	650 9 O
with	660 4 O
thalidomide	665 11 B-Chemical
and	677 3 O
up	681 2 O
to	684 2 O
47	687 2 O
months	690 6 O
after	697 5 O
discontinuation	703 15 O
of	719 2 O
treatment	722 9 O
were	732 4 O
analysed	737 8 O
.	745 1 O

Sural	747 5 O
nerve	753 5 O
SAP	759 3 O
amplitude	763 9 O
reduction	773 9 O
>	783 1 O
or	785 2 O
=	788 1 O
40	789 2 O
%	791 1 O
was	793 3 O
the	797 3 O
criteria	801 8 O
for	810 3 O
discontinuing	814 13 O
therapy	828 7 O
.	835 1 O

RESULTS	837 7 O
:	844 1 O
During	846 6 O
treatment	853 9 O
,	862 1 O
11	864 2 O
patients	867 8 O
showed	876 6 O
a	883 1 O
reduction	885 9 O
in	895 2 O
sural	898 5 O
nerve	904 5 O
SAP	910 3 O
amplitude	914 9 O
compared	924 8 O
to	933 2 O
baseline	936 8 O
values	945 6 O
(	952 1 O
9	953 1 O
with	955 4 O
a	960 1 O
reduction	962 9 O
>	972 1 O
or	974 2 O
=	977 1 O
50	978 2 O
%	980 1 O
and	982 3 O
2	986 1 O
<	988 1 O
50	989 2 O
%	991 1 O
)	992 1 O
.	993 1 O

One	995 3 O
patient	999 7 O
showed	1007 6 O
no	1014 2 O
changes	1017 7 O
in	1025 2 O
SAP	1028 3 O
amplitude	1032 9 O
.	1041 1 O

Five	1043 4 O
patients	1048 8 O
complained	1057 10 O
of	1068 2 O
paresthesias	1071 12 B-Disease
and	1084 3 O
leg	1088 3 O
cramps	1092 6 B-Disease
.	1098 1 O

After	1100 5 O
thalidomide	1106 11 B-Chemical
treatment	1118 9 O
,	1127 1 O
sural	1129 5 O
SAP	1135 3 O
amplitude	1139 9 O
recovered	1149 9 O
in	1159 2 O
3	1162 1 O
patients	1164 8 O
.	1172 1 O

At	1174 2 O
detection	1177 9 O
of	1187 2 O
reduction	1190 9 O
in	1200 2 O
sural	1203 5 O
nerve	1209 5 O
SAP	1215 3 O
amplitude	1219 9 O
,	1228 1 O
the	1230 3 O
median	1234 6 O
thalidomide	1241 11 B-Chemical
cumulative	1253 10 O
dose	1264 4 O
was	1269 3 O
21	1273 2 O
.	1275 1 O
4	1276 1 O
g	1278 1 O
.	1279 1 O

The	1281 3 O
threshold	1285 9 O
neurotoxic	1295 10 B-Disease
dosage	1306 6 O
is	1313 2 O
lower	1316 5 O
than	1322 4 O
previously	1327 10 O
reported	1338 8 O
.	1346 1 O

CONCLUSIONS	1348 11 O
:	1359 1 O
Sural	1361 5 O
nerve	1367 5 O
SAP	1373 3 O
amplitude	1377 9 O
reduction	1387 9 O
is	1397 2 O
a	1400 1 O
reliable	1402 8 O
and	1411 3 O
sensitive	1415 9 O
marker	1425 6 O
of	1432 2 O
degeneration	1435 12 O
and	1448 3 O
recovery	1452 8 O
of	1461 2 O
sensory	1464 7 O
fibres	1472 6 O
.	1478 1 O

This	1480 4 O
electrophysiological	1485 20 O
parameter	1506 9 O
provides	1516 8 O
information	1525 11 O
about	1537 5 O
subclinical	1543 11 O
neurotoxic	1555 10 B-Disease
potential	1566 9 O
of	1576 2 O
thalidomide	1579 11 B-Chemical
but	1591 3 O
is	1595 2 O
not	1598 3 O
helpful	1602 7 O
in	1610 2 O
predicting	1613 10 O
the	1624 3 O
appearance	1628 10 O
of	1639 2 O
sensory	1642 7 O
symptoms	1650 8 O
.	1658 1 O

Amiodarone	0 10 B-Chemical
-	10 1 O
related	11 7 O
pulmonary	19 9 B-Disease
mass	29 4 I-Disease
and	34 3 O
unique	38 6 O
membranous	45 10 B-Disease
glomerulonephritis	56 18 I-Disease
in	75 2 O
a	78 1 O
patient	80 7 O
with	88 4 O
valvular	93 8 B-Disease
heart	102 5 I-Disease
disease	108 7 I-Disease
:	115 1 O
Diagnostic	117 10 O
pitfall	128 7 O
and	136 3 O
new	140 3 O
findings	144 8 O
.	152 1 O

Amiodarone	154 10 B-Chemical
is	165 2 O
an	168 2 O
anti	171 4 O
-	175 1 O
arrhythmic	176 10 B-Disease
drug	187 4 O
for	192 3 O
life	196 4 O
-	200 1 O
threatening	201 11 O
tachycardia	213 11 B-Disease
,	224 1 O
but	226 3 O
various	230 7 O
adverse	238 7 O
effects	246 7 O
have	254 4 O
been	259 4 O
reported	264 8 O
.	272 1 O

Reported	274 8 O
herein	283 6 O
is	290 2 O
an	293 2 O
autopsy	296 7 O
case	304 4 O
of	309 2 O
valvular	312 8 B-Disease
heart	321 5 I-Disease
disease	327 7 I-Disease
,	334 1 O
in	336 2 O
a	339 1 O
patient	341 7 O
who	349 3 O
developed	353 9 O
a	363 1 O
lung	365 4 B-Disease
mass	370 4 I-Disease
(	375 1 O
1	376 1 O
.	377 1 O
5	378 1 O
cm	380 2 O
in	383 2 O
diameter	386 8 O
)	394 1 O
and	396 3 O
proteinuria	400 11 B-Disease
(	412 1 O
2	413 1 O
.	414 1 O
76	415 2 O
g	418 1 O
/	419 1 O
day	420 3 O
)	423 1 O
after	425 5 O
treatment	431 9 O
with	441 4 O
amiodarone	446 10 B-Chemical
for	457 3 O
a	461 1 O
long	463 4 O
time	468 4 O
.	472 1 O

The	474 3 O
lung	478 4 B-Disease
mass	483 4 I-Disease
was	488 3 O
highly	492 6 O
suspected	499 9 O
to	509 2 O
be	512 2 O
lung	515 4 B-Disease
cancer	520 6 I-Disease
on	527 2 O
CT	530 2 O
and	533 3 O
positron	537 8 O
emission	546 8 O
tomography	555 10 O
,	565 1 O
but	567 3 O
histologically	571 14 O
the	586 3 O
lesion	590 6 O
was	597 3 O
composed	601 8 O
of	610 2 O
lymphoplasmacytic	613 17 O
infiltrates	631 11 O
in	643 2 O
alveolar	646 8 O
walls	655 5 O
and	661 3 O
intra	665 5 O
-	670 1 O
alveolar	671 8 O
accumulation	680 12 O
of	693 2 O
foamy	696 5 O
macrophages	702 11 O
containing	714 10 O
characteristic	725 14 O
myelinoid	740 9 O
bodies	750 6 O
,	756 1 O
indicating	758 10 O
that	769 4 O
it	774 2 O
was	777 3 O
an	781 2 O
amiodarone	784 10 B-Chemical
-	794 1 O
related	795 7 O
lesion	803 6 O
.	809 1 O

In	811 2 O
addition	814 8 O
,	822 1 O
the	824 3 O
lung	828 4 O
tissue	833 6 O
had	840 3 O
unevenly	844 8 O
distributed	853 11 O
hemosiderin	865 11 B-Disease
deposition	877 10 O
,	887 1 O
and	889 3 O
abnormally	893 10 O
tortuous	904 8 O
capillaries	913 11 O
were	925 4 O
seen	930 4 O
in	935 2 O
the	938 3 O
mass	942 4 O
and	947 3 O
in	951 2 O
heavily	954 7 O
hemosiderotic	962 13 B-Disease
lung	976 4 O
portions	981 8 O
outside	990 7 O
the	998 3 O
mass	1002 4 O
.	1006 1 O

In	1008 2 O
the	1011 3 O
kidneys	1015 7 O
,	1022 1 O
glomeruli	1024 9 O
had	1034 3 O
membrane	1038 8 O
spikes	1047 6 O
,	1053 1 O
prominent	1055 9 O
swelling	1065 8 O
of	1074 2 O
podocytes	1077 9 O
and	1087 3 O
subepithelial	1091 13 O
deposits	1105 8 O
,	1113 1 O
which	1115 5 O
were	1121 4 O
sometimes	1126 9 O
large	1136 5 O
and	1142 3 O
hump	1146 4 O
-	1150 1 O
like	1151 4 O
.	1155 1 O

Autoimmune	1157 10 B-Disease
diseases	1168 8 I-Disease
,	1176 1 O
viral	1178 5 B-Disease
hepatitis	1184 9 I-Disease
,	1193 1 O
malignant	1195 9 O
neoplasms	1205 9 B-Disease
or	1215 2 O
other	1218 5 O
diseases	1224 8 O
with	1233 4 O
a	1238 1 O
known	1240 5 O
relationship	1246 12 O
to	1259 2 O
membranous	1262 10 B-Disease
glomerulonephritis	1273 18 I-Disease
were	1292 4 O
not	1297 3 O
found	1301 5 O
.	1306 1 O

The	1308 3 O
present	1312 7 O
case	1320 4 O
highlights	1325 10 O
the	1336 3 O
possibility	1340 11 O
that	1352 4 O
differential	1357 12 O
diagnosis	1370 9 O
between	1380 7 O
an	1388 2 O
amiodarone	1391 10 B-Chemical
-	1401 1 O
related	1402 7 O
pulmonary	1410 9 B-Disease
lesion	1420 6 I-Disease
and	1427 3 O
a	1431 1 O
neoplasm	1433 8 B-Disease
can	1442 3 O
be	1446 2 O
very	1449 4 O
difficult	1454 9 O
radiologically	1464 14 O
,	1478 1 O
and	1480 3 O
suggests	1484 8 O
that	1493 4 O
membranous	1498 10 B-Disease
glomerulonephritis	1509 18 I-Disease
might	1528 5 O
be	1534 2 O
another	1537 7 O
possible	1545 8 O
complication	1554 12 O
of	1567 2 O
amiodarone	1570 10 B-Chemical
treatment	1581 9 O
.	1590 1 O

Risk	0 4 O
of	5 2 O
coronary	8 8 B-Disease
artery	17 6 I-Disease
disease	24 7 I-Disease
associated	32 10 O
with	43 4 O
initial	48 7 O
sulphonylurea	56 13 B-Chemical
treatment	70 9 O
of	80 2 O
patients	83 8 O
with	92 4 O
type	97 4 B-Disease
2	102 1 I-Disease
diabetes	104 8 I-Disease
:	112 1 O
a	114 1 O
matched	116 7 O
case	124 4 O
-	128 1 O
control	129 7 O
study	137 5 O
.	142 1 O

AIMS	144 4 O
:	148 1 O
This	150 4 O
study	155 5 O
sought	161 6 O
to	168 2 O
assess	171 6 O
the	178 3 O
risk	182 4 O
of	187 2 O
developing	190 10 O
coronary	201 8 B-Disease
artery	210 6 I-Disease
disease	217 7 I-Disease
(	225 1 O
CAD	226 3 B-Disease
)	229 1 O
associated	231 10 O
with	242 4 O
initial	247 7 O
treatment	255 9 O
of	265 2 O
type	268 4 B-Disease
2	273 1 I-Disease
diabetes	275 8 I-Disease
with	284 4 O
different	289 9 O
sulphonylureas	299 14 B-Chemical
.	313 1 O

METHODS	315 7 O
:	322 1 O
In	324 2 O
type	327 4 B-Disease
2	332 1 I-Disease
diabetic	334 8 I-Disease
patients	343 8 O
,	351 1 O
cases	353 5 O
who	359 3 O
developed	363 9 O
CAD	373 3 B-Disease
were	377 4 O
compared	382 8 O
retrospectively	391 15 O
with	407 4 O
controls	412 8 O
that	421 4 O
did	426 3 O
not	430 3 O
.	433 1 O

The	435 3 O
20	439 2 O
-	441 1 O
year	442 4 O
risk	447 4 O
of	452 2 O
CAD	455 3 B-Disease
at	459 2 O
diagnosis	462 9 O
of	472 2 O
diabetes	475 8 B-Disease
,	483 1 O
using	485 5 O
the	491 3 O
UKPDS	495 5 O
risk	501 4 O
engine	506 6 O
,	512 1 O
was	514 3 O
used	518 4 O
to	523 2 O
match	526 5 O
cases	532 5 O
with	538 4 O
controls	543 8 O
.	551 1 O

RESULTS	553 7 O
:	560 1 O
The	562 3 O
76	566 2 O
cases	569 5 O
of	575 2 O
CAD	578 3 B-Disease
were	582 4 O
compared	587 8 O
with	596 4 O
152	601 3 O
controls	605 8 O
.	613 1 O

The	615 3 O
hazard	619 6 O
of	626 2 O
developing	629 10 O
CAD	640 3 B-Disease
(	644 1 O
95	645 2 O
%	647 1 O
CI	649 2 O
)	651 1 O
associated	653 10 O
with	664 4 O
initial	669 7 O
treatment	677 9 O
increased	687 9 O
by	697 2 O
2	700 1 O
.	701 1 O
4	702 1 O
-	703 1 O
fold	704 4 O
(	709 1 O
1	710 1 O
.	711 1 O
3	712 1 O
-	713 1 O
4	714 1 O
.	715 1 O
3	716 1 O
,	717 1 O
P	719 1 O
=	720 1 O
0	721 1 O
.	722 1 O
004	723 3 O
)	726 1 O
with	728 4 O
glibenclamide	733 13 B-Chemical
;	746 1 O
2	748 1 O
-	749 1 O
fold	750 4 O
(	755 1 O
0	756 1 O
.	757 1 O
9	758 1 O
-	759 1 O
4	760 1 O
.	761 1 O
6	762 1 O
,	763 1 O
P	765 1 O
=	766 1 O
0	767 1 O
.	768 1 O
099	769 3 O
)	772 1 O
with	774 4 O
glipizide	779 9 B-Chemical
;	788 1 O
2	790 1 O
.	791 1 O
9	792 1 O
-	793 1 O
fold	794 4 O
(	799 1 O
1	800 1 O
.	801 1 O
6	802 1 O
-	803 1 O
5	804 1 O
.	805 1 O
1	806 1 O
,	807 1 O
P	809 1 O
=	810 1 O
0	811 1 O
.	812 1 O
000	813 3 O
)	816 1 O
with	818 4 O
either	823 6 O
,	829 1 O
and	831 3 O
was	835 3 O
unchanged	839 9 O
with	849 4 O
metformin	854 9 B-Chemical
.	863 1 O

The	865 3 O
hazard	869 6 O
decreased	876 9 O
0	886 1 O
.	887 1 O
3	888 1 O
-	889 1 O
fold	890 4 O
(	895 1 O
0	896 1 O
.	897 1 O
7	898 1 O
-	899 1 O
1	900 1 O
.	901 1 O
7	902 1 O
,	903 1 O
P	905 1 O
=	906 1 O
0	907 1 O
.	908 1 O
385	909 3 O
)	912 1 O
with	914 4 O
glimepiride	919 11 B-Chemical
,	930 1 O
0	932 1 O
.	933 1 O
4	934 1 O
-	935 1 O
fold	936 4 O
(	941 1 O
0	942 1 O
.	943 1 O
7	944 1 O
-	945 1 O
1	946 1 O
.	947 1 O
3	948 1 O
,	949 1 O
P	951 1 O
=	952 1 O
0	953 1 O
.	954 1 O
192	955 3 O
)	958 1 O
with	960 4 O
gliclazide	965 10 B-Chemical
,	975 1 O
and	977 3 O
0	981 1 O
.	982 1 O
4	983 1 O
-	984 1 O
fold	985 4 O
(	990 1 O
0	991 1 O
.	992 1 O
7	993 1 O
-	994 1 O
1	995 1 O
.	996 1 O
1	997 1 O
,	998 1 O
P	1000 1 O
=	1001 1 O
0	1002 1 O
.	1003 1 O
09	1004 2 O
)	1006 1 O
with	1008 4 O
either	1013 6 O
.	1019 1 O

CONCLUSIONS	1021 11 O
:	1032 1 O
Initiating	1034 10 O
treatment	1045 9 O
of	1055 2 O
type	1058 4 B-Disease
2	1063 1 I-Disease
diabetes	1065 8 I-Disease
with	1074 4 O
glibenclamide	1079 13 B-Chemical
or	1093 2 O
glipizide	1096 9 B-Chemical
is	1106 2 O
associated	1109 10 O
with	1120 4 O
increased	1125 9 O
risk	1135 4 O
of	1140 2 O
CAD	1143 3 B-Disease
in	1147 2 O
comparison	1150 10 O
to	1161 2 O
gliclazide	1164 10 B-Chemical
or	1175 2 O
glimepiride	1178 11 B-Chemical
.	1189 1 O

If	1191 2 O
confirmed	1194 9 O
,	1203 1 O
this	1205 4 O
may	1210 3 O
be	1214 2 O
important	1217 9 O
because	1227 7 O
most	1235 4 O
Indian	1240 6 O
patients	1247 8 O
receive	1256 7 O
the	1264 3 O
cheaper	1268 7 O
older	1276 5 O
sulphonylureas	1282 14 B-Chemical
,	1296 1 O
and	1298 3 O
present	1302 7 O
guidelines	1310 10 O
do	1321 2 O
not	1324 3 O
distinguish	1328 11 O
between	1340 7 O
individual	1348 10 O
agents	1359 6 O
.	1365 1 O

Reduced	0 7 O
progression	8 11 O
of	20 2 O
adriamycin	23 10 B-Chemical
nephropathy	34 11 B-Disease
in	46 2 O
spontaneously	49 13 O
hypertensive	63 12 B-Disease
rats	76 4 O
treated	81 7 O
by	89 2 O
losartan	92 8 B-Chemical
.	100 1 O

BACKGROUND	102 10 O
:	112 1 O
The	114 3 O
aim	118 3 O
of	122 2 O
the	125 3 O
study	129 5 O
was	135 3 O
to	139 2 O
investigate	142 11 O
the	154 3 O
antihypertensive	158 16 O
effects	175 7 O
of	183 2 O
angiotensin	186 11 B-Chemical
II	198 2 I-Chemical
type	201 4 O
-	205 1 O
1	206 1 O
receptor	208 8 O
blocker	217 7 O
,	224 1 O
losartan	226 8 B-Chemical
,	234 1 O
and	236 3 O
its	240 3 O
potential	244 9 O
in	254 2 O
slowing	257 7 O
down	265 4 O
renal	270 5 B-Disease
disease	276 7 I-Disease
progression	284 11 O
in	296 2 O
spontaneously	299 13 O
hypertensive	313 12 B-Disease
rats	326 4 O
(	331 1 O
SHR	332 3 O
)	335 1 O
with	337 4 O
adriamycin	342 10 B-Chemical
(	353 1 O
ADR	354 3 B-Chemical
)	357 1 O
nephropathy	359 11 B-Disease
.	370 1 O

METHODS	372 7 O
:	379 1 O
Six	381 3 O
-	384 1 O
month	385 5 O
-	390 1 O
old	391 3 O
female	395 6 O
SHR	402 3 O
were	406 4 O
randomly	411 8 O
selected	420 8 O
in	429 2 O
six	432 3 O
groups	436 6 O
.	442 1 O

Two	444 3 O
control	448 7 O
groups	456 6 O
(	463 1 O
SH	464 2 O
(	466 1 O
6	467 1 O
)	468 1 O
,	469 1 O
SH	471 2 O
(	473 1 O
12	474 2 O
)	476 1 O
)	477 1 O
received	479 8 O
vehicle	488 7 O
.	495 1 O

Groups	497 6 O
ADR	504 3 B-Chemical
(	507 1 O
6	508 1 O
)	509 1 O
,	510 1 O
ADR	512 3 B-Chemical
+	515 1 O
LOS	516 3 B-Chemical
(	519 1 O
6	520 1 O
)	521 1 O
and	523 3 O
ADR	527 3 B-Chemical
(	530 1 O
12	531 2 O
)	533 1 O
,	534 1 O
and	536 3 O
ADR	540 3 B-Chemical
+	543 1 O
LOS	544 3 B-Chemical
(	547 1 O
12	548 2 O
)	550 1 O
received	552 8 O
ADR	561 3 B-Chemical
(	565 1 O
2	566 1 O
mg	568 2 O
/	570 1 O
kg	571 2 O
/	573 1 O
b	574 1 O
.	575 1 O
w	576 1 O
.	577 1 O
i	579 1 O
.	580 1 O
v	581 1 O
.	582 1 O
)	583 1 O
twice	585 5 O
in	591 2 O
a	594 1 O
3	596 1 O
-	597 1 O
week	598 4 O
interval	603 8 O
.	611 1 O

Group	613 5 O
ADR	619 3 B-Chemical
+	622 1 O
LOS	623 3 B-Chemical
(	626 1 O
6	627 1 O
)	628 1 O
received	630 8 O
losartan	639 8 B-Chemical
(	648 1 O
10	649 2 O
mg	652 2 O
/	654 1 O
kg	655 2 O
/	657 1 O
b	658 1 O
.	659 1 O
w	660 1 O
.	661 1 O
/	662 1 O
day	663 3 O
by	667 2 O
gavages	670 7 O
)	677 1 O
for	679 3 O
6	683 1 O
weeks	685 5 O
and	691 3 O
group	695 5 O
ADR	701 3 B-Chemical
+	704 1 O
LOS	705 3 B-Chemical
(	708 1 O
12	709 2 O
)	711 1 O
for	713 3 O
12	717 2 O
weeks	720 5 O
after	726 5 O
second	732 6 O
injection	739 9 O
of	749 2 O
ADR	752 3 B-Chemical
.	755 1 O

Animals	757 7 O
were	765 4 O
killed	770 6 O
after	777 5 O
6	783 1 O
or	785 2 O
12	788 2 O
weeks	791 5 O
,	796 1 O
respectively	798 12 O
.	810 1 O

Haemodynamic	812 12 O
measurements	825 12 O
were	838 4 O
performed	843 9 O
on	853 2 O
anaesthetized	856 13 O
animals	870 7 O
,	877 1 O
blood	879 5 O
and	885 3 O
urine	889 5 O
samples	895 7 O
were	903 4 O
taken	908 5 O
for	914 3 O
biochemical	918 11 O
analysis	930 8 O
and	939 3 O
the	943 3 O
left	947 4 O
kidney	952 6 O
was	959 3 O
processed	963 9 O
for	973 3 O
morphological	977 13 O
studies	991 7 O
.	998 1 O

RESULTS	1000 7 O
:	1007 1 O
Short	1009 5 O
-	1014 1 O
term	1015 4 O
losartan	1020 8 B-Chemical
treatment	1029 9 O
,	1038 1 O
besides	1040 7 O
antihypertensive	1048 16 O
effect	1065 6 O
,	1071 1 O
improved	1073 8 O
glomerular	1082 10 O
filtration	1093 10 O
rate	1104 4 O
and	1109 3 O
ameliorated	1113 11 O
glomerulosclerosis	1125 18 B-Disease
resulting	1144 9 O
in	1154 2 O
decreased	1157 9 O
proteinuria	1167 11 B-Disease
.	1178 1 O

Prolonged	1180 9 O
treatment	1190 9 O
with	1200 4 O
losartan	1205 8 B-Chemical
showed	1214 6 O
further	1221 7 O
reduction	1229 9 O
of	1239 2 O
glomerulosclerosis	1242 18 B-Disease
associated	1261 10 O
with	1272 4 O
reduced	1277 7 O
progression	1285 11 O
of	1297 2 O
tubular	1300 7 O
atrophy	1308 7 B-Disease
and	1316 3 O
interstitial	1320 12 B-Disease
fibrosis	1333 8 I-Disease
,	1341 1 O
thus	1343 4 O
preventing	1348 10 O
heavy	1359 5 O
proteinuria	1365 11 B-Disease
and	1377 3 O
chronic	1381 7 B-Disease
renal	1389 5 I-Disease
failure	1395 7 I-Disease
.	1402 1 O

Losartan	1404 8 B-Chemical
reduced	1413 7 O
uraemia	1421 7 B-Disease
and	1429 3 O
increased	1433 9 O
urea	1443 4 B-Chemical
clearance	1448 9 O
in	1458 2 O
advanced	1461 8 O
ADR	1470 3 B-Chemical
nephropathy	1474 11 B-Disease
in	1486 2 O
SHR	1489 3 O
.	1492 1 O

Histological	1494 12 O
examination	1507 11 O
showed	1519 6 O
that	1526 4 O
losartan	1531 8 B-Chemical
could	1540 5 O
prevent	1546 7 O
tubular	1554 7 O
atrophy	1562 7 B-Disease
,	1569 1 O
interstitial	1571 12 O
infiltration	1584 12 O
and	1597 3 O
fibrosis	1601 8 B-Disease
in	1610 2 O
ADR	1613 3 B-Chemical
nephropathy	1617 11 B-Disease
.	1628 1 O

CONCLUSION	1630 10 O
:	1640 1 O
Losartan	1642 8 B-Chemical
reduces	1651 7 O
the	1659 3 O
rate	1663 4 O
of	1668 2 O
progression	1671 11 O
of	1683 2 O
ADR	1686 3 B-Chemical
-	1689 1 O
induced	1690 7 O
focal	1698 5 B-Disease
segmental	1704 9 I-Disease
glomerulosclerosis	1714 18 I-Disease
to	1733 2 O
end	1736 3 B-Disease
-	1739 1 I-Disease
stage	1740 5 I-Disease
renal	1746 5 I-Disease
disease	1752 7 I-Disease
in	1760 2 O
SHR	1763 3 O
.	1766 1 O

The	0 3 O
risks	4 5 O
of	10 2 O
aprotinin	13 9 O
and	23 3 O
tranexamic	27 10 B-Chemical
acid	38 4 I-Chemical
in	43 2 O
cardiac	46 7 O
surgery	54 7 O
:	61 1 O
a	63 1 O
one	65 3 O
-	68 1 O
year	69 4 O
follow	74 6 O
-	80 1 O
up	81 2 O
of	84 2 O
1188	87 4 O
consecutive	92 11 O
patients	104 8 O
.	112 1 O

BACKGROUND	114 10 O
:	124 1 O
Our	126 3 O
aim	130 3 O
was	134 3 O
to	138 2 O
investigate	141 11 O
postoperative	153 13 O
complications	167 13 O
and	181 3 O
mortality	185 9 O
after	195 5 O
administration	201 14 O
of	216 2 O
aprotinin	219 9 O
compared	229 8 O
to	238 2 O
tranexamic	241 10 B-Chemical
acid	252 4 I-Chemical
in	257 2 O
an	260 2 O
unselected	263 10 O
,	273 1 O
consecutive	275 11 O
cohort	287 6 O
.	293 1 O

METHODS	295 7 O
:	302 1 O
Perioperative	304 13 O
data	318 4 O
from	323 4 O
consecutive	328 11 O
cardiac	340 7 O
surgery	348 7 O
patients	356 8 O
were	365 4 O
prospectively	370 13 O
collected	384 9 O
between	394 7 O
September	402 9 O
2005	412 4 O
and	417 3 O
June	421 4 O
2006	426 4 O
in	431 2 O
a	434 1 O
university	436 10 O
-	446 1 O
affiliated	447 10 O
clinic	458 6 O
(	465 1 O
n	466 1 O
=	468 1 O
1188	470 4 O
)	474 1 O
.	475 1 O

During	477 6 O
the	484 3 O
first	488 5 O
5	494 1 O
mo	496 2 O
,	498 1 O
596	500 3 O
patients	504 8 O
received	513 8 O
aprotinin	522 9 O
(	532 1 O
Group	533 5 O
A	539 1 O
)	540 1 O
;	541 1 O
in	543 2 O
the	546 3 O
next	550 4 O
5	555 1 O
mo	557 2 O
,	559 1 O
592	561 3 O
patients	565 8 O
were	574 4 O
treated	579 7 O
with	587 4 O
tranexamic	592 10 B-Chemical
acid	603 4 I-Chemical
(	608 1 O
Group	609 5 O
T	615 1 O
)	616 1 O
.	617 1 O

Except	619 6 O
for	626 3 O
antifibrinolytic	630 16 O
therapy	647 7 O
,	654 1 O
the	656 3 O
anesthetic	660 10 O
and	671 3 O
surgical	675 8 O
protocols	684 9 O
remained	694 8 O
unchanged	703 9 O
.	712 1 O

RESULTS	714 7 O
:	721 1 O
The	723 3 O
pre	727 3 O
-	730 1 O
and	732 3 O
intraoperative	736 14 O
variables	751 9 O
were	761 4 O
comparable	766 10 O
between	777 7 O
the	785 3 O
treatment	789 9 O
groups	799 6 O
.	805 1 O

Postoperatively	807 15 O
,	822 1 O
a	824 1 O
significantly	826 13 O
higher	840 6 O
incidence	847 9 O
of	857 2 O
seizures	860 8 B-Disease
was	869 3 O
found	873 5 O
in	879 2 O
Group	882 5 O
T	888 1 O
(	890 1 O
4	891 1 O
.	892 1 O
6	893 1 O
%	894 1 O
vs	896 2 O
1	899 1 O
.	900 1 O
2	901 1 O
%	902 1 O
,	903 1 O
P	905 1 O
<	907 1 O
0	909 1 O
.	910 1 O
001	911 3 O
)	914 1 O
.	915 1 O

This	917 4 O
difference	922 10 O
was	933 3 O
also	937 4 O
significant	942 11 O
in	954 2 O
the	957 3 O
primary	961 7 O
valve	969 5 O
surgery	975 7 O
and	983 3 O
the	987 3 O
high	991 4 O
risk	996 4 O
surgery	1001 7 O
subgroups	1009 9 O
(	1019 1 O
7	1020 1 O
.	1021 1 O
9	1022 1 O
%	1023 1 O
vs	1025 2 O
1	1028 1 O
.	1029 1 O
2	1030 1 O
%	1031 1 O
,	1032 1 O
P	1034 1 O
=	1036 1 O
0	1038 1 O
.	1039 1 O
003	1040 3 O
;	1043 1 O
7	1045 1 O
.	1046 1 O
3	1047 1 O
%	1048 1 O
vs	1050 2 O
2	1053 1 O
.	1054 1 O
4	1055 1 O
%	1056 1 O
,	1057 1 O
P	1059 1 O
=	1061 1 O
0	1063 1 O
.	1064 1 O
035	1065 3 O
,	1068 1 O
respectively	1070 12 O
)	1082 1 O
.	1083 1 O

Persistent	1085 10 O
atrial	1096 6 O
fibrillation	1103 12 O
(	1116 1 O
7	1117 1 O
.	1118 1 O
9	1119 1 O
%	1120 1 O
vs	1122 2 O
2	1125 1 O
.	1126 1 O
3	1127 1 O
%	1128 1 O
,	1129 1 O
P	1131 1 O
=	1133 1 O
0	1135 1 O
.	1136 1 O
020	1137 3 O
)	1140 1 O
and	1142 3 O
renal	1146 5 B-Disease
failure	1152 7 I-Disease
(	1160 1 O
9	1161 1 O
.	1162 1 O
7	1163 1 O
%	1164 1 O
vs	1166 2 O
1	1169 1 O
.	1170 1 O
7	1171 1 O
%	1172 1 O
,	1173 1 O
P	1175 1 O
=	1177 1 O
0	1179 1 O
.	1180 1 O
002	1181 3 O
)	1184 1 O
were	1186 4 O
also	1191 4 O
more	1196 4 O
common	1201 6 O
in	1208 2 O
Group	1211 5 O
T	1217 1 O
,	1218 1 O
in	1220 2 O
the	1223 3 O
primary	1227 7 O
valve	1235 5 O
surgery	1241 7 O
subgroup	1249 8 O
.	1257 1 O

On	1259 2 O
the	1262 3 O
contrary	1266 8 O
,	1274 1 O
among	1276 5 O
primary	1282 7 O
coronary	1290 8 O
artery	1299 6 O
bypass	1306 6 O
surgery	1313 7 O
patients	1321 8 O
,	1329 1 O
there	1331 5 O
were	1337 4 O
more	1342 4 O
acute	1347 5 O
myocardial	1353 10 B-Disease
infarctions	1364 11 I-Disease
and	1376 3 O
renal	1380 5 B-Disease
dysfunction	1386 11 I-Disease
in	1398 2 O
Group	1401 5 O
A	1407 1 O
(	1409 1 O
5	1410 1 O
.	1411 1 O
8	1412 1 O
%	1413 1 O
vs	1415 2 O
2	1418 1 O
.	1419 1 O
0	1420 1 O
%	1421 1 O
,	1422 1 O
P	1424 1 O
=	1426 1 O
0	1428 1 O
.	1429 1 O
027	1430 3 O
;	1433 1 O
22	1435 2 O
.	1437 1 O
5	1438 1 O
%	1439 1 O
vs	1441 2 O
15	1444 2 O
.	1446 1 O
2	1447 1 O
%	1448 1 O
,	1449 1 O
P	1451 1 O
=	1453 1 O
0	1455 1 O
.	1456 1 O
036	1457 3 O
,	1460 1 O
respectively	1462 12 O
)	1474 1 O
.	1475 1 O

The	1477 3 O
1	1481 1 O
-	1482 1 O
yr	1483 2 O
mortality	1486 9 O
was	1496 3 O
significantly	1500 13 O
higher	1514 6 O
after	1521 5 O
aprotinin	1527 9 O
treatment	1537 9 O
in	1547 2 O
the	1550 3 O
high	1554 4 O
risk	1559 4 O
surgery	1564 7 O
group	1572 5 O
(	1578 1 O
17	1579 2 O
.	1581 1 O
7	1582 1 O
%	1583 1 O
vs	1585 2 O
9	1588 1 O
.	1589 1 O
8	1590 1 O
%	1591 1 O
,	1592 1 O
P	1594 1 O
=	1596 1 O
0	1598 1 O
.	1599 1 O
034	1600 3 O
)	1603 1 O
.	1604 1 O

CONCLUSION	1606 10 O
:	1616 1 O
Both	1618 4 O
antifibrinolytic	1623 16 O
drugs	1640 5 O
bear	1646 4 O
the	1651 3 O
risk	1655 4 O
of	1660 2 O
adverse	1663 7 O
outcome	1671 7 O
depending	1679 9 O
on	1689 2 O
the	1692 3 O
type	1696 4 O
of	1701 2 O
cardiac	1704 7 O
surgery	1712 7 O
.	1719 1 O

Administration	1721 14 O
of	1736 2 O
aprotinin	1739 9 O
should	1749 6 O
be	1756 2 O
avoided	1759 7 O
in	1767 2 O
coronary	1770 8 O
artery	1779 6 O
bypass	1786 6 O
graft	1793 5 O
and	1799 3 O
high	1803 4 O
risk	1808 4 O
patients	1813 8 O
,	1821 1 O
whereas	1823 7 O
administration	1831 14 O
of	1846 2 O
tranexamic	1849 10 B-Chemical
acid	1860 4 I-Chemical
is	1865 2 O
not	1868 3 O
recommended	1872 11 O
in	1884 2 O
valve	1887 5 O
surgery	1893 7 O
.	1900 1 O

The	0 3 O
biological	4 10 O
properties	15 10 O
of	26 2 O
the	29 3 O
optical	33 7 O
isomers	41 7 O
of	49 2 O
propranolol	52 11 B-Chemical
and	64 3 O
their	68 5 O
effects	74 7 O
on	82 2 O
cardiac	85 7 B-Disease
arrhythmias	93 11 I-Disease
.	104 1 O

1	106 1 O
.	107 1 O

The	109 3 O
optical	113 7 O
isomers	121 7 O
of	129 2 O
propranolol	132 11 B-Chemical
have	144 4 O
been	149 4 O
compared	154 8 O
for	163 3 O
their	167 5 O
beta	173 4 O
-	177 1 O
blocking	178 8 O
and	187 3 O
antiarrhythmic	191 14 O
activities	206 10 O
.	216 1 O
2	217 1 O
.	218 1 O

In	220 2 O
blocking	223 8 O
the	232 3 O
positive	236 8 O
inotropic	245 9 O
and	255 3 O
chronotropic	259 12 O
responses	272 9 O
to	282 2 O
isoprenaline	285 12 B-Chemical
,	297 1 O
(	299 1 O
+	300 1 O
)	301 1 O
-	302 1 O
propranolol	303 11 B-Chemical
had	315 3 O
less	319 4 O
than	324 4 O
one	329 3 O
hundredth	333 9 O
the	343 3 O
potency	347 7 O
of	355 2 O
(	358 1 O
-	359 1 O
)	360 1 O
-	361 1 O
propranolol	362 11 B-Chemical
.	373 1 O

At	375 2 O
dose	378 4 O
levels	383 6 O
of	390 2 O
(	393 1 O
+	394 1 O
)	395 1 O
-	396 1 O
propranolol	397 11 B-Chemical
which	409 5 O
attenuated	415 10 O
the	426 3 O
responses	430 9 O
to	440 2 O
isoprenaline	443 12 B-Chemical
,	455 1 O
there	457 5 O
was	463 3 O
a	467 1 O
significant	469 11 O
prolongation	481 12 O
of	494 2 O
the	497 3 O
PR	501 2 O
interval	504 8 O
of	513 2 O
the	516 3 O
electrocardiogram	520 17 O
.	537 1 O
3	538 1 O
.	539 1 O

The	541 3 O
metabolic	545 9 O
responses	555 9 O
to	565 2 O
isoprenaline	568 12 B-Chemical
in	581 2 O
dogs	584 4 O
(	589 1 O
an	590 2 O
increase	593 8 O
in	602 2 O
circulating	605 11 O
glucose	617 7 B-Chemical
,	624 1 O
lactate	626 7 B-Chemical
and	634 3 O
free	638 4 O
fatty	643 5 B-Chemical
acids	649 5 I-Chemical
)	654 1 O
were	656 4 O
all	661 3 O
blocked	665 7 O
by	673 2 O
(	676 1 O
-	677 1 O
)	678 1 O
-	679 1 O
propranolol	680 11 B-Chemical
.	691 1 O

(	693 1 O
+	694 1 O
)	695 1 O
-	696 1 O
Propranolol	697 11 B-Chemical
had	709 3 O
no	713 2 O
effect	716 6 O
on	723 2 O
fatty	726 5 B-Chemical
acid	732 4 I-Chemical
mobilization	737 12 O
but	750 3 O
significantly	754 13 O
reduced	768 7 O
the	776 3 O
increments	780 10 O
in	791 2 O
both	794 4 O
lactate	799 7 B-Chemical
and	807 3 O
glucose	811 7 B-Chemical
.	818 1 O
4	819 1 O
.	820 1 O

Both	822 4 O
isomers	827 7 O
of	835 2 O
propranolol	838 11 B-Chemical
possessed	850 9 O
similar	860 7 O
depressant	868 10 O
potency	879 7 O
on	887 2 O
isolated	890 8 O
atrial	899 6 O
muscle	906 6 O
taken	913 5 O
from	919 4 O
guinea	924 6 O
-	930 1 O
pigs	931 4 O
.	935 1 O
5	936 1 O
.	937 1 O

The	939 3 O
isomers	943 7 O
of	951 2 O
propranolol	954 11 B-Chemical
exhibited	966 9 O
similar	976 7 O
local	984 5 O
anaesthetic	990 11 O
potencies	1002 9 O
on	1012 2 O
an	1015 2 O
isolated	1018 8 O
frog	1027 4 O
nerve	1032 5 O
preparation	1038 11 O
at	1050 2 O
a	1053 1 O
level	1055 5 O
approximately	1061 13 O
three	1075 5 O
times	1081 5 O
that	1087 4 O
of	1092 2 O
procaine	1095 8 B-Chemical
.	1103 1 O

The	1105 3 O
racemic	1109 7 O
compound	1117 8 O
was	1126 3 O
significantly	1130 13 O
less	1144 4 O
potent	1149 6 O
than	1156 4 O
either	1161 6 O
isomer	1168 6 O
.	1174 1 O
6	1175 1 O
.	1176 1 O

Both	1178 4 O
isomers	1183 7 O
of	1191 2 O
propranolol	1194 11 B-Chemical
were	1206 4 O
capable	1211 7 O
of	1219 2 O
preventing	1222 10 O
adrenaline	1233 10 B-Chemical
-	1243 1 O
induced	1244 7 O
cardiac	1252 7 B-Disease
arrhythmias	1260 11 I-Disease
in	1272 2 O
cats	1275 4 O
anaesthetized	1280 13 O
with	1294 4 O
halothane	1299 9 B-Chemical
,	1308 1 O
but	1310 3 O
the	1314 3 O
mean	1318 4 O
dose	1323 4 O
of	1328 2 O
(	1331 1 O
-	1332 1 O
)	1333 1 O
-	1334 1 O
propranolol	1335 11 B-Chemical
was	1347 3 O
0	1351 1 O
.	1352 1 O
09	1353 2 O
+	1355 1 O
/	1356 1 O
-	1357 1 O
0	1358 1 O
.	1359 1 O
02	1360 2 O
mg	1363 2 O
/	1365 1 O
kg	1366 2 O
whereas	1369 7 O
that	1377 4 O
of	1382 2 O
(	1385 1 O
+	1386 1 O
)	1387 1 O
-	1388 1 O
propranolol	1389 11 B-Chemical
was	1401 3 O
4	1405 1 O
.	1406 1 O
2	1407 1 O
+	1408 1 O
/	1409 1 O
-	1410 1 O
1	1411 1 O
.	1412 1 O
2	1413 1 O
mg	1415 2 O
/	1417 1 O
kg	1418 2 O
.	1420 1 O

At	1422 2 O
the	1425 3 O
effective	1429 9 O
dose	1439 4 O
level	1444 5 O
of	1450 2 O
(	1453 1 O
+	1454 1 O
)	1455 1 O
-	1456 1 O
propranolol	1457 11 B-Chemical
there	1469 5 O
was	1475 3 O
a	1479 1 O
significant	1481 11 O
prolongation	1493 12 O
of	1506 2 O
the	1509 3 O
PR	1513 2 O
interval	1516 8 O
of	1525 2 O
the	1528 3 O
electrocardiogram	1532 17 O
.	1549 1 O

Blockade	1551 8 O
of	1560 2 O
arrhythmias	1563 11 B-Disease
with	1575 4 O
both	1580 4 O
isomers	1585 7 O
was	1593 3 O
surmountable	1597 12 O
by	1610 2 O
increasing	1613 10 O
the	1624 3 O
dose	1628 4 O
of	1633 2 O
adrenaline	1636 10 B-Chemical
.	1646 1 O
7	1647 1 O
.	1648 1 O

Both	1650 4 O
isomers	1655 7 O
of	1663 2 O
propranolol	1666 11 B-Chemical
were	1678 4 O
also	1683 4 O
capable	1688 7 O
of	1696 2 O
reversing	1699 9 O
ventricular	1709 11 B-Disease
tachycardia	1721 11 I-Disease
caused	1733 6 O
by	1740 2 O
ouabain	1743 7 B-Chemical
in	1751 2 O
anaesthetized	1754 13 O
cats	1768 4 O
and	1773 3 O
dogs	1777 4 O
.	1781 1 O

The	1783 3 O
dose	1787 4 O
of	1792 2 O
(	1795 1 O
-	1796 1 O
)	1797 1 O
-	1798 1 O
propranolol	1799 11 B-Chemical
was	1811 3 O
significantly	1815 13 O
smaller	1829 7 O
than	1837 4 O
that	1842 4 O
of	1847 2 O
(	1850 1 O
+	1851 1 O
)	1852 1 O
-	1853 1 O
propranolol	1854 11 B-Chemical
in	1866 2 O
both	1869 4 O
species	1874 7 O
but	1882 3 O
much	1886 4 O
higher	1891 6 O
than	1898 4 O
that	1903 4 O
required	1908 8 O
to	1917 2 O
produce	1920 7 O
evidence	1928 8 O
of	1937 2 O
beta	1940 4 O
-	1944 1 O
blockade	1945 8 O
.	1953 1 O
8	1954 1 O
.	1955 1 O

The	1957 3 O
implications	1961 12 O
of	1974 2 O
these	1977 5 O
results	1983 7 O
are	1991 3 O
discussed	1995 9 O
.	2004 1 O

Topotecan	0 9 B-Chemical
in	10 2 O
combination	13 11 O
with	25 4 O
radiotherapy	30 12 O
in	43 2 O
unresectable	46 12 O
glioblastoma	59 12 B-Disease
:	71 1 O
a	73 1 O
phase	75 5 O
2	81 1 O
study	83 5 O
.	88 1 O

Improving	90 9 O
glioblastoma	100 12 B-Disease
multiforme	113 10 I-Disease
(	124 1 O
GBM	125 3 B-Disease
)	128 1 O
treatment	130 9 O
with	140 4 O
radio	145 5 O
-	150 1 O
chemotherapy	151 12 O
remains	164 7 O
a	172 1 O
challenge	174 9 O
.	183 1 O

Topotecan	185 9 B-Chemical
is	195 2 O
an	198 2 O
attractive	201 10 O
option	212 6 O
as	219 2 O
it	222 2 O
exhibits	225 8 O
growth	234 6 O
inhibition	241 10 O
of	252 2 O
human	255 5 O
glioma	261 6 B-Disease
as	268 2 O
well	271 4 O
as	276 2 O
brain	279 5 O
penetration	285 11 O
.	296 1 O

The	298 3 O
present	302 7 O
study	310 5 O
assessed	316 8 O
the	325 3 O
combination	329 11 O
of	341 2 O
radiotherapy	344 12 O
(	357 1 O
60	358 2 O
Gy	361 2 O
/	363 1 O
30	364 2 O
fractions	367 9 O
/	376 1 O
40	377 2 O
days	380 4 O
)	384 1 O
and	386 3 O
topotecan	390 9 B-Chemical
(	400 1 O
0	401 1 O
.	402 1 O
9	403 1 O
mg	405 2 O
/	407 1 O
m	408 1 O
(	409 1 O
2	410 1 O
)	411 1 O
/	412 1 O
day	413 3 O
on	417 2 O
days	420 4 O
1	425 1 O
-	426 1 O
5	427 1 O
on	429 2 O
weeks	432 5 O
1	438 1 O
,	439 1 O
3	441 1 O
and	443 3 O
5	447 1 O
)	448 1 O
in	450 2 O
50	453 2 O
adults	456 6 O
with	463 4 O
histologically	468 14 O
proven	483 6 O
and	490 3 O
untreated	494 9 O
GBM	504 3 B-Disease
.	507 1 O

The	509 3 O
incidence	513 9 O
of	523 2 O
non	526 3 O
-	529 1 O
hematological	530 13 O
toxicities	544 10 B-Disease
was	555 3 O
low	559 3 O
and	563 3 O
grade	567 5 O
3	573 1 O
-	574 1 O
4	575 1 O
hematological	577 13 O
toxicities	591 10 B-Disease
were	602 4 O
reported	607 8 O
in	616 2 O
20	619 2 O
patients	622 8 O
(	631 1 O
mainly	632 6 O
lymphopenia	639 11 B-Disease
and	651 3 O
neutropenia	655 11 B-Disease
)	666 1 O
.	667 1 O

Partial	669 7 O
response	677 8 O
and	686 3 O
stabilization	690 13 O
rates	704 5 O
were	710 4 O
2	715 1 O
%	716 1 O
and	718 3 O
32	722 2 O
%	724 1 O
,	725 1 O
respectively	727 12 O
,	739 1 O
with	741 4 O
an	746 2 O
overall	749 7 O
time	757 4 O
to	762 2 O
progression	765 11 O
of	777 2 O
12	780 2 O
weeks	783 5 O
.	788 1 O

One	790 3 O
-	793 1 O
year	794 4 O
overall	799 7 O
survival	807 8 O
(	816 1 O
OS	817 2 O
)	819 1 O
rate	821 4 O
was	826 3 O
42	830 2 O
%	832 1 O
,	833 1 O
with	835 4 O
a	840 1 O
median	842 6 O
OS	849 2 O
of	852 2 O
40	855 2 O
weeks	858 5 O
.	863 1 O

Topotecan	865 9 B-Chemical
in	875 2 O
combination	878 11 O
with	890 4 O
radiotherapy	895 12 O
was	908 3 O
well	912 4 O
tolerated	917 9 O
.	926 1 O

However	928 7 O
,	935 1 O
while	937 5 O
response	943 8 O
and	952 3 O
stabilization	956 13 O
concerned	970 9 O
one	980 3 O
-	983 1 O
third	984 5 O
of	990 2 O
the	993 3 O
patients	997 8 O
,	1005 1 O
the	1007 3 O
study	1011 5 O
did	1017 3 O
not	1021 3 O
show	1025 4 O
increased	1030 9 O
benefits	1040 8 O
in	1049 2 O
terms	1052 5 O
of	1058 2 O
survival	1061 8 O
in	1070 2 O
patients	1073 8 O
with	1082 4 O
unresectable	1087 12 O
GBM	1100 3 B-Disease
.	1103 1 O

Long	0 4 O
-	4 1 O
term	5 4 O
lithium	10 7 B-Chemical
therapy	18 7 O
leading	26 7 O
to	34 2 O
hyperparathyroidism	37 19 B-Disease
:	56 1 O
a	58 1 O
case	60 4 O
report	65 6 O
.	71 1 O

PURPOSE	73 7 O
:	80 1 O
This	82 4 O
paper	87 5 O
reviews	93 7 O
the	101 3 O
effect	105 6 O
of	112 2 O
chronic	115 7 O
lithium	123 7 B-Chemical
therapy	131 7 O
on	139 2 O
serum	142 5 O
calcium	148 7 B-Chemical
level	156 5 O
and	162 3 O
parathyroid	166 11 O
glands	178 6 O
,	184 1 O
its	186 3 O
pathogenesis	190 12 O
,	202 1 O
and	204 3 O
treatment	208 9 O
options	218 7 O
.	225 1 O

We	227 2 O
examined	230 8 O
the	239 3 O
case	243 4 O
of	248 2 O
a	251 1 O
lithium	253 7 B-Chemical
-	260 1 O
treated	261 7 O
patient	269 7 O
who	277 3 O
had	281 3 O
recurrent	285 9 O
hypercalcemia	295 13 B-Disease
to	309 2 O
better	312 6 O
understand	319 10 O
the	330 3 O
disease	334 7 O
process	342 7 O
.	349 1 O

CONCLUSION	351 10 O
:	361 1 O
Primary	363 7 B-Disease
hyperparathyroidism	371 19 I-Disease
is	391 2 O
a	394 1 O
rare	396 4 O
but	401 3 O
potentially	405 11 O
life	417 4 O
-	421 1 O
threatening	422 11 O
side	434 4 O
effect	439 6 O
of	446 2 O
long	449 4 O
-	453 1 O
term	454 4 O
lithium	459 7 B-Chemical
therapy	467 7 O
.	474 1 O

Careful	476 7 O
patient	484 7 O
selection	492 9 O
and	502 3 O
long	506 4 O
-	510 1 O
term	511 4 O
follow	516 6 O
-	522 1 O
up	523 2 O
can	526 3 O
reduce	530 6 O
morbidity	537 9 O
.	546 1 O

PRACTICAL	548 9 O
IMPLICATIONS	558 12 O
:	570 1 O
As	572 2 O
much	575 4 O
as	580 2 O
15	583 2 O
%	585 1 O
of	587 2 O
lithium	590 7 B-Chemical
-	597 1 O
treated	598 7 O
patients	606 8 O
become	615 6 O
hypercalcemic	622 13 B-Disease
.	635 1 O

By	637 2 O
routinely	640 9 O
monitoring	650 10 O
serum	661 5 O
calcium	667 7 B-Chemical
levels	675 6 O
,	681 1 O
healthcare	683 10 O
providers	694 9 O
can	704 3 O
improve	708 7 O
the	716 3 O
quality	720 7 O
of	728 2 O
life	731 4 O
of	736 2 O
this	739 4 O
patient	744 7 O
group	752 5 O
.	757 1 O

Comparison	0 10 O
of	11 2 O
laryngeal	14 9 O
mask	24 4 O
with	29 4 O
endotracheal	34 12 O
tube	47 4 O
for	52 3 O
anesthesia	56 10 O
in	67 2 O
endoscopic	70 10 O
sinus	81 5 O
surgery	87 7 O
.	94 1 O

BACKGROUND	96 10 O
:	106 1 O
The	108 3 O
purpose	112 7 O
of	120 2 O
this	123 4 O
study	128 5 O
was	134 3 O
to	138 2 O
compare	141 7 O
surgical	149 8 O
conditions	158 10 O
,	168 1 O
including	170 9 O
the	180 3 O
amount	184 6 O
of	191 2 O
intraoperative	194 14 O
bleeding	209 8 B-Disease
as	218 2 O
well	221 4 O
as	226 2 O
intraoperative	229 14 O
blood	244 5 O
pressure	250 8 O
,	258 1 O
during	260 6 O
functional	267 10 O
endoscopic	278 10 O
sinus	289 5 O
surgery	295 7 O
(	303 1 O
FESS	304 4 O
)	308 1 O
using	310 5 O
flexible	316 8 O
reinforced	325 10 O
laryngeal	336 9 O
mask	346 4 O
airway	351 6 O
(	358 1 O
FRLMA	359 5 O
)	364 1 O
versus	366 6 O
endotracheal	373 12 O
tube	386 4 O
(	391 1 O
ETT	392 3 O
)	395 1 O
in	397 2 O
maintaining	400 11 O
controlled	412 10 O
hypotension	423 11 B-Disease
anesthesia	435 10 O
induced	446 7 O
by	454 2 O
propofol	457 8 B-Chemical
-	465 1 O
remifentanil	466 12 B-Chemical
total	479 5 O
i	485 1 O
.	486 1 O
v	487 1 O
.	488 1 O
anesthesia	490 10 O
(	501 1 O
TIVA	502 4 O
)	506 1 O
.	507 1 O

METHODS	509 7 O
:	516 1 O
Sixty	518 5 O
normotensive	524 12 O
American	537 8 O
Society	546 7 O
of	554 2 O
Anesthesiologists	557 17 O
I	575 1 O
-	576 1 O
II	577 2 O
adult	580 5 O
patients	586 8 O
undergoing	595 10 O
FESS	606 4 O
under	611 5 O
controlled	617 10 O
hypotension	628 11 B-Disease
anesthesia	640 10 O
caused	651 6 O
by	658 2 O
propofol	661 8 B-Chemical
-	669 1 O
remifentanil	670 12 B-Chemical
-	682 1 O
TIVA	683 4 O
were	688 4 O
randomly	693 8 O
assigned	702 8 O
into	711 4 O
two	716 3 O
groups	720 6 O
:	726 1 O
group	728 5 O
I	734 1 O
,	735 1 O
FRLMA	737 5 O
;	742 1 O
group	744 5 O
II	750 2 O
,	752 1 O
ETT	754 3 O
.	757 1 O

Hemorrhage	759 10 B-Disease
was	770 3 O
measured	774 8 O
and	783 3 O
the	787 3 O
visibility	791 10 O
of	802 2 O
the	805 3 O
operative	809 9 O
field	819 5 O
was	825 3 O
evaluated	829 9 O
according	839 9 O
to	849 2 O
a	852 1 O
six	854 3 O
-	857 1 O
point	858 5 O
scale	864 5 O
.	869 1 O

RESULTS	871 7 O
:	878 1 O
Controlled	880 10 O
hypotension	891 11 B-Disease
was	903 3 O
achieved	907 8 O
within	916 6 O
a	923 1 O
shorter	925 7 O
period	933 6 O
using	940 5 O
laryngeal	946 9 O
mask	956 4 O
using	961 5 O
lower	967 5 O
rates	973 5 O
of	979 2 O
remifentanil	982 12 B-Chemical
infusion	995 8 O
and	1004 3 O
lower	1008 5 O
total	1014 5 O
dose	1020 4 O
of	1025 2 O
remifentanil	1028 12 B-Chemical
.	1040 1 O

CONCLUSION	1042 10 O
:	1052 1 O
In	1054 2 O
summary	1057 7 O
,	1064 1 O
our	1066 3 O
results	1070 7 O
indicate	1078 8 O
that	1087 4 O
airway	1092 6 O
management	1099 10 O
using	1110 5 O
FRLMA	1116 5 O
during	1122 6 O
controlled	1129 10 O
hypotension	1140 11 B-Disease
anesthesia	1152 10 O
provided	1163 8 O
better	1172 6 O
surgical	1179 8 O
conditions	1188 10 O
in	1199 2 O
terms	1202 5 O
of	1208 2 O
quality	1211 7 O
of	1219 2 O
operative	1222 9 O
field	1232 5 O
and	1238 3 O
blood	1242 5 O
loss	1248 4 O
and	1253 3 O
allowed	1257 7 O
for	1265 3 O
convenient	1269 10 O
induced	1280 7 O
hypotension	1288 11 B-Disease
with	1300 4 O
low	1305 3 O
doses	1309 5 O
of	1315 2 O
remifentanil	1318 12 B-Chemical
during	1331 6 O
TIVA	1338 4 O
in	1343 2 O
patients	1346 8 O
undergoing	1355 10 O
FESS	1366 4 O
.	1370 1 O

Nonalcoholic	0 12 B-Disease
fatty	13 5 I-Disease
liver	19 5 I-Disease
disease	25 7 I-Disease
during	33 6 O
valproate	40 9 B-Chemical
therapy	50 7 O
.	57 1 O

Valproic	59 8 B-Chemical
acid	68 4 I-Chemical
(	73 1 O
VPA	74 3 B-Chemical
)	77 1 O
is	79 2 O
effective	82 9 O
for	92 3 O
the	96 3 O
treatment	100 9 O
of	110 2 O
many	113 4 O
types	118 5 O
of	124 2 O
epilepsy	127 8 B-Disease
,	135 1 O
but	137 3 O
its	141 3 O
use	145 3 O
can	149 3 O
be	153 2 O
associated	156 10 O
with	167 4 O
an	172 2 O
increase	175 8 O
in	184 2 O
body	187 4 O
weight	192 6 O
.	198 1 O

We	200 2 O
report	203 6 O
a	210 1 O
case	212 4 O
of	217 2 O
nonalcoholic	220 12 B-Disease
fatty	233 5 I-Disease
liver	239 5 I-Disease
disease	245 7 I-Disease
(	253 1 O
NAFLD	254 5 B-Disease
)	259 1 O
arising	261 7 O
in	269 2 O
a	272 1 O
child	274 5 O
who	280 3 O
developed	284 9 O
obesity	294 7 B-Disease
during	302 6 O
VPA	309 3 B-Chemical
treatment	313 9 O
.	322 1 O

Laboratory	324 10 O
data	335 4 O
revealed	340 8 O
hyperinsulinemia	349 16 B-Disease
with	366 4 O
insulin	371 7 B-Disease
resistance	379 10 I-Disease
.	389 1 O

After	391 5 O
the	397 3 O
withdrawal	401 10 O
of	412 2 O
VPA	415 3 B-Chemical
therapy	419 7 O
,	426 1 O
our	428 3 O
patient	432 7 O
showed	440 6 O
a	447 1 O
significant	449 11 O
weight	461 6 B-Disease
loss	468 4 I-Disease
,	472 1 O
a	474 1 O
decrease	476 8 O
of	485 2 O
body	488 4 O
mass	493 4 O
index	498 5 O
,	503 1 O
and	505 3 O
normalization	509 13 O
of	523 2 O
metabolic	526 9 O
and	536 3 O
endocrine	540 9 O
parameters	550 10 O
;	560 1 O
moreover	562 8 O
,	570 1 O
ultrasound	572 10 O
measurements	583 12 O
showed	596 6 O
a	603 1 O
complete	605 8 O
normalization	614 13 O
.	627 1 O

The	629 3 O
present	633 7 O
case	641 4 O
suggests	646 8 O
that	655 4 O
obesity	660 7 B-Disease
,	667 1 O
hyperinsulinemia	669 16 B-Disease
,	685 1 O
insulin	687 7 B-Disease
resistance	695 10 I-Disease
,	705 1 O
and	707 3 O
long	711 4 O
-	715 1 O
term	716 4 O
treatment	721 9 O
with	731 4 O
VPA	736 3 B-Chemical
may	740 3 O
be	744 2 O
all	747 3 O
associated	751 10 O
with	762 4 O
the	767 3 O
development	771 11 O
of	783 2 O
NAFLD	786 5 B-Disease
;	791 1 O
this	793 4 O
side	798 4 O
effect	803 6 O
is	810 2 O
reversible	813 10 O
after	824 5 O
VPA	830 3 B-Chemical
withdrawal	834 10 O
.	844 1 O

Carbimazole	0 11 B-Chemical
induced	12 7 O
ANCA	20 4 B-Disease
positive	25 8 I-Disease
vasculitis	34 10 I-Disease
.	44 1 O

Anti	46 4 B-Chemical
-	50 1 I-Chemical
thyroid	51 7 I-Chemical
drugs	59 5 I-Chemical
,	64 1 O
like	66 4 O
carbimazole	71 11 B-Chemical
and	83 3 O
propylthiouracil	87 16 B-Chemical
(	104 1 O
PTU	105 3 B-Chemical
)	108 1 O
are	110 3 O
commonly	114 8 O
prescribed	123 10 O
for	134 3 O
the	138 3 O
treatment	142 9 O
of	152 2 O
hyperthyroidism	155 15 B-Disease
.	170 1 O

One	172 3 O
should	176 6 O
be	183 2 O
aware	186 5 O
of	192 2 O
the	195 3 O
side	199 4 O
effects	204 7 O
of	212 2 O
antithyroid	215 11 B-Chemical
medications	227 11 I-Chemical
.	238 1 O

Antineutrophil	240 14 B-Disease
cytoplasmic	255 11 I-Disease
antibody	267 8 I-Disease
(	276 1 I-Disease
ANCA	277 4 I-Disease
)	281 1 I-Disease
-	282 1 I-Disease
-	283 1 I-Disease
associated	284 10 I-Disease
vasculitis	295 10 I-Disease
is	306 2 O
a	309 1 O
potentially	311 11 O
life	323 4 O
-	327 1 O
threatening	328 11 O
adverse	340 7 O
effect	348 6 O
of	355 2 O
antithyroidmedications	358 22 B-Chemical
.	380 1 O

We	382 2 O
report	385 6 O
a	392 1 O
patient	394 7 O
with	402 4 O
Graves	407 6 B-Disease
'	413 1 I-Disease
disease	415 7 I-Disease
who	423 3 O
developed	427 9 O
ANCA	437 4 O
positive	442 8 O
carbimazole	451 11 B-Chemical
induced	463 7 O
vasculitis	471 10 B-Disease
.	481 1 O

The	483 3 O
episode	487 7 O
was	495 3 O
characterized	499 13 O
by	513 2 O
a	516 1 O
vasculitic	518 10 B-Disease
skin	529 4 B-Disease
rash	534 4 I-Disease
associated	539 10 O
with	550 4 O
large	555 5 O
joint	561 5 O
arthritis	567 9 B-Disease
,	576 1 O
pyrexia	578 7 B-Disease
and	586 3 O
parotiditis	590 11 B-Disease
but	602 3 O
no	606 2 O
renal	609 5 O
or	615 2 O
pulmonary	618 9 O
involvement	628 11 O
.	639 1 O

He	641 2 O
was	644 3 O
referred	648 8 O
to	657 2 O
us	660 2 O
for	663 3 O
neurological	667 12 O
evaluation	680 10 O
because	691 7 O
he	699 2 O
had	702 3 O
difficulty	706 10 O
in	717 2 O
getting	720 7 O
up	728 2 O
from	731 4 O
squatting	736 9 O
position	746 8 O
and	755 3 O
was	759 3 O
suspected	763 9 O
to	773 2 O
have	776 4 O
myositis	781 8 B-Disease
.	789 1 O

Carbimazole	791 11 B-Chemical
and	803 3 O
methimazole	807 11 B-Chemical
have	819 4 O
a	824 1 O
lower	826 5 O
incidence	832 9 O
of	842 2 O
reported	845 8 O
ANCA	854 4 O
positive	859 8 O
side	868 4 O
effects	873 7 O
than	881 4 O
PUT	886 3 O
.	889 1 O

To	891 2 O
the	894 3 O
best	898 4 O
of	903 2 O
our	906 3 O
knowledge	910 9 O
this	920 4 O
is	925 2 O
the	928 3 O
first	932 5 O
ANCA	938 4 O
positive	943 8 O
carbimazole	952 11 B-Chemical
induced	964 7 O
vasculitis	972 10 B-Disease
case	983 4 O
reported	988 8 O
from	997 4 O
India	1002 5 O
.	1007 1 O

Aspirin	0 7 B-Chemical
for	8 3 O
the	12 3 O
primary	16 7 O
prevention	24 10 O
of	35 2 O
cardiovascular	38 14 O
events	53 6 O
:	59 1 O
an	61 2 O
update	64 6 O
of	71 2 O
the	74 3 O
evidence	78 8 O
for	87 3 O
the	91 3 O
U	95 1 O
.	96 1 O
S	97 1 O
.	98 1 O

Preventive	100 10 O
Services	111 8 O
Task	120 4 O
Force	125 5 O
.	130 1 O

BACKGROUND	132 10 O
:	142 1 O
Coronary	144 8 B-Disease
heart	153 5 I-Disease
disease	159 7 I-Disease
and	167 3 O
cerebrovascular	171 15 B-Disease
disease	187 7 I-Disease
are	195 3 O
leading	199 7 O
causes	207 6 O
of	214 2 O
death	217 5 O
in	223 2 O
the	226 3 O
United	230 6 O
States	237 6 O
.	243 1 O

In	245 2 O
2002	248 4 O
,	252 1 O
the	254 3 O
U	258 1 O
.	259 1 O
S	260 1 O
.	261 1 O

Preventive	263 10 O
Services	274 8 O
Task	283 4 O
Force	288 5 O
(	294 1 O
USPSTF	295 6 O
)	301 1 O
strongly	303 8 O
recommended	312 11 O
that	324 4 O
clinicians	329 10 O
discuss	340 7 O
aspirin	348 7 B-Chemical
with	356 4 O
adults	361 6 O
who	368 3 O
are	372 3 O
at	376 2 O
increased	379 9 O
risk	389 4 O
for	394 3 O
coronary	398 8 B-Disease
heart	407 5 I-Disease
disease	413 7 I-Disease
.	420 1 O

PURPOSE	422 7 O
:	429 1 O
To	431 2 O
determine	434 9 O
the	444 3 O
benefits	448 8 O
and	457 3 O
harms	461 5 O
of	467 2 O
taking	470 6 O
aspirin	477 7 B-Chemical
for	485 3 O
the	489 3 O
primary	493 7 O
prevention	501 10 O
of	512 2 O
myocardial	515 10 B-Disease
infarctions	526 11 I-Disease
,	537 1 O
strokes	539 7 B-Disease
,	546 1 O
and	548 3 O
death	552 5 O
.	557 1 O

DATA	559 4 O
SOURCES	564 7 O
:	571 1 O
MEDLINE	573 7 O
and	581 3 O
Cochrane	585 8 O
Library	594 7 O
(	602 1 O
search	603 6 O
dates	610 5 O
,	615 1 O
1	617 1 O
January	619 7 O
2001	627 4 O
to	632 2 O
28	635 2 O
August	638 6 O
2008	645 4 O
)	649 1 O
,	650 1 O
recent	652 6 O
systematic	659 10 O
reviews	670 7 O
,	677 1 O
reference	679 9 O
lists	689 5 O
of	695 2 O
retrieved	698 9 O
articles	708 8 O
,	716 1 O
and	718 3 O
suggestions	722 11 O
from	734 4 O
experts	739 7 O
.	746 1 O

STUDY	748 5 O
SELECTION	754 9 O
:	763 1 O
English	765 7 O
-	772 1 O
language	773 8 O
randomized	782 10 O
,	792 1 O
controlled	794 10 O
trials	805 6 O
(	812 1 O
RCTs	813 4 O
)	817 1 O
;	818 1 O
case	820 4 O
-	824 1 O
control	825 7 O
studies	833 7 O
;	840 1 O
meta	842 4 O
-	846 1 O
analyses	847 8 O
;	855 1 O
and	857 3 O
systematic	861 10 O
reviews	872 7 O
of	880 2 O
aspirin	883 7 B-Chemical
versus	891 6 O
control	898 7 O
for	906 3 O
the	910 3 O
primary	914 7 O
prevention	922 10 O
of	933 2 O
cardiovascular	936 14 B-Disease
disease	951 7 I-Disease
(	959 1 O
CVD	960 3 B-Disease
)	963 1 O
were	965 4 O
selected	970 8 O
to	979 2 O
answer	982 6 O
the	989 3 O
following	993 9 O
questions	1003 9 O
:	1012 1 O
Does	1014 4 O
aspirin	1019 7 B-Chemical
decrease	1027 8 O
coronary	1036 8 O
heart	1045 5 O
events	1051 6 O
,	1057 1 O
strokes	1059 7 B-Disease
,	1066 1 O
death	1068 5 O
from	1074 4 O
coronary	1079 8 O
heart	1088 5 O
events	1094 6 O
or	1101 2 O
stroke	1104 6 B-Disease
,	1110 1 O
or	1112 2 O
all	1115 3 O
-	1118 1 O
cause	1119 5 O
mortality	1125 9 O
in	1135 2 O
adults	1138 6 O
without	1145 7 O
known	1153 5 O
CVD	1159 3 B-Disease
?	1162 1 O

Does	1164 4 O
aspirin	1169 7 B-Chemical
increase	1177 8 O
gastrointestinal	1186 16 B-Disease
bleeding	1203 8 I-Disease
or	1212 2 O
hemorrhagic	1215 11 B-Disease
strokes	1227 7 I-Disease
?	1234 1 O

DATA	1236 4 O
EXTRACTION	1241 10 O
:	1251 1 O
All	1253 3 O
studies	1257 7 O
were	1265 4 O
reviewed	1270 8 O
,	1278 1 O
abstracted	1280 10 O
,	1290 1 O
and	1292 3 O
rated	1296 5 O
for	1302 3 O
quality	1306 7 O
by	1314 2 O
using	1317 5 O
predefined	1323 10 O
USPSTF	1334 6 O
criteria	1341 8 O
.	1349 1 O

DATA	1351 4 O
SYNTHESIS	1356 9 O
:	1365 1 O
New	1367 3 O
evidence	1371 8 O
from	1380 4 O
1	1385 1 O
good	1387 4 O
-	1391 1 O
quality	1392 7 O
RCT	1400 3 O
,	1403 1 O
1	1405 1 O
good	1407 4 O
-	1411 1 O
quality	1412 7 O
meta	1420 4 O
-	1424 1 O
analysis	1425 8 O
,	1433 1 O
and	1435 3 O
2	1439 1 O
fair	1441 4 O
-	1445 1 O
quality	1446 7 O
subanalyses	1454 11 O
of	1466 2 O
RCTs	1469 4 O
demonstrates	1474 12 O
that	1487 4 O
aspirin	1492 7 B-Chemical
use	1500 3 O
reduces	1504 7 O
the	1512 3 O
number	1516 6 O
of	1523 2 O
CVD	1526 3 B-Disease
events	1530 6 O
in	1537 2 O
patients	1540 8 O
without	1549 7 O
known	1557 5 O
CVD	1563 3 B-Disease
.	1566 1 O

Men	1568 3 O
in	1572 2 O
these	1575 5 O
studies	1581 7 O
experienced	1589 11 O
fewer	1601 5 O
myocardial	1607 10 B-Disease
infarctions	1618 11 I-Disease
and	1630 3 O
women	1634 5 O
experienced	1640 11 O
fewer	1652 5 O
ischemic	1658 8 O
strokes	1667 7 B-Disease
.	1674 1 O

Aspirin	1676 7 B-Chemical
does	1684 4 O
not	1689 3 O
seem	1693 4 O
to	1698 2 O
affect	1701 6 O
CVD	1708 3 B-Disease
mortality	1712 9 O
or	1722 2 O
all	1725 3 O
-	1728 1 O
cause	1729 5 O
mortality	1735 9 O
in	1745 2 O
either	1748 6 O
men	1755 3 O
or	1759 2 O
women	1762 5 O
.	1767 1 O

The	1769 3 O
use	1773 3 O
of	1777 2 O
aspirin	1780 7 B-Chemical
for	1788 3 O
primary	1792 7 O
prevention	1800 10 O
increases	1811 9 O
the	1821 3 O
risk	1825 4 O
for	1830 3 O
major	1834 5 O
bleeding	1840 8 B-Disease
events	1849 6 O
,	1855 1 O
primarily	1857 9 O
gastrointestinal	1867 16 B-Disease
bleeding	1884 8 I-Disease
events	1893 6 O
,	1899 1 O
in	1901 2 O
both	1904 4 O
men	1909 3 O
and	1913 3 O
women	1917 5 O
.	1922 1 O

Men	1924 3 O
have	1928 4 O
an	1933 2 O
increased	1936 9 O
risk	1946 4 O
for	1951 3 O
hemorrhagic	1955 11 B-Disease
strokes	1967 7 I-Disease
with	1975 4 O
aspirin	1980 7 B-Chemical
use	1988 3 O
.	1991 1 O

A	1993 1 O
new	1995 3 O
RCT	1999 3 O
and	2003 3 O
meta	2007 4 O
-	2011 1 O
analysis	2012 8 O
suggest	2021 7 O
that	2029 4 O
the	2034 3 O
risk	2038 4 O
for	2043 3 O
hemorrhagic	2047 11 B-Disease
strokes	2059 7 I-Disease
in	2067 2 O
women	2070 5 O
is	2076 2 O
not	2079 3 O
statistically	2083 13 O
significantly	2097 13 O
increased	2111 9 O
.	2120 1 O

LIMITATIONS	2122 11 O
:	2133 1 O
New	2135 3 O
evidence	2139 8 O
on	2148 2 O
aspirin	2151 7 B-Chemical
for	2159 3 O
the	2163 3 O
primary	2167 7 O
prevention	2175 10 O
of	2186 2 O
CVD	2189 3 B-Disease
is	2193 2 O
limited	2196 7 O
.	2203 1 O

The	2205 3 O
dose	2209 4 O
of	2214 2 O
aspirin	2217 7 B-Chemical
used	2225 4 O
in	2230 2 O
the	2233 3 O
RCTs	2237 4 O
varied	2242 6 O
,	2248 1 O
which	2250 5 O
prevented	2256 9 O
the	2266 3 O
estimation	2270 10 O
of	2281 2 O
the	2284 3 O
most	2288 4 O
appropriate	2293 11 O
dose	2305 4 O
for	2310 3 O
primary	2314 7 O
prevention	2322 10 O
.	2332 1 O

Several	2334 7 O
of	2342 2 O
the	2345 3 O
RCTs	2349 4 O
were	2354 4 O
conducted	2359 9 O
within	2369 6 O
populations	2376 11 O
of	2388 2 O
health	2391 6 O
professionals	2398 13 O
,	2411 1 O
which	2413 5 O
potentially	2419 11 O
limits	2431 6 O
generalizability	2438 16 O
.	2454 1 O

CONCLUSION	2456 10 O
:	2466 1 O
Aspirin	2468 7 B-Chemical
reduces	2476 7 O
the	2484 3 O
risk	2488 4 O
for	2493 3 O
myocardial	2497 10 B-Disease
infarction	2508 10 I-Disease
in	2519 2 O
men	2522 3 O
and	2526 3 O
strokes	2530 7 B-Disease
in	2538 2 O
women	2541 5 O
.	2546 1 O

Aspirin	2548 7 B-Chemical
use	2556 3 O
increases	2560 9 O
the	2570 3 O
risk	2574 4 O
for	2579 3 O
serious	2583 7 O
bleeding	2591 8 B-Disease
events	2600 6 O
.	2606 1 O

Reducing	0 8 O
harm	9 4 O
associated	14 10 O
with	25 4 O
anticoagulation	30 15 O
:	45 1 O
practical	47 9 O
considerations	57 14 O
of	72 2 O
argatroban	75 10 B-Chemical
therapy	86 7 O
in	94 2 O
heparin	97 7 B-Chemical
-	104 1 O
induced	105 7 O
thrombocytopenia	113 16 B-Disease
.	129 1 O

Argatroban	131 10 B-Chemical
is	142 2 O
a	145 1 O
hepatically	147 11 O
metabolized	159 11 O
,	170 1 O
direct	172 6 O
thrombin	179 8 O
inhibitor	188 9 O
used	198 4 O
for	203 3 O
prophylaxis	207 11 O
or	219 2 O
treatment	222 9 O
of	232 2 O
thrombosis	235 10 B-Disease
in	246 2 O
heparin	249 7 B-Chemical
-	256 1 O
induced	257 7 O
thrombocytopenia	265 16 B-Disease
(	282 1 O
HIT	283 3 B-Disease
)	286 1 O
and	288 3 O
for	292 3 O
patients	296 8 O
with	305 4 O
or	310 2 O
at	313 2 O
risk	316 4 O
of	321 2 O
HIT	324 3 B-Disease
undergoing	328 10 O
percutaneous	339 12 O
coronary	352 8 O
intervention	361 12 O
(	374 1 O
PCI	375 3 O
)	378 1 O
.	379 1 O

The	381 3 O
objective	385 9 O
of	395 2 O
this	398 4 O
review	403 6 O
is	410 2 O
to	413 2 O
summarize	416 9 O
practical	426 9 O
considerations	436 14 O
of	451 2 O
argatroban	454 10 B-Chemical
therapy	465 7 O
in	473 2 O
HIT	476 3 B-Disease
.	479 1 O

The	481 3 O
US	485 2 O
FDA	488 3 O
-	491 1 O
recommended	492 11 O
argatroban	504 10 B-Chemical
dose	515 4 O
in	520 2 O
HIT	523 3 B-Disease
is	527 2 O
2	530 1 O
microg	532 6 O
/	538 1 O
kg	539 2 O
/	541 1 O
min	542 3 O
(	546 1 O
reduced	547 7 O
in	555 2 O
patients	558 8 O
with	567 4 O
hepatic	572 7 B-Disease
impairment	580 10 I-Disease
and	591 3 O
in	595 2 O
paediatric	598 10 O
patients	609 8 O
)	617 1 O
,	618 1 O
adjusted	620 8 O
to	629 2 O
achieve	632 7 O
activated	640 9 O
partial	650 7 O
thromboplastin	658 14 O
times	673 5 O
(	679 1 O
aPTTs	680 5 O
)	685 1 O
1	687 1 O
.	688 1 O
5	689 1 O
-	690 1 O
3	691 1 O
times	693 5 O
baseline	699 8 O
(	708 1 O
not	709 3 O
>	713 1 O
100	714 3 O
seconds	718 7 O
)	725 1 O
.	726 1 O

Contemporary	728 12 O
experiences	741 11 O
indicate	753 8 O
that	762 4 O
reduced	767 7 O
doses	775 5 O
are	781 3 O
also	785 4 O
needed	790 6 O
in	797 2 O
patients	800 8 O
with	809 4 O
conditions	814 10 O
associated	825 10 O
with	836 4 O
hepatic	841 7 O
hypoperfusion	849 13 O
,	862 1 O
e	864 1 O
.	865 1 O
g	866 1 O
.	867 1 O
heart	869 5 B-Disease
failure	875 7 I-Disease
,	882 1 O
yet	884 3 O
are	888 3 O
unnecessary	892 11 O
for	904 3 O
renal	908 5 B-Disease
dysfunction	914 11 I-Disease
,	925 1 O
adult	927 5 O
age	933 3 O
,	936 1 O
sex	938 3 O
,	941 1 O
race	943 4 O
/	947 1 O
ethnicity	948 9 O
or	958 2 O
obesity	961 7 B-Disease
.	968 1 O

Argatroban	970 10 B-Chemical
0	981 1 O
.	982 1 O
5	983 1 O
-	984 1 O
1	985 1 O
.	986 1 O
2	987 1 O
microg	989 6 O
/	995 1 O
kg	996 2 O
/	998 1 O
min	999 3 O
typically	1003 9 O
supports	1013 8 O
therapeutic	1022 11 O
aPTTs	1034 5 O
.	1039 1 O

The	1041 3 O
FDA	1045 3 O
-	1048 1 O
recommended	1049 11 O
dose	1061 4 O
during	1066 6 O
PCI	1073 3 O
is	1077 2 O
25	1080 2 O
microg	1083 6 O
/	1089 1 O
kg	1090 2 O
/	1092 1 O
min	1093 3 O
(	1097 1 O
350	1098 3 O
microg	1102 6 O
/	1108 1 O
kg	1109 2 O
initial	1112 7 O
bolus	1120 5 O
)	1125 1 O
,	1126 1 O
adjusted	1128 8 O
to	1137 2 O
achieve	1140 7 O
activated	1148 9 O
clotting	1158 8 O
times	1167 5 O
(	1173 1 O
ACTs	1174 4 O
)	1178 1 O
of	1180 2 O
300	1183 3 O
-	1186 1 O
450	1187 3 O
sec	1191 3 O
.	1194 1 O

For	1196 3 O
PCI	1200 3 O
,	1203 1 O
argatroban	1205 10 B-Chemical
has	1216 3 O
not	1220 3 O
been	1224 4 O
investigated	1229 12 O
in	1242 2 O
hepatically	1245 11 O
impaired	1257 8 O
patients	1266 8 O
;	1274 1 O
dose	1276 4 O
adjustment	1281 10 O
is	1292 2 O
unnecessary	1295 11 O
for	1307 3 O
adult	1311 5 O
age	1317 3 O
,	1320 1 O
sex	1322 3 O
,	1325 1 O
race	1327 4 O
/	1331 1 O
ethnicity	1332 9 O
or	1342 2 O
obesity	1345 7 B-Disease
,	1352 1 O
and	1354 3 O
lesser	1358 6 O
doses	1365 5 O
may	1371 3 O
be	1375 2 O
adequate	1378 8 O
with	1387 4 O
concurrent	1392 10 O
glycoprotein	1403 12 O
IIb	1416 3 O
/	1419 1 O
IIIa	1420 4 O
inhibition	1425 10 O
.	1435 1 O

Argatroban	1437 10 B-Chemical
prolongs	1448 8 O
the	1457 3 O
International	1461 13 O
Normalized	1475 10 O
Ratio	1486 5 O
,	1491 1 O
and	1493 3 O
published	1497 9 O
approaches	1507 10 O
for	1518 3 O
monitoring	1522 10 O
the	1533 3 O
argatroban	1537 10 B-Chemical
-	1547 1 O
to	1548 2 O
-	1550 1 O
warfarin	1551 8 B-Chemical
transition	1560 10 O
should	1571 6 O
be	1578 2 O
followed	1581 8 O
.	1589 1 O

Major	1591 5 O
bleeding	1597 8 B-Disease
with	1606 4 O
argatroban	1611 10 B-Chemical
is	1622 2 O
0	1625 1 O
-	1626 1 O
10	1627 2 O
%	1629 1 O
in	1631 2 O
the	1634 3 O
non	1638 3 O
-	1641 1 O
interventional	1642 14 O
setting	1657 7 O
and	1665 3 O
0	1669 1 O
-	1670 1 O
5	1671 1 O
.	1672 1 O
8	1673 1 O
%	1674 1 O
periprocedurally	1676 16 O
.	1692 1 O

Argatroban	1694 10 B-Chemical
has	1705 3 O
no	1709 2 O
specific	1712 8 O
antidote	1721 8 O
,	1729 1 O
and	1731 3 O
if	1735 2 O
excessive	1738 9 O
anticoagulation	1748 15 O
occurs	1764 6 O
,	1770 1 O
argatroban	1772 10 B-Chemical
infusion	1783 8 O
should	1792 6 O
be	1799 2 O
stopped	1802 7 O
or	1810 2 O
reduced	1813 7 O
.	1820 1 O

Improved	1822 8 O
familiarity	1831 11 O
of	1843 2 O
healthcare	1846 10 O
professionals	1857 13 O
with	1871 4 O
argatroban	1876 10 B-Chemical
therapy	1887 7 O
in	1895 2 O
HIT	1898 3 B-Disease
,	1901 1 O
including	1903 9 O
in	1913 2 O
special	1916 7 O
populations	1924 11 O
and	1936 3 O
during	1940 6 O
PCI	1947 3 O
,	1950 1 O
may	1952 3 O
facilitate	1956 10 O
reduction	1967 9 O
of	1977 2 O
harm	1980 4 O
associated	1985 10 O
with	1996 4 O
HIT	2001 3 B-Disease
(	2005 1 O
e	2006 1 O
.	2007 1 O
g	2008 1 O
.	2009 1 O
fewer	2011 5 O
thromboses	2017 10 O
)	2027 1 O
or	2029 2 O
its	2032 3 O
treatment	2036 9 O
(	2046 1 O
e	2047 1 O
.	2048 1 O
g	2049 1 O
.	2050 1 O
fewer	2052 5 O
argatroban	2058 10 B-Chemical
medication	2069 10 O
errors	2080 6 O
)	2086 1 O
.	2087 1 O

Rhabdomyolysis	0 14 B-Disease
and	15 3 O
brain	19 5 O
ischemic	25 8 B-Disease
stroke	34 6 I-Disease
in	41 2 O
a	44 1 O
heroin	46 6 B-Chemical
-	52 1 O
dependent	53 9 O
male	63 4 O
under	68 5 O
methadone	74 9 B-Chemical
maintenance	84 11 O
therapy	96 7 O
.	103 1 O

OBJECTIVE	105 9 O
:	114 1 O
There	116 5 O
are	122 3 O
several	126 7 O
complications	134 13 O
associated	148 10 O
with	159 4 O
heroin	164 6 B-Disease
abuse	171 5 I-Disease
,	176 1 O
some	178 4 O
of	183 2 O
which	186 5 O
are	192 3 O
life	196 4 O
-	200 1 O
threatening	201 11 O
.	212 1 O

Methadone	214 9 B-Chemical
may	224 3 O
aggravate	228 9 O
this	238 4 O
problem	243 7 O
.	250 1 O

METHOD	252 6 O
:	258 1 O
A	260 1 O
clinical	262 8 O
case	271 4 O
description	276 11 O
.	287 1 O

RESULTS	289 7 O
:	296 1 O
A	298 1 O
33	300 2 O
-	302 1 O
year	303 4 O
-	307 1 O
old	308 3 O
man	312 3 O
presented	316 9 O
with	326 4 O
rhabdomyolysis	331 14 B-Disease
and	346 3 O
cerebral	350 8 O
ischemic	359 8 B-Disease
stroke	368 6 I-Disease
after	375 5 O
intravenous	381 11 O
heroin	393 6 B-Chemical
.	399 1 O

He	401 2 O
had	404 3 O
used	408 4 O
heroin	413 6 B-Chemical
since	420 5 O
age	426 3 O
20	430 2 O
,	432 1 O
and	434 3 O
had	438 3 O
used	442 4 O
150	447 3 O
mg	451 2 O
methadone	454 9 B-Chemical
daily	464 5 O
for	470 3 O
6	474 1 O
months	476 6 O
.	482 1 O

He	484 2 O
was	487 3 O
found	491 5 O
unconsciousness	497 15 B-Disease
at	513 2 O
home	516 4 O
and	521 3 O
was	525 3 O
sent	529 4 O
to	534 2 O
our	537 3 O
hospital	541 8 O
.	549 1 O

In	551 2 O
the	554 3 O
ER	558 2 O
,	560 1 O
his	562 3 O
opiate	566 6 O
level	573 5 O
was	579 3 O
4497	583 4 O
ng	588 2 O
/	590 1 O
ml	591 2 O
.	593 1 O

In	595 2 O
the	598 3 O
ICU	602 3 O
,	605 1 O
we	607 2 O
found	610 5 O
rhabdomyolysis	616 14 B-Disease
,	630 1 O
acute	632 5 B-Disease
renal	638 5 I-Disease
failure	644 7 I-Disease
and	652 3 O
acute	656 5 O
respiratory	662 11 B-Disease
failure	674 7 I-Disease
.	681 1 O

After	683 5 O
transfer	689 8 O
to	698 2 O
an	701 2 O
internal	704 8 O
ward	713 4 O
,	717 1 O
we	719 2 O
noted	722 5 O
aphasia	728 7 B-Disease
and	736 3 O
weakness	740 8 B-Disease
of	749 2 O
his	752 3 O
left	756 4 O
limbs	761 5 O
.	766 1 O

After	768 5 O
MRI	774 3 O
,	777 1 O
we	779 2 O
found	782 5 O
cerebral	788 8 B-Disease
ischemic	797 8 I-Disease
infarction	806 10 I-Disease
.	816 1 O

CONCLUSION	818 10 O
:	828 1 O
Those	830 5 O
using	836 5 O
methadone	842 9 B-Chemical
and	852 3 O
heroin	856 6 B-Chemical
simultaneously	863 14 O
may	878 3 O
increase	882 8 O
risk	891 4 O
of	896 2 O
rhabdomyolysis	899 14 B-Disease
and	914 3 O
ischemic	918 8 B-Disease
stroke	927 6 I-Disease
.	933 1 O

Patients	935 8 O
under	944 5 O
methadone	950 9 B-Chemical
maintenance	960 11 O
therapy	972 7 O
should	980 6 O
be	987 2 O
warned	990 6 O
regarding	997 9 O
these	1007 5 O
serious	1013 7 O
adverse	1021 7 O
events	1029 6 O
.	1035 1 O

Hypotheses	1037 10 O
of	1048 2 O
heroin	1051 6 B-Chemical
-	1057 1 O
related	1058 7 O
rhabdomyolysis	1066 14 B-Disease
and	1081 3 O
stroke	1085 6 B-Disease
in	1092 2 O
heroin	1095 6 B-Chemical
abusers	1102 7 O
are	1110 3 O
discussed	1114 9 O
.	1123 1 O

Increased	0 9 O
vulnerability	10 13 O
to	24 2 O
6	27 1 B-Chemical
-	28 1 I-Chemical
hydroxydopamine	29 15 I-Chemical
lesion	45 6 O
and	52 3 O
reduced	56 7 O
development	64 11 O
of	76 2 O
dyskinesias	79 11 B-Disease
in	91 2 O
mice	94 4 O
lacking	99 7 O
CB1	107 3 O
cannabinoid	111 11 O
receptors	123 9 O
.	132 1 O

Motor	134 5 O
impairment	140 10 O
,	150 1 O
dopamine	152 8 B-Chemical
(	161 1 O
DA	162 2 B-Chemical
)	164 1 O
neuronal	166 8 O
activity	175 8 O
and	184 3 O
proenkephalin	188 13 B-Chemical
(	202 1 O
PENK	203 4 B-Chemical
)	207 1 O
gene	209 4 O
expression	214 10 O
in	225 2 O
the	228 3 O
caudate	232 7 O
-	239 1 O
putamen	240 7 O
(	248 1 O
CPu	249 3 O
)	252 1 O
were	254 4 O
measured	259 8 O
in	268 2 O
6	271 1 B-Chemical
-	272 1 I-Chemical
OHDA	273 4 I-Chemical
-	277 1 O
lesioned	278 8 O
and	287 3 O
treated	291 7 O
(	299 1 O
L	300 1 B-Chemical
-	301 1 I-Chemical
DOPA	302 4 I-Chemical
+	306 1 I-Chemical
benserazide	307 11 I-Chemical
)	318 1 O
CB1	320 3 O
KO	324 2 O
and	327 3 O
WT	331 2 O
mice	334 4 O
.	338 1 O

A	340 1 O
lesion	342 6 O
induced	349 7 O
by	357 2 O
6	360 1 B-Chemical
-	361 1 I-Chemical
OHDA	362 4 I-Chemical
produced	367 8 O
more	376 4 O
severe	381 6 O
motor	388 5 O
deterioration	394 13 O
in	408 2 O
CB1	411 3 O
KO	415 2 O
mice	418 4 O
accompanied	423 11 O
by	435 2 O
more	438 4 O
loss	443 4 O
of	448 2 O
DA	451 2 B-Chemical
neurons	454 7 O
and	462 3 O
increased	466 9 O
PENK	476 4 B-Chemical
gene	481 4 O
expression	486 10 O
in	497 2 O
the	500 3 O
CPu	504 3 O
.	507 1 O

Oxidative	509 9 O
/	518 1 O
nitrosative	519 11 O
and	531 3 O
neuroinflammatory	535 17 O
parameters	553 10 O
were	564 4 O
estimated	569 9 O
in	579 2 O
the	582 3 O
CPu	586 3 O
and	590 3 O
cingulate	594 9 O
cortex	604 6 O
(	611 1 O
Cg	612 2 O
)	614 1 O
.	615 1 O

CB1	617 3 O
KO	621 2 O
mice	624 4 O
exhibited	629 9 O
higher	639 6 O
MDA	646 3 B-Chemical
levels	650 6 O
and	657 3 O
iNOS	661 4 O
protein	666 7 O
expression	674 10 O
in	685 2 O
the	688 3 O
CPu	692 3 O
and	696 3 O
Cg	700 2 O
compared	703 8 O
to	712 2 O
WT	715 2 O
mice	718 4 O
.	722 1 O

Treatment	724 9 O
with	734 4 O
L	739 1 B-Chemical
-	740 1 I-Chemical
DOPA	741 4 I-Chemical
+	745 1 I-Chemical
benserazide	746 11 I-Chemical
(	758 1 O
12	759 2 O
weeks	762 5 O
)	767 1 O
resulted	769 8 O
in	778 2 O
less	781 4 O
severe	786 6 O
dyskinesias	793 11 B-Disease
in	805 2 O
CB1	808 3 O
KO	812 2 O
than	815 4 O
in	820 2 O
WT	823 2 O
mice	826 4 O
.	830 1 O

The	832 3 O
results	836 7 O
revealed	844 8 O
that	853 4 O
the	858 3 O
lack	862 4 O
of	867 2 O
cannabinoid	870 11 O
CB1	882 3 O
receptors	886 9 O
increased	896 9 O
the	906 3 O
severity	910 8 O
of	919 2 O
motor	922 5 O
impairment	928 10 O
and	939 3 O
DA	943 2 B-Chemical
lesion	946 6 O
,	952 1 O
and	954 3 O
reduced	958 7 O
L	966 1 B-Chemical
-	967 1 I-Chemical
DOPA	968 4 I-Chemical
-	972 1 O
induced	973 7 O
dyskinesias	981 11 B-Disease
.	992 1 O

These	994 5 O
results	1000 7 O
suggest	1008 7 O
that	1016 4 O
activation	1021 10 O
of	1032 2 O
CB1	1035 3 O
receptors	1039 9 O
offers	1049 6 O
neuroprotection	1056 15 O
against	1072 7 O
dopaminergic	1080 12 O
lesion	1093 6 O
and	1100 3 O
the	1104 3 O
development	1108 11 O
of	1120 2 O
L	1123 1 B-Chemical
-	1124 1 I-Chemical
DOPA	1125 4 I-Chemical
-	1129 1 O
induced	1130 7 O
dyskinesias	1138 11 B-Disease
.	1149 1 O

Animal	0 6 O
model	7 5 O
of	13 2 O
mania	16 5 B-Disease
induced	22 7 O
by	30 2 O
ouabain	33 7 B-Chemical
:	40 1 O
Evidence	42 8 O
of	51 2 O
oxidative	54 9 O
stress	64 6 O
in	71 2 O
submitochondrial	74 16 O
particles	91 9 O
of	101 2 O
the	104 3 O
rat	108 3 O
brain	112 5 O
.	117 1 O

The	119 3 O
intracerebroventricular	123 23 O
(	147 1 O
ICV	148 3 O
)	151 1 O
administration	153 14 O
of	168 2 O
ouabain	171 7 B-Chemical
(	179 1 O
a	180 1 O
Na	182 2 B-Chemical
(	184 1 O
+	185 1 O
)	186 1 O
/	187 1 O
K	188 1 B-Chemical
(	189 1 O
+	190 1 O
)	191 1 O
-	192 1 O
ATPase	193 6 O
inhibitor	200 9 O
)	209 1 O
in	211 2 O
rats	214 4 O
has	219 3 O
been	223 4 O
suggested	228 9 O
to	238 2 O
mimic	241 5 O
some	247 4 O
symptoms	252 8 O
of	261 2 O
human	264 5 O
bipolar	270 7 B-Disease
mania	278 5 I-Disease
.	283 1 O

Clinical	285 8 O
studies	294 7 O
have	302 4 O
shown	307 5 O
that	313 4 O
bipolar	318 7 B-Disease
disorder	326 8 I-Disease
may	335 3 O
be	339 2 O
related	342 7 O
to	350 2 O
mitochondrial	353 13 B-Disease
dysfunction	367 11 I-Disease
.	378 1 O

Herein	380 6 O
,	386 1 O
we	388 2 O
investigated	391 12 O
the	404 3 O
behavioral	408 10 O
and	419 3 O
biochemical	423 11 O
effects	435 7 O
induced	443 7 O
by	451 2 O
the	454 3 O
ICV	458 3 O
administration	462 14 O
of	477 2 O
ouabain	480 7 B-Chemical
in	488 2 O
rats	491 4 O
.	495 1 O

To	497 2 O
achieve	500 7 O
this	508 4 O
aim	513 3 O
,	516 1 O
the	518 3 O
effects	522 7 O
of	530 2 O
ouabain	533 7 B-Chemical
injection	541 9 O
immediately	551 11 O
after	563 5 O
and	569 3 O
7	573 1 O
days	575 4 O
following	580 9 O
a	590 1 O
single	592 6 O
ICV	599 3 O
administration	603 14 O
(	618 1 O
at	619 2 O
concentrations	622 14 O
of	637 2 O
10	640 2 O
(	642 1 O
-	643 1 O
2	644 1 O
)	645 1 O
and	647 3 O
10	651 2 O
(	653 1 O
-	654 1 O
3	655 1 O
)	656 1 O
M	657 1 O
)	658 1 O
on	660 2 O
locomotion	663 10 O
was	674 3 O
measured	678 8 O
using	687 5 O
the	693 3 O
open	697 4 O
-	701 1 O
field	702 5 O
test	708 4 O
.	712 1 O

Additionally	714 12 O
,	726 1 O
thiobarbituric	728 14 B-Chemical
acid	743 4 I-Chemical
reactive	748 8 O
substances	757 10 O
(	768 1 O
TBARSs	769 6 O
)	775 1 O
and	777 3 O
superoxide	781 10 B-Chemical
production	792 10 O
were	803 4 O
measured	808 8 O
in	817 2 O
submitochondrial	820 16 O
particles	837 9 O
of	847 2 O
the	850 3 O
prefrontal	854 10 O
cortex	865 6 O
,	871 1 O
hippocampus	873 11 O
,	884 1 O
striatum	886 8 O
and	895 3 O
amygdala	899 8 O
.	907 1 O

Our	909 3 O
findings	913 8 O
demonstrated	922 12 O
that	935 4 O
ouabain	940 7 B-Chemical
at	948 2 O
10	951 2 O
(	953 1 O
-	954 1 O
2	955 1 O
)	956 1 O
and	958 3 O
10	962 2 O
(	964 1 O
-	965 1 O
3	966 1 O
)	967 1 O
M	968 1 O
induced	970 7 O
hyperlocomotion	978 15 B-Disease
in	994 2 O
rats	997 4 O
,	1001 1 O
and	1003 3 O
this	1007 4 O
response	1012 8 O
remained	1021 8 O
up	1030 2 O
to	1033 2 O
7	1036 1 O
days	1038 4 O
following	1043 9 O
a	1053 1 O
single	1055 6 O
ICV	1062 3 O
injection	1066 9 O
.	1075 1 O

In	1077 2 O
addition	1080 8 O
,	1088 1 O
we	1090 2 O
observed	1093 8 O
that	1102 4 O
the	1107 3 O
persistent	1111 10 O
increase	1122 8 O
in	1131 2 O
the	1134 3 O
rat	1138 3 O
spontaneous	1142 11 O
locomotion	1154 10 O
is	1165 2 O
associated	1168 10 O
with	1179 4 O
increased	1184 9 O
TBARS	1194 5 O
levels	1200 6 O
and	1207 3 O
superoxide	1211 10 B-Chemical
generation	1222 10 O
in	1233 2 O
submitochondrial	1236 16 O
particles	1253 9 O
in	1263 2 O
the	1266 3 O
prefrontal	1270 10 O
cortex	1281 6 O
,	1287 1 O
striatum	1289 8 O
and	1298 3 O
amygdala	1302 8 O
.	1310 1 O

In	1312 2 O
conclusion	1315 10 O
,	1325 1 O
ouabain	1327 7 B-Chemical
-	1334 1 O
induced	1335 7 O
mania	1343 5 B-Disease
-	1348 1 O
like	1349 4 O
behavior	1354 8 O
may	1363 3 O
provide	1367 7 O
a	1375 1 O
useful	1377 6 O
animal	1384 6 O
model	1391 5 O
to	1397 2 O
test	1400 4 O
the	1405 3 O
hypothesis	1409 10 O
of	1420 2 O
the	1423 3 O
involvement	1427 11 O
of	1439 2 O
oxidative	1442 9 O
stress	1452 6 O
in	1459 2 O
bipolar	1462 7 B-Disease
disorder	1470 8 I-Disease
.	1478 1 O

Intraoperative	0 14 O
dialysis	15 8 O
during	24 6 O
liver	31 5 O
transplantation	37 15 O
with	53 4 O
citrate	58 7 B-Chemical
dialysate	66 9 O
.	75 1 O

Liver	77 5 O
transplantation	83 15 O
for	99 3 O
acutely	103 7 O
ill	111 3 O
patients	115 8 O
with	124 4 O
fulminant	129 9 B-Disease
liver	139 5 I-Disease
failure	145 7 I-Disease
carries	153 7 O
high	161 4 O
intraoperative	166 14 O
and	181 3 O
immediate	185 9 O
postoperative	195 13 O
risks	209 5 O
.	214 1 O

These	216 5 O
are	222 3 O
increased	226 9 O
with	236 4 O
the	241 3 O
presence	245 8 O
of	254 2 O
concomitant	257 11 O
acute	269 5 B-Disease
kidney	275 6 I-Disease
injury	282 6 I-Disease
(	289 1 O
AKI	290 3 B-Disease
)	293 1 O
and	295 3 O
intraoperative	299 14 O
dialysis	314 8 O
is	323 2 O
sometimes	326 9 O
required	336 8 O
to	345 2 O
allow	348 5 O
the	354 3 O
transplant	358 10 O
to	369 2 O
proceed	372 7 O
.	379 1 O

The	381 3 O
derangements	385 12 O
in	398 2 O
the	401 3 O
procoagulant	405 12 O
and	418 3 O
anticoagulant	422 13 O
pathways	436 8 O
during	445 6 O
fulminant	452 9 B-Disease
liver	462 5 I-Disease
failure	468 7 I-Disease
can	476 3 O
lead	480 4 O
to	485 2 O
difficulties	488 12 O
with	501 4 O
anticoagulation	506 15 O
during	522 6 O
dialysis	529 8 O
,	537 1 O
especially	539 10 O
when	550 4 O
continued	555 9 O
in	565 2 O
the	568 3 O
operating	572 9 O
room	582 4 O
.	586 1 O

Systemic	588 8 O
anticoagulation	597 15 O
is	613 2 O
unsafe	616 6 O
and	623 3 O
regional	627 8 O
citrate	636 7 B-Chemical
anticoagulation	644 15 O
in	660 2 O
the	663 3 O
absence	667 7 O
of	675 2 O
a	678 1 O
functional	680 10 O
liver	691 5 O
carries	697 7 O
the	705 3 O
risk	709 4 O
of	714 2 O
citrate	717 7 B-Chemical
toxicity	725 8 B-Disease
.	733 1 O

Citrate	735 7 B-Chemical
dialysate	743 9 O
,	752 1 O
a	754 1 O
new	756 3 O
dialysate	760 9 O
with	770 4 O
citric	775 6 B-Chemical
acid	782 4 I-Chemical
can	787 3 O
be	791 2 O
used	794 4 O
for	799 3 O
anticoagulation	803 15 O
in	819 2 O
patients	822 8 O
who	831 3 O
cannot	835 6 O
tolerate	842 8 O
heparin	851 7 B-Chemical
or	859 2 O
regional	862 8 O
citrate	871 7 B-Chemical
.	878 1 O

We	880 2 O
report	883 6 O
a	890 1 O
case	892 4 O
of	897 2 O
a	900 1 O
40	902 2 O
-	904 1 O
year	905 4 O
-	909 1 O
old	910 3 O
female	914 6 O
with	921 4 O
acetaminophen	926 13 B-Chemical
-	939 1 O
induced	940 7 O
fulminant	948 9 B-Disease
liver	958 5 I-Disease
failure	964 7 I-Disease
with	972 4 O
associated	977 10 O
AKI	988 3 B-Disease
who	992 3 O
underwent	996 9 O
intraoperative	1006 14 O
dialytic	1021 8 O
support	1030 7 O
during	1038 6 O
liver	1045 5 O
transplantation	1051 15 O
anticoagulated	1067 14 O
with	1082 4 O
citrate	1087 7 B-Chemical
dialysate	1095 9 O
during	1105 6 O
the	1112 3 O
entire	1116 6 O
procedure	1123 9 O
.	1132 1 O

The	1134 3 O
patient	1138 7 O
tolerated	1146 9 O
the	1156 3 O
procedure	1160 9 O
well	1170 4 O
without	1175 7 O
any	1183 3 O
signs	1187 5 O
of	1193 2 O
citrate	1196 7 B-Chemical
toxicity	1204 8 B-Disease
and	1213 3 O
maintained	1217 10 O
adequate	1228 8 O
anticoagulation	1237 15 O
for	1253 3 O
patency	1257 7 O
of	1265 2 O
the	1268 3 O
dialysis	1272 8 O
circuit	1281 7 O
.	1288 1 O

Citrate	1290 7 B-Chemical
dialysate	1298 9 O
is	1308 2 O
a	1311 1 O
safe	1313 4 O
alternative	1318 11 O
for	1330 3 O
intradialytic	1334 13 O
support	1348 7 O
of	1356 2 O
liver	1359 5 O
transplantation	1365 15 O
in	1381 2 O
fulminant	1384 9 B-Disease
liver	1394 5 I-Disease
failure	1400 7 I-Disease
.	1407 1 O

Delirium	0 8 B-Disease
in	9 2 O
a	12 1 O
patient	14 7 O
with	22 4 O
toxic	27 5 O
flecainide	33 10 B-Chemical
plasma	44 6 O
concentrations	51 14 O
:	65 1 O
the	67 3 O
role	71 4 O
of	76 2 O
a	79 1 O
pharmacokinetic	81 15 O
drug	97 4 O
interaction	102 11 O
with	114 4 O
paroxetine	119 10 B-Chemical
.	129 1 O

OBJECTIVE	131 9 O
:	140 1 O
To	142 2 O
describe	145 8 O
a	154 1 O
case	156 4 O
of	161 2 O
flecainide	164 10 B-Chemical
-	174 1 O
induced	175 7 O
delirium	183 8 B-Disease
associated	192 10 O
with	203 4 O
a	208 1 O
pharmacokinetic	210 15 O
drug	226 4 O
interaction	231 11 O
with	243 4 O
paroxetine	248 10 B-Chemical
.	258 1 O

CASE	260 4 O
SUMMARY	265 7 O
:	272 1 O
A	274 1 O
69	276 2 O
-	278 1 O
year	279 4 O
-	283 1 O
old	284 3 O
white	288 5 O
female	294 6 O
presented	301 9 O
to	311 2 O
the	314 3 O
emergency	318 9 O
department	328 10 O
with	339 4 O
a	344 1 O
history	346 7 O
of	354 2 O
confusion	357 9 B-Disease
and	367 3 O
paranoia	371 8 B-Disease
over	380 4 O
the	385 3 O
past	389 4 O
several	394 7 O
days	402 4 O
.	406 1 O

On	408 2 O
admission	411 9 O
the	421 3 O
patient	425 7 O
was	433 3 O
taking	437 6 O
carvedilol	444 10 B-Chemical
12	455 2 O
mg	458 2 O
twice	461 5 O
daily	467 5 O
,	472 1 O
warfarin	474 8 B-Chemical
2	483 1 O
mg	485 2 O
/	487 1 O
day	488 3 O
,	491 1 O
folic	493 5 B-Chemical
acid	499 4 I-Chemical
1	504 1 O
mg	506 2 O
/	508 1 O
day	509 3 O
,	512 1 O
levothyroxine	514 13 B-Chemical
100	528 3 O
microg	532 6 O
/	538 1 O
day	539 3 O
,	542 1 O
pantoprazole	544 12 B-Chemical
40	557 2 O
mg	560 2 O
/	562 1 O
day	563 3 O
,	566 1 O
paroxetine	568 10 B-Chemical
40	579 2 O
mg	582 2 O
/	584 1 O
day	585 3 O
,	588 1 O
and	590 3 O
flecainide	594 10 B-Chemical
100	605 3 O
mg	609 2 O
twice	612 5 O
daily	618 5 O
.	623 1 O

Flecainide	625 10 B-Chemical
had	636 3 O
been	640 4 O
started	645 7 O
2	653 1 O
weeks	655 5 O
prior	661 5 O
for	667 3 O
atrial	671 6 B-Disease
fibrillation	678 12 I-Disease
.	690 1 O

Laboratory	692 10 O
test	703 4 O
findings	708 8 O
on	717 2 O
admission	720 9 O
were	730 4 O
notable	735 7 O
only	743 4 O
for	748 3 O
a	752 1 O
flecainide	754 10 B-Chemical
plasma	765 6 O
concentration	772 13 O
of	786 2 O
1360	789 4 O
microg	794 6 O
/	800 1 O
L	801 1 O
(	803 1 O
reference	804 9 O
range	814 5 O
200	820 3 O
-	823 1 O
1000	824 4 O
)	828 1 O
.	829 1 O

A	831 1 O
metabolic	833 9 O
drug	843 4 O
interaction	848 11 O
between	860 7 O
flecainide	868 10 B-Chemical
and	879 3 O
paroxetine	883 10 B-Chemical
,	893 1 O
which	895 5 O
the	901 3 O
patient	905 7 O
had	913 3 O
been	917 4 O
taking	922 6 O
for	929 3 O
more	933 4 O
than	938 4 O
5	943 1 O
years	945 5 O
,	950 1 O
was	952 3 O
considered	956 10 O
.	966 1 O

Paroxetine	968 10 B-Chemical
was	979 3 O
discontinued	983 12 O
and	996 3 O
the	1000 3 O
dose	1004 4 O
of	1009 2 O
flecainide	1012 10 B-Chemical
was	1023 3 O
reduced	1027 7 O
to	1035 2 O
50	1038 2 O
mg	1041 2 O
twice	1044 5 O
daily	1050 5 O
.	1055 1 O

Her	1057 3 O
delirium	1061 8 B-Disease
resolved	1070 8 O
3	1079 1 O
days	1081 4 O
later	1086 5 O
.	1091 1 O

DISCUSSION	1093 10 O
:	1103 1 O
Flecainide	1105 10 B-Chemical
and	1116 3 O
pharmacologically	1120 17 O
similar	1138 7 O
agents	1146 6 O
that	1153 4 O
interact	1158 8 O
with	1167 4 O
sodium	1172 6 B-Chemical
channels	1179 8 O
may	1188 3 O
cause	1192 5 O
delirium	1198 8 B-Disease
in	1207 2 O
susceptible	1210 11 O
patients	1222 8 O
.	1230 1 O

A	1232 1 O
MEDLINE	1234 7 O
search	1242 6 O
(	1249 1 O
1966	1250 4 O
-	1254 1 O
January	1255 7 O
2009	1263 4 O
)	1267 1 O
revealed	1269 8 O
one	1278 3 O
in	1282 2 O
vivo	1285 4 O
pharmacokinetic	1290 15 O
study	1306 5 O
on	1312 2 O
the	1315 3 O
interaction	1319 11 O
between	1331 7 O
flecainide	1339 10 B-Chemical
,	1349 1 O
a	1351 1 O
CYP2D6	1353 6 O
substrate	1360 9 O
,	1369 1 O
and	1371 3 O
paroxetine	1375 10 B-Chemical
,	1385 1 O
a	1387 1 O
CYP2D6	1389 6 O
inhibitor	1396 9 O
,	1405 1 O
as	1407 2 O
well	1410 4 O
as	1415 2 O
3	1418 1 O
case	1420 4 O
reports	1425 7 O
of	1433 2 O
flecainide	1436 10 B-Chemical
-	1446 1 O
induced	1447 7 O
delirium	1455 8 B-Disease
.	1463 1 O

According	1465 9 O
to	1475 2 O
the	1478 3 O
Naranjo	1482 7 O
probability	1490 11 O
scale	1502 5 O
,	1507 1 O
flecainide	1509 10 B-Chemical
was	1520 3 O
the	1524 3 O
probable	1528 8 O
cause	1537 5 O
of	1543 2 O
the	1546 3 O
patient	1550 7 O
'	1557 1 O
s	1558 1 O
delirium	1560 8 B-Disease
;	1568 1 O
the	1570 3 O
Horn	1574 4 O
Drug	1579 4 O
Interaction	1584 11 O
Probability	1596 11 O
Scale	1608 5 O
indicates	1614 9 O
a	1624 1 O
possible	1626 8 O
pharmacokinetic	1635 15 O
drug	1651 4 O
interaction	1656 11 O
between	1668 7 O
flecainide	1676 10 B-Chemical
and	1687 3 O
paroxetine	1691 10 B-Chemical
.	1701 1 O

CONCLUSIONS	1703 11 O
:	1714 1 O
Supratherapeutic	1716 16 O
flecainide	1733 10 B-Chemical
plasma	1744 6 O
concentrations	1751 14 O
may	1766 3 O
cause	1770 5 O
delirium	1776 8 B-Disease
.	1784 1 O

Because	1786 7 O
toxicity	1794 8 B-Disease
may	1803 3 O
occur	1807 5 O
when	1813 4 O
flecainide	1818 10 B-Chemical
is	1829 2 O
prescribed	1832 10 O
with	1843 4 O
paroxetine	1848 10 B-Chemical
and	1859 3 O
other	1863 5 O
potent	1869 6 O
CYP2D6	1876 6 O
inhibitors	1883 10 O
,	1893 1 O
flecainide	1895 10 B-Chemical
plasma	1906 6 O
concentrations	1913 14 O
should	1928 6 O
be	1935 2 O
monitored	1938 9 O
closely	1948 7 O
with	1956 4 O
commencement	1961 12 O
of	1974 2 O
CYP2D6	1977 6 O
inhibitors	1984 10 O
.	1994 1 O

Efficacy	0 8 O
of	9 2 O
everolimus	12 10 B-Chemical
(	23 1 O
RAD001	24 6 B-Chemical
)	30 1 O
in	32 2 O
patients	35 8 O
with	44 4 O
advanced	49 8 O
NSCLC	58 5 B-Disease
previously	64 10 O
treated	75 7 O
with	83 4 O
chemotherapy	88 12 O
alone	101 5 O
or	107 2 O
with	110 4 O
chemotherapy	115 12 O
and	128 3 O
EGFR	132 4 O
inhibitors	137 10 O
.	147 1 O

BACKGROUND	149 10 O
:	159 1 O
Treatment	161 9 O
options	171 7 O
are	179 3 O
scarce	183 6 O
in	190 2 O
pretreated	193 10 O
advanced	204 8 O
non	213 3 B-Disease
-	216 1 I-Disease
small	217 5 I-Disease
-	222 1 I-Disease
cell	223 4 I-Disease
lung	228 4 I-Disease
cancer	233 6 I-Disease
(	240 1 O
NSCLC	241 5 B-Disease
)	246 1 O
patients	248 8 O
.	256 1 O

RAD001	258 6 B-Chemical
,	264 1 O
an	266 2 O
oral	269 4 O
inhibitor	274 9 O
of	284 2 O
the	287 3 O
mammalian	291 9 O
target	301 6 O
of	308 2 O
rapamycin	311 9 B-Chemical
(	321 1 O
mTOR	322 4 O
)	326 1 O
,	327 1 O
has	329 3 O
shown	333 5 O
phase	339 5 O
I	345 1 O
efficacy	347 8 O
in	356 2 O
NSCLC	359 5 B-Disease
.	364 1 O

METHODS	366 7 O
:	373 1 O
Stage	375 5 O
IIIb	381 4 O
or	386 2 O
IV	389 2 O
NSCLC	392 5 B-Disease
patients	398 8 O
,	406 1 O
with	408 4 O
two	413 3 O
or	417 2 O
fewer	420 5 O
prior	426 5 O
chemotherapy	432 12 O
regimens	445 8 O
,	453 1 O
one	455 3 O
platinum	459 8 B-Chemical
based	468 5 O
(	474 1 O
stratum	475 7 O
1	483 1 O
)	484 1 O
or	486 2 O
both	489 4 O
chemotherapy	494 12 O
and	507 3 O
epidermal	511 9 O
growth	521 6 O
factor	528 6 O
receptor	535 8 O
tyrosine	544 8 B-Chemical
kinase	553 6 O
inhibitors	560 10 O
(	571 1 O
stratum	572 7 O
2	580 1 O
)	581 1 O
,	582 1 O
received	584 8 O
RAD001	593 6 B-Chemical
10	600 2 O
mg	603 2 O
/	605 1 O
day	606 3 O
until	610 5 O
progression	616 11 O
or	628 2 O
unacceptable	631 12 O
toxicity	644 8 B-Disease
.	652 1 O

Primary	654 7 O
objective	662 9 O
was	672 3 O
overall	676 7 O
response	684 8 O
rate	693 4 O
(	698 1 O
ORR	699 3 O
)	702 1 O
.	703 1 O

Analyses	705 8 O
of	714 2 O
markers	717 7 O
associated	725 10 O
with	736 4 O
the	741 3 O
mTOR	745 4 O
pathway	750 7 O
were	758 4 O
carried	763 7 O
out	771 3 O
on	775 2 O
archival	778 8 O
tumor	787 5 B-Disease
from	793 4 O
a	798 1 O
subgroup	800 8 O
using	809 5 O
immunohistochemistry	815 20 O
(	836 1 O
IHC	837 3 O
)	840 1 O
and	842 3 O
direct	846 6 O
mutation	853 8 O
sequencing	862 10 O
.	872 1 O

RESULTS	874 7 O
:	881 1 O
Eighty	883 6 O
-	889 1 O
five	890 4 O
patients	895 8 O
were	904 4 O
enrolled	909 8 O
,	917 1 O
42	919 2 O
in	922 2 O
stratum	925 7 O
1	933 1 O
and	935 3 O
43	939 2 O
in	942 2 O
stratum	945 7 O
.	952 1 O

ORR	954 3 O
was	958 3 O
4	962 1 O
.	963 1 O
7	964 1 O
%	965 1 O
(	967 1 O
7	968 1 O
.	969 1 O
1	970 1 O
%	971 1 O
stratum	973 7 O
1	981 1 O
;	982 1 O
2	984 1 O
.	985 1 O
3	986 1 O
%	987 1 O
stratum	989 7 O
2	997 1 O
)	998 1 O
.	999 1 O

Overall	1001 7 O
disease	1009 7 O
control	1017 7 O
rate	1025 4 O
was	1030 3 O
47	1034 2 O
.	1036 1 O
1	1037 1 O
%	1038 1 O
.	1039 1 O

Median	1041 6 O
progression	1048 11 O
-	1059 1 O
free	1060 4 O
survivals	1065 9 O
(	1075 1 O
PFSs	1076 4 O
)	1080 1 O
were	1082 4 O
2	1087 1 O
.	1088 1 O
6	1089 1 O
(	1091 1 O
stratum	1092 7 O
1	1100 1 O
)	1101 1 O
and	1103 3 O
2	1107 1 O
.	1108 1 O
7	1109 1 O
months	1111 6 O
(	1118 1 O
stratum	1119 7 O
2	1127 1 O
)	1128 1 O
.	1129 1 O

Common	1131 6 O
>	1138 1 O
or	1140 2 O
=	1143 1 O
grade	1144 5 O
3	1150 1 O
events	1152 6 O
were	1159 4 O
fatigue	1164 7 B-Disease
,	1171 1 O
dyspnea	1173 7 B-Disease
,	1180 1 O
stomatitis	1182 10 B-Disease
,	1192 1 O
anemia	1194 6 B-Disease
,	1200 1 O
and	1202 3 O
thrombocytopenia	1206 16 B-Disease
.	1222 1 O

Pneumonitis	1224 11 B-Disease
,	1235 1 O
probably	1237 8 O
or	1246 2 O
possibly	1249 8 O
related	1258 7 O
,	1265 1 O
mainly	1267 6 O
grade	1274 5 O
1	1280 1 O
/	1281 1 O
2	1282 1 O
,	1283 1 O
occurred	1285 8 O
in	1294 2 O
25	1297 2 O
%	1299 1 O
.	1300 1 O

Cox	1302 3 O
regression	1306 10 O
analysis	1317 8 O
of	1326 2 O
IHC	1329 3 O
scores	1333 6 O
found	1340 5 O
that	1346 4 O
only	1351 4 O
phospho	1356 7 O
AKT	1364 3 O
(	1368 1 O
pAKT	1369 4 O
)	1373 1 O
was	1375 3 O
a	1379 1 O
significant	1381 11 O
independent	1393 11 O
predictor	1405 9 O
of	1415 2 O
worse	1418 5 O
PFS	1424 3 O
.	1427 1 O

CONCLUSIONS	1429 11 O
:	1440 1 O
RAD001	1442 6 B-Chemical
10	1449 2 O
mg	1452 2 O
/	1454 1 O
day	1455 3 O
was	1459 3 O
well	1463 4 O
tolerated	1468 9 O
,	1477 1 O
showing	1479 7 O
modest	1487 6 O
clinical	1494 8 O
activity	1503 8 O
in	1512 2 O
pretreated	1515 10 O
NSCLC	1526 5 B-Disease
.	1531 1 O

Evaluation	1533 10 O
of	1544 2 O
RAD001	1547 6 B-Chemical
plus	1554 4 O
standard	1559 8 O
therapy	1568 7 O
for	1576 3 O
metastatic	1580 10 O
NSCLC	1591 5 B-Disease
continues	1597 9 O
.	1606 1 O

Posttransplant	0 14 O
anemia	15 6 B-Disease
:	21 1 O
the	23 3 O
role	27 4 O
of	32 2 O
sirolimus	35 9 B-Chemical
.	44 1 O

Posttransplant	46 14 O
anemia	61 6 B-Disease
is	68 2 O
a	71 1 O
common	73 6 O
problem	80 7 O
that	88 4 O
may	93 3 O
hinder	97 6 O
patients	104 8 O
'	112 1 O
quality	114 7 O
of	122 2 O
life	125 4 O
.	129 1 O

It	131 2 O
occurs	134 6 O
in	141 2 O
12	144 2 O
to	147 2 O
76	150 2 O
%	152 1 O
of	154 2 O
patients	157 8 O
,	165 1 O
and	167 3 O
is	171 2 O
most	174 4 O
common	179 6 O
in	186 2 O
the	189 3 O
immediate	193 9 O
posttransplant	203 14 O
period	218 6 O
.	224 1 O

A	226 1 O
variety	228 7 O
of	236 2 O
factors	239 7 O
have	247 4 O
been	252 4 O
identified	257 10 O
that	268 4 O
increase	273 8 O
the	282 3 O
risk	286 4 O
of	291 2 O
posttransplant	294 14 O
anemia	309 6 B-Disease
,	315 1 O
of	317 2 O
which	320 5 O
the	326 3 O
level	330 5 O
of	336 2 O
renal	339 5 O
function	345 8 O
is	354 2 O
most	357 4 O
important	362 9 O
.	371 1 O

Sirolimus	373 9 B-Chemical
,	382 1 O
a	384 1 O
mammalian	386 9 O
target	396 6 O
of	403 2 O
rapamycin	406 9 B-Chemical
inhibitor	416 9 O
,	425 1 O
has	427 3 O
been	431 4 O
implicated	436 10 O
as	447 2 O
playing	450 7 O
a	458 1 O
special	460 7 O
role	468 4 O
in	473 2 O
posttransplant	476 14 O
anemia	491 6 B-Disease
.	497 1 O

This	499 4 O
review	504 6 O
considers	511 9 O
anemia	521 6 B-Disease
associated	528 10 O
with	539 4 O
sirolimus	544 9 B-Chemical
,	553 1 O
including	555 9 O
its	565 3 O
presentation	569 12 O
,	581 1 O
mechanisms	583 10 O
,	593 1 O
and	595 3 O
management	599 10 O
.	609 1 O

Coronary	0 8 O
computerized	9 12 O
tomography	22 10 O
angiography	33 11 O
for	45 3 O
rapid	49 5 O
discharge	55 9 O
of	65 2 O
low	68 3 O
-	71 1 O
risk	72 4 O
patients	77 8 O
with	86 4 O
cocaine	91 7 B-Chemical
-	98 1 O
associated	99 10 O
chest	110 5 B-Disease
pain	116 4 I-Disease
.	120 1 O

BACKGROUND	122 10 O
:	132 1 O
Most	134 4 O
patients	139 8 O
presenting	148 10 O
to	159 2 O
emergency	162 9 O
departments	172 11 O
(	184 1 O
EDs	185 3 O
)	188 1 O
with	190 4 O
cocaine	195 7 B-Chemical
-	202 1 O
associated	203 10 O
chest	214 5 B-Disease
pain	220 4 I-Disease
are	225 3 O
admitted	229 8 O
for	238 3 O
at	242 2 O
least	245 5 O
12	251 2 O
hours	254 5 O
and	260 3 O
receive	264 7 O
a	272 1 O
"	274 1 O
rule	275 4 O
out	280 3 O
acute	284 5 B-Disease
coronary	290 8 I-Disease
syndrome	299 8 I-Disease
"	307 1 O
protocol	309 8 O
,	317 1 O
often	319 5 O
with	325 4 O
noninvasive	330 11 O
testing	342 7 O
prior	350 5 O
to	356 2 O
discharge	359 9 O
.	368 1 O

In	370 2 O
patients	373 8 O
without	382 7 O
cocaine	390 7 B-Chemical
use	398 3 O
,	401 1 O
coronary	403 8 O
computerized	412 12 O
tomography	425 10 O
angiography	436 11 O
(	448 1 O
CTA	449 3 O
)	452 1 O
has	454 3 O
been	458 4 O
shown	463 5 O
to	469 2 O
be	472 2 O
useful	475 6 O
for	482 3 O
identifying	486 11 O
a	498 1 O
group	500 5 O
of	506 2 O
patients	509 8 O
at	518 2 O
low	521 3 O
risk	525 4 O
for	530 3 O
cardiac	534 7 O
events	542 6 O
who	549 3 O
can	553 3 O
be	557 2 O
safely	560 6 O
discharged	567 10 O
.	577 1 O

It	579 2 O
is	582 2 O
unclear	585 7 O
whether	593 7 O
a	601 1 O
coronary	603 8 O
CTA	612 3 O
strategy	616 8 O
would	625 5 O
be	631 2 O
efficacious	634 11 O
in	646 2 O
cocaine	649 7 B-Chemical
-	656 1 O
associated	657 10 O
chest	668 5 B-Disease
pain	674 4 I-Disease
,	678 1 O
as	680 2 O
coronary	683 8 B-Disease
vasospasm	692 9 I-Disease
may	702 3 O
account	706 7 O
for	714 3 O
some	718 4 O
of	723 2 O
the	726 3 O
ischemia	730 8 B-Disease
.	738 1 O

We	740 2 O
studied	743 7 O
whether	751 7 O
a	759 1 O
negative	761 8 O
coronary	770 8 O
CTA	779 3 O
in	783 2 O
patients	786 8 O
with	795 4 O
cocaine	800 7 B-Chemical
-	807 1 O
associated	808 10 O
chest	819 5 B-Disease
pain	825 4 I-Disease
could	830 5 O
identify	836 8 O
a	845 1 O
subset	847 6 O
safe	854 4 O
for	859 3 O
discharge	863 9 O
.	872 1 O

METHODS	874 7 O
:	881 1 O
We	883 2 O
prospectively	886 13 O
evaluated	900 9 O
the	910 3 O
safety	914 6 O
of	921 2 O
coronary	924 8 O
CTA	933 3 O
for	937 3 O
low	941 3 O
-	944 1 O
risk	945 4 O
patients	950 8 O
who	959 3 O
presented	963 9 O
to	973 2 O
the	976 3 O
ED	980 2 O
with	983 4 O
cocaineassociated	988 17 O
chest	1006 5 B-Disease
pain	1012 4 I-Disease
(	1017 1 O
self	1018 4 O
-	1022 1 O
reported	1023 8 O
or	1032 2 O
positive	1035 8 O
urine	1044 5 O
test	1050 4 O
)	1054 1 O
.	1055 1 O

Consecutive	1057 11 O
patients	1069 8 O
received	1078 8 O
either	1087 6 O
immediate	1094 9 O
coronary	1104 8 O
CTA	1113 3 O
in	1117 2 O
the	1120 3 O
ED	1124 2 O
(	1127 1 O
without	1128 7 O
serial	1136 6 O
markers	1143 7 O
)	1150 1 O
or	1152 2 O
underwent	1155 9 O
coronary	1165 8 O
CTA	1174 3 O
after	1178 5 O
a	1184 1 O
brief	1186 5 O
observation	1192 11 O
period	1204 6 O
with	1211 4 O
serial	1216 6 O
cardiac	1223 7 O
marker	1231 6 O
measurements	1238 12 O
.	1250 1 O

Patients	1252 8 O
with	1261 4 O
negative	1266 8 O
coronary	1275 8 O
CTA	1284 3 O
(	1288 1 O
maximal	1289 7 O
stenosis	1297 8 B-Disease
less	1306 4 O
than	1311 4 O
50	1316 2 O
%	1318 1 O
)	1319 1 O
were	1321 4 O
discharged	1326 10 O
.	1336 1 O

The	1338 3 O
main	1342 4 O
outcome	1347 7 O
was	1355 3 O
30	1359 2 O
-	1361 1 O
day	1362 3 O
cardiovascular	1366 14 O
death	1381 5 O
or	1387 2 O
myocardial	1390 10 B-Disease
infarction	1401 10 I-Disease
.	1411 1 O

RESULTS	1413 7 O
:	1420 1 O
A	1422 1 O
total	1424 5 O
of	1430 2 O
59	1433 2 O
patients	1436 8 O
with	1445 4 O
cocaine	1450 7 B-Chemical
-	1457 1 O
associated	1458 10 O
chest	1469 5 B-Disease
pain	1475 4 I-Disease
were	1480 4 O
evaluated	1485 9 O
.	1494 1 O

Patients	1496 8 O
had	1505 3 O
a	1509 1 O
mean	1511 4 O
age	1516 3 O
of	1520 2 O
45	1523 2 O
.	1525 1 O
6	1526 1 O
+	1528 1 O
/	1529 1 O
-	1530 1 O
6	1532 1 O
.	1533 1 O
6	1534 1 O
yrs	1536 3 O
and	1540 3 O
were	1544 4 O
86	1549 2 O
%	1551 1 O
black	1553 5 O
,	1558 1 O
66	1560 2 O
%	1562 1 O
male	1564 4 O
.	1568 1 O

Seventy	1570 7 O
-	1577 1 O
nine	1578 4 O
percent	1583 7 O
had	1591 3 O
a	1595 1 O
normal	1597 6 O
or	1604 2 O
nonspecific	1607 11 O
ECG	1619 3 O
and	1623 3 O
85	1627 2 O
%	1629 1 O
had	1631 3 O
a	1635 1 O
TIMI	1637 4 O
score	1642 5 O
<	1648 1 O
2	1649 1 O
.	1650 1 O

Twenty	1652 6 O
patients	1659 8 O
received	1668 8 O
coronary	1677 8 O
CTA	1686 3 O
immediately	1690 11 O
in	1702 2 O
the	1705 3 O
ED	1709 2 O
,	1711 1 O
18	1713 2 O
of	1716 2 O
whom	1719 4 O
were	1724 4 O
discharged	1729 10 O
following	1740 9 O
CTA	1750 3 O
(	1754 1 O
90	1755 2 O
%	1757 1 O
)	1758 1 O
.	1759 1 O

Thirty	1761 6 O
-	1767 1 O
nine	1768 4 O
received	1773 8 O
coronary	1782 8 O
CTA	1791 3 O
after	1795 5 O
a	1801 1 O
brief	1803 5 O
observation	1809 11 O
period	1821 6 O
,	1827 1 O
with	1829 4 O
37	1834 2 O
discharged	1837 10 O
home	1848 4 O
following	1853 9 O
CTA	1863 3 O
(	1867 1 O
95	1868 2 O
%	1870 1 O
)	1871 1 O
.	1872 1 O

Six	1874 3 O
patients	1878 8 O
had	1887 3 O
coronary	1891 8 B-Disease
stenosis	1900 8 I-Disease
>	1909 1 O
or	1910 2 O
=	1912 1 O
50	1913 2 O
%	1915 1 O
.	1916 1 O

During	1918 6 O
the	1925 3 O
30	1929 2 O
-	1931 1 O
day	1932 3 O
follow	1936 6 O
-	1942 1 O
up	1943 2 O
period	1946 6 O
,	1952 1 O
no	1954 2 O
patients	1957 8 O
died	1966 4 O
of	1971 2 O
a	1974 1 O
cardiovascular	1976 14 O
event	1991 5 O
(	1997 1 O
0	1998 1 O
%	1999 1 O
;	2000 1 O
95	2002 2 O
%	2004 1 O
CI	2006 2 O
,	2008 1 O
0	2010 1 O
-	2011 1 O
6	2012 1 O
.	2013 1 O
1	2014 1 O
%	2015 1 O
)	2016 1 O
and	2018 3 O
no	2022 2 O
patient	2025 7 O
sustained	2033 9 O
a	2043 1 O
nonfatal	2045 8 O
myocardial	2054 10 B-Disease
infarction	2065 10 I-Disease
(	2076 1 O
0	2077 1 O
%	2078 1 O
;	2079 1 O
95	2081 2 O
%	2083 1 O
CI	2085 2 O
,	2087 1 O
0	2089 1 O
-	2090 1 O
6	2091 1 O
.	2092 1 O
1	2093 1 O
%	2094 1 O
)	2095 1 O
.	2096 1 O

CONCLUSIONS	2098 11 O
:	2109 1 O
Although	2111 8 O
cocaine	2120 7 B-Chemical
-	2127 1 O
associated	2128 10 O
myocardial	2139 10 B-Disease
ischemia	2150 8 I-Disease
can	2159 3 O
result	2163 6 O
from	2170 4 O
coronary	2175 8 O
vasoconstriction	2184 16 O
,	2200 1 O
patients	2202 8 O
with	2211 4 O
cocaine	2216 7 B-Chemical
associated	2224 10 O
chest	2235 5 B-Disease
pain	2241 4 I-Disease
,	2245 1 O
a	2247 1 O
non	2249 3 O
-	2252 1 O
ischemic	2253 8 B-Disease
ECG	2262 3 O
,	2265 1 O
and	2267 3 O
a	2271 1 O
TIMI	2273 4 O
risk	2278 4 O
score	2283 5 O
<	2289 1 O
2	2290 1 O
may	2292 3 O
be	2296 2 O
safely	2299 6 O
discharged	2306 10 O
from	2317 4 O
the	2322 3 O
ED	2326 2 O
after	2329 5 O
a	2335 1 O
negative	2337 8 O
coronary	2346 8 O
CTA	2355 3 O
with	2359 4 O
a	2364 1 O
low	2366 3 O
risk	2370 4 O
of	2375 2 O
30	2378 2 O
-	2380 1 O
day	2381 3 O
adverse	2385 7 O
events	2393 6 O
.	2399 1 O

Late	0 4 O
fulminant	5 9 O
posterior	15 9 B-Disease
reversible	25 10 I-Disease
encephalopathy	36 14 I-Disease
syndrome	51 8 I-Disease
after	60 5 O
liver	66 5 O
transplant	72 10 O
.	82 1 O

OBJECTIVES	84 10 O
:	94 1 O
Posterior	96 9 B-Disease
leukoencephalopathy	106 19 I-Disease
due	126 3 O
to	130 2 O
calcineurin	133 11 O
-	144 1 O
inhibitor	145 9 O
-	154 1 O
related	155 7 O
neurotoxicity	163 13 B-Disease
is	177 2 O
a	180 1 O
rare	182 4 O
but	187 3 O
severe	191 6 O
complication	198 12 O
that	211 4 O
results	216 7 O
from	224 4 O
treatment	229 9 O
with	239 4 O
immunosuppressive	244 17 O
agents	262 6 O
(	269 1 O
primarily	270 9 O
those	280 5 O
administered	286 12 O
after	299 5 O
a	305 1 O
liver	307 5 O
or	313 2 O
kidney	316 6 O
transplant	323 10 O
)	333 1 O
.	334 1 O

The	336 3 O
pathophysiologic	340 16 O
mechanisms	357 10 O
of	368 2 O
that	371 4 O
disorder	376 8 O
remain	385 6 O
unknown	392 7 O
.	399 1 O

CASE	401 4 O
:	405 1 O
We	407 2 O
report	410 6 O
the	417 3 O
case	421 4 O
of	426 2 O
a	429 1 O
46	431 2 O
-	433 1 O
year	434 4 O
-	438 1 O
old	439 3 O
woman	443 5 O
who	449 3 O
received	453 8 O
a	462 1 O
liver	464 5 O
transplant	470 10 O
in	481 2 O
our	484 3 O
center	488 6 O
as	495 2 O
treatment	498 9 O
for	508 3 O
alcoholic	512 9 B-Disease
cirrhosis	522 9 I-Disease
and	532 3 O
in	536 2 O
whom	539 4 O
either	544 6 O
a	551 1 O
fulminant	553 9 O
course	563 6 O
of	570 2 O
posterior	573 9 B-Disease
leukoencephalopathy	583 19 I-Disease
or	603 2 O
posterior	606 9 B-Disease
reversible	616 10 I-Disease
encephalopathy	627 14 I-Disease
syndrome	642 8 I-Disease
developed	651 9 O
110	661 3 O
days	665 4 O
after	670 5 O
transplant	676 10 O
.	686 1 O

After	688 5 O
an	694 2 O
initially	697 9 O
uneventful	707 10 O
course	718 6 O
after	725 5 O
the	731 3 O
transplant	735 10 O
,	745 1 O
the	747 3 O
patient	751 7 O
rapidly	759 7 O
fell	767 4 O
into	772 4 O
deep	777 4 O
coma	782 4 O
.	786 1 O

RESULTS	788 7 O
:	795 1 O
Cerebral	797 8 O
MRI	806 3 O
scan	810 4 O
showed	815 6 O
typical	822 7 O
signs	830 5 O
of	836 2 O
enhancement	839 11 O
in	851 2 O
the	854 3 O
pontine	858 7 O
and	866 3 O
posterior	870 9 O
regions	880 7 O
.	887 1 O

Switching	889 9 O
the	899 3 O
immunosuppressive	903 17 O
regimen	921 7 O
from	929 4 O
tacrolimus	934 10 B-Chemical
to	945 2 O
cyclosporine	948 12 B-Chemical
did	961 3 O
not	965 3 O
improve	969 7 O
the	977 3 O
clinical	981 8 O
situation	990 9 O
.	999 1 O

The	1001 3 O
termination	1005 11 O
of	1017 2 O
treatment	1020 9 O
with	1030 4 O
any	1035 3 O
calcineurin	1039 11 O
inhibitor	1051 9 O
resulted	1061 8 O
in	1070 2 O
a	1073 1 O
complete	1075 8 O
resolution	1084 10 O
of	1095 2 O
that	1098 4 O
complication	1103 12 O
.	1115 1 O

CONCLUSIONS	1117 11 O
:	1128 1 O
Posterior	1130 9 B-Disease
reversible	1140 10 I-Disease
encephalopathy	1151 14 I-Disease
syndrome	1166 8 I-Disease
after	1175 5 O
liver	1181 5 O
transplant	1187 10 O
is	1198 2 O
rare	1201 4 O
.	1205 1 O

We	1207 2 O
recommend	1210 9 O
a	1220 1 O
complete	1222 8 O
cessation	1231 9 O
of	1241 2 O
any	1244 3 O
calcineurin	1248 11 O
inhibitor	1260 9 O
rather	1270 6 O
than	1277 4 O
a	1282 1 O
dose	1284 4 O
reduction	1289 9 O
.	1298 1 O

Prolonged	0 9 O
hypothermia	10 11 B-Disease
as	22 2 O
a	25 1 O
bridge	27 6 O
to	34 2 O
recovery	37 8 O
for	46 3 O
cerebral	50 8 B-Disease
edema	59 5 I-Disease
and	65 3 O
intracranial	69 12 B-Disease
hypertension	82 12 I-Disease
associated	95 10 O
with	106 4 O
fulminant	111 9 B-Disease
hepatic	121 7 I-Disease
failure	129 7 I-Disease
.	136 1 O

BACKGROUND	138 10 O
:	148 1 O
To	150 2 O
review	153 6 O
evidence	160 8 O
-	168 1 O
based	169 5 O
treatment	175 9 O
options	185 7 O
in	193 2 O
patients	196 8 O
with	205 4 O
cerebral	210 8 B-Disease
edema	219 5 I-Disease
complicating	225 12 O
fulminant	238 9 B-Disease
hepatic	248 7 I-Disease
failure	256 7 I-Disease
(	264 1 O
FHF	265 3 B-Disease
)	268 1 O
and	270 3 O
discuss	274 7 O
the	282 3 O
potential	286 9 O
applications	296 12 O
of	309 2 O
hypothermia	312 11 B-Disease
.	323 1 O

METHOD	325 6 O
:	331 1 O
Case	333 4 O
-	337 1 O
based	338 5 O
observations	344 12 O
from	357 4 O
a	362 1 O
medical	364 7 O
intensive	372 9 O
care	382 4 O
unit	387 4 O
(	392 1 O
MICU	393 4 O
)	397 1 O
in	399 2 O
a	402 1 O
tertiary	404 8 O
care	413 4 O
facility	418 8 O
in	427 2 O
a	430 1 O
27	432 2 O
-	434 1 O
year	435 4 O
-	439 1 O
old	440 3 O
female	444 6 O
with	451 4 O
FHF	456 3 B-Disease
from	460 4 O
acetaminophen	465 13 B-Chemical
and	479 3 O
resultant	483 9 O
cerebral	493 8 B-Disease
edema	502 5 I-Disease
.	507 1 O

RESULTS	509 7 O
:	516 1 O
Our	518 3 O
patient	522 7 O
was	530 3 O
admitted	534 8 O
to	543 2 O
the	546 3 O
MICU	550 4 O
after	555 5 O
being	561 5 O
found	567 5 O
unresponsive	573 12 O
with	586 4 O
presumed	591 8 O
toxicity	600 8 B-Disease
from	609 4 O
acetaminophen	614 13 B-Chemical
which	628 5 O
was	634 3 O
ingested	638 8 O
over	647 4 O
a	652 1 O
2	654 1 O
-	655 1 O
day	656 3 O
period	660 6 O
.	666 1 O

The	668 3 O
patient	672 7 O
had	680 3 O
depressed	684 9 O
of	694 2 O
mental	697 6 O
status	704 6 O
lasting	711 7 O
at	719 2 O
least	722 5 O
24	728 2 O
h	731 1 O
prior	733 5 O
to	739 2 O
admission	742 9 O
.	751 1 O

Initial	753 7 O
evaluation	761 10 O
confirmed	772 9 O
FHF	782 3 B-Disease
from	786 4 O
acetaminophen	791 13 B-Chemical
and	805 3 O
cerebral	809 8 B-Disease
edema	818 5 I-Disease
.	823 1 O

The	825 3 O
patient	829 7 O
was	837 3 O
treated	841 7 O
with	849 4 O
hyperosmolar	854 12 O
therapy	867 7 O
,	874 1 O
hyperventilation	876 16 B-Disease
,	892 1 O
sedation	894 8 O
,	902 1 O
and	904 3 O
chemical	908 8 O
paralysis	917 9 B-Disease
.	926 1 O

Her	928 3 O
intracranial	932 12 O
pressure	945 8 O
remained	954 8 O
elevated	963 8 O
despite	972 7 O
maximal	980 7 O
medical	988 7 O
therapy	996 7 O
.	1003 1 O

We	1005 2 O
then	1008 4 O
initiated	1013 9 O
therapeutic	1023 11 O
hypothermia	1035 11 B-Disease
which	1047 5 O
was	1053 3 O
continued	1057 9 O
for	1067 3 O
5	1071 1 O
days	1073 4 O
.	1077 1 O

At	1079 2 O
re	1082 2 O
-	1084 1 O
warming	1085 7 O
,	1092 1 O
patient	1094 7 O
had	1102 3 O
resolution	1106 10 O
of	1117 2 O
her	1120 3 O
cerebral	1124 8 B-Disease
edema	1133 5 I-Disease
and	1139 3 O
intracranial	1143 12 B-Disease
hypertension	1156 12 I-Disease
.	1168 1 O

At	1170 2 O
discharge	1173 9 O
,	1182 1 O
she	1184 3 O
had	1188 3 O
complete	1192 8 O
recovery	1201 8 O
of	1210 2 O
neurological	1213 12 O
and	1226 3 O
hepatic	1230 7 O
functions	1238 9 O
.	1247 1 O

CONCLUSION	1249 10 O
:	1259 1 O
In	1261 2 O
patients	1264 8 O
with	1273 4 O
FHF	1278 3 B-Disease
and	1282 3 O
cerebral	1286 8 B-Disease
edema	1295 5 I-Disease
from	1301 4 O
acetaminophen	1306 13 B-Chemical
overdose	1320 8 B-Disease
,	1328 1 O
prolonged	1330 9 O
therapeutic	1340 11 O
hypothermia	1352 11 B-Disease
could	1364 5 O
potentially	1370 11 O
be	1382 2 O
used	1385 4 O
as	1390 2 O
a	1393 1 O
life	1395 4 O
saving	1400 6 O
therapy	1407 7 O
and	1415 3 O
a	1419 1 O
bridge	1421 6 O
to	1428 2 O
hepatic	1431 7 O
and	1439 3 O
neurological	1443 12 O
recovery	1456 8 O
.	1464 1 O

A	1466 1 O
clinical	1468 8 O
trial	1477 5 O
of	1483 2 O
hypothermia	1486 11 B-Disease
in	1498 2 O
patients	1501 8 O
with	1510 4 O
this	1515 4 O
condition	1520 9 O
is	1530 2 O
warranted	1533 9 O
.	1542 1 O

Binasal	0 7 B-Disease
visual	8 6 I-Disease
field	15 5 I-Disease
defects	21 7 I-Disease
are	29 3 O
not	33 3 O
specific	37 8 O
to	46 2 O
vigabatrin	49 10 B-Chemical
.	59 1 O

This	61 4 O
study	66 5 O
investigated	72 12 O
the	85 3 O
visual	89 6 B-Disease
defects	96 7 I-Disease
associated	104 10 O
with	115 4 O
the	120 3 O
antiepileptic	124 13 O
drug	138 4 O
vigabatrin	143 10 B-Chemical
(	154 1 O
VGB	155 3 B-Chemical
)	158 1 O
.	159 1 O

Two	161 3 O
hundred	165 7 O
four	173 4 O
people	178 6 O
with	185 4 O
epilepsy	190 8 B-Disease
were	199 4 O
grouped	204 7 O
on	212 2 O
the	215 3 O
basis	219 5 O
of	225 2 O
antiepileptic	228 13 O
drug	242 4 O
therapy	247 7 O
(	255 1 O
current	256 7 O
,	263 1 O
previous	265 8 O
,	273 1 O
or	275 2 O
no	278 2 O
exposure	281 8 O
to	290 2 O
VGB	293 3 B-Chemical
)	296 1 O
.	297 1 O

Groups	299 6 O
were	306 4 O
matched	311 7 O
with	319 4 O
respect	324 7 O
to	332 2 O
age	335 3 O
,	338 1 O
gender	340 6 O
,	346 1 O
and	348 3 O
seizure	352 7 B-Disease
frequency	360 9 O
.	369 1 O

All	371 3 O
patients	375 8 O
underwent	384 9 O
objective	394 9 O
assessment	404 10 O
of	415 2 O
electrophysiological	418 20 O
function	439 8 O
(	448 1 O
wide	449 4 O
-	453 1 O
field	454 5 O
multifocal	460 10 O
electroretinography	471 19 O
)	490 1 O
and	492 3 O
conventional	496 12 O
visual	509 6 O
field	516 5 O
testing	522 7 O
(	530 1 O
static	531 6 O
perimetry	538 9 O
)	547 1 O
.	548 1 O

Bilateral	550 9 O
visual	560 6 O
field	567 5 O
constriction	573 12 O
was	586 3 O
observed	590 8 O
in	599 2 O
59	602 2 O
%	604 1 O
of	606 2 O
patients	609 8 O
currently	618 9 O
taking	628 6 O
VGB	635 3 B-Chemical
,	638 1 O
43	640 2 O
%	642 1 O
of	644 2 O
patients	647 8 O
who	656 3 O
previously	660 10 O
took	671 4 O
VGB	676 3 B-Chemical
,	679 1 O
and	681 3 O
24	685 2 O
%	687 1 O
of	689 2 O
patients	692 8 O
with	701 4 O
no	706 2 O
exposure	709 8 O
to	718 2 O
VGB	721 3 B-Chemical
.	724 1 O

Assessment	726 10 O
of	737 2 O
retinal	740 7 O
function	748 8 O
revealed	757 8 O
abnormal	766 8 O
responses	775 9 O
in	785 2 O
48	788 2 O
%	790 1 O
of	792 2 O
current	795 7 O
VGB	803 3 B-Chemical
users	807 5 O
and	813 3 O
22	817 2 O
%	819 1 O
of	821 2 O
prior	824 5 O
VGB	830 3 B-Chemical
users	834 5 O
,	839 1 O
but	841 3 O
in	845 2 O
none	848 4 O
of	853 2 O
the	856 3 O
patients	860 8 O
without	869 7 O
previous	877 8 O
exposure	886 8 O
to	895 2 O
VGB	898 3 B-Chemical
.	901 1 O

Bilateral	903 9 B-Disease
visual	913 6 I-Disease
field	920 5 I-Disease
abnormalities	926 13 I-Disease
are	940 3 O
common	944 6 O
in	951 2 O
the	954 3 O
treated	958 7 O
epilepsy	966 8 B-Disease
population	975 10 O
,	985 1 O
irrespective	987 12 O
of	1000 2 O
drug	1003 4 O
history	1008 7 O
.	1015 1 O

Assessment	1017 10 O
by	1028 2 O
conventional	1031 12 O
static	1044 6 O
perimetry	1051 9 O
may	1061 3 O
neither	1065 7 O
be	1073 2 O
sufficiently	1076 12 O
sensitive	1089 9 O
nor	1099 3 O
specific	1103 8 O
to	1112 2 O
reliably	1115 8 O
identify	1124 8 O
retinal	1133 7 B-Disease
toxicity	1141 8 I-Disease
associated	1150 10 O
with	1161 4 O
VGB	1166 3 B-Chemical
.	1169 1 O

Smoking	0 7 O
of	8 2 O
crack	11 5 B-Chemical
cocaine	17 7 I-Chemical
as	25 2 O
a	28 1 O
risk	30 4 O
factor	35 6 O
for	42 3 O
HIV	46 3 B-Disease
infection	50 9 I-Disease
among	60 5 O
people	66 6 O
who	73 3 O
use	77 3 O
injection	81 9 O
drugs	91 5 O
.	96 1 O

BACKGROUND	98 10 O
:	108 1 O
Little	110 6 O
is	117 2 O
known	120 5 O
about	126 5 O
the	132 3 O
possible	136 8 O
role	145 4 O
that	150 4 O
smoking	155 7 O
crack	163 5 B-Chemical
cocaine	169 7 I-Chemical
has	177 3 O
on	181 2 O
the	184 3 O
incidence	188 9 O
of	198 2 O
HIV	201 3 B-Disease
infection	205 9 I-Disease
.	214 1 O

Given	216 5 O
the	222 3 O
increasing	226 10 O
use	237 3 O
of	241 2 O
crack	244 5 B-Chemical
cocaine	250 7 I-Chemical
,	257 1 O
we	259 2 O
sought	262 6 O
to	269 2 O
examine	272 7 O
whether	280 7 O
use	288 3 O
of	292 2 O
this	295 4 O
illicit	300 7 O
drug	308 4 O
has	313 3 O
become	317 6 O
a	324 1 O
risk	326 4 O
factor	331 6 O
for	338 3 O
HIV	342 3 B-Disease
infection	346 9 I-Disease
.	355 1 O

METHODS	357 7 O
:	364 1 O
We	366 2 O
included	369 8 O
data	378 4 O
from	383 4 O
people	388 6 O
participating	395 13 O
in	409 2 O
the	412 3 O
Vancouver	416 9 O
Injection	426 9 O
Drug	436 4 O
Users	441 5 O
Study	447 5 O
who	453 3 O
reported	457 8 O
injecting	466 9 O
illicit	476 7 O
drugs	484 5 O
at	490 2 O
least	493 5 O
once	499 4 O
in	504 2 O
the	507 3 O
month	511 5 O
before	517 6 O
enrolment	524 9 O
,	533 1 O
lived	535 5 O
in	541 2 O
the	544 3 O
greater	548 7 O
Vancouver	556 9 O
area	566 4 O
,	570 1 O
were	572 4 O
HIV	577 3 O
-	580 1 O
negative	581 8 O
at	590 2 O
enrolment	593 9 O
and	603 3 O
completed	607 9 O
at	617 2 O
least	620 5 O
1	626 1 O
follow	628 6 O
-	634 1 O
up	635 2 O
study	638 5 O
visit	644 5 O
.	649 1 O

To	651 2 O
determine	654 9 O
whether	664 7 O
the	672 3 O
risk	676 4 O
of	681 2 O
HIV	684 3 B-Disease
seroconversion	688 14 I-Disease
among	703 5 O
daily	709 5 O
smokers	715 7 O
of	723 2 O
crack	726 5 B-Chemical
cocaine	732 7 I-Chemical
changed	740 7 O
over	748 4 O
time	753 4 O
,	757 1 O
we	759 2 O
used	762 4 O
Cox	767 3 O
proportional	771 12 O
hazards	784 7 O
regression	792 10 O
and	803 3 O
divided	807 7 O
the	815 3 O
study	819 5 O
into	825 4 O
3	830 1 O
periods	832 7 O
:	839 1 O
May	841 3 O
1	845 1 O
,	846 1 O
1996	848 4 O
-	852 1 O
Nov	853 3 O
.	856 1 O

30	858 2 O
,	860 1 O
1999	862 4 O
(	867 1 O
period	868 6 O
1	875 1 O
)	876 1 O
,	877 1 O
Dec	879 3 O
.	882 1 O

1	884 1 O
,	885 1 O
1999	887 4 O
-	891 1 O
Nov	892 3 O
.	895 1 O

30	897 2 O
,	899 1 O
2002	901 4 O
(	906 1 O
period	907 6 O
2	914 1 O
)	915 1 O
,	916 1 O
and	918 3 O
Dec	922 3 O
.	925 1 O

1	927 1 O
,	928 1 O
2002	930 4 O
-	934 1 O
Dec	935 3 O
.	938 1 O

30	940 2 O
,	942 1 O
2005	944 4 O
(	949 1 O
period	950 6 O
3	957 1 O
)	958 1 O
.	959 1 O

RESULTS	961 7 O
:	968 1 O
Overall	970 7 O
,	977 1 O
1048	979 4 O
eligible	984 8 O
injection	993 9 O
drug	1003 4 O
users	1008 5 O
were	1014 4 O
included	1019 8 O
in	1028 2 O
our	1031 3 O
study	1035 5 O
.	1040 1 O

Of	1042 2 O
these	1045 5 O
,	1050 1 O
137	1052 3 O
acquired	1056 8 O
HIV	1065 3 B-Disease
infection	1069 9 I-Disease
during	1079 6 O
follow	1086 6 O
-	1092 1 O
up	1093 2 O
.	1095 1 O

The	1097 3 O
mean	1101 4 O
proportion	1106 10 O
of	1117 2 O
participants	1120 12 O
who	1133 3 O
reported	1137 8 O
daily	1146 5 O
smoking	1152 7 O
of	1160 2 O
crack	1163 5 B-Chemical
cocaine	1169 7 I-Chemical
increased	1177 9 O
from	1187 4 O
11	1192 2 O
.	1194 1 O
6	1195 1 O
%	1196 1 O
in	1198 2 O
period	1201 6 O
1	1208 1 O
to	1210 2 O
39	1213 2 O
.	1215 1 O
7	1216 1 O
%	1217 1 O
in	1219 2 O
period	1222 6 O
3	1229 1 O
.	1230 1 O

After	1232 5 O
adjusting	1238 9 O
for	1248 3 O
potential	1252 9 O
confounders	1262 11 O
,	1273 1 O
we	1275 2 O
found	1278 5 O
that	1284 4 O
the	1289 3 O
risk	1293 4 O
of	1298 2 O
HIV	1301 3 B-Disease
seroconversion	1305 14 I-Disease
among	1320 5 O
participants	1326 12 O
who	1339 3 O
were	1343 4 O
daily	1348 5 O
smokers	1354 7 O
of	1362 2 O
crack	1365 5 B-Chemical
cocaine	1371 7 I-Chemical
increased	1379 9 O
over	1389 4 O
time	1394 4 O
(	1399 1 O
period	1400 6 O
1	1407 1 O
:	1408 1 O
hazard	1410 6 O
ratio	1417 5 O
[	1423 1 O
HR	1424 2 O
]	1426 1 O
1	1428 1 O
.	1429 1 O
03	1430 2 O
,	1432 1 O
95	1434 2 O
%	1436 1 O
confidence	1438 10 O
interval	1449 8 O
[	1458 1 O
CI	1459 2 O
]	1461 1 O
0	1463 1 O
.	1464 1 O
57	1465 2 O
-	1467 1 O
1	1468 1 O
.	1469 1 O
85	1470 2 O
;	1472 1 O
period	1474 6 O
2	1481 1 O
:	1482 1 O
HR	1484 2 O
1	1487 1 O
.	1488 1 O
68	1489 2 O
,	1491 1 O
95	1493 2 O
%	1495 1 O
CI	1497 2 O
1	1500 1 O
.	1501 1 O
01	1502 2 O
-	1504 1 O
2	1505 1 O
.	1506 1 O
80	1507 2 O
;	1509 1 O
and	1511 3 O
period	1515 6 O
3	1522 1 O
:	1523 1 O
HR	1525 2 O
2	1528 1 O
.	1529 1 O
74	1530 2 O
,	1532 1 O
95	1534 2 O
%	1536 1 O
CI	1538 2 O
1	1541 1 O
.	1542 1 O
06	1543 2 O
-	1545 1 O
7	1546 1 O
.	1547 1 O
11	1548 2 O
)	1550 1 O
.	1551 1 O

INTERPRETATION	1553 14 O
:	1567 1 O
Smoking	1569 7 O
of	1577 2 O
crack	1580 5 B-Chemical
cocaine	1586 7 I-Chemical
was	1594 3 O
found	1598 5 O
to	1604 2 O
be	1607 2 O
an	1610 2 O
independent	1613 11 O
risk	1625 4 O
factor	1630 6 O
for	1637 3 O
HIV	1641 3 B-Disease
seroconversion	1645 14 I-Disease
among	1660 5 O
people	1666 6 O
who	1673 3 O
were	1677 4 O
injection	1682 9 O
drug	1692 4 O
users	1697 5 O
.	1702 1 O

This	1704 4 O
finding	1709 7 O
points	1717 6 O
to	1724 2 O
the	1727 3 O
urgent	1731 6 O
need	1738 4 O
for	1743 3 O
evidence	1747 8 O
-	1755 1 O
based	1756 5 O
public	1762 6 O
health	1769 6 O
initiatives	1776 11 O
targeted	1788 8 O
at	1797 2 O
people	1800 6 O
who	1807 3 O
smoke	1811 5 O
crack	1817 5 B-Chemical
cocaine	1823 7 I-Chemical
.	1830 1 O

Fluoxetine	0 10 B-Chemical
improves	11 8 O
the	20 3 O
memory	24 6 B-Disease
deficits	31 8 I-Disease
caused	40 6 O
by	47 2 O
the	50 3 O
chemotherapy	54 12 O
agent	67 5 O
5	73 1 B-Chemical
-	74 1 I-Chemical
fluorouracil	75 12 I-Chemical
.	87 1 O

Cancer	89 6 B-Disease
patients	96 8 O
who	105 3 O
have	109 4 O
been	114 4 O
treated	119 7 O
with	127 4 O
systemic	132 8 O
adjuvant	141 8 O
chemotherapy	150 12 O
have	163 4 O
described	168 9 O
experiencing	178 12 O
deteriorations	191 14 O
in	206 2 O
cognition	209 9 O
.	218 1 O

A	220 1 O
widely	222 6 O
used	229 4 O
chemotherapeutic	234 16 O
agent	251 5 O
,	256 1 O
5	258 1 B-Chemical
-	259 1 I-Chemical
fluorouracil	260 12 I-Chemical
(	273 1 O
5	274 1 B-Chemical
-	275 1 I-Chemical
FU	276 2 I-Chemical
)	278 1 O
,	279 1 O
readily	281 7 O
crosses	289 7 O
the	297 3 O
blood	301 5 O
-	306 1 O
brain	307 5 O
barrier	313 7 O
and	321 3 O
so	325 2 O
could	328 5 O
have	334 4 O
a	339 1 O
direct	341 6 O
effect	348 6 O
on	355 2 O
brain	358 5 O
function	364 8 O
.	372 1 O

In	374 2 O
particular	377 10 O
this	388 4 O
anti	393 4 O
mitotic	398 7 O
drug	406 4 O
could	411 5 O
reduce	417 6 O
cell	424 4 O
proliferation	429 13 O
in	443 2 O
the	446 3 O
neurogenic	450 10 O
regions	461 7 O
of	469 2 O
the	472 3 O
adult	476 5 O
brain	482 5 O
.	487 1 O

In	489 2 O
contrast	492 8 O
reports	501 7 O
indicate	509 8 O
that	518 4 O
hippocampal	523 11 O
dependent	535 9 O
neurogenesis	545 12 O
and	558 3 O
cognition	562 9 O
are	572 3 O
enhanced	576 8 O
by	585 2 O
the	588 3 O
SSRI	592 4 B-Chemical
antidepressant	597 14 O
Fluoxetine	612 10 B-Chemical
.	622 1 O

In	624 2 O
this	627 4 O
investigation	632 13 O
the	646 3 O
behavioural	650 11 O
effects	662 7 O
of	670 2 O
chronic	673 7 O
(	681 1 O
two	682 3 O
week	686 4 O
)	690 1 O
treatment	692 9 O
with	702 4 O
5	707 1 B-Chemical
-	708 1 I-Chemical
FU	709 2 I-Chemical
and	712 3 O
(	716 1 O
three	717 5 O
weeks	723 5 O
)	728 1 O
with	730 4 O
Fluoxetine	735 10 B-Chemical
either	746 6 O
separately	753 10 O
or	764 2 O
in	767 2 O
combination	770 11 O
with	782 4 O
5	787 1 B-Chemical
-	788 1 I-Chemical
FU	789 2 I-Chemical
were	792 4 O
tested	797 6 O
on	804 2 O
adult	807 5 O
Lister	813 6 O
hooded	820 6 O
rats	827 4 O
.	831 1 O

Behavioural	833 11 O
effects	845 7 O
were	853 4 O
tested	858 6 O
using	865 5 O
a	871 1 O
context	873 7 O
dependent	881 9 O
conditioned	891 11 O
emotional	903 9 O
response	913 8 O
test	922 4 O
(	927 1 O
CER	928 3 O
)	931 1 O
which	933 5 O
showed	939 6 O
that	946 4 O
animals	951 7 O
treated	959 7 O
with	967 4 O
5	972 1 B-Chemical
-	973 1 I-Chemical
FU	974 2 I-Chemical
had	977 3 O
a	981 1 O
significant	983 11 O
reduction	995 9 O
in	1005 2 O
freezing	1008 8 O
time	1017 4 O
compared	1022 8 O
to	1031 2 O
controls	1034 8 O
.	1042 1 O

A	1044 1 O
separate	1046 8 O
group	1055 5 O
of	1061 2 O
animals	1064 7 O
was	1072 3 O
tested	1076 6 O
using	1083 5 O
a	1089 1 O
hippocampal	1091 11 O
dependent	1103 9 O
spatial	1113 7 O
working	1121 7 O
memory	1129 6 O
test	1136 4 O
,	1140 1 O
the	1142 3 O
object	1146 6 O
location	1153 8 O
recognition	1162 11 O
test	1174 4 O
(	1179 1 O
OLR	1180 3 O
)	1183 1 O
.	1184 1 O

Animals	1186 7 O
treated	1194 7 O
only	1202 4 O
with	1207 4 O
5	1212 1 B-Chemical
-	1213 1 I-Chemical
FU	1214 2 I-Chemical
showed	1217 6 O
significant	1224 11 O
deficits	1236 8 O
in	1245 2 O
their	1248 5 O
ability	1254 7 O
to	1262 2 O
carry	1265 5 O
out	1271 3 O
the	1275 3 O
OLR	1279 3 O
task	1283 4 O
but	1288 3 O
co	1292 2 O
administration	1295 14 O
of	1310 2 O
Fluoxetine	1313 10 B-Chemical
improved	1324 8 O
their	1333 5 O
performance	1339 11 O
.	1350 1 O

5	1352 1 B-Chemical
-	1353 1 I-Chemical
FU	1354 2 I-Chemical
chemotherapy	1357 12 O
caused	1370 6 O
a	1377 1 O
significant	1379 11 O
reduction	1391 9 O
in	1401 2 O
the	1404 3 O
number	1408 6 O
of	1415 2 O
proliferating	1418 13 O
cells	1432 5 O
in	1438 2 O
the	1441 3 O
sub	1445 3 O
granular	1449 8 O
zone	1458 4 O
of	1463 2 O
the	1466 3 O
dentate	1470 7 O
gyrus	1478 5 O
compared	1484 8 O
to	1493 2 O
controls	1496 8 O
.	1504 1 O

This	1506 4 O
reduction	1511 9 O
was	1521 3 O
eliminated	1525 10 O
when	1536 4 O
Fluoxetine	1541 10 B-Chemical
was	1552 3 O
co	1556 2 O
administered	1559 12 O
with	1572 4 O
5	1577 1 B-Chemical
-	1578 1 I-Chemical
FU	1579 2 I-Chemical
.	1581 1 O

Fluoxetine	1583 10 B-Chemical
on	1594 2 O
its	1597 3 O
own	1601 3 O
had	1605 3 O
no	1609 2 O
effect	1612 6 O
on	1619 2 O
proliferating	1622 13 O
cell	1636 4 O
number	1641 6 O
or	1648 2 O
behaviour	1651 9 O
.	1660 1 O

These	1662 5 O
findings	1668 8 O
suggest	1677 7 O
that	1685 4 O
5	1690 1 B-Chemical
-	1691 1 I-Chemical
FU	1692 2 I-Chemical
can	1695 3 O
negatively	1699 10 O
affect	1710 6 O
both	1717 4 O
cell	1722 4 O
proliferation	1727 13 O
and	1741 3 O
hippocampal	1745 11 O
dependent	1757 9 O
working	1767 7 O
memory	1775 6 O
and	1782 3 O
that	1786 4 O
these	1791 5 O
deficits	1797 8 O
can	1806 3 O
be	1810 2 O
reversed	1813 8 O
by	1822 2 O
the	1825 3 O
simultaneous	1829 12 O
administration	1842 14 O
of	1857 2 O
the	1860 3 O
antidepressant	1864 14 O
Fluoxetine	1879 10 B-Chemical
.	1889 1 O

Liver	0 5 O
-	5 1 O
specific	6 8 O
ablation	15 8 O
of	24 2 O
integrin	27 8 O
-	35 1 O
linked	36 6 O
kinase	43 6 O
in	50 2 O
mice	53 4 O
results	58 7 O
in	66 2 O
enhanced	69 8 O
and	78 3 O
prolonged	82 9 O
cell	92 4 O
proliferation	97 13 O
and	111 3 O
hepatomegaly	115 12 B-Disease
after	128 5 O
phenobarbital	134 13 B-Chemical
administration	148 14 O
.	162 1 O

We	164 2 O
have	167 4 O
recently	172 8 O
demonstrated	181 12 O
that	194 4 O
disruption	199 10 O
of	210 2 O
extracellular	213 13 O
matrix	227 6 O
(	234 1 O
ECM	235 3 O
)	238 1 O
/	239 1 O
integrin	240 8 O
signaling	249 9 O
via	259 3 O
elimination	263 11 O
of	275 2 O
integrin	278 8 O
-	286 1 O
linked	287 6 O
kinase	294 6 O
(	301 1 O
ILK	302 3 O
)	305 1 O
in	307 2 O
hepatocytes	310 11 O
interferes	322 10 O
with	333 4 O
signals	338 7 O
leading	346 7 O
to	354 2 O
termination	357 11 O
of	369 2 O
liver	372 5 O
regeneration	378 12 O
.	390 1 O

This	392 4 O
study	397 5 O
investigates	403 12 O
the	416 3 O
role	420 4 O
of	425 2 O
ILK	428 3 O
in	432 2 O
liver	435 5 O
enlargement	441 11 O
induced	453 7 O
by	461 2 O
phenobarbital	464 13 B-Chemical
(	478 1 O
PB	479 2 B-Chemical
)	481 1 O
.	482 1 O

Wild	484 4 O
-	488 1 O
type	489 4 O
(	494 1 O
WT	495 2 O
)	497 1 O
and	499 3 O
ILK	503 3 O
:	506 1 O
liver	507 5 O
-	512 1 O
/	513 1 O
-	514 1 O
mice	516 4 O
were	521 4 O
given	526 5 O
PB	532 2 B-Chemical
(	535 1 O
0	536 1 O
.	537 1 O
1	538 1 O
%	539 1 O
in	541 2 O
drinking	544 8 O
water	553 5 O
)	558 1 O
for	560 3 O
10	564 2 O
days	567 4 O
.	571 1 O

Livers	573 6 O
were	580 4 O
harvested	585 9 O
on	595 2 O
2	598 1 O
,	599 1 O
5	601 1 O
,	602 1 O
and	604 3 O
10	608 2 O
days	611 4 O
during	616 6 O
PB	623 2 B-Chemical
administration	626 14 O
.	640 1 O

In	642 2 O
the	645 3 O
hepatocyte	649 10 O
-	659 1 O
specific	660 8 O
ILK	669 3 O
/	672 1 O
liver	673 5 O
-	678 1 O
/	679 1 O
-	680 1 O
mice	682 4 O
,	686 1 O
the	688 3 O
liver	692 5 O
:	697 1 O
body	698 4 O
weight	703 6 O
ratio	710 5 O
was	716 3 O
more	720 4 O
than	725 4 O
double	730 6 O
as	737 2 O
compared	740 8 O
to	749 2 O
0	752 1 O
h	754 1 O
at	756 2 O
day	759 3 O
2	763 1 O
(	765 1 O
2	766 1 O
.	767 1 O
5	768 1 O
times	770 5 O
)	775 1 O
,	776 1 O
while	778 5 O
at	784 2 O
days	787 4 O
5	792 1 O
and	794 3 O
10	798 2 O
,	800 1 O
it	802 2 O
was	805 3 O
enlarged	809 8 O
three	818 5 O
times	824 5 O
.	829 1 O

In	831 2 O
the	834 3 O
WT	838 2 O
mice	841 4 O
,	845 1 O
the	847 3 O
increase	851 8 O
was	860 3 O
as	864 2 O
expected	867 8 O
from	876 4 O
previous	881 8 O
literature	890 10 O
(	901 1 O
1	902 1 O
.	903 1 O
8	904 1 O
times	906 5 O
)	911 1 O
and	913 3 O
seems	917 5 O
to	923 2 O
have	926 4 O
leveled	931 7 O
off	939 3 O
after	943 5 O
day	949 3 O
2	953 1 O
.	954 1 O

There	956 5 O
were	962 4 O
slightly	967 8 O
increased	976 9 O
proliferating	986 13 O
cell	1000 4 O
nuclear	1005 7 O
antigen	1013 7 O
-	1020 1 O
positive	1021 8 O
cells	1030 5 O
in	1036 2 O
the	1039 3 O
ILK	1043 3 O
/	1046 1 O
liver	1047 5 O
-	1052 1 O
/	1053 1 O
-	1054 1 O
animals	1056 7 O
at	1064 2 O
day	1067 3 O
2	1071 1 O
as	1073 2 O
compared	1076 8 O
to	1085 2 O
WT	1088 2 O
after	1091 5 O
PB	1097 2 B-Chemical
administration	1100 14 O
.	1114 1 O

In	1116 2 O
the	1119 3 O
WT	1123 2 O
animals	1126 7 O
,	1133 1 O
the	1135 3 O
proliferative	1139 13 O
response	1153 8 O
had	1162 3 O
come	1166 4 O
back	1171 4 O
to	1176 2 O
normal	1179 6 O
by	1186 2 O
days	1189 4 O
5	1194 1 O
and	1196 3 O
10	1200 2 O
.	1202 1 O

Hepatocytes	1204 11 O
of	1216 2 O
the	1219 3 O
ILK	1223 3 O
/	1226 1 O
liver	1227 5 O
-	1232 1 O
/	1233 1 O
-	1234 1 O
mice	1236 4 O
continued	1241 9 O
to	1251 2 O
proliferate	1254 11 O
up	1266 2 O
until	1269 5 O
day	1275 3 O
10	1279 2 O
.	1281 1 O

ILK	1283 3 O
/	1286 1 O
liver	1287 5 O
-	1292 1 O
/	1293 1 O
-	1294 1 O
mice	1296 4 O
also	1301 4 O
showed	1306 6 O
increased	1313 9 O
expression	1323 10 O
of	1334 2 O
key	1337 3 O
genes	1341 5 O
involved	1347 8 O
in	1356 2 O
hepatocyte	1359 10 O
proliferation	1370 13 O
at	1384 2 O
different	1387 9 O
time	1397 4 O
points	1402 6 O
during	1409 6 O
PB	1416 2 B-Chemical
administration	1419 14 O
.	1433 1 O

In	1435 2 O
summary	1438 7 O
,	1445 1 O
ECM	1447 3 O
proteins	1451 8 O
communicate	1460 11 O
with	1472 4 O
the	1477 3 O
signaling	1481 9 O
machinery	1491 9 O
of	1501 2 O
dividing	1504 8 O
cells	1513 5 O
via	1519 3 O
ILK	1523 3 O
to	1527 2 O
regulate	1530 8 O
hepatocyte	1539 10 O
proliferation	1550 13 O
and	1564 3 O
termination	1568 11 O
of	1580 2 O
the	1583 3 O
proliferative	1587 13 O
response	1601 8 O
.	1609 1 O

Lack	1611 4 O
of	1616 2 O
ILK	1619 3 O
in	1623 2 O
the	1626 3 O
hepatocytes	1630 11 O
imparts	1642 7 O
prolonged	1650 9 O
proliferative	1660 13 O
response	1674 8 O
not	1683 3 O
only	1687 4 O
to	1692 2 O
stimuli	1695 7 O
related	1703 7 O
to	1711 2 O
liver	1714 5 O
regeneration	1720 12 O
but	1733 3 O
also	1737 4 O
to	1742 2 O
xenobiotic	1745 10 O
chemical	1756 8 O
mitogens	1765 8 O
,	1773 1 O
such	1775 4 O
as	1780 2 O
PB	1783 2 B-Chemical
.	1785 1 O

Decreased	0 9 O
Expression	10 10 O
of	21 2 O
Na	24 2 B-Chemical
/	26 1 O
K	27 1 B-Chemical
-	28 1 O
ATPase	29 6 O
,	35 1 O
NHE3	37 4 O
,	41 1 O
NBC1	43 4 O
,	47 1 O
AQP1	49 4 O
and	54 3 O
OAT	58 3 O
in	62 2 O
Gentamicin	65 10 B-Chemical
-	75 1 O
induced	76 7 O
Nephropathy	84 11 B-Disease
.	95 1 O

The	97 3 O
present	101 7 O
study	109 5 O
was	115 3 O
aimed	119 5 O
to	125 2 O
determine	128 9 O
whether	138 7 O
there	146 5 O
is	152 2 O
an	155 2 O
altered	158 7 O
regulation	166 10 O
of	177 2 O
tubular	180 7 O
transporters	188 12 O
in	201 2 O
gentamicin	204 10 B-Chemical
-	214 1 O
induced	215 7 O
nephropathy	223 11 B-Disease
.	234 1 O

Sprague	236 7 O
-	243 1 O
Dawley	244 6 O
male	251 4 O
rats	256 4 O
(	261 1 O
200	262 3 O
~	265 1 O
250	266 3 O
g	270 1 O
)	271 1 O
were	273 4 O
subcutaneously	278 14 O
injected	293 8 O
with	302 4 O
gentamicin	307 10 B-Chemical
(	318 1 O
100	319 3 O
mg	323 2 O
/	325 1 O
kg	326 2 O
per	329 3 O
day	333 3 O
)	336 1 O
for	338 3 O
7	342 1 O
days	344 4 O
,	348 1 O
and	350 3 O
the	354 3 O
expression	358 10 O
of	369 2 O
tubular	372 7 O
transporters	380 12 O
was	393 3 O
determined	397 10 O
by	408 2 O
immunoblotting	411 14 O
and	426 3 O
immunohistochemistry	430 20 O
.	450 1 O

The	452 3 O
mRNA	456 4 O
and	461 3 O
protein	465 7 O
expression	473 10 O
of	484 2 O
OAT	487 3 O
was	491 3 O
also	495 4 O
determined	500 10 O
.	510 1 O

Gentamicin	512 10 B-Chemical
-	522 1 O
treated	523 7 O
rats	531 4 O
exhibited	536 9 O
significantly	546 13 O
decreased	560 9 O
creatinine	570 10 B-Chemical
clearance	581 9 O
along	591 5 O
with	597 4 O
increased	602 9 O
plasma	612 6 O
creatinine	619 10 B-Chemical
levels	630 6 O
.	636 1 O

Accordingly	638 11 O
,	649 1 O
the	651 3 O
fractional	655 10 O
excretion	666 9 O
of	676 2 O
sodium	679 6 B-Chemical
increased	686 9 O
.	695 1 O

Urine	697 5 O
volume	703 6 O
was	710 3 O
increased	714 9 O
,	723 1 O
while	725 5 O
urine	731 5 O
osmolality	737 10 O
and	748 3 O
free	752 4 O
water	757 5 O
reabsorption	763 12 O
were	776 4 O
decreased	781 9 O
.	790 1 O

Immunoblotting	792 14 O
and	807 3 O
immunohistochemistry	811 20 O
revealed	832 8 O
decreased	841 9 O
expression	851 10 O
of	862 2 O
Na	865 2 B-Chemical
(	867 1 O
+	868 1 O
)	869 1 O
/	870 1 O
K	871 1 B-Chemical
(	872 1 O
+	873 1 O
)	874 1 O
-	875 1 O
ATPase	876 6 O
,	882 1 O
NHE3	884 4 O
,	888 1 O
NBC1	890 4 O
,	894 1 O
and	896 3 O
AQP1	900 4 O
in	905 2 O
the	908 3 O
kidney	912 6 O
of	919 2 O
gentamicin	922 10 B-Chemical
-	932 1 O
treated	933 7 O
rats	941 4 O
.	945 1 O

The	947 3 O
expression	951 10 O
of	962 2 O
OAT1	965 4 O
and	970 3 O
OAT3	974 4 O
was	979 3 O
also	983 4 O
decreased	988 9 O
.	997 1 O

Gentamicin	999 10 B-Chemical
-	1009 1 O
induced	1010 7 O
nephropathy	1018 11 B-Disease
may	1030 3 O
at	1034 2 O
least	1037 5 O
in	1043 2 O
part	1046 4 O
be	1051 2 O
causally	1054 8 O
related	1063 7 O
with	1071 4 O
a	1076 1 O
decreased	1078 9 O
expression	1088 10 O
of	1099 2 O
Na	1102 2 B-Chemical
(	1104 1 O
+	1105 1 O
)	1106 1 O
/	1107 1 O
K	1108 1 B-Chemical
(	1109 1 O
+	1110 1 O
)	1111 1 O
-	1112 1 O
ATPase	1113 6 O
,	1119 1 O
NHE3	1121 4 O
,	1125 1 O
NBC1	1127 4 O
,	1131 1 O
AQP1	1133 4 O
and	1138 3 O
OAT	1142 3 O
.	1145 1 O

Longitudinal	0 12 O
association	13 11 O
of	25 2 O
alcohol	28 7 B-Chemical
use	36 3 O
with	40 4 O
HIV	45 3 B-Disease
disease	49 7 I-Disease
progression	57 11 O
and	69 3 O
psychological	73 13 O
health	87 6 O
of	94 2 O
women	97 5 O
with	103 4 O
HIV	108 3 O
.	111 1 O

We	113 2 O
evaluated	116 9 O
the	126 3 O
association	130 11 O
of	142 2 O
alcohol	145 7 B-Chemical
consumption	153 11 O
and	165 3 O
depression	169 10 B-Disease
,	179 1 O
and	181 3 O
their	185 5 O
effects	191 7 O
on	199 2 O
HIV	202 3 B-Disease
disease	206 7 I-Disease
progression	214 11 O
among	226 5 O
women	232 5 O
with	238 4 O
HIV	243 3 O
.	246 1 O

The	248 3 O
study	252 5 O
included	258 8 O
871	267 3 O
women	271 5 O
with	277 4 O
HIV	282 3 O
who	286 3 O
were	290 4 O
recruited	295 9 O
from	305 4 O
1993	310 4 O
-	314 1 O
1995	315 4 O
in	320 2 O
four	323 4 O
US	328 2 O
cities	331 6 O
.	337 1 O

The	339 3 O
participants	343 12 O
had	356 3 O
physical	360 8 O
examination	369 11 O
,	380 1 O
medical	382 7 O
record	390 6 O
extraction	397 10 O
,	407 1 O
and	409 3 O
venipuncture	413 12 O
,	425 1 O
CD4	427 3 O
+	430 1 O
T	431 1 O
-	432 1 O
cell	433 4 O
counts	438 6 O
determination	445 13 O
,	458 1 O
measurement	460 11 O
of	472 2 O
depression	475 10 B-Disease
symptoms	486 8 O
(	495 1 O
using	496 5 O
the	502 3 O
self	506 4 O
-	510 1 O
report	511 6 O
Center	518 6 O
for	525 3 O
Epidemiological	529 15 O
Studies	545 7 O
-	552 1 O
Depression	553 10 B-Disease
Scale	564 5 O
)	569 1 O
,	570 1 O
and	572 3 O
alcohol	576 7 B-Chemical
use	584 3 O
assessment	588 10 O
at	599 2 O
enrollment	602 10 O
,	612 1 O
and	614 3 O
semiannually	618 12 O
until	631 5 O
March	637 5 O
2000	643 4 O
.	647 1 O

Multilevel	649 10 O
random	660 6 O
coefficient	667 11 O
ordinal	679 7 O
models	687 6 O
as	694 2 O
well	697 4 O
as	702 2 O
multilevel	705 10 O
models	716 6 O
with	723 4 O
joint	728 5 O
responses	734 9 O
were	744 4 O
used	749 4 O
in	754 2 O
the	757 3 O
analysis	761 8 O
.	769 1 O

There	771 5 O
was	777 3 O
no	781 2 O
significant	784 11 O
association	796 11 O
between	808 7 O
level	816 5 O
of	822 2 O
alcohol	825 7 B-Chemical
use	833 3 O
and	837 3 O
CD4	841 3 O
+	844 1 O
T	846 1 O
-	847 1 O
cell	848 4 O
counts	853 6 O
.	859 1 O

When	861 4 O
participants	866 12 O
were	879 4 O
stratified	884 10 O
by	895 2 O
antiretroviral	898 14 O
therapy	913 7 O
(	921 1 O
ART	922 3 O
)	925 1 O
use	927 3 O
,	930 1 O
the	932 3 O
association	936 11 O
between	948 7 O
alcohol	956 7 B-Chemical
and	964 3 O
CD4	968 3 O
+	971 1 O
T	973 1 O
-	974 1 O
cell	975 4 O
did	980 3 O
not	984 3 O
reach	988 5 O
statistical	994 11 O
significance	1006 12 O
.	1018 1 O

The	1020 3 O
association	1024 11 O
between	1036 7 O
alcohol	1044 7 B-Chemical
consumption	1052 11 O
and	1064 3 O
depression	1068 10 B-Disease
was	1079 3 O
significant	1083 11 O
(	1095 1 O
p	1096 1 O
<	1097 1 O
0	1098 1 O
.	1099 1 O
001	1100 3 O
)	1103 1 O
.	1104 1 O

Depression	1106 10 B-Disease
had	1117 3 O
a	1121 1 O
significant	1123 11 O
negative	1135 8 O
effect	1144 6 O
on	1151 2 O
CD4	1154 3 O
+	1157 1 O
T	1159 1 O
-	1160 1 O
cell	1161 4 O
counts	1166 6 O
over	1173 4 O
time	1178 4 O
regardless	1183 10 O
of	1194 2 O
ART	1197 3 O
use	1201 3 O
.	1204 1 O

Our	1206 3 O
findings	1210 8 O
suggest	1219 7 O
that	1227 4 O
alcohol	1232 7 B-Chemical
consumption	1240 11 O
has	1252 3 O
a	1256 1 O
direct	1258 6 O
association	1265 11 O
with	1277 4 O
depression	1282 10 B-Disease
.	1292 1 O

Moreover	1294 8 O
,	1302 1 O
depression	1304 10 B-Disease
is	1315 2 O
associated	1318 10 O
with	1329 4 O
HIV	1334 3 B-Disease
disease	1338 7 I-Disease
progression	1346 11 O
.	1357 1 O

Our	1359 3 O
findings	1363 8 O
have	1372 4 O
implications	1377 12 O
for	1390 3 O
the	1394 3 O
provision	1398 9 O
of	1408 2 O
alcohol	1411 7 B-Chemical
use	1419 3 O
interventions	1423 13 O
and	1437 3 O
psychological	1441 13 O
resources	1455 9 O
to	1465 2 O
improve	1468 7 O
the	1476 3 O
health	1480 6 O
of	1487 2 O
women	1490 5 O
with	1496 4 O
HIV	1501 3 O
.	1504 1 O

Chemokine	0 9 O
CCL2	10 4 O
and	15 3 O
its	19 3 O
receptor	23 8 O
CCR2	32 4 O
are	37 3 O
increased	41 9 O
in	51 2 O
the	54 3 O
hippocampus	58 11 O
following	70 9 O
pilocarpine	80 11 B-Chemical
-	91 1 O
induced	92 7 O
status	100 6 B-Disease
epilepticus	107 11 I-Disease
.	118 1 O

BACKGROUND	120 10 O
:	130 1 O
Neuroinflammation	132 17 B-Disease
occurs	150 6 O
after	157 5 O
seizures	163 8 B-Disease
and	172 3 O
is	176 2 O
implicated	179 10 O
in	190 2 O
epileptogenesis	193 15 O
.	208 1 O

CCR2	210 4 O
is	215 2 O
a	218 1 O
chemokine	220 9 O
receptor	230 8 O
for	239 3 O
CCL2	243 4 O
and	248 3 O
their	252 5 O
interaction	258 11 O
mediates	270 8 O
monocyte	279 8 O
infiltration	288 12 O
in	301 2 O
the	304 3 O
neuroinflammatory	308 17 B-Disease
cascade	326 7 O
triggered	334 9 O
in	344 2 O
different	347 9 O
brain	357 5 O
pathologies	363 11 O
.	374 1 O

In	376 2 O
this	379 4 O
work	384 4 O
CCR2	389 4 O
and	394 3 O
CCL2	398 4 O
expression	403 10 O
were	414 4 O
examined	419 8 O
following	428 9 O
status	438 6 B-Disease
epilepticus	445 11 I-Disease
(	457 1 O
SE	458 2 B-Disease
)	460 1 O
induced	462 7 O
by	470 2 O
pilocarpine	473 11 B-Chemical
injection	485 9 O
.	494 1 O

METHODS	496 7 O
:	503 1 O
SE	505 2 B-Disease
was	508 3 O
induced	512 7 O
by	520 2 O
pilocarpine	523 11 B-Chemical
injection	535 9 O
.	544 1 O

Control	546 7 O
rats	554 4 O
were	559 4 O
injected	564 8 O
with	573 4 O
saline	578 6 O
instead	585 7 O
of	593 2 O
pilocarpine	596 11 B-Chemical
.	607 1 O

Five	609 4 O
days	614 4 O
after	619 5 O
SE	625 2 B-Disease
,	627 1 O
CCR2	629 4 O
staining	634 8 O
in	643 2 O
neurons	646 7 O
and	654 3 O
glial	658 5 O
cells	664 5 O
was	670 3 O
examined	674 8 O
using	683 5 O
imunohistochemical	689 18 O
analyses	708 8 O
.	716 1 O

The	718 3 O
number	722 6 O
of	729 2 O
CCR2	732 4 O
positive	737 8 O
cells	746 5 O
was	752 3 O
determined	756 10 O
using	767 5 O
stereology	773 10 O
probes	784 6 O
in	791 2 O
the	794 3 O
hippocampus	798 11 O
.	809 1 O

CCL2	811 4 O
expression	816 10 O
in	827 2 O
the	830 3 O
hippocampus	834 11 O
was	846 3 O
examined	850 8 O
by	859 2 O
molecular	862 9 O
assay	872 5 O
.	877 1 O

RESULTS	879 7 O
:	886 1 O
Increased	888 9 O
CCR2	898 4 O
was	903 3 O
observed	907 8 O
in	916 2 O
the	919 3 O
hippocampus	923 11 O
after	935 5 O
SE	941 2 B-Disease
.	943 1 O

Seizures	945 8 B-Disease
also	954 4 O
resulted	959 8 O
in	968 2 O
alterations	971 11 O
to	983 2 O
the	986 3 O
cell	990 4 O
types	995 5 O
expressing	1001 10 O
CCR2	1012 4 O
.	1016 1 O

Increased	1018 9 O
numbers	1028 7 O
of	1036 2 O
neurons	1039 7 O
that	1047 4 O
expressed	1052 9 O
CCR2	1062 4 O
was	1067 3 O
observed	1071 8 O
following	1080 9 O
SE	1090 2 B-Disease
.	1092 1 O

Microglial	1094 10 O
cells	1105 5 O
were	1111 4 O
more	1116 4 O
closely	1121 7 O
apposed	1129 7 O
to	1137 2 O
the	1140 3 O
CCR2	1144 4 O
-	1148 1 O
labeled	1149 7 O
cells	1157 5 O
in	1163 2 O
SE	1166 2 B-Disease
rats	1169 4 O
.	1173 1 O

In	1175 2 O
addition	1178 8 O
,	1186 1 O
rats	1188 4 O
that	1193 4 O
experienced	1198 11 O
SE	1210 2 B-Disease
exhibited	1213 9 O
CCR2	1223 4 O
-	1227 1 O
labeling	1228 8 O
in	1237 2 O
populations	1240 11 O
of	1252 2 O
hypertrophied	1255 13 B-Disease
astrocytes	1269 10 O
,	1279 1 O
especially	1281 10 O
in	1292 2 O
CA1	1295 3 O
and	1299 3 O
dentate	1303 7 O
gyrus	1311 5 O
.	1316 1 O

These	1318 5 O
CCR2	1324 4 O
+	1328 1 O
astroctytes	1330 11 O
were	1342 4 O
not	1347 3 O
observed	1351 8 O
in	1360 2 O
control	1363 7 O
rats	1371 4 O
.	1375 1 O

Examination	1377 11 O
of	1389 2 O
CCL2	1392 4 O
expression	1397 10 O
showed	1408 6 O
that	1415 4 O
it	1420 2 O
was	1423 3 O
elevated	1427 8 O
in	1436 2 O
the	1439 3 O
hippocampus	1443 11 O
following	1455 9 O
SE	1465 2 B-Disease
.	1467 1 O

CONCLUSION	1469 10 O
:	1479 1 O
The	1481 3 O
data	1485 4 O
show	1490 4 O
that	1495 4 O
CCR2	1500 4 O
and	1505 3 O
CCL2	1509 4 O
are	1514 3 O
up	1518 2 O
-	1520 1 O
regulated	1521 9 O
in	1531 2 O
the	1534 3 O
hippocampus	1538 11 O
after	1550 5 O
pilocarpine	1556 11 B-Chemical
-	1567 1 O
induced	1568 7 O
SE	1576 2 B-Disease
.	1578 1 O

Seizures	1580 8 B-Disease
also	1589 4 O
result	1594 6 O
in	1601 2 O
changes	1604 7 O
to	1612 2 O
CCR2	1615 4 O
receptor	1620 8 O
expression	1629 10 O
in	1640 2 O
neurons	1643 7 O
and	1651 3 O
astrocytes	1655 10 O
.	1665 1 O

These	1667 5 O
changes	1673 7 O
might	1681 5 O
be	1687 2 O
involved	1690 8 O
in	1699 2 O
detrimental	1702 11 O
neuroplasticity	1714 15 O
and	1730 3 O
neuroinflammatory	1734 17 B-Disease
changes	1752 7 O
that	1760 4 O
occur	1765 5 O
following	1771 9 O
seizures	1781 8 B-Disease
.	1789 1 O

Metallothionein	0 15 B-Chemical
induction	16 9 O
reduces	26 7 O
caspase	34 7 O
-	41 1 O
3	42 1 O
activity	44 8 O
and	53 3 O
TNFalpha	57 8 O
levels	66 6 O
with	73 4 O
preservation	78 12 O
of	91 2 O
cognitive	94 9 O
function	104 8 O
and	113 3 O
intact	117 6 O
hippocampal	124 11 O
neurons	136 7 O
in	144 2 O
carmustine	147 10 B-Chemical
-	157 1 O
treated	158 7 O
rats	166 4 O
.	170 1 O

Hippocampal	172 11 O
integrity	184 9 O
is	194 2 O
essential	197 9 O
for	207 3 O
cognitive	211 9 O
functions	221 9 O
.	230 1 O

On	232 2 O
the	235 3 O
other	239 5 O
hand	245 4 O
,	249 1 O
induction	251 9 O
of	261 2 O
metallothionein	264 15 B-Chemical
(	280 1 O
MT	281 2 B-Chemical
)	283 1 O
by	285 2 O
ZnSO	288 4 B-Chemical
(	292 1 I-Chemical
4	293 1 I-Chemical
)	294 1 I-Chemical
and	296 3 O
its	300 3 O
role	304 4 O
in	309 2 O
neuroprotection	312 15 O
has	328 3 O
been	332 4 O
documented	337 10 O
.	347 1 O

The	349 3 O
present	353 7 O
study	361 5 O
aimed	367 5 O
to	373 2 O
explore	376 7 O
the	384 3 O
effect	388 6 O
of	395 2 O
MT	398 2 B-Chemical
induction	401 9 O
on	411 2 O
carmustine	414 10 B-Chemical
(	425 1 O
BCNU	426 4 B-Chemical
)	430 1 O
-	431 1 O
induced	432 7 O
hippocampal	440 11 O
cognitive	452 9 B-Disease
dysfunction	462 11 I-Disease
in	474 2 O
rats	477 4 O
.	481 1 O

A	483 1 O
total	485 5 O
of	491 2 O
60	494 2 O
male	497 4 O
Wistar	502 6 O
albino	509 6 O
rats	516 4 O
were	521 4 O
randomly	526 8 O
divided	535 7 O
into	543 4 O
four	548 4 O
groups	553 6 O
(	560 1 O
15	561 2 O
/	563 1 O
group	564 5 O
)	569 1 O
:	570 1 O
The	572 3 O
control	576 7 O
group	584 5 O
injected	590 8 O
with	599 4 O
single	604 6 O
doses	611 5 O
of	617 2 O
normal	620 6 O
saline	627 6 O
(	634 1 O
i	635 1 O
.	636 1 O
c	637 1 O
.	638 1 O
v	639 1 O
)	640 1 O
followed	642 8 O
24	651 2 O
h	654 1 O
later	656 5 O
by	662 2 O
BCNU	665 4 B-Chemical
solvent	670 7 O
(	678 1 O
i	679 1 O
.	680 1 O
v	681 1 O
)	682 1 O
.	683 1 O

The	685 3 O
second	689 6 O
group	696 5 O
administered	702 12 O
ZnSO	715 4 B-Chemical
(	719 1 I-Chemical
4	720 1 I-Chemical
)	721 1 I-Chemical
(	723 1 O
0	724 1 O
.	725 1 O
1	726 1 O
micromol	728 8 O
/	736 1 O
10	737 2 O
microl	740 6 O
normal	747 6 O
saline	754 6 O
,	760 1 O
i	762 1 O
.	763 1 O
c	764 1 O
.	765 1 O
v	766 1 O
,	767 1 O
once	769 4 O
)	773 1 O
then	775 4 O
BCNU	780 4 B-Chemical
solvent	785 7 O
(	793 1 O
i	794 1 O
.	795 1 O
v	796 1 O
)	797 1 O
after	799 5 O
24	805 2 O
h	808 1 O
.	809 1 O

Third	811 5 O
group	817 5 O
received	823 8 O
BCNU	832 4 B-Chemical
(	837 1 O
20	838 2 O
mg	841 2 O
/	843 1 O
kg	844 2 O
,	846 1 O
i	848 1 O
.	849 1 O
v	850 1 O
,	851 1 O
once	853 4 O
)	857 1 O
24	859 2 O
h	862 1 O
after	864 5 O
injection	870 9 O
with	880 4 O
normal	885 6 O
saline	892 6 O
(	899 1 O
i	900 1 O
.	901 1 O
c	902 1 O
.	903 1 O
v	904 1 O
)	905 1 O
.	906 1 O

Fourth	908 6 O
group	915 5 O
received	921 8 O
a	930 1 O
single	932 6 O
dose	939 4 O
of	944 2 O
ZnSO	947 4 B-Chemical
(	951 1 I-Chemical
4	952 1 I-Chemical
)	953 1 I-Chemical
(	955 1 O
0	956 1 O
.	957 1 O
1	958 1 O
micromol	960 8 O
/	968 1 O
10	969 2 O
microl	972 6 O
normal	979 6 O
saline	986 6 O
,	992 1 O
i	994 1 O
.	995 1 O
c	996 1 O
.	997 1 O
v	998 1 O
)	999 1 O
then	1001 4 O
BCNU	1006 4 B-Chemical
(	1011 1 O
20	1012 2 O
mg	1015 2 O
/	1017 1 O
kg	1018 2 O
,	1020 1 O
i	1022 1 O
.	1023 1 O
v	1024 1 O
,	1025 1 O
once	1027 4 O
)	1031 1 O
after	1033 5 O
24	1039 2 O
h	1042 1 O
.	1043 1 O

The	1045 3 O
obtained	1049 8 O
data	1058 4 O
revealed	1063 8 O
that	1072 4 O
BCNU	1077 4 B-Chemical
administration	1082 14 O
resulted	1097 8 O
in	1106 2 O
deterioration	1109 13 B-Disease
of	1123 2 I-Disease
learning	1126 8 I-Disease
and	1135 3 I-Disease
short	1139 5 I-Disease
-	1144 1 I-Disease
term	1145 4 I-Disease
memory	1150 6 I-Disease
(	1157 1 O
STM	1158 3 O
)	1161 1 O
,	1162 1 O
as	1164 2 O
measured	1167 8 O
by	1176 2 O
using	1179 5 O
radial	1185 6 O
arm	1192 3 O
water	1196 5 O
maze	1202 4 O
,	1206 1 O
accompanied	1208 11 O
with	1220 4 O
decreased	1225 9 O
hippocampal	1235 11 O
glutathione	1247 11 B-Chemical
reductase	1259 9 O
(	1269 1 O
GR	1270 2 O
)	1272 1 O
activity	1274 8 O
and	1283 3 O
reduced	1287 7 O
glutathione	1295 11 B-Chemical
(	1307 1 O
GSH	1308 3 B-Chemical
)	1311 1 O
content	1313 7 O
.	1320 1 O

Also	1322 4 O
,	1326 1 O
BCNU	1328 4 B-Chemical
administration	1333 14 O
increased	1348 9 O
serum	1358 5 O
tumor	1364 5 B-Disease
necrosis	1370 8 B-Disease
factor	1379 6 O
-	1385 1 O
alpha	1386 5 O
(	1392 1 O
TNFalpha	1393 8 O
)	1401 1 O
,	1402 1 O
hippocampal	1404 11 O
MT	1416 2 B-Chemical
and	1419 3 O
malondialdehyde	1423 15 B-Chemical
(	1439 1 O
MDA	1440 3 B-Chemical
)	1443 1 O
contents	1445 8 O
as	1454 2 O
well	1457 4 O
as	1462 2 O
caspase	1465 7 O
-	1472 1 O
3	1473 1 O
activity	1475 8 O
in	1484 2 O
addition	1487 8 O
to	1496 2 O
histological	1499 12 O
alterations	1512 11 O
.	1523 1 O

ZnSO	1525 4 B-Chemical
(	1529 1 I-Chemical
4	1530 1 I-Chemical
)	1531 1 I-Chemical
pretreatment	1533 12 O
counteracted	1546 12 O
BCNU	1559 4 B-Chemical
-	1563 1 O
induced	1564 7 O
inhibition	1572 10 O
of	1583 2 O
GR	1586 2 O
and	1589 3 O
depletion	1593 9 O
of	1603 2 O
GSH	1606 3 B-Chemical
and	1610 3 O
resulted	1614 8 O
in	1623 2 O
significant	1626 11 O
reduction	1638 9 O
in	1648 2 O
the	1651 3 O
levels	1655 6 O
of	1662 2 O
MDA	1665 3 B-Chemical
and	1669 3 O
TNFalpha	1673 8 O
as	1682 2 O
well	1685 4 O
as	1690 2 O
the	1693 3 O
activity	1697 8 O
of	1706 2 O
caspase	1709 7 O
-	1716 1 O
3	1717 1 O
.	1718 1 O

The	1720 3 O
histological	1724 12 O
features	1737 8 O
were	1746 4 O
improved	1751 8 O
in	1760 2 O
hippocampus	1763 11 O
of	1775 2 O
rats	1778 4 O
treated	1783 7 O
with	1791 4 O
ZnSO	1796 4 B-Chemical
(	1800 1 I-Chemical
4	1801 1 I-Chemical
)	1802 1 I-Chemical
+	1804 1 O
BCNU	1806 4 B-Chemical
compared	1811 8 O
to	1820 2 O
only	1823 4 O
BCNU	1828 4 B-Chemical
-	1832 1 O
treated	1833 7 O
animals	1841 7 O
.	1848 1 O

In	1850 2 O
conclusion	1853 10 O
,	1863 1 O
MT	1865 2 B-Chemical
induction	1868 9 O
halts	1878 5 O
BCNU	1884 4 B-Chemical
-	1888 1 O
induced	1889 7 O
hippocampal	1897 11 O
toxicity	1909 8 B-Disease
as	1918 2 O
it	1921 2 O
prevented	1924 9 O
GR	1934 2 O
inhibition	1937 10 O
and	1948 3 O
GSH	1952 3 B-Chemical
depletion	1956 9 O
and	1966 3 O
counteracted	1970 12 O
the	1983 3 O
increased	1987 9 O
levels	1997 6 O
of	2004 2 O
TNFalpha	2007 8 O
,	2015 1 O
MDA	2017 3 B-Chemical
and	2021 3 O
caspase	2025 7 O
-	2032 1 O
3	2033 1 O
activity	2035 8 O
with	2044 4 O
subsequent	2049 10 O
preservation	2060 12 O
of	2073 2 O
cognition	2076 9 O
.	2085 1 O

Fatal	0 5 O
carbamazepine	6 13 B-Chemical
induced	20 7 O
fulminant	28 9 B-Disease
eosinophilic	38 12 I-Disease
(	51 1 O
hypersensitivity	52 16 B-Disease
)	68 1 O
myocarditis	70 11 B-Disease
:	81 1 O
emphasis	83 8 O
on	92 2 O
anatomical	95 10 O
and	106 3 O
histological	110 12 O
characteristics	123 15 O
,	138 1 O
mechanisms	140 10 O
and	151 3 O
genetics	155 8 O
of	164 2 O
drug	167 4 B-Disease
hypersensitivity	172 16 I-Disease
and	189 3 O
differential	193 12 O
diagnosis	206 9 O
.	215 1 O

The	217 3 O
most	221 4 O
severe	226 6 O
adverse	233 7 O
reactions	241 9 O
to	251 2 O
carbamazepine	254 13 B-Chemical
have	268 4 O
been	273 4 O
observed	278 8 O
in	287 2 O
the	290 3 O
haemopoietic	294 12 O
system	307 6 O
,	313 1 O
the	315 3 O
liver	319 5 O
and	325 3 O
the	329 3 O
cardiovascular	333 14 O
system	348 6 O
.	354 1 O

A	356 1 O
frequently	358 10 O
fatal	369 5 O
,	374 1 O
although	376 8 O
exceptionally	385 13 O
rare	399 4 O
side	404 4 O
effect	409 6 O
of	416 2 O
carbamazepine	419 13 B-Chemical
is	433 2 O
necrotizing	436 11 O
eosinophilic	448 12 O
(	461 1 O
hypersensitivity	462 16 B-Disease
)	478 1 O
myocarditis	480 11 B-Disease
.	491 1 O

We	493 2 O
report	496 6 O
a	503 1 O
case	505 4 O
of	510 2 O
hypersensitivity	513 16 B-Disease
myocarditis	530 11 B-Disease
secondary	542 9 O
to	552 2 O
administration	555 14 O
of	570 2 O
carbamazepine	573 13 B-Chemical
.	586 1 O

Acute	588 5 O
hypersensitivity	594 16 B-Disease
myocarditis	611 11 B-Disease
was	623 3 O
not	627 3 O
suspected	631 9 O
clinically	641 10 O
,	651 1 O
and	653 3 O
the	657 3 O
diagnosis	661 9 O
was	671 3 O
made	675 4 O
post	680 4 O
-	684 1 O
mortem	685 6 O
.	691 1 O

Histology	693 9 O
revealed	703 8 O
diffuse	712 7 O
infiltration	720 12 O
of	733 2 O
the	736 3 O
myocardium	740 10 O
by	751 2 O
eosinophils	754 11 O
and	766 3 O
lymphocytes	770 11 O
with	782 4 O
myocyte	787 7 O
damage	795 6 O
.	801 1 O

Clinically	803 10 O
,	813 1 O
death	815 5 O
was	821 3 O
due	825 3 O
to	829 2 O
cardiogenic	832 11 B-Disease
shock	844 5 I-Disease
.	849 1 O

To	851 2 O
best	854 4 O
of	859 2 O
our	862 3 O
knowledge	866 9 O
this	876 4 O
is	881 2 O
the	884 3 O
second	888 6 O
case	895 4 O
of	900 2 O
fatal	903 5 O
carbamazepine	909 13 B-Chemical
induced	923 7 O
myocarditis	931 11 B-Disease
reported	943 8 O
in	952 2 O
English	955 7 O
literature	963 10 O
.	973 1 O

Neuropsychiatric	0 16 O
behaviors	17 9 O
in	27 2 O
the	30 3 O
MPTP	34 4 B-Chemical
marmoset	39 8 O
model	48 5 O
of	54 2 O
Parkinson	57 9 B-Disease
'	66 1 I-Disease
s	67 1 I-Disease
disease	69 7 I-Disease
.	76 1 O

OBJECTIVES	78 10 O
:	88 1 O
Neuropsychiatric	90 16 O
symptoms	107 8 O
are	116 3 O
increasingly	120 12 O
recognised	133 10 O
as	144 2 O
a	147 1 O
significant	149 11 O
problem	161 7 O
in	169 2 O
patients	172 8 O
with	181 4 O
Parkinson	186 9 B-Disease
'	195 1 I-Disease
s	196 1 I-Disease
disease	198 7 I-Disease
(	206 1 O
PD	207 2 B-Disease
)	209 1 O
.	210 1 O

These	212 5 O
symptoms	218 8 O
may	227 3 O
be	231 2 O
due	234 3 O
to	238 2 O
'	241 1 O
sensitisation	242 13 O
'	255 1 O
following	257 9 O
repeated	267 8 O
levodopa	276 8 B-Chemical
treatment	285 9 O
or	295 2 O
a	298 1 O
direct	300 6 O
effect	307 6 O
of	314 2 O
dopamine	317 8 B-Chemical
on	326 2 O
the	329 3 O
disease	333 7 O
state	341 5 O
.	346 1 O

The	348 3 O
levodopa	352 8 B-Chemical
-	360 1 O
treated	361 7 O
MPTP	369 4 B-Chemical
-	373 1 O
lesioned	374 8 O
marmoset	383 8 O
was	392 3 O
used	396 4 O
as	401 2 O
a	404 1 O
model	406 5 O
of	412 2 O
neuropsychiatric	415 16 B-Disease
symptoms	432 8 I-Disease
in	441 2 O
PD	444 2 B-Disease
patients	447 8 O
.	455 1 O

Here	457 4 O
we	462 2 O
compare	465 7 O
the	473 3 O
time	477 4 O
course	482 6 O
of	489 2 O
levodopa	492 8 B-Chemical
-	500 1 O
induced	501 7 O
motor	509 5 O
fluctuations	515 12 O
and	528 3 O
neuropsychiatric	532 16 B-Disease
-	548 1 I-Disease
like	549 4 I-Disease
behaviors	554 9 I-Disease
to	564 2 O
determine	567 9 O
the	577 3 O
relationship	581 12 O
between	594 7 O
duration	602 8 O
of	611 2 O
treatment	614 9 O
and	624 3 O
onset	628 5 O
of	634 2 O
symptoms	637 8 O
.	645 1 O

METHODS	647 7 O
:	654 1 O
Marmosets	656 9 O
were	666 4 O
administered	671 12 O
1	684 1 B-Chemical
-	685 1 I-Chemical
methyl	686 6 I-Chemical
-	692 1 I-Chemical
4	693 1 I-Chemical
-	694 1 I-Chemical
phenyl	695 6 I-Chemical
-	701 1 I-Chemical
1	702 1 I-Chemical
,	703 1 I-Chemical
2	704 1 I-Chemical
,	705 1 I-Chemical
3	706 1 I-Chemical
,	707 1 I-Chemical
6	708 1 I-Chemical
-	709 1 I-Chemical
tetrahydropyridine	710 18 I-Chemical
(	729 1 O
2	730 1 O
.	731 1 O
0	732 1 O
mg	734 2 O
/	736 1 O
kg	737 2 O
s	740 1 O
.	741 1 O
c	742 1 O
.	743 1 O
)	744 1 O
for	746 3 O
five	750 4 O
days	755 4 O
,	759 1 O
resulting	761 9 O
in	771 2 O
stable	774 6 O
parkinsonism	781 12 B-Disease
.	793 1 O

Levodopa	795 8 B-Chemical
(	804 1 O
15	805 2 O
mg	808 2 O
/	810 1 O
kg	811 2 O
and	814 3 O
benserazide	818 11 B-Chemical
,	829 1 O
3	831 1 O
.	832 1 O
75	833 2 O
mg	836 2 O
/	838 1 O
kg	839 2 O
)	841 1 O
p	843 1 O
.	844 1 O
o	845 1 O
.	846 1 O

b	848 1 O
.	849 1 O
i	850 1 O
.	851 1 O
d	852 1 O
,	853 1 O
was	855 3 O
administered	859 12 O
for	872 3 O
30	876 2 O
days	879 4 O
.	883 1 O

Animals	885 7 O
were	893 4 O
evaluated	898 9 O
for	908 3 O
parkinsonian	912 12 B-Disease
disability	925 10 I-Disease
,	935 1 O
dyskinesia	937 10 B-Disease
and	948 3 O
on	952 2 O
-	954 1 O
time	955 4 O
(	960 1 O
motor	961 5 O
fluctuations	967 12 O
)	979 1 O
and	981 3 O
neuropsychiatric	985 16 B-Disease
-	1001 1 I-Disease
like	1002 4 I-Disease
behaviors	1007 9 I-Disease
on	1017 2 O
Day	1020 3 O
0	1024 1 O
(	1026 1 O
prior	1027 5 O
to	1033 2 O
levodopa	1036 8 B-Chemical
)	1044 1 O
and	1046 3 O
on	1050 2 O
Days	1053 4 O
1	1058 1 O
,	1059 1 O
7	1061 1 O
,	1062 1 O
13	1064 2 O
,	1066 1 O
27	1068 2 O
and	1071 3 O
30	1075 2 O
of	1078 2 O
treatment	1081 9 O
using	1091 5 O
post	1097 4 O
hoc	1102 3 O
DVD	1106 3 O
analysis	1110 8 O
by	1119 2 O
a	1122 1 O
trained	1124 7 O
rater	1132 5 O
,	1137 1 O
blind	1139 5 O
to	1145 2 O
the	1148 3 O
treatment	1152 9 O
day	1162 3 O
.	1165 1 O

RESULTS	1167 7 O
:	1174 1 O
The	1176 3 O
neuropsychiatric	1180 16 B-Disease
-	1196 1 I-Disease
like	1197 4 I-Disease
behavior	1202 8 I-Disease
rating	1211 6 O
scale	1218 5 O
demonstrated	1224 12 O
high	1237 4 O
interrater	1242 10 O
reliability	1253 11 O
between	1265 7 O
three	1273 5 O
trained	1279 7 O
raters	1287 6 O
of	1294 2 O
differing	1297 9 O
professional	1307 12 O
backgrounds	1320 11 O
.	1331 1 O

As	1333 2 O
anticipated	1336 11 O
,	1347 1 O
animals	1349 7 O
exhibited	1357 9 O
a	1367 1 O
progressive	1369 11 O
increase	1381 8 O
in	1390 2 O
levodopa	1393 8 B-Chemical
-	1401 1 O
induced	1402 7 O
motor	1410 5 O
fluctuations	1416 12 O
,	1428 1 O
dyskinesia	1430 10 B-Disease
and	1441 3 O
wearing	1445 7 O
-	1452 1 O
off	1453 3 O
,	1456 1 O
that	1458 4 O
correlated	1463 10 O
with	1474 4 O
the	1479 3 O
duration	1483 8 O
of	1492 2 O
levodopa	1495 8 B-Chemical
therapy	1504 7 O
.	1511 1 O

In	1513 2 O
contrast	1516 8 O
,	1524 1 O
levodopa	1526 8 B-Chemical
-	1534 1 O
induced	1535 7 O
neuropsychiatric	1543 16 B-Disease
-	1559 1 I-Disease
like	1560 4 I-Disease
behaviors	1565 9 I-Disease
were	1575 4 O
present	1580 7 O
on	1588 2 O
Day	1591 3 O
1	1595 1 O
of	1597 2 O
levodopa	1600 8 B-Chemical
treatment	1609 9 O
and	1619 3 O
their	1623 5 O
severity	1629 8 O
did	1638 3 O
not	1642 3 O
correlate	1646 9 O
with	1656 4 O
duration	1661 8 O
of	1670 2 O
treatment	1673 9 O
.	1682 1 O

CONCLUSIONS	1684 11 O
:	1695 1 O
The	1697 3 O
data	1701 4 O
suggest	1706 7 O
that	1714 4 O
neuropsychiatric	1719 16 B-Disease
disorders	1736 9 I-Disease
in	1746 2 O
PD	1749 2 B-Disease
are	1752 3 O
more	1756 4 O
likely	1761 6 O
an	1768 2 O
interaction	1771 11 O
between	1783 7 O
levodopa	1791 8 B-Chemical
and	1800 3 O
the	1804 3 O
disease	1808 7 O
state	1816 5 O
than	1822 4 O
a	1827 1 O
consequence	1829 11 O
of	1841 2 O
sensitisation	1844 13 O
to	1858 2 O
repeated	1861 8 O
dopaminergic	1870 12 O
therapy	1883 7 O
.	1890 1 O

Contrast	0 8 B-Chemical
medium	9 6 I-Chemical
nephrotoxicity	16 14 B-Disease
after	31 5 O
renal	37 5 O
artery	43 6 O
and	50 3 O
coronary	54 8 O
angioplasty	63 11 O
.	74 1 O

BACKGROUND	76 10 O
:	86 1 O
Renal	88 5 B-Disease
dysfunction	94 11 I-Disease
induced	106 7 O
by	114 2 O
iodinated	117 9 O
contrast	127 8 B-Chemical
medium	136 6 I-Chemical
(	143 1 O
CM	144 2 B-Chemical
)	146 1 O
administration	148 14 O
can	163 3 O
minimize	167 8 O
the	176 3 O
benefit	180 7 O
of	188 2 O
the	191 3 O
interventional	195 14 O
procedure	210 9 O
in	220 2 O
patients	223 8 O
undergoing	232 10 O
renal	243 5 O
angioplasty	249 11 O
(	261 1 O
PTRA	262 4 O
)	266 1 O
.	267 1 O

PURPOSE	269 7 O
:	276 1 O
To	278 2 O
compare	281 7 O
the	289 3 O
susceptibility	293 14 O
to	308 2 O
nephrotoxic	311 11 B-Disease
effect	323 6 O
of	330 2 O
CM	333 2 B-Chemical
in	336 2 O
patients	339 8 O
undergoing	348 10 O
PTRA	359 4 O
with	364 4 O
that	369 4 O
of	374 2 O
patients	377 8 O
submitted	386 9 O
to	396 2 O
percutaneous	399 12 O
coronary	412 8 O
intervention	421 12 O
(	434 1 O
PCI	435 3 O
)	438 1 O
.	439 1 O

MATERIAL	441 8 O
AND	450 3 O
METHODS	454 7 O
:	461 1 O
A	463 1 O
total	465 5 O
of	471 2 O
33	474 2 O
patients	477 8 O
successfully	486 12 O
treated	499 7 O
with	507 4 O
PTRA	512 4 O
(	517 1 O
PTRA	518 4 O
group	523 5 O
,	528 1 O
mean	530 4 O
age	535 3 O
70	539 2 O
+	541 1 O
/	542 1 O
-	543 1 O
12	544 2 O
years	547 5 O
,	552 1 O
23	554 2 O
female	557 6 O
,	563 1 O
basal	565 5 O
creatinine	571 10 B-Chemical
1	582 1 O
.	583 1 O
46	584 2 O
+	586 1 O
/	587 1 O
-	588 1 O
0	589 1 O
.	590 1 O
79	591 2 O
,	593 1 O
range	595 5 O
0	601 1 O
.	602 1 O
7	603 1 O
-	604 1 O
4	605 1 O
.	606 1 O
9	607 1 O
mg	609 2 O
/	611 1 O
dl	612 2 O
)	614 1 O
were	616 4 O
compared	621 8 O
with	630 4 O
33	635 2 O
patients	638 8 O
undergoing	647 10 O
successful	658 10 O
PCI	669 3 O
(	673 1 O
PCI	674 3 O
group	678 5 O
)	683 1 O
,	684 1 O
matched	686 7 O
for	694 3 O
basal	698 5 O
creatinine	704 10 B-Chemical
(	715 1 O
1	716 1 O
.	717 1 O
44	718 2 O
+	720 1 O
/	721 1 O
-	722 1 O
0	723 1 O
.	724 1 O
6	725 1 O
,	726 1 O
range	728 5 O
0	734 1 O
.	735 1 O
7	736 1 O
-	737 1 O
3	738 1 O
.	739 1 O
4	740 1 O
mg	742 2 O
/	744 1 O
dl	745 2 O
)	747 1 O
,	748 1 O
gender	750 6 O
,	756 1 O
and	758 3 O
age	762 3 O
.	765 1 O

In	767 2 O
both	770 4 O
groups	775 6 O
postprocedural	782 14 O
(	797 1 O
48	798 2 O
h	801 1 O
)	802 1 O
serum	804 5 O
creatinine	810 10 B-Chemical
was	821 3 O
measured	825 8 O
.	833 1 O

RESULTS	835 7 O
:	842 1 O
Postprocedural	844 14 O
creatinine	859 10 B-Chemical
level	870 5 O
decreased	876 9 O
nonsignificantly	886 16 O
in	903 2 O
the	906 3 O
PTRA	910 4 O
group	915 5 O
(	921 1 O
1	922 1 O
.	923 1 O
46	924 2 O
+	926 1 O
/	927 1 O
-	928 1 O
0	929 1 O
.	930 1 O
8	931 1 O
vs	933 2 O
.	935 1 O
1	937 1 O
.	938 1 O
34	939 2 O
+	941 1 O
/	942 1 O
-	943 1 O
0	944 1 O
.	945 1 O
5	946 1 O
mg	948 2 O
/	950 1 O
dl	951 2 O
,	953 1 O
P	955 1 O
=	956 1 O
NS	957 2 O
)	959 1 O
and	961 3 O
increased	965 9 O
significantly	975 13 O
in	989 2 O
the	992 3 O
PCI	996 3 O
group	1000 5 O
(	1006 1 O
1	1007 1 O
.	1008 1 O
44	1009 2 O
+	1011 1 O
/	1012 1 O
-	1013 1 O
0	1014 1 O
.	1015 1 O
6	1016 1 O
vs	1018 2 O
.	1020 1 O
1	1022 1 O
.	1023 1 O
57	1024 2 O
+	1026 1 O
/	1027 1 O
-	1028 1 O
0	1029 1 O
.	1030 1 O
7	1031 1 O
mg	1033 2 O
/	1035 1 O
dl	1036 2 O
,	1038 1 O
P	1040 1 O
<	1041 1 O
0	1042 1 O
.	1043 1 O
02	1044 2 O
)	1046 1 O
.	1047 1 O

Changes	1049 7 O
in	1057 2 O
serum	1060 5 O
creatinine	1066 10 B-Chemical
after	1077 5 O
intervention	1083 12 O
(	1096 1 O
after	1097 5 O
-	1102 1 O
before	1103 6 O
)	1109 1 O
were	1111 4 O
significantly	1116 13 O
different	1130 9 O
between	1140 7 O
the	1148 3 O
PTRA	1152 4 O
and	1157 3 O
PCI	1161 3 O
groups	1165 6 O
(	1172 1 O
-	1173 1 O
0	1174 1 O
.	1175 1 O
12	1176 2 O
+	1178 1 O
/	1179 1 O
-	1180 1 O
0	1181 1 O
.	1182 1 O
5	1183 1 O
vs	1185 2 O
.	1187 1 O
0	1189 1 O
.	1190 1 O
13	1191 2 O
+	1193 1 O
/	1194 1 O
-	1195 1 O
0	1196 1 O
.	1197 1 O
3	1198 1 O
,	1199 1 O
P	1201 1 O
=	1202 1 O
0	1203 1 O
.	1204 1 O
014	1205 3 O
)	1208 1 O
.	1209 1 O

This	1211 4 O
difference	1216 10 O
was	1227 3 O
not	1231 3 O
related	1235 7 O
to	1243 2 O
either	1246 6 O
a	1253 1 O
different	1255 9 O
clinical	1265 8 O
risk	1274 4 O
profile	1279 7 O
or	1287 2 O
to	1290 2 O
the	1293 3 O
volume	1297 6 O
of	1304 2 O
CM	1307 2 B-Chemical
administered	1310 12 O
.	1322 1 O

CONCLUSION	1324 10 O
:	1334 1 O
In	1336 2 O
this	1339 4 O
preliminary	1344 11 O
study	1356 5 O
patients	1362 8 O
submitted	1371 9 O
to	1381 2 O
PTRA	1384 4 O
showed	1389 6 O
a	1396 1 O
lower	1398 5 O
susceptibility	1404 14 O
to	1419 2 O
renal	1422 5 B-Disease
damage	1428 6 I-Disease
induced	1435 7 O
by	1443 2 O
CM	1446 2 B-Chemical
administration	1449 14 O
than	1464 4 O
PCI	1469 3 O
patients	1473 8 O
.	1481 1 O

The	1483 3 O
effectiveness	1487 13 O
of	1501 2 O
PTRA	1504 4 O
on	1509 2 O
renal	1512 5 O
function	1518 8 O
seems	1527 5 O
to	1533 2 O
be	1536 2 O
barely	1539 6 O
influenced	1546 10 O
by	1557 2 O
CM	1560 2 B-Chemical
toxicity	1563 8 B-Disease
.	1571 1 O

Medical	0 7 O
and	8 3 O
psychiatric	12 11 O
outcomes	24 8 O
for	33 3 O
patients	37 8 O
transplanted	46 12 O
for	59 3 O
acetaminophen	63 13 B-Chemical
-	76 1 O
induced	77 7 O
acute	85 5 B-Disease
liver	91 5 I-Disease
failure	97 7 I-Disease
:	104 1 O
a	106 1 O
case	108 4 O
-	112 1 O
control	113 7 O
study	121 5 O
.	126 1 O

BACKGROUND	128 10 O
:	138 1 O
Acetaminophen	140 13 B-Chemical
-	153 1 O
induced	154 7 O
hepatotoxicity	162 14 B-Disease
is	177 2 O
the	180 3 O
most	184 4 O
common	189 6 O
cause	196 5 O
of	202 2 O
acute	205 5 B-Disease
liver	211 5 I-Disease
failure	217 7 I-Disease
(	225 1 O
ALF	226 3 B-Disease
)	229 1 O
in	231 2 O
the	234 3 O
UK	238 2 O
.	240 1 O

Patients	242 8 O
often	251 5 O
consume	257 7 O
the	265 3 O
drug	269 4 O
with	274 4 O
suicidal	279 8 O
intent	288 6 O
or	295 2 O
with	298 4 O
a	303 1 O
background	305 10 O
of	316 2 O
substance	319 9 O
dependence	329 10 O
.	339 1 O

AIMS	341 4 O
AND	346 3 O
METHODS	350 7 O
:	357 1 O
We	359 2 O
compared	362 8 O
the	371 3 O
severity	375 8 O
of	384 2 O
pretransplant	387 13 O
illness	401 7 O
,	408 1 O
psychiatric	410 11 O
co	422 2 O
-	424 1 O
morbidity	425 9 O
,	434 1 O
medical	436 7 O
and	444 3 O
psychosocial	448 12 O
outcomes	461 8 O
of	470 2 O
all	473 3 O
patients	477 8 O
who	486 3 O
had	490 3 O
undergone	494 9 O
liver	504 5 O
transplantation	510 15 O
(	526 1 O
LT	527 2 O
)	529 1 O
emergently	531 10 O
between	542 7 O
1999	550 4 O
-	554 1 O
2004	555 4 O
for	560 3 O
acetaminophen	564 13 B-Chemical
-	577 1 O
induced	578 7 O
ALF	586 3 B-Disease
(	590 1 O
n	591 1 O
=	592 1 O
36	593 2 O
)	595 1 O
with	597 4 O
age	602 3 O
-	605 1 O
and	607 3 O
sex	611 3 O
-	614 1 O
matched	615 7 O
patients	623 8 O
undergoing	632 10 O
emergent	643 8 O
LT	652 2 O
for	655 3 O
non	659 3 O
-	662 1 O
acetaminophen	663 13 B-Chemical
-	676 1 O
induced	677 7 O
ALF	685 3 B-Disease
(	689 1 O
n	690 1 O
=	691 1 O
35	692 2 O
)	694 1 O
and	696 3 O
elective	700 8 O
LT	709 2 O
for	712 3 O
chronic	716 7 B-Disease
liver	724 5 I-Disease
disease	730 7 I-Disease
(	738 1 O
CLD	739 3 B-Disease
,	742 1 O
n	744 1 O
=	745 1 O
34	746 2 O
)	748 1 O
.	749 1 O

RESULTS	751 7 O
:	758 1 O
Acetaminophen	760 13 B-Chemical
-	773 1 O
induced	774 7 O
ALF	782 3 B-Disease
patients	786 8 O
undergoing	795 10 O
LT	806 2 O
had	809 3 O
a	813 1 O
greater	815 7 O
severity	823 8 O
of	832 2 O
pre	835 3 O
-	838 1 O
LT	839 2 O
illness	842 7 O
reflected	850 9 O
by	860 2 O
higher	863 6 O
Acute	870 5 O
Physiology	876 10 O
and	887 3 O
Chronic	891 7 O
Health	899 6 O
Evaluation	906 10 O
II	917 2 O
scores	920 6 O
and	927 3 O
requirement	931 11 O
for	943 3 O
organ	947 5 O
support	953 7 O
compared	961 8 O
with	970 4 O
the	975 3 O
other	979 5 O
two	985 3 O
groups	989 6 O
.	995 1 O

Twenty	997 6 O
(	1004 1 O
56	1005 2 O
%	1007 1 O
)	1008 1 O
acetaminophen	1010 13 B-Chemical
-	1023 1 O
induced	1024 7 O
ALF	1032 3 B-Disease
patients	1036 8 O
had	1045 3 O
a	1049 1 O
formal	1051 6 O
psychiatric	1058 11 O
diagnosis	1070 9 O
before	1080 6 O
LT	1087 2 O
(	1090 1 O
non	1091 3 O
-	1094 1 O
acetaminophen	1095 13 B-Chemical
-	1108 1 O
induced	1109 7 O
ALF	1117 3 B-Disease
=	1120 1 O
0	1121 1 O
/	1122 1 O
35	1123 2 O
,	1125 1 O
CLD	1127 3 B-Disease
=	1130 1 O
2	1131 1 O
/	1132 1 O
34	1133 2 O
;	1135 1 O
P	1137 1 O
<	1138 1 O
0	1139 1 O
.	1140 1 O
01	1141 2 O
for	1144 3 O
all	1148 3 O
)	1151 1 O
and	1153 3 O
nine	1157 4 O
(	1162 1 O
25	1163 2 O
%	1165 1 O
)	1166 1 O
had	1168 3 O
a	1172 1 O
previous	1174 8 O
suicide	1183 7 O
attempt	1191 7 O
.	1198 1 O

During	1200 6 O
follow	1207 6 O
-	1213 1 O
up	1214 2 O
(	1217 1 O
median	1218 6 O
5	1225 1 O
years	1227 5 O
)	1232 1 O
,	1233 1 O
there	1235 5 O
were	1241 4 O
no	1246 2 O
significant	1249 11 O
differences	1261 11 O
in	1273 2 O
rejection	1276 9 O
(	1286 1 O
acute	1287 5 O
and	1293 3 O
chronic	1297 7 O
)	1304 1 O
,	1305 1 O
graft	1307 5 O
failure	1313 7 O
or	1321 2 O
survival	1324 8 O
between	1333 7 O
the	1341 3 O
groups	1345 6 O
(	1352 1 O
acetaminophen	1353 13 B-Chemical
-	1366 1 O
induced	1367 7 O
ALF	1375 3 B-Disease
1	1379 1 O
year	1381 4 O
87	1386 2 O
%	1388 1 O
,	1389 1 O
5	1391 1 O
years	1393 5 O
75	1399 2 O
%	1401 1 O
;	1402 1 O
non	1404 3 O
-	1407 1 O
acetaminophen	1408 13 B-Chemical
-	1421 1 O
induced	1422 7 O
ALF	1430 3 B-Disease
88	1434 2 O
%	1436 1 O
,	1437 1 O
78	1439 2 O
%	1441 1 O
;	1442 1 O
CLD	1444 3 B-Disease
93	1448 2 O
%	1450 1 O
,	1451 1 O
82	1453 2 O
%	1455 1 O
:	1456 1 O
P	1458 1 O
>	1459 1 O
0	1460 1 O
.	1461 1 O
6	1462 1 O
log	1464 3 O
rank	1468 4 O
)	1472 1 O
.	1473 1 O

Two	1475 3 O
acetaminophen	1479 13 B-Chemical
-	1492 1 O
induced	1493 7 O
ALF	1501 3 B-Disease
patients	1505 8 O
reattempted	1514 11 O
suicide	1526 7 O
post	1534 4 O
-	1538 1 O
LT	1539 2 O
(	1542 1 O
one	1543 3 O
died	1547 4 O
8	1552 1 O
years	1554 5 O
post	1560 4 O
-	1564 1 O
LT	1565 2 O
)	1567 1 O
.	1568 1 O

CONCLUSIONS	1570 11 O
:	1581 1 O
Despite	1583 7 O
a	1591 1 O
high	1593 4 O
prevalence	1598 10 O
of	1609 2 O
psychiatric	1612 11 O
disturbance	1624 11 O
,	1635 1 O
outcomes	1637 8 O
for	1646 3 O
patients	1650 8 O
transplanted	1659 12 O
emergently	1672 10 O
for	1683 3 O
acetaminophen	1687 13 B-Chemical
-	1700 1 O
induced	1701 7 O
ALF	1709 3 B-Disease
were	1713 4 O
comparable	1718 10 O
to	1729 2 O
those	1732 5 O
transplanted	1738 12 O
for	1751 3 O
non	1755 3 O
-	1758 1 O
acetaminophen	1759 13 B-Chemical
-	1772 1 O
induced	1773 7 O
ALF	1781 3 B-Disease
and	1785 3 O
electively	1789 10 O
for	1800 3 O
CLD	1804 3 B-Disease
.	1807 1 O

Multidisciplinary	1809 17 O
approaches	1827 10 O
with	1838 4 O
long	1843 4 O
-	1847 1 O
term	1848 4 O
psychiatric	1853 11 O
follow	1865 6 O
-	1871 1 O
up	1872 2 O
may	1875 3 O
contribute	1879 10 O
to	1890 2 O
low	1893 3 O
post	1897 4 O
-	1901 1 O
transplant	1902 10 O
suicide	1913 7 O
rates	1921 5 O
seen	1927 4 O
and	1932 3 O
low	1936 3 O
rates	1940 5 O
of	1946 2 O
graft	1949 5 O
loss	1955 4 O
because	1960 7 O
of	1968 2 O
non	1971 3 O
-	1974 1 O
compliance	1975 10 O
.	1985 1 O

Studies	0 7 O
of	8 2 O
synergy	11 7 O
between	19 7 O
morphine	27 8 B-Chemical
and	36 3 O
a	40 1 O
novel	42 5 O
sodium	48 6 B-Chemical
channel	55 7 O
blocker	63 7 O
,	70 1 O
CNSB002	72 7 B-Chemical
,	79 1 O
in	81 2 O
rat	84 3 O
models	88 6 O
of	95 2 O
inflammatory	98 12 O
and	111 3 O
neuropathic	115 11 B-Disease
pain	127 4 I-Disease
.	131 1 O

OBJECTIVE	133 9 O
:	142 1 O
This	144 4 O
study	149 5 O
determined	155 10 O
the	166 3 O
antihyperalgesic	170 16 O
effect	187 6 O
of	194 2 O
CNSB002	197 7 B-Chemical
,	204 1 O
a	206 1 O
sodium	208 6 B-Chemical
channel	215 7 O
blocker	223 7 O
with	231 4 O
antioxidant	236 11 O
properties	248 10 O
given	259 5 O
alone	265 5 O
and	271 3 O
in	275 2 O
combinations	278 12 O
with	291 4 O
morphine	296 8 B-Chemical
in	305 2 O
rat	308 3 O
models	312 6 O
of	319 2 O
inflammatory	322 12 O
and	335 3 O
neuropathic	339 11 B-Disease
pain	351 4 I-Disease
.	355 1 O

DESIGN	357 6 O
:	363 1 O
Dose	365 4 O
response	370 8 O
curves	379 6 O
for	386 3 O
nonsedating	390 11 O
doses	402 5 O
of	408 2 O
morphine	411 8 B-Chemical
and	420 3 O
CNSB002	424 7 B-Chemical
given	432 5 O
intraperitoneally	438 17 O
alone	456 5 O
and	462 3 O
together	466 8 O
in	475 2 O
combinations	478 12 O
were	491 4 O
constructed	496 11 O
for	508 3 O
antihyperalgesic	512 16 O
effect	529 6 O
using	536 5 O
paw	542 3 O
withdrawal	546 10 O
from	557 4 O
noxious	562 7 O
heat	570 4 O
in	575 2 O
two	578 3 O
rat	582 3 O
pain	586 4 B-Disease
models	591 6 O
:	597 1 O
carrageenan	599 11 B-Chemical
-	610 1 O
induced	611 7 O
paw	619 3 O
inflammation	623 12 B-Disease
and	636 3 O
streptozotocin	640 14 B-Chemical
(	655 1 O
STZ	656 3 B-Chemical
)	659 1 O
-	660 1 O
induced	661 7 O
diabetic	669 8 B-Disease
neuropathy	678 10 I-Disease
.	688 1 O

RESULTS	690 7 O
:	697 1 O
The	699 3 O
maximum	703 7 O
nonsedating	711 11 O
doses	723 5 O
were	729 4 O
:	733 1 O
morphine	735 8 B-Chemical
,	743 1 O
3	745 1 O
.	746 1 O
2	747 1 O
mg	749 2 O
/	751 1 O
kg	752 2 O
;	754 1 O
CNSB002	756 7 B-Chemical
10	764 2 O
.	766 1 O
0	767 1 O
mg	769 2 O
/	771 1 O
kg	772 2 O
;	774 1 O
5	776 1 O
.	777 1 O
0	778 1 O
mg	780 2 O
/	782 1 O
kg	783 2 O
CNSB002	786 7 B-Chemical
with	794 4 O
morphine	799 8 B-Chemical
3	808 1 O
.	809 1 O
2	810 1 O
mg	812 2 O
/	814 1 O
kg	815 2 O
in	818 2 O
combination	821 11 O
.	832 1 O

The	834 3 O
doses	838 5 O
calculated	844 10 O
to	855 2 O
cause	858 5 O
50	864 2 O
%	866 1 O
reversal	868 8 O
of	877 2 O
hyperalgesia	880 12 B-Disease
(	893 1 O
ED50	894 4 O
)	898 1 O
were	900 4 O
7	905 1 O
.	906 1 O
54	907 2 O
(	910 1 O
1	911 1 O
.	912 1 O
81	913 2 O
)	915 1 O
and	917 3 O
4	921 1 O
.	922 1 O
83	923 2 O
(	926 1 O
1	927 1 O
.	928 1 O
54	929 2 O
)	931 1 O
in	933 2 O
the	936 3 O
carrageenan	940 11 B-Chemical
model	952 5 O
and	958 3 O
44	962 2 O
.	964 1 O
18	965 2 O
(	968 1 O
1	969 1 O
.	970 1 O
37	971 2 O
)	973 1 O
and	975 3 O
9	979 1 O
.	980 1 O
14	981 2 O
(	984 1 O
1	985 1 O
.	986 1 O
24	987 2 O
)	989 1 O
in	991 2 O
the	994 3 O
STZ	998 3 B-Chemical
-	1001 1 O
induced	1002 7 O
neuropathy	1010 10 B-Disease
model	1021 5 O
for	1027 3 O
CNSB002	1031 7 B-Chemical
and	1039 3 O
morphine	1043 8 B-Chemical
,	1051 1 O
respectively	1053 12 O
(	1066 1 O
mg	1067 2 O
/	1069 1 O
kg	1070 2 O
;	1072 1 O
mean	1074 4 O
,	1078 1 O
SEM	1080 3 O
)	1083 1 O
.	1084 1 O

These	1086 5 O
values	1092 6 O
were	1099 4 O
greater	1104 7 O
than	1112 4 O
the	1117 3 O
maximum	1121 7 O
nonsedating	1129 11 O
doses	1141 5 O
.	1146 1 O

The	1148 3 O
ED50	1152 4 O
values	1157 6 O
for	1164 3 O
morphine	1168 8 B-Chemical
when	1177 4 O
given	1182 5 O
in	1188 2 O
combination	1191 11 O
with	1203 4 O
CNSB002	1208 7 B-Chemical
(	1216 1 O
5	1217 1 O
mg	1219 2 O
/	1221 1 O
kg	1222 2 O
)	1224 1 O
were	1226 4 O
less	1231 4 O
than	1236 4 O
the	1241 3 O
maximum	1245 7 O
nonsedating	1253 11 O
dose	1265 4 O
:	1269 1 O
0	1271 1 O
.	1272 1 O
56	1273 2 O
(	1276 1 O
1	1277 1 O
.	1278 1 O
55	1279 2 O
)	1281 1 O
in	1283 2 O
the	1286 3 O
carrageenan	1290 11 B-Chemical
model	1302 5 O
and	1308 3 O
1	1312 1 O
.	1313 1 O
37	1314 2 O
(	1317 1 O
1	1318 1 O
.	1319 1 O
23	1320 2 O
)	1322 1 O
in	1324 2 O
the	1327 3 O
neuropathy	1331 10 B-Disease
model	1342 5 O
(	1348 1 O
mg	1349 2 O
/	1351 1 O
kg	1352 2 O
;	1354 1 O
mean	1356 4 O
,	1360 1 O
SEM	1362 3 O
)	1365 1 O
.	1366 1 O

The	1368 3 O
antinociception	1372 15 O
after	1388 5 O
morphine	1394 8 B-Chemical
(	1403 1 O
3	1404 1 O
.	1405 1 O
2	1406 1 O
mg	1408 2 O
/	1410 1 O
kg	1411 2 O
)	1413 1 O
was	1415 3 O
increased	1419 9 O
by	1429 2 O
co	1432 2 O
-	1434 1 O
administration	1435 14 O
with	1450 4 O
CNSB002	1455 7 B-Chemical
from	1463 4 O
28	1468 2 O
.	1470 1 O
0	1471 1 O
and	1473 3 O
31	1477 2 O
.	1479 1 O
7	1480 1 O
%	1481 1 O
to	1483 2 O
114	1486 3 O
.	1489 1 O
6	1490 1 O
and	1492 3 O
56	1496 2 O
.	1498 1 O
9	1499 1 O
%	1500 1 O
reversal	1502 8 O
of	1511 2 O
hyperalgesia	1514 12 B-Disease
in	1527 2 O
the	1530 3 O
inflammatory	1534 12 O
and	1547 3 O
neuropathic	1551 11 B-Disease
models	1563 6 O
,	1569 1 O
respectively	1571 12 O
(	1584 1 O
P	1585 1 O
<	1587 1 O
0	1589 1 O
.	1590 1 O
01	1591 2 O
;	1593 1 O
one	1595 3 O
-	1598 1 O
way	1599 3 O
analysis	1603 8 O
of	1612 2 O
variance	1615 8 O
-	1623 1 O
significantly	1624 13 O
greater	1638 7 O
than	1646 4 O
either	1651 6 O
drug	1658 4 O
given	1663 5 O
alone	1669 5 O
)	1674 1 O
.	1675 1 O

CONCLUSIONS	1677 11 O
:	1688 1 O
The	1690 3 O
maximum	1694 7 O
antihyperalgesic	1702 16 O
effect	1719 6 O
achievable	1726 10 O
with	1737 4 O
nonsedating	1742 11 O
doses	1754 5 O
of	1760 2 O
morphine	1763 8 B-Chemical
may	1772 3 O
be	1776 2 O
increased	1779 9 O
significantly	1789 13 O
when	1803 4 O
the	1808 3 O
drug	1812 4 O
is	1817 2 O
used	1820 4 O
in	1825 2 O
combination	1828 11 O
with	1840 4 O
CNSB002	1845 7 B-Chemical
.	1852 1 O

Heparin	0 7 B-Chemical
-	7 1 O
induced	8 7 O
thrombocytopenia	16 16 B-Disease
:	32 1 O
a	34 1 O
practical	36 9 O
review	46 6 O
.	52 1 O

Heparin	54 7 B-Chemical
-	61 1 O
induced	62 7 O
thrombocytopenia	70 16 B-Disease
(	87 1 O
HIT	88 3 B-Disease
)	91 1 O
remains	93 7 O
under	101 5 O
-	106 1 O
recognized	107 10 O
despite	118 7 O
its	126 3 O
potentially	130 11 O
devastating	142 11 O
outcomes	154 8 O
.	162 1 O

It	164 2 O
begins	167 6 O
when	174 4 O
heparin	179 7 B-Chemical
exposure	187 8 O
stimulates	196 10 O
the	207 3 O
formation	211 9 O
of	221 2 O
heparin	224 7 B-Chemical
-	231 1 O
platelet	232 8 O
factor	241 6 O
4	248 1 O
antibodies	250 10 O
,	260 1 O
which	262 5 O
in	268 2 O
turn	271 4 O
triggers	276 8 O
the	285 3 O
release	289 7 O
of	297 2 O
procoagulant	300 12 O
platelet	313 8 O
particles	322 9 O
.	331 1 O

Thrombosis	333 10 B-Disease
and	344 3 O
thrombocytopenia	348 16 B-Disease
that	365 4 O
follow	370 6 O
comprise	377 8 O
the	386 3 O
2	390 1 O
hallmark	392 8 O
traits	401 6 O
of	408 2 O
HIT	411 3 B-Disease
,	414 1 O
with	416 4 O
the	421 3 O
former	425 6 O
largely	432 7 O
responsible	440 11 O
for	452 3 O
significant	456 11 O
vascular	468 8 O
complications	477 13 O
.	490 1 O

The	492 3 O
prevalence	496 10 O
of	507 2 O
HIT	510 3 B-Disease
varies	514 6 O
among	521 5 O
several	527 7 O
subgroups	535 9 O
,	544 1 O
with	546 4 O
greater	551 7 O
incidence	559 9 O
in	569 2 O
surgical	572 8 O
as	581 2 O
compared	584 8 O
with	593 4 O
medical	598 7 O
populations	606 11 O
.	617 1 O

HIT	619 3 B-Disease
must	623 4 O
be	628 2 O
acknowledged	631 12 O
for	644 3 O
its	648 3 O
intense	652 7 O
predilection	660 12 O
for	673 3 O
thrombosis	677 10 B-Disease
and	688 3 O
suspected	692 9 O
whenever	702 8 O
thrombosis	711 10 B-Disease
occurs	722 6 O
after	729 5 O
heparin	735 7 B-Chemical
exposure	743 8 O
.	751 1 O

Early	753 5 O
recognition	759 11 O
that	771 4 O
incorporates	776 12 O
the	789 3 O
clinical	793 8 O
and	802 3 O
serologic	806 9 O
clues	816 5 O
is	822 2 O
paramount	825 9 O
to	835 2 O
timely	838 6 O
institution	845 11 O
of	857 2 O
treatment	860 9 O
,	869 1 O
as	871 2 O
its	874 3 O
delay	878 5 O
may	884 3 O
result	888 6 O
in	895 2 O
catastrophic	898 12 O
outcomes	911 8 O
.	919 1 O

The	921 3 O
treatment	925 9 O
of	935 2 O
HIT	938 3 B-Disease
mandates	942 8 O
an	951 2 O
immediate	954 9 O
cessation	964 9 O
of	974 2 O
all	977 3 O
heparin	981 7 B-Chemical
exposure	989 8 O
and	998 3 O
the	1002 3 O
institution	1006 11 O
of	1018 2 O
an	1021 2 O
antithrombotic	1024 14 O
therapy	1039 7 O
,	1046 1 O
most	1048 4 O
commonly	1053 8 O
using	1062 5 O
a	1068 1 O
direct	1070 6 B-Chemical
thrombin	1077 8 I-Chemical
inhibitor	1086 9 I-Chemical
.	1095 1 O

Current	1097 7 O
"	1105 1 O
diagnostic	1106 10 O
"	1116 1 O
tests	1118 5 O
,	1123 1 O
which	1125 5 O
primarily	1131 9 O
include	1141 7 O
functional	1149 10 O
and	1160 3 O
antigenic	1164 9 O
assays	1174 6 O
,	1180 1 O
have	1182 4 O
more	1187 4 O
of	1192 2 O
a	1195 1 O
confirmatory	1197 12 O
than	1210 4 O
diagnostic	1215 10 O
role	1226 4 O
in	1231 2 O
the	1234 3 O
management	1238 10 O
of	1249 2 O
HIT	1252 3 B-Disease
.	1255 1 O

Special	1257 7 O
attention	1265 9 O
must	1275 4 O
be	1280 2 O
paid	1283 4 O
to	1288 2 O
cardiac	1291 7 O
patients	1299 8 O
who	1308 3 O
are	1312 3 O
often	1316 5 O
exposed	1322 7 O
to	1330 2 O
heparin	1333 7 B-Chemical
multiple	1341 8 O
times	1350 5 O
during	1356 6 O
their	1363 5 O
course	1369 6 O
of	1376 2 O
treatment	1379 9 O
.	1388 1 O

Direct	1390 6 B-Chemical
thrombin	1397 8 I-Chemical
inhibitors	1406 10 I-Chemical
are	1417 3 O
appropriate	1421 11 O
,	1432 1 O
evidence	1434 8 O
-	1442 1 O
based	1443 5 O
alternatives	1449 12 O
to	1462 2 O
heparin	1465 7 B-Chemical
in	1473 2 O
patients	1476 8 O
with	1485 4 O
a	1490 1 O
history	1492 7 O
of	1500 2 O
HIT	1503 3 B-Disease
,	1506 1 O
who	1508 3 O
need	1512 4 O
to	1517 2 O
undergo	1520 7 O
percutaneous	1528 12 O
coronary	1541 8 O
intervention	1550 12 O
.	1562 1 O

As	1564 2 O
heparin	1567 7 B-Chemical
remains	1575 7 O
one	1583 3 O
of	1587 2 O
the	1590 3 O
most	1594 4 O
frequently	1599 10 O
used	1610 4 O
medications	1615 11 O
today	1627 5 O
with	1633 4 O
potential	1638 9 O
for	1648 3 O
HIT	1652 3 B-Disease
with	1656 4 O
every	1661 5 O
heparin	1667 7 B-Chemical
exposure	1675 8 O
,	1683 1 O
a	1685 1 O
close	1687 5 O
vigilance	1693 9 O
of	1703 2 O
platelet	1706 8 O
counts	1715 6 O
must	1722 4 O
be	1727 2 O
practiced	1730 9 O
whenever	1740 8 O
heparin	1749 7 B-Chemical
is	1757 2 O
initiated	1760 9 O
.	1769 1 O

Abductor	0 8 O
paralysis	9 9 B-Disease
after	19 5 O
botox	25 5 B-Chemical
injection	31 9 O
for	41 3 O
adductor	45 8 B-Disease
spasmodic	54 9 I-Disease
dysphonia	64 9 I-Disease
.	73 1 O

OBJECTIVES	75 10 O
/	85 1 O
HYPOTHESIS	86 10 O
:	96 1 O
Botulinum	98 9 O
toxin	108 5 O
(	114 1 O
Botox	115 5 B-Chemical
)	120 1 O
injections	122 10 O
into	133 4 O
the	138 3 O
thyroarytenoid	142 14 O
muscles	157 7 O
are	165 3 O
the	169 3 O
current	173 7 O
standard	181 8 O
of	190 2 O
care	193 4 O
for	198 3 O
adductor	202 8 B-Disease
spasmodic	211 9 I-Disease
dysphonia	221 9 I-Disease
(	231 1 O
ADSD	232 4 B-Disease
)	236 1 O
.	237 1 O

Reported	239 8 O
adverse	248 7 O
effects	256 7 O
include	264 7 O
a	272 1 O
period	274 6 O
of	281 2 O
breathiness	284 11 O
,	295 1 O
throat	297 6 B-Disease
pain	304 4 I-Disease
,	308 1 O
and	310 3 O
difficulty	314 10 O
with	325 4 O
swallowing	330 10 O
liquids	341 7 O
.	348 1 O

Here	350 4 O
we	355 2 O
report	358 6 O
multiple	365 8 O
cases	374 5 O
of	380 2 O
bilateral	383 9 O
abductor	393 8 O
paralysis	402 9 B-Disease
following	412 9 O
Botox	422 5 B-Chemical
injections	428 10 O
for	439 3 O
ADSD	443 4 B-Disease
,	447 1 O
a	449 1 O
complication	451 12 O
previously	464 10 O
unreported	475 10 O
.	485 1 O

STUDY	487 5 O
DESIGN	493 6 O
:	499 1 O
Retrospective	501 13 O
case	515 4 O
series	520 6 O
.	526 1 O

METHODS	528 7 O
:	535 1 O
Patients	537 8 O
that	546 4 O
received	551 8 O
Botox	560 5 B-Chemical
injections	566 10 O
for	577 3 O
spasmodic	581 9 B-Disease
dysphonia	591 9 I-Disease
between	601 7 O
January	609 7 O
2000	617 4 O
and	622 3 O
October	626 7 O
2009	634 4 O
were	639 4 O
evaluated	644 9 O
.	653 1 O

Patients	655 8 O
with	664 4 O
ADSD	669 4 B-Disease
were	674 4 O
identified	679 10 O
.	689 1 O

The	691 3 O
number	695 6 O
of	702 2 O
treatments	705 10 O
received	716 8 O
and	725 3 O
adverse	729 7 O
effects	737 7 O
were	745 4 O
noted	750 5 O
.	755 1 O

For	757 3 O
patients	761 8 O
with	770 4 O
bilateral	775 9 O
abductor	785 8 O
paralysis	794 9 B-Disease
,	803 1 O
age	805 3 O
,	808 1 O
sex	810 3 O
,	813 1 O
paralytic	815 9 O
Botox	825 5 B-Chemical
dose	831 4 O
,	835 1 O
prior	837 5 O
Botox	843 5 B-Chemical
dose	849 4 O
,	853 1 O
and	855 3 O
course	859 6 O
following	866 9 O
paralysis	876 9 B-Disease
were	886 4 O
noted	891 5 O
.	896 1 O

RESULTS	898 7 O
:	905 1 O
From	907 4 O
a	912 1 O
database	914 8 O
of	923 2 O
452	926 3 O
patients	930 8 O
receiving	939 9 O
Botox	949 5 B-Chemical
,	954 1 O
352	956 3 O
patients	960 8 O
had	969 3 O
been	973 4 O
diagnosed	978 9 O
with	988 4 O
ADSD	993 4 B-Disease
.	997 1 O

Of	999 2 O
these	1002 5 O
352	1008 3 O
patients	1012 8 O
,	1020 1 O
eight	1022 5 O
patients	1028 8 O
suffered	1037 8 O
bilateral	1046 9 O
abductor	1056 8 O
paralysis	1065 9 B-Disease
,	1074 1 O
and	1076 3 O
two	1080 3 O
suffered	1084 8 O
this	1093 4 O
complication	1098 12 O
twice	1111 5 O
.	1116 1 O

All	1118 3 O
affected	1122 8 O
patients	1131 8 O
were	1140 4 O
females	1145 7 O
over	1153 4 O
the	1158 3 O
age	1162 3 O
of	1166 2 O
50	1169 2 O
years	1172 5 O
.	1177 1 O

Most	1179 4 O
patients	1184 8 O
had	1193 3 O
received	1197 8 O
treatments	1206 10 O
prior	1217 5 O
to	1223 2 O
abductor	1226 8 O
paralysis	1235 9 B-Disease
and	1245 3 O
continued	1249 9 O
receiving	1259 9 O
after	1269 5 O
paralysis	1275 9 B-Disease
.	1284 1 O

Seven	1286 5 O
patients	1292 8 O
recovered	1301 9 O
after	1311 5 O
a	1317 1 O
brief	1319 5 O
period	1325 6 O
of	1332 2 O
activity	1335 8 O
restrictions	1344 12 O
,	1356 1 O
and	1358 3 O
one	1362 3 O
underwent	1366 9 O
a	1376 1 O
tracheotomy	1378 11 O
.	1389 1 O

The	1391 3 O
incidence	1395 9 O
of	1405 2 O
abductor	1408 8 O
paralysis	1417 9 B-Disease
after	1427 5 O
Botox	1433 5 B-Chemical
injection	1439 9 O
for	1449 3 O
ADSD	1453 4 B-Disease
was	1458 3 O
0	1462 1 O
.	1463 1 O
34	1464 2 O
%	1466 1 O
.	1467 1 O

CONCLUSIONS	1469 11 O
:	1480 1 O
Bilateral	1482 9 O
abductor	1492 8 O
paralysis	1501 9 B-Disease
is	1511 2 O
a	1514 1 O
rare	1516 4 O
complication	1521 12 O
of	1534 2 O
Botox	1537 5 B-Chemical
injections	1543 10 O
for	1554 3 O
ADSD	1558 4 B-Disease
,	1562 1 O
causing	1564 7 O
difficulty	1572 10 O
with	1583 4 O
breathing	1588 9 O
upon	1598 4 O
exertion	1603 8 O
.	1611 1 O

The	1613 3 O
likely	1617 6 O
mechanism	1624 9 O
of	1634 2 O
paralysis	1637 9 B-Disease
is	1647 2 O
diffusion	1650 9 O
of	1660 2 O
Botox	1663 5 B-Chemical
around	1669 6 O
the	1676 3 O
muscular	1680 8 O
process	1689 7 O
of	1697 2 O
the	1700 3 O
arytenoid	1704 9 O
to	1714 2 O
the	1717 3 O
posterior	1721 9 O
cricoarytenoid	1731 14 O
muscles	1746 7 O
.	1753 1 O

The	1755 3 O
paralysis	1759 9 B-Disease
is	1769 2 O
temporary	1772 9 O
,	1781 1 O
and	1783 3 O
watchful	1787 8 O
waiting	1796 7 O
with	1804 4 O
restriction	1809 11 O
of	1821 2 O
activity	1824 8 O
is	1833 2 O
the	1836 3 O
recommended	1840 11 O
management	1852 10 O
.	1862 1 O

Mitochondrial	0 13 B-Disease
impairment	14 10 I-Disease
contributes	25 11 O
to	37 2 O
cocaine	40 7 B-Chemical
-	47 1 O
induced	48 7 O
cardiac	56 7 B-Disease
dysfunction	64 11 I-Disease
:	75 1 O
Prevention	77 10 O
by	88 2 O
the	91 3 O
targeted	95 8 O
antioxidant	104 11 O
MitoQ	116 5 B-Chemical
.	121 1 O

The	123 3 O
goal	127 4 O
of	132 2 O
this	135 4 O
study	140 5 O
was	146 3 O
to	150 2 O
assess	153 6 O
mitochondrial	160 13 O
function	174 8 O
and	183 3 O
ROS	187 3 O
production	191 10 O
in	202 2 O
an	205 2 O
experimental	208 12 O
model	221 5 O
of	227 2 O
cocaine	230 7 B-Chemical
-	237 1 O
induced	238 7 O
cardiac	246 7 B-Disease
dysfunction	254 11 I-Disease
.	265 1 O

We	267 2 O
hypothesized	270 12 O
that	283 4 O
cocaine	288 7 B-Disease
abuse	296 5 I-Disease
may	302 3 O
lead	306 4 O
to	311 2 O
altered	314 7 O
mitochondrial	322 13 O
function	336 8 O
that	345 4 O
in	350 2 O
turn	353 4 O
may	358 3 O
cause	362 5 O
left	368 4 B-Disease
ventricular	373 11 I-Disease
dysfunction	385 11 I-Disease
.	396 1 O

Seven	398 5 O
days	404 4 O
of	409 2 O
cocaine	412 7 B-Chemical
administration	420 14 O
to	435 2 O
rats	438 4 O
led	443 3 O
to	447 2 O
an	450 2 O
increased	453 9 O
oxygen	463 6 B-Chemical
consumption	470 11 O
detected	482 8 O
in	491 2 O
cardiac	494 7 O
fibers	502 6 O
,	508 1 O
specifically	510 12 O
through	523 7 O
complex	531 7 O
I	539 1 O
and	541 3 O
complex	545 7 O
III	553 3 O
.	556 1 O

ROS	558 3 O
levels	562 6 O
were	569 4 O
increased	574 9 O
,	583 1 O
specifically	585 12 O
in	598 2 O
interfibrillar	601 14 O
mitochondria	616 12 O
.	628 1 O

In	630 2 O
parallel	633 8 O
there	642 5 O
was	648 3 O
a	652 1 O
decrease	654 8 O
in	663 2 O
ATP	666 3 B-Chemical
synthesis	670 9 O
,	679 1 O
whereas	681 7 O
no	689 2 O
difference	692 10 O
was	703 3 O
observed	707 8 O
in	716 2 O
subsarcolemmal	719 14 O
mitochondria	734 12 O
.	746 1 O

This	748 4 O
uncoupling	753 10 O
effect	764 6 O
on	771 2 O
oxidative	774 9 O
phosphorylation	784 15 O
was	800 3 O
not	804 3 O
detectable	808 10 O
after	819 5 O
short	825 5 O
-	830 1 O
term	831 4 O
exposure	836 8 O
to	845 2 O
cocaine	848 7 B-Chemical
,	855 1 O
suggesting	857 10 O
that	868 4 O
these	873 5 O
mitochondrial	879 13 B-Disease
abnormalities	893 13 I-Disease
were	907 4 O
a	912 1 O
late	914 4 O
rather	919 6 O
than	926 4 O
a	931 1 O
primary	933 7 O
event	941 5 O
in	947 2 O
the	950 3 O
pathological	954 12 O
response	967 8 O
to	976 2 O
cocaine	979 7 B-Chemical
.	986 1 O

MitoQ	988 5 B-Chemical
,	993 1 O
a	995 1 O
mitochondrial	997 13 O
-	1010 1 O
targeted	1011 8 O
antioxidant	1020 11 O
,	1031 1 O
was	1033 3 O
shown	1037 5 O
to	1043 2 O
completely	1046 10 O
prevent	1057 7 O
these	1065 5 O
mitochondrial	1071 13 B-Disease
abnormalities	1085 13 I-Disease
as	1099 2 O
well	1102 4 O
as	1107 2 O
cardiac	1110 7 B-Disease
dysfunction	1118 11 I-Disease
characterized	1130 13 O
here	1144 4 O
by	1149 2 O
a	1152 1 O
diastolic	1154 9 B-Disease
dysfunction	1164 11 I-Disease
studied	1176 7 O
with	1184 4 O
a	1189 1 O
conductance	1191 11 O
catheter	1203 8 O
to	1212 2 O
obtain	1215 6 O
pressure	1222 8 O
-	1230 1 O
volume	1231 6 O
data	1238 4 O
.	1242 1 O

Taken	1244 5 O
together	1250 8 O
,	1258 1 O
these	1260 5 O
results	1266 7 O
extend	1274 6 O
previous	1281 8 O
studies	1290 7 O
and	1298 3 O
demonstrate	1302 11 O
that	1314 4 O
cocaine	1319 7 B-Chemical
-	1326 1 O
induced	1327 7 O
cardiac	1335 7 B-Disease
dysfunction	1343 11 I-Disease
may	1355 3 O
be	1359 2 O
due	1362 3 O
to	1366 2 O
a	1369 1 O
mitochondrial	1371 13 B-Disease
defect	1385 6 I-Disease
.	1391 1 O

Trimethoprim	0 12 B-Chemical
-	12 1 O
induced	13 7 O
immune	21 6 O
hemolytic	28 9 B-Disease
anemia	38 6 I-Disease
in	45 2 O
a	48 1 O
pediatric	50 9 O
oncology	60 8 O
patient	69 7 O
presenting	77 10 O
as	88 2 O
an	91 2 O
acute	94 5 O
hemolytic	100 9 O
transfusion	110 11 O
reaction	122 8 O
.	130 1 O

A	132 1 O
10	134 2 O
-	136 1 O
year	137 4 O
-	141 1 O
old	142 3 O
male	146 4 O
with	151 4 O
acute	156 5 B-Disease
leukemia	162 8 I-Disease
presented	171 9 O
with	181 4 O
post	186 4 O
-	190 1 O
chemotherapy	191 12 O
anemia	204 6 B-Disease
.	210 1 O

During	212 6 O
red	219 3 O
cell	223 4 O
transfusion	228 11 O
,	239 1 O
he	241 2 O
developed	244 9 O
hemoglobinuria	254 14 B-Disease
.	268 1 O

Transfusion	270 11 O
reaction	282 8 O
workup	291 6 O
was	298 3 O
negative	302 8 O
.	310 1 O

Drug	312 4 O
-	316 1 O
induced	317 7 O
immune	325 6 O
hemolytic	332 9 B-Disease
anemia	342 6 I-Disease
was	349 3 O
suspected	353 9 O
because	363 7 O
of	371 2 O
positive	374 8 O
direct	383 6 O
antiglobulin	390 12 O
test	403 4 O
,	407 1 O
negative	409 8 O
eluate	418 6 O
,	424 1 O
and	426 3 O
microspherocytes	430 16 O
on	447 2 O
smear	450 5 O
pre	456 3 O
-	459 1 O
and	461 3 O
post	465 4 O
-	469 1 O
transfusion	470 11 O
.	481 1 O

Drug	483 4 O
studies	488 7 O
using	496 5 O
the	502 3 O
indirect	506 8 O
antiglobulin	515 12 O
test	528 4 O
were	533 4 O
strongly	538 8 O
positive	547 8 O
with	556 4 O
trimethoprim	561 12 B-Chemical
and	574 3 O
trimethoprim	578 12 B-Chemical
-	590 1 I-Chemical
sulfamethoxazole	591 16 I-Chemical
but	608 3 O
negative	612 8 O
with	621 4 O
sulfamethoxazole	626 16 B-Chemical
.	642 1 O

The	644 3 O
patient	648 7 O
recovered	656 9 O
after	666 5 O
discontinuing	672 13 O
the	686 3 O
drug	690 4 O
,	694 1 O
with	696 4 O
no	701 2 O
recurrence	704 10 O
in	715 2 O
2	718 1 O
years	720 5 O
.	725 1 O

Other	727 5 O
causes	733 6 O
of	740 2 O
anemia	743 6 B-Disease
should	750 6 O
be	757 2 O
considered	760 10 O
in	771 2 O
patients	774 8 O
with	783 4 O
worse	788 5 O
-	793 1 O
than	794 4 O
-	798 1 O
expected	799 8 O
anemia	808 6 B-Disease
after	815 5 O
chemotherapy	821 12 O
.	833 1 O

Furthermore	835 11 O
,	846 1 O
hemolysis	848 9 B-Disease
during	858 6 O
transfusion	865 11 O
is	877 2 O
not	880 3 O
always	884 6 O
a	891 1 O
transfusion	893 11 O
reaction	905 8 O
.	913 1 O

Blockade	0 8 O
of	9 2 O
endothelial	12 11 O
-	23 1 O
mesenchymal	24 11 O
transition	36 10 O
by	47 2 O
a	50 1 O
Smad3	52 5 O
inhibitor	58 9 O
delays	68 6 O
the	75 3 O
early	79 5 O
development	85 11 O
of	97 2 O
streptozotocin	100 14 B-Chemical
-	114 1 O
induced	115 7 O
diabetic	123 8 B-Disease
nephropathy	132 11 I-Disease
.	143 1 O

OBJECTIVE	145 9 O
:	154 1 O
A	156 1 O
multicenter	158 11 O
,	169 1 O
controlled	171 10 O
trial	182 5 O
showed	188 6 O
that	195 4 O
early	200 5 O
blockade	206 8 O
of	215 2 O
the	218 3 O
renin	222 5 O
-	227 1 O
angiotensin	228 11 B-Chemical
system	240 6 O
in	247 2 O
patients	250 8 O
with	259 4 O
type	264 4 B-Disease
1	269 1 I-Disease
diabetes	271 8 I-Disease
and	280 3 O
normoalbuminuria	284 16 O
did	301 3 O
not	305 3 O
retard	309 6 O
the	316 3 O
progression	320 11 O
of	332 2 O
nephropathy	335 11 B-Disease
,	346 1 O
suggesting	348 10 O
that	359 4 O
other	364 5 O
mechanism	370 9 O
(	379 1 O
s	380 1 O
)	381 1 O
are	383 3 O
involved	387 8 O
in	396 2 O
the	399 3 O
pathogenesis	403 12 O
of	416 2 O
early	419 5 O
diabetic	425 8 B-Disease
nephropathy	434 11 I-Disease
(	446 1 O
diabetic	447 8 B-Disease
nephropathy	456 11 I-Disease
)	467 1 O
.	468 1 O

We	470 2 O
have	473 4 O
previously	478 10 O
demonstrated	489 12 O
that	502 4 O
endothelial	507 11 O
-	518 1 O
mesenchymal	519 11 O
-	530 1 O
transition	531 10 O
(	542 1 O
EndoMT	543 6 O
)	549 1 O
contributes	551 11 O
to	563 2 O
the	566 3 O
early	570 5 O
development	576 11 O
of	588 2 O
renal	591 5 O
interstitial	597 12 O
fibrosis	610 8 B-Disease
independently	619 13 O
of	633 2 O
microalbuminuria	636 16 O
in	653 2 O
mice	656 4 O
with	661 4 O
streptozotocin	666 14 B-Chemical
(	681 1 O
STZ	682 3 B-Chemical
)	685 1 O
-	686 1 O
induced	687 7 O
diabetes	695 8 B-Disease
.	703 1 O

In	705 2 O
the	708 3 O
present	712 7 O
study	720 5 O
,	725 1 O
we	727 2 O
hypothesized	730 12 O
that	743 4 O
blocking	748 8 O
EndoMT	757 6 O
reduces	764 7 O
the	772 3 O
early	776 5 O
development	782 11 O
of	794 2 O
diabetic	797 8 B-Disease
nephropathy	806 11 I-Disease
.	817 1 O

RESEARCH	819 8 O
DESIGN	828 6 O
AND	835 3 O
METHODS	839 7 O
:	846 1 O
EndoMT	848 6 O
was	855 3 O
induced	859 7 O
in	867 2 O
a	870 1 O
mouse	872 5 O
pancreatic	878 10 O
microvascular	889 13 O
endothelial	903 11 O
cell	915 4 O
line	920 4 O
(	925 1 O
MMEC	926 4 O
)	930 1 O
in	932 2 O
the	935 3 O
presence	939 8 O
of	948 2 O
advanced	951 8 O
glycation	960 9 O
end	970 3 O
products	974 8 O
(	983 1 O
AGEs	984 4 O
)	988 1 O
and	990 3 O
in	994 2 O
the	997 3 O
endothelial	1001 11 O
lineage	1013 7 O
-	1020 1 O
traceble	1021 8 O
mouse	1030 5 O
line	1036 4 O
Tie2	1041 4 O
-	1045 1 O
Cre	1046 3 O
;	1049 1 O
Loxp	1050 4 O
-	1054 1 O
EGFP	1055 4 O
by	1060 2 O
administration	1063 14 O
of	1078 2 O
AGEs	1081 4 O
,	1085 1 O
with	1087 4 O
nonglycated	1092 11 O
mouse	1104 5 O
albumin	1110 7 O
serving	1118 7 O
as	1126 2 O
a	1129 1 O
control	1131 7 O
.	1138 1 O

Phosphorylated	1140 14 O
Smad3	1155 5 O
was	1161 3 O
detected	1165 8 O
by	1174 2 O
immunoprecipitation	1177 19 O
/	1196 1 O
Western	1197 7 O
blotting	1205 8 O
and	1214 3 O
confocal	1218 8 O
microscopy	1227 10 O
.	1237 1 O

Blocking	1239 8 O
studies	1248 7 O
using	1256 5 O
receptor	1262 8 O
for	1271 3 O
AGE	1275 3 O
siRNA	1279 5 O
and	1285 3 O
a	1289 1 O
specific	1291 8 O
inhibitor	1300 9 O
of	1310 2 O
Smad3	1313 5 O
(	1319 1 O
SIS3	1320 4 O
)	1324 1 O
were	1326 4 O
performed	1331 9 O
in	1341 2 O
MMECs	1344 5 O
and	1350 3 O
in	1354 2 O
STZ	1357 3 B-Chemical
-	1360 1 O
induced	1361 7 O
diabetic	1369 8 B-Disease
nephropathy	1378 11 I-Disease
in	1390 2 O
Tie2	1393 4 O
-	1397 1 O
Cre	1398 3 O
;	1401 1 O
Loxp	1402 4 O
-	1406 1 O
EGFP	1407 4 O
mice	1412 4 O
.	1416 1 O

RESULTS	1418 7 O
:	1425 1 O
Confocal	1427 8 O
microscopy	1436 10 O
and	1447 3 O
real	1451 4 O
-	1455 1 O
time	1456 4 O
PCR	1461 3 O
demonstrated	1465 12 O
that	1478 4 O
AGEs	1483 4 O
induced	1488 7 O
EndoMT	1496 6 O
in	1503 2 O
MMECs	1506 5 O
and	1512 3 O
in	1516 2 O
Tie2	1519 4 O
-	1523 1 O
Cre	1524 3 O
;	1527 1 O
Loxp	1528 4 O
-	1532 1 O
EGFP	1533 4 O
mice	1538 4 O
.	1542 1 O

Immunoprecipitation	1544 19 O
/	1563 1 O
Western	1564 7 O
blotting	1572 8 O
showed	1581 6 O
that	1588 4 O
Smad3	1593 5 O
was	1599 3 O
activated	1603 9 O
by	1613 2 O
AGEs	1616 4 O
but	1621 3 O
was	1625 3 O
inhibited	1629 9 O
by	1639 2 O
SIS3	1642 4 O
in	1647 2 O
MMECs	1650 5 O
and	1656 3 O
in	1660 2 O
STZ	1663 3 B-Chemical
-	1666 1 O
induced	1667 7 O
diabetic	1675 8 B-Disease
nephropathy	1684 11 I-Disease
.	1695 1 O

Confocal	1697 8 O
microscopy	1706 10 O
and	1717 3 O
real	1721 4 O
-	1725 1 O
time	1726 4 O
PCR	1731 3 O
further	1735 7 O
demonstrated	1743 12 O
that	1756 4 O
SIS3	1761 4 O
abrogated	1766 9 O
EndoMT	1776 6 O
,	1782 1 O
reduced	1784 7 O
renal	1792 5 O
fibrosis	1798 8 B-Disease
,	1806 1 O
and	1808 3 O
retarded	1812 8 O
progression	1821 11 O
of	1833 2 O
nephropathy	1836 11 B-Disease
.	1847 1 O

CONCLUSIONS	1849 11 O
:	1860 1 O
EndoMT	1862 6 O
is	1869 2 O
a	1872 1 O
novel	1874 5 O
pathway	1880 7 O
leading	1888 7 O
to	1896 2 O
early	1899 5 O
development	1905 11 O
of	1917 2 O
diabetic	1920 8 B-Disease
nephropathy	1929 11 I-Disease
.	1940 1 O

Blockade	1942 8 O
of	1951 2 O
EndoMT	1954 6 O
by	1961 2 O
SIS3	1964 4 O
may	1969 3 O
provide	1973 7 O
a	1981 1 O
new	1983 3 O
strategy	1987 8 O
to	1996 2 O
retard	1999 6 O
the	2006 3 O
progression	2010 11 O
of	2022 2 O
diabetic	2025 8 B-Disease
nephropathy	2034 11 I-Disease
and	2046 3 O
other	2050 5 O
diabetes	2056 8 B-Disease
complications	2065 13 I-Disease
.	2078 1 O

Cytostatic	0 10 O
and	11 3 O
anti	15 4 O
-	19 1 O
angiogenic	20 10 O
effects	31 7 O
of	39 2 O
temsirolimus	42 12 B-Chemical
in	55 2 O
refractory	58 10 O
mantle	69 6 B-Disease
cell	76 4 I-Disease
lymphoma	81 8 I-Disease
.	89 1 O

Mantle	91 6 B-Disease
cell	98 4 I-Disease
lymphoma	103 8 I-Disease
(	112 1 O
MCL	113 3 B-Disease
)	116 1 O
is	118 2 O
a	121 1 O
rare	123 4 O
and	128 3 O
aggressive	132 10 O
type	143 4 O
of	148 2 O
B	151 1 B-Disease
-	152 1 I-Disease
cell	153 4 I-Disease
non	158 3 I-Disease
-	161 1 I-Disease
Hodgkin	162 7 I-Disease
'	169 1 I-Disease
s	170 1 I-Disease
lymphoma	172 8 I-Disease
.	180 1 O

Patients	182 8 O
become	191 6 O
progressively	198 13 O
refractory	212 10 O
to	223 2 O
conventional	226 12 O
chemotherapy	239 12 O
,	251 1 O
and	253 3 O
their	257 5 O
prognosis	263 9 O
is	273 2 O
poor	276 4 O
.	280 1 O

However	282 7 O
,	289 1 O
a	291 1 O
38	293 2 O
%	295 1 O
remission	297 9 O
rate	307 4 O
has	312 3 O
been	316 4 O
recently	321 8 O
reported	330 8 O
in	339 2 O
refractory	342 10 O
MCL	353 3 B-Disease
treated	357 7 O
with	365 4 O
temsirolimus	370 12 B-Chemical
,	382 1 O
a	384 1 O
mTOR	386 4 O
inhibitor	391 9 O
.	400 1 O
Here	401 4 O
we	406 2 O
had	409 3 O
the	413 3 O
opportunity	417 11 O
to	429 2 O
study	432 5 O
a	438 1 O
case	440 4 O
of	445 2 O
refractory	448 10 O
MCL	459 3 B-Disease
who	463 3 O
had	467 3 O
tumor	471 5 B-Disease
regression	477 10 O
two	488 3 O
months	492 6 O
after	499 5 O
temsirolimus	505 12 B-Chemical
treatment	518 9 O
,	527 1 O
and	529 3 O
a	533 1 O
progression	535 11 O
-	546 1 O
free	547 4 O
survival	552 8 O
of	561 2 O
10	564 2 O
months	567 6 O
.	573 1 O

In	575 2 O
this	578 4 O
case	583 4 O
,	587 1 O
lymph	589 5 O
node	595 4 O
biopsies	600 8 O
were	609 4 O
performed	614 9 O
before	624 6 O
and	631 3 O
six	635 3 O
months	639 6 O
after	646 5 O
temsirolimus	652 12 B-Chemical
therapy	665 7 O
.	672 1 O

Comparison	674 10 O
of	685 2 O
the	688 3 O
two	692 3 O
biopsies	696 8 O
showed	705 6 O
that	712 4 O
temsirolimus	717 12 B-Chemical
inhibited	730 9 O
tumor	740 5 B-Disease
cell	746 4 O
proliferation	751 13 O
through	765 7 O
cell	773 4 O
cycle	778 5 O
arrest	784 6 O
,	790 1 O
but	792 3 O
did	796 3 O
not	800 3 O
induce	804 6 O
any	811 3 O
change	815 6 O
in	822 2 O
the	825 3 O
number	829 6 O
of	836 2 O
apoptotic	839 9 O
tumor	849 5 B-Disease
cells	855 5 O
.	860 1 O

Apart	862 5 O
from	868 4 O
this	873 4 O
cytostatic	878 10 O
effect	889 6 O
,	895 1 O
temsirolimus	897 12 B-Chemical
had	910 3 O
an	914 2 O
antiangiogenic	917 14 O
effect	932 6 O
with	939 4 O
decrease	944 8 O
of	953 2 O
tumor	956 5 B-Disease
microvessel	962 11 O
density	974 7 O
and	982 3 O
of	986 2 O
VEGF	989 4 O
expression	994 10 O
.	1004 1 O

Moreover	1006 8 O
,	1014 1 O
numerous	1016 8 O
patchy	1025 6 O
,	1031 1 O
well	1033 4 O
-	1037 1 O
limited	1038 7 O
fibrotic	1046 8 O
areas	1055 5 O
,	1060 1 O
compatible	1062 10 O
with	1073 4 O
post	1078 4 O
-	1082 1 O
necrotic	1083 8 B-Disease
tissue	1092 6 O
repair	1099 6 O
,	1105 1 O
were	1107 4 O
found	1112 5 O
after	1118 5 O
6	1124 1 O
-	1125 1 O
month	1126 5 O
temsirolimus	1132 12 B-Chemical
therapy	1145 7 O
.	1152 1 O

Thus	1154 4 O
,	1158 1 O
temsirolimus	1160 12 B-Chemical
reduced	1173 7 O
tumor	1181 5 B-Disease
burden	1187 6 O
through	1194 7 O
associated	1202 10 O
cytostatic	1213 10 O
and	1224 3 O
anti	1228 4 O
-	1232 1 O
angiogenic	1233 10 O
effects	1244 7 O
.	1251 1 O
This	1252 4 O
dual	1257 4 O
effect	1262 6 O
of	1269 2 O
temsirolimus	1272 12 B-Chemical
on	1285 2 O
tumor	1288 5 B-Disease
tissue	1294 6 O
could	1301 5 O
contribute	1307 10 O
to	1318 2 O
its	1321 3 O
recently	1325 8 O
reported	1334 8 O
efficiency	1343 10 O
in	1354 2 O
refractory	1357 10 O
MCL	1368 3 B-Disease
resistant	1372 9 O
to	1382 2 O
conventional	1385 12 O
chemotherapy	1398 12 O
.	1410 1 O

Syncope	0 7 B-Disease
caused	8 6 O
by	15 2 O
hyperkalemia	18 12 B-Disease
during	31 6 O
use	38 3 O
of	42 2 O
a	45 1 O
combined	47 8 O
therapy	56 7 O
with	64 4 O
the	69 3 O
angiotensin	73 11 B-Chemical
-	84 1 O
converting	85 10 O
enzyme	96 6 O
inhibitor	103 9 O
and	113 3 O
spironolactone	117 14 B-Chemical
.	131 1 O

A	133 1 O
76	135 2 O
year	138 4 O
-	142 1 O
old	143 3 O
woman	147 5 O
with	153 4 O
a	158 1 O
history	160 7 O
of	168 2 O
coronary	171 8 O
artery	180 6 O
bypass	187 6 O
grafting	194 8 O
and	203 3 O
prior	207 5 O
myocardial	213 10 B-Disease
infarction	224 10 I-Disease
was	235 3 O
transferred	239 11 O
to	251 2 O
the	254 3 O
emergency	258 9 O
room	268 4 O
with	273 4 O
loss	278 4 B-Disease
of	283 2 I-Disease
consciousness	286 13 I-Disease
due	300 3 O
to	304 2 O
marked	307 6 O
bradycardia	314 11 B-Disease
caused	326 6 O
by	333 2 O
hyperkalemia	336 12 B-Disease
.	348 1 O

The	350 3 O
concentration	354 13 O
of	368 2 O
serum	371 5 O
potassium	377 9 B-Chemical
was	387 3 O
high	391 4 O
,	395 1 O
and	397 3 O
normal	401 6 O
sinus	408 5 O
rhythm	414 6 O
was	421 3 O
restored	425 8 O
after	434 5 O
correction	440 10 O
of	451 2 O
the	454 3 O
serum	458 5 O
potassium	464 9 B-Chemical
level	474 5 O
.	479 1 O

The	481 3 O
cause	485 5 O
of	491 2 O
hyperkalemia	494 12 B-Disease
was	507 3 O
considered	511 10 O
to	522 2 O
be	525 2 O
several	528 7 O
doses	536 5 O
of	542 2 O
spiranolactone	545 14 B-Chemical
,	559 1 O
an	561 2 O
aldosterone	564 11 B-Chemical
antagonist	576 10 O
,	586 1 O
in	588 2 O
addition	591 8 O
to	600 2 O
the	603 3 O
long	607 4 O
-	611 1 O
term	612 4 O
intake	617 6 O
of	624 2 O
ramipril	627 8 B-Chemical
,	635 1 O
an	637 2 O
ACE	640 3 O
inhibitor	644 9 O
.	653 1 O

This	655 4 O
case	660 4 O
is	665 2 O
a	668 1 O
good	670 4 O
example	675 7 O
of	683 2 O
electrolyte	686 11 O
imbalance	698 9 O
causing	708 7 O
acute	716 5 O
life	722 4 O
-	726 1 O
threatening	727 11 O
cardiac	739 7 O
events	747 6 O
.	753 1 O

Clinicians	755 10 O
should	766 6 O
be	773 2 O
alert	776 5 O
to	782 2 O
the	785 3 O
possibility	789 11 O
of	801 2 O
hyperkalemia	804 12 B-Disease
,	816 1 O
especially	818 10 O
in	829 2 O
elderly	832 7 O
patients	840 8 O
using	849 5 O
ACE	855 3 O
/	858 1 O
ARB	859 3 O
in	863 2 O
combination	866 11 O
with	878 4 O
potassium	883 9 B-Chemical
sparing	893 7 O
agents	901 6 O
and	908 3 O
who	912 3 O
have	916 4 O
mild	921 4 O
renal	926 5 B-Disease
disturbance	932 11 I-Disease
.	943 1 O

Diffuse	0 7 O
skeletal	8 8 O
pain	17 4 B-Disease
after	22 5 O
administration	28 14 O
of	43 2 O
alendronate	46 11 B-Chemical
.	57 1 O

BACKGROUND	59 10 O
:	69 1 O
Osteoporosis	71 12 B-Disease
is	84 2 O
caused	87 6 O
by	94 2 O
bone	97 4 O
resorption	102 10 O
in	113 2 O
excess	116 6 O
of	123 2 O
bone	126 4 O
formation	131 9 O
,	140 1 O
and	142 3 O
bisphosphonates	146 15 B-Chemical
,	161 1 O
are	163 3 O
used	167 4 O
to	172 2 O
inhibit	175 7 O
bone	183 4 O
resorption	188 10 O
.	198 1 O

Alendronate	200 11 B-Chemical
,	211 1 O
a	213 1 O
biphosphonate	215 13 B-Chemical
,	228 1 O
is	230 2 O
effective	233 9 O
for	243 3 O
both	247 4 O
the	252 3 O
treatment	256 9 O
and	266 3 O
prevention	270 10 O
of	281 2 O
osteoporosis	284 12 B-Disease
in	297 2 O
postmenopausal	300 14 O
women	315 5 O
.	320 1 O

Side	322 4 O
effects	327 7 O
are	335 3 O
relatively	339 10 O
few	350 3 O
and	354 3 O
prominently	358 11 O
gastrointestinal	370 16 O
.	386 1 O

Musculoskeletal	388 15 B-Disease
pain	404 4 I-Disease
may	409 3 O
be	413 2 O
an	416 2 O
important	419 9 O
side	429 4 O
effect	434 6 O
in	441 2 O
these	444 5 O
patients	450 8 O
.	458 1 O

We	460 2 O
presented	463 9 O
a	473 1 O
patient	475 7 O
admitted	483 8 O
to	492 2 O
our	495 3 O
out	499 3 O
-	502 1 O
patient	503 7 O
clinic	511 6 O
with	518 4 O
diffuse	523 7 O
skeletal	531 8 O
pain	540 4 B-Disease
after	545 5 O
three	551 5 O
consecutive	557 11 O
administration	569 14 O
of	584 2 O
alendronate	587 11 B-Chemical
.	598 1 O

CONCLUSION	600 10 O
:	610 1 O
We	612 2 O
conclude	615 8 O
that	624 4 O
patients	629 8 O
with	638 4 O
osteoporosis	643 12 B-Disease
can	656 3 O
report	660 6 O
pain	667 4 B-Disease
,	671 1 O
and	673 3 O
bisphosphonate	677 14 B-Chemical
-	691 1 O
related	692 7 O
pain	700 4 B-Disease
should	705 6 O
also	712 4 O
be	717 2 O
considered	720 10 O
before	731 6 O
ascribing	738 9 O
this	748 4 O
complaint	753 9 O
to	763 2 O
osteoporosis	766 12 B-Disease
.	778 1 O

Cerebrospinal	0 13 O
fluid	14 5 O
penetration	20 11 O
of	32 2 O
high	35 4 O
-	39 1 O
dose	40 4 O
daptomycin	45 10 B-Chemical
in	56 2 O
suspected	59 9 O
Staphylococcus	69 14 O
aureus	84 6 O
meningitis	91 10 B-Disease
.	101 1 O

OBJECTIVE	103 9 O
:	112 1 O
To	114 2 O
report	117 6 O
a	124 1 O
case	126 4 O
of	131 2 O
methicillin	134 11 B-Chemical
-	145 1 O
sensitive	146 9 O
Staphylococcus	156 14 O
aureus	171 6 O
(	178 1 O
MSSA	179 4 O
)	183 1 O
bacteremia	185 10 B-Disease
with	196 4 O
suspected	201 9 O
MSSA	211 4 O
meningitis	216 10 B-Disease
treated	227 7 O
with	235 4 O
high	240 4 O
-	244 1 O
dose	245 4 O
daptomycin	250 10 B-Chemical
assessed	261 8 O
with	270 4 O
concurrent	275 10 O
serum	286 5 O
and	292 3 O
cerebrospinal	296 13 O
fluid	310 5 O
(	316 1 O
CSF	317 3 O
)	320 1 O
concentrations	322 14 O
.	336 1 O

CASE	338 4 O
SUMMARY	343 7 O
:	350 1 O
A	352 1 O
54	354 2 O
-	356 1 O
year	357 4 O
-	361 1 O
old	362 3 O
male	366 4 O
presented	371 9 O
to	381 2 O
the	384 3 O
emergency	388 9 O
department	398 10 O
with	409 4 O
generalized	414 11 O
weakness	426 8 B-Disease
and	435 3 O
presumed	439 8 O
health	448 6 O
-	454 1 O
care	455 4 O
-	459 1 O
associated	460 10 O
pneumonia	471 9 B-Disease
shown	481 5 O
on	487 2 O
chest	490 5 O
radiograph	496 10 O
.	506 1 O

Treatment	508 9 O
was	518 3 O
empirically	522 11 O
initiated	534 9 O
with	544 4 O
vancomycin	549 10 B-Chemical
,	559 1 O
levofloxacin	561 12 B-Chemical
,	573 1 O
and	575 3 O
piperacillin	579 12 B-Chemical
/	591 1 O
tazobactam	592 10 B-Chemical
.	602 1 O

Blood	604 5 O
cultures	610 8 O
revealed	619 8 O
S	628 1 O
.	629 1 O
aureus	631 6 O
susceptible	638 11 O
to	650 2 O
oxacillin	653 9 B-Chemical
.	662 1 O

Empiric	664 7 O
antibiotic	672 10 O
treatment	683 9 O
was	693 3 O
narrowed	697 8 O
to	706 2 O
nafcillin	709 9 B-Chemical
on	719 2 O
day	722 3 O
4	726 1 O
.	727 1 O

On	729 2 O
day	732 3 O
8	736 1 O
,	737 1 O
the	739 3 O
patient	743 7 O
developed	751 9 O
acute	761 5 B-Disease
renal	767 5 I-Disease
failure	773 7 I-Disease
(	781 1 O
serum	782 5 O
creatinine	788 10 B-Chemical
1	799 1 O
.	800 1 O
9	801 1 O
mg	803 2 O
/	805 1 O
dL	806 2 O
,	808 1 O
increased	810 9 O
from	820 4 O
1	825 1 O
.	826 1 O
2	827 1 O
mg	829 2 O
/	831 1 O
dL	832 2 O
the	835 3 O
previous	839 8 O
day	848 3 O
and	852 3 O
0	856 1 O
.	857 1 O
8	858 1 O
mg	860 2 O
/	862 1 O
dL	863 2 O
on	866 2 O
admission	869 9 O
)	878 1 O
.	879 1 O

The	881 3 O
patient	885 7 O
'	892 1 O
s	893 1 O
Glasgow	895 7 O
Coma	903 4 O
Score	908 5 O
was	914 3 O
3	918 1 O
,	919 1 O
with	921 4 O
normal	926 6 O
findings	933 8 O
shown	942 5 O
on	948 2 O
computed	951 8 O
tomography	960 10 O
scan	971 4 O
of	976 2 O
the	979 3 O
head	983 4 O
72	988 2 O
hours	991 5 O
following	997 9 O
an	1007 2 O
episode	1010 7 O
of	1018 2 O
cardiac	1021 7 B-Disease
arrest	1029 6 I-Disease
on	1036 2 O
day	1039 3 O
10	1043 2 O
.	1045 1 O

The	1047 3 O
patient	1051 7 O
experienced	1059 11 O
relapsing	1071 9 O
MSSA	1081 4 O
bacteremia	1086 10 B-Disease
on	1097 2 O
day	1100 3 O
9	1104 1 O
,	1105 1 O
increasing	1107 10 O
the	1118 3 O
suspicion	1122 9 O
for	1132 3 O
a	1136 1 O
central	1138 7 O
nervous	1146 7 O
system	1154 6 O
(	1161 1 O
CNS	1162 3 O
)	1165 1 O
infection	1167 9 B-Disease
.	1176 1 O

Nafcillin	1178 9 B-Chemical
was	1188 3 O
discontinued	1192 12 O
and	1205 3 O
daptomycin	1209 10 B-Chemical
9	1220 1 O
mg	1222 2 O
/	1224 1 O
kg	1225 2 O
daily	1228 5 O
was	1234 3 O
initiated	1238 9 O
for	1248 3 O
suspected	1252 9 O
meningitis	1262 10 B-Disease
and	1273 3 O
was	1277 3 O
continued	1281 9 O
until	1291 5 O
the	1297 3 O
patient	1301 7 O
'	1308 1 O
s	1309 1 O
death	1311 5 O
on	1317 2 O
day	1320 3 O
16	1324 2 O
.	1326 1 O

Daptomycin	1328 10 B-Chemical
serum	1339 5 O
and	1345 3 O
CSF	1349 3 O
trough	1353 6 O
concentrations	1360 14 O
were	1375 4 O
11	1380 2 O
.	1382 1 O
21	1383 2 O
ug	1386 2 O
/	1388 1 O
mL	1389 2 O
and	1392 3 O
0	1396 1 O
.	1397 1 O
52	1398 2 O
ug	1401 2 O
/	1403 1 O
mL	1404 2 O
,	1406 1 O
respectively	1408 12 O
,	1420 1 O
prior	1422 5 O
to	1428 2 O
the	1431 3 O
third	1435 5 O
dose	1441 4 O
.	1445 1 O

Lumbar	1447 6 O
puncture	1454 8 O
results	1463 7 O
were	1471 4 O
inconclusive	1476 12 O
and	1489 3 O
no	1493 2 O
further	1496 7 O
blood	1504 5 O
cultures	1510 8 O
were	1519 4 O
positive	1524 8 O
for	1533 3 O
MSSA	1537 4 O
.	1541 1 O

Creatine	1543 8 B-Chemical
kinase	1552 6 O
levels	1559 6 O
were	1566 4 O
normal	1571 6 O
prior	1578 5 O
to	1584 2 O
daptomycin	1587 10 B-Chemical
therapy	1598 7 O
and	1606 3 O
were	1610 4 O
not	1615 3 O
reassessed	1619 10 O
.	1629 1 O

DISCUSSION	1631 10 O
:	1641 1 O
Daptomycin	1643 10 B-Chemical
was	1654 3 O
initiated	1658 9 O
in	1668 2 O
our	1671 3 O
patient	1675 7 O
secondary	1683 9 O
to	1693 2 O
possible	1696 8 O
nafcillin	1705 9 B-Chemical
-	1714 1 O
induced	1715 7 O
acute	1723 5 O
interstitial	1729 12 B-Disease
nephritis	1742 9 I-Disease
and	1752 3 O
relapsing	1756 9 O
bacteremia	1766 10 B-Disease
.	1776 1 O

At	1778 2 O
a	1781 1 O
dose	1783 4 O
of	1788 2 O
9	1791 1 O
mg	1793 2 O
/	1795 1 O
kg	1796 2 O
,	1798 1 O
resultant	1800 9 O
penetration	1810 11 O
of	1822 2 O
5	1825 1 O
%	1826 1 O
was	1828 3 O
higher	1832 6 O
than	1839 4 O
in	1844 2 O
previous	1847 8 O
reports	1856 7 O
,	1863 1 O
more	1865 4 O
consistent	1870 10 O
with	1881 4 O
inflamed	1886 8 O
meninges	1895 8 O
.	1903 1 O

CONCLUSIONS	1905 11 O
:	1916 1 O
High	1918 4 O
-	1922 1 O
dose	1923 4 O
daptomycin	1928 10 B-Chemical
may	1939 3 O
be	1943 2 O
an	1946 2 O
alternative	1949 11 O
option	1961 6 O
for	1968 3 O
MSSA	1972 4 O
bacteremia	1977 10 B-Disease
with	1988 4 O
or	1993 2 O
without	1996 7 O
a	2004 1 O
CNS	2006 3 O
source	2010 6 O
in	2017 2 O
patients	2020 8 O
who	2029 3 O
have	2033 4 O
failed	2038 6 O
or	2045 2 O
cannot	2048 6 O
tolerate	2055 8 O
standard	2064 8 O
therapy	2073 7 O
.	2080 1 O

Further	2082 7 O
clinical	2090 8 O
evaluation	2099 10 O
in	2110 2 O
patients	2113 8 O
with	2122 4 O
confirmed	2127 9 O
meningitis	2137 10 B-Disease
is	2148 2 O
warranted	2151 9 O
.	2160 1 O

The	0 3 O
role	4 4 O
of	9 2 O
nitric	12 6 B-Chemical
oxide	19 5 I-Chemical
in	25 2 O
convulsions	28 11 B-Disease
induced	40 7 O
by	48 2 O
lindane	51 7 B-Chemical
in	59 2 O
rats	62 4 O
.	66 1 O

Lindane	68 7 B-Chemical
is	76 2 O
an	79 2 O
organochloride	82 14 O
pesticide	97 9 O
and	107 3 O
scabicide	111 9 O
.	120 1 O

It	122 2 O
evokes	125 6 O
convulsions	132 11 B-Disease
mainly	144 6 O
trough	151 6 O
the	158 3 O
blockage	162 8 O
of	171 2 O
GABA	174 4 B-Chemical
(	178 1 O
A	179 1 O
)	180 1 O
receptors	182 9 O
.	191 1 O

Nitric	193 6 B-Chemical
oxide	200 5 I-Chemical
(	206 1 O
NO	207 2 B-Chemical
)	209 1 O
,	210 1 O
gaseous	212 7 O
neurotransmitter	220 16 O
,	236 1 O
has	238 3 O
contradictor	242 12 O
role	255 4 O
in	260 2 O
epileptogenesis	263 15 O
due	279 3 O
to	283 2 O
opposite	286 8 O
effects	295 7 O
of	303 2 O
L	306 1 B-Chemical
-	307 1 I-Chemical
arginine	308 8 I-Chemical
,	316 1 O
precursor	318 9 O
of	328 2 O
NO	331 2 B-Chemical
syntheses	334 9 O
(	344 1 O
NOS	345 3 O
)	348 1 O
,	349 1 O
and	351 3 O
L	355 1 B-Chemical
-	356 1 I-Chemical
NAME	357 4 I-Chemical
(	362 1 O
NOS	363 3 O
inhibitor	367 9 O
)	376 1 O
observed	378 8 O
in	387 2 O
different	390 9 O
epilepsy	400 8 B-Disease
models	409 6 O
.	415 1 O

The	417 3 O
aim	421 3 O
of	425 2 O
the	428 3 O
current	432 7 O
study	440 5 O
was	446 3 O
to	450 2 O
determine	453 9 O
the	463 3 O
effects	467 7 O
of	475 2 O
NO	478 2 B-Chemical
on	481 2 O
the	484 3 O
behavioral	488 10 O
and	499 3 O
EEG	503 3 O
characteristics	507 15 O
of	523 2 O
lindane	526 7 B-Chemical
-	533 1 O
induced	534 7 O
epilepsy	542 8 B-Disease
in	551 2 O
male	554 4 O
Wistar	559 6 O
albino	566 6 O
rats	573 4 O
.	577 1 O

The	579 3 O
administration	583 14 O
of	598 2 O
L	601 1 B-Chemical
-	602 1 I-Chemical
arginine	603 8 I-Chemical
(	612 1 O
600	613 3 O
,	616 1 O
800	618 3 O
and	622 3 O
1000	626 4 O
mg	631 2 O
/	633 1 O
kg	634 2 O
,	636 1 O
i	638 1 O
.	639 1 O
p	640 1 O
.	641 1 O
)	642 1 O
in	644 2 O
dose	647 4 O
-	651 1 O
dependent	652 9 O
manner	662 6 O
significantly	669 13 O
increased	683 9 O
convulsion	693 10 B-Disease
incidence	704 9 O
and	714 3 O
severity	718 8 O
and	727 3 O
shortened	731 9 O
latency	741 7 O
time	749 4 O
to	754 2 O
first	757 5 O
convulsion	763 10 B-Disease
elicited	774 8 O
by	783 2 O
lower	786 5 O
lindane	792 7 B-Chemical
dose	800 4 O
(	805 1 O
4	806 1 O
mg	808 2 O
/	810 1 O
kg	811 2 O
,	813 1 O
i	815 1 O
.	816 1 O
p	817 1 O
.	818 1 O
)	819 1 O
.	820 1 O

On	822 2 O
the	825 3 O
contrary	829 8 O
,	837 1 O
pretreatment	839 12 O
with	852 4 O
L	857 1 B-Chemical
-	858 1 I-Chemical
NAME	859 4 I-Chemical
(	864 1 O
500	865 3 O
,	868 1 O
700	870 3 O
and	874 3 O
900	878 3 O
mg	882 2 O
/	884 1 O
kg	885 2 O
,	887 1 O
i	889 1 O
.	890 1 O
p	891 1 O
.	892 1 O
)	893 1 O
decreased	895 9 O
convulsion	905 10 B-Disease
incidence	916 9 O
and	926 3 O
severity	930 8 O
and	939 3 O
prolonged	943 9 O
latency	953 7 O
time	961 4 O
to	966 2 O
convulsion	969 10 B-Disease
following	980 9 O
injection	990 9 O
with	1000 4 O
a	1005 1 O
convulsive	1007 10 B-Disease
dose	1018 4 O
of	1023 2 O
lindane	1026 7 B-Chemical
(	1034 1 O
8	1035 1 O
mg	1037 2 O
/	1039 1 O
kg	1040 2 O
,	1042 1 O
i	1044 1 O
.	1045 1 O
p	1046 1 O
.	1047 1 O
)	1048 1 O
.	1049 1 O

EEG	1051 3 O
analyses	1055 8 O
showed	1064 6 O
increase	1071 8 O
of	1080 2 O
number	1083 6 O
and	1090 3 O
duration	1094 8 O
of	1103 2 O
ictal	1106 5 O
periods	1112 7 O
in	1120 2 O
EEG	1123 3 O
of	1127 2 O
rats	1130 4 O
receiving	1135 9 O
l	1145 1 B-Chemical
-	1146 1 I-Chemical
arginine	1147 8 I-Chemical
prior	1156 5 O
to	1162 2 O
lindane	1165 7 B-Chemical
and	1173 3 O
decrease	1177 8 O
of	1186 2 O
this	1189 4 O
number	1194 6 O
in	1201 2 O
rats	1204 4 O
pretreated	1209 10 O
with	1220 4 O
L	1225 1 B-Chemical
-	1226 1 I-Chemical
NAME	1227 4 I-Chemical
.	1231 1 O

These	1233 5 O
results	1239 7 O
support	1247 7 O
the	1255 3 O
conclusion	1259 10 O
that	1270 4 O
NO	1275 2 B-Chemical
plays	1278 5 O
a	1284 1 O
role	1286 4 O
of	1291 2 O
endogenous	1294 10 O
convulsant	1305 10 O
in	1316 2 O
rat	1319 3 O
model	1323 5 O
of	1329 2 O
lindane	1332 7 B-Chemical
seizures	1340 8 B-Disease
.	1348 1 O

Long	0 4 O
-	4 1 O
term	5 4 O
oral	10 4 O
galactose	15 9 B-Chemical
treatment	25 9 O
prevents	35 8 O
cognitive	44 9 B-Disease
deficits	54 8 I-Disease
in	63 2 O
male	66 4 O
Wistar	71 6 O
rats	78 4 O
treated	83 7 O
intracerebroventricularly	91 25 O
with	117 4 O
streptozotocin	122 14 B-Chemical
.	136 1 O

Basic	138 5 O
and	144 3 O
clinical	148 8 O
research	157 8 O
has	166 3 O
demonstrated	170 12 O
that	183 4 O
dementia	188 8 B-Disease
of	197 2 O
sporadic	200 8 O
Alzheimer	209 9 B-Disease
'	218 1 I-Disease
s	219 1 I-Disease
disease	221 7 I-Disease
(	229 1 O
sAD	230 3 O
)	233 1 O
type	235 4 O
is	240 2 O
associated	243 10 O
with	254 4 O
dysfunction	259 11 O
of	271 2 O
the	274 3 O
insulin	278 7 O
-	285 1 O
receptor	286 8 O
(	295 1 O
IR	296 2 O
)	298 1 O
system	300 6 O
followed	307 8 O
by	316 2 O
decreased	319 9 O
glucose	329 7 B-Chemical
transport	337 9 O
via	347 3 O
glucose	351 7 B-Chemical
transporter	359 11 O
GLUT4	371 5 O
and	377 3 O
decreased	381 9 O
glucose	391 7 B-Chemical
metabolism	399 10 O
in	410 2 O
brain	413 5 O
cells	419 5 O
.	424 1 O

An	426 2 O
alternative	429 11 O
source	441 6 O
of	448 2 O
energy	451 6 O
is	458 2 O
d	461 1 B-Chemical
-	462 1 I-Chemical
galactose	463 9 I-Chemical
(	473 1 O
the	474 3 O
C	478 1 O
-	479 1 O
4	480 1 O
-	481 1 O
epimer	482 6 O
of	489 2 O
d	492 1 B-Chemical
-	493 1 I-Chemical
glucose	494 7 I-Chemical
)	501 1 O
which	503 5 O
is	509 2 O
transported	512 11 O
into	524 4 O
the	529 3 O
brain	533 5 O
by	539 2 O
insulin	542 7 O
-	549 1 O
independent	550 11 O
GLUT3	562 5 O
transporter	568 11 O
where	580 5 O
it	586 2 O
might	589 5 O
be	595 2 O
metabolized	598 11 O
to	610 2 O
glucose	613 7 B-Chemical
via	621 3 O
the	625 3 O
Leloir	629 6 O
pathway	636 7 O
.	643 1 O

Exclusively	645 11 O
parenteral	657 10 O
daily	668 5 O
injections	674 10 O
of	685 2 O
galactose	688 9 B-Chemical
induce	698 6 O
memory	705 6 B-Disease
deterioration	712 13 I-Disease
in	726 2 O
rodents	729 7 O
and	737 3 O
are	741 3 O
used	745 4 O
to	750 2 O
generate	753 8 O
animal	762 6 O
aging	769 5 O
model	775 5 O
,	780 1 O
but	782 3 O
the	786 3 O
effects	790 7 O
of	798 2 O
oral	801 4 O
galactose	806 9 B-Chemical
treatment	816 9 O
on	826 2 O
cognitive	829 9 O
functions	839 9 O
have	849 4 O
never	854 5 O
been	860 4 O
tested	865 6 O
.	871 1 O

We	873 2 O
have	876 4 O
investigated	881 12 O
the	894 3 O
effects	898 7 O
of	906 2 O
continuous	909 10 O
daily	920 5 O
oral	926 4 O
galactose	931 9 B-Chemical
(	941 1 O
200	942 3 O
mg	946 2 O
/	948 1 O
kg	949 2 O
/	951 1 O
day	952 3 O
)	955 1 O
treatment	957 9 O
on	967 2 O
cognitive	970 9 B-Disease
deficits	980 8 I-Disease
in	989 2 O
streptozotocin	992 14 B-Chemical
-	1006 1 O
induced	1007 7 O
(	1015 1 O
STZ	1016 3 B-Chemical
-	1019 1 O
icv	1020 3 O
)	1023 1 O
rat	1025 3 O
model	1029 5 O
of	1035 2 O
sAD	1038 3 O
,	1041 1 O
tested	1043 6 O
by	1050 2 O
Morris	1053 6 O
Water	1060 5 O
Maze	1066 4 O
and	1071 3 O
Passive	1075 7 O
Avoidance	1083 9 O
test	1093 4 O
,	1097 1 O
respectively	1099 12 O
.	1111 1 O

One	1113 3 O
month	1117 5 O
of	1123 2 O
oral	1126 4 O
galactose	1131 9 B-Chemical
treatment	1141 9 O
initiated	1151 9 O
immediately	1161 11 O
after	1173 5 O
the	1179 3 O
STZ	1183 3 B-Chemical
-	1186 1 O
icv	1187 3 O
administration	1191 14 O
,	1205 1 O
successfully	1207 12 O
prevented	1220 9 O
development	1230 11 O
of	1242 2 O
the	1245 3 O
STZ	1249 3 B-Chemical
-	1252 1 O
icv	1253 3 O
-	1256 1 O
induced	1257 7 O
cognitive	1265 9 B-Disease
deficits	1275 8 I-Disease
.	1283 1 O

Beneficial	1285 10 O
effect	1296 6 O
of	1303 2 O
oral	1306 4 O
galactose	1311 9 B-Chemical
was	1321 3 O
independent	1325 11 O
of	1337 2 O
the	1340 3 O
rat	1344 3 O
age	1348 3 O
and	1352 3 O
of	1356 2 O
the	1359 3 O
galactose	1363 9 B-Chemical
dose	1373 4 O
ranging	1378 7 O
from	1386 4 O
100	1391 3 O
to	1395 2 O
300	1398 3 O
mg	1402 2 O
/	1404 1 O
kg	1405 2 O
/	1407 1 O
day	1408 3 O
.	1411 1 O

Additionally	1413 12 O
,	1425 1 O
oral	1427 4 O
galactose	1432 9 B-Chemical
administration	1442 14 O
led	1457 3 O
to	1461 2 O
the	1464 3 O
appearance	1468 10 O
of	1479 2 O
galactose	1482 9 B-Chemical
in	1492 2 O
the	1495 3 O
blood	1499 5 O
.	1504 1 O

The	1506 3 O
increase	1510 8 O
of	1519 2 O
galactose	1522 9 B-Chemical
concentration	1532 13 O
in	1546 2 O
the	1549 3 O
cerebrospinal	1553 13 O
fluid	1567 5 O
was	1573 3 O
several	1577 7 O
times	1585 5 O
lower	1591 5 O
after	1597 5 O
oral	1603 4 O
than	1608 4 O
after	1613 5 O
parenteral	1619 10 O
administration	1630 14 O
of	1645 2 O
the	1648 3 O
same	1652 4 O
galactose	1657 9 B-Chemical
dose	1667 4 O
.	1671 1 O

Oral	1673 4 O
galactose	1678 9 B-Chemical
exposure	1688 8 O
might	1697 5 O
have	1703 4 O
beneficial	1708 10 O
effects	1719 7 O
on	1727 2 O
learning	1730 8 O
and	1739 3 O
memory	1743 6 O
ability	1750 7 O
and	1758 3 O
could	1762 5 O
be	1768 2 O
worth	1771 5 O
investigating	1777 13 O
for	1791 3 O
improvement	1795 11 O
of	1807 2 O
cognitive	1810 9 B-Disease
deficits	1820 8 I-Disease
associated	1829 10 O
with	1840 4 O
glucose	1845 7 B-Disease
hypometabolism	1853 14 I-Disease
in	1868 2 O
AD	1871 2 B-Disease
.	1873 1 O

